{"text": "We show that murine Rdh12 and human RDH13 do not reveal activity towards the checked steroids, but that human type 12 RDH reduces dihydrotestosterone to androstanediol, and is thus also involved in steroid metabolism.", "spo_list": [{"subject": "androstanediol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "human type 12 RDH", "object_type": "GENE-Y"}]}
{"text": "The h-OB were 10-100 fold more sensitive to DPHD than transformed osteoblasts: DPHD increased h-OB proliferation at 10nM and, at 100nM, activated MAP kinase signaling within 30min.", "spo_list": [{"subject": "DPHD", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MAP kinase", "object_type": "GENE-N"}]}
{"text": "Effects of DPHD were eliminated by the estrogen receptor antagonist ICI182780.", "spo_list": [{"subject": "ICI182780", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "DPHD", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}]}
{"text": "During differentiation, DPHD promoted early expression of osteoblast transcription factors, RUNX2 and osterix.", "spo_list": [{"subject": "DPHD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "RUNX2", "object_type": "GENE-Y"}, {"subject": "DPHD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "osterix", "object_type": "GENE-Y"}]}
{"text": "Subsequently, DPHD accelerated production of bone structural genes, including COL1A1 and osteocalcin comparably to 17Î²-estradiol.", "spo_list": [{"subject": "DPHD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "COL1A1", "object_type": "GENE-Y"}, {"subject": "DPHD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "osteocalcin", "object_type": "GENE-Y"}]}
{"text": "The reduction was more pronounced in the fructose-fed group and attributed to decreased hepatic expression of ACC2, FAS, SCD1, and MTTP and a decrease in the rate of hepatic triglyceride secretion.", "spo_list": [{"subject": "fructose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ACC2", "object_type": "GENE-Y"}, {"subject": "fructose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "FAS", "object_type": "GENE-Y"}, {"subject": "fructose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "SCD1", "object_type": "GENE-Y"}, {"subject": "fructose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MTTP", "object_type": "GENE-Y"}]}
{"text": "Interestingly, fructose-fed rats treated with ChREBP ASO had increased plasma uric acid, alanine transaminase, and aspartate aminotransferase concentrations.", "spo_list": [{"subject": "fructose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "alanine transaminase", "object_type": "GENE-N"}, {"subject": "fructose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "aspartate aminotransferase", "object_type": "GENE-N"}]}
{"text": "This was associated with decreased expression of fructose aldolase and fructokinase, reminiscent of inherited disorders of fructose metabolism.", "spo_list": [{"subject": "fructose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "fructose aldolase", "object_type": "GENE-N"}, {"subject": "fructose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "fructokinase", "object_type": "GENE-Y"}]}
{"text": "Administration of AC3174 resulted in a 4-fold increase in insulin concentrations in normal mice following an IP glucose challenge.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-N"}]}
{"text": "Previous work has extensively characterized a common allosteric site on mGlu5, termed the MPEP (2-Methyl-6-(phenylethynyl)pyridine) binding site.", "spo_list": [{"subject": "MPEP", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "mGlu5", "object_type": "GENE-Y"}, {"subject": "2-Methyl-6-(phenylethynyl)pyridine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "mGlu5", "object_type": "GENE-Y"}]}
{"text": "However, one mGlu5 PAM, CPPHA (N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide), interacts with a separate allosteric site on mGlu5.", "spo_list": [{"subject": "N-(4-chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl)-2-hydroxybenzamide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mGlu5", "object_type": "GENE-Y"}, {"subject": "CPPHA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mGlu5", "object_type": "GENE-Y"}]}
{"text": "NCFP binds to the CPPHA site on mGlu5 and potentiates mGlu5-mediated responses in both recombinant and native systems.", "spo_list": [{"subject": "NCFP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mGlu5", "object_type": "GENE-Y"}, {"subject": "NCFP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "mGlu5", "object_type": "GENE-Y"}]}
{"text": "To study the influence of dopaminergic activity on the expression of dopamine D2 receptors and glutamic acid decarboxylase in substantia nigra, mice were treated daily for several days with an irreversibly acting dopamine D1 and dopamine D2 receptor antagonist N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) or with a selective irreversible D2 dopamine receptor antagonist fluphenazine-N-mustard.", "spo_list": [{"subject": "N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D2 receptor", "object_type": "GENE-Y"}, {"subject": "EEDQ", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D2 receptor", "object_type": "GENE-Y"}, {"subject": "N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D1", "object_type": "GENE-Y"}, {"subject": "EEDQ", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D1", "object_type": "GENE-Y"}, {"subject": "fluphenazine-N-mustard", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "D2 dopamine receptor", "object_type": "GENE-Y"}]}
{"text": "The results showed that treatment with EEDQ, which blocked 80% to 85% of the dopamine D2 and dopamine D1 receptors in substantia nigra, increased the levels of dopamine D2 receptor mRNA in substantia nigra by about 27%.", "spo_list": [{"subject": "EEDQ", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dopamine D2", "object_type": "GENE-Y"}, {"subject": "EEDQ", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dopamine D1 receptors", "object_type": "GENE-Y"}, {"subject": "EEDQ", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "dopamine D2 receptor", "object_type": "GENE-Y"}]}
{"text": "Treatment with fluphenazine-N-mustard, which blocked about 85% of the dopamine D2 receptors in substantia nigra but had no significant effect on dopamine D1 receptors, increased the levels of dopamine D2 receptor mRNA by about 34%.", "spo_list": [{"subject": "fluphenazine-N-mustard", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dopamine D2 receptors", "object_type": "GENE-Y"}, {"subject": "fluphenazine-N-mustard", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "dopamine D2 receptor", "object_type": "GENE-Y"}]}
{"text": "Nabumetone itself is non-acidic and, following absorption, it undergoes extensive first-pass metabolism to form the main circulating active metabolite (6-MNA) which is a much more potent inhibitor of preferentially cyclo-oxygenase (COX)-2.", "spo_list": [{"subject": "6-MNA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclo-oxygenase (COX)-2", "object_type": "GENE-Y"}, {"subject": "Nabumetone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclo-oxygenase (COX)-2", "object_type": "GENE-Y"}]}
{"text": "This has been attributed mainly to the non-acidic chemical properties of nabumetone but also to its COX-1/COX-2 inhibitor profile.", "spo_list": [{"subject": "nabumetone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "nabumetone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Compared with COX-2 selective inhibitors, nabumetone exhibits similar anti-inflammatory and analgesic properties in patients with arthritis and there is no evidence of excess GI or other forms of complications to date.", "spo_list": [{"subject": "nabumetone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "There was significant inhibition of the I(SC) responses to 30 microM ASC by the flavanoid quercetin (50 microM) and by 100 microM 4,4'-diisothiocyanostilbene-2,2'-disulfonic acid (DIDS) and 5-ethylisopropylamiloride (EIPA), blockers of anion exchangers and sodium-proton exchangers, respectively.", "spo_list": [{"subject": "4,4'-diisothiocyanostilbene-2,2'-disulfonic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "anion exchangers", "object_type": "GENE-N"}, {"subject": "DIDS", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "anion exchangers", "object_type": "GENE-N"}, {"subject": "5-ethylisopropylamiloride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "sodium-proton exchangers", "object_type": "GENE-N"}, {"subject": "EIPA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "sodium-proton exchangers", "object_type": "GENE-N"}]}
{"text": "There was no inhibition, however, by the chloride channel blocker 5-nitro-2(3-phenylpropylamino)benzoic acid (NPPB).", "spo_list": [{"subject": "5-nitro-2(3-phenylpropylamino)benzoic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "chloride channel", "object_type": "GENE-N"}, {"subject": "NPPB", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "chloride channel", "object_type": "GENE-N"}]}
{"text": "Phorbol 12-myristate 13 acetate (PMA), the phorbol ester activator of protein kinase C, caused a 37% decrease in the I(SC) response to ASC.", "spo_list": [{"subject": "Phorbol 12-myristate 13 acetate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "protein kinase C", "object_type": "GENE-N"}, {"subject": "PMA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "protein kinase C", "object_type": "GENE-N"}, {"subject": "phorbol ester", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "protein kinase C", "object_type": "GENE-N"}]}
{"text": "TCDD decreased the expression of the glucose transporter, SLC2A1, and most of the glycolytic transcripts, followed by decreases in glycolytic intermediates, including pyruvate.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "glucose transporter", "object_type": "GENE-N"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "SLC2A1", "object_type": "GENE-Y"}]}
{"text": "Mitochondrial glutathione (GSH) reductase activity and the GSH/glutathione disulfide ratio were decreased by TCDD, ultimately leading to mitochondrial dysfunction, characterized by decreased inner mitochondrial membrane potential and ATP production, and increased production of the reactive oxygen species (ROS), hydrogen peroxide.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "glutathione (GSH) reductase", "object_type": "GENE-N"}]}
{"text": "The present study examined the role of cyclo-oxygenase (COX)-synthetized eicosanoids in the pathogenesis of Ang II-induced endothelial dysfunction in transgenic rats harboring mouse renin-2 gene (mREN2 rats).", "spo_list": [{"subject": "eicosanoids", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclo-oxygenase", "object_type": "GENE-N"}, {"subject": "eicosanoids", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX", "object_type": "GENE-N"}]}
{"text": "Isoliquiritigenin showed strong inhibitory effects towards multiple UDP-glucuronosyltransferase (UGT) isoform-catalyzed 4-methylumbelliferone (4-MU) glucuronidation.", "spo_list": [{"subject": "Isoliquiritigenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UDP-glucuronosyltransferase", "object_type": "GENE-N"}, {"subject": "Isoliquiritigenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UGT", "object_type": "GENE-N"}, {"subject": "4-methylumbelliferone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UDP-glucuronosyltransferase", "object_type": "GENE-N"}, {"subject": "4-methylumbelliferone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT", "object_type": "GENE-N"}, {"subject": "4-MU", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UDP-glucuronosyltransferase", "object_type": "GENE-N"}, {"subject": "4-MU", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT", "object_type": "GENE-N"}]}
{"text": "Isoliquiritigenin, a herbal ingredient with chalcone structure, has been speculated to be able to inhibit one of the most drug-metabolizing enzymes (DMEs) UDP-glucuronosyltransferase (UGT).", "spo_list": [{"subject": "Isoliquiritigenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UDP-glucuronosyltransferase", "object_type": "GENE-N"}, {"subject": "Isoliquiritigenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UGT", "object_type": "GENE-N"}, {"subject": "chalcone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UDP-glucuronosyltransferase", "object_type": "GENE-N"}, {"subject": "chalcone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UGT", "object_type": "GENE-N"}]}
{"text": "The recombinant UGT-catalyzed 4-methylumbelliferone (4-MU) glucuronidation was used as probe reactions.", "spo_list": [{"subject": "4-methylumbelliferone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT", "object_type": "GENE-N"}, {"subject": "4-MU", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT", "object_type": "GENE-N"}]}
{"text": "The results showed that 100Î¼M of isoliquiritigenin inhibited the activity of UGT1A1, UGT1A3, UGT1A6, UGT1A7, UGT1A8, UGT1A9, and UGT1A10 by 95.2%, 76.1%, 78.9%, 87.2%, 67.2%, 94.8%, and 91.7%, respectively.", "spo_list": [{"subject": "isoliquiritigenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UGT1A1", "object_type": "GENE-Y"}, {"subject": "isoliquiritigenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UGT1A3", "object_type": "GENE-Y"}, {"subject": "isoliquiritigenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UGT1A6", "object_type": "GENE-Y"}, {"subject": "isoliquiritigenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UGT1A7", "object_type": "GENE-Y"}, {"subject": "isoliquiritigenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UGT1A8", "object_type": "GENE-Y"}, {"subject": "isoliquiritigenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UGT1A9", "object_type": "GENE-Y"}, {"subject": "isoliquiritigenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UGT1A10", "object_type": "GENE-Y"}]}
{"text": "The data fitting using Dixon plot and Lineweaver-Burk plot showed that the inhibition of UGT1A1, UGT1A9 and UGT1A10 by isoliquiritigenin was all best fit to the competitive inhibition, and the second plot using the slopes from the Lineweaver-Burk plot versus isoliquiritigenin concentrations was used to calculate the inhibition kinetic parameter (K(i)) to be 0.7Î¼M, 0.3Î¼M, and 18.3Î¼M for UGT1A1, UGT1A9, and UGT1A10, respectively.", "spo_list": [{"subject": "isoliquiritigenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UGT1A1", "object_type": "GENE-Y"}, {"subject": "isoliquiritigenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UGT1A9", "object_type": "GENE-Y"}, {"subject": "isoliquiritigenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UGT1A10", "object_type": "GENE-Y"}, {"subject": "isoliquiritigenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UGT1A1", "object_type": "GENE-Y"}, {"subject": "isoliquiritigenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UGT1A9", "object_type": "GENE-Y"}, {"subject": "isoliquiritigenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UGT1A10", "object_type": "GENE-Y"}]}
{"text": "All these results indicated the risk of clinical application of isoliquiritigenin on the drug-drug interaction and other possible diseases induced by the inhibition of isoliquiritigenin towards these UGT isoforms.", "spo_list": [{"subject": "isoliquiritigenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UGT", "object_type": "GENE-N"}]}
{"text": "Tiapride, a D2 antagonist that lacks antipsychotic activity, was also included.", "spo_list": [{"subject": "Tiapride", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "D2", "object_type": "GENE-Y"}]}
{"text": "Tiapride, in contrast, significantly up-regulated only the level of D2-long mRNA in these areas.", "spo_list": [{"subject": "Tiapride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "D2-long", "object_type": "GENE-Y"}]}
{"text": "In both the cerebral cortex and striatum, D4 receptor mRNA was upregulated by certain typical (chlorpromazine and haloperidol) and certain atypical (clozapine, olanzapine and risperidone) antipsychotic agents as well as by tiapride.", "spo_list": [{"subject": "chlorpromazine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "D4 receptor", "object_type": "GENE-Y"}, {"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "D4 receptor", "object_type": "GENE-Y"}, {"subject": "clozapine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "D4 receptor", "object_type": "GENE-Y"}, {"subject": "olanzapine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "D4 receptor", "object_type": "GENE-Y"}, {"subject": "risperidone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "D4 receptor", "object_type": "GENE-Y"}, {"subject": "tiapride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "D4 receptor", "object_type": "GENE-Y"}]}
{"text": "The finding that up-regulation of D2 dopamine receptor mRNAs was a consistently observed effect of a wide range of antipsychotic agents in the cerebral cortex but not in the neostriatum, coupled with the fact that the D2-short isoforms in the cortex were not regulated by a nonantipsychotic D2 antagonist, tiapride, draws attention to the importance of the D2 dopamine receptor in the cerebral cortex as a potentially critical, common site of action of antipsychotic medications.", "spo_list": [{"subject": "tiapride", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "D2", "object_type": "GENE-Y"}]}
{"text": "For these reasons, the use of irreversible DNA methyltransferase inhibitors, such as 5-azacytidine and Decitabine, appears to be a promising option for the treatment of MDS and acute myeloid leukemia.", "spo_list": [{"subject": "5-azacytidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA methyltransferase", "object_type": "GENE-N"}, {"subject": "Decitabine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA methyltransferase", "object_type": "GENE-N"}]}
{"text": "The synergistic effect of histone deacetylase inhibitors, including phenylbutyrate (PB), in reactivating silenced genes encouraged clinical studies on the combination of PB and demethylating agents in hematological diseases, characterized by p15 silencing.", "spo_list": [{"subject": "phenylbutyrate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "histone deacetylase", "object_type": "GENE-N"}, {"subject": "PB", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "histone deacetylase", "object_type": "GENE-N"}]}
{"text": "Candesartan is an angiotensin II type 1 receptor blocker (ARB) that has been to shown to limit ischemic stroke and improve stroke outcome.", "spo_list": [{"subject": "Candesartan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "angiotensin II type 1 receptor", "object_type": "GENE-Y"}]}
{"text": "Candesartan significantly increased the expression of BDNF in the SHR (P < 0.05).", "spo_list": [{"subject": "Candesartan", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "BDNF", "object_type": "GENE-Y"}]}
{"text": "Treatment with the AT2 antagonist PD-123319 significantly reduced tube-like formation in endothelial cells.", "spo_list": [{"subject": "PD-123319", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "AT2", "object_type": "GENE-Y"}]}
{"text": "Analysis of splice variants and site-directed mutants of the AMPA receptor GluR3 expressed in Xenopus oocytes has shown that lithium produces a large potentiation of the GluR3 flop splice variant and suggested that lithium might inhibit rapid desensitization, which is characteristic of this receptor (Karkanias, N. and Papke, R., Subtype-specific effects of lithium on glutamate receptor function.", "spo_list": [{"subject": "lithium", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GluR3 flop", "object_type": "GENE-Y"}]}
{"text": "Science, 9(266) (1994) 1709-1713) greatly attenuates the lithium-induced potentiation of GluR3.", "spo_list": [{"subject": "lithium", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GluR3", "object_type": "GENE-Y"}]}
{"text": "Neuron, 21 (1998) 907-918) further confirms that lithium enhances GluR3 responses by reducing desensitization, since lithium's effects are reversed in this mutant.", "spo_list": [{"subject": "lithium", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GluR3", "object_type": "GENE-Y"}]}
{"text": "Specifically, aniracetam, which potentiates wild-type AMPA receptors, is ineffective on the non-desensitizing GluR3(L507Y) mutant, but has synergistic effects with lithium on wild-type receptors.", "spo_list": [{"subject": "aniracetam", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPA receptors", "object_type": "GENE-N"}, {"subject": "lithium", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GluR3", "object_type": "GENE-Y"}, {"subject": "lithium", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "L507Y", "object_type": "GENE-N"}]}
{"text": "MCT-induced pulmonary hypertension resulted in decreased GSH level, decreased GST and SOD activities and increased CAT activity in lung and liver tissues of both male and female rats.", "spo_list": [{"subject": "MCT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GST", "object_type": "GENE-N"}, {"subject": "MCT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SOD", "object_type": "GENE-N"}, {"subject": "MCT", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CAT", "object_type": "GENE-Y"}]}
{"text": "Fluorescence of the reporter dye is turned on by rapid removal of the quinone quencher, an event that immediately occurs only after highly selective, two-electron reduction of the sterically and conformationally restricted quinone substrate by the cancer-associated human NAD(P)H:quinone oxidoreductase isozyme 1 (hNQO1).", "spo_list": [{"subject": "quinone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human NAD(P)H:quinone oxidoreductase isozyme 1", "object_type": "GENE-Y"}, {"subject": "quinone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hNQO1", "object_type": "GENE-Y"}]}
{"text": "Organic anion transport inhibitors including betamipron, cilastatin, KW-3902 (8-(noradamantan-3-yl)-1,3-dipropylxanthine) and probenecid significantly inhibited human-OAT1- and human-OAT3-mediated organic anion uptake in a dose-dependent manner.", "spo_list": [{"subject": "8-(noradamantan-3-yl)-1,3-dipropylxanthine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human-OAT1", "object_type": "GENE-Y"}, {"subject": "betamipron", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human-OAT1", "object_type": "GENE-Y"}, {"subject": "cilastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human-OAT1", "object_type": "GENE-Y"}, {"subject": "KW-3902", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human-OAT1", "object_type": "GENE-Y"}, {"subject": "betamipron", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human-OAT3", "object_type": "GENE-Y"}, {"subject": "cilastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human-OAT3", "object_type": "GENE-Y"}, {"subject": "KW-3902", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human-OAT3", "object_type": "GENE-Y"}]}
{"text": "The Ki values of betamipron, cilastatin, KW-3902 and probencid for human-OAT1 were 23.6, 1470, 7.82 and 12.1 microM, whereas those for human-OAT3 were 48.3, 231, 3.70 and 9.0 microM.", "spo_list": [{"subject": "betamipron", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human-OAT1", "object_type": "GENE-Y"}, {"subject": "cilastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human-OAT1", "object_type": "GENE-Y"}, {"subject": "KW-3902", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human-OAT1", "object_type": "GENE-Y"}, {"subject": "probencid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human-OAT1", "object_type": "GENE-Y"}, {"subject": "betamipron", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human-OAT3", "object_type": "GENE-Y"}, {"subject": "cilastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human-OAT3", "object_type": "GENE-Y"}, {"subject": "KW-3902", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human-OAT3", "object_type": "GENE-Y"}, {"subject": "probencid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human-OAT3", "object_type": "GENE-Y"}]}
{"text": "These results suggest that betamipron and probenecid could inhibit both human-OAT1- and human-OAT3-mediated organic anion transport in vivo, whereas cilastatin could inhibit only human-OAT3-mediated one.", "spo_list": [{"subject": "betamipron", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human-OAT1", "object_type": "GENE-Y"}, {"subject": "betamipron", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human-OAT3", "object_type": "GENE-Y"}, {"subject": "cilastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human-OAT3", "object_type": "GENE-Y"}]}
{"text": "Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex.", "spo_list": [{"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}]}
{"text": "Tomudex (ZD1694) is a specific antifolate-based thymidylate synthase inhibitor active in a variety of solid tumor malignancies.", "spo_list": [{"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}]}
{"text": "Studies were carried out in vitro to evaluate downstream molecular alterations induced as a consequence of the potent and sustained inhibition of thymidylate synthase by Tomudex.", "spo_list": [{"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}]}
{"text": "Tomudex treatment resulted in the decrease in p27(kip1) expression, with an increase in cyclin E and cdk2 protein expression and kinase activities 24 h after a 2-h exposure.", "spo_list": [{"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "p27(kip1)", "object_type": "GENE-Y"}, {"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cyclin E", "object_type": "GENE-Y"}, {"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cdk2", "object_type": "GENE-Y"}, {"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "kinase", "object_type": "GENE-N"}]}
{"text": "The studies with dThyd rescue from cyclin E-cdk2 protein overexpression and growth inhibition by Tomudex indicate that increased cyclin E-cdk2 protein expression is associated with effective inhibition of thymidylate synthase and resultant dNTP pool imbalance.", "spo_list": [{"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cyclin E", "object_type": "GENE-Y"}, {"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cdk2", "object_type": "GENE-Y"}, {"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclin E", "object_type": "GENE-Y"}, {"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cdk2", "object_type": "GENE-Y"}, {"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cyclin E", "object_type": "GENE-Y"}, {"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cdk2", "object_type": "GENE-Y"}, {"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}]}
{"text": "These results suggest that the megabase DNA fragmentation is induced as a consequence of inhibition of thymidylate synthase by Tomudex and kilobase DNA fragmentation may correlate with the reduction of p27(kip1) expression and the increase in cyclin E and cdk2 kinase activities.", "spo_list": [{"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}, {"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "p27(kip1)", "object_type": "GENE-Y"}, {"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "cyclin E", "object_type": "GENE-Y"}, {"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "cdk2", "object_type": "GENE-Y"}, {"subject": "Tomudex", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "kinase", "object_type": "GENE-N"}]}
{"text": "Differential pharmacokinetics and pharmacodynamics of methylphenidate enantiomers: does chirality matter? d,l-threo-methylphenidate (MPH) is an effective first-line treatment for the symptoms associated with attention-deficit/hyperactivity disorder. threo-methylphenidate inhibits the dopamine transporter and the norepinephrine transporter, resulting in elevations of these monoamines after impulse release.", "spo_list": [{"subject": "threo-methylphenidate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dopamine transporter", "object_type": "GENE-Y"}, {"subject": "threo-methylphenidate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "norepinephrine transporter", "object_type": "GENE-Y"}, {"subject": "monoamines", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "dopamine transporter", "object_type": "GENE-Y"}, {"subject": "monoamines", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "norepinephrine transporter", "object_type": "GENE-Y"}]}
{"text": "In both rodent and primate animal models, the binding of radiolabeled d-MPH to dopamine transporter was found to be selective, saturable, and reversible, whereas binding of l-MPH was diffuse and nonspecific.", "spo_list": [{"subject": "d-MPH", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "dopamine transporter", "object_type": "GENE-N"}, {"subject": "l-MPH", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "dopamine transporter", "object_type": "GENE-N"}]}
{"text": "After CFVs were observed for 30 min, the animals were randomly divided in four groups: 5 animals received via a small catheter (26G) placed proximally to the stenosis, an intra-arterial infusion of human recombinant FVIIai (0.1 mg/kg/min for 10 min); 9 animals received AP-1, a monoclonal antibody against rabbit TF (0.1 mg/kg i.v. bolus); 7 animals received ridogrel, a dual thromboxane A2 synthetase inhibitor and thromboxane A2 receptor antagonist (10 mg/kg i.v. bolus); finally, 8 rabbits received aurintrycarboxilic acid (ATA), an inhibitor of platelet glycoprotein Ib/von Willebrand factor interaction (10 mg/kg i.v. bolus).", "spo_list": [{"subject": "ATA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "glycoprotein Ib", "object_type": "GENE-N"}, {"subject": "aurintrycarboxilic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "glycoprotein Ib", "object_type": "GENE-N"}, {"subject": "aurintrycarboxilic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "von Willebrand factor", "object_type": "GENE-Y"}, {"subject": "ATA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "von Willebrand factor", "object_type": "GENE-Y"}]}
{"text": "Computational modeling suggests that the BSPSA luminogens prefer docking in the hydrophobic cavity in the EPO folding structures, and the assembly of BSPSA in this cavity makes the AIE available, making the monitoring of unfolding of EPO possible.", "spo_list": [{"subject": "BSPSA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EPO", "object_type": "GENE-Y"}, {"subject": "BSPSA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EPO", "object_type": "GENE-Y"}]}
{"text": "A KINOMEscan of 19,20-anhydrosipholenol A 4Î²-benzoate ester against 451 human protein kinases identified protein tyrosine kinase 6 (PTK6) as a potential target.", "spo_list": [{"subject": "19,20-anhydrosipholenol A 4Î²-benzoate ester", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "protein tyrosine kinase 6", "object_type": "GENE-Y"}, {"subject": "19,20-anhydrosipholenol A 4Î²-benzoate ester", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PTK6", "object_type": "GENE-Y"}]}
{"text": "In breast tumor cells, PTK6 promotes growth factor signaling and migration, and as such the semisynthetic sipholanes were evaluated for their ability to inhibit PTK6 phosphorylation in vitro.", "spo_list": [{"subject": "sipholanes", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PTK6", "object_type": "GENE-Y"}]}
{"text": "The two analogues with the highest antimigratory activities, sipholenol A 4Î²-4-chlorobenzoate and 19,20-anhydrosipholenol A 4Î²-4-chlorobenzoate esters, also exhibited the most potent inhibition of PTK6 phosphorylation inhibition.", "spo_list": [{"subject": "sipholenol A 4Î²-4-chlorobenzoate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PTK6", "object_type": "GENE-Y"}, {"subject": "19,20-anhydrosipholenol A 4Î²-4-chlorobenzoate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PTK6", "object_type": "GENE-Y"}, {"subject": "esters", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PTK6", "object_type": "GENE-Y"}]}
{"text": "The acute toxicity of organophosphorus (OP) compounds in mammals is due to their irreversible inhibition of acetylcholinesterase (AChE) in the nervous system, which leads to increased synaptic acetylcholine levels.", "spo_list": [{"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-N"}, {"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-N"}, {"subject": "acetylcholine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "acetylcholinesterase", "object_type": "GENE-N"}, {"subject": "acetylcholine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AChE", "object_type": "GENE-N"}]}
{"text": "In phosphotriesterase and physostigmine-treated mice, a 4- and 2-fold higher sarin dose, respectively, was needed to cause a 50% inhibition of brain AChE activity.", "spo_list": [{"subject": "sarin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "When dual angiogenic growth factors (GFs), such as platelet-derived GF (PDGF) and vascular endothelial GF (VEGF), are encapsulated separately in the core and shell domains, respectively, the VEGF release rate is much greater than that of PDGF, and the difference of the cumulative release percentage between the two GFs is about 30% on day 7 with LMW core PLGA and more than 45% with HMW core PLGA.", "spo_list": [{"subject": "PLGA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "VEGF", "object_type": "GENE-N"}, {"subject": "PLGA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PDGF", "object_type": "GENE-N"}, {"subject": "PLGA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "VEGF", "object_type": "GENE-N"}, {"subject": "PLGA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PDGF", "object_type": "GENE-N"}]}
{"text": "The first model was induced by tranylcypromine, a nonselective monoamine oxidase (MAO) inhibitor (3.5 mg/kg) and fluoxetine, a selective serotonin reuptake inhibitor (SSRI) (10 mg/kg).", "spo_list": [{"subject": "tranylcypromine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase", "object_type": "GENE-N"}, {"subject": "tranylcypromine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO", "object_type": "GENE-N"}]}
{"text": "The second model was induced by clorgyline, an MAO-A inhibitor (1.2 mg/kg) and 5-hydroxy-L-tryptophan, a precursor of 5-HT (5-HTP) (80 mg/kg).", "spo_list": [{"subject": "clorgyline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}]}
{"text": "Characterization of the NifS-like domain of ABA3 from Arabidopsis thaliana provides insight into the mechanism of molybdenum cofactor sulfuration.", "spo_list": [{"subject": "molybdenum", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NifS-like domain", "object_type": "GENE-N"}, {"subject": "molybdenum", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ABA3", "object_type": "GENE-Y"}]}
{"text": "The molybdenum cofactor sulfurase ABA3 from Arabidopsis thaliana specifically regulates the activity of the molybdenum enzymes aldehyde oxidase and xanthine dehydrogenase by converting their molybdenum cofactor from the desulfo-form into the sulfo-form.", "spo_list": [{"subject": "molybdenum", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "aldehyde oxidase", "object_type": "GENE-N"}, {"subject": "molybdenum", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "xanthine dehydrogenase", "object_type": "GENE-N"}, {"subject": "molybdenum", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "molybdenum cofactor sulfurase", "object_type": "GENE-Y"}, {"subject": "molybdenum", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ABA3", "object_type": "GENE-Y"}]}
{"text": "ABA3 is a two-domain protein with an NH2-terminal domain sharing significant similarities to NifS proteins that catalyze the decomposition of l-cysteine to l-alanine and elemental sulfur for iron-sulfur cluster synthesis.", "spo_list": [{"subject": "NH2", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ABA3", "object_type": "GENE-Y"}, {"subject": "l-cysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NifS", "object_type": "GENE-Y"}, {"subject": "l-alanine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "NifS", "object_type": "GENE-Y"}, {"subject": "NH2", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "NifS", "object_type": "GENE-Y"}, {"subject": "iron-sulfur", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "NifS", "object_type": "GENE-Y"}, {"subject": "sulfur", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NifS", "object_type": "GENE-Y"}]}
{"text": "Although different in its physiological function, the mechanism of ABA3 for sulfur mobilization was found to be similar to NifS proteins.", "spo_list": [{"subject": "sulfur", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NifS", "object_type": "GENE-Y"}, {"subject": "sulfur", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ABA3", "object_type": "GENE-Y"}]}
{"text": "In vitro, the NifS-like domain of ABA3 activates aldehyde oxidase and xanthine dehydrogenase in the absence of the C-terminal domain, but in vivo, the C-terminal domain is required for proper activation of both target enzymes.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "NifS-like domain", "object_type": "GENE-N"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ABA3", "object_type": "GENE-Y"}]}
{"text": "Although l-selenocysteine is unlikely to be a natural substrate for ABA3, it is decomposed more efficiently than l-cysteine.", "spo_list": [{"subject": "l-selenocysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ABA3", "object_type": "GENE-Y"}, {"subject": "l-cysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ABA3", "object_type": "GENE-Y"}]}
{"text": "Besides mitochondrial AtNFS1 and plastidial AtNFS2, which are both proposed to be involved in iron-sulfur cluster formation, ABA3 is proposed to be a third and cytosolic NifS-like cysteine desulfurase in A. thaliana.", "spo_list": [{"subject": "iron-sulfur", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AtNFS1", "object_type": "GENE-Y"}, {"subject": "iron-sulfur", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AtNFS2", "object_type": "GENE-Y"}, {"subject": "iron-sulfur", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ABA3", "object_type": "GENE-Y"}]}
{"text": "However, the sulfur transferase activity of ABA3 is used for post-translational activation of molybdenum enzymes rather than for iron-sulfur cluster assembly.", "spo_list": [{"subject": "iron-sulfur", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ABA3", "object_type": "GENE-Y"}]}
{"text": "3. Inactivation of cardiac alpha 1B-adrenoceptors by treatment with chloroethylclonidine slightly enhanced the maximal inotropic effects of the full agonist, adrenaline and of several partial agonists.", "spo_list": [{"subject": "chloroethylclonidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "alpha 1B-adrenoceptors", "object_type": "GENE-Y"}, {"subject": "adrenaline", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "alpha 1B-adrenoceptors", "object_type": "GENE-Y"}]}
{"text": "4. Schild analysis of inhibition experiments with the alpha 1A-adrenoceptor-selective antagonists, 5-methyl-urapidil and (+/-)-tamsulosin, demonstrated that adrenaline causes its inotropic effects mainly via the alpha 1B-adrenoceptor subtype.", "spo_list": [{"subject": "5-methyl-urapidil", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha 1A-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "(+/-)-tamsulosin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha 1A-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Schild analysis of 5-methyl-urapidil inhibition experiments in chloroethylclonidine-treated ventricles indicated that only alpha 1A-adrenoceptors mediate the inotropic effects of adrenaline following inactivation of the alpha 1B-adrenoceptors.", "spo_list": [{"subject": "chloroethylclonidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "alpha 1B-adrenoceptors", "object_type": "GENE-Y"}, {"subject": "5-methyl-urapidil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "alpha 1A-adrenoceptors", "object_type": "GENE-Y"}]}
{"text": "Following inactivation of alpha 1B-adrenoceptors by chloroethylclonidine treatment, alpha lA-adrenoceptors can fully compensate and mediate inotropic effects by promoting influx of extracellular Ca2+ at least partly via voltage-operated channels.Therefore, we speculate that alpha 1B-adrenoceptors exert a tonic inhibitory effect on alpha 1A-adrenoceptors.", "spo_list": [{"subject": "chloroethylclonidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "alpha 1B-adrenoceptors", "object_type": "GENE-Y"}, {"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "voltage-operated channels", "object_type": "GENE-N"}]}
{"text": "RESULTS: We found no associations between the GSTM3, GSTP1, NQO1, CYP1A1, GSTM1, or GSTT1 polymorphisms and adult brain tumor risk with the possible exception of a weak association between the G-C (Val-Ala) GSTP1 105/114 haplotype and glioma [odds ratio (OR), 0.73; 95% confidence interval (95% CI), 0.54, 0.99], nor was there an interaction between the effects of the GSTM3 or GSTP1 polymorphisms and cigarette smoking.", "spo_list": [{"subject": "Val-Ala", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GSTP1", "object_type": "GENE-Y"}]}
{"text": "Inactivation of prostaglandin H synthase and prostacyclin synthase by phenylbutazone.", "spo_list": [{"subject": "phenylbutazone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "prostaglandin H synthase", "object_type": "GENE-N"}, {"subject": "phenylbutazone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "prostacyclin synthase", "object_type": "GENE-Y"}]}
{"text": "Most reducing cofactors for the peroxidase protect PHS and prostacyclin synthase from inactivation by hydroperoxides.", "spo_list": [{"subject": "hydroperoxides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PHS", "object_type": "GENE-N"}, {"subject": "hydroperoxides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "prostacyclin synthase", "object_type": "GENE-Y"}]}
{"text": "Chromatographic analysis of the metabolism of 14C-labeled arachidonic acid in this system revealed that PB-dependent inactivation of PHS is markedly increased in the presence of 100 microM H2O2.", "spo_list": [{"subject": "H2O2", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PHS", "object_type": "GENE-N"}, {"subject": "14C-labeled arachidonic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PHS", "object_type": "GENE-N"}]}
{"text": "The enzyme cyclo-oxygenase catalyses the oxygenation of arachidonic acid, leading to the formation of prostaglandins.", "spo_list": [{"subject": "arachidonic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cyclo-oxygenase", "object_type": "GENE-N"}, {"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclo-oxygenase", "object_type": "GENE-N"}]}
{"text": "Constitutive and inducible forms of human cyclo-oxygenase (hCOX-1 and hCOX-2) were cloned and expressed in insect cells, utilizing a baculovirus expression system. hCOX-1 had a specific activity of 18.8 mumol of O2/mg with a Km of 13.8 microM for arachidonate and Vmax. of 1500 nmol of O2/nmol of enzyme, whereas hCOX-2 had a specific activity of 12.2 mumol of O2/mg with a Km of 8.7 microM for arachidonate and a Vmax. of 1090 nmol of O2/nmol of enzyme.", "spo_list": [{"subject": "arachidonate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hCOX-1", "object_type": "GENE-Y"}, {"subject": "arachidonate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hCOX-2", "object_type": "GENE-Y"}]}
{"text": "Indomethacin inhibited both hCOX-1 and hCOX-2, whereas NS-398 and Dup-697 selectively inhibited hCOX-2.", "spo_list": [{"subject": "Indomethacin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hCOX-1", "object_type": "GENE-Y"}, {"subject": "Indomethacin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hCOX-2", "object_type": "GENE-Y"}, {"subject": "NS-398", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hCOX-2", "object_type": "GENE-Y"}, {"subject": "Dup-697", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hCOX-2", "object_type": "GENE-Y"}]}
{"text": "Both NS-398 and Dup-697 exhibited time-dependent inactivation of hCOX-2, as did indomethacin on both enzymes.", "spo_list": [{"subject": "NS-398", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hCOX-2", "object_type": "GENE-Y"}, {"subject": "Dup-697", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hCOX-2", "object_type": "GENE-Y"}, {"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hCOX-2", "object_type": "GENE-Y"}]}
{"text": "The competitive inhibitor of hCOX-1, mefenamic acid, also displayed competitive inhibition of hCOX-2.", "spo_list": [{"subject": "mefenamic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hCOX-1", "object_type": "GENE-Y"}, {"subject": "mefenamic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hCOX-2", "object_type": "GENE-Y"}]}
{"text": "Fragment-based drug design and identification of HJC0123, a novel orally bioavailable STAT3 inhibitor for cancer therapy.", "spo_list": [{"subject": "HJC0123", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "STAT3", "object_type": "GENE-Y"}]}
{"text": "The most potent compound 5 (HJC0123) has demonstrated to inhibit STAT3 promoter activity, downregulate phosphorylation of STAT3, increase the expression of cleaved caspase-3, inhibit cell cycle progression and promote apoptosis in breast and pancreatic cancer cells with low micromolar to nanomolar IC50 values.", "spo_list": [{"subject": "HJC0123", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "STAT3 promoter", "object_type": "GENE-N"}, {"subject": "HJC0123", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "STAT3", "object_type": "GENE-Y"}, {"subject": "HJC0123", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "caspase-3", "object_type": "GENE-Y"}]}
{"text": "Tiagabine (0.1 microM), an antiepileptic drug that specifically inhibits the GAT-1 GABA transporter inhibited GABA uptake 50% in temporal cortex and 60-68% in white structures.", "spo_list": [{"subject": "Tiagabine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GAT-1", "object_type": "GENE-Y"}, {"subject": "Tiagabine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GABA transporter", "object_type": "GENE-N"}, {"subject": "GABA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GABA transporter", "object_type": "GENE-N"}, {"subject": "GABA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GAT-1", "object_type": "GENE-Y"}]}
{"text": "This finding indicates that GAT-1 is an important GABA transporter in white matter and suggests that white matter GABA uptake is inhibited during tiagabine therapy.", "spo_list": [{"subject": "GABA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GAT-1", "object_type": "GENE-Y"}, {"subject": "GABA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GABA transporter", "object_type": "GENE-N"}, {"subject": "tiagabine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GAT-1", "object_type": "GENE-Y"}, {"subject": "tiagabine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GABA transporter", "object_type": "GENE-N"}]}
{"text": "Since white matter activity of citrate synthase of the tricarboxylic acid cycle was approximately 25% of neocortical values ( approximately 0.4 nmol/mg tissue x min(-1) versus approximately 1.5 nmol/mg tissue x min(-1)), the low GAD activity suggests a slower metabolic turnover of GABA in white than in gray matter.", "spo_list": [{"subject": "GABA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "GAD", "object_type": "GENE-Y"}]}
{"text": "Adenosine kinase is a well-known enzyme which catalyzes the phosphorylation of adenosine to AMP: Its metabolic and kinetic properties are well studied.", "spo_list": [{"subject": "adenosine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Adenosine kinase", "object_type": "GENE-Y"}, {"subject": "AMP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Adenosine kinase", "object_type": "GENE-Y"}]}
{"text": "Here, we report new properties of rat liver enzyme, demonstrating a new reaction: ADP can be a phosphate donor instead ATP, according to the reaction: adenosine + ADP --> 2AMP) demonstrating the efficiency of AdK to phosphorylate adenosine, also starting from ADP.", "spo_list": [{"subject": "adenosine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AdK", "object_type": "GENE-Y"}]}
{"text": "Rasagiline is a novel, potent, and irreversible monoamine oxidase type B (MAO-B) inhibitor which has been approved for treatment of PD.", "spo_list": [{"subject": "Rasagiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase type B", "object_type": "GENE-Y"}, {"subject": "Rasagiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "Rasagiline inhibits MAO-B more potently than selegiline and has the advantage of once-daily dosing.", "spo_list": [{"subject": "Rasagiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "The carboxylation of glutamic acid residues to gamma-carboxyglutamic acid (Gla) by the vitamin K-dependent gamma-glutamyl carboxylase (gamma-carboxylase) is an essential posttranslational modification required for the biological activity of a number of proteins, including proteins involved in blood coagulation and its regulation.", "spo_list": [{"subject": "glutamic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "vitamin K-dependent gamma-glutamyl carboxylase", "object_type": "GENE-Y"}, {"subject": "gamma-carboxyglutamic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "vitamin K-dependent gamma-glutamyl carboxylase", "object_type": "GENE-Y"}, {"subject": "Gla", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "vitamin K-dependent gamma-glutamyl carboxylase", "object_type": "GENE-Y"}, {"subject": "glutamic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "gamma-carboxylase", "object_type": "GENE-Y"}, {"subject": "gamma-carboxyglutamic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "gamma-carboxylase", "object_type": "GENE-Y"}, {"subject": "Gla", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "gamma-carboxylase", "object_type": "GENE-Y"}]}
{"text": "The thymidine monophosphate kinase (TMPK) of Mycobacterium tuberculosis (M.Â tuberculosis), which is an essential enzyme for the maintenance of the thymidine triphosphate pools, is considered an attractive target for the development of effective antibiotics against tuberculosis.", "spo_list": [{"subject": "thymidine triphosphate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "thymidine monophosphate kinase", "object_type": "GENE-Y"}, {"subject": "thymidine triphosphate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "TMPK", "object_type": "GENE-Y"}]}
{"text": "Human UDP-glucuronosyltransferase (UGT) 1A1 catalyzes the metabolism of numerous clinically and pharmacologically important compounds such as bilirubin and SN-38.", "spo_list": [{"subject": "bilirubin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Human UDP-glucuronosyltransferase (UGT) 1A1", "object_type": "GENE-Y"}, {"subject": "SN-38", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Human UDP-glucuronosyltransferase (UGT) 1A1", "object_type": "GENE-Y"}]}
{"text": "Bisulfite sequence analysis revealed that the CpG-rich region near the UGT1A1 promoter (-85 to +40) was hypermethylated (83%) in the kidney, whereas it was hypomethylated (37%) in the liver.", "spo_list": [{"subject": "CpG", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "UGT1A1 promoter", "object_type": "GENE-N"}]}
{"text": "Treatment with 5-aza-2'-deoxycytidine (5-Aza-dC), an inhibitor of DNA methylation, resulted in an increase of UGT1A1 mRNA expression in both cell types, but the increase was much larger in HK-2 cells than in HuH-7 cells.", "spo_list": [{"subject": "5-aza-2'-deoxycytidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "UGT1A1", "object_type": "GENE-Y"}, {"subject": "5-Aza-dC", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "UGT1A1", "object_type": "GENE-Y"}]}
{"text": "The transfection of an HNF1Î± expression plasmid into the HK-2 cells resulted in an increase of UGT1A1 mRNA only in the presence of 5-Aza-dC.", "spo_list": [{"subject": "5-Aza-dC", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "UGT1A1", "object_type": "GENE-Y"}]}
{"text": "Of these, only three linked single nucleotide polymorphisms (SNPs) located in the shared UGT1A-3'UTR region (rs10929303, rs1042640, rs8330) were associated with acetaminophen glucuronidation activity, with rs8330 consistently showing higher acetaminophen glucuronidation at all the tested concentrations of acetaminophen.", "spo_list": [{"subject": "acetaminophen", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT1A", "object_type": "GENE-N"}]}
{"text": "Cotransfection studies demonstrated an inhibitory effect of exon 5b containing cDNAs on acetaminophen glucuronidation by UGT1A1 and UGT1A6 cDNAs containing exon 5a.", "spo_list": [{"subject": "acetaminophen", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT1A1", "object_type": "GENE-Y"}, {"subject": "acetaminophen", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT1A6", "object_type": "GENE-Y"}]}
{"text": "L-2-hydroxyglutaric aciduria is a metabolic disorder in which L-2-hydroxyglutarate accumulates as a result of a deficiency in FAD-linked L-2-hydroxyglutarate dehydrogenase, a mitochondrial enzyme converting L-2-hydroxyglutarate to alpha-ketoglutarate.", "spo_list": [{"subject": "L-2-hydroxyglutarate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "L-2-hydroxyglutarate dehydrogenase", "object_type": "GENE-Y"}, {"subject": "L-2-hydroxyglutarate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "L-2-hydroxyglutarate dehydrogenase", "object_type": "GENE-Y"}, {"subject": "alpha-ketoglutarate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "L-2-hydroxyglutarate dehydrogenase", "object_type": "GENE-Y"}]}
{"text": "The oxidation-reduction potential of the 2-hydroxyglutarate/alpha-ketoglutarate couple is such that L-2-hydroxyglutarate could potentially be produced through the reduction of alpha-ketoglutarate by a NAD- or NADP-linked oxidoreductase.", "spo_list": [{"subject": "alpha-ketoglutarate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NAD- or NADP-linked oxidoreductase", "object_type": "GENE-N"}, {"subject": "L-2-hydroxyglutarate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "NAD- or NADP-linked oxidoreductase", "object_type": "GENE-N"}]}
{"text": "Purified mMDH catalysed the reduction of alpha-ketoglutarate to L-2-hydroxyglutarate with a catalytic efficiency that was about 10(7)-fold lower than that observed with oxaloacetate.", "spo_list": [{"subject": "alpha-ketoglutarate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "mMDH", "object_type": "GENE-Y"}, {"subject": "L-2-hydroxyglutarate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "mMDH", "object_type": "GENE-Y"}, {"subject": "oxaloacetate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE_PRODUCT-OF", "object": "mMDH", "object_type": "GENE-Y"}]}
{"text": "Both cMDH and mMDH are highly active in tissues and alpha-ketoglutarate is much more abundant than oxaloacetate and more concentrated in mitochondria than in the cytosol.", "spo_list": [{"subject": "oxaloacetate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cMDH", "object_type": "GENE-Y"}, {"subject": "oxaloacetate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE_PRODUCT-OF", "object": "mMDH", "object_type": "GENE-Y"}]}
{"text": "As a result of this, the weak activity of mMDH on alpha-ketoglutarate is sufficient to account for the amount of L-2-hydroxyglutarate that is excreted by patients deficient in FAD-linked L-2-hydroxyglutarate dehydrogenase.", "spo_list": [{"subject": "L-2-hydroxyglutarate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "L-2-hydroxyglutarate dehydrogenase", "object_type": "GENE-Y"}, {"subject": "alpha-ketoglutarate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "mMDH", "object_type": "GENE-Y"}]}
{"text": "DPEP induced dose-dependent reduction of the protein levels of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) and concomitant reduction in the production of NO and prostaglandin E(2) (PGE(2)).", "spo_list": [{"subject": "DPEP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "inducible nitric oxide synthase", "object_type": "GENE-Y"}, {"subject": "DPEP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "DPEP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "DPEP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Additionally, DPEP suppressed the production of inflammatory cytokines, including tumor necrosis factor-Î± (TNF-Î±), interleukin (IL)-1Î², and IL-6.", "spo_list": [{"subject": "DPEP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cytokines", "object_type": "GENE-N"}, {"subject": "DPEP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "tumor necrosis factor-Î±", "object_type": "GENE-Y"}, {"subject": "DPEP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF-Î±", "object_type": "GENE-Y"}, {"subject": "DPEP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-6", "object_type": "GENE-Y"}, {"subject": "DPEP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "interleukin (IL)-1Î²", "object_type": "GENE-Y"}]}
{"text": "DPEP inhibited LPS-induced phosphorylation of ERK, JNK, and p38.", "spo_list": [{"subject": "DPEP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ERK", "object_type": "GENE-N"}, {"subject": "DPEP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JNK", "object_type": "GENE-N"}, {"subject": "DPEP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38", "object_type": "GENE-N"}]}
{"text": "Furthermore, DPEP inhibited the LPS-induced phosphorylation of inhibitor ÎºB (IÎºB)-Î± and NF-ÎºB p50.", "spo_list": [{"subject": "DPEP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "inhibitor ÎºB (IÎºB)-Î±", "object_type": "GENE-Y"}, {"subject": "DPEP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "DPEP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p50", "object_type": "GENE-Y"}]}
{"text": "Taken together, the results of this study demonstrate that DPEP inhibits LPS-stimulated inflammation by blocking the NF-ÎºB and MAPK pathways in macrophages.", "spo_list": [{"subject": "DPEP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "DPEP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAPK", "object_type": "GENE-N"}]}
{"text": "Apigenin caused apoptosis via the elevation of c-Myc levels in conjunction with the phosphorylation of p38 and p53.", "spo_list": [{"subject": "Apigenin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "c-Myc", "object_type": "GENE-Y"}, {"subject": "Apigenin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "Apigenin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p53", "object_type": "GENE-Y"}]}
{"text": "In the c-Myc siRNA-transfected and apigenin-treated cells, compared with the apigenin-treated control cells, apoptosis and phosphorylation of p38 and p53 were ameliorated.", "spo_list": [{"subject": "apigenin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "apigenin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p53", "object_type": "GENE-Y"}]}
{"text": "In the presence of apigenin, diminution of p38 and p53 did not affect cell survival although apigenin activated the phosphorylation of p38 and p53 via increased c-Myc levels.", "spo_list": [{"subject": "apigenin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "apigenin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p53", "object_type": "GENE-Y"}, {"subject": "apigenin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "c-Myc", "object_type": "GENE-Y"}]}
{"text": "In conclusion, our results indicate that apigenin induces apoptosis mediated via c-Myc with concomitant phosphorylation of p53 and p38 in FRO ATC cells.", "spo_list": [{"subject": "apigenin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p53", "object_type": "GENE-Y"}, {"subject": "apigenin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p38", "object_type": "GENE-N"}]}
{"text": "Minocycline inhibits the production of inducible nitric oxide synthase in articular chondrocytes.", "spo_list": [{"subject": "Minocycline", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "inducible nitric oxide synthase", "object_type": "GENE-Y"}]}
{"text": "RESULTS: Minocycline dose dependently reduced IL-1 stimulated NO production by inhibition of the mRNA expression (IC50 = 69.9 microM) and protein synthesis (IC50 = 37.11 microM) of iNOS.", "spo_list": [{"subject": "Minocycline", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "iNOS", "object_type": "GENE-Y"}]}
{"text": "Diclofenac-Na at a concentration of 10 microM only weakly reduced nitrite accumulation and mRNA expression of iNOS.", "spo_list": [{"subject": "Diclofenac-Na", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "iNOS", "object_type": "GENE-Y"}]}
{"text": "CONCLUSION: Inhibition of iNOS in articular chondrocytes may be a new mechanism by which minocycline could exert its beneficial effects in the treatment of joint diseases.", "spo_list": [{"subject": "minocycline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "iNOS", "object_type": "GENE-Y"}]}
{"text": "Characterization of efflux transporters involved in distribution and disposition of apixaban.", "spo_list": [{"subject": "apixaban", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "efflux transporters", "object_type": "GENE-N"}]}
{"text": "In human permeability glycoprotein (P-gp)- and breast cancer resistance protein (BCRP)-cDNA-transfected cell monolayers as well as Caco-2 cell monolayers, the apparent efflux ratio of basolateral-to-apical (PcB-A) versus apical-to-basolateral permeability (PcA-B) of apixaban was >10.", "spo_list": [{"subject": "apixaban", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human permeability glycoprotein", "object_type": "GENE-N"}, {"subject": "apixaban", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-gp", "object_type": "GENE-N"}, {"subject": "apixaban", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "breast cancer resistance protein", "object_type": "GENE-Y"}, {"subject": "apixaban", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "BCRP", "object_type": "GENE-Y"}]}
{"text": "The P-gp- and BCRP-facilitated transport of apixaban was concentration- and time-dependent and did not show saturation over a wide range of concentrations (1-100 Î¼M).", "spo_list": [{"subject": "apixaban", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-gp", "object_type": "GENE-N"}, {"subject": "apixaban", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "BCRP", "object_type": "GENE-Y"}]}
{"text": "Ketoconazole decreased the P-gp-mediated apixaban efflux in Caco-2 and the P-gp-cDNA-transfected cell monolayers, but did not affect the apixaban efflux to a meaningful extent in the BCRP-cDNA-transfected cell monolayers.", "spo_list": [{"subject": "apixaban", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-gp", "object_type": "GENE-N"}, {"subject": "apixaban", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "BCRP", "object_type": "GENE-Y"}]}
{"text": "Coincubation of a P-gp inhibitor (ketoconazole or cyclosporin A) and a BCRP inhibitor (Ko134) provided more complete inhibition of apixaban efflux in Caco-2 cells than separate inhibition by individual inhibitors.", "spo_list": [{"subject": "ketoconazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P-gp", "object_type": "GENE-N"}, {"subject": "cyclosporin A", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P-gp", "object_type": "GENE-N"}, {"subject": "Ko134", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BCRP", "object_type": "GENE-Y"}]}
{"text": "Naproxen inhibited apixaban efflux in Caco-2 cells but showed only a minimal effect on apixaban transport in the BCRP-transfected cells.", "spo_list": [{"subject": "apixaban", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "BCRP", "object_type": "GENE-Y"}]}
{"text": "These results demonstrate that apixaban is a substrate for efflux transporters P-gp and BCRP, which can help explain its low brain penetration, and low fetal exposures and high milk excretion in rats.", "spo_list": [{"subject": "apixaban", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "efflux transporters", "object_type": "GENE-N"}, {"subject": "apixaban", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-gp", "object_type": "GENE-N"}, {"subject": "apixaban", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "BCRP", "object_type": "GENE-Y"}]}
{"text": "Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.", "spo_list": [{"subject": "lorglumide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "cholecystokinin", "object_type": "GENE-Y"}]}
{"text": "Derivatives of 5-(dipentylamino)-5-oxo-pentanoic acid are a new class of non-peptide cholecystokinin (CCK) antagonists.", "spo_list": [{"subject": "5-(dipentylamino)-5-oxo-pentanoic acid", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "cholecystokinin", "object_type": "GENE-Y"}, {"subject": "5-(dipentylamino)-5-oxo-pentanoic acid", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CCK", "object_type": "GENE-Y"}]}
{"text": "The most potent compound, D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid (lorglumide, CR 1409), has a great affinity for the pancreatic CCK receptors and is a competitive, specific and potent CCK antagonist on the smooth muscles of the gall bladder and ileum of the guinea pig and on the CCK-induced amylase secretion of isolated pancreatic acini.", "spo_list": [{"subject": "D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CCK receptors", "object_type": "GENE-N"}, {"subject": "lorglumide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CCK receptors", "object_type": "GENE-N"}, {"subject": "CR 1409", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CCK receptors", "object_type": "GENE-N"}, {"subject": "D,L-4-(3,4-dichlorobenzoylamino)-5-(dipentylamino)-5-oxo-pen tanoic acid", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CCK", "object_type": "GENE-Y"}, {"subject": "lorglumide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CCK", "object_type": "GENE-Y"}, {"subject": "CR 1409", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CCK", "object_type": "GENE-Y"}]}
{"text": "In vivo lorglumide antagonizes the contraction of the gall bladder of the guinea pig and of the dog provoked by i.v. CCK-8 or ceruletide (caerulein).", "spo_list": [{"subject": "lorglumide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CCK-8", "object_type": "GENE-N"}]}
{"text": "In overexpressing cell lines, OATP1B1- and OATP1B3-mediated estradiol-17Î²-glucuronide uptake and OATP2B1-mediated estrone-3-sulfate uptake were inhibited by most of the silymarin flavonolignans investigated.", "spo_list": [{"subject": "estradiol-17Î²-glucuronide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B1", "object_type": "GENE-Y"}, {"subject": "estradiol-17Î²-glucuronide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B3", "object_type": "GENE-Y"}, {"subject": "estrone-3-sulfate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP2B1", "object_type": "GENE-Y"}, {"subject": "flavonolignans", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP1B1", "object_type": "GENE-Y"}, {"subject": "flavonolignans", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP1B3", "object_type": "GENE-Y"}, {"subject": "flavonolignans", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP2B1", "object_type": "GENE-Y"}]}
{"text": "OATP1B1-, OATP1B3-, and OATP2B1-mediated substrate transport was inhibited efficiently by silymarin (IC50 values of 1.3, 2.2 and 0.3 ÂµM, respectively), silybin A (IC50 values of 9.7, 2.7 and 4.5 ÂµM, respectively), silybin B (IC50 values of 8.5, 5.0 and 0.8 ÂµM, respectively), and silychristin (IC50 values of 9.0, 36.4, and 3.6 ÂµM, respectively).", "spo_list": [{"subject": "silybin A", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP1B1", "object_type": "GENE-Y"}, {"subject": "silybin A", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP1B3", "object_type": "GENE-Y"}, {"subject": "silybin A", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP2B1", "object_type": "GENE-Y"}, {"subject": "silybin B", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP1B1", "object_type": "GENE-Y"}, {"subject": "silybin B", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP1B3", "object_type": "GENE-Y"}, {"subject": "silybin B", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP2B1", "object_type": "GENE-Y"}, {"subject": "silychristin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP1B1", "object_type": "GENE-Y"}, {"subject": "silychristin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP1B3", "object_type": "GENE-Y"}, {"subject": "silychristin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP2B1", "object_type": "GENE-Y"}]}
{"text": "Furthermore, silymarin, silybin A, and silybin B (100 ÂµM) significantly inhibited OATP-mediated estradiol-17Î²-glucuronide and rosuvastatin uptake into human hepatocytes.", "spo_list": [{"subject": "estradiol-17Î²-glucuronide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP", "object_type": "GENE-N"}, {"subject": "rosuvastatin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP", "object_type": "GENE-N"}, {"subject": "silybin A", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP", "object_type": "GENE-N"}, {"subject": "silybin B", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP", "object_type": "GENE-N"}]}
{"text": "Prokinetic effects of a new ghrelin receptor agonist TZP-101 in a rat model of postoperative ileus.", "spo_list": [{"subject": "TZP-101", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ghrelin receptor", "object_type": "GENE-Y"}]}
{"text": "The present study investigates whether TZP-101 (0.03-1 mg/kg i.v.), a synthetic ghrelin-receptor agonist, could improve gastrointestinal transit in rats with POI.", "spo_list": [{"subject": "TZP-101", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ghrelin-receptor", "object_type": "GENE-Y"}]}
{"text": "Our results demonstrate that 3% O(2) augmented proliferation of BMSC, as well as the formation of colonies in the colony-forming unit assay (CFU-A), the percentage of quiescent cells, and the expression of stemness markers Rex-1 and Oct-4, thereby suggesting an increase in the stemness of culture when exposed to hypoxia.", "spo_list": [{"subject": "O(2)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Rex-1", "object_type": "GENE-Y"}, {"subject": "O(2)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Oct-4", "object_type": "GENE-Y"}]}
{"text": "Rosiglitazone inhibits acyl-CoA synthetase activity and fatty acid partitioning to diacylglycerol and triacylglycerol via a peroxisome proliferator-activated receptor-gamma-independent mechanism in human arterial smooth muscle cells and macrophages.", "spo_list": [{"subject": "Rosiglitazone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acyl-CoA synthetase", "object_type": "GENE-N"}, {"subject": "fatty acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "acyl-CoA synthetase", "object_type": "GENE-N"}, {"subject": "diacylglycerol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "acyl-CoA synthetase", "object_type": "GENE-N"}, {"subject": "triacylglycerol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "acyl-CoA synthetase", "object_type": "GENE-N"}]}
{"text": "In addition to peroxisome proliferator-activated receptor (PPAR)-gamma, rosiglitazone can affect other targets, such as directly inhibiting recombinant long-chain acyl-CoA synthetase (ACSL)-4 activity.", "spo_list": [{"subject": "rosiglitazone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "long-chain acyl-CoA synthetase (ACSL)-4", "object_type": "GENE-Y"}]}
{"text": "Human and murine SMCs and human macrophages expressed Acsl4, and rosiglitazone inhibited Acsl activity in these cells.", "spo_list": [{"subject": "rosiglitazone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Acsl", "object_type": "GENE-N"}]}
{"text": "Conversely, murine macrophages did not express ACSL4, and rosiglitazone did not inhibit ACSL activity in these cells, nor did it affect acute fatty acid partitioning into cellular lipids.", "spo_list": [{"subject": "fatty acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ACSL", "object_type": "GENE-N"}]}
{"text": "Thus, rosiglitazone inhibits ACSL activity and fatty acid partitioning in human and murine SMCs and in human macrophages through a PPAR-gamma-independent mechanism likely to be mediated by ACSL4 inhibition.", "spo_list": [{"subject": "rosiglitazone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACSL", "object_type": "GENE-N"}, {"subject": "fatty acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ACSL", "object_type": "GENE-N"}, {"subject": "rosiglitazone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACSL4", "object_type": "GENE-N"}]}
{"text": "In the second experiment, when the ovaries were surgically removed in adult female rats, and local production of estrogens was suppressed with the aromatase inhibitor anastrozole, females fed the saccharin-sweetened yogurt consumed more energy and gained more weight than females fed the glucose-sweetened yogurt.", "spo_list": [{"subject": "anastrozole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "A number of potential mechanisms have been proposed to explain the hypotensive and anticholesterol effects, but the most common explanation is the antioxidant effects of the anthocyanins inhibition of LDL-C oxidation, which impedes atherosclerosis, an important cardiovascular risk factor.", "spo_list": [{"subject": "anthocyanins", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "LDL", "object_type": "GENE-N"}]}
{"text": "Molecular cloning of a novel diacylglycerol kinase isozyme with a pleckstrin homology domain and a C-terminal tail similar to those of the EPH family of protein-tyrosine kinases.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "diacylglycerol kinase", "object_type": "GENE-N"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "pleckstrin homology domain", "object_type": "GENE-N"}]}
{"text": "However, DGK delta lacks the EF-hand motifs (C2) and contains a long Glu- and Ser-rich insertion (317 residues), which divides the C4 region into two portions.", "spo_list": [{"subject": "Glu", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "DGK delta", "object_type": "GENE-Y"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "DGK delta", "object_type": "GENE-Y"}]}
{"text": "The enzyme activity was independent of phosphatidylserine, which is a common activator for the previously sequenced DGKs.", "spo_list": [{"subject": "phosphatidylserine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "DGKs", "object_type": "GENE-N"}]}
{"text": "Add-on therapy with the DPP-4 inhibitor sitagliptin improves glycemic control in insulin-treated Japanese patients with type 2 diabetes mellitus.", "spo_list": [{"subject": "sitagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}]}
{"text": "The hemoglobin A1c (HbA1c) of all patients improved significantly from 8.1Â±1.2% to 7.6Â±1.1% after 12 weeks of add-on therapy with sitagliptin (p<0.01), and the insulin dosage was reduced from 27.3Â±15.8 U/day to 24.5Â±16.5 U/day (p<0.001).", "spo_list": [{"subject": "sitagliptin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "hemoglobin A1c", "object_type": "GENE-Y"}, {"subject": "sitagliptin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HbA1c", "object_type": "GENE-Y"}]}
{"text": "BACKGROUND: Clinical trial data have shown that among breast cancer patients who were disease free after 5 years of adjuvant treatment with tamoxifen, further extended treatment with the nonsteroidal aromatase inhibitor letrozole reduces breast cancer recurrence.", "spo_list": [{"subject": "letrozole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "We examined the efficacy and tolerability of extended adjuvant therapy with another aromatase inhibitor, anastrozole, for 3 years among women who had completed 5 years of adjuvant therapy.", "spo_list": [{"subject": "anastrozole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "METHODS: Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 6a is an extension of ABCSG Trial 6, in which hormone receptor-positive postmenopausal patients received 5 years of adjuvant tamoxifen, with or without the aromatase inhibitor aminoglutethimide, for the first 2 years of therapy.", "spo_list": [{"subject": "aminoglutethimide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "Melatonin or silymarin also reduced OCP-induced signs of apoptosis (increased caspase-3 activity and Bax-alpha upregulation) in all the organs assayed.", "spo_list": [{"subject": "Melatonin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "caspase-3", "object_type": "GENE-Y"}, {"subject": "silymarin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "caspase-3", "object_type": "GENE-Y"}]}
{"text": "These included, biliverdin-IX alpha reductase and the sodium-dependent vitamin C transport proteins SVCT1 and SVCT2, whose expression levels were enhanced in maternal and fetal liver by melatonin treatment.", "spo_list": [{"subject": "vitamin C", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SVCT1", "object_type": "GENE-Y"}, {"subject": "vitamin C", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SVCT2", "object_type": "GENE-Y"}, {"subject": "melatonin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SVCT1", "object_type": "GENE-Y"}, {"subject": "melatonin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SVCT2", "object_type": "GENE-Y"}]}
{"text": "Artemisinic acid inhibits melanogenesis through downregulation of C/EBP Î±-dependent expression of HMG-CoA reductase gene.", "spo_list": [{"subject": "Artemisinic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "C/EBP Î±", "object_type": "GENE-Y"}, {"subject": "Artemisinic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "HMG-CoA reductase", "object_type": "GENE-Y"}]}
{"text": "The mRNA levels of microphthalmia-associated transcription factor (MITF) and its downstream genes tyrosinase, tyrosinase-related protein (TRP)-1, and TRP-2 were reduced by artemisinic acid treatment.", "spo_list": [{"subject": "artemisinic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "microphthalmia-associated transcription factor", "object_type": "GENE-Y"}, {"subject": "artemisinic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MITF", "object_type": "GENE-Y"}, {"subject": "artemisinic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "tyrosinase", "object_type": "GENE-Y"}, {"subject": "artemisinic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "tyrosinase-related protein (TRP)-1", "object_type": "GENE-Y"}, {"subject": "artemisinic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TRP-2", "object_type": "GENE-Y"}]}
{"text": "Additionally, the mRNA levels of melanogenesis-related genes (c-KIT, stem cell factor (SCF), and macrophage migration inhibitory factor (MIF)) were down-regulated by artemisinic acid.", "spo_list": [{"subject": "artemisinic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "c-KIT", "object_type": "GENE-Y"}, {"subject": "artemisinic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "stem cell factor", "object_type": "GENE-Y"}, {"subject": "artemisinic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "SCF", "object_type": "GENE-Y"}, {"subject": "artemisinic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "macrophage migration inhibitory factor", "object_type": "GENE-Y"}, {"subject": "artemisinic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MIF", "object_type": "GENE-Y"}]}
{"text": "Furthermore, cAMP production and protein kinase A (PKA) activity were suppressed by artemisinic acid.", "spo_list": [{"subject": "artemisinic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "protein kinase A", "object_type": "GENE-N"}, {"subject": "artemisinic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PKA", "object_type": "GENE-N"}]}
{"text": "Moreover, attempts to elucidate a possible mechanism underlying the artemisinic acid-mediated effects revealed that artemisinic acid regulated melanogenesis by inhibiting cholesterol synthesis through downregulation of the hydroxymethylglutaryl CoA (HMG CoA) reductase gene, which was mediated through reduced expression of the CCAAT/enhancer-binding protein (C/EBP) Î± gene.", "spo_list": [{"subject": "artemisinic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "hydroxymethylglutaryl CoA (HMG CoA) reductase", "object_type": "GENE-Y"}, {"subject": "artemisinic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CCAAT/enhancer-binding protein (C/EBP) Î±", "object_type": "GENE-Y"}]}
{"text": "Taken together, these findings indicate that the inhibition of melanogenesis by artemisinic acid occurs through reduced expression of the HMG CoA reductase gene, which is mediated by C/EBP Î± inhibition and suggest that artemisinic acid may be useful as a hyperpigmentation inhibitor.", "spo_list": [{"subject": "artemisinic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "HMG CoA reductase", "object_type": "GENE-Y"}, {"subject": "artemisinic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "C/EBP Î±", "object_type": "GENE-Y"}]}
{"text": "Monosodium urate crystals stimulate monocytes and macrophages to release IL-1beta through the NALP3 component of the inflammasome.", "spo_list": [{"subject": "Monosodium urate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-1beta", "object_type": "GENE-Y"}]}
{"text": "In plasma membranes prepared from these isolated brown fat cells by borate extraction there was a similar enrichment of activity of SSAO and of the plasma membrane marker enzyme, phosphodiesterase I. However in preparations of cell membranes made by binding the cells to polycation-coated beads, enrichment of phosphodiesterase I activity was much greater than that of SSAO.", "spo_list": [{"subject": "borate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "SSAO", "object_type": "GENE-Y"}]}
{"text": "Positive staining of mitochondria was achieved in the presence of the MAO substrate, tryptamine.", "spo_list": [{"subject": "tryptamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MAO", "object_type": "GENE-N"}]}
{"text": "Staining around the edges of the brown fat cells was observed with the SSAO substrates, tyramine and benzylamine.", "spo_list": [{"subject": "tyramine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SSAO", "object_type": "GENE-Y"}, {"subject": "benzylamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SSAO", "object_type": "GENE-Y"}]}
{"text": "Staining was largely absent when substrate was omitted or after pretreatment with the irreversible SSAO inhibitor, hydralazine and the slowly reversible inhibitor, semicarbazide.", "spo_list": [{"subject": "hydralazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SSAO", "object_type": "GENE-Y"}, {"subject": "semicarbazide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SSAO", "object_type": "GENE-Y"}]}
{"text": "Inhibitors of phosphodiesterase type 4 (PDE4) act by increasing intracellular concentrations of cyclic AMP, which has a broad range of anti-inflammatory effects on various key effector cells involved in asthma and chronic obstructive pulmonary disease (COPD).", "spo_list": [{"subject": "cyclic AMP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "phosphodiesterase type 4", "object_type": "GENE-N"}, {"subject": "cyclic AMP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PDE4", "object_type": "GENE-N"}]}
{"text": "The two main orally active PDE4 inhibitors in the late phase III of clinical development are cilomilast and roflumilast; the latter (and its active metabolite N-oxide) is more selective and potent with a superior therapeutic ratio.", "spo_list": [{"subject": "cilomilast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}, {"subject": "roflumilast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}, {"subject": "N-oxide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}]}
{"text": "Ultimately, clinicians will want to know whether PDE4 inhibitors are anything more than expensive \"designer\" theophylline, the archetypal non-selective phosphodiesterase inhibitor.", "spo_list": [{"subject": "theophylline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase", "object_type": "GENE-N"}]}
{"text": "The cyclooxygenase-2 inhibitor, diflunisal, is used in the clinic for its anti-inflammatory activity.", "spo_list": [{"subject": "diflunisal", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}]}
{"text": "About 99% of a dose of diflunisal is unavailable for reaction with the target enzyme, because diflunisal strongly binds to human serum albumin (HSA).", "spo_list": [{"subject": "diflunisal", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human serum albumin", "object_type": "GENE-Y"}, {"subject": "diflunisal", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "HSA", "object_type": "GENE-Y"}]}
{"text": "To reduce the binding affinity of diflunisal to albumin, we designed and synthesized the prodrug acetyldiflunisal.", "spo_list": [{"subject": "diflunisal", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "albumin", "object_type": "GENE-Y"}]}
{"text": "The crystal structure of HSA complexed with fatty acid and acetyldiflunisal revealed that acetyldiflunisal binds to the IIA subdomain and that upon binding, it acetylates lysine 199.", "spo_list": [{"subject": "fatty acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "HSA", "object_type": "GENE-Y"}, {"subject": "acetyldiflunisal", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "HSA", "object_type": "GENE-Y"}, {"subject": "acetyldiflunisal", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "IIA subdomain", "object_type": "GENE-N"}, {"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "IIA subdomain", "object_type": "GENE-N"}]}
{"text": "For some, pharmacologic inhibitors are available, including sorafenib for BRAF, farnesyltransferase inhibitors for NRAS, PD-0325901 for mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, rapamycin analogues for mammalian target of rapamycin, and agents that inhibit either vascular endothelial growth factor or its receptors.", "spo_list": [{"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BRAF", "object_type": "GENE-Y"}, {"subject": "PD-0325901", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mitogen-activated protein kinase", "object_type": "GENE-N"}, {"subject": "PD-0325901", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "extracellular signal-regulated kinase kinase", "object_type": "GENE-N"}, {"subject": "rapamycin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mammalian target of rapamycin", "object_type": "GENE-Y"}]}
{"text": "The IC50-values obtained for the inhibition of lipopolysaccharide (LPS)-induced release of prostaglandin E2 (PGE2) reflecting cyclooxygenase (COX)-2-mediated PGE2 release were 47 microg/ml and 0.6 microg/ml, for the Salix extract 1520L and rofecoxib-like research compound L745337, respectively.", "spo_list": [{"subject": "PGE2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclooxygenase (COX)-2", "object_type": "GENE-Y"}]}
{"text": "Our results indicate that Salix extract 1520L inhibits COX-2-mediated PGE2 release through compounds other than salicin or salicylate.", "spo_list": [{"subject": "PGE2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Effects of fenofibrate, a PPAR-Î± ligand, on the haemodynamics of glycerol-induced renal failure in rats.", "spo_list": [{"subject": "fenofibrate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PPAR-Î±", "object_type": "GENE-Y"}]}
{"text": "For AII and ET1, MAP was also increased for the fenofibrate group but not in a dose-dependent fashion.", "spo_list": [{"subject": "fenofibrate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AII", "object_type": "GENE-Y"}, {"subject": "fenofibrate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ET1", "object_type": "GENE-Y"}]}
{"text": "The selective 5-HT reuptake inhibitors paroxetine, indalpine and fluvoxamine displayed a high affinity for the 5-HT transporter, whereas the norepinephrine reuptake inhibitor desipramine had a high affinity for the norepinephrine transporter.", "spo_list": [{"subject": "paroxetine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT transporter", "object_type": "GENE-Y"}, {"subject": "indalpine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT transporter", "object_type": "GENE-Y"}, {"subject": "fluvoxamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT transporter", "object_type": "GENE-Y"}, {"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "norepinephrine transporter", "object_type": "GENE-Y"}]}
{"text": "Interestingly, venlafaxine, a dual 5-HT and norepinephrine reuptake inhibitor, displayed only a moderate affinity for the 5-HT transporter (Ki = 74 nM) and a very low affinity for the norepinephrine transporter (Ki = 1.26 microM).", "spo_list": [{"subject": "venlafaxine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT transporter", "object_type": "GENE-Y"}]}
{"text": "Furthermore, tPA induced rapid tyrosine phosphorylation on the beta subunit of LRP-1, which was followed by the activation of Mek1 and its downstream Erk-1 and -2.", "spo_list": [{"subject": "tyrosine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "LRP-1", "object_type": "GENE-Y"}]}
{"text": "Collectively, these results suggest that besides its classical proteolytic activity, tPA acts as a cytokine that binds to the cell membrane receptor LRP-1, induces its tyrosine phosphorylation, and triggers intracellular signal transduction, thereby inducing specific gene expression in renal interstitial fibroblasts.", "spo_list": [{"subject": "tyrosine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "LRP-1", "object_type": "GENE-Y"}]}
{"text": "PURPOSE: To characterise further the previously observed cytochrome P450 3A4 (CYP3A4) interaction of the dual orexin receptor antagonist almorexant.", "spo_list": [{"subject": "almorexant", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "orexin receptor", "object_type": "GENE-N"}]}
{"text": "The pathogenesis of PDE is unknown, but an alteration in the binding of pyridoxal 5-phosphate to glutamic acid decarboxylase (GAD) has been postulated in patients with PDE.", "spo_list": [{"subject": "pyridoxal 5-phosphate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glutamic acid decarboxylas", "object_type": "GENE-N"}, {"subject": "pyridoxal 5-phosphate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD", "object_type": "GENE-N"}]}
{"text": "TNF-alpha plasma peak concentrations were significantly higher in the LPS compared to the DON+LPS group (94.3Â±17.2ng/mL vs. 79.2Â±15.7ng/mL) while IL-6 climaxed earlier in the latter group (3h p.i. vs. 2h p.i.).", "spo_list": [{"subject": "DON", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TNF-alpha", "object_type": "GENE-Y"}, {"subject": "DON", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-6", "object_type": "GENE-Y"}]}
{"text": "From the tested clinical-chemical plasma characteristics the total bilirubin concentration and the ASAT activity were strongly elevated by the LPS infusion and additionally increased and decreased by DON, respectively.", "spo_list": [{"subject": "DON", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ASAT", "object_type": "GENE-N"}]}
{"text": "Therefore, in the present studies, animals were rendered tolerant to the delta-opioid receptor-selective agonist [D-Pen2,D-Pen5]enkephalin (DPDPE), and receptor binding activities were measured.", "spo_list": [{"subject": "[D-Pen2,D-Pen5]enkephalin", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "delta-opioid receptor", "object_type": "GENE-Y"}, {"subject": "DPDPE", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "delta-opioid receptor", "object_type": "GENE-Y"}]}
{"text": "When delta-receptor binding was determined by using [3H]DPDPE, a 40-50% decrease in binding in the midbrain and cortex, and 25-35% decrease in binding in the striatum were observed after 3 or 4 days of DPDPE treatment.", "spo_list": [{"subject": "[3H]DPDPE", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "delta-receptor", "object_type": "GENE-Y"}, {"subject": "DPDPE", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "delta-receptor", "object_type": "GENE-Y"}]}
{"text": "To our surprise, when mu-receptor binding was determined by using [3H]Tyr-D-Ala-Gly-MePhe-Gly-ol (DAMGO), a 10-15% decrease in binding was also observed in the midbrain and cortex after 4 days of DPDPE treatment.", "spo_list": [{"subject": "[3H]Tyr-D-Ala-Gly-MePhe-Gly-ol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mu-receptor", "object_type": "GENE-Y"}, {"subject": "DAMGO", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mu-receptor", "object_type": "GENE-Y"}, {"subject": "DPDPE", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mu-receptor", "object_type": "GENE-Y"}]}
{"text": "Our conclusion is that chronic DPDPE treatment preferentially reduces delta-opioid receptor binding activity.", "spo_list": [{"subject": "DPDPE", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "delta-opioid receptor", "object_type": "GENE-Y"}]}
{"text": "Several inhibitors of Lp-PLA(2) have been described, including darapladib, which is currently in phase 3 clinical development for the treatment of atherosclerosis.", "spo_list": [{"subject": "darapladib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Lp-PLA(2)", "object_type": "GENE-Y"}]}
{"text": "We show that both darapladib and a novel class of structurally distinct carbamate inhibitors inactivate Lp-PLA(2) in mouse tissues and human cell lines with high selectivity.", "spo_list": [{"subject": "darapladib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Lp-PLA(2)", "object_type": "GENE-Y"}, {"subject": "carbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Lp-PLA(2)", "object_type": "GENE-Y"}]}
{"text": "Rabbit aldo-keto reductase (AKR) 1B19 is an ortholog of human aldose reductase-like protein (ARLP), AKR1B10, showing 86% amino acid sequence identity.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "human aldose reductase-like protein", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ARLP", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "AKR1B10", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Rabbit aldo-keto reductase (AKR) 1B19", "object_type": "GENE-Y"}]}
{"text": "In this study, we found that the reductase activity of AKR1B19 was activated to about 5-fold immediately after the addition of 10 Î¼M SH-reagents (p-chloromercuriphenylsulfonic acid and p-chloromercuribenzoic acid) in the absence or presence of NADPH.", "spo_list": [{"subject": "SH", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "reductase", "object_type": "GENE-N"}, {"subject": "SH", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AKR1B19", "object_type": "GENE-Y"}, {"subject": "p-chloromercuriphenylsulfonic acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "reductase", "object_type": "GENE-N"}, {"subject": "p-chloromercuriphenylsulfonic acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AKR1B19", "object_type": "GENE-Y"}, {"subject": "p-chloromercuribenzoic acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "reductase", "object_type": "GENE-N"}, {"subject": "p-chloromercuribenzoic acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AKR1B19", "object_type": "GENE-Y"}]}
{"text": "In addition, a maximum of 3-fold activation of AKR1B19 was induced by incubation with glutathione disulfide (GSSG) for 1h.", "spo_list": [{"subject": "glutathione disulfide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AKR1B19", "object_type": "GENE-Y"}, {"subject": "GSSG", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AKR1B19", "object_type": "GENE-Y"}]}
{"text": "The activation was abolished by the C299S mutation of AKR1B19, and the glutathionylated Cys299 was identified by mass spectrometry analysis.", "spo_list": [{"subject": "Cys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "AKR1B19", "object_type": "GENE-Y"}, {"subject": "Cys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "C299S", "object_type": "GENE-N"}]}
{"text": "Thus, AKR1B10 may be modulated by cellular ratio of GSSG/glutathione and more efficiently act as a detoxifying enzyme for the cytotoxic aldehyde under oxidatively stressed conditions.", "spo_list": [{"subject": "aldehyde", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AKR1B10", "object_type": "GENE-Y"}]}
{"text": "Furthermore, such an activity alteration by GSSG was not detected in AKR1B10 and rat ARLPs, suggesting the presence of a GSSG-binding site near Cys299 in AKR1B19.", "spo_list": [{"subject": "Cys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "AKR1B19", "object_type": "GENE-Y"}, {"subject": "GSSG", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AKR1B19", "object_type": "GENE-Y"}]}
{"text": "In pigeons trained to discriminate 1.7 mg/kg dezocine from saline, a series of opioids with activity at the mu opioid receptor substituted completely for the dezocine stimulus with a rank order of potency similar to that obtained in other assays sensitive to the effects of mu agonists (i.e., fentanyl >[-]-cyclazocine >buprenorphine = butorphanol >l-methadone >nalbuphine >[-]-metazocine >morphine).", "spo_list": [{"subject": "fentanyl", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mu opioid receptor", "object_type": "GENE-N"}, {"subject": "[-]-cyclazocine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mu opioid receptor", "object_type": "GENE-N"}, {"subject": "buprenorphine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mu opioid receptor", "object_type": "GENE-N"}, {"subject": "butorphanol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mu opioid receptor", "object_type": "GENE-N"}, {"subject": "l-methadone", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mu opioid receptor", "object_type": "GENE-N"}, {"subject": "nalbuphine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mu opioid receptor", "object_type": "GENE-N"}, {"subject": "[-]-metazocine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mu opioid receptor", "object_type": "GENE-N"}, {"subject": "morphine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mu opioid receptor", "object_type": "GENE-N"}]}
{"text": "Here, we report that genistein at physiologically relevant concentrations (0.1-10 Î¼M) significantly inhibited thrombin-induced increase in endothelial monolayer permeability.", "spo_list": [{"subject": "genistein", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thrombin", "object_type": "GENE-Y"}]}
{"text": "Genistein also reduced the formation of stress fibers by thrombin and suppressed thrombin-induced phosphorylation of myosin light chain (MLC) on Ser(19)/Thr(18) in endothelial cells (ECs).", "spo_list": [{"subject": "Genistein", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thrombin", "object_type": "GENE-Y"}, {"subject": "Genistein", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thrombin", "object_type": "GENE-Y"}, {"subject": "Genistein", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "myosin light chain", "object_type": "GENE-N"}, {"subject": "Genistein", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MLC", "object_type": "GENE-N"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "myosin light chain", "object_type": "GENE-N"}, {"subject": "Thr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "myosin light chain", "object_type": "GENE-N"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MLC", "object_type": "GENE-N"}, {"subject": "Thr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MLC", "object_type": "GENE-N"}]}
{"text": "Furthermore, thrombin diminished cAMP production in ECs, which were prevented by treatment with genistein.", "spo_list": [{"subject": "genistein", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thrombin", "object_type": "GENE-Y"}]}
{"text": "Design and synthesis of novel 2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one derivatives as telomerase inhibitors.", "spo_list": [{"subject": "2-methyl-4,5-substitutedbenzo[f]-3,3a,4,5-tetrahydro-pyrazolo[1,5-d][1,4]oxazepin-8(7H)-one", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "telomerase", "object_type": "GENE-N"}]}
{"text": "We have previously shown that retinoic acid (RA) synthesized by the retinaldehyde dehydrogenase 2 (RALDH2) is required in forebrain development.", "spo_list": [{"subject": "retinoic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "retinaldehyde dehydrogenase 2", "object_type": "GENE-Y"}, {"subject": "RA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "retinaldehyde dehydrogenase 2", "object_type": "GENE-Y"}, {"subject": "retinoic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "RALDH2", "object_type": "GENE-Y"}, {"subject": "RA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "RALDH2", "object_type": "GENE-Y"}]}
{"text": "It has been previously shown that retinoids act mainly on cell proliferation and survival in the ventral forebrain by regulating SHH and FGF8 signaling.", "spo_list": [{"subject": "retinoids", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SHH", "object_type": "GENE-Y"}, {"subject": "retinoids", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "FGF8", "object_type": "GENE-Y"}]}
{"text": "The binding of FHA-HIS was inhibited on 35-79% of the platelets by the histamine H1 receptor antagonists diphenhydramine and clemastine.", "spo_list": [{"subject": "diphenhydramine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1 receptor", "object_type": "GENE-Y"}, {"subject": "clemastine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1 receptor", "object_type": "GENE-Y"}, {"subject": "diphenhydramine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FHA", "object_type": "GENE-Y"}, {"subject": "clemastine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FHA", "object_type": "GENE-Y"}]}
{"text": "The histamine H2 receptor antagonist cimetidine blocked the FHA-HIS binding on 14-37% of the platelets.", "spo_list": [{"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H2 receptor", "object_type": "GENE-Y"}, {"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FHA", "object_type": "GENE-Y"}]}
{"text": "Imatinib mesilate (STI-571, Gleevec(TM)), an inhibitior of bcr-abl TK, which was primarily designed to treat chronic myeloid leukemia is also an inhibitor of c-kit receptor TK, and is currently the drug of choice for the therapy of metastatic gastrointestinal stromal tumors (GISTs), which frequently express constitutively activated forms of the c-kit-receptor.", "spo_list": [{"subject": "Imatinib mesilate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "bcr", "object_type": "GENE-Y"}, {"subject": "STI-571", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "bcr", "object_type": "GENE-Y"}, {"subject": "Gleevec", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "bcr", "object_type": "GENE-Y"}, {"subject": "Imatinib mesilate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "abl", "object_type": "GENE-Y"}, {"subject": "STI-571", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "abl", "object_type": "GENE-Y"}, {"subject": "Gleevec", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "abl", "object_type": "GENE-Y"}, {"subject": "Imatinib mesilate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TK", "object_type": "GENE-N"}, {"subject": "STI-571", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TK", "object_type": "GENE-N"}, {"subject": "Gleevec", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TK", "object_type": "GENE-N"}, {"subject": "Imatinib mesilate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "c-kit", "object_type": "GENE-Y"}, {"subject": "STI-571", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "c-kit", "object_type": "GENE-Y"}, {"subject": "Gleevec", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "c-kit", "object_type": "GENE-Y"}, {"subject": "Imatinib mesilate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "receptor TK", "object_type": "GENE-N"}, {"subject": "STI-571", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "receptor TK", "object_type": "GENE-N"}, {"subject": "Gleevec", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "receptor TK", "object_type": "GENE-N"}]}
{"text": "Other promising new drugs currently under preclinical and clinical evaluation, are VEGFR2 inhibitor PTK787/ZK 222584, thalidomide, farnesyl transferase inhibitor R115777 (tipifarnib, Zarnestra(TM)), matrix metalloproteinase inhibitors, proteasome inhibitor bortezomib (Velcade(TM)), mammalian target of rapamycin (mTOR) inhibitors, cyclooxygenase-2 (COX-2) inhibitors, platelet derived growth factor receptor (PDGF-R) inhibitors, protein kinase C (PKC) inhibitors, mitogen-activated protein kinase kinase (MEK) 1/2 inhibitors, Rous sarcoma virus transforming oncogene (SRC) kinase inhibitors, histondeacetylase (HDAC) inhibitors, small hypoxia-inducible factor (HIF) inhibitors, aurora kinase inhibitors, hedgehog inhibitors, and TGF-beta signalling inhibitors.", "spo_list": [{"subject": "thalidomide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR2", "object_type": "GENE-Y"}, {"subject": "R115777", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "farnesyl transferase", "object_type": "GENE-Y"}, {"subject": "tipifarnib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "farnesyl transferase", "object_type": "GENE-Y"}, {"subject": "Zarnestra", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "farnesyl transferase", "object_type": "GENE-Y"}, {"subject": "bortezomib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "proteasome", "object_type": "GENE-N"}, {"subject": "Velcade", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "proteasome", "object_type": "GENE-N"}]}
{"text": "The sibutramine group showed significant retardation in gastric emptying of solids (P = .03), reduced maximum tolerated volume (P = .03), and increased postprandial peptide YY compared with the placebo group.", "spo_list": [{"subject": "sibutramine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "peptide YY", "object_type": "GENE-Y"}]}
{"text": "CONCLUSIONS: Weight reduction with sibutramine is associated with altered gastric functions and increased peptide YY and is significantly associated with SLC6A4 genotype.", "spo_list": [{"subject": "sibutramine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "peptide YY", "object_type": "GENE-Y"}]}
{"text": "A significant decrease of aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase (LDH) activities and glutathione (GSH) levels and an increase of malondialdehyde (MDA) quantity was observed after CCl4 and PC administration alone.", "spo_list": [{"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aspartate aminotransferase", "object_type": "GENE-Y"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "alanine aminotransferase", "object_type": "GENE-N"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "lactate dehydrogenase", "object_type": "GENE-N"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "LDH", "object_type": "GENE-N"}]}
{"text": "In the CCl4 hepatotoxicity model, pre-treatment with PSM or silymarin resulted in significantly increased activities of ethylmorphine-N-demethylase and aniline 4-hydroxylase activity and cytochrome P450, compared to the CCl4 only group.", "spo_list": [{"subject": "silymarin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ethylmorphine-N-demethylase", "object_type": "GENE-N"}, {"subject": "silymarin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "aniline 4-hydroxylase", "object_type": "GENE-N"}, {"subject": "silymarin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "cytochrome P450", "object_type": "GENE-N"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "cytochrome P450", "object_type": "GENE-N"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "aniline 4-hydroxylase", "object_type": "GENE-N"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ethylmorphine-N-demethylase", "object_type": "GENE-N"}]}
{"text": "Binding of (-)-[3H]-CGP12177 at two sites in recombinant human beta 1-adrenoceptors and interaction with beta-blockers.", "spo_list": [{"subject": "(-)-[3H]-CGP12177", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human beta 1-adrenoceptors", "object_type": "GENE-Y"}]}
{"text": "To verify the hypothesis that the non-conventional partial agonist (-)-CGP12177 binds at two beta(1)-adrenoceptor sites, human beta(1)-adrenoceptors, expressed in CHO cells, were labelled with (-)-[(3)H]-CGP12177.", "spo_list": [{"subject": "(-)-CGP12177", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta(1)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "(-)-CGP12177", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human beta(1)-adrenoceptors", "object_type": "GENE-Y"}, {"subject": "(-)-[(3)H]-CGP12177", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta(1)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "(-)-[(3)H]-CGP12177", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human beta(1)-adrenoceptors", "object_type": "GENE-Y"}, {"subject": "(-)-CGP12177", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(1)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "(-)-CGP12177", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta(1)-adrenoceptors", "object_type": "GENE-Y"}]}
{"text": "(-)-[(3)H]-CGP12177 dissociated from the beta(1)-adrenoceptors with a fast component (k(off)=0.45 min(-1)), consistent with the L-site, and a slow component (k(off)=0.017-0.033 min(-1)), consistent with the H-site.", "spo_list": [{"subject": "(-)-[(3)H]-CGP12177", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta(1)-adrenoceptors", "object_type": "GENE-Y"}]}
{"text": "We conclude that (-)-[(3)H]-CGP12177 binds at two sites in the recombinant beta(1)-adrenoceptor.", "spo_list": [{"subject": "(-)-[(3)H]-CGP12177", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta(1)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Results presented here show that bile acids are physiological ligands for the farnesoid X receptor (FXR), an orphan nuclear receptor.", "spo_list": [{"subject": "bile acids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "farnesoid X receptor", "object_type": "GENE-Y"}, {"subject": "bile acids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "FXR", "object_type": "GENE-Y"}, {"subject": "bile acids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "orphan nuclear receptor", "object_type": "GENE-N"}]}
{"text": "When bound to bile acids, FXR repressed transcription of the gene encoding cholesterol 7alpha-hydroxylase, which is the rate-limiting enzyme in bile acid synthesis, and activated the gene encoding intestinal bile acid-binding protein, which is a candidate bile acid transporter.", "spo_list": [{"subject": "bile acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cholesterol 7alpha-hydroxylase", "object_type": "GENE-Y"}]}
{"text": "The 5-lipoxygenase inhibitor diethylcarbamazine (DEC), administered before the PAF injection, inhibited the elevations of PAP and all LTs.", "spo_list": [{"subject": "diethylcarbamazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-lipoxygenase", "object_type": "GENE-Y"}, {"subject": "DEC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-lipoxygenase", "object_type": "GENE-Y"}, {"subject": "LTs", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "5-lipoxygenase", "object_type": "GENE-Y"}]}
{"text": "The 5-lipoxygenase-activating protein inhibitor MK886, administered orally 2-6 h before perfusion, also inhibited the pressor response to PAF as well as LT production, as did DEC.", "spo_list": [{"subject": "MK886", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-lipoxygenase-activating protein", "object_type": "GENE-Y"}]}
{"text": "We conclude that 1) the extended pulmonary hypertension induced by PAF was caused mainly by prolonged activation of 5-lipoxygenase with LTC4 production, 2) the relative overall lung clearance of LTB4, LTD4, and LTE4 was slower than that of LTC4, and 3) LTB4, LTD4, and LTE4 had no appreciable pressor effect.", "spo_list": [{"subject": "LTC4", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "5-lipoxygenase", "object_type": "GENE-Y"}]}
{"text": "The presence of steroid hormones most probably causes the degradation of the Tat2 permease and impairment of tryptophan import.", "spo_list": [{"subject": "steroid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Tat2", "object_type": "GENE-N"}]}
{"text": "The contribution of ERalpha and ERbeta to ER-mediated immune modulation was studied in delayed type hypersensitivity (DTH) and in experimental arthritis METHODS: ER-mediated suppression of rat adjuvant arthritis (AA) was studied using ethinyl-estradiol (EE) and a selective ERbeta agonist (ERB-79).", "spo_list": [{"subject": "ERB-79", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERbeta", "object_type": "GENE-Y"}]}
{"text": "Next, effects of ER agonists (ethinyl-estradiol, an ERalpha selective agonist (ERA-63) and a selective ERbeta agonist (ERB-79) on the development of a tetanus toxoid (TT)-specific delayed type hypersensitivity response in wild type (WT) and in ERalpha- or ERbeta-deficient mice were investigated.", "spo_list": [{"subject": "ethinyl-estradiol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ER", "object_type": "GENE-Y"}, {"subject": "ERA-63", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERalpha", "object_type": "GENE-Y"}, {"subject": "ERB-79", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERbeta", "object_type": "GENE-Y"}]}
{"text": "The selective ERbeta agonist ERB-79 had no effect on arthritis symptoms in this model.", "spo_list": [{"subject": "ERB-79", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERbeta", "object_type": "GENE-Y"}]}
{"text": "In the TT-specific DTH model, EE and the selective ERalpha agonist ERA-63 suppressed the TT-specific swelling response in WT and ERbetaKO mice but not in ERalphaKO mice.", "spo_list": [{"subject": "ERA-63", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERalpha", "object_type": "GENE-Y"}]}
{"text": "As seen in the AA model, the selective ERbeta agonist ERB-79 did not suppress inflammation.", "spo_list": [{"subject": "ERB-79", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERbeta", "object_type": "GENE-Y"}]}
{"text": "At PND35, the medial prefrontal cortex (mPFC) of rats given MPH showed 55% greater immunoreactivity (-ir) for the catecholamine marker tyrosine hydroxylase (TH), 60% more Nissl-stained cells, and 40% less norepinephrine transporter (NET)-ir density.", "spo_list": [{"subject": "MPH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TH", "object_type": "GENE-Y"}, {"subject": "MPH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "norepinephrine transporter", "object_type": "GENE-Y"}, {"subject": "MPH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NET", "object_type": "GENE-Y"}, {"subject": "MPH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "tyrosine hydroxylase", "object_type": "GENE-Y"}]}
{"text": "In hippocampal dentate gyrus, MPH-receiving rats showed a 51% decrease in NET-ir density and a 61% expanded distribution of the new-cell marker PSA-NCAM (polysialylated form of neural cell adhesion molecule).", "spo_list": [{"subject": "MPH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NET", "object_type": "GENE-Y"}, {"subject": "MPH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NCAM", "object_type": "GENE-Y"}, {"subject": "MPH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "neural cell adhesion molecule", "object_type": "GENE-Y"}]}
{"text": "In medial striatum, TH-ir decreased by 21%, and in hypothalamus neuropeptide Y-ir increased by 10% in MPH-exposed rats.", "spo_list": [{"subject": "MPH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TH", "object_type": "GENE-Y"}, {"subject": "MPH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "neuropeptide Y", "object_type": "GENE-Y"}]}
{"text": "Menthol, popularly known for its cooling effect, activates TRPM8--a cold-activated thermoTRP ion channel.", "spo_list": [{"subject": "Menthol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRPM8", "object_type": "GENE-Y"}, {"subject": "Menthol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "thermoTRP ion channel", "object_type": "GENE-N"}]}
{"text": "However, human physiological studies demonstrate a paradoxical role of menthol in modulation of warm sensation, and here, we show that menthol also activates heat-activated TRPV3.", "spo_list": [{"subject": "menthol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRPV3", "object_type": "GENE-Y"}]}
{"text": "We further show that menthol inhibits TRPA1, potentially explaining the use of menthol as an analgesic.", "spo_list": [{"subject": "menthol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TRPA1", "object_type": "GENE-Y"}]}
{"text": "Similar to menthol, both camphor and cinnamaldehyde (initially reported to be specific activators of TRPV3 and TRPA1, respectively) also modulate other thermoTRPs.", "spo_list": [{"subject": "menthol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRPV3", "object_type": "GENE-Y"}, {"subject": "camphor", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRPV3", "object_type": "GENE-Y"}, {"subject": "cinnamaldehyde", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRPV3", "object_type": "GENE-Y"}, {"subject": "menthol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRPA1", "object_type": "GENE-Y"}, {"subject": "camphor", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRPA1", "object_type": "GENE-Y"}, {"subject": "cinnamaldehyde", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRPA1", "object_type": "GENE-Y"}]}
{"text": "AMPK activators metformin and AICAR partly prevented the cell cycle block, oxidative stress and apoptosis induced by compound C. The small interfering RNA (siRNA) targeting of human AMPK mimicked compound C-induced G(2)/M cell cycle arrest, but failed to induce oxidative stress and apoptosis in U251 glioma cells.", "spo_list": [{"subject": "metformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "AICAR", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}]}
{"text": "The results showed that Pb(2+) significantly induced cardiotoxicity and heart failure as evidenced by increase cardiac enzymes, lactate dehydrogenase and creatine kinase and changes in histopathology in vivo.", "spo_list": [{"subject": "Pb(2+)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "lactate dehydrogenase", "object_type": "GENE-N"}, {"subject": "Pb(2+)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "creatine kinase", "object_type": "GENE-N"}]}
{"text": "In addition, Pb(2+) treatment induced Î²-MHC and BNP whereas inhibited Î±-MHC mRNA and protein levels in vivo in a dose-dependent manner.", "spo_list": [{"subject": "Pb(2+)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î²-MHC", "object_type": "GENE-N"}, {"subject": "Pb(2+)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "BNP", "object_type": "GENE-Y"}, {"subject": "Pb(2+)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Î±-MHC", "object_type": "GENE-N"}]}
{"text": "In contrast, at the in vitro level, Pb(2+) treatment induced both Î²-MHC and Î±-MHC mRNA levels in time- and dose-dependent manner.", "spo_list": [{"subject": "Pb(2+)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î²-MHC", "object_type": "GENE-N"}, {"subject": "Pb(2+)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î±-MHC", "object_type": "GENE-N"}]}
{"text": "The direct evidence for the involvement of CYP1A1 in the induction of cardiotoxicity by Pb(2+) was evidenced by the ability of AhR antagonist, resveratrol, to significantly inhibit the Pb(2+)-modulated effect on Î²-MHC and Î±-MHC mRNAs.", "spo_list": [{"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "AhR", "object_type": "GENE-Y"}, {"subject": "Pb(2+)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î²-MHC", "object_type": "GENE-N"}, {"subject": "Pb(2+)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î±-MHC", "object_type": "GENE-N"}, {"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Î²-MHC", "object_type": "GENE-N"}, {"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Î±-MHC", "object_type": "GENE-N"}]}
{"text": "Rev1 stably interacts with Rad5 (a central component of the template switching pathway) via the C-terminal region of Rev1 and the N-terminal region of Rad5.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Rev1", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Rad5", "object_type": "GENE-Y"}]}
{"text": "Deletion analysis revealed that the C-terminal 21-amino acid sequence of Rev1 is uniquely required for its interaction with Rad5 and is essential for its non-catalytic function.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Rev1", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Rev1", "object_type": "GENE-Y"}]}
{"text": "Deletion analysis additionally implicated a C-terminal region of Rev1 in its negative regulation.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Rev1", "object_type": "GENE-Y"}]}
{"text": "Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.", "spo_list": [{"subject": "Cabozantinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MET", "object_type": "GENE-Y"}, {"subject": "Cabozantinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR2", "object_type": "GENE-Y"}, {"subject": "XL184", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MET", "object_type": "GENE-Y"}, {"subject": "XL184", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR2", "object_type": "GENE-Y"}]}
{"text": "Cabozantinib (XL184) is a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a number of other receptor tyrosine kinases that have also been implicated in tumor pathobiology, including RET, KIT, AXL, and FLT3.", "spo_list": [{"subject": "Cabozantinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "XL184", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "Cabozantinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MET", "object_type": "GENE-Y"}, {"subject": "XL184", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MET", "object_type": "GENE-Y"}, {"subject": "Cabozantinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGF receptor 2", "object_type": "GENE-Y"}, {"subject": "XL184", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGF receptor 2", "object_type": "GENE-Y"}, {"subject": "Cabozantinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR2", "object_type": "GENE-Y"}, {"subject": "XL184", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR2", "object_type": "GENE-Y"}, {"subject": "Cabozantinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "receptor tyrosine kinases", "object_type": "GENE-N"}, {"subject": "XL184", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "receptor tyrosine kinases", "object_type": "GENE-N"}, {"subject": "Cabozantinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RET", "object_type": "GENE-Y"}, {"subject": "Cabozantinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "KIT", "object_type": "GENE-Y"}, {"subject": "Cabozantinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AXL", "object_type": "GENE-Y"}, {"subject": "Cabozantinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FLT3", "object_type": "GENE-Y"}, {"subject": "XL184", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RET", "object_type": "GENE-Y"}, {"subject": "XL184", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "KIT", "object_type": "GENE-Y"}, {"subject": "XL184", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AXL", "object_type": "GENE-Y"}, {"subject": "XL184", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FLT3", "object_type": "GENE-Y"}]}
{"text": "Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant reductions in cell invasion in vitro.", "spo_list": [{"subject": "cabozantinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MET", "object_type": "GENE-Y"}, {"subject": "cabozantinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR2", "object_type": "GENE-Y"}]}
{"text": "Importantly, treatment with cabozantinib did not increase lung tumor burden in an experimental model of metastasis, which has been observed with inhibitors of VEGF signaling that do not target MET.", "spo_list": [{"subject": "cabozantinib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "VEGF", "object_type": "GENE-Y"}]}
{"text": "Collectively, these data suggest that cabozantinib is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.", "spo_list": [{"subject": "cabozantinib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MET", "object_type": "GENE-Y"}, {"subject": "cabozantinib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "VEGFR", "object_type": "GENE-N"}]}
{"text": "When menadione was omitted from the diet, however, 4HPR-dosed animals had elevated prothrombin times.", "spo_list": [{"subject": "4HPR", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "prothrombin", "object_type": "GENE-Y"}]}
{"text": "In the high-dose ROAc group, there was a twofold increase in prothrombin times but only after prolonged dosing.", "spo_list": [{"subject": "ROAc", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "prothrombin", "object_type": "GENE-Y"}]}
{"text": "The order of effect was 4HPR greater than ROAc greater than 13cisRA, with increases in prothrombin times correlating with increases in hemorrhagic deaths.", "spo_list": [{"subject": "4HPR", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "prothrombin", "object_type": "GENE-Y"}, {"subject": "ROAc", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "prothrombin", "object_type": "GENE-Y"}, {"subject": "13cisRA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "prothrombin", "object_type": "GENE-Y"}]}
{"text": "13cisRA and ROAc, but not 4HPR, caused a dose-dependent reduction in plasma osteocalcin, an effect that correlated with retinoid-induced bone effects.", "spo_list": [{"subject": "13cisRA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "osteocalcin", "object_type": "GENE-Y"}, {"subject": "ROAc", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "osteocalcin", "object_type": "GENE-Y"}, {"subject": "4HPR", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "osteocalcin", "object_type": "GENE-Y"}]}
{"text": "In contrast, serum alkaline phosphatase was elevated in animals dosed with 13cisRA or 4HPR but not in those dose with ROAc.", "spo_list": [{"subject": "13cisRA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "alkaline phosphatase", "object_type": "GENE-N"}, {"subject": "4HPR", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "alkaline phosphatase", "object_type": "GENE-N"}]}
{"text": "The cytotoxic effect of Î²-eudesmol on HL60 cells was associated with apoptosis, which was characterized by the presence of DNA fragmentation. Î²-eudesmol-induced apoptosis was accompanied by cleavage of caspase-3, caspase-9, and poly (ADP-ribose) polymerase; downregulation of Bcl-2 expression; release of cytochrome c from mitochondria; and decrease in mitochondrial membrane potential (MMP).", "spo_list": [{"subject": "Î²-eudesmol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Bcl-2", "object_type": "GENE-Y"}, {"subject": "Î²-eudesmol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytochrome c", "object_type": "GENE-Y"}]}
{"text": "Activation of c-Jun N-terminal kinases (JNK) mitogen-activated protein kinases was observed in Î²-eudesmol-treated HL60 cells, and the inhibitor of JNK blocked the Î²-eudesmol-induced apoptosis, downregulation of Bcl-2, and the loss of MMP.", "spo_list": [{"subject": "Î²-eudesmol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "c-Jun N-terminal kinases", "object_type": "GENE-N"}, {"subject": "Î²-eudesmol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "JNK", "object_type": "GENE-N"}, {"subject": "Î²-eudesmol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "mitogen-activated protein kinases", "object_type": "GENE-N"}]}
{"text": "PbAc increased the activities of lactate dehydrogenase and NADP-malic enzyme, whereas it decreased malate and glucose-6-phosphate dehydrogenase, glucose-6-phosphatase, fructose-1, 6-bisphosphatase, and BBM enzyme activities.", "spo_list": [{"subject": "PbAc", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "lactate dehydrogenase", "object_type": "GENE-N"}, {"subject": "PbAc", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NADP-malic enzyme", "object_type": "GENE-N"}, {"subject": "PbAc", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "glucose-6-phosphatase", "object_type": "GENE-Y"}, {"subject": "PbAc", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "fructose-1, 6-bisphosphatase", "object_type": "GENE-N"}]}
{"text": "PbAc caused oxidant/antioxidant imbalances as reflected by increased lipid peroxidation and decreased activities of superoxide dismutase, glutathione peroxidase, and catalase.", "spo_list": [{"subject": "PbAc", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "superoxide dismutase", "object_type": "GENE-N"}, {"subject": "PbAc", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "glutathione peroxidase", "object_type": "GENE-N"}, {"subject": "PbAc", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "catalase", "object_type": "GENE-Y"}]}
{"text": "Inhibition of angiogenesis and invasion by DMBT is mediated by downregulation of VEGF and MMP-9 through Akt pathway in MDA-MB-231 breast cancer cells.", "spo_list": [{"subject": "DMBT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}]}
{"text": "Gelatin zymography showed that DMBT inhibited secretion and activity of MMP-9.", "spo_list": [{"subject": "DMBT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-9", "object_type": "GENE-Y"}]}
{"text": "Western blotting demonstrated that DMBT effectively suppressed the expression of VEGF, p-VEGFR-2, p-EGFR, and p-Akt.", "spo_list": [{"subject": "DMBT", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "VEGF", "object_type": "GENE-N"}, {"subject": "DMBT", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "p-VEGFR-2", "object_type": "GENE-Y"}, {"subject": "DMBT", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "p-EGFR", "object_type": "GENE-Y"}, {"subject": "DMBT", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "p-Akt", "object_type": "GENE-N"}]}
{"text": "These results suggested that DMBT could inhibit invasion and angiogenesis by downregulation of VEGFand MMP-9, resulting from the inhibition of Akt pathway.", "spo_list": [{"subject": "DMBT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}]}
{"text": "Nitric oxide (NO*), generated by nitric oxide synthase (NOS II) from immunostimulated cells during infection, plays an important role in host immune defense against microbial invasion.", "spo_list": [{"subject": "Nitric oxide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "nitric oxide synthase", "object_type": "GENE-N"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "nitric oxide synthase", "object_type": "GENE-N"}, {"subject": "Nitric oxide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "NOS II", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "NOS II", "object_type": "GENE-Y"}]}
{"text": "Stable expression of NOS II was assessed by measuring nitrite accumulation in media every 2 days.", "spo_list": [{"subject": "nitrite", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "NOS II", "object_type": "GENE-Y"}]}
{"text": "By day 10, endothelial cells on Gelfoam were found to secrete NO* at a rate exceeding 1.0 microM/h/10(6) cells, concomitant with an enhanced level of NOS II activity.", "spo_list": [{"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "NOS II", "object_type": "GENE-Y"}]}
{"text": "Argininosuccinate synthetase, a key enzyme in the metabolism of l-citrulline to l-arginine, increased as well, perhaps in response to dimunition of the intracellular arginine pool corresponding to the observed high output of NO*.", "spo_list": [{"subject": "l-citrulline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Argininosuccinate synthetase", "object_type": "GENE-Y"}, {"subject": "l-arginine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Argininosuccinate synthetase", "object_type": "GENE-Y"}]}
{"text": "Rescue of this impaired extinction consolidation/retrieval was achieved with d-cycloserine (N-methly-d-aspartate partial agonist) or MS-275 (histone deacetylase (HDAC) inhibitor), applied after extinction training.", "spo_list": [{"subject": "MS-275", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "histone deacetylase", "object_type": "GENE-N"}, {"subject": "MS-275", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC", "object_type": "GENE-N"}]}
{"text": "Rescue of both impaired extinction acquisition and deficient extinction consolidation/retrieval was achieved with prior extinction training administration of valproic acid (a GABAergic enhancer and HDAC inhibitor) or AMN082 [metabotropic glutamate receptor 7 (mGlu7) agonist], while MS-275 or PEPA (AMPA receptor potentiator) failed to affect extinction acquisition in S1 mice.", "spo_list": [{"subject": "valproic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC", "object_type": "GENE-N"}, {"subject": "AMN082", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "metabotropic glutamate receptor 7", "object_type": "GENE-Y"}, {"subject": "AMN082", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mGlu7", "object_type": "GENE-Y"}, {"subject": "MS-275", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPA receptor", "object_type": "GENE-N"}, {"subject": "PEPA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPA receptor", "object_type": "GENE-N"}]}
{"text": "AID initiates somatic hypermutation and class switch recombination (CSR) by deaminating cytosine to uracil in specific immunoglobulin (Ig) gene regions.", "spo_list": [{"subject": "cytosine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AID", "object_type": "GENE-Y"}, {"subject": "uracil", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AID", "object_type": "GENE-Y"}]}
{"text": "Moreover, we demonstrate that release of AID from nucleoli is dependent on its C-terminal motif.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "AID", "object_type": "GENE-Y"}]}
{"text": "Our findings suggest that directional nucleolar transit is important for the physiological function of AID and demonstrate that nuclear/nucleolar import and DNA cytosine deamination together define the biological activity of AID.", "spo_list": [{"subject": "cytosine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AID", "object_type": "GENE-Y"}]}
{"text": "Leukotriene D4 induces cognitive impairment through enhancement of CysLTâ R-mediated amyloid-Î² generation in mice.", "spo_list": [{"subject": "Leukotriene D4", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CysLTâ R", "object_type": "GENE-Y"}, {"subject": "Leukotriene D4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "amyloid-Î²", "object_type": "GENE-Y"}]}
{"text": "The results demonstrated that intracerebral infusions of LTD4 (1 ng/mouse) produced memory impairment as determined by Morris water maze test and Y-maze test in mice, and caused the accumulation of AÎ²1-40 and AÎ²1-42 in the hippocampus and cortex through increased activity of Î²- and Î³-secretases accompanied with increased expression of amyloid precursor protein (APP).", "spo_list": [{"subject": "LTD4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AÎ²1-40", "object_type": "GENE-Y"}, {"subject": "LTD4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AÎ²1-42", "object_type": "GENE-Y"}, {"subject": "LTD4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "amyloid precursor protein", "object_type": "GENE-Y"}, {"subject": "LTD4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "APP", "object_type": "GENE-Y"}]}
{"text": "LTD4 also induced expression of cysteinyl leukotriene receptor 1 (CysLT(1)R) and NF-ÎºB p65 in the hippocampus and cortex.", "spo_list": [{"subject": "LTD4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cysteinyl leukotriene receptor 1", "object_type": "GENE-Y"}, {"subject": "LTD4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CysLT(1)R", "object_type": "GENE-Y"}, {"subject": "LTD4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "LTD4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p65", "object_type": "GENE-Y"}]}
{"text": "Pretreatment with pranlukast (1.5 ng/mouse, intracerebroventricularly), a CysLT(1)R antagonist, blocked LTD4-induced amyloidogenesis, memory deficits.", "spo_list": [{"subject": "pranlukast", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CysLT(1)R", "object_type": "GENE-Y"}]}
{"text": "Moreover, LTD4-induced increases in CysLT(1)R and NF-ÎºB p65 in the brain were also attenuated by pranlukast.", "spo_list": [{"subject": "LTD4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CysLT(1)R", "object_type": "GENE-Y"}, {"subject": "LTD4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "LTD4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p65", "object_type": "GENE-Y"}, {"subject": "pranlukast", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CysLT(1)R", "object_type": "GENE-Y"}, {"subject": "pranlukast", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "pranlukast", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "p65", "object_type": "GENE-Y"}]}
{"text": "These results suggest that LTD4 increases AÎ² peptide burden via activation of CysLT(1)R, which further affects APP levels and activity of Î²- and Î³-secretases via the NF-ÎºB pathway.", "spo_list": [{"subject": "LTD4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AÎ² peptide", "object_type": "GENE-Y"}, {"subject": "LTD4", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CysLT(1)R", "object_type": "GENE-Y"}]}
{"text": "Pyridoxal 5'-phosphate (PLP) stimulation of erythrocyte alanine and aspartate aminotransferase (EALT, EAST) activities is a frequently used functional measure of vitamin B-6 status.", "spo_list": [{"subject": "Pyridoxal 5'-phosphate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "EALT", "object_type": "GENE-N"}, {"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "EALT", "object_type": "GENE-N"}, {"subject": "Pyridoxal 5'-phosphate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "EAST", "object_type": "GENE-Y"}, {"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "EAST", "object_type": "GENE-Y"}]}
{"text": "The antiaggregating effect of clopidogrel is attributed to an irreversible inhibition of ADP binding to a purinergic receptor present at the platelet surface.", "spo_list": [{"subject": "ADP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "purinergic receptor", "object_type": "GENE-N"}, {"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "purinergic receptor", "object_type": "GENE-N"}]}
{"text": "These results demonstrate that this receptor corresponds to the previously called \"P2t\" platelet receptor and show that the active metabolite of clopidogrel binds in a covalent manner to this receptor, thus explaining how it blocks the aggregating effect of ADP on platelets.", "spo_list": [{"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "P2t", "object_type": "GENE-Y"}, {"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "platelet receptor", "object_type": "GENE-N"}, {"subject": "ADP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "P2t", "object_type": "GENE-Y"}, {"subject": "ADP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "platelet receptor", "object_type": "GENE-N"}]}
{"text": "Doxycycline was shown to decrease cerebral MMP-9 activities and angiogenesis induced by vascular endothelial growth factor (VEGF).", "spo_list": [{"subject": "Doxycycline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-9", "object_type": "GENE-Y"}, {"subject": "Doxycycline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "vascular endothelial growth factor", "object_type": "GENE-Y"}, {"subject": "Doxycycline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGF", "object_type": "GENE-Y"}]}
{"text": "Our results have shown that MMP-9 messenger ribonucleic acid (mRNA) expression was inhibited by doxycycline starting at 10 mg/kg/day (P<0.02).", "spo_list": [{"subject": "doxycycline", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MMP-9", "object_type": "GENE-Y"}]}
{"text": "Minocycline showed more potent inhibition on MMP-9 mRNA expression, starting at 1 (P<0.005) and further at more than 30 (P<0.001) mg/kg/day.", "spo_list": [{"subject": "Minocycline", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MMP-9", "object_type": "GENE-Y"}]}
{"text": "At the enzymatic activity level, doxycycline started to suppress MMP-9 activity at 5 mg/kg/day (P<0.001), while minocycline had an effect at a lower dose, 1 mg/kg/day (P<0.02).", "spo_list": [{"subject": "doxycycline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-9", "object_type": "GENE-Y"}]}
{"text": "We also assessed the potential relevant signaling pathway in vitro to elucidate the mechanisms underlying the MMP-9 inhibition by tetracyclines.", "spo_list": [{"subject": "tetracyclines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-9", "object_type": "GENE-Y"}]}
{"text": "In vitro, minocycline, but not doxycycline, inhibits MMP-9, at least in part, via the extracellular signaling-related kinase 1/2 (ERK1/2)-mediated pathway.", "spo_list": [{"subject": "minocycline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-9", "object_type": "GENE-Y"}, {"subject": "doxycycline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-9", "object_type": "GENE-Y"}]}
{"text": "This study provided the evidence that the tetracyclines inhibit stimulated cerebral MMP-9 at multiple levels and are effective at very low doses, offering great potential for therapeutic use.", "spo_list": [{"subject": "tetracyclines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-9", "object_type": "GENE-Y"}]}
{"text": "Purification of nonantibiotic insulinase inhibitors from bacitracin.", "spo_list": [{"subject": "bacitracin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "insulinase", "object_type": "GENE-N"}]}
{"text": "Bacitracin is commonly used in metabolic studies as an insulinase inhibitor.", "spo_list": [{"subject": "Bacitracin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "insulinase", "object_type": "GENE-N"}]}
{"text": "Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity.", "spo_list": [{"subject": "Amitriptyline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "TrkA", "object_type": "GENE-Y"}, {"subject": "Amitriptyline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "TrkB", "object_type": "GENE-Y"}]}
{"text": "We report here that amitriptyline, an antidepressant drug, directly binds TrkA and TrkB and triggers their dimerization and activation.", "spo_list": [{"subject": "amitriptyline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "TrkA", "object_type": "GENE-Y"}, {"subject": "amitriptyline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "TrkB", "object_type": "GENE-Y"}]}
{"text": "Amitriptyline, but not any other tricyclic or selective serotonin reuptake inhibitor antidepressants, promotes TrkA autophosphorylation in primary neurons and induces neurite outgrowth in PC12 cells.", "spo_list": [{"subject": "Amitriptyline", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TrkA", "object_type": "GENE-Y"}]}
{"text": "Amitriptyline binds the extracellular domain of both TrkA and TrkB and promotes TrkA-TrkB receptor heterodimerization.", "spo_list": [{"subject": "Amitriptyline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "TrkA", "object_type": "GENE-Y"}, {"subject": "Amitriptyline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "TrkB", "object_type": "GENE-Y"}]}
{"text": "Truncation of amitriptyline binding motif on TrkA abrogates the receptor dimerization by amitriptyline.", "spo_list": [{"subject": "amitriptyline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "TrkA", "object_type": "GENE-Y"}]}
{"text": "Thus, amitriptyline acts as a TrkA and TrkB agonist and possesses marked neurotrophic activity.", "spo_list": [{"subject": "amitriptyline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "TrkA", "object_type": "GENE-Y"}, {"subject": "amitriptyline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "TrkB", "object_type": "GENE-Y"}]}
{"text": "However, AII receptor blockers differ from ACE inhibitors with respect to side effects, and induce less cough, a side effect which may be related to bradykinin or other mediators such as substance P. Within the class of AII blockers, eprosartan differs from other currently available agents in terms of chemical structure, as it is a non-biphenyl, non-tetrazole, non-peptide antagonist with a dual pharmacological mode of action.", "spo_list": [{"subject": "eprosartan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AII", "object_type": "GENE-Y"}]}
{"text": "In clinical trials, eprosartan has been demonstrated to be at least as effective in reducing blood pressure as the ACE inhibitor enalapril, and has significantly lower side effects.", "spo_list": [{"subject": "enalapril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACE", "object_type": "GENE-Y"}]}
{"text": "9-cis-retinoic acid analogues with bulky hydrophobic rings: new RXR-selective agonists.", "spo_list": [{"subject": "9-cis-retinoic acid", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "RXR", "object_type": "GENE-N"}]}
{"text": "In contrast to the pan-RAR/RXR agonistic profile of the lower homologue of 8a, compound 7 (LG100567), retinoids 8 showed selective binding and transactivation of RXR, devoid of significant RAR activation.", "spo_list": [{"subject": "LG100567", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "RXR", "object_type": "GENE-N"}, {"subject": "LG100567", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "RAR", "object_type": "GENE-N"}, {"subject": "retinoids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RXR", "object_type": "GENE-N"}, {"subject": "retinoids", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "RXR", "object_type": "GENE-N"}]}
{"text": "DNA damage is accepted as a consequence of thymidylate deprivation induced by chemotherapeutic inhibitors of thymidylate synthase (TS), but the types of damage and signaling responses remain incompletely understood.", "spo_list": [{"subject": "thymidylate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "thymidylate synthase", "object_type": "GENE-Y"}, {"subject": "thymidylate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "TS", "object_type": "GENE-Y"}]}
{"text": "When RAD51, which is a central component of HR, was depleted by siRNA cells were sensitized to raltitrexed (RTX), which specifically inhibits TS.", "spo_list": [{"subject": "RTX", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}]}
{"text": "RTX treatment also induced foci of RAD51, gamma-H2AX, phospho-Chk1, and phospho-NBS1, although the extent of co-localization with RPA2 foci varied.", "spo_list": [{"subject": "RTX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "RAD51", "object_type": "GENE-Y"}, {"subject": "RTX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "gamma-H2AX", "object_type": "GENE-Y"}, {"subject": "RTX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "phospho-Chk1", "object_type": "GENE-Y"}, {"subject": "RTX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "phospho-NBS1", "object_type": "GENE-Y"}]}
{"text": "A head-to-head comparison between insulin detemir and NPH insulin in women with type 1 diabetes showed that while foetal outcomes did not differ, fasting plasma glucose improved with insulin detemir without an increased incidence of hypoglycaemia.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-Y"}]}
{"text": "S-nitrosation of glutathione transferase P1-1 is controlled by the conformation of a dynamic active-site helix.", "spo_list": [{"subject": "S", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "glutathione transferase P1-1", "object_type": "GENE-Y"}]}
{"text": "C47 of GSTP1-1 is S-nitrosated in two steps, with the chemical step limited by a pre-equilibrium between the open and closed conformations of helix Î±2 at the active site.", "spo_list": [{"subject": "S", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GSTP1-1", "object_type": "GENE-Y"}]}
{"text": "Despite the presence of a GSNO binding site at the active site of GSTP1-1, isothermal titration calorimetry as well as nitrosation experiments using CysNO demonstrate that GSNO binding does not precede S-nitrosation of GSTP1-1.", "spo_list": [{"subject": "S", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GSTP1-1", "object_type": "GENE-Y"}]}
{"text": "A number of selective 5-HT3 antagonists have been developed including ondansetron, granisetron, tropisetron renzapride and zacopride.", "spo_list": [{"subject": "ondansetron", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT3", "object_type": "GENE-Y"}, {"subject": "granisetron", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT3", "object_type": "GENE-Y"}, {"subject": "tropisetron", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT3", "object_type": "GENE-Y"}, {"subject": "renzapride", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT3", "object_type": "GENE-Y"}, {"subject": "zacopride", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT3", "object_type": "GENE-Y"}]}
{"text": "While the substituted benzamide prokinetics (for example, metoclopramide, cisapride) also block 5-HT3 receptors in high concentrations, their prokinetic action is believed to be on the basis of their agonist effects on the putative 5-HT4 receptor.", "spo_list": [{"subject": "benzamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-HT3", "object_type": "GENE-Y"}, {"subject": "metoclopramide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-HT3", "object_type": "GENE-Y"}, {"subject": "cisapride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-HT3", "object_type": "GENE-Y"}, {"subject": "benzamide", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT4", "object_type": "GENE-Y"}, {"subject": "metoclopramide", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT4", "object_type": "GENE-Y"}, {"subject": "cisapride", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT4", "object_type": "GENE-Y"}]}
{"text": "Some 5-HT3 antagonists have 5-HT4 agonist activity (for example, renzapride, zacopride) and others do not (for example, ondansetron, granisetron), while tropisetron in high concentrations is a 5-HT4 antagonist.", "spo_list": [{"subject": "renzapride", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT3", "object_type": "GENE-Y"}, {"subject": "renzapride", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT4", "object_type": "GENE-Y"}, {"subject": "zacopride", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT3", "object_type": "GENE-Y"}, {"subject": "zacopride", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT4", "object_type": "GENE-Y"}, {"subject": "tropisetron", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT4", "object_type": "GENE-Y"}]}
{"text": "Characterization of an allosteric citalopram-binding site at the serotonin transporter.", "spo_list": [{"subject": "citalopram", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "serotonin transporter", "object_type": "GENE-Y"}]}
{"text": "In the present study we show that the dissociation rate, of [3H]S-citalopram from human SERT, is retarded by the presence of serotonin, as well as by several antidepressants, when present in the dissociation buffer.", "spo_list": [{"subject": "[3H]S-citalopram", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human SERT", "object_type": "GENE-Y"}]}
{"text": "Dissociation of [3H]S-citalopram from SERT is most potently inhibited by S-citalopram followed by R-citalopram, sertraline, serotonin and paroxetine.", "spo_list": [{"subject": "[3H]S-citalopram", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "S-citalopram", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "R-citalopram", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "sertraline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "serotonin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "paroxetine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SERT", "object_type": "GENE-Y"}]}
{"text": "Dissociation of [3H]S-citalopram from a complex with the SERT double-mutant, N208Q/N217Q, which has been suggested to be unable to self-assemble into oligomeric complexes, is retarded to an extent similar to that found with the wild-type, raising the possibility that the allosteric mechanism is mediated within a single subunit.", "spo_list": [{"subject": "[3H]S-citalopram", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "[3H]S-citalopram", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "N208Q", "object_type": "GENE-N"}, {"subject": "[3H]S-citalopram", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "N217Q", "object_type": "GENE-N"}]}
{"text": "Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: comparison with other beta-adrenoceptor antagonists.", "spo_list": [{"subject": "Betaxolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta(1)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "Betaxolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Na(+) channels", "object_type": "GENE-N"}]}
{"text": "Betaxolol, a beta(1)-adrenoceptor antagonist used for the treatment of glaucoma, is known to be neuroprotective in paradigms of ischaemia/excitotoxicity.", "spo_list": [{"subject": "Betaxolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta(1)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Betaxolol inhibited specific [(3)H]-batrachotoxinin-A 20-alpha-benzoate ([(3)H]-BTX-B) binding to neurotoxin site 2 in a concentration-dependent manner with an IC(50) value of 9.8 microM.", "spo_list": [{"subject": "Betaxolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "neurotoxin site 2", "object_type": "GENE-N"}, {"subject": "[(3)H]-BTX-B", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "neurotoxin site 2", "object_type": "GENE-N"}]}
{"text": "Comparison of all the beta-adrenoceptor antagonists tested revealed a potency order of propranolol>betaxolol approximately levobetaxolol>levobunolol approximately carteolol>/=timolol>atenolol.", "spo_list": [{"subject": "propranolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta-adrenoceptor", "object_type": "GENE-N"}, {"subject": "betaxolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta-adrenoceptor", "object_type": "GENE-N"}, {"subject": "levobetaxolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta-adrenoceptor", "object_type": "GENE-N"}, {"subject": "levobunolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta-adrenoceptor", "object_type": "GENE-N"}, {"subject": "carteolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta-adrenoceptor", "object_type": "GENE-N"}, {"subject": "timolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta-adrenoceptor", "object_type": "GENE-N"}, {"subject": "atenolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "None of the drugs caused a significant inhibition of [(3)H]-saxitoxin binding to neurotoxin receptor site 1, even at concentrations as high as 250 microM.", "spo_list": [{"subject": "[(3)H]-saxitoxin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "neurotoxin receptor site 1", "object_type": "GENE-N"}]}
{"text": "The ability of betaxolol to interact with neurotoxin site 2 of the Na(+) channel and inhibit Na(+) influx may have a role in its neuroprotective action in paradigms of excitotoxicity/ischaemia and in its therapeutic effect in glaucoma.", "spo_list": [{"subject": "betaxolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Na(+) channel", "object_type": "GENE-N"}]}
{"text": "COX-2 produces prostaglandins that inhibit apoptosis and stimulate angiogenesis and invasiveness.", "spo_list": [{"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "In contrast, aspirin-like nonselective NSAIDs such as sulindac and indomethacin inhibit not only the enzymatic action of the highly inducible, proinflammatory COX-2 but the constitutively expressed, cytoprotective COX-1 as well.", "spo_list": [{"subject": "aspirin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "sulindac", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "aspirin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "sulindac", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}]}
{"text": "Selective COX-2 inhibitors, such as meloxicam, celecoxib (SC-58635), and rofecoxib (MK-0966), are NSAIDs that have been modified chemically to preferentially inhibit COX-2 but not COX-1.", "spo_list": [{"subject": "meloxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "celecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "SC-58635", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "MK-0966", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "meloxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "celecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "SC-58635", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "MK-0966", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "For instance, meloxicam inhibits the growth of cultured colon cancer cells (HCA-7 and Moser-S) that express COX-2 but has no effect on HCT-116 tumor cells that do not express COX-2.", "spo_list": [{"subject": "meloxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "This effect may due to induction of apoptosis through uncoupling of oxidative phosphorylation and down-regulation of Bcl-2, as has been demonstrated for some nonselective NSAIDs, for instance, flurbiprofen.", "spo_list": [{"subject": "flurbiprofen", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Bcl-2", "object_type": "GENE-Y"}]}
{"text": "Study of the interaction between aryloxypropanolamines and Asn386 in helix VII of the human 5-hydroxytryptamine1A receptor.", "spo_list": [{"subject": "aryloxypropanolamines", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human 5-hydroxytryptamine1A", "object_type": "GENE-Y"}]}
{"text": "We studied the stereoselective interaction between aryloxypropanolamines and the human 5-hydroxytryptamine1A (5-HT1A) receptor.", "spo_list": [{"subject": "aryloxypropanolamines", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human 5-hydroxytryptamine1A (5-HT1A) receptor", "object_type": "GENE-Y"}]}
{"text": "Receptor affinities of other structurally unrelated 5-HT1A ligands were not decreased by the mutation of Asn386 to valine.", "spo_list": [{"subject": "valine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "5-HT1A", "object_type": "GENE-Y"}]}
{"text": "Both the hydroxyl and the ether oxygen atoms of the oxypropanol moiety seem to be required for binding at wild-type 5-HT1A receptors.", "spo_list": [{"subject": "hydroxyl", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "oxygen", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "oxypropanol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1A", "object_type": "GENE-Y"}]}
{"text": "These findings are in agreement with the interactions of aryloxypropanolamines with Asn386 in rat 5-HT1A receptors that we previously proposed.", "spo_list": [{"subject": "aryloxypropanolamines", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "rat 5-HT1A", "object_type": "GENE-Y"}]}
{"text": "The loss of affinity for propranolol by the Asn386Val mutation could be regained by replacement of the hydroxyl group of the ligand by a methoxy group.", "spo_list": [{"subject": "methoxy", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Asn386Val", "object_type": "GENE-N"}]}
{"text": "Methylation-specific PCR and bisulfite sequencing identified methylation of this CpG ((m)CpG) island of the glut3 gene, frequency of methylation increasing 2.5-fold with a 1.6-fold increase in DNA methyl transferase 3a concentrations noted with advancing postnatal age (PN14 vs PN3).", "spo_list": [{"subject": "CpG", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "DNA methyl transferase 3a", "object_type": "GENE-Y"}, {"subject": "(m)CpG", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "DNA methyl transferase 3a", "object_type": "GENE-Y"}]}
{"text": "5'-flanking region of glut3-luciferase reporter transient transfection in HT22 hippocampal neurons demonstrated that (m)CpGs inhibit glut3 transcription.", "spo_list": [{"subject": "(m)CpGs", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "glut3", "object_type": "GENE-Y"}]}
{"text": "Chromatin immunoprecipitation (IP) revealed that methyl-CpG binding protein 2 (Mecp2) bound the glut3-(m)CpGs.", "spo_list": [{"subject": "(m)CpGs", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glut3", "object_type": "GENE-Y"}]}
{"text": "Sequential chromatin IP uncovered the glut3-(m)CpGs to bind Mecp2 exponentially upon recruitment of Creb1 rather than histone deacetylase 1.", "spo_list": [{"subject": "(m)CpGs", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glut3", "object_type": "GENE-Y"}]}
{"text": "Co-IP and coimmunolocalization confirmed that Creb1 associated with Mecp2 and cotransfection with glut3-(m)CpG in HT22 cells enhanced glut3 transcription.", "spo_list": [{"subject": "(m)CpG", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glut3", "object_type": "GENE-Y"}]}
{"text": "Separate 5-aza-2'-deoxycytidine pretreatment or in combination with trichostatin A reduced (m)CpG and specific small interference RNAs targeting Mecp2 and Creb1 separately or together depleting Mecp2 and/or Creb1 binding of glut3-(m)CpGs reduced glut3 expression in HT22 cells.", "spo_list": [{"subject": "5-aza-2'-deoxycytidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Mecp2", "object_type": "GENE-Y"}, {"subject": "trichostatin A", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Mecp2", "object_type": "GENE-Y"}, {"subject": "5-aza-2'-deoxycytidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Creb1", "object_type": "GENE-Y"}, {"subject": "trichostatin A", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Creb1", "object_type": "GENE-Y"}]}
{"text": "Recruitment of Creb1-Mecp2 by glut3-(m)CpG contributes towards transactivation, formulating an escape from (m)CpG-induced gene suppression, and thereby promoting developmental neuronal glut3 gene transcription and expression.", "spo_list": [{"subject": "(m)CpG", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glut3", "object_type": "GENE-Y"}]}
{"text": "Here, we report the initial characterization of I3A as a protein kinase C (PKC) ligand.", "spo_list": [{"subject": "I3A", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "protein kinase C", "object_type": "GENE-N"}, {"subject": "I3A", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PKC", "object_type": "GENE-N"}]}
{"text": "I3A bound to PKC-alpha in the presence of phosphatidylserine with high affinity; however, under these assay conditions, little PKC isoform selectivity was observed.", "spo_list": [{"subject": "I3A", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PKC-alpha", "object_type": "GENE-Y"}, {"subject": "I3A", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PKC", "object_type": "GENE-N"}]}
{"text": "In intact CHO-K1 cells, I3A was able to translocate different green fluorescent protein-tagged PKC isoforms, visualized by confocal microscopy, with equal or higher potency than PMA.", "spo_list": [{"subject": "I3A", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PKC", "object_type": "GENE-N"}, {"subject": "PMA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PKC", "object_type": "GENE-N"}]}
{"text": "PKC-delta in particular showed a different pattern of translocation in response to I3A and PMA.", "spo_list": [{"subject": "I3A", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PKC-delta", "object_type": "GENE-Y"}, {"subject": "PMA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PKC-delta", "object_type": "GENE-Y"}]}
{"text": "I3A induced a higher level of secretion of the inflammatory cytokine interleukin 6 compared with PMA in the WEHI-231 cells and displayed a marked biphasic dose-response curve for the induction.", "spo_list": [{"subject": "I3A", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytokine", "object_type": "GENE-N"}, {"subject": "I3A", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "interleukin 6", "object_type": "GENE-Y"}, {"subject": "PMA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytokine", "object_type": "GENE-N"}, {"subject": "PMA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "interleukin 6", "object_type": "GENE-Y"}]}
{"text": "I3A was unable to cause the same extent of association of the C1b domain of PKC-delta with lipids, compared with PMA or the physiological regulator diacylglycerol, and was able to partially block the association induced by these agents, measured by surface plasmon resonance.", "spo_list": [{"subject": "diacylglycerol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PKC-delta", "object_type": "GENE-Y"}, {"subject": "PMA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PKC-delta", "object_type": "GENE-Y"}, {"subject": "PMA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "C1b domain", "object_type": "GENE-N"}, {"subject": "diacylglycerol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "C1b domain", "object_type": "GENE-N"}]}
{"text": "The in vitro kinase activity of PKC-alpha induced by I3A was lower than that induced by PMA.", "spo_list": [{"subject": "I3A", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PKC-alpha", "object_type": "GENE-Y"}, {"subject": "PMA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PKC-alpha", "object_type": "GENE-Y"}]}
{"text": "An amphiphile with branched poly(ethylene glycol) architecture also activated the lectin pathway but only through L-ficolin recognition.", "spo_list": [{"subject": "poly(ethylene glycol)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "lectin", "object_type": "GENE-N"}]}
{"text": "Spiro heterocycles as potential inhibitors of SIRT1: Pd/C-mediated synthesis of novel N-indolylmethyl spiroindoline-3,2'-quinazolines.", "spo_list": [{"subject": "N-indolylmethyl spiroindoline-3,2'-quinazolines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SIRT1", "object_type": "GENE-Y"}]}
{"text": "Novel N-indolylmethyl substituted spiroindoline-3,2'-quinazolines were designed as potential inhibitiors of SIRT1.", "spo_list": [{"subject": "N-indolylmethyl substituted spiroindoline-3,2'-quinazolines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SIRT1", "object_type": "GENE-Y"}]}
{"text": "Exposure of Jurkat cells to either (5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine [(+)-MK 801] or D-(-)-2-amino-5-phosphonopentanoic acid (D-AP5), two selective NMDA receptor antagonists, limited cell growth by inhibiting cell cycle progression and inducing apoptosis, whereas l-glutamate (1 microM) and NMDA (10 microM) significantly increased (137.2+/-22.0%; P<0.01) Jurkat T cell adhesion to fibronectin.", "spo_list": [{"subject": "(5S,10R)-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,b]cyclohepten-5,10-imine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NMDA receptor", "object_type": "GENE-N"}, {"subject": "(+)-MK 801", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NMDA receptor", "object_type": "GENE-N"}, {"subject": "D-(-)-2-amino-5-phosphonopentanoic acid", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NMDA receptor", "object_type": "GENE-N"}, {"subject": "D-AP5", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NMDA receptor", "object_type": "GENE-N"}]}
{"text": "Treatment with diclofenac resulted in nuclear condensation (a morphological change due to apoptosis of NSCs) 24hr after the treatment and activated caspase-3 after 6 hr, indicating that diclofenac may cause apoptosis of neuronal cells via activation of the caspase cascade.", "spo_list": [{"subject": "diclofenac", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "caspase-3", "object_type": "GENE-Y"}, {"subject": "diclofenac", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "caspase", "object_type": "GENE-N"}]}
{"text": "There was no significant difference in T-cell expression of the activation markers HLA-DR and CD25 (IL-2 receptor), or in PMA-induced production of the intracellular cytokines IFN-gamma, IL-2, IL-4, IL-5, and IL-10.", "spo_list": [{"subject": "PMA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytokines", "object_type": "GENE-N"}, {"subject": "PMA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IFN-gamma", "object_type": "GENE-Y"}, {"subject": "PMA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-2", "object_type": "GENE-Y"}, {"subject": "PMA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-4", "object_type": "GENE-Y"}, {"subject": "PMA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-5", "object_type": "GENE-Y"}, {"subject": "PMA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-10", "object_type": "GENE-Y"}]}
{"text": "METHODS: Avidin-biotin-enhanced horseradish peroxidase immunohistochemistry was used on paraffin sections of rat kidney to localize FGFR-1 through FGFR-3, whereas reverse transcriptase-polymerase chain reaction was used to examine expression of the receptor variants and also of FGF-1 through FGF-10 in cortex, outer medulla, and inner medulla.", "spo_list": [{"subject": "biotin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "horseradish peroxidase", "object_type": "GENE-Y"}]}
{"text": "Puerarin stimulates proliferation and differentiation and protects against cell death in human osteoblastic MG-63 cells via ER-dependent MEK/ERK and PI3K/Akt activation.", "spo_list": [{"subject": "Puerarin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MEK", "object_type": "GENE-N"}, {"subject": "Puerarin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ERK", "object_type": "GENE-N"}, {"subject": "Puerarin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Akt", "object_type": "GENE-N"}]}
{"text": "Puerarin promotes proliferation by altering cell cycle distribution whereas puerarin-mediated survival may be associated with up-regulation of Bcl-xL expression.", "spo_list": [{"subject": "puerarin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bcl-xL", "object_type": "GENE-Y"}]}
{"text": "Treatment with the ER antagonist ICI 182,780 abolishes the above actions of puerarin on osteoblast-derived cells.", "spo_list": [{"subject": "ICI 182,780", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ER", "object_type": "GENE-Y"}]}
{"text": "Moreover, we also demonstrate that puerarin functions at least partially through activation of MEK/ERK and PI3K/Akt signaling.", "spo_list": [{"subject": "puerarin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MEK", "object_type": "GENE-N"}, {"subject": "puerarin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PI3K", "object_type": "GENE-N"}, {"subject": "puerarin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "puerarin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ERK", "object_type": "GENE-N"}]}
{"text": "Sorafenib, which belongs chemically to a class that can be described as bis-aryl ureas, was selected for further pharmacologic characterization based on potent inhibition of Raf-1 and its favorable kinase selectivity profile.", "spo_list": [{"subject": "bis-aryl ureas", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Raf-1", "object_type": "GENE-Y"}, {"subject": "bis-aryl ureas", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "Sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Raf-1", "object_type": "GENE-Y"}, {"subject": "Sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}]}
{"text": "Further characterization showed that sorafenib suppresses both wild-type and V599E mutant B-Raf activity in vitro.", "spo_list": [{"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "V599E", "object_type": "GENE-N"}, {"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "B-Raf", "object_type": "GENE-Y"}]}
{"text": "The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey.", "spo_list": [{"subject": "THPP-1", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase 10A", "object_type": "GENE-Y"}]}
{"text": "PDE10A is highly expressed in the brain and functions to metabolically inactivate the important second messengers cAMP and cGMP.", "spo_list": [{"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PDE10A", "object_type": "GENE-Y"}, {"subject": "cGMP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PDE10A", "object_type": "GENE-Y"}]}
{"text": "Here we describe effects of a potent and orally bioavailable PDE10A inhibitor [2-(6-chloropyridin-3-yl)-4-(2-methoxyethoxy)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl](imidazo[1,5-a]pyridin-1-yl)methanone] (THPP-1) on striatal signaling pathways, in behavioral tests that predict antipsychotic potential, and assays that measure episodic-like memory in rat and executive function in rhesus monkey.", "spo_list": [{"subject": "2-(6-chloropyridin-3-yl)-4-(2-methoxyethoxy)-7,8-dihydropyrido[4,3-d]pyrimidin-6(5H)-yl](imidazo[1,5-a]pyridin-1-yl)methanone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE10A", "object_type": "GENE-Y"}, {"subject": "THPP-1", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE10A", "object_type": "GENE-Y"}]}
{"text": "THPP-1 exhibits nanomolar potency on the PDE10A enzyme, demonstrates excellent pharmacokinetic properties in multiple preclinical animal species, and is selective for PDE10A over other PDE families of enzymes.", "spo_list": [{"subject": "THPP-1", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE10A", "object_type": "GENE-Y"}, {"subject": "THPP-1", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE10A", "object_type": "GENE-Y"}]}
{"text": "THPP-1 significantly increased phosphorylation of proteins in the striatum involved in synaptic plasticity, including the a-amino-3-hydroxy-5-methylisoxazole-4-proprionic acid receptor (AMPA) GluR1 subunit, extracellular receptor kinase (ERK), and cAMP-response element binding protein (CREB).", "spo_list": [{"subject": "THPP-1", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "amino-3-hydroxy-5-methylisoxazole-4-proprionic acid receptor", "object_type": "GENE-N"}, {"subject": "THPP-1", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GluR1", "object_type": "GENE-Y"}, {"subject": "THPP-1", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "extracellular receptor kinase", "object_type": "GENE-N"}, {"subject": "THPP-1", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ERK", "object_type": "GENE-N"}, {"subject": "THPP-1", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "cAMP-response element binding protein", "object_type": "GENE-N"}, {"subject": "THPP-1", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CREB", "object_type": "GENE-N"}]}
{"text": "The cystic fibrosis transmembrane conductance regulator (CFTR) is an ion channel that conducts Cl- current.", "spo_list": [{"subject": "Cl-", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cystic fibrosis transmembrane conductance regulator", "object_type": "GENE-Y"}, {"subject": "Cl-", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CFTR", "object_type": "GENE-Y"}, {"subject": "Cl-", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ion channel", "object_type": "GENE-N"}]}
{"text": "We explored the CFTR pore by studying voltage-dependent blockade of the channel by two organic anions: glibenclamide and isethionate.", "spo_list": [{"subject": "glibenclamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CFTR", "object_type": "GENE-Y"}, {"subject": "isethionate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CFTR", "object_type": "GENE-Y"}]}
{"text": "Glibenclamide blocks CFTR from the intracellular side of the membrane with slow kinetics.", "spo_list": [{"subject": "Glibenclamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CFTR", "object_type": "GENE-Y"}]}
{"text": "This report concerns the marked up-regulation in differentiated CaCo-2 colonic epithelial cells of two key inflammatory interleukins, IL-6 and IL-8, caused by a mixture of oxysterols representative of a high cholesterol diet.", "spo_list": [{"subject": "oxysterols", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "interleukins", "object_type": "GENE-N"}, {"subject": "oxysterols", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-6", "object_type": "GENE-Y"}, {"subject": "oxysterols", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-8", "object_type": "GENE-Y"}, {"subject": "cholesterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "interleukins", "object_type": "GENE-N"}, {"subject": "cholesterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-6", "object_type": "GENE-Y"}, {"subject": "cholesterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-8", "object_type": "GENE-Y"}]}
{"text": "Oxysterol-dependent NOX1 activation, as well as interleukin synthesis, were completely prevented by Cannonau red wine extract that contains an abundant phenolic fraction, in particular phenolic acids and flavonoids.", "spo_list": [{"subject": "Oxysterol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NOX1", "object_type": "GENE-Y"}, {"subject": "Oxysterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "interleukin", "object_type": "GENE-N"}, {"subject": "phenolic acids", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NOX1", "object_type": "GENE-Y"}, {"subject": "phenolic acids", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "interleukin", "object_type": "GENE-N"}, {"subject": "flavonoids", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NOX1", "object_type": "GENE-Y"}, {"subject": "flavonoids", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "interleukin", "object_type": "GENE-N"}]}
{"text": "Conversely, cell pre-treatment with Vermentino white wine extract with smaller phenolic fraction showed only a partial NOX1 down-regulation and was ineffective in interleukin synthesis induced by dietary oxysterols.", "spo_list": [{"subject": "oxysterols", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "interleukin", "object_type": "GENE-N"}]}
{"text": "Besides this direct activity, an excess of phenolic compounds detectable in red wine, may exert an additional indirect action by blocking oxysterol-related NOX1 induction, thus totally preventing the pro-oxidant and pro-inflammatory events triggered by dietary oxysterols.", "spo_list": [{"subject": "oxysterol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NOX1", "object_type": "GENE-Y"}, {"subject": "phenolic", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NOX1", "object_type": "GENE-Y"}]}
{"text": "Alcohol dehydrogenases (ADH) participate in the biosynthetic pathway of aroma volatiles in fruit by interconverting aldehydes to alcohols and providing substrates for the formation of esters.", "spo_list": [{"subject": "aldehydes", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Alcohol dehydrogenases", "object_type": "GENE-N"}, {"subject": "alcohols", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Alcohol dehydrogenases", "object_type": "GENE-N"}, {"subject": "aldehydes", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ADH", "object_type": "GENE-N"}, {"subject": "alcohols", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ADH", "object_type": "GENE-N"}]}
{"text": "Two highly divergent ADH genes (15% identity at the amino acid level) of Cantaloupe Charentais melon (Cucumis melo var.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ADH", "object_type": "GENE-N"}]}
{"text": "Cm-ADH1 belongs to the medium-chain zinc-binding type of ADHs and is highly similar to all ADH genes expressed in fruit isolated so far.", "spo_list": [{"subject": "zinc", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ADHs", "object_type": "GENE-N"}]}
{"text": "Both Cm-ADH proteins are much more active as reductases with K (m)s 10-20 times lower for the conversion of aldehydes to alcohols than for the dehydrogenation of alcohols to aldehydes.", "spo_list": [{"subject": "alcohols", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Cm-ADH", "object_type": "GENE-N"}, {"subject": "aldehydes", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Cm-ADH", "object_type": "GENE-N"}]}
{"text": "They both show strong preference for aliphatic aldehydes but Cm-ADH1 is capable of reducing branched aldehydes such as 3-methylbutyraldehyde, whereas Cm-ADH2 cannot.", "spo_list": [{"subject": "aldehydes", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Cm-ADH1", "object_type": "GENE-N"}, {"subject": "3-methylbutyraldehyde", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Cm-ADH1", "object_type": "GENE-N"}, {"subject": "aliphatic aldehyde", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Cm-ADH1", "object_type": "GENE-N"}, {"subject": "aliphatic aldehyde", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Cm-ADH2", "object_type": "GENE-N"}]}
{"text": "Gene expression as well as total ADH activity are strongly inhibited in antisense ACC oxidase melons and in melon fruit treated with the ethylene antagonist 1-methylcyclopropene (1-MCP), indicating a positive regulation by ethylene.", "spo_list": [{"subject": "1-methylcyclopropene", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ADH", "object_type": "GENE-N"}, {"subject": "1-MCP", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ADH", "object_type": "GENE-N"}, {"subject": "ethylene", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ADH", "object_type": "GENE-N"}, {"subject": "ethylene", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ADH", "object_type": "GENE-N"}]}
{"text": "The chemoprotective activity of DHEA is attributed to its inhibitory potential for the expression of CYP1A enzymes, which are highly responsible for metabolic activation of several mutagenic and carcinogenic chemicals.", "spo_list": [{"subject": "DHEA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CYP1A", "object_type": "GENE-N"}]}
{"text": "In primary human hepatocytes, DHEA diminished the increase in CYP1A activities (7-ethoxyresorufin O-dealkylation and phenacetin O-dealkylation) and in CYP1A2 mRNA level induced by 3-methylcholanthrene, but did not alter the amount of CYP1A1 and CYP1B1 mRNA.", "spo_list": [{"subject": "DHEA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP1A", "object_type": "GENE-N"}, {"subject": "DHEA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CYP1A2", "object_type": "GENE-Y"}, {"subject": "3-methylcholanthrene", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP1A2", "object_type": "GENE-Y"}, {"subject": "7-ethoxyresorufin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP1A", "object_type": "GENE-N"}, {"subject": "O", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP1A", "object_type": "GENE-N"}]}
{"text": "The androgen receptor seemed to be involved in DHEA-mediated diminishment of CYP1A2 induction, which was attenuated in the presence of bicalutamide, the androgen receptor antagonist.", "spo_list": [{"subject": "bicalutamide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "androgen receptor", "object_type": "GENE-Y"}]}
{"text": "The hypothesis was confirmed by the results of actinomycin D-chase experiments in MCF-7 and LNCaP cells, displaying that the degradation rates of CYP1A2 mRNA were significantly higher in the cells exposed to DHEA.", "spo_list": [{"subject": "DHEA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CYP1A2", "object_type": "GENE-Y"}]}
{"text": "Fingolimod (FTY720), a novel drug approved for the treatment of relapsing-remitting multiple sclerosis, activates different sphingosine-1-phosphate receptor (S1PR) subtypes.", "spo_list": [{"subject": "Fingolimod", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "sphingosine-1-phosphate receptor", "object_type": "GENE-N"}, {"subject": "Fingolimod", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "S1PR", "object_type": "GENE-N"}, {"subject": "FTY720", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "sphingosine-1-phosphate receptor", "object_type": "GENE-N"}, {"subject": "FTY720", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "S1PR", "object_type": "GENE-N"}]}
{"text": "Neuroprotection was attenuated by pertussis toxin, and inhibited by the selective type-1 S1PR (S1P1R) antagonist, W146, and by inhibitors of the mitogen associated protein kinase (MAPK) and the phosphatidylinositol-3-kinase (PtdIns-3-K) pathways.", "spo_list": [{"subject": "W146", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "S1P1R", "object_type": "GENE-Y"}, {"subject": "W146", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "type-1 S1PR", "object_type": "GENE-Y"}]}
{"text": "Discovery of novel cannabinoid receptor ligands by a virtual screening approach: further development of 2,4,6-trisubstituted 1,3,5-triazines as CB2 agonists.", "spo_list": [{"subject": "2,4,6-trisubstituted 1,3,5-triazines", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "CB2", "object_type": "GENE-Y"}]}
{"text": "One of the CB2 agonists, N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine (19, -logEC(50)=7.5, E(max)=255%) was selected for further development.", "spo_list": [{"subject": "N-cyclopentyl-4-ethoxy-6-(4-methylpiperidin-1-yl)-1,3,5-triazin-2-amine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "CB2", "object_type": "GENE-Y"}]}
{"text": "As far as we are aware, the compound's 1,3,5-triazine scaffold represents a new core structure for CB2 agonists.", "spo_list": [{"subject": "1,3,5-triazine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "CB2", "object_type": "GENE-Y"}]}
{"text": "Both types of granules contain catechol oxidase that catalyzes oxidative cross-linking of L-DOPA.", "spo_list": [{"subject": "L-DOPA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "catechol oxidase", "object_type": "GENE-N"}]}
{"text": "Nitrogen-containing bisphosphonates induce apoptosis of hematopoietic tumor cells via inhibition of Ras signaling pathways and Bim-mediated activation of the intrinsic apoptotic pathway.", "spo_list": [{"subject": "Nitrogen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Ras", "object_type": "GENE-N"}, {"subject": "bisphosphonates", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Ras", "object_type": "GENE-N"}, {"subject": "Nitrogen", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Bim", "object_type": "GENE-Y"}, {"subject": "bisphosphonates", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Bim", "object_type": "GENE-Y"}]}
{"text": "Nitrogen-containing bisphosphonates (N-BPs) induce apoptosis in tumor cells by inhibiting the prenylation of small G-proteins.", "spo_list": [{"subject": "Nitrogen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "G-proteins", "object_type": "GENE-N"}, {"subject": "bisphosphonates", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "G-proteins", "object_type": "GENE-N"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "G-proteins", "object_type": "GENE-N"}, {"subject": "BPs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "G-proteins", "object_type": "GENE-N"}]}
{"text": "Furthermore, N-BPs decreased the levels of phosphorylated extracellular signal-regulated kinase (ERK) and mTOR via suppression of Ras prenylation and enhanced Bim expression.", "spo_list": [{"subject": "BPs", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "phosphorylated extracellular signal-regulated kinase", "object_type": "GENE-N"}, {"subject": "BPs", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "mTOR", "object_type": "GENE-Y"}, {"subject": "BPs", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ERK", "object_type": "GENE-N"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "phosphorylated extracellular signal-regulated kinase", "object_type": "GENE-N"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ERK", "object_type": "GENE-N"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "mTOR", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Ras", "object_type": "GENE-N"}, {"subject": "BPs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Ras", "object_type": "GENE-N"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bim", "object_type": "GENE-Y"}, {"subject": "BPs", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bim", "object_type": "GENE-Y"}]}
{"text": "The present results indicated that N-BPs induce apoptosis by decreasing the mitochondrial transmembrane potential, increasing the activation of caspase-9 and caspase-3, and enhancing Bim expression through inhibition of the Ras/MEK/ERK and Ras/mTOR pathways.", "spo_list": [{"subject": "BPs", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "caspase-9", "object_type": "GENE-Y"}, {"subject": "BPs", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "caspase-3", "object_type": "GENE-Y"}, {"subject": "BPs", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bim", "object_type": "GENE-Y"}, {"subject": "BPs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Ras", "object_type": "GENE-N"}, {"subject": "BPs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MEK", "object_type": "GENE-N"}, {"subject": "BPs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ERK", "object_type": "GENE-N"}, {"subject": "BPs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Ras", "object_type": "GENE-N"}, {"subject": "BPs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "caspase-9", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "caspase-3", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bim", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Ras", "object_type": "GENE-N"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MEK", "object_type": "GENE-N"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ERK", "object_type": "GENE-N"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Ras", "object_type": "GENE-N"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}]}
{"text": "In vitro inhibition of diacylglycerol acyltransferase by prenylflavonoids from Sophora flavescens.", "spo_list": [{"subject": "prenylflavonoids", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "diacylglycerol acyltransferase", "object_type": "GENE-Y"}]}
{"text": "Four prenylflavonoids, kurarinone ( 1), a chalcone of 1, kuraridin ( 2), kurarinol ( 3), kushenol H ( 4) and kushenol K ( 5) isolated from the roots of Sophora flavescens were investigated for their inhibitory effects on diacylglycerol acyltransferase (DGAT).", "spo_list": [{"subject": "prenylflavonoids", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "diacylglycerol acyltransferase", "object_type": "GENE-Y"}, {"subject": "kurarinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "diacylglycerol acyltransferase", "object_type": "GENE-Y"}, {"subject": "chalcone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "diacylglycerol acyltransferase", "object_type": "GENE-Y"}, {"subject": "kuraridin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "diacylglycerol acyltransferase", "object_type": "GENE-Y"}, {"subject": "kurarinol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "diacylglycerol acyltransferase", "object_type": "GENE-Y"}, {"subject": "kushenol H", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "diacylglycerol acyltransferase", "object_type": "GENE-Y"}, {"subject": "kushenol K", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "diacylglycerol acyltransferase", "object_type": "GENE-Y"}, {"subject": "prenylflavonoids", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DGAT", "object_type": "GENE-Y"}, {"subject": "kurarinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DGAT", "object_type": "GENE-Y"}, {"subject": "chalcone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DGAT", "object_type": "GENE-Y"}, {"subject": "kuraridin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DGAT", "object_type": "GENE-Y"}, {"subject": "kurarinol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DGAT", "object_type": "GENE-Y"}, {"subject": "kushenol H", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DGAT", "object_type": "GENE-Y"}, {"subject": "kushenol K", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DGAT", "object_type": "GENE-Y"}]}
{"text": "The flavonoids inhibited DGAT activity in a dose-dependent manner with IC50 values of 10.9 microM ( 1), 9.8 microM ( 2), 8.6 microM ( 3), 142.0 microM ( 4) and 250 microM ( 5).", "spo_list": [{"subject": "flavonoids", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DGAT", "object_type": "GENE-Y"}]}
{"text": "These data suggest that the lavandulyl side chain and the position of the hydroxy group are important for high DGAT inhibitory activity.", "spo_list": [{"subject": "lavandulyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DGAT", "object_type": "GENE-Y"}, {"subject": "hydroxy", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DGAT", "object_type": "GENE-Y"}]}
{"text": "Bradykinetic alcohol dehydrogenases make yeast fitter for growth in the presence of allyl alcohol.", "spo_list": [{"subject": "allyl alcohol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "alcohol dehydrogenases", "object_type": "GENE-N"}]}
{"text": "Previous studies showed that fitter yeast (Saccharomyces cerevisiae) that can grow by fermenting glucose in the presence of allyl alcohol, which is oxidized by alcohol dehydrogenase I (ADH1) to toxic acrolein, had mutations in the ADH1 gene that led to decreased ADH activity.", "spo_list": [{"subject": "allyl alcohol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "alcohol dehydrogenase I", "object_type": "GENE-Y"}, {"subject": "allyl alcohol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ADH1", "object_type": "GENE-Y"}, {"subject": "acrolein", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "alcohol dehydrogenase I", "object_type": "GENE-Y"}, {"subject": "acrolein", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ADH1", "object_type": "GENE-Y"}]}
{"text": "The E67Q substitution near the catalytic zinc was shown previously to increase the Michaelis constant for acetaldehyde and to decrease turnover for ethanol oxidation.", "spo_list": [{"subject": "acetaldehyde", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "E67Q", "object_type": "GENE-N"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "E67Q", "object_type": "GENE-N"}, {"subject": "zinc", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "E67Q", "object_type": "GENE-N"}]}
{"text": "Most of the spermidine and the unknown product were found in the cell incubation medium, indicating they were released from the cell. bis(Ethyl) oligoamine analogues of polyamines, such as SL-11144 and SL-11158, as well as arylamine analogues [BW-1, a bis(phenylbenzyl) 3-7-3 analogue] blocked uptake and interconversion of spermine at micromolar levels and, in the case of BW-1, acted as substrate for PAO.", "spo_list": [{"subject": "BW-1", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PAO", "object_type": "GENE-N"}]}
{"text": "SL-11158 inhibited SSAT activity with a mixed type of inhibition in which the analogue had a 70-fold higher affinity for the enzyme than the natural substrate, spermine.", "spo_list": [{"subject": "SL-11158", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SSAT", "object_type": "GENE-N"}, {"subject": "spermine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SSAT", "object_type": "GENE-N"}]}
{"text": "These findings demonstrate that puerarin successfully reverses hepatotoxicity in CCl(4)-induced HF rats via the underlying mechanisms of regulating serum enzymes and attenuating TNF-Î±/NF-ÎºB pathway for anti-inflammation response, as well as improving metabolic function in liver tissue.", "spo_list": [{"subject": "puerarin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TNF-Î±", "object_type": "GENE-Y"}, {"subject": "puerarin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}]}
{"text": "Furthermore, the enzymatic activity of alanine aminotransferase (ALT), which converts the critical gluconeogenic amino acid alanine into pyruvate, is decreased (approximately 50%) in KLF15-/- hepatocytes.", "spo_list": [{"subject": "alanine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ALT", "object_type": "GENE-N"}, {"subject": "pyruvate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ALT", "object_type": "GENE-N"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ALT", "object_type": "GENE-N"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "alanine aminotransferase", "object_type": "GENE-N"}, {"subject": "alanine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "alanine aminotransferase", "object_type": "GENE-N"}, {"subject": "pyruvate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "alanine aminotransferase", "object_type": "GENE-N"}]}
{"text": "Injection of in vitro-transcribed RNA from this clone into Xenopus laevis oocytes results in the robust expression of homo-oligomeric cation channels that can be gated by L-glutamate (EC50 = 1.2 +/- 0.3 micron) and several other glutamate receptor agonists; rank order of potency: glutamate >> kainate > ibotenate > AMPA.", "spo_list": [{"subject": "glutamate", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "glutamate receptor", "object_type": "GENE-N"}, {"subject": "kainate", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "glutamate receptor", "object_type": "GENE-N"}, {"subject": "ibotenate", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "glutamate receptor", "object_type": "GENE-N"}, {"subject": "AMPA", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "glutamate receptor", "object_type": "GENE-N"}]}
{"text": "These currents can be blocked by the mammalian non-NMDA receptor antagonists 6,7-dinitroquinoxaline-2,3-dione, 6-cyano-7-nitroquinoxaline-2,3-dione, and 1-(4-chlorobenzoyl)piperazine-2,3-dicarboxylic acid.", "spo_list": [{"subject": "6,7-dinitroquinoxaline-2,3-dione, 6-cyano-7-nitroquinoxaline-2,3-dione, and 1-(4-chlorobenzoyl)piperazine-2,3-dicarboxylic acid", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "mammalian non-NMDA receptor", "object_type": "GENE-N"}]}
{"text": "BACKGROUND: Increasing evidence from clinical trials indicates that carvedilol, an antagonist of alpha1- and beta-adrenergic receptors (ARs), provides an effective treatment for chronic heart failure, whereas nonselective alpha1-AR blockade has an adverse outcome in this disease.", "spo_list": [{"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha1-AR", "object_type": "GENE-N"}]}
{"text": "Our results showed that the affinities of alpha1D-AR and alpha1B-AR for carvedilol are higher than that of the beta1-AR subtype, a major target in heart failure treatment.", "spo_list": [{"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha1D-AR", "object_type": "GENE-Y"}, {"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha1B-AR", "object_type": "GENE-Y"}, {"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta1-AR", "object_type": "GENE-Y"}]}
{"text": "The affinity rank order and pKi values of ARs for carvedilol were as follows: alpha1D-AR (8.9)>alpha1B-AR (8.6)>beta1-AR (8.4)>beta2-AR (8.0)>alpha1A-AR (7.9)?alpha2C-AR (5.9)>alpha2B-AR (5.5)>alpha2A-AR (5.3).", "spo_list": [{"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ARs", "object_type": "GENE-N"}, {"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha1D-AR", "object_type": "GENE-Y"}, {"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha1B-AR", "object_type": "GENE-Y"}, {"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta1-AR", "object_type": "GENE-Y"}, {"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta2-AR", "object_type": "GENE-Y"}, {"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha1A-AR", "object_type": "GENE-Y"}, {"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha2C-AR", "object_type": "GENE-Y"}, {"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha2B-AR", "object_type": "GENE-Y"}, {"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha2A-AR", "object_type": "GENE-Y"}]}
{"text": "When oscillatory alpha1B-AR and non-oscillatory alpha1A-AR were co-expressed and heteromer receptors were detected with bioluminescence resonance energy transfer and co-immunoprecipitation, carvedilol suppressed only oscillatory component of global cytosolic free calcium change.", "spo_list": [{"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "alpha1B-AR", "object_type": "GENE-Y"}]}
{"text": "CONCLUSIONS: These results indicate that in addition to beta-ARs, receptor inhibition by carvedilol is directed to alpha1-ARs, preferably to alpha1D- and alpha1B-AR-mediated signaling events, including intracellular calcium oscillations in vascular smooth muscle.", "spo_list": [{"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "beta-ARs", "object_type": "GENE-N"}, {"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "alpha1-ARs", "object_type": "GENE-N"}]}
{"text": "The kinase activity of EGFR was little inhibited by TT-B in a cell-free system.", "spo_list": [{"subject": "TT-B", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EGFR", "object_type": "GENE-Y"}, {"subject": "TT-B", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}]}
{"text": "Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives.", "spo_list": [{"subject": "roscovitine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "pyridoxal kinase", "object_type": "GENE-Y"}]}
{"text": "Pyridoxal kinase (PDXK) catalyzes the phosphorylation of pyridoxal, pyridoxamine, and pyridoxine in the presence of ATP and Zn2+.", "spo_list": [{"subject": "pyridoxal", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Pyridoxal kinase", "object_type": "GENE-Y"}, {"subject": "pyridoxamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Pyridoxal kinase", "object_type": "GENE-Y"}, {"subject": "pyridoxine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Pyridoxal kinase", "object_type": "GENE-Y"}, {"subject": "pyridoxal", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PDXK", "object_type": "GENE-Y"}, {"subject": "pyridoxamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PDXK", "object_type": "GENE-Y"}, {"subject": "pyridoxine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PDXK", "object_type": "GENE-Y"}]}
{"text": "(R)-Roscovitine (CYC202, Seliciclib) is a relatively selective inhibitor of cyclin-dependent kinases (CDKs), currently evaluated for the treatment of cancers, neurodegenerative disorders, renal diseases, and several viral infections.", "spo_list": [{"subject": "(R)-Roscovitine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclin-dependent kinases", "object_type": "GENE-N"}, {"subject": "CYC202", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclin-dependent kinases", "object_type": "GENE-N"}, {"subject": "Seliciclib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclin-dependent kinases", "object_type": "GENE-N"}, {"subject": "(R)-Roscovitine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CDKs", "object_type": "GENE-N"}, {"subject": "CYC202", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CDKs", "object_type": "GENE-N"}, {"subject": "Seliciclib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CDKs", "object_type": "GENE-N"}]}
{"text": "Affinity chromatography investigations have shown that (R)-roscovitine also interacts with PDXK.", "spo_list": [{"subject": "(R)-roscovitine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDXK", "object_type": "GENE-Y"}]}
{"text": "To understand this interaction, we determined the crystal structure of PDXK in complex with (R)-roscovitine, N6-methyl-(R)-roscovitine, and O6-(R)-roscovitine, the two latter derivatives being designed to bind to PDXK but not to CDKs.", "spo_list": [{"subject": "(R)-roscovitine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDXK", "object_type": "GENE-Y"}, {"subject": "N6-methyl-(R)-roscovitine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDXK", "object_type": "GENE-Y"}, {"subject": "O6-(R)-roscovitine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDXK", "object_type": "GENE-Y"}, {"subject": "N6-methyl-(R)-roscovitine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDXK", "object_type": "GENE-Y"}, {"subject": "O6-(R)-roscovitine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDXK", "object_type": "GENE-Y"}]}
{"text": "Structural analysis revealed that these three roscovitines bind similarly in the pyridoxal-binding site of PDXK rather than in the anticipated ATP-binding site.", "spo_list": [{"subject": "pyridoxal", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDXK", "object_type": "GENE-Y"}, {"subject": "roscovitines", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDXK", "object_type": "GENE-Y"}, {"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDXK", "object_type": "GENE-Y"}]}
{"text": "This work provides detailed structural information on the interactions between PDXK and roscovitine and analogs.", "spo_list": [{"subject": "roscovitine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDXK", "object_type": "GENE-Y"}]}
{"text": "Pre-treatment with the selective 5-HT2C receptor antagonist, SB-242084 (0.3-3 mg/kg), dose-dependently inhibited both d-fenfluramine- (3 mg/kg) and d-norfenfluramine-induced (2 mg/kg) hypophagia.", "spo_list": [{"subject": "SB-242084", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT2C", "object_type": "GENE-Y"}, {"subject": "d-fenfluramine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT2C", "object_type": "GENE-Y"}, {"subject": "d-norfenfluramine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT2C", "object_type": "GENE-Y"}]}
{"text": "In contrast, the hypophagic effect of d-fenfluramine and d-norfenfluramine was unaffected by prior treatment with the highly selective 5-HT2B receptor antagonists, SB-215505 (0.3-3 mg/kg) and RS-127445 (1-3 mg/kg) or the 5-HT2A receptor antagonists MDL 100,907 (0.003-0.03 mg/kg) and ketanserin (0.2, 0.5 mg/kg).", "spo_list": [{"subject": "SB-215505", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT2B", "object_type": "GENE-Y"}, {"subject": "RS-127445", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT2B", "object_type": "GENE-Y"}, {"subject": "MDL 100,907", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT2A", "object_type": "GENE-Y"}, {"subject": "ketanserin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT2A", "object_type": "GENE-Y"}, {"subject": "d-fenfluramine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT2B", "object_type": "GENE-Y"}, {"subject": "d-norfenfluramine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT2B", "object_type": "GENE-Y"}, {"subject": "d-fenfluramine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT2A", "object_type": "GENE-Y"}, {"subject": "d-norfenfluramine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT2A", "object_type": "GENE-Y"}]}
{"text": "In addition, the 5-HT1A receptor antagonist WAY-100635 (0.3, 1 mg/kg) and the 5-HT1B receptor antagonists GR-127935 (1, 2 mg/kg) and SB-224289 (2-10 mg/kg) did not affect d-fenfluramine-induced hypophagia.", "spo_list": [{"subject": "WAY-100635", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "GR-127935", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT1B", "object_type": "GENE-Y"}, {"subject": "SB-224289", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT1B", "object_type": "GENE-Y"}, {"subject": "d-fenfluramine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "d-fenfluramine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT1B", "object_type": "GENE-Y"}]}
{"text": "These data provide unequivocal evidence for an important role of the 5-HT2C receptor in the mediation of d-fenfluramine and d-norfenfluramine-induced hypophagia in the rat and do not support the involvement of 5-HT1A/1B/2A/2B receptors.", "spo_list": [{"subject": "d-fenfluramine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT2C", "object_type": "GENE-Y"}, {"subject": "d-norfenfluramine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT2C", "object_type": "GENE-Y"}]}
{"text": "Structure of the angiogenesis inhibitor ovalicin bound to its noncognate target, human Type 1 methionine aminopeptidase.", "spo_list": [{"subject": "ovalicin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human Type 1 methionine aminopeptidase", "object_type": "GENE-Y"}]}
{"text": "The anti-angiogenic compound fumagillin binds tightly to the Type 2 MetAPs but only weakly to Type 1.", "spo_list": [{"subject": "fumagillin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Type 2 MetAPs", "object_type": "GENE-Y"}]}
{"text": "High-affinity complexes of fumagillin and its relative ovalicin with Type 2 human MetAP have been reported.", "spo_list": [{"subject": "fumagillin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Type 2 human MetAP", "object_type": "GENE-Y"}, {"subject": "ovalicin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Type 2 human MetAP", "object_type": "GENE-Y"}]}
{"text": "Here we describe the crystallographic structure of the low-affinity complex between ovalicin and Type 1 human MetAP at 1.1 A resolution.", "spo_list": [{"subject": "ovalicin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Type 1 human MetAP", "object_type": "GENE-Y"}]}
{"text": "It has been argued that the lower affinity of ovalicin and fumagillin for the Type 1 MetAPs is due to the smaller size of their active sites relative to the Type 2 enzymes.", "spo_list": [{"subject": "ovalicin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Type 1 MetAPs", "object_type": "GENE-Y"}, {"subject": "fumagillin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Type 1 MetAPs", "object_type": "GENE-Y"}]}
{"text": "Our study demonstrated that curcumin inhibited OVA-induced increases in eosinophil count; interleukin (IL)-17A level were recovered in bronchoalveolar lavage fluid increased IL-10 level in bronchoalveolar lavage fluid.", "spo_list": [{"subject": "curcumin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "interleukin (IL)-17A", "object_type": "GENE-Y"}, {"subject": "curcumin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OVA", "object_type": "GENE-Y"}, {"subject": "curcumin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-10", "object_type": "GENE-Y"}]}
{"text": "Histological studies demonstrated that curcumin substantially inhibited OVA-induced eosinophilia in lung tissue.", "spo_list": [{"subject": "curcumin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OVA", "object_type": "GENE-Y"}]}
{"text": "The results in vivo show ovalbumin-induced significantly broke Treg/Th17 balance; curcumin treatments markedly attenuated the inflammatory in asthma model by regulating Treg/Th17 balance.", "spo_list": [{"subject": "curcumin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ovalbumin", "object_type": "GENE-Y"}]}
{"text": "Benzodiazepine receptor binding of triazolobenzodiazepines in vivo: increased receptor number with low-dose alprazolam.", "spo_list": [{"subject": "triazolobenzodiazepines", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Benzodiazepine receptor", "object_type": "GENE-N"}]}
{"text": "The apparent affinity of benzodiazepine receptors for clonazepam in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of alprazolam increased receptor number.", "spo_list": [{"subject": "clonazepam", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "benzodiazepine receptors", "object_type": "GENE-N"}, {"subject": "alprazolam", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "benzodiazepine receptors", "object_type": "GENE-N"}]}
{"text": "[3H]-RS-15385-197, a selective and high affinity radioligand for alpha 2-adrenoceptors: implications for receptor classification.", "spo_list": [{"subject": "[3H]-RS-15385-197", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 2-adrenoceptors", "object_type": "GENE-N"}]}
{"text": "1. RS-15385-197 is the most potent and selective alpha 2-adrenoceptor antagonist available.", "spo_list": [{"subject": "RS-15385-197", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha 2-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "2. The selective alpha 2-adrenoceptor antagonists, idazoxan, yohimbine, rauwolscine and WY 26703 displaced [3H]-RS-15385-197 binding to rat cerebral cortex in a simple manner with Hill slopes close to unity.", "spo_list": [{"subject": "idazoxan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha 2-adrenoceptor", "object_type": "GENE-N"}, {"subject": "yohimbine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha 2-adrenoceptor", "object_type": "GENE-N"}, {"subject": "rauwolscine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha 2-adrenoceptor", "object_type": "GENE-N"}, {"subject": "WY 26703", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha 2-adrenoceptor", "object_type": "GENE-N"}, {"subject": "[3H]-RS-15385-197", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 2-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "The affinities derived for these antagonists against [3H]-RS-15385-197 were similar to the values obtained for the displacement of [3H]-yohimbine indicating the alpha 2-adrenoceptor nature of the binding site.", "spo_list": [{"subject": "[3H]-yohimbine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 2-adrenoceptor", "object_type": "GENE-N"}, {"subject": "[3H]-RS-15385-197", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 2-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "3. alpha 2A-Adrenoceptor selective compounds, oxymetazoline and BRL 44409, showed high affinity for [3H]-RS-15385-197 binding in the human platelet and lower affinity in the neonate lung, while the alpha 2B-selective compounds, prazosin and imiloxan, showed high affinity for [3H]-RS-15385-197 binding in the neonate lung.This suggests that [3H]-RS-15385-197 labels both alpha2A- and alpha2B-adrenoceptor subtypes.4.", "spo_list": [{"subject": "oxymetazoline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 2A-Adrenoceptor", "object_type": "GENE-Y"}, {"subject": "BRL 44409", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 2A-Adrenoceptor", "object_type": "GENE-Y"}, {"subject": "[3H]-RS-15385-197", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 2A-Adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Identification of a novel benzimidazole derivative as a highly potent NPY Y5 receptor antagonist with an anti-obesity profile.", "spo_list": [{"subject": "benzimidazole", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NPY Y5 receptor", "object_type": "GENE-Y"}]}
{"text": "The results showed that oral administration of quercetin at doses of 30-60 mg/kg to hyperlipidemia rats for 14 days were highly effective in decreasing the levels of serum total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), alanine aminotransferase (ALT) and aspartate aminotransferase (AST).", "spo_list": [{"subject": "quercetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "low-density lipoprotein", "object_type": "GENE-N"}, {"subject": "quercetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "LDL", "object_type": "GENE-N"}, {"subject": "quercetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "alanine aminotransferase", "object_type": "GENE-N"}, {"subject": "quercetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ALT", "object_type": "GENE-N"}, {"subject": "quercetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "aspartate aminotransferase", "object_type": "GENE-N"}, {"subject": "quercetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "AST", "object_type": "GENE-N"}]}
{"text": "We recently showed that clones of Th1 cells, but not Th2 cells, expressed a functional beta-2-adrenergic receptor (beta2AR) and that either norepinephrine or the beta2AR agonist terbutaline stimulated this receptor to modulate the level of Th1 cytokines produced.", "spo_list": [{"subject": "terbutaline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta2AR", "object_type": "GENE-Y"}, {"subject": "norepinephrine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "beta2AR", "object_type": "GENE-Y"}]}
{"text": "In the present study, we show that norepinephrine and terbutaline stimulate the beta2AR to decrease the level of IL-2 produced by freshly isolated murine splenic naive CD4+ T cells from either Balb/C or DO11.10 transgenic mice and activated polyclonally with anti-CD3 and anti-CD28 mAbs.", "spo_list": [{"subject": "norepinephrine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "beta2AR", "object_type": "GENE-Y"}, {"subject": "terbutaline", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "beta2AR", "object_type": "GENE-Y"}, {"subject": "norepinephrine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-2", "object_type": "GENE-Y"}, {"subject": "terbutaline", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-2", "object_type": "GENE-Y"}, {"subject": "norepinephrine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CD3", "object_type": "GENE-N"}, {"subject": "terbutaline", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CD3", "object_type": "GENE-N"}, {"subject": "norepinephrine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CD28", "object_type": "GENE-Y"}]}
{"text": "HIF-2Î± is involved in blocking the effects of arsenite in activating the ATM/Chk-2 pathway and in repair of DNA damage induced by BaP.", "spo_list": [{"subject": "arsenite", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ATM", "object_type": "GENE-Y"}, {"subject": "arsenite", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Chk-2", "object_type": "GENE-Y"}]}
{"text": "HSYA was able to effectively inhibit oxidative stress mediated hepatic injury by increasing the activities of antioxidant enzymes, up regulating the expression of PPARÎ³ and MMP-2, and down regulating the expression of TGF-Î²1 and TIMP-1, and reducing Î±-SMA level.", "spo_list": [{"subject": "HSYA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PPARÎ³", "object_type": "GENE-Y"}, {"subject": "HSYA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "MMP-2", "object_type": "GENE-Y"}, {"subject": "HSYA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TGF-Î²1", "object_type": "GENE-Y"}, {"subject": "HSYA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TIMP-1", "object_type": "GENE-Y"}, {"subject": "HSYA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Î±-SMA", "object_type": "GENE-Y"}]}
{"text": "The protective effect of HSYA can be significantly attenuated by GW9662 via blocking PPARÎ³ (p<0.05 or p<0.01).", "spo_list": [{"subject": "GW9662", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PPARÎ³", "object_type": "GENE-Y"}]}
{"text": "Taken together, these results demonstrate that HSYA is able to significantly protect the liver from oxidative stress, which requires for HSYA to stimulate PPARÎ³ activity, reduce cell proliferation and suppress ECM synthesis.", "spo_list": [{"subject": "HSYA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PPARÎ³", "object_type": "GENE-Y"}]}
{"text": "An inhibitor of type B monoamine oxidase (MAO-B), (-)deprenyl (selegiline), was reported to have neuroprotective activity, but clinical trials failed to confirm it.", "spo_list": [{"subject": "(-)deprenyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "type B monoamine oxidase", "object_type": "GENE-Y"}, {"subject": "(-)deprenyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "selegiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "type B monoamine oxidase", "object_type": "GENE-Y"}, {"subject": "selegiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "Rasagiline prevented the PT in mitochondria directly and also indirectly through induction of antiapoptotic Bcl-2 and a neurotrophic factor, glial cell line-derived neurotrophic factor (GDNF).", "spo_list": [{"subject": "Rasagiline", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bcl-2", "object_type": "GENE-Y"}, {"subject": "Rasagiline", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "neurotrophic factor", "object_type": "GENE-N"}, {"subject": "Rasagiline", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "glial cell line-derived neurotrophic factor", "object_type": "GENE-Y"}, {"subject": "Rasagiline", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GDNF", "object_type": "GENE-Y"}]}
{"text": "Long-term administration of propargylamines to rats increased the activities of antioxidative enzymes superoxide dismutase (SOD) and catalase in the brain regions containing dopamine neurons.", "spo_list": [{"subject": "propargylamines", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "superoxide dismutase", "object_type": "GENE-N"}, {"subject": "propargylamines", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "SOD", "object_type": "GENE-N"}, {"subject": "propargylamines", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "catalase", "object_type": "GENE-Y"}]}
{"text": "Agonist actions of dihydroergotamine at 5-HT2B and 5-HT2C receptors and their possible relevance to antimigraine efficacy.", "spo_list": [{"subject": "dihydroergotamine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT2B", "object_type": "GENE-Y"}, {"subject": "dihydroergotamine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT2C", "object_type": "GENE-Y"}]}
{"text": "8'-OH-DHE interaction at (5-HT2BRs) was best fitted by a biphasic competition curve and displayed the highest affinity with a Ki of 5 nm.", "spo_list": [{"subject": "8'-OH-DHE", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT2BRs", "object_type": "GENE-Y"}]}
{"text": "5. Chronic exposure to 8'-OH-DHE caused a persistent agonist-mediated desensitisation of 5-HT2B, but not 5-HT2CRs.", "spo_list": [{"subject": "8'-OH-DHE", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT2B", "object_type": "GENE-Y"}]}
{"text": "These proteins, when phosphorylated, promote protein translation and RNA transcription in the nutrient-rich condition. mTOR inhibitors such as Temsirolimus (CCI779) and Everolimus (RAD001) are effective for suppressing cell growth with inhibiting mTOR kinase activity.", "spo_list": [{"subject": "Temsirolimus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}, {"subject": "CCI779", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}, {"subject": "Everolimus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}, {"subject": "RAD001", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}, {"subject": "Temsirolimus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}, {"subject": "CCI779", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}, {"subject": "Everolimus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}, {"subject": "RAD001", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}, {"subject": "Temsirolimus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "CCI779", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "Everolimus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "RAD001", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}]}
{"text": "Since they do not have inhibitory activity against mTORC2 complex, the ability of mTOR inhibition by Temsirolimus is supposed to be 40 to 50% of full inhibition in mTOR kinase.", "spo_list": [{"subject": "Temsirolimus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}, {"subject": "Temsirolimus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}, {"subject": "Temsirolimus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}]}
{"text": "Limitation of SRF was produced by the anticonvulsant BDZs (diazepam, clonazepam, nitrazepam and lorazepam) at low to mid nanomolar concentrations, by a convulsant BDZ which does not bind to high affinity BDZ receptors (Ro 5-4864) at high nanomolar concentrations and by a BDZ receptor weak partial agonist (Ro 15-1788) at micromolar concentrations.", "spo_list": [{"subject": "Ro 15-1788", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "BDZ receptor", "object_type": "GENE-N"}]}
{"text": "The limitation of SRF by diazepam was not prevented by inverse or partial agonists at the BDZ receptor, including Ro 15-1788 and the beta CCs.", "spo_list": [{"subject": "Ro 15-1788", "subject_type": "CHEMICAL", "predicate": "AGONIST-INHIBITOR", "object": "BDZ receptor", "object_type": "GENE-N"}, {"subject": "Ro 15-1788", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "BDZ receptor", "object_type": "GENE-N"}, {"subject": "beta CCs", "subject_type": "CHEMICAL", "predicate": "AGONIST-INHIBITOR", "object": "BDZ receptor", "object_type": "GENE-N"}, {"subject": "beta CCs", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "BDZ receptor", "object_type": "GENE-N"}]}
{"text": "These findings suggest that limitation of SRF was produced by binding of BDZs, but not beta CCs, to voltage-dependent sodium channels and not to high affinity central BDZ receptors, and that BDZs limit SRF by slowing recovery of sodium channels from inactivation.", "spo_list": [{"subject": "BDZs", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "voltage-dependent sodium channels", "object_type": "GENE-N"}, {"subject": "BDZs", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "sodium channels", "object_type": "GENE-N"}, {"subject": "BDZs", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "BDZ receptors", "object_type": "GENE-N"}]}
{"text": "Discovery, biological evaluation, and structure-activity and -selectivity relationships of 6'-substituted (E)-2-(benzofuran-3(2H)-ylidene)-N-methylacetamides, a novel class of potent and selective monoamine oxidase inhibitors.", "spo_list": [{"subject": "6'-substituted (E)-2-(benzofuran-3(2H)-ylidene)-N-methylacetamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase", "object_type": "GENE-N"}]}
{"text": "Here, the discovery of a new class of compounds acting as monoamine oxidase inhibitors (MAO-Is) and bearing a 6'-substituted (E)-2-(benzofuran-3(2H)-ylidene)-N-alkylacetamide skeleton is reported.", "spo_list": [{"subject": "6'-substituted (E)-2-(benzofuran-3(2H)-ylidene)-N-alkylacetamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase", "object_type": "GENE-N"}, {"subject": "6'-substituted (E)-2-(benzofuran-3(2H)-ylidene)-N-alkylacetamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO", "object_type": "GENE-N"}]}
{"text": "6'-Sulfonyloxy derivatives exhibited outstanding affinities to MAO-A (7.0 nM < IC50 < 49 nM, much higher than moclobemide) and a pronounced MAO-A/B selectivity.", "spo_list": [{"subject": "6'-Sulfonyloxy", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MAO-A", "object_type": "GENE-Y"}]}
{"text": "The corresponding 6'-benzyloxy derivatives showed potent MAO-B inhibition and inverted selectivity profile.", "spo_list": [{"subject": "6'-benzyloxy", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "In conclusion our in vitro results demonstrate that exposure to high doses of glycidamide/acrylamide - exceeding the dietary exposure of the general population by far - can induce genes with growth promoting potential like the oncogene cMYC and genes involved in the MAPK pathway.", "spo_list": [{"subject": "glycidamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cMYC", "object_type": "GENE-Y"}, {"subject": "acrylamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cMYC", "object_type": "GENE-Y"}, {"subject": "glycidamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "MAPK", "object_type": "GENE-N"}, {"subject": "acrylamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "MAPK", "object_type": "GENE-N"}]}
{"text": "New data on the pharmacology of tricyclic antidepressants (TCAs), their affinities for human cloned CNS receptors and their cytochrome P450 enzyme inhibition profiles, allow improved deductions concerning their effects and interactions and indicate which of the TCAs are the most useful.", "spo_list": [{"subject": "tricyclic", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human cloned CNS receptors", "object_type": "GENE-N"}, {"subject": "tricyclic", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cytochrome P450", "object_type": "GENE-N"}]}
{"text": "Novel electrophysiological properties of dronedarone: inhibition of human cardiac two-pore-domain potassium (K2P) channels.", "spo_list": [{"subject": "dronedarone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human cardiac two-pore-domain potassium (K2P) channels", "object_type": "GENE-N"}]}
{"text": "We hypothesized that blockade of human K(2P) channels contributes to the electrophysiological efficacy of dronedarone in AF.", "spo_list": [{"subject": "dronedarone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human K(2P) channels", "object_type": "GENE-N"}]}
{"text": "All functional human K(2P) channels were screened for dronedarone sensitivity, revealing significant and concentration-dependent inhibition of cardiac K(2P)2.1 (TREK1; IC(50) = 26.7 muM) and K(2P)3.1 channels (TASK1; IC(50) = 18.7 muM) with maximum current reduction of 60.3 and 65.5 % in oocytes.", "spo_list": [{"subject": "dronedarone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human K(2P) channels", "object_type": "GENE-N"}, {"subject": "dronedarone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "K(2P)2.1", "object_type": "GENE-Y"}, {"subject": "dronedarone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TREK1", "object_type": "GENE-Y"}, {"subject": "dronedarone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "K(2P)3.1", "object_type": "GENE-Y"}, {"subject": "dronedarone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TASK1", "object_type": "GENE-Y"}]}
{"text": "Mutagenesis studies revealed that amino acid residues implicated in K(2P)3.1 drug interactions were not required for dronedarone blockade.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "K(2P)3.1", "object_type": "GENE-Y"}, {"subject": "dronedarone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "K(2P)3.1", "object_type": "GENE-Y"}]}
{"text": "The class III antiarrhythmic drug dronedarone targets multiple human cardiac two-pore-domain potassium channels, including atrial-selective K(2P)3.1 currents.", "spo_list": [{"subject": "dronedarone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human cardiac two-pore-domain potassium channels", "object_type": "GENE-N"}, {"subject": "dronedarone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "K(2P)3.1", "object_type": "GENE-Y"}]}
{"text": "K(2P) current inhibition by dronedarone represents a previously unrecognized mechanism of action that extends the multichannel blocking profile of the drug.", "spo_list": [{"subject": "dronedarone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "K(2P)", "object_type": "GENE-N"}]}
{"text": "The dopaminergic antagonist haloperidol has an eight- to 10-fold higher affinity for NMDA receptors containing the NR2B (epsilon2) subunit, showing the same subunit specificity as ifenprodil, polyamines, and magnesium.", "spo_list": [{"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "NMDA receptors", "object_type": "GENE-N"}, {"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "NR2B (epsilon2)", "object_type": "GENE-Y"}]}
{"text": "As seen for spermidine stimulation, high-affinity haloperidol inhibition is governed by the region around amino acid 198, based on results from chimeric murine NR2A/NR2B (epislon1/epsilon2) receptors.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "murine NR2A", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "NR2B", "object_type": "GENE-Y"}, {"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "murine NR2A", "object_type": "GENE-Y"}, {"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR2B", "object_type": "GENE-Y"}, {"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "murine NR2A", "object_type": "GENE-Y"}, {"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "NR2B", "object_type": "GENE-Y"}]}
{"text": "The highest PR and c-fos mRNA content was observed 3 h and 2 h after 17 beta-estradiol administration, respectively.", "spo_list": [{"subject": "17 beta-estradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PR", "object_type": "GENE-Y"}, {"subject": "17 beta-estradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "c-fos", "object_type": "GENE-Y"}]}
{"text": "The increase in c-fos mRNA content induced by these reduced compounds was lower than that found with estradiol treatment.", "spo_list": [{"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "c-fos", "object_type": "GENE-Y"}]}
{"text": "Galangin decreased expression of pro-inflammatory cytokines, such as tumor necrosis factor (TNF)-Î±, interleukin (IL)-6, IL-1Î², and IL-8.", "spo_list": [{"subject": "Galangin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cytokines", "object_type": "GENE-N"}, {"subject": "Galangin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "tumor necrosis factor (TNF)-Î±", "object_type": "GENE-Y"}, {"subject": "Galangin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "interleukin", "object_type": "GENE-Y"}, {"subject": "Galangin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "(IL)-6", "object_type": "GENE-Y"}, {"subject": "Galangin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-1Î²", "object_type": "GENE-Y"}, {"subject": "Galangin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-8", "object_type": "GENE-Y"}]}
{"text": "The inhibitory effect of galangin on theses pro-inflammatory cytokines was related with c-Jun N-terminal kinases, and p38 mitogen-activated protein kinase, nuclear factor-ÎºB, and caspase-1.", "spo_list": [{"subject": "galangin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cytokines", "object_type": "GENE-N"}]}
{"text": "Furthermore, galangin attenuated IgE-mediated passive cutaneous anaphylaxis and the expression of histamine receptor 1 at the inflamed tissue.", "spo_list": [{"subject": "galangin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "histamine receptor 1", "object_type": "GENE-Y"}]}
{"text": "Our results showed that galangin down-regulates mast cell-derived allergic inflammatory reactions by blocking histamine release and expression of pro-inflammatory cytokines.", "spo_list": [{"subject": "galangin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cytokines", "object_type": "GENE-N"}]}
{"text": "The influenza virus sialidase is an effective drug target, and a number of inhibitors are clinically effective against the virus (zanamivir, oseltamivir, peramivir).", "spo_list": [{"subject": "zanamivir", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "influenza virus sialidase", "object_type": "GENE-N"}, {"subject": "oseltamivir", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "influenza virus sialidase", "object_type": "GENE-N"}, {"subject": "peramivir", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "influenza virus sialidase", "object_type": "GENE-N"}]}
{"text": "In particular, we demonstrate that upon stress-induced phosphorylation of p53 on Ser46 by homeodomain interacting protein kinase 2, Pin1 stimulates its mitochondrial trafficking signal, that is, monoubiquitination.", "spo_list": [{"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "p53", "object_type": "GENE-Y"}]}
{"text": "In contrast, the actions of the VDR that regulate postmorphogenic hair cycling do not require 1,25-dihydroxyvitamin D. The VDR also has immunomodulatory actions that are dependent on its ligand, 1,25-dihydroxyvitamin D. To determine whether the ligand-dependent or -independent actions of the VDR regulate the inflammatory response to cutaneous injury, studies were performed in control, VDR knockout, and vitamin D-deficient mice.", "spo_list": [{"subject": "1,25-dihydroxyvitamin D", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "VDR", "object_type": "GENE-Y"}]}
{"text": "Mechanisms that have been proposed for peroxidase-catalyzed iodination require the utilization of 1 mol of H2O2 for organic binding of 1 mol of iodide.", "spo_list": [{"subject": "H2O2", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "peroxidase", "object_type": "GENE-N"}, {"subject": "iodide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "peroxidase", "object_type": "GENE-N"}]}
{"text": "This was shown to be attributable to catalase-like activity of these enzymes, resulting in unproductive cleavage of H2O2.", "spo_list": [{"subject": "H2O2", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "catalase", "object_type": "GENE-Y"}]}
{"text": "4) High concentrations of I- inhibited the catalatic activity of thyroid peroxidase and lactoperoxidase in a manner similar to that described previously for peroxidase-catalyzed iodination.", "spo_list": [{"subject": "I-", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thyroid peroxidase", "object_type": "GENE-Y"}, {"subject": "I-", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "lactoperoxidase", "object_type": "GENE-Y"}, {"subject": "I-", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "peroxidase", "object_type": "GENE-N"}]}
{"text": "We suggest that the latter can react with H2O2 in a catalase-like reaction, with evolution of O2.", "spo_list": [{"subject": "O2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "catalase", "object_type": "GENE-Y"}]}
{"text": "A new single-photon emission computed tomography (SPECT) imaging agent for serotonin transporters: [(125)I]Flip-IDAM, (2-((2-((dimethylamino)methyl)-4-iodophenyl)thio)phenyl)methanol.", "spo_list": [{"subject": "[(125)I]Flip-IDAM", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "serotonin transporters", "object_type": "GENE-Y"}, {"subject": "(2-((2-((dimethylamino)methyl)-4-iodophenyl)thio)phenyl)methanol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "serotonin transporters", "object_type": "GENE-Y"}]}
{"text": "New [(125)I]Flip-IDAM exhibited excellent binding affinity to SERT binding sites with a high hypothalamus to cerebellum ratio of 4 at 30 min post iv injection.", "spo_list": [{"subject": "[(125)I]Flip-IDAM", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SERT", "object_type": "GENE-Y"}]}
{"text": "This new agent, when labeled with (123)I, may be a useful imaging agent for mapping SERT binding sites in the human brain.", "spo_list": [{"subject": "(123)I", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SERT", "object_type": "GENE-Y"}]}
{"text": "Molecular determinants for the selective inhibition of cyclooxygenase-2 by lumiracoxib.", "spo_list": [{"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}]}
{"text": "Lumiracoxib is the first example of a marketed COX-2 inhibitor of the arylacetic acid class, and it is reported to be the most selective COXIB in vivo.", "spo_list": [{"subject": "Lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "arylacetic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Using standard assays, lumiracoxib was found to be a poor inhibitor of purified ovine COX-1 and a relatively weak inhibitor of purified human COX-2.", "spo_list": [{"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ovine COX-1", "object_type": "GENE-Y"}, {"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human COX-2", "object_type": "GENE-Y"}]}
{"text": "Kinetic studies with lumiracoxib demonstrated that it was a time-dependent and slowly reversible inhibitor of human COX-2 that exhibited at least two binding steps during inhibition.", "spo_list": [{"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human COX-2", "object_type": "GENE-Y"}]}
{"text": "Inhibition studies demonstrated that the methyl group on the phenylacetic acid ring is required for COX-2 selectivity.", "spo_list": [{"subject": "methyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "phenylacetic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "The chemical identity and position of the substituents on the lower aniline ring were important in determining the potency and extent of COX inhibition as well as COX-2 selectivity.", "spo_list": [{"subject": "aniline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX", "object_type": "GENE-N"}]}
{"text": "Mutation of Ser-530 to Ala or Val-349 to Ala or Leu abolished the potent inhibition observed with wild-type human COX-2 and key lumiracoxib analogs.", "spo_list": [{"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human COX-2", "object_type": "GENE-Y"}]}
{"text": "Interestingly, a Val-349 to Ile mutant was inhibited with equal potency to human COX-2 with 2,6-dichloro-, 2,6-dimethyl-, or 2-chloro-6-methyl-substituted inhibitors and, in the case of lumiracoxib, actually showed an increase in potency.", "spo_list": [{"subject": "2,6-dichloro", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human COX-2", "object_type": "GENE-Y"}, {"subject": "2,6-dimethyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human COX-2", "object_type": "GENE-Y"}, {"subject": "2-chloro-6-methyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human COX-2", "object_type": "GENE-Y"}, {"subject": "2,6-dichloro", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Val-349 to Ile", "object_type": "GENE-N"}, {"subject": "2,6-dimethyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Val-349 to Ile", "object_type": "GENE-N"}, {"subject": "2-chloro-6-methyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Val-349 to Ile", "object_type": "GENE-N"}, {"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human COX-2", "object_type": "GENE-Y"}, {"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Val-349 to Ile", "object_type": "GENE-N"}]}
{"text": "Taken together with a recent crystal structure of a lumiracoxib-COX-2 complex, the kinetic analyses presented herein of the inhibition of mutant COX-2s by lumiracoxib allows the definition of the molecular basis of COX-2 inhibition.", "spo_list": [{"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2s", "object_type": "GENE-Y"}]}
{"text": "The selective CaMKIIÎ± inhibitor KN-62 reversed the blockade produced by ionomycin and K(+)-depolarization.", "spo_list": [{"subject": "KN-62", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CaMKIIÎ±", "object_type": "GENE-Y"}, {"subject": "ionomycin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CaMKIIÎ±", "object_type": "GENE-Y"}]}
{"text": "In K(+)-depolarized tissues, D3 receptors potentiated D1 receptor-induced stimulation of [(3)H]GABA release only when CaMKIIÎ± was blocked with KN-62.", "spo_list": [{"subject": "KN-62", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CaMKIIÎ±", "object_type": "GENE-Y"}]}
{"text": "In the presence of this inhibitor, the selective D3 agonist PD 128,907 reduced the ED50 for the D1 agonist SKF 38393 from 56 to 4Â nM.", "spo_list": [{"subject": "PD 128,907", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "D3", "object_type": "GENE-Y"}, {"subject": "SKF 38393", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "D1", "object_type": "GENE-Y"}]}
{"text": "A factor X peptide duplicating the inter-EGF sequence Leu83-Phe84-Thr85-Arg86-Lys87-Leu88- (Gly) inhibited factor V/Va-independent prothrombin activation by HUVEC and blocked binding of 125I-factor Xa to these cells in a dose-dependent manner (IC50 approximately 20-40 microM).", "spo_list": [{"subject": "Gly", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "factor X", "object_type": "GENE-Y"}]}
{"text": "METHODS: Human mononuclear cells were stimulated with LPS (1 microg/mL), in the presence and absence of Pentoxifylline (PTX; 20 mM), a nonspecific phosphodiesterase inhibitor.", "spo_list": [{"subject": "Pentoxifylline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase", "object_type": "GENE-N"}, {"subject": "PTX", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase", "object_type": "GENE-N"}]}
{"text": "RESULTS: PTX was demonstrated to significantly reduce cytoplasmic I-kBalpha phosphorylation, nuclear p65 phosphorylation, and the DNA binding activity of NF-kB.", "spo_list": [{"subject": "PTX", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "I-kBalpha", "object_type": "GENE-Y"}, {"subject": "PTX", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p65", "object_type": "GENE-Y"}, {"subject": "PTX", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kB", "object_type": "GENE-N"}]}
{"text": "In contrast, PTX markedly enhanced the phosphorylation and DNA binding activity of CREB.", "spo_list": [{"subject": "PTX", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CREB", "object_type": "GENE-N"}]}
{"text": "Cells concomitantly treated with PTX and LPS secreted similar levels of TNF-a in the presence and absence Protein kinase A inhibition.", "spo_list": [{"subject": "PTX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TNF-a", "object_type": "GENE-Y"}]}
{"text": "DISCUSSION: The increased level of cAMP that results from phosphodiesterase inhibition affects cytoplasmic and nuclear events, resulting in the attenuation of NF-kB and the activation of CREB transcriptional DNA binding through pathways that are partially Protein kinase A-independent.", "spo_list": [{"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "phosphodiesterase", "object_type": "GENE-N"}, {"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kB", "object_type": "GENE-N"}, {"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CREB", "object_type": "GENE-N"}]}
{"text": "CONCLUSION: PTX-mediated phosphodiesterase inhibition occurs partially through a Protein kinase A-independent pathway and may serve as a useful tool in the attenuation of LPS-induced inflammation.", "spo_list": [{"subject": "PTX", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase", "object_type": "GENE-N"}]}
{"text": "BACKGROUND/AIMS: It has been proposed that, in acute liver failure, skeletal muscle adapts to become the principle organ responsible for removal of blood-borne ammonia by increasing glutamine synthesis, a reaction that is catalyzed by the cytosolic ATP-dependent enzyme glutamine synthetase.", "spo_list": [{"subject": "glutamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "glutamine synthetase", "object_type": "GENE-Y"}]}
{"text": "Glutamine synthetase activity and glutamine de novo synthesis were measured using, respectively, a standard enzymatic assay and [13C]-nuclear magnetic resonance spectroscopy.", "spo_list": [{"subject": "glutamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Glutamine synthetase", "object_type": "GENE-Y"}, {"subject": "13C", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Glutamine synthetase", "object_type": "GENE-Y"}]}
{"text": "RESULTS: Glutamine synthetase protein (but not gene) expression and enzyme activities were significantly up-regulated leading to increased de novo synthesis of glutamine and increased skeletal muscle capacity for ammonia removal in acute liver failure.", "spo_list": [{"subject": "glutamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Glutamine synthetase", "object_type": "GENE-Y"}]}
{"text": "Atomoxetine has a high affinity and selectivity for norepinephrine transporters, but little or no affinity for various neurotransmitter receptors.", "spo_list": [{"subject": "Atomoxetine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "norepinephrine transporters", "object_type": "GENE-Y"}]}
{"text": "It undergoes extensive biotransformation, which is affected by poor metabolism by cytochrome P450 (CYP) 2D6 in a small percentage of the population; these patients have greater exposure to and slower elimination of atomoxetine than extensive metabolizers.", "spo_list": [{"subject": "atomoxetine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cytochrome P450 (CYP) 2D6", "object_type": "GENE-Y"}]}
{"text": "CYP2D6 inhibitors, such as paroxetine, are associated with changes in atomoxetine pharmacokinetics similar to those observed among poor CYP2D6 metabolizers.", "spo_list": [{"subject": "paroxetine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2D6", "object_type": "GENE-Y"}, {"subject": "atomoxetine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2D6", "object_type": "GENE-Y"}]}
{"text": "Atomoxetine appeared better tolerated among extensive CYP2D6 metabolizers than among poor metabolizers.", "spo_list": [{"subject": "Atomoxetine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2D6", "object_type": "GENE-Y"}]}
{"text": "It has been reported that cimetidine, a histamine type-2 receptor (H2R) antagonist, inhibits the growth of glandular tumors such as colorectal cancer.", "spo_list": [{"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine type-2 receptor", "object_type": "GENE-Y"}, {"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "H2R", "object_type": "GENE-Y"}]}
{"text": "Expression of both NCAM mRNA and protein was found to decrease in a dose-dependent manner upon treatment with cimetidine for 24 h. The MTT assay and confocal laser microscopy clearly showed that HSG cells underwent apoptosis after treatment with cimetidine.", "spo_list": [{"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NCAM", "object_type": "GENE-Y"}]}
{"text": "Activation of caspases 3, 7, 8 and 9 was observed in HSG cells after cimetidine treatment, thus confirming that the apoptosis was induced by the activated caspases.", "spo_list": [{"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "caspases", "object_type": "GENE-N"}]}
{"text": "Apaf-1 activity was also detected in HSG cells in a dose-dependent manner after treatment with cimetidine.", "spo_list": [{"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Apaf-1", "object_type": "GENE-N"}]}
{"text": "We also found that the cimetidine-mediated down-regulation of NCAM expression in HSG cells did not occur via blocking of the histamine receptor, even though H2R expression was observed on HSG cells, as two other H2R antagonists, famotidine and ranitidine, did not show similar effects.", "spo_list": [{"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NCAM", "object_type": "GENE-Y"}, {"subject": "famotidine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "H2R", "object_type": "GENE-Y"}, {"subject": "ranitidine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "H2R", "object_type": "GENE-Y"}]}
{"text": "We demonstrated for the first time that cimetidine can induce significant apoptosis of salivary gland tumor cells, which express NCAM, at least in part by down-regulation of NCAM expression on the cells.", "spo_list": [{"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NCAM", "object_type": "GENE-Y"}]}
{"text": "These findings suggest that the growth, development and perineural/neural invasion of salivary gland tumor cells can be blocked by cimetidine administration through down-regulation of NCAM expression, as well as induction of apoptosis.", "spo_list": [{"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NCAM", "object_type": "GENE-Y"}]}
{"text": "In rats, it has been reported that rofecoxib, a cyclooxygenase-2 (COX-2) inhibitor, reacts with the aldehyde group of allysine in elastin to give a condensation covalent adduct, thereby preventing the formation of cross-linkages in the elastin and causing degradation of the elastic fibers in aortas in vivo.", "spo_list": [{"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "aldehyde", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "elastin", "object_type": "GENE-Y"}, {"subject": "allysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "elastin", "object_type": "GENE-Y"}]}
{"text": "Acid, organic solvent, and proteolytic enzyme treatments of human aortic homogenate after incubation with [(14)C]rofecoxib demonstrated that most of the radioactivity is covalently bound to elastin.", "spo_list": [{"subject": "[(14)C]rofecoxib", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "elastin", "object_type": "GENE-Y"}]}
{"text": "The in vitro covalent binding was inhibited in the presence of beta-aminopropionitrile, D-penicillamine, and hydralazine, which suggested that the aldehyde group of allysine in human elastin was relevant to the covalent binding.", "spo_list": [{"subject": "beta-aminopropionitrile", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human elastin", "object_type": "GENE-Y"}, {"subject": "aldehyde", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "human elastin", "object_type": "GENE-Y"}, {"subject": "allysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "human elastin", "object_type": "GENE-Y"}, {"subject": "D-penicillamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human elastin", "object_type": "GENE-Y"}, {"subject": "hydralazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human elastin", "object_type": "GENE-Y"}]}
{"text": "The in vitro covalent binding of [(14)C]rofecoxib was significantly decreased by the addition of only nonradiolabeled rofecoxib but not the other COX-2 inhibitors, celecoxib, valdecoxib, etoricoxib, and CS-706 [2-(4-ethoxyphenyl)-4-methyl 1-(4-sulfamoylphenyl)-1H-pyrrole], a novel selective COX-2 inhibitor.", "spo_list": [{"subject": "[(14)C]rofecoxib", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "All the above COX-2 inhibitors except for rofecoxib had no reactivity with the aldehyde group of benzaldehyde used as a model compound of allysine aldehyde under a physiological pH condition.", "spo_list": [{"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "These results suggest that rofecoxib, but not other COX-2 inhibitors, is capable of covalently binding to the aldehyde group of allysine in human elastin.", "spo_list": [{"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "aldehyde", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "human elastin", "object_type": "GENE-Y"}]}
{"text": "Scaffold of the cyclooxygenase-2 (COX-2) inhibitor carprofen provides Alzheimer gamma-secretase modulators.", "spo_list": [{"subject": "carprofen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "carprofen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "The introduction of a lipophilic substituent transformed the COX-2 inhibitor carprofen into a potent gamma-secretase modulator.", "spo_list": [{"subject": "carprofen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "The ZEN metabolites induced loss of mitochondrial membrane potential (MMP), mitochondrial changes in Bcl-2 and Bax proteins, and cytoplasmic release of cytochrome c and apoptosis-inducing factor (AIF).", "spo_list": [{"subject": "ZEN", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytochrome c", "object_type": "GENE-Y"}, {"subject": "ZEN", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "apoptosis-inducing factor", "object_type": "GENE-Y"}, {"subject": "ZEN", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AIF", "object_type": "GENE-Y"}]}
{"text": "Collectively, these results suggest that the activation of p53, JNK or p38 kinase by ZEN metabolites is the main upstream signal required for the mitochondrial alteration of Bcl-2/Bax signaling pathways and intracellular ROS generation, while MMP loss and nuclear translocation of AIF are the critical downstream events for ZEN metabolite-mediated apoptosis in macrophages.", "spo_list": [{"subject": "ZEN", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p53", "object_type": "GENE-Y"}, {"subject": "ZEN", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "JNK", "object_type": "GENE-N"}, {"subject": "ZEN", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "ZEN", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "kinase", "object_type": "GENE-N"}]}
{"text": "The present studies were undertaken to compare two compounds, a vitamin D(3) analogue (CB1093) with minimal calcaemic effects, and clenbuterol, a long-acting beta(2)-adrenoceptor agonist, both of which induce NGF synthesis in vivo.", "spo_list": [{"subject": "clenbuterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "clenbuterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NGF", "object_type": "GENE-Y"}, {"subject": "CB1093", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NGF", "object_type": "GENE-Y"}, {"subject": "vitamin D(3)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NGF", "object_type": "GENE-Y"}]}
{"text": "Clenbuterol caused significant increases in both NGF mRNA and protein in 3T3 cells; with maxima at 10 nM and at 8-12 h exposure.", "spo_list": [{"subject": "Clenbuterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NGF", "object_type": "GENE-Y"}]}
{"text": "Mobility shift assays on whole cell extracts showed that clenbuterol increased AP1 binding in 3T3 cells prior to increasing NGF synthesis.", "spo_list": [{"subject": "clenbuterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NGF", "object_type": "GENE-Y"}]}
{"text": "Clenbuterol was without effect on NGF mRNA levels in L929 cells, whereas CB1093 caused significant increases in both NGF mRNA and protein levels in both 3T3 and L929 cells.", "spo_list": [{"subject": "CB1093", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NGF", "object_type": "GENE-Y"}]}
{"text": "This study demonstrates that CB1093 and clenbuterol stimulate NGF levels in vitro and that AP-1 binding could be a commonality between the mechanism of NGF induction of these two compounds.", "spo_list": [{"subject": "CB1093", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NGF", "object_type": "GENE-Y"}, {"subject": "clenbuterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NGF", "object_type": "GENE-Y"}, {"subject": "CB1093", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NGF", "object_type": "GENE-Y"}, {"subject": "clenbuterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NGF", "object_type": "GENE-Y"}]}
{"text": "Determination of key receptor-ligand interactions of dopaminergic arylpiperazines and the dopamine D2 receptor homology model.", "spo_list": [{"subject": "arylpiperazines", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "dopamine D2 receptor", "object_type": "GENE-Y"}]}
{"text": "The x-ray structure of the enzyme revealed an important structural difference between this protein and other aldehyde dehydrogenases of the same enzyme superfamily; a 20-amino acid span in the substrate access channel in retinaldehyde dehydrogenase II is disordered, whereas in other aldehyde dehydrogenases this region forms a well defined wall of the substrate access channel.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "retinaldehyde dehydrogenase II", "object_type": "GENE-Y"}]}
{"text": "BACKGROUND: Statins are the most effective agents currently available for lowering plasma levels of low-density lipoprotein cholesterol (LDL-C) and are the mainstay of therapy for hyperlipidemia.", "spo_list": [{"subject": "Statins", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "low-density lipoprotein", "object_type": "GENE-N"}, {"subject": "Statins", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "LDL", "object_type": "GENE-N"}]}
{"text": "The statins are highly liver-selective, inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, a key enzyme in the synthesis of cholesterol.", "spo_list": [{"subject": "statins", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase", "object_type": "GENE-Y"}, {"subject": "cholesterol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase", "object_type": "GENE-Y"}]}
{"text": "We found that the 6 statins currently marketed-atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, and simvastatin-differ in their inhibitory action on the HMG-CoA reductase enzyme.", "spo_list": [{"subject": "statins", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HMG-CoA reductase", "object_type": "GENE-Y"}, {"subject": "atorvastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HMG-CoA reductase", "object_type": "GENE-Y"}, {"subject": "cerivastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HMG-CoA reductase", "object_type": "GENE-Y"}, {"subject": "fluvastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HMG-CoA reductase", "object_type": "GENE-Y"}, {"subject": "lovastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HMG-CoA reductase", "object_type": "GENE-Y"}, {"subject": "pravastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HMG-CoA reductase", "object_type": "GENE-Y"}, {"subject": "simvastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HMG-CoA reductase", "object_type": "GENE-Y"}]}
{"text": "CONCLUSIONS: The use of more potent statins such as atorvastatin and simvastatin affords greater lowering of LDL-C and triglyceride levels, allowing more patients to achieve target goals.", "spo_list": [{"subject": "atorvastatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "LDL", "object_type": "GENE-N"}, {"subject": "simvastatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "LDL", "object_type": "GENE-N"}]}
{"text": "Adenylosuccinate synthetase (AdSS) catalyzes the Mg2+ dependent condensation of a molecule of IMP with aspartate to form adenylosuccinate, in a reaction driven by the hydrolysis of GTP to GDP.", "spo_list": [{"subject": "adenylosuccinate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Adenylosuccinate synthetase", "object_type": "GENE-Y"}, {"subject": "adenylosuccinate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AdSS", "object_type": "GENE-Y"}, {"subject": "Mg2+", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AdSS", "object_type": "GENE-Y"}]}
{"text": "AdSS from the thermophilic archaea, Methanocaldococcus jannaschii (MjAdSS) is 345 amino acids long against an average length of 430-457 amino acids for most mesophilic AdSS.", "spo_list": [{"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MjAdSS", "object_type": "GENE-Y"}, {"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "AdSS", "object_type": "GENE-Y"}, {"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "AdSS", "object_type": "GENE-Y"}]}
{"text": "This short AdSS has two large deletions that map to the middle and C-terminus of the protein.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "AdSS", "object_type": "GENE-Y"}]}
{"text": "Phosphate, a product of the reaction, was found to be a potent inhibitor of MjAdSS showing biphasic inhibition of enzyme activity.", "spo_list": [{"subject": "Phosphate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MjAdSS", "object_type": "GENE-Y"}]}
{"text": "Inhibitors based on a benzo-fused spirocyclic oxazepine scaffold were discovered for stearoyl-coenzyme A (CoA) desaturase 1 (SCD1) and subsequently optimized to potent compounds with favorable pharmacokinetic profiles and in vivo efficacy in reducing the desaturation index in a mouse model.", "spo_list": [{"subject": "benzo-fused spirocyclic oxazepine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "stearoyl-coenzyme A (CoA) desaturase 1", "object_type": "GENE-Y"}, {"subject": "benzo-fused spirocyclic oxazepine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SCD1", "object_type": "GENE-Y"}]}
{"text": "Selective and potent adenosine A3 receptor antagonists by methoxyaryl substitution on the N-(2,6-diarylpyrimidin-4-yl)acetamide scaffold.", "spo_list": [{"subject": "methoxyaryl", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "adenosine A3 receptor", "object_type": "GENE-Y"}, {"subject": "N-(2,6-diarylpyrimidin-4-yl)acetamide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "adenosine A3 receptor", "object_type": "GENE-Y"}]}
{"text": "The influence of diverse methoxyphenyl substitution patterns on the N-(2,6-diarylpyrimidin-4-yl)acetamide scaffold is herein explored in order to modulate the A(3) adenosine receptor antagonistic profile.", "spo_list": [{"subject": "methoxyphenyl", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "A(3) adenosine receptor", "object_type": "GENE-Y"}, {"subject": "N-(2,6-diarylpyrimidin-4-yl)acetamide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "A(3) adenosine receptor", "object_type": "GENE-Y"}]}
{"text": "The activation appears to be due to an increase of GAD affinity for its cofactor, pyridoxal phosphate (PLP).", "spo_list": [{"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD", "object_type": "GENE-Y"}, {"subject": "pyridoxal phosphate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD", "object_type": "GENE-Y"}]}
{"text": "Firstly, the V(max) of GAD was increased when ApoCaM was present whereas the affinity for the substrate, glutamate, was not affected.", "spo_list": [{"subject": "glutamate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GAD", "object_type": "GENE-Y"}]}
{"text": "Secondly, the affinity of GAD for PLP was increased in the presence of ApoCaM.", "spo_list": [{"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD", "object_type": "GENE-Y"}]}
{"text": "Hence, it is proposed that a conformational change is induced when ApoCaM interacts with GAD65 or tGAD67, resulting in an increase of GAD affinity for PLP and the activation of GAD.", "spo_list": [{"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD", "object_type": "GENE-Y"}]}
{"text": "We demonstrate that two flavin mono-oxygenase family members, FMO1 and FMO3, oxidize trimethylamine (TMA), derived from gut flora metabolism of choline, to TMAO.", "spo_list": [{"subject": "trimethylamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "flavin mono-oxygenase", "object_type": "GENE-N"}, {"subject": "trimethylamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FMO1", "object_type": "GENE-Y"}, {"subject": "trimethylamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FMO3", "object_type": "GENE-Y"}, {"subject": "TMA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "flavin mono-oxygenase", "object_type": "GENE-N"}, {"subject": "TMA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FMO1", "object_type": "GENE-Y"}, {"subject": "TMA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FMO3", "object_type": "GENE-Y"}, {"subject": "choline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "flavin mono-oxygenase", "object_type": "GENE-N"}, {"subject": "choline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FMO1", "object_type": "GENE-Y"}, {"subject": "choline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FMO3", "object_type": "GENE-Y"}, {"subject": "TMAO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "flavin mono-oxygenase", "object_type": "GENE-N"}, {"subject": "TMAO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "FMO1", "object_type": "GENE-Y"}, {"subject": "TMAO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "FMO3", "object_type": "GENE-Y"}]}
{"text": "FMO3 overexpression in mice significantly increases plasma TMAO levels while silencing FMO3 decreases TMAO levels.", "spo_list": [{"subject": "TMAO", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FMO3", "object_type": "GENE-Y"}, {"subject": "TMAO", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FMO3", "object_type": "GENE-Y"}]}
{"text": "In mice, this reduction in FMO3 expression is due primarily to downregulation by androgens.", "spo_list": [{"subject": "androgens", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "FMO3", "object_type": "GENE-Y"}]}
{"text": "FMO3 expression is induced by dietary bile acids by a mechanism that involves the farnesoid X receptor (FXR), a bile acid-activated nuclear receptor.", "spo_list": [{"subject": "bile acids", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "FMO3", "object_type": "GENE-Y"}, {"subject": "bile acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "farnesoid X receptor", "object_type": "GENE-Y"}, {"subject": "bile acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "FXR", "object_type": "GENE-Y"}]}
{"text": "Analysis of natural genetic variation among inbred strains of mice indicates that FMO3 and TMAO are significantly correlated, and TMAO levels explain 11% of the variation in atherosclerosis.", "spo_list": [{"subject": "TMAO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "FMO3", "object_type": "GENE-Y"}]}
{"text": "The alpha1H channel is sensitive to mibefradil, a nondihydropyridine Ca2+ channel blocker, with an IC50 of 1.4 micromol/L, consistent with the reported potency of mibefradil for T-type Ca2+ channels.", "spo_list": [{"subject": "mibefradil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Ca2+ channel", "object_type": "GENE-N"}]}
{"text": "Excess of cholesterol converted into 24OHC may up-regulate ApoE synthesis which is a scavenger for AÎ² and Tau.", "spo_list": [{"subject": "24OHC", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ApoE", "object_type": "GENE-Y"}, {"subject": "cholesterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ApoE", "object_type": "GENE-Y"}]}
{"text": "Structure of acetylcholinesterase complexed with E2020 (Aricept): implications for the design of new anti-Alzheimer drugs.", "spo_list": [{"subject": "E2020", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "Aricept", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}]}
{"text": "E2020, marketed as Aricept, is a member of a large family of N-benzylpiperidine-based acetylcholinesterase (AChE) inhibitors developed, synthesized and evaluated by the Eisai Company in Japan.", "spo_list": [{"subject": "Aricept", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "Aricept", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "N-benzylpiperidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "N-benzylpiperidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "RESULTS: Our experimental structure of the E2020-TcAChE complex pinpoints specific interactions responsible for the high affinity and selectivity demonstrated previously.", "spo_list": [{"subject": "E2020", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "TcAChE", "object_type": "GENE-Y"}]}
{"text": "CONCLUSIONS: Our study shows, a posteriori, that the design of E2020 took advantage of several important features of the active-site gorge of AChE to produce a drug with both high affinity for AChE and a high degree of selectivity for AChE versus butyrylcholinesterase (BChE).", "spo_list": [{"subject": "E2020", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "E2020", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "E2020", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "Here we found that arsenic trioxide, a frontline agent for acute promyelocytic leukemia, inhibits ÎNp63 but not TAp63 expression in time- and dose-dependent manners.", "spo_list": [{"subject": "arsenic trioxide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ÎNp63", "object_type": "GENE-Y"}]}
{"text": "In addition, we found that arsenic trioxide decreases the stability of ÎNp63 protein via a proteasome-dependent pathway but has little effect on the level of ÎNp63 transcript.", "spo_list": [{"subject": "arsenic trioxide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ÎNp63", "object_type": "GENE-Y"}]}
{"text": "Furthermore, we found that arsenic trioxide activates the Pirh2 promoter and consequently induces Pirh2 expression.", "spo_list": [{"subject": "arsenic trioxide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Pirh2 promoter", "object_type": "GENE-N"}, {"subject": "arsenic trioxide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Pirh2", "object_type": "GENE-Y"}]}
{"text": "Consistent with this, we found that knockdown of Pirh2 inhibits, whereas ectopic expression of Pirh2 enhances, arsenic-induced degradation of ÎNp63 protein.", "spo_list": [{"subject": "arsenic", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ÎNp63", "object_type": "GENE-Y"}]}
{"text": "Together, these data suggest that arsenic degrades ÎNp63 protein at least in part via Pirh2-dependent proteolysis and that inhibition of ÎNp63 expression facilitates tumor cells to arsenic-induced death.", "spo_list": [{"subject": "arsenic", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ÎNp63", "object_type": "GENE-Y"}, {"subject": "arsenic", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ÎNp63", "object_type": "GENE-Y"}]}
{"text": "Indoxyl 3-sulfate stimulates Th17 differentiation enhancing phosphorylation of c-Src and STAT3 to worsen experimental autoimmune encephalomyelitis.", "spo_list": [{"subject": "Indoxyl 3-sulfate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "c-Src", "object_type": "GENE-Y"}, {"subject": "Indoxyl 3-sulfate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "STAT3", "object_type": "GENE-Y"}]}
{"text": "In the present study, using in vitro Th17 differentiation model, we examined effects of AhR activation by indoxyl 3-sulfate (I3S), a uremic toxin, on Th17 differentiation and investigated underlying mechanisms.", "spo_list": [{"subject": "indoxyl 3-sulfate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AhR", "object_type": "GENE-Y"}, {"subject": "I3S", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AhR", "object_type": "GENE-Y"}]}
{"text": "I3S increased expression of RORÎ³t, the master transcription factor for Th17 differentiation, and stimulated Th17 differentiation, in a comparative manner as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), a prototypical AhR ligand.", "spo_list": [{"subject": "I3S", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "RORÎ³t", "object_type": "GENE-Y"}, {"subject": "2,3,7,8-tetrachlorodibenzo-p-dioxin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "RORÎ³t", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "RORÎ³t", "object_type": "GENE-Y"}, {"subject": "2,3,7,8-tetrachlorodibenzo-p-dioxin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AhR", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AhR", "object_type": "GENE-Y"}]}
{"text": "Activation of STAT3, which is phosphorylated by the IL-6 signaling pathways and thus is necessary for Th17 differentiation, was strongly stimulated by I3S and TCDD.", "spo_list": [{"subject": "I3S", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "STAT3", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "STAT3", "object_type": "GENE-Y"}]}
{"text": "Phosphorylation of c-Src, which was shown to be activated by AhR ligands, was also increased by I3S and TCDD, and blocking of c-Src activity by 4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine (PP2) inhibited phosphorylation of both c-Src and STAT3, raising a possibility that stimulatory activities of I3S and TCDD on Th17 differentiation could be exerted via increased phosphorylation of c-Src, which in turn stimulates STAT3 activation.", "spo_list": [{"subject": "I3S", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "c-Src", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "c-Src", "object_type": "GENE-Y"}, {"subject": "4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "c-Src", "object_type": "GENE-Y"}, {"subject": "4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "c-Src", "object_type": "GENE-Y"}, {"subject": "4-amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "STAT3", "object_type": "GENE-Y"}, {"subject": "I3S", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "c-Src", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "c-Src", "object_type": "GENE-Y"}, {"subject": "I3S", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "STAT3", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "STAT3", "object_type": "GENE-Y"}]}
{"text": "Finally, we found that I3S worsened experimental autoimmune encephalomyelitis (EAE), which is primarily mediated by Th17 cells, enhancing the frequency of IL-17-producing cells in draining lymph nodes.", "spo_list": [{"subject": "I3S", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-17", "object_type": "GENE-Y"}]}
{"text": "1 The principal aim of the present study was to determine whether long-term treatment of human lung mast cells (HLMC) with the clinically-relevant beta(2)-adrenoceptor agonists, salbutamol and terbutaline, leads to desensitization of beta(2)-adrenoceptor-mediated responses in these cells.", "spo_list": [{"subject": "salbutamol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "terbutaline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "2 The non-selective beta-adrenoceptor agonist, isoprenaline, and the selective beta(2)-adrenoceptor agonists, salbutamol and terbutaline, inhibited the IgE-mediated release of histamine from HLMC.", "spo_list": [{"subject": "isoprenaline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta-adrenoceptor", "object_type": "GENE-N"}, {"subject": "salbutamol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "terbutaline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "The nonselective monoamine oxidase inhibitors tranylcypromine (0.01-5 mg/kg) and phenelzine (1-25 mg/kg), the monoamine oxidase-A selective compound clorgyline (1-25 mg/kg), and the monoamine oxidase-B selective compounds pargyline (0.005-50 mg/kg) and selegiline (1-25 mg/kg) were tested for substitution 15 min or 24 h following administration, and in combination with 10 mg/kg of cocaine 24 and 48 h after administration.", "spo_list": [{"subject": "tranylcypromine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase", "object_type": "GENE-N"}, {"subject": "phenelzine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase", "object_type": "GENE-N"}, {"subject": "pargyline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase-B", "object_type": "GENE-Y"}, {"subject": "selegiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase-B", "object_type": "GENE-Y"}]}
{"text": "A dimeric version of FXI/PKA4 (FXI/PKA4-Gly326) was prepared as a control.", "spo_list": [{"subject": "Gly326", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PKA4", "object_type": "GENE-N"}, {"subject": "Gly326", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PKA4", "object_type": "GENE-N"}]}
{"text": "Activated FXI/PKA4 and FXI/PKA4-Gly326 activate factor IX with kinetic parameters similar to those of FXIa.", "spo_list": [{"subject": "Gly326", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PKA4", "object_type": "GENE-N"}, {"subject": "Gly326", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PKA4", "object_type": "GENE-N"}]}
{"text": "In kaolin-triggered plasma clotting assays containing purified phospholipid, FXI/PKA4 and FXI/PKA4-Gly326 have coagulant activity similar to FXI.", "spo_list": [{"subject": "Gly326", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PKA4", "object_type": "GENE-N"}, {"subject": "Gly326", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PKA4", "object_type": "GENE-N"}]}
{"text": "In competition binding assays FXI/PKA4, FXI/PKA4-Gly326, and FXI have similar affinities for activated platelets (K(i) = 12-16 nM).", "spo_list": [{"subject": "Gly326", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PKA4", "object_type": "GENE-N"}, {"subject": "Gly326", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PKA4", "object_type": "GENE-N"}]}
{"text": "Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance.", "spo_list": [{"subject": "celecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase", "object_type": "GENE-N"}]}
{"text": "Intolerance reactions to acetyl salicylic acid (ASA) and nonsteroidal anti-inflammatory drugs (NSAIDs) are common and caused by inhibition of COX-1 enzyme.", "spo_list": [{"subject": "acetyl salicylic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "ASA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}]}
{"text": "In this study, we evaluated the tolerability of celecoxib, a selective COX-2 inhibitor, in patients with analgesic intolerance.", "spo_list": [{"subject": "celecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Our results show that cell growth and DNA synthesis were inhibited, and the cell cycle was arrested at the G0/G1 phase in a dose-dependent manner in cells treated with Î²-ionone (25, 50, 100 and 200Â Î¼mol/L) for 24Â h. We found that the Î²-ionone significantly decreased the extracellular signal-regulated kinase protein expression and significantly increased the levels of p38 and Jun-amino-terminal kinase protein expression (PÂ <Â 0.01). Î²-Ionone also inhibited cell cycle-related proteins of Cdk4, Cyclin B1, D1 and increased p27 protein expression in SGC-7901 cells.", "spo_list": [{"subject": "Î²-ionone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "extracellular signal-regulated kinase", "object_type": "GENE-N"}, {"subject": "Î²-ionone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "Î²-ionone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Jun-amino-terminal kinase", "object_type": "GENE-N"}, {"subject": "Î²-Ionone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cell cycle-related proteins", "object_type": "GENE-N"}, {"subject": "Î²-Ionone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Cdk4", "object_type": "GENE-Y"}, {"subject": "Î²-Ionone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p27", "object_type": "GENE-Y"}]}
{"text": "GIP potentiates glucose-stimulated insulin secretion and induces energy accumulation into adipose tissue, resulting in obesity.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-Y"}]}
{"text": "Kinetics of allopregnanolone formation catalyzed by human 3 alpha-hydroxysteroid dehydrogenase type III (AKR1C2).", "spo_list": [{"subject": "allopregnanolone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "human 3 alpha-hydroxysteroid dehydrogenase type III", "object_type": "GENE-Y"}, {"subject": "allopregnanolone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AKR1C2", "object_type": "GENE-Y"}]}
{"text": "Allopregnanolone is a neurosteroid which exhibits anxiolytic and anticonvulsant activities through potentiation of the GABA(A) receptor.", "spo_list": [{"subject": "Allopregnanolone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GABA(A) receptor", "object_type": "GENE-N"}]}
{"text": "The reduction of 5alpha-dihydroprogesterone (5alpha-DHP), the last step in allopregnanolone biosynthesis, is catalyzed by 3alpha-hydroxysteroid dehydrogenases (3alpha-HSDs).", "spo_list": [{"subject": "5alpha-dihydroprogesterone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "3alpha-hydroxysteroid dehydrogenases", "object_type": "GENE-N"}, {"subject": "5alpha-DHP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "3alpha-hydroxysteroid dehydrogenases", "object_type": "GENE-N"}, {"subject": "allopregnanolone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "3alpha-hydroxysteroid dehydrogenases", "object_type": "GENE-N"}, {"subject": "5alpha-dihydroprogesterone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "3alpha-HSDs", "object_type": "GENE-N"}, {"subject": "5alpha-DHP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "3alpha-HSDs", "object_type": "GENE-N"}, {"subject": "allopregnanolone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "3alpha-HSDs", "object_type": "GENE-N"}]}
{"text": "While the mechanism of action of allopregnanolone and the physiological and pharmacological modulation of allopregnanolone concentrations in vivo have been extensively studied, there has been little characterization of the kinetics of human 3alpha-HSD catalyzed allopregnanolone formation.", "spo_list": [{"subject": "allopregnanolone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "human 3alpha-HSD", "object_type": "GENE-N"}]}
{"text": "We report here determination of the kinetic mechanism for 5alpha-DHP reduction catalyzed by human 3alpha-HSD type III by using steady-state kinetics studies and assessment of the ability of fluoxetine and various other small molecules to activate 3alpha-HSD type III catalyzed allopregnanolone formation.", "spo_list": [{"subject": "5alpha-DHP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human 3alpha-HSD type III", "object_type": "GENE-Y"}, {"subject": "fluoxetine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "3alpha-HSD type III", "object_type": "GENE-Y"}, {"subject": "allopregnanolone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "3alpha-HSD type III", "object_type": "GENE-Y"}]}
{"text": "Two-substrate kinetic analysis and dead-end inhibition studies for 5alpha-DHP reduction and allopregnanolone oxidation indicated that 3alpha-HSD type III utilized a ternary complex (sequential) kinetic mechanism, with nicotinamide adenine dinucleotide cofactor binding before steroid substrate and leaving after steroid product.", "spo_list": [{"subject": "5alpha-DHP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "3alpha-HSD type III", "object_type": "GENE-Y"}, {"subject": "allopregnanolone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "3alpha-HSD type III", "object_type": "GENE-Y"}, {"subject": "steroid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "3alpha-HSD type III", "object_type": "GENE-Y"}, {"subject": "steroid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "3alpha-HSD type III", "object_type": "GENE-Y"}]}
{"text": "Since previous reports suggested that fluoxetine and certain other small molecules increased allopregnanolone concentrations in vivo by activating 3alpha-HSD type III, we investigated whether these small molecules were able to activate human 3alpha-HSD type III.", "spo_list": [{"subject": "fluoxetine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "3alpha-HSD type III", "object_type": "GENE-Y"}, {"subject": "allopregnanolone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "3alpha-HSD type III", "object_type": "GENE-Y"}]}
{"text": "These results characterize the role of 3alpha-HSD type III in allopregnanolone formation and suggest that activation of this enzyme by fluoxetine is likely not the mechanism by which fluoxetine increases allopregnanolone concentrations.", "spo_list": [{"subject": "allopregnanolone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "3alpha-HSD type III", "object_type": "GENE-Y"}, {"subject": "fluoxetine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "3alpha-HSD type III", "object_type": "GENE-Y"}]}
{"text": "Methylenetetrahydrofolate reductase deficiency impairs methyltetrahydrofolate synthesis, defects in cytosolic reduction of hydroxocobalamin (CblC/D) impair the synthesis of both methyl- and adenosyl cobalamin and deficiencies of methionine synthase (CblE/G) are associated with defective methyl cobalamin synthesis.", "spo_list": [{"subject": "methyltetrahydrofolate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Methylenetetrahydrofolate reductase", "object_type": "GENE-Y"}, {"subject": "methyl cobalamin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "methionine synthase", "object_type": "GENE-Y"}]}
{"text": "SOD levels of serum and hippocampus tissue were significantly increased and MDA levels were significantly decreased in the PTUÂ +Â Vit E and PTUÂ +Â L-T4Â +Â Vit E groups than the PTU and PTUÂ +Â L-T4 groups.", "spo_list": [{"subject": "PTU", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SOD", "object_type": "GENE-N"}, {"subject": "Vit E", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SOD", "object_type": "GENE-N"}, {"subject": "PTU", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SOD", "object_type": "GENE-N"}, {"subject": "L-T4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SOD", "object_type": "GENE-N"}, {"subject": "Vit E", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SOD", "object_type": "GENE-N"}]}
{"text": "Today, we used cobalt chloride, a hypoxia mimetic that inhibits proteasomal HIF-1 degradation and generates reactive oxygen species (ROS).", "spo_list": [{"subject": "cobalt chloride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HIF-1", "object_type": "GENE-Y"}]}
{"text": "An autophagic signaling was evidenced by an increase of Beclin-1, ATG 5-12, and LC3-II expression whereas the p53(mut) presence decreased with CoCl2 time exposure.", "spo_list": [{"subject": "CoCl2", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "p53", "object_type": "GENE-Y"}]}
{"text": "After inflammation was established mice were dosed with the H4R antagonist, JNJ 7777120, or anti-IL-13 antibody for comparison.", "spo_list": [{"subject": "JNJ 7777120", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "H4R", "object_type": "GENE-Y"}]}
{"text": "Expression of WWOX and FHIT is downregulated by exposure to arsenite in human uroepithelial cells.", "spo_list": [{"subject": "arsenite", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "WWOX", "object_type": "GENE-Y"}, {"subject": "arsenite", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "FHIT", "object_type": "GENE-Y"}]}
{"text": "In fact, the results for the arsenite-treated groups showed that ATR, WWOX and FHIT are downregulated by arsenite in SV-HUC-1.", "spo_list": [{"subject": "arsenite", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ATR", "object_type": "GENE-Y"}, {"subject": "arsenite", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "WWOX", "object_type": "GENE-Y"}, {"subject": "arsenite", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "FHIT", "object_type": "GENE-Y"}]}
{"text": "Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. l-Deprenyl (selegiline), an irreversible and selective inhibitor of monoamine oxidase type B (MAO-B), is rapidly absorbed from the gastrointestinal tract and distributed into tissues.", "spo_list": [{"subject": "selegiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase type B", "object_type": "GENE-Y"}, {"subject": "l-Deprenyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase type B", "object_type": "GENE-Y"}, {"subject": "l-Deprenyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "selegiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "Selegiline is metabolized into l-(-)-desmethylselegiline, l-(-)-methamphetamine, and l-(-)-amphetamine mainly in the liver through the microsomal P-450 system.", "spo_list": [{"subject": "Selegiline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-450", "object_type": "GENE-N"}, {"subject": "l-(-)-desmethylselegiline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-450", "object_type": "GENE-N"}, {"subject": "l-(-)-methamphetamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-450", "object_type": "GENE-N"}, {"subject": "l-(-)-amphetamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-450", "object_type": "GENE-N"}]}
{"text": "The metabolites are excreted mainly via urine l-(-)-Desmethylselegiline has been shown to be an irreversible inhibitor of MAO-B in the rat and in humans.", "spo_list": [{"subject": "l-(-)-Desmethylselegiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "Blockage of the HERG human cardiac K+ channel by the gastrointestinal prokinetic agent cisapride.", "spo_list": [{"subject": "cisapride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HERG human cardiac K+ channel", "object_type": "GENE-Y"}]}
{"text": "We tested the hypothesis that cisapride blocks HERG.", "spo_list": [{"subject": "cisapride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HERG", "object_type": "GENE-Y"}]}
{"text": "Under voltage-clamp conditions, cisapride block of HERG is dose dependent with a half-maximal inhibitory concentration of 6.5 nM at 22 degrees C (n = 25 cells).", "spo_list": [{"subject": "cisapride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HERG", "object_type": "GENE-Y"}]}
{"text": "Block of HERG with cisapride after channel activation was voltage dependent.", "spo_list": [{"subject": "cisapride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HERG", "object_type": "GENE-Y"}]}
{"text": "At -20 mV, 10 nM cisapride reduced HERG tail-current amplitude by 5%, whereas, at + 20 mV, the tail-current amplitude was reduced by 45% (n = 4 cells).", "spo_list": [{"subject": "cisapride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "HERG", "object_type": "GENE-Y"}]}
{"text": "We conclude that cisapride is a potent blocker of HERG channels expressed in HEK293 cells.", "spo_list": [{"subject": "cisapride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HERG", "object_type": "GENE-Y"}]}
{"text": "BACKGROUND: Two clinical trials have shown that users of 5Î±-reductase inhibitors finasteride and dutasteride (5-ARIs) have reduced overall prostate cancer risk, while the proportion of high-grade tumors is increased.", "spo_list": [{"subject": "finasteride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5Î±-reductase", "object_type": "GENE-N"}, {"subject": "dutasteride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5Î±-reductase", "object_type": "GENE-N"}]}
{"text": "FXa inhibitors, e.g. rivaroxaban and apixaban, are potent, oral direct inhibitors of prothrombinase-bound, clot-associated or free FXa.", "spo_list": [{"subject": "rivaroxaban", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FXa", "object_type": "GENE-Y"}, {"subject": "apixaban", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FXa", "object_type": "GENE-Y"}, {"subject": "rivaroxaban", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "prothrombinase", "object_type": "GENE-N"}, {"subject": "apixaban", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "prothrombinase", "object_type": "GENE-N"}, {"subject": "rivaroxaban", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FXa", "object_type": "GENE-Y"}, {"subject": "apixaban", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FXa", "object_type": "GENE-Y"}]}
{"text": "Although parenteral oral direct thrombin inhibitors (DTIs), such as argatroban and bivalirudin, have been on the market for years, DTIs such as dabigatran are novel synthetic thrombin antagonists.", "spo_list": [{"subject": "argatroban", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thrombin", "object_type": "GENE-Y"}, {"subject": "dabigatran", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "thrombin", "object_type": "GENE-Y"}]}
{"text": "Dabigatran has an advantage over the indirect thrombin inhibitors, unfractionated heparin and low-molecular-weight heparin, in that it inhibits free and fibrin-bound thrombin.", "spo_list": [{"subject": "Dabigatran", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thrombin", "object_type": "GENE-Y"}, {"subject": "Dabigatran", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "fibrin", "object_type": "GENE-N"}, {"subject": "Dabigatran", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thrombin", "object_type": "GENE-Y"}]}
{"text": "The reversible binding of dabigatran may provide safer and more predictable anticoagulant treatment than seen with irreversible, non-covalent thrombin inhibitors, e.g. hirudin.", "spo_list": [{"subject": "dabigatran", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thrombin", "object_type": "GENE-Y"}]}
{"text": "Specific control of group IVA cytosolic phospholipase A2 (cPLA2Î± or PLA2G4A) expression modulates arachidonic acid production, thus tightly regulating the downstream effects of pro- and anti-inflammatory eicosanoids.", "spo_list": [{"subject": "arachidonic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "group IVA cytosolic phospholipase A2", "object_type": "GENE-Y"}, {"subject": "arachidonic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cPLA2Î±", "object_type": "GENE-Y"}, {"subject": "arachidonic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PLA2G4A", "object_type": "GENE-Y"}]}
{"text": "We studied the antitumor activity and toxicity of ZD1694 (tomudex), a specific inhibitor of thymidylate synthase (TS), in nude mice bearing human head and neck squamous cell carcinoma A253 and FaDu xenografts.", "spo_list": [{"subject": "ZD1694", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}, {"subject": "tomudex", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}, {"subject": "ZD1694", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "tomudex", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}]}
{"text": "To test this hypothesis, we preadministered methoxypolyethyleneglycol-conjugated thymidine phosphorylase (MPEG-TPase; 2500 units/kg/dose) to reduce mouse plasma thymidine, then treated with various doses of ZD1694 using the daily x 5 or i.v. x 1 schedules in the A253 tumor model.", "spo_list": [{"subject": "thymidine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "methoxypolyethyleneglycol-conjugated thymidine phosphorylase", "object_type": "GENE-Y"}, {"subject": "thymidine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MPEG-TPase", "object_type": "GENE-Y"}]}
{"text": "The activity of the human nasal mucosa microsomes was inhibited by 8-methoxypsoralen, a known CYP2A inhibitor.", "spo_list": [{"subject": "8-methoxypsoralen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2A", "object_type": "GENE-N"}]}
{"text": "Saccharomyces cerevisiae Ï55, a subunit of the RNA polymerase III-specific general transcription factor TFIIIC, comprises an N-terminal histidine phosphatase domain (Ï55-HPD) whose catalytic activity and cellular function is poorly understood.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Saccharomyces cerevisiae Ï55", "object_type": "GENE-Y"}, {"subject": "histidine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Saccharomyces cerevisiae Ï55", "object_type": "GENE-Y"}]}
{"text": "SA9 inhibited tumor necrosis factor Î±-induced upregulation of adhesion molecules in ECs at both mRNA and protein levels, as well as the consequent monocyte adhesion to ECs.", "spo_list": [{"subject": "SA9", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tumor necrosis factor Î±", "object_type": "GENE-Y"}]}
{"text": "To study the molecular mechanism, results from luciferase assay, nuclear translocation of NF-ÎºB, and Western blot indicated that the mechanism of the anti-inflammatory effects of SA9 might be suppression of intracellular generation of ROS and inhibition of NF-ÎºB activation in ECs.", "spo_list": [{"subject": "SA9", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}]}
{"text": "SK-Br3 cells cultured in the presence of topoisomerase IIalpha (TOP2A) inhibitors doxorubicin and etopoxide (VP-16) demonstrated a 2- to 3-fold increase in FAS promoter activity when compared with control cells growing in drug-free culture conditions.", "spo_list": [{"subject": "doxorubicin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "topoisomerase IIalpha", "object_type": "GENE-Y"}, {"subject": "doxorubicin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TOP2A", "object_type": "GENE-Y"}, {"subject": "etopoxide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "topoisomerase IIalpha", "object_type": "GENE-Y"}, {"subject": "etopoxide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TOP2A", "object_type": "GENE-Y"}, {"subject": "VP-16", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "topoisomerase IIalpha", "object_type": "GENE-Y"}, {"subject": "VP-16", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TOP2A", "object_type": "GENE-Y"}, {"subject": "doxorubicin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "FAS promoter", "object_type": "GENE-N"}, {"subject": "etopoxide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "FAS promoter", "object_type": "GENE-N"}, {"subject": "VP-16", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "FAS promoter", "object_type": "GENE-N"}]}
{"text": "Cisapride was found to bind the human ether-a-go-go-related gene (HERG) potassium channel, which provides a plausible mechanism for QTc interval prolongation/arrhythmia.", "spo_list": [{"subject": "Cisapride", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human ether-a-go-go-related gene (HERG) potassium channel", "object_type": "GENE-Y"}]}
{"text": "Other QTc interval-prolonging/arrhythmic drugs that also bind to HERG provided an analogy for cisapride causing QTc interval prolongation/arrhythmia via this mechanism.", "spo_list": [{"subject": "cisapride", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "HERG", "object_type": "GENE-Y"}]}
{"text": "However, calmodulin antagonists were found to inhibit [3H]nitrendipine binding with the order of potency: pimozide greater than less than calmidazolium (R 24571) greater than trifluoperazine greater than chlorpromazine greater than promethazine greater than chlorpromazine sulfoxide, that correlates quite well with the potency of these drugs as inhibitors of calmodulin-dependent processes.", "spo_list": [{"subject": "[3H]nitrendipine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "pimozide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "calmidazolium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "R 24571", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "trifluoperazine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "chlorpromazine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "promethazine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "chlorpromazine sulfoxide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "pimozide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "calmidazolium", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "R 24571", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "trifluoperazine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "chlorpromazine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "promethazine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "chlorpromazine sulfoxide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "pimozide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "calmidazolium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "R 24571", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "trifluoperazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "chlorpromazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "promethazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "chlorpromazine sulfoxide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calmodulin", "object_type": "GENE-N"}]}
{"text": "The results suggest that calmodulin antagonists bind to a protein associated with the [3H]nitrendipine binding site that has a hydrophobic domain similar to that exposed on calmodulin by Ca++, but that this protein is not calmodulin itself.", "spo_list": [{"subject": "[3H]nitrendipine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calmodulin", "object_type": "GENE-N"}]}
{"text": "Results demonstrate that predominantly FUT7, and to a lesser extent FUT4, forms the selectin-ligand at the N terminus of leukocyte P-selectin glycoprotein ligand-1 (PSGL-1) in humans and mice.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "P-selectin glycoprotein ligand-1", "object_type": "GENE-N"}]}
{"text": "Keap1 is expressed in differentiating osteoclast-like cells and the S349T mutation selectively impairs the SQSTM1-Keap1 interaction in co-immunoprecipitations, which molecular modelling indicates results from effects on critical hydrogen bonds required to stabilise the KIR-Keap1 complex.", "spo_list": [{"subject": "hydrogen", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "KIR", "object_type": "GENE-N"}, {"subject": "hydrogen", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Keap1", "object_type": "GENE-Y"}]}
{"text": "tert-Butylcarbamate-Containing Histone Deacetylase Inhibitors: Apoptosis Induction, Cytodifferentiation, and Antiproliferative Activities in Cancer Cells.", "spo_list": [{"subject": "tert-Butylcarbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Histone Deacetylase", "object_type": "GENE-N"}]}
{"text": "Herein we report novel pyrrole- and benzene-based hydroxamates (8, 10) and 2'-aminoanilides (9, 11) bearing the tert-butylcarbamate group at the CAP moiety as histone deacetylase (HDAC) inhibitors.", "spo_list": [{"subject": "pyrrole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "histone deacetylase", "object_type": "GENE-N"}, {"subject": "benzene", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "histone deacetylase", "object_type": "GENE-N"}, {"subject": "hydroxamates", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "histone deacetylase", "object_type": "GENE-N"}, {"subject": "2'-aminoanilides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "histone deacetylase", "object_type": "GENE-N"}, {"subject": "tert-butylcarbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "histone deacetylase", "object_type": "GENE-N"}, {"subject": "pyrrole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC", "object_type": "GENE-N"}, {"subject": "benzene", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC", "object_type": "GENE-N"}, {"subject": "hydroxamates", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC", "object_type": "GENE-N"}, {"subject": "2'-aminoanilides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC", "object_type": "GENE-N"}, {"subject": "tert-butylcarbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC", "object_type": "GENE-N"}]}
{"text": "Compounds 8âb and 10âc selectively inhibited HDAC6 at the nanomolar level, whereas the other hydroxamates effected an increase in acetyl-Î±-tubulin levels in human acute myeloid leukemia U937 cells.", "spo_list": [{"subject": "hydroxamates", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "acetyl-Î±-tubulin", "object_type": "GENE-N"}]}
{"text": "GABA-evoked currents were completely and reversibly blocked by the competitive GABAA receptor antagonist bicuculline (IC50 = 1.7 microM), indicating expression of GABAA but not GABAC receptors.", "spo_list": [{"subject": "bicuculline", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "GABAA receptor", "object_type": "GENE-N"}]}
{"text": "Their affinity for GABA was moderate (EC50 = 30 microM), and the Hill coefficient was 1.3, corresponding to two GABA binding sites.", "spo_list": [{"subject": "GABA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GABA binding sites", "object_type": "GENE-N"}]}
{"text": "Adenylosuccinate synthetase (AdSS) catalyses the Mg(2+) dependent formation of adenylosuccinate from IMP and aspartate, the reaction being driven by the hydrolysis of GTP to GDP.", "spo_list": [{"subject": "adenylosuccinate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Adenylosuccinate synthetase", "object_type": "GENE-Y"}, {"subject": "adenylosuccinate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AdSS", "object_type": "GENE-Y"}, {"subject": "IMP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Adenylosuccinate synthetase", "object_type": "GENE-Y"}, {"subject": "IMP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AdSS", "object_type": "GENE-Y"}, {"subject": "aspartate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Adenylosuccinate synthetase", "object_type": "GENE-Y"}, {"subject": "aspartate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AdSS", "object_type": "GENE-Y"}, {"subject": "GTP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Adenylosuccinate synthetase", "object_type": "GENE-Y"}, {"subject": "GTP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AdSS", "object_type": "GENE-Y"}, {"subject": "GDP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Adenylosuccinate synthetase", "object_type": "GENE-Y"}, {"subject": "GDP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AdSS", "object_type": "GENE-Y"}]}
{"text": "Regulation of PfAdSS in vivo can therefore, be expected to be similar to the mouse acidic isozyme, in agreement with the role of PfAdSS as the only pathway for the synthesis of adenine nucleotides in the parasite.", "spo_list": [{"subject": "adenine nucleotides", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PfAdSS", "object_type": "GENE-Y"}]}
{"text": "However, PfAdSS differs from both the mammalian homologs in that fructose-1,6-bisphosphate, a potent inhibitor of the mammalian enzyme, is an activator of PfAdSS.", "spo_list": [{"subject": "fructose-1,6-bisphosphate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PfAdSS", "object_type": "GENE-Y"}]}
{"text": "Etazolate, an Î±-secretase activator, reduces neuroinflammation and offers persistent neuroprotection following traumatic brain injury in mice.", "spo_list": [{"subject": "Etazolate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Î±-secretase", "object_type": "GENE-N"}]}
{"text": "Hence, the aim of this study was to examine the effects of etazolate, an Î±-secretase activator, on acute and belated post-TBI consequences.", "spo_list": [{"subject": "etazolate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Î±-secretase", "object_type": "GENE-N"}]}
{"text": "The Intermediate-conductance Calcium-activated Potassium Channel KCa3.1 Regulates Vascular Smooth Muscle Cell Proliferation via Controlling Calcium-dependent Signaling.", "spo_list": [{"subject": "Calcium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Intermediate-conductance Calcium-activated Potassium Channel KCa3.1", "object_type": "GENE-Y"}]}
{"text": "Memantine is an uncompetitive (channel blocking) NMDA receptor antagonist.", "spo_list": [{"subject": "Memantine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NMDA receptor", "object_type": "GENE-N"}]}
{"text": "Like other NMDA receptor antagonists, memantine at high concentrations can inhibit mechanisms of synaptic plasticity that are believed to underlie learning and memory.", "spo_list": [{"subject": "memantine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NMDA receptor", "object_type": "GENE-N"}]}
{"text": "Blockade of NMDA receptors by memantine could theoretically confer disease-modifying activity in AD by inhibiting the \"weak\" NMDA receptor-dependent excitotoxicity that has been hypothesized to play a role in the progressive neuronal loss that underlies the evolving dementia.", "spo_list": [{"subject": "memantine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NMDA receptors", "object_type": "GENE-N"}, {"subject": "memantine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NMDA receptor", "object_type": "GENE-N"}]}
{"text": "Moreover, recent in vitro studies suggest that memantine abrogates beta-amyloid (Abeta) toxicity and possibly inhibits Abeta production.", "spo_list": [{"subject": "memantine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Abeta", "object_type": "GENE-Y"}]}
{"text": "Considerable attention has focused on the investigation of theories to explain the better tolerability of memantine over other NMDA receptor antagonists, particularly those that act by a similar channel blocking mechanism such as dissociative anesthetic-like agents (phencyclidine, ketamine, MK-801).", "spo_list": [{"subject": "memantine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NMDA receptor", "object_type": "GENE-N"}]}
{"text": "The selective norepinephrine (NE) transporter inhibitor atomoxetine (formerly called tomoxetine or LY139603) has been shown to alleviate symptoms in Attention Deficit/Hyperactivity Disorder (ADHD).", "spo_list": [{"subject": "atomoxetine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "norepinephrine (NE) transporter", "object_type": "GENE-Y"}, {"subject": "tomoxetine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "norepinephrine (NE) transporter", "object_type": "GENE-Y"}, {"subject": "LY139603", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "norepinephrine (NE) transporter", "object_type": "GENE-Y"}]}
{"text": "We investigated the mechanism of action of atomoxetine in ADHD by evaluating the interaction of atomoxetine with monoamine transporters, the effects on extracellular levels of monoamines, and the expression of the neuronal activity marker Fos in brain regions.", "spo_list": [{"subject": "atomoxetine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "monoamine transporters", "object_type": "GENE-N"}]}
{"text": "Atomoxetine inhibited binding of radioligands to clonal cell lines transfected with human NE, serotonin (5-HT) and dopamine (DA) transporters with dissociation constants (K(i)) values of 5, 77 and 1451 nM, respectively, demonstrating selectivity for NE transporters.", "spo_list": [{"subject": "Atomoxetine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "NE transporters", "object_type": "GENE-Y"}]}
{"text": "The glutamate-aspartate transporter GLAST mediates glutamate uptake at inner hair cell afferent synapses in the mammalian cochlea.", "spo_list": [{"subject": "glutamate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "glutamate-aspartate transporter", "object_type": "GENE-N"}, {"subject": "glutamate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GLAST", "object_type": "GENE-N"}]}
{"text": "Focal application of the transporter substrate D-aspartate elicited inward currents in IPCs, which were larger in the presence of anions that permeate the transporter-associated anion channel and blocked by the transporter antagonist D,L-threo-beta-benzyloxyaspartate.", "spo_list": [{"subject": "D,L-threo-beta-benzyloxyaspartate", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "anion channel", "object_type": "GENE-N"}]}
{"text": "These currents were produced by glutamate-aspartate transporters (GLAST) (excitatory amino acid transporter 1) because they were weakly inhibited by dihydrokainate, an antagonist of glutamate transporter-1 (excitatory amino acid transporter 2) and were absent from IPCs in GLAST-/- cochleas.", "spo_list": [{"subject": "dihydrokainate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "glutamate-aspartate transporters", "object_type": "GENE-Y"}, {"subject": "dihydrokainate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GLAST", "object_type": "GENE-Y"}, {"subject": "dihydrokainate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "excitatory amino acid transporter 1", "object_type": "GENE-Y"}, {"subject": "dihydrokainate", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "glutamate transporter-1", "object_type": "GENE-Y"}, {"subject": "dihydrokainate", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "excitatory amino acid transporter 2", "object_type": "GENE-Y"}]}
{"text": "Furthermore, D-aspartate-induced currents in outside-out patches from IPCs exhibited larger steady-state currents than responses elicited by L-glutamate, a prominent feature of GLAST, and examination of cochlea from GLAST-Discosoma red (DsRed) promoter reporter mice revealed that DsRed expression was restricted to IPCs and other supporting cells surrounding IHCs.", "spo_list": [{"subject": "L-glutamate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GLAST", "object_type": "GENE-Y"}]}
{"text": "Increases in the rate of spontaneously beating right atria and the force of electrically driven left atria caused by beta-adrenoceptor agonists were also measured. pA2 values for non-subtype selective beta-adrenoceptor antagonists in inhibiting isoprenaline-induced increases in rate and force were highly correlated with KD values determined for specific 125IPIN binding. pA2 values for beta 1- and beta 2-selective antagonists in inhibiting isoprenaline-induced increases in rate and force correlated well with the pKD values of these drugs in binding to beta 1-adrenoceptors, but not with the pKD values in binding to beta 2-adrenoceptors.", "spo_list": [{"subject": "isoprenaline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta-adrenoceptor", "object_type": "GENE-N"}, {"subject": "125IPIN", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta-adrenoceptor", "object_type": "GENE-N"}, {"subject": "isoprenaline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta 1-adrenoceptors", "object_type": "GENE-Y"}, {"subject": "isoprenaline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta 1-adrenoceptors", "object_type": "GENE-Y"}]}
{"text": "Dose-response curves for stimulation of both rate and force by the beta 2-selective agonists procaterol and zinterol were shifted to a much greater extent by selective blockade of beta 1-adrenoceptors with metoprolol than by selective blockade of beta 2-adrenoceptors with ICI 118,551, suggesting that these compounds caused their effects by activating beta 1-adrenoceptors.", "spo_list": [{"subject": "ICI 118,551", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "beta 2-adrenoceptors", "object_type": "GENE-Y"}, {"subject": "procaterol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "beta 1-adrenoceptors", "object_type": "GENE-Y"}, {"subject": "zinterol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "beta 1-adrenoceptors", "object_type": "GENE-Y"}]}
{"text": "New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 (COX-2)-specific inhibitors celecoxib and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.", "spo_list": [{"subject": "celecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "celecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Sepiapterin reductase (SPR) is the enzyme that catalyzes the final step of the synthesis of tetrahydrobiopterin (BH4), the cofactor for phenylalanine hydroxylase, tyrosine hydroxylase (TH), tryptophan hydroxylase, and nitric oxide synthase (NOS).", "spo_list": [{"subject": "tetrahydrobiopterin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Sepiapterin reductase", "object_type": "GENE-Y"}, {"subject": "BH4", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Sepiapterin reductase", "object_type": "GENE-Y"}, {"subject": "tetrahydrobiopterin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SPR", "object_type": "GENE-Y"}, {"subject": "BH4", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "SPR", "object_type": "GENE-Y"}]}
{"text": "Although SPR is essential for synthesizing BH4, the distribution of SPR in the human brain has not yet been clarified.", "spo_list": [{"subject": "BH4", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "SPR", "object_type": "GENE-Y"}]}
{"text": "The results indicate that there might be a BH4 biosynthetic pathway where GCH is not involved and that SPR might have some yet unidentified function(s) in addition to BH4 biosynthesis.", "spo_list": [{"subject": "BH4", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "SPR", "object_type": "GENE-Y"}]}
{"text": "The Na(+)/Ca(2+) exchanger (NCX) is a bidirectional transporter that normally extrudes Ca(2+) from the cell (forward mode), but also brings Ca(2+) into the cell (reverse mode) under special conditions such as intracellular Na(+) (Na(+)(i)) accumulation or membrane depolarization.", "spo_list": [{"subject": "Ca(2+)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Na(+)/Ca(2+) exchanger", "object_type": "GENE-N"}, {"subject": "Ca(2+)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Na(+)/Ca(2+) exchanger", "object_type": "GENE-N"}]}
{"text": "The pharmacology of NCX inhibitors has been studied extensively since the development of KB-R7943, a prototype benzyloxyphenyl NCX inhibitor, in 1996.", "spo_list": [{"subject": "KB-R7943", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NCX", "object_type": "GENE-N"}, {"subject": "benzyloxyphenyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NCX", "object_type": "GENE-N"}]}
{"text": "Intriguingly, the inhibitory potency of benzyloxyphenyl NCX inhibitors is directly coupled to the rate of Na(+)(i)-dependent inactivation.", "spo_list": [{"subject": "benzyloxyphenyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NCX", "object_type": "GENE-N"}]}
{"text": "Existing ion channel blockers, such as amiodarone, dronedarone, bepridil, aprindine, and cibenzoline, have been found to have an NCX inhibitory action.", "spo_list": [{"subject": "amiodarone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ion channel", "object_type": "GENE-N"}, {"subject": "dronedarone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ion channel", "object_type": "GENE-N"}, {"subject": "bepridil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ion channel", "object_type": "GENE-N"}, {"subject": "aprindine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ion channel", "object_type": "GENE-N"}, {"subject": "cibenzoline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ion channel", "object_type": "GENE-N"}, {"subject": "amiodarone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NCX", "object_type": "GENE-N"}, {"subject": "dronedarone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NCX", "object_type": "GENE-N"}, {"subject": "bepridil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NCX", "object_type": "GENE-N"}, {"subject": "aprindine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NCX", "object_type": "GENE-N"}, {"subject": "cibenzoline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NCX", "object_type": "GENE-N"}]}
{"text": "5. L-Glutamate (1 x 10(-6) M; 18 h) significantly (P < or = 0.05) inhibited FasL expression (40.8+/-11.3%) (cytofluorimetric analysis), whereas it did not affect Fas signalling.", "spo_list": [{"subject": "L-Glutamate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "FasL", "object_type": "GENE-Y"}]}
{"text": "Oxidation and S-nitrosylation of cysteines in human cytosolic and mitochondrial glutaredoxins: effects on structure and activity.", "spo_list": [{"subject": "S", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "human cytosolic and mitochondrial glutaredoxins", "object_type": "GENE-N"}, {"subject": "cysteines", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "human cytosolic and mitochondrial glutaredoxins", "object_type": "GENE-N"}]}
{"text": "Human Grx1 and Grx2 contain Cys-Pro-Tyr-Cys and Cys-Ser-Tyr-Cys active sites and have three and two additional structural Cys residues, respectively.", "spo_list": [{"subject": "Cys-Pro-Tyr-Cys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Human Grx1", "object_type": "GENE-Y"}, {"subject": "Cys-Pro-Tyr-Cys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Grx2", "object_type": "GENE-Y"}, {"subject": "Cys-Ser-Tyr-Cys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Human Grx1", "object_type": "GENE-Y"}, {"subject": "Cys-Ser-Tyr-Cys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Grx2", "object_type": "GENE-Y"}, {"subject": "Cys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Human Grx1", "object_type": "GENE-Y"}, {"subject": "Cys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Grx2", "object_type": "GENE-Y"}]}
{"text": "Cytosolic/nuclear Grx1 was partly inactivated by both S-nitrosylation and oxidation.", "spo_list": [{"subject": "S", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Grx1", "object_type": "GENE-Y"}]}
{"text": "Oxidation of Grx1 induced a complex pattern of disulfide-bonded dimers and oligomers formed between Cys-8 and either Cys-79 or Cys-83.", "spo_list": [{"subject": "Cys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Grx1", "object_type": "GENE-Y"}, {"subject": "Cys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Grx1", "object_type": "GENE-Y"}, {"subject": "Cys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Grx1", "object_type": "GENE-Y"}]}
{"text": "In contrast, mitochondrial Grx2 retains activity upon oxidation, did not form disulfide-bonded dimers or oligomers, and could not be S-nitrosylated.", "spo_list": [{"subject": "S", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Grx2", "object_type": "GENE-Y"}]}
{"text": "To further investigate this positive correlation and its possible therapeutic implications, a selective COX-2 inhibitor, etodolac, was tested on three variants of HT-29 colon cancer cell lines, HT-29/Inv1, HT-29/Inv2 and HT-29/Inv3, with graded increases of in vitro Matrigel invasive potential and COX-2 expression levels.", "spo_list": [{"subject": "etodolac", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.", "spo_list": [{"subject": "(R)-omeprazole", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C19", "object_type": "GENE-Y"}]}
{"text": "PURPOSE: Omeprazole has (R)- and (S)-enantiomers, which exhibit different pharmacokinetics (PK) among patients with cytochrome P450 (CYP) 2C19 genotype groups.", "spo_list": [{"subject": "Omeprazole", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cytochrome P450 (CYP) 2C19", "object_type": "GENE-Y"}]}
{"text": "Additionally, there was a significant difference in plasma concentrations of (R)-5-hydroxyomeprazole among CYP2C19 genotype groups, whereas no significant differences were observed in that of (S)-5-hydroxyomeprazole.", "spo_list": [{"subject": "(R)-5-hydroxyomeprazole", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C19", "object_type": "GENE-Y"}, {"subject": "(S)-5-hydroxyomeprazole", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C19", "object_type": "GENE-Y"}]}
{"text": "CONCLUSION: Our findings demonstrate that (R)-omeprazole HI correlated better with CYP2C19 genotype groups than racemic-omeprazole HI, and these results may be useful for classification among patients in CYP2C19 genotype groups prior to omeprazole treatment.", "spo_list": [{"subject": "(R)-omeprazole", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C19", "object_type": "GENE-Y"}, {"subject": "racemic-omeprazole", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C19", "object_type": "GENE-Y"}]}
{"text": "Androstanol and androstenol, estrone, 17Î²-estradiol, TCPOBOP, and CITCO showed compound-specific but similar affinities for both CARs.", "spo_list": [{"subject": "Androstanol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CARs", "object_type": "GENE-N"}, {"subject": "androstenol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CARs", "object_type": "GENE-N"}, {"subject": "estrone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CARs", "object_type": "GENE-N"}, {"subject": "17Î²-estradiol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CARs", "object_type": "GENE-N"}, {"subject": "TCPOBOP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CARs", "object_type": "GENE-N"}, {"subject": "CITCO", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CARs", "object_type": "GENE-N"}]}
{"text": "Binding and GTPgammaS autoradiographic analysis of preproorphanin precursor peptide products at the ORL1 and opioid receptors.", "spo_list": [{"subject": "GTPgammaS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ORL1", "object_type": "GENE-Y"}, {"subject": "GTPgammaS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "opioid receptors", "object_type": "GENE-N"}]}
{"text": "Orphanin FQ (OFQ) stimulated [35S]-GTPgammaS binding in a pattern similar to that described for [125I]-OFQ at the endogenous opioid receptor-like (ORL1) receptor.", "spo_list": [{"subject": "125I", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "opioid receptor-like (ORL1) receptor", "object_type": "GENE-Y"}, {"subject": "[35S]-GTPgammaS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "opioid receptor-like (ORL1) receptor", "object_type": "GENE-Y"}]}
{"text": "Unlike OFQ II(1-17), high concentrations of its C-terminal extension, OFQ II(1-28), stimulated [35S]-GTPgammaS binding in a mu (mu) opioid receptor-like distribution and the effect was blocked by naloxone.", "spo_list": [{"subject": "[35S]-GTPgammaS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mu (mu) opioid receptor", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "OFQ II(1-17)", "object_type": "GENE-Y"}, {"subject": "naloxone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mu (mu) opioid receptor", "object_type": "GENE-Y"}]}
{"text": "Taken together, these findings support the view that (1) OFQ is the only ppOFQ peptide that binds to and activates the ORL1 receptor and (2) OFQ II(1-28) does not bind or stimulate [35S]-GTPgammaS binding in cells expressing the mu opioid receptor.", "spo_list": [{"subject": "[35S]-GTPgammaS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mu opioid receptor", "object_type": "GENE-Y"}]}
{"text": "Furthermore, the metabolic activities for all three compounds in HIC were largely inhibited by menadione, which has been used as a carbonyl reductase (CBR)-selective chemical inhibitor.", "spo_list": [{"subject": "menadione", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonyl reductase", "object_type": "GENE-N"}, {"subject": "menadione", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CBR", "object_type": "GENE-N"}]}
{"text": "Preferential inhibition of human phosphodiesterase 4 by ibudilast.", "spo_list": [{"subject": "ibudilast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human phosphodiesterase 4", "object_type": "GENE-N"}]}
{"text": "Ibudilast effectively blocks lipopolysaccharide (LPS)-induced tumor necrosis factor (TNFalpha, IC50 = 6.2 microM) and N-formyl-Met-Leu-Phe (fMLP)-induced leukotriene (LT) B4 biosynthesis (IC50 = 2.5 microM) in human whole blood, which are 3 and 6-fold more potent than cilomilast, respectively.", "spo_list": [{"subject": "Ibudilast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TNFalpha", "object_type": "GENE-Y"}]}
{"text": "The attenuated inflammatory and allergic responses from the potent and preferential PDE4 inhibition of ibudilast may have contributed significantly to its beneficial pharmacological responses and distinguishes ibudilast from the other ophthalmic solutions in the treatment of ocular allergy.", "spo_list": [{"subject": "ibudilast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}]}
{"text": "Rats were fed experimental diets containing SPI or casein as a nitrogen source.", "spo_list": [{"subject": "nitrogen", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "casein", "object_type": "GENE-N"}]}
{"text": "Astemizole, a potent histamine H1-receptor antagonist: effect in allergic rhinoconjunctivitis, on antigen and histamine induced skin weal responses and relationship to serum levels.", "spo_list": [{"subject": "Astemizole", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}]}
{"text": "The efficacy of astemizole, a new, long acting, oral histamine H1-receptor antagonist was compared to placebo for the treatment of allergic rhinitis and conjunctivitis during the grass pollen season of 1982.", "spo_list": [{"subject": "astemizole", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}]}
{"text": "The activity of PAL, which plays an important role in plant defence, was also activated by SNP in the light, not in the dark.", "spo_list": [{"subject": "SNP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PAL", "object_type": "GENE-N"}]}
{"text": "LXRs are thought to be activated predominantly by oxysterols generated enzymatically from cholesterol in different cell organelles.", "spo_list": [{"subject": "oxysterols", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "LXRs", "object_type": "GENE-N"}]}
{"text": "Defects resulting in slowed release of cholesterol from late endosomes and lysosomes or reduction in sterol-27-hydroxylase activity lead to specific blocks in oxysterol production and impaired LXR-dependent gene activation.", "spo_list": [{"subject": "oxysterol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "sterol-27-hydroxylase", "object_type": "GENE-Y"}]}
{"text": "The purpose of this review is to summarize current knowledge about oxysterol-dependent activation by LXR of genes involved in reverse cholesterol transport, and what these defects of cell cholesterol homeostasis can teach us about the critical pathways of oxysterol generation for expression of LXR-dependent genes.", "spo_list": [{"subject": "oxysterol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "LXR", "object_type": "GENE-N"}]}
{"text": "A series of indazole arylsulfonamides were synthesized and examined as human CCR4 antagonists.", "spo_list": [{"subject": "indazole arylsulfonamides", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "human CCR4", "object_type": "GENE-Y"}]}
{"text": "Aryl sulfonamide antagonists bind to CCR4 at an intracellular allosteric site denoted site II.", "spo_list": [{"subject": "Aryl sulfonamide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CCR4", "object_type": "GENE-Y"}]}
{"text": "Wattakaka volubilis steroidal glycoside mixture (WVSM) and PPG (1-50Î¼M) significantly inhibited the COX-2 and iNOS enzymes resulting in low levels of PGE2 and NO in LPS-induced RAW 264.7 macrophage cells.", "spo_list": [{"subject": "steroidal glycoside", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "PPG", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "steroidal glycoside", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "PPG", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "iNOS", "object_type": "GENE-Y"}]}
{"text": "Once formed, the molecule can be converted to glycine by alanine-glyoxylate aminotransferase (AGAT).", "spo_list": [{"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "alanine-glyoxylate aminotransferase", "object_type": "GENE-Y"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AGAT", "object_type": "GENE-Y"}]}
{"text": "The considerable potential of the epidermal growth factor receptor-selective tyrosine kinase inhibitor, ZD 1839 (Iressa; AstraZeneca) to efficiently treat, and perhaps even prevent, endocrine-resistant breast cancer is highlighted.", "spo_list": [{"subject": "ZD 1839", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "Iressa", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "ZD 1839", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "epidermal growth factor receptor", "object_type": "GENE-Y"}, {"subject": "Iressa", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "epidermal growth factor receptor", "object_type": "GENE-Y"}]}
{"text": "Synthesis and antitumor activity of 1,3,4-oxadiazole possessing 1,4-benzodioxan moiety as a novel class of potent methionine aminopeptidase type II inhibitors.", "spo_list": [{"subject": "1,4-benzodioxan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "methionine aminopeptidase type II", "object_type": "GENE-Y"}, {"subject": "1,3,4-oxadiazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "methionine aminopeptidase type II", "object_type": "GENE-Y"}]}
{"text": "Moreover, limited cleavage of SNAP-25 was conferred onto the protease from BoNT/E when fused to the N-terminus of BoNT/A.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "BoNT/A", "object_type": "GENE-Y"}]}
{"text": "The basis of the model is the generally accepted mechanism of action of steroid hormones in which corticosteroids bind to cytosolic receptors forming steroid-receptor complexes, which are activated and translocated into the nucleus.", "spo_list": [{"subject": "corticosteroids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "cytosolic receptors", "object_type": "GENE-N"}, {"subject": "corticosteroids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "steroid-receptor", "object_type": "GENE-N"}]}
{"text": "The association/dissociation kinetics of prednisolone binding to the glucocorticoid receptor were measured separately in vitro at 37 degrees C. Total plasma, free plasma, and CBG-free plasma prednisolone concentrations could be used equally well in the model to account for the time course of receptor concentrations and TAT activity.", "spo_list": [{"subject": "prednisolone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}]}
{"text": "Biocatalytic production of alpha-hydroxy ketones and vicinal diols by yeast and human aldo-keto reductases.", "spo_list": [{"subject": "alpha-hydroxy ketones", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "yeast and human aldo-keto reductases", "object_type": "GENE-N"}, {"subject": "vicinal diols", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "yeast and human aldo-keto reductases", "object_type": "GENE-N"}]}
{"text": "The Î±-hydroxy ketones are used as building blocks for compounds of pharmaceutical interest (such as antidepressants, HIV-protease inhibitors and antitumorals).", "spo_list": [{"subject": "Î±-hydroxy ketones", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HIV-protease", "object_type": "GENE-N"}]}
{"text": "The reactions have been carried out with pure enzymes and with an NADPH-regenerating system consisting of glucose-6-phosphate and glucose-6-phosphate dehydrogenase.", "spo_list": [{"subject": "NADPH", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "glucose-6-phosphate dehydrogenase", "object_type": "GENE-Y"}]}
{"text": "According to the regioselectivity and stereoselectivity, the AKRs studied can be divided in two groups: one of them showed preference for the reduction of the proximal keto group, resulting in the S-enantiomer of the corresponding Î±-hydroxy ketones.", "spo_list": [{"subject": "keto", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AKRs", "object_type": "GENE-N"}, {"subject": "Î±-hydroxy ketones", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AKRs", "object_type": "GENE-N"}]}
{"text": "Three of the AKRs used (AKR1B1, AKR1B10 and AKR3C1) could produce 2,3-butanediol from acetoin.", "spo_list": [{"subject": "2,3-butanediol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AKRs", "object_type": "GENE-N"}, {"subject": "2,3-butanediol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AKR1B1", "object_type": "GENE-Y"}, {"subject": "2,3-butanediol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AKR1B10", "object_type": "GENE-Y"}, {"subject": "2,3-butanediol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AKR3C1", "object_type": "GENE-N"}, {"subject": "acetoin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AKRs", "object_type": "GENE-N"}, {"subject": "acetoin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AKR1B1", "object_type": "GENE-Y"}, {"subject": "acetoin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AKR1B10", "object_type": "GENE-Y"}, {"subject": "acetoin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AKR3C1", "object_type": "GENE-N"}]}
{"text": "In addition, we have demonstrated the utility of these AKRs in the synthesis of selected Î±-hydroxy ketones and diols.", "spo_list": [{"subject": "Î±-hydroxy ketones", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AKRs", "object_type": "GENE-N"}, {"subject": "diols", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AKRs", "object_type": "GENE-N"}]}
{"text": "Hydrogen peroxide-mediated oxidative stress disrupts calcium binding on calmodulin: more evidence for oxidative stress in vitiligo.", "spo_list": [{"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calmodulin", "object_type": "GENE-Y"}]}
{"text": "Patients with acute vitiligo have low epidermal catalase expression/activities and accumulate 10(-3) M H(2)O(2).", "spo_list": [{"subject": "H(2)O(2)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "catalase", "object_type": "GENE-Y"}]}
{"text": "Since 10(-3)M H(2)O(2) oxidises methionine and tryptophan residues in proteins, we examined calcium binding to calmodulin in the presence and absence of H(2)O(2) utilising (45)calcium.", "spo_list": [{"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calmodulin", "object_type": "GENE-Y"}]}
{"text": "The results showed that all four calcium atoms exchanged per molecule of calmodulin.", "spo_list": [{"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calmodulin", "object_type": "GENE-Y"}]}
{"text": "Taken together H(2)O(2)-mediated oxidation affects calcium binding in calmodulin leading to perturbed calcium homeostasis and perturbed l-phenylalanine-uptake in the epidermis of acute vitiligo.", "spo_list": [{"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calmodulin", "object_type": "GENE-Y"}]}
{"text": "Benzoquinone Reveals a Cysteine-Dependent Desensitization Mechanism of TRPA1.", "spo_list": [{"subject": "Cysteine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "TRPA1", "object_type": "GENE-Y"}]}
{"text": "Electrophilic chemicals activate both insect and vertebrate TRPA1 via covalent modification of cysteine residues in the amino-terminal region.", "spo_list": [{"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "TRPA1", "object_type": "GENE-Y"}, {"subject": "amino", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "TRPA1", "object_type": "GENE-Y"}]}
{"text": "Although naturally occurring electrophilic plant compounds, such as mustard oil and cinnamaldehyde, are TRPA1 agonists, it is unknown whether arthropod-produced electrophiles activate mammalian TRPA1.", "spo_list": [{"subject": "cinnamaldehyde", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "TRPA1", "object_type": "GENE-Y"}]}
{"text": "We used whole-cell recordings of human embryonic kidney cells heterologously expressing either wild-type TRPA1 or TRPA1 with three serine-substituted cysteines crucial for electrophile activation (C621S, C641S, C665S).", "spo_list": [{"subject": "serine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "TRPA1", "object_type": "GENE-Y"}, {"subject": "cysteines", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "TRPA1", "object_type": "GENE-Y"}, {"subject": "serine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "C621S", "object_type": "GENE-N"}, {"subject": "cysteines", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "C621S", "object_type": "GENE-N"}, {"subject": "serine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "C641S", "object_type": "GENE-N"}, {"subject": "cysteines", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "C641S", "object_type": "GENE-N"}, {"subject": "serine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "C665S", "object_type": "GENE-N"}, {"subject": "cysteines", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "C665S", "object_type": "GENE-N"}]}
{"text": "We found that pBQN activates TRPA1 starting at 10 nM and peaking at 300 nM; higher concentrations caused rapid activation followed by a fast decline.", "spo_list": [{"subject": "pBQN", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRPA1", "object_type": "GENE-Y"}]}
{"text": "Interestingly, following pBQN desensitization, wild-type TRPA1 had dramatically reduced response to the nonelectrophile agonist carvacrol, whereas the triple cysteine mutant TRPA1 retained its full response.", "spo_list": [{"subject": "carvacrol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "TRPA1", "object_type": "GENE-Y"}, {"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "TRPA1", "object_type": "GENE-Y"}, {"subject": "carvacrol", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "TRPA1", "object_type": "GENE-Y"}]}
{"text": "Our results suggest that modification of multiple cysteine residues by electrophilic compounds can generate both activation and desensitization of the TRPA1 channel.", "spo_list": [{"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "TRPA1", "object_type": "GENE-Y"}]}
{"text": "Fourteen of 17 parabens exhibited hERÎ± and/or hERÎ² agonistic activity at concentrations of â©½1Ã10(-5)M, whereas none of the 17 parabens showed AR agonistic or antagonistic activity.", "spo_list": [{"subject": "parabens", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "hERÎ±", "object_type": "GENE-Y"}, {"subject": "parabens", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "hERÎ²", "object_type": "GENE-Y"}]}
{"text": "Among 12 parabens with linear alkyl chains ranging in length from C1 to C12, heptylparaben (C7) and pentylparaben (C5) showed the most potent ERÎ± and ERÎ² agonistic activity in the order of 10(-7)M and 10(-8)M, respectively, and the activities decreased in a stepwise manner as the alkyl chain was shortened to C1 or lengthened to C12.", "spo_list": [{"subject": "parabens", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "alkyl", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "heptylparaben", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "pentylparaben", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "parabens", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERÎ²", "object_type": "GENE-Y"}, {"subject": "alkyl", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERÎ²", "object_type": "GENE-Y"}, {"subject": "heptylparaben", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERÎ²", "object_type": "GENE-Y"}, {"subject": "pentylparaben", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERÎ²", "object_type": "GENE-Y"}]}
{"text": "Most parabens showing estrogenic activity exhibited ERÎ²-agonistic activity at lower concentrations than those inducing ERÎ±-agonistic activity.", "spo_list": [{"subject": "parabens", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERÎ²", "object_type": "GENE-Y"}, {"subject": "parabens", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERÎ±", "object_type": "GENE-Y"}]}
{"text": "These results indicate that parabens are selective agonists for ERÎ² over ERÎ±; their interactions with ERÎ±/Î² are dependent on the size and bulkiness of the alkyl groups; and they are metabolized by carboxylesterases, leading to attenuation of their estrogenic activity.", "spo_list": [{"subject": "parabens", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERÎ²", "object_type": "GENE-Y"}, {"subject": "parabens", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "parabens", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "carboxylesterases", "object_type": "GENE-N"}]}
{"text": "Interspecies variation in the metabolism of zoniporide by aldehyde oxidase.", "spo_list": [{"subject": "zoniporide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "aldehyde oxidase", "object_type": "GENE-Y"}]}
{"text": "8. The domestic animals also showed marked species differences in the AO activity and affinity toward zoniporide.", "spo_list": [{"subject": "zoniporide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AO", "object_type": "GENE-N"}]}
{"text": "Among neuroleptics, the four most potent compounds at the human serotonin transporter were triflupromazine, fluperlapine, chlorpromazine, and ziprasidone (K(D) 24-39 nM); and at the norepinephrine transporter, chlorpromazine, zotepine, chlorprothixene, and promazine (K(D) 19-25 nM).", "spo_list": [{"subject": "neuroleptics", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human serotonin transporter", "object_type": "GENE-Y"}, {"subject": "triflupromazine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human serotonin transporter", "object_type": "GENE-Y"}, {"subject": "fluperlapine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human serotonin transporter", "object_type": "GENE-Y"}, {"subject": "chlorpromazine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human serotonin transporter", "object_type": "GENE-Y"}, {"subject": "ziprasidone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human serotonin transporter", "object_type": "GENE-Y"}, {"subject": "chlorpromazine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "norepinephrine transporter", "object_type": "GENE-Y"}, {"subject": "zotepine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "norepinephrine transporter", "object_type": "GENE-Y"}, {"subject": "chlorprothixene", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "norepinephrine transporter", "object_type": "GENE-Y"}, {"subject": "promazine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "norepinephrine transporter", "object_type": "GENE-Y"}]}
{"text": "At the human dopamine transporter, only pimozide (K(D) = 69+/-3) ziprasidone (K(D) = 76+/-5) had notable potency.", "spo_list": [{"subject": "pimozide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human dopamine transporter", "object_type": "GENE-Y"}, {"subject": "ziprasidone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human dopamine transporter", "object_type": "GENE-Y"}]}
{"text": "Adult male rats were i.m injected 20 min before i.p injection of IL-1beta, with (i): a COX-1/COX-2 inhibitor (ketoprofen); (ii) a COX-2 selective inhibitor (NS 398); or (iii) a 5-LOX inhibitor (BW A4C).", "spo_list": [{"subject": "ketoprofen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "ketoprofen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "NS 398", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "BW A4C", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-LOX", "object_type": "GENE-Y"}]}
{"text": "In a previous study using isolated rat liver mitochondria, we observed that ABA inhibited the activity of adenine nucleotide translocator and FoF1-ATPase.", "spo_list": [{"subject": "ABA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "adenine nucleotide translocator", "object_type": "GENE-N"}, {"subject": "ABA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FoF1-ATPase", "object_type": "GENE-N"}]}
{"text": "The hepatocytes that were previously incubated with proadifen, a cytochrome P450 inhibitor, are more sensitive to the compound as observed by a rapid decrease in the mitochondrial membrane potential accompanied by reductions in ATP concentration and cell viability and a disruption of intracellular Ca(2+) homeostasis followed by necrosis.", "spo_list": [{"subject": "proadifen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cytochrome P450", "object_type": "GENE-N"}]}
{"text": "H2AX is thought to operate primarily through its C-terminal S139 phosphorylation, which mediates the recruitment of DNA damage response (DDR) factors to chromatin at DSB sites.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "H2AX", "object_type": "GENE-Y"}]}
{"text": "Determinants of voltage-dependent inactivation affect Mibefradil block of calcium channels.", "spo_list": [{"subject": "Mibefradil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calcium channels", "object_type": "GENE-N"}]}
{"text": "Mibefradil (Ro 40-5967) belongs to a new chemical class of these molecules which differs from other Ca2+ antagonists by its ability to potently block T-type Ca2+ channels.", "spo_list": [{"subject": "Ro 40-5967", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "T-type Ca2+ channels", "object_type": "GENE-N"}, {"subject": "Mibefradil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "T-type Ca2+ channels", "object_type": "GENE-N"}]}
{"text": "To further analyze the mechanism governing the Ca2+ channel-Mibefradil interaction, we examined the effect of Mibefradil on various recombinant Ca2+ channels expressed in mammalian cells from their cloned cDNAs, using Ca2+ as the permeant ion at physiological concentration.", "spo_list": [{"subject": "Mibefradil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Ca2+ channel", "object_type": "GENE-N"}]}
{"text": "Mibefradil blocked alpha1A and alpha1E with a Kd comparable to that reported for T-type channels, but had a lower affinity (approximately 30-fold) for alpha1C.", "spo_list": [{"subject": "Mibefradil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "T-type channels", "object_type": "GENE-N"}]}
{"text": "Pharmacological doses of the mTOR inhibitor rapamycin reduce albuminura in diabetes.", "spo_list": [{"subject": "rapamycin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}]}
{"text": "High glucose (HG) induces apoptosis of podocytes, inhibits AMPK activation, inactivates tuberin and activates mTOR.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "mTOR", "object_type": "GENE-Y"}]}
{"text": "Inhibition of mTOR by low dose rapamycin decreases HG-induced Nox4 and Nox1, NADPH oxidase activity and podocyte apoptosis.", "spo_list": [{"subject": "rapamycin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}, {"subject": "rapamycin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Nox4", "object_type": "GENE-Y"}, {"subject": "rapamycin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Nox1", "object_type": "GENE-Y"}, {"subject": "rapamycin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NADPH oxidase", "object_type": "GENE-N"}]}
{"text": "Inhibition of mTOR by small dose of rapamycin reduces podocyte apoptosis, attenuates glomerular injury and albuminuria.", "spo_list": [{"subject": "rapamycin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}]}
{"text": "The use of Delta 6 desaturase (D6D) twice in the conversion of alpha-linolenic acid (ALA; 18:3n-3) to docosahexaenoic acid (DHA; 22:6n-3) suggests that this enzyme may play a key regulatory role in the synthesis and accumulation of DHA from ALA.", "spo_list": [{"subject": "alpha-linolenic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "D6D", "object_type": "GENE-Y"}, {"subject": "alpha-linolenic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Delta 6 desaturase", "object_type": "GENE-Y"}, {"subject": "ALA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "D6D", "object_type": "GENE-Y"}, {"subject": "ALA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Delta 6 desaturase", "object_type": "GENE-Y"}, {"subject": "docosahexaenoic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "D6D", "object_type": "GENE-Y"}, {"subject": "docosahexaenoic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Delta 6 desaturase", "object_type": "GENE-Y"}, {"subject": "DHA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "D6D", "object_type": "GENE-Y"}, {"subject": "DHA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Delta 6 desaturase", "object_type": "GENE-Y"}, {"subject": "DHA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Delta 6 desaturase", "object_type": "GENE-Y"}, {"subject": "ALA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Delta 6 desaturase", "object_type": "GENE-Y"}, {"subject": "DHA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "D6D", "object_type": "GENE-Y"}, {"subject": "ALA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "D6D", "object_type": "GENE-Y"}]}
{"text": "The accumulation of the post-D6D products of 22:5n-3, 24:6n-3 and DHA, in cell phospholipids was saturated at concentrations of >18 microM ALA.", "spo_list": [{"subject": "DHA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "D6D", "object_type": "GENE-Y"}]}
{"text": "The parallel pattern of accumulation of 24:6n-3 and DHA in response to increasing concentrations of ALA suggests that the competition between 24:5n-3 and ALA for D6D may contribute to the limited accumulation of DHA in cell membranes.", "spo_list": [{"subject": "ALA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "D6D", "object_type": "GENE-Y"}, {"subject": "DHA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "D6D", "object_type": "GENE-Y"}]}
{"text": "At the h5-HT2A receptor, d-lysergic acid diethylamide (LSD) and the antiparkinsonian agents lisuride, bromocriptine and pergolide exhibit a higher potency for Gq/11 activation than calcium release in contrast with all the other tested ligands such as 5-HT, mCPP and BW723C86, that show an opposite preference of signalling pathway.", "spo_list": [{"subject": "d-lysergic acid diethylamide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Gq/11", "object_type": "GENE-N"}, {"subject": "LSD", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Gq/11", "object_type": "GENE-N"}, {"subject": "lisuride", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Gq/11", "object_type": "GENE-N"}, {"subject": "bromocriptine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Gq/11", "object_type": "GENE-N"}, {"subject": "pergolide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Gq/11", "object_type": "GENE-N"}, {"subject": "d-lysergic acid diethylamide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "h5-HT2A", "object_type": "GENE-Y"}, {"subject": "LSD", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "h5-HT2A", "object_type": "GENE-Y"}, {"subject": "lisuride", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "h5-HT2A", "object_type": "GENE-Y"}, {"subject": "bromocriptine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "h5-HT2A", "object_type": "GENE-Y"}, {"subject": "pergolide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "h5-HT2A", "object_type": "GENE-Y"}]}
{"text": "Interestingly, the non-hallucinogenic compound lisuride behaves as a partial agonist for both Gq/11 activation and calcium release at the three 5-HT2 receptors, in contrast with DOI, LSD, pergolide and bromocriptine, which are known to provoke hallucinations, and behave as more efficacious agonists.", "spo_list": [{"subject": "lisuride", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "Gq/11", "object_type": "GENE-N"}, {"subject": "LSD", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "5-HT2", "object_type": "GENE-Y"}, {"subject": "lisuride", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT2", "object_type": "GENE-Y"}, {"subject": "pergolide", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "5-HT2", "object_type": "GENE-Y"}, {"subject": "bromocriptine", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "5-HT2", "object_type": "GENE-Y"}]}
{"text": "A common ala-to-val mutation in the methylenetetrahydrofolate reductase gene (MTHFR) is associated with an elevated level of plasma homocysteine.", "spo_list": [{"subject": "homocysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "methylenetetrahydrofolate reductase gene", "object_type": "GENE-Y"}, {"subject": "homocysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MTHFR", "object_type": "GENE-Y"}]}
{"text": "The results of this study showed that methylation of NIS promoter is a very frequent event in both benign and malignant tumors as well as in their surrounding tissues, and characterized a non-homogeneous methylation pattern along the CpG island.", "spo_list": [{"subject": "CpG", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "NIS promoter", "object_type": "GENE-N"}]}
{"text": "Dicumarol, a potent inhibitor of quinone oxidoreductase, at high concentration (500 microm ) caused only a 72% decrease in the utilization of resorufin.", "spo_list": [{"subject": "Dicumarol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "quinone oxidoreductase", "object_type": "GENE-N"}]}
{"text": "Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines: an in vitro study.", "spo_list": [{"subject": "Cerivastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HMG-CoA reductase", "object_type": "GENE-Y"}]}
{"text": "Cerivastatin is used in the treatment of hypercholesterolemia to inhibit 3-hydroxy 3-methylglutaryl coenzyme A reductase and thus prevent the synthesis of cholesterol precursors, such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), responsible, respectively, for translocation of Ras and Rho to the cell membrane, a step required for their cell signaling, leading to cell proliferation and migration.", "spo_list": [{"subject": "Cerivastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "3-hydroxy 3-methylglutaryl coenzyme A reductase", "object_type": "GENE-Y"}, {"subject": "cholesterol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "3-hydroxy 3-methylglutaryl coenzyme A reductase", "object_type": "GENE-Y"}, {"subject": "farnesyl pyrophosphate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "3-hydroxy 3-methylglutaryl coenzyme A reductase", "object_type": "GENE-Y"}, {"subject": "FPP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "3-hydroxy 3-methylglutaryl coenzyme A reductase", "object_type": "GENE-Y"}, {"subject": "geranylgeranyl pyrophosphate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "3-hydroxy 3-methylglutaryl coenzyme A reductase", "object_type": "GENE-Y"}, {"subject": "GGPP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "3-hydroxy 3-methylglutaryl coenzyme A reductase", "object_type": "GENE-Y"}]}
{"text": "Moreover, cerivastatin was also shown to induce inactivation of NFkappaB, in a RhoA inhibition-dependent manner, resulting in a decrease in urokinase and metalloproteinase-9 expression, two proteases involved in cell migration.", "spo_list": [{"subject": "cerivastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NFkappaB", "object_type": "GENE-N"}, {"subject": "cerivastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RhoA", "object_type": "GENE-Y"}, {"subject": "cerivastatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "urokinase", "object_type": "GENE-Y"}, {"subject": "cerivastatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "metalloproteinase-9", "object_type": "GENE-Y"}]}
{"text": "G protein dependent alterations in [125I]iodocyanopindolol and +/- cyanopindolol binding at 5-HT1B binding sites in rat brain membranes.", "spo_list": [{"subject": "+/- cyanopindolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1B", "object_type": "GENE-Y"}, {"subject": "[125I]iodocyanopindolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1B", "object_type": "GENE-Y"}]}
{"text": "Several manipulations that affect G protein/receptor coupling also alter the binding of [125I]iodocyanopindolol ([125I]ICYP) and [corrected] +/- cyanopindolol (+/- CYP) to rat brain 5-HT1B binding sites in radioligand binding assays.", "spo_list": [{"subject": "[125I]iodocyanopindolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1B", "object_type": "GENE-Y"}, {"subject": "[125I]ICYP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1B", "object_type": "GENE-Y"}, {"subject": "+/- cyanopindolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1B", "object_type": "GENE-Y"}, {"subject": "+/- CYP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1B", "object_type": "GENE-Y"}]}
{"text": "+/- CYP affinity for 5-HT1B sites labeled by [3H]dihydroergotamine [( 3H]DE) also displays a small but significant reduction (from Ki = 1.4 nM to Ki = 3.5nM) by the inclusion of 100 microM GTP.", "spo_list": [{"subject": "+/- CYP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1B", "object_type": "GENE-Y"}]}
{"text": "The N-terminus of the type 1 interferon receptor subunit, IFNAR1, has high amino acid sequence similarity to the receptor binding B subunit of the Escherichia coli-derived verotoxin 1, VT1.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "type 1 interferon receptor subunit", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "IFNAR1", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "type 1 interferon receptor subunit", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "IFNAR1", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "B subunit of the Escherichia coli-derived verotoxin 1, VT1", "object_type": "GENE-N"}]}
{"text": "Pancreatic tissues of rats and blood samples were obtained.Tau treatment significantly decreased serum amylase activity (p < 0.001), total injury score (p < 0.001), malondialdehyde levels (p < 0.001) and myeloperoxidase (MPO) activity (p < 0.001).", "spo_list": [{"subject": "Tau", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "serum amylase", "object_type": "GENE-N"}, {"subject": "Tau", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "myeloperoxidase", "object_type": "GENE-Y"}, {"subject": "Tau", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MPO", "object_type": "GENE-Y"}]}
{"text": "Histopathologic scores in the AP + Tau and Tau groups were significantly lower compared with the AP group (both p < 0.001).These results showed that Tau reduces lipid peroxidation, amylase and MPO activities and the concentrations of proinflammatory cytokines secondary to AP and also increases superoxide dismutase and glutathione peroxidase activities in rats with sodium taurocholate-induced AP.", "spo_list": [{"subject": "Tau", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cytokines", "object_type": "GENE-N"}, {"subject": "Tau", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "superoxide dismutase", "object_type": "GENE-N"}, {"subject": "Tau", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "glutathione peroxidase", "object_type": "GENE-N"}]}
{"text": "Endogenously produced asymmetrically methylated arginine residues are competitive inhibitors of all three isoforms of nitric oxide synthase (NOS).", "spo_list": [{"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "nitric oxide synthase", "object_type": "GENE-N"}, {"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NOS", "object_type": "GENE-N"}]}
{"text": "The enzyme dimethylarginine dimethylaminohydrolase (DDAH) specifically hydrolyzes these asymmetrically methylated arginine residues to citrulline and methylamines.", "spo_list": [{"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "dimethylarginine dimethylaminohydrolase", "object_type": "GENE-N"}, {"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DDAH", "object_type": "GENE-N"}]}
{"text": "Previously we have proposed that regulation of asymmetric methylarginine concentration by DDAH may provide a novel mechanism for the regulation of NOS activity in vivo.", "spo_list": [{"subject": "methylarginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DDAH", "object_type": "GENE-N"}]}
{"text": "Characterization study showed that mPPO from Snake fruit was optimally active at pH 6.5, temperature 30Â°C and active towards diphenols as substrates.", "spo_list": [{"subject": "diphenols", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "mPPO", "object_type": "GENE-N"}]}
{"text": "Aripiprazole, (+)terguride, OPC-4392 and (-)3-PPP have been classified as dopamine D(2) receptor partial agonists based largely on their activity in second messenger-based assays of dopamine D(2) receptor signalling.", "spo_list": [{"subject": "Aripiprazole", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "dopamine D(2) receptor", "object_type": "GENE-Y"}, {"subject": "(+)terguride", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "dopamine D(2) receptor", "object_type": "GENE-Y"}, {"subject": "OPC-4392", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "dopamine D(2) receptor", "object_type": "GENE-Y"}, {"subject": "(-)3-PPP", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "dopamine D(2) receptor", "object_type": "GENE-Y"}]}
{"text": "These compounds were all less potent and displayed lower intrinsic activity in the Ca(2+) assay (aripiprazole = 24.3%, (+)terguride = 56.9%, OPC-4392 = 58.6% and (-)3-PPP = 75.1%), and aripiprazole (E(max) = 54.5%) displayed a substantially lower intrinsic activity than (+)terguride (E(max) = 92.3%), OPC-4392 (E(max) = 93.1%) and (-)3-PPP (E(max) = 101.1%) in the more downstream-based ERK2 phosphoprotein expression assay.", "spo_list": [{"subject": "(+)terguride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ERK2", "object_type": "GENE-Y"}, {"subject": "OPC-4392", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ERK2", "object_type": "GENE-Y"}, {"subject": "(-)3-PPP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ERK2", "object_type": "GENE-Y"}]}
{"text": "These drug effects on Ca(2+) mobilization and ERK2 phosphoprotein expression were mediated through dopamine hD(2L) receptors, as they all were blocked by (-)raclopride, whereas (-)raclopride and other dopamine D(2) receptor antagonists (haloperidol, risperidone, ziprasidone, olanzapine, clozapine and quetiapine) were inactive on their own in both assays.", "spo_list": [{"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D(2) receptor", "object_type": "GENE-Y"}, {"subject": "risperidone", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D(2) receptor", "object_type": "GENE-Y"}, {"subject": "ziprasidone", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D(2) receptor", "object_type": "GENE-Y"}, {"subject": "olanzapine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D(2) receptor", "object_type": "GENE-Y"}, {"subject": "clozapine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D(2) receptor", "object_type": "GENE-Y"}, {"subject": "quetiapine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D(2) receptor", "object_type": "GENE-Y"}, {"subject": "(-)raclopride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ERK2", "object_type": "GENE-Y"}, {"subject": "(-)raclopride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dopamine hD(2L) receptors", "object_type": "GENE-Y"}]}
{"text": "However, those for P4-H activity remained uniformly elevated after one hundred days on NTBC, the PIIINP biomarker even increasing above its grossly abnormal, initial level.", "spo_list": [{"subject": "NTBC", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "P4-H", "object_type": "GENE-N"}]}
{"text": "Anti-inflammatory activity of hexane extracts from bones and internal organs of Anguilla japonica suppresses cyclooxygenase-2-dependent prostaglandin D2 generation in mast cells and anaphylaxis in mice.", "spo_list": [{"subject": "prostaglandin D2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}]}
{"text": "The purpose of this study is to investigate the effects of n-hexane extracts from bones and internal organs of Japanese eel, Anguilla japonica (HEE), on cyclooxygenase-2 (COX-2)-dependent prostaglandin D2 (PGD2) generation in stem cell factor (SCF), IL-10, plus LPS-induced mouse bone marrow-derived mast cells (BMMCs) and on passive cutaneous anaphylaxis (PCA) in mice.", "spo_list": [{"subject": "prostaglandin D2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "prostaglandin D2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "PGD2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "PGD2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Modulation of the nitric oxide producing system (demonstrated via the NADPH-diaphorase histochemical reaction) by oestradiol has been established in several structures of the rat brain.", "spo_list": [{"subject": "nitric oxide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "NADPH-diaphorase", "object_type": "GENE-N"}]}
{"text": "Adult ovariectomised rats were divided into six groups and injected either with vehicle or a single dose of oestradiol, a selective ERÎ± agonist-PPT [4,4',4â³-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol], a selective ERÎ² agonist-DPN [2,3-bis(4-hydroxyphenyl)-propionitrile], a selective ERÎ± antagonist-MPP [1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride] or a selective ERÎ² antagonist-PHTPP (4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol).", "spo_list": [{"subject": "PPT", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "4,4',4â³-(4-propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "DPN", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERÎ²", "object_type": "GENE-Y"}, {"subject": "2,3-bis(4-hydroxyphenyl)-propionitrile", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERÎ²", "object_type": "GENE-Y"}, {"subject": "MPP", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "1,3-bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "1H-pyrazole dihydrochloride", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "PHTPP", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ERÎ²", "object_type": "GENE-Y"}, {"subject": "4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ERÎ²", "object_type": "GENE-Y"}]}
{"text": "Inhibitors of PDE4 (rolipram; 0.1-10 microM) and PDE3 (cilostazol; 0.1-10 microM) delayed spontaneous eosinophil apoptosis maximally by 25% and 15%, respectively.", "spo_list": [{"subject": "rolipram", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}, {"subject": "cilostazol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE3", "object_type": "GENE-N"}]}
{"text": "Inhibitor of cGMP-specific PDE5 (zaprinast; 0.1-10 microM) did not affect eosinophil apoptosis and only slightly increased spontaneous neutrophil apoptosis.", "spo_list": [{"subject": "zaprinast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cGMP-specific PDE5", "object_type": "GENE-Y"}]}
{"text": "These studies identified 4-{(Z)-[(2Z)-2-(2-fluorobenzylidene)-4-oxo-1,3-thiazolidin-5-ylidene]methyl}benzoic acid (compound 1) as the highest potency full agonist of human GPR35 yet described.", "spo_list": [{"subject": "4-{(Z)-[(2Z)-2-(2-fluorobenzylidene)-4-oxo-1,3-thiazolidin-5-ylidene]methyl}benzoic acid", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "human GPR35", "object_type": "GENE-Y"}]}
{"text": "Compound 1 also displayed competitive behavior when assessed against the human GPR35 antagonist, ML-145 (2-hydroxy-4-[4-(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoylamino]benzoic acid).", "spo_list": [{"subject": "ML-145", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "human GPR35", "object_type": "GENE-Y"}, {"subject": "2-hydroxy-4-[4-(5Z)-5-[(E)-2-methyl-3-phenylprop-2-enylidene]-4-oxo-2-sulfanylidene-1,3-thiazolidin-3-yl]butanoylamino]benzoic acid", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "human GPR35", "object_type": "GENE-Y"}]}
{"text": "Canagliflozin , an inhibitor of sodium-glucose cotransporter 2, for the treatment of type 2 diabetes mellitus.", "spo_list": [{"subject": "Canagliflozin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "sodium-glucose cotransporter 2", "object_type": "GENE-Y"}]}
{"text": "INTRODUCTION: Canagliflozin is an orally administered sodium glucose cotransporter 2 inhibitor proposed for the treatment of type 2 diabetes.", "spo_list": [{"subject": "Canagliflozin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "sodium glucose cotransporter 2", "object_type": "GENE-Y"}]}
{"text": "EXPERT OPINION: Canagliflozin offers a relatively modest reduction in HbA1c, FPG, and PPG.", "spo_list": [{"subject": "Canagliflozin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "HbA1c", "object_type": "GENE-Y"}]}
{"text": "The high fat diet significantly increased hepatic mRNA expressions of PPARÎ³, SREBP1C and SCD-1 genes in comparison to the control diet, which was subsequently reversed by supplementation with fisetin.", "spo_list": [{"subject": "fisetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "PPARÎ³", "object_type": "GENE-Y"}, {"subject": "fisetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "SREBP1C", "object_type": "GENE-Y"}, {"subject": "fisetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "SCD-1", "object_type": "GENE-Y"}]}
{"text": "In addition, fisetin supplementation significantly reduced hepatic mRNA abundance of FAS, ATPCL and G6Pase compared to the control group.", "spo_list": [{"subject": "fisetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "FAS", "object_type": "GENE-Y"}, {"subject": "fisetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ATPCL", "object_type": "GENE-Y"}, {"subject": "fisetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "G6Pase", "object_type": "GENE-Y"}]}
{"text": "Finally, epididymal mRNA abundance of GLUT4 was significantly increased by fisetin supplementation, compared to levels in the control and HF groups.", "spo_list": [{"subject": "fisetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GLUT4", "object_type": "GENE-Y"}]}
{"text": "Enhancement of GLUT4 expression by fisetin was further confirmed in differentiated 3T3-L1 adipocytes.", "spo_list": [{"subject": "fisetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GLUT4", "object_type": "GENE-Y"}]}
{"text": "The arachidonic acid 5-lipoxygenase inhibitor nordihydroguaiaretic acid inhibits tumor necrosis factor alpha activation of microglia and extends survival of G93A-SOD1 transgenic mice.", "spo_list": [{"subject": "nordihydroguaiaretic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "arachidonic acid 5-lipoxygenase", "object_type": "GENE-Y"}, {"subject": "nordihydroguaiaretic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tumor necrosis factor alpha", "object_type": "GENE-Y"}]}
{"text": "The arachidonic acid 5-lipoxygenase (5LOX) and tyrosine kinase inhibitor nordihydroguaiaretic acid (NDGA), a natural dicatechol, was one of the most potent non-cytotoxic antagonists tested (IC50 8 +/- 3 microm).", "spo_list": [{"subject": "nordihydroguaiaretic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "NDGA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "dicatechol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "nordihydroguaiaretic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-lipoxygenase", "object_type": "GENE-Y"}, {"subject": "NDGA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-lipoxygenase", "object_type": "GENE-Y"}, {"subject": "dicatechol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-lipoxygenase", "object_type": "GENE-Y"}, {"subject": "nordihydroguaiaretic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5LOX", "object_type": "GENE-Y"}, {"subject": "NDGA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5LOX", "object_type": "GENE-Y"}, {"subject": "dicatechol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5LOX", "object_type": "GENE-Y"}]}
{"text": "Disease-associated gliosis and cleaved microtubule-associated tau protein, an indicator of axon damage, were likewise reduced by NDGA.", "spo_list": [{"subject": "NDGA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "microtubule-associated tau protein", "object_type": "GENE-Y"}]}
{"text": "We demonstrated that human SR-B1 is transcriptionally activated by 17Î²-estradiol (E2) in HEPG2 and JAR cells.", "spo_list": [{"subject": "17Î²-estradiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "human SR-B1", "object_type": "GENE-Y"}]}
{"text": "Methods: Cocktail approach was used to evaluate the influence of IR and IPC on the activities of CYP1A2, CYP2C9, CYP2E1, CYP2D6 and CYP3A4, which were reflected by the changes of pharmacokinetic parameters of five specific probe drugs: caffeine, chlorzoxazone, tolbutamide, metoprolol and midazolam, respectively.", "spo_list": [{"subject": "caffeine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CYP1A2", "object_type": "GENE-Y"}, {"subject": "chlorzoxazone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CYP2C9", "object_type": "GENE-Y"}, {"subject": "tolbutamide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CYP2E1", "object_type": "GENE-Y"}, {"subject": "metoprolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CYP2D6", "object_type": "GENE-Y"}, {"subject": "midazolam", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CYP3A4", "object_type": "GENE-Y"}]}
{"text": "Regulation of gene expression by activation of the peroxisome proliferator-activated receptor gamma with rosiglitazone (BRL 49653) in human adipocytes.", "spo_list": [{"subject": "rosiglitazone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "peroxisome proliferator-activated receptor gamma", "object_type": "GENE-Y"}, {"subject": "BRL 49653", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "peroxisome proliferator-activated receptor gamma", "object_type": "GENE-Y"}]}
{"text": "Rosiglitazone (10(-6) M, 4 h) increased p85alphaphosphatidylinositol 3-kinase (p85alphaPI-3K) and uncoupling protein-2 mRNA levels and decreased leptin expression.", "spo_list": [{"subject": "Rosiglitazone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p85alphaphosphatidylinositol 3-kinase", "object_type": "GENE-Y"}, {"subject": "Rosiglitazone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p85alphaPI-3K", "object_type": "GENE-Y"}, {"subject": "Rosiglitazone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "uncoupling protein-2", "object_type": "GENE-Y"}, {"subject": "Rosiglitazone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "leptin", "object_type": "GENE-Y"}]}
{"text": "Activation of RXR, the partner of PPARgamma, in the presence of rosiglitazone, increased further p85alphaPI-3K and UCP2 mRNA levels and produced a significant augmentation of Glut 4 expression.", "spo_list": [{"subject": "rosiglitazone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "RXR", "object_type": "GENE-N"}, {"subject": "rosiglitazone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PPARgamma", "object_type": "GENE-Y"}, {"subject": "rosiglitazone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p85alphaPI-3K", "object_type": "GENE-Y"}, {"subject": "rosiglitazone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "UCP2", "object_type": "GENE-Y"}, {"subject": "rosiglitazone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Glut 4", "object_type": "GENE-Y"}]}
{"text": "Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP.", "spo_list": [{"subject": "valsartan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AT1", "object_type": "GENE-Y"}, {"subject": "losartan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AT1", "object_type": "GENE-Y"}]}
{"text": "The present study employed an animal model to demonstrate angiotensin II-receptor blocker-specific effects and to quantify these differences by comparing two common agents, losartan and valsartan.", "spo_list": [{"subject": "losartan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "angiotensin II-receptor", "object_type": "GENE-N"}, {"subject": "valsartan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "angiotensin II-receptor", "object_type": "GENE-N"}]}
{"text": "The effects of losartan and valsartan on cGMP were completely inhibited by AT2-receptor blockade.", "spo_list": [{"subject": "losartan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AT2", "object_type": "GENE-Y"}, {"subject": "valsartan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AT2", "object_type": "GENE-Y"}]}
{"text": "CONCLUSION: The results indicate that AT1-receptor blockade with valsartan influences AT2-receptor-mediated angiotensin II responses to a greater extent than with losartan, as quantified by renal interstitial fluid cGMP.", "spo_list": [{"subject": "valsartan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AT1", "object_type": "GENE-Y"}]}
{"text": "Halothane, isoflurane and sevoflurane inhibit NADH:ubiquinone oxidoreductase (complex I) of cardiac mitochondria.", "spo_list": [{"subject": "Halothane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NADH:ubiquinone oxidoreductase", "object_type": "GENE-Y"}, {"subject": "isoflurane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NADH:ubiquinone oxidoreductase", "object_type": "GENE-Y"}, {"subject": "sevoflurane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NADH:ubiquinone oxidoreductase", "object_type": "GENE-Y"}, {"subject": "Halothane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "complex I", "object_type": "GENE-Y"}, {"subject": "isoflurane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "complex I", "object_type": "GENE-Y"}, {"subject": "sevoflurane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "complex I", "object_type": "GENE-Y"}]}
{"text": "Succinate oxidation was unaffected by either isoflurane or sevoflurane, indicating that these agents selectively inhibit complex I (NADH:ubiquinone oxidoreductase).", "spo_list": [{"subject": "isoflurane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "complex I", "object_type": "GENE-N"}, {"subject": "sevoflurane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "complex I", "object_type": "GENE-N"}, {"subject": "isoflurane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NADH:ubiquinone oxidoreductase", "object_type": "GENE-N"}, {"subject": "sevoflurane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NADH:ubiquinone oxidoreductase", "object_type": "GENE-N"}]}
{"text": "To test the hypothesis that complex I is a target of volatile anaesthetics, we examined the effects of these agents on NADH:ubiquinone oxidoreductase (EC 1.6.99.3) activity using the ubiquinone analogue DBQ (decylubiquinone) as substrate.", "spo_list": [{"subject": "ubiquinone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NADH:ubiquinone oxidoreductase", "object_type": "GENE-N"}, {"subject": "ubiquinone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 1.6.99.3", "object_type": "GENE-N"}, {"subject": "DBQ", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NADH:ubiquinone oxidoreductase", "object_type": "GENE-N"}, {"subject": "DBQ", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 1.6.99.3", "object_type": "GENE-N"}, {"subject": "decylubiquinone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NADH:ubiquinone oxidoreductase", "object_type": "GENE-N"}, {"subject": "decylubiquinone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 1.6.99.3", "object_type": "GENE-N"}]}
{"text": "Halothane, isoflurane and sevoflurane dose-dependently inhibited NADH:DBQ oxidoreductase activity.", "spo_list": [{"subject": "Halothane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NADH:DBQ oxidoreductase", "object_type": "GENE-N"}, {"subject": "isoflurane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NADH:DBQ oxidoreductase", "object_type": "GENE-N"}, {"subject": "sevoflurane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NADH:DBQ oxidoreductase", "object_type": "GENE-N"}]}
{"text": "Unlike the classical inhibitor rotenone, none of the anaesthetics completely inhibited enzyme activity at high concentration, suggesting that these agents bind weakly to the 'hydrophobic inhibitory site' of complex I. In conclusion, halothane, isoflurane and sevoflurane inhibit complex I (NADH:ubiquinone oxidoreductase) of the electron transport chain.", "spo_list": [{"subject": "rotenone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "complex I", "object_type": "GENE-N"}, {"subject": "halothane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "complex I", "object_type": "GENE-N"}, {"subject": "isoflurane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "complex I", "object_type": "GENE-N"}, {"subject": "sevoflurane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "complex I", "object_type": "GENE-N"}, {"subject": "halothane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NADH:ubiquinone oxidoreductase", "object_type": "GENE-N"}, {"subject": "isoflurane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NADH:ubiquinone oxidoreductase", "object_type": "GENE-N"}, {"subject": "sevoflurane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NADH:ubiquinone oxidoreductase", "object_type": "GENE-N"}]}
{"text": "At concentrations of approximately 2 MAC (minimal alveolar concentration), the activity of NADH:ubiquinone oxidoreductase was reduced by about 20 % in the presence of halothane or isoflurane, and by about 10 % in the presence of sevoflurane.", "spo_list": [{"subject": "halothane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NADH:ubiquinone oxidoreductase", "object_type": "GENE-N"}, {"subject": "isoflurane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NADH:ubiquinone oxidoreductase", "object_type": "GENE-N"}, {"subject": "sevoflurane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NADH:ubiquinone oxidoreductase", "object_type": "GENE-N"}]}
{"text": "Am80 slightly inhibited the growth of both myeloma cells and HUVECs, and remarkably inhibited the growth of HUVECs stimulated by VEGF.", "spo_list": [{"subject": "Am80", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGF", "object_type": "GENE-Y"}]}
{"text": "Am80 inhibited VEGF-induced phosphorylation of VEGF receptor.", "spo_list": [{"subject": "Am80", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGF", "object_type": "GENE-Y"}, {"subject": "Am80", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGF receptor", "object_type": "GENE-N"}]}
{"text": "In addition, VEGF-induced formation of tube-like structures in vitro and neovascularization in mouse corneas were significantly inhibited by Am80.", "spo_list": [{"subject": "Am80", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGF", "object_type": "GENE-Y"}]}
{"text": "Pirfenidone inhibits TGF-beta expression in malignant glioma cells.", "spo_list": [{"subject": "Pirfenidone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TGF-beta", "object_type": "GENE-Y"}]}
{"text": "Here, we report that the antifibrotic drug 5-methyl-1-phenyl-2-(1H)-pyridone (pirfenidone, PFD) elicits growth-inhibitory effects and reduces TGF-beta2 protein levels in human glioma cell lines.", "spo_list": [{"subject": "5-methyl-1-phenyl-2-(1H)-pyridone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TGF-beta2", "object_type": "GENE-Y"}, {"subject": "pirfenidone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TGF-beta2", "object_type": "GENE-Y"}, {"subject": "PFD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TGF-beta2", "object_type": "GENE-Y"}]}
{"text": "This reduction in TGF-beta2 is biologically relevant since PFD treatment reduces the growth inhibition of TGF-beta-sensitive CCL-64 cells mediated by conditioned media of glioma cells.", "spo_list": [{"subject": "PFD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TGF-beta2", "object_type": "GENE-Y"}, {"subject": "PFD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TGF-beta", "object_type": "GENE-Y"}]}
{"text": "PFD leads to a reduction of TGF-beta2 mRNA levels and of the mature TGF-beta2 protein due to decreased expression and direct inhibition of the TGF-beta pro-protein convertase furin.", "spo_list": [{"subject": "PFD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TGF-beta2", "object_type": "GENE-Y"}, {"subject": "PFD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TGF-beta2", "object_type": "GENE-Y"}, {"subject": "PFD", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TGF-beta", "object_type": "GENE-Y"}, {"subject": "PFD", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "pro-protein convertase", "object_type": "GENE-N"}, {"subject": "PFD", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "furin", "object_type": "GENE-Y"}, {"subject": "PFD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TGF-beta", "object_type": "GENE-Y"}, {"subject": "PFD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "pro-protein convertase", "object_type": "GENE-N"}, {"subject": "PFD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "furin", "object_type": "GENE-Y"}]}
{"text": "In addition, PFD reduces the protein levels of the matrix metalloproteinase (MMP)-11, a TGF-beta target gene and furin substrate involved in carcinogenesis.", "spo_list": [{"subject": "PFD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "matrix metalloproteinase (MMP)-11", "object_type": "GENE-Y"}, {"subject": "PFD", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TGF-beta", "object_type": "GENE-Y"}]}
{"text": "Electroencephalographic recordings during substance consumption showed reduced alpha activity and P300 latencies in the nicotine group compared to the control group.", "spo_list": [{"subject": "nicotine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "P300", "object_type": "GENE-Y"}]}
{"text": "These findings suggest that oral consumption of nicotine enhances the efficacy of nicotinic acetylcholine receptors.", "spo_list": [{"subject": "nicotine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "nicotinic acetylcholine receptors", "object_type": "GENE-N"}]}
{"text": "Over the past 20 years, studies of transient receptor potential (TRP) channels have significantly extended our knowledge regarding the molecular basis of Ca2+ signals in cardiac myocytes.", "spo_list": [{"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "transient receptor potential (TRP) channels", "object_type": "GENE-N"}]}
{"text": "The functional significance of cardiac TRP channels is likely connected to the alteration of membrane potential or Ca2+ entry into a noncontractile compartment, where gene expression responsible for various cardiac diseases is induced.", "spo_list": [{"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "TRP channels", "object_type": "GENE-N"}]}
{"text": "Palonosetron is a second-generation serotonin 5-HT3 receptor antagonist, with a distinct pharmacological profile that differs from first-generation 5-HT3 receptor antagonists.", "spo_list": [{"subject": "Palonosetron", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "serotonin 5-HT3 receptor", "object_type": "GENE-N"}, {"subject": "Palonosetron", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT3 receptor", "object_type": "GENE-N"}]}
{"text": "Oral palonosetron is likely to be a useful addition to oral formulations of other 5-HT3 receptor antagonists in preventing CINV in patients receiving MEC.", "spo_list": [{"subject": "palonosetron", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT3 recepto", "object_type": "GENE-N"}]}
{"text": "TNF-Î±-mediated NF-ÎºB survival signaling impairment by cisplatin enhances JNK activation allowing synergistic apoptosis of renal proximal tubular cells.", "spo_list": [{"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "JNK", "object_type": "GENE-N"}]}
{"text": "Transcriptomic analysis revealed that cisplatin inhibited the typical TNF-Î± response and cisplatin/TNF-Î± treatment up-regulated cell death pathways while it down-regulated survival pathways compared to cisplatin alone.", "spo_list": [{"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF-Î±", "object_type": "GENE-Y"}]}
{"text": "Furthermore, combined cisplatin/TNF-Î± treatment inhibited NF-ÎºB nuclear translocation and NF-ÎºB-mediated gene transcription leading to enhanced and prolonged JNK and c-Jun phosphorylation.", "spo_list": [{"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "JNK", "object_type": "GENE-N"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "c-Jun", "object_type": "GENE-Y"}]}
{"text": "Alanine:glyoxylate aminotransferase (AGT) in the liver catalyzes most of the glyoxylate transamination in mammalian tissues (E. V. Rowsell, K. Snell, J. A. Carnie, and K. V. Rowsell (1972) Biochem.", "spo_list": [{"subject": "glyoxylate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Alanine:glyoxylate aminotransferase", "object_type": "GENE-N"}, {"subject": "glyoxylate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AGT", "object_type": "GENE-N"}]}
{"text": "The holo activity of combined peroxisomal and mitochondrial AGT 1 with a low Km for L-alanine rapidly decreased after a lag time of about 2 days during feeding of the vitamin B6-deficient diet (by 50% in 5 days, by 86% in 14 days).", "spo_list": [{"subject": "L-alanine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AGT 1", "object_type": "GENE-Y"}]}
{"text": "The holo activity of AGT 2 with a high Km for L-alanine decreased more slowly than AGT 1 (by 33% in 14 days, by 60% in 28 days).", "spo_list": [{"subject": "L-alanine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AGT 2", "object_type": "GENE-Y"}, {"subject": "L-alanine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AGT 1", "object_type": "GENE-Y"}]}
{"text": "Pretreatment with 1,25-dihydroxyvitamin Dâ, previously shown to increase PLD1 expression and activity, had no effect on, and a PLD2-selective (but not a PLD1-selective) inhibitor decreased, cell lifting-induced PLD activation, suggesting PLD2 as the isoform activated.", "spo_list": [{"subject": "1,25-dihydroxyvitamin Dâ", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PLD1", "object_type": "GENE-Y"}, {"subject": "1,25-dihydroxyvitamin Dâ", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PLD1", "object_type": "GENE-Y"}, {"subject": "1,25-dihydroxyvitamin Dâ", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PLD2", "object_type": "GENE-Y"}]}
{"text": "PLD2 interacts functionally with the glycerol channel aquaporin-3 (AQP3) to produce phosphatidylglycerol (PG); however, wounding resulted in decreased PG production, suggesting a potential PG deficiency in wounded cells.", "spo_list": [{"subject": "phosphatidylglycerol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PLD2", "object_type": "GENE-Y"}]}
{"text": "Even though the activities of MAT and GNMT were elevated, the concentration of liver S-adenosylmethionine was decreased (24%, p<0.001) and S-adenosylhomocysteine increased (113%, p<0.001) in the dwarf mice.", "spo_list": [{"subject": "S-adenosylmethionine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MAT", "object_type": "GENE-N"}, {"subject": "S-adenosylmethionine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GNMT", "object_type": "GENE-Y"}, {"subject": "S-adenosylhomocysteine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "MAT", "object_type": "GENE-N"}, {"subject": "S-adenosylhomocysteine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "GNMT", "object_type": "GENE-Y"}]}
{"text": "In comparison, pretreatment of the aorta of diabetic rats with N-[3(aminomethyl) benzyl]-acetamidine, dihydrochloride (10(-5) âM), a selective inhibitor of iNOS, produced a similar recovery in vascular reactivity.", "spo_list": [{"subject": "N-[3(aminomethyl) benzyl]-acetamidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "dihydrochloride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "iNOS", "object_type": "GENE-Y"}]}
{"text": "In great contrast, activation of NR2A-mediated cell survival signaling with administration of either glycine alone or in the presence of NR2B antagonist significantly attenuated ischemic brain damage even when delivered 4.5 h after stroke onset.", "spo_list": [{"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NR2A", "object_type": "GENE-Y"}]}
{"text": "Together, the present work provides a molecular basis for the dual roles of NMDA receptors in promoting neuronal survival and mediating neuronal damage and suggests that selective enhancement of NR2A-containing NMDA receptor activation with glycine may constitute a promising therapy for stroke.", "spo_list": [{"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NR2A", "object_type": "GENE-Y"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NMDA receptor", "object_type": "GENE-N"}]}
{"text": "The PPACK-bound structure of W215A/E217A is identical to the structure of the PPACK-bound slow form of thrombin.", "spo_list": [{"subject": "PPACK", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "W215A", "object_type": "GENE-N"}, {"subject": "PPACK", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "E217A", "object_type": "GENE-N"}, {"subject": "PPACK", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "thrombin", "object_type": "GENE-Y"}]}
{"text": "Identification and characterization of a novel flavin-containing spermine oxidase of mammalian cell origin.", "spo_list": [{"subject": "flavin", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "spermine oxidase", "object_type": "GENE-N"}]}
{"text": "During polyamine catabolism, spermine and spermidine are first acetylated by spermidine/spermine N(1)-acetyltransferase (SSAT) and subsequently oxidized by polyamine oxidase (PAO) to produce spermidine and putrescine, respectively.", "spo_list": [{"subject": "spermidine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "polyamine oxidase", "object_type": "GENE-Y"}, {"subject": "putrescine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "polyamine oxidase", "object_type": "GENE-Y"}, {"subject": "spermidine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PAO", "object_type": "GENE-Y"}, {"subject": "putrescine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PAO", "object_type": "GENE-Y"}, {"subject": "polyamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "spermidine/spermine N(1)-acetyltransferase", "object_type": "GENE-Y"}, {"subject": "spermine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "spermidine/spermine N(1)-acetyltransferase", "object_type": "GENE-Y"}, {"subject": "spermidine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "spermidine/spermine N(1)-acetyltransferase", "object_type": "GENE-Y"}, {"subject": "polyamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SSAT", "object_type": "GENE-Y"}, {"subject": "spermine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SSAT", "object_type": "GENE-Y"}, {"subject": "spermidine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SSAT", "object_type": "GENE-Y"}]}
{"text": "In attempting to clone the PAO involved in this back-conversion pathway, we encountered an oxidase that preferentially cleaves spermine in the absence of prior acetylation by SSAT.", "spo_list": [{"subject": "spermine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SSAT", "object_type": "GENE-Y"}]}
{"text": "A BLAST search using maize PAO sequences identified homologous mammalian cDNAs derived from human hepatoma and mouse mammary carcinoma: the encoded proteins differed by 20 amino acids.", "spo_list": [{"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "maize PAO", "object_type": "GENE-Y"}]}
{"text": "Substrate specificity using lysates of oxidase-transfected HEK-293 cells revealed that the newly identified oxidase strongly favoured spermine over N (1)-acetylspermine and that it failed to act on N (1)-acetylspermidine, spermidine or the preferred PAO substrate, N (1), N (12)-diacetylspermine.", "spo_list": [{"subject": "N (1), N (12)-diacetylspermine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PAO", "object_type": "GENE-Y"}, {"subject": "spermine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "oxidase", "object_type": "GENE-N"}, {"subject": "N (1)-acetylspermine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "oxidase", "object_type": "GENE-N"}]}
{"text": "The PAO inhibitor, MDL-72,527, only partially blocked oxidation of spermine while a previously reported PAO substrate, N (1)-( n -octanesulphonyl)spermine, potently inhibited the reaction.", "spo_list": [{"subject": "MDL-72,527", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PAO", "object_type": "GENE-Y"}, {"subject": "N (1)-( n -octanesulphonyl)spermine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PAO", "object_type": "GENE-Y"}]}
{"text": "They all expressed ASS, but not ornithine transcarbamylase (OTC), the enzyme that converts ornithine, the product of degradation of arginine with rhArg, to citrulline, which is converted back to arginine via ASS.", "spo_list": [{"subject": "ornithine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ornithine transcarbamylase", "object_type": "GENE-Y"}, {"subject": "ornithine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OTC", "object_type": "GENE-Y"}, {"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "rhArg", "object_type": "GENE-N"}, {"subject": "citrulline", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "rhArg", "object_type": "GENE-N"}, {"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ASS", "object_type": "GENE-Y"}]}
{"text": "This surprising correlation between the lack of OTC expression and sensitivity of ASS-positive HCC cells shows that OTC-deficient HCCs are sensitive to rhArg-mediated arginine depletion.", "spo_list": [{"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "rhArg", "object_type": "GENE-N"}]}
{"text": "Therefore, pretreatment tumor gene expression profiling of ASS and OTC could aid in predicting tumor response to arginine depletion with arginine-depleting enzymes.", "spo_list": [{"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "arginine-depleting enzymes", "object_type": "GENE-N"}]}
{"text": "Peripheral site ligands accelerate inhibition of acetylcholinesterase by neutral organophosphates.", "spo_list": [{"subject": "organophosphates", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}]}
{"text": "The rates of inhibition of mouse acetylcholinesterase (AChE; EC 3.1.1.7) by paraoxon, haloxon, DDVP and enantiomers of neutral alkyl methylphosphonyl thioates and cationic alkyl methylphosphonyl thiocholines were measured in the presence and absence of AChE peripheral site inhibitors: gallamine, d-tubocurarine, propidium, atropine and derivatives of coumarin.", "spo_list": [{"subject": "paraoxon", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mouse acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "paraoxon", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "paraoxon", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 3.1.1.7", "object_type": "GENE-Y"}, {"subject": "haloxon", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mouse acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "haloxon", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "haloxon", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 3.1.1.7", "object_type": "GENE-Y"}, {"subject": "DDVP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mouse acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "DDVP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "DDVP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 3.1.1.7", "object_type": "GENE-Y"}, {"subject": "alkyl methylphosphonyl thioates", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mouse acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "alkyl methylphosphonyl thioates", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "alkyl methylphosphonyl thioates", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 3.1.1.7", "object_type": "GENE-Y"}, {"subject": "alkyl methylphosphonyl thiocholines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mouse acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "alkyl methylphosphonyl thiocholines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "alkyl methylphosphonyl thiocholines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 3.1.1.7", "object_type": "GENE-Y"}, {"subject": "gallamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "d-tubocurarine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "propidium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "atropine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "coumarin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "These observations suggest that peripheral site ligands are capable of allosterically affecting the conformation of residues in the choline binding site of AChE, thus optimizing the position of the leaving group of uncharged organophosphates during the inhibition reaction.", "spo_list": [{"subject": "organophosphate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "organophosphate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "Because these isoflavones have estrogenic properties, we hypothesized that, like estrogens, they would inhibit acute vascular injury and the detrimental acute increase in hypoxia-induced vascular endothelial growth factor (VEGF) that leads to cerebral edema after stroke.", "spo_list": [{"subject": "isoflavones", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "vascular endothelial growth factor", "object_type": "GENE-Y"}, {"subject": "isoflavones", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "VEGF", "object_type": "GENE-Y"}, {"subject": "estrogens", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "vascular endothelial growth factor", "object_type": "GENE-Y"}, {"subject": "estrogens", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "VEGF", "object_type": "GENE-Y"}]}
{"text": "In further evaluation, the representative compound N,N-diethyl-N-(2-(N-methyltetradecanamido)ethyl)prop-2-en-1-aminium bromide (3b) exhibited potent pro-apoptotic activity, through RhoB activation, in HeLa cells.", "spo_list": [{"subject": "N,N-diethyl-N-(2-(N-methyltetradecanamido)ethyl)prop-2-en-1-aminium bromide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "RhoB", "object_type": "GENE-Y"}]}
{"text": "CAN significantly inhibited the production of NO and the release of TNF-Î± induced by LPS in macrophage RAW 264.7.", "spo_list": [{"subject": "CAN", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF-Î±", "object_type": "GENE-Y"}]}
{"text": "Western blot showed that CAN can downregulate the expression of iNOS protein.", "spo_list": [{"subject": "CAN", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "iNOS", "object_type": "GENE-Y"}]}
{"text": "Structural determinants of arylacetic acid nonsteroidal anti-inflammatory drugs necessary for binding and activation of the prostaglandin D2 receptor CRTH2.", "spo_list": [{"subject": "arylacetic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "prostaglandin D2 receptor", "object_type": "GENE-N"}, {"subject": "arylacetic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CRTH2", "object_type": "GENE-Y"}, {"subject": "arylacetic acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "prostaglandin D2 receptor", "object_type": "GENE-N"}, {"subject": "arylacetic acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CRTH2", "object_type": "GENE-Y"}]}
{"text": "In addition to PGD2, CRTH2 can be activated by indomethacin, a nonselective cyclooxygenase inhibitor and widely used nonsteroidal anti-inflammatory drug (NSAID).", "spo_list": [{"subject": "PGD2", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CRTH2", "object_type": "GENE-Y"}, {"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CRTH2", "object_type": "GENE-Y"}, {"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase", "object_type": "GENE-N"}]}
{"text": "Indomethacin, sulindac sulfide, and zomepirac displaced [3H]PGD2 binding at the mouse CRTH2 receptor (mCRTH2) with comparable affinity (Ki = 1.5 +/- 0.1, 2.5 +/- 0.4, and 3.3 +/- 0.3 microM, respectively).", "spo_list": [{"subject": "[3H]PGD2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mouse CRTH2 receptor", "object_type": "GENE-Y"}, {"subject": "[3H]PGD2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mCRTH2", "object_type": "GENE-Y"}, {"subject": "Indomethacin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mCRTH2", "object_type": "GENE-Y"}, {"subject": "sulindac sulfide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mCRTH2", "object_type": "GENE-Y"}, {"subject": "zomepirac", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mCRTH2", "object_type": "GENE-Y"}, {"subject": "Indomethacin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mouse CRTH2 receptor", "object_type": "GENE-Y"}, {"subject": "sulindac sulfide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mouse CRTH2 receptor", "object_type": "GENE-Y"}, {"subject": "zomepirac", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mouse CRTH2 receptor", "object_type": "GENE-Y"}]}
{"text": "Neutral derivatives of indomethacin also failed to bind to mCRTH2, suggesting that the negatively charged carboxylate moiety participates in a key ligand-receptor interaction.", "spo_list": [{"subject": "carboxylate", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "mCRTH2", "object_type": "GENE-Y"}]}
{"text": "In contrast, zomepirac did not inhibit [cAMP]i generation or stimulate cell migration but weakly antagonized the effects of indomethacin on [cAMP]i. Together, these results reveal structural features of arylacetic acid NSAIDs that may be exploited for the development of selective CRTH2 ligands.", "spo_list": [{"subject": "arylacetic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CRTH2", "object_type": "GENE-Y"}]}
{"text": "In DU-PM cells with acquired resistance to elisidepsin, ErbB3 expression was decreased, while Bcl2 was increased.", "spo_list": [{"subject": "elisidepsin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ErbB3", "object_type": "GENE-Y"}, {"subject": "elisidepsin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bcl2", "object_type": "GENE-Y"}]}
{"text": "Ethanol inhibits glutamate-induced currents in heteromeric NMDA receptor subtypes.", "spo_list": [{"subject": "Ethanol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NMDA receptor", "object_type": "GENE-N"}, {"subject": "glutamate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NMDA receptor", "object_type": "GENE-N"}]}
{"text": "Maximal L-glutamate/glycine-evoked currents were inhibited by ethanol in Xenopus laevis oocytes expressing recombinant heteromeric NMDA receptors consisting of NR1-NR2A, NR1-NR2B, and NR1-NR2C subunit combinations.", "spo_list": [{"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NMDA receptors", "object_type": "GENE-N"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR1", "object_type": "GENE-Y"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR2A", "object_type": "GENE-Y"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR1", "object_type": "GENE-Y"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR2B", "object_type": "GENE-Y"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR1", "object_type": "GENE-Y"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR2C", "object_type": "GENE-Y"}, {"subject": "L-glutamate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NMDA receptors", "object_type": "GENE-N"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NMDA receptors", "object_type": "GENE-N"}, {"subject": "L-glutamate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NR1", "object_type": "GENE-Y"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NR1", "object_type": "GENE-Y"}, {"subject": "L-glutamate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NR2A", "object_type": "GENE-Y"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NR2A", "object_type": "GENE-Y"}, {"subject": "L-glutamate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NR1", "object_type": "GENE-Y"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NR1", "object_type": "GENE-Y"}, {"subject": "L-glutamate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NR2B", "object_type": "GENE-Y"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NR2B", "object_type": "GENE-Y"}, {"subject": "L-glutamate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NR1", "object_type": "GENE-Y"}, {"subject": "L-glutamate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NR2C", "object_type": "GENE-Y"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NR1", "object_type": "GENE-Y"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NR2C", "object_type": "GENE-Y"}]}
{"text": "The NR1-NR2C channels were slightly less sensitive to ethanol inhibition than the other heteromeric channels in Ca(2+)-deficient, Ba(2+)-containing medium.", "spo_list": [{"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR2C", "object_type": "GENE-Y"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR1", "object_type": "GENE-Y"}]}
{"text": "The inhibition was unaffected by the clamping-voltage and by a mutation [NR1-NR2A(N595Q)] that prevents the Mg(2+)-blockade of the channels, indicating that the mechanism of action of ethanol differs from that of Mg2+.", "spo_list": [{"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR1", "object_type": "GENE-Y"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR2A", "object_type": "GENE-Y"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "N595Q", "object_type": "GENE-N"}]}
{"text": "We used nutlin-3, a well-known disruptor of p53-Mdm2 interaction, to validate the specificity of the assay.", "spo_list": [{"subject": "nutlin-3", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p53", "object_type": "GENE-Y"}, {"subject": "nutlin-3", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Mdm2", "object_type": "GENE-Y"}]}
{"text": "The reduction of BiFC signal mediated by nutlin-3 was correlated with an increase in Puma transactivation, PARP cleavage, and cell death.", "spo_list": [{"subject": "nutlin-3", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Puma", "object_type": "GENE-Y"}, {"subject": "nutlin-3", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PARP", "object_type": "GENE-N"}]}
{"text": "Blocking EGFR signaling with the EGFR/HER-2 kinase inhibitor (KI) GW572016 decreased the postradiation survival of irradiated Ras-transformed cells and normal cells but had no effect on the survival of unirradiated cells.", "spo_list": [{"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "EGFR", "object_type": "GENE-Y"}, {"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EGFR", "object_type": "GENE-Y"}, {"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HER-2", "object_type": "GENE-Y"}, {"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Ras", "object_type": "GENE-N"}]}
{"text": "Ras-CM and TGF-alpha also increase PI3-K activity downstream of the EGFR and increase postradiation survival, both of which are abrogated by GW572016.", "spo_list": [{"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EGFR", "object_type": "GENE-Y"}, {"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PI3-K", "object_type": "GENE-N"}]}
{"text": "Thus, Ras utilizes autocrine signaling through EGFR to increase radioresistance, and the EGFR KI GW572016 acts as a radiosensitizer.", "spo_list": [{"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EGFR", "object_type": "GENE-Y"}, {"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Ras", "object_type": "GENE-N"}]}
{"text": "The observation that Ras-transformed cells can be sensitized to killing by ionizing radiation with GW572016 demonstrates that EGFR KIs could potentially be used to radiosensitize tumors in which radioresistance is dependent on Ras-driven autocrine signaling through EGFR.", "spo_list": [{"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Ras", "object_type": "GENE-N"}, {"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EGFR", "object_type": "GENE-Y"}]}
{"text": "Monoclonal antibody 25B1 generated against diisopropyl phosphorofluoridate inhibited fetal bovine serum acetylcholinesterase has been extensively characterized with respect to its anticholinesterase properties.", "spo_list": [{"subject": "diisopropyl phosphorofluoridate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "bovine serum acetylcholinesterase", "object_type": "GENE-Y"}]}
{"text": "Among all the organophosphates tested, the combination of a methyl group and a negatively charged oxygen attached to the P atom, CH3P(O)(O-)-AChE, conferred the greatest protection to the active site of aged or nonaged organophosphoryl conjugates of acetylcholinesterase.", "spo_list": [{"subject": "organophosphoryl", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "organophosphates", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "oxygen", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "P", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "CH3P(O)(O-)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "The 536-amino acid protein sequence encoded by OAT3 showed 49, 39, and 36% identity to those of OAT1, OAT2, and OCT1, respectively.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "OAT1", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "OAT2", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "OCT1", "object_type": "GENE-Y"}]}
{"text": "When expressed in Xenopus laevis oocytes, OAT3 mediated the uptake of organic anions, such as p-aminohippurate (Km = 65 microM), ochratoxin A (Km = 0.74 microM), and estrone sulfate (Km = 2.3 microM) and a cationic compound, cimetidine.", "spo_list": [{"subject": "p-aminohippurate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "ochratoxin A", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "estrone sulfate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OAT3", "object_type": "GENE-Y"}]}
{"text": "OAT3-mediated uptake of [3H]estrone sulfate was sodium-independent. para-Aminohippuric acid, estrone sulfate or ochratoxin A did not show any trans-stimulatory effect on either influx or efflux of [3H]estrone sulfate via OAT3.", "spo_list": [{"subject": "[3H]estrone sulfate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "[3H]estrone sulfate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OAT3", "object_type": "GENE-Y"}]}
{"text": "Organic anions such as sulfobromophthalein, probenecid, indocyanine green, bumetanide, piroxicam, furosemide, azidodeoxythymidine, 4, 4'-diisothiocyanostilbene-3,3'-disulfonic acid, and benzylpenicillin inhibited OAT3-mediated estrone sulfate uptake, while ouabain and digoxin did not.", "spo_list": [{"subject": "estrone sulfate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "sulfobromophthalein", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "probenecid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "indocyanine green", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "bumetanide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "piroxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "furosemide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "azidodeoxythymidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "4, 4'-diisothiocyanostilbene-3,3'-disulfonic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "benzylpenicillin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OAT3", "object_type": "GENE-Y"}]}
{"text": "Acidic metabolites of neurotransmitters derived from dopamine, epinephrine, norepinephrine, and serotonin inhibited the uptake of estrone sulfate via OAT3.", "spo_list": [{"subject": "estrone sulfate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "dopamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "epinephrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "norepinephrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "serotonin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OAT3", "object_type": "GENE-Y"}]}
{"text": "Phenobarbital (PB), a typical CAR activator, increased the gene expression of HIF-target genes in the livers of mice, including erythropoietin, heme oxygenase-1 and vascular endothelial growth factor-a.", "spo_list": [{"subject": "Phenobarbital", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CAR", "object_type": "GENE-Y"}, {"subject": "Phenobarbital", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "erythropoietin", "object_type": "GENE-Y"}, {"subject": "Phenobarbital", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "heme oxygenase-1", "object_type": "GENE-Y"}, {"subject": "Phenobarbital", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "vascular endothelial growth factor-a", "object_type": "GENE-Y"}]}
{"text": "Cobalt chloride, a typical HIF activator, induced the gene expression of CAR-target genes, including cyp2b9 and cyp2b10, an accumulation of nuclear CAR and an increase in the PB-responsive enhancer module-mediated transactivation in the mouse liver.", "spo_list": [{"subject": "Cobalt chloride", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "HIF", "object_type": "GENE-N"}, {"subject": "Cobalt chloride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cyp2b9", "object_type": "GENE-Y"}, {"subject": "Cobalt chloride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cyp2b10", "object_type": "GENE-Y"}]}
{"text": "Second, EPSCs were recorded from rat hippocampal slices before and after their superfusion with the reversible AChE inhibitor donepezil (100nM).", "spo_list": [{"subject": "donepezil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "Carbonic anhydrase inhibitors: aromatic and heterocyclic sulfonamides incorporating adamantyl moieties with strong anticonvulsant activity.", "spo_list": [{"subject": "aromatic and heterocyclic sulfonamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Carbonic anhydrase", "object_type": "GENE-N"}, {"subject": "adamantyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Carbonic anhydrase", "object_type": "GENE-N"}]}
{"text": "Some of these derivatives showed good inhibitory potency against two human CA isozymes involved in important physiological processes, CA I, and CA II, of the same order of magnitude as the clinically used drugs acetazolamide and methazolamide.", "spo_list": [{"subject": "acetazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human CA", "object_type": "GENE-N"}, {"subject": "methazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human CA", "object_type": "GENE-N"}, {"subject": "acetazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA I", "object_type": "GENE-Y"}, {"subject": "methazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA I", "object_type": "GENE-Y"}, {"subject": "acetazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA II", "object_type": "GENE-Y"}, {"subject": "methazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA II", "object_type": "GENE-Y"}]}
{"text": "The juvenile visceral steatosis (jvs) mouse, having a mutation in the carnitine transporter gene Octn2, is a model of primary systemic carnitine deficiency in humans (SCD, OMIM 212140).", "spo_list": [{"subject": "carnitine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Octn2", "object_type": "GENE-Y"}]}
{"text": "We initially demonstrated significant GR activation 60 minutes after inhalation of 800 microg beclomethasone dipropionate in six healthy subjects.", "spo_list": [{"subject": "beclomethasone dipropionate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GR", "object_type": "GENE-Y"}]}
{"text": "We observed dose-dependent GR activation with 100- and 500-microg doses of FP, and to a lesser extent with 50 microg salmeterol alone.", "spo_list": [{"subject": "FP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GR", "object_type": "GENE-Y"}, {"subject": "salmeterol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GR", "object_type": "GENE-Y"}]}
{"text": "However, combination therapy with 100 microg FP and salmeterol augmented the action of FP on GR nuclear localization.", "spo_list": [{"subject": "FP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GR", "object_type": "GENE-Y"}, {"subject": "salmeterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GR", "object_type": "GENE-Y"}]}
{"text": "In vitro, salmeterol enhanced FP effects on GR nuclear translocation in epithelial and macrophage-like airway cell lines.", "spo_list": [{"subject": "salmeterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GR", "object_type": "GENE-Y"}]}
{"text": "In addition, salmeterol in combination with FP enhanced glucocorticoid response element (GRE)-luciferase reporter gene activity and mitogen-activated protein kinase phosphatase 1 (MKP-1) and secretory leuko-proteinase inhibitor (SLPI) gene induction.", "spo_list": [{"subject": "salmeterol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "glucocorticoid response element", "object_type": "GENE-N"}, {"subject": "FP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "glucocorticoid response element", "object_type": "GENE-N"}, {"subject": "salmeterol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GRE", "object_type": "GENE-N"}, {"subject": "FP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GRE", "object_type": "GENE-N"}, {"subject": "salmeterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "mitogen-activated protein kinase phosphatase 1", "object_type": "GENE-Y"}, {"subject": "FP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "mitogen-activated protein kinase phosphatase 1", "object_type": "GENE-Y"}, {"subject": "salmeterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "MKP-1", "object_type": "GENE-Y"}, {"subject": "FP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "MKP-1", "object_type": "GENE-Y"}, {"subject": "salmeterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "secretory leuko-proteinase inhibitor", "object_type": "GENE-Y"}, {"subject": "FP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "secretory leuko-proteinase inhibitor", "object_type": "GENE-Y"}, {"subject": "salmeterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SLPI", "object_type": "GENE-Y"}, {"subject": "FP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SLPI", "object_type": "GENE-Y"}]}
{"text": "Accumulated evidence in humans and animals shows that both aspirin and H. pylori upregulate the expression of cyclooxygenase (COX)-2 both at mRNA and protein levels at the ulcer margin, but failed to influence significantly that of COX-1.", "spo_list": [{"subject": "aspirin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cyclooxygenase (COX)-2", "object_type": "GENE-N"}]}
{"text": "It was, therefore, proposed that H. pylori may in fact, antagonize, aspirin-induced delay of ulcer healing due to suppression of acid secretion by the enhancement in PGE(2) possibly derived from COX-2 expression and activity and to the overexpression of growth factors such as TGF alpha and VEGF.", "spo_list": [{"subject": "PGE(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-2", "object_type": "GENE-N"}, {"subject": "aspirin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "COX-2", "object_type": "GENE-N"}, {"subject": "aspirin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "COX-2", "object_type": "GENE-N"}, {"subject": "aspirin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TGF alpha", "object_type": "GENE-N"}, {"subject": "aspirin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "VEGF", "object_type": "GENE-N"}]}
{"text": "Removing medium Ca2+, blocking Ca2+ channels with 50 mumol/l verapamil, or inhibiting calmodulin activation with 20 mumol/l trifluoperazine, 10 mumol/l chlorpromazine or 10 mumol/l pimozide almost completely blocked hyposmolarity-induced secretion.", "spo_list": [{"subject": "verapamil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Ca2+ channels", "object_type": "GENE-N"}, {"subject": "trifluoperazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calmodulin", "object_type": "GENE-Y"}, {"subject": "chlorpromazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calmodulin", "object_type": "GENE-Y"}, {"subject": "pimozide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calmodulin", "object_type": "GENE-Y"}]}
{"text": "The smooth muscle relaxant, W-7, which is believed relatively specific in inhibiting the Ca2(+)-calmodulin interaction, depressed hyposmolarity-induced PRL secretion in a dose-dependent manner (r = -0.991, p less than 0.01).", "spo_list": [{"subject": "Ca2(+)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calmodulin", "object_type": "GENE-Y"}, {"subject": "W-7", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calmodulin", "object_type": "GENE-Y"}, {"subject": "W-7", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "PRL", "object_type": "GENE-Y"}]}
{"text": "Here, we show that oral administration of resveratrol, which leads to activation of an NAD(+)-dependent protein deacetylase SIRT1, suppresses cardiac hypertrophy and fibrosis and restores cardiac diastolic function in dystrophin-deficient mdx mice.", "spo_list": [{"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NAD(+)-dependent protein deacetylase SIRT1", "object_type": "GENE-Y"}]}
{"text": "The pro-hypertrophic co-activator p300 protein but not p300 mRNA was up-regulated in the mdx heart, and resveratrol administration down-regulated the p300 protein level.", "spo_list": [{"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "p300", "object_type": "GENE-Y"}]}
{"text": "In cultured cardiomyocytes, cardiomyocyte hypertrophy induced by the Î±(1)-agonist phenylephrine was inhibited by the overexpression of SIRT1 as well as resveratrol, both of which down-regulated p300 protein levels but not p300 mRNA levels.", "spo_list": [{"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "p300", "object_type": "GENE-Y"}, {"subject": "phenylephrine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p300", "object_type": "GENE-Y"}]}
{"text": "We found that SIRT1 induced p300 down-regulation via the ubiquitin-proteasome pathway by deacetylation of lysine residues for ubiquitination.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "p300", "object_type": "GENE-Y"}]}
{"text": "In MOR mRNA expression study, cotreatment of morphine with mitragynine significantly reduced the down-regulation of MOR mRNA expression as compared to morphine treatment only.", "spo_list": [{"subject": "mitragynine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "MOR", "object_type": "GENE-Y"}, {"subject": "morphine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "MOR", "object_type": "GENE-Y"}, {"subject": "morphine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "MOR", "object_type": "GENE-Y"}]}
{"text": "CONCLUSION: These finding suggest that mitragynine could possibly avoid the tolerance and dependence on chronic morphine treatment by reducing the up-regulation of cAMP level as well as reducing the down-regulation of MOR at a lower concentration of mitragynine.", "spo_list": [{"subject": "mitragynine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "MOR", "object_type": "GENE-Y"}, {"subject": "mitragynine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "MOR", "object_type": "GENE-Y"}]}
{"text": "Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity.", "spo_list": [{"subject": "sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "secretory phospholipase A2", "object_type": "GENE-N"}, {"subject": "sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "sPLA2", "object_type": "GENE-N"}]}
{"text": "Since the synthesis of eicosanoids is induced by phospholipase A2 and since secretory phospholipase A2 (sPLA2) is proinflammatory, we investigated the impact of sulfasalazine and related compounds on mRNA, protein synthesis, and release of sPLA2 from osteoblasts.", "spo_list": [{"subject": "eicosanoids", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "phospholipase A2", "object_type": "GENE-N"}]}
{"text": "Sulfasalazine and CL 42A markedly inhibited extracellular release of sPLA2.", "spo_list": [{"subject": "Sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "sPLA2", "object_type": "GENE-N"}]}
{"text": "Exposure of stimulated fetal rat calvaria osteoblasts (FRCO) to sulfasalazine did not show accumulation of the intracellular sPLA2 protein as tested by western blot; however, enzymatic activity of PLA2 in disrupted cells was definitely increased.", "spo_list": [{"subject": "sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PLA2", "object_type": "GENE-N"}]}
{"text": "We conclude that the anti-inflammatory activity of sulfasalazine may be related, in part, to the selective inhibition of the extracellular release of proinflammatory sPLA2.", "spo_list": [{"subject": "sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "sPLA2", "object_type": "GENE-N"}]}
{"text": "L-BOAA causes loss of GSH and inhibition of mitochondrial complex I in lumbosacral cord of male mice through oxidation of thiol groups, while female mice are resistant.", "spo_list": [{"subject": "L-BOAA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mitochondrial complex I", "object_type": "GENE-N"}]}
{"text": "Ovariectomy downregulates glutaredoxin and renders female mice vulnerable to L-BOAA toxicity as evidenced by activation of AP1, loss of GSH and complex I activity indicating the important role of glutaredoxin in neuroprotection.", "spo_list": [{"subject": "L-BOAA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AP1", "object_type": "GENE-Y"}, {"subject": "L-BOAA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "complex I", "object_type": "GENE-N"}]}
{"text": "Estrogen protects against mitochondrial dysfunction caused by excitotoxicity by maintaining cellular redox status through higher constitutive expression of glutaredoxin in the CNS.", "spo_list": [{"subject": "Estrogen", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "glutaredoxin", "object_type": "GENE-N"}]}
{"text": "CSA activated Nrf2 as evaluated by Western blotting.", "spo_list": [{"subject": "CSA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Nrf2", "object_type": "GENE-Y"}]}
{"text": "A luciferase reporter assay also demonstrated that CSA-activated signaling resulted in the increased transcriptional activity of Nrf2 through binding to the antioxidant response element (ARE) enhancer sequence.", "spo_list": [{"subject": "CSA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Nrf2", "object_type": "GENE-Y"}, {"subject": "CSA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "antioxidant response element", "object_type": "GENE-N"}, {"subject": "CSA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ARE", "object_type": "GENE-N"}]}
{"text": "Our study indicated that treatment of HepG2 cells with CSA induces Nrf2-dependent ARE activity and gene expression of heme oxygenase-1 (HO-1), NAD(P)H quinone oxidoreductase 1 (NQO1), and glutamate-cysteine ligase modifier subunits by activation of PI3K/AKT, ERK and JNK signaling pathways.", "spo_list": [{"subject": "CSA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ARE", "object_type": "GENE-N"}, {"subject": "CSA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "heme oxygenase-1", "object_type": "GENE-Y"}, {"subject": "CSA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HO-1", "object_type": "GENE-Y"}, {"subject": "CSA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NAD(P)H quinone oxidoreductase 1", "object_type": "GENE-Y"}, {"subject": "CSA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NQO1", "object_type": "GENE-Y"}, {"subject": "CSA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "glutamate-cysteine ligase", "object_type": "GENE-N"}, {"subject": "CSA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PI3K", "object_type": "GENE-N"}, {"subject": "CSA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AKT", "object_type": "GENE-N"}, {"subject": "CSA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ERK", "object_type": "GENE-N"}, {"subject": "CSA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "JNK", "object_type": "GENE-N"}]}
{"text": "In this study, using reverse transcriptase PCR (RT-PCR) and ELISA, we showed that TCDD up-regulated the expression and secretion of tumor necrosis factor-alpha (TNF-Î±) in a time-dependent manner in cultured HAPI microglial cells.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "tumor necrosis factor-alpha", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TNF-Î±", "object_type": "GENE-Y"}]}
{"text": "TCDD also caused a fast (within 30min as judged by the increase in its mRNA level) activation of cytosolic phospholipase A2 (cPLA2).", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytosolic phospholipase A2", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cPLA2", "object_type": "GENE-Y"}]}
{"text": "This initial action was accompanied by up-regulation of cyclooxygenase-2 (COX-2), an important inflammation marker within 1h after TCDD treatment.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Further, TCDD exposure could induce phosphorylation- and ubiquitination-dependent degradation of IÐºBÎ±, and the translocation of NF-ÎºB p65 from the cytosol to the nucleus in this microglial cell line.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "IÐºBÎ±", "object_type": "GENE-Y"}]}
{"text": "Thus, the NF-ÎºB signaling pathway can be activated after TCDD treatment.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}]}
{"text": "However, Ca(2+) blockers also obviously attenuated NF-ÎºB activation and transnuclear transport induced by TCDD.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}]}
{"text": "In concert with these results, we highlighted that the secretion of pro-inflammatory cytokine and NF-ÎºB activation induced by TCDD can be mediated by elevation of [Ca(2+)]i in HAPI microglial cells.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "cytokine", "object_type": "GENE-N"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}]}
{"text": "Intracellular DA, DOPA, DOPAC and HVA levels, as well as DOPA accumulation as an index of tyrosine hydroxylase activity in the rat brain in vivo, DA re-uptake in the striatum and hippocampus, and monoamine oxidase (MAO) activities were also determined.", "spo_list": [{"subject": "DOPA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "tyrosine hydroxylase", "object_type": "GENE-Y"}]}
{"text": "A case of therapy-related acute myeloblastic leukemia with t(16;21)(q24;q22) after chemotherapy with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and the alkylating agent, cyclophosphamide.", "spo_list": [{"subject": "etoposide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA-topoisomerase II", "object_type": "GENE-Y"}, {"subject": "mitoxantrone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA-topoisomerase II", "object_type": "GENE-Y"}]}
{"text": "A 59-year-old female suffering from malignant lymphoma developed therapy-related acute myeloblastic leukemia (t-AML) after chemotherapy consisting of treatment with DNA-topoisomerase II inhibitors, etoposide and mitoxantrone, and an alkylating agent, cyclophosphamide.", "spo_list": [{"subject": "etoposide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA-topoisomerase II", "object_type": "GENE-Y"}, {"subject": "mitoxantrone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA-topoisomerase II", "object_type": "GENE-Y"}]}
{"text": "None were found to bind to ERalpha, but Rb1(S) and 20(S)-Rg3 were shown to bind to peroxisome proliferator-activated receptor gamma.", "spo_list": [{"subject": "Rb1(S)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "peroxisome proliferator-activated receptor gamma", "object_type": "GENE-Y"}, {"subject": "20(S)-Rg3", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "peroxisome proliferator-activated receptor gamma", "object_type": "GENE-Y"}]}
{"text": "In eukaryotes, Fe-S clusters are synthesized by the mitochondrial iron-sulfur cluster (ISC) machinery and the cytosolic iron-sulfur assembly (CIA) system.", "spo_list": [{"subject": "Fe-S", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "mitochondrial iron-sulfur cluster", "object_type": "GENE-N"}, {"subject": "Fe-S", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ISC", "object_type": "GENE-N"}, {"subject": "Fe-S", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cytosolic iron-sulfur assembly", "object_type": "GENE-N"}, {"subject": "Fe-S", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CIA", "object_type": "GENE-N"}]}
{"text": "In the mammalian ISC machinery, preassembly of the Fe-S cluster on the scaffold protein (ISCU) involves a cysteine desulfurase complex (NFS1/ISD11) and frataxin (FXN), the protein deficient in Friedreich's ataxia.", "spo_list": [{"subject": "Fe-S", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ISCU", "object_type": "GENE-Y"}, {"subject": "Fe-S", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "mammalian ISC", "object_type": "GENE-N"}]}
{"text": "Here, by comparing the biochemical and spectroscopic properties of quaternary (ISCU/NFS1/ISD11/FXN) and ternary (ISCU/NFS1/ISD11) complexes, we show that FXN stabilizes the quaternary complex and controls iron entry to the complex through activation of cysteine desulfurization.", "spo_list": [{"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ISCU", "object_type": "GENE-Y"}, {"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "NFS1", "object_type": "GENE-Y"}, {"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ISD11", "object_type": "GENE-Y"}, {"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "FXN", "object_type": "GENE-Y"}, {"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ISCU", "object_type": "GENE-Y"}, {"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "NFS1", "object_type": "GENE-Y"}, {"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ISD11", "object_type": "GENE-Y"}, {"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "FXN", "object_type": "GENE-Y"}]}
{"text": "Reduced plasma membrane surface expression of GLAST mediates decreased glutamate regulation in the aged striatum.", "spo_list": [{"subject": "glutamate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GLAST", "object_type": "GENE-Y"}]}
{"text": "Duloxetine is a substrate for CYP1A2 and CYP2D6 and a moderate inhibitor of CYP2D6.", "spo_list": [{"subject": "Duloxetine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP1A2", "object_type": "GENE-Y"}, {"subject": "Duloxetine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2D6", "object_type": "GENE-Y"}, {"subject": "Duloxetine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2D6", "object_type": "GENE-Y"}]}
{"text": "Concomitant use of duloxetine and potent CYP1A2 inhibitors should be avoided and duloxetine should be used with caution in patients receiving drugs that are extensively metabolized by CYP2D6, particularly those with a narrow therapeutic index.", "spo_list": [{"subject": "duloxetine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2D6", "object_type": "GENE-Y"}]}
{"text": "OBJECTIVES: This study examined the effect of a small-molecule, direct thrombin inhibitor, argatroban, on reperfusion induced by tissue plasminogen activator (TPA) in patients with acute myocardial infarction (AMI).", "spo_list": [{"subject": "argatroban", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thrombin", "object_type": "GENE-Y"}]}
{"text": "In vitro and in vivo studies have shown that argatroban has advantages over heparin for the inhibition of clot-bound thrombin and for the enhancement of thrombolysis with TPA.", "spo_list": [{"subject": "argatroban", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thrombin", "object_type": "GENE-Y"}]}
{"text": "Quinone oxidoreductases are flavoproteins that catalyze two-electron reduction and detoxification of quinones.", "spo_list": [{"subject": "quinones", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Quinone oxidoreductases", "object_type": "GENE-N"}]}
{"text": "A role of cytosolic NQO1 in protection of cells from oxidative stress, cytotoxicity, and mutagenicity of quinones was established.", "spo_list": [{"subject": "quinones", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NQO1", "object_type": "GENE-Y"}]}
{"text": "The mNQO activity showed significantly higher affinity for NADH than NADPH as electron donors and catalyzed reduction of 2,6-dichlorophenolindophenol and menadione.", "spo_list": [{"subject": "2,6-dichlorophenolindophenol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "mNQO", "object_type": "GENE-N"}, {"subject": "menadione", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "mNQO", "object_type": "GENE-N"}]}
{"text": "The mNQO activity was insensitive to dicoumarol, a potent inhibitor of cytosolic NQO1.", "spo_list": [{"subject": "dicoumarol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NQO1", "object_type": "GENE-Y"}]}
{"text": "Neuroprotective effect of nimesulide, a preferential COX-2 inhibitor, against pentylenetetrazol (PTZ)-induced chemical kindling and associated biochemical parameters in mice.", "spo_list": [{"subject": "nimesulide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Brain cyclooxygenases (COX), the rate-limiting enzyme in prostaglandin synthesis, is rapidly and transiently induced by convulsions in hippocampal and cortical neurons.", "spo_list": [{"subject": "prostaglandin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX", "object_type": "GENE-N"}, {"subject": "prostaglandin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclooxygenases", "object_type": "GENE-N"}]}
{"text": "Previous studies have explored the protective effect of naproxen (non-selective COX-inhibitor) or rofecoxib (selective COX-2 inhibitor) against chemical kindling in mice.", "spo_list": [{"subject": "naproxen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX", "object_type": "GENE-N"}, {"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "With this background, the present study was designed to explore the possible effect of nimesulide (a preferential COX-2 inhibitor) against pentylenetetrazol (PTZ)-induced kindling epilepsy in mice.", "spo_list": [{"subject": "nimesulide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Compared with normal control group, PTZ-kindled mice had significantly higher levels of malondialdehyde, nitrite, myeloperoxidase but had lower levels of reduced glutathione in the whole brain homogenate.", "spo_list": [{"subject": "PTZ", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "myeloperoxidase", "object_type": "GENE-Y"}]}
{"text": "These results suggested that nimesulide, a preferential COX-2 inhibitor offered neuroprotection against PTZ-induced kindling in mice.", "spo_list": [{"subject": "nimesulide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid (1) is a potent AMPA receptor agonist with moderate affinity for native kainic acid (KA) receptors, whereas (S)-E-4-(2,2-dimethylpropylidene)glutamic acid (3) show high affinity for the GluR5 subtype of KA receptors and much lower affinity for the GluR2 subtype of AMPA receptors.", "spo_list": [{"subject": "2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "AMPA receptor", "object_type": "GENE-N"}, {"subject": "2-Amino-3-[3-hydroxy-5-(2-thiazolyl)-4-isoxazolyl]propionic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "kainic acid (KA) receptors", "object_type": "GENE-N"}, {"subject": "(S)-E-4-(2,2-dimethylpropylidene)glutamic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GluR5", "object_type": "GENE-Y"}, {"subject": "(S)-E-4-(2,2-dimethylpropylidene)glutamic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "KA receptors", "object_type": "GENE-N"}, {"subject": "(S)-E-4-(2,2-dimethylpropylidene)glutamic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GluR2", "object_type": "GENE-Y"}, {"subject": "(S)-E-4-(2,2-dimethylpropylidene)glutamic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AMPA receptors", "object_type": "GENE-N"}]}
{"text": "In addition, soy isoflavones regulated plasma glucose, leptin and adiponectin contents after treatment for two months.", "spo_list": [{"subject": "isoflavones", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "leptin", "object_type": "GENE-Y"}, {"subject": "isoflavones", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "adiponectin", "object_type": "GENE-Y"}]}
{"text": "The MWFE polypeptide of mammalian complex I (the proton-translocating NADH-quinone oxidoreductase) is 70 amino acids long, and it is predicted to be a membrane protein.", "spo_list": [{"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MWFE", "object_type": "GENE-Y"}, {"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "mammalian complex I", "object_type": "GENE-N"}, {"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "NADH-quinone oxidoreductase", "object_type": "GENE-N"}]}
{"text": "To investigate the role of mGluR8 in modulating the synaptic responses of retinal ganglion cells, we used a recently identified positive allosteric modulator of mGluR8, AZ12216052 (AZ) and the mGluR8-specific orthosteric agonist (S)-3,4-dicarboxyphenylglycine (DCPG).", "spo_list": [{"subject": "(S)-3,4-dicarboxyphenylglycine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mGluR8", "object_type": "GENE-Y"}, {"subject": "DCPG", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mGluR8", "object_type": "GENE-Y"}]}
{"text": "Dexamethasone probes glucocorticoid receptor (GR) function, while prednisolone probes both GR and mineralocorticoid receptor (MR) function.", "spo_list": [{"subject": "Dexamethasone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}, {"subject": "Dexamethasone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GR", "object_type": "GENE-Y"}, {"subject": "prednisolone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GR", "object_type": "GENE-Y"}, {"subject": "prednisolone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mineralocorticoid receptor", "object_type": "GENE-Y"}, {"subject": "prednisolone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MR", "object_type": "GENE-Y"}]}
{"text": "Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide.", "spo_list": [{"subject": "Hydrogen sulfide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "nuclear factor-kappaB", "object_type": "GENE-N"}]}
{"text": "Hydrogen sulfide (H(2)S), a regulatory gaseous molecule that is endogenously synthesized by cystathionine gamma-lyase (CSE) and/or cystathionine beta-synthase (CBS) from L-cysteine (L-Cys) metabolism, is a putative vasodilator, and its role in nitric oxide (NO) production is unexplored.", "spo_list": [{"subject": "Hydrogen sulfide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cystathionine gamma-lyase", "object_type": "GENE-Y"}, {"subject": "H(2)S", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cystathionine gamma-lyase", "object_type": "GENE-Y"}, {"subject": "Hydrogen sulfide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CSE", "object_type": "GENE-Y"}, {"subject": "H(2)S", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CSE", "object_type": "GENE-Y"}, {"subject": "Hydrogen sulfide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cystathionine beta-synthase", "object_type": "GENE-Y"}, {"subject": "H(2)S", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cystathionine beta-synthase", "object_type": "GENE-Y"}, {"subject": "Hydrogen sulfide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CBS", "object_type": "GENE-Y"}, {"subject": "H(2)S", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CBS", "object_type": "GENE-Y"}, {"subject": "L-cysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cystathionine gamma-lyase", "object_type": "GENE-Y"}, {"subject": "L-cysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CSE", "object_type": "GENE-Y"}, {"subject": "L-cysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cystathionine beta-synthase", "object_type": "GENE-Y"}, {"subject": "L-cysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CBS", "object_type": "GENE-Y"}, {"subject": "L-Cys", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cystathionine gamma-lyase", "object_type": "GENE-Y"}, {"subject": "L-Cys", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CSE", "object_type": "GENE-Y"}, {"subject": "L-Cys", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cystathionine beta-synthase", "object_type": "GENE-Y"}, {"subject": "L-Cys", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CBS", "object_type": "GENE-Y"}]}
{"text": "Here, we show that at noncytotoxic concentrations, H(2)S was able to inhibit NO production and inducible NO synthase (iNOS) expression via heme oxygenase (HO-1) expression in RAW264.7 macrophages stimulated with lipopolysaccharide (LPS).", "spo_list": [{"subject": "H(2)S", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "inducible NO synthase", "object_type": "GENE-Y"}, {"subject": "H(2)S", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "inducible NO synthase", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "iNOS", "object_type": "GENE-Y"}]}
{"text": "Both H(2)S solution prepared by bubbling pure H(2)S gas and NaSH, a H(2)S donor, dose dependently induced HO-1 expression through the activation of the extracellular signal-regulated kinase (ERK).", "spo_list": [{"subject": "H(2)S", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HO-1", "object_type": "GENE-Y"}, {"subject": "H(2)S", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "extracellular signal-regulated kinase", "object_type": "GENE-N"}, {"subject": "H(2)S", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ERK", "object_type": "GENE-N"}]}
{"text": "Pretreatment with H(2)S or NaHS significantly inhibited LPS-induced iNOS expression and NO production.", "spo_list": [{"subject": "NaHS", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "H(2)S", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "iNOS", "object_type": "GENE-Y"}]}
{"text": "Moreover, NO production in LPS-stimulated macrophages that are expressing CSE mRNA was significantly reduced by the addition of L-Cys, a substrate for H(2)S, but enhanced by the selective CSE inhibitor beta-cyano-L-alanine but not by the CBS inhibitor aminooxyacetic acid.", "spo_list": [{"subject": "L-Cys", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CSE", "object_type": "GENE-Y"}, {"subject": "beta-cyano-L-alanine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CSE", "object_type": "GENE-Y"}, {"subject": "aminooxyacetic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CBS", "object_type": "GENE-Y"}]}
{"text": "While either blockage of HO activity by the HO inhibitor, tin protoporphyrin IX, or down-regulation of HO-1 expression by HO-1 small interfering RNA (siRNA) reversed the inhibitory effects of H(2)S on iNOS expression and NO production, HO-1 overexpression produced the same inhibitory effects of H(2)S. In addition, LPS-induced nuclear factor (NF)-kappaB activation was diminished in RAW264.7 macrophages preincubated with H(2)S. Interestingly, the inhibitory effect of H(2)S on NF-kappaB activation was reversed by the transient transfection with HO-1 siRNA, but was mimicked by either HO-1 gene transfection or treatment with carbon monoxide (CO), an end product of HO-1.", "spo_list": [{"subject": "H(2)S", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "H(2)S", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "(NF)-kappaB", "object_type": "GENE-N"}, {"subject": "H(2)S", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}, {"subject": "carbon monoxide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "HO-1", "object_type": "GENE-Y"}, {"subject": "CO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "HO-1", "object_type": "GENE-Y"}]}
{"text": "CO treatment also inhibited LPS-induced NO production and iNOS expression via its inactivation of NF-kappaB.", "spo_list": [{"subject": "CO", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "CO", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "iNOS", "object_type": "GENE-Y"}]}
{"text": "Collectively, our results suggest that H(2)S can inhibit NO production and NF-kappaB activation in LPS-stimulated macrophages through a mechanism that involves the action of HO-1/CO.", "spo_list": [{"subject": "H(2)S", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}, {"subject": "CO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "HO-1", "object_type": "GENE-Y"}]}
{"text": "A chemical biology approach identifies a beta 2 adrenergic receptor (beta2AR) agonist ARA-211 (Pirbuterol), which causes apoptosis and human tumor regression in animal models. beta2AR stimulation of cAMP formation and protein kinase A (PKA) activation leads to Raf-1 (but not B-Raf) kinase inactivation, inhibition of Mek-1 kinase and decreased phospho-extracellular signal-regulated kinase (Erk)1/2 levels.", "spo_list": [{"subject": "ARA-211", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta 2 adrenergic receptor", "object_type": "GENE-Y"}, {"subject": "ARA-211", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta2AR", "object_type": "GENE-Y"}, {"subject": "Pirbuterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta 2 adrenergic receptor", "object_type": "GENE-Y"}, {"subject": "Pirbuterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta2AR", "object_type": "GENE-Y"}, {"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "protein kinase A", "object_type": "GENE-N"}, {"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PKA", "object_type": "GENE-N"}, {"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Raf-1", "object_type": "GENE-Y"}, {"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Mek-1", "object_type": "GENE-Y"}, {"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}]}
{"text": "ARA-211 inhibition of the Raf/Mek/Erk1/2 pathway is mediated by PKA and not exchange protein activated by cAMP (EPAC).", "spo_list": [{"subject": "ARA-211", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Raf", "object_type": "GENE-Y"}, {"subject": "ARA-211", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Mek", "object_type": "GENE-N"}]}
{"text": "Thus, beta2AR stimulation results in significant suppression of malignant transformation in cancers where it blocks the Raf-1/Mek-1/Erk1/2 pathway by a cAMP-dependent activation of PKA but not EPAC.", "spo_list": [{"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PKA", "object_type": "GENE-N"}]}
{"text": "New data for cattle (Bos taurus) indicates a gene encoding GnRH-II decapeptide possessing arginine (codon: CGG) rather than tryptophan (TGG) at position three in the mature peptide.", "spo_list": [{"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GnRH-II", "object_type": "GENE-Y"}, {"subject": "CGG", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GnRH-II", "object_type": "GENE-Y"}, {"subject": "tryptophan", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GnRH-II", "object_type": "GENE-Y"}, {"subject": "TGG", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GnRH-II", "object_type": "GENE-Y"}]}
{"text": "A premature stop codon (TGA) replaces the expected tryptophan codon at position seven of GnRH-II in sheep DNA.", "spo_list": [{"subject": "tryptophan", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GnRH-II", "object_type": "GENE-Y"}]}
{"text": "The updated bovine type II GnRH receptor gene sequence revealed inactivation by frame shifts, premature stop codons, and nucleotide changes specifying nonconservative replacement of amino acid residues, similar to inactivation of sheep type II GnRH receptor.", "spo_list": [{"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "bovine type II GnRH receptor", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "bovine type II GnRH receptor", "object_type": "GENE-Y"}]}
{"text": "Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug.", "spo_list": [{"subject": "Sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "x(c)- cystine transporter", "object_type": "GENE-Y"}]}
{"text": "Sulfasalazine was fortuitously found to be a novel, potent inhibitor of the x(c)- transporter.", "spo_list": [{"subject": "Sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "x(c)- transporter", "object_type": "GENE-Y"}]}
{"text": "It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of x(c)--mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid.", "spo_list": [{"subject": "cystine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "x(c)", "object_type": "GENE-Y"}, {"subject": "sulfapyridine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "x(c)", "object_type": "GENE-Y"}, {"subject": "5-aminosalicylic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "x(c)", "object_type": "GENE-Y"}]}
{"text": "The x(c)- cystine transporter represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular cyst(e)ine.", "spo_list": [{"subject": "cyst(e)ine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "x(c)- cystine transporter", "object_type": "GENE-Y"}]}
{"text": "Ang II is a powerful stimulator of vascular oxidases but BS/GS patients show reduced total volatile LDL oxidation products and reduced LDL susceptibility to oxidation suggesting low level of oxidative stress.", "spo_list": [{"subject": "Ang II", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "vascular oxidases", "object_type": "GENE-N"}]}
{"text": "After acute Ang II exposure, p22(phox), TGFbeta and HO-1 gene expression significantly increased only in controls (from 0.59 +/- 0.12 to 0.96 +/- 0.11, P < 0.001, from 0.97 +/- 0.1 to 1.27 +/- 0.22, P < 0.008, and from 0.62 +/- 0.1 to 0.82 +/- 0.09, P < 0.001, respectively).", "spo_list": [{"subject": "Ang II", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p22(phox)", "object_type": "GENE-Y"}, {"subject": "Ang II", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TGFbeta", "object_type": "GENE-Y"}, {"subject": "Ang II", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HO-1", "object_type": "GENE-Y"}]}
{"text": "Design, Synthesis, and Structure-Activity Relationship Studies of Novel 3-Alkylindole Derivatives as Selective and Highly Potent Myeloperoxidase Inhibitors.", "spo_list": [{"subject": "3-Alkylindole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Myeloperoxidase", "object_type": "GENE-Y"}]}
{"text": "Due to its production of potent antimicrobial oxidants including hypochlorous acid, human myeloperoxidase (MPO) plays a critical role in innate immunity and inflammatory diseases.", "spo_list": [{"subject": "hypochlorous acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "human myeloperoxidase", "object_type": "GENE-Y"}, {"subject": "hypochlorous acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "MPO", "object_type": "GENE-Y"}]}
{"text": "(Aminoalkyl)fluoroindole derivatives were detected to be very potent MPO inhibitors; however, they also promote inhibition of the serotonin reuptake transporter (SERT) at the same concentration range.", "spo_list": [{"subject": "(Aminoalkyl)fluoroindole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MPO", "object_type": "GENE-Y"}, {"subject": "(Aminoalkyl)fluoroindole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "serotonin reuptake transporter", "object_type": "GENE-Y"}, {"subject": "(Aminoalkyl)fluoroindole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SERT", "object_type": "GENE-Y"}]}
{"text": "Via structure-based drug design, a new series of MPO inhibitors derived from 3-alkylindole were synthesized and their effects were assessed on MPO-mediated taurine chlorination and low-density lipoprotein oxidation as well as on inhibition of SERT.", "spo_list": [{"subject": "3-alkylindole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MPO", "object_type": "GENE-Y"}, {"subject": "taurine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MPO", "object_type": "GENE-Y"}]}
{"text": "The fluoroindole compound with three carbons in the side chain and one amide group exhibited a selectivity index of 35 (Ki/IC50) with high inhibition of MPO activity (IC50 = 18 nM), whereas its effect on SERT was in the micromolar range.", "spo_list": [{"subject": "fluoroindole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MPO", "object_type": "GENE-Y"}, {"subject": "carbons", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MPO", "object_type": "GENE-Y"}, {"subject": "amide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MPO", "object_type": "GENE-Y"}, {"subject": "fluoroindole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "carbons", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "amide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SERT", "object_type": "GENE-Y"}]}
{"text": "Flavopiridol, a cyclin-dependent kinase inhibitor, arrests cell division and causes apoptosis in non-small lung cancer cells [283660].", "spo_list": [{"subject": "Flavopiridol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclin-dependent kinase", "object_type": "GENE-N"}]}
{"text": "In ex vivo experiments with tumor cells from refractory chronic lymphoblastic leukemia, dose-dependent CDK2 inhibition associated with apoptotic changes was seen at concentrations greater than 100 nM of flavopiridol.", "spo_list": [{"subject": "flavopiridol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CDK2", "object_type": "GENE-Y"}]}
{"text": "Flavopiridol inhibits CDK with an IC50 value of 0.4 mM [285707].", "spo_list": [{"subject": "Flavopiridol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CDK", "object_type": "GENE-N"}]}
{"text": "Post-hoc analysis of two phase III clinical studies found that the phosphodiesterase 4 (PDE4) inhibitor, roflumilast, reduced exacerbation frequency in patients with severe chronic obstructive pulmonary disease (COPD) who were taking inhaled corticosteroids (ICS) concomitantly, whereas patients not taking ICS derived no such benefit.", "spo_list": [{"subject": "roflumilast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase 4", "object_type": "GENE-N"}, {"subject": "roflumilast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}]}
{"text": "In contrast, in two different trials also performed in patients with severe COPD, roflumilast reduced exacerbation rates in the absence of ICS, indicating that PDE4 inhibition alone is sufficient for therapeutic activity to be realized.", "spo_list": [{"subject": "roflumilast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}]}
{"text": "Using a glucocorticoid response element (GRE) luciferase reporter transfected into human airway epithelial cells [both bronchial epithelium + adenovirus 12 - SV40 hybrid (BEAS-2B) cells and primary cultures], roflumilast enhanced fluticasone propionate-induced GRE-dependent transcription.", "spo_list": [{"subject": "fluticasone propionate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GRE", "object_type": "GENE-N"}, {"subject": "roflumilast", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GRE", "object_type": "GENE-N"}]}
{"text": "Initial human experience with MK-462 (rizatriptan): a novel 5-HT1D agonist.", "spo_list": [{"subject": "MK-462", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT1D", "object_type": "GENE-Y"}, {"subject": "rizatriptan", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT1D", "object_type": "GENE-Y"}]}
{"text": "CONCLUSIONS: These results indicate that the novel 5-HT1D agonist, MK-462, is rapidly absorbed following oral administration and warrants further investigation of its utility in the treatment of acute migraine.", "spo_list": [{"subject": "MK-462", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT1D", "object_type": "GENE-Y"}]}
{"text": "Rasagiline [N-propargyl-1R(+)-aminoindan; TVP1012] is a potent irreversible monoamine oxidase (MAO) inhibitor with selectivity for type B of the enzyme, which is being developed for treatment of Parkinson's disease.", "spo_list": [{"subject": "Rasagiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase", "object_type": "GENE-N"}, {"subject": "N-propargyl-1R(+)-aminoindan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase", "object_type": "GENE-N"}, {"subject": "TVP1012", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase", "object_type": "GENE-N"}, {"subject": "Rasagiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO", "object_type": "GENE-N"}, {"subject": "N-propargyl-1R(+)-aminoindan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO", "object_type": "GENE-N"}, {"subject": "TVP1012", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO", "object_type": "GENE-N"}]}
{"text": "Reserpine-induced ptosis was reversed by rasagiline at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as MAO-B, but not at MAO-B-selective doses.", "spo_list": [{"subject": "rasagiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "rasagiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "Reserpine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "Reserpine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "However, combination of rasagiline (10 mg x kg(-1) i.p.) with L-DOPA or L-tryptophan (50 mg x kg(-1) i.p.), or rasagiline (10 mg x kg(-1) p.o.) with fluoxetine (10 mg x kg(-1) p.o.), did not induce the behavioural hyperactivity syndrome which is seen following inhibition of both MAO-A and MAO-B by tranylcypromine together with the monoamine precursors.", "spo_list": [{"subject": "rasagiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "L-DOPA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "L-tryptophan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "rasagiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "fluoxetine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "rasagiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "L-DOPA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "L-tryptophan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "rasagiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "fluoxetine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "tranylcypromine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "tranylcypromine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "Rasagiline does not modify CNS monoamine tissue levels or monoamine-induced behavioural syndromes at doses which selectively inhibit MAO-B but not MAO-A.", "spo_list": [{"subject": "Rasagiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "Phillyrin attenuates high glucose-induced lipid accumulation in human HepG2 hepatocytes through the activation of LKB1/AMP-activated protein kinase-dependent signalling.", "spo_list": [{"subject": "Phillyrin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "LKB1", "object_type": "GENE-Y"}, {"subject": "Phillyrin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMP-activated protein kinase", "object_type": "GENE-N"}]}
{"text": "Phillyrin strongly inhibited high glucose-induced fatty acid synthase (FAS) expression by modulating sterol regulatory element-binding protein-1c (SREBP-1c) activation.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "fatty acid synthase", "object_type": "GENE-Y"}, {"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "FAS", "object_type": "GENE-Y"}, {"subject": "Phillyrin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "fatty acid synthase", "object_type": "GENE-Y"}, {"subject": "Phillyrin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "FAS", "object_type": "GENE-Y"}]}
{"text": "Moreover, use of the pharmacological AMP-activated protein kinase (AMPK) inhibitor compound C revealed that AMPK is essential for suppressing SREBP-1c expression in phillyrin-treated cells.", "spo_list": [{"subject": "compound C", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AMP-activated protein kinase", "object_type": "GENE-N"}, {"subject": "compound C", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "compound C", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AMPK", "object_type": "GENE-N"}]}
{"text": "Finally, we found that liver kinase B1 (LKB1) phosphorylation is required for the phillyrin-enhanced activation of AMPK in HepG2 hepatocytes.", "spo_list": [{"subject": "phillyrin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}]}
{"text": "These results indicate that phillyrin prevents lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through LKB1/AMPK activation, suggesting that phillyrin is a novel AMPK activator with a role in the prevention and treatment of obesity.", "spo_list": [{"subject": "phillyrin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "SREBP-1c", "object_type": "GENE-Y"}, {"subject": "phillyrin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "FAS", "object_type": "GENE-Y"}, {"subject": "phillyrin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "LKB1", "object_type": "GENE-Y"}, {"subject": "phillyrin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "phillyrin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}]}
{"text": "We now report that 58K is a formiminotransferase cyclodeaminase (FTCD), a bifunctional enzyme that catalyzes two consecutive steps in the modification of tetrahydrofolate to 5,10-methenyl tetrahydrofolate.", "spo_list": [{"subject": "tetrahydrofolate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "formiminotransferase cyclodeaminase", "object_type": "GENE-Y"}, {"subject": "tetrahydrofolate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FTCD", "object_type": "GENE-Y"}, {"subject": "5,10-methenyl tetrahydrofolate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "formiminotransferase cyclodeaminase", "object_type": "GENE-Y"}, {"subject": "5,10-methenyl tetrahydrofolate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "FTCD", "object_type": "GENE-Y"}]}
{"text": "Benzenesulfonamides: a unique class of chemokine receptor type 4 inhibitors.", "spo_list": [{"subject": "Benzenesulfonamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "chemokine receptor type 4", "object_type": "GENE-Y"}]}
{"text": "Based on our previously published work on CXCR4 antagonists, we have synthesized a series of aryl sulfonamides that inhibit the CXCR4/CXCL12 interaction.", "spo_list": [{"subject": "aryl sulfonamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CXCR4", "object_type": "GENE-Y"}, {"subject": "aryl sulfonamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CXCL12", "object_type": "GENE-Y"}]}
{"text": "These data demonstrate that benzenesulfonamides are a unique class of CXCR4 inhibitors with high potency.", "spo_list": [{"subject": "benzenesulfonamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CXCR4", "object_type": "GENE-Y"}]}
{"text": "Cardiomyoblast cells pretreated with Fulvestrant (ICI 182,780), an estrogen receptor antagonist was applied to investigate the estrogenic activity of Danshen.", "spo_list": [{"subject": "Fulvestrant", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "ICI 182,780", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "estrogen receptor", "object_type": "GENE-Y"}]}
{"text": "ASIC3 channels integrate agmatine and multiple inflammatory signals through the nonproton ligand sensing domain.", "spo_list": [{"subject": "agmatine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ASIC3", "object_type": "GENE-Y"}]}
{"text": "We recently reported the use of a synthetic compound, 2-guanidine-4-methylquinazoline (GMQ), to identify a novel nonproton sensing domain in the ASIC3 channel, and proposed that, based on its structural similarity with GMQ, the arginine metabolite agmatine (AGM) may be an endogenous nonproton ligand for ASIC3 channels.", "spo_list": [{"subject": "GMQ", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ASIC3", "object_type": "GENE-Y"}, {"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ASIC3", "object_type": "GENE-Y"}, {"subject": "agmatine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ASIC3", "object_type": "GENE-Y"}]}
{"text": "Among arginine metabolites, only AGM and its analog arcaine (ARC) activated ASIC3 channels at neutral pH in a sustained manner similar to GMQ.", "spo_list": [{"subject": "arcaine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ASIC3", "object_type": "GENE-Y"}, {"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ASIC3", "object_type": "GENE-Y"}, {"subject": "GMQ", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ASIC3", "object_type": "GENE-Y"}]}
{"text": "Cross-linking of Trx2 and Tsa1 to other proteins by DVSF and DAD is dependent on modification of the active site Cys residues within these proteins.", "spo_list": [{"subject": "Cys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Trx2", "object_type": "GENE-Y"}, {"subject": "Cys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Tsa1", "object_type": "GENE-Y"}]}
{"text": "L-serine dehydratase (SDH), a member of the beta-family of pyridoxal phosphate-dependent (PLP) enzymes, catalyzes the deamination of L-serine and L-threonine to yield pyruvate or 2-oxobutyrate.", "spo_list": [{"subject": "L-serine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "L-serine dehydratase", "object_type": "GENE-Y"}, {"subject": "L-threonine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "L-serine dehydratase", "object_type": "GENE-Y"}, {"subject": "pyruvate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "L-serine dehydratase", "object_type": "GENE-Y"}, {"subject": "2-oxobutyrate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "L-serine dehydratase", "object_type": "GENE-Y"}, {"subject": "L-serine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SDH", "object_type": "GENE-Y"}, {"subject": "L-threonine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SDH", "object_type": "GENE-Y"}, {"subject": "pyruvate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "SDH", "object_type": "GENE-Y"}, {"subject": "2-oxobutyrate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "SDH", "object_type": "GENE-Y"}]}
{"text": "Amphetamine-induced loss of human dopamine transporter activity: an internalization-dependent and cocaine-sensitive mechanism.", "spo_list": [{"subject": "Amphetamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human dopamine transporter", "object_type": "GENE-Y"}]}
{"text": "These psychostimulants attenuate DAT clearance efficiency, thereby increasing synaptic dopamine (DA) levels.", "spo_list": [{"subject": "dopamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DAT", "object_type": "GENE-Y"}, {"subject": "DA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DAT", "object_type": "GENE-Y"}]}
{"text": "Here, we present evidence that DAT substrates, including AMPH and DA, cause internalization of human DAT, thereby reducing transport capacity.", "spo_list": [{"subject": "AMPH", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DAT", "object_type": "GENE-Y"}, {"subject": "DA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DAT", "object_type": "GENE-Y"}]}
{"text": "Acute treatment with AMPH reduced the maximal rate of [(3)H]DA uptake, decreased AMPH-induced currents, and significantly redistributed the immunofluorescence of an epitope-tagged DAT from the plasma membrane to the cytosol in human embryonic kidney 293 cells.", "spo_list": [{"subject": "[(3)H]DA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DAT", "object_type": "GENE-Y"}]}
{"text": "Conversely, DAT inhibitors, such as cocaine, mazindol, and nomifensine, when administered with AMPH, blocked the reduction in [(3)H]DA uptake and the redistribution of DAT immunofluorescence to the cytosol.", "spo_list": [{"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DAT", "object_type": "GENE-Y"}, {"subject": "mazindol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DAT", "object_type": "GENE-Y"}, {"subject": "nomifensine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DAT", "object_type": "GENE-Y"}, {"subject": "[(3)H]DA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DAT", "object_type": "GENE-Y"}]}
{"text": "The reductions of [(3)H]DA uptake and AMPH-induced DAT internalization also were inhibited by coexpression of a dominant negative mutant of dynamin I (K44A), indicating that endocytosis modulates transport capacity, likely through a clathrin-mediated pathway.", "spo_list": [{"subject": "[(3)H]DA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DAT", "object_type": "GENE-Y"}]}
{"text": "With this mechanism of regulation, acute application of AMPH would reduce DA uptake not only by direct competition for uptake, but also by reducing the available cell-surface DAT.", "spo_list": [{"subject": "DA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DAT", "object_type": "GENE-Y"}]}
{"text": "Moreover, AMPH-induced internalization might diminish the amount of DAT available for DA efflux, thereby modulating the cytotoxic effects of elevated extracellular DA.", "spo_list": [{"subject": "DA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DAT", "object_type": "GENE-Y"}, {"subject": "DA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DAT", "object_type": "GENE-Y"}]}
{"text": "INTRODUCTION: The principal aim of this study was to assess the efficacy of quinidine in suppressing IKr in vitro and in modulating the rate dependence of the QT interval in the \"SQT1\" form of the short QT syndrome.", "spo_list": [{"subject": "quinidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IKr", "object_type": "GENE-N"}]}
{"text": "CONCLUSION: Oral quinidine is effective in suppressing the gain of function in IKr responsible for some cases of short QT syndrome with a mutation in HERG and thus restoring normal rate dependence of the QT interval and rendering ventricular tachycardia/ventricular fibrillation noninducible.", "spo_list": [{"subject": "quinidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IKr", "object_type": "GENE-N"}]}
{"text": "Even though its inability to shift between the trivalent and a divalent oxidation state precludes that gallium behaves as an iron analogue in every respect, it strongly interferes with cellular acquisition of iron from blood by competitive interaction with transferrin and transferrin receptor-mediated endocytosis.", "spo_list": [{"subject": "gallium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "transferrin", "object_type": "GENE-Y"}, {"subject": "iron", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "transferrin", "object_type": "GENE-Y"}, {"subject": "gallium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "transferrin receptor", "object_type": "GENE-N"}, {"subject": "iron", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "transferrin receptor", "object_type": "GENE-N"}]}
{"text": "Furthermore, gallium also seems to affect intracellular availability of iron already taken up via this pathway, probably due to its inhibitory activity on vacuolar-type H(+)-ATPases.", "spo_list": [{"subject": "gallium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "vacuolar-type H(+)-ATPases", "object_type": "GENE-N"}]}
{"text": "Apart from the consequences of iron deprivation, gallium exerts cytotoxic effects by direct interaction with the iron-dependent enzyme ribonucleotide reductase, resulting in reduced dNTP pools and inhibition of DNA synthesis.", "spo_list": [{"subject": "gallium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ribonucleotide reductase", "object_type": "GENE-N"}]}
{"text": "However, some experimental findings raise the question whether these effects resulting from the iron-mimicking properties of gallium are solely responsible for its antineoplastic activity or whether additional mechanisms are involved, such as antimitotic effects which result from its capability of inhibiting tubulin polymerization.", "spo_list": [{"subject": "gallium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tubulin", "object_type": "GENE-N"}, {"subject": "iron", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tubulin", "object_type": "GENE-N"}]}
{"text": "Inhibition of carbonic anhydrase (CA, EC 4.2.1.1) isoforms present in the eyes (CA I, II, IV and XII), with sulfonamides such as acetazolamide, methazolamide, ethoxzolamide and dichlorophenamide, is still widely used for the systemic treatment of glaucoma.", "spo_list": [{"subject": "sulfonamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase", "object_type": "GENE-N"}, {"subject": "sulfonamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA", "object_type": "GENE-N"}, {"subject": "sulfonamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 4.2.1.1", "object_type": "GENE-Y"}, {"subject": "acetazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase", "object_type": "GENE-N"}, {"subject": "acetazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA", "object_type": "GENE-N"}, {"subject": "acetazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 4.2.1.1", "object_type": "GENE-Y"}, {"subject": "methazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase", "object_type": "GENE-N"}, {"subject": "methazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA", "object_type": "GENE-N"}, {"subject": "methazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 4.2.1.1", "object_type": "GENE-Y"}, {"subject": "ethoxzolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase", "object_type": "GENE-N"}, {"subject": "ethoxzolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA", "object_type": "GENE-N"}, {"subject": "ethoxzolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 4.2.1.1", "object_type": "GENE-Y"}, {"subject": "dichlorophenamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase", "object_type": "GENE-N"}, {"subject": "dichlorophenamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA", "object_type": "GENE-N"}, {"subject": "dichlorophenamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 4.2.1.1", "object_type": "GENE-Y"}]}
{"text": "The mechanism of action of these drugs consists in inhibition of CA isozymes present in ciliary processes of the eye, with the consequent reduction of bicarbonate and aqueous humour secretion, and of elevated intraocular pressure (IOP) characteristic of this disease.", "spo_list": [{"subject": "bicarbonate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CA", "object_type": "GENE-N"}]}
{"text": "AlCl3 markedly reduced AA performance and activities of cytochrome c oxidase (COX) and acetylcholinesterase (AChE) in all regions.", "spo_list": [{"subject": "AlCl3", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cytochrome c oxidase", "object_type": "GENE-N"}, {"subject": "AlCl3", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX", "object_type": "GENE-N"}, {"subject": "AlCl3", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "AlCl3", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "GTLE pretreatment completely reversed the damaging effects of AlCl3 on AA and superoxide dismutase activity, markedly corrected COX and AChE activities, and moderately improved TGC.", "spo_list": [{"subject": "AlCl3", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "superoxide dismutase", "object_type": "GENE-N"}, {"subject": "AlCl3", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX", "object_type": "GENE-N"}, {"subject": "AlCl3", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "Uptake of estrone-3-sulfate (5ânM) by OATP1B1 was reduced by 82%-95%.", "spo_list": [{"subject": "estrone-3-sulfate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B1", "object_type": "GENE-Y"}]}
{"text": "This methodology was subsequently used to assess the relative contribution of OATP1B1 uptake in human hepatocytes for olmesartan (42%-62%), valsartan (28%-81%), rosuvastatin (64%-72%), pitavastatin (84%-98%) and lopinavir (64%-89%).", "spo_list": [{"subject": "olmesartan", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B1", "object_type": "GENE-Y"}, {"subject": "valsartan", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B1", "object_type": "GENE-Y"}, {"subject": "rosuvastatin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B1", "object_type": "GENE-Y"}, {"subject": "pitavastatin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B1", "object_type": "GENE-Y"}, {"subject": "lopinavir", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B1", "object_type": "GENE-Y"}]}
{"text": "Two sodium-dependent vitamin C transporter isoforms (SVCT1 and SVCT2) were identified as ascorbic acid transporters, but their roles in skin have, as yet, not been elucidated.", "spo_list": [{"subject": "ascorbic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "sodium-dependent vitamin C transporter", "object_type": "GENE-N"}, {"subject": "ascorbic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SVCT1", "object_type": "GENE-Y"}, {"subject": "ascorbic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SVCT2", "object_type": "GENE-Y"}]}
{"text": "Uptake experiments revealed that ascorbic acid affinity of SVCT1 was lower than SVCT2 (K(m)=75 muM and K(m)=44 muM, respectively), but maximal velocity was 9-times higher (36 nmol/min/well).", "spo_list": [{"subject": "ascorbic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SVCT1", "object_type": "GENE-Y"}]}
{"text": "In keratinocytes, SVCT1 was found to be responsible for vitamin C transport, although SVCT2 gene expression was higher.", "spo_list": [{"subject": "vitamin C", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SVCT1", "object_type": "GENE-Y"}]}
{"text": "In summary, these data indicate that the two vitamin C transporter isoforms fulfill specific functions in skin: SVCT1 is responsible for epidermal ascorbic acid supply, whereas SVCT2 mainly facilitates ascorbic acid transport in the dermal compartment.", "spo_list": [{"subject": "ascorbic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SVCT1", "object_type": "GENE-Y"}, {"subject": "ascorbic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SVCT2", "object_type": "GENE-Y"}]}
{"text": "UVB-induced oxidative stress in mice resulted in depletion of SVCT1 mRNA levels and led to significantly decreased ascorbic acid uptake in keratinocytes, providing evidence on why ascorbic acid levels are decreased on UVB irradiation in vivo.", "spo_list": [{"subject": "ascorbic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SVCT1", "object_type": "GENE-Y"}]}
{"text": "While DNA damage does not affect phosphorylation at the PDK-1 site Thr350/Thr308 of AKT-1, it increased phosphorylation at Ser517/Ser473.", "spo_list": [{"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "AKT-1", "object_type": "GENE-Y"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "AKT-1", "object_type": "GENE-Y"}]}
{"text": "Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril.", "spo_list": [{"subject": "omapatrilat", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Vasopeptidase", "object_type": "GENE-N"}, {"subject": "captopril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACE", "object_type": "GENE-Y"}]}
{"text": "BIO TO-2 cardiomyopathic hamsters (CMHs) in the early stages of dilated heart failure were treated with vehicle or maximal ACE inhibitory doses of captopril (750 micromol/kg/day) or omapatrilat (200 micromol/kg/day).", "spo_list": [{"subject": "captopril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACE", "object_type": "GENE-Y"}, {"subject": "omapatrilat", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACE", "object_type": "GENE-Y"}]}
{"text": "Prolonged vasopeptidase inhibition increased median survival time after the start of treatment by 99 and 31% compared with vehicle and captopril, respectively (median survival times: 146, 221, and 290 days with vehicle, captopril, and omapatrilat, respectively; p < 0.001 for all comparisons).", "spo_list": [{"subject": "captopril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "vasopeptidase", "object_type": "GENE-N"}, {"subject": "captopril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "vasopeptidase", "object_type": "GENE-N"}, {"subject": "omapatrilat", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "vasopeptidase", "object_type": "GENE-N"}]}
{"text": "Omapatrilat, but not captopril, significantly increased urinary atrial natriuretic peptide excretion, indicating NEP inhibition.", "spo_list": [{"subject": "Omapatrilat", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "atrial natriuretic peptide", "object_type": "GENE-N"}, {"subject": "Omapatrilat", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NEP", "object_type": "GENE-Y"}]}
{"text": "Thus vasopeptidase inhibition with omapatrilat was more effective than ACE inhibition with captopril in preventing changes in LV geometry and premature mortality in hamsters with dilated heart failure.", "spo_list": [{"subject": "omapatrilat", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "vasopeptidase", "object_type": "GENE-N"}, {"subject": "captopril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACE", "object_type": "GENE-Y"}]}
{"text": "The selective SYK inhibitor P505-15 (PRT062607) inhibits B cell signaling and function in vitro and in vivo and augments the activity of fludarabine in chronic lymphocytic leukemia.", "spo_list": [{"subject": "P505-15", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SYK", "object_type": "GENE-Y"}, {"subject": "PRT062607", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SYK", "object_type": "GENE-Y"}]}
{"text": "P505-15 (also known as PRT062607) is a novel, highly selective, and orally bioavailable small molecule SYK inhibitor (SYK IC(50) = 1 nM) with anti-SYK activity that is at least 80-fold greater than its affinity for other kinases.", "spo_list": [{"subject": "P505-15", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SYK", "object_type": "GENE-Y"}, {"subject": "PRT062607", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SYK", "object_type": "GENE-Y"}, {"subject": "P505-15", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SYK", "object_type": "GENE-Y"}, {"subject": "PRT062607", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SYK", "object_type": "GENE-Y"}, {"subject": "P505-15", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SYK", "object_type": "GENE-Y"}, {"subject": "PRT062607", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SYK", "object_type": "GENE-Y"}]}
{"text": "P505-15 successfully inhibited SYK-mediated B-cell receptor signaling and decreased cell viability in NHL and CLL.", "spo_list": [{"subject": "P505-15", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SYK", "object_type": "GENE-Y"}, {"subject": "P505-15", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "B-cell receptor", "object_type": "GENE-N"}]}
{"text": "Desipramine and imipramine, inhibitors of acid sphingomyelinase (ASMase), suppressed RGDfV-induced ceramide increase.", "spo_list": [{"subject": "Desipramine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acid sphingomyelinase", "object_type": "GENE-Y"}, {"subject": "imipramine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acid sphingomyelinase", "object_type": "GENE-Y"}, {"subject": "Desipramine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ASMase", "object_type": "GENE-Y"}, {"subject": "imipramine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ASMase", "object_type": "GENE-Y"}]}
{"text": "Importantly, desipramine, imipramine, and a third ASMase inhibitor, SR33557, but not inhibitors of neutral sphingomyelinase, suppressed RGDfV-induced apoptosis, suggesting that ASMase was required for integrin-mediated apoptosis.", "spo_list": [{"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ASMase", "object_type": "GENE-Y"}, {"subject": "imipramine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ASMase", "object_type": "GENE-Y"}, {"subject": "SR33557", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ASMase", "object_type": "GENE-Y"}]}
{"text": "Effects of the histamine H1 antagonist chlorcyclizine on rat fetal palate development.", "spo_list": [{"subject": "chlorcyclizine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1", "object_type": "GENE-Y"}]}
{"text": "BACKGROUND: The effects of histamine H1 antagonist chlorcyclizine on rat palate development were characterized following in utero exposure.", "spo_list": [{"subject": "chlorcyclizine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1", "object_type": "GENE-Y"}]}
{"text": "Among the LAs tested, procaine and other ester-type LAs inhibited [3H]DA uptake and binding of [3H]2-beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane (CFT), a cocaine analogue, in COS cells expressing rat dopamine transporter (DAT).", "spo_list": [{"subject": "[3H]DA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "rat dopamine transporter", "object_type": "GENE-Y"}, {"subject": "[3H]DA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DAT", "object_type": "GENE-Y"}, {"subject": "[3H]2-beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "rat dopamine transporter", "object_type": "GENE-Y"}, {"subject": "[3H]2-beta-carbomethoxy-3-beta-(4-fluorophenyl)tropane", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DAT", "object_type": "GENE-Y"}, {"subject": "CFT", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "rat dopamine transporter", "object_type": "GENE-Y"}, {"subject": "CFT", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DAT", "object_type": "GENE-Y"}, {"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "rat dopamine transporter", "object_type": "GENE-Y"}, {"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DAT", "object_type": "GENE-Y"}, {"subject": "procaine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DAT", "object_type": "GENE-Y"}, {"subject": "procaine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "rat dopamine transporter", "object_type": "GENE-Y"}, {"subject": "ester", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "rat dopamine transporter", "object_type": "GENE-Y"}, {"subject": "ester", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DAT", "object_type": "GENE-Y"}]}
{"text": "The inhibitory effect on [3H]DA uptake was reversible and not dependent on pH, as observed in HeLa cells stably expressing DAT.", "spo_list": [{"subject": "[3H]DA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DAT", "object_type": "GENE-Y"}]}
{"text": "Procaine also inhibited uptake of norepinephrine (NE) and serotonin (5-HT) by the norepinephrine transporter (NET) or serotonin transporter (SERT) expressed in COS cells.", "spo_list": [{"subject": "norepinephrine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "norepinephrine transporter", "object_type": "GENE-Y"}, {"subject": "NE", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "norepinephrine transporter", "object_type": "GENE-Y"}, {"subject": "norepinephrine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NET", "object_type": "GENE-Y"}, {"subject": "NE", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NET", "object_type": "GENE-Y"}, {"subject": "serotonin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "serotonin transporter", "object_type": "GENE-Y"}, {"subject": "serotonin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "serotonin transporter", "object_type": "GENE-Y"}, {"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "Procaine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "norepinephrine transporter", "object_type": "GENE-Y"}, {"subject": "Procaine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NET", "object_type": "GENE-Y"}, {"subject": "Procaine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "serotonin transporter", "object_type": "GENE-Y"}, {"subject": "Procaine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SERT", "object_type": "GENE-Y"}]}
{"text": "Kinetic analysis of monoamine uptake inhibition by procaine in COS cells expressing rat DAT, NET or SERT revealed a competitive action similar to that of cocaine.", "spo_list": [{"subject": "monoamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "rat DAT", "object_type": "GENE-Y"}, {"subject": "monoamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NET", "object_type": "GENE-Y"}, {"subject": "monoamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "procaine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "rat DAT", "object_type": "GENE-Y"}, {"subject": "procaine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NET", "object_type": "GENE-Y"}, {"subject": "procaine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "rat DAT", "object_type": "GENE-Y"}, {"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NET", "object_type": "GENE-Y"}, {"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SERT", "object_type": "GENE-Y"}]}
{"text": "2. In vitro MRP2 activity was determined by measuring the ATP-dependent uptake of 5(6)-carboxy-2',7'-dichlorofluorescein (CDCF) in inside-out membrane vesicles isolated from MDCK-ABCC2 cells.", "spo_list": [{"subject": "5(6)-carboxy-2',7'-dichlorofluorescein", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP2", "object_type": "GENE-Y"}, {"subject": "CDCF", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP2", "object_type": "GENE-Y"}, {"subject": "5(6)-carboxy-2',7'-dichlorofluorescein", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ABCC2", "object_type": "GENE-Y"}, {"subject": "CDCF", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ABCC2", "object_type": "GENE-Y"}]}
{"text": "4. This study demonstrates, for the first time, that inhibition of CDCF uptake in MDCKII-ABCC2 vesicles not only provides a screening assay to assess MRP2 drug-drug interaction potential, but is also predictive of human MRP2-mediated biliary excretion.", "spo_list": [{"subject": "CDCF", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ABCC2", "object_type": "GENE-Y"}, {"subject": "CDCF", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP2", "object_type": "GENE-Y"}, {"subject": "CDCF", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human MRP2", "object_type": "GENE-Y"}]}
{"text": "Dimethylarginine dimethylaminohydrolase 1 (DDAH1) is an enzyme that metabolizes methylated arginine to citrulline and methylamine, thus working to produce nitric oxide (NO).", "spo_list": [{"subject": "citrulline", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Dimethylarginine dimethylaminohydrolase 1", "object_type": "GENE-N"}, {"subject": "methylamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Dimethylarginine dimethylaminohydrolase 1", "object_type": "GENE-N"}, {"subject": "nitric oxide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Dimethylarginine dimethylaminohydrolase 1", "object_type": "GENE-N"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Dimethylarginine dimethylaminohydrolase 1", "object_type": "GENE-N"}, {"subject": "citrulline", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "DDAH1", "object_type": "GENE-N"}, {"subject": "methylamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "DDAH1", "object_type": "GENE-N"}, {"subject": "nitric oxide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "DDAH1", "object_type": "GENE-N"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "DDAH1", "object_type": "GENE-N"}]}
{"text": "It is more potent and selective than citalopram in inhibiting serotonin re-uptake in the CNS, and less potent than various other selective serotonin re-uptake inhibitors in relation to other transporter proteins and receptors: in particular, it is six times less potent than citalopram in binding to the histamine H1 and muscarinic receptors.", "spo_list": [{"subject": "citalopram", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "histamine H1", "object_type": "GENE-Y"}, {"subject": "citalopram", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "muscarinic receptors", "object_type": "GENE-N"}]}
{"text": "Caution is necessary only when it is coadministered with drugs metabolised by CYP2D6, such as metoprolol, or administered to the elderly or patients with severe hepatic or renal impairment.", "spo_list": [{"subject": "metoprolol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2D6", "object_type": "GENE-Y"}]}
{"text": "The ATP required for potentiation of skeletal muscle contraction is released via pannexin hemichannels.", "spo_list": [{"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "pannexin", "object_type": "GENE-N"}]}
{"text": "During repetitive stimulation of skeletal muscle, extracellular ATP levels raise, activating purinergic receptors, increasing Ca(2+) influx, and enhancing contractile force, a response called potentiation.", "spo_list": [{"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "purinergic receptors", "object_type": "GENE-N"}]}
{"text": "Consistent with two glucose uptake pathways, induced uptake of 2-NBDG, a fluorescent glucose derivative, was decreased by inhibition of HCs or glucose transporter (GLUT4), and blocked by dual blockade.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "glucose transporter", "object_type": "GENE-N"}, {"subject": "2-NBDG", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "glucose transporter", "object_type": "GENE-N"}, {"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GLUT4", "object_type": "GENE-Y"}, {"subject": "2-NBDG", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GLUT4", "object_type": "GENE-Y"}]}
{"text": "MRS2179, a P2Y1R blocker, prevented potentiation in EDL, but not soleus muscles, suggesting that in fast muscles ATP activates P2Y1 but not P2X receptors.", "spo_list": [{"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "P2Y1", "object_type": "GENE-Y"}]}
{"text": "Phosphorylation on Ser and Thr residues of pannexin1 was increased during potentiation, possibly mediating HC opening.", "spo_list": [{"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "pannexin1", "object_type": "GENE-Y"}, {"subject": "Thr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "pannexin1", "object_type": "GENE-Y"}]}
{"text": "Opening of Panx1 HCs during repetitive activation allows efflux of ATP, influx of glucose and possibly Ca(2+) too, which are required for potentiation of contraction.", "spo_list": [{"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Panx1", "object_type": "GENE-Y"}, {"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Panx1", "object_type": "GENE-Y"}, {"subject": "Ca(2+)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Panx1", "object_type": "GENE-Y"}]}
{"text": "OBJECTIVE: Preclinical evaluation of DRF 2655, a peroxisome proliferator-activated receptor alpha (PPARalpha) and PPARgamma agonist, as a body-weight lowering, hypolipidemic and euglycemic agent.", "spo_list": [{"subject": "DRF 2655", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "peroxisome proliferator-activated receptor alpha", "object_type": "GENE-Y"}, {"subject": "DRF 2655", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "PPARalpha", "object_type": "GENE-Y"}, {"subject": "DRF 2655", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "PPARgamma", "object_type": "GENE-Y"}]}
{"text": "RESULTS: DRF 2655 showed concentration-dependent transactivation of PPARalpha and PPARgamma.", "spo_list": [{"subject": "DRF 2655", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "PPARalpha", "object_type": "GENE-Y"}, {"subject": "DRF 2655", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "PPARgamma", "object_type": "GENE-Y"}]}
{"text": "DRF 2655 showed body-weight lowering and euglycemic and hypolipidemic effects in various animal models. db/db mice treated with DRF 2655 showed 5- and 3.6-fold inhibition in phosphoenolpyruvate carboxykinase and glucose 6-phosphatase activity and 651% and 77% increases in the beta-oxidation enzymes carnitine palmitoyltransferase and carnitine acetyltransferase, respectively.", "spo_list": [{"subject": "DRF 2655", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphoenolpyruvate carboxykinase", "object_type": "GENE-Y"}, {"subject": "DRF 2655", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "glucose 6-phosphatase", "object_type": "GENE-Y"}]}
{"text": "Radioligand binding studies were performed in membranes of rabbit whole brain and striatum using the novel iodinated radioligand for 5-hydroxytryptamine 5-HT1B and 5-HT1D sites, Serotonin-5-O-Carboxymethyl-Glycyl[125I]Tyrosinamide ([125I]GTI).", "spo_list": [{"subject": "Serotonin-5-O-Carboxymethyl-Glycyl[125I]Tyrosinamide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-hydroxytryptamine 5-HT1B", "object_type": "GENE-Y"}, {"subject": "Serotonin-5-O-Carboxymethyl-Glycyl[125I]Tyrosinamide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-Y"}, {"subject": "[125I]GTI", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-hydroxytryptamine 5-HT1B", "object_type": "GENE-Y"}, {"subject": "[125I]GTI", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-Y"}]}
{"text": "The pharmacological profile of [125I]GTI binding was fully comparable to that reported previously in human and other brain preparations known to possess 5-HT1D sites (using either [3H]5-HT or [125I]GTI) and displayed a characteristic rank order of affinity: 5-carboxamido-tryptamine greater than 5-HT = dihydroergotamine greater than or equal to ergotamine greater than or equal to sumatriptan greater than or equal to CGS 12066 greater than or equal to metergoline greater than yohimbine greater than or equal to methysergide greater than ICYP greater than 8-OH-DPAT greater than or equal to CP 93129 greater than (-)pindolol greater than ketanserin greater than isamoltane greater than mesulergine greater than corynanthine greater than buspirone greater than MDL 72222.", "spo_list": [{"subject": "[3H]5-HT", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "[125I]GTI", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "[125I]GTI", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "5-carboxamido-tryptamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "dihydroergotamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "ergotamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "sumatriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "CGS 12066", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "metergoline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "yohimbine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "methysergide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "8-OH-DPAT", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "CP 93129", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "(-)pindolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "ketanserin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "isamoltane", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "mesulergine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "corynanthine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "buspirone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}, {"subject": "MDL 72222", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-N"}]}
{"text": "Autoradiographic studies were performed on rabbit brain slices using [3H]5-HT in the presence of 100 nmol/l 8-OH-DPAT and mesulergine (in order to mask 5-HT1A and 5-HT1C binding sites) and [125I]CYP (iodocyanopindolol) in the presence of 3 mumol/l isoprenaline and 100 nmol/l 8-OH-DPAT (in order to mask beta adrenoceptor and 5-HT1A binding sites).", "spo_list": [{"subject": "[3H]5-HT", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "[3H]5-HT", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1C", "object_type": "GENE-N"}, {"subject": "8-OH-DPAT", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "8-OH-DPAT", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1C", "object_type": "GENE-N"}, {"subject": "mesulergine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "mesulergine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1C", "object_type": "GENE-N"}, {"subject": "[125I]CYP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta adrenoceptor", "object_type": "GENE-N"}, {"subject": "[125I]CYP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "isoprenaline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta adrenoceptor", "object_type": "GENE-N"}, {"subject": "isoprenaline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "iodocyanopindolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta adrenoceptor", "object_type": "GENE-N"}, {"subject": "iodocyanopindolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "8-OH-DPAT", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta adrenoceptor", "object_type": "GENE-N"}, {"subject": "8-OH-DPAT", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1A", "object_type": "GENE-Y"}]}
{"text": "The membrane-associated signaling pathways include rapid production of diacylglycerol and activation of protein kinase C (PKC), as well as activation of phospholipase A(2) (PLA(2)), increased production of arachidonic acid, and increased production of prostaglandins.", "spo_list": [{"subject": "arachidonic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "phospholipase A(2)", "object_type": "GENE-N"}, {"subject": "arachidonic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PLA(2)", "object_type": "GENE-N"}, {"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "phospholipase A(2)", "object_type": "GENE-N"}, {"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PLA(2)", "object_type": "GENE-N"}]}
{"text": "The effects of Cox inhibition were not rate limiting, based on experiments in which PLA(2) was activated with melittin or inhibited with quinacrine.", "spo_list": [{"subject": "quinacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PLA(2)", "object_type": "GENE-N"}]}
{"text": "The test procedure was verified with respect to intestinal lactose hydrolysis by demonstrating a linear relationship between lactose/lactulose excretion and log jejunal mucosal lactase activity by in vitro assay (R2 = 0.95) in a further group of subjects.", "spo_list": [{"subject": "lactose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "lactase", "object_type": "GENE-Y"}, {"subject": "lactose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "lactase", "object_type": "GENE-Y"}, {"subject": "lactulose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "lactase", "object_type": "GENE-Y"}]}
{"text": "Differential lactose/lactulose/L-rhamnose absorption provides a non-invasive and sensitive index of small intestinal integrity of value for the interpretation of prolonged or otherwise complicated enteritis and the distinction of primary secondary intestinal lactase deficiency.", "spo_list": [{"subject": "lactose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "lactase", "object_type": "GENE-Y"}, {"subject": "lactulose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "lactase", "object_type": "GENE-Y"}, {"subject": "L-rhamnose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "lactase", "object_type": "GENE-Y"}]}
{"text": "Bupropion, an efficacious antidepressant and smoking cessation agent, inhibits dopamine and norepinephrine transporters (DAT and NET, respectively).", "spo_list": [{"subject": "Bupropion", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DAT", "object_type": "GENE-Y"}, {"subject": "Bupropion", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NET", "object_type": "GENE-Y"}]}
{"text": "To eliminate the interaction of bupropion with DAT or NET, nomifensine or desipramine, respectively, was included in the superfusion buffer.", "spo_list": [{"subject": "bupropion", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DAT", "object_type": "GENE-Y"}, {"subject": "bupropion", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NET", "object_type": "GENE-Y"}]}
{"text": "Thus, bupropion acts as an antagonist at alpha3beta2* and alpha3beta4* nAChRs in rat striatum and hippocampus, respectively, across the same concentration range that inhibits DAT and NET function.", "spo_list": [{"subject": "bupropion", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DAT", "object_type": "GENE-Y"}, {"subject": "bupropion", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NET", "object_type": "GENE-Y"}]}
{"text": "The combination of nAChR and transporter inhibition produced by bupropion may contribute to its clinical efficacy as a smoking cessation agent.", "spo_list": [{"subject": "bupropion", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "nAChR", "object_type": "GENE-N"}]}
{"text": "The suppressive effect of ceruletide on barrel rotation could be partially countered by MK-329, a selective peripheral CCK (CCK-A) receptor antagonist.", "spo_list": [{"subject": "MK-329", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CCK", "object_type": "GENE-Y"}, {"subject": "MK-329", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "(CCK-A) receptor", "object_type": "GENE-Y"}]}
{"text": "The acute reinforcing effects of cocaine are thought by some to result from cocaine binding to the dopamine (DA) transporter, which inhibits DA uptake and increases synaptic DA levels in the mesolimbic system.", "spo_list": [{"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "dopamine (DA) transporter", "object_type": "GENE-Y"}, {"subject": "DA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "dopamine (DA) transporter", "object_type": "GENE-Y"}, {"subject": "DA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "dopamine (DA) transporter", "object_type": "GENE-Y"}]}
{"text": "One strategy is to identify drugs which bind to the DA transporter (DAT ligands) but which do not inhibit DA uptake as effectively as cocaine.", "spo_list": [{"subject": "DA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DA transporter", "object_type": "GENE-Y"}, {"subject": "DA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DAT", "object_type": "GENE-Y"}, {"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DA transporter", "object_type": "GENE-Y"}, {"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DAT", "object_type": "GENE-Y"}]}
{"text": "A positional scanning hexapeptide D-amino acid library was screened for inhibition of [(125)I]RTI-55 binding to rat caudate DA transporters.", "spo_list": [{"subject": "[(125)I]RTI-55", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "rat caudate DA transporters", "object_type": "GENE-Y"}]}
{"text": "All 12 peptides inhibited [(125)I]RTI-55 binding to DA transporters with IC(50) values, which ranged from 1.8 microM to 12 microM.", "spo_list": [{"subject": "[(125)I]RTI-55", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DA transporters", "object_type": "GENE-Y"}]}
{"text": "We also examined the effects of WEB 2086, a platelet-activating factor (PAF) receptor antagonist, in parallel.", "spo_list": [{"subject": "WEB 2086", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "platelet-activating factor (PAF) receptor", "object_type": "GENE-Y"}]}
{"text": "However, exposure to 6OH-DCA and NOH-DCA reduces IL-2 secretion and NFAT activity but has no effect on calcium flux.", "spo_list": [{"subject": "NOH-DCA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-2", "object_type": "GENE-Y"}, {"subject": "6OH-DCA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-2", "object_type": "GENE-Y"}, {"subject": "6OH-DCA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NFAT", "object_type": "GENE-N"}, {"subject": "NOH-DCA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NFAT", "object_type": "GENE-N"}]}
{"text": "In conclusion, we have shown that retigabine acts as a KCNQ potassium channel opener.", "spo_list": [{"subject": "retigabine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "KCNQ", "object_type": "GENE-N"}, {"subject": "retigabine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "potassium channel", "object_type": "GENE-N"}]}
{"text": "We report that two common variants of high-temperature requirement A1 (HTRA1) that increase the inherited risk of neovascular age-related macular degeneration (NvAMD) harbor synonymous SNPs within exon 1 of HTRA1 that convert common codons for Ala34 and Gly36 to less frequently used codons.", "spo_list": [{"subject": "Ala", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "high-temperature requirement A1", "object_type": "GENE-Y"}, {"subject": "Gly", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "high-temperature requirement A1", "object_type": "GENE-Y"}, {"subject": "Ala", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "HTRA1", "object_type": "GENE-Y"}, {"subject": "Gly", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "HTRA1", "object_type": "GENE-Y"}, {"subject": "Ala", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "HTRA1", "object_type": "GENE-Y"}, {"subject": "Gly", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "HTRA1", "object_type": "GENE-Y"}]}
{"text": "[6]-gingerol: a novel ATâ antagonist for the treatment of cardiovascular disease.", "spo_list": [{"subject": "[6]-gingerol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ATâ", "object_type": "GENE-Y"}]}
{"text": "[6]-Gingerol derived from Zingiber officinale Roscoe (ginger) was identified as a novel angiotensin II type 1 receptor antagonist, with an IC50 value of 8.173 ÂµM.", "spo_list": [{"subject": "[6]-Gingerol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "angiotensin II type 1 receptor", "object_type": "GENE-Y"}]}
{"text": "The major ingredient of ginger, [6]-gingerol, could inhibit angiotensin II type 1 receptor activation, which partially clarified the mechanism of ginger regulating blood pressure and strengthening heart in the cardiovascular system.", "spo_list": [{"subject": "[6]-gingerol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "angiotensin II type 1 receptor", "object_type": "GENE-Y"}]}
{"text": "Synthesis, Antidepressant Evaluation and Docking Studies of Long-Chain Alkylnitroquipazines as Serotonin Transporter Inhibitors.", "spo_list": [{"subject": "Alkylnitroquipazines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Serotonin Transporter", "object_type": "GENE-Y"}]}
{"text": "Twelve alkyl analogues (1-12) of the high-affinity serotonin transporter (SERT) inhibitor 6-nitroquipazine (6-NQ) were synthesized and studied using in vitro radioligand competition binding assays to determine their binding affinity (Ki ).", "spo_list": [{"subject": "6-nitroquipazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "serotonin transporter", "object_type": "GENE-Y"}, {"subject": "6-NQ", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "serotonin transporter", "object_type": "GENE-Y"}, {"subject": "6-nitroquipazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "6-NQ", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "alkyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "serotonin transporter", "object_type": "GENE-Y"}, {"subject": "alkyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "6-nitroquipazine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "serotonin transporter", "object_type": "GENE-Y"}, {"subject": "6-NQ", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "serotonin transporter", "object_type": "GENE-Y"}, {"subject": "6-nitroquipazine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "6-NQ", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SERT", "object_type": "GENE-Y"}]}
{"text": "Furthermore, a mixture of isoflavonoid parent compounds, and a mixture of isoflavonoid metabolites were found to have PPARÎ³ activating abilities.", "spo_list": [{"subject": "isoflavonoid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PPARÎ³", "object_type": "GENE-Y"}, {"subject": "isoflavonoid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PPARÎ³", "object_type": "GENE-Y"}]}
{"text": "Since the original discovery of azoles analogs as PXR antagonists, we have preliminarily defined an important PXR antagonist pharmacophore and developed less-toxic PXR antagonists.", "spo_list": [{"subject": "azoles", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "PXR", "object_type": "GENE-Y"}]}
{"text": "In the last 10 years, the catechol-O-methyltransferase (COMT) inhibitor tolcapone has been studied for its efficacy as an adjunctive treatment to levodopa plus a dopa decarboxylase inhibitor.", "spo_list": [{"subject": "tolcapone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "catechol-O-methyltransferase", "object_type": "GENE-Y"}, {"subject": "tolcapone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COMT", "object_type": "GENE-Y"}, {"subject": "tolcapone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dopa decarboxylase", "object_type": "GENE-Y"}]}
{"text": "INTERVENTIONS: In the 8-week run-in period, all participants received the ACE inhibitor cilazapril (5 mg), the ARB telmisartan (80 mg), and the diuretic hydrochlorothiazide (12.5 mg) as double RAAS blockade to achieve the target blood pressure of less than 130/80 mm Hg.", "spo_list": [{"subject": "cilazapril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACE", "object_type": "GENE-Y"}]}
{"text": "Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates.", "spo_list": [{"subject": "phenylalkylphosphonamidates", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "prostate-specific membrane antigen", "object_type": "GENE-Y"}]}
{"text": "To explore for the existence of an auxiliary hydrophobic binding register remote from the active site of PSMA a series of phenylalkylphosphonamidate derivatives of glutamic acid were synthesized and evaluated for their inhibitory potencies against PSMA.", "spo_list": [{"subject": "phenylalkylphosphonamidate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PSMA", "object_type": "GENE-Y"}, {"subject": "glutamic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PSMA", "object_type": "GENE-Y"}]}
{"text": "Nitric oxide (NO) is an important vasorelaxant produced along with L-citrulline from L-arginine in a reaction catalyzed by endothelial nitric oxide synthase (eNOS).", "spo_list": [{"subject": "Nitric oxide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "endothelial nitric oxide synthase", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "endothelial nitric oxide synthase", "object_type": "GENE-Y"}, {"subject": "L-citrulline", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "endothelial nitric oxide synthase", "object_type": "GENE-Y"}, {"subject": "L-arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "endothelial nitric oxide synthase", "object_type": "GENE-Y"}, {"subject": "L-arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "eNOS", "object_type": "GENE-Y"}, {"subject": "L-citrulline", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "eNOS", "object_type": "GENE-Y"}, {"subject": "Nitric oxide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "eNOS", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "eNOS", "object_type": "GENE-Y"}]}
{"text": "As further support, alpha-methyl-DL-aspartate, an inhibitor of argininosuccinate synthase (AS), a component of the citrulline-NO cycle, inhibited NO production in a dose-dependent manner.", "spo_list": [{"subject": "alpha-methyl-DL-aspartate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "argininosuccinate synthase", "object_type": "GENE-Y"}, {"subject": "alpha-methyl-DL-aspartate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AS", "object_type": "GENE-Y"}, {"subject": "citrulline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "argininosuccinate synthase", "object_type": "GENE-Y"}, {"subject": "citrulline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AS", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "argininosuccinate synthase", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AS", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "argininosuccinate synthase", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AS", "object_type": "GENE-Y"}]}
{"text": "Aphidicolin is a specific inhibitor of DNA polymerase alpha, the enzyme responsible for the replicative synthesis of DNA.", "spo_list": [{"subject": "Aphidicolin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA polymerase alpha", "object_type": "GENE-N"}]}
{"text": "OBJECTIVE: To evaluate the extent of human cyclooxygenase-1 (COX-1) inhibition by meloxicam, which has been reported to preferentially inhibit cyclooxygenase-2 (COX-2).", "spo_list": [{"subject": "meloxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human cyclooxygenase-1", "object_type": "GENE-Y"}, {"subject": "meloxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "meloxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "meloxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "The effects of meloxicam were compared with those of diclofenac, a nonselective COX inhibitor.", "spo_list": [{"subject": "diclofenac", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX", "object_type": "GENE-N"}, {"subject": "meloxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX", "object_type": "GENE-N"}]}
{"text": "METHODS: COX-1 inhibition was determined by measuring thromboxane B2 (TXB2)-generation from clotting whole blood ex vivo after single oral doses of 7.5 and 15 mg meloxicam and 75 mg diclofenac and at steady state (15 mg meloxicam daily and 150 mg diclofenac daily).", "spo_list": [{"subject": "meloxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "diclofenac", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "meloxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "diclofenac", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}]}
{"text": "Thus our data suggest that the COX-2 preference of meloxicam observed in vitro may not result in clinical advantages when the higher dose of 15 mg is needed.", "spo_list": [{"subject": "meloxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Strain JR4 (erg3 erg11), which produces 14-methylfecosterol [14 alpha-methyl-ergosta-8,24(28)-dien- 3-beta-ol) as the major sterol in the presence or absence of fenpropimorph, was also found to be resistant to the drug.", "spo_list": [{"subject": "14-methylfecosterol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "erg3", "object_type": "GENE-Y"}, {"subject": "14-methylfecosterol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "erg11", "object_type": "GENE-Y"}, {"subject": "14 alpha-methyl-ergosta-8,24(28)-dien- 3-beta-ol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "erg3", "object_type": "GENE-Y"}, {"subject": "14 alpha-methyl-ergosta-8,24(28)-dien- 3-beta-ol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "erg11", "object_type": "GENE-Y"}, {"subject": "sterol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "erg3", "object_type": "GENE-Y"}, {"subject": "sterol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "erg11", "object_type": "GENE-Y"}]}
{"text": "Cyan fluorescent protein was fused to the C terminus of the M(2) muscarinic receptor, and a specific binding sequence for the small fluorescent compound fluorescein arsenical hairpin binder, FlAsH, was inserted into the third intracellular loop; the latter site was labeled in intact cells by incubation with FlAsH.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "M(2) muscarinic receptor", "object_type": "GENE-Y"}, {"subject": "fluorescein", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "M(2) muscarinic receptor", "object_type": "GENE-Y"}]}
{"text": "Real-time fluorescence turn-on detection of alkaline phosphatase activity with a novel perylene probe.", "spo_list": [{"subject": "perylene", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alkaline phosphatase", "object_type": "GENE-N"}]}
{"text": "Ornithine decarboxylase (ODC) catalyses the first step in the synthesis of the polyamines putrescine, spermidine and spermine.", "spo_list": [{"subject": "putrescine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Ornithine decarboxylase", "object_type": "GENE-Y"}, {"subject": "spermidine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Ornithine decarboxylase", "object_type": "GENE-Y"}, {"subject": "spermine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Ornithine decarboxylase", "object_type": "GENE-Y"}, {"subject": "putrescine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ODC", "object_type": "GENE-Y"}, {"subject": "spermidine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ODC", "object_type": "GENE-Y"}, {"subject": "spermine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ODC", "object_type": "GENE-Y"}]}
{"text": "RESULTS: When compared with non-NP (nNP) nasal mucosa, contents of TNF-alpha and TNF-alpha+ cells markedly increased in NP nasal mucosa; immune staining colocalized M3 receptor+ and TNF-alpha+ cells in NP nasal mucosa; exposure of isolated CD4+ T cells to methacholine induced the release of TNF-alpha.", "spo_list": [{"subject": "methacholine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TNF-alpha", "object_type": "GENE-Y"}]}
{"text": "Methacholine increased the expression of OX40L in dendritic cells.", "spo_list": [{"subject": "Methacholine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "OX40L", "object_type": "GENE-Y"}]}
{"text": "RESULT(S): Buserelin acetate, a GnRH agonist (0.1-10 ng/mL), had no significant effect on MCP-1 expression, whereas danazol (10(-7)-10(-5) M), a testosterone analog, and dexamethasone, an anti-inflammatory glucocorticoid hormone (10(-12)-10(-6)M), showed a direct and a dose-dependent inhibitory effect on MCP-1 expression.", "spo_list": [{"subject": "danazol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MCP-1", "object_type": "GENE-Y"}, {"subject": "testosterone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MCP-1", "object_type": "GENE-Y"}, {"subject": "dexamethasone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MCP-1", "object_type": "GENE-Y"}, {"subject": "Buserelin acetate", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "GnRH", "object_type": "GENE-Y"}]}
{"text": "In the DRN, brexpiprazole completely inhibited the firing of 5-HT neurons via 5-HT1A agonism and was more potent than aripiprazole (ED50 = 230 and 700 mug/kg, respectively).", "spo_list": [{"subject": "brexpiprazole", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "aripiprazole", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT1A", "object_type": "GENE-Y"}]}
{"text": "In the locus coeruleus, brexpiprazole reversed the inhibitory effect of the preferential 5-HT2A receptor agonist DOI (2,5-dimethoxy-4-iodoamphetamine) on norepinephrine neuronal firing (ED50 = 110 mug/kg), demonstrating 5-HT2A antagonistic action.", "spo_list": [{"subject": "DOI", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT2A", "object_type": "GENE-Y"}, {"subject": "2,5-dimethoxy-4-iodoamphetamine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT2A", "object_type": "GENE-Y"}]}
{"text": "Brexpiprazole reversed the inhibitory effect of the DA agonist apomorphine on VTA DA neurons (ED50 = 61 mug/kg), whereas it was ineffective when administered alone, indicating partial agonistic action on D2 receptors.", "spo_list": [{"subject": "apomorphine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "D2 receptors", "object_type": "GENE-Y"}]}
{"text": "Compared with aripiprazole, which significantly inhibited the firing activity of VTA DA neurons, brexpiprazole displayed less efficacy at D2 receptors.", "spo_list": [{"subject": "brexpiprazole", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "D2 receptors", "object_type": "GENE-Y"}]}
{"text": "In the hippocampus, brexpiprazole acted as a full agonist at 5-HT1A receptors on pyramidal neurons.", "spo_list": [{"subject": "brexpiprazole", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "5-HT1A", "object_type": "GENE-Y"}]}
{"text": "In the lateral geniculate nucleus, brexpiprazole displayed alpha1B-adrenoceptor antagonistic action.", "spo_list": [{"subject": "brexpiprazole", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha1B-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "The CBC physically associates with these complexes to recruit them during transcription and mediates phosphorylation at Ser-2 of the C-terminal domain (CTD) of RNA polymerase II.", "spo_list": [{"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "RNA polymerase II", "object_type": "GENE-N"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "RNA polymerase II", "object_type": "GENE-N"}]}
{"text": "Recent observations revealed that human UDP-glucuronosyltransferase (UGT) 2B10 catalyzes N-glucuronidation of amine-containing compounds.", "spo_list": [{"subject": "amine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human UDP-glucuronosyltransferase (UGT) 2B10", "object_type": "GENE-Y"}]}
{"text": "Using recombinant UGT2B10, we found that it catalyzes the N-glucuronidation of amitriptyline, imipramine, ketotifen, pizotifen, olanzapine, diphenhydramine, tamoxifen, ketoconazole and midazolam.", "spo_list": [{"subject": "amitriptyline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT2B10", "object_type": "GENE-Y"}, {"subject": "imipramine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT2B10", "object_type": "GENE-Y"}, {"subject": "ketotifen", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT2B10", "object_type": "GENE-Y"}, {"subject": "pizotifen", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT2B10", "object_type": "GENE-Y"}, {"subject": "olanzapine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT2B10", "object_type": "GENE-Y"}, {"subject": "diphenhydramine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT2B10", "object_type": "GENE-Y"}, {"subject": "tamoxifen", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT2B10", "object_type": "GENE-Y"}, {"subject": "ketoconazole", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT2B10", "object_type": "GENE-Y"}, {"subject": "midazolam", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT2B10", "object_type": "GENE-Y"}]}
{"text": "These are drugs that were previously reported to be substrates for UGT1A4 or UGT1A3 and that contain in their structure either tertiary aliphatic amines, cyclic amines, or an imidazole group.", "spo_list": [{"subject": "tertiary aliphatic amines", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT1A4", "object_type": "GENE-Y"}, {"subject": "tertiary aliphatic amines", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT1A3", "object_type": "GENE-Y"}, {"subject": "cyclic amines", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT1A4", "object_type": "GENE-Y"}, {"subject": "cyclic amines", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT1A3", "object_type": "GENE-Y"}, {"subject": "imidazole", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT1A4", "object_type": "GENE-Y"}, {"subject": "imidazole", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT1A3", "object_type": "GENE-Y"}]}
{"text": "This group of drugs contains secondary or primary amines, and these results suggest that UGT2B10 preferably conjugates tertiary amines.", "spo_list": [{"subject": "tertiary amines", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT2B10", "object_type": "GENE-Y"}]}
{"text": "Kinetic analyses revealed that the affinity and clearance of UGT2B10 for amitriptyline, imipramine, and diphenhydramine are significantly higher than the corresponding values of UGT1A4 and UGT1A3, although the Vmax values of UGT1A4 toward these drugs are considerably higher.", "spo_list": [{"subject": "amitriptyline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "UGT2B10", "object_type": "GENE-Y"}, {"subject": "imipramine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "UGT2B10", "object_type": "GENE-Y"}, {"subject": "diphenhydramine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "UGT2B10", "object_type": "GENE-Y"}, {"subject": "amitriptyline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT2B10", "object_type": "GENE-Y"}, {"subject": "imipramine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT2B10", "object_type": "GENE-Y"}, {"subject": "diphenhydramine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT2B10", "object_type": "GENE-Y"}]}
{"text": "In conclusion, this study expands the understanding of the substrate specificity of UGT2B10, highlighting its preference for tertiary amines with higher affinities and clearance values than those of UGT1A4 and UGT1A3.", "spo_list": [{"subject": "tertiary amines", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT2B10", "object_type": "GENE-Y"}, {"subject": "tertiary amines", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "UGT2B10", "object_type": "GENE-Y"}]}
{"text": "The macrocyclic tetrapeptide natural product CJ-15,208 (cyclo[Phe-d-Pro-Phe-Trp]) exhibited both dose-dependent antinociception and kappa opioid receptor (KOR) antagonist activity after oral administration.", "spo_list": [{"subject": "macrocyclic tetrapeptide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "kappa opioid receptor", "object_type": "GENE-Y"}, {"subject": "CJ-15,208", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "kappa opioid receptor", "object_type": "GENE-Y"}, {"subject": "cyclo[Phe-d-Pro-Phe-Trp]", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "kappa opioid receptor", "object_type": "GENE-Y"}, {"subject": "macrocyclic tetrapeptide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "KOR", "object_type": "GENE-Y"}, {"subject": "CJ-15,208", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "KOR", "object_type": "GENE-Y"}, {"subject": "cyclo[Phe-d-Pro-Phe-Trp]", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "KOR", "object_type": "GENE-Y"}]}
{"text": "CJ-15,208 antagonized a centrally administered KOR selective agonist, providing strong evidence it crosses the blood-brain barrier to reach KOR in the CNS.", "spo_list": [{"subject": "CJ-15,208", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "KOR", "object_type": "GENE-Y"}, {"subject": "CJ-15,208", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "KOR", "object_type": "GENE-Y"}]}
{"text": "In myeloid cells, arginine is mainly metabolized either by inducible nitric oxide (NO) synthases (iNOS) or by arginase 1, enzymes that are stimulated by T helper 1 or 2 cytokines, respectively.", "spo_list": [{"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "inducible nitric oxide (NO) synthases", "object_type": "GENE-Y"}, {"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "arginase 1", "object_type": "GENE-Y"}]}
{"text": "Dimethylfumarate attenuates renal fibrosis via NF-E2-related factor 2-mediated inhibition of transforming growth factor-beta/Smad signaling.", "spo_list": [{"subject": "Dimethylfumarate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "transforming growth factor-beta", "object_type": "GENE-Y"}, {"subject": "Dimethylfumarate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Smad", "object_type": "GENE-N"}]}
{"text": "Results showed that DMF increased nuclear levels of Nrf2, and both DMF and adenovirus-mediated overexpression of Nrf2 (Ad-Nrf2) decreased PAI-1, alpha-smooth muscle actin (alpha-SMA), fibronectin and type 1 collagen expression in TGF-beta-treated rat mesangial cells (RMCs) and renal fibroblast cells (NRK-49F).", "spo_list": [{"subject": "DMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Nrf2", "object_type": "GENE-Y"}, {"subject": "DMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Nrf2", "object_type": "GENE-Y"}, {"subject": "DMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "PAI-1", "object_type": "GENE-Y"}, {"subject": "DMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "alpha-smooth muscle actin", "object_type": "GENE-Y"}, {"subject": "DMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "alpha-SMA", "object_type": "GENE-Y"}, {"subject": "DMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "fibronectin", "object_type": "GENE-Y"}, {"subject": "DMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "type 1 collagen", "object_type": "GENE-N"}]}
{"text": "Additionally, DMF and Ad-Nrf2 repressed TGF-beta-stimulated Smad3 activity by inhibiting Smad3 phosphorylation, which was restored by siRNA-mediated knockdown of Nrf2 expression.", "spo_list": [{"subject": "DMF", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Smad3", "object_type": "GENE-Y"}, {"subject": "DMF", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Smad3", "object_type": "GENE-Y"}]}
{"text": "Finally, DMF suppressed unilateral ureteral obstruction (UUO)-induced renal fibrosis and alpha-SMA, fibronectin and type 1 collagen expression in the obstructed kidneys from UUO mice, along with increased and decreased expression of Nrf2 and phospho-Smad3, respectively.", "spo_list": [{"subject": "DMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "alpha-SMA", "object_type": "GENE-Y"}, {"subject": "DMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "fibronectin", "object_type": "GENE-Y"}, {"subject": "DMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "type 1 collagen", "object_type": "GENE-N"}, {"subject": "DMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Nrf2", "object_type": "GENE-Y"}, {"subject": "DMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "phospho-Smad3", "object_type": "GENE-Y"}]}
{"text": "In summary, DMF attenuated renal fibrosis via the Nrf2-mediated inhibition of TGF-beta/Smad3 signaling in an ARE-independent manner, suggesting that DMF could be used to treat renal fibrosis.", "spo_list": [{"subject": "DMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TGF-beta", "object_type": "GENE-Y"}, {"subject": "DMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Smad3", "object_type": "GENE-Y"}]}
{"text": "Orlistat is an inhibitor of pancreatic lipase which is able to block the absorption of 30% of ingested fat.", "spo_list": [{"subject": "Orlistat", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "pancreatic lipase", "object_type": "GENE-N"}]}
{"text": "The most intensive stimulating DOAs were further investigated and compared with the known P-gp model substrates sertraline and verapamil.", "spo_list": [{"subject": "sertraline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-gp", "object_type": "GENE-N"}, {"subject": "verapamil", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-gp", "object_type": "GENE-N"}]}
{"text": "ATPase stimulation kinetics could be modeled for the entactogen 3,4-methylenedioxy-Î±-ethylphenethylamine (3,4-BDB), the hallucinogen 2,5-dimethoxy-4-iodoamphetamine (DOI), the abused alkaloid glaucine, the opioid-like drugs N-iso-propyl-1,2-diphenylethylamine (NPDPA), and N-(1-phenylcyclohexyl)-3-ethoxypropanamine (PCEPA), with K(m) and V(max) values within the same range as for verapamil or sertraline.", "spo_list": [{"subject": "3,4-methylenedioxy-Î±-ethylphenethylamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "3,4-BDB", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "2,5-dimethoxy-4-iodoamphetamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "DOI", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "glaucine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "N-iso-propyl-1,2-diphenylethylamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "NPDPA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "N-(1-phenylcyclohexyl)-3-ethoxypropanamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "PCEPA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "verapamil", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "sertraline", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ATPase", "object_type": "GENE-N"}]}
{"text": "Chronic dietary exposure to chlorpyrifos causes behavioral impairments, low activity of brain membrane-bound acetylcholinesterase, and increased brain acetylcholinesterase-R mRNA.", "spo_list": [{"subject": "chlorpyrifos", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "acetylcholinesterase-R", "object_type": "GENE-Y"}]}
{"text": "In addition, increased brain AChE-R mRNA levels were detected after four weeks of CPF dietary exposure.", "spo_list": [{"subject": "CPF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AChE-R", "object_type": "GENE-Y"}]}
{"text": "Itopride, a dopamine D2 antagonist and acetylcholinesterase inhibitor, significantly improved symptoms in patients with functional dyspepsia in one phase II randomized trial.", "spo_list": [{"subject": "Itopride", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D2", "object_type": "GENE-Y"}, {"subject": "Itopride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}]}
{"text": "Polo-like kinase-2 (Plk-2) is a potential therapeutic target for Parkinson's disease and this Letter describes the SAR of a series of dihydropteridinone based Plk-2 inhibitors.", "spo_list": [{"subject": "dihydropteridinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Plk-2", "object_type": "GENE-Y"}]}
{"text": "Considering apoptosis-related factors, the polysaccharides suppressed AKT activity through the inhibition of AKT phosphorylation at Thr(308) and/or Ser(473).", "spo_list": [{"subject": "Thr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "AKT", "object_type": "GENE-N"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "AKT", "object_type": "GENE-N"}]}
{"text": "In combination with clofarabine, the ability of resveratrol to reduce the contents of Sp1 and its target gene products was also evident in a time- and dose-dependent experiment.", "spo_list": [{"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Sp1", "object_type": "GENE-Y"}, {"subject": "clofarabine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Sp1", "object_type": "GENE-Y"}]}
{"text": "The inhibition of phosphoinositide 3-kinase using Ly294002 augmented a decrease in the p21 level induced by their combination, but it showed no significant effects on expression of Sp1 and cyclin D1.", "spo_list": [{"subject": "Ly294002", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphoinositide 3-kinase", "object_type": "GENE-N"}, {"subject": "Ly294002", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "p21", "object_type": "GENE-Y"}]}
{"text": "Taken together, the data provide evidence that the synergistic antiproliferative effect of resveratrol and clofarabine is linked to the inhibition of Akt and Sp1 activities, and suggest that this combination may have therapeutic value in treatment of malignant mesothelioma.", "spo_list": [{"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Sp1", "object_type": "GENE-Y"}, {"subject": "clofarabine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "clofarabine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Sp1", "object_type": "GENE-Y"}]}
{"text": "Both interventions restored the liver function markers (alanine transaminase: ALT, aspartate transaminase: AST, alkaline phosphatase: ALP, total bilirubin and total protein) and hepatic antioxidants (superoxide dismutase: SOD, catalase: CAT, reduced glutathione: GSH and glutathione peroxidase: GPx) to the normal levels than elevated levels noticed on paracetamol control at P<0.001.", "spo_list": [{"subject": "paracetamol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "alanine transaminase", "object_type": "GENE-N"}, {"subject": "paracetamol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ALT", "object_type": "GENE-N"}, {"subject": "paracetamol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "aspartate transaminase", "object_type": "GENE-N"}, {"subject": "paracetamol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AST", "object_type": "GENE-N"}, {"subject": "paracetamol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "alkaline phosphatase", "object_type": "GENE-N"}, {"subject": "paracetamol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ALP", "object_type": "GENE-N"}, {"subject": "paracetamol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "superoxide dismutase", "object_type": "GENE-N"}, {"subject": "paracetamol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SOD", "object_type": "GENE-N"}, {"subject": "paracetamol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "catalase", "object_type": "GENE-Y"}, {"subject": "paracetamol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CAT", "object_type": "GENE-Y"}, {"subject": "paracetamol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "glutathione peroxidase", "object_type": "GENE-N"}, {"subject": "paracetamol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GPx", "object_type": "GENE-N"}]}
{"text": "Similarly, substantial elevations of blood glucose, distorted lipid profile (total cholesterol: TC, triglycerides: TGs, high density lipoprotein cholesterol: HDL-C and low density lipoprotein cholesterol: LDL-C) and kidney function signs (creatinine and urea) have been refurbished to the desirable levels on par with the standard antidiabetic glibenclamide.", "spo_list": [{"subject": "glibenclamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "high density lipoprotein", "object_type": "GENE-N"}, {"subject": "glibenclamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "HDL", "object_type": "GENE-N"}, {"subject": "glibenclamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "low density lipoprotein", "object_type": "GENE-N"}, {"subject": "glibenclamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "LDL", "object_type": "GENE-N"}]}
{"text": "Selective antagonism of A(2A) adenosine receptors by ZM241385 significantly prevents or delays the appearance of AD and protects from the irreversible block of neurotransmission induced by 9-min OGD in the DG.", "spo_list": [{"subject": "ZM241385", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "A(2A) adenosine receptors", "object_type": "GENE-Y"}]}
{"text": "The adenosine A(2A) antagonist ZM241385 protects from synaptic failure and from decreased proliferation of immature neuronal cells at a precocious time after OGD.", "spo_list": [{"subject": "ZM241385", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "adenosine A(2A)", "object_type": "GENE-Y"}]}
{"text": "The purpose of our study is to investigate if C. pilosula attenuates AngII plus Leu(27)-IGFII-induced calcium influx and apoptosis in H9c2 cardiomyoblasts.", "spo_list": [{"subject": "Leu", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "IGFII", "object_type": "GENE-Y"}]}
{"text": "Leu(27)-IGFII was applied to enhance the AngII effect.", "spo_list": [{"subject": "Leu", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "IGFII", "object_type": "GENE-Y"}]}
{"text": "C. pilosula also reversed Ca(2+) influx, MOMP and apoptosis increased by AngII plus Leu(27)-IGFII.", "spo_list": [{"subject": "Leu", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "IGFII", "object_type": "GENE-Y"}]}
{"text": "However, p-Bad(Ser136) and Bcl-2 were increased.", "spo_list": [{"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "p-Bad", "object_type": "GENE-Y"}]}
{"text": "Therefore, C. pilosula suppresses AngII plus Leu(27)-IGFII-induced IGFII/IGFIIR pathway in myocardial cells.", "spo_list": [{"subject": "Leu", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "IGFII", "object_type": "GENE-Y"}]}
{"text": "Sodium arsenite induces cyclooxygenase-2 expression in human uroepithelial cells through MAPK pathway activation and reactive oxygen species induction.", "spo_list": [{"subject": "Sodium arsenite", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "Sodium arsenite", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MAPK", "object_type": "GENE-N"}]}
{"text": "Our results demonstrate that arsenite (1-10 Î¼M) elevates COX-2 expression, GSH levels, ROS and Nrf2 expression.", "spo_list": [{"subject": "arsenite", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "arsenite", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Nrf2", "object_type": "GENE-Y"}]}
{"text": "Arsenite treatment for 24h stimulates phosphorylation of ERK and p38, but not JNK in SV-HUC-1 cells.", "spo_list": [{"subject": "Arsenite", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ERK", "object_type": "GENE-N"}, {"subject": "Arsenite", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p38", "object_type": "GENE-N"}]}
{"text": "Induction of Cox-2 mRNA levels by arsenite was attenuated by inhibitors of ERK, p38 and JNK.", "spo_list": [{"subject": "arsenite", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Cox-2", "object_type": "GENE-Y"}]}
{"text": "Arsenite-induced ROS generation and COX-2 expression were significantly attenuated by treatment with melatonin (a ROS scavenger), but enhanced by DL-buthionine-(S, R)-sulfoximine (BSO, an inhibitor of gamma-glutamylcysteine synthetase (Î³-GCS) resulting in lower GSH and increased ROS levels).", "spo_list": [{"subject": "Arsenite", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "melatonin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "DL-buthionine-(S, R)-sulfoximine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "BSO", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "DL-buthionine-(S, R)-sulfoximine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "gamma-glutamylcysteine synthetase", "object_type": "GENE-Y"}, {"subject": "BSO", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "gamma-glutamylcysteine synthetase", "object_type": "GENE-Y"}, {"subject": "DL-buthionine-(S, R)-sulfoximine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Î³-GCS", "object_type": "GENE-Y"}, {"subject": "BSO", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Î³-GCS", "object_type": "GENE-Y"}]}
{"text": "These data indicate that arsenite promotes an induction of ROS, which results in an induction of COX-2 expression through activation of the MAPK pathway.", "spo_list": [{"subject": "arsenite", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "arsenite", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MAPK", "object_type": "GENE-N"}]}
{"text": "KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the beta(2)-adrenoceptor over the beta(1) or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity.", "spo_list": [{"subject": "formoterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "salmeterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "isoprenaline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "salmeterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(1)", "object_type": "GENE-Y"}, {"subject": "formoterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(3)", "object_type": "GENE-Y"}, {"subject": "isoprenaline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(1)", "object_type": "GENE-Y"}, {"subject": "isoprenaline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(3)", "object_type": "GENE-Y"}]}
{"text": "Other ligands (e.g. denopamine for beta(1); clenbuterol, AZ 40140d, salbutamol for beta(2)) were found to have subtype-selective intrinsic efficacy.", "spo_list": [{"subject": "denopamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta(1)", "object_type": "GENE-Y"}, {"subject": "clenbuterol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta(2)", "object_type": "GENE-Y"}, {"subject": "AZ 40140d", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta(2)", "object_type": "GENE-Y"}, {"subject": "salbutamol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta(2)", "object_type": "GENE-Y"}]}
{"text": "Organophosphorus nerve agents (NA), potent irreversible cholinesterase inhibitors, could induce severe seizures, status epilepticus (SE), seizure-related brain damage (SRBD) and lethality.", "spo_list": [{"subject": "Organophosphorus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cholinesterase", "object_type": "GENE-Y"}]}
{"text": "Ketamine (KET) is the only NMDA antagonist licensed as an injectable drug in different countries and remains an anesthetic of choice in some difficult field conditions.", "spo_list": [{"subject": "Ketamine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NMDA", "object_type": "GENE-N"}, {"subject": "KET", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NMDA", "object_type": "GENE-N"}]}
{"text": "Similarly, the tube formation induced by standard VEGF, FGF-2, or TNF-alpha was 100% inhibited by enoxaparin, and 70-90% by dalteparin, whereas minor or no inhibition was observed with UFH.", "spo_list": [{"subject": "enoxaparin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGF", "object_type": "GENE-Y"}, {"subject": "enoxaparin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FGF-2", "object_type": "GENE-Y"}, {"subject": "enoxaparin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TNF-alpha", "object_type": "GENE-Y"}, {"subject": "dalteparin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGF", "object_type": "GENE-Y"}, {"subject": "dalteparin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FGF-2", "object_type": "GENE-Y"}, {"subject": "dalteparin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TNF-alpha", "object_type": "GENE-Y"}]}
{"text": "Evaluation of histamine H1-, H2-, and H3-receptor ligands at the human histamine H4 receptor: identification of 4-methylhistamine as the first potent and selective H4 receptor agonist.", "spo_list": [{"subject": "4-methylhistamine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "H4 receptor", "object_type": "GENE-Y"}]}
{"text": "Almost all of the tested H(1)R and H(2)R antagonists, including several important therapeutics, displaced less than 30% of specific [(3)H]histamine binding to the hH(4)R at concentrations up to 10 microM.", "spo_list": [{"subject": "[(3)H]histamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hH(4)R", "object_type": "GENE-Y"}]}
{"text": "Most of the tested H(2)R agonists and imidazole-based H(3)R ligands show micromolar-to-nanomolar range hH(4)R affinity, and these ligands exert different intrinsic hH(4)R activities, ranging from full agonists to inverse agonists.", "spo_list": [{"subject": "imidazole", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "H(3)R", "object_type": "GENE-Y"}, {"subject": "imidazole", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hH(4)R", "object_type": "GENE-Y"}, {"subject": "imidazole", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "hH(4)R", "object_type": "GENE-Y"}, {"subject": "imidazole", "subject_type": "CHEMICAL", "predicate": "AGONIST-INHIBITOR", "object": "hH(4)R", "object_type": "GENE-Y"}]}
{"text": "Interestingly, we identified 4-methylhistamine as a high-affinity H(4)R ligand (K(i) = 50 nM) that has a >100-fold selectivity for the hH(4)R over the other histamine receptor subtypes.", "spo_list": [{"subject": "4-methylhistamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "H(4)R", "object_type": "GENE-Y"}, {"subject": "4-methylhistamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hH(4)R", "object_type": "GENE-Y"}, {"subject": "4-methylhistamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "histamine receptor", "object_type": "GENE-N"}]}
{"text": "Moreover, 4-methylhistamine potently activated the hH(4)R (pEC(50) = 7.4 +/- 0.1; alpha = 1), and this response was competitively antagonized by the selective H(4)R antagonist JNJ 7777120 [1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine] (pA(2) = 7.8).", "spo_list": [{"subject": "4-methylhistamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "hH(4)R", "object_type": "GENE-Y"}, {"subject": "JNJ 7777120", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "H(4)R", "object_type": "GENE-Y"}, {"subject": "1-[(5-chloro-1H-indol-2-yl)-carbonyl]-4-methylpiperazine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "H(4)R", "object_type": "GENE-Y"}]}
{"text": "The identification of 4-methylhistamine as a potent H(4)R agonist is of major importance for future studies to unravel the physiological roles of the H(4)R.", "spo_list": [{"subject": "4-methylhistamine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "H(4)R", "object_type": "GENE-Y"}]}
{"text": "Ketotifen, a histamine H1-receptor antagonist and mast cell stabilizer, significantly protected the rat gastric mucosa against lesions induced by necrotizing agents, histamine or compound 48/80.", "spo_list": [{"subject": "Ketotifen", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}]}
{"text": "Pharmacological concentrations of biotin enhance insulin secretion and the expression of genes and signaling pathways that favor islet function in vitro.", "spo_list": [{"subject": "biotin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-Y"}]}
{"text": "Insulin secretion increased from the islets of biotin-supplemented mice, together with the messenger RNA (mRNA) expression of several transcription factors regulating insulin expression and secretion, including forkhead box A2, pancreatic and duodenal homeobox 1 and hepatocyte nuclear factor 4Î±.", "spo_list": [{"subject": "biotin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Insulin", "object_type": "GENE-N"}, {"subject": "biotin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-N"}, {"subject": "biotin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "forkhead box A2", "object_type": "GENE-Y"}, {"subject": "biotin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "pancreatic and duodenal homeobox 1", "object_type": "GENE-Y"}, {"subject": "biotin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "hepatocyte nuclear factor 4Î±", "object_type": "GENE-Y"}]}
{"text": "Consistent with these effects, glucose tolerance improved, and glucose-stimulated serum insulin levels increased in biotin-supplemented mice, without changes in fasting glucose levels or insulin tolerance.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-N"}, {"subject": "biotin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-N"}]}
{"text": "Biotin supplementation augmented the proportion of beta cells by enlarging islet size and, unexpectedly, also increased the percentage of islets with alpha cells at the islet core. mRNA expression of neural cell adhesion molecule 1, an adhesion protein participating in the maintenance of islet architecture, decreased in biotin-supplemented islets.", "spo_list": [{"subject": "biotin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "neural cell adhesion molecule 1", "object_type": "GENE-Y"}]}
{"text": "Glutathione-S-transferase, a phase II enzyme, was inhibited by both arsenic and nicotine but no such inhibition was noted in arsenic-treated animals pre-exposed to nicotine.", "spo_list": [{"subject": "arsenic", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Glutathione-S-transferase", "object_type": "GENE-N"}, {"subject": "nicotine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Glutathione-S-transferase", "object_type": "GENE-N"}]}
{"text": "N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase (EC 3.1.4.45; phosphodiester alpha-GlcNAcase) catalyzes the second step in the synthesis of the mannose 6-phosphate determinant required for efficient intracellular targeting of newly synthesized lysosomal hydrolases to the lysosome.", "spo_list": [{"subject": "mannose 6-phosphate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "N-Acetylglucosamine-1-phosphodiester alpha-N-Acetylglucosaminidase", "object_type": "GENE-Y"}, {"subject": "mannose 6-phosphate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "EC 3.1.4.45", "object_type": "GENE-Y"}, {"subject": "mannose 6-phosphate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "phosphodiester alpha-GlcNAcase", "object_type": "GENE-Y"}]}
{"text": "The purified phosphodiester alpha-GlcNAcase has a specific activity of 498 micromol of [3H]GlcNAc-alpha-phosphomannose-alpha-methyl cleaved per h per mg of protein using 0.5 mM [3H]GlcNAc-alpha-phosphomannose-alpha-methyl as substrate.", "spo_list": [{"subject": "[3H]GlcNAc-alpha-phosphomannose-alpha-methyl", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "phosphodiester alpha-GlcNAcase", "object_type": "GENE-Y"}, {"subject": "[3H]GlcNAc-alpha-phosphomannose-alpha-methyl", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "phosphodiester alpha-GlcNAcase", "object_type": "GENE-Y"}]}
{"text": "Both forms of the enzyme reacted with a rabbit antibody raised to the amino-terminal peptide of the liver enzyme, suggesting that phosphodiester alpha-GlcNAcase is a type I membrane-spanning glycoprotein with its amino terminus in the lumen of the Golgi apparatus.", "spo_list": [{"subject": "amino", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "type I membrane-spanning glycoprotein", "object_type": "GENE-N"}, {"subject": "amino", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "phosphodiester alpha-GlcNAcase", "object_type": "GENE-Y"}]}
{"text": "Methionine synthase catalyzes the conversion of N5-methyltetrahydrofolate and homocysteine to tetrahydrofolate and methionine.", "spo_list": [{"subject": "N5-methyltetrahydrofolate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Methionine synthase", "object_type": "GENE-Y"}, {"subject": "homocysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Methionine synthase", "object_type": "GENE-Y"}, {"subject": "tetrahydrofolate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Methionine synthase", "object_type": "GENE-Y"}, {"subject": "methionine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Methionine synthase", "object_type": "GENE-Y"}]}
{"text": "Methylcobalamin (Me-Cbl) is tightly bound to methionine synthase and is required for enzymatic activity.", "spo_list": [{"subject": "Methylcobalamin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "methionine synthase", "object_type": "GENE-Y"}, {"subject": "Me-Cbl", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "methionine synthase", "object_type": "GENE-Y"}]}
{"text": "When added to crude tissue homogenates, Me-Cbl stimulates methionine synthase but similar stimulation is observed with hydroxocobalamin, cyanocobalamin (CN-Cbl), and adenosyl-Cbl, although the mechanisms involved are unknown.", "spo_list": [{"subject": "Me-Cbl", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "methionine synthase", "object_type": "GENE-Y"}, {"subject": "hydroxocobalamin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "methionine synthase", "object_type": "GENE-Y"}, {"subject": "cyanocobalamin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "methionine synthase", "object_type": "GENE-Y"}, {"subject": "CN-Cbl", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "methionine synthase", "object_type": "GENE-Y"}, {"subject": "adenosyl-Cbl", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "methionine synthase", "object_type": "GENE-Y"}]}
{"text": "We prepared human apomethionine synthase and studied its activation in the presence of [14C]CN-Cbl and [14CH3]Me-Cbl with concentrations of 2-mercaptoethanol ranging from 0.15 to 100 mM.", "spo_list": [{"subject": "[14C]CN-Cbl", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human apomethionine synthase", "object_type": "GENE-Y"}, {"subject": "[14CH3]Me-Cbl", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human apomethionine synthase", "object_type": "GENE-Y"}]}
{"text": "We observed that the removal of the labeled upper axial ligands from CN-Cbl and Me-Cbl both paralleled the activation of human apomethionine synthase.", "spo_list": [{"subject": "Me-Cbl", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "human apomethionine synthase", "object_type": "GENE-Y"}, {"subject": "CN-Cbl", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "human apomethionine synthase", "object_type": "GENE-Y"}]}
{"text": "Spectral studies employing CN-Cbl and Me-Cbl showed that both forms of Cbl must be converted to Cob(II)alamin before they can bind to human apomethionine synthase and convert it to its activated holoenzyme form.", "spo_list": [{"subject": "Cob(II)alamin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human apomethionine synthase", "object_type": "GENE-Y"}]}
{"text": "Studies with 14 different Cbl analogues with alterations in various portions of the corrin ring and the nucleotide showed that all of the analogues were able to fully activate human methionine synthase when they were reduced with 2-mercaptoethanol.", "spo_list": [{"subject": "Cbl", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "human methionine synthase", "object_type": "GENE-Y"}, {"subject": "2-mercaptoethanol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "human methionine synthase", "object_type": "GENE-Y"}]}
{"text": "We conclude that Me-Cbl and other forms of Cob(III)alamin do not bind to human apomethionine synthase and that all must first be reduced to Cob(II)alamin before such binding can occur.", "spo_list": [{"subject": "Cob(II)alamin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human apomethionine synthase", "object_type": "GENE-Y"}]}
{"text": "The fact that human methionine synthase shows little absolute specificity for alterations in various portions of the Cbl molecule suggests that the potent inhibition of mammalian methionine synthase activity observed in vivo with various Cbl analogues is due to inhibition of intracellular Cbl transport or to inhibition of the enzymatic formation of Cob(II)alamin rather than to direct inhibition of mammalian methionine synthase itself.", "spo_list": [{"subject": "Cbl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mammalian methionine synthase", "object_type": "GENE-Y"}]}
{"text": "In humans, prolonged administration of the beta 2-adrenoceptor agonist terbutaline leads to a desensitization of beta 2-adrenoceptor-mediated cardiovascular responses, which can be blunted by concomitant administration of the antianaphylactic drug ketotifen.", "spo_list": [{"subject": "terbutaline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta 2-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "In a double-blind, placebo-controlled, randomized design, nine healthy male volunteers received disodium cromoglycate (4 x 200 mg/day, p.o.) or placebo for 3 weeks with terbutaline (3 x 5 mg/day, p.o.) administered concomitantly during the last 2 weeks. beta 2-Adrenoceptor cardiovascular function was assessed by the increase in heart rate and reduction of diastolic blood pressure induced by an incremental intravenous infusion of the unselective beta-adrenoceptor agonist isoprenaline; beta 1-adrenoceptor cardiovascular function was assessed by exercise-induced tachycardia.", "spo_list": [{"subject": "isoprenaline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "These include: (i) centrally-acting drugs, such as the noradrenergic and dopaminergic reuptake inhibitor radafaxine, the endocannabinoid antagonist rimonabant, the selective serotonin 5-HT2c agonist APD-356, and oleoyl-estrone; (ii) drugs that target peripheral episodic satiety signals, such as glucagon-like peptide-1 (exenatide, exenatide-LAR and liraglutide), peptide YY (intranasal PYY3-36 and AC-162325) and amylin (pramlintide); (iii) drugs that block fat absorption, such as the novel lipase inhibitors cetilistat and GT-389255; and (iv) a human growth hormone fragment (AOD-9604) that increases adipose tissue breakdown.", "spo_list": [{"subject": "cetilistat", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "lipase", "object_type": "GENE-N"}, {"subject": "GT-389255", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "lipase", "object_type": "GENE-N"}, {"subject": "APD-356", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT2c", "object_type": "GENE-Y"}]}
{"text": "Previous studies have reported that cimetidine, an H2-receptor antagonist used to treat gastric and duodenal ulcers, can inhibit alcohol dehydrogenases (ADHs) and ethanol metabolism.", "spo_list": [{"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "H2-receptor", "object_type": "GENE-Y"}, {"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "alcohol dehydrogenases", "object_type": "GENE-N"}, {"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ADHs", "object_type": "GENE-N"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "alcohol dehydrogenases", "object_type": "GENE-N"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ADHs", "object_type": "GENE-N"}]}
{"text": "Human alcohol dehydrogenases and aldehyde dehydrogenases (ALDHs), the principal enzymes responsible for metabolism of ethanol, are complex enzyme families that exhibit functional polymorphisms among ethnic groups and distinct tissue distributions.", "spo_list": [{"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Human alcohol dehydrogenases", "object_type": "GENE-N"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "aldehyde dehydrogenases", "object_type": "GENE-N"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ALDHs", "object_type": "GENE-N"}]}
{"text": "Cimetidine acted as competitive or noncompetitive inhibitors for the ADH and ALDH isozymes/allozymes with near mM inhibition constants.", "spo_list": [{"subject": "Cimetidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ADH", "object_type": "GENE-N"}, {"subject": "Cimetidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ALDH", "object_type": "GENE-N"}]}
{"text": "At therapeutic drug levels (0.015 mM) and physiologically relevant concentrations of ethanol (10 mM) and acetaldehyde (10 Î¼M) in target tissues, cimetidine could weakly inhibit (<5%) the activities of ADH1B2 and ADH1B3 in liver, ADH2 in liver and small intestine, ADH4 in stomach, and ALDH1A1 in the three tissues, but not significantly affect ADH1A, ADH1B1, ADH1C1/2, or ALDH2.", "spo_list": [{"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ADH1B2", "object_type": "GENE-Y"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ADH1B3", "object_type": "GENE-Y"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ADH1A", "object_type": "GENE-Y"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ADH1B1", "object_type": "GENE-Y"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ALDH2", "object_type": "GENE-Y"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ADH2", "object_type": "GENE-Y"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ADH4", "object_type": "GENE-N"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ALDH1A1", "object_type": "GENE-Y"}, {"subject": "acetaldehyde", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ALDH1A1", "object_type": "GENE-Y"}]}
{"text": "The quantitative effects of cimetidine on metabolism of ethanol and other physiological substrates of ADHs need further investigation.", "spo_list": [{"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ADHs", "object_type": "GENE-N"}, {"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ADHs", "object_type": "GENE-N"}]}
{"text": "Majority of the investigations on phlorotannins derived from brown algae have exhibited their various anti-diabetic mechanisms such as Î±-glucosidase and Î±-amylase inhibitory effect, glucose uptake effect in skeletal muscle, protein tyrosine phosphatase 1B (PTP 1B) enzyme inhibition, improvement of insulin sensitivity in type 2 diabetic db/db mice, and protective effect against diabetes complication.", "spo_list": [{"subject": "phlorotannins", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Î±-glucosidase", "object_type": "GENE-N"}, {"subject": "phlorotannins", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Î±-amylase", "object_type": "GENE-N"}, {"subject": "phlorotannins", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "protein tyrosine phosphatase 1B", "object_type": "GENE-Y"}, {"subject": "phlorotannins", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PTP 1B", "object_type": "GENE-Y"}]}
{"text": "Sirolimus and second-generation mTOR inhibitors, such as temsirolimus and everolimus, are safe and relatively well-tolerated, making them potentially attractive as single agents or in combination with conventional cytotoxics and other targeted therapies.", "spo_list": [{"subject": "Sirolimus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}, {"subject": "temsirolimus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}, {"subject": "everolimus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}]}
{"text": "At the beginning of the calving and breeding seasons, cows supplemented with Se had greater (Pâ<â0.01) whole blood Se concentration (WBSe) and glutathione peroxidase activities (GSH-Px) than cows receiving no supplemental Se; cows fed seleno-yeast had greater (Pââ¤â0.05) WBSe than cows fed sodium selenite, but GSH-Px did not differ (Pââ¥â0.25) between the two sources.", "spo_list": [{"subject": "Se", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "glutathione peroxidase", "object_type": "GENE-N"}, {"subject": "Se", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GSH-Px", "object_type": "GENE-N"}]}
{"text": "At birth and near peak lactation (late May), calves from cows supplemented with Se had greater (Pâ<â0.01) WBSe than calves from cows fed no Se and calves from cows fed seleno-yeast had greater (Pââ¤â0.01) WBSe and GSH-Px than calves from cows fed sodium selenite.", "spo_list": [{"subject": "seleno", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GSH-Px", "object_type": "GENE-N"}]}
{"text": "Selenium supplementation of gestating beef cows benefited cows and calves by increasing WBSe and GSH-Px.", "spo_list": [{"subject": "Selenium", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GSH-Px", "object_type": "GENE-N"}]}
{"text": "Verrucarin A sensitizes TRAIL-induced apoptosis via the upregulation of DR5 in an eIF2Î±/CHOP-dependent manner.", "spo_list": [{"subject": "Verrucarin A", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "DR5", "object_type": "GENE-Y"}, {"subject": "Verrucarin A", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "eIF2Î±", "object_type": "GENE-Y"}, {"subject": "Verrucarin A", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CHOP", "object_type": "GENE-Y"}]}
{"text": "Furthermore, salubrinal, a specific eIF2Î± phosphorylation-inducing agent, increased CHOP and DR5 expression in the presence of VA.", "spo_list": [{"subject": "salubrinal", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "eIF2Î±", "object_type": "GENE-Y"}, {"subject": "salubrinal", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CHOP", "object_type": "GENE-Y"}, {"subject": "salubrinal", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "DR5", "object_type": "GENE-Y"}]}
{"text": "The triphosphates of 4'-thio-FAC (4'-thio-FACTP) exhibited the potent inhibitory action against DNA polymerase alpha, whereas it showed moderate inhibition against DNA polymerase beta and little inhibition against DNA polymerase gamma.", "spo_list": [{"subject": "4'-thio-FACTP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA polymerase alpha", "object_type": "GENE-Y"}, {"subject": "triphosphates of 4'-thio-FAC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA polymerase alpha", "object_type": "GENE-Y"}, {"subject": "triphosphates of 4'-thio-FAC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA polymerase beta", "object_type": "GENE-Y"}, {"subject": "4'-thio-FACTP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA polymerase beta", "object_type": "GENE-Y"}, {"subject": "triphosphates of 4'-thio-FAC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA polymerase gamma", "object_type": "GENE-Y"}, {"subject": "4'-thio-FACTP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA polymerase gamma", "object_type": "GENE-Y"}]}
{"text": "The serotonin (5-HT) receptors of type 6 (5-HT6) are quite different from all other 5-HT receptors, as they include a short third cytoplasmatic loop and a long C-terminal tail, and one intron located in the middle of the third cytoplasmatic loop.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "serotonin (5-HT) receptors", "object_type": "GENE-N"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "5-HT6", "object_type": "GENE-Y"}]}
{"text": "Substituted imidazopyridazines are potent and selective inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1).", "spo_list": [{"subject": "imidazopyridazines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Plasmodium falciparum calcium-dependent protein kinase 1", "object_type": "GENE-Y"}, {"subject": "imidazopyridazines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PfCDPK1", "object_type": "GENE-Y"}]}
{"text": "A series of imidazopyridazines which are potent inhibitors of Plasmodium falciparum calcium-dependent protein kinase 1 (PfCDPK1) was identified from a high-throughput screen against the isolated enzyme.", "spo_list": [{"subject": "imidazopyridazines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Plasmodium falciparum calcium-dependent protein kinase 1", "object_type": "GENE-Y"}, {"subject": "imidazopyridazines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PfCDPK1", "object_type": "GENE-Y"}]}
{"text": "The platelet response to streptokinase was also blocked by an antibody directed against the cleavage site of the platelet thrombin receptor, protease-activated receptor-1 (PAR-1), but not by hirudin or an active site thrombin inhibitor, Ro46-6240.", "spo_list": [{"subject": "Ro46-6240", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thrombin", "object_type": "GENE-Y"}]}
{"text": "For determination of plasmin activity, 10 microL thereof was incubated with 150 microL 1.5 M arginine, pH 8.7, and 100 microL 20 mM CT preoxidized (15 minutes 37 degrees C) pooled normal citrate buffered EDTA-plasma for 30 minutes (37 degrees C).", "spo_list": [{"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "plasmin", "object_type": "GENE-Y"}]}
{"text": "For determination of [PA+Pli]-activity, arginine was added after this incubation.", "spo_list": [{"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Pli", "object_type": "GENE-Y"}, {"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PA", "object_type": "GENE-N"}]}
{"text": "Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor in man.", "spo_list": [{"subject": "Acetaminophen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "paracetamol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}]}
{"text": "The fact that acetaminophen acts functionally as a selective COX-2 inhibitor led us to investigate the hypothesis of whether it works via preferential COX-2 blockade.", "spo_list": [{"subject": "acetaminophen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Ex vivo COX inhibition and pharmacokinetics of acetaminophen were assessed in 5 volunteers receiving single 1000 mg doses orally.", "spo_list": [{"subject": "acetaminophen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX", "object_type": "GENE-N"}]}
{"text": "Coagulation-induced thromboxane B(2) and lipopolysaccharide-induced prostaglandin E(2) were measured ex vivo and in vitro in human whole blood as indices of COX-1 and COX-2 activity.", "spo_list": [{"subject": "thromboxane B(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "prostaglandin E(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "In vitro, acetaminophen elicited a 4.4-fold selectivity toward COX-2 inhibition (IC(50)=113.7 micromol/L for COX-1; IC(50)=25.8 micromol/L for COX-2).", "spo_list": [{"subject": "acetaminophen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "acetaminophen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "acetaminophen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Acetaminophen plasma concentrations remained above the in vitro IC(50) for COX-2 for at least 5 h postadministration.", "spo_list": [{"subject": "Acetaminophen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Ex vivo IC(50) values (COX-1: 105.2 micromol/L; COX-2: 26.3 micromol/L) of acetaminophen compared favorably with its in vitro IC(50) values.", "spo_list": [{"subject": "acetaminophen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "acetaminophen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}]}
{"text": "In contrast to previous concepts, acetaminophen inhibited COX-2 by more than 80%, i.e., to a degree comparable to nonsteroidal antiinflammatory drugs (NSAIDs) and selective COX-2 inhibitors.", "spo_list": [{"subject": "acetaminophen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "In view of its substantial COX-2 inhibition, recently defined cardiovascular warnings for use of COX-2 inhibitors should also be considered for acetaminophen.", "spo_list": [{"subject": "acetaminophen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Emodin-6-O-Î²-D-glucoside inhibits HMGB1-induced inflammatory responses in vitro and in vivo.", "spo_list": [{"subject": "Emodin-6-O-Î²-D-glucoside", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HMGB1", "object_type": "GENE-Y"}]}
{"text": "Protein expression of Ugt1a6 also decreased and corresponded with reduced in vitro glucuronidation of bisphenol A in S9 fractions from livers of pregnant mice.", "spo_list": [{"subject": "bisphenol A", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Ugt1a6", "object_type": "GENE-Y"}]}
{"text": "In addition, we evaluated whether the phosphodiesterase-5 (PDE-5) inhibitor tadalafil, in a randomized double blind placebo controlled design, might attenuate postprandial glucose levels in obese women.", "spo_list": [{"subject": "tadalafil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase-5", "object_type": "GENE-Y"}, {"subject": "tadalafil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE-5", "object_type": "GENE-Y"}]}
{"text": "However, we were unable to demonstrate any acute effect on either vascular function or glucose uptake of the phosphodiesterase-5 (PDE-5) inhibitor tadalafil.", "spo_list": [{"subject": "tadalafil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase-5", "object_type": "GENE-Y"}, {"subject": "tadalafil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE-5", "object_type": "GENE-Y"}]}
{"text": "Preferential block of late sodium current in the LQT3 DeltaKPQ mutant by the class I(C) antiarrhythmic flecainide.", "spo_list": [{"subject": "flecainide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "LQT3 DeltaKPQ mutant", "object_type": "GENE-Y"}]}
{"text": "Flecainide block of Na(+) current (I(Na)) was investigated in wild-type (WT) or the long QT syndrome 3 (LQT3) sodium channel alpha subunit mutation with three amino acids deleted (DeltaKPQ) stably transfected into human embryonic kidney 293 cells using whole-cell, patch-clamp recordings.", "spo_list": [{"subject": "Flecainide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "long QT syndrome 3 (LQT3) sodium channel alpha", "object_type": "GENE-Y"}, {"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "long QT syndrome 3 (LQT3) sodium channel alpha", "object_type": "GENE-Y"}]}
{"text": "Loperamide, an opiate agonist of high specificity for mu-receptors, was recently reported to suppress ACTH and cortisol levels in normal subjects, but not in patients with proven ACTH-dependent Cushing's disease.", "spo_list": [{"subject": "Loperamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ACTH", "object_type": "GENE-Y"}]}
{"text": "In seven normal subjects, basal ACTH plasma levels were significantly suppressed 3 h after loperamide administration (16 mg, orally) from 5 +/- 1 to 2 +/- 0 pmol/L (P less than 0.0001).", "spo_list": [{"subject": "loperamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ACTH", "object_type": "GENE-Y"}]}
{"text": "In summary, loperamide is able to reduce basal and CRH-induced ACTH and cortisol levels in normal subjects, but not in patients with Cushing's disease or secondary adrenal failure of hypothalamic origin.", "spo_list": [{"subject": "loperamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CRH", "object_type": "GENE-Y"}, {"subject": "loperamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ACTH", "object_type": "GENE-Y"}]}
{"text": "Molecular genetic studies revealed a heterozygote missense mutation, MCCA-R385S, converting arginine to serine in a highly conserved region of the MCCA gene.", "spo_list": [{"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MCCA", "object_type": "GENE-Y"}, {"subject": "serine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MCCA", "object_type": "GENE-Y"}]}
{"text": "Carvedilol decreased CK, LDH and infarct size compared with the IR rats; after 30 minutes of ischemia, both carvedilol and heptanol significantly reduced the GJIC, associated with a significant augmentation of dephosphorylated CX43.", "spo_list": [{"subject": "Carvedilol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CK", "object_type": "GENE-N"}, {"subject": "Carvedilol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "LDH", "object_type": "GENE-N"}, {"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dephosphorylated CX43", "object_type": "GENE-Y"}, {"subject": "heptanol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dephosphorylated CX43", "object_type": "GENE-Y"}]}
{"text": "CONCLUSIONS: These results suggest that carvedilol reduces GJIC during ischemia presumably by dephosphorylating Cx43, which may be one of the mechanisms of lessening myocardial ischemia-reperfusion injury.", "spo_list": [{"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Cx43", "object_type": "GENE-Y"}]}
{"text": "Zinc Promotes the Death of Hypoxic Astrocytes by Upregulating Hypoxia-Induced Hypoxia-Inducible Factor-1alpha Expression via Poly(ADP-ribose) Polymerase-1.", "spo_list": [{"subject": "Zinc", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Hypoxia-Induced Hypoxia-Inducible Factor-1alpha", "object_type": "GENE-N"}]}
{"text": "Exposure of astrocytes to hypoxia for 3Â h remarkably increased the levels of intracellular zinc and HIF-1Î± protein, which was further augmented by added exogenous zinc.", "spo_list": [{"subject": "zinc", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HIF-1Î±", "object_type": "GENE-N"}]}
{"text": "CONCLUSIONS: Our studies show that zinc promotes hypoxic cell death through overexpression of the hypoxia response factor HIF-1Î± via the cell fate determine factor PARP-1 modification, which provides a novel mechanism for zinc-mediated ischemic brain injury.", "spo_list": [{"subject": "zinc", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "hypoxia response factor", "object_type": "GENE-N"}, {"subject": "zinc", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HIF-1Î±", "object_type": "GENE-N"}]}
{"text": "In the present report, we show that Fer associates with the activated PDGFbeta receptor (PDGFRbeta) through multiple autophosphorylation sites, i.e. Tyr579, Tyr581, Tyr740 and Tyr1021.", "spo_list": [{"subject": "Tyr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDGFbeta receptor", "object_type": "GENE-Y"}, {"subject": "Tyr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDGFbeta receptor", "object_type": "GENE-Y"}, {"subject": "Tyr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDGFbeta receptor", "object_type": "GENE-Y"}, {"subject": "Tyr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDGFbeta receptor", "object_type": "GENE-Y"}, {"subject": "Tyr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDGFRbeta", "object_type": "GENE-Y"}, {"subject": "Tyr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDGFRbeta", "object_type": "GENE-Y"}, {"subject": "Tyr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDGFRbeta", "object_type": "GENE-Y"}, {"subject": "Tyr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDGFRbeta", "object_type": "GENE-Y"}]}
{"text": "Disposition of a specific cyclooxygenase-2 inhibitor, valdecoxib, in human.", "spo_list": [{"subject": "valdecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}]}
{"text": "Valdecoxib is a potent and specific inhibitor of cyclooxygenase-2, which is used for the treatment of rheumatoid arthritis, osteoarthritis, and the dysmenorrhea pain.", "spo_list": [{"subject": "Valdecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}]}
{"text": "Inhibition of eukaryote serine/threonine-specific protein kinases by piceatannol.", "spo_list": [{"subject": "piceatannol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "serine/threonine-specific protein kinases", "object_type": "GENE-N"}]}
{"text": "The protein tyrosine kinase (PTK) inhibitor piceatannol is also an inhibitor of the rat liver cyclic AMP-dependent protein kinase (PKA) catalytic subunit (cAK), rat brain Ca(2+)- and phospholipid-dependent protein kinase C (PKC), avian gizzard Ca(2+)-calmodulin-dependent myosin light chain kinae (MLCK), and of wheat embryo Ca(2+)-dependent protein kinase (CDPK) (IC50 values 3, 8, 12, and 19 microM, respectively).", "spo_list": [{"subject": "piceatannol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "protein tyrosine kinase", "object_type": "GENE-N"}, {"subject": "piceatannol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "rat liver cyclic AMP-dependent protein kinase", "object_type": "GENE-N"}, {"subject": "piceatannol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PKA", "object_type": "GENE-N"}, {"subject": "piceatannol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "protein kinase C", "object_type": "GENE-N"}, {"subject": "piceatannol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PKC", "object_type": "GENE-N"}, {"subject": "piceatannol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PTK", "object_type": "GENE-N"}, {"subject": "piceatannol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "piceatannol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "myosin light chain kinae", "object_type": "GENE-N"}, {"subject": "piceatannol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MLCK", "object_type": "GENE-N"}, {"subject": "piceatannol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Ca(2+)-dependent protein kinase", "object_type": "GENE-N"}, {"subject": "piceatannol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CDPK", "object_type": "GENE-N"}]}
{"text": "Similarly, the PTK inhibitor ellagic acid is a potent inhibitor of cAK and of PKC (IC50 values 2 and 8 microM, respectively), whereas the non-phenolic perylene is ineffective as a protein kinase inhibitor.", "spo_list": [{"subject": "non-phenolic perylene", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "protein kinase", "object_type": "GENE-N"}, {"subject": "ellagic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PTK", "object_type": "GENE-N"}, {"subject": "ellagic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PKC", "object_type": "GENE-N"}]}
{"text": "Ellagic acid is a competitive inhibitor of both cAK and of PKC but piceatannol inhibits these enzymes in a fashion that is competitive and non-competitive, respectively.", "spo_list": [{"subject": "Ellagic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PKC", "object_type": "GENE-N"}, {"subject": "piceatannol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PKC", "object_type": "GENE-N"}]}
{"text": "Interaction with calmodulin may contribute to the inhibition of MLCK and CDPK by piceatannol.", "spo_list": [{"subject": "piceatannol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MLCK", "object_type": "GENE-N"}, {"subject": "piceatannol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CDPK", "object_type": "GENE-N"}]}
{"text": "Structure-based design, synthesis and evaluation of novel anthra[1,2-d]imidazole-6,11-dione derivatives as telomerase inhibitors and potential for cancer polypharmacology.", "spo_list": [{"subject": "anthra[1,2-d]imidazole-6,11-dione", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "telomerase", "object_type": "GENE-Y"}]}
{"text": "A series of anthra[1,2-d]imidazole-6,11-dione derivatives were synthesized and evaluated for telomerase inhibition, hTERT expression and suppression of cancer cell growth in vitro.", "spo_list": [{"subject": "anthra[1,2-d]imidazole-6,11-dione", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "telomerase", "object_type": "GENE-Y"}]}
{"text": "Serine hydroxymethyltransferase (SHMT) catalyses the reversible conversion of serine and tetrahydrofolate to glycine and methylene-tetrahydrofolate.", "spo_list": [{"subject": "serine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Serine hydroxymethyltransferase", "object_type": "GENE-N"}, {"subject": "tetrahydrofolate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Serine hydroxymethyltransferase", "object_type": "GENE-N"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Serine hydroxymethyltransferase", "object_type": "GENE-N"}, {"subject": "methylene-tetrahydrofolate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Serine hydroxymethyltransferase", "object_type": "GENE-N"}, {"subject": "serine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SHMT", "object_type": "GENE-N"}, {"subject": "tetrahydrofolate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SHMT", "object_type": "GENE-N"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "SHMT", "object_type": "GENE-N"}, {"subject": "methylene-tetrahydrofolate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "SHMT", "object_type": "GENE-N"}]}
{"text": "These findings suggest that folate metabolism is compartmentalised in Leishmania and that SHMT RNA levels are responsive to environmental conditions.", "spo_list": [{"subject": "folate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SHMT", "object_type": "GENE-N"}]}
{"text": "Inhibitory effect of synthetic progestins, 4-MA and cyanoketone on human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase activity.", "spo_list": [{"subject": "progestins", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase", "object_type": "GENE-N"}, {"subject": "4-MA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase", "object_type": "GENE-N"}, {"subject": "cyanoketone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene-isomerase", "object_type": "GENE-N"}]}
{"text": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase (3 beta-HSD) purified from human placenta transforms C-21 (pregnenolone and 17 alpha-hydroxy pregnenolone) as well as C-19 (dehydroepiandrosterone and androst-5-ene-3 beta, 17 beta-diol) steroids into the corresponding 3-keto-4-ene-steroids and is thus involved in the biosynthesis of all classes of hormonal steroids.", "spo_list": [{"subject": "pregnenolone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase", "object_type": "GENE-N"}, {"subject": "17 alpha-hydroxy pregnenolone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase", "object_type": "GENE-N"}, {"subject": "dehydroepiandrosterone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase", "object_type": "GENE-N"}, {"subject": "androst-5-ene-3 beta, 17 beta-diol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase", "object_type": "GENE-N"}, {"subject": "3-keto-4-ene-steroids", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Human placental 3 beta-hydroxysteroid dehydrogenase/5----4-ene isomerase", "object_type": "GENE-N"}, {"subject": "pregnenolone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "3 beta-HSD", "object_type": "GENE-N"}, {"subject": "17 alpha-hydroxy pregnenolone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "3 beta-HSD", "object_type": "GENE-N"}, {"subject": "dehydroepiandrosterone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "3 beta-HSD", "object_type": "GENE-N"}, {"subject": "androst-5-ene-3 beta, 17 beta-diol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "3 beta-HSD", "object_type": "GENE-N"}, {"subject": "3-keto-4-ene-steroids", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "3 beta-HSD", "object_type": "GENE-N"}]}
{"text": "Trilostane, epostane and cyanoketone are potent inhibitors of 3 beta-HSD with Ki values of approximately 50 nM.", "spo_list": [{"subject": "Trilostane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "3 beta-HSD", "object_type": "GENE-N"}, {"subject": "epostane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "3 beta-HSD", "object_type": "GENE-N"}, {"subject": "cyanoketone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "3 beta-HSD", "object_type": "GENE-N"}]}
{"text": "4-MA, a well known 5 alpha-reductase inhibitor, is also a potent inhibitor of 3 beta-HSD with a Ki value of 56 nM.", "spo_list": [{"subject": "4-MA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5 alpha-reductase", "object_type": "GENE-N"}, {"subject": "4-MA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "3 beta-HSD", "object_type": "GENE-N"}]}
{"text": "Cyproterone acetate, a progestin used in the treatment of hirsutism, acne and prostate cancer as well as norgestrel and norethindrone that are widely used as oral contraceptives also inhibit 3 beta-HSD activity at Ki values of 1.5, 1.7 and 2.5 microM, respectively.", "spo_list": [{"subject": "Cyproterone acetate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "3 beta-HSD", "object_type": "GENE-N"}, {"subject": "progestin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "3 beta-HSD", "object_type": "GENE-N"}, {"subject": "norgestrel", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "3 beta-HSD", "object_type": "GENE-N"}, {"subject": "norethindrone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "3 beta-HSD", "object_type": "GENE-N"}]}
{"text": "Here, we report the first crystal structure of KIF4 complexed with the non-hydrolyzable ATP analog, AMPPNP (adenylyl imidodiphosphate), at 1.7Ã resolution.", "spo_list": [{"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "KIF4", "object_type": "GENE-Y"}, {"subject": "AMPPNP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "KIF4", "object_type": "GENE-Y"}, {"subject": "adenylyl imidodiphosphate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "KIF4", "object_type": "GENE-Y"}]}
{"text": "By combining our structure with previously solved KIF1A structures complexed with two ATP analogs, molecular snapshots during ATP binding reveal that the closure of the nucleotide-binding pocket during ATP binding is achieved by closure of the backdoor.", "spo_list": [{"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "KIF1A", "object_type": "GENE-Y"}]}
{"text": "ATP-binding cassette transporter A1 is involved in hepatic alpha-tocopherol secretion.", "spo_list": [{"subject": "alpha-tocopherol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ATP-binding cassette transporter A1", "object_type": "GENE-Y"}]}
{"text": "First, addition of apolipoprotein A-I (apoA-I), a direct acceptor of the ATP-binding cassette transporter A1 (ABCA1)-secreted lipids, increased alpha-tocopherol secretion in a dose-dependent manner.", "spo_list": [{"subject": "alpha-tocopherol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "apolipoprotein A-I", "object_type": "GENE-Y"}, {"subject": "alpha-tocopherol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "apoA-I", "object_type": "GENE-Y"}, {"subject": "alpha-tocopherol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ATP-binding cassette transporter A1", "object_type": "GENE-Y"}, {"subject": "alpha-tocopherol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ABCA1", "object_type": "GENE-Y"}]}
{"text": "Third, ABCA1-RNAi suppressed hepatic alpha-tocopherol secretion.", "spo_list": [{"subject": "alpha-tocopherol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ABCA1", "object_type": "GENE-Y"}]}
{"text": "These results strongly suggest that ABCA1 is substantially involved in hepatic alpha-tocopherol secretion.", "spo_list": [{"subject": "alpha-tocopherol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ABCA1", "object_type": "GENE-Y"}]}
{"text": "Npas4 is activated by melatonin, and drives the clock gene Cry1 in the ovine pars tuberalis.", "spo_list": [{"subject": "melatonin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Npas4", "object_type": "GENE-Y"}]}
{"text": "Melatonin offset at dawn is linked to cAMP accumulation, which directly induces transcription of the clock gene Per1.", "spo_list": [{"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Per1", "object_type": "GENE-Y"}]}
{"text": "Here, we used next generation sequencing of the ovine PT transcriptome at melatonin onset, and identified Npas4 as a rapidly induced bHLH-PAS domain transcription factor.", "spo_list": [{"subject": "melatonin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Npas4", "object_type": "GENE-Y"}, {"subject": "melatonin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "bHLH-PAS domain transcription factor", "object_type": "GENE-N"}]}
{"text": "We conclude that activation of the alpha(1)AR is primarily responsible for the anticonvulsant activity of endogenous NE in the murine PTZ model of epilepsy.", "spo_list": [{"subject": "NE", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "alpha(1)AR", "object_type": "GENE-N"}]}
{"text": "Porphyrins are transported in blood mainly by lipoproteins, and the low density lipoprotein (LDL) receptor-mediated pathway is probably one of the important factors involved in the selective accumulation of porphyrins by tumor tissues, as cancer cells generally express much more LDL receptors than normal cells.", "spo_list": [{"subject": "Porphyrins", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "lipoproteins", "object_type": "GENE-N"}]}
{"text": "During the course of glycine oxidation catalysed by the matrix extract a steady-state equilibrium in the production and utilization of 5,10-methylene-H4 folate was reached, suggesting that glycine cleavage and SHMT are linked together via a soluble pool of H4 folate.", "spo_list": [{"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SHMT", "object_type": "GENE-Y"}, {"subject": "H4 folate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "SHMT", "object_type": "GENE-Y"}]}
{"text": "The rate of glycine oxidation catalysed by the matrix extract was sensitive to the NADH/NAD+ molar ratios, because NADH competitively inhibited the reaction catalysed by lipoamide dehydrogenase.", "spo_list": [{"subject": "NADH", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "lipoamide dehydrogenase", "object_type": "GENE-Y"}]}
{"text": "Glutamate dehydrogenase (GLUD) is an important mitochondrial enzyme that participates in neuronal transmission by catalyzing the deamination of L-glutamate, which serves as a potent excitatory neurotransmitter.", "spo_list": [{"subject": "L-glutamate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GLUD", "object_type": "GENE-N"}, {"subject": "L-glutamate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Glutamate dehydrogenase", "object_type": "GENE-N"}]}
{"text": "5-Aminolevulinic acid synthase (ALAS), the first enzyme of the heme biosynthesis pathway, catalyses the pyridoxal 5'-phosphate-dependent condensation between glycine and succinyl-CoA to yield 5-aminolevulinic acid (5-amino-4-oxopentanoate).", "spo_list": [{"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "5-Aminolevulinic acid synthase", "object_type": "GENE-N"}, {"subject": "succinyl-CoA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "5-Aminolevulinic acid synthase", "object_type": "GENE-N"}, {"subject": "5-aminolevulinic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "5-Aminolevulinic acid synthase", "object_type": "GENE-N"}, {"subject": "5-amino-4-oxopentanoate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "5-Aminolevulinic acid synthase", "object_type": "GENE-N"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ALAS", "object_type": "GENE-N"}, {"subject": "succinyl-CoA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ALAS", "object_type": "GENE-N"}, {"subject": "5-aminolevulinic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ALAS", "object_type": "GENE-N"}, {"subject": "5-amino-4-oxopentanoate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ALAS", "object_type": "GENE-N"}]}
{"text": "A three-dimensional structural model of Rhodobacter spheroides ALAS has been constructed and used to identify amino acid residues at the active site that are likely to be important for the recognition of glycine, the only amino acid substrate.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Rhodobacter spheroides ALAS", "object_type": "GENE-Y"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Rhodobacter spheroides ALAS", "object_type": "GENE-Y"}]}
{"text": "Raloxifene and estrogen also produce a similar activation of TGF-beta3 (a cytokine associated with inhibition of osteoclast differentiation and activity) in ovariectomized rats.", "spo_list": [{"subject": "Raloxifene", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TGF-beta3", "object_type": "GENE-Y"}, {"subject": "estrogen", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TGF-beta3", "object_type": "GENE-Y"}, {"subject": "Raloxifene", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "cytokine", "object_type": "GENE-N"}, {"subject": "estrogen", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "cytokine", "object_type": "GENE-N"}]}
{"text": "Like 17beta-estradiol, raloxifene binds with high affinity to both estrogen receptor-alpha (ER alpha) and estrogen receptor-beta (ER beta).", "spo_list": [{"subject": "17beta-estradiol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor-alpha", "object_type": "GENE-Y"}, {"subject": "17beta-estradiol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ER alpha", "object_type": "GENE-Y"}, {"subject": "17beta-estradiol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor-beta", "object_type": "GENE-Y"}, {"subject": "17beta-estradiol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ER beta", "object_type": "GENE-Y"}, {"subject": "raloxifene", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor-alpha", "object_type": "GENE-Y"}, {"subject": "raloxifene", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ER alpha", "object_type": "GENE-Y"}, {"subject": "raloxifene", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor-beta", "object_type": "GENE-Y"}, {"subject": "raloxifene", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ER beta", "object_type": "GENE-Y"}]}
{"text": "Crystal structure analyses have shown that 17beta-estradiol and raloxifene bind to ER alpha with small, but important, differences in three dimensional structure.", "spo_list": [{"subject": "17beta-estradiol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ER alpha", "object_type": "GENE-N"}, {"subject": "raloxifene", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ER alpha", "object_type": "GENE-N"}]}
{"text": "An increase in the energy required to remove the same anion from the tridentate receptor when compared to the bidentate and monodentate receptors is explained as being due to the increase in halogen bonding interactions.", "spo_list": [{"subject": "halogen", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "tridentate receptor", "object_type": "GENE-N"}]}
{"text": "Substantial evidence shows that H(2)S is involved in aging by inhibiting free-radical reactions, activating SIRT1, and probably interacting with the age-related gene Klotho.", "spo_list": [{"subject": "H(2)S", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "SIRT1", "object_type": "GENE-Y"}]}
{"text": "Repeated potentiation of the metabotropic glutamate receptor 5 and the alpha 7 nicotinic acetylcholine receptor modulates behavioural and GABAergic deficits induced by early postnatal phencyclidine (PCP) treatment.", "spo_list": [{"subject": "phencyclidine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "metabotropic glutamate receptor 5", "object_type": "GENE-Y"}, {"subject": "phencyclidine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "alpha 7 nicotinic acetylcholine receptor", "object_type": "GENE-Y"}, {"subject": "PCP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "metabotropic glutamate receptor 5", "object_type": "GENE-Y"}, {"subject": "PCP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "alpha 7 nicotinic acetylcholine receptor", "object_type": "GENE-Y"}]}
{"text": "We wanted to determine whether behavioural and GABAergic functional deficits induced by the NMDA receptor channel blocker, phencyclidine (PCP), could be reversed by repeated administration of two drugs known to enhance GABAergic transmission: the positive allosteric modulator (PAM) of the metabotropic glutamate receptor 5 (mGluR5), ADX47273, and the partial agonist of the Î±7 nicotinic acetylcholine receptor (Î±7 nAChR), SSR180711.", "spo_list": [{"subject": "phencyclidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NMDA receptor", "object_type": "GENE-N"}, {"subject": "PCP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NMDA receptor", "object_type": "GENE-N"}, {"subject": "SSR180711", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "Î±7 nicotinic acetylcholine receptor", "object_type": "GENE-Y"}, {"subject": "SSR180711", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "Î±7 nAChR", "object_type": "GENE-Y"}]}
{"text": "We examined GABAergic transmission by whole cell patch-clamp recordings of miniature inhibitory postsynaptic currents (mIPSC) in pyramidal neurons in layer II/III of prefrontal cortex (PFC) and by activation of extrasynaptic Î´-containing GABAA receptors by THIP.", "spo_list": [{"subject": "THIP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GABAA receptors", "object_type": "GENE-N"}]}
{"text": "Finally, we showed that repeated treatment with ADX47273 and SSR180711 decreased the induction of spontaneous inhibitory current caused by acute and direct agonism of mGluR5s and Î±7 nAChRs in slices.", "spo_list": [{"subject": "ADX47273", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mGluR5s", "object_type": "GENE-Y"}, {"subject": "ADX47273", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Î±7 nAChRs", "object_type": "GENE-Y"}, {"subject": "SSR180711", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mGluR5s", "object_type": "GENE-Y"}, {"subject": "SSR180711", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Î±7 nAChRs", "object_type": "GENE-Y"}]}
{"text": "These results show that repeated administration of ADX47273 or SSR180711 reverses certain behavioural and functional deficits induced by PCP, likely through down-regulation or desensitisation of mGluR5s and Î±7 nAChRs, respectively.", "spo_list": [{"subject": "ADX47273", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mGluR5s", "object_type": "GENE-Y"}, {"subject": "SSR180711", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mGluR5s", "object_type": "GENE-Y"}, {"subject": "PCP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "mGluR5s", "object_type": "GENE-Y"}]}
{"text": "In January of 2012, vismodegib, a SMO antagonist, became the first agent to target the Hh pathway to receive approval by the United States Food and Drug Administration (FDA) after this agent showed remarkable activity in phase I and II trials for the treatment of BCC.", "spo_list": [{"subject": "vismodegib", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "SMO", "object_type": "GENE-Y"}]}
{"text": "Similar to MIN6 Î² cells, human islets elicited glucose-stimulated PAK1 activation that was sensitive to the PAK1 inhibitor, IPA3.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PAK1", "object_type": "GENE-Y"}, {"subject": "IPA3", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PAK1", "object_type": "GENE-Y"}]}
{"text": "Live-cell imaging captured the glucose-induced cortical F-actin remodeling in MIN6 Î² cells; IPA3-mediated inhibition of PAK1 abolished this remodeling.", "spo_list": [{"subject": "IPA3", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PAK1", "object_type": "GENE-Y"}]}
{"text": "IPA3 also ablated glucose-stimulated insulin granule accumulation at the plasma membrane, consistent with its role in sustained/second-phase insulin release.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-Y"}]}
{"text": "Both IPA3 and a selective inhibitor of the Cdc42 GTPase, ML-141, blunted the glucose-stimulated activation of Raf-1, suggesting Raf-1 to be downstream of Cdc42âPAK1.", "spo_list": [{"subject": "ML-141", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Cdc42", "object_type": "GENE-Y"}, {"subject": "ML-141", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GTPase", "object_type": "GENE-N"}, {"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Raf-1", "object_type": "GENE-Y"}, {"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Raf-1", "object_type": "GENE-Y"}, {"subject": "IPA3", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Raf-1", "object_type": "GENE-Y"}, {"subject": "ML-141", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Raf-1", "object_type": "GENE-Y"}, {"subject": "IPA3", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Raf-1", "object_type": "GENE-Y"}]}
{"text": "Importantly, PD0325901, a new selective inhibitor of MEK1/2âERK1/2 activation, impaired F-actin remodeling and the sustained/amplification pathway of insulin release.", "spo_list": [{"subject": "PD0325901", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "insulin", "object_type": "GENE-Y"}]}
{"text": "Taken together, these data suggest that glucose-mediated activation of Cdc42 leads to activation of PAK1 and prompts activation of its downstream targets Raf-1, MEK1/2 and ERK1/2 to elicit F-actin remodeling and recruitment of insulin granules to the plasma membrane to support the sustained phase of insulin release.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Cdc42", "object_type": "GENE-Y"}, {"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PAK1", "object_type": "GENE-Y"}, {"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Raf-1", "object_type": "GENE-Y"}]}
{"text": "Inhibition of MCP-1 and MIP-2 transcription and translation by mimosine in muscle tissue infected with the parasite Trichinella spiralis.", "spo_list": [{"subject": "mimosine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MCP-1", "object_type": "GENE-Y"}, {"subject": "mimosine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MIP-2", "object_type": "GENE-Y"}]}
{"text": "In addition, we found that MCP-1 transcription and translation was completely inhibited by mimosine, while MIP-2 transcription and translation was partially inhibited at 30 and 40 days; yet it was totally inhibited after 10 and 20 days in encysted diaphragm tissue infected by T. spiralis.", "spo_list": [{"subject": "mimosine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MCP-1", "object_type": "GENE-Y"}, {"subject": "mimosine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MIP-2", "object_type": "GENE-Y"}]}
{"text": "2. All three detergents blocked K(ATP) channel activity with the following order of potency: Tween 80 (Ki< approximately 83 nM)>Triton X100 (Ki=350 nM)>Cremophor.", "spo_list": [{"subject": "Tween 80", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "K(ATP) channel", "object_type": "GENE-N"}, {"subject": "Triton X100", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "K(ATP) channel", "object_type": "GENE-N"}]}
{"text": "8. Like other insulin secretagogues that act by blocking the K(ATP) channel, Cremophor elevated intracellular Ca2+ in single beta-cells to levels that would be expected to elicit insulin secretion.", "spo_list": [{"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-N"}]}
{"text": "SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile.", "spo_list": [{"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "somatotropin release inhibiting factor (SRIF) receptor", "object_type": "GENE-N"}, {"subject": "somatostatin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "somatotropin release inhibiting factor (SRIF) receptor", "object_type": "GENE-N"}]}
{"text": "OBJECTIVE: The aim of the present study was to identify a small, metabolically stable somatotropin release inhibiting factor (SRIF) analog with a more universal binding profile similar to that of natural somatostatin, resulting in improved pharmacological properties and hence new therapeutic uses.", "spo_list": [{"subject": "somatostatin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SRIF", "object_type": "GENE-N"}, {"subject": "somatostatin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "somatotropin release inhibiting factor", "object_type": "GENE-N"}]}
{"text": "DESIGN: A rational drug design approach was followed by synthesizing alanine-substituted SRIF-14 analogs to determine the importance of single amino acids in SRIF-14 for SRIF receptor subtype binding.", "spo_list": [{"subject": "alanine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "SRIF-14", "object_type": "GENE-Y"}, {"subject": "alanine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "SRIF-14", "object_type": "GENE-Y"}, {"subject": "alanine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "SRIF receptor", "object_type": "GENE-N"}]}
{"text": "RESULTS: SOM230 binds with high affinity to SRIF receptor subtypes sst1, sst2, sst3 and sst5 and displays a 30- to 40-fold higher affinity for sst1 and sst5 than Sandostatin (octreotide; SMS 201-995) or Somatuline (BIM 23014).", "spo_list": [{"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SRIF receptor", "object_type": "GENE-N"}, {"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "sst1", "object_type": "GENE-N"}, {"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "sst2", "object_type": "GENE-N"}, {"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "sst3", "object_type": "GENE-N"}, {"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "sst5", "object_type": "GENE-N"}, {"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "sst1", "object_type": "GENE-N"}, {"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "sst5", "object_type": "GENE-N"}]}
{"text": "In vitro, SOM230 effectively inhibited the growth hormone releasing hormone (GHRH)-induced growth hormone (GH) release in primary cultures of rat pituitary cells with an IC(50) of 0.4+/-0.1 nmol/l (n=5).", "spo_list": [{"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "growth hormone releasing hormone", "object_type": "GENE-Y"}, {"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "growth hormone", "object_type": "GENE-Y"}, {"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "GH", "object_type": "GENE-Y"}, {"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GHRH", "object_type": "GENE-Y"}]}
{"text": "In vivo, SOM230 also potently suppressed GH secretion in rats.", "spo_list": [{"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "GH", "object_type": "GENE-Y"}]}
{"text": "Furthermore, in rats SOM230 demonstrated a much higher efficacy in lowering plasma insulin-like growth factor-I (IGF-I) levels compared with SMS 201-995.", "spo_list": [{"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "insulin-like growth factor-I", "object_type": "GENE-Y"}, {"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IGF-I", "object_type": "GENE-Y"}]}
{"text": "The infusion of 10 microg/kg/h of SOM230 using subcutaneously implanted minipumps decreased plasma IGF-I levels far more effectively than SMS 201-995.", "spo_list": [{"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IGF-I", "object_type": "GENE-Y"}]}
{"text": "After 126 days of continuous infusion of SOM230 plasma IGF-I levels were decreased by 75% of placebo-treated control animals.", "spo_list": [{"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IGF-I", "object_type": "GENE-Y"}]}
{"text": "For comparison SMS 201-995, when used under the same experimental conditions, resulted in only a 28% reduction of plasma IGF-I levels, indicating a much higher efficacy for SOM230 in this animal model.", "spo_list": [{"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IGF-I", "object_type": "GENE-Y"}]}
{"text": "It is important to note that the inhibitory effect of SOM230 was relatively selective for GH and IGF-I in that insulin and glucagon secretion was inhibited only at higher doses of SOM230.", "spo_list": [{"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GH", "object_type": "GENE-Y"}, {"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IGF-I", "object_type": "GENE-Y"}, {"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "insulin", "object_type": "GENE-N"}, {"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "glucagon", "object_type": "GENE-Y"}]}
{"text": "Therefore SOM230 is a promising development candidate for effective GH and IGF-I inhibition and is currently under evaluation in phase 1 clinical trials.", "spo_list": [{"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GH", "object_type": "GENE-Y"}, {"subject": "SOM230", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IGF-I", "object_type": "GENE-Y"}]}
{"text": "CCl(4) intoxication caused hepatic necrosis and increased serum ALT activity.", "spo_list": [{"subject": "CCl(4)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ALT", "object_type": "GENE-N"}]}
{"text": "CCl(4) administration triggered inflammatory response in mice livers by activating nuclear factor-kappaB (NF-ÎºB), which coincided with the induction of tumor necrosis factor-alpha (TNF-Î±) and cyclooxygenase-2 (COX-2).", "spo_list": [{"subject": "CCl(4)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "nuclear factor-kappaB", "object_type": "GENE-N"}, {"subject": "CCl(4)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "CCl(4)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "tumor necrosis factor-alpha", "object_type": "GENE-Y"}, {"subject": "CCl(4)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TNF-Î±", "object_type": "GENE-Y"}, {"subject": "CCl(4)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "CCl(4)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Furthermore, RA significantly inhibited the CCl(4)-induced apoptosis, which was evident from decreased cleavage of caspase-3.", "spo_list": [{"subject": "CCl(4)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "caspase-3", "object_type": "GENE-Y"}]}
{"text": "Paeoniflorin protects human EA.hy926 endothelial cells against gamma-radiation induced oxidative injury by activating the NF-E2-related factor 2/heme oxygenase-1 pathway.", "spo_list": [{"subject": "Paeoniflorin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NF-E2-related factor 2", "object_type": "GENE-Y"}, {"subject": "Paeoniflorin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "heme oxygenase-1", "object_type": "GENE-Y"}]}
{"text": "In particular, we showed that Paeoniflorin significantly reduced the formation of intracellular reactive oxygen species (ROS), the level of malondialdehyde (MDA) and lactate dehydrogenase (LDH) leakage, and enhanced production of the endogenous antioxidants, glutathione (GSH) and superoxide dismutase (SOD) in EA.hy926 cells.", "spo_list": [{"subject": "Paeoniflorin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "lactate dehydrogenase", "object_type": "GENE-N"}, {"subject": "Paeoniflorin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "LDH", "object_type": "GENE-N"}, {"subject": "Paeoniflorin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "superoxide dismutase", "object_type": "GENE-N"}, {"subject": "Paeoniflorin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SOD", "object_type": "GENE-N"}]}
{"text": "Treatment of these cells with Paeoniflorin significantly induced HO-1 expression.", "spo_list": [{"subject": "Paeoniflorin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HO-1", "object_type": "GENE-Y"}]}
{"text": "The Paeoniflorin-induced HO-1 expression was abrogated by Nrf2 siRNA.", "spo_list": [{"subject": "Paeoniflorin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HO-1", "object_type": "GENE-Y"}]}
{"text": "Furthermore, inhibition of HO-1 with zinc protoporphyrin IX (ZNPP) significantly reversed the protective effect of Paeoniflorin against radiation-induced damage in EA.hy926 cells.", "spo_list": [{"subject": "zinc protoporphyrin IX", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HO-1", "object_type": "GENE-Y"}, {"subject": "ZNPP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HO-1", "object_type": "GENE-Y"}, {"subject": "Paeoniflorin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "HO-1", "object_type": "GENE-Y"}]}
{"text": "Our findings confirmed that Paeoniflorin protected EA.hy926 cells against radiation-induced injury through the Nrf2/HO-1 pathway.", "spo_list": [{"subject": "Paeoniflorin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "HO-1", "object_type": "GENE-Y"}, {"subject": "Paeoniflorin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Nrf2", "object_type": "GENE-Y"}]}
{"text": "Phosphorylation of AMPK at Thr172 increased by 1.4-fold within 5 min, and remained elevated throughout a 30-min time course, in response to 2-deoxyglucose.", "spo_list": [{"subject": "Thr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "2-deoxyglucose", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}]}
{"text": "Phosphorylation of ER-stress marker eIF2Î± was also increased but only at 30 min of 2-deoxyglucose exposure.", "spo_list": [{"subject": "2-deoxyglucose", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "eIF2Î±", "object_type": "GENE-Y"}]}
{"text": "2-Deoxyglucose increased phosphorylation of tuberous sclerosis complex 2 (TSC2) on AMPK consensus sites but did not change the amount of TSC1 bound to TSC2.", "spo_list": [{"subject": "2-Deoxyglucose", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "tuberous sclerosis complex 2", "object_type": "GENE-Y"}, {"subject": "2-Deoxyglucose", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TSC2", "object_type": "GENE-Y"}, {"subject": "2-Deoxyglucose", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "2-Deoxyglucose", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TSC2", "object_type": "GENE-Y"}]}
{"text": "CP-690550, a JAK3 inhibitor is currently in phase II clinical trials.FK778, is a synthetic malononitrilamide that targets the critical enzyme of the de novo pyrimidine synthesis, dihydroorotic acid dehydrogenase, and receptor-associated tyrosine kinases has completed phase II trials.", "spo_list": [{"subject": "CP-690550", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JAK3", "object_type": "GENE-Y"}]}
{"text": "In a previous study, we showed that the sphingosine kinase/sphingosine 1-phosphate (S1P) pathway couples TNF receptor to induction of the cyclooxygenase 2 gene and prostaglandin synthesis (Pettus, B. J., Bielawski, J., Porcelli, A. M., Reames, D. L., Johnson, K. R., Morrow, J., Chalfant, C. E., Obeid, L. M., and Hannun, Y. A.", "spo_list": [{"subject": "prostaglandin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclooxygenase 2", "object_type": "GENE-Y"}]}
{"text": "The amphiphilic compound desipramine, a frequently employed inhibitor of acid sphingomyelinase (ASMase), blocked PGE(2) production.", "spo_list": [{"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acid sphingomyelinase", "object_type": "GENE-Y"}, {"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ASMase", "object_type": "GENE-Y"}, {"subject": "PGE(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "acid sphingomyelinase", "object_type": "GENE-Y"}, {"subject": "PGE(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ASMase", "object_type": "GENE-Y"}]}
{"text": "However, the action of desipramine was independent of its action on ASMase, since neither genetic loss of ASMase (Niemann-Pick fibroblasts) nor knockdown of ASMase using RNA interference affected TNFalpha-induced PGE(2) synthesis.", "spo_list": [{"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ASMase", "object_type": "GENE-Y"}]}
{"text": "Further investigations revealed that desipramine down-regulated acid ceramidase (AC), but not sphingosine kinase, at the protein level.", "spo_list": [{"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "acid ceramidase", "object_type": "GENE-Y"}, {"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "AC", "object_type": "GENE-Y"}]}
{"text": "Interestingly, knockdown of endogenous AC by RNA interference attenuated cyclooxygenase 2 induction by TNFalpha and subsequent PGE(2) biosynthesis.", "spo_list": [{"subject": "PGE(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclooxygenase 2", "object_type": "GENE-Y"}]}
{"text": "Taken together, these results define a novel role for AC in the TNFalpha/PGE(2) pathway.", "spo_list": [{"subject": "PGE(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AC", "object_type": "GENE-Y"}]}
{"text": "In addition, the results of this study warrant careful reconsideration of desipramine as a specific inhibitor for ASMase.", "spo_list": [{"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ASMase", "object_type": "GENE-Y"}]}
{"text": "Increased Cat3-mediated cationic amino acid transport functionally compensates in Cat1 knockout cell lines.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Cat3", "object_type": "GENE-Y"}]}
{"text": "The majority of L-Arg transport is mediated by System y+, although several other carriers have been kinetically defined.", "spo_list": [{"subject": "L-Arg", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "System y+", "object_type": "GENE-N"}]}
{"text": "System y+ cationic amino acid transport is mediated by proteins encoded by a family of genes, Cat1, Cat2, and Cat3.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "System y+", "object_type": "GENE-N"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Cat1", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Cat2", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Cat3", "object_type": "GENE-Y"}]}
{"text": "However, the apparent affinity for lysine transport was 2.4 times lower in Cat1(-/-) cells when compared with wild type cells, a property characteristic of Cat3-mediated transport.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Cat3", "object_type": "GENE-Y"}]}
{"text": "These results suggest that Cat3 compensates for the loss of functional Cat1 in cells derived from Cat1 knockout mice and mediates the majority of high affinity arginine transport.", "spo_list": [{"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Cat3", "object_type": "GENE-Y"}]}
{"text": "In cases of chorioamnionitis regardless of betamethasone treatment, placental 11beta HSD-2 expression and activity was decreased compared to controls.", "spo_list": [{"subject": "betamethasone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "11beta HSD-2", "object_type": "GENE-Y"}, {"subject": "betamethasone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "11beta HSD-2", "object_type": "GENE-Y"}]}
{"text": "Synthesis and evaluation of 3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines as Bcl-2 inhibitory anticancer agents.", "spo_list": [{"subject": "3-(benzylthio)-5-(1H-indol-3-yl)-1,2,4-triazol-4-amines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Bcl-2", "object_type": "GENE-Y"}]}
{"text": "A series of substituted 3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines has been synthesised and tested in vitro as potential pro-apoptotic Bcl-2-inhibitory anticancer agents.", "spo_list": [{"subject": "3-(benzylthio)-5-(1H-indol-3-yl)-4H-1,2,4-triazol-4-amines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Bcl-2", "object_type": "GENE-Y"}]}
{"text": "Active compounds, such as the nitrobenzyl analogue 6c, were found to exhibit sub-micromolar IC50 values in Bcl-2 expressing human cancer cell lines.", "spo_list": [{"subject": "nitrobenzyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Bcl-2", "object_type": "GENE-Y"}]}
{"text": "The major toxicological effects were associated with dopamine agonist-related pharmacodynamic properties of rotigotine (e.g., hyperactivity and stereotype, decreased serum prolactin level) and foreign body removal reaction induced by poly(lactide-co-glycolide) and carboxymethycellulose sodium (e.g., increased mononuclear cells and neutrophils, thymus atrophy and vacuolar degeneration of adrenal cortex, foreign body granuloma with foam cells accumulation at injection sites and foam cells accumulation in spleen and multiple lymph sinuses).", "spo_list": [{"subject": "rotigotine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "prolactin", "object_type": "GENE-Y"}]}
{"text": "Captopril directly inhibits matrix metalloproteinase-2 activity in continuous ambulatory peritoneal dialysis therapy.", "spo_list": [{"subject": "Captopril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "matrix metalloproteinase-2", "object_type": "GENE-Y"}]}
{"text": "We determined whether an angiotensin-converting enzyme (ACE) inhibitor, captopril, inhibits MMP-2 activity in peritoneal effluents from patients on CAPD, and simulated molecular models of the MMP-2-captopril complex.", "spo_list": [{"subject": "captopril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "angiotensin-converting enzyme", "object_type": "GENE-Y"}, {"subject": "captopril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACE", "object_type": "GENE-Y"}, {"subject": "captopril", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MMP-2", "object_type": "GENE-Y"}]}
{"text": "METHODS: The inhibitory effect of captopril on MMP-2 activity was measured in peritoneal effluents from 17 patients on CAPD.", "spo_list": [{"subject": "captopril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-2", "object_type": "GENE-Y"}]}
{"text": "Molecular models of the MMP-2-captopril complex were simulated by 1000 iterations of random docking and energy minimization.", "spo_list": [{"subject": "captopril", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MMP-2", "object_type": "GENE-Y"}]}
{"text": "RESULTS: Captopril directly inhibited MMP-2 activity in peritoneal effluents from patients on CAPD (IC50; 48 micromol/l), and that captopril binding to the MMP-2 active site could be formed in each complex model without molecular distortion.", "spo_list": [{"subject": "Captopril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-2", "object_type": "GENE-Y"}, {"subject": "captopril", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MMP-2", "object_type": "GENE-Y"}]}
{"text": "CONCLUSION: ACE inhibitors, such as captopril, may be applied as important compounds for MMP-2 inhibition in inflammation caused by CAPD.", "spo_list": [{"subject": "captopril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACE", "object_type": "GENE-Y"}, {"subject": "captopril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-2", "object_type": "GENE-Y"}]}
{"text": "Genistin decreased myosin light chain kinase (MLCK) protein contents and MLCK mRNA expression in IJS, and inhibited both phosphorylation and Mg(2+)-ATPase activity of purified myosin, implicating that the decrease of MLCK contents and inhibition of MLCK activity are involved in the genistin-induced inhibitory effects.", "spo_list": [{"subject": "Genistin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "myosin light chain kinase", "object_type": "GENE-Y"}, {"subject": "Genistin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MLCK", "object_type": "GENE-Y"}, {"subject": "Genistin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MLCK", "object_type": "GENE-Y"}, {"subject": "Genistin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "genistin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MLCK", "object_type": "GENE-Y"}, {"subject": "genistin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MLCK", "object_type": "GENE-Y"}]}
{"text": "Anti-inflammatory effect of prunetin via the suppression of NF-ÎºB pathway.", "spo_list": [{"subject": "prunetin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}]}
{"text": "Promoter assay revealed that prunetin inhibits LPS-induced nitric oxide and prostaglandin E2 production through the suppression of iNOS and COX-2 at the transcriptional level.", "spo_list": [{"subject": "prunetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "prunetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "In addition, prunetin inhibits NF-ÎºB-dependent inflammatory responses by modulating IÎºB kinase (IKK)-inhibitor ÎºBÎ± (IÎºBÎ±)-NF-ÎºB signaling.", "spo_list": [{"subject": "prunetin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}]}
{"text": "Consistent with these results, prunetin significantly reduced serum levels of inflammatory cytokines and mortality in mice challenged with lipopolysaccharide.", "spo_list": [{"subject": "prunetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cytokines", "object_type": "GENE-N"}]}
{"text": "Plerixafor, a CXCR4 antagonist for the mobilization of hematopoietic stem cells.", "spo_list": [{"subject": "Plerixafor", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CXCR4", "object_type": "GENE-Y"}]}
{"text": "Plerixafor (AMD3100, Genzyme Corporation) is a bicyclam molecule that antagonizes the binding of the chemokine stromal cell-derived factor-1 (SDF-1) to its cognate receptor CXCR4.", "spo_list": [{"subject": "Plerixafor", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "chemokine", "object_type": "GENE-N"}, {"subject": "AMD3100", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "chemokine", "object_type": "GENE-N"}, {"subject": "bicyclam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "chemokine", "object_type": "GENE-N"}, {"subject": "Plerixafor", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "stromal cell-derived factor-1", "object_type": "GENE-Y"}, {"subject": "AMD3100", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "stromal cell-derived factor-1", "object_type": "GENE-Y"}, {"subject": "bicyclam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "stromal cell-derived factor-1", "object_type": "GENE-Y"}, {"subject": "Plerixafor", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SDF-1", "object_type": "GENE-Y"}, {"subject": "AMD3100", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SDF-1", "object_type": "GENE-Y"}, {"subject": "bicyclam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SDF-1", "object_type": "GENE-Y"}, {"subject": "Plerixafor", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CXCR4", "object_type": "GENE-Y"}, {"subject": "AMD3100", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CXCR4", "object_type": "GENE-Y"}, {"subject": "bicyclam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CXCR4", "object_type": "GENE-Y"}]}
{"text": "CD1 mice were used, treated with saline, morphine CHl (5 mg/kg), and 1 or 10 mg/kg of the H1-antihistaminics tripelennamine, chlorpheniramine, diphenhydramine and cyclizine and the H2-antihistaminics ranitidine and cimetidine, all compounds by s.c. route.", "spo_list": [{"subject": "tripelennamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "H1", "object_type": "GENE-Y"}, {"subject": "chlorpheniramine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "H1", "object_type": "GENE-Y"}, {"subject": "diphenhydramine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "H1", "object_type": "GENE-Y"}, {"subject": "cyclizine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "H1", "object_type": "GENE-Y"}, {"subject": "ranitidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "H2", "object_type": "GENE-Y"}, {"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "H2", "object_type": "GENE-Y"}]}
{"text": "An antiangiogenic drug, AGM-1470, given to mice bearing tumors produced by FGF-transfected MCF-7 cells, produced a decrease in tumor size.", "spo_list": [{"subject": "AGM-1470", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FGF", "object_type": "GENE-N"}]}
{"text": "The latter effect was mimicked by a CXCR7-selective agonist TC14012 and abolished by siRNA knockdown of CXCR7.", "spo_list": [{"subject": "TC14012", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "CXCR7", "object_type": "GENE-Y"}]}
{"text": "Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension.", "spo_list": [{"subject": "Candoxatril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "neutral endopeptidase", "object_type": "GENE-Y"}]}
{"text": "OBJECTIVE: Candoxatril (UK79,300) is an orally available inhibitor of the neutral endopeptidase (E.C.3.4.24.11) which degrades atrial natriuretic factor (ANF).", "spo_list": [{"subject": "Candoxatril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "neutral endopeptidase", "object_type": "GENE-Y"}, {"subject": "UK79,300", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "neutral endopeptidase", "object_type": "GENE-Y"}, {"subject": "Candoxatril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "E.C.3.4.24.11", "object_type": "GENE-Y"}, {"subject": "UK79,300", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "E.C.3.4.24.11", "object_type": "GENE-Y"}]}
{"text": "RESULTS: Plasma ANF concentrations rose significantly in all patients within 2 h of candoxatril administration compared with placebo although peak and integrated ANF levels were similar at all three doses.", "spo_list": [{"subject": "candoxatril", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Plasma ANF", "object_type": "GENE-Y"}]}
{"text": "The uptake of entecavir was nearly identical in hPEPT1- as in vector-HELA cells.", "spo_list": [{"subject": "entecavir", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hPEPT1", "object_type": "GENE-Y"}]}
{"text": "In hOAT1- and hOAT3-HEK293 cells, uptake of entecavir was significantly higher compared to vector-HEK293 cells and was markedly inhibited by p-aminohippurate, benzylpenicillin, and JBP485.", "spo_list": [{"subject": "entecavir", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "entecavir", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT3", "object_type": "GENE-Y"}, {"subject": "p-aminohippurate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "p-aminohippurate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT3", "object_type": "GENE-Y"}, {"subject": "benzylpenicillin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "benzylpenicillin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT3", "object_type": "GENE-Y"}, {"subject": "JBP485", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "JBP485", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT3", "object_type": "GENE-Y"}]}
{"text": "Km and Vmax values of entecavir were 250 Î¼M and 0.83 nmol/mg protein/30s (OAT1) and 23 Î¼M and 1.1 nmol/mg protein/30 s (OAT3), respectively.", "spo_list": [{"subject": "entecavir", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OAT1", "object_type": "GENE-Y"}, {"subject": "entecavir", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OAT3", "object_type": "GENE-Y"}]}
{"text": "Entecavir is the substrate of OAT1, OAT3, and OCT.", "spo_list": [{"subject": "Entecavir", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OAT1", "object_type": "GENE-Y"}, {"subject": "Entecavir", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "Entecavir", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OCT", "object_type": "GENE-N"}]}
{"text": "Moreover, OAT1 and OAT3 are the targets of DDI between entecavir and JBP485.", "spo_list": [{"subject": "entecavir", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OAT1", "object_type": "GENE-Y"}, {"subject": "entecavir", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "JBP485", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OAT1", "object_type": "GENE-Y"}, {"subject": "JBP485", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OAT3", "object_type": "GENE-Y"}]}
{"text": "BACKGROUND: Norepinephrine transporter (NET) is involved in the regulation of norepinephrine (NE) turnover and metabolism.", "spo_list": [{"subject": "norepinephrine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Norepinephrine transporter", "object_type": "GENE-Y"}, {"subject": "norepinephrine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NET", "object_type": "GENE-Y"}, {"subject": "NE", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Norepinephrine transporter", "object_type": "GENE-Y"}, {"subject": "NE", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NET", "object_type": "GENE-Y"}]}
{"text": "Neuronal NE reuptake may be impaired in individuals with renal disease and/or hypertension due to dysfunction of the NE transporter.", "spo_list": [{"subject": "NE", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NE transporter", "object_type": "GENE-Y"}]}
{"text": "A silent G1287A nucleotide substitution in exon 9 of the NET gene was studied in human conditions involving hypertension.", "spo_list": [{"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "G1287A", "object_type": "GENE-N"}, {"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "NET", "object_type": "GENE-Y"}]}
{"text": "Our data suggest that l-arginine is taken up by Sertoli cells and peritubular cells, principally via system y(+)L (SLC3A2/SLC7A6) and system y(+) (SLC7A1 and SLC7A2), with system B(0+) making a minor contribution.", "spo_list": [{"subject": "l-arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SLC3A2", "object_type": "GENE-Y"}]}
{"text": "The cytochrome P450 enzyme, CYP51, catalyzes an essential early step in sterol metabolism, removing a methyl group from lanosterol in animals and fungi, or from obtusifoliol in plants.", "spo_list": [{"subject": "sterol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cytochrome P450", "object_type": "GENE-N"}, {"subject": "sterol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP51", "object_type": "GENE-N"}, {"subject": "lanosterol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cytochrome P450", "object_type": "GENE-N"}, {"subject": "lanosterol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP51", "object_type": "GENE-N"}, {"subject": "obtusifoliol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cytochrome P450", "object_type": "GENE-N"}, {"subject": "obtusifoliol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP51", "object_type": "GENE-N"}]}
{"text": "Azoles inhibit CYP51 function, leading to an accumulation of methylated sterol precursors.", "spo_list": [{"subject": "Azoles", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP51", "object_type": "GENE-Y"}, {"subject": "sterol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP51", "object_type": "GENE-Y"}]}
{"text": "We have cloned and characterized a CYP51 from MAC that functions as a lanosterol 14alpha-demethylase.", "spo_list": [{"subject": "lanosterol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP51", "object_type": "GENE-Y"}]}
{"text": "We show the direct interactions of azoles with purified MAC-CYP51 by absorbance and electron paramagnetic resonance spectroscopy, and determine the minimum inhibitory concentrations (MICs) of econazole, ketoconazole, itraconazole, fluconazole, and voriconazole against MAC.", "spo_list": [{"subject": "azoles", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CYP51", "object_type": "GENE-Y"}]}
{"text": "Major biological roles of GTK are to maintain low levels of phenylpyruvate and to close the methionine salvage pathway.", "spo_list": [{"subject": "phenylpyruvate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GTK", "object_type": "GENE-Y"}]}
{"text": "GTK also catalyzes the transamination of cystathionine, lanthionine, and thialysine to the corresponding alpha-keto acids, which cyclize to ketimines.", "spo_list": [{"subject": "cystathionine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GTK", "object_type": "GENE-Y"}, {"subject": "lanthionine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GTK", "object_type": "GENE-Y"}, {"subject": "thialysine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GTK", "object_type": "GENE-Y"}, {"subject": "alpha-keto acids", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "GTK", "object_type": "GENE-Y"}]}
{"text": "However, owing to strong competition from other amino acid substrates, the turnover of kynurenine to kynurenate by GTK/KAT I in nervous tissue must be slow unless kynurenine and GTK are sequestered in a compartment distinct from the major amino acid pools.", "spo_list": [{"subject": "kynurenine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GTK", "object_type": "GENE-Y"}, {"subject": "kynurenine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "KAT I", "object_type": "GENE-Y"}, {"subject": "kynurenate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "KAT I", "object_type": "GENE-Y"}, {"subject": "kynurenate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "GTK", "object_type": "GENE-Y"}]}
{"text": "The possibility is discussed that the spontaneous hypertension in rats carrying the GTK/KAT I mutation may be due in part to disruption of glutamine transamination.", "spo_list": [{"subject": "glutamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "KAT I", "object_type": "GENE-Y"}, {"subject": "glutamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GTK", "object_type": "GENE-N"}]}
{"text": "GTK is one of several pyridoxal 5'-phosphate (PLP)-containing enzymes that can catalyze non-physiological beta-elimination reactions with cysteine S-conjugates containing a good leaving group attached at the sulfur.", "spo_list": [{"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GTK", "object_type": "GENE-Y"}, {"subject": "S", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GTK", "object_type": "GENE-Y"}]}
{"text": "On the other hand, the beta-lyase reaction catalyzed by GTK may be useful in the conversion of some cysteine S-conjugate prodrugs to active components in vivo.", "spo_list": [{"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GTK", "object_type": "GENE-Y"}, {"subject": "S", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GTK", "object_type": "GENE-Y"}]}
{"text": "The roles of GTK in (a) brain nitrogen, sulfur, and aromatic amino acid/kynurenine metabolism, (b) brain alpha-keto acid metabolism, (c) bioactivation of certain electrophiles in brain, (d) prodrug targeting, and (e) maintenance of normal blood pressure deserve further study.", "spo_list": [{"subject": "nitrogen", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GTK", "object_type": "GENE-Y"}, {"subject": "sulfur", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GTK", "object_type": "GENE-Y"}, {"subject": "aromatic amino acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GTK", "object_type": "GENE-Y"}, {"subject": "kynurenine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GTK", "object_type": "GENE-Y"}, {"subject": "alpha-keto acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GTK", "object_type": "GENE-Y"}]}
{"text": "Ebastine is a long-acting nonsedating second generation histamine H1 receptor antagonist which binds preferentially to peripheral H1 receptors in vivo.", "spo_list": [{"subject": "Ebastine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1 receptor", "object_type": "GENE-Y"}, {"subject": "Ebastine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "H1 receptors", "object_type": "GENE-Y"}]}
{"text": "Serious adverse cardiac events, observed on rare occasions with some other histamine H1 receptor antagonists, have not been reported with ebastine, and there has been no evidence of QTc interval prolongation related to ebastine therapy.", "spo_list": [{"subject": "ebastine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1 receptor", "object_type": "GENE-Y"}]}
{"text": "Next to Glut-4, the predominant protein influencing glucose metabolism is PPARÎ± and Î³ whose expressions were also positively modulated.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Glut-4", "object_type": "GENE-Y"}]}
{"text": "Precipitated morphine withdrawal was associated with enhanced dopamine-, SKF 82958 (D1 receptor agonist)-, and forskolin-induced CREB phosphorylation.", "spo_list": [{"subject": "SKF 82958", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "D1 receptor", "object_type": "GENE-Y"}, {"subject": "forskolin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CREB", "object_type": "GENE-N"}, {"subject": "dopamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CREB", "object_type": "GENE-N"}, {"subject": "SKF 82958", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CREB", "object_type": "GENE-N"}]}
{"text": "Precipitated withdrawal also led to up-regulation of c-fos mRNA in response to SKF 82958.", "spo_list": [{"subject": "SKF 82958", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "c-fos", "object_type": "GENE-Y"}]}
{"text": "In a previous work we showed that a new class of compounds derived from XR9576 (tariquidar) selectively inhibits BCRP.", "spo_list": [{"subject": "XR9576", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BCRP", "object_type": "GENE-Y"}, {"subject": "tariquidar", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BCRP", "object_type": "GENE-Y"}]}
{"text": "When expressed in Xenopus oocytes, the encoded protein designated LAT3 (L-type amino acid transporter 3) transported neutral amino acids such as l-leucine, l-isoleucine, l-valine, and l-phenylalanine.", "spo_list": [{"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT3", "object_type": "GENE-Y"}, {"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "L-type amino acid transporter 3", "object_type": "GENE-Y"}, {"subject": "l-leucine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT3", "object_type": "GENE-Y"}, {"subject": "l-leucine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "L-type amino acid transporter 3", "object_type": "GENE-Y"}, {"subject": "l-isoleucine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT3", "object_type": "GENE-Y"}, {"subject": "l-isoleucine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "L-type amino acid transporter 3", "object_type": "GENE-Y"}, {"subject": "l-valine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT3", "object_type": "GENE-Y"}, {"subject": "l-valine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "L-type amino acid transporter 3", "object_type": "GENE-Y"}, {"subject": "l-phenylalanine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT3", "object_type": "GENE-Y"}, {"subject": "l-phenylalanine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "L-type amino acid transporter 3", "object_type": "GENE-Y"}]}
{"text": "The LAT3-mediated transport was Na+-independent and inhibited by 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid, consistent with the properties of system L. Distinct from already known system L transporters LAT1 and LAT2, which form heterodimeric complex with 4F2 heavy chain, LAT3 was functional by itself in Xenopus oocytes.", "spo_list": [{"subject": "2-aminobicyclo[2.2.1]heptane-2-carboxylic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "LAT3", "object_type": "GENE-Y"}]}
{"text": "The deduced amino acid sequence of LAT3 was identical to the gene product of POV1 reported as a prostate cancer-up-regulated gene whose function was not determined, whereas it did not exhibit significant similarity to already identified transporters.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "LAT3", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "POV1", "object_type": "GENE-Y"}]}
{"text": "The Eadie-Hofstee plots of LAT3-mediated transport were curvilinear, whereas the low affinity component is predominant at physiological plasma amino acid concentration.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT3", "object_type": "GENE-Y"}]}
{"text": "In addition to amino acid substrates, LAT3 recognized amino acid alcohols.", "spo_list": [{"subject": "amino acid alcohols", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT3", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT3", "object_type": "GENE-Y"}]}
{"text": "In contrast, l-leucinol, l-valinol, and l-phenylalaninol, which have a net positive charge induced inward currents under voltage clamp, suggesting these compounds are transported by LAT3.", "spo_list": [{"subject": "l-leucinol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT3", "object_type": "GENE-Y"}, {"subject": "l-valinol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT3", "object_type": "GENE-Y"}, {"subject": "l-phenylalaninol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT3", "object_type": "GENE-Y"}]}
{"text": "LAT3-mediated transport was inhibited by the pretreatment with N-ethylmaleimide, consistent with the property of system L2 originally characterized in hepatocyte primary culture.", "spo_list": [{"subject": "N-ethylmaleimide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "LAT3", "object_type": "GENE-Y"}]}
{"text": "Irbesartan (Aprovel, Avapro, Irbetan, Karvea), an angiotensin II receptor type 1 antagonist, is approved in many countries worldwide for the treatment of hypertension.", "spo_list": [{"subject": "Irbesartan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "angiotensin II receptor type 1", "object_type": "GENE-Y"}, {"subject": "Aprovel", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "angiotensin II receptor type 1", "object_type": "GENE-Y"}, {"subject": "Avapro", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "angiotensin II receptor type 1", "object_type": "GENE-Y"}, {"subject": "Irbetan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "angiotensin II receptor type 1", "object_type": "GENE-Y"}, {"subject": "Karvea", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "angiotensin II receptor type 1", "object_type": "GENE-Y"}]}
{"text": "The inactivation of human CYP2E1 by phenethyl isothiocyanate, a naturally occurring chemopreventive agent, and its oxidative bioactivation.", "spo_list": [{"subject": "phenethyl isothiocyanate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human CYP2E1", "object_type": "GENE-Y"}]}
{"text": "Phenethylisothiocyanate (PEITC), a naturally occurring isothiocyanate and potent cancer chemopreventive agent, works by multiple mechanisms, including the inhibition of cytochrome P450 (P450) enzymes, such as CYP2E1, that are involved in the bioactivation of carcinogens.", "spo_list": [{"subject": "Phenethylisothiocyanate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cytochrome P450", "object_type": "GENE-N"}, {"subject": "PEITC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cytochrome P450", "object_type": "GENE-N"}, {"subject": "isothiocyanate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cytochrome P450", "object_type": "GENE-N"}, {"subject": "Phenethylisothiocyanate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P450", "object_type": "GENE-N"}, {"subject": "PEITC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P450", "object_type": "GENE-N"}, {"subject": "isothiocyanate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P450", "object_type": "GENE-N"}, {"subject": "Phenethylisothiocyanate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2E1", "object_type": "GENE-Y"}, {"subject": "PEITC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2E1", "object_type": "GENE-Y"}, {"subject": "isothiocyanate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2E1", "object_type": "GENE-Y"}]}
{"text": "PEITC has been reported to be a mechanism-based inactivator of some P450s.", "spo_list": [{"subject": "PEITC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P450s", "object_type": "GENE-N"}]}
{"text": "We describe here the possible mechanism for the inactivation of human CYP2E1 by PEITC, as well as the putative intermediate that might be involved in the bioactivation of PEITC.", "spo_list": [{"subject": "PEITC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human CYP2E1", "object_type": "GENE-Y"}]}
{"text": "PEITC inactivated recombinant CYP2E1 with a partition ratio of 12, and the inactivation was not inhibited in the presence of glutathione (GSH) and not fully recovered by dialysis.", "spo_list": [{"subject": "PEITC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2E1", "object_type": "GENE-Y"}]}
{"text": "The inactivation of CYP2E1 by PEITC is due to both heme destruction and protein modification, with the latter being the major pathway for inactivation.", "spo_list": [{"subject": "PEITC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2E1", "object_type": "GENE-Y"}]}
{"text": "GSH-adducts of phenethyl isocyanate (PIC) and phenethylamine were detected during the metabolism by CYP2E1, indicating formation of PIC as a reactive intermediate following P450-catalyzed desulfurization of PEITC.", "spo_list": [{"subject": "PIC", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CYP2E1", "object_type": "GENE-Y"}, {"subject": "phenethylamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2E1", "object_type": "GENE-Y"}, {"subject": "PEITC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P450", "object_type": "GENE-N"}]}
{"text": "Surprisingly, PIC bound covalently to CYP2E1 to form protein adducts but did not inactivate the enzyme.", "spo_list": [{"subject": "PIC", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CYP2E1", "object_type": "GENE-Y"}]}
{"text": "Liquid chromatography mass spectroscopy analysis of the inactivated CYP2E1 apo-protein suggests that a reactive sulfur atom generated during desulfurization of PEITC is involved in the inactivation of CYP2E1.", "spo_list": [{"subject": "PEITC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2E1", "object_type": "GENE-Y"}, {"subject": "sulfur", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2E1", "object_type": "GENE-Y"}]}
{"text": "Our data suggest that the metabolism of PEITC by CYP2E1 that results in the inactivation of CYP2E1 may occur by a mechanism similar to that observed with other sulfur-containing compounds, such as parathion.", "spo_list": [{"subject": "PEITC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2E1", "object_type": "GENE-Y"}, {"subject": "PEITC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2E1", "object_type": "GENE-Y"}, {"subject": "sulfur", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2E1", "object_type": "GENE-Y"}, {"subject": "parathion", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2E1", "object_type": "GENE-Y"}]}
{"text": "Moreover, elevated levels of pyridoxal kinase (PDXK), the enzyme that converts pyridoxine and other vitamin B6 precursors into PLP, have been shown to constitute a good, therapy-independent prognostic marker in patients affected by non-small cell lung carcinoma (NSCLC).", "spo_list": [{"subject": "pyridoxine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "pyridoxal kinase", "object_type": "GENE-Y"}, {"subject": "pyridoxine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PDXK", "object_type": "GENE-Y"}, {"subject": "vitamin B6", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "pyridoxal kinase", "object_type": "GENE-Y"}, {"subject": "vitamin B6", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PDXK", "object_type": "GENE-Y"}, {"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "pyridoxal kinase", "object_type": "GENE-Y"}, {"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PDXK", "object_type": "GENE-Y"}]}
{"text": "Treatment with adenosine dialdehyde (AdOx), an inhibitor of transmethylation-suppressive adenosylhomocysteine (SAH) hydrolase (SAHH), enhanced the level of SAH and effectively blocked the proliferation, migration, and invasion of cancer cells; the treatment also induced the differentiation of C6 glioma cells and suppressed the neovascular genesis of eggs in a dose-dependent manner.", "spo_list": [{"subject": "adenosine dialdehyde", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "adenosylhomocysteine (SAH) hydrolase", "object_type": "GENE-Y"}, {"subject": "AdOx", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "adenosylhomocysteine (SAH) hydrolase", "object_type": "GENE-Y"}, {"subject": "adenosine dialdehyde", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SAHH", "object_type": "GENE-Y"}, {"subject": "AdOx", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SAHH", "object_type": "GENE-Y"}, {"subject": "SAH", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "adenosylhomocysteine (SAH) hydrolase", "object_type": "GENE-Y"}, {"subject": "SAH", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SAHH", "object_type": "GENE-Y"}]}
{"text": "Through immunoblotting analysis, it was found that AdOx was capable of indirectly diminishing the phosphorylation of oncogenic Src and its kinase activity.", "spo_list": [{"subject": "AdOx", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Src", "object_type": "GENE-Y"}, {"subject": "AdOx", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}]}
{"text": "Interestingly, AdOx disrupted actin cytoskeleton structures, leading to morphological changes, and suppressed the formation of a signaling complex composed of Src and p85/PI3K, which is linked to various tumorigenic responses.", "spo_list": [{"subject": "AdOx", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "actin", "object_type": "GENE-N"}, {"subject": "AdOx", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Src", "object_type": "GENE-Y"}, {"subject": "AdOx", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "p85", "object_type": "GENE-N"}, {"subject": "AdOx", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "PI3K", "object_type": "GENE-N"}]}
{"text": "In agreement with these data, the exogenous treatment of SAH or inhibition of SAHH by specific siRNA or another type of inhibitor, 3-deazaadenosine (DAZA), similarly resulted in antitumorigenic responses, suppressive activity on Src, the alteration of actin cytoskeleton, and a change of the colocalization pattern between actin and Src.", "spo_list": [{"subject": "3-deazaadenosine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SAHH", "object_type": "GENE-Y"}, {"subject": "DAZA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SAHH", "object_type": "GENE-Y"}]}
{"text": "When stably expressed in transfected rat basophilic leukemia (RBL-2H3) cells, mFpr1 was readily activated by N-formylated peptides derived from Listeria monocytogenes (fMIVTLF), Staphylococcus aureus (fMIFL), and mitochondria (fMMYALF).", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "mFpr1", "object_type": "GENE-Y"}]}
{"text": "The aforementioned peptides were much less efficacious at mFpr2, which responded better to the synthetic hexapeptide WKYMVm, the synthetic agonists Quin-C1 (a substituted quinazolinone), and compound 43 (a nitrosylated pyrazolone derivative).", "spo_list": [{"subject": "Quin-C1", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mFpr2", "object_type": "GENE-Y"}, {"subject": "quinazolinone", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mFpr2", "object_type": "GENE-Y"}, {"subject": "nitrosylated pyrazolone", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mFpr2", "object_type": "GENE-Y"}]}
{"text": "Saturation binding assays showed that mFpr1 and mFpr2 were expressed at similar levels on the cell surface, although their affinity for N-formyl-Met-Leu-Phe-Ile-Ile-Lys-fluorescein isothiocyanate varied by more than 1000-fold [dissociation constant (K(d)) values of 2.8 nM for mFpr1 and 4.8 Î¼M for mFpr2]).", "spo_list": [{"subject": "N-formyl-Met-Leu-Phe-Ile-Ile-Lys-fluorescein isothiocyanate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mFpr1", "object_type": "GENE-Y"}, {"subject": "N-formyl-Met-Leu-Phe-Ile-Ile-Lys-fluorescein isothiocyanate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mFpr2", "object_type": "GENE-Y"}, {"subject": "N-formyl-Met-Leu-Phe-Ile-Ile-Lys-fluorescein isothiocyanate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mFpr1", "object_type": "GENE-Y"}, {"subject": "N-formyl-Met-Leu-Phe-Ile-Ile-Lys-fluorescein isothiocyanate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mFpr2", "object_type": "GENE-Y"}]}
{"text": "Thiopurine S-methyltransferase (TPMT; EC 2.1.1.67), an enzyme that catalyzes S-methylation of these drugs, exhibits a genetic polymorphism in 10% of Caucasians, with 1/300 individuals having complete deficiency.", "spo_list": [{"subject": "S", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Thiopurine S-methyltransferase", "object_type": "GENE-Y"}, {"subject": "S", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "TPMT", "object_type": "GENE-Y"}, {"subject": "S", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 2.1.1.67", "object_type": "GENE-N"}]}
{"text": "Patients with intermediate or deficient TPMT activity are at risk for excessive toxicity after receiving standard doses of thiopurine medications.", "spo_list": [{"subject": "thiopurine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "TPMT", "object_type": "GENE-Y"}]}
{"text": "This report reviews the recent advances in the knowledge of the mechanism of action as well as the molecular basis and interethnic variations of TPMT and inosine triphosphate pyrophosphatase (ITPase; EC 3.6.1.19), another enzyme implicated in thiopurine toxicity.", "spo_list": [{"subject": "thiopurine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "TPMT", "object_type": "GENE-Y"}, {"subject": "thiopurine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "inosine triphosphate pyrophosphatase", "object_type": "GENE-Y"}, {"subject": "thiopurine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ITPase", "object_type": "GENE-Y"}, {"subject": "thiopurine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 3.6.1.19", "object_type": "GENE-N"}]}
{"text": "H2O2 caused cell loss and increased cell death with features of apoptosis, i.e. TdT-mediated dUTP nick-end labelling (TUNEL) reaction and caspase-3 activation.", "spo_list": [{"subject": "H2O2", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "caspase-3", "object_type": "GENE-Y"}]}
{"text": "Pre-treatment with arsenite increased protein kinase B (Akt) and extracellular signal regulated kinase 1/2 (ERK1/2) phosphorylation after H2O2.", "spo_list": [{"subject": "H2O2", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "protein kinase B", "object_type": "GENE-N"}, {"subject": "H2O2", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Akt", "object_type": "GENE-N"}]}
{"text": "However, while Akt phosphorylation was prevented by CHX, Erk1/2 phosphorylation was further enhanced by CHX.", "spo_list": [{"subject": "CHX", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}]}
{"text": "The results show that transient arsenite pre-treatment induces Hsp72, HO-1 and, to a lesser extent, Hsp27; it reduces H2O2-induced astrocyte death; and it causes selective activation of Akt following H2O2.", "spo_list": [{"subject": "arsenite", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "H2O2", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Akt", "object_type": "GENE-N"}]}
{"text": "5-Fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd) and 5-trifluorothymidine (F3(d)Thd) are antimetabolites which are metabolized to their corresponding active forms which inhibit DNA synthesis via inhibition of thymidylate synthase (TS).", "spo_list": [{"subject": "5-Fluorouracil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}, {"subject": "5-FU", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}, {"subject": "5-fluoro-2'-deoxyuridine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}, {"subject": "FdUrd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}, {"subject": "5-trifluorothymidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}, {"subject": "F3(d)Thd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}, {"subject": "5-Fluorouracil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "5-FU", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "5-fluoro-2'-deoxyuridine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "FdUrd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "5-trifluorothymidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "F3(d)Thd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}]}
{"text": "When DLD-1/FdUrd cells expressing increased TS mRNA were treated with FdUrd and F3(d)Thd for only 4 h, the resistance ratios of DLD-1/FdUrd cells to parental DLD-1 cells were markedly different for FdUrd and F3(d)Thd, suggesting that the cytotoxicity with short-time exposure to F3(d)Thd is due to a mechanism other than TS inhibition, although the cytotoxicity of F3(d)Thd in the short-time is low compared to that of long-time exposure.", "spo_list": [{"subject": "F3(d)Thd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}]}
{"text": "In conclusion, F3(d)Thd, an antimetabolite that inhibits TS activity, may be effective against 5-FU and/or FdUrd-resistance in colorectal cancer cells caused by amplification of TS and/or deletion of orotate phosphoribosyltransferase.", "spo_list": [{"subject": "F3(d)Thd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}]}
{"text": "The feasibility of administering a relatively high dose of the gonadotrophin-releasing hormone (GnRH) antagonist ganirelix by means of a needle-free injection device, which could be useful in the long-term treatment of sex-steroid-dependent disorders, was evaluated in a randomized, crossover study in 16 healthy females.", "spo_list": [{"subject": "ganirelix", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "gonadotrophin-releasing hormone", "object_type": "GENE-Y"}, {"subject": "ganirelix", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "GnRH", "object_type": "GENE-Y"}]}
{"text": "To investigate the possible drug interaction, this study is designed to evaluate the ability of Schisandrin B (Sch B) to modulate cytochrome P450 3A activity (CYP3A) in vivo and to alter the pharmacokinetic profiles of CYP3A substrate (midazolam) in treated rats.", "spo_list": [{"subject": "midazolam", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A", "object_type": "GENE-N"}]}
{"text": "The results indicated that Sch B significantly dose-dependently inhibited rat hepatic microsomal CYP3A activity with Ki value of 16.64mg/kg and showed the characteristic of a noncompetitive inhibitor.", "spo_list": [{"subject": "Sch B", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP3A", "object_type": "GENE-N"}]}
{"text": "These results suggested that 3-day treatment of Sch B could increase concentration and oral bioavailability of drug metabolized by CYP3A.", "spo_list": [{"subject": "Sch B", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A", "object_type": "GENE-N"}]}
{"text": "The atypical antidepressant mianserin exhibits agonist activity at kappa-opioid receptors.", "spo_list": [{"subject": "mianserin", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "kappa-opioid receptors", "object_type": "GENE-Y"}]}
{"text": "We previously reported that tricyclic antidepressants act as agonists at distinct opioid receptors.", "spo_list": [{"subject": "tricyclic", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "opioid receptors", "object_type": "GENE-N"}]}
{"text": "In [(35)S]GTPgammaS assays, mianserin selectively activated kappa-opioid receptors.", "spo_list": [{"subject": "[(35)S]GTPgammaS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "kappa-opioid receptors", "object_type": "GENE-Y"}, {"subject": "mianserin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "kappa-opioid receptors", "object_type": "GENE-Y"}]}
{"text": "The agonist activity was antagonized by the selective kappa-opioid blocker nor-binaltorphimine (nor-BNI).", "spo_list": [{"subject": "nor-binaltorphimine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "kappa-opioid", "object_type": "GENE-Y"}, {"subject": "nor-BNI", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "kappa-opioid", "object_type": "GENE-Y"}, {"subject": "nor-binaltorphimine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kappa-opioid", "object_type": "GENE-Y"}, {"subject": "nor-BNI", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kappa-opioid", "object_type": "GENE-Y"}]}
{"text": "The mianserin analogue mirtazapine also displayed kappa-opioid agonist activity.", "spo_list": [{"subject": "mianserin", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "kappa-opioid", "object_type": "GENE-Y"}, {"subject": "mirtazapine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "kappa-opioid", "object_type": "GENE-Y"}]}
{"text": "In rat striatum and nucleus accumbens, mianserin stimulated [35S]GTPgammaS binding in a nor-BNI-sensitive manner with maximal effects lower than those of the full kappa-opioid agonists (-)-U50,488 and dynorphin A. When combined, mianserin antagonized the effects of the full kappa-opioid receptor agonists in [(35)S]GTPgammaS assays and reduced the stimulation of p38 MAPK and ERK1/2 phosphorylation by dynorphin A. CONCLUSIONS AND IMPLICATIONS: In different cell systems, mianserin directly activates kappa-opioid receptors, displaying partial agonist activity at brain receptors.", "spo_list": [{"subject": "(-)-U50,488", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "kappa-opioid", "object_type": "GENE-Y"}, {"subject": "dynorphin A", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "kappa-opioid", "object_type": "GENE-Y"}, {"subject": "[35S]GTPgammaS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "kappa-opioid", "object_type": "GENE-Y"}, {"subject": "mianserin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "kappa-opioid receptor", "object_type": "GENE-Y"}, {"subject": "[(35)S]GTPgammaS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "kappa-opioid receptor", "object_type": "GENE-Y"}, {"subject": "dynorphin A", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "dynorphin A", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MAPK", "object_type": "GENE-N"}, {"subject": "mianserin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "kappa-opioid receptors", "object_type": "GENE-Y"}, {"subject": "mianserin", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "kappa-opioid receptors", "object_type": "GENE-Y"}, {"subject": "mianserin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "mianserin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAPK", "object_type": "GENE-N"}]}
{"text": "The glucagon-like peptide-1 receptor (GLP-1R) is a major therapeutic target for the treatment of type 2 diabetes due to its role in glucose homeostasis.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "glucagon-like peptide-1 receptor", "object_type": "GENE-Y"}, {"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GLP-1R", "object_type": "GENE-Y"}]}
{"text": "Moreover, 1,25(OH)(2)D(3) decreased expression of Oat1 and Oat3 in rat kidney.", "spo_list": [{"subject": "1,25(OH)(2)D(3)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Oat1", "object_type": "GENE-Y"}, {"subject": "1,25(OH)(2)D(3)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Oat3", "object_type": "GENE-Y"}]}
{"text": "The mechanism of interaction between JBP485 and 1,25(OH)(2)D(3) could be explained at least in part by inhibitory effect of 1,25(OH)(2)D(3) on expression of Oats in rat kidney.", "spo_list": [{"subject": "1,25(OH)(2)D(3)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Oats", "object_type": "GENE-N"}]}
{"text": "Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders.", "spo_list": [{"subject": "acarbose", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "alpha-glucosidase", "object_type": "GENE-Y"}]}
{"text": "Acarbose, an alpha-glucosidase inhibitor, delays the absorption of carbohydrate from the small intestine, thereby reducing postprandial hyperglycemia.", "spo_list": [{"subject": "Acarbose", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "alpha-glucosidase", "object_type": "GENE-Y"}]}
{"text": "Transport by OATP1B1 and OATP1B3 enhances the cytotoxicity of epigallocatechin 3-O-gallate and several quercetin derivatives.", "spo_list": [{"subject": "epigallocatechin 3-O-gallate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B3", "object_type": "GENE-Y"}, {"subject": "epigallocatechin 3-O-gallate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B1", "object_type": "GENE-Y"}, {"subject": "quercetin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B3", "object_type": "GENE-Y"}, {"subject": "quercetin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B1", "object_type": "GENE-Y"}]}
{"text": "Uptake of the radiolabeled model substrates estradiol 17Î²-glucuronide, estrone 3-sulfate, and dehydroepiandrosterone sulfate (DHEAS) was determined in the absence and presence of compounds 1-6 using Chinese hamster ovary (CHO) cells stably expressing either OATP1B1 or OATP1B3.", "spo_list": [{"subject": "estradiol 17Î²-glucuronide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B1", "object_type": "GENE-Y"}, {"subject": "estrone 3-sulfate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B1", "object_type": "GENE-Y"}, {"subject": "dehydroepiandrosterone sulfate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B1", "object_type": "GENE-Y"}, {"subject": "DHEAS", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B1", "object_type": "GENE-Y"}, {"subject": "estradiol 17Î²-glucuronide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B3", "object_type": "GENE-Y"}, {"subject": "estrone 3-sulfate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B3", "object_type": "GENE-Y"}, {"subject": "dehydroepiandrosterone sulfate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B3", "object_type": "GENE-Y"}, {"subject": "DHEAS", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B3", "object_type": "GENE-Y"}]}
{"text": "Compound 6 stimulated OATP1B3-mediated estradiol 17Î²-glucuronide uptake by increasing the apparent affinity of OATP1B3 for its substrate.", "spo_list": [{"subject": "estradiol 17Î²-glucuronide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B3", "object_type": "GENE-Y"}, {"subject": "estradiol 17Î²-glucuronide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B3", "object_type": "GENE-Y"}]}
{"text": "Cytotoxicity assays demonstrated that epigallocatechin 3-O-gallate (EGCG) and most of compounds 1-6 killed preferentially OATP-expressing CHO cells.", "spo_list": [{"subject": "epigallocatechin 3-O-gallate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP", "object_type": "GENE-N"}, {"subject": "EGCG", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP", "object_type": "GENE-N"}]}
{"text": "EGCG, 1, and 3 were the most potent cytotoxic compounds, with EGCG and 3 selectively killing OATP1B3-expressing cells.", "spo_list": [{"subject": "EGCG", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B3", "object_type": "GENE-Y"}]}
{"text": "Fisetin treatment of preadipocytes reduced the phosphorylation of S6K1 and mTORC1 in a time- and concentration-dependent manner.", "spo_list": [{"subject": "Fisetin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "S6K1", "object_type": "GENE-Y"}, {"subject": "Fisetin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTORC1", "object_type": "GENE-N"}]}
{"text": "The results suggested that fisetin treatment inhibits mTORC1 activity in an Akt-dependent manner.", "spo_list": [{"subject": "fisetin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTORC1", "object_type": "GENE-N"}, {"subject": "fisetin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}]}
{"text": "We also observed that fisetin efficiently suppressed the phosphorylation of Akt, S6K1 and mTORC1 in adipose tissue.", "spo_list": [{"subject": "fisetin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "fisetin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "S6K1", "object_type": "GENE-Y"}, {"subject": "fisetin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTORC1", "object_type": "GENE-N"}]}
{"text": "Collectively, these results suggest that inhibition of mTORC1 signaling by fisetin prevents adipocyte differentiation of 3T3-L1 preadipocytes and obesity in HFD-fed mice.", "spo_list": [{"subject": "fisetin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTORC1", "object_type": "GENE-N"}]}
{"text": "Actions of Xanthurenic acid, a putative endogenous Group II metabotropic glutamate receptor agonist, on sensory transmission in the thalamus.", "spo_list": [{"subject": "Xanthurenic acid", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "Group II metabotropic glutamate receptor", "object_type": "GENE-N"}]}
{"text": "Xanthurenic acid (XA), a molecule arising from tryptophan metabolism by transamination of 3-hydroxykynurenine, has recently been identified as an endogenous Group II (mGlu2 and mGlu3) metabotropic glutamate (mGlu) receptor ligand in vitro.", "spo_list": [{"subject": "Xanthurenic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mGlu2", "object_type": "GENE-Y"}, {"subject": "Xanthurenic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mGlu3", "object_type": "GENE-Y"}, {"subject": "Xanthurenic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "metabotropic glutamate (mGlu) receptor", "object_type": "GENE-N"}]}
{"text": "Based on animal and in vitro studies, resveratrol reverts these risk factors via stimulation of silent mating type information regulation 2 homolog 1 (SIRT1), but data in human subjects are scarce.", "spo_list": [{"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "silent mating type information regulation 2 homolog 1", "object_type": "GENE-Y"}, {"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "SIRT1", "object_type": "GENE-Y"}]}
{"text": "Type I deiodinase, liver fatty-acid binding protein and cytochrome P450 (CYP) 3A37 mRNA levels were significantly induced by TCPP, while TDCPP induced CYP3A37 and CYP2H1.", "spo_list": [{"subject": "TCPP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Type I deiodinase", "object_type": "GENE-Y"}, {"subject": "TCPP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "liver fatty-acid binding protein", "object_type": "GENE-Y"}, {"subject": "TCPP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytochrome P450 (CYP) 3A37", "object_type": "GENE-Y"}, {"subject": "TDCPP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP3A37", "object_type": "GENE-Y"}, {"subject": "TDCPP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP2H1", "object_type": "GENE-Y"}]}
{"text": "Pretreatment with E(2) prevented MPTP opening induced by H(2)O(2), which preceded loss of mitochondrial membrane potential.", "spo_list": [{"subject": "H(2)O(2)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MPTP", "object_type": "GENE-N"}]}
{"text": "TAS-102 currently undergoing clinical trials, has been demonstrated to have at least two mechanisms, inhibition of TS and incorporation into DNA.", "spo_list": [{"subject": "TAS-102", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}]}
{"text": "Romidepsin is a histone deacetylase inhibitor with potent antitumor effects both in vitro and in vivo.", "spo_list": [{"subject": "Romidepsin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "histone deacetylase", "object_type": "GENE-N"}]}
{"text": "In thyroid cancer cell lines, romidepsin increases expression of both thyroglobulin and the sodium iodide symporter messenger RNAs, suggesting the possibility of improved iodine concentrating ability of RAI-resistant tumors.", "spo_list": [{"subject": "iodine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "sodium iodide symporter", "object_type": "GENE-Y"}]}
{"text": "For example, organophosphates, which inhibit acetylcholinesterase as do the drugs used in treating AD symptoms, have also been shown to lead to microtubule derangements and tau hyperphosphorylation, a hallmark of AD.", "spo_list": [{"subject": "organophosphates", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "organophosphates", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "tau", "object_type": "GENE-Y"}]}
{"text": "Ergovaline binding and activation of D2 dopamine receptors in GH4ZR7 cells.", "spo_list": [{"subject": "Ergovaline", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "D2 dopamine receptors", "object_type": "GENE-Y"}, {"subject": "Ergovaline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "D2 dopamine receptors", "object_type": "GENE-Y"}]}
{"text": "Ergovaline inhibition of radioligand binding to the D2 dopamine receptor and ergot alkaloid inhibition of vasoactive intestinal peptide (VIP)-stimulated cyclic AMP production in GH4ZR7 cells, stably transfected with a rat D2 dopamine receptor, were evaluated.", "spo_list": [{"subject": "Ergovaline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "D2 dopamine receptor", "object_type": "GENE-Y"}, {"subject": "ergot alkaloid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "vasoactive intestinal peptide", "object_type": "GENE-Y"}, {"subject": "ergot alkaloid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VIP", "object_type": "GENE-Y"}, {"subject": "cyclic AMP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "vasoactive intestinal peptide", "object_type": "GENE-Y"}, {"subject": "cyclic AMP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "VIP", "object_type": "GENE-Y"}]}
{"text": "Ergovaline inhibition of the binding of the D2-specific radioligand, [3H]YM-09151-2, exhibited a KI (inhibition constant) of 6.9 +/- 2.6 nM, whereas dopamine was much less potent (370 +/- 160 nM).", "spo_list": [{"subject": "[3H]YM-09151-2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "D2", "object_type": "GENE-Y"}, {"subject": "Ergovaline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "D2", "object_type": "GENE-Y"}, {"subject": "dopamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "D2", "object_type": "GENE-Y"}]}
{"text": "Ergot alkaloids were also effective in inhibiting VIP-stimulated cyclic AMP production, with EC50 values for ergovaline, ergonovine, alpha-ergocryptine, ergotamine, and dopamine of 8 +/- 2, 47 +/- 2, 28 +/- 2, 2 +/- 1, and 8 +/- 1 nM, respectively.", "spo_list": [{"subject": "Ergot alkaloids", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VIP", "object_type": "GENE-Y"}, {"subject": "cyclic AMP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "VIP", "object_type": "GENE-Y"}, {"subject": "ergovaline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VIP", "object_type": "GENE-Y"}, {"subject": "ergonovine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VIP", "object_type": "GENE-Y"}, {"subject": "alpha-ergocryptine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VIP", "object_type": "GENE-Y"}, {"subject": "ergotamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VIP", "object_type": "GENE-Y"}, {"subject": "dopamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VIP", "object_type": "GENE-Y"}]}
{"text": "Inhibition of cyclic AMP production by ergovaline was blocked by the dopamine receptor antagonist, (-)-sulpiride (IC50, 300 +/- 150 nM).", "spo_list": [{"subject": "(-)-sulpiride", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine receptor", "object_type": "GENE-N"}]}
{"text": "Our results indicate that ergot compounds, especially ergovaline, bind to D2 dopamine receptors and elicit second messenger responses similar to that of dopamine.", "spo_list": [{"subject": "ergovaline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "D2 dopamine receptors", "object_type": "GENE-Y"}, {"subject": "dopamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "D2 dopamine receptors", "object_type": "GENE-Y"}]}
{"text": "These findings suggest that some of the deleterious effects of consumption of endophyte-infected tall fescue, which contains several ergot alkaloids including ergovaline, may be due to D2 dopamine receptor activation.", "spo_list": [{"subject": "ergovaline", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "D2 dopamine receptor", "object_type": "GENE-Y"}, {"subject": "ergot alkaloids", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "D2 dopamine receptor", "object_type": "GENE-Y"}]}
{"text": "Palonosetron, a second-generation 5-HT3 receptor antagonist with a different half-life, a different binding capacity and a different mechanism of action than the first-generation 5-HT3 receptor antagonists appears to be the most effective agent in its class.", "spo_list": [{"subject": "Palonosetron", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT3", "object_type": "GENE-Y"}]}
{"text": "Aprepitant, the first and only agent clinically available in the NK1 receptor antagonist drug class has been used effectively as an additive agent to the 5-HT3 receptor antagonists and dexamethasone to control CINV.", "spo_list": [{"subject": "Aprepitant", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NK1 receptor", "object_type": "GENE-Y"}]}
{"text": "Rolapitant and netupitant are other NK1 receptor antagonists that are currently in phase III clinical trials.", "spo_list": [{"subject": "Rolapitant", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NK1 receptor", "object_type": "GENE-Y"}, {"subject": "netupitant", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NK1 receptor", "object_type": "GENE-Y"}]}
{"text": "11Beta-HSD1 activates cortisone to cortisol to facilitate glucocorticoid receptor (GR)-mediated action.", "spo_list": [{"subject": "cortisone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "11Beta-HSD1", "object_type": "GENE-Y"}, {"subject": "cortisol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "11Beta-HSD1", "object_type": "GENE-Y"}]}
{"text": "By contrast, 11beta-HSD2 plays a pivotal role in aldosterone target tissues where it catalyses the opposite reaction (i.e. inactivation of cortisol to cortisone) to prevent activation of the mineralocorticoid receptor (MR) by cortisol.", "spo_list": [{"subject": "cortisol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "11beta-HSD2", "object_type": "GENE-Y"}, {"subject": "cortisone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "11beta-HSD2", "object_type": "GENE-Y"}]}
{"text": "Mutations in the 11beta-HSD2 gene cause a rare form of inherited hypertension, the syndrome of apparent mineralocorticoid excess (AME), in which cortisol activates the MR resulting in severe hypertension and hypokalemia.", "spo_list": [{"subject": "cortisol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MR", "object_type": "GENE-Y"}]}
{"text": "Ingestion of competitive inhibitors of 11beta-HSD2 such as liquorice and carbenoxolone result in a similar but milder clinical phenotype.", "spo_list": [{"subject": "carbenoxolone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "11beta-HSD2", "object_type": "GENE-Y"}]}
{"text": "Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.", "spo_list": [{"subject": "dasatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "BMS-354825", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "dasatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SRC", "object_type": "GENE-Y"}, {"subject": "BMS-354825", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SRC", "object_type": "GENE-Y"}, {"subject": "dasatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BCR", "object_type": "GENE-Y"}, {"subject": "dasatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ABL", "object_type": "GENE-Y"}, {"subject": "BMS-354825", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ABL", "object_type": "GENE-Y"}]}
{"text": "PURPOSE: Dasatinib (BMS-354825), a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL, has recently been approved for the treatment of chronic myelogenous leukaemia (CML) in imatinib-acquired resistance and intolerance.", "spo_list": [{"subject": "Dasatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "BMS-354825", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "Dasatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SRC", "object_type": "GENE-Y"}, {"subject": "BMS-354825", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SRC", "object_type": "GENE-Y"}, {"subject": "Dasatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BCR", "object_type": "GENE-Y"}, {"subject": "BMS-354825", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BCR", "object_type": "GENE-Y"}, {"subject": "Dasatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ABL", "object_type": "GENE-Y"}, {"subject": "BMS-354825", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ABL", "object_type": "GENE-Y"}]}
{"text": "To investigate how the observed GABA(A) receptor-mediated modulation operates, we determined the sensitivity of this process to the Na-K-2Cl cotransporter 1 antagonist bumetanide, as well as substitution of Ca(2+) with Ba(2+), or Ca(2+)/calmodulin inhibition by W7.", "spo_list": [{"subject": "bumetanide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "Na-K-2Cl cotransporter 1", "object_type": "GENE-Y"}]}
{"text": "Although its precise primary target is not clear, the action mechanisms of minocycline for neuroprotection reported so far are; via; the inhibition of mitochondrial permeability-transition mediated cytochrome c release from mitochondria, the inhibition of caspase-1 and -3 expressions, and the suppression of microglial activation, involvement in some signaling pathways, metalloprotease activity inhibition.", "spo_list": [{"subject": "minocycline", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cytochrome c", "object_type": "GENE-Y"}]}
{"text": "In patients who do not reach the LDL-C target, combination therapy with additional LDL-C lowering drugs (e.g. ezetimibe, bile acid sequestrants or fibrates) should be considered.", "spo_list": [{"subject": "ezetimibe", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "LDL", "object_type": "GENE-N"}, {"subject": "bile acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "LDL", "object_type": "GENE-N"}, {"subject": "fibrates", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "LDL", "object_type": "GENE-N"}]}
{"text": "Tamsulosin: assessment of affinityof (3)H-P razosin binding to two alpha-1- adrenoceptor subtypes in the canine aorta.", "spo_list": [{"subject": "(3)H-P razosin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha-1- adrenoceptor", "object_type": "GENE-N"}]}
{"text": "The pKi value of tamsulosin for the alpha(1B)-subtype in the canine aorta was similar to that of prazosin.", "spo_list": [{"subject": "tamsulosin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha(1B)", "object_type": "GENE-Y"}, {"subject": "prazosin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha(1B)", "object_type": "GENE-Y"}]}
{"text": "Thus, although the affinity of tamsulosin to the alpha(1B)-AR subtype in the canine aorta was as high as that in the bovine prostate reported in our previous study, the affinity (pKi 7.", "spo_list": [{"subject": "tamsulosin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha(1B)-AR", "object_type": "GENE-Y"}]}
{"text": "In contrast, in the presence of Ca UFH accelerated the inhibition of factor Xa by antithrombin 10-fold more efficiently than comparable concentrations of the high affinity fractions of enoxaparin and fragmin.", "spo_list": [{"subject": "Ca", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "factor Xa", "object_type": "GENE-Y"}, {"subject": "Ca", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "antithrombin", "object_type": "GENE-Y"}]}
{"text": "Protective effect of halothane anesthesia on retinal light damage: inhibition of metabolic rhodopsin regeneration.", "spo_list": [{"subject": "halothane", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "rhodopsin", "object_type": "GENE-N"}]}
{"text": "RESULTS: Halothane anesthesia reversibly inhibited metabolic rhodopsin regeneration and thus prevented rhodopsin from absorbing high numbers of photons during light exposure.", "spo_list": [{"subject": "Halothane", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "rhodopsin", "object_type": "GENE-N"}, {"subject": "Halothane", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "rhodopsin", "object_type": "GENE-N"}]}
{"text": "CONCLUSIONS: After the initial bleach, halothane impeded photon absorption by rhodopsin by inhibiting metabolic rhodopsin regeneration.", "spo_list": [{"subject": "halothane", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "rhodopsin", "object_type": "GENE-N"}]}
{"text": "A decrease in ADA activity was observed when the slices were exposed to organoselenium at the concentrations of 1, 10 and 30 ÂµM.", "spo_list": [{"subject": "organoselenium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ADA", "object_type": "GENE-Y"}]}
{"text": "Devazepide and L-365,260 were used to block CCKA and CCK(B) receptors and ondansetron and tropisetron to block 5-HT3 and 5-HT4 receptors, respectively.", "spo_list": [{"subject": "ondansetron", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-HT3", "object_type": "GENE-Y"}, {"subject": "tropisetron", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-HT4", "object_type": "GENE-Y"}]}
{"text": "The CCK receptor antagonists blocked, in a dose-dependent manner, the response to 5-HT and to the selective agonists at 5-HT3 and 5-HT4 receptors, 2-methyl-5-hydroxytryptamine (2-Me-5-HT) and 5-methoxytryptamine (5-MeOT), respectively.", "spo_list": [{"subject": "2-methyl-5-hydroxytryptamine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT3", "object_type": "GENE-Y"}, {"subject": "2-Me-5-HT", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT3", "object_type": "GENE-Y"}, {"subject": "5-methoxytryptamine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT4", "object_type": "GENE-Y"}, {"subject": "5-MeOT", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT4", "object_type": "GENE-Y"}, {"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT3", "object_type": "GENE-Y"}, {"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT4", "object_type": "GENE-Y"}]}
{"text": "In the 2-Me-5-HT-induced contractile response there was a component with the same sensitivity to devazepide and to the selective NK1 receptor antagonist, GR 82334, and another resistant component that was abolished by atropine.", "spo_list": [{"subject": "GR 82334", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NK1", "object_type": "GENE-Y"}]}
{"text": "These results suggest that CCK is involved in the 5-HT-induced contractile response, particularly in the response induced by 5-HT4 receptor stimulation.", "spo_list": [{"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "5-HT4", "object_type": "GENE-Y"}]}
{"text": "In this study, we present the synthesis and pharmacological properties of new analogues of arginine vasopressin modified in the N-terminal part of the molecule with proline derivatives: indoline-2-carboxylic acid (Ica) and (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "arginine vasopressin", "object_type": "GENE-Y"}]}
{"text": "On the other hand, peptides modified with (2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid, apart from their moderate antioxytocic activity, turned out to be weak antagonists of the pressor response to arginine vasopressin.", "spo_list": [{"subject": "(2S,4R)-4-(naphthalene-2-ylmethyl)pyrrolidine-2-carboxylic acid", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "arginine vasopressin", "object_type": "GENE-Y"}]}
{"text": "Mammalian ALDH1B1, another mitochondrial enzyme sharing 72% identity with ALDH2, is also capable of metabolizing acetaldehyde but has a tissue distribution and pattern of activity distinct from that of ALDH2.", "spo_list": [{"subject": "acetaldehyde", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Mammalian ALDH1B1", "object_type": "GENE-Y"}, {"subject": "acetaldehyde", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ALDH2", "object_type": "GENE-Y"}]}
{"text": "Bioinformatic analyses of several vertebrate genomes were undertaken using known ALDH2 and ALDH1B1 amino acid sequences.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ALDH1B1", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ALDH2", "object_type": "GENE-Y"}]}
{"text": "Subsequently, we confirmed these proteins with the Western blotting approach, and found that methylselenol increased the expression of GADD 153 and p21 but reduced the level of c-Myc, E2F1 and Phos p38 MAP kinase.", "spo_list": [{"subject": "methylselenol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GADD 153", "object_type": "GENE-Y"}, {"subject": "methylselenol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p21", "object_type": "GENE-Y"}, {"subject": "methylselenol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "c-Myc", "object_type": "GENE-Y"}, {"subject": "methylselenol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "E2F1", "object_type": "GENE-Y"}, {"subject": "methylselenol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Phos p38", "object_type": "GENE-N"}, {"subject": "methylselenol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MAP kinase", "object_type": "GENE-N"}]}
{"text": "Different VDRAs are known to have differential effects on serum calcium (Ca), which may also affect serum PTH levels since serum Ca regulates PTH secretion mediated by the Ca-sensing receptor (CaSR).", "spo_list": [{"subject": "Ca", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PTH", "object_type": "GENE-Y"}]}
{"text": "Both drugs at the tested doses (0.042-0.33 mug/kg) suppressed PTH mRNA expression and serum PTH effectively in the 5/6 NX rats, but paricalcitol was less potent in raising serum Ca than doxercalciferol.", "spo_list": [{"subject": "paricalcitol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "PTH", "object_type": "GENE-Y"}, {"subject": "doxercalciferol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "PTH", "object_type": "GENE-Y"}]}
{"text": "In pig parathyroid cells, paricalcitol and the active form of doxercalciferol induced VDR translocation from the cytoplasm into the nucleus, suppressed PTH mRNA expression and inhibited cell proliferation in a similar manner, although paricalcitol induced the expression of CaSR mRNA more effectively.", "spo_list": [{"subject": "paricalcitol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "PTH", "object_type": "GENE-Y"}, {"subject": "doxercalciferol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "PTH", "object_type": "GENE-Y"}, {"subject": "paricalcitol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CaSR", "object_type": "GENE-Y"}]}
{"text": "Pretreatment of human breast carcinoma MCF-7 cells for 24 h with the groundnut extract and soybean isoflavone increased gene expression of heme oxygenase-1 (HO-1), a major antioxidative stress enzyme.", "spo_list": [{"subject": "isoflavone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "heme oxygenase-1", "object_type": "GENE-Y"}, {"subject": "isoflavone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HO-1", "object_type": "GENE-Y"}]}
{"text": "IKK phosphorylates BAD at serine-26 (Ser26) and primes it for inactivation.", "spo_list": [{"subject": "serine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "BAD", "object_type": "GENE-Y"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "BAD", "object_type": "GENE-Y"}]}
{"text": "Elimination of Ser26 phosphorylation promotes BAD proapoptotic activity, thereby accelerating TNFÎ±-induced apoptosis in cultured cells and increasing mortality in animals.", "spo_list": [{"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "BAD", "object_type": "GENE-Y"}]}
{"text": "The rate-limiting step of the BH4 synthesis is catalyzed by GTP cyclohydrolase I (GCH).", "spo_list": [{"subject": "BH4", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "GTP cyclohydrolase I", "object_type": "GENE-Y"}, {"subject": "BH4", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "GCH", "object_type": "GENE-Y"}]}
{"text": "Concanavalin A (Con A)-induced IFN-gamma, GM-CSF, and IL-3 mRNAs are dose-dependently inhibited by the nonselective betaAR agonist isoproterenol and by the selective beta2AR agonist fenoterol.", "spo_list": [{"subject": "isoproterenol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "betaAR", "object_type": "GENE-N"}, {"subject": "fenoterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta2AR", "object_type": "GENE-Y"}, {"subject": "isoproterenol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IFN-gamma", "object_type": "GENE-Y"}, {"subject": "isoproterenol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "GM-CSF", "object_type": "GENE-Y"}, {"subject": "isoproterenol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-3", "object_type": "GENE-Y"}, {"subject": "fenoterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IFN-gamma", "object_type": "GENE-Y"}, {"subject": "fenoterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "GM-CSF", "object_type": "GENE-Y"}, {"subject": "fenoterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-3", "object_type": "GENE-Y"}]}
{"text": "The observed inhibition on IFN-gamma, GM-CSF, and IL-3 mRNA was blocked by the selective beta2AR antagonist ICI 118,551 (10(-6) M) and by timolol (10(-6) M), a nonselective antagonist.", "spo_list": [{"subject": "ICI 118,551", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta2AR", "object_type": "GENE-Y"}, {"subject": "timolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta2AR", "object_type": "GENE-Y"}, {"subject": "ICI 118,551", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IFN-gamma", "object_type": "GENE-Y"}, {"subject": "ICI 118,551", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GM-CSF", "object_type": "GENE-Y"}, {"subject": "ICI 118,551", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-3", "object_type": "GENE-Y"}, {"subject": "timolol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IFN-gamma", "object_type": "GENE-Y"}, {"subject": "timolol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GM-CSF", "object_type": "GENE-Y"}, {"subject": "timolol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-3", "object_type": "GENE-Y"}]}
{"text": "The selective beta1AR antagonist atenolol (0.3 x 10(-6) M) did not have any effect.", "spo_list": [{"subject": "atenolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta1AR", "object_type": "GENE-Y"}]}
{"text": "Secretion of GM-CSF protein in the presence of increasing concentrations of isoproterenol followed a similar pattern as observed for GM-CSF mRNA.", "spo_list": [{"subject": "isoproterenol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GM-CSF", "object_type": "GENE-Y"}, {"subject": "isoproterenol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GM-CSF", "object_type": "GENE-Y"}]}
{"text": "Although beta3AR mRNA was detectable in Con A-activated T lymphocytes, we could not demonstrate a functional activity in the regulation of cytokine expression: the beta3AR agonist BRL 37344 had no effect on the accumulation of the studied cytokine mRNAs, and did not significantly affect cellular cAMP levels.", "spo_list": [{"subject": "BRL 37344", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta3AR", "object_type": "GENE-Y"}]}
{"text": "Serum levels of 25-hydroxyvitamin D and the CYP3A biomarker 4Î²-hydroxycholesterol in a high-dose vitamin D supplementation study.", "spo_list": [{"subject": "4Î²-hydroxycholesterol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A", "object_type": "GENE-N"}]}
{"text": "The primary aim was to study the relationship between individual serum levels of 25-hydroxyvitamin D and 4Î²-hydroxycholesterol, which is an endogenous biomarker of the drug-metabolizing CYP3A enzymes.", "spo_list": [{"subject": "4Î²-hydroxycholesterol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A", "object_type": "GENE-N"}]}
{"text": "This study in patients with highly variable serum levels of 25-hydroxyvitamin D could not reveal any relationship between vitamin D and 4Î²-hydroxycholesterol, an endogenous biomarker of CYP3A activity.", "spo_list": [{"subject": "4Î²-hydroxycholesterol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A", "object_type": "GENE-N"}]}
{"text": "Sorafenib (BAY 43-9006) is a small-molecule inhibitor that has been shown to target members of multiple classes of tyrosine kinases that are known to be involved in tumor cell proliferation and tumor angiogenesis.", "spo_list": [{"subject": "Sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinases", "object_type": "GENE-N"}, {"subject": "BAY 43-9006", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinases", "object_type": "GENE-N"}]}
{"text": "Loss of agonist binding was observed on intact human embryonic kidney 293 cells expressing the W203A receptor, conditions where high GTP levels are present; however, high affinity binding [(3)H]PGE(2) was observed in broken cell preparations washed free of GTP.", "spo_list": [{"subject": "[(3)H]PGE(2)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "W203A", "object_type": "GENE-N"}]}
{"text": "The [(3)H]PGE(2) binding of W203A in broken cell membrane fractions was inhibited by addition of GTPÎ³S (IC(50) 21 Â± 1.8 nM).", "spo_list": [{"subject": "[(3)H]PGE(2)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "W203A", "object_type": "GENE-N"}, {"subject": "GTPÎ³S", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "W203A", "object_type": "GENE-N"}]}
{"text": "This suggests that for the mutant receptors, ECII plays a critical role in linking the agonist bound receptor conformation to the G protein nucleotide bound state.", "spo_list": [{"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "G protein", "object_type": "GENE-N"}]}
{"text": "In contrast, TSH-induced differentiation of progenitor cells, in particular the expression of the sodium iodide symporter, was significantly inhibited by 17beta-oestradiol.In conclusion, oestrogen stimulated growth and simultaneously inhibited differentiation of thyroid nodules derived stem/progenitor cells.", "spo_list": [{"subject": "17beta-oestradiol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "sodium iodide symporter", "object_type": "GENE-Y"}]}
{"text": "We herein demonstrate that in addition to non-selective group II mGlu receptor agonists, (2R,4R)-APDC, LY379268 and DCG-IV, a selective mGlu2 agonist, LY541850, and mGlu2 positive allosteric modulators, BINA and CBiPES, inhibit the frequency of synchronised Ca(2+) oscillations in primary cultures of rat and mouse cortical neurons.", "spo_list": [{"subject": "(2R,4R)-APDC", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "group II mGlu receptor", "object_type": "GENE-N"}, {"subject": "LY379268", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "group II mGlu receptor", "object_type": "GENE-N"}, {"subject": "DCG-IV", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "group II mGlu receptor", "object_type": "GENE-N"}, {"subject": "LY541850", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mGlu2", "object_type": "GENE-N"}]}
{"text": "Use of cultures from wild-type, mGlu2(-/-), mGlu3(-/-) and mGlu2/3(-/-) mice allowed us to further probe the contribution of mGlu2 and mGlu3, and revealed LY541850 to be a partial mGlu2 agonist and a full mGlu3 antagonist.", "spo_list": [{"subject": "LY541850", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mGlu2", "object_type": "GENE-Y"}, {"subject": "LY541850", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "mGlu3", "object_type": "GENE-Y"}]}
{"text": "Previous studies demonstrated that the Group III mGlu receptor-selective orthosteric agonist, LSP1-2111 produced anxiolytic- but not antidepressant-like effects upon peripheral administration.", "spo_list": [{"subject": "LSP1-2111", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "Group III mGlu receptor", "object_type": "GENE-N"}]}
{"text": "The anti-hyperthermic effect of Lu AF21934 (5 mg/kg) in the SIH test was inhibited by the benzodiazepine receptor antagonist flumazenil (10 mg/kg) and was not serotonin-dependent, as it persisted in serotonin-deficient mice and upon blockade of either 5-HT(1A) receptors by WAY100635, or 5-HT(2A/2C) receptors by ritanserin.", "spo_list": [{"subject": "flumazenil", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "benzodiazepine receptor", "object_type": "GENE-Y"}, {"subject": "WAY100635", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-HT(1A)", "object_type": "GENE-Y"}, {"subject": "ritanserin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-HT(2A/2C)", "object_type": "GENE-N"}]}
{"text": "PURPOSE: Beta-2 adrenoceptor antagonists such as timolol have been used in the treatment of glaucoma for more than 30 years.", "spo_list": [{"subject": "timolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "Beta-2 adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Etorphine, a potent opioid agonist, has been reported to bind to both mu and epsilon opioid receptors.", "spo_list": [{"subject": "Etorphine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "opioid", "object_type": "GENE-N"}, {"subject": "Etorphine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mu", "object_type": "GENE-Y"}, {"subject": "Etorphine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "epsilon opioid receptors", "object_type": "GENE-N"}]}
{"text": "Morphine, a typical mu opioid receptor agonist, and beta-endorphin, an epsilon opioid receptor agonist, were used for comparison.", "spo_list": [{"subject": "Morphine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mu opioid receptor", "object_type": "GENE-Y"}]}
{"text": "Inhibition of binding of both plasminogen and plasmin to gp330 by benzamidine was similar, although EACA inhibited the binding of plasmin to gp330 slightly more than the binding of plasminogen to gp330.", "spo_list": [{"subject": "benzamidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "plasminogen", "object_type": "GENE-Y"}, {"subject": "benzamidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "plasmin", "object_type": "GENE-Y"}, {"subject": "benzamidine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "gp330", "object_type": "GENE-Y"}, {"subject": "EACA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "plasmin", "object_type": "GENE-Y"}, {"subject": "EACA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "gp330", "object_type": "GENE-Y"}, {"subject": "EACA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "plasminogen", "object_type": "GENE-Y"}, {"subject": "EACA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "gp330", "object_type": "GENE-Y"}]}
{"text": "Mitochondria appear to have a Ca2+-inhibited phosphatase, which dephosphorylates the 18-kDa phosphoprotein.", "spo_list": [{"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphatase", "object_type": "GENE-N"}]}
{"text": "Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.", "spo_list": [{"subject": "Sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RAF", "object_type": "GENE-N"}, {"subject": "BAY 43-9006", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RAF", "object_type": "GENE-N"}, {"subject": "Nexavar", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RAF", "object_type": "GENE-N"}, {"subject": "Sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MEK", "object_type": "GENE-N"}, {"subject": "BAY 43-9006", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MEK", "object_type": "GENE-N"}, {"subject": "Nexavar", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MEK", "object_type": "GENE-N"}, {"subject": "Sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ERK", "object_type": "GENE-N"}, {"subject": "BAY 43-9006", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ERK", "object_type": "GENE-N"}, {"subject": "Nexavar", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ERK", "object_type": "GENE-N"}, {"subject": "Sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinases", "object_type": "GENE-N"}, {"subject": "Sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR", "object_type": "GENE-N"}, {"subject": "Sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDGFR", "object_type": "GENE-N"}, {"subject": "BAY 43-9006", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinases", "object_type": "GENE-N"}, {"subject": "BAY 43-9006", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR", "object_type": "GENE-N"}, {"subject": "BAY 43-9006", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDGFR", "object_type": "GENE-N"}, {"subject": "Nexavar", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinases", "object_type": "GENE-N"}, {"subject": "Nexavar", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR", "object_type": "GENE-N"}, {"subject": "Nexavar", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDGFR", "object_type": "GENE-N"}]}
{"text": "A novel class of biaryl urea that inhibits C-RAF kinase was discovered using a combination of medicinal and combinatorial chemistry approaches.", "spo_list": [{"subject": "biaryl urea", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "C-RAF", "object_type": "GENE-Y"}, {"subject": "biaryl urea", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}]}
{"text": "Sorafenib inhibited the kinase activity of both C-RAF and B-RAF (wild type and V600E mutant).", "spo_list": [{"subject": "Sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "Sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "C-RAF", "object_type": "GENE-Y"}, {"subject": "Sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "B-RAF", "object_type": "GENE-Y"}, {"subject": "Sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "V600E", "object_type": "GENE-N"}]}
{"text": "Further characterization of sorafenib revealed that this molecule was a multikinase inhibitor that targeted the vascular endothelial growth factor receptor family (VEGFR-2 and VEGFR-3) and platelet-derived growth factor receptor family (PDGFR-beta and Kit), which play key roles in tumor progression and angiogenesis.", "spo_list": [{"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "vascular endothelial growth factor receptor", "object_type": "GENE-N"}, {"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR-2", "object_type": "GENE-Y"}, {"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR-3", "object_type": "GENE-Y"}, {"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "platelet-derived growth factor receptor", "object_type": "GENE-N"}, {"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDGFR-beta", "object_type": "GENE-Y"}, {"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Kit", "object_type": "GENE-Y"}]}
{"text": "Thus, sorafenib may inhibit tumor growth by a dual mechanism, acting either directly on the tumor (through inhibition of Raf and Kit signaling) and/or on tumor angiogenesis (through inhibition of VEGFR and PDGFR signaling).", "spo_list": [{"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Raf", "object_type": "GENE-N"}, {"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Kit", "object_type": "GENE-Y"}, {"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "VEGFR", "object_type": "GENE-N"}, {"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "PDGFR", "object_type": "GENE-N"}]}
{"text": "However, cloxacillin, cyclosporin A and midecamycin inhibited BSEP, and cyclosporin A and midecamycin inhibited MRP2 with an inhibition constant close to the clinical concentration.", "spo_list": [{"subject": "cloxacillin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BSEP", "object_type": "GENE-Y"}, {"subject": "cyclosporin A", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BSEP", "object_type": "GENE-Y"}, {"subject": "midecamycin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BSEP", "object_type": "GENE-Y"}, {"subject": "cyclosporin A", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MRP2", "object_type": "GENE-Y"}, {"subject": "midecamycin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MRP2", "object_type": "GENE-Y"}]}
{"text": "By comparing the inhibition potential between rat and human CMVs, the inhibition of BSEP- and MRP2-mediated transport by midecamycin and cyclosporin A was relatively similar whereas the inhibitory effect on BSEP-mediated transport by cloxacillin and glibenclamide was more marked in humans than in rats.", "spo_list": [{"subject": "midecamycin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BSEP", "object_type": "GENE-N"}, {"subject": "midecamycin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MRP2", "object_type": "GENE-N"}, {"subject": "cyclosporin A", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BSEP", "object_type": "GENE-N"}, {"subject": "cyclosporin A", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MRP2", "object_type": "GENE-N"}, {"subject": "cloxacillin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BSEP", "object_type": "GENE-N"}, {"subject": "glibenclamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BSEP", "object_type": "GENE-N"}]}
{"text": "An Arg/Ser substitution in the second epidermal growth factor-like module of factor IX introduces an O-linked carbohydrate and markedly impairs activation by factor XIa and factor VIIa/Tissue factor and catalytic efficiency of factor IXa.", "spo_list": [{"subject": "Arg", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "epidermal growth factor-like module", "object_type": "GENE-N"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "epidermal growth factor-like module", "object_type": "GENE-N"}, {"subject": "Arg", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "factor IX", "object_type": "GENE-Y"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "factor IX", "object_type": "GENE-Y"}]}
{"text": "Factor IXR94S is a naturally occurring hemophilia B defect, which results from an Arg 94 to Ser mutation in the second epidermal growth factor (EGF)-like module of factor IX.", "spo_list": [{"subject": "Arg", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "epidermal growth factor (EGF)-like module", "object_type": "GENE-N"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "epidermal growth factor (EGF)-like module", "object_type": "GENE-N"}, {"subject": "Arg", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "factor IX", "object_type": "GENE-Y"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "factor IX", "object_type": "GENE-Y"}]}
{"text": "Recombinant factor IXR94S was activated by factor XIa/calcium with an approximately 50-fold reduced rate and by factor VIIa/tissue factor/phospholipid/calcium with an approximately 20-fold reduced rate compared with wild-type factor IX.", "spo_list": [{"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "factor IX", "object_type": "GENE-Y"}, {"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "R94S", "object_type": "GENE-N"}, {"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "factor IX", "object_type": "GENE-Y"}, {"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "R94S", "object_type": "GENE-N"}]}
{"text": "The initial rate of activation of factor X by factor IXaR94S in the presence of polylysine was 7% +/- 1% of the initial rate of activation of factor X by plasma factor IXa, and the kc/Km for activation of factor X by factor IXaR94S/factor VIIIa/phospholipid/calcium was 4% +/- 1% of the kc/Km for activation of factor X by plasma factor IXa/factor VIIIa/phospholipid/calcium.", "spo_list": [{"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "factor X", "object_type": "GENE-Y"}, {"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "factor X", "object_type": "GENE-Y"}]}
{"text": "In utero exposure to valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, causes neural tube, heart, and limb defects.", "spo_list": [{"subject": "valproic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "histone deacetylase", "object_type": "GENE-N"}, {"subject": "VPA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "histone deacetylase", "object_type": "GENE-N"}, {"subject": "valproic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC", "object_type": "GENE-N"}, {"subject": "VPA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC", "object_type": "GENE-N"}]}
{"text": "VPA caused a significant concentration- dependent increase in limb abnormalities, which was correlated with its HDAC inhibitory effect.", "spo_list": [{"subject": "VPA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC", "object_type": "GENE-N"}]}
{"text": "The signaling of both Sox9 and Runx2, key regulators of chondrogenesis, was downregulated by VPA.", "spo_list": [{"subject": "VPA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Sox9", "object_type": "GENE-Y"}, {"subject": "VPA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Runx2", "object_type": "GENE-Y"}]}
{"text": "SSTR2 and SSTR5 are usually expressed in GH-secreting pituitary tumors, and both octreotide and lanreotide bind preferentially to SSTR2 and, to a lesser extent, to SSTR5.", "spo_list": [{"subject": "octreotide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SSTR2", "object_type": "GENE-Y"}, {"subject": "lanreotide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SSTR2", "object_type": "GENE-Y"}, {"subject": "octreotide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SSTR5", "object_type": "GENE-Y"}, {"subject": "lanreotide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SSTR5", "object_type": "GENE-Y"}]}
{"text": "The obtained results showed that Cd increased lipid peroxidation and abnormal sperm count and decreased plasma testosterone, lactate dehydrogenase, acid phosphatase, alkaline phosphatase and testicular steroidogenic enzymes: 3Î²-hydroxysteroid dehydrogenase (HSD), 17Î²-HSD activities as well as epididymal sperm counts and motility, while RUT and Se treatment reversed this change to control values.", "spo_list": [{"subject": "Cd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "lactate dehydrogenase", "object_type": "GENE-N"}, {"subject": "Cd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acid phosphatase", "object_type": "GENE-N"}, {"subject": "Cd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "alkaline phosphatase", "object_type": "GENE-N"}, {"subject": "Cd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "testicular steroidogenic enzymes", "object_type": "GENE-N"}, {"subject": "Cd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "3Î²-hydroxysteroid dehydrogenase", "object_type": "GENE-N"}, {"subject": "Cd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HSD", "object_type": "GENE-N"}, {"subject": "Cd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "17Î²-HSD", "object_type": "GENE-N"}]}
{"text": "Acute intoxication with Cd was also followed by significantly decreased activity of the antioxidant defence system (superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GSH-Px), glutathione reductase (GR), glutathione (GSH), and glutathione-S-transferase (GST)).", "spo_list": [{"subject": "Cd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "superoxide dismutase", "object_type": "GENE-N"}, {"subject": "Cd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SOD", "object_type": "GENE-N"}, {"subject": "Cd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "catalase", "object_type": "GENE-Y"}, {"subject": "Cd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CAT", "object_type": "GENE-Y"}, {"subject": "Cd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "glutathione peroxidase", "object_type": "GENE-N"}, {"subject": "Cd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GSH-Px", "object_type": "GENE-N"}, {"subject": "Cd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "glutathione reductase", "object_type": "GENE-Y"}, {"subject": "Cd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GR", "object_type": "GENE-Y"}, {"subject": "Cd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "glutathione-S-transferase", "object_type": "GENE-N"}, {"subject": "Cd", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GST", "object_type": "GENE-N"}]}
{"text": "POR supported CYP19A1 activity with a calculated Km of 126 nm for androstenedione and a Vmax of 1.7 pmol/min.", "spo_list": [{"subject": "androstenedione", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP19A1", "object_type": "GENE-Y"}, {"subject": "androstenedione", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "POR", "object_type": "GENE-Y"}]}
{"text": "Synthesis and Structure-Activity Relationship Studies of Derivatives of the Dual Aromatase-Sulfatase Inhibitor 4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate.", "spo_list": [{"subject": "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Aromatase", "object_type": "GENE-Y"}, {"subject": "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Sulfatase", "object_type": "GENE-Y"}]}
{"text": "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate and its ortho-halogenated (F, Cl, Br) derivatives are first-generation dual aromatase and sulfatase inhibitors (DASIs).", "spo_list": [{"subject": "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "F", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "Cl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "Br", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "4-{[(4-Cyanophenyl)(4H-1,2,4-triazol-4-yl)amino]methyl}phenyl sulfamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "sulfatase", "object_type": "GENE-Y"}, {"subject": "F", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "sulfatase", "object_type": "GENE-Y"}, {"subject": "Cl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "sulfatase", "object_type": "GENE-Y"}, {"subject": "Br", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "sulfatase", "object_type": "GENE-Y"}]}
{"text": "The most potent inâvitro DASI discovered is an imidazole derivative with IC50 values against aromatase and steroid sulfatase in a JEG-3 cell preparation of 0.2 and 2.5ânM, respectively.", "spo_list": [{"subject": "imidazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "imidazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "steroid sulfatase", "object_type": "GENE-Y"}]}
{"text": "The parent phenol of this compound inhibits aromatase with an IC50 value of 0.028ânM in the same assay.", "spo_list": [{"subject": "phenol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis.", "spo_list": [{"subject": "etodolac", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "retinoid X receptor", "object_type": "GENE-N"}]}
{"text": "R-etodolac specifically bound recombinant RXRalpha, inhibited RXRalpha transcriptional activity, and induced its degradation by a ubiquitin and proteasome-dependent pathway.", "spo_list": [{"subject": "R-etodolac", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RXRalpha", "object_type": "GENE-Y"}, {"subject": "R-etodolac", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RXRalpha", "object_type": "GENE-Y"}]}
{"text": "Consistent with these locations, N-ethylmaleimide, an inhibitor of ACS4, inhibited ACS activity 47% in MAM and 28% in endoplasmic reticulum.", "spo_list": [{"subject": "N-ethylmaleimide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACS4", "object_type": "GENE-Y"}, {"subject": "N-ethylmaleimide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACS", "object_type": "GENE-N"}]}
{"text": "Troglitazone, a second ACS4 inhibitor, inhibited ACS activity <10% in microsomes and mitochondria and 45% in MAM.", "spo_list": [{"subject": "Troglitazone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACS4", "object_type": "GENE-Y"}, {"subject": "Troglitazone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACS", "object_type": "GENE-N"}]}
{"text": "Triacsin C, a competitive inhibitor of both ACS1 and ACS4, inhibited ACS activity similarly in endoplasmic reticulum, MAM, and mitochondria, suggesting that a hitherto unidentified triacsin-sensitive ACS is present in mitochondria.", "spo_list": [{"subject": "Triacsin C", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACS1", "object_type": "GENE-Y"}, {"subject": "Triacsin C", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACS4", "object_type": "GENE-Y"}, {"subject": "Triacsin C", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACS", "object_type": "GENE-N"}]}
{"text": "Re-feeding normal chow or a high sucrose diet for 24 h after a 48-h fast increased both ACS1 and ACS4 protein expression 1.5-2.0-fold, consistent with inhibition studies.", "spo_list": [{"subject": "sucrose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ACS1", "object_type": "GENE-Y"}, {"subject": "sucrose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ACS4", "object_type": "GENE-Y"}]}
{"text": "These results suggest that ACS1 and ACS4 may be linked to triacylglycerol synthesis.", "spo_list": [{"subject": "triacylglycerol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ACS1", "object_type": "GENE-Y"}, {"subject": "triacylglycerol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ACS4", "object_type": "GENE-Y"}]}
{"text": "Although inhibition of LH release can be achieved by estrogen and progestins, an optimal inhibitory effect on the prostate is obtained by the combined administration of the antiandrogen with an LHRH agonist that causes a specific blockage of testicular androgen biosynthesis as well as an inhibition of the LH responsiveness to LHRH.", "spo_list": [{"subject": "estrogen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "LH", "object_type": "GENE-N"}, {"subject": "progestins", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "LH", "object_type": "GENE-N"}]}
{"text": "The results show that (1) smaller diameter TG neurons (<30 microm) respond to L-glutamate and kainate, and the currents gated by kainate desensitize with prolonged agonist exposure; (2) all kainate receptor subunits are detected to some extent by reverse transcriptase-PCR, whereas glutamate receptor subunits GluR5 and KA-2 are expressed at high levels in the TG; (3) there is an obvious similarity between the features of native kainate receptor channels in TG neurons and of heteromeric recombinant GluR5(R)/KA-2 channels in pharmacological properties, desensitization, rectification, ion permeability, and mean channel conductance; and (4) the age-dependent increase in GluR5 and KA-2 RNA levels in the TG is correlated well with an increased number of kainate-sensitive cells during postnatal development.", "spo_list": [{"subject": "kainate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GluR5", "object_type": "GENE-Y"}, {"subject": "kainate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "KA-2", "object_type": "GENE-Y"}]}
{"text": "Tadalafil is an inhibitor of phosphodiesterase type 5, and is currently undergoing regulatory review in the US and in Europe.", "spo_list": [{"subject": "Tadalafil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase type 5", "object_type": "GENE-Y"}]}
{"text": "Engineered monomeric human histidine triad nucleotide-binding protein 1 hydrolyzes fluorogenic acyl-adenylate and lysyl-tRNA synthetase-generated lysyl-adenylate.", "spo_list": [{"subject": "acyl", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human histidine triad nucleotide-binding protein 1", "object_type": "GENE-Y"}, {"subject": "adenylate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human histidine triad nucleotide-binding protein 1", "object_type": "GENE-Y"}, {"subject": "lysyl", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "lysyl-tRNA synthetase", "object_type": "GENE-Y"}, {"subject": "adenylate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "lysyl-tRNA synthetase", "object_type": "GENE-Y"}]}
{"text": "Hint1 catalyzes the hydrolysis of purine phosphoramidates and lysyl-adenylate generated by lysyl-tRNA synthetase (LysRS).", "spo_list": [{"subject": "purine phosphoramidates", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Hint1", "object_type": "GENE-Y"}, {"subject": "lysyl", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "lysyl-tRNA synthetase", "object_type": "GENE-Y"}, {"subject": "adenylate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "lysyl-tRNA synthetase", "object_type": "GENE-Y"}, {"subject": "lysyl", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "LysRS", "object_type": "GENE-Y"}, {"subject": "adenylate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "LysRS", "object_type": "GENE-Y"}, {"subject": "lysyl", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Hint1", "object_type": "GENE-Y"}, {"subject": "adenylate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Hint1", "object_type": "GENE-Y"}]}
{"text": "To determine the importance of homodimerization on the biological and catalytic activity of Hint1, the dimer interface of human Hint1 (hHint1) was destabilized by replacement of Val(97) of hHint1 with Asp, Glu, or Arg.", "spo_list": [{"subject": "Asp", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "hHint1", "object_type": "GENE-Y"}, {"subject": "Glu", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "hHint1", "object_type": "GENE-Y"}, {"subject": "Arg", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "hHint1", "object_type": "GENE-Y"}]}
{"text": "Relative to wild-type and the V97E mutant, however, significant perturbation of the V97D mutant structure was observed. hHint1 was shown to prefer 3-indolepropionic acyl-adenylate (AIPA) over tryptamine adenosine phosphoramidate monoester (TpAd).", "spo_list": [{"subject": "3-indolepropionic acyl-adenylate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hHint1", "object_type": "GENE-Y"}, {"subject": "AIPA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hHint1", "object_type": "GENE-Y"}]}
{"text": "Adenylation of wild-type, V97D, and V97E hHint1 by human LysRS was shown to correlate with the mutant k(cat)/K(m) values using 3-indolepropionic acyl-adenylate as a substrate, but not tryptamine adenosine phosphoramidate monoester.", "spo_list": [{"subject": "3-indolepropionic acyl-adenylate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "V97D", "object_type": "GENE-N"}, {"subject": "3-indolepropionic acyl-adenylate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "V97E", "object_type": "GENE-N"}, {"subject": "3-indolepropionic acyl-adenylate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hHint1", "object_type": "GENE-Y"}]}
{"text": "Taken together, these results demonstrate that for hHint1; 1) the efficiency (k(cat)/K(m)) of acylated AMP hydrolysis, but not maximal catalytic turnover (k(cat)), is dependent on homodimerization and 2) the hydrolysis of lysyl-AMP generated by LysRS is not dependent on homodimerization if the monomer structure is similar to the wild-type structure.", "spo_list": [{"subject": "lysyl-AMP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "LysRS", "object_type": "GENE-Y"}, {"subject": "lysyl-AMP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hHint1", "object_type": "GENE-Y"}]}
{"text": "Synthesis and biological evaluation of analogues of the kinase inhibitor nilotinib as Abl and Kit inhibitors.", "spo_list": [{"subject": "nilotinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "nilotinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Abl", "object_type": "GENE-Y"}, {"subject": "nilotinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Kit", "object_type": "GENE-Y"}]}
{"text": "While these analogues were less active than nilotinib toward Abl, their activity toward Kit was comparable, with the monofluorinated analogue being the most active.", "spo_list": [{"subject": "nilotinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Abl", "object_type": "GENE-Y"}, {"subject": "nilotinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Kit", "object_type": "GENE-Y"}]}
{"text": "Docking of nilotinib and of analogues 2a-c to the binding pocket of Abl and of Kit showed that the lack of shape complementarity in Kit is compensated by the stabilizing effect from its juxtamembrane region.", "spo_list": [{"subject": "nilotinib", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Abl", "object_type": "GENE-Y"}, {"subject": "nilotinib", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Kit", "object_type": "GENE-Y"}, {"subject": "nilotinib", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Kit", "object_type": "GENE-Y"}]}
{"text": "Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4).", "spo_list": [{"subject": "moexipril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cAMP phosphodiesterase-4", "object_type": "GENE-N"}, {"subject": "moexipril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}]}
{"text": "PDE4 is one of eleven known cyclic nucleotide phosphodiesterase families and plays a pivotal role in mediating hydrolytic degradation of the important cyclic nucleotide second messenger, cyclic 3'5' adenosine monophosphate (cAMP).", "spo_list": [{"subject": "cyclic 3'5' adenosine monophosphate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PDE4", "object_type": "GENE-N"}, {"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PDE4", "object_type": "GENE-N"}]}
{"text": "With this objective, we utilised a high-throughput computational approach that identified moexipril, a well tolerated and safe angiotensin-converting enzyme (ACE) inhibitor, as a PDE4 inhibitor.", "spo_list": [{"subject": "moexipril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "angiotensin-converting enzyme", "object_type": "GENE-Y"}, {"subject": "moexipril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACE", "object_type": "GENE-Y"}, {"subject": "moexipril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}]}
{"text": "Experimentally we showed that moexipril and two structurally related analogues acted in the micro molar range to inhibit PDE4 activity.", "spo_list": [{"subject": "moexipril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}]}
{"text": "Finally, we demonstrated that the PDE4 inhibitory effect of moexipril is functionally able to induce phosphorylation of the small heat shock protein, Hsp20, by cAMP dependent protein kinase A. Our data suggest that moexipril is a bona fide PDE4 inhibitor that may provide the starting point for development of novel PDE4 inhibitors with an improved therapeutic window.", "spo_list": [{"subject": "moexipril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}, {"subject": "moexipril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}, {"subject": "moexipril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}]}
{"text": "Role of endogenous endothelin in myocardial and coronary endothelial injury after ischaemia and reperfusion in rats: studies with bosentan, a mixed ETA-ETB antagonist.", "spo_list": [{"subject": "bosentan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ETA", "object_type": "GENE-Y"}, {"subject": "bosentan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ETB", "object_type": "GENE-Y"}]}
{"text": "This study was designed to test the effect of a new nonpeptide antagonist of endothelin ETA and ETB receptors, bosentan, on myocardial infarct size, ventricular arrhythmias, and coronary endothelial dysfunction after ischaemia and reperfusion.", "spo_list": [{"subject": "bosentan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ETA", "object_type": "GENE-Y"}, {"subject": "bosentan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ETB", "object_type": "GENE-Y"}]}
{"text": "Removal of Pro128 from the hepatic SDH consisting of 328 residues, which is missing in the corresponding position of the isoform consisting of 329 residues, significantly changed the Michaelis constants and Kd value for pyridoxal 5'-phosphate, whereas addition of a proline residue to the isoform was without effect.", "spo_list": [{"subject": "proline", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "SDH", "object_type": "GENE-Y"}]}
{"text": "Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons.", "spo_list": [{"subject": "topiramate", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "GluR5", "object_type": "GENE-Y"}, {"subject": "topiramate", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "kainate-receptor", "object_type": "GENE-N"}]}
{"text": "In whole-cell voltage-clamp recordings from principal neurons of the rat basolateral amygdala, topiramate at low concentrations (IC50, approximately 0.5 microm) selectively inhibited pharmacologically isolated excitatory synaptic currents mediated by kainate receptors containing the GluR5 subunit.", "spo_list": [{"subject": "topiramate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "kainate receptors", "object_type": "GENE-N"}, {"subject": "topiramate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "GluR5", "object_type": "GENE-Y"}]}
{"text": "Topiramate also partially depressed predominantly AMPA-receptor-mediated EPSCs, but with lower efficacy.", "spo_list": [{"subject": "Topiramate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "AMPA-receptor", "object_type": "GENE-N"}]}
{"text": "Inhibition of GluR5 kainate receptors could represent a key mechanism underlying the anticonvulsant activity of topiramate.", "spo_list": [{"subject": "topiramate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GluR5", "object_type": "GENE-Y"}, {"subject": "topiramate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kainate receptors", "object_type": "GENE-N"}]}
{"text": "The fragment indole-6-carboxylic acid (1F1), previously identified as a flap site binder in a fragment-based screen against HIV protease (PR), has been cocrystallized with pepstatin-inhibited PR and with apo-PR.", "spo_list": [{"subject": "pepstatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PR", "object_type": "GENE-N"}, {"subject": "indole-6-carboxylic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PR", "object_type": "GENE-N"}, {"subject": "indole-6-carboxylic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "HIV protease", "object_type": "GENE-N"}, {"subject": "indole-6-carboxylic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PR", "object_type": "GENE-N"}, {"subject": "indole-6-carboxylic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PR", "object_type": "GENE-N"}]}
{"text": "Both 1F1 and 1F1-N bind to the closed form of apo-PR and to pepstatin:PR.", "spo_list": [{"subject": "pepstatin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PR", "object_type": "GENE-N"}]}
{"text": "In solution, 1F1 and 1F1-N raise the Tm of apo-PR by 3.5-5 Â°C as assayed by differential scanning fluorimetry (DSF) and show equivalent low-micromolar binding constants to both apo-PR and pepstatin:PR, assayed by backscattering interferometry (BSI).", "spo_list": [{"subject": "pepstatin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PR", "object_type": "GENE-N"}]}
{"text": "The observed signal intensities in BSI are greater for each fragment upon binding to apo-PR than to pepstatin-bound PR, consistent with greater conformational change in the former binding event.", "spo_list": [{"subject": "pepstatin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PR", "object_type": "GENE-N"}]}
{"text": "1) The primary action of budipine is an indirect dopaminergic effect as shown by facilitation of dopamine (DA) release, inhibition of monoamine oxidase type B (MAO-B) and of DA (re) up-take and stimulation of aromatic L-amino acid decarboxylase (AADC), which in sum might be responsible for enhancing the endogenous dopaminergic activity.", "spo_list": [{"subject": "budipine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase type B", "object_type": "GENE-Y"}, {"subject": "budipine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "budipine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "aromatic L-amino acid decarboxylase", "object_type": "GENE-Y"}, {"subject": "budipine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AADC", "object_type": "GENE-Y"}, {"subject": "budipine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "aromatic L-amino acid decarboxylase", "object_type": "GENE-Y"}, {"subject": "budipine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AADC", "object_type": "GENE-Y"}]}
{"text": "2) Radioligand and functional studies at the N-methyl-D-aspartate (NMDA) type glutamate receptor characterize budipine as a low-affinity, uncompetitive antagonist with fast kinetics and moderate voltage-dependency at the phencyclidine (PCP) binding site, comparable to that observed with amantadine, thereby counteracting an increased excitatory glutamatergic activity.", "spo_list": [{"subject": "budipine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "N-methyl-D-aspartate (NMDA) type glutamate receptor", "object_type": "GENE-N"}, {"subject": "phencyclidine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "N-methyl-D-aspartate (NMDA) type glutamate receptor", "object_type": "GENE-N"}, {"subject": "PCP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "N-methyl-D-aspartate (NMDA) type glutamate receptor", "object_type": "GENE-N"}, {"subject": "amantadine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "N-methyl-D-aspartate (NMDA) type glutamate receptor", "object_type": "GENE-N"}]}
{"text": "Functional roles of cationic amino acid residues in the sodium-dicarboxylate cotransporter 3 (NaDC-3) from winter flounder.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "sodium-dicarboxylate cotransporter 3", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "NaDC-3", "object_type": "GENE-Y"}]}
{"text": "In the present study, we determined the functional role of 15 positively charged amino acid residues at or within 1 of the predicted 11 transmembrane helixes of the flounder renal sodium-dicarboxylate cotransporter fNaDC-3.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "flounder renal sodium-dicarboxylate cotransporter", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "fNaDC-3", "object_type": "GENE-Y"}]}
{"text": "Using site-directed mutagenesis, histidine (H), lysine (K), and arginine (R) residues of fNaDC-3 were replaced by alanine (A), isoleucine (I), or leucine (L).", "spo_list": [{"subject": "histidine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "fNaDC-3", "object_type": "GENE-Y"}, {"subject": "H", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "fNaDC-3", "object_type": "GENE-Y"}, {"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "fNaDC-3", "object_type": "GENE-Y"}, {"subject": "K", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "fNaDC-3", "object_type": "GENE-Y"}, {"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "fNaDC-3", "object_type": "GENE-Y"}, {"subject": "alanine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "fNaDC-3", "object_type": "GENE-Y"}, {"subject": "A", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "fNaDC-3", "object_type": "GENE-Y"}, {"subject": "isoleucine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "fNaDC-3", "object_type": "GENE-Y"}, {"subject": "I", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "fNaDC-3", "object_type": "GENE-Y"}, {"subject": "leucine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "fNaDC-3", "object_type": "GENE-Y"}, {"subject": "L", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "fNaDC-3", "object_type": "GENE-Y"}]}
{"text": "Most mutants showed sodium-dependent, lithium-inhibitable [14C]succinate uptake and, in two-electrode voltage-clamp (TEVC) experiments, Km and DeltaI(max) values comparable to wild-type (WT) fNaDC-3.", "spo_list": [{"subject": "14C", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "fNaDC-3", "object_type": "GENE-Y"}]}
{"text": "The replacement of R109 and R110 by alanine and isoleucine (RR109/110AI) prevented the expression of fNaDC-3 at the plasma membrane.", "spo_list": [{"subject": "alanine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "RR109/110AI", "object_type": "GENE-N"}, {"subject": "isoleucine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "RR109/110AI", "object_type": "GENE-N"}, {"subject": "alanine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "fNaDC-3", "object_type": "GENE-Y"}, {"subject": "isoleucine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "fNaDC-3", "object_type": "GENE-Y"}]}
{"text": "When the lysines at positions 232 and 235 were replaced by isoleucine (KK232/235II), the transporter was expressed but showed small transport rates and succinate-induced currents.", "spo_list": [{"subject": "lysines", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "KK232/235II", "object_type": "GENE-N"}]}
{"text": "K114I, located within transmembrane helix 4, showed [14C]succinate uptake similar to WT but relatively small inward currents.", "spo_list": [{"subject": "[14C]succinate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "K114I", "object_type": "GENE-N"}, {"subject": "[14C]succinate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "transmembrane helix 4", "object_type": "GENE-N"}]}
{"text": "In [14C]succinate uptake and TEVC experiments performed simultaneously on the same oocytes, uptake was similar to or higher than WT, whereas succinate-induced currents were either comparable (K114R) to, or considerably smaller (K114E, K114I, K114Q) than, those evoked by WT.", "spo_list": [{"subject": "[14C]succinate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "K114R", "object_type": "GENE-N"}, {"subject": "[14C]succinate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "K114E", "object_type": "GENE-N"}, {"subject": "[14C]succinate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "K114I", "object_type": "GENE-N"}, {"subject": "[14C]succinate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "K114Q", "object_type": "GENE-N"}]}
{"text": "Whole-exome analysis of the Pik3ca(H1047R)-driven mammary tumors identified multiple mutations, including Trp53 mutations that appeared spontaneously during the development of adenocarinoma and spindle cell tumors.", "spo_list": [{"subject": "Trp", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Pik3ca", "object_type": "GENE-Y"}, {"subject": "Trp", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "H1047R", "object_type": "GENE-N"}]}
{"text": "Further, we used this model to test the efficacy of GDC-0941, a PI3K inhibitor, in clinical development, and showed that the tumors respond to PI3K inhibition.", "spo_list": [{"subject": "GDC-0941", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PI3K", "object_type": "GENE-N"}, {"subject": "GDC-0941", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PI3K", "object_type": "GENE-N"}]}
{"text": "The fatty acid amide hydrolase inhibitor, URB597, promotes retinal ganglion cell neuroprotection in a rat model of optic nerve axotomy.", "spo_list": [{"subject": "URB597", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "fatty acid amide hydrolase", "object_type": "GENE-Y"}]}
{"text": "The endocannabinoid, N-arachidonoylethanolamine (AEA), is degraded by the enzyme fatty acid amide hydrolase (FAAH).", "spo_list": [{"subject": "N-arachidonoylethanolamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "fatty acid amide hydrolase", "object_type": "GENE-Y"}, {"subject": "AEA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "fatty acid amide hydrolase", "object_type": "GENE-Y"}, {"subject": "N-arachidonoylethanolamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FAAH", "object_type": "GENE-Y"}, {"subject": "AEA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FAAH", "object_type": "GENE-Y"}]}
{"text": "The CB1 antagonist, AM281, but not the CB2 antagonist, AM630, ablated URB597-mediated RGC neuroprotection.", "spo_list": [{"subject": "AM281", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CB1", "object_type": "GENE-Y"}, {"subject": "AM630", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CB2", "object_type": "GENE-Y"}]}
{"text": "Retinal Iba-1 positive microglia were also decreased in URB597-treated axotomized young animals and this decrease was mitigated by CB1 but not CB2 antagonism.", "spo_list": [{"subject": "URB597", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Iba-1", "object_type": "GENE-Y"}]}
{"text": "As seen with phagocytotic microglia, the CB2 antagonist, AM630, increased Iba-1 positive microglia in the absence of URB597 treatment.", "spo_list": [{"subject": "AM630", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CB2", "object_type": "GENE-Y"}, {"subject": "AM630", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Iba-1", "object_type": "GENE-Y"}]}
{"text": "The data produced has highlighted that the atypical profile of APD such as olanzapine and clozapine may reflect antagonism of the 5-HT(2A) and 5-HT(2C) receptors, whilst that of, ziprasidone and quetiapine may reflect partial agonist activity at the 5-HT(1A) receptor, and that of aripiprazole may reflect partial agonist activity at the 5-HT(1A) receptor as well as is its claimed partial agonist activity at the dopamine D(2) receptor.", "spo_list": [{"subject": "clozapine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT(2A)", "object_type": "GENE-Y"}, {"subject": "olanzapine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT(2A)", "object_type": "GENE-Y"}, {"subject": "olanzapine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT(2C)", "object_type": "GENE-Y"}, {"subject": "clozapine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT(2C)", "object_type": "GENE-Y"}, {"subject": "ziprasidone", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT(1A)", "object_type": "GENE-Y"}, {"subject": "quetiapine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT(1A)", "object_type": "GENE-Y"}, {"subject": "aripiprazole", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT(1A)", "object_type": "GENE-Y"}, {"subject": "aripiprazole", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "dopamine D(2) receptor", "object_type": "GENE-Y"}]}
{"text": "A high throughput assay for the glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin by recombinant human UDP-glucuronosyltransferases and liver microsomes.", "spo_list": [{"subject": "7-hydroxy-4-trifluoromethylcoumarin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human UDP-glucuronosyltransferases", "object_type": "GENE-N"}]}
{"text": "2. We have developed a convenient quantitative multi-well plate assay to measure the glucuronidation rate of 7-hydroxy-4-trifluoromethylcoumarin (HFC) for several UGTs.", "spo_list": [{"subject": "7-hydroxy-4-trifluoromethylcoumarin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGTs", "object_type": "GENE-N"}, {"subject": "HFC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGTs", "object_type": "GENE-N"}]}
{"text": "3. We have used this method to screen 11 recombinant human UGTs for HFC glucuronidation activity and studied the reaction kinetics with the most active enzymes.", "spo_list": [{"subject": "HFC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human UGTs", "object_type": "GENE-N"}]}
{"text": "4. At a substrate concentration of 20âÂµM, the most active HFC glucuronidation catalysts were UGT1A10 followed by UGT1A6 >UGT1A7 >UGT2A1, whereas at 300âÂµM UGT1A6 was about 10 times better catalyst than the other recombinant UGTs.", "spo_list": [{"subject": "HFC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT1A10", "object_type": "GENE-Y"}, {"subject": "HFC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT1A6", "object_type": "GENE-Y"}, {"subject": "HFC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT1A7", "object_type": "GENE-Y"}, {"subject": "HFC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT2A1", "object_type": "GENE-Y"}, {"subject": "HFC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT1A6", "object_type": "GENE-Y"}, {"subject": "HFC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGTs", "object_type": "GENE-N"}]}
{"text": "UGT1A6 exhibited a significantly higher Vmax and Km values toward both HFC and UDP-glucuronic acid than the other UGTs.", "spo_list": [{"subject": "HFC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT1A6", "object_type": "GENE-Y"}, {"subject": "UDP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT1A6", "object_type": "GENE-Y"}, {"subject": "glucuronic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT1A6", "object_type": "GENE-Y"}, {"subject": "HFC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGTs", "object_type": "GENE-N"}, {"subject": "UDP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGTs", "object_type": "GENE-N"}, {"subject": "glucuronic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGTs", "object_type": "GENE-N"}]}
{"text": "Bile acid gavage (TUDCA/UDCA) in diet-induced obese rats, elevated serum TUDCA and concomitantly reduced hepatic steatosis and ER stress (CHOP mRNA).", "spo_list": [{"subject": "Bile acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CHOP", "object_type": "GENE-Y"}, {"subject": "TUDCA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CHOP", "object_type": "GENE-Y"}, {"subject": "UDCA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CHOP", "object_type": "GENE-Y"}]}
{"text": "BACKGROUND: Sunitinib malate (SUTENT) is an oral, multitargeted tyrosine kinase inhibitor, approved multinationally for the treatment of advanced RCC and of imatinib-resistant or - intolerant GIST.", "spo_list": [{"subject": "Sunitinib malate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "SUTENT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}]}
{"text": "Active site aromatic and acidic residues are involved in binding the Ï-aminoaldehydes in plant ALDH10 enzymes.", "spo_list": [{"subject": "Ï-aminoaldehydes", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "plant ALDH10", "object_type": "GENE-N"}]}
{"text": "In order to ascertain the degree of conservation of these residues among AMADHs and to evaluate their possible relevance in determining the aminoaldehyde specificity, we compared the known amino acid sequences of every ALDH family that have at least one member with known crystal structure, as well as the electrostatic potential surface of the aldehyde binding sites of these structures.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ALDH", "object_type": "GENE-N"}]}
{"text": "Our analyses showed that four or three aromatic residues form a similar \"aromatic box\" in the active site of the AMADH enzymes, being the equivalents to Phe170 and Trp177 (human ALDH2 numbering) strictly conserved in all of them, which supports their relevance in binding the aminoaldehyde by cation-Ï interactions.", "spo_list": [{"subject": "Phe", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "human ALDH2", "object_type": "GENE-Y"}, {"subject": "Trp", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "human ALDH2", "object_type": "GENE-Y"}, {"subject": "aminoaldehyde", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human ALDH2", "object_type": "GENE-Y"}]}
{"text": "Finally, our comparative sequence analyses revealed that the residues equivalent to Asp121 and Phe170 are highly conserved in many ALDH families irrespective of their substrate specificity-suggesting that they perform a role in catalysis additional or different to binding of the substrate-and that the positions Met124, Cys301, and Cys303 are hot spots changed during evolution to confer aldehyde specificity to several ALDH families.", "spo_list": [{"subject": "Asp", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ALDH", "object_type": "GENE-N"}, {"subject": "Phe", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ALDH", "object_type": "GENE-N"}, {"subject": "Met", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ALDH", "object_type": "GENE-N"}, {"subject": "Cys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ALDH", "object_type": "GENE-N"}, {"subject": "Cys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ALDH", "object_type": "GENE-N"}]}
{"text": "Histone deacetylase 3 (Hdac3) is a nuclear enzyme that removes acetyl groups from lysine residues in histones and other proteins to epigenetically regulate gene expression.", "spo_list": [{"subject": "acetyl", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "histones", "object_type": "GENE-N"}, {"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "histones", "object_type": "GENE-N"}]}
{"text": "Mn exposure (20Â mg/kg) increased p38(MAPK) and Akt phosphorylation, but decreased DARPP-32-Thr-34 phosphorylation.", "spo_list": [{"subject": "Mn", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "Mn", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MAPK", "object_type": "GENE-N"}, {"subject": "Mn", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "Mn", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DARPP-32", "object_type": "GENE-Y"}]}
{"text": "Mn (10 and 20Â mg/kg) increased caspase activity and F(2)-isoprostane production (a biological marker of lipid peroxidation).", "spo_list": [{"subject": "Mn", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "caspase", "object_type": "GENE-N"}]}
{"text": "Notably, the antioxidant Troloxâ¢ reversed the Mn (20Â mg/kg)-dependent augmentation in p38(MAPK) phosphorylation and reduced the Mn (20Â mg/kg)-induced caspase activity and F(2)-isoprostane production.", "spo_list": [{"subject": "Mn", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MAPK", "object_type": "GENE-N"}, {"subject": "Mn", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "Trolox", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAPK", "object_type": "GENE-N"}, {"subject": "Trolox", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "Mn", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "caspase", "object_type": "GENE-N"}, {"subject": "Trolox", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "caspase", "object_type": "GENE-N"}]}
{"text": "These findings are the first to show that long-term exposure to Mn during a critical period of neurodevelopment causes motor coordination dysfunction with parallel increment in oxidative stress markers, p38(MAPK) phosphorylation and caspase activity in the striatum.", "spo_list": [{"subject": "Mn", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "Mn", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MAPK", "object_type": "GENE-N"}, {"subject": "Mn", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "caspase", "object_type": "GENE-N"}]}
{"text": "In contrast, TRPM8 activation by menthol produced no axon reflex reaction and resulted in cold hyperalgesia.", "spo_list": [{"subject": "menthol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRPM8", "object_type": "GENE-Y"}]}
{"text": "Three cynomolgus monkey OATPs (cOATPs), with a high degree of amino acid sequence identity (91.9, 93.5, and 96.6% for OATP1B1, 1B3, and 2B1, respectively) to their human counterparts, were cloned, expressed, and characterized.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "cynomolgus monkey OATPs", "object_type": "GENE-N"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "cOATPs", "object_type": "GENE-N"}]}
{"text": "(-)-Pindolol, which possesses significant affinity for 5-HT1A, 5-HT1B, and beta 1/2-adrenergic receptors (AR)s, dose-dependently increased extracellular levels of dopamine (DA) and noradrenaline (NAD) versus 5-HT, in dialysates of the frontal cortex (FCX), but not accumbens and striatum, of freely-moving rats.", "spo_list": [{"subject": "(-)-Pindolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "(-)-Pindolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1B", "object_type": "GENE-Y"}, {"subject": "(-)-Pindolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "(AR)s", "object_type": "GENE-N"}]}
{"text": "In distinction, the preferential beta 1-AR antagonist, betaxolol, and the preferential beta 2-AR antagonist, ICI118,551, did not increase basal levels of DA, NAD, or 5-HT.", "spo_list": [{"subject": "betaxolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta 1-AR", "object_type": "GENE-Y"}, {"subject": "ICI118,551", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta 2-AR", "object_type": "GENE-Y"}]}
{"text": "The selective 5-HT1A receptor antagonist, WAY100,635, slightly attenuated the (-)-pindolol-induced increase in DA and NAD levels, while the selective 5-HT1B antagonist, SB224,289, was ineffective.", "spo_list": [{"subject": "WAY100,635", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "SB224,289", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT1B", "object_type": "GENE-Y"}]}
{"text": "In conclusion, (-)-pindolol modulates, both alone and together with 5-HT reuptake inhibitors, dopaminergic, adrenergic, and serotonergic transmission in the FCX via a complex pattern of actions at beta 1/2-ARs, 5-HT1A, and 5-HT1B receptors.", "spo_list": [{"subject": "(-)-pindolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "(-)-pindolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1B", "object_type": "GENE-Y"}]}
{"text": "Pterostilbene exerts antitumor activity against human osteosarcoma cells by inhibiting the JAK2/STAT3 signaling pathway.", "spo_list": [{"subject": "Pterostilbene", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JAK2", "object_type": "GENE-Y"}, {"subject": "Pterostilbene", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "STAT3", "object_type": "GENE-Y"}]}
{"text": "Furthermore, PTE treatment directly inhibited the phosphorylation of JAK2 at Tyr 1007 and the downstream activation of STAT3.", "spo_list": [{"subject": "PTE", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JAK2", "object_type": "GENE-Y"}, {"subject": "Tyr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "JAK2", "object_type": "GENE-Y"}, {"subject": "PTE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "STAT3", "object_type": "GENE-Y"}]}
{"text": "PTE also down-regulated the expression of STAT3 target genes, including the anti-apoptotic proteins Bcl-xL and Mcl-1, leading to the up-regulation of mitochondrial apoptosis pathway-related proteins (Bax, Bak, cytosolic Cytochrome c, and cleaved Caspase3) and cyclin-dependent kinase inhibitors such as p21 and p27.", "spo_list": [{"subject": "PTE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "STAT3", "object_type": "GENE-Y"}, {"subject": "PTE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Bcl-xL", "object_type": "GENE-Y"}, {"subject": "PTE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Mcl-1", "object_type": "GENE-Y"}, {"subject": "PTE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bax", "object_type": "GENE-Y"}, {"subject": "PTE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bak", "object_type": "GENE-Y"}, {"subject": "PTE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Cytochrome c", "object_type": "GENE-Y"}, {"subject": "PTE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Caspase3", "object_type": "GENE-Y"}, {"subject": "PTE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p21", "object_type": "GENE-Y"}, {"subject": "PTE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p27", "object_type": "GENE-Y"}]}
{"text": "PTE, used in combination with a known JAK2/STAT3 inhibitor, AG490, further decreased the viability of osteosarcoma cells.", "spo_list": [{"subject": "AG490", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "STAT3", "object_type": "GENE-Y"}, {"subject": "AG490", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JAK2", "object_type": "GENE-Y"}]}
{"text": "Taken together, PTE is a potent inhibitor of osteosarcoma cell growth that targets the JAK2/STAT3 signaling pathway.", "spo_list": [{"subject": "PTE", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JAK2", "object_type": "GENE-Y"}, {"subject": "PTE", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "STAT3", "object_type": "GENE-Y"}]}
{"text": "These data suggest that inhibition of JAK2/STAT3 signaling is a novel mechanism of action for PTE during therapeutic intervention in osteosarcoma cancers.", "spo_list": [{"subject": "PTE", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "STAT3", "object_type": "GENE-Y"}, {"subject": "PTE", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JAK2", "object_type": "GENE-Y"}]}
{"text": "In humans, cytochrome P450 (CYP) 2A6 metabolizes nicotine to cotinine, and CYP2A-like activity and protein have been reported in some birds.", "spo_list": [{"subject": "nicotine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cytochrome P450 (CYP) 2A6", "object_type": "GENE-Y"}, {"subject": "cotinine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cytochrome P450 (CYP) 2A6", "object_type": "GENE-Y"}]}
{"text": "Zebra finch liver microsomes metabolized nicotine and bupropion (CYP2B substrate) but not coumarin (CYP2A substrate).", "spo_list": [{"subject": "nicotine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2B", "object_type": "GENE-N"}, {"subject": "bupropion", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2B", "object_type": "GENE-N"}]}
{"text": "Nicotine and bupropion metabolism were inhibited by C-8-xanthate (specific CYP2B inhibitor) but not CYP2A-specific inhibitors, and hepatic levels of CYP2B-like but not CYP2A-like proteins correlated with nicotine (r = 0.52, p = 0.04) and bupropion metabolism (r = 0.81, p < 0.001), suggesting CYP2B-mediation of nicotine metabolism as seen in rats.", "spo_list": [{"subject": "C-8-xanthate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2B", "object_type": "GENE-N"}, {"subject": "Nicotine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2B", "object_type": "GENE-N"}, {"subject": "bupropion", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2B", "object_type": "GENE-N"}, {"subject": "nicotine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2B", "object_type": "GENE-N"}, {"subject": "nicotine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2B", "object_type": "GENE-N"}, {"subject": "bupropion", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2B", "object_type": "GENE-N"}]}
{"text": "We show here that the acidic sequence of PEP-19 has intrinsic Ca(2+) binding activity, which may modulate Ca(2+) binding to CaM by stabilizing an initial Ca(2+)-CaM complex or by electrostatically steering Ca(2+) to and from CaM.", "spo_list": [{"subject": "Ca(2+)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PEP-19", "object_type": "GENE-Y"}, {"subject": "Ca(2+)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CaM", "object_type": "GENE-Y"}, {"subject": "Ca(2+)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CaM", "object_type": "GENE-Y"}, {"subject": "Ca(2+)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CaM", "object_type": "GENE-Y"}]}
{"text": "Mutations in the acidic sequence of PEP-19 that inhibit or prevent it from modulating Ca(2+) binding to CaM greatly inhibit its effect on ATP-induced Ca(2+) release.", "spo_list": [{"subject": "Ca(2+)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CaM", "object_type": "GENE-Y"}]}
{"text": "Secondary point mutations in the Fms-like tyrosine kinase 3 (FLT3) tyrosine kinase domain (KD) are common causes of acquired clinical resistance to the FLT3 inhibitors AC220 (quizartinib) and sorafenib.", "spo_list": [{"subject": "AC220", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FLT3", "object_type": "GENE-Y"}, {"subject": "quizartinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FLT3", "object_type": "GENE-Y"}, {"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FLT3", "object_type": "GENE-Y"}]}
{"text": "Ponatinib (AP24534) is a multikinase inhibitor with in vitro and clinical activity in tyrosine kinase inhibitor (TKI)-resistant chronic myeloid leukemia, irrespective of BCR-ABL KD mutation.", "spo_list": [{"subject": "Ponatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "multikinase", "object_type": "GENE-N"}, {"subject": "AP24534", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "multikinase", "object_type": "GENE-N"}]}
{"text": "Substitution of the FLT3 \"gatekeeper\" phenylalanine with leucine (F691L) conferred mild resistance to ponatinib, but substitutions at the FLT3 activation loop (AL) residue D835 conferred a high degree of resistance.", "spo_list": [{"subject": "phenylalanine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "FLT3", "object_type": "GENE-Y"}, {"subject": "leucine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "FLT3", "object_type": "GENE-Y"}]}
{"text": "A Structural Snapshot of Cytochrome P450 2B4 in Complex with Paroxetine Provides Insights into Ligand Binding and Clusters of Conformational States.", "spo_list": [{"subject": "Paroxetine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Cytochrome P450 2B4", "object_type": "GENE-Y"}]}
{"text": "An X-ray crystal structure of cytochrome P450 2B4 in complex with the drug paroxetine was solved at 2.14 Ã resolution.", "spo_list": [{"subject": "paroxetine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "cytochrome P450 2B4", "object_type": "GENE-Y"}]}
{"text": "The 2B4-paroxetine structure is nearly superimposable on a previously solved closed structure in a ligand free state.", "spo_list": [{"subject": "paroxetine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "2B4", "object_type": "GENE-Y"}]}
{"text": "In the pituitary, haloperidol and sulpiride induced similar increases of mRNAs of pro-opiomelanocortin (POMC) (+65% and +73%), prolactin (PRL) (+821% and +840%) and growth hormone (GH) (+32% and +47%), but sulpiride induced a greater increase of D2R mRNA (+125%) than haloperidol (+92%).", "spo_list": [{"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "pro-opiomelanocortin", "object_type": "GENE-Y"}, {"subject": "sulpiride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "pro-opiomelanocortin", "object_type": "GENE-Y"}, {"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "POMC", "object_type": "GENE-Y"}, {"subject": "sulpiride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "POMC", "object_type": "GENE-Y"}, {"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "prolactin", "object_type": "GENE-Y"}, {"subject": "sulpiride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "prolactin", "object_type": "GENE-Y"}, {"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PRL", "object_type": "GENE-Y"}, {"subject": "sulpiride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PRL", "object_type": "GENE-Y"}, {"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "growth hormone", "object_type": "GENE-Y"}, {"subject": "sulpiride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "growth hormone", "object_type": "GENE-Y"}, {"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GH", "object_type": "GENE-Y"}, {"subject": "sulpiride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GH", "object_type": "GENE-Y"}, {"subject": "sulpiride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "D2R", "object_type": "GENE-Y"}]}
{"text": "In the striatum, sulpiride and haloperidol had different effects: sulpiride induced a higher increase than haloperidol of both preproenkephalin A (PPA) mRNA (+67% versus +47%) and D2 dopamine receptor (D2R) mRNAs (+72% versus +40%).", "spo_list": [{"subject": "sulpiride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "preproenkephalin A", "object_type": "GENE-Y"}, {"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "preproenkephalin A", "object_type": "GENE-Y"}, {"subject": "sulpiride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PPA", "object_type": "GENE-Y"}, {"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PPA", "object_type": "GENE-Y"}, {"subject": "sulpiride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "D2 dopamine receptor", "object_type": "GENE-Y"}, {"subject": "sulpiride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "D2R", "object_type": "GENE-Y"}, {"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "D2 dopamine receptor", "object_type": "GENE-Y"}, {"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "D2R", "object_type": "GENE-Y"}]}
{"text": "Haloperidol decreased the amount of SP mRNA by 20% while sulpiride increased it by 20%.", "spo_list": [{"subject": "Haloperidol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "SP", "object_type": "GENE-Y"}, {"subject": "sulpiride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SP", "object_type": "GENE-Y"}]}
{"text": "We demonstrate that activation of STAT3 serine-727 and tyrosine-705 phosphorylations is promoted by B-RAF(V600E) activity and that the Mcl-1 promoter is dependent on a STAT consensus-site for B-RAF-mediated activation.", "spo_list": [{"subject": "serine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "STAT3", "object_type": "GENE-Y"}, {"subject": "tyrosine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "STAT3", "object_type": "GENE-Y"}]}
{"text": "It was recently reported that acute cocaine pretreatment can reduce the (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced 5-hydroxytryptamine2 (5-HT2)-receptor mediated head-twitch response (HTR) in mice via indirect stimulation of adrenergic alpha 2- and serotonergic 5-HT1A-receptors.", "spo_list": [{"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "adrenergic alpha 2", "object_type": "GENE-N"}, {"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "5-HT1A", "object_type": "GENE-Y"}]}
{"text": "The present results further support the previously suggested hypothesis that acute cocaine administration inhibits the 5-HT2-receptor function by increasing the synaptic concentration of norepinephrine and serotonin via inhibition of their uptake and therefore indirectly stimulating the respective inhibitory adrenergic alpha 2- and serotonergic 5-HT1A-receptors.", "spo_list": [{"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-HT2", "object_type": "GENE-N"}]}
{"text": "This inhibition was blocked when mice were pretreated with the selective H3R agonist R-(alpha)-methyl-histamine (10Â mg/kg).", "spo_list": [{"subject": "R-(alpha)-methyl-histamine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "H3R", "object_type": "GENE-Y"}]}
{"text": "Their deduced amino acid sequences show a high degree of conservation compared with orthologues from other mammalian species, with the notable exception of the N-terminus of ovine M-CPT 1.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ovine M-CPT 1", "object_type": "GENE-Y"}]}
{"text": "These differences were also present in bovine M-CPT 1, whose N-terminal sequence we determined.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "bovine M-CPT 1", "object_type": "GENE-Y"}]}
{"text": "Expression in yeast allowed kinetic characterization of the two native enzymes, and of a chimaera in which the distinctive N-terminal segment of ovine M-CPT 1 was replaced with that from rat M-CPT 1.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ovine M-CPT 1", "object_type": "GENE-Y"}]}
{"text": "MK571, an MRP inhibitor, increased both the cell-to-medium ratio of etoposide and the etoposide sensitivity of MRP1-expressing stomach cancer cell lines.", "spo_list": [{"subject": "MK571", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MRP", "object_type": "GENE-Y"}]}
{"text": "Initial uptake rate and steady-state cell-to-medium ratio of [(3)H]MTX were correlated with both RFC1 expression level and MTX sensitivity.", "spo_list": [{"subject": "[(3)H]MTX", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "RFC1", "object_type": "GENE-Y"}]}
{"text": "Moreover, ganodermanondiol increased cellular glutathione levels and the expression of the glutamine-cysteine ligase gene in a dose-dependent manner.", "spo_list": [{"subject": "ganodermanondiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "glutamine-cysteine ligase", "object_type": "GENE-Y"}, {"subject": "glutathione", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "glutamine-cysteine ligase", "object_type": "GENE-Y"}]}
{"text": "Furthermore, ganodermanondiol exposure enhanced the phosphorylation of adenosine monophosphate-activated protein kinase (AMPK) and its upstream kinase activators, LKB1 and Ca(2+)/calmodulin-dependent protein kinase-II (CaMKII).", "spo_list": [{"subject": "ganodermanondiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "adenosine monophosphate-activated protein kinase", "object_type": "GENE-N"}, {"subject": "ganodermanondiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "ganodermanondiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Ca(2+)/calmodulin-dependent protein kinase-II", "object_type": "GENE-N"}, {"subject": "ganodermanondiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CaMKII", "object_type": "GENE-N"}, {"subject": "ganodermanondiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "LKB1", "object_type": "GENE-Y"}]}
{"text": "These models, in combination with a strong correlation between the levels of striatal DOPAC and the affinities to DA D2 and MAO A, provides a comprehensive understanding of the biological response for compounds in this class.", "spo_list": [{"subject": "DOPAC", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DA D2", "object_type": "GENE-Y"}, {"subject": "DOPAC", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MAO A", "object_type": "GENE-Y"}]}
{"text": "Activation of AMP-activated Protein Kinase and Phosphorylation of Glycogen Synthase Kinase3 Î² Mediate Ursolic Acid Induced Apoptosis in HepG2 Liver Cancer Cells.", "spo_list": [{"subject": "Ursolic Acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMP-activated Protein Kinase", "object_type": "GENE-N"}, {"subject": "Ursolic Acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Glycogen Synthase Kinase3 Î²", "object_type": "GENE-Y"}]}
{"text": "Interestingly, ursolic acid increased the phosphorylation of AMPK and coenzyme A carboxylase and also enhanced phosphorylation of GSK3Î² at inactive form serine 9, whereas ursolic acid attenuated the phosphorylation of AKT and mTOR in HepG2 cells.", "spo_list": [{"subject": "ursolic acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "ursolic acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "coenzyme A carboxylase", "object_type": "GENE-N"}, {"subject": "ursolic acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GSK3Î²", "object_type": "GENE-Y"}, {"subject": "serine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GSK3Î²", "object_type": "GENE-Y"}, {"subject": "ursolic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AKT", "object_type": "GENE-N"}, {"subject": "ursolic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}]}
{"text": "Conversely, AMPK inhibitor compound C or GSK3Î² inhibitor SB216763 blocked the cleavages of PARP and caspase 3 induced by ursolic acid in HepG2 cells.", "spo_list": [{"subject": "compound C", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "SB216763", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GSK3Î²", "object_type": "GENE-Y"}, {"subject": "ursolic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PARP", "object_type": "GENE-N"}, {"subject": "ursolic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "caspase 3", "object_type": "GENE-Y"}, {"subject": "compound C", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "caspase 3", "object_type": "GENE-Y"}, {"subject": "SB216763", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "caspase 3", "object_type": "GENE-Y"}]}
{"text": "Furthermore, proteosomal inhibitor MG132 suppressed AMPK activation, GSK3Î² phosphorylation, cleaved PARP and deceased AEG-1 induced by ursolic acid in HepG2 cells.", "spo_list": [{"subject": "MG132", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "MG132", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GSK3Î²", "object_type": "GENE-Y"}, {"subject": "MG132", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AEG-1", "object_type": "GENE-Y"}, {"subject": "ursolic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AEG-1", "object_type": "GENE-Y"}, {"subject": "ursolic acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "ursolic acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GSK3Î²", "object_type": "GENE-Y"}, {"subject": "ursolic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "AEG-1", "object_type": "GENE-Y"}]}
{"text": "Overall, our findings suggest that ursolic acid induced apoptosis in HepG2 cells via AMPK activation and GSK3Î² phosphorylation as a potent chemopreventive agent.", "spo_list": [{"subject": "ursolic acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "ursolic acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GSK3Î²", "object_type": "GENE-Y"}]}
{"text": "Na(+)-dependent transporters mediate HCO(3)(-) salvage across the luminal membrane of the main pancreatic duct.", "spo_list": [{"subject": "HCO(3)(-)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Na(+)-dependent transporters", "object_type": "GENE-N"}]}
{"text": "Basolateral Na(+)-dependent H(+) efflux in the microperfused duct was inhibited by 1.5 microM of the amiloride analogue HOE 694, consistent with expression of NHE1, whereas the luminal activity required 50 microM HOE 694 for effective inhibition, suggesting that the efflux might be mediated by NHE2.", "spo_list": [{"subject": "HOE 694", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NHE2", "object_type": "GENE-Y"}]}
{"text": "However, disruption of NHE2 had no effect on luminal transport, while disruption of the NHE3 gene reduced luminal Na(+)-dependent H(+) efflux by approximately 45%.", "spo_list": [{"subject": "H(+)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NHE3", "object_type": "GENE-Y"}]}
{"text": "H(+) transport by NHE3 and the novel transporter is inhibited by cAMP, albeit to different extents.", "spo_list": [{"subject": "H(+)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NHE3", "object_type": "GENE-Y"}, {"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NHE3", "object_type": "GENE-Y"}]}
{"text": "Calpain and caspase-3 were differentially activated in a dose-dependent manner under copper-induced reactive oxygen species production.", "spo_list": [{"subject": "copper", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Calpain", "object_type": "GENE-N"}, {"subject": "copper", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "caspase-3", "object_type": "GENE-Y"}]}
{"text": "ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets.", "spo_list": [{"subject": "ABT-199", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BCL-2", "object_type": "GENE-Y"}]}
{"text": "The therapeutic potential of directly inhibiting prosurvival proteins was unveiled with the development of navitoclax, a selective inhibitor of both BCL-2 and BCL-2-like 1 (BCL-X(L)), which has shown clinical efficacy in some BCL-2-dependent hematological cancers.", "spo_list": [{"subject": "navitoclax", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BCL-2", "object_type": "GENE-Y"}, {"subject": "navitoclax", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BCL-2-like 1", "object_type": "GENE-Y"}, {"subject": "navitoclax", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BCL-X(L)", "object_type": "GENE-Y"}]}
{"text": "Here we report the re-engineering of navitoclax to create a highly potent, orally bioavailable and BCL-2-selective inhibitor, ABT-199.", "spo_list": [{"subject": "ABT-199", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BCL-2", "object_type": "GENE-Y"}, {"subject": "navitoclax", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BCL-2", "object_type": "GENE-Y"}]}
{"text": "The nonspecific PKC inhibitor bisindolylmaleimide I also rescued the decrease of I(Na).", "spo_list": [{"subject": "bisindolylmaleimide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PKC", "object_type": "GENE-N"}]}
{"text": "From these data, it is inferred that in certain regions of brain (dentate gyrus), both the SERT and NET contribute to the active clearance of exogenously applied 5-HT.", "spo_list": [{"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NET", "object_type": "GENE-Y"}]}
{"text": "A common mechanism for resistance to oxime reactivation of acetylcholinesterase inhibited by organophosphorus compounds.", "spo_list": [{"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}]}
{"text": "Administration of oxime therapy is currently the standard approach used to reverse the acute toxicity of organophosphorus (OP) compounds, which is usually attributed to OP inhibition of acetylcholinesterase (AChE).", "spo_list": [{"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "Rate constants for reactivation of OP-inhibited AChE by even the best oximes, such as HI-6 and obidoxime, can vary >100-fold between OP-AChE conjugates that are easily reactivated and those that are difficult to reactivate.", "spo_list": [{"subject": "HI-6", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "obidoxime", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "To gain a better understanding of this oxime specificity problem for future design of improved reactivators, we conducted a QSAR analysis for oxime reactivation of AChE inhibited by OP agents and their analogues.", "spo_list": [{"subject": "oxime", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "Our evaluation of oxime reactivation of AChE inhibited by a sarin analogue, O-methyl isopropylphosphonofluoridate, or a cyclosarin analogue, O-methyl cyclohexylphosphonofluoridate, indicated that AChE inhibited by these analogues was at least 70-fold more difficult to reactivate than AChE inhibited by sarin or cyclosarin.", "spo_list": [{"subject": "oxime", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "O-methyl isopropylphosphonofluoridate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "cyclosarin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "O-methyl cyclohexylphosphonofluoridate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "O-methyl isopropylphosphonofluoridate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "cyclosarin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "O-methyl cyclohexylphosphonofluoridate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "sarin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "cyclosarin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "In addition, AChE inhibited by an analogue of tabun (i.e., O-ethyl isopropylphosphonofluoridate) was nearly as resistant to reactivation as tabun-inhibited AChE.", "spo_list": [{"subject": "tabun", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "tabun", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "O-ethyl isopropylphosphonofluoridate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "QSAR analysis of oxime reactivation of AChE inhibited by these OP compounds and others suggested that the presence of both a large substituent (i.e., â©¾the size of dimethylamine) and an alkoxy substituent in the structure of OP compounds is the common feature that results in resistance to oxime reactivation of OP-AChE conjugates whether the OP is a phosphate, phosphonate or phosphoramidate.", "spo_list": [{"subject": "dimethylamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "alkoxy", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "phosphate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "phosphonate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "phosphoramidate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "One is that the binding of retinoids to nuclear retinoic acid receptors (RARs) does not match their therapeutic efficacy: acitretin activates the three receptor subtypes, RAR-alpha, -beta and -gamma, without measurable receptor binding, whereas tazarotene preferentially binds to and activates RAR-beta and -gamma in preference to RAR-alpha.", "spo_list": [{"subject": "retinoids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "retinoic acid receptors", "object_type": "GENE-N"}, {"subject": "retinoids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RARs", "object_type": "GENE-N"}, {"subject": "tazarotene", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "RAR-alpha", "object_type": "GENE-Y"}, {"subject": "tazarotene", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RAR-alpha", "object_type": "GENE-Y"}]}
{"text": "Discovery of 4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide (AZD5363), an orally bioavailable, potent inhibitor of Akt kinases.", "spo_list": [{"subject": "4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "AZD5363", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "4-amino-N-[(1S)-1-(4-chlorophenyl)-3-hydroxypropyl]-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinases", "object_type": "GENE-N"}, {"subject": "AZD5363", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinases", "object_type": "GENE-N"}]}
{"text": "Discovery of a synthetic Aminopeptidase N inhibitor LB-4b as a potential anticancer agent.", "spo_list": [{"subject": "LB-4b", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Aminopeptidase N", "object_type": "GENE-Y"}]}
{"text": "LB-4b is the first synthetic APN inhibitor to be evaluated for both of its anti-invasion and anti-angiogenesis effects.", "spo_list": [{"subject": "LB-4b", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "APN", "object_type": "GENE-Y"}]}
{"text": "As a potent synthetic APN inhibitor (IC50=850nM, versus bestatin of 8.1Î¼M), LB-4b was determined to have more significant block effects to cancer cell invasion and angiogenesis than bestatin.", "spo_list": [{"subject": "bestatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "APN", "object_type": "GENE-Y"}, {"subject": "LB-4b", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "APN", "object_type": "GENE-Y"}, {"subject": "bestatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "APN", "object_type": "GENE-Y"}]}
{"text": "CONCLUSION: The peptide sequences containing Tyr, Phe conservative residues identified in this study can bind to cell surface IL-2Ralpha.", "spo_list": [{"subject": "Tyr", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "IL-2Ralpha", "object_type": "GENE-Y"}, {"subject": "Phe", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "IL-2Ralpha", "object_type": "GENE-Y"}]}
{"text": "OBJECTIVE: To determine the efficacy and safety of the cyclooxygenase 2 (COX-2) specific inhibitor, rofecoxib in patients with osteoarthritis (OA) of the knee.", "spo_list": [{"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase 2", "object_type": "GENE-Y"}, {"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "CONCLUSION: Specific inhibition of COX-2 by 25 and 125 mg rofecoxib, administered once daily, resulted in clinically meaningful improvements in patients with OA.", "spo_list": [{"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "This study confirms that COX-2 derived prostanoids are important clinical mediators of pain and other symptoms of knee OA and that inhibition of COX-1 is not required to provide clinical benefit.", "spo_list": [{"subject": "prostanoids", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Digoxin (10(-5) M) or digitoxin (10(-5) M) inhibited cytochrome P450 side chain cleavage enzyme (cytochrome P450(scc)) activity (conversion of 25-hydroxyl cholesterol to pregnenolone) in rat granulosa cells but did not influence the activity of 3beta-hydroxysteroid dehydrogenase (3beta-HSD).", "spo_list": [{"subject": "Digoxin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cytochrome P450 side chain cleavage enzyme", "object_type": "GENE-Y"}, {"subject": "digitoxin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cytochrome P450 side chain cleavage enzyme", "object_type": "GENE-Y"}, {"subject": "Digoxin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cytochrome P450(scc)", "object_type": "GENE-Y"}, {"subject": "digitoxin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cytochrome P450(scc)", "object_type": "GENE-Y"}, {"subject": "25-hydroxyl cholesterol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cytochrome P450 side chain cleavage enzyme", "object_type": "GENE-Y"}, {"subject": "25-hydroxyl cholesterol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cytochrome P450(scc)", "object_type": "GENE-Y"}, {"subject": "pregnenolone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cytochrome P450 side chain cleavage enzyme", "object_type": "GENE-Y"}, {"subject": "pregnenolone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cytochrome P450(scc)", "object_type": "GENE-Y"}]}
{"text": "Digoxin (10(-5) M) or digitoxin (10(-5) M), but not ouabain, decreased the expression of P450scc and steroidogenic acute regulatory (StAR) protein in rat granulosa cells.", "spo_list": [{"subject": "Digoxin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "P450scc", "object_type": "GENE-Y"}, {"subject": "digitoxin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "P450scc", "object_type": "GENE-Y"}, {"subject": "Digoxin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "steroidogenic acute regulatory (StAR) protein", "object_type": "GENE-Y"}, {"subject": "digitoxin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "steroidogenic acute regulatory (StAR) protein", "object_type": "GENE-Y"}]}
{"text": "Multiple exposure to theophylline, a phosphodiesterase (PDE) inhibitor, induces acinar hypertrophy in the salivary gland.", "spo_list": [{"subject": "theophylline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase", "object_type": "GENE-N"}, {"subject": "theophylline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE", "object_type": "GENE-N"}]}
{"text": "Theophylline exposure resulted in a sustained increase in mRNA expression for CysS and PDE3A, but PDE4D gene expression was unchanged.", "spo_list": [{"subject": "Theophylline", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CysS", "object_type": "GENE-Y"}, {"subject": "Theophylline", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PDE3A", "object_type": "GENE-Y"}]}
{"text": "Ziprasidone is a novel antipsychotic agent which binds with high affinity to 5-HT1A receptors (Ki = 3.4 nM), in addition to 5-HT1D, 5-HT2, and D2 sites.", "spo_list": [{"subject": "Ziprasidone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1A receptors", "object_type": "GENE-Y"}, {"subject": "Ziprasidone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-Y"}, {"subject": "Ziprasidone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT2", "object_type": "GENE-Y"}, {"subject": "Ziprasidone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "D2", "object_type": "GENE-Y"}]}
{"text": "While it is an antagonist at these latter receptors, ziprasidone behaves as a 5-HT1A agonist in vitro in adenylate cyclase measurements.", "spo_list": [{"subject": "ziprasidone", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT1A", "object_type": "GENE-Y"}]}
{"text": "Pretreatment with the 5-HT1A antagonist WAY-100,635 (10 micrograms/kg i.v.) prevented the ziprasidone-induced inhibition; the same dose of WAY-100,635 had little effect on the inhibition produced by clozapine and olanzapine.", "spo_list": [{"subject": "WAY-100,635", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "WAY-100,635", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT1A", "object_type": "GENE-Y"}]}
{"text": "These profiles suggest a mechanism of action for each agent, 5-HT1A agonism for ziprasidone and alpha 1 antagonism for clozapine and olanzapine.", "spo_list": [{"subject": "ziprasidone", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT1A", "object_type": "GENE-Y"}]}
{"text": "The 5-HT1A agonist activity reported here clearly distinguishes ziprasidone from currently available antipsychotic agents and suggests that this property may play a significant role in its pharmacologic actions.", "spo_list": [{"subject": "ziprasidone", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT1A", "object_type": "GENE-Y"}]}
{"text": "Male Sprague-Dawley rats when administered sc a sublethal dose of organophosphorus cholinesterase inhibitors such as the nerve agents, soman (100 micrograms/kg, sc), sarin (110 micrograms/kg, sc), tabun (200 micrograms/kg, sc), or VX (12 micrograms/kg, sc), developed seizures and severe muscle fasciculations within 15-20 min, lasting for 4-6 hr.", "spo_list": [{"subject": "soman", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cholinesterase", "object_type": "GENE-N"}, {"subject": "sarin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cholinesterase", "object_type": "GENE-N"}, {"subject": "tabun", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cholinesterase", "object_type": "GENE-N"}, {"subject": "VX", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cholinesterase", "object_type": "GENE-N"}]}
{"text": "Pretreatment with memantine HCl (MEM, 18 mg/kg, sc) together with atropine sulfate (ATS, 16 mg/kg, sc), 60 min and 15 min, respectively, prior to nerve agents attenuated AChE inhibition, prevented myonecrosis, and muscle fasciculations as well as other signs of cholinergic toxicity.", "spo_list": [{"subject": "memantine HCl", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "MEM", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "atropine sulfate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "ATS", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "(+)-Tramadol and the metabolite (+)-O-desmethyl-tramadol (M1) are agonists of the mu opioid receptor.", "spo_list": [{"subject": "(+)-Tramadol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mu opioid receptor", "object_type": "GENE-Y"}, {"subject": "(+)-O-desmethyl-tramadol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mu opioid receptor", "object_type": "GENE-Y"}]}
{"text": "The O-demethylation of tramadol to M1, the main analgesic effective metabolite, is catalysed by cytochrome P450 (CYP) 2D6, whereas N-demethylation to M2 is catalysed by CYP2B6 and CYP3A4.", "spo_list": [{"subject": "O", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cytochrome P450 (CYP) 2D6", "object_type": "GENE-Y"}, {"subject": "tramadol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cytochrome P450 (CYP) 2D6", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2B6", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A4", "object_type": "GENE-Y"}]}
{"text": "The wide variability in the pharmacokinetic properties of tramadol can partly be ascribed to CYP polymorphism.", "spo_list": [{"subject": "tramadol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP", "object_type": "GENE-N"}]}
{"text": "Because TIG1 has been proposed to act as a tumor suppressor, we tested the hypothesis that cytosine methylation of the TIG1 promoter suppresses its expression and causes a loss of responsiveness to retinoic acid in some neoplastic cells.", "spo_list": [{"subject": "cytosine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "TIG1 promoter", "object_type": "GENE-N"}]}
{"text": "Treatment with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine for 5 days restored TIG1 expression in all eight silenced cell lines tested.", "spo_list": [{"subject": "5-aza-2'-deoxycytidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA methyltransferase", "object_type": "GENE-Y"}, {"subject": "5-aza-2'-deoxycytidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TIG1", "object_type": "GENE-Y"}]}
{"text": "TIG1 expression was also inducible by treatment with 1 micro M all-trans-retinoic acid for 3 days except in densely methylated cell lines.", "spo_list": [{"subject": "all-trans-retinoic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TIG1", "object_type": "GENE-Y"}]}
{"text": "Using paraoxon as a reference acetylcholinesterase (AChE) inhibitor, the objective of this study was to develop an adverse outcome pathway (AOP) that provided quantitative linkages across levels of biological organization during zebrafish embryogenesis.", "spo_list": [{"subject": "paraoxon", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "paraoxon", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "We then showed that static exposure of embryos to paraoxon (31.2-500 nM) from 5 to 96 hpf resulted in significant stage- and concentration-dependent AChE inhibition, albeit these effects were fully reversible within 48 h following transfer to clean water.", "spo_list": [{"subject": "paraoxon", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "Based on these studies, the frequency of spontaneous tail contractions at 26 hpf - a developmental stage with minimal AChE expression and activity - was significantly higher following exposure to paraoxon concentrations as low as 31.2 nM.", "spo_list": [{"subject": "paraoxon", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "paraoxon", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "Interactions are dynamic during differentiation, as for example evidenced by the mESC-specific binding of Klf4 to mC and the NPC-specific binding of Uhrf2 to hmC, suggesting specific biological roles for mC and hmC.", "spo_list": [{"subject": "hmC", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Uhrf2", "object_type": "GENE-Y"}]}
{"text": "In heart, menadione undergoes one-electron reduction to semiquinone, a reaction mainly catalysed by mitochondrial NADH: ubiquinone oxidoreductase.", "spo_list": [{"subject": "menadione", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NADH: ubiquinone oxidoreductase", "object_type": "GENE-N"}, {"subject": "semiquinone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "NADH: ubiquinone oxidoreductase", "object_type": "GENE-N"}]}
{"text": "It is also converted to hydroquinone by the soluble two-electron reductase, DT-diaphorase, and is conjugated with GSH by glutathione S-transferase.", "spo_list": [{"subject": "hydroquinone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "DT-diaphorase", "object_type": "GENE-Y"}, {"subject": "GSH", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DT-diaphorase", "object_type": "GENE-Y"}, {"subject": "GSH", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "glutathione S-transferase", "object_type": "GENE-N"}]}
{"text": "In myocardial preparations isolated from guinea pigs treated with beta-naphthoflavone (80 mg/kg i.p.for 2 days), DT-diaphorase activity was enhanced (+36% with respect to control animals, P < 0.", "spo_list": [{"subject": "beta-naphthoflavone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "DT-diaphorase", "object_type": "GENE-Y"}]}
{"text": "The Bcl2/Bax ratio increased and Mfn2 expression decreased in MIN6 cells after glucose stimulation.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bcl2", "object_type": "GENE-Y"}, {"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bax", "object_type": "GENE-Y"}, {"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Mfn2", "object_type": "GENE-Y"}]}
{"text": "Additionally, treatment with glucose/iron showed a higher HO activity.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "HO", "object_type": "GENE-N"}, {"subject": "iron", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "HO", "object_type": "GENE-N"}]}
{"text": "Our study revealed that high glucose/Fe concentrations in MIN6 cells induced an increase of the Bcl2/Bax ratio, an indicator of increased cell apoptosis.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bcl2", "object_type": "GENE-Y"}, {"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bax", "object_type": "GENE-Y"}, {"subject": "Fe", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bax", "object_type": "GENE-Y"}, {"subject": "Fe", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bcl2", "object_type": "GENE-Y"}]}
{"text": "By using the purified and reconstituted protein we demonstrate that cholesterol is an essential activator, whereas bile acids are important modulators of ABCG2 activity.", "spo_list": [{"subject": "cholesterol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ABCG2", "object_type": "GENE-Y"}]}
{"text": "Both wild-type ABCG2 and its R482G mutant variant require cholesterol for full activity, although they exhibit different cholesterol sensitivities.", "spo_list": [{"subject": "cholesterol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ABCG2", "object_type": "GENE-Y"}, {"subject": "cholesterol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "R482G", "object_type": "GENE-N"}]}
{"text": "Bile acids strongly decrease the basal ABCG2-ATPase activity both in the wild-type ABCG2 and in the mutant variant.", "spo_list": [{"subject": "Bile acids", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ABCG2", "object_type": "GENE-Y"}, {"subject": "Bile acids", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "Bile acids", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ABCG2", "object_type": "GENE-Y"}]}
{"text": "Inorganic anions such as cyanate, cyanide, hydrogen sulfide, hydrogen sulfite, and trithiocarbonate were effective VchCA inhibitors with inhibition constants in the range of 33-88Î¼M.", "spo_list": [{"subject": "cyanate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VchCA", "object_type": "GENE-Y"}, {"subject": "cyanide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VchCA", "object_type": "GENE-Y"}, {"subject": "hydrogen sulfide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VchCA", "object_type": "GENE-Y"}, {"subject": "hydrogen sulfite", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VchCA", "object_type": "GENE-Y"}, {"subject": "trithiocarbonate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VchCA", "object_type": "GENE-Y"}]}
{"text": "Selegiline (deprenyl), a selective, irreversible inhibitor of monoamine oxidase type B (MAO-B) is widely used in the treatment of Parkinson's disease.", "spo_list": [{"subject": "Selegiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase type B", "object_type": "GENE-Y"}, {"subject": "deprenyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase type B", "object_type": "GENE-Y"}, {"subject": "Selegiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "deprenyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "Unlike the nonselective MAO inhibitors, selegiline does not significantly potentiate tyramine-induced hypertension (the 'cheese effect') at the dosages (5 to 10 mg daily) used for the treatment of Parkinson's disease.", "spo_list": [{"subject": "selegiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO", "object_type": "GENE-N"}]}
{"text": "A low tyramine diet is recommended if selegiline is used together with nonselective MAO inhibitors or the selective, reversible MAO-A inhibitor, moclobemide.", "spo_list": [{"subject": "selegiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO", "object_type": "GENE-N"}, {"subject": "moclobemide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}]}
{"text": "One exception is tranexamic acid (TXA), which, as a lysine mimetic, inhibits binding of plasminogen to fibrin.", "spo_list": [{"subject": "TXA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "plasminogen", "object_type": "GENE-Y"}, {"subject": "tranexamic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "plasminogen", "object_type": "GENE-Y"}, {"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "plasminogen", "object_type": "GENE-Y"}, {"subject": "tranexamic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "fibrin", "object_type": "GENE-N"}, {"subject": "TXA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "fibrin", "object_type": "GENE-N"}, {"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "fibrin", "object_type": "GENE-N"}]}
{"text": "Coupling this computational technique with a high-quality low-throughput screen identified 5-(4-piperidyl)-3-isoxazolol (4-PIOL) as a potent plasminogen binding inhibitor with the potential for the treatment of various bleeding disorders.", "spo_list": [{"subject": "5-(4-piperidyl)-3-isoxazolol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "plasminogen", "object_type": "GENE-Y"}, {"subject": "4-PIOL", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "plasminogen", "object_type": "GENE-Y"}]}
{"text": "Rats received a concomitant treatment with the selective beta(1)-adrenoceptor antagonist, bisoprolol (50 mg/kg/day p.o.) or were chronically pretreated with the selective beta(2)-adrenoceptor agonist salbutamol (40 microg/kg/h) for 1 week to induce beta(2)-adrenoceptor desensitization.", "spo_list": [{"subject": "bisoprolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta(1)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "salbutamol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Oxycodone is primarily metabolized in the liver by the cytochrome P450 (CYP) enzymes with CYP3A as the major metabolic pathway and CYP2D6 as the minor metabolic pathway to noroxycodone, oxymorphone and noroxymorphone.", "spo_list": [{"subject": "Oxycodone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cytochrome P450", "object_type": "GENE-N"}, {"subject": "Oxycodone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP", "object_type": "GENE-N"}, {"subject": "noroxycodone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "noroxycodone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2D6", "object_type": "GENE-Y"}, {"subject": "oxymorphone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "oxymorphone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2D6", "object_type": "GENE-Y"}, {"subject": "noroxymorphone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "noroxymorphone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2D6", "object_type": "GENE-Y"}]}
{"text": "Simultaneous inhibition of both CYP3A and CYP2D6 results in increased oxycodone concentrations and such a combination should be avoided.", "spo_list": [{"subject": "oxycodone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "oxycodone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2D6", "object_type": "GENE-Y"}]}
{"text": "To compare in vivo effects of eleven compounds of different classes of histamine H1-receptor antagonists (alcoholamines: diphenhydramine, carbinoxamine, and clemastine; ethylenediamines: mepyramine, tripelennamine, and clemizole; alkylamines: triprolidine and chlorpheniramine; piperazines: meclizine and homochlorcyclizine; phenothiazines: promethazine) on neuronal uptake of dopamine (DA), noradrenaline (NA), and 5-hydroxytryptamine (5-HT), the effects on the turnover of these monoamines were examined in the mouse brain, based on the alpha-methyl-p-tyrosine-induced depletion of DA and NA or probenecid-induced accumulation of 5-hydroxyindoleacetic acid.", "spo_list": [{"subject": "alcoholamines", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}, {"subject": "diphenhydramine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}, {"subject": "carbinoxamine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}, {"subject": "clemastine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}, {"subject": "ethylenediamines", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}, {"subject": "mepyramine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}, {"subject": "tripelennamine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}, {"subject": "clemizole", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}, {"subject": "alkylamines", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}, {"subject": "triprolidine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}, {"subject": "chlorpheniramine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}, {"subject": "piperazines", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}, {"subject": "meclizine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}, {"subject": "homochlorcyclizine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}, {"subject": "phenothiazines", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}, {"subject": "promethazine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}]}
{"text": "In contrast, the NA turnover was increased by promethazine and homochlorcyclizine, possibly due to their antagonistic effects on alpha-adrenoceptors.", "spo_list": [{"subject": "promethazine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha-adrenoceptors", "object_type": "GENE-N"}, {"subject": "homochlorcyclizine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha-adrenoceptors", "object_type": "GENE-N"}]}
{"text": "Nordihydroguaiaretic acid inhibits IFN-gamma-induced STAT tyrosine phosphorylation in rat brain astrocytes.", "spo_list": [{"subject": "Nordihydroguaiaretic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IFN-gamma", "object_type": "GENE-Y"}, {"subject": "Nordihydroguaiaretic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "STAT", "object_type": "GENE-N"}, {"subject": "tyrosine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "STAT", "object_type": "GENE-N"}]}
{"text": "In this study, we found that nordihydroguaiaretic acid (NDGA), a well-known lipoxygenase (LO) inhibitor, suppressed IFN-gamma-induced inflammatory responses in brain astrocytes.", "spo_list": [{"subject": "nordihydroguaiaretic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "lipoxygenase", "object_type": "GENE-N"}, {"subject": "nordihydroguaiaretic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "LO", "object_type": "GENE-N"}, {"subject": "NDGA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "lipoxygenase", "object_type": "GENE-N"}, {"subject": "NDGA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "LO", "object_type": "GENE-N"}]}
{"text": "In the presence of NDGA, interferon regulatory factor-1 expression was significantly reduced.", "spo_list": [{"subject": "NDGA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "interferon regulatory factor-1", "object_type": "GENE-Y"}]}
{"text": "Expression of monocyte chemotactic protein-1 and interferon-gamma inducible protein-10 mRNA in response to IFN-gamma was significantly suppressed in the presence of NDGA, as was tyrosine-phosphorylation of JAK and STAT.", "spo_list": [{"subject": "tyrosine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "JAK", "object_type": "GENE-N"}, {"subject": "tyrosine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "STAT", "object_type": "GENE-N"}, {"subject": "NDGA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JAK", "object_type": "GENE-N"}, {"subject": "NDGA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "STAT", "object_type": "GENE-N"}, {"subject": "NDGA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "monocyte chemotactic protein-1", "object_type": "GENE-Y"}, {"subject": "NDGA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "interferon-gamma inducible protein-10", "object_type": "GENE-Y"}, {"subject": "NDGA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IFN-gamma", "object_type": "GENE-Y"}]}
{"text": "However, the 5-LO products, leukotriene B(4) (LTB(4)) and leukotriene C(4), were not detected in cells treated with IFN-gamma, indicating that the effect of NDGA seemed to be independent of 5-LO inhibition.", "spo_list": [{"subject": "leukotriene B(4)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "5-LO", "object_type": "GENE-Y"}, {"subject": "LTB(4)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "5-LO", "object_type": "GENE-Y"}, {"subject": "leukotriene C(4)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "5-LO", "object_type": "GENE-Y"}]}
{"text": "In addition, two other 5-LO inhibitors (Rev5901 and AA861) did not mimic the effect of NDGA, and the 5-LO metabolites, 5-hydroxyeicosatetraenoic acid and LTB(4), were unable to reverse NDGA-driven suppression of STAT activation or affect basal STAT phosphorylation.", "spo_list": [{"subject": "Rev5901", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-LO", "object_type": "GENE-Y"}, {"subject": "AA861", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-LO", "object_type": "GENE-Y"}, {"subject": "NDGA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "STAT", "object_type": "GENE-N"}, {"subject": "NDGA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "STAT", "object_type": "GENE-N"}, {"subject": "LTB(4)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "5-LO", "object_type": "GENE-Y"}, {"subject": "5-hydroxyeicosatetraenoic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "5-LO", "object_type": "GENE-Y"}]}
{"text": "Synthesis and dual biological effects of hydroxycinnamoyl phenylalanyl/prolyl hydroxamic acid derivatives as tyrosinase inhibitor and antioxidant.", "spo_list": [{"subject": "hydroxycinnamoyl phenylalanyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosinase", "object_type": "GENE-Y"}, {"subject": "prolyl hydroxamic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosinase", "object_type": "GENE-Y"}]}
{"text": "We previously reported that caffeoyl-amino acidyl-hydroxamic acid (CA-Xaa-NHOH) acted as both a good antioxidant and tyrosinase inhibitor, in particular when caffeic acid was conjugated with proline or amino acids having aromatic ring like phenylalanine.", "spo_list": [{"subject": "caffeoyl-amino acidyl-hydroxamic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosinase", "object_type": "GENE-Y"}, {"subject": "CA-Xaa-NHOH", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosinase", "object_type": "GENE-Y"}]}
{"text": "In addition, derivatives of caffeic acid and sinapic acid efficiently inhibited tyrosinase activity and reduced melanin content in melanocytes Mel-Ab cell.", "spo_list": [{"subject": "caffeic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosinase", "object_type": "GENE-Y"}, {"subject": "sinapic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosinase", "object_type": "GENE-Y"}]}
{"text": "Adenosine and dipyridamole are nonselective adenosine receptor agonists that have been associated with myocardial infarction (MI) during intravenous infusion.", "spo_list": [{"subject": "Adenosine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "adenosine receptor", "object_type": "GENE-N"}, {"subject": "dipyridamole", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "adenosine receptor", "object_type": "GENE-N"}]}
{"text": "Regadenoson, a direct A2A agonist, was approved for use in stress testing in 2008.", "spo_list": [{"subject": "Regadenoson", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "A2A", "object_type": "GENE-Y"}]}
{"text": "11Î²-Hydroxysteroid dehydrogenase type 1 contributes to the balance between 7-keto- and 7-hydroxy-oxysterols in vivo.", "spo_list": [{"subject": "7-keto- and 7-hydroxy-oxysterols", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE_PRODUCT-OF", "object": "11Î²-Hydroxysteroid dehydrogenase type 1", "object_type": "GENE-Y"}]}
{"text": "11Î²-Hydroxysteroid dehydrogenase 1 (11Î²HSD1; EC 1.1.1.146) generates active glucocorticoids from inert 11-keto metabolites.", "spo_list": [{"subject": "11-keto", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "11Î²-Hydroxysteroid dehydrogenase 1", "object_type": "GENE-Y"}, {"subject": "11-keto", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "11Î²HSD1", "object_type": "GENE-Y"}, {"subject": "11-keto", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 1.1.1.146", "object_type": "GENE-N"}]}
{"text": "Disruption of 11Î²HSD1 in mice increased (p<0.05) the 7KC/7Î²OHC ratio in plasma (by 20%) and also in isolated microsomes (2 fold).", "spo_list": [{"subject": "7KC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "11Î²HSD1", "object_type": "GENE-Y"}, {"subject": "7Î²OHC", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "11Î²HSD1", "object_type": "GENE-Y"}]}
{"text": "The 7KC/7Î²OHC ratio was similarly increased when NADPH generation was restricted by disruption of hexose-6-phosphate dehydrogenase.", "spo_list": [{"subject": "NADPH", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "hexose-6-phosphate dehydrogenase", "object_type": "GENE-Y"}, {"subject": "7Î²OHC", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "hexose-6-phosphate dehydrogenase", "object_type": "GENE-Y"}, {"subject": "7KC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hexose-6-phosphate dehydrogenase", "object_type": "GENE-Y"}]}
{"text": "Reduction and oxidation of 7-oxysterols by murine 11Î²HSD1 proceeded more slowly and substrate affinity was lower than for glucocorticoids. in vitro 7Î²OHC was a competitive inhibitor of oxidation of corticosterone (Ki=0.9Î¼M), whereas 7KC only weakly inhibited reduction of 11-dehydrocorticosterone.", "spo_list": [{"subject": "7-oxysterols", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "murine 11Î²HSD1", "object_type": "GENE-Y"}]}
{"text": "Thus, in mouse, 11Î²HSD1 influenced the abundance and balance of circulating and tissue levels of 7Î²OHC and 7KC, promoting reduction of 7KC.", "spo_list": [{"subject": "7Î²OHC", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "11Î²HSD1", "object_type": "GENE-Y"}, {"subject": "7KC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "11Î²HSD1", "object_type": "GENE-Y"}, {"subject": "7KC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "11Î²HSD1", "object_type": "GENE-Y"}]}
{"text": "Recent studies indicate that tamoxifen initially acts as an antagonist, but later functions as an ER agonist, promoting tumor growth.", "spo_list": [{"subject": "tamoxifen", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ER", "object_type": "GENE-N"}, {"subject": "tamoxifen", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ER", "object_type": "GENE-N"}]}
{"text": "With the pentapeptide linked through the C7alpha position of estradiol, the resulting PROTAC shows the most effective ER degradation and highest affinity for the estrogen receptor.", "spo_list": [{"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor", "object_type": "GENE-N"}]}
{"text": "Arsenic trioxide induces cardiac fibroblast apoptosis in vitro and in vivo by up-regulating TGF-Î²1 expression.", "spo_list": [{"subject": "Arsenic trioxide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TGF-Î²1", "object_type": "GENE-N"}]}
{"text": "The current study demonstrated that ATO induced morphological characteristics of apoptosis and Caspase-3 activation in CFs of guinea pigs along with a significant up-regulation in TGF-Î²1 protein expression, Bax/Bcl-2 ratio and ERK1/2 phosphorylation.", "spo_list": [{"subject": "ATO", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Caspase-3", "object_type": "GENE-Y"}, {"subject": "ATO", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TGF-Î²1", "object_type": "GENE-Y"}, {"subject": "ATO", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bax", "object_type": "GENE-Y"}, {"subject": "ATO", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bcl-2", "object_type": "GENE-Y"}]}
{"text": "Consistent with the notions in vivo, ATO significantly induced the apoptosis in NRCFs, dramatically up-regulated TGF-Î²1 protein level and Bax/Bcl-2 ratio in a time-dependent fashion and activated Caspase-3 and ERK1/2.", "spo_list": [{"subject": "ATO", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TGF-Î²1", "object_type": "GENE-Y"}, {"subject": "ATO", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bax", "object_type": "GENE-Y"}, {"subject": "ATO", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bcl-2", "object_type": "GENE-Y"}, {"subject": "ATO", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Caspase-3", "object_type": "GENE-Y"}]}
{"text": "Finally, pretreatment with LY364947, an inhibitor of TGF-Î² signaling could apparently reverse these changes.", "spo_list": [{"subject": "LY364947", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TGF-Î²", "object_type": "GENE-N"}]}
{"text": "An in silico computational method to predict the binding conformation of mitragynine to the active site of the CYP3A4 enzyme was performed and further validated using in vitro CYP3A4 inhibition assays.", "spo_list": [{"subject": "mitragynine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CYP3A4", "object_type": "GENE-Y"}]}
{"text": "Mitragynine was found to induce mRNA and protein expression of CYP1A2.", "spo_list": [{"subject": "Mitragynine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP1A2", "object_type": "GENE-Y"}]}
{"text": "Thus, mitragynine is a significant in vitro CYP1A2 inducer.", "spo_list": [{"subject": "mitragynine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CYP1A2", "object_type": "GENE-Y"}]}
{"text": "Cooperative homotropic interaction of L-noradrenaline with the catalytic site of phenylalanine 4-monooxygenase.", "spo_list": [{"subject": "L-noradrenaline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "phenylalanine 4-monooxygenase", "object_type": "GENE-Y"}]}
{"text": "Catecholamines (adrenaline, noradrenaline and dopamine) are potent inhibitors of phenylalanine 4-monooxygenase (phenylalanine hydroxylase, EC 1.14.16.1).", "spo_list": [{"subject": "Catecholamines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phenylalanine 4-monooxygenase", "object_type": "GENE-Y"}, {"subject": "adrenaline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phenylalanine 4-monooxygenase", "object_type": "GENE-Y"}, {"subject": "noradrenaline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phenylalanine 4-monooxygenase", "object_type": "GENE-Y"}, {"subject": "dopamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phenylalanine 4-monooxygenase", "object_type": "GENE-Y"}, {"subject": "Catecholamines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phenylalanine hydroxylase", "object_type": "GENE-Y"}, {"subject": "adrenaline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phenylalanine hydroxylase", "object_type": "GENE-Y"}, {"subject": "noradrenaline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phenylalanine hydroxylase", "object_type": "GENE-Y"}, {"subject": "dopamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phenylalanine hydroxylase", "object_type": "GENE-Y"}, {"subject": "Catecholamines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 1.14.16.1", "object_type": "GENE-Y"}, {"subject": "adrenaline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 1.14.16.1", "object_type": "GENE-Y"}, {"subject": "noradrenaline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 1.14.16.1", "object_type": "GENE-Y"}, {"subject": "dopamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 1.14.16.1", "object_type": "GENE-Y"}]}
{"text": "The high-affinity binding of L-noradrenaline to phenylalanine hydroxylase, as studied by equilibrium microdialysis (anaerobically) and ultrafiltration (aerobically), shows positive cooperativity (h = 1.9); at pH 7.2 and 20 degrees C the rat enzyme binds about 0.5 mol L-noradrenaline/mol subunit with a half-maximal binding (S50) at 0.25 microM L-noradrenaline.", "spo_list": [{"subject": "L-noradrenaline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "phenylalanine hydroxylase", "object_type": "GENE-Y"}]}
{"text": "The high-affinity of catecholamines to phenylalanine hydroxylase is a valuable probe to study the active site of this enzyme and is also relevant for the homologous enzyme tyrosine hydroxylase, which is purified as a stable catecholamine-Fe(III) complex.", "spo_list": [{"subject": "catecholamines", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "phenylalanine hydroxylase", "object_type": "GENE-Y"}, {"subject": "catecholamines", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "tyrosine hydroxylase", "object_type": "GENE-Y"}]}
{"text": "Vitamin E and probucol significantly suppressed an increase in plasma total-cholesterol (total-C) and low-density lipoprotein cholesterol compared to HC-control group.", "spo_list": [{"subject": "Vitamin E", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "low-density lipoprotein", "object_type": "GENE-N"}, {"subject": "probucol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "low-density lipoprotein", "object_type": "GENE-N"}]}
{"text": "However, plasma high-density lipoprotein-cholesterol (HDL-C) and HDL-C/total-C ratio levels and plasma paraoxonase activity were only significantly higher in vitamin E group after 8 weeks.", "spo_list": [{"subject": "vitamin E", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "paraoxonase", "object_type": "GENE-Y"}, {"subject": "vitamin E", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "high-density lipoprotein", "object_type": "GENE-N"}, {"subject": "vitamin E", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HDL", "object_type": "GENE-N"}, {"subject": "vitamin E", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HDL", "object_type": "GENE-N"}]}
{"text": "Hepatic ACAT activity was significantly lower in both vitamin E and probucol groups than in HC-control group, while HMG-CoA reductase activity was the highest only in the probucol group.", "spo_list": [{"subject": "vitamin E", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACAT", "object_type": "GENE-Y"}, {"subject": "probucol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACAT", "object_type": "GENE-Y"}, {"subject": "probucol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "HMG-CoA reductase", "object_type": "GENE-Y"}]}
{"text": "Hepatic mRNA expressions of apo B-100 and apo C-III were significantly lower in probucol group than in other groups.", "spo_list": [{"subject": "probucol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "apo B-100", "object_type": "GENE-Y"}, {"subject": "probucol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "apo C-III", "object_type": "GENE-Y"}]}
{"text": "Vitamin E supplementation was found to alter the plasma HDL-C-related factors; meanwhile, probucol supplementation was very effective in enhancing cholesterol metabolism, except for a negative effect that reduced plasma HDL-C concentration.", "spo_list": [{"subject": "probucol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "HDL", "object_type": "GENE-N"}]}
{"text": "We evaluated imatinib, a tyrosine kinase inhibitor currently used to treat chronic myelogenous leukemia and gastrointestinal stromal tumors, as a potential drug for systemic treatment of MTC, in 2 MTC-derived cell lines expressing multiple endocrine neoplasia-associated mutant RET receptors.", "spo_list": [{"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}]}
{"text": "RESULTS: Imatinib inhibited RET Y1062 phosphorylation in a dose-dependent manner after 1.5 hours of exposure.", "spo_list": [{"subject": "Imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RET", "object_type": "GENE-Y"}, {"subject": "Imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Y1062", "object_type": "GENE-N"}]}
{"text": "CONCLUSIONS: Imatinib inhibits RET-mediated MTC cell growth affecting RET protein levels in vitro in a dose-dependent manner.", "spo_list": [{"subject": "Imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RET", "object_type": "GENE-Y"}, {"subject": "Imatinib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "RET", "object_type": "GENE-Y"}]}
{"text": "The concentration of imatinib necessary to inhibit RET in vitro, however, makes it impossible to conclude that imatinib monotherapy will be a good option for systemic therapy of MTC.", "spo_list": [{"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RET", "object_type": "GENE-Y"}]}
{"text": "Derivatization of the carboxylate moiety in moderately selective COX-1 inhibitors, such as 5,8,11,14-eicosatetraynoic acid (ETYA) and arylacetic and fenamic acid NSAIDs, exemplified by indomethacin and meclofenamic acid, respectively, generated potent and selective COX-2 inhibitors.", "spo_list": [{"subject": "5,8,11,14-eicosatetraynoic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "ETYA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "arylacetic", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "fenamic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "meclofenamic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "meclofenamic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}]}
{"text": "Only the amide derivatives of ETYA and meclofenamic acid inhibit COX-2; the esters are either inactive or nonselective.", "spo_list": [{"subject": "amide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "ETYA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "meclofenamic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Inhibition kinetics reveal that indomethacin amides behave as slow, tight-binding inhibitors of COX-2 and that selectivity is a function of the time-dependent step.", "spo_list": [{"subject": "indomethacin amides", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Expansion of this approach can be envisioned for the modification of all carboxylic acid-containing NSAIDs into selective COX-2 inhibitors.", "spo_list": [{"subject": "carboxylic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Pranlukast, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism.", "spo_list": [{"subject": "Pranlukast", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "leukotriene receptor", "object_type": "GENE-N"}, {"subject": "Pranlukast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "interleukin-5", "object_type": "GENE-Y"}, {"subject": "Pranlukast", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "leukotriene receptor", "object_type": "GENE-N"}]}
{"text": "BACKGROUND: Pranlukast, a cysteinyl leukotriene receptor 1 (CysLTR1) antagonist, inhibits not only airway smooth muscle contraction, but also allergic inflammation.", "spo_list": [{"subject": "Pranlukast", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "cysteinyl leukotriene receptor 1", "object_type": "GENE-Y"}, {"subject": "Pranlukast", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CysLTR1", "object_type": "GENE-Y"}]}
{"text": "The aim of this study was to determine the mechanism of pranlukast-induced interleukin-5 (IL-5) inhibition in allergic inflammation.", "spo_list": [{"subject": "pranlukast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "interleukin-5", "object_type": "GENE-Y"}, {"subject": "pranlukast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IL-5", "object_type": "GENE-Y"}]}
{"text": "RESULTS: Pretreatment of lung tissues with pranlukast alone significantly decreased the amount of IL-5 protein in the culture medium by 40%.", "spo_list": [{"subject": "pranlukast", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-5", "object_type": "GENE-Y"}]}
{"text": "Pranlukast-induced inhibition of IL-5 mRNA expression was noted in various cells, irrespective of their CysLTR1 mRNA expression status.", "spo_list": [{"subject": "Pranlukast", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-5", "object_type": "GENE-Y"}]}
{"text": "CONCLUSION: Our results indicate that pranlukast inhibits IL-5 synthesis via a mechanism distinct from CysLTR1 antagonism.", "spo_list": [{"subject": "pranlukast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IL-5", "object_type": "GENE-Y"}, {"subject": "pranlukast", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CysLTR1", "object_type": "GENE-Y"}]}
{"text": "Peptidylarginine deiminase catalyzes the post-translational modification of proteins through the conversion of arginine to citrulline in the presence of calcium ions.", "spo_list": [{"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Peptidylarginine deiminase", "object_type": "GENE-N"}, {"subject": "citrulline", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Peptidylarginine deiminase", "object_type": "GENE-N"}]}
{"text": "The aim of this study was to propose a new methodology to produce diacylglycerol by hydrolysis of palm oil using Lipozyme RM IM commercial lipase as a catalyst under ultrasound irradiation.", "spo_list": [{"subject": "diacylglycerol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "lipase", "object_type": "GENE-N"}]}
{"text": "During early pregnancy in sheep, the elongating conceptus secretes interferon-Ï (IFNT) and the conceptus as well as endometrial epithelia produce prostaglandins (PG) via PG synthase 2 (PTGS2) and cortisol via hydroxysteroid (11-Î²) dehydrogenase 1 (HSD11B1).", "spo_list": [{"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PG synthase 2", "object_type": "GENE-Y"}, {"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PTGS2", "object_type": "GENE-Y"}, {"subject": "cortisol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "hydroxysteroid (11-Î²) dehydrogenase 1", "object_type": "GENE-Y"}, {"subject": "cortisol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "HSD11B1", "object_type": "GENE-Y"}]}
{"text": "In study 1, cyclic ewes received vehicle, cortisol, PF 915275 (PF; a selective inhibitor of HSD11B1), cortisol and PF, meloxicam (a selective inhibitor of PTGS2), cortisol and meloxicam, recombinant ovine IFNT, or IFNT and PF into the uterus from day 10 to day14 after estrus.", "spo_list": [{"subject": "PF 915275", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HSD11B1", "object_type": "GENE-Y"}, {"subject": "meloxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PTGS2", "object_type": "GENE-Y"}]}
{"text": "Cortisol and IFNT stimulated endometrial HSD11B1 expression and activity, increased endometrial PTGS2 activity and the amount of PG in the uterine lumen, and up-regulated many conceptus elongation-related genes in the endometrium.", "spo_list": [{"subject": "Cortisol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "HSD11B1", "object_type": "GENE-Y"}, {"subject": "Cortisol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HSD11B1", "object_type": "GENE-Y"}, {"subject": "Cortisol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PTGS2", "object_type": "GENE-Y"}]}
{"text": "These results suggest that HSD11B1-derived cortisol mediates, in part, actions of ovarian progesterone and the conceptus on endometrial function and support the hypothesis that IFNT, PG, and cortisol coordinately regulate endometrial functions important for conceptus elongation and implantation during early pregnancy in sheep.", "spo_list": [{"subject": "cortisol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "HSD11B1", "object_type": "GENE-Y"}]}
{"text": "Previously, we have found that BRN-103, a nicotinamide derivative, inhibits vascular endothelial growth factor (VEGF)-mediated angiogenesis signaling in human endothelial cells.", "spo_list": [{"subject": "BRN-103", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "vascular endothelial growth factor", "object_type": "GENE-Y"}, {"subject": "BRN-103", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGF", "object_type": "GENE-Y"}, {"subject": "nicotinamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "vascular endothelial growth factor", "object_type": "GENE-Y"}, {"subject": "nicotinamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGF", "object_type": "GENE-Y"}]}
{"text": "Furthermore, BRN-250 inhibited the VEGF-induced phosphorylation and intracellular tyrosine kinase activity of VEGF receptor 2 (VEGFR2) and the activation of its downstream AKT pathway.", "spo_list": [{"subject": "BRN-250", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "BRN-250", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGF receptor 2", "object_type": "GENE-Y"}, {"subject": "BRN-250", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR2", "object_type": "GENE-Y"}, {"subject": "BRN-250", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AKT", "object_type": "GENE-N"}]}
{"text": "Xestospongin C induces monocytic differentiation of HL60 cells through activation of the ERK pathway.", "spo_list": [{"subject": "Xestospongin C", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ERK", "object_type": "GENE-N"}]}
{"text": "Xestospongin C (XC), which is a group of macrocyclic bis-1-oxaquinolizidines, is a potent inhibitor of sarcoendoplasmic reticulum calcium transport ATPase and IP3 receptor.", "spo_list": [{"subject": "bis-1-oxaquinolizidines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "sarcoendoplasmic reticulum calcium transport ATPase", "object_type": "GENE-N"}, {"subject": "bis-1-oxaquinolizidines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IP3 receptor", "object_type": "GENE-N"}, {"subject": "Xestospongin C", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "sarcoendoplasmic reticulum calcium transport ATPase", "object_type": "GENE-N"}, {"subject": "Xestospongin C", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IP3 receptor", "object_type": "GENE-N"}]}
{"text": "Inhibition of ERK activation using PD98059 significantly decreased NBT+HL60 cells induced by XC treatment.", "spo_list": [{"subject": "PD98059", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ERK", "object_type": "GENE-N"}]}
{"text": "In this current study, paclitaxel was found to increase phosphorylation of mitogen-activated protein kinase (MAPK) kinase 3/6 (MKK3/6)-p38 MAPK as well as protein and mRNA levels of ERCC1 in H1650 and H1703 cells.", "spo_list": [{"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "mitogen-activated protein kinase", "object_type": "GENE-N"}, {"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MAPK", "object_type": "GENE-N"}, {"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ERCC1", "object_type": "GENE-Y"}]}
{"text": "Moreover, paclitaxel-induced ERCC1 protein and mRNA levels significantly decreased via the downregulation of p38 activity by either a p38 MAPK inhibitor SB202190 or p38 knockdown with specific small interfering RNA (siRNA).", "spo_list": [{"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ERCC1", "object_type": "GENE-Y"}, {"subject": "SB202190", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAPK", "object_type": "GENE-N"}, {"subject": "SB202190", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "SB202190", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38", "object_type": "GENE-N"}]}
{"text": "Furthermore, metformin was able to not only decrease the paclitaxel-induced p38 MAPK-mediated ERCC1 expression, but also augment the cytotoxic effect induced by paclitaxel.", "spo_list": [{"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MAPK", "object_type": "GENE-N"}, {"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ERCC1", "object_type": "GENE-Y"}, {"subject": "metformin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "metformin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAPK", "object_type": "GENE-N"}, {"subject": "metformin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ERCC1", "object_type": "GENE-Y"}]}
{"text": "Finally, expression of constitutive activate MKK6 or HA-p38 MAPK vectors in lung cancer cells was able to abrogate ERCC1 downregulation by metformin and paclitaxel as well as cell viability and DNA repair capacity.", "spo_list": [{"subject": "metformin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ERCC1", "object_type": "GENE-Y"}, {"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ERCC1", "object_type": "GENE-Y"}]}
{"text": "Overall, our results suggest that inhibition of the p38 MAPK signaling by metformin coupled with paclitaxel therapy in human NSCLC cells may be a clinically useful combination, which however will require further validation.", "spo_list": [{"subject": "metformin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAPK", "object_type": "GENE-N"}, {"subject": "metformin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38", "object_type": "GENE-N"}]}
{"text": "Our microarray analysis of the rodent hypothalamus has revealed that estradiol increases the expression of a number of glial-specific genes, including glutamine synthetase, an enzyme that inactivates glutamate through its conversion to glutamine.", "spo_list": [{"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "glutamine synthetase", "object_type": "GENE-Y"}, {"subject": "glutamate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "glutamine synthetase", "object_type": "GENE-Y"}, {"subject": "glutamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "glutamine synthetase", "object_type": "GENE-Y"}]}
{"text": "Given that glutamine is the predominant precursor for releasable pools of glutamate, our observation that estradiol increases glutamine synthetase gene and protein expression suggests that hormonal regulation of glutamate neurotransmission involves hormonally responsive glia.", "spo_list": [{"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "glutamine synthetase", "object_type": "GENE-Y"}, {"subject": "glutamate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "glutamine synthetase", "object_type": "GENE-Y"}, {"subject": "glutamate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "glutamine synthetase", "object_type": "GENE-Y"}, {"subject": "glutamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "glutamine synthetase", "object_type": "GENE-Y"}]}
{"text": "In healthy rats, ATB-429 dose dependently (25, 50, or 100 mg/kg) attenuated CRD-induced hypersensitivity and significantly inhibited CRD-induced overexpression of spinal c-FOS mRNA, whereas mesalamine had no effect.", "spo_list": [{"subject": "ATB-429", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "c-FOS", "object_type": "GENE-Y"}]}
{"text": "ATB-429-induced antinociception was reversed by glibenclamide, a ATP-sensitive K(+) (K(ATP)) channel inhibitor.", "spo_list": [{"subject": "glibenclamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATP-sensitive K(+) (K(ATP)) channel", "object_type": "GENE-N"}]}
{"text": "Colonic cyclooxygenase-2 and interkeukin-1beta mRNA and spinal c-FOS mRNA expression were significantly down-regulated by ATB-429, but not by mesalamine.", "spo_list": [{"subject": "ATB-429", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "ATB-429", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "interkeukin-1beta", "object_type": "GENE-Y"}, {"subject": "ATB-429", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "c-FOS", "object_type": "GENE-Y"}]}
{"text": "New (R)-4-benzamido-5-oxopentanoic acid derivatives were synthesized by a stereoconservative procedure and evaluated in vitro for their capacity to inhibit the binding of [125I](BH)-CCK-8 to either rat peripheral (CCK-A) or central (CCK-B) CCK receptors, or the binding of [3H]pentagastrin to rabbit gastric glands, as well as to inhibit, in vivo, the acid secretion induced by pentagastrin infusion in the perfused rat stomach.", "spo_list": [{"subject": "125I", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CCK-A", "object_type": "GENE-Y"}, {"subject": "125I", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CCK-B", "object_type": "GENE-Y"}, {"subject": "125I", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CCK receptors", "object_type": "GENE-N"}, {"subject": "(R)-4-benzamido-5-oxopentanoic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CCK-A", "object_type": "GENE-Y"}, {"subject": "(R)-4-benzamido-5-oxopentanoic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CCK-B", "object_type": "GENE-Y"}]}
{"text": "The parent compound of this series (lorglumide) is the first nonpeptidic, potent and selective antagonist of the CCK-A receptor.", "spo_list": [{"subject": "lorglumide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CCK-A receptor", "object_type": "GENE-N"}]}
{"text": "Chemical manipulations of the structure of lorglumide led to the discovery of selective antagonists of the CCK-B/gastrin receptors.", "spo_list": [{"subject": "lorglumide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CCK-B", "object_type": "GENE-Y"}, {"subject": "lorglumide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "gastrin receptors", "object_type": "GENE-Y"}]}
{"text": "N-terminal sequencing indicated that pro-BMP-2 was cleaved by FSAP at the canonical PC cleavage site, giving rise to mature BMP-2 (Arg(282)âGln(283)), as well as in the N-terminal heparin binding region of mature BMP-2, generating a truncated mature BMP-2 peptide (Arg(289)âLys(290)).", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "pro-BMP-2", "object_type": "GENE-Y"}, {"subject": "Arg", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "BMP-2", "object_type": "GENE-Y"}, {"subject": "Gln", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "BMP-2", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "BMP-2", "object_type": "GENE-Y"}, {"subject": "Arg", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "BMP-2", "object_type": "GENE-Y"}, {"subject": "Lys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "BMP-2", "object_type": "GENE-Y"}]}
{"text": "Similarly, mature BMP-2 was also cleaved to a truncated peptide within its N-terminal region (Arg(289)âLys(290)).", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "BMP-2", "object_type": "GENE-Y"}, {"subject": "Arg", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "BMP-2", "object_type": "GENE-Y"}, {"subject": "Lys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "BMP-2", "object_type": "GENE-Y"}]}
{"text": "A series of xanthine derivatives in which a methylene was inserted at position 8 of xanthine scaffold was synthesized and evaluated as inhibitors of dipeptidyl peptidase 4 (DPP-4) for the treatment of type 2 diabetes.", "spo_list": [{"subject": "xanthine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dipeptidyl peptidase 4", "object_type": "GENE-Y"}, {"subject": "xanthine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}, {"subject": "xanthine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dipeptidyl peptidase 4", "object_type": "GENE-Y"}, {"subject": "xanthine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}]}
{"text": "BPA (10(-4)M) reduced the phosphorylation of C-Jun N-terminal kinase (JNK) and CREB, and increased the mRNA expression level of Bax and p53.", "spo_list": [{"subject": "BPA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "C-Jun N-terminal kinase", "object_type": "GENE-N"}, {"subject": "BPA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JNK", "object_type": "GENE-N"}, {"subject": "BPA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CREB", "object_type": "GENE-N"}, {"subject": "BPA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bax", "object_type": "GENE-Y"}, {"subject": "BPA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p53", "object_type": "GENE-Y"}]}
{"text": "It appears likely that the histamine H2 receptor blocked by cimetidine obviated the pulmonary vasodilator effect of tolazoline therapy.", "spo_list": [{"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "histamine H2 receptor", "object_type": "GENE-Y"}]}
{"text": "Binding assays showed affinity of alpha-TOS for TAP1.", "spo_list": [{"subject": "alpha-TOS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "TAP1", "object_type": "GENE-Y"}]}
{"text": "Finally, TAP1 over-expressing cells accumulated alpha-TOS at higher levels compared to their normal counterparts.", "spo_list": [{"subject": "alpha-TOS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "TAP1", "object_type": "GENE-Y"}]}
{"text": "Second, in order to study the response of RHE to chemical sensitizers, the ((13)C)methyldodecanesulfonate was chosen as an NMR probe, and we compared adducts formed on human serum albumin (HSA) in solution and adducts formed in RHE.", "spo_list": [{"subject": "((13)C)methyldodecanesulfonate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human serum albumin", "object_type": "GENE-Y"}, {"subject": "((13)C)methyldodecanesulfonate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "HSA", "object_type": "GENE-Y"}]}
{"text": "Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels.", "spo_list": [{"subject": "dofetilide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ether a-go-go (EAG) channels", "object_type": "GENE-Y"}, {"subject": "dofetilide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EAG-related K(+) channels", "object_type": "GENE-Y"}]}
{"text": "HERG/I(Kr) channels are blocked selectively by class III antiarrhythmic methanesulfonanilide drugs such as dofetilide.", "spo_list": [{"subject": "methanesulfonanilide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HERG", "object_type": "GENE-Y"}, {"subject": "methanesulfonanilide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "I(Kr)", "object_type": "GENE-Y"}, {"subject": "dofetilide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HERG", "object_type": "GENE-Y"}, {"subject": "dofetilide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "I(Kr)", "object_type": "GENE-Y"}]}
{"text": "To gain further insight into the binding site, we examined the minimal structural changes necessary to transform low-affinity binding of dofetilide by the related bovine ether a-go-go channel bEAG to high-affinity binding of HERG.", "spo_list": [{"subject": "dofetilide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "bovine ether a-go-go channel", "object_type": "GENE-Y"}, {"subject": "dofetilide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "bEAG", "object_type": "GENE-Y"}, {"subject": "dofetilide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "HERG", "object_type": "GENE-Y"}]}
{"text": "Low concentrations of dofetilide produced block of bEAG T432S/A443S; unlike HERG, block was almost irreversible.", "spo_list": [{"subject": "dofetilide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "bEAG", "object_type": "GENE-Y"}, {"subject": "dofetilide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "T432S", "object_type": "GENE-N"}, {"subject": "dofetilide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "A443S", "object_type": "GENE-N"}, {"subject": "dofetilide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HERG", "object_type": "GENE-Y"}]}
{"text": "Dofetilide blocked the triply mutated bEAG T432S/A443S/A453S with an IC(50) value of 1.1 microM.", "spo_list": [{"subject": "Dofetilide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "bEAG", "object_type": "GENE-Y"}, {"subject": "Dofetilide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "T432S", "object_type": "GENE-N"}, {"subject": "Dofetilide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "A443S", "object_type": "GENE-N"}, {"subject": "Dofetilide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "A453S", "object_type": "GENE-N"}]}
{"text": "We conclude that high affinity methanesulfonanilide binding to HERG channels is strongly dependent on C-type inactivation.", "spo_list": [{"subject": "methanesulfonanilide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "HERG", "object_type": "GENE-Y"}]}
{"text": "Furthermore, knockdown of OPN enhanced cell death caused by other drugs, including paclitaxel, doxorubicin, actinomycin-D, and rapamycin, which are also P-gp substrates.", "spo_list": [{"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-gp", "object_type": "GENE-N"}, {"subject": "doxorubicin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-gp", "object_type": "GENE-N"}, {"subject": "actinomycin-D", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-gp", "object_type": "GENE-N"}, {"subject": "rapamycin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-gp", "object_type": "GENE-N"}]}
{"text": "Identification of the fused bicyclic 4-amino-2-phenylpyrimidine derivatives as novel and potent PDE4 inhibitors.", "spo_list": [{"subject": "4-amino-2-phenylpyrimidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}]}
{"text": "2-Phenyl-4-piperidinyl-6,7-dihydrothieno[3,4-d]pyrimidine derivative (2) was found to be a new PDE4 inhibitor with moderate PDE4B activity (IC50=150nM).", "spo_list": [{"subject": "2-Phenyl-4-piperidinyl-6,7-dihydrothieno[3,4-d]pyrimidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}, {"subject": "2-Phenyl-4-piperidinyl-6,7-dihydrothieno[3,4-d]pyrimidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4B", "object_type": "GENE-Y"}]}
{"text": "Among these, 5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine derivative (18) showed potent PDE4B inhibitory activity (IC50=25 nM).", "spo_list": [{"subject": "5,5-dioxo-7,8-dihydro-6H-thiopyrano[3,2-d]pyrimidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4B", "object_type": "GENE-Y"}]}
{"text": "Finally, N-propylacetamide derivative (31b) was determined as a potent inhibitor for both PDE4B (IC50=7.5nM) and TNF-Î± production in mouse splenocytes (IC50=9.8nM) and showed good in vivo anti-inflammatory activity in the LPS-induced lung inflammation model in mice (ID50=18mg/kg).", "spo_list": [{"subject": "N-propylacetamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4B", "object_type": "GENE-Y"}, {"subject": "N-propylacetamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF-Î±", "object_type": "GENE-Y"}]}
{"text": "Crizotinib is an oral tyrosine kinase inhibitor (TKI), which silences the protein product of the ALK fusion gene and has recently been approved for the treatment of NSCLC aberrantly expressing ALK.", "spo_list": [{"subject": "Crizotinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "Crizotinib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ALK", "object_type": "GENE-Y"}]}
{"text": "Effect of halothane on the guanosine 5' triphosphate binding activity of G-protein alphai subunits.", "spo_list": [{"subject": "guanosine 5' triphosphate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "G-protein alphai", "object_type": "GENE-N"}]}
{"text": "The authors hypothesized that halothane would inhibit the ability of Galpha(i) subunits to bind a nonhydrolyzable analog of GTP (GTPgammaS).", "spo_list": [{"subject": "halothane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Galpha(i)", "object_type": "GENE-N"}, {"subject": "GTP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Galpha(i)", "object_type": "GENE-N"}, {"subject": "GTPgammaS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Galpha(i)", "object_type": "GENE-N"}]}
{"text": "In separate experiments, [35S]GTPgammaS binding to Galpha(i) in crude airway smooth muscle membrane preparations was assayed using an immunoprecipitation technique in the presence and absence of halothane.", "spo_list": [{"subject": "[35S]GTPgammaS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Galpha(i)", "object_type": "GENE-N"}]}
{"text": "The mole fractions of recombinant Galpha(i1) bound to [35S]GTPgammaS were 0.49 +/- 0.02 and 0.60 +/- 0.02 at 10 and 20 min, respectively.", "spo_list": [{"subject": "[35S]GTPgammaS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Galpha(i1)", "object_type": "GENE-Y"}]}
{"text": "Halothane did not affect the binding of [35S]GTPgammaS to Galpha(i) subunits in membrane fractions of airway smooth muscle as measured using immunoprecipitation.", "spo_list": [{"subject": "[35S]GTPgammaS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Galpha(i)", "object_type": "GENE-N"}]}
{"text": "CONCLUSION: These results suggest that halothane, which inhibits receptor-activated Galpha(i)-coupled pathways in intact airway smooth muscle, must functionally target a component of the G protein-coupled receptor complex other than Galpha(i).", "spo_list": [{"subject": "halothane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Galpha(i)", "object_type": "GENE-N"}]}
{"text": "Via large-scale, random screening of a portion of the receptorome, we have discovered that the amphetamine derivative 3,4-methylenedioxymethamphetamine (MDMA, \"Ecstasy\") and its N-demethylated metabolite 3,4-methylenedioxyamphetamine (MDA) each preferentially bind to and activate human recombinant 5-HT2B receptors.", "spo_list": [{"subject": "amphetamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human recombinant 5-HT2B receptors", "object_type": "GENE-Y"}, {"subject": "amphetamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "human recombinant 5-HT2B receptors", "object_type": "GENE-Y"}, {"subject": "3,4-methylenedioxymethamphetamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human recombinant 5-HT2B receptors", "object_type": "GENE-Y"}, {"subject": "3,4-methylenedioxymethamphetamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "human recombinant 5-HT2B receptors", "object_type": "GENE-Y"}, {"subject": "MDMA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human recombinant 5-HT2B receptors", "object_type": "GENE-Y"}, {"subject": "MDMA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "human recombinant 5-HT2B receptors", "object_type": "GENE-Y"}, {"subject": "Ecstasy", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human recombinant 5-HT2B receptors", "object_type": "GENE-Y"}, {"subject": "Ecstasy", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "human recombinant 5-HT2B receptors", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human recombinant 5-HT2B receptors", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "human recombinant 5-HT2B receptors", "object_type": "GENE-Y"}, {"subject": "3,4-methylenedioxyamphetamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human recombinant 5-HT2B receptors", "object_type": "GENE-Y"}, {"subject": "3,4-methylenedioxyamphetamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "human recombinant 5-HT2B receptors", "object_type": "GENE-Y"}, {"subject": "MDA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human recombinant 5-HT2B receptors", "object_type": "GENE-Y"}, {"subject": "MDA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "human recombinant 5-HT2B receptors", "object_type": "GENE-Y"}]}
{"text": "We also demonstrate that MDMA and MDA, like fenfluramine and its N-deethylated metabolite norfenfluramine, elicit prolonged mitogenic responses in human valvular interstitial cells via activation of 5-HT2B receptors.", "spo_list": [{"subject": "MDMA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "5-HT2B", "object_type": "GENE-Y"}, {"subject": "MDA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "5-HT2B", "object_type": "GENE-Y"}, {"subject": "fenfluramine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "5-HT2B", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "5-HT2B", "object_type": "GENE-Y"}, {"subject": "norfenfluramine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "5-HT2B", "object_type": "GENE-Y"}]}
{"text": "We also report that pergolide and dihydroergotamine, two drugs recently demonstrated to induce VHD in humans, potently activate 5-HT2B receptors, thus validating this assay system for its ability to predict medications that might induce VHD.", "spo_list": [{"subject": "pergolide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "5-HT2B", "object_type": "GENE-Y"}, {"subject": "dihydroergotamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "5-HT2B", "object_type": "GENE-Y"}]}
{"text": "MDV3100, however, shares its 4-cyano-3-(trifluoromethyl)phenyl group with bicalutamide and hydroxyflutamide required for binding to the AR.", "spo_list": [{"subject": "MDV3100", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AR", "object_type": "GENE-Y"}, {"subject": "4-cyano-3-(trifluoromethyl)phenyl", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AR", "object_type": "GENE-Y"}, {"subject": "bicalutamide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AR", "object_type": "GENE-Y"}, {"subject": "hydroxyflutamide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AR", "object_type": "GENE-Y"}]}
{"text": "We aim to \"tilt\" the stability of the H1 loop structure from a noncanonical conformation to a (humanized) type 1 canonical conformation by studying the effect of selected mutations to the amino acid sequence of the H1, H2, and proximal residues.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "H1", "object_type": "GENE-N"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "H2", "object_type": "GENE-N"}]}
{"text": "Erlotinib HCl (Tarceva; Genentech, Inc, South San Francisco, CA) is an orally available, highly selective, reversible inhibitor of epidermal growth factor receptor (HER1/EGFR) tyrosine kinase.", "spo_list": [{"subject": "Erlotinib HCl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "epidermal growth factor receptor", "object_type": "GENE-Y"}, {"subject": "Erlotinib HCl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HER1", "object_type": "GENE-Y"}, {"subject": "Erlotinib HCl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EGFR", "object_type": "GENE-Y"}, {"subject": "Erlotinib HCl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "Tarceva", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "epidermal growth factor receptor", "object_type": "GENE-Y"}, {"subject": "Tarceva", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HER1", "object_type": "GENE-Y"}, {"subject": "Tarceva", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EGFR", "object_type": "GENE-Y"}, {"subject": "Tarceva", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}]}
{"text": "Arm B consisted of high-risk patients (Stage T2b-T3, Gleason score >6, pretreatment PSA level >10 ng/mL) treated with combined RT-gene therapy and hormonal therapy (luteinizing hormone-releasing hormone agonist [30-mg Lupron, 4-month depot] and an antiandrogen [flutamide, 250 mg t.i.d. for 14 days]).", "spo_list": [{"subject": "Lupron", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "luteinizing hormone-releasing hormone", "object_type": "GENE-Y"}]}
{"text": "10-Formyltetrahydrofolate dehydrogenase has previously been identified as a tight binding protein of the polyglutamate forms of tetrahydrofolate (R. J. Cook and C. Wagner, Biochemistry 21, 4427-4434, 1982).", "spo_list": [{"subject": "polyglutamate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "10-Formyltetrahydrofolate dehydrogenase", "object_type": "GENE-Y"}, {"subject": "tetrahydrofolate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "10-Formyltetrahydrofolate dehydrogenase", "object_type": "GENE-Y"}]}
{"text": "By using the stable substrate and product analogs 10-formyl 5,8-dideazafolate and 5, 8-dideazafolate, respectively, we have determined that the tight binding folate site is separate from the catalytic site and that it is located on the N-terminal domain of the protein.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "tight binding folate site", "object_type": "GENE-N"}]}
{"text": "This was achieved by cross-linking 10-formyl 5,8-dideazafolate to the dehydrogenase through the carboxyl group of the substrate analog.", "spo_list": [{"subject": "10-formyl 5,8-dideazafolate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "dehydrogenase", "object_type": "GENE-N"}]}
{"text": "Surprisingly, the C-terminal transmembrane domain of T1R3 is required for recognizing sweetener cyclamate and sweet taste inhibitor lactisole.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "T1R3", "object_type": "GENE-Y"}]}
{"text": "Lactisole inhibits the activity of the human T1R1/T1R3 receptor, and, as predicted, blocked the umami taste of l-glutamate in human taste tests.", "spo_list": [{"subject": "Lactisole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "T1R1", "object_type": "GENE-Y"}, {"subject": "Lactisole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "T1R3", "object_type": "GENE-Y"}]}
{"text": "Herein we utilize a library of SRC2 peptidomimetics to select for specific inhibitors of the interaction of SRC2 with the two estrogen receptor (ER) isoforms, ERalpha and ERbeta, in the presence of three different ligands: 17beta-estradiol, diethylstilbesterol, and genistein.", "spo_list": [{"subject": "17beta-estradiol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "17beta-estradiol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ER", "object_type": "GENE-Y"}, {"subject": "diethylstilbesterol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "diethylstilbesterol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ER", "object_type": "GENE-Y"}, {"subject": "genistein", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "genistein", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ER", "object_type": "GENE-Y"}, {"subject": "17beta-estradiol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERalpha", "object_type": "GENE-Y"}, {"subject": "diethylstilbesterol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERalpha", "object_type": "GENE-Y"}, {"subject": "genistein", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERalpha", "object_type": "GENE-Y"}, {"subject": "17beta-estradiol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERbeta", "object_type": "GENE-Y"}, {"subject": "diethylstilbesterol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERbeta", "object_type": "GENE-Y"}, {"subject": "genistein", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERbeta", "object_type": "GENE-Y"}]}
{"text": "This treatment was followed by the treatment with TRPA1 antagonist HC 030031 (50mg/kg, p.o.).", "spo_list": [{"subject": "HC 030031", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "TRPA1", "object_type": "GENE-Y"}]}
{"text": "The treatment with the TRPA1 antagonist HC 030031 significantly decreased mechanical hyperalgesia induced by cyclophosphamide without interfere with locomotor activity.", "spo_list": [{"subject": "HC 030031", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "TRPA1", "object_type": "GENE-Y"}]}
{"text": "Our data demonstrates that nociceptive symptoms and urinary bladder overactivity caused by cyclophosphamide, in part, are dependent upon the activation of TRPA1.", "spo_list": [{"subject": "cyclophosphamide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRPA1", "object_type": "GENE-Y"}]}
{"text": "The present study characterized the kinetics of the separate R- and S- enantiomers of lorazepam by human liver microsomes (HLM) and by a panel of recombinant human UDP-glucuronosyltransferase (UGT) enzymes.", "spo_list": [{"subject": "lorazepam", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human UDP-glucuronosyltransferase", "object_type": "GENE-N"}, {"subject": "lorazepam", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT", "object_type": "GENE-N"}]}
{"text": "Based on in vitro clearances and consideration of available in vivo and in vitro data, UGT2B15 is likely to play an important role in the glucuronidation of R- and S-lorazepam.", "spo_list": [{"subject": "R- and S-lorazepam", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT2B15", "object_type": "GENE-Y"}]}
{"text": "However, the possible contribution of other enzymes and the low activities observed in vitro indicate that the lorazepam enantiomers are of limited use as substrate probes for UGT2B15.", "spo_list": [{"subject": "lorazepam", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT2B15", "object_type": "GENE-Y"}]}
{"text": "Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity.", "spo_list": [{"subject": "Rasagiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase-B", "object_type": "GENE-Y"}]}
{"text": "Rasagiline (N-propargyl-1-(R)-aminoindan) is a novel, highly potent irreversible monoamine oxidase (MAO)-B inhibitor, anti-Parkinsonian drug.", "spo_list": [{"subject": "Rasagiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase (MAO)-B", "object_type": "GENE-Y"}, {"subject": "N-propargyl-1-(R)-aminoindan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase (MAO)-B", "object_type": "GENE-Y"}]}
{"text": "Its S-isomer, TVP1022 is thousand times less potent as an MAO-B inhibitor.", "spo_list": [{"subject": "TVP1022", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "However, both compounds have similar molecular mechanisms of neuroprotection in neuronal cell cultures and animal neurodegenerative models, indicating that the neuroprotective effect of rasagiline does not depend on inhibition of MAO-B, but rather is associated with the N-propargyl moiety, which promotes mitochondrial viability and stabilizes permeability transition by regulating Bcl-2 family proteins.", "spo_list": [{"subject": "N-propargyl", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bcl-2", "object_type": "GENE-Y"}, {"subject": "rasagiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "Substitution of the C terminus of OCTN2 (amino acid residues 342-557) with the corresponding residues of OCTN1 completely abolished carnitine transport.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "OCTN2", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "OCTN2", "object_type": "GENE-Y"}]}
{"text": "The progressive substitution of the N terminus of OCTN2 with OCTN1 resulted in a decrease in carnitine transport associated with a progressive increase in the Km toward carnitine from 3.9 +/- 0.5 to 141 +/- 19 microM.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "OCTN2", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "OCTN1", "object_type": "GENE-Y"}]}
{"text": "Involvement of these residues in carnitine transport was further supported by the partial restoration of carnitine transport by the introduction of these OCTN2 residues in the OCTN1 portion of CHIM-9.", "spo_list": [{"subject": "carnitine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OCTN2", "object_type": "GENE-Y"}, {"subject": "carnitine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OCTN1", "object_type": "GENE-Y"}, {"subject": "carnitine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CHIM-9", "object_type": "GENE-Y"}]}
{"text": "These studies indicate that multiple domains of the OCTN2 transporter are required for carnitine transport and identify transmembrane residues important for carnitine recognition.", "spo_list": [{"subject": "carnitine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OCTN2", "object_type": "GENE-Y"}, {"subject": "carnitine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OCTN2", "object_type": "GENE-Y"}]}
{"text": "NO derived from inducible NO synthase (iNOS) can activate macrophage apoptosis.", "spo_list": [{"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "inducible NO synthase", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "iNOS", "object_type": "GENE-Y"}]}
{"text": "Arginase competes with iNOS by converting L-arginine to L-ornithine.", "spo_list": [{"subject": "L-arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Arginase", "object_type": "GENE-N"}, {"subject": "L-arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "L-ornithine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Arginase", "object_type": "GENE-N"}, {"subject": "L-ornithine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "iNOS", "object_type": "GENE-Y"}]}
{"text": "Surprisingly, apoptosis was blocked by the arginase inhibitors N(omega)-hydroxy-L-arginine or N(omega)-hydroxy-nor-L-arginine, but not by the iNOS inhibitor N-iminoethyl-L-lysine.", "spo_list": [{"subject": "N(omega)-hydroxy-L-arginine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "arginase", "object_type": "GENE-N"}, {"subject": "N(omega)-hydroxy-nor-L-arginine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "arginase", "object_type": "GENE-N"}, {"subject": "N-iminoethyl-L-lysine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "iNOS", "object_type": "GENE-Y"}]}
{"text": "Ornithine decarboxylase (ODC), which metabolizes L-ornithine to polyamines, was also induced in H. pylori-stimulated macrophages.", "spo_list": [{"subject": "L-ornithine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Ornithine decarboxylase", "object_type": "GENE-Y"}, {"subject": "L-ornithine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ODC", "object_type": "GENE-Y"}, {"subject": "polyamines", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Ornithine decarboxylase", "object_type": "GENE-Y"}, {"subject": "polyamines", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ODC", "object_type": "GENE-Y"}]}
{"text": "Apoptosis was abolished by inhibition of ODC and was restored by the polyamines spermidine and spermine.", "spo_list": [{"subject": "polyamines", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ODC", "object_type": "GENE-Y"}, {"subject": "spermidine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ODC", "object_type": "GENE-Y"}, {"subject": "spermine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ODC", "object_type": "GENE-Y"}]}
{"text": "Therefore, we describe arginase- and ODC-dependent macrophage apoptosis, which implicates polyamines in the pathophysiology of H. pylori infection.", "spo_list": [{"subject": "polyamines", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "arginase", "object_type": "GENE-N"}, {"subject": "polyamines", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ODC", "object_type": "GENE-Y"}]}
{"text": "We isolated partial cDNAs that codified for enzymes implicated in the anthocyanin biosynthesis such as l-phenylalanine ammonia-lyase (PAL) and chalcone synthase (CHS), and an antioxidant enzyme such as ascorbate peroxidase (APX).", "spo_list": [{"subject": "anthocyanin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "l-phenylalanine ammonia-lyase", "object_type": "GENE-Y"}, {"subject": "anthocyanin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PAL", "object_type": "GENE-Y"}, {"subject": "anthocyanin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "chalcone synthase", "object_type": "GENE-Y"}, {"subject": "anthocyanin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CHS", "object_type": "GENE-Y"}, {"subject": "anthocyanin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ascorbate peroxidase", "object_type": "GENE-Y"}, {"subject": "anthocyanin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "APX", "object_type": "GENE-Y"}]}
{"text": "Currently, the most important insecticides are neonicotinoids, which are metabolized in vitro by AOX on reduction of the nitroimino group and by CYPs via oxidation reactions.", "spo_list": [{"subject": "neonicotinoids", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AOX", "object_type": "GENE-N"}, {"subject": "neonicotinoids", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYPs", "object_type": "GENE-N"}, {"subject": "nitroimino", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AOX", "object_type": "GENE-N"}]}
{"text": "The procedure was to reduce liver AOX activity by providing tungsten or hydralazine in the drinking water or to use the AOX-deficient DBA/2 mouse strain.", "spo_list": [{"subject": "tungsten", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AOX", "object_type": "GENE-N"}, {"subject": "hydralazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AOX", "object_type": "GENE-N"}]}
{"text": "Liver AOX activity was reduced by 45% with tungsten and 61% with hydralazine and 81% in AOX-deficient mice relative to controls.", "spo_list": [{"subject": "tungsten", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AOX", "object_type": "GENE-N"}, {"subject": "hydralazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AOX", "object_type": "GENE-N"}]}
{"text": "When mice were treated ip with the major neonicotinoid imidacloprid (IMI), metabolism by CYP oxidation reactions was not appreciably affected, whereas the AOX-generated nitrosoguanidine metabolite was decreased by 30% with tungsten and 56% with hydralazine and 86% in the AOX-deficient mice.", "spo_list": [{"subject": "nitrosoguanidine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "AOX", "object_type": "GENE-N"}, {"subject": "tungsten", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AOX", "object_type": "GENE-N"}, {"subject": "hydralazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AOX", "object_type": "GENE-N"}]}
{"text": "Thus, decreasing liver AOX activity by three quite different procedures gave a corresponding decrease for in vivo reductive metabolites in the liver of IMI-treated mice.", "spo_list": [{"subject": "IMI", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AOX", "object_type": "GENE-N"}]}
{"text": "Possible AOX involvement in IMI metabolism in insects was evaluated using AOX-expressing and AOX-deficient Drosophila, but no differences were found in IMI nitroreduction or sensitivity between the two strains.", "spo_list": [{"subject": "IMI", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AOX", "object_type": "GENE-N"}, {"subject": "IMI", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AOX", "object_type": "GENE-N"}]}
{"text": "This is the first study to establish the in vivo relevance of AOX in neonicotinoid metabolism in mammals and one of the first for xenobiotics in general.", "spo_list": [{"subject": "neonicotinoid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AOX", "object_type": "GENE-N"}]}
{"text": "Immunological titration of opioid binding activity from rat brain showed that the antibody was able to displace specific binding of [3H]etorphine (universal opioid) and [3H]dihydromorphine (mu opioid) from rat membranes, but was ineffective against the binding of [3H]ethylketocyclazocine (kappa [3H]D-Ala2,D-Leu5-enkephalin (delta opioid) or [3H]phencyclidine (phencyclidine/sigma receptor ligand).", "spo_list": [{"subject": "[3H]dihydromorphine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mu opioid", "object_type": "GENE-Y"}]}
{"text": "HDN-induced renal biomarker changes in male rats were potentially compound specific: (1) 2-propanol induced mild HDN without increased renal biomarkers, (2) potassium bromate induced moderate HDN with increased clusterin, and (3) D-limonene induced marked HDN with increased Î±GST, Î¼GST and albumin.", "spo_list": [{"subject": "potassium bromate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "clusterin", "object_type": "GENE-Y"}, {"subject": "D-limonene", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î±GST", "object_type": "GENE-N"}, {"subject": "D-limonene", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î¼GST", "object_type": "GENE-N"}, {"subject": "D-limonene", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "albumin", "object_type": "GENE-Y"}]}
{"text": "The compound D-limonene induced a dose dependent increase in HDN severity and renal biomarker changes without altering BUN, creatinine or NAG: (1) minimal induction of HDN and no altered biomarkers at 10 mg/kg/day, (2) mild induction of HDN with increased Î±GST and Î¼GST at 50 mg/kg/day and (3) marked induction of HDN with increased Î±GST, Î¼GST and albumin at 300 mg/kg/day.", "spo_list": [{"subject": "D-limonene", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î±GST", "object_type": "GENE-N"}, {"subject": "D-limonene", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î¼GST", "object_type": "GENE-N"}, {"subject": "D-limonene", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î±GST", "object_type": "GENE-N"}, {"subject": "D-limonene", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î¼GST", "object_type": "GENE-N"}, {"subject": "D-limonene", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "albumin", "object_type": "GENE-Y"}]}
{"text": "HDN induced by D-limonene was reversible, but with a variable renal biomarker pattern over time: Day 8 there was increased Î±GST, Î¼GST and albumin; on Day 15 increased clusterin, albumin and Kim-1.", "spo_list": [{"subject": "D-limonene", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î±GST", "object_type": "GENE-N"}, {"subject": "D-limonene", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î¼GST", "object_type": "GENE-N"}, {"subject": "D-limonene", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "albumin", "object_type": "GENE-Y"}, {"subject": "D-limonene", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "clusterin", "object_type": "GENE-Y"}, {"subject": "D-limonene", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "albumin", "object_type": "GENE-Y"}, {"subject": "D-limonene", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Kim-1", "object_type": "GENE-Y"}]}
{"text": "In pulse-chase experiments, the mutant islets incorporate lesser amounts of isotopic amino acids into insulin-related components than normal islets.", "spo_list": [{"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "insulin", "object_type": "GENE-N"}]}
{"text": "The overall half-time for the conversion of proinsulin to insulin is increased approximately 3-fold in the mutant islets and is associated with a 4-5-fold greater elevation of des-31,32 proinsulin, an intermediate that is formed by the preferential cleavage of proinsulin at the B chain-C-peptide junction by PC3 and is C-terminally processed to remove Arg31 and Arg32 by carboxypeptidase E. The constitutive release of newly synthesized proinsulin from both mutant and wild-type islets during the first 1-2 h of chase was normal (<2% of total).", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "des-31,32 proinsulin", "object_type": "GENE-N"}]}
{"text": "Practical asymmetric synthesis of aprepitant, a potent human NK-1 receptor antagonist, via a stereoselective Lewis acid-catalyzed trans acetalization reaction.", "spo_list": [{"subject": "aprepitant", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NK-1 receptor", "object_type": "GENE-Y"}]}
{"text": "A streamlined and high-yielding synthesis of aprepitant (1), a potent substance P (SP) receptor antagonist, is described.", "spo_list": [{"subject": "aprepitant", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "substance P (SP) receptor", "object_type": "GENE-Y"}]}
{"text": "Melamine activates NFÎºB/COX-2/PGE2 pathway and increases NADPH oxidase-dependent ROS production in macrophages and human embryonic kidney cells.", "spo_list": [{"subject": "Melamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NFÎºB", "object_type": "GENE-N"}, {"subject": "Melamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "Melamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NADPH oxidase", "object_type": "GENE-N"}]}
{"text": "Results indicated melamine activated nuclear factor (NF)-ÎºB through increasing IÎºB-Î± degradation and NF-ÎºB p65/p50 DNA-binding activity.", "spo_list": [{"subject": "melamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "nuclear factor (NF)-ÎºB", "object_type": "GENE-N"}, {"subject": "melamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "melamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p65", "object_type": "GENE-Y"}, {"subject": "melamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p50", "object_type": "GENE-Y"}]}
{"text": "In addition, melamine significantly increased COX-2 expression and prostaglandin E2 (PGE2) production.", "spo_list": [{"subject": "melamine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "prostaglandin E2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "PGE2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Moreover, melamine activated NADPH oxidase (NOX), including NOX1, 2 and 4, accompanied with an increase in reactive oxygen species (ROS) production.", "spo_list": [{"subject": "melamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NADPH oxidase", "object_type": "GENE-N"}, {"subject": "melamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NOX", "object_type": "GENE-N"}]}
{"text": "Furthermore, melamine-induced ROS production could be attenuated by apocynin, a NOX inhibitor.", "spo_list": [{"subject": "melamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NOX", "object_type": "GENE-N"}, {"subject": "apocynin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NOX", "object_type": "GENE-N"}]}
{"text": "In conclusion, our findings suggest melamine increased inflammation and oxidative stress via activation of NF-ÎºB/COX-2 and NOX/ROS pathway, and first revealed the critical role of NOX in melamine-induced ROS production, suggesting the potential of NOX inhibitor against melamine toxicity.", "spo_list": [{"subject": "melamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "melamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "melamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NOX", "object_type": "GENE-N"}, {"subject": "melamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NOX", "object_type": "GENE-N"}, {"subject": "melamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NOX", "object_type": "GENE-N"}, {"subject": "melamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NOX", "object_type": "GENE-N"}]}
{"text": "We show that cytosolic aspartate aminotransferase (cAspAT) is involved in adipocyte glyceroneogenesis, a regulated pathway that controls fatty acid homeostasis by promoting glycerol 3-phosphate formation for fatty acid re-esterification during fasting. cAspAT activity, as well as the incorporation of [(14)C]aspartate into the neutral lipid fraction of 3T3-F442A adipocytes was stimulated by the thiazolidinedione (TZD) rosiglitazone.", "spo_list": [{"subject": "thiazolidinedione", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "cAspAT", "object_type": "GENE-Y"}, {"subject": "TZD", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "cAspAT", "object_type": "GENE-Y"}, {"subject": "rosiglitazone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "cAspAT", "object_type": "GENE-Y"}]}
{"text": "The cAspAT TZD-responsive site was restricted to a single AGGACA hexanucleotide located at -381 to -376 bp whose mutation impaired the specific RORalpha binding.", "spo_list": [{"subject": "AGGACA", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "cAspAT", "object_type": "GENE-Y"}, {"subject": "hexanucleotide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "cAspAT", "object_type": "GENE-Y"}]}
{"text": "RORalpha ectopic expression activated the cAspAT gene transcription in absence of rosiglitazone, and its protein amount in nuclear extracts is 1.8-fold increased by rosiglitazone treatment of adipocytes.", "spo_list": [{"subject": "rosiglitazone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "RORalpha", "object_type": "GENE-Y"}, {"subject": "rosiglitazone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cAspAT", "object_type": "GENE-Y"}]}
{"text": "Finally, the amounts of RORalpha and cAspAT mRNAs were similarly increased by TZD treatment of human adipose tissue explants, confirming coordinated regulation.", "spo_list": [{"subject": "TZD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "RORalpha", "object_type": "GENE-Y"}, {"subject": "TZD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cAspAT", "object_type": "GENE-Y"}]}
{"text": "Our data identify cAspAT as a new member of glyceroneogenesis, transcriptionally regulated by TZD via the control of RORalpha expression by PPARgamma in adipocytes.", "spo_list": [{"subject": "TZD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cAspAT", "object_type": "GENE-Y"}]}
{"text": "Patients can also use weak COX-1 inhibitors, such as sodium salicylate or choline magnesium trisalicylate.", "spo_list": [{"subject": "sodium salicylate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "choline magnesium trisalicylate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}]}
{"text": "3. The putative alpha 1L-adrenoceptor antagonist JTH-601, but not the alpha 1B-adrenoceptor antagonist chloroethylclonidine (10 microM) antagonized noradrenaline-induced contractions of SMA.", "spo_list": [{"subject": "JTH-601", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha 1L-adrenoceptor", "object_type": "GENE-N"}, {"subject": "chloroethylclonidine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha 1B-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "The potency of the selective alpha 1D-adrenoceptor antagonist BMY 7378 against noradrenaline (pA2 = 6.16 +/- 0.13) and of the selective alpha 1A-adrenoceptor antagonist RS-17053 against noradrenaline (pKB = 8.35 +/- 0.10) and against the selective alpha 1A-adrenoceptor agonist A-61603 (pKB = 8.40 +/- 0.09) were too low to account for alpha 1D- and alpha 1A-adrenoceptor involvement.", "spo_list": [{"subject": "BMY 7378", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha 1D-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "RS-17053", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha 1A-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "A-61603", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha 1A-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "6. Combined concentration-ratio analysis demonstrated that tamsulosin, which does not discriminate between alpha 1A- and alpha 1L-adrenoceptors, and RS-17053 competed for binding at the same site in the SMA.", "spo_list": [{"subject": "tamsulosin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 1A", "object_type": "GENE-Y"}, {"subject": "tamsulosin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 1L-adrenoceptors", "object_type": "GENE-N"}, {"subject": "RS-17053", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 1A", "object_type": "GENE-Y"}, {"subject": "RS-17053", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 1L-adrenoceptors", "object_type": "GENE-N"}]}
{"text": "The rate limiting enzyme of beta-oxidation (ACOX1) was significantly over-expressed in the liver with tBHQ treatment.", "spo_list": [{"subject": "tBHQ", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ACOX1", "object_type": "GENE-Y"}]}
{"text": "These results indicate that tBHQ suppresses body weight gain in mice, possibly at least related to the up-regulation of ACOX1 gene expression.", "spo_list": [{"subject": "tBHQ", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ACOX1", "object_type": "GENE-Y"}]}
{"text": "Synthesis, biological evaluation, and molecular modeling of glycyrrhizin derivatives as potent high-mobility group box-1 inhibitors with anti-heart-failure activity in vivo.", "spo_list": [{"subject": "glycyrrhizin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "high-mobility group box-1", "object_type": "GENE-Y"}]}
{"text": "This trial investigated the possibility of pharmacokinetic interactions between the AT1 receptor antagonist olmesartan medoxomil and the thiazide diuretic hydrochlorothiazide in healthy subjects.", "spo_list": [{"subject": "olmesartan medoxomil", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "AT1 receptor", "object_type": "GENE-Y"}]}
{"text": "The Î±- and Î²-adrenergic classes of insect octopamine receptor are better activated by octopamine than tyramine.", "spo_list": [{"subject": "octopamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "octopamine receptor", "object_type": "GENE-Y"}]}
{"text": "Similarly, the Tyramine 1 subgroup of receptors (or Octopamine/Tyramine receptors) are better activated by tyramine than octopamine.", "spo_list": [{"subject": "tyramine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Tyramine 1 subgroup of receptors", "object_type": "GENE-Y"}]}
{"text": "However, recently, a new Tyramine 2 subgroup of receptors was identified, which appears to be activated highly preferentially by tyramine.", "spo_list": [{"subject": "tyramine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Tyramine 2 subgroup of receptors", "object_type": "GENE-Y"}]}
{"text": "Hypoxia-selective O6-alkylguanine-DNA alkyltransferase inhibitors: design, synthesis, and evaluation of 6-(benzyloxy)-2-(aryldiazenyl)-9H-purines as prodrugs of O6-benzylguanine.", "spo_list": [{"subject": "6-(benzyloxy)-2-(aryldiazenyl)-9H-purines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "O6-alkylguanine-DNA alkyltransferase", "object_type": "GENE-Y"}, {"subject": "O6-benzylguanine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "O6-alkylguanine-DNA alkyltransferase", "object_type": "GENE-Y"}]}
{"text": "O(6)-Alkylguanine-DNA alkyltransferase (AGT) is a DNA repair protein which removes alkyl groups from the O-6 position of guanine, thereby providing strong resistance to anticancer agents which alkylate this position.", "spo_list": [{"subject": "guanine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "O(6)-Alkylguanine-DNA alkyltransferase", "object_type": "GENE-Y"}, {"subject": "guanine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AGT", "object_type": "GENE-Y"}]}
{"text": "Hypotensive effect of hydroxylamine, an endogenous nitric oxide donor and SSAO inhibitor.", "spo_list": [{"subject": "hydroxylamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SSAO", "object_type": "GENE-Y"}]}
{"text": "Hydroxylamine hypotension was enhanced by the SSAO inhibitor isoniazid and the SSAO substrate methylamine, a pattern shared by hydralazine.", "spo_list": [{"subject": "isoniazid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SSAO", "object_type": "GENE-Y"}, {"subject": "methylamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SSAO", "object_type": "GENE-Y"}]}
{"text": "Responses were blocked by the guanylate cyclase inhibitor methylene blue and were increased by the nitric oxide synthase inhibitor L-NAME, a pattern shared by nitroprusside.", "spo_list": [{"subject": "methylene blue", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "guanylate cyclase", "object_type": "GENE-N"}, {"subject": "L-NAME", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "nitric oxide synthase", "object_type": "GENE-N"}]}
{"text": "It was concluded that hydroxylamine exerts hypotension partly through conversion to nitric oxide and partly by a \"hydralazine-like\" mechanism involving SSAO inhibition.", "spo_list": [{"subject": "hydroxylamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SSAO", "object_type": "GENE-Y"}]}
{"text": "It is caused by a deficiency of propionyl-CoA carboxylase (PCC, EC 6.4.1.3), a biotin-dependent enzyme that catalyzes the carboxylation of propionyl-CoA to D-methylmalonyl-CoA.", "spo_list": [{"subject": "propionyl-CoA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "propionyl-CoA carboxylase", "object_type": "GENE-N"}, {"subject": "propionyl-CoA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PCC", "object_type": "GENE-N"}, {"subject": "propionyl-CoA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 6.4.1.3", "object_type": "GENE-Y"}, {"subject": "D-methylmalonyl-CoA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "propionyl-CoA carboxylase", "object_type": "GENE-N"}, {"subject": "D-methylmalonyl-CoA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PCC", "object_type": "GENE-N"}, {"subject": "D-methylmalonyl-CoA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 6.4.1.3", "object_type": "GENE-Y"}]}
{"text": "In this study, Wistar-Kyoto rats received intracerebroventricular (I.C.V.) infusion of artificial cerebrospinal fluid (aCSF) while SHRs received I.C.V. infusion of aCSF, Ang-(1-7), Mas receptor antagonist A-779, or angiotensin II type 2 receptor antagonist PD123319 for 4 weeks.", "spo_list": [{"subject": "PD123319", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "angiotensin II type 2 receptor", "object_type": "GENE-Y"}, {"subject": "A-779", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "Mas receptor", "object_type": "GENE-Y"}, {"subject": "A-779", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "Ang-(1-7)", "object_type": "GENE-Y"}]}
{"text": "Of note, the anti-autophagic effects of Ang-(1-7) were independent of blood pressure reduction and can be inhibited by A-779 and PD123319.", "spo_list": [{"subject": "A-779", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Ang-(1-7)", "object_type": "GENE-Y"}, {"subject": "PD123319", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Ang-(1-7)", "object_type": "GENE-Y"}]}
{"text": "Structural Explanation for Allolactose (lac Operon Inducer) Synthesis by lacZ Î²-Galactosidase and the Evolutionary Relationship between Allolactose Synthesis and the lac Repressor. Î²-Galactosidase (lacZ) has bifunctional activity.", "spo_list": [{"subject": "Allolactose", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "lacZ", "object_type": "GENE-N"}, {"subject": "Allolactose", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Î²-Galactosidase", "object_type": "GENE-N"}]}
{"text": "In this study, we assessed the effects of clopidogrel and clarithromycin, known CYP2B6 and CYP3A inhibitors, respectively, on the enantioselective disposition of racemic sibutramine in conjunction with CYP2B6 polymorphisms in humans.", "spo_list": [{"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2B6", "object_type": "GENE-Y"}, {"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "clarithromycin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2B6", "object_type": "GENE-Y"}, {"subject": "clarithromycin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP3A", "object_type": "GENE-N"}]}
{"text": "Probes were perfused with artificial cerebrospinal fluid containing nicotine, the specific alpha(4)beta(2*) nAChR agonist metanicotine, or nicotine plus nAChR antagonists and norepinephrine measured in the microdialysates.", "spo_list": [{"subject": "metanicotine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha(4)beta(2*) nAChR", "object_type": "GENE-Y"}, {"subject": "nicotine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha(4)beta(2*) nAChR", "object_type": "GENE-Y"}]}
{"text": "Other groups received either an infusion of the selective NMDA receptor antagonist (AP7; 10 nmol; intra-mPFC) or vehicle, 10 min prior to PILO preceding LFS600, or prior to a supra-threshold LTD protocol (900 pulses, 1 Hz; LFS900).", "spo_list": [{"subject": "AP7", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NMDA receptor", "object_type": "GENE-N"}]}
{"text": "Our data also indicate that NMDA receptor pre-activation is essential to the muscarinic enhancement of mPFC synaptic depression, since AP7 microinjection into the mPFC blocked the conversion of transient depression into long-lasting LTD produced by PILO.", "spo_list": [{"subject": "AP7", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NMDA receptor", "object_type": "GENE-N"}]}
{"text": "(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole (GSK2251052) is a novel boron-containing antibiotic that inhibits bacterial leucyl tRNA synthetase, and that has been in development for the treatment of serious Gram-negative infections.", "spo_list": [{"subject": "(S)-3-(Aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "bacterial leucyl tRNA synthetase", "object_type": "GENE-N"}, {"subject": "GSK2251052", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "bacterial leucyl tRNA synthetase", "object_type": "GENE-N"}]}
{"text": "Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients.", "spo_list": [{"subject": "piclamilast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase-4", "object_type": "GENE-N"}]}
{"text": "We studied the in vitro effect of piclamilast (RP73401), a selective phosphodiesterase (PDE)-4 inhibitor, compared to theophylline and prednisolone, on respiratory burst of sputum cells from mild asthmatics and COPD patients.", "spo_list": [{"subject": "RP73401", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase (PDE)-4", "object_type": "GENE-N"}, {"subject": "piclamilast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase (PDE)-4", "object_type": "GENE-N"}]}
{"text": "Inhibition by piclamilast was largely reversed through pretreatment of cells with the adenylcyclase inhibitor SQ22536.", "spo_list": [{"subject": "SQ22536", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "adenylcyclase", "object_type": "GENE-N"}]}
{"text": "We concluded that piclamilast, a selective PDE-4 inhibitor, attenuates the respiratory burst of sputum cells from mild asthmatics and COPD patients in vitro.", "spo_list": [{"subject": "piclamilast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE-4", "object_type": "GENE-N"}]}
{"text": "We have investigated the effects of CP-99,994 [(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine], a tachykinin NK1 receptor antagonist, HOE 140 (D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin), a bradykinin B2 receptor antagonist, and ketotifen (4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate), a histamine H1 receptor antagonist with mast cell-stabilizing properties, on microvascular leakage induced by gaseous formaldehyde.", "spo_list": [{"subject": "[(+)-(2s,3s)-3-(2-methoxybenzylamino)-2-phenylpiperidine]", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "tachykinin NK1 receptor", "object_type": "GENE-Y"}, {"subject": "CP-99,994", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "tachykinin NK1 receptor", "object_type": "GENE-Y"}, {"subject": "HOE 140", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "bradykinin B2 receptor", "object_type": "GENE-Y"}, {"subject": "(D-Arg[Hyp3,Thi5,D-Tic7,Oic8]bradykinin)", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "bradykinin B2 receptor", "object_type": "GENE-Y"}, {"subject": "(4-(1-methyl-4-piperidylidene)4 H-benzo[4,5]cycloheptal[1,2-b]thiophen-10(9H)-one hydrogen fumarate)", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1 receptor", "object_type": "GENE-Y"}, {"subject": "ketotifen", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1 receptor", "object_type": "GENE-Y"}]}
{"text": "Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes.", "spo_list": [{"subject": "AZD6140", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "P2Y12", "object_type": "GENE-Y"}, {"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "P2Y12", "object_type": "GENE-Y"}]}
{"text": "AZD6140 is a reversible oral P2Y(12) receptor antagonist that has been studied in ACS patients in comparison with clopidogrel (DISPERSE-2 study).", "spo_list": [{"subject": "AZD6140", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "P2Y(12)", "object_type": "GENE-Y"}, {"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "P2Y(12)", "object_type": "GENE-Y"}]}
{"text": "From these data, it is inferred that both the SERT and NET contribute to the active clearance of exogenously applied 5-HT in the dentate gyrus.", "spo_list": [{"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NET", "object_type": "GENE-Y"}]}
{"text": "In another experiment, cyanopindolol, an antagonist of the serotonin terminal autoreceptor, also prolonged the clearance of 5-HT from the CA3 region.", "spo_list": [{"subject": "cyanopindolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "serotonin terminal autoreceptor", "object_type": "GENE-N"}]}
{"text": "These and other data have generated a working hypothesis that activation of the terminal serotonin autoreceptor enhances the kinetics of 5-HT uptake through an effect on the serotonin transporter.", "spo_list": [{"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "serotonin autoreceptor", "object_type": "GENE-N"}, {"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "serotonin transporter", "object_type": "GENE-Y"}]}
{"text": "Attenuated expression of the tight junction proteins is involved in clopidogrel-induced gastric injury through p38 MAPK activation.", "spo_list": [{"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MAPK", "object_type": "GENE-N"}]}
{"text": "Results showed that clopidogrel significantly increased dextran permeability, induced apoptosis, suppressed GES-1 cell viability, and reduced the expression of the TJ proteins (occludin and ZO-1), acting through p38 MAPK phosphorylation.", "spo_list": [{"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TJ proteins", "object_type": "GENE-N"}, {"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "occludin", "object_type": "GENE-Y"}, {"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ZO-1", "object_type": "GENE-Y"}, {"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MAPK", "object_type": "GENE-N"}]}
{"text": "Furthermore, these observed effects were partially abolished by SB-203580 (a p38 MAPK inhibitor), rather than by either U-0126 (an ERK inhibitor) or SP-600125 (a JNK inhibitor), suggesting that clopidogrel-induced disruption in the gastric epithelial cells is mediated by the p38 MAPK pathway.", "spo_list": [{"subject": "SB-203580", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "SB-203580", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAPK", "object_type": "GENE-N"}, {"subject": "U-0126", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ERK", "object_type": "GENE-N"}, {"subject": "SP-600125", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JNK", "object_type": "GENE-N"}]}
{"text": "It is concluded that attenuated expression of the TJ proteins occludin and ZO-1 in human gastric epithelial cells could be involved in clopidogrel-induced gastric mucosal injury through activation of the p38 MAPK pathway.", "spo_list": [{"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MAPK", "object_type": "GENE-N"}, {"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TJ proteins", "object_type": "GENE-N"}, {"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "occludin", "object_type": "GENE-Y"}, {"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ZO-1", "object_type": "GENE-Y"}]}
{"text": "Fenamiphos is recalcitrant to the hydrolysis by alloforms PON1 Q192R of human serum.", "spo_list": [{"subject": "Fenamiphos", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PON1", "object_type": "GENE-Y"}, {"subject": "Fenamiphos", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Q192R", "object_type": "GENE-N"}]}
{"text": "The paraoxonase 1 from human serum (PON1) is a phosphotriesterase (PTE) that hydrolyses several xenobiotics including drugs and organophosphorus compounds (OPs).", "spo_list": [{"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "paraoxonase 1", "object_type": "GENE-Y"}, {"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PON1", "object_type": "GENE-Y"}, {"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "phosphotriesterase", "object_type": "GENE-N"}, {"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PTE", "object_type": "GENE-N"}]}
{"text": "The levels of the Ca(2+)-dependent hydrolysis (residual concentration [Î¼M]) quantified during 30min of reaction were only just 4-14% for both fenamiphos enantiomers with the three alloforms of PON1 Q192R of the two groups of serum studied.", "spo_list": [{"subject": "fenamiphos", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PON1", "object_type": "GENE-Y"}, {"subject": "fenamiphos", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Q192R", "object_type": "GENE-N"}]}
{"text": "These results demonstrate that human serum PON1 is could be involved in the detoxification of a limited number of organophosphorus insecticides.", "spo_list": [{"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human serum PON1", "object_type": "GENE-Y"}]}
{"text": "Cytochrome P450 epoxygenase 2J2 (CYP2J2) metabolizes arachidonic acids to form epoxyeicosatrienoic acids (EETs), which possess various beneficial effects on the cardiovascular system.", "spo_list": [{"subject": "arachidonic acids", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2J2", "object_type": "GENE-Y"}, {"subject": "arachidonic acids", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Cytochrome P450 epoxygenase 2J2", "object_type": "GENE-Y"}, {"subject": "epoxyeicosatrienoic acids", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CYP2J2", "object_type": "GENE-Y"}, {"subject": "epoxyeicosatrienoic acids", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Cytochrome P450 epoxygenase 2J2", "object_type": "GENE-Y"}, {"subject": "EETs", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CYP2J2", "object_type": "GENE-Y"}, {"subject": "EETs", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Cytochrome P450 epoxygenase 2J2", "object_type": "GENE-Y"}]}
{"text": "However, whether increasing EETs production by CYP2J2 overexpression in vivo could prevent abdominal aortic aneurysm (AAA) remains unknown.", "spo_list": [{"subject": "EETs", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CYP2J2", "object_type": "GENE-Y"}]}
{"text": "In cultured vascular smooth muscle cells (VSMCs), rAAV-mediated CYP2J2 overexpression and EETs markedly suppressed Ang II-induced inflammatory cytokine expression.", "spo_list": [{"subject": "EETs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Ang II", "object_type": "GENE-Y"}, {"subject": "EETs", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cytokine", "object_type": "GENE-N"}]}
{"text": "Moreover, overexpressed CYP2J2 and EETs inhibited Ang II-induced macrophage migration in a VSMC-macrophage coculture system.", "spo_list": [{"subject": "EETs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Ang II", "object_type": "GENE-Y"}]}
{"text": "Both MRP1 and MRP2 actively transported leukotriene C(4) and N-ethylmaleimide glutathione (NEM-GS), although the relative affinity of MRP2 for these substrates was found to be significantly lower than that of MRP1.", "spo_list": [{"subject": "leukotriene C(4)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP1", "object_type": "GENE-Y"}, {"subject": "leukotriene C(4)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP2", "object_type": "GENE-Y"}, {"subject": "leukotriene C(4)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP2", "object_type": "GENE-Y"}, {"subject": "leukotriene C(4)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP1", "object_type": "GENE-Y"}]}
{"text": "Methotrexate was actively transported by both proteins, although more efficiently by MRP2.", "spo_list": [{"subject": "Methotrexate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP2", "object_type": "GENE-Y"}]}
{"text": "Probenecid and furosemide inhibited, whereas under certain conditions sulfinpyrazone, penicillin G, and indomethacin greatly stimulated, MRP2-mediated NEM-GS uptake.", "spo_list": [{"subject": "Probenecid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MRP2", "object_type": "GENE-Y"}, {"subject": "furosemide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MRP2", "object_type": "GENE-Y"}, {"subject": "sulfinpyrazone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MRP2", "object_type": "GENE-Y"}, {"subject": "penicillin G", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MRP2", "object_type": "GENE-Y"}, {"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MRP2", "object_type": "GENE-Y"}]}
{"text": "ATP hydrolysis by MRP2 was also effectively stimulated by methotrexate.", "spo_list": [{"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP2", "object_type": "GENE-Y"}, {"subject": "methotrexate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MRP2", "object_type": "GENE-Y"}]}
{"text": "Probenecid, sulfinpyrazone, indomethacin, furosemide, and penicillin G all significantly increased MRP2-ATPase activity, whereas these compounds acted more as ATPase inhibitors on MRP1.", "spo_list": [{"subject": "Probenecid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MRP2", "object_type": "GENE-Y"}, {"subject": "sulfinpyrazone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MRP2", "object_type": "GENE-Y"}, {"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MRP2", "object_type": "GENE-Y"}, {"subject": "furosemide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MRP2", "object_type": "GENE-Y"}, {"subject": "penicillin G", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MRP2", "object_type": "GENE-Y"}, {"subject": "Probenecid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "sulfinpyrazone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "Probenecid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "sulfinpyrazone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "furosemide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "penicillin G", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATPase", "object_type": "GENE-N"}, {"subject": "Probenecid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MRP1", "object_type": "GENE-Y"}, {"subject": "sulfinpyrazone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MRP1", "object_type": "GENE-Y"}, {"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MRP1", "object_type": "GENE-Y"}, {"subject": "furosemide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MRP1", "object_type": "GENE-Y"}, {"subject": "penicillin G", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MRP1", "object_type": "GENE-Y"}]}
{"text": "These results indicate that MRP1 is a more efficient transporter of glutathione conjugates and free glutathione than MRP2, whereas several anions are preferred substrates for MRP2.", "spo_list": [{"subject": "glutathione", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP1", "object_type": "GENE-Y"}, {"subject": "glutathione", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP1", "object_type": "GENE-Y"}, {"subject": "glutathione", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP2", "object_type": "GENE-Y"}, {"subject": "glutathione", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP2", "object_type": "GENE-Y"}]}
{"text": "When cultured in YPD medium containing 15% glucose under aerobic conditions, the KGD1 (alpha-ketoglutarate dehydrogenase) gene disrupted mutant produced a lower level of succinate than the wild-type strain, while the SDH1 (succinate dehydrogenase) gene-disrupted mutant produced an increased level of succinate.", "spo_list": [{"subject": "succinate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "KGD1", "object_type": "GENE-Y"}, {"subject": "succinate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "alpha-ketoglutarate dehydrogenase", "object_type": "GENE-Y"}, {"subject": "succinate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "SDH1", "object_type": "GENE-Y"}, {"subject": "succinate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "succinate dehydrogenase", "object_type": "GENE-Y"}]}
{"text": "On the other hand, the FUM1 (fumarase) gene disrupted mutant produced significantly higher levels of fumarate but did not form malate at all.", "spo_list": [{"subject": "fumarate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "FUM1", "object_type": "GENE-Y"}, {"subject": "fumarate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "fumarase", "object_type": "GENE-Y"}]}
{"text": "When the growth condition was shifted from aerobic to anaerobic, the increased level of succinate in SDH1 disruptants was no longer observed, whereas the decreased level of succinate in the KGD1 diruptant was still observed.", "spo_list": [{"subject": "succinate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "SDH1", "object_type": "GENE-Y"}, {"subject": "succinate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "KGD1", "object_type": "GENE-Y"}]}
{"text": "A double mutant of the two fumarate reductase isozyme genes (OSM1 and FRDS) showed a succinate productivity of 50% as compared to the parent when cells were incubated in glucose-buffered solution.", "spo_list": [{"subject": "succinate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "fumarate reductase", "object_type": "GENE-N"}, {"subject": "succinate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "OSM1", "object_type": "GENE-Y"}, {"subject": "succinate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "FRDS", "object_type": "GENE-Y"}]}
{"text": "Furthermore, a humanized CYP3A4/3A7 mouse model showed in vivo induction of CYP3A4 mRNA and protein by [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (WY14,643) in liver but not in intestine, whereas hepatic occupancy of PBRs by PPARÎ± was ligand independent.", "spo_list": [{"subject": "4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP3A4", "object_type": "GENE-Y"}, {"subject": "WY14,643", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP3A4", "object_type": "GENE-Y"}]}
{"text": "Interestingly, the common phospholipid 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine (16:0/18:1-PC), previously proposed to reflect nutritional status and shown to be a specific endogenous ligand of PPARÎ±, induced CYP3A4 (up to 4-fold) and other biotransformation genes in hepatocytes with similar selectivity and potency as WY14,643.", "spo_list": [{"subject": "1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PPARÎ±", "object_type": "GENE-Y"}, {"subject": "1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP3A4", "object_type": "GENE-Y"}, {"subject": "WY14,643", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP3A4", "object_type": "GENE-Y"}]}
{"text": "While PBDEs and OH-BDEs have been shown to inhibit the activity and expression of deiodionases, a family of enzymes that regulate thyroid hormone concentrations intracellularly, it is unclear whether or not they can affect regional expression of the different isoforms during early development.", "spo_list": [{"subject": "PBDEs", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "deiodionases", "object_type": "GENE-N"}, {"subject": "OH-BDEs", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "deiodionases", "object_type": "GENE-N"}, {"subject": "PBDEs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "deiodionases", "object_type": "GENE-N"}, {"subject": "OH-BDEs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "deiodionases", "object_type": "GENE-N"}, {"subject": "thyroid hormone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "deiodionases", "object_type": "GENE-N"}]}
{"text": "Î²-catenin regulates GnRH-induced FSHÎ² gene expression.", "spo_list": [{"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "FSHÎ²", "object_type": "GENE-Y"}]}
{"text": "GnRH caused a sustained increase in nuclear Î²-catenin levels, which was significantly reduced by c-Jun N-terminal kinase (JNK) inhibition.", "spo_list": [{"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î²-catenin", "object_type": "GENE-Y"}]}
{"text": "Small interfering RNA-mediated knockdown of Î²-catenin mRNA demonstrated that induction of FSHÎ² mRNA by GnRH depended on Î²-catenin and that regulation of FSHÎ² by Î²-catenin occurred independently of the JNK-c-jun pathway. Î²-Catenin depletion had no impact on FSHÎ² mRNA stability.", "spo_list": [{"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "FSHÎ²", "object_type": "GENE-Y"}]}
{"text": "Furthermore, knockdown of Brms1L significantly attenuated GnRH-induced FSHÎ² expression.", "spo_list": [{"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "FSHÎ²", "object_type": "GENE-Y"}]}
{"text": "Thus, our findings indicate that the expression of Brms1L depends on Î²-catenin activity and contributes to FSHÎ² induction by GnRH.", "spo_list": [{"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "FSHÎ²", "object_type": "GENE-Y"}]}
{"text": "N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide (NS-398), a selective cyclooxygenase-2 inhibitor, also inhibited cell proliferation, whereas it did not cause apoptosis.", "spo_list": [{"subject": "N-[2-(cyclohexyloxyl)-4-nitrophenyl]-methanesulfonamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "NS-398", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}]}
{"text": "Rheumatoid synovial cells expressed PPARgamma mRNA, and the PPARgamma ligands 15-deoxy-Delta(12,14)-prostaglandin J(2) and troglitazone reduced the proliferation and induced apoptosis in synovial cells.", "spo_list": [{"subject": "15-deoxy-Delta(12,14)-prostaglandin J(2)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PPARgamma", "object_type": "GENE-Y"}, {"subject": "troglitazone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PPARgamma", "object_type": "GENE-Y"}]}
{"text": "Human liver prolidase, a metal-dependent dipeptidase, is being tested as a potential catalytic bioscavenger against organophosphorus (OP) chemical warfare nerve agents.", "spo_list": [{"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Human liver prolidase", "object_type": "GENE-Y"}, {"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "dipeptidase", "object_type": "GENE-N"}]}
{"text": "A single injection of CCl4 (2Â ml/kg, i.p.) increased serum aminotransferases (ALT and AST) activities.", "spo_list": [{"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "serum aminotransferases", "object_type": "GENE-N"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ALT", "object_type": "GENE-N"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AST", "object_type": "GENE-Y"}]}
{"text": "In addition, CCl4 treatment led to elevation of hepatic malondialdehyde (MDA) content as well as decrease in superoxide dismutase (SOD) and catalase (CAT) activities.", "spo_list": [{"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "superoxide dismutase", "object_type": "GENE-N"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SOD", "object_type": "GENE-N"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "catalase", "object_type": "GENE-Y"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CAT", "object_type": "GENE-Y"}]}
{"text": "Furthermore, cytochrome P450 2E1 (CYP2E1) content was suppressed while proinflammatory cytokines tumour necrosis factor-Î± (TNF-Î±) and interleukin-6 (IL-6) levels increased in liver tissue after CCl4 administration.", "spo_list": [{"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cytochrome P450 2E1", "object_type": "GENE-Y"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CYP2E1", "object_type": "GENE-Y"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytokines", "object_type": "GENE-N"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "tumour necrosis factor-Î±", "object_type": "GENE-Y"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TNF-Î±", "object_type": "GENE-Y"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "interleukin-6", "object_type": "GENE-Y"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-6", "object_type": "GENE-Y"}]}
{"text": "We showed that acute CCl4-induced damage was accompanied by a rise in Bax/Bcl2 ratio indicating apoptosis.", "spo_list": [{"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bax", "object_type": "GENE-Y"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bcl2", "object_type": "GENE-Y"}]}
{"text": "Pre-treatment with MSM (400Â mg/kg) inhibited the increases of serum ALT and AST activities, decreased hepatic MDA, TNF-Î±, IL-6 and Bax/Bcl2 ratio compared to CCl4 treated group.", "spo_list": [{"subject": "MSM", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ALT", "object_type": "GENE-N"}, {"subject": "MSM", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AST", "object_type": "GENE-Y"}, {"subject": "MSM", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF-Î±", "object_type": "GENE-Y"}, {"subject": "MSM", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-6", "object_type": "GENE-Y"}, {"subject": "MSM", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Bax", "object_type": "GENE-Y"}, {"subject": "MSM", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Bcl2", "object_type": "GENE-Y"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ALT", "object_type": "GENE-N"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AST", "object_type": "GENE-Y"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TNF-Î±", "object_type": "GENE-Y"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-6", "object_type": "GENE-Y"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bax", "object_type": "GENE-Y"}, {"subject": "CCl4", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bcl2", "object_type": "GENE-Y"}]}
{"text": "On the other hand, MSM raised SOD and CAT activities as well as CYP2E1 level in liver tissues.", "spo_list": [{"subject": "MSM", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "SOD", "object_type": "GENE-N"}, {"subject": "MSM", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CAT", "object_type": "GENE-Y"}, {"subject": "MSM", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP2E1", "object_type": "GENE-Y"}]}
{"text": "Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease.", "spo_list": [{"subject": "quinoline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase 5", "object_type": "GENE-Y"}]}
{"text": "Phosphodiesterase type 5 (PDE5) mediates the degradation of cGMP in a variety of tissues including brain.", "spo_list": [{"subject": "cGMP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Phosphodiesterase type 5", "object_type": "GENE-Y"}, {"subject": "cGMP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PDE5", "object_type": "GENE-Y"}]}
{"text": "Catecholamines exhibit a 3-fold higher affinity, and histamine exhibits a 30-fold higher affinity, for VMAT2.", "spo_list": [{"subject": "Catecholamines", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "VMAT2", "object_type": "GENE-Y"}]}
{"text": "Reserpine and ketanserin are slightly more potent inhibitors of VMAT2-mediated transport than of VMAT1-mediated transport, whereas tetrabenazine binds to and inhibits only VMAT2.", "spo_list": [{"subject": "ketanserin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VMAT2", "object_type": "GENE-Y"}, {"subject": "Reserpine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VMAT2", "object_type": "GENE-Y"}, {"subject": "tetrabenazine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "VMAT2", "object_type": "GENE-Y"}, {"subject": "tetrabenazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VMAT2", "object_type": "GENE-Y"}]}
{"text": "N-methyl-4-phenylpyridinium, phenylethylamine, amphetamine, and methylenedioxymethamphetamine are all more potent inhibitors of VMAT2 than of VMAT1, whereas fenfluramine is a more potent inhibitor of VMAT1-mediated monamine transport than of VMAT2-mediated monoamine transport.", "spo_list": [{"subject": "N-methyl-4-phenylpyridinium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VMAT2", "object_type": "GENE-Y"}, {"subject": "phenylethylamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VMAT2", "object_type": "GENE-Y"}, {"subject": "amphetamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VMAT2", "object_type": "GENE-Y"}, {"subject": "methylenedioxymethamphetamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VMAT2", "object_type": "GENE-Y"}, {"subject": "fenfluramine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VMAT1", "object_type": "GENE-Y"}, {"subject": "monamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "VMAT1", "object_type": "GENE-Y"}, {"subject": "monoamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "VMAT2", "object_type": "GENE-Y"}]}
{"text": "Structural basis of inhibition of the human NAD+-dependent deacetylase SIRT5 by suramin.", "spo_list": [{"subject": "suramin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human NAD+-dependent deacetylase SIRT5", "object_type": "GENE-Y"}]}
{"text": "We identified suramin as a compound that binds to human SIRT5 and showed that it inhibits SIRT5 NAD(+)-dependent deacetylase activity with an IC(50) value of 22 microM.", "spo_list": [{"subject": "suramin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human SIRT5", "object_type": "GENE-Y"}, {"subject": "suramin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SIRT5 NAD(+)-dependent deacetylase", "object_type": "GENE-Y"}]}
{"text": "To provide insights into how sirtuin function is altered by inhibitors, we determined two crystal structures of SIRT5, one in complex with ADP-ribose, the other bound to suramin.", "spo_list": [{"subject": "ADP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SIRT5", "object_type": "GENE-Y"}, {"subject": "suramin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SIRT5", "object_type": "GENE-Y"}]}
{"text": "Our structural studies provide a view of a synthetic inhibitory compound in a sirtuin active site revealing that suramin binds into the NAD(+), the product, and the substrate-binding site.", "spo_list": [{"subject": "suramin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "sirtuin", "object_type": "GENE-N"}, {"subject": "NAD(+)", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "sirtuin", "object_type": "GENE-N"}]}
{"text": "Chronic treatment with the NET inhibitor, desipramine (DMI), reduced NET levels in both control and Dbh -/- mice, demonstrating that NE is not required for the regulation of NET by antidepressant drugs.", "spo_list": [{"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NET", "object_type": "GENE-Y"}, {"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NET", "object_type": "GENE-Y"}]}
{"text": "Reactivators showed different activity in the reactivation of rat brain AChE after dichlorvos, paraoxon and tabun inhibition.", "spo_list": [{"subject": "dichlorvos", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "rat brain AChE", "object_type": "GENE-Y"}, {"subject": "paraoxon", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "rat brain AChE", "object_type": "GENE-Y"}, {"subject": "tabun", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "rat brain AChE", "object_type": "GENE-Y"}]}
{"text": "AChE was easier reactivated after paraoxon treatment.", "spo_list": [{"subject": "paraoxon", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "The reactivation of brain AChE inhibited with tabun demonstrated better activity of new compound BT-07-4M, TMB-4 and obidoxime from symmetric oximes, and BT-05 and BT-03 possessing asymmetric structure.", "spo_list": [{"subject": "BT-07-4M", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "TMB-4", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "obidoxime", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "oximes", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "BT-05", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "BT-03", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "All compounds showed low activity toward inhibition of AChE caused by dichlorvos.", "spo_list": [{"subject": "dichlorvos", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "In addition, this compound inhibited Tyr705 phosphorylation of STAT3 and had no obvious effect on upstream tyrosine kinases.", "spo_list": [{"subject": "Tyr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "STAT3", "object_type": "GENE-Y"}]}
{"text": "The catalytic DNA topoisomerase II inhibitor dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells.", "spo_list": [{"subject": "dexrazoxane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA topoisomerase II", "object_type": "GENE-Y"}, {"subject": "ICRF-187", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA topoisomerase II", "object_type": "GENE-Y"}]}
{"text": "The bisdioxopiperazines ICRF-187 (dexrazoxane), ICRF-193, and ICRF-154 are catalytic noncleavable complex-forming inhibitors of DNA topoisomerase II that do not produce protein-linked DNA strand breaks.", "spo_list": [{"subject": "bisdioxopiperazines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA topoisomerase II", "object_type": "GENE-Y"}, {"subject": "ICRF-187", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA topoisomerase II", "object_type": "GENE-Y"}, {"subject": "dexrazoxane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA topoisomerase II", "object_type": "GENE-Y"}, {"subject": "ICRF-193", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA topoisomerase II", "object_type": "GENE-Y"}, {"subject": "ICRF-154", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA topoisomerase II", "object_type": "GENE-Y"}]}
{"text": "Use of the Bcr-Abl tyrosine kinase inhibitor STI-571 resulted in a reduction in Bcl-xL levels and potentiation of dexrazoxane-induced apoptosis related to an earlier onset and more extensive cleavage of caspase-3.", "spo_list": [{"subject": "STI-571", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Bcr", "object_type": "GENE-Y"}, {"subject": "STI-571", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Abl", "object_type": "GENE-Y"}, {"subject": "STI-571", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "STI-571", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Bcl-xL", "object_type": "GENE-Y"}]}
{"text": "These results indicated that dexrazoxane-induced apoptosis is associated with a caspase-3 activation/cleavage pathway.", "spo_list": [{"subject": "dexrazoxane", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "caspase-3", "object_type": "GENE-Y"}]}
{"text": "We hypothesized that sorafenib, a multikinase inhibitor of the BRaf, vascular endothelial growth factor receptor-2, and platelet-derived growth factor receptor-beta kinase, would decrease tumor growth and angiogenesis in an orthotopic model of ATC.", "spo_list": [{"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BRaf", "object_type": "GENE-Y"}, {"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "vascular endothelial growth factor receptor-2", "object_type": "GENE-Y"}, {"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "platelet-derived growth factor receptor-beta", "object_type": "GENE-Y"}, {"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}]}
{"text": "Argininosuccinate synthetase (ASS, EC 6.3.4.5) catalyses the condensation of citrulline and aspartate to form argininosuccinate, the immediate precursor of arginine.", "spo_list": [{"subject": "citrulline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Argininosuccinate synthetase", "object_type": "GENE-Y"}, {"subject": "citrulline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ASS", "object_type": "GENE-Y"}, {"subject": "citrulline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 6.3.4.5", "object_type": "GENE-Y"}, {"subject": "argininosuccinate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Argininosuccinate synthetase", "object_type": "GENE-Y"}, {"subject": "argininosuccinate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ASS", "object_type": "GENE-Y"}, {"subject": "argininosuccinate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "EC 6.3.4.5", "object_type": "GENE-Y"}, {"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Argininosuccinate synthetase", "object_type": "GENE-Y"}, {"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ASS", "object_type": "GENE-Y"}, {"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "EC 6.3.4.5", "object_type": "GENE-Y"}]}
{"text": "Depending on arginine utilization, location and regulation of ASS are quite different.", "spo_list": [{"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ASS", "object_type": "GENE-Y"}]}
{"text": "In contrast, in NO-producing cells, where arginine is the direct substrate in the NO synthesis, ASS gene is expressed at a low level and in this way, proinflammatory signals constitute the main factors of regulation of the gene expression.", "spo_list": [{"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ASS", "object_type": "GENE-Y"}]}
{"text": "Tomatidine inhibits invasion of human lung adenocarcinoma cell A549 by reducing matrix metalloproteinases expression.", "spo_list": [{"subject": "Tomatidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "matrix metalloproteinases", "object_type": "GENE-N"}]}
{"text": "Tomatidine reduces the mRNA level of matrix metalloproteinase-2 (MMP-2), MMP-9 and increases the expression of reversion-inducing cysteine-rich protein with kazal motifs (RECK), as well as tissue inhibitor of metalloproteinase-1 (TIMP-1).", "spo_list": [{"subject": "Tomatidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "matrix metalloproteinase-2", "object_type": "GENE-Y"}, {"subject": "Tomatidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MMP-2", "object_type": "GENE-Y"}, {"subject": "Tomatidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MMP-9", "object_type": "GENE-Y"}, {"subject": "Tomatidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "reversion-inducing cysteine-rich protein with kazal motifs", "object_type": "GENE-Y"}, {"subject": "Tomatidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "RECK", "object_type": "GENE-Y"}, {"subject": "Tomatidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "tissue inhibitor of metalloproteinase-1", "object_type": "GENE-Y"}, {"subject": "Tomatidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TIMP-1", "object_type": "GENE-Y"}]}
{"text": "The immunoblotting assays indicate that tomatidine is very effective in suppressing the phosphorylation of Akt and extracellular signal regulating kinase (ERK).", "spo_list": [{"subject": "tomatidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "tomatidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "extracellular signal regulating kinase", "object_type": "GENE-N"}, {"subject": "tomatidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ERK", "object_type": "GENE-N"}]}
{"text": "In addition, tomatidine significantly decreases the nuclear level of nuclear factor kappa B (NF-ÎºB), which suggests that tomatidine inhibits NF-ÎºB activity.", "spo_list": [{"subject": "tomatidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "nuclear factor kappa B", "object_type": "GENE-N"}, {"subject": "tomatidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "tomatidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}]}
{"text": "Furthermore, the treatment of inhibitors specific for PI3K/Akt (LY294002), ERK (U0126), or NF-ÎºB (pyrrolidine dithiocarbamate) to A549 cells reduced cell invasion and MMP-2/9 expression.", "spo_list": [{"subject": "LY294002", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PI3K", "object_type": "GENE-N"}, {"subject": "LY294002", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "U0126", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ERK", "object_type": "GENE-N"}, {"subject": "pyrrolidine dithiocarbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}]}
{"text": "The results suggest that tomatidine inhibits the invasion of A549 cells by reducing the expression of MMPs.", "spo_list": [{"subject": "tomatidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MMPs", "object_type": "GENE-N"}]}
{"text": "Dietary EPA/DHA treatment restored endogenous biosynthesis of n-3 derived lipid mediators in obesity while attenuating adipose tissue inflammation and improving insulin sensitivity.", "spo_list": [{"subject": "DHA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-N"}, {"subject": "EPA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-N"}]}
{"text": "Notably, 17-HDHA treatment reduced adipose tissue expression of inflammatory cytokines, increased adiponectin expression and improved glucose tolerance parallel to insulin sensitivity in obese mice.", "spo_list": [{"subject": "17-HDHA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cytokines", "object_type": "GENE-N"}, {"subject": "17-HDHA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "adiponectin", "object_type": "GENE-Y"}, {"subject": "17-HDHA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-N"}]}
{"text": "Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans.", "spo_list": [{"subject": "laropiprant", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human recombinant UDP-glucuronosyltransferase", "object_type": "GENE-N"}, {"subject": "MK-0524", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human recombinant UDP-glucuronosyltransferase", "object_type": "GENE-N"}]}
{"text": "A major pathway of elimination of the prostaglandin D2 receptor 1 antagonist laropiprant in humans is by uridine diphosphate-glucuronosyltransferase (UGT)-mediated biotransformation.", "spo_list": [{"subject": "laropiprant", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "prostaglandin D2 receptor 1", "object_type": "GENE-Y"}, {"subject": "laropiprant", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "uridine diphosphate-glucuronosyltransferase", "object_type": "GENE-N"}, {"subject": "laropiprant", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "UGT", "object_type": "GENE-N"}]}
{"text": "In this study, liver and kidney relative activity factors were developed for UGT1A1, 1A9 and 2B7 to allow for in vitro-in vivo extrapolation of intrinsic clearance data to whole organ clearance using recombinant human UGT isoforms applying this to laropiprant as a model substrate.", "spo_list": [{"subject": "laropiprant", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human UGT", "object_type": "GENE-N"}]}
{"text": "Dorzolamide and brinzolamide are two topical CA inhibitors which are currently available to treat ocular hypertension and/or glaucoma.", "spo_list": [{"subject": "Dorzolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA", "object_type": "GENE-N"}, {"subject": "brinzolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA", "object_type": "GENE-N"}]}
{"text": "Dorzolamide is a very potent inhibitor of CA-II and its site of action is local within the eye.", "spo_list": [{"subject": "Dorzolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA-II", "object_type": "GENE-Y"}]}
{"text": "Cells were supplemented with [3H]-oleate (5000 dpm/nmole) bound to 1.5% fatty acid free bovine serum albumin in order to permit detection of the new synthesis and secretion of neutral lipids.", "spo_list": [{"subject": "[3H]-oleate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "bovine serum albumin", "object_type": "GENE-Y"}]}
{"text": "Markers of activation in freshly isolated HSC were decreased by either retinol or retinoic acid without increases in HSC retinoid concentration. mRNA levels for RAR-alpha, RAR-beta and RAR-gamma, the nuclear receptors for retinoic acid, decreased during activation of freshly isolated HSC even with retinoid supplementation.", "spo_list": [{"subject": "retinoid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "RAR-alpha", "object_type": "GENE-Y"}, {"subject": "retinoid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "RAR-beta", "object_type": "GENE-Y"}, {"subject": "retinoid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "RAR-gamma", "object_type": "GENE-Y"}, {"subject": "retinoid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "nuclear receptors", "object_type": "GENE-N"}]}
{"text": "PURPOSE: The fluoropyrimidine carbamate (capecitabine) is converted to 5-fluorouracil (5-FU) by thymidine phosphorylase (TP) inside target tissues.", "spo_list": [{"subject": "fluoropyrimidine carbamate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "thymidine phosphorylase", "object_type": "GENE-Y"}, {"subject": "capecitabine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "thymidine phosphorylase", "object_type": "GENE-Y"}, {"subject": "5-fluorouracil", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "thymidine phosphorylase", "object_type": "GENE-Y"}, {"subject": "5-FU", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "thymidine phosphorylase", "object_type": "GENE-Y"}, {"subject": "fluoropyrimidine carbamate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "TP", "object_type": "GENE-Y"}, {"subject": "capecitabine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "TP", "object_type": "GENE-Y"}, {"subject": "5-fluorouracil", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "TP", "object_type": "GENE-Y"}, {"subject": "5-FU", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "TP", "object_type": "GENE-Y"}]}
{"text": "5-FU interferes with DNA synthesis by blocking thymidylate synthase (TS) but is inactivated by dihydropyrimidine dehydrogenase (DPD).", "spo_list": [{"subject": "5-FU", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}, {"subject": "5-FU", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}]}
{"text": "Favorable enzyme profiles (high TP and low DPD) generate high intratumor levels of 5-FU that are effective against many tumors, especially those with low TS.", "spo_list": [{"subject": "5-FU", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "TP", "object_type": "GENE-Y"}, {"subject": "5-FU", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "DPD", "object_type": "GENE-Y"}]}
{"text": "The mechanisms that specify the vesicular phenotype of inhibitory interneurons in vertebrates are poorly understood because the two main inhibitory transmitters, glycine and GABA, share the same vesicular inhibitory amino acid transporter (VIAAT) and are both present in neurons during postnatal development.", "spo_list": [{"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "vesicular inhibitory amino acid transporter", "object_type": "GENE-Y"}, {"subject": "GABA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "vesicular inhibitory amino acid transporter", "object_type": "GENE-Y"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "VIAAT", "object_type": "GENE-Y"}, {"subject": "GABA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "VIAAT", "object_type": "GENE-Y"}]}
{"text": "We have expressed VIAAT and the plasmalemmal transporters for glycine and GABA in a neuroendocrine cell line and measured the quantal release of glycine and GABA using a novel double-sniffer patch-clamp technique.", "spo_list": [{"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "plasmalemmal transporters", "object_type": "GENE-N"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "VIAAT", "object_type": "GENE-Y"}, {"subject": "GABA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "plasmalemmal transporters", "object_type": "GENE-N"}, {"subject": "GABA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "VIAAT", "object_type": "GENE-Y"}]}
{"text": "We found that glycine is released from vesicles when VIAAT is coexpressed with either the neuronal transporter GlyT2 or the glial transporter GlyT1.", "spo_list": [{"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "VIAAT", "object_type": "GENE-Y"}]}
{"text": "However, GlyT2 was more effective than GlyT1, probably because GlyT2 is unable to operate in the reverse mode, which gives it an advantage in maintaining the high cytosolic glycine concentration required for efficient vesicular loading by VIAAT.", "spo_list": [{"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "VIAAT", "object_type": "GENE-Y"}]}
{"text": "The vesicular inhibitory phenotype was gradually altered from glycinergic to GABAergic through mixed events when GABA is introduced into the secretory cell and competes for uptake by VIAAT.", "spo_list": [{"subject": "GABA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "VIAAT", "object_type": "GENE-Y"}]}
{"text": "Interestingly, the VIAAT ortholog from Caenorhabditis elegans (UNC-47), a species lacking glycine transmission, also supports glycine exocytosis in the presence of GlyT2, and a point mutation of UNC-47 that abolishes GABA transmission in the worm confers glycine specificity.", "spo_list": [{"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GlyT2", "object_type": "GENE-N"}]}
{"text": "Together, these results suggest that an increased cytosolic availability of glycine in VIAAT-containing terminals was crucial for the emergence of glycinergic transmission in vertebrates.", "spo_list": [{"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "VIAAT", "object_type": "GENE-Y"}]}
{"text": "Dynamics of NO rebinding to the heme domain of NO synthase-like proteins from bacterial pathogens.", "spo_list": [{"subject": "NO", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "heme domain of NO synthase-like proteins", "object_type": "GENE-N"}]}
{"text": "NO rebinding in HNS from Staphylococcus aureus (SA-HNS) is faster than that measured for either Bacillus anthracis (BA-HNS) or for eNOS(HD) in both oxidized and reduced forms in the presence of arginine.", "spo_list": [{"subject": "NO", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "HNS", "object_type": "GENE-N"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SA-HNS", "object_type": "GENE-N"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "BA-HNS", "object_type": "GENE-N"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "eNOS(HD)", "object_type": "GENE-N"}]}
{"text": "PRINCIPAL FINDINGS: With the knowledge that all general anesthetics positively modulate GABA(A)-R-mediated inhibitory transmission, site-directed mutagenesis comparing sequences of GABA(A)-R subunits of varying sensitivity led to identification of amino acid residues in the transmembrane domain that are critical for the drug actions in vitro.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GABA(A)-R", "object_type": "GENE-N"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GABA(A)-R", "object_type": "GENE-N"}]}
{"text": "Using a photo incorporable analogue of the general anesthetic, R(+)etomidate, we identified two transmembrane amino acids that were affinity labelled in purified bovine brain GABA(A)-R. Homology protein structural modelling positions these two residues, alphaM1-11' and betaM3-4', close to each other in a single type of intersubunit etomidate binding pocket at the beta/alpha interface.", "spo_list": [{"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "bovine brain GABA(A)-R", "object_type": "GENE-N"}, {"subject": "R(+)etomidate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "bovine brain GABA(A)-R", "object_type": "GENE-N"}]}
{"text": "Using biotinylated FGF-2 and FGF-7 (KGF) as probes, we have identified specific interactions between FGFs and heparan sulfates in human tissues.", "spo_list": [{"subject": "sulfates", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "FGFs", "object_type": "GENE-N"}]}
{"text": "Although FGF-2 strongly binds to basement membrane heparan sulfate in skin and most other tissue sites examined, FGF-7 fails to bind to basement membrane heparan sulfate in most locations.", "spo_list": [{"subject": "sulfate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "FGF-2", "object_type": "GENE-Y"}]}
{"text": "In summary, distinct and specific affinities of heparan sulfates for different FGFs were identified that may affect growth factor activation and local distribution.", "spo_list": [{"subject": "sulfates", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "FGFs", "object_type": "GENE-N"}]}
{"text": "Adult-onset citrullinemia (CTLN2) is a rare hereditary metabolic disorder characterized by highly increased concentration of citrulline and ammonia in the plasma, which is ascribed to a deficiency of argininosuccinate synthetase (ASS), one of the urea cycle enzymes mainly located in the liver.", "spo_list": [{"subject": "citrulline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "argininosuccinate synthetase", "object_type": "GENE-Y"}, {"subject": "citrulline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ASS", "object_type": "GENE-Y"}]}
{"text": "The aim of this study was, therefore, to provide comparative binding characteristics of agonists (epinephrine, norepinephrine, isoproterenol, fenoterol, salbutamol, salmeterol, terbutalin, formoterol, broxaterol) and antagonists (propranolol, alprenolol, atenolol, metoprolol, bisoprolol, carvedilol, pindolol, BRL 37344, CGP 20712, SR 59230A, CGP 12177, ICI 118551) at all three subtypes of human beta-adrenergic receptors in an identical cellular background.", "spo_list": [{"subject": "epinephrine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "norepinephrine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "isoproterenol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "fenoterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "salbutamol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "salmeterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "terbutalin", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "formoterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "broxaterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "propranolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "alprenolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "atenolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "metoprolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "bisoprolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "pindolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "BRL 37344", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "CGP 20712", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "SR 59230A", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "CGP 12177", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}, {"subject": "ICI 118551", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "human beta-adrenergic receptors", "object_type": "GENE-N"}]}
{"text": "Two mechanisms of action have been identified for A77 1726: inhibition of dihydroorotate dehydrogenase (DHODH) and inhibition of tyrosine kinases.", "spo_list": [{"subject": "A77 1726", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dihydroorotate dehydrogenase", "object_type": "GENE-Y"}, {"subject": "A77 1726", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinases", "object_type": "GENE-N"}]}
{"text": "DHODH inhibition occurs at lower concentrations of A77 1726 than that of tyrosine kinases and is currently considered the major mode of action.", "spo_list": [{"subject": "A77 1726", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DHODH", "object_type": "GENE-Y"}, {"subject": "A77 1726", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinases", "object_type": "GENE-N"}]}
{"text": "Since both TFP and W-7 are potent inhibitors of calmodulin, we investigated the possibility that inhibition of calmodulin was responsible for the loss of receptors.", "spo_list": [{"subject": "TFP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "W-7", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calmodulin", "object_type": "GENE-N"}]}
{"text": "Three lines of evidence suggest that calmodulin inhibition is not responsible for the inhibition of binding and endocytosis: 1) Promethazine, a phenothiazine that is a poor inhibitor of calmodulin, is nearly as effective as TFP at inhibiting endocytosis; calmidazolium, a potent inhibitor of several calmodulin functions, did not cause a loss of binding; 2) the microinjection of calmodulin into cells did not reverse the effects of W-7; using pressure microinjection, we introduced up to a 100-fold excess of calmodulin over native levels into individual gerbil fibroma cells; using rhodamine-labeled alpha 2-macroglobulin, we saw that the W-7 induced inhibition of receptor-mediated endocytosis was the same in injected and uninjected cells; 3) we injected calcineurin, a calmodulin-binding protein, into cells (1-3 pg/cell) and observed no effect on the receptor-mediated endocytosis of rhodamine-labeled alpha 2-macroglobulin.", "spo_list": [{"subject": "Promethazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "phenothiazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "TFP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calmodulin", "object_type": "GENE-N"}]}
{"text": "We determined the short-term and long-term competition of cyproterone acetate and chlormadinone acetate with [3H]DHT for receptor binding at 0 degrees C and showed, that the complexes formed by these antiandrogens with the androgen receptor have equally reduced stabilities compared to the DHT-receptor complex.", "spo_list": [{"subject": "[3H]DHT", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "androgen receptor", "object_type": "GENE-Y"}]}
{"text": "In the current study we investigated the activity of the aromatase inhibitor exemestane in human NSCLC cell lines H23 and A549.", "spo_list": [{"subject": "exemestane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "Aromatase protein and mRNA levels were not affected by exemestane in A549 cells, whereas an increase in both protein and mRNA levels was observed in H23 cells, 48 h after exemestane application.", "spo_list": [{"subject": "exemestane", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Aromatase", "object_type": "GENE-Y"}]}
{"text": "Exemestane increased EGFR activation 15 min after its application in H23 cells.", "spo_list": [{"subject": "Exemestane", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "EGFR", "object_type": "GENE-Y"}]}
{"text": "(-)-Isoprenaline and a nonconventional beta(3)-adrenoceptor agonist, (+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride ((+/-)-CGP12177A), induced concentration-dependent relaxation of (-)-phenylephrine (0.3 microM) preconstricted spiral preparations.", "spo_list": [{"subject": "(+/-)-[4-[3-[(1,1-dimethylethyl)amino]-2-hydroxypropoxy]-1,3-dihydro-2H-benzimida zol-2-one] hydrochloride", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(3)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "(+/-)-CGP12177A", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(3)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Pretreatment with a combination of (+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate (CGP20712A, a selective beta(1)-adrenoceptor antagonist) and (+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride (ICI-118,5511, a selective beta(2)-adrenoceptor antagonist) (0.1 microM for each) produced a 14-fold rightward shift of the concentration-response curve for (-)-isoprenaline; however, the relaxation in response to (+/-)-CGP12177A was unaffected by the blockade of beta(1)- and beta(2)-adrenoceptors.", "spo_list": [{"subject": "(+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2 -yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta(1)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "CGP20712A", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta(1)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "(+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-buta nol hydrochloride", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "ICI-118,5511", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Agmatine is an endogenous amine that is synthesized following the decarboxylation of L-arginine by arginine decarboxylase.", "spo_list": [{"subject": "L-arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "arginine decarboxylase", "object_type": "GENE-Y"}, {"subject": "Agmatine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "arginine decarboxylase", "object_type": "GENE-Y"}]}
{"text": "Agmatine binds to several targets and is considered as an endogenous ligand for imidazoline receptors.", "spo_list": [{"subject": "Agmatine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "imidazoline receptors", "object_type": "GENE-N"}]}
{"text": "Hyperphenylalaninemia, which can cause neurological disorders and mental retardation, results from a mutation in phenylalanine hydroxylase or an enzyme required for biosynthesis or regeneration of its cofactor, tetrahydrobiopterin.", "spo_list": [{"subject": "tetrahydrobiopterin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "phenylalanine hydroxylase", "object_type": "GENE-Y"}]}
{"text": "However, accumulation of a 4a-hydroxy-tetrahydrobiopterin degradation product (a side-chain cyclic adduct), which has been observed in vitro and appears to be a dehydratase inhibitor, may further exacerbate the problem.", "spo_list": [{"subject": "4a-hydroxy-tetrahydrobiopterin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dehydratase", "object_type": "GENE-N"}]}
{"text": "Inhibitory effects of lysine analogues on t-PA induced whole blood clot lysis.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "t-PA", "object_type": "GENE-Y"}]}
{"text": "The present study utilized blood from normal volunteers and 125I-fibrinogen in a dilute whole blood clot assay to determine the relative concentrations of lysine analogues required for inhibition of clot lysis induced by exogenous t-PA.", "spo_list": [{"subject": "125I", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "fibrinogen", "object_type": "GENE-N"}, {"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "t-PA", "object_type": "GENE-Y"}]}
{"text": "AMCA (0.06 mM) and EACA (0.6 mM) were effective in prolonging clot lysis if (1) whole blood clots were formed and then exposed to a lysine analogue and exogenous t-PA or if (2) whole blood clots were formed in the presence of exogenous t-PA and a lysine analogue.", "spo_list": [{"subject": "AMCA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "t-PA", "object_type": "GENE-Y"}, {"subject": "EACA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "t-PA", "object_type": "GENE-Y"}, {"subject": "AMCA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "t-PA", "object_type": "GENE-Y"}, {"subject": "EACA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "t-PA", "object_type": "GENE-Y"}]}
{"text": "However, their inhibitory effect was markedly reduced if clots were formed in the presence of t-PA and then exposed to either of the lysine analogues.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "t-PA", "object_type": "GENE-Y"}]}
{"text": "The data suggest that lysine analogues, even at low concentrations, reduce the rate of t-PA induced whole blood clot lysis by several mechanisms.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "t-PA", "object_type": "GENE-Y"}]}
{"text": "Mechanistic studies reveal that the NOGEL is dependent upon repair of O(6)-methylguanine (O(6)MeG) by the suicide enzyme O(6)MeG-DNA methyltransferase (MGMT).", "spo_list": [{"subject": "O(6)-methylguanine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "O(6)MeG-DNA methyltransferase", "object_type": "GENE-Y"}, {"subject": "O(6)-methylguanine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MGMT", "object_type": "GENE-Y"}, {"subject": "O(6)MeG", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "O(6)MeG-DNA methyltransferase", "object_type": "GENE-Y"}, {"subject": "O(6)MeG", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MGMT", "object_type": "GENE-Y"}]}
{"text": "Sunitinib, a tyrosine kinase inhibitor, induces cytochrome P450 1A1 gene in human breast cancer MCF7 cells through ligand-independent aryl hydrocarbon receptor activation.", "spo_list": [{"subject": "Sunitinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "Sunitinib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytochrome P450 1A1", "object_type": "GENE-Y"}]}
{"text": "Sunitinib (SUN) is a new multi-targeted oral tyrosine kinase inhibitor that has both anti-angiogenic and anti-tumor activities.", "spo_list": [{"subject": "Sunitinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "SUN", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}]}
{"text": "Our results showed that SUN induced the CYP1A1 mRNA, protein, and activity levels in a concentration-dependent manner in MCF7 cells.", "spo_list": [{"subject": "SUN", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP1A1", "object_type": "GENE-Y"}, {"subject": "SUN", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CYP1A1", "object_type": "GENE-Y"}]}
{"text": "The increase in CYP1A1 mRNA by SUN was completely blocked by the transcriptional inhibitor, actinomycin D; implying that SUN increased de novo RNA synthesis.", "spo_list": [{"subject": "SUN", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP1A1", "object_type": "GENE-Y"}, {"subject": "actinomycin D", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP1A1", "object_type": "GENE-Y"}, {"subject": "SUN", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP1A1", "object_type": "GENE-Y"}]}
{"text": "Furthermore, the ability of SUN to increase luciferase reporter gene expression suggests an aryl hydrocarbon receptor (AhR)-dependent transcriptional control and excludes the possibility of any posttranscriptional mechanisms.", "spo_list": [{"subject": "SUN", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "aryl hydrocarbon receptor", "object_type": "GENE-Y"}, {"subject": "SUN", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AhR", "object_type": "GENE-Y"}]}
{"text": "In addition, blocking of AhR activation by resveratrol, a well-known AhR antagonist, prevented the SUN-induced CYP1A1 gene expression, further confirms the involvement of AhR.", "spo_list": [{"subject": "SUN", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP1A1", "object_type": "GENE-Y"}]}
{"text": "The current manuscript provides the first evidence for the ability of SUN to induce CYP1A1 gene expression in MCF7 cells through AhR ligand-independent mechanisms.", "spo_list": [{"subject": "SUN", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP1A1", "object_type": "GENE-Y"}]}
{"text": "SUR-dependent modulation of KATP channels by an N-terminal KIR6.2 peptide.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "KIR6.2", "object_type": "GENE-Y"}]}
{"text": "Ntp and Ctp, synthetic peptides based on the N- and C-terminal sequences of K(IR)6.0, respectively, were used to probe gating of K(IR)6.0/SUR K(ATP) channels.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "K(IR)6.0", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "K(IR)6.0", "object_type": "GENE-Y"}]}
{"text": "Micromolar Ntp dose-dependently increased the mean open channel probability in ligand-free solution (P(O(max))) and attenuated the ATP inhibition of K(IR)6.2/SUR1, but had no effect on homomeric K(IR)6.2 channels.", "spo_list": [{"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "K(IR)6.2", "object_type": "GENE-Y"}, {"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SUR1", "object_type": "GENE-Y"}]}
{"text": "Ntp opened K(IR)6.1/SUR1 channels normally silent in the absence of stimulatory Mg(-) nucleotide(s) and attenuated the coupling of high-affinity sulfonylurea binding with K(ATP) pore closure.", "spo_list": [{"subject": "sulfonylurea", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "K(ATP)", "object_type": "GENE-N"}]}
{"text": "These effects resemble those seen with N-terminal deletions (DeltaN) of K(IR)6.0, and application of Ntp to DeltaNK(ATP) channels decreased their P(O(max)) and apparent IC(50) for ATP in the absence of Mg(2+).", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "K(IR)6.0", "object_type": "GENE-Y"}, {"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DeltaNK(ATP) channels", "object_type": "GENE-N"}]}
{"text": "The K(IR) N terminus and the TMD0-L0 segment of SUR1 are known to control the P(O(max)).", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "K(IR)", "object_type": "GENE-Y"}]}
{"text": "The L0 linker has been reported to be required for glibenclamide binding, and DeltaNK(IR)6.2/SUR1 channels exhibit reduced labeling of K(IR) with (125)I-azidoglibenclamide, implying that the K(IR) N terminus and L0 of SUR1 are in proximity.", "spo_list": [{"subject": "(125)I-azidoglibenclamide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "K(IR)", "object_type": "GENE-Y"}, {"subject": "(125)I-azidoglibenclamide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SUR1", "object_type": "GENE-Y"}, {"subject": "(125)I-azidoglibenclamide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DeltaNK(IR)6.2", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "K(IR)", "object_type": "GENE-Y"}]}
{"text": "We hypothesize that L0 interacts with the K(IR) N terminus in ligand-inhibited K(ATP) channels and put forward a model, based on the architecture of BtuCD, MsbA, and the KcsA channel, in which TMD0-L0 links the MDR-like core of SUR with the K(IR) pore.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "K(IR)", "object_type": "GENE-Y"}]}
{"text": "Toona sinensis and its major bioactive compound gallic acid inhibit LPS-induced inflammation in nuclear factor-ÎºB transgenic mice as evaluated by in vivo bioluminescence imaging.", "spo_list": [{"subject": "gallic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "nuclear factor-ÎºB", "object_type": "GENE-N"}]}
{"text": "Miglustat, a small iminosugar molecule approved for the treatment of Gaucher disease, reversibly inhibits glucosylceramide synthase, which catalyses the first committed step in glycosphingolipid synthesis.", "spo_list": [{"subject": "Miglustat", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "glucosylceramide synthase", "object_type": "GENE-Y"}]}
{"text": "We evaluated the effects of angiotensin II and an angiotensin-converting enzyme inhibitor (cilazapril) on nerve blood flow (NBF) and electrophysiology in control and diabetic rats.", "spo_list": [{"subject": "cilazapril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "angiotensin II", "object_type": "GENE-Y"}, {"subject": "cilazapril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "angiotensin-converting enzyme", "object_type": "GENE-Y"}]}
{"text": "We topically applied the nitric oxide synthase (NOS) inhibitor, NG-nitro-L-arginine, on sciatic nerve and observed reduced inhibition of NBF in EDN, which was correctable with a cilazapril diet.", "spo_list": [{"subject": "NG-nitro-L-arginine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "nitric oxide synthase", "object_type": "GENE-N"}, {"subject": "NG-nitro-L-arginine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NOS", "object_type": "GENE-N"}]}
{"text": "Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: a novel therapeutic drug for sleep disorders.", "spo_list": [{"subject": "ramelteon", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "MT1", "object_type": "GENE-Y"}, {"subject": "ramelteon", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "MT2", "object_type": "GENE-Y"}]}
{"text": "Ramelteon (Rozerem; Takeda Pharmaceutical Company Limited, Osaka, Japan) is an orally active, highly selective melatonin MT(1)/MT(2) receptor agonist.", "spo_list": [{"subject": "Ramelteon", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "MT(1)", "object_type": "GENE-Y"}, {"subject": "Ramelteon", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "MT(2)", "object_type": "GENE-Y"}]}
{"text": "Unlike the sedative hypnotics that target GABA(A) receptor complexes, ramelteon is a chronohypnotic that acts on the melatonin MT(1) and MT(2) receptors, which are primarily located in the suprachiasmatic nucleus, the body's \"master clock.\"", "spo_list": [{"subject": "ramelteon", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "MT(1)", "object_type": "GENE-Y"}, {"subject": "ramelteon", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "MT(2)", "object_type": "GENE-Y"}]}
{"text": "Amantadine induces c-fos in rat striatum: reversal with dopamine D1 and NMDA receptor antagonists.", "spo_list": [{"subject": "Amantadine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "c-fos", "object_type": "GENE-Y"}]}
{"text": "Amantadine (1-aminoadamantane) induced Fos expression in the central, dorsal-medial and ventral-medial part of the striatum.", "spo_list": [{"subject": "Amantadine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Fos", "object_type": "GENE-Y"}, {"subject": "1-aminoadamantane", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Fos", "object_type": "GENE-Y"}]}
{"text": "The distribution pattern of Fos induced by amantadine was more similar to those seen with dopaminomimetics than with N-methyl-D-aspartate (NMDA) receptor antagonists.", "spo_list": [{"subject": "amantadine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Fos", "object_type": "GENE-Y"}]}
{"text": "Pretreatment with the dopamine D1 receptor antagonist, SCH23390, and the NMDA receptor antagonist, MK-801, blocked amantadine induction of Fos in the striatum.", "spo_list": [{"subject": "SCH23390", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D1 receptor", "object_type": "GENE-Y"}, {"subject": "MK-801", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NMDA receptor", "object_type": "GENE-N"}, {"subject": "SCH23390", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Fos", "object_type": "GENE-Y"}, {"subject": "MK-801", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Fos", "object_type": "GENE-Y"}, {"subject": "amantadine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Fos", "object_type": "GENE-Y"}]}
{"text": "However, amantadine induction of Fos in the striatum was unaffected by the dopamine D2 receptor antagonist, sulpiride.", "spo_list": [{"subject": "amantadine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Fos", "object_type": "GENE-Y"}, {"subject": "sulpiride", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D2 receptor", "object_type": "GENE-Y"}]}
{"text": "These results suggest that amantadine induction of Fos in the rat striatum is related to dopamine D1 and NMDA receptors.", "spo_list": [{"subject": "amantadine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Fos", "object_type": "GENE-Y"}]}
{"text": "Five classes of chalcogenopyrylium dyes (CGPs) were examined for their ability to modulate transport of [(3)H]estradiol glucuronide (E217Î²G) (a prototypical MRP substrate) into MRP-enriched inside-out membrane vesicles.", "spo_list": [{"subject": "[(3)H]estradiol glucuronide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP", "object_type": "GENE-N"}, {"subject": "E217Î²G", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP", "object_type": "GENE-N"}]}
{"text": "Sixteen of 34 CGPs inhibited MRP1-mediated E217Î²G uptake by >50% (IC50's 0.7-7.6 Î¼M).", "spo_list": [{"subject": "CGPs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MRP1", "object_type": "GENE-Y"}, {"subject": "E217Î²G", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP1", "object_type": "GENE-Y"}]}
{"text": "Of 9 CGPs with IC50's â¤2 Î¼M, two belonged to Class I, two to Class III and five to Class V. When tested in the intact cells, only 4 of 16 CGPs (at 10 Î¼M) inhibited MRP1-mediated calcein efflux by >50% (III-1, V-3, -4, -6) while a fifth (I-5) inhibited efflux by just 23%.", "spo_list": [{"subject": "CGPs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MRP1", "object_type": "GENE-Y"}, {"subject": "calcein", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP1", "object_type": "GENE-Y"}]}
{"text": "These five CGPs also inhibited [(3)H]E217Î²G uptake by MRP4.", "spo_list": [{"subject": "CGPs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MRP4", "object_type": "GENE-Y"}, {"subject": "[(3)H]E217Î²G", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP4", "object_type": "GENE-Y"}]}
{"text": "DNMT1-associated protein 1 (DMAP1) is a member of the TIP60-p400 histone acetyl transferase (HAT) complex, which acetylates histone H4 at lysine 16 (H4K16) to affect chromatin relaxation and modulate ATM activation.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "histone H4", "object_type": "GENE-Y"}]}
{"text": "Oral l-glutamine increases active GLP-1 (7-36) amide secretion and improves glycemic control in stretpozotocin-nicotinamide induced diabetic rats. l-glutamine is a non-essential amino acid.", "spo_list": [{"subject": "l-glutamine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GLP-1", "object_type": "GENE-Y"}]}
{"text": "The objective of the present investigation was to evaluate l-glutamine increases glucagon like peptide-1 (GLP-1) (7-36) amide secretion in streptozotocin-nicotinamide (STZ-NTM) induced diabetic Sprague Dawley rats.", "spo_list": [{"subject": "l-glutamine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "glucagon like peptide-1", "object_type": "GENE-Y"}, {"subject": "l-glutamine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GLP-1", "object_type": "GENE-Y"}]}
{"text": "The docking data indicated that l-glutamine bind to the GLP-1 receptor. l-glutamine decreased plasma glucose, increased plasma and pancreatic insulin, increased plasma and colonic active GLP-1 (7-36) amide secretion as well as decreased oxidative stress in streptozotocin-nicotinamide induced diabetic rats.", "spo_list": [{"subject": "l-glutamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GLP-1 receptor", "object_type": "GENE-Y"}, {"subject": "l-glutamine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-N"}, {"subject": "l-glutamine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GLP-1", "object_type": "GENE-Y"}]}
{"text": "Triflusal (30 mg/kg) also significantly decreased the protein levels of IL-Ibeta but not nuclear factor kappa B or tumor necrosis factor-alpha in the cortex ipsilateral to the middle cerebral artery occlusion.", "spo_list": [{"subject": "Triflusal", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-Ibeta", "object_type": "GENE-Y"}]}
{"text": "The highest DPmax of 15 was achieved in a one-step and two-step synthesis of oligo(p-xylylene sebacamide) catalyzed by CLEA cutinase.", "spo_list": [{"subject": "oligo(p-xylylene sebacamide)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CLEA cutinase", "object_type": "GENE-N"}]}
{"text": "Association with the cholinergic precursor choline alphoscerate and the cholinesterase inhibitor rivastigmine: an approach for enhancing cholinergic neurotransmission.", "spo_list": [{"subject": "rivastigmine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cholinesterase", "object_type": "GENE-Y"}]}
{"text": "The effects of association of cholinergic precursors choline or choline alphoscerate with the cholinesterase inhibitor rivastigmine on acetylcholine levels and [(3)H]hemicholinium-3 binding were assessed in rat frontal cortex, hippocampus and striatum.", "spo_list": [{"subject": "rivastigmine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cholinesterase", "object_type": "GENE-Y"}]}
{"text": "Choline alphoscerate or rivastigmine, but not choline increased acetylcholine levels as well as [(3)H]hemicholinium-3 binding used as a marker of high affinity cholinergic transporter.", "spo_list": [{"subject": "[(3)H]hemicholinium-3", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "cholinergic transporter", "object_type": "GENE-N"}]}
{"text": "Rivastigmine alone or in association with either choline or choline alphoscerate decreased acetylcholinesterase (AChE), whereas choline or choline alphoscerate alone did not affect AChE activity.", "spo_list": [{"subject": "Rivastigmine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "choline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "choline alphoscerate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "Rivastigmine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "choline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "choline alphoscerate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "We now show that lysine-specific molecular tweezers bind to a 14-3-3 adapter protein and modulate its interaction with partner proteins.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "14-3-3 adapter protein", "object_type": "GENE-N"}]}
{"text": "Protein crystallography shows that this effect arises from the binding of the tweezers to a single surface-exposed lysine (Lys214) of the 14-3-3 protein in the proximity of its central channel, which normally binds the partner proteins.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "14-3-3 protein", "object_type": "GENE-N"}, {"subject": "Lys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "14-3-3 protein", "object_type": "GENE-N"}]}
{"text": "Regulation of sexual reproduction by estradiol involves the activation of estrogen receptors (ERs) in the hypothalamus.", "spo_list": [{"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "estrogen receptors", "object_type": "GENE-Y"}, {"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ERs", "object_type": "GENE-Y"}]}
{"text": "Using surface biotinylation, we observed that treatment of N-38 neurons with estradiol or with a membrane impermeant estradiol elevated plasma membrane ERÎ± protein levels, indicating that membrane signaling increased receptor insertion into the cell membrane.", "spo_list": [{"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ERÎ±", "object_type": "GENE-Y"}]}
{"text": "Insertion of ERÎ± was blocked by the ER antagonist ICI 182,780 or with the protein kinase C (PKC) pathway inhibitor bisindolylmaleimide (BIS).", "spo_list": [{"subject": "ICI 182,780", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ER", "object_type": "GENE-Y"}, {"subject": "ICI 182,780", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "bisindolylmaleimide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "protein kinase C", "object_type": "GENE-N"}, {"subject": "bisindolylmaleimide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PKC", "object_type": "GENE-N"}, {"subject": "BIS", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "protein kinase C", "object_type": "GENE-N"}, {"subject": "BIS", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PKC", "object_type": "GENE-N"}, {"subject": "bisindolylmaleimide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "BIS", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ERÎ±", "object_type": "GENE-Y"}]}
{"text": "These results indicate that membrane ERÎ± levels in N-38 neurons are dynamically autoregulated by estradiol.", "spo_list": [{"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ERÎ±", "object_type": "GENE-Y"}]}
{"text": "Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil.", "spo_list": [{"subject": "sildenafil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase-5", "object_type": "GENE-Y"}]}
{"text": "Vardenafil has higher affinity to phosphodiesterase-5 (PDE5) than sildenafil and lower administered dosage for the treatment of erectile dysfunction.", "spo_list": [{"subject": "Vardenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "phosphodiesterase-5", "object_type": "GENE-Y"}, {"subject": "Vardenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "sildenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "phosphodiesterase-5", "object_type": "GENE-Y"}, {"subject": "sildenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDE5", "object_type": "GENE-Y"}]}
{"text": "Reported here is a crystal structure of the fully active and nonmutated PDE5A1 catalytic domain in complex with vardenafil.", "spo_list": [{"subject": "vardenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDE5A1 catalytic domain", "object_type": "GENE-N"}]}
{"text": "The structure shows that the conformation of the H-loop in the PDE5A1-vardenafil complex is different from those of any known structures of the unliganded PDE5 and its complexes with the inhibitors.", "spo_list": [{"subject": "vardenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDE5A1", "object_type": "GENE-Y"}]}
{"text": "In addition, the molecular configuration of vardenafil differs from that of sildenafil when bound to PDE5.", "spo_list": [{"subject": "vardenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "sildenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDE5", "object_type": "GENE-Y"}]}
{"text": "It is noteworthy that the binding of vardenafil causes loss of the divalent metal ions that have been observed in all the previously published PDE structures.", "spo_list": [{"subject": "vardenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDE", "object_type": "GENE-N"}]}
{"text": "SB-408124 (100 pmol/100 nl, an antagonist of OX1R) or TCS OX2 29 (100 pmol/100 nl, an antagonist of OX2R) partly abolished the cardiovascular effects of exogenously-administrated OXA into the RVLM of control rats and SIHR, and lowered the increased systolic blood pressure (SBP) and heart rate (HR) of SIHR, with no difference in statistical significance between the two antagonists' effects.", "spo_list": [{"subject": "SB-408124", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "OX1R", "object_type": "GENE-Y"}, {"subject": "TCS OX2 29", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "OX2R", "object_type": "GENE-Y"}, {"subject": "SB-408124", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "OXA", "object_type": "GENE-Y"}, {"subject": "TCS OX2 29", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "OXA", "object_type": "GENE-Y"}]}
{"text": "Microinjection into the RVLM of both control and SIHR groups of 7-Ni (0.05 pmol/100 nl, nNOS inhibitor) or Methylene Blue [100 pmol/100 nl, an inhibitor of soluble guanylate cyclase (sGC)] suppressed the OXA-induced increase of SBP and HR, whereas microinjection of AG (1, 10, 100 pmol/100 nl) had no obvious effects on the OXA-induced increase of SBP and HR.", "spo_list": [{"subject": "Methylene Blue", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "soluble guanylate cyclase", "object_type": "GENE-N"}, {"subject": "Methylene Blue", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "sGC", "object_type": "GENE-N"}, {"subject": "Methylene Blue", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OXA", "object_type": "GENE-Y"}]}
{"text": "The cardiovascular effects of OXA in the RVLM may be induced by nNOS-derived NO, which activated sGC-associated signaling pathway.", "spo_list": [{"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "nNOS", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "sGC", "object_type": "GENE-N"}]}
{"text": "Suppression of Delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells.", "spo_list": [{"subject": "Delta(5)-androstenediol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "androgen receptor", "object_type": "GENE-Y"}, {"subject": "steroids", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "androgen receptor", "object_type": "GENE-Y"}]}
{"text": "Our earlier report suggested that androst-5-ene-3beta,7beta-diol (Delta(5)-androstenediol or Adiol) is a natural hormone with androgenic activity and that two potent antiandrogens, hydroxyflutamide (Eulexin) and bicalutamide (Casodex), fail to block completely the Adiol-induced androgen receptor (AR) transactivation in prostate cancer cells.", "spo_list": [{"subject": "Adiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "androgen receptor", "object_type": "GENE-Y"}, {"subject": "Adiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AR", "object_type": "GENE-Y"}]}
{"text": "Among 22 derivatives/metabolites of dehydroepiandrosterone, we found 4 steroids [no. 4, 1,3,5(10)-estratriene-17alpha-ethynyl-3, 17beta-diol; no. 6, 17alpha-ethynyl-androstene-diol; no. 8, 3beta, 17beta-dihydroxy-androst-5-ene-16-one; and no. 10, 3beta-methylcarbonate-androst-5-ene-7,17-dione] that have no androgenic activity and could also block the Adiol-induced AR transactivation in prostate cancer PC-3 cells.", "spo_list": [{"subject": "Adiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AR", "object_type": "GENE-Y"}, {"subject": "dehydroepiandrosterone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AR", "object_type": "GENE-Y"}, {"subject": "steroids", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AR", "object_type": "GENE-Y"}, {"subject": "4, 1,3,5(10)-estratriene-17alpha-ethynyl-3, 17beta-diol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AR", "object_type": "GENE-Y"}, {"subject": "6, 17alpha-ethynyl-androstene-diol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AR", "object_type": "GENE-Y"}, {"subject": "8, 3beta, 17beta-dihydroxy-androst-5-ene-16-one", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AR", "object_type": "GENE-Y"}, {"subject": "10, 3beta-methylcarbonate-androst-5-ene-7,17-dione", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AR", "object_type": "GENE-Y"}]}
{"text": "Interestingly, these compounds, in combination with hydroxyflutamide, further suppressed the Adiol-induced AR transactivation.", "spo_list": [{"subject": "hydroxyflutamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AR", "object_type": "GENE-Y"}, {"subject": "Adiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AR", "object_type": "GENE-Y"}]}
{"text": "Actions of nizatidine, a selective histamine H2-receptor antagonist, on gastric acid secretion in dogs, rats and frogs.", "spo_list": [{"subject": "nizatidine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H2-receptor", "object_type": "GENE-N"}]}
{"text": "Nizatidine (LY139037), a selective histamine H2-receptor antagonist, is a potent inhibitor of gastric acid secretion.", "spo_list": [{"subject": "Nizatidine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H2-receptor", "object_type": "GENE-N"}, {"subject": "LY139037", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H2-receptor", "object_type": "GENE-N"}]}
{"text": "Incubation of eosinophils with isoproterenol or formoterol dose-dependently inhibited both spontaneous eosinophil apoptosis and apoptosis induced by Fas receptor activation.", "spo_list": [{"subject": "isoproterenol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Fas receptor", "object_type": "GENE-Y"}, {"subject": "formoterol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Fas receptor", "object_type": "GENE-Y"}]}
{"text": "The PI3K inhibitors wortmannin and LY-294002 and an Akt inhibitor, 1-L-6-hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate, but not a mitogen-activated protein kinase kinase inhibitor PD-98059, blocked isoproterenol-mediated eosinophil survival.", "spo_list": [{"subject": "wortmannin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PI3K", "object_type": "GENE-N"}, {"subject": "LY-294002", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PI3K", "object_type": "GENE-N"}, {"subject": "1-L-6-hydroxymethyl-chiro-inositol 2-(R)-2-O-methyl-3-O-octadecylcarbonate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "PD-98059", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mitogen-activated protein kinase kinase", "object_type": "GENE-N"}]}
{"text": "Isoproterenol rapidly induced phosphorylation of Akt and FKHR in eosinophils in a PI3K-dependent manner.", "spo_list": [{"subject": "Isoproterenol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "Isoproterenol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "FKHR", "object_type": "GENE-Y"}, {"subject": "Isoproterenol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PI3K", "object_type": "GENE-N"}]}
{"text": "Induction of hepatic multidrug resistance-associated protein 3 by ethynylestradiol is independent of cholestasis and mediated by estrogen receptor.", "spo_list": [{"subject": "ethynylestradiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "multidrug resistance-associated protein 3", "object_type": "GENE-Y"}]}
{"text": "Multidrug resistance-associated protein 3 (Mrp3; Abcc3) expression and activity are up-regulated in rat liver after in vivo repeated administration of ethynylestradiol (EE), a cholestatic synthetic estrogen, whereas multidrug resistance-associated protein 2 (Mrp2) is down-regulated.", "spo_list": [{"subject": "ethynylestradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Multidrug resistance-associated protein 3", "object_type": "GENE-Y"}, {"subject": "ethynylestradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Mrp3", "object_type": "GENE-Y"}, {"subject": "ethynylestradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Abcc3", "object_type": "GENE-Y"}, {"subject": "estrogen", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Multidrug resistance-associated protein 3", "object_type": "GENE-Y"}, {"subject": "estrogen", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Mrp3", "object_type": "GENE-Y"}, {"subject": "estrogen", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Abcc3", "object_type": "GENE-Y"}, {"subject": "ethynylestradiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Multidrug resistance-associated protein 3", "object_type": "GENE-Y"}, {"subject": "ethynylestradiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Mrp3", "object_type": "GENE-Y"}, {"subject": "ethynylestradiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Abcc3", "object_type": "GENE-Y"}, {"subject": "estrogen", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Multidrug resistance-associated protein 3", "object_type": "GENE-Y"}, {"subject": "estrogen", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Mrp3", "object_type": "GENE-Y"}, {"subject": "estrogen", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Abcc3", "object_type": "GENE-Y"}, {"subject": "ethynylestradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "multidrug resistance-associated protein 2", "object_type": "GENE-Y"}, {"subject": "estrogen", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "multidrug resistance-associated protein 2", "object_type": "GENE-Y"}, {"subject": "ethynylestradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Mrp2", "object_type": "GENE-Y"}, {"subject": "estrogen", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Mrp2", "object_type": "GENE-Y"}, {"subject": "ethynylestradiol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "multidrug resistance-associated protein 2", "object_type": "GENE-Y"}, {"subject": "ethynylestradiol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Mrp2", "object_type": "GENE-Y"}, {"subject": "estrogen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "multidrug resistance-associated protein 2", "object_type": "GENE-Y"}, {"subject": "estrogen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Mrp2", "object_type": "GENE-Y"}]}
{"text": "The increase in Mrp3 mRNA by EE was prevented by actinomycin D, indicating transcriptional regulation.", "spo_list": [{"subject": "actinomycin D", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Mrp3", "object_type": "GENE-Y"}]}
{"text": "When hepatocytes were incubated with an ER antagonist [7Î±,17Î²-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol (ICI182/780), 1 ÂµM], in addition to EE, induction of Mrp3 mRNA was abolished, implicating ER as a key mediator.", "spo_list": [{"subject": "7Î±,17Î²-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ER", "object_type": "GENE-Y"}, {"subject": "ICI182/780", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ER", "object_type": "GENE-Y"}, {"subject": "7Î±,17Î²-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Mrp3", "object_type": "GENE-Y"}, {"subject": "ICI182/780", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Mrp3", "object_type": "GENE-Y"}]}
{"text": "The Lac-GLN formulation contained N-lactobionyl-dioleoyl phosphatidylethanolamine (Lac-DOPE), a ligand for the asialoglycoprotein receptor (ASGR), and an antibiotic peptide gramicidin A. The nanoparticles exhibited a mean particle diameter of 73nm, zeta potential of +3.5mV, anti-miR encapsulation efficiency of 88%, and excellent colloidal stability at 4Â°C.", "spo_list": [{"subject": "N-lactobionyl-dioleoyl phosphatidylethanolamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "asialoglycoprotein receptor", "object_type": "GENE-N"}, {"subject": "N-lactobionyl-dioleoyl phosphatidylethanolamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ASGR", "object_type": "GENE-N"}, {"subject": "Lac-DOPE", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "asialoglycoprotein receptor", "object_type": "GENE-N"}, {"subject": "Lac-DOPE", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ASGR", "object_type": "GENE-N"}]}
{"text": "Accumulation of glutathione disulfide mediates NF-kappaB activation during immune stimulation with CpG DNA.", "spo_list": [{"subject": "glutathione disulfide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NF-kappaB", "object_type": "GENE-N"}]}
{"text": "Treatment of cells with BCNU to inhibit glutathione reductase (GR) enhanced the CpG-induced intracellular oxidation and decreased the GSH/GSSG, with increased activation of NF-kappaB and a doubling in the CpG-induced production of IL-6 and TNF-alpha.", "spo_list": [{"subject": "BCNU", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "glutathione reductase", "object_type": "GENE-Y"}, {"subject": "BCNU", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GR", "object_type": "GENE-Y"}, {"subject": "BCNU", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NF-kappaB", "object_type": "GENE-N"}, {"subject": "BCNU", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-6", "object_type": "GENE-Y"}, {"subject": "BCNU", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TNF-alpha", "object_type": "GENE-Y"}]}
{"text": "Experimental manipulation of the intracellular GSSG concentration during inhibition of cellular prooxidant production demonstrated that increased intracellular GSSG is a primary signal that is directly or indirectly required for CpG-induced NF-kappaB activation but is not in itself sufficient to trigger this in the absence of CpG ODN.", "spo_list": [{"subject": "GSSG", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NF-kappaB", "object_type": "GENE-N"}]}
{"text": "These events are stimulated by NE and by guanethidine, an hNET substrate, and they are blocked by cocaine and the antidepressant desipramine.", "spo_list": [{"subject": "NE", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "guanethidine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hNET", "object_type": "GENE-Y"}]}
{"text": "Voltage-clamp data combined with NE uptake data from these same cells indicate that hNETs have two functional modes of conduction: a classical transporter mode (T-mode) and a novel channel mode (C-mode).", "spo_list": [{"subject": "NE", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hNETs", "object_type": "GENE-Y"}]}
{"text": "Meperidine exerts agonist activity at the alpha(2B)-adrenoceptor subtype.", "spo_list": [{"subject": "Meperidine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha(2B)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Agonists at the alpha(2) adrenoceptors, such as clonidine, are very effective antishivering drugs.", "spo_list": [{"subject": "clonidine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha(2) adrenoceptors", "object_type": "GENE-N"}]}
{"text": "The ability of the opioid antagonist naloxone and the alpha(2)-adrenoceptor antagonists yohimbine and RX821002 to block the analgesic action of meperidine in the hot-plate test was also assessed.", "spo_list": [{"subject": "yohimbine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2)-adrenoceptor", "object_type": "GENE-N"}, {"subject": "RX821002", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2)-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "The ability of meperidine to fit into the alpha(2B) adrenoceptor was assessed using molecular modeling techniques.", "spo_list": [{"subject": "meperidine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha(2B) adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "RESULTS: Meperidine bound to all alpha2-adrenoceptor subtypes, with alpha(2B) having the highest affinity (alpha(2B), 8.6 +/- 0.3 microm; alpha(2C), 13.6 +/- 1.5 microm, P < 0.05; alpha(2A), 38.6 +/- 0.7 microm).", "spo_list": [{"subject": "Meperidine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha2-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "Meperidine inhibited the production of forskolin-stimulated cyclic adenosine monophosphate mediated by all receptor subtypes but was most effective at the alpha(2B) adrenoceptor (alpha(2B), 0.6 microm; alpha(2A), 1.3 mm; alpha(2C), 0.3 mm), reaching the same level of inhibition (approximately 70%) as achieved with the alpha2-adrenoceptor agonist dexmedetomidine.", "spo_list": [{"subject": "dexmedetomidine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha2-adrenoceptor", "object_type": "GENE-N"}, {"subject": "Meperidine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "alpha(2B) adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "The analgesic action of meperidine was blocked by naloxone but not by the alpha 2-adrenoceptor antagonists yohimbine and RX821002.", "spo_list": [{"subject": "yohimbine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha 2-adrenoceptor", "object_type": "GENE-N"}, {"subject": "RX821002", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha 2-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "The modeling studies demonstrated that meperidine can fit into the alpha(2B)-adrenoceptor subtype.", "spo_list": [{"subject": "meperidine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha(2B)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "CONCLUSION: Meperidine is a potent agonist at the alpha2 adrenoceptors at its clinically relevant concentrations, especially at the alpha(2B)-adrenoceptor subtype.", "spo_list": [{"subject": "Meperidine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha2 adrenoceptors", "object_type": "GENE-N"}, {"subject": "Meperidine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha(2B)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "We have previously found that 3-phenyl-CPP blocks hClC-Ka and rClC-K1 from the extracellular side in the pore entrance.", "spo_list": [{"subject": "3-phenyl-CPP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hClC-Ka", "object_type": "GENE-Y"}, {"subject": "3-phenyl-CPP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "rClC-K1", "object_type": "GENE-Y"}]}
{"text": "Differently from ClC-Ka, on the rat homologue ClC-K1, NFA has only an inhibitory effect.", "spo_list": [{"subject": "NFA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "rat homologue ClC-K1", "object_type": "GENE-Y"}]}
{"text": "We developed a quantitative model to describe the complex action of NFA on ClC-Ka.", "spo_list": [{"subject": "NFA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ClC-Ka", "object_type": "GENE-Y"}]}
{"text": "The model predicts that ClC-Ka possesses two NFA binding sites: when only one site is occupied, NFA increases ClC-Ka currents, whereas the occupation of both binding sites leads to channel block.", "spo_list": [{"subject": "NFA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ClC-Ka", "object_type": "GENE-Y"}]}
{"text": "N-methyl-D-aspartate receptor channel block by meperidine is dependent on extracellular pH.", "spo_list": [{"subject": "meperidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "N-methyl-D-aspartate receptor", "object_type": "GENE-N"}]}
{"text": "UNLABELLED: Large concentrations of meperidine inhibit N-methyl-D-aspartate-(NMDA) receptor channels by channel block mechanisms.", "spo_list": [{"subject": "meperidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "N-methyl-D-aspartate-(NMDA) receptor", "object_type": "GENE-N"}]}
{"text": "Inhibition of epsilon1/zeta1, epsilon2/zeta1, epsilon3/zeta1, and epsilon4/zeta1 channels by meperidine was dependent on pH, with more inhibition at acidic pH and less inhibition at alkaline pH.", "spo_list": [{"subject": "meperidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "epsilon1/zeta1", "object_type": "GENE-N"}, {"subject": "meperidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "epsilon2/zeta1", "object_type": "GENE-N"}, {"subject": "meperidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "epsilon3/zeta1", "object_type": "GENE-N"}, {"subject": "meperidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "epsilon4/zeta1 channels", "object_type": "GENE-N"}]}
{"text": "IMPLICATIONS: At acidic pH the potency of meperidine for N-methyl-D-aspartate-receptor channels was increased.", "spo_list": [{"subject": "meperidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "N-methyl-D-aspartate-receptor", "object_type": "GENE-N"}]}
{"text": "Any antinociceptive and neuroprotective benefit from the N-methyl-D-aspartate-receptor antagonist property of meperidine may be pH dependent.", "spo_list": [{"subject": "meperidine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "N-methyl-D-aspartate-receptor", "object_type": "GENE-N"}]}
{"text": "5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone inhibits nitric oxide production in lipopolysaccharide-stimulated BV2 microglia via NF-ÎºB suppression and Nrf-2-dependent heme oxygenase-1 induction.", "spo_list": [{"subject": "5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Nrf-2", "object_type": "GENE-Y"}, {"subject": "5-Hydroxy-3,6,7,8,3'4'-hexamethoxyflavone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "heme oxygenase-1", "object_type": "GENE-Y"}]}
{"text": "In this study, we found that 5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone (5HHMF) from Hizikia fusiforme considerably inhibits lipopolysaccharide (LPS)-stimulated NO production by suppressing the expression of inducible NO synthase (iNOS) in BV2 microglia.", "spo_list": [{"subject": "5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "inducible NO synthase", "object_type": "GENE-Y"}, {"subject": "5-hydroxy-3,6,7,8,3'4'-hexamethoxyflavone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "5HHMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "inducible NO synthase", "object_type": "GENE-Y"}, {"subject": "5HHMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "iNOS", "object_type": "GENE-Y"}]}
{"text": "In addition, 5HHMF blocked LPS-induced phosphorylation of IÎºB, resulting in suppression of the nuclear translocation of nuclear factor-ÎºB (NF-ÎºB) subunits, namely p65 and p50, which are important molecules involved in the regulation of iNOS expression.", "spo_list": [{"subject": "5HHMF", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IÎºB", "object_type": "GENE-N"}, {"subject": "5HHMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "nuclear factor-ÎºB", "object_type": "GENE-N"}, {"subject": "5HHMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "5HHMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "p65", "object_type": "GENE-Y"}, {"subject": "5HHMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "p50", "object_type": "GENE-Y"}]}
{"text": "Pyrrolidine dithiocarbamate (PDTC), a specific NF-ÎºB inhibitor, along with 20S proteasome inhibitor (PSI) significantly inhibited LPS-induced iNOS expression, which indirectly suggested that 5HHMF downregulated iNOS expression by suppressing NF-ÎºB activity.", "spo_list": [{"subject": "Pyrrolidine dithiocarbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "PDTC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "Pyrrolidine dithiocarbamate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "PDTC", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "5HHMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "5HHMF", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}]}
{"text": "Thus, we found that 5HHMF enhances heme oxygenase-1 (HO-1) expression via nuclear factor-erythroid 2-related factor 2 (Nrf2) activation.", "spo_list": [{"subject": "5HHMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "heme oxygenase-1", "object_type": "GENE-Y"}, {"subject": "5HHMF", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HO-1", "object_type": "GENE-Y"}, {"subject": "5HHMF", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "nuclear factor-erythroid 2-related factor 2", "object_type": "GENE-Y"}, {"subject": "5HHMF", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Nrf2", "object_type": "GENE-Y"}]}
{"text": "In addition, cobalt protoporphyrin (CoPP), a specific HO-1 inducer, predominantly suppressed LPS-induced NO production.", "spo_list": [{"subject": "cobalt protoporphyrin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "HO-1", "object_type": "GENE-Y"}, {"subject": "CoPP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "HO-1", "object_type": "GENE-Y"}]}
{"text": "In contrast, zinc protoporphyrin (ZnPP), a specific HO-1 inhibitor, showed a partial suppressive effect of 5HHMF on LPS-induced NO production.", "spo_list": [{"subject": "zinc protoporphyrin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HO-1", "object_type": "GENE-Y"}, {"subject": "ZnPP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HO-1", "object_type": "GENE-Y"}]}
{"text": "Further, 5HHMF increased specific DNA-binding activity of Nrf2, and transient knockdown with Nrf2 siRNA subsequently reversed 5HHMF-induced NO inhibition, which was followed by suppression of HO-1 activity.", "spo_list": [{"subject": "5HHMF", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Nrf2", "object_type": "GENE-Y"}, {"subject": "5HHMF", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HO-1", "object_type": "GENE-Y"}]}
{"text": "Taken together, our findings indicate that 5HHMF suppresses NO production through modulation of iNOS, consequently suppressing NF-ÎºB activity and induction of Nrf2-dependent HO-1 activity.", "spo_list": [{"subject": "5HHMF", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "5HHMF", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "HO-1", "object_type": "GENE-Y"}, {"subject": "5HHMF", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Nrf2", "object_type": "GENE-Y"}]}
{"text": "Amino acid sequence alignments of cholinesterases revealed that 6 of 14 aromatic amino acid residues lining the active center gorge of acetylcholinesterase are replaced by aliphatic amino acid residues in butyrylcholinesterase.", "spo_list": [{"subject": "aromatic amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "aliphatic amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "Amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "Amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "butyrylcholinesterase", "object_type": "GENE-Y"}]}
{"text": "The Y337 (F330) in mammalian acetylcholinesterase, which is replaced by A328 in human butyrylcholinesterase, is implicated in the binding of ligands such as huperzine A, edrophonium, and acridines and one end of bisquaternary compounds such as BW284C51 and decamethonium.", "spo_list": [{"subject": "huperzine A", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "acetylcholinesterase", "object_type": "GENE-N"}, {"subject": "edrophonium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "acetylcholinesterase", "object_type": "GENE-N"}, {"subject": "acridines", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "acetylcholinesterase", "object_type": "GENE-N"}, {"subject": "huperzine A", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "edrophonium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "acridines", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "bisquaternary", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "acetylcholinesterase", "object_type": "GENE-N"}, {"subject": "bisquaternary", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "BW284C51", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "acetylcholinesterase", "object_type": "GENE-N"}, {"subject": "BW284C51", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "decamethonium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "acetylcholinesterase", "object_type": "GENE-N"}, {"subject": "decamethonium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human butyrylcholinesterase", "object_type": "GENE-Y"}]}
{"text": "Inhibition studies of (-)-huperzine A with human butyrylcholinesterase mutants, where A328 (KI = 194.6 microM) was modified to either F (KI = 0.6 microM, as in Torpedo acetylcholinesterase) or Y (KI = 0.032 microM, as in mammalian acetylcholinesterase), confirmed previous observations made with acetylcholinesterase mutants that this residue is important for binding huperzine A. Inhibition studies of ethopropazine with butyrylcholinesterase mutants, where A328 (KI = 0.18 microM) was modified to either F (KI = 0.82 microM) or Y (KI = 0.28 microM), suggested that A328 was not solely responsible for the selectivity of ethopropazine.", "spo_list": [{"subject": "(-)-huperzine A", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "(-)-huperzine A", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Torpedo acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "(-)-huperzine A", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-N"}, {"subject": "(-)-huperzine A", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "huperzine A", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "ethopropazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "butyrylcholinesterase", "object_type": "GENE-Y"}]}
{"text": "Volume calculations for the active site gorge showed that the poor inhibitory activity of ethopropazine toward acetylcholinesterase was due to the smaller dimension of the active site gorge which was unable to accommodate the bulky inhibitor molecule.", "spo_list": [{"subject": "ethopropazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}]}
{"text": "The volume of the butyrylcholinesterase active site gorge is approximately 200 A3 larger than that of the acetylcholinesterase gorge, which allows the accommodation of ethopropazine in two different orientations as demonstrated by rigid-body refinement and molecular dynamics calculations.", "spo_list": [{"subject": "ethopropazine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "ethopropazine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "butyrylcholinesterase", "object_type": "GENE-Y"}]}
{"text": "Role of human organic anion transporter 4 in the transport of ochratoxin A. The purpose of this study was to investigate the characteristics of ochratoxin A (OTA) transport by multispecific human organic anion transporter 4 (hOAT4) using mouse proximal tubule cells stably transfected with hOAT4 (S(2) hOAT4).", "spo_list": [{"subject": "ochratoxin A", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human organic anion transporter 4", "object_type": "GENE-Y"}]}
{"text": "S(2) hOAT4 exhibited a time- and concentration-dependent, and a saturable increase in OTA uptake, with an apparent K(m) value of 22.9+/-2.44 microM.", "spo_list": [{"subject": "OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT4", "object_type": "GENE-Y"}]}
{"text": "The OTA uptakes were inhibited by several substrates for the OATs.", "spo_list": [{"subject": "OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATs", "object_type": "GENE-N"}]}
{"text": "Probenecid, piroxicam, octanoate and citrinin inhibited OTA uptake by hOAT4 in a competitive manner (K(i)=44.4-336.4 microM), with the following order of potency: probenecid > piroxicam > octanoate >citrinin.", "spo_list": [{"subject": "OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT4", "object_type": "GENE-Y"}, {"subject": "Probenecid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hOAT4", "object_type": "GENE-Y"}, {"subject": "piroxicam", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hOAT4", "object_type": "GENE-Y"}, {"subject": "octanoate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hOAT4", "object_type": "GENE-Y"}, {"subject": "citrinin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hOAT4", "object_type": "GENE-Y"}, {"subject": "probenecid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hOAT4", "object_type": "GENE-Y"}, {"subject": "piroxicam", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hOAT4", "object_type": "GENE-Y"}, {"subject": "octanoate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hOAT4", "object_type": "GENE-Y"}, {"subject": "citrinin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hOAT4", "object_type": "GENE-Y"}]}
{"text": "Addition of OTA resulted in slight decrease in viability of S(2) hOAT4 compared with mock.", "spo_list": [{"subject": "OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT4", "object_type": "GENE-Y"}]}
{"text": "These results indicate that hOAT4 mediates the high-affinity transport of OTA on the apical side of the proximal tubule, whereas the transport characteristics of OTA are distinct from those by basolateral OATs.", "spo_list": [{"subject": "OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT4", "object_type": "GENE-Y"}, {"subject": "OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT4", "object_type": "GENE-Y"}]}
{"text": "YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.", "spo_list": [{"subject": "YM-359445", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "vascular endothelial growth factor receptor-2", "object_type": "GENE-Y"}, {"subject": "YM-359445", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}]}
{"text": "YM-359445 was a (3Z)-3-quinolin-2(1H)-ylidene-1,3-dihydro-2H-indol-2-one derivative found while screening based on the inhibition of VEGFR2 tyrosine kinase.", "spo_list": [{"subject": "YM-359445", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR2", "object_type": "GENE-Y"}, {"subject": "YM-359445", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "(3Z)-3-quinolin-2(1H)-ylidene-1,3-dihydro-2H-indol-2-one", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR2", "object_type": "GENE-Y"}, {"subject": "(3Z)-3-quinolin-2(1H)-ylidene-1,3-dihydro-2H-indol-2-one", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}]}
{"text": "The antitumor activity of YM-359445 was also tested in nude mice bearing various established tumors and compared with other VEGFR2 tyrosine kinase inhibitors (ZD6474, CP-547632, CGP79787, SU11248, and AZD2171), a cytotoxic agent (paclitaxel), and an epidermal growth factor receptor tyrosine kinase inhibitor (gefitinib).", "spo_list": [{"subject": "gefitinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "gefitinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "epidermal growth factor receptor", "object_type": "GENE-N"}, {"subject": "ZD6474", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "CP-547632", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "CGP79787", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "SU11248", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "AZD2171", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "ZD6474", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR2", "object_type": "GENE-Y"}, {"subject": "CP-547632", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR2", "object_type": "GENE-Y"}, {"subject": "CGP79787", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR2", "object_type": "GENE-Y"}, {"subject": "SU11248", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR2", "object_type": "GENE-Y"}, {"subject": "AZD2171", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR2", "object_type": "GENE-Y"}]}
{"text": "RESULTS: The IC50 of YM-359445 for VEGFR2 tyrosine kinase was 0.0085 micromol/L.", "spo_list": [{"subject": "YM-359445", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR2", "object_type": "GENE-Y"}, {"subject": "YM-359445", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}]}
{"text": "YM-359445 had greater antitumor activity than other VEGFR2 tyrosine kinase inhibitors.", "spo_list": [{"subject": "YM-359445", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR2", "object_type": "GENE-Y"}, {"subject": "YM-359445", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}]}
{"text": "CONCLUSION: Our results show that YM-359445 is more potent than orally bioavailable VEGFR2 tyrosine kinase inhibitors, which leads to great expectations for clinical applicability.", "spo_list": [{"subject": "YM-359445", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR2", "object_type": "GENE-Y"}, {"subject": "YM-359445", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}]}
{"text": "We have previously shown that human placental estradiol-17 beta dehydrogenase (EC 1.1.1.62; 17 beta-EDH) catalyzes the conversion of estradiol-17 beta to estrone and stereospecifically reduces NAD+ to [4-pro-S]NADH, [( 4-B]NADH).", "spo_list": [{"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human placental estradiol-17 beta dehydrogenase", "object_type": "GENE-Y"}, {"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 1.1.1.62", "object_type": "GENE-Y"}, {"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "17 beta-EDH", "object_type": "GENE-Y"}, {"subject": "estrone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "human placental estradiol-17 beta dehydrogenase", "object_type": "GENE-Y"}, {"subject": "estrone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "EC 1.1.1.62", "object_type": "GENE-Y"}, {"subject": "estrone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "17 beta-EDH", "object_type": "GENE-Y"}, {"subject": "NAD+", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human placental estradiol-17 beta dehydrogenase", "object_type": "GENE-Y"}, {"subject": "NAD+", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 1.1.1.62", "object_type": "GENE-Y"}, {"subject": "NAD+", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "17 beta-EDH", "object_type": "GENE-Y"}, {"subject": "[4-pro-S]NADH", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "human placental estradiol-17 beta dehydrogenase", "object_type": "GENE-Y"}, {"subject": "[4-pro-S]NADH", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "EC 1.1.1.62", "object_type": "GENE-Y"}, {"subject": "[4-pro-S]NADH", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "17 beta-EDH", "object_type": "GENE-Y"}, {"subject": "[( 4-B]NADH)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "human placental estradiol-17 beta dehydrogenase", "object_type": "GENE-Y"}, {"subject": "[( 4-B]NADH)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "EC 1.1.1.62", "object_type": "GENE-Y"}, {"subject": "[( 4-B]NADH)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "17 beta-EDH", "object_type": "GENE-Y"}]}
{"text": "The cofactor, [4B-3H]NADPH, was generated with homogeneous 17 beta-EDH from term human placenta, utilizing [17 alpha-3H]estradiol-17 beta and NADP+.", "spo_list": [{"subject": "[4B-3H]NADPH", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "17 beta-EDH", "object_type": "GENE-Y"}, {"subject": "[17 alpha-3H]estradiol-17 beta", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "17 beta-EDH", "object_type": "GENE-Y"}, {"subject": "NADP+", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "17 beta-EDH", "object_type": "GENE-Y"}]}
{"text": "Western blot analysis revealed that OMT decreased the expression of Bax and repaired the balance of pro- and anti-apoptotic proteins.", "spo_list": [{"subject": "OMT", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Bax", "object_type": "GENE-Y"}]}
{"text": "Furthermore, OMT significantly reversed the up-regulation of NR2B and inhibited the calcium overload in the cultured neurons after challenging the NMDA.", "spo_list": [{"subject": "OMT", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NR2B", "object_type": "GENE-Y"}]}
{"text": "OMT showed partial protection in the cortical neurons via down-regulation of NR2B containing NMDA receptors and up-regulation of Bcl-2 family.", "spo_list": [{"subject": "OMT", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NR2B", "object_type": "GENE-Y"}, {"subject": "OMT", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bcl-2", "object_type": "GENE-Y"}]}
{"text": "ErbB2 becomes phosphorylated at tyrosine 877 in a dose- and time- dependent manner following exposure to X-rays, and activates downstream signaling cascades including PI3K/Akt.", "spo_list": [{"subject": "tyrosine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ErbB2", "object_type": "GENE-Y"}]}
{"text": "On the basis of FIP1L1-PDGFRa fusion gene hypereosinophilic syndrome would be classified as a clonal disease and in the FIP1L1-PDGFRa positive cases the tyrosine kinase inhibitor imatinib mesylate (Glivec) would be effective.", "spo_list": [{"subject": "imatinib mesylate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}]}
{"text": "The beta(2)-adrenoceptor (beta(2)-AR) agonists clenbuterol and fenoterol have similar beneficial effects in animal models of heart failure.", "spo_list": [{"subject": "clenbuterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "clenbuterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(2)-AR", "object_type": "GENE-Y"}, {"subject": "fenoterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "fenoterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(2)-AR", "object_type": "GENE-Y"}]}
{"text": "At 3 mmol kg(-1), all agonists induced apoptosis (fenoterol, 1.1 +/- 0.1%; isoprenaline, 0.9 +/- 0.8%; and clenbuterol, 0.4 +/- 0.07%; P < 0.05). beta(1)-Adrenoceptor antagonism (10 mg kg(-1) bisoprolol) prevented 92% (P < 0.05) of apoptosis induced by all three agonists, but clenbuterol-induced apoptosis could also be prevented by 96% (P < 0.05) by beta(2)-AR antagonism (10 mg kg(-1) ICI 118 551).", "spo_list": [{"subject": "bisoprolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta(1)-Adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "To identify amino acid residues involved in PDE3-selective inhibitor binding, we selected eight presumed interacting residues in the substrate-binding pocket of PDE3A using a model created on basis of homology to the PDE4B crystal structure.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDE3", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDE3A", "object_type": "GENE-Y"}]}
{"text": "We changed the residues to alanine using site-directed mutagenesis technique, expressed the mutants in a baculovirus/Sf9 cell system, and analyzed the kinetic characteristics of inhibition of the mutant enzymes by milrinone and cilostazol, specific inhibitors of PDE3.", "spo_list": [{"subject": "milrinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE3", "object_type": "GENE-Y"}, {"subject": "cilostazol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE3", "object_type": "GENE-Y"}, {"subject": "alanine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDE3", "object_type": "GENE-Y"}]}
{"text": "Mutants Y751A, D950A, and F1004A had reduced sensitivity to milrinone (K(i) changed from 0.66 microM for the recombinant PDE3A to 7.5 to 156 microM for the mutants), and diminished sensitivity to cilostazol (K(i) of the mutants were 18- to 371-fold higher than that of the recombinant PDE3A).", "spo_list": [{"subject": "milrinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Y751A", "object_type": "GENE-N"}, {"subject": "milrinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "D950A", "object_type": "GENE-N"}, {"subject": "milrinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "F1004A", "object_type": "GENE-N"}, {"subject": "milrinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE3A", "object_type": "GENE-Y"}, {"subject": "cilostazol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE3A", "object_type": "GENE-Y"}]}
{"text": "In contrast, the mutants T844A, F972A and Q975A showed increased K(i) for cilostazol but no difference for milrinone from the recombinant PDE3A.", "spo_list": [{"subject": "cilostazol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "T844A", "object_type": "GENE-N"}, {"subject": "cilostazol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "F972A", "object_type": "GENE-N"}, {"subject": "cilostazol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Q975A", "object_type": "GENE-N"}, {"subject": "cilostazol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE3A", "object_type": "GENE-Y"}, {"subject": "milrinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE3A", "object_type": "GENE-Y"}, {"subject": "milrinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "T844A", "object_type": "GENE-N"}, {"subject": "milrinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "F972A", "object_type": "GENE-N"}, {"subject": "milrinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Q975A", "object_type": "GENE-N"}]}
{"text": "Molecular models show that the PDE3 inhibitors cilostazol and milrinone share some of common residues but interact with distinct residues at the active site, suggesting that selective inhibitors can be designed with flexible size against PDE3 active site.", "spo_list": [{"subject": "cilostazol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE3", "object_type": "GENE-Y"}, {"subject": "milrinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE3", "object_type": "GENE-Y"}]}
{"text": "Our study implies that highly conserved residuals Y751, D950 and F1004 in the PDE families are key residues for binding of both substrate and inhibitors, and nonconserved T844 may be responsible for the cilostazol selectivity of PDE3A.", "spo_list": [{"subject": "cilostazol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE", "object_type": "GENE-Y"}, {"subject": "cilostazol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE3A", "object_type": "GENE-Y"}]}
{"text": "Tryptamine induces tryptophanyl-tRNA synthetase-mediated neurodegeneration with neurofibrillary tangles in human cell and mouse models.", "spo_list": [{"subject": "Tryptamine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "tryptophanyl-tRNA synthetase", "object_type": "GENE-N"}]}
{"text": "Here it is shown that expression of cytoplasmic-TrpRS is inversely correlated with neurofibrillary degeneration, whereas a nonionic detergent-insoluble presumably aggregated TrpRS is simultaneously accumulated in human cells treated by tryptamine, a metabolic tryptophan analog that acts as a competitive inhibitor of TrpRS.", "spo_list": [{"subject": "tryptamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TrpRS", "object_type": "GENE-N"}, {"subject": "tryptophan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TrpRS", "object_type": "GENE-N"}]}
{"text": "Tryptophan-dependent tRNAtrp aminoacylation catalyzed by TrpRS can be inhibited by its substrate tryptophan at physiological concentrations was demonstrated.", "spo_list": [{"subject": "tryptophan", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "TrpRS", "object_type": "GENE-N"}, {"subject": "tryptophan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TrpRS", "object_type": "GENE-N"}]}
{"text": "OHT is a competitive inhibitor whereas trilostane has direct, but non-competitive effects on ER.", "spo_list": [{"subject": "OHT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ER", "object_type": "GENE-Y"}]}
{"text": "A selective up-regulation of ERbeta by trilostane, but not OHT, was observed and confirmed by qRT-PCR.", "spo_list": [{"subject": "trilostane", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ERbeta", "object_type": "GENE-Y"}]}
{"text": "Similar up-regulation of this gene by trilostane was observed in the uterus of trilostane-treated (4 mg/kg for 7 days) rats, in which ERbeta mRNA (3-fold) and ERbeta protein expression (10-fold) were both increased.", "spo_list": [{"subject": "trilostane", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ERbeta", "object_type": "GENE-Y"}, {"subject": "trilostane", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ERbeta", "object_type": "GENE-Y"}, {"subject": "trilostane", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ERbeta", "object_type": "GENE-Y"}, {"subject": "trilostane", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ERbeta", "object_type": "GENE-Y"}]}
{"text": "We substituted 24 amino acids within this region in the human NET with their counterparts in the human DAT, resulting in 22 different mutants.", "spo_list": [{"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "human NET", "object_type": "GENE-Y"}, {"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "human DAT", "object_type": "GENE-Y"}]}
{"text": "Three point mutations in TMD6 (F316C), -7 (V356S), and -8 (G400L) induced a loss of TCA binding affinity of 8-, 5-, and 4-fold, respectively, without affecting the affinity of cocaine.", "spo_list": [{"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "F316C", "object_type": "GENE-N"}, {"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "V356S", "object_type": "GENE-N"}, {"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "G400L", "object_type": "GENE-N"}]}
{"text": "The triple mutation F316C/V356S/G400L produced a 40-fold shift in desipramine affinity.", "spo_list": [{"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "F316C", "object_type": "GENE-N"}, {"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "V356S", "object_type": "GENE-N"}, {"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "G400L", "object_type": "GENE-N"}]}
{"text": "A strong shift in TCA affinity (IC(50)) was also observed for double mutants F316C/D336T (35-fold) and S399P/G400L (80-fold for nortriptyline and 1000-fold for desipramine).", "spo_list": [{"subject": "nortriptyline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "F316C", "object_type": "GENE-N"}, {"subject": "nortriptyline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "D336T", "object_type": "GENE-N"}, {"subject": "nortriptyline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "S399P", "object_type": "GENE-N"}, {"subject": "nortriptyline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "G400L", "object_type": "GENE-N"}, {"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "F316C", "object_type": "GENE-N"}, {"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "D336T", "object_type": "GENE-N"}, {"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "S399P", "object_type": "GENE-N"}, {"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "G400L", "object_type": "GENE-N"}]}
{"text": "We report here two crystal structures of QR2: in its native form and bound to menadione (vitamin K(3)), a physiological substrate.", "spo_list": [{"subject": "menadione", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "QR2", "object_type": "GENE-Y"}, {"subject": "vitamin K(3)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "QR2", "object_type": "GENE-Y"}]}
{"text": "QR2 shares the overall fold of the major catalytic domain of QR1, but lacks the smaller C-terminal domain.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "QR1", "object_type": "GENE-Y"}]}
{"text": "Tetrahydrocannabinol (THC), the major psychoactive component of marijuana, is a cannabinoid agonist that exerts its effects by activating at least two specific receptors (CB1 and CB2) that belong to the seven transmembrane G-protein coupled receptor (GPCR) family.", "spo_list": [{"subject": "Tetrahydrocannabinol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CB1", "object_type": "GENE-Y"}, {"subject": "Tetrahydrocannabinol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CB2", "object_type": "GENE-Y"}, {"subject": "THC", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CB1", "object_type": "GENE-Y"}, {"subject": "THC", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CB2", "object_type": "GENE-Y"}]}
{"text": "In the case of THC treatment 2h before MI, fractional shortening was elevated (37Â±4% vs. 42Â±1%, p<0.04), troponin T leakage to the blood was reduced (14Â±3ng/ml vs. 10Â±4ng/ml, p<0.008), infarct size decreased (29Â±4% vs. 23Â±4%, p<0.02), and the accumulation of neutrophils to the infarct area declined (36Â±10cells/field vs. 19Â±4cells/field, p<0.007) in THC- compared to vehicle-pretreated mice, 24h after MI.", "spo_list": [{"subject": "THC", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "troponin T", "object_type": "GENE-Y"}]}
{"text": "Kynurenic acid (KA) is an endogenous glutamate receptor antagonist at the level of the different ionotropic glutamate receptors.", "spo_list": [{"subject": "Kynurenic acid", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "glutamate receptor", "object_type": "GENE-N"}, {"subject": "KA", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "glutamate receptor", "object_type": "GENE-N"}, {"subject": "Kynurenic acid", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ionotropic glutamate receptors", "object_type": "GENE-N"}, {"subject": "KA", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ionotropic glutamate receptors", "object_type": "GENE-N"}]}
{"text": "One of the enzymes responsible for the production of KA, kynurenine aminotransferase I (KATI), also catalyses the reversible transamination of glutamine to oxoglutaramic acid (GTK, EC 2.6.1.15).", "spo_list": [{"subject": "KA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "kynurenine aminotransferase I", "object_type": "GENE-Y"}, {"subject": "KA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "KATI", "object_type": "GENE-Y"}, {"subject": "glutamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE_PRODUCT-OF", "object": "KATI", "object_type": "GENE-Y"}, {"subject": "glutamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE_PRODUCT-OF", "object": "kynurenine aminotransferase I", "object_type": "GENE-Y"}, {"subject": "oxoglutaramic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE_PRODUCT-OF", "object": "KATI", "object_type": "GENE-Y"}, {"subject": "oxoglutaramic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE_PRODUCT-OF", "object": "kynurenine aminotransferase I", "object_type": "GENE-Y"}, {"subject": "oxoglutaramic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE_PRODUCT-OF", "object": "GTK", "object_type": "GENE-Y"}, {"subject": "oxoglutaramic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE_PRODUCT-OF", "object": "EC 2.6.1.15", "object_type": "GENE-Y"}, {"subject": "glutamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE_PRODUCT-OF", "object": "GTK", "object_type": "GENE-Y"}]}
{"text": "BACKGROUND: As amifostine is rapidly metabolised by the membrane-bound and capillary alkaline phosphatase to the active metabolite WR-1065, microvessel density in normal and cancer tissue may influence the therapeutic potential of the pro-drug WR-2721.", "spo_list": [{"subject": "amifostine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "alkaline phosphatase", "object_type": "GENE-N"}, {"subject": "WR-1065", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "alkaline phosphatase", "object_type": "GENE-N"}]}
{"text": "There was also a significant (p < 0.001) difference in endothelial cell proliferation (PCNA) between untreated controls with a mean PCNA positivity of 14.05 (+/- 5.28 SD) and amifostine treated area vasculosa with a mean PCNA positivity of 32.22 (+/- 18.14 SD).", "spo_list": [{"subject": "amifostine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PCNA", "object_type": "GENE-N"}]}
{"text": "These agents led to potentiation of the renal injury from hemoglobinuric tubulopathy, probably from the iodine, and renal dysfunction from alteration of renal perfusion by selective COX-1 inhibition of prostaglandin production, and induction of acute interstitial nephritis from mefenamic acid, leading to acute renal failure which was reversible by hemodialysis and supportive therapy.", "spo_list": [{"subject": "prostaglandin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-1", "object_type": "GENE-Y"}]}
{"text": "METHODS: In isolated rat aorta, isometric tension was recorded to examine the anesthetic effects on vasodilator response to levcromakalim, a selective KATP channel opener.", "spo_list": [{"subject": "levcromakalim", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "KATP channel", "object_type": "GENE-N"}]}
{"text": "Etomidate (> or = 3 x 10 m), but not midazolam (up to 10 m), inhibited the native KATP channel activity in both cell-attached and inside-out configurations with IC50 values of 1.68 x 10 m and 1.52 x 10 m, respectively.", "spo_list": [{"subject": "Etomidate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "KATP channel", "object_type": "GENE-N"}]}
{"text": "Etomidate (10 m) also inhibited the activity of various types of recombinant SUR/Kir6.0KATP channels, Kir6.2DeltaC36 channels, and Kir6.2DeltaC36-K185Q channels with equivalent potency.", "spo_list": [{"subject": "Etomidate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SUR", "object_type": "GENE-Y"}, {"subject": "Etomidate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Kir6.0KATP channels", "object_type": "GENE-N"}, {"subject": "Etomidate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Kir6.2DeltaC36", "object_type": "GENE-Y"}, {"subject": "Etomidate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Kir6.2DeltaC36", "object_type": "GENE-Y"}, {"subject": "Etomidate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "K185Q", "object_type": "GENE-N"}]}
{"text": "CONCLUSIONS: Clinical concentrations of etomidate, but not midazolam, inhibit the KATP channel activity in vascular smooth muscle cells.", "spo_list": [{"subject": "etomidate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "KATP channel", "object_type": "GENE-N"}, {"subject": "midazolam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "KATP channel", "object_type": "GENE-N"}]}
{"text": "The inhibition is presumably through its effects on the Kir6.0 subunit, but not on the SUR subunit, with the binding site different from adenosine triphosphate at the amino acid level.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Kir6.0", "object_type": "GENE-N"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "SUR", "object_type": "GENE-Y"}, {"subject": "adenosine triphosphate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Kir6.0", "object_type": "GENE-N"}, {"subject": "adenosine triphosphate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SUR", "object_type": "GENE-Y"}]}
{"text": "The LTD can be blocked by systemic application of the selective GluN2B antagonist Ro25-6981 (6 mg/kg, i.p.) or a synthetic peptide Tat-GluA2(3Y) (3 Î¼mol/kg, i.p.) that interferes with the endocytosis of AMPA receptors.", "spo_list": [{"subject": "Ro25-6981", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "GluN2B", "object_type": "GENE-Y"}]}
{"text": "Indoleamine 2,3-dioxygenase (IDO), a tryptophan catabolizing enzyme, has been implicated in the pathogenesis of various neurological disorders.", "spo_list": [{"subject": "tryptophan", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Indoleamine 2,3-dioxygenase", "object_type": "GENE-Y"}, {"subject": "tryptophan", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "IDO", "object_type": "GENE-Y"}]}
{"text": "The results showed that (1) 15mg/kg body weight PhIP induced obvious histopathological changes in gastric mucosa; (2) PhIP (10 and/or 15mg/kg) significantly decreased superoxide dismutase (SOD) and glutathioneperoxidase (GPx) activities, while increased catalase (CAT) activity compared with the control.", "spo_list": [{"subject": "PhIP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "superoxide dismutase", "object_type": "GENE-N"}, {"subject": "PhIP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SOD", "object_type": "GENE-N"}, {"subject": "PhIP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "glutathioneperoxidase", "object_type": "GENE-N"}, {"subject": "PhIP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GPx", "object_type": "GENE-N"}, {"subject": "PhIP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "catalase", "object_type": "GENE-Y"}, {"subject": "PhIP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CAT", "object_type": "GENE-Y"}]}
{"text": "With the elevated doses of PhIP, malondialdehyde (MDA) contents, protein carbonyl (PCO) contents and DNA-protein crosslinks (DPC) coefficients were significantly raised in a dose-dependent manner; (3) PhIP at the doses of 10mg/kg and/or 15mg/kg significantly inhibited p16 mRNA and protein expression, whereas enhanced c-fos and c-jun expression relative to control.", "spo_list": [{"subject": "PhIP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "p16", "object_type": "GENE-Y"}, {"subject": "PhIP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "c-fos", "object_type": "GENE-Y"}, {"subject": "PhIP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "c-jun", "object_type": "GENE-Y"}]}
{"text": "The data indicated that PhIP could cause stomach injury, oxidative stress in rat stomachs as well as the activation of c-fos and c-jun and inactivation of p16, which may play a role in the pathogenesis of PhIP-associated stomach cancer.", "spo_list": [{"subject": "PhIP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "c-fos", "object_type": "GENE-Y"}, {"subject": "PhIP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "c-jun", "object_type": "GENE-Y"}, {"subject": "PhIP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "p16", "object_type": "GENE-Y"}]}
{"text": "Selective dopamine D4 receptor antagonists reverse apomorphine-induced blockade of prepulse inhibition.", "spo_list": [{"subject": "apomorphine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "dopamine D4 receptor", "object_type": "GENE-Y"}]}
{"text": "Recent evidence suggests that the dopamine D4 receptor may play a role in schizophrenia, and that the atypical properties of the antipsychotic clozapine may be attributable in part to its antagonistic actions at this receptor.", "spo_list": [{"subject": "clozapine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D4 receptor", "object_type": "GENE-Y"}]}
{"text": "In the present study, clozapine and three other compounds having D4 dopamine receptor antagonist properties were examined for their effectiveness in reducing losses in prepulse inhibition (PPI) induced in rats by the dopamine receptor agonist apomorphine.", "spo_list": [{"subject": "clozapine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "D4 dopamine receptor", "object_type": "GENE-Y"}, {"subject": "apomorphine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "dopamine receptor", "object_type": "GENE-N"}]}
{"text": "The three D4-selective compounds, CP-293,019 (5.6-17.8 mg/kg), U-101,387 (3-30 mg/kg) and L-745,870 (1-10 mg/kg), also significantly blocked the losses in PPI produced by apomorphine.", "spo_list": [{"subject": "CP-293,019", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "D4", "object_type": "GENE-Y"}, {"subject": "U-101,387", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "D4", "object_type": "GENE-Y"}, {"subject": "L-745,870", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "D4", "object_type": "GENE-Y"}, {"subject": "apomorphine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "D4", "object_type": "GENE-Y"}]}
{"text": "Agents which have recently been shown to block cyclin D1 translation by regulating calcium levels are the unsaturated essential fatty acid, eicosapentaenoic acid (EPA), the antidiabetic thiazolidinediones, and the antifungal agent, clotrimazole.", "spo_list": [{"subject": "unsaturated essential fatty acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cyclin D1", "object_type": "GENE-Y"}, {"subject": "eicosapentaenoic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cyclin D1", "object_type": "GENE-Y"}, {"subject": "EPA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cyclin D1", "object_type": "GENE-Y"}, {"subject": "thiazolidinediones", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cyclin D1", "object_type": "GENE-Y"}, {"subject": "clotrimazole", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cyclin D1", "object_type": "GENE-Y"}]}
{"text": "Meanwhile, autophagy was detected as early as 12Â h after an exposure to low-dose dioscin, as indicated by an up-regulated expression of LC3-II and beclin-1 proteins.", "spo_list": [{"subject": "dioscin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "LC3-II", "object_type": "GENE-Y"}, {"subject": "dioscin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "beclin-1", "object_type": "GENE-Y"}]}
{"text": "Treatment of A549 and H1299 cells with dioscin caused a dose-dependent increase in ERK1/2 and JNK1/2 activity, accompanied with a decreased PI3K expression and decreased phosphorylation of Akt and mTOR.", "spo_list": [{"subject": "dioscin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "PI3K", "object_type": "GENE-N"}, {"subject": "dioscin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "dioscin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-N"}]}
{"text": "Sophocarpine alleviates hepatocyte steatosis through activating AMPK signaling pathway.", "spo_list": [{"subject": "Sophocarpine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-Y"}]}
{"text": "While sophocarpine treatment resulted in: significant improvement of steatosis (>50% decrease), decrease of leptin expression (<0.57-fold) and increase of adiponectin expression (>1.48-fold).", "spo_list": [{"subject": "sophocarpine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "leptin", "object_type": "GENE-Y"}, {"subject": "sophocarpine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "adiponectin", "object_type": "GENE-Y"}]}
{"text": "Moreover, compared with the model group, sophocarpine could significantly increase P-AMPKÎ± (>5.82-fold), AMPKÎ± (>1.29-fold) and ACC (>3.27-fold) protein expressions, and reduce P-ACC (<0.30-fold) and HNF-4Î± (<0.20-fold) protein expression.", "spo_list": [{"subject": "sophocarpine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "P-AMPKÎ±", "object_type": "GENE-N"}, {"subject": "sophocarpine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AMPKÎ±", "object_type": "GENE-N"}, {"subject": "sophocarpine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ACC", "object_type": "GENE-N"}, {"subject": "sophocarpine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "P-ACC", "object_type": "GENE-N"}, {"subject": "sophocarpine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "HNF-4Î±", "object_type": "GENE-Y"}]}
{"text": "We concluded that sophocarpine could alleviate hepatocyte steatosis and the potential mechanism might be the activated signaling pathway of AMPK.", "spo_list": [{"subject": "sophocarpine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-Y"}]}
{"text": "UNLABELLED: Apparent muscarinic acetylcholine (mAch) receptor occupancy in mouse cerebral cortex, hippocampus, and striatum by scopolamine, an antagonist, and biperiden, a relatively selective M1 antagonist, was estimated with competitive binding studies using two different radioligands: 3H-N-methyl piperidyl benzilate (3H-NMPB) and 3H-quinuclidinyl benzilate (3H-QNB).", "spo_list": [{"subject": "scopolamine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic acetylcholine (mAch) receptor", "object_type": "GENE-N"}, {"subject": "biperiden", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "M1", "object_type": "GENE-Y"}, {"subject": "3H-N-methyl piperidyl benzilate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "muscarinic acetylcholine (mAch) receptor", "object_type": "GENE-N"}, {"subject": "3H-NMPB", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "muscarinic acetylcholine (mAch) receptor", "object_type": "GENE-N"}, {"subject": "3H-quinuclidinyl benzilate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "muscarinic acetylcholine (mAch) receptor", "object_type": "GENE-N"}, {"subject": "3H-QNB", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "muscarinic acetylcholine (mAch) receptor", "object_type": "GENE-N"}]}
{"text": "Both radioligands labeled mAch receptors in these brain regions, and the relative regional distributions of the specific binding of 3H-NMPB in vivo paralleled the distribution of mAch receptors.", "spo_list": [{"subject": "3H-NMPB", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mAch receptors", "object_type": "GENE-N"}, {"subject": "3H-NMPB", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mAch receptors", "object_type": "GENE-N"}]}
{"text": "A similar discrepancy in sensitivity to competitors between 3H-NMPB and 3H-QNB was also observed when biperiden was used as a competitor, indicating that binding to different subtypes of the mAch receptor could not account for the observed differences in sensitivity to competition.", "spo_list": [{"subject": "biperiden", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mAch receptor", "object_type": "GENE-N"}, {"subject": "3H-NMPB", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mAch receptor", "object_type": "GENE-N"}, {"subject": "3H-QNB", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mAch receptor", "object_type": "GENE-N"}]}
{"text": "This finding, together with the more favorable accumulation of 3H-NMPB in cerebral cortex, hippocampus, and striatum, leads us to conclude that 3H-NMPB, or its positron emitting counterpart, should be the more favorable radiotracer for the estimation of mAch receptor occupancy by cholinergic drugs in the brain.", "spo_list": [{"subject": "3H-NMPB", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mAch receptor", "object_type": "GENE-N"}]}
{"text": "When differentiated U937 cells were incubated with both LPS and the beta-agonist clenbuterol the production of TNF-alpha and IL-6 was significantly reduced.", "spo_list": [{"subject": "clenbuterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF-alpha", "object_type": "GENE-Y"}, {"subject": "clenbuterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-6", "object_type": "GENE-Y"}]}
{"text": "Lithium treatment induces proteasomal degradation of over-expressed acetylcholinesterase (AChE-S) and inhibit GSK3Î².", "spo_list": [{"subject": "Lithium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GSK3Î²", "object_type": "GENE-Y"}]}
{"text": "Lithium is also a potent inhibitor of glycogen synthase kinase-3Î² (GSK3Î²) activity, which is linked to Alzheimer's disease (AD).", "spo_list": [{"subject": "Lithium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "glycogen synthase kinase-3Î²", "object_type": "GENE-Y"}, {"subject": "Lithium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GSK3Î²", "object_type": "GENE-Y"}]}
{"text": "Furthermore treatment of the cells with MG132, an inhibitor of the 26S proteasome, prevented the destabilizing effect of lithium on AChE-S.", "spo_list": [{"subject": "MG132", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "26S proteasome", "object_type": "GENE-N"}, {"subject": "MG132", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE-S", "object_type": "GENE-Y"}]}
{"text": "Increased mRNA expression levels of brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor were also found in the apomorphine-treated mesencephalic cells along with concomitant protein expression increases in the conditioned medium.", "spo_list": [{"subject": "apomorphine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "brain-derived neurotrophic factor", "object_type": "GENE-Y"}, {"subject": "apomorphine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "glial cell line-derived neurotrophic factor", "object_type": "GENE-Y"}]}
{"text": "Particularly, the effects of doxycycline used as a non selective MMP inhibitor in experimental and clinical studies will be discussed.", "spo_list": [{"subject": "doxycycline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP", "object_type": "GENE-N"}]}
{"text": "Cholesterol uptake from lipoproteins, intracellular vesicle transport and lipid transfer are also modified by oxysterols.", "spo_list": [{"subject": "Cholesterol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "lipoproteins", "object_type": "GENE-N"}]}
{"text": "Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine.", "spo_list": [{"subject": "caffeine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATM", "object_type": "GENE-Y"}, {"subject": "caffeine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATR", "object_type": "GENE-Y"}, {"subject": "caffeine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}]}
{"text": "The similarity of these checkpoint defects to those seen in ataxia-telangiectasia (A-T) suggested that caffeine might inhibit one or more components in an A-T mutated (ATM)-dependent checkpoint pathway in DNA-damaged cells.", "spo_list": [{"subject": "caffeine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "A-T mutated", "object_type": "GENE-Y"}, {"subject": "caffeine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATM", "object_type": "GENE-Y"}]}
{"text": "We now show that caffeine inhibits the catalytic activity of both ATM and the related kinase, ATM and Rad3-related (ATR), at drug concentrations similar to those that induce radiosensitization.", "spo_list": [{"subject": "caffeine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATM", "object_type": "GENE-Y"}, {"subject": "caffeine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "caffeine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATM and Rad3-related", "object_type": "GENE-Y"}, {"subject": "caffeine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATR", "object_type": "GENE-Y"}]}
{"text": "Similar concentrations of caffeine also inhibit gamma- and UV radiation-induced phosphorylation of p53 on Ser15, a modification that may be directly mediated by the ATM and ATR kinases.", "spo_list": [{"subject": "caffeine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p53", "object_type": "GENE-N"}, {"subject": "caffeine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATM", "object_type": "GENE-Y"}, {"subject": "caffeine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATR", "object_type": "GENE-Y"}, {"subject": "caffeine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinases", "object_type": "GENE-N"}]}
{"text": "Likewise, the catalytic activity of the G2 checkpoint kinase, hChk1, was only marginally suppressed by caffeine but was inhibited potently by the structurally distinct radiosensitizer, UCN-01.", "spo_list": [{"subject": "UCN-01", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "checkpoint kinase", "object_type": "GENE-N"}, {"subject": "UCN-01", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hChk1", "object_type": "GENE-Y"}]}
{"text": "These data suggest that the radiosensitizing effects of caffeine are related to inhibition of the protein kinase activities of ATM and ATR and that both proteins are relevant targets for the development of novel anticancer agents.", "spo_list": [{"subject": "caffeine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "protein kinase", "object_type": "GENE-N"}, {"subject": "caffeine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATM", "object_type": "GENE-Y"}, {"subject": "caffeine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATR", "object_type": "GENE-Y"}]}
{"text": "Conivaptan, the first vasopressin receptor antagonist approved by the FDA, is available for the treatment of hyponatremia in euvolemic and hypervolemic patients.", "spo_list": [{"subject": "Conivaptan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "vasopressin receptor", "object_type": "GENE-N"}]}
{"text": "In addition to the anti-inflammatory lipid, lipoxin A4, several other endogenous agonists also bind FPR2, including serum amyloid A, glucocorticoid-induced annexin 1, urokinase and its receptor, suggesting that the activation of FPR2 may result in potent pro- or anti-inflammatory responses.", "spo_list": [{"subject": "lipoxin A4", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "FPR2", "object_type": "GENE-N"}, {"subject": "lipoxin A4", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "serum amyloid A", "object_type": "GENE-N"}, {"subject": "lipoxin A4", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glucocorticoid-induced annexin 1", "object_type": "GENE-Y"}, {"subject": "lipoxin A4", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "urokinase", "object_type": "GENE-Y"}, {"subject": "lipoxin A4", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "FPR2", "object_type": "GENE-Y"}]}
{"text": "D-glucose stimulation of L-arginine transport and nitric oxide synthesis results from activation of mitogen-activated protein kinases p42/44 and Smad2 requiring functional type II TGF-beta receptors in human umbilical vein endothelium.", "spo_list": [{"subject": "D-glucose", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Smad2", "object_type": "GENE-Y"}]}
{"text": "Elevated extracellular D-glucose increases transforming growth factor beta1 (TGF-beta1) release from human umbilical vein endothelium (HUVEC).", "spo_list": [{"subject": "D-glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "transforming growth factor beta1", "object_type": "GENE-Y"}, {"subject": "D-glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TGF-beta1", "object_type": "GENE-Y"}]}
{"text": "TGF-beta1 release was higher ( approximately 1.6-fold) in 25 mM (high) compared with 5 mM (normal) D-glucose.", "spo_list": [{"subject": "D-glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TGF-beta1", "object_type": "GENE-Y"}]}
{"text": "TGF-beta1 and high D-glucose increased hCAT-1 mRNA expression ( approximately 8-fold) and maximal transport velocity (V(max)), L-[(3)H]citrulline formation from L-[(3)H]arginine (index of NO synthesis) and endothelial NO synthase (eNOS) protein abundance, but did not alter eNOS phosphorylation.", "spo_list": [{"subject": "D-glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "hCAT-1", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "endothelial NO synthase", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "eNOS", "object_type": "GENE-Y"}]}
{"text": "TGF-beta1 and high D-glucose increased p42/44(mapk) and Smad2 phosphorylation, an effect blocked by PD-98059 (MEK1/2 inhibitor).", "spo_list": [{"subject": "D-glucose", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Smad2", "object_type": "GENE-Y"}, {"subject": "PD-98059", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Smad2", "object_type": "GENE-Y"}]}
{"text": "High D-glucose increases L-arginine transport and eNOS expression following TbetaRII activation by TGF-beta1 involving p42/44(mapk) and Smad2 in HUVEC.", "spo_list": [{"subject": "D-glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "eNOS", "object_type": "GENE-Y"}, {"subject": "D-glucose", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TbetaRII", "object_type": "GENE-Y"}, {"subject": "D-glucose", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Smad2", "object_type": "GENE-Y"}]}
{"text": "The sensitivity of G protein-activated K+ channels toward halothane is essentially determined by the C terminus.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "G protein-activated K+ channels", "object_type": "GENE-N"}]}
{"text": "When coexpressed with the m(2) acetylcholine (ACh) receptor in Xenopus oocytes, agonist-activated GIRK1(F137S)- and GIRK2-mediated currents are inhibited by halothane, whereas in the absence of ACh, high concentrations of halothane induce GIRK1(F137S)-mediated currents.", "spo_list": [{"subject": "halothane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GIRK1", "object_type": "GENE-Y"}, {"subject": "halothane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "F137S", "object_type": "GENE-N"}, {"subject": "halothane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GIRK2", "object_type": "GENE-Y"}, {"subject": "halothane", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GIRK1", "object_type": "GENE-Y"}, {"subject": "halothane", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "F137S", "object_type": "GENE-N"}]}
{"text": "To elucidate the molecular mechanism of halothane action on GIRK currents of different subunit compositions, we constructed deletion mutants of GIRK1(F137S) (GIRK1(Delta363*)) and GIRK2 (GIRK2(Delta356)) lacking the C-terminal ends, as well as chimeric GIRK channels.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GIRK1", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "F137S", "object_type": "GENE-N"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GIRK1", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GIRK2", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GIRK2", "object_type": "GENE-Y"}]}
{"text": "Mutated GIRK channels showed normal currents when activated by ACh but exhibited different pharmacological properties toward halothane.", "spo_list": [{"subject": "ACh", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GIRK", "object_type": "GENE-N"}]}
{"text": "GIRK2(Delta356) showed no sensitivity against the inhibitory action of halothane but was activated by halothane in the absence of an agonist.", "spo_list": [{"subject": "halothane", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GIRK2", "object_type": "GENE-Y"}]}
{"text": "Single channel experiments revealed an influence of halothane on the gating of the channels: The agonist-induced currents of GIRK1 and GIRK2, carried mainly by brief openings, were inhibited, whereas higher concentrations of the anesthetic promoted long openings of GIRK1 channels.", "spo_list": [{"subject": "halothane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GIRK1", "object_type": "GENE-Y"}, {"subject": "halothane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GIRK2", "object_type": "GENE-Y"}, {"subject": "halothane", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GIRK1", "object_type": "GENE-Y"}]}
{"text": "This report reviews published and unpublished data that suggest that aripiprazole acts as a selective partial agonist at the dopamine D(2) receptor and does not affect 5-HT receptors at therapeutic doses.", "spo_list": [{"subject": "aripiprazole", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "dopamine D(2) receptor", "object_type": "GENE-Y"}]}
{"text": "We found that treatment of both differentiated dopaminergic-like SH-SY5Y cells and rat midbrain slices with the dopamine D2 receptor (D2R) agonist, quinpirole, triggered an increase in the expression of GDNF that was temporally preceded by an increase in the levels of zinc-finger protein 268 (Zif268), a DNA-binding transcription factor encoded by an immediate-early gene.", "spo_list": [{"subject": "quinpirole", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "dopamine D2 receptor", "object_type": "GENE-N"}, {"subject": "quinpirole", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "D2R", "object_type": "GENE-N"}, {"subject": "quinpirole", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GDNF", "object_type": "GENE-N"}, {"subject": "quinpirole", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "zinc-finger protein 268", "object_type": "GENE-N"}, {"subject": "quinpirole", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Zif268", "object_type": "GENE-N"}]}
{"text": "Moreover, the D2R inhibitor raclopride blocked the increase of both GDNF and Zif268 expression following potassium-evoked dopamine release in SH-SY5Y cells.", "spo_list": [{"subject": "raclopride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "D2R", "object_type": "GENE-Y"}, {"subject": "raclopride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "GDNF", "object_type": "GENE-Y"}, {"subject": "raclopride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Zif268", "object_type": "GENE-Y"}]}
{"text": "After a lag time of 2 days, incubation with a GnRH analog leuprolide (10 microM) induced significant growth inhibition of the Fas- and GnRH receptor-bearing cells (p<0.01).", "spo_list": [{"subject": "leuprolide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Fas", "object_type": "GENE-Y"}, {"subject": "leuprolide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GnRH receptor", "object_type": "GENE-Y"}]}
{"text": "Administration of d-GalN/LPS combination resulted in significantly higher plasma levels of aminotransferases, as well as increased mRNA and protein expressions of both HO-1 and NOS-2 enzymes.", "spo_list": [{"subject": "d-GalN", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "aminotransferases", "object_type": "GENE-N"}, {"subject": "d-GalN", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HO-1", "object_type": "GENE-Y"}, {"subject": "d-GalN", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NOS-2", "object_type": "GENE-Y"}]}
{"text": "Quercetin exhibited cytoprotective effects on the liver, as evidenced by decreased aminotransferase plasma levels.", "spo_list": [{"subject": "Quercetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "aminotransferase", "object_type": "GENE-N"}]}
{"text": "Additionally, quercetin treatment in d-GalN/LPS treated rats significantly increased HO-1 mRNA and its protein expressions.", "spo_list": [{"subject": "quercetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HO-1", "object_type": "GENE-Y"}]}
{"text": "It can be concluded that the quercetin's induction of HO-1 and its byproducts, without concomitant NOS-2 activity reduction, is among mechanisms contributing to the hepatoprotective effect in d-GalN/LPS hepatotoxicity.", "spo_list": [{"subject": "quercetin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HO-1", "object_type": "GENE-Y"}]}
{"text": "Naltrexone was injected subcutaneously (0.02-2Â mg/kg) or intrathecally (0.07Â Î¼g/10Â Î¼l-350Â Î¼g/10Â Î¼l), while selective Î¼-antagonist naloxonazine was administered intraperitoneally (5Â mg/kg) prior to nociceptive testing.", "spo_list": [{"subject": "naloxonazine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "Î¼", "object_type": "GENE-Y"}]}
{"text": "Antinociceptive effects of BTX-A in formalin and sciatic nerve transection-induced pain were prevented by non-selective opioid antagonist naltrexone.", "spo_list": [{"subject": "naltrexone", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "opioid", "object_type": "GENE-N"}]}
{"text": "Similarly, BTX-A-induced pain reduction was abolished by low dose of intrathecal naltrexone and by selective Î¼-antagonist naloxonazine.", "spo_list": [{"subject": "naloxonazine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "Î¼", "object_type": "GENE-Y"}]}
{"text": "BTX-A-induced decrease in dorsal horn c-Fos expression was prevented by naltrexone.", "spo_list": [{"subject": "naltrexone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "c-Fos", "object_type": "GENE-Y"}]}
{"text": "The transsulfuration pathway, which aids in regulating homocysteine concentration and mediates cysteine synthesis, may be sensitive to vitamin B-6 status because cystathionine beta-synthase (CBS) and cystathionine gamma-lyase (CGL) require pyridoxal 5'-phosphate (PLP).", "spo_list": [{"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cystathionine beta-synthase", "object_type": "GENE-Y"}, {"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CBS", "object_type": "GENE-Y"}, {"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cystathionine gamma-lyase", "object_type": "GENE-Y"}, {"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CGL", "object_type": "GENE-Y"}, {"subject": "homocysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cystathionine beta-synthase", "object_type": "GENE-Y"}, {"subject": "homocysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CBS", "object_type": "GENE-Y"}, {"subject": "homocysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cystathionine gamma-lyase", "object_type": "GENE-Y"}, {"subject": "homocysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CGL", "object_type": "GENE-Y"}]}
{"text": "Agonistic activity of ICI 182 780 on activation of GSK 3Î²/AKT pathway in the rat uterus during the estrous cycle.", "spo_list": [{"subject": "ICI 182 780", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "GSK 3Î²", "object_type": "GENE-Y"}, {"subject": "ICI 182 780", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AKT", "object_type": "GENE-N"}]}
{"text": "Both ICI treatments, induced a significant decrease (p<0.01) in uterine estrogen receptor alpha (ERÎ±) content, had no effect on uterine progesterone receptor (PR) protein expression and caused marked nuclear localization of cyclin D1, in both luminal and glandular uterine epithelium, as compared to vehicle-treated animals.", "spo_list": [{"subject": "ICI", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "estrogen receptor alpha", "object_type": "GENE-Y"}, {"subject": "ICI", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ERÎ±", "object_type": "GENE-Y"}]}
{"text": "Furthermore, we detected that ICI treatment induced glycogen synthase kinase (Gsk3-Î²) Ser 9 phosphorylation, which correlates with cyclin D1 nuclear localization.", "spo_list": [{"subject": "ICI", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "glycogen synthase kinase", "object_type": "GENE-N"}, {"subject": "ICI", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Gsk3-Î²", "object_type": "GENE-Y"}]}
{"text": "We observed that the administration of ICI at 08:00h on proestrus day produced a 15% inhibition of luminal epithelial cell proliferation, reduced uterine wet weight by 21% and caused reduction of Akt phosphorylation at Ser 473 as compared to vehicle-treated animals, whereas ICI treatment at 00:00h on estrus day had no effect on these parameters.", "spo_list": [{"subject": "ICI", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Akt", "object_type": "GENE-N"}]}
{"text": "The overall results indicate that ICI may exert agonistic and antagonistic effects on uterine cell proliferation through differential activation of the Akt pathway depending on the administration period during the estrous cycle, and indicates that the mechanism of cell proliferation during the physiological conditions of the estrous cycle, is under a different and more complex regulation than in the ovariectomized +E2 animal model.", "spo_list": [{"subject": "ICI", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Akt", "object_type": "GENE-N"}]}
{"text": "Reversal of inhibition by D2 agonist quinpirole was produced by serotonin (50 ÂµM) and by neurotensin (5-10 nM).", "spo_list": [{"subject": "quinpirole", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "D2", "object_type": "GENE-Y"}]}
{"text": "Serotonin-induced or neurotensin-induced reversal was blocked by Î²-ARK1 inhibitor, dynasore, or cPKC antagonist 5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile (GÃ¶6976).", "spo_list": [{"subject": "5,6,7,13-tetrahydro-13-methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4c]carbazole-12-propanenitrile", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "cPKC", "object_type": "GENE-N"}, {"subject": "GÃ¶6976", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "cPKC", "object_type": "GENE-N"}]}
{"text": "Furthermore, we could show that the GSH level decreased significantly after exposure to magnetite particles, while catalase (CAT) activity was increased.", "spo_list": [{"subject": "magnetite", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "catalase", "object_type": "GENE-Y"}, {"subject": "magnetite", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CAT", "object_type": "GENE-Y"}]}
{"text": "We were able to show that incubation of A549 cells prior to particle treatment with diphenyleneiodonium (DPI), a NADPH-oxidase (NOX) inhibitor, leads to decreased ROS formation, but this effect was not observed for the NOX inhibitor apocynin.", "spo_list": [{"subject": "diphenyleneiodonium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NADPH-oxidase", "object_type": "GENE-N"}, {"subject": "diphenyleneiodonium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NOX", "object_type": "GENE-N"}, {"subject": "DPI", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NADPH-oxidase", "object_type": "GENE-N"}, {"subject": "DPI", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NOX", "object_type": "GENE-N"}, {"subject": "apocynin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NOX", "object_type": "GENE-N"}]}
{"text": "A Na(+)/Cl(-)-dependent transporter for catecholamines, identified as a norepinephrine transporter, is expressed in the brain of the teleost fish medaka (Oryzias latipes).", "spo_list": [{"subject": "catecholamines", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "norepinephrine transporter", "object_type": "GENE-Y"}, {"subject": "catecholamines", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Na(+)/Cl(-)-dependent transporter", "object_type": "GENE-N"}]}
{"text": "This carrier is very similar to the human neuronal norepinephrine transporter (NET) and the human neuronal dopamine transporter (DAT), showing 70 and 64% amino acid identity, respectively.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "human neuronal norepinephrine transporter", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "NET", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "human neuronal dopamine transporter", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "DAT", "object_type": "GENE-Y"}]}
{"text": "Its pharmacological profile reveals more similarities with NET, including a high affinity for the tricyclic antidepressants desipramine (IC(50) = 0.92 nM) and nortriptyline (IC(50) = 16 nM).", "spo_list": [{"subject": "tricyclic", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "NET", "object_type": "GENE-N"}, {"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "NET", "object_type": "GENE-N"}, {"subject": "nortriptyline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "NET", "object_type": "GENE-N"}]}
{"text": "Compound 1 exhibited activity comparable to the clinically approved elastase inhibitor sivelestat in short-term assays and demonstrated superior sustained activity in longer-term assays.", "spo_list": [{"subject": "sivelestat", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "elastase", "object_type": "GENE-N"}]}
{"text": "We performed a study in spontaneous hypertensive rats (SHR) to determine whether carvedilol, a nonselective beta-adrenoceptor antagonist, activates capsaicin-sensitive sensory neurons (CSSNs), thereby promoting the release of calcitonin gene-related peptide (CGRP), a neuropeptide with an important role in maintenance of cardiovascular homeostasis.", "spo_list": [{"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta-adrenoceptor", "object_type": "GENE-N"}, {"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "calcitonin gene-related peptide", "object_type": "GENE-N"}, {"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CGRP", "object_type": "GENE-N"}]}
{"text": "Carvedilol given intravenously at a dose of 0.3 mg/kg transiently decreased the mean arterial blood pressure (MABP) and increased renal tissue blood flow with increases in CGRP levels in plasma and kidney.", "spo_list": [{"subject": "Carvedilol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CGRP", "object_type": "GENE-N"}]}
{"text": "Prazosin, a selective alpha(1)-adrenoceptor antagonist, and bisoprolol, a selective beta(1)-adrenoceptor antagonist, decreased MABP with capsazepine, showing no antagonistic action in either cases, and these agents increased neither renal tissue blood flow nor levels of CGRP in plasma and kidney.", "spo_list": [{"subject": "Prazosin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(1)-adrenoceptor", "object_type": "GENE-N"}, {"subject": "bisoprolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta(1)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Both ICI 118,551 [(+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-but anol], a selective beta(2)-adrenoceptor antagonist, at a dose of 0.25 mg/kg and capsaicin mimicked effects induced by 0.3 mg/kg carvedilol.", "spo_list": [{"subject": "ICI 118,551", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "(+/-)-1-[2,3-(dihydro-7-methyl-1H-inden-4-yl)oxy]-3-[(1-methylethyl)amino]-2-but anol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "These observations strongly suggested that the low dose of carvedilol might activate CSSNs in SHR to increase the release of CGRP, thereby decreasing blood pressure with an increase in renal tissue blood flow.", "spo_list": [{"subject": "carvedilol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CGRP", "object_type": "GENE-N"}]}
{"text": "We found that TR-MUL5 cells exhibited [(14)C]L-cystine uptake activity and expressed xCT and 4F2hc, which involve system x(c) (-).", "spo_list": [{"subject": "[(14)C]L-cystine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "xCT", "object_type": "GENE-N"}, {"subject": "[(14)C]L-cystine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "4F2hc", "object_type": "GENE-N"}, {"subject": "[(14)C]L-cystine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "system x(c) (-)", "object_type": "GENE-N"}]}
{"text": "Following diethyl maleate (DEM) treatment, the glutathione concentration in TR-MUL5 cells was reduced in the first 24 h, then gradually recovered for more than 24 h. The L-cystine uptake rate and the xCT expression level in TR-MUL5 cells were enhanced by DEM treatment.", "spo_list": [{"subject": "DEM", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "xCT", "object_type": "GENE-N"}, {"subject": "L-cystine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "xCT", "object_type": "GENE-N"}]}
{"text": "In conclusion, TR-MUL cells have the properties of Muller cells and exhibit system x(c) (-)-mediated L-cystine uptake activity.", "spo_list": [{"subject": "L-cystine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "system x(c) (-)", "object_type": "GENE-N"}]}
{"text": "The oxidative stress conditions following DEM treatment activate L-cystine transport in TR-MUL cells due to the enhanced transcription of the xCT gene.", "spo_list": [{"subject": "DEM", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "L-cystine transport", "object_type": "GENE-N"}, {"subject": "DEM", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "xCT", "object_type": "GENE-N"}]}
{"text": "In differentiated cells, TSH/cAMP treatment decreases FoxO1 mRNA and protein levels through proteasome activation, whereas both TSH and IGF-I control FoxO1 localization by promoting a rapid exclusion from the nucleus in an Akt-dependent manner.", "spo_list": [{"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "FoxO1", "object_type": "GENE-Y"}, {"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "proteasome", "object_type": "GENE-N"}]}
{"text": "Absorbable drugs (fibric acids, nicotinic acid, probucol, HMG-CoA reductase inhibitors) reduce plasma very-low-density lipoproteins (VLDL) and/or low-density lipoproteins (LDL) by a variety of mechanisms.", "spo_list": [{"subject": "fibric acids", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "plasma very-low-density lipoproteins", "object_type": "GENE-N"}, {"subject": "nicotinic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "plasma very-low-density lipoproteins", "object_type": "GENE-N"}, {"subject": "probucol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "plasma very-low-density lipoproteins", "object_type": "GENE-N"}, {"subject": "fibric acids", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "VLDL", "object_type": "GENE-N"}, {"subject": "nicotinic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "VLDL", "object_type": "GENE-N"}, {"subject": "probucol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "VLDL", "object_type": "GENE-N"}, {"subject": "fibric acids", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "low-density lipoproteins", "object_type": "GENE-N"}, {"subject": "fibric acids", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "LDL", "object_type": "GENE-N"}, {"subject": "nicotinic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "low-density lipoproteins", "object_type": "GENE-N"}, {"subject": "nicotinic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "LDL", "object_type": "GENE-N"}, {"subject": "probucol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "LDL", "object_type": "GENE-N"}, {"subject": "probucol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "low-density lipoproteins", "object_type": "GENE-N"}]}
{"text": "Fibric acids, in particular, act by stimulating the catabolism of VLDL and also, as a consequence, improving LDL delipidation, thus favoring receptor uptake.", "spo_list": [{"subject": "Fibric acids", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "VLDL", "object_type": "GENE-N"}]}
{"text": "Probucol acts by a newly described mechanism, i.e. accelerating reverse transport of cholesteryl esters from high-density lipoproteins to lower-density lipoproteins.", "spo_list": [{"subject": "cholesteryl esters", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "high-density lipoproteins", "object_type": "GENE-N"}, {"subject": "cholesteryl esters", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "lower-density lipoproteins", "object_type": "GENE-N"}]}
{"text": "Binding of progestins to the glucocorticoid receptor.", "spo_list": [{"subject": "progestins", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}]}
{"text": "A number of physiological and synthetic progestins were tested for their ability to compete with [3H]dexamethasone for the binding to the glucocorticoid receptor of human mononuclear leukocytes and their ability to elicit glucocorticoid-like effects on the same cells.", "spo_list": [{"subject": "[3H]dexamethasone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}, {"subject": "progestins", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}]}
{"text": "The effective binding of medroxyprogesterone acetate to the glucocorticoid receptor was confirmed by direct binding studies utilizing a tritiated derivative of this steroid.", "spo_list": [{"subject": "medroxyprogesterone acetate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}, {"subject": "steroid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}]}
{"text": "No evidence for the existence of a specific progesterone receptor in human mononuclear leukocytes was obtained as judged by the results of competition experiments where a progesterone receptor-specific ligand [3H]Org 2058 was used.", "spo_list": [{"subject": "[3H]Org 2058", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "progesterone receptor", "object_type": "GENE-Y"}, {"subject": "[3H]Org 2058", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "progesterone receptor", "object_type": "GENE-Y"}]}
{"text": "The concentration response to levcromakalim (LEVC), a K(ATP) channel opener, was significantly shifted to the left in the inflamed smooth-muscle cells.", "spo_list": [{"subject": "levcromakalim", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "K(ATP) channel", "object_type": "GENE-N"}, {"subject": "LEVC", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "K(ATP) channel", "object_type": "GENE-N"}]}
{"text": "Sulfhydration of sulfonylurea receptor 2B (SUR2B) was induced by NaHS and colonic inflammation.", "spo_list": [{"subject": "NaHS", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "sulfonylurea receptor 2B", "object_type": "GENE-Y"}, {"subject": "NaHS", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "SUR2B", "object_type": "GENE-Y"}]}
{"text": "Ceramide phosphoethanolamine biosynthesis in Drosophila is mediated by a unique ethanolamine phosphotransferase in the Golgi lumen.", "spo_list": [{"subject": "Ceramide phosphoethanolamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ethanolamine phosphotransferase", "object_type": "GENE-N"}]}
{"text": "Its production involves the transfer of phosphocholine from phosphatidylcholine onto ceramide, a reaction catalyzed by SM synthase in the Golgi lumen.", "spo_list": [{"subject": "ceramide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SM synthase", "object_type": "GENE-N"}, {"subject": "phosphatidylcholine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SM synthase", "object_type": "GENE-N"}]}
{"text": "Using a functional cloning strategy, we here identified a CDP-ethanolamine:ceramide ethanolamine phosphotransferase as the enzyme responsible for CPE production in Drosophila.", "spo_list": [{"subject": "CPE", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ceramide ethanolamine phosphotransferase", "object_type": "GENE-N"}]}
{"text": "Treatment with Bosentan, a mixed ET-1 receptor antagonist, significantly reduced the incidence and intensity of arteriosclerotic lesions in rat cardiac allografts, as well as total intragraft ET(A) and ET(B) mRNA expression and intimal cell ET-1 and receptor immunoreactivity.", "spo_list": [{"subject": "Bosentan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ET-1 receptor", "object_type": "GENE-Y"}, {"subject": "Bosentan", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ET(A)", "object_type": "GENE-Y"}, {"subject": "Bosentan", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ET(B)", "object_type": "GENE-Y"}]}
{"text": "In contrast, CGP 53716, a protein tyrosine kinase inhibitor selective for the PDGF receptor, did not reduce intragraft ET-1, ET(A) or ET(B) mRNA expression.", "spo_list": [{"subject": "CGP 53716", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}]}
{"text": "Postoperative concentrations of plasminogen were decreased significantly in the tranexamic acid group (P < 0.001).", "spo_list": [{"subject": "tranexamic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "plasminogen", "object_type": "GENE-Y"}]}
{"text": "Pyrrolopyrazines as Selective Spleen Tyrosine Kinase Inhibitors.", "spo_list": [{"subject": "Pyrrolopyrazines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Spleen Tyrosine Kinase", "object_type": "GENE-Y"}]}
{"text": "We describe the discovery of several pyrrolopyrazines as potent and selective Syk inhibitors and the efforts that eventually led to the desired improvements in physicochemical properties and human whole blood potencies.", "spo_list": [{"subject": "pyrrolopyrazines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Syk", "object_type": "GENE-Y"}]}
{"text": "Interaction of antidepressants and neuroleptics with histamine stimulated parietal cell adenylate cyclase and H+ secretion.", "spo_list": [{"subject": "histamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "adenylate cyclase", "object_type": "GENE-N"}]}
{"text": "All compounds inhibited histamine-stimulated adenylate cyclase and H+ secretion in a concentration-dependent manner.", "spo_list": [{"subject": "histamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "adenylate cyclase", "object_type": "GENE-N"}]}
{"text": "All drugs caused a rightward shift in the concentration-response curves of histamine-induced adenylate cyclase activation with Schild-plot lines having a slope significantly different from unity.", "spo_list": [{"subject": "histamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "adenylate cyclase", "object_type": "GENE-N"}]}
{"text": "RIHP and fractional excretion of sodium (FE(Na)) were measured before and after direct renal interstitial volume expansion in control rats (n=7), rats infused with the COX-1 inhibitor piroxicam (n=6, 1.5 mg/kg), and rats infused with the COX-2 inhibitors NS-398 (n=5, 1.5 mg/kg) and meloxicam (n=6, 0.3 mg/kg).", "spo_list": [{"subject": "piroxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "NS-398", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "meloxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Infusion of piroxicam but not NS-398 or meloxicam blunted the natriuretic response to increased renal interstitial hydrostatic pressure, suggesting that the natriuretic response to increased blood pressure may be preserved during inhibition of COX-2.", "spo_list": [{"subject": "NS-398", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "meloxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Because minocycline inhibits matrix metalloprotease-9 (MMP-9), we also compared minocycline's protective effect in wild type (wt) and MMP-9 knock-out (ko) mice.", "spo_list": [{"subject": "minocycline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "matrix metalloprotease-9", "object_type": "GENE-Y"}, {"subject": "minocycline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-9", "object_type": "GENE-Y"}]}
{"text": "Minocycline inhibited ischemia-provoked pro-MMP-9 induction in wt mice, but was not protective in MMP-9 ko mice.", "spo_list": [{"subject": "Minocycline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "pro-MMP-9", "object_type": "GENE-Y"}]}
{"text": "Comparison of the effect of rofecoxib (a cyclooxygenase 2 inhibitor), ibuprofen, and placebo on the gastroduodenal mucosa of patients with osteoarthritis: a randomized, double-blind, placebo-controlled trial.", "spo_list": [{"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase 2", "object_type": "GENE-Y"}]}
{"text": "OBJECTIVE: This randomized, double-blind study tested the hypothesis that rofecoxib, a drug that specifically inhibits cyclooxygenase 2, would cause fewer gastroduodenal ulcers than ibuprofen (in a multicenter trial), and its side effects would be equivalent to those of placebo (in a prespecified analysis combining the results with another trial of identical design).", "spo_list": [{"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase 2", "object_type": "GENE-Y"}]}
{"text": "OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of nebulized arformoterol tartrate (a selective, long-acting beta(2)-adrenergic agonist that is the [R,R] isomer of formoterol) and salmeterol xinafoate versus placebo in patients with chronic obstructive pulmonary disease (COPD).", "spo_list": [{"subject": "[R,R] isomer of formoterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(2)-adrenergic", "object_type": "GENE-Y"}, {"subject": "arformoterol tartrate", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta(2)-adrenergic", "object_type": "GENE-Y"}]}
{"text": "Glucocorticoid receptors were activated by dexamethasone as assessed using a glucocorticoid-responsive reporter plasmid, pTAT3-CAT.", "spo_list": [{"subject": "dexamethasone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Glucocorticoid receptors", "object_type": "GENE-Y"}]}
{"text": "The glucocorticoid receptor antagonist RU-486 (mifepristone) significantly counteracted the effect of dexamethasone on glucocorticoid receptor activation, indicating that the dexamethasone effect is specific and is mediated through the glucocorticoid receptor.", "spo_list": [{"subject": "RU-486", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}, {"subject": "mifepristone", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}]}
{"text": "Mitochondrial function(s) of tRNA(Lys)(CUU), tRK1, targeted into Saccharomyces cerevisiae mitochondria was mysterious, since mitochondrial DNA-encoded tRNA(Lys)(UUU), tRK3, was hypothesized to decode both lysine codons, AAA and AAG.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "tRNA(Lys)(UUU)", "object_type": "GENE-N"}, {"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "tRK3", "object_type": "GENE-N"}]}
{"text": "Leptin is a 167 amino acid protein encoded by the obesity gene that is synthesized in adipose tissue and interacts with receptors in the hypothalamus linked to the regulation of appetite and metabolism.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Leptin", "object_type": "GENE-Y"}]}
{"text": "The mean body weight at baseline (52.59 kg) did not differ significantly from that at 1 week after treatment (52.84 kg; P > .05), but the mean leptin level after 1 week of treatment with cyproheptadine (3.14 ng/mL) was 14.2% higher than that at baseline (2.75 ng/mL; P < .05).", "spo_list": [{"subject": "cyproheptadine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "leptin", "object_type": "GENE-Y"}]}
{"text": "Enhanced beta cell function and anti-inflammatory effect after chronic treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin in an advanced-aged diet-induced obesity mouse model.", "spo_list": [{"subject": "vildagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dipeptidyl peptidase-4", "object_type": "GENE-Y"}]}
{"text": "METHODS: After 1Â month of HFD alone, the mice were given the DPP4 inhibitor vildagliptin for a further 11Â months.", "spo_list": [{"subject": "vildagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP4", "object_type": "GENE-Y"}]}
{"text": "The improved survival rates for obese mice chronically treated with vildagliptin suggest that chronic DPP4 inhibition potentially results in additional quality-adjusted life-years for individuals with type 2 diabetes, which is the primary goal of any diabetes therapy.", "spo_list": [{"subject": "vildagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP4", "object_type": "GENE-Y"}]}
{"text": "Prucalopride was a 5-HT(4) receptor agonist in the guinea-pig colon, as it induced contractions (pEC(50)=7.48+/-0.06; insensitive to a 5-HT(2A) or 5-HT(3) receptor antagonist, but inhibited by a 5-HT(4) receptor antagonist) as well as the facilitation of electrical stimulation-induced noncholinergic contractions (blocked by a 5-HT(4) receptor antagonist).", "spo_list": [{"subject": "Prucalopride", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT(4)", "object_type": "GENE-Y"}]}
{"text": "It is concluded that prucalopride is a potent, selective and specific 5-HT(4) receptor agonist.", "spo_list": [{"subject": "prucalopride", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT(4)", "object_type": "GENE-Y"}]}
{"text": "Phospholipase D (PLD) catalyzes the hydrolysis of the phosphodiester bond of glycerophospholipid phosphatidylcholine to generate phosphatidic acid (PA) and choline.", "spo_list": [{"subject": "phosphatidylcholine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Phospholipase D", "object_type": "GENE-N"}, {"subject": "phosphatidylcholine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PLD", "object_type": "GENE-N"}, {"subject": "phosphatidic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Phospholipase D", "object_type": "GENE-N"}, {"subject": "phosphatidic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PLD", "object_type": "GENE-N"}, {"subject": "PA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Phospholipase D", "object_type": "GENE-N"}, {"subject": "PA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PLD", "object_type": "GENE-N"}, {"subject": "choline", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Phospholipase D", "object_type": "GENE-N"}, {"subject": "choline", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PLD", "object_type": "GENE-N"}, {"subject": "phosphodiester", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Phospholipase D", "object_type": "GENE-N"}, {"subject": "phosphodiester", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PLD", "object_type": "GENE-N"}]}
{"text": "Several effects of polyphenols are useful in this scenario, including a reduction in the activities of cytokines and modulation of cellular metabolism through histone deacetylase inhibitors, AMPK activators, calorie-restriction mimetics or epigenetic regulators.", "spo_list": [{"subject": "polyphenols", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cytokines", "object_type": "GENE-N"}, {"subject": "polyphenols", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "histone deacetylase", "object_type": "GENE-N"}, {"subject": "polyphenols", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-Y"}]}
{"text": "AVP is activated by two cofactors, the viral DNA and pVIc, an 11-amino acid peptide originating from the C terminus of the precursor protein pVI.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "pVI", "object_type": "GENE-N"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "pVIc", "object_type": "GENE-N"}, {"subject": "pVIc", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AVP", "object_type": "GENE-N"}]}
{"text": "AVP, partially activated by being bound to DNA, excises pVIc, which binds to the AVP molecule that cut it out. pVIc then forms a disulfide bond with AVP forming the fully active AVP-pVIc complex bound to DNA.", "spo_list": [{"subject": "pVIc", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AVP", "object_type": "GENE-N"}, {"subject": "pVIc", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AVP", "object_type": "GENE-N"}, {"subject": "pVIc", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AVP", "object_type": "GENE-N"}]}
{"text": "The effects of the phosphodiesterase type 5 inhibitor vardenafil on cognitive performance in healthy adults: a behavioral- electroencephalography study.", "spo_list": [{"subject": "vardenafil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase type 5", "object_type": "GENE-Y"}]}
{"text": "Therefore, we examined whether the PDE5-I vardenafil improves memory and executive functioning and affect electroencephalography (EEG) in healthy young adults.", "spo_list": [{"subject": "vardenafil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE5", "object_type": "GENE-Y"}]}
{"text": "In this study, we present the signaling mechanisms of a newly developed LMW dihydropyridine agonist of the FSHR, Org 214444-0.", "spo_list": [{"subject": "dihydropyridine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "FSHR", "object_type": "GENE-Y"}, {"subject": "Org 214444-0", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "FSHR", "object_type": "GENE-Y"}]}
{"text": "Org 214444-0 is shown to be a stereoselective, nanomolar potent FSHR agonist and selective over the structurally related LHR and TSHR.", "spo_list": [{"subject": "Org 214444-0", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "FSHR", "object_type": "GENE-Y"}]}
{"text": "When co-incubated with FSH, Org 214444-0 augments FSH's potency in binding (6.5-fold) and adenylyl cyclase/cAMP activation (3.5-fold) in a concentration-dependent manner.", "spo_list": [{"subject": "Org 214444-0", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "adenylyl cyclase", "object_type": "GENE-N"}, {"subject": "Org 214444-0", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "FSH's", "object_type": "GENE-N"}, {"subject": "Org 214444-0", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "adenylyl cyclase", "object_type": "GENE-N"}]}
{"text": "Like FSH, Org 214444-0 induces FSHR internalization and is only marginally effective in stimulating phospholipase C. Moreover, Org 214444-0 stimulates cAMP and estradiol production in human granulosa cells in culture and supports the follicular phase in mature female rats.", "spo_list": [{"subject": "Org 214444-0", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "phospholipase C.", "object_type": "GENE-N"}]}
{"text": "We conclude that Org 214444-0 is a bonafide FSHR agonist.", "spo_list": [{"subject": "Org 214444-0", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "FSHR", "object_type": "GENE-Y"}]}
{"text": "They display sensitivity to TK inhibitors, including gefitinib and erlotinib.", "spo_list": [{"subject": "gefitinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TK", "object_type": "GENE-N"}, {"subject": "erlotinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TK", "object_type": "GENE-N"}]}
{"text": "The G719S/T790M double mutant has enhanced activity and retains high gefitinib-binding affinity.", "spo_list": [{"subject": "gefitinib", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "G719S", "object_type": "GENE-N"}, {"subject": "gefitinib", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "T790M", "object_type": "GENE-N"}]}
{"text": "The T790M mutation increases the ATP affinity of the G719S mutant, explaining the acquired drug resistance of the double mutant.", "spo_list": [{"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "G719S", "object_type": "GENE-N"}]}
{"text": "The Met790 side chain of the G719S/T790M double mutant, in the apo form and gefitinib- and AMPPNP-bound forms, adopts different conformations that explain the accommodation of these ligands.", "spo_list": [{"subject": "Met", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "G719S", "object_type": "GENE-N"}, {"subject": "Met", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "T790M", "object_type": "GENE-N"}]}
{"text": "In the L858R mutant structure, the active-site cleft is expanded by the repositioning of Phe723 within the P-loop.", "spo_list": [{"subject": "Phe", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "L858R", "object_type": "GENE-N"}]}
{"text": "Ang II level in plasma and mesenteric arteries in SHR group was the same or lower than that in WKY group, and was higher in irbesartan group and lower in imidapril group.", "spo_list": [{"subject": "irbesartan", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Ang II", "object_type": "GENE-Y"}, {"subject": "imidapril", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Ang II", "object_type": "GENE-Y"}]}
{"text": "The ratio of TGF-beta1 absorbed light value to GAPDH absorbed light value in the SHR group was 0.887+/-0.019, which was significantly higher than that in WKY group, imidapril group, and irbesartan group with the ratios of 0.780+/-0.018, 0.803+/-0.005, and 0.847+/-0.017, respectively (P<0.01).", "spo_list": [{"subject": "imidapril", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TGF-beta1", "object_type": "GENE-Y"}, {"subject": "irbesartan", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TGF-beta1", "object_type": "GENE-Y"}, {"subject": "imidapril", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GAPDH", "object_type": "GENE-Y"}, {"subject": "irbesartan", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GAPDH", "object_type": "GENE-Y"}]}
{"text": "Ang II level in plasma and mesenteric arteries in imidapril group was significantly lower than that in irbesartan group (P<0.05).", "spo_list": [{"subject": "imidapril", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Ang II", "object_type": "GENE-Y"}, {"subject": "irbesartan", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Ang II", "object_type": "GENE-Y"}]}
{"text": "The c-Jun absorbed light value/GAPDH absorbed light value of mesenteric arteries in the SHR group was 0.850+/-0.015, which was significantly higher than that in the WKY, imidapril, and irbesartan groups (0.582+/-0.013, 0.743+/-0.012, and 0.789+/-0.013, respectively, P<0.01), and was significantly lower in imidapril group than in irbesartan group (P<0.05).", "spo_list": [{"subject": "imidapril", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "c-Jun", "object_type": "GENE-Y"}, {"subject": "irbesartan", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "c-Jun", "object_type": "GENE-Y"}, {"subject": "imidapril", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GAPDH", "object_type": "GENE-Y"}, {"subject": "irbesartan", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GAPDH", "object_type": "GENE-Y"}]}
{"text": "CONCLUSION: Imidapril and irbesartan can not only control blood pressure but also inhibit mesenteric arteries remodeling and mRNA expression of TGF-beta1, c-Jun in SHR.", "spo_list": [{"subject": "Imidapril", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TGF-beta1", "object_type": "GENE-Y"}, {"subject": "irbesartan", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TGF-beta1", "object_type": "GENE-Y"}, {"subject": "Imidapril", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "c-Jun", "object_type": "GENE-Y"}, {"subject": "irbesartan", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "c-Jun", "object_type": "GENE-Y"}]}
{"text": "Prolonged (18 h) incubation of isolated bovine tracheal smooth muscle with the beta2-adrenoceptor agonist fenoterol (10 microM) induced desensitization of isoprenaline-induced adenylyl cyclase activity in bovine tracheal smooth muscle membranes, characterized by a 25% decrease in maximal effect (Emax) (P < 0.05), while the sensitivity to the agonist (pEC50) was unchanged.", "spo_list": [{"subject": "fenoterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta2-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "isoprenaline", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "adenylyl cyclase", "object_type": "GENE-N"}]}
{"text": "As determined by 30 microM gallamine-induced muscarinic M2 receptor antagonism and pertussis toxin-induced inactivation of G(i alpha), muscarinic M2 receptor-mediated functional antagonism did not play a role in isoprenaline-induced relaxation of bovine tracheal smooth muscle contracted by methacholine, both in control and in 18-h fenoterol-treated tissue.", "spo_list": [{"subject": "gallamine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic M2 receptor", "object_type": "GENE-Y"}]}
{"text": "In line with these observations, we found no enhanced muscarinic M2 receptor-mediated inhibition of 1 microM forskolin-stimulated adenylyl cyclase activity after 18-h fenoterol treatment.", "spo_list": [{"subject": "forskolin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "adenylyl cyclase", "object_type": "GENE-N"}]}
{"text": "All tested compounds displaced 17 beta-[3H]estradiol from the cytosolic estrogen receptor, but to varying degrees; and there was no discernible relationship between their ability to compete for this receptor and their efficacy in stimulating DNA synthesis.", "spo_list": [{"subject": "17 beta-[3H]estradiol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}]}
{"text": "The effect of the test compounds on the levels of estrogen receptor in cytosol and in nuclei was measured by [3H]estradiol exchange.", "spo_list": [{"subject": "[3H]estradiol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}]}
{"text": "17 beta-Estradiol, equilin, 17 alpha-ethinylestradiol, diethylstilbestrol, hexestrol, dienestrol, coumestrol, and nafoxidine provoked a complete estrogen receptor response: acutely a decrease in the level of cytosolic estrogen receptor and an increase in the nuclear estrogen receptor.", "spo_list": [{"subject": "17 beta-Estradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "17 alpha-ethinylestradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "diethylstilbestrol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "hexestrol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "dienestrol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "coumestrol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "nafoxidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "17 beta-Estradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "17 alpha-ethinylestradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "diethylstilbestrol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "hexestrol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "dienestrol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "coumestrol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "nafoxidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}]}
{"text": "Characterization of ochratoxin A transport by human organic anion transporters.", "spo_list": [{"subject": "ochratoxin A", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human organic anion transporters", "object_type": "GENE-N"}]}
{"text": "S2 hOAT1 and S2 hOAT3 exhibited a time- and dose-dependent, and a saturable increase in uptake of [3H]-OTA, with apparent Km values of 0.42 microM (hOAT1) and 0.75 microM (hOAT3).", "spo_list": [{"subject": "[3H]-OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "[3H]-OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT3", "object_type": "GENE-Y"}, {"subject": "[3H]-OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "[3H]-OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT3", "object_type": "GENE-Y"}]}
{"text": "These OTA uptakes were inhibited by several substrates for the OATs.", "spo_list": [{"subject": "OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATs", "object_type": "GENE-N"}]}
{"text": "Para-aminohippuric acid (PAH), probenecid, piroxicam, octanoate and citrinin inhibited [3H]-OTA uptake by hOAT1 and hOAT3 in a competitive manner (Ki = 4.29-3080 microM), with the following order of potency: probenecid > octanoate > PAH > piroxicam > citrinin for hOAT1; probenecid > piroxicam > octanoate> citrinin > PAH for hOAT3.", "spo_list": [{"subject": "[3H]-OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "[3H]-OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT3", "object_type": "GENE-Y"}, {"subject": "Para-aminohippuric acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "PAH", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "probenecid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "piroxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "octanoate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "citrinin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "Para-aminohippuric acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT3", "object_type": "GENE-Y"}, {"subject": "PAH", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT3", "object_type": "GENE-Y"}, {"subject": "probenecid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT3", "object_type": "GENE-Y"}, {"subject": "piroxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT3", "object_type": "GENE-Y"}, {"subject": "octanoate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT3", "object_type": "GENE-Y"}, {"subject": "citrinin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT3", "object_type": "GENE-Y"}, {"subject": "probenecid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "PAH", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "piroxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "citrinin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "probenecid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT3", "object_type": "GENE-Y"}, {"subject": "piroxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT3", "object_type": "GENE-Y"}, {"subject": "citrinin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT3", "object_type": "GENE-Y"}, {"subject": "PAH", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hOAT3", "object_type": "GENE-Y"}]}
{"text": "These results indicate that hOAT1, as well as hOAT3, mediates a high-affinity transport of OTA on the basolateral side of the proximal tubule, but hOAT1- and hOAT3-mediated OTA transport are differently influenced by the substrates for the OATs.", "spo_list": [{"subject": "OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT3", "object_type": "GENE-Y"}, {"subject": "OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT3", "object_type": "GENE-Y"}]}
{"text": "These pharmacological characteristics of hOAT1 and hOAT3 may be significantly related with the events in the development of OTA-induced nephrotoxicity in the human kidney.", "spo_list": [{"subject": "OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "OTA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT3", "object_type": "GENE-Y"}]}
{"text": "While HIF-1Î± in hypoxia translocates to the nucleus where it transcribes the target genes including vascular endothelial growth factor (VEGF) mRNA, HIF-1Î± is degraded under normoxia, which involves its proline hydroxylation and subsequent binding to the von Hippel-Lindau protein-Elongin B-Elogin C (VBC) complex.", "spo_list": [{"subject": "proline", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "HIF-1Î±", "object_type": "GENE-Y"}]}
{"text": "This localization is in turn dependent on the Homer family of scaffolding proteins which bind to a small motif on the distal C-termini of mGluR1 and 5, localize the receptors near the PSD, strengthen coupling to post-synaptic effectors and simultaneously uncouple the mGluRs from extra-synaptic effectors such as voltage dependent ion channels.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "mGluR1 and 5", "object_type": "GENE-N"}]}
{"text": "Uncoupling from this channel was achieved by co-expression of an mGluR1 C-terminal protein designed to disrupt a previously described direct interaction between these two proteins, suggesting that this interaction allows incorporation of Ca(V2.1) into the mGluR1/Homer signaling complex, thereby preserving modulation in the presence of scaffolding Homer proteins.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "mGluR1", "object_type": "GENE-Y"}]}
{"text": "In kidneys, stimulation of adenylyl cyclase causes egress of cAMP, conversion of cAMP to AMP by ecto-phosphodiesterase, and metabolism of AMP to adenosine by ecto-5'-nucleotidase.", "spo_list": [{"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "phosphodiesterase", "object_type": "GENE-N"}, {"subject": "AMP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "phosphodiesterase", "object_type": "GENE-N"}, {"subject": "AMP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ecto-5'-nucleotidase", "object_type": "GENE-Y"}, {"subject": "adenosine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ecto-5'-nucleotidase", "object_type": "GENE-Y"}]}
{"text": "A broad-spectrum phosphodiesterase (PDE) inhibitor (1,3-isobutyl-1-methylxanthine, 300 microM, n=6) and an ecto-phosphodiesterase inhibitor (1,3-dipropyl-8-p-sulfophenylxanthine, 1 mM, n=6) significantly attenuated cAMP-induced AMP secretion by 60 and 74%, respectively.", "spo_list": [{"subject": "1,3-isobutyl-1-methylxanthine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase", "object_type": "GENE-N"}, {"subject": "1,3-isobutyl-1-methylxanthine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE", "object_type": "GENE-N"}]}
{"text": "Blockade of PDE1 (8-methoxymethyl-3-isobutyl-1-methylxanthine, 100 microM), PDE2 [erythro-9-(2-hydroxy-3-nonyl)adenine, 30 microM], PDE3 (milrinone, 10 microM; cGMP, 10 microM), PDE4 (Ro 20-1724 [4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one], 100 microM), PDE5 and PDE6 (zaprinast, 30 microM), and PDE7 [BRL-50481 (5-nitro-2,N,N-trimethylbenzenesulfonamide), 10 microM] did not alter renal ecto-phosphodiesterase activity.", "spo_list": [{"subject": "8-methoxymethyl-3-isobutyl-1-methylxanthine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE1", "object_type": "GENE-N"}, {"subject": "erythro-9-(2-hydroxy-3-nonyl)adenine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE2", "object_type": "GENE-N"}, {"subject": "milrinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE3", "object_type": "GENE-N"}, {"subject": "4-(3-butoxy-4-methoxybenzyl)imidazolidin-2-one", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}, {"subject": "zaprinast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "zaprinast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE6", "object_type": "GENE-N"}, {"subject": "BRL-50481", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE7", "object_type": "GENE-N"}, {"subject": "5-nitro-2,N,N-trimethylbenzenesulfonamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE7", "object_type": "GENE-N"}]}
{"text": "Administration of a concentration (100 microM) of dipyridamole that blocks PDE8 inhibited ecto-phosphodiesterase activity (by 44%).", "spo_list": [{"subject": "dipyridamole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE8", "object_type": "GENE-N"}, {"subject": "dipyridamole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase", "object_type": "GENE-N"}]}
{"text": "However, a lower concentration of dipyridamole (3 microM) that blocks PDE9, PDE10, and PDE11, but not PDE8, did not inhibit ecto-phosphodiesterase activity.", "spo_list": [{"subject": "dipyridamole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE9", "object_type": "GENE-N"}, {"subject": "dipyridamole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE10", "object_type": "GENE-Y"}, {"subject": "dipyridamole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE11", "object_type": "GENE-Y"}]}
{"text": "These data support the conclusion that renal ecto-phosphodiesterase activity is not mediated by PDE1, PDE2, PDE3, PDE4, PDE5, PDE6, PDE7, PDE9, PDE10, or PDE11 and is inhibited by high concentrations of dipyridamole.", "spo_list": [{"subject": "dipyridamole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase", "object_type": "GENE-N"}]}
{"text": "Immunohistochemical analysis also revealed that LPS-induced lipocalin-2 is expressed by brain endothelial cells and is partly co-localised with cyclooxygenase-2 (Cox-2), the rate-limiting enzyme for the production of inflammatory induced prostaglandin E(2) (PGE(2) ), which is the key mediator of fever.", "spo_list": [{"subject": "prostaglandin E(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "PGE(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "prostaglandin E(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Cox-2", "object_type": "GENE-Y"}, {"subject": "PGE(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Cox-2", "object_type": "GENE-Y"}]}
{"text": "Our findings suggest that IL-6 influences the expression of lipocalin-2, which in turn may be involved in the control of the formation of Cox-2, and hence central PGE(2) -production.", "spo_list": [{"subject": "PGE(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Cox-2", "object_type": "GENE-Y"}]}
{"text": "Immunohistochemical assays showed that in tumors from parental and CMV xenografts, estradiol decreased estrogen receptor-alpha expression and induced progesterone receptor expression and Akt phosphorylation, effects that were inhibited by tamoxifen, AG825, and R25C-Akt1 by 89, 82, and 77% for progesterone receptor expression and 48, 66, and 73% for pAkt expression, respectively.", "spo_list": [{"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "estrogen receptor-alpha", "object_type": "GENE-Y"}, {"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "progesterone receptor", "object_type": "GENE-Y"}, {"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "tamoxifen", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "estrogen receptor-alpha", "object_type": "GENE-Y"}, {"subject": "tamoxifen", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "progesterone receptor", "object_type": "GENE-Y"}, {"subject": "tamoxifen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "AG825", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "estrogen receptor-alpha", "object_type": "GENE-Y"}, {"subject": "AG825", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "progesterone receptor", "object_type": "GENE-Y"}, {"subject": "AG825", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Akt1", "object_type": "GENE-Y"}, {"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "R25C", "object_type": "GENE-N"}, {"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "pAkt", "object_type": "GENE-N"}, {"subject": "tamoxifen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "R25C", "object_type": "GENE-N"}, {"subject": "AG825", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "R25C", "object_type": "GENE-N"}, {"subject": "tamoxifen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt1", "object_type": "GENE-Y"}, {"subject": "AG825", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt1", "object_type": "GENE-Y"}, {"subject": "tamoxifen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "pAkt", "object_type": "GENE-N"}, {"subject": "tamoxifen", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "pAkt", "object_type": "GENE-N"}, {"subject": "AG825", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "pAkt", "object_type": "GENE-N"}, {"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "progesterone receptor", "object_type": "GENE-Y"}, {"subject": "tamoxifen", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "progesterone receptor", "object_type": "GENE-Y"}, {"subject": "AG825", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "progesterone receptor", "object_type": "GENE-Y"}]}
{"text": "The vitamin D hormone, 1,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)], binds with high affinity to the nuclear vitamin D receptor (VDR), which recruits its retinoid X receptor (RXR) heterodimeric partner to recognize vitamin D responsive elements (VDREs) in target genes.", "spo_list": [{"subject": "1,25-dihydroxyvitamin D(3)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "vitamin D receptor", "object_type": "GENE-Y"}, {"subject": "1,25(OH)(2)D(3)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "vitamin D receptor", "object_type": "GENE-Y"}, {"subject": "1,25-dihydroxyvitamin D(3)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "VDR", "object_type": "GENE-Y"}, {"subject": "1,25(OH)(2)D(3)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "VDR", "object_type": "GENE-Y"}]}
{"text": "After structure-based drug selection, SGI-1776, ETP-45299, and tryptanthrin were selected as candidates of PIM1 inhibitors that act as radiosensitizers.", "spo_list": [{"subject": "SGI-1776", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PIM1", "object_type": "GENE-Y"}, {"subject": "ETP-45299", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PIM1", "object_type": "GENE-Y"}, {"subject": "tryptanthrin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PIM1", "object_type": "GENE-Y"}]}
{"text": "Taken together, our findings provided evidence that PIM1-specific inhibitors, SGI-1776, ETP-45299, and tryptanthrin, can act as novel radiosensitizers to enhance the efficacy of radiotherapy by inhibiting irradiation-induced signaling pathway associated with radioresistance.", "spo_list": [{"subject": "SGI-1776", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PIM1", "object_type": "GENE-Y"}, {"subject": "ETP-45299", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PIM1", "object_type": "GENE-Y"}, {"subject": "tryptanthrin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PIM1", "object_type": "GENE-Y"}]}
{"text": "AA effects of vinclozolin are mediated by two metabolites, which have an antagonistic effect on the androgen receptor.", "spo_list": [{"subject": "vinclozolin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "androgen receptor", "object_type": "GENE-Y"}]}
{"text": "Using vinclozolin as a case study, results indicate: (1) an effect on steroid synthesis in vitro, (2) an antagonistic effect on the androgen receptor and (3) that the metabolome profile of vinclozolin is similar to that of other receptor mediated anti-androgens (e.g. flutamide).", "spo_list": [{"subject": "vinclozolin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "androgen receptor", "object_type": "GENE-Y"}]}
{"text": "The most important group of antifungals is the azoles (e.g. miconazole), which act by inhibiting lanosterol demethylase in the sterol biosynthesis pathway.", "spo_list": [{"subject": "azoles", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "lanosterol demethylase", "object_type": "GENE-N"}, {"subject": "miconazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "lanosterol demethylase", "object_type": "GENE-N"}, {"subject": "sterol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "lanosterol demethylase", "object_type": "GENE-N"}]}
{"text": "All the above treatments had comparable effects on the activity of terbinafine, an inhibitor of squalene epoxidase within the sterol biosynthesis pathway, but had little or no effect on the activity of drugs with unrelated targets.", "spo_list": [{"subject": "terbinafine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "squalene epoxidase", "object_type": "GENE-N"}]}
{"text": "MELANOTAN (NDP-MSH) binds the MC1 receptor to significantly increase the eumelanin content of human skin cells.", "spo_list": [{"subject": "MELANOTAN", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MC1 receptor", "object_type": "GENE-Y"}, {"subject": "NDP-MSH", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MC1 receptor", "object_type": "GENE-Y"}]}
{"text": "Dexamethasone suppressed IL-11 gene transcription enhanced by PTH(1-34) without affecting ÎFosB expression or Smad1 phosphorylation, and dexamethasone-GC receptor complex was bound to JunD, which forms heterodimers with ÎFosB.", "spo_list": [{"subject": "Dexamethasone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-11", "object_type": "GENE-Y"}, {"subject": "dexamethasone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GC receptor", "object_type": "GENE-Y"}, {"subject": "dexamethasone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "JunD", "object_type": "GENE-Y"}, {"subject": "dexamethasone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ÎFosB", "object_type": "GENE-Y"}]}
{"text": "AF10 has mostly been studied in the context of the leukemic MLL-AF10 fusion protein, which lacks the N-terminal PHD fingers of AF10.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "AF10", "object_type": "GENE-Y"}]}
{"text": "We demonstrate that the PHD1-PHD2 region is essential for viability and that the first PHD finger contributes to the preferred binding of PHD1-PHD2 to lysine 4-methylated histone H3 tails.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PHD1-PHD2", "object_type": "GENE-N"}]}
{"text": "Inhibition of P-gp and Bcrp by the dual inhibitor elacridar dramatically increased erlotinib delivery to the tumor core, rim, and normal brain.", "spo_list": [{"subject": "elacridar", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P-gp", "object_type": "GENE-N"}, {"subject": "elacridar", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Bcrp", "object_type": "GENE-Y"}]}
{"text": "Blood was assayed for serum-generated thromboxane B2 synthesis (COX-1 assay) and for lipopolysaccharide-stimulated prostaglandin E2 synthesis (COX-2 assay).", "spo_list": [{"subject": "prostaglandin E2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Some NSAIDs (eg, flurbiprofen, ketoprofen) were COX-1 selective, some (eg, ibuprofen, naproxen) were essentially nonselective, while others (eg, diclofenac, mefenamic acid) were COX-2 selective.", "spo_list": [{"subject": "flurbiprofen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "ketoprofen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "diclofenac", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "mefenamic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "ibuprofen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "naproxen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "ibuprofen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "naproxen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Inhibitory effects of NSAIDs on gastric prostaglandin E2 synthesis correlated with COX-1 inhibitory potency in blood (P < 0.001) and with COX-1 selectivity (P < 0.01), but not with COX-2 inhibitory potency.", "spo_list": [{"subject": "prostaglandin E2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "prostaglandin E2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-1", "object_type": "GENE-Y"}]}
{"text": "Even COX-2 \"selective\" NSAIDs still had sufficient COX-1 activity to cause potent inhibitory effects on gastric prostaglandin E2 synthesis at concentrations achieved in vivo.", "spo_list": [{"subject": "prostaglandin E2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-1", "object_type": "GENE-Y"}]}
{"text": "The pharmacologic properties of fluticasone propionate-including high lipophilicity, high selectivity and affinity for the glucocorticoid receptor, low systemic absorption, and rapid metabolism and clearance-combine to give fluticasone propionate a high therapeutic index.", "spo_list": [{"subject": "fluticasone propionate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}]}
{"text": "Intraperitoneal administration of (+/- )propranolol HCl (2.5-10 mg/kg), a nonselective beta-adrenoceptor antagonist, dose dependently attenuated the desipramine-induced enhancement of aggressive behavior without significantly affecting the basal aggressive responses.", "spo_list": [{"subject": "(+/- )propranolol HCl", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "ICI118,551 HCl (1.25-5 mg/kg, IP), a selective beta 2-adrenoceptor antagonist, also blocked the desipramine-induced enhancement of aggressive behavior in a dose-dependent manner, whereas metoprolol tartrate (5-20 mg/kg, IP), a selective beta 1-adrenoceptor antagonist, did not affect it.", "spo_list": [{"subject": "ICI118,551 HCl", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta 2-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "metoprolol tartrate", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta 1-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Moreover, clenbuterol HCl (0.1-0.5 mg/kg, IP), a lipophilic beta 2-adrenoceptor agonist, significantly increased the duration of basal aggressive behavior.", "spo_list": [{"subject": "clenbuterol HCl", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta 2-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Taken together with our previous finding that the desipramine-induced enhancement of aggressive behavior can be blocked by yohimbine, an alpha 2-adrenoceptor antagonist, the present results indicate that not only alpha 2- but also beta 2-adrenoceptor stimulation plays important roles in modulation of aggressive behavior in long-term isolated mice.", "spo_list": [{"subject": "yohimbine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha 2-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "Mechanisms limiting distribution of the threonine-protein kinase B-RaF(V600E) inhibitor dabrafenib to the brain: implications for the treatment of melanoma brain metastases.", "spo_list": [{"subject": "dabrafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "threonine-protein kinase B-RaF", "object_type": "GENE-Y"}, {"subject": "dabrafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "V600E", "object_type": "GENE-N"}]}
{"text": "Dabrafenib is a BRAF (gene encoding serine/threonine-protein kinase B-Raf) inhibitor that has been developed to selectively target the valine 600 to glutamic acid substitution (BRAF(V600E)), which is commonly found in metastatic melanoma.", "spo_list": [{"subject": "valine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "BRAF", "object_type": "GENE-Y"}, {"subject": "glutamic acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "BRAF", "object_type": "GENE-Y"}]}
{"text": "In vitro accumulation studies conducted in Madin-Darby canine kidney II cells indicate that dabrafenib is an avid substrate for both P-gp and BCRP.", "spo_list": [{"subject": "dabrafenib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-gp", "object_type": "GENE-N"}, {"subject": "dabrafenib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "BCRP", "object_type": "GENE-Y"}]}
{"text": "Further, compared with vemurafenib, another BRAF(V600E) inhibitor, dabrafenib showed greater brain penetration with a similar dose.", "spo_list": [{"subject": "vemurafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BRAF", "object_type": "GENE-Y"}, {"subject": "vemurafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "V600E", "object_type": "GENE-N"}]}
{"text": "Our results showed that bone remodeling was significantly decreased in CCL3(-/-) and CCR1(-/-) mice and in animals treated with Met-RANTES (an antagonist of CCR5 and CCR1). mRNA levels of receptor activator of nuclear factor kappa-B (RANK), its ligand RANKL, tumor necrosis factor alpha (TNF-Î±) and RANKL/osteoprotegerin (OPG) ratio were diminished in the periodontium of CCL3(-/-) mice and in the group treated with Met-RANTES.", "spo_list": [{"subject": "Met", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CCR5", "object_type": "GENE-Y"}, {"subject": "Met", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CCR1", "object_type": "GENE-Y"}, {"subject": "Met", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "receptor activator of nuclear factor kappa-B", "object_type": "GENE-Y"}, {"subject": "Met", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "RANK", "object_type": "GENE-Y"}, {"subject": "Met", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "RANKL", "object_type": "GENE-Y"}, {"subject": "Met", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "tumor necrosis factor alpha", "object_type": "GENE-Y"}, {"subject": "Met", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF-Î±", "object_type": "GENE-Y"}, {"subject": "Met", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "RANKL", "object_type": "GENE-Y"}, {"subject": "Met", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "osteoprotegerin", "object_type": "GENE-Y"}, {"subject": "Met", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "OPG", "object_type": "GENE-Y"}]}
{"text": "Met-RANTES treatment also reduced the levels of cathepsin K and metalloproteinase 13 (MMP13).", "spo_list": [{"subject": "Met", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cathepsin K", "object_type": "GENE-Y"}, {"subject": "Met", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "metalloproteinase 13", "object_type": "GENE-Y"}, {"subject": "Met", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MMP13", "object_type": "GENE-Y"}]}
{"text": "The expression of the osteoblast markers runt-related transcription factor 2 (RUNX2) and periostin was decreased, while osteocalcin (OCN) was augmented in CCL3(-/-) and Met-RANTES-treated mice.", "spo_list": [{"subject": "Met", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "runt-related transcription factor 2", "object_type": "GENE-Y"}, {"subject": "Met", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "RUNX2", "object_type": "GENE-Y"}, {"subject": "Met", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "periostin", "object_type": "GENE-Y"}, {"subject": "Met", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "osteocalcin", "object_type": "GENE-Y"}, {"subject": "Met", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "OCN", "object_type": "GENE-Y"}]}
{"text": "Vandetanib (Caprelsa(Â®), AstraZeneca) is a once-daily oral tyrosine kinase inhibitor that selectively inhibits signalling mediated by growth-factor receptor tyrosine kinase RET (constitutively activated in roughly 60Â % of all MTCs), vascular endothelial growth-factor receptors 2 and 3, and epidermal growth-factor receptors.", "spo_list": [{"subject": "Vandetanib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "Caprelsa", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "Vandetanib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "growth-factor receptor tyrosine kinase", "object_type": "GENE-N"}, {"subject": "Caprelsa", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "growth-factor receptor tyrosine kinase", "object_type": "GENE-N"}, {"subject": "Vandetanib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RET", "object_type": "GENE-Y"}, {"subject": "Caprelsa", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RET", "object_type": "GENE-Y"}, {"subject": "Vandetanib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "epidermal growth-factor receptors", "object_type": "GENE-Y"}, {"subject": "Caprelsa", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "epidermal growth-factor receptors", "object_type": "GENE-Y"}]}
{"text": "TCDD inhibition of canonical wnt signaling disrupts prostatic bud formation in mouse urogenital sinus.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "wnt", "object_type": "GENE-N"}]}
{"text": "In support of the hypothesis that TCDD decreases canonical Wnt signaling, we identify inhibitory effects of TCDD on multiple components of the canonical Wnt signaling pathway in the UGS that temporally coincide with the inhibitory effect of TCDD on prostatic bud formation: (1) expression of R-spondins (Rspo2 and Rspo3) that promote canonical Wnt signaling is reduced; (2) expression of Lef1, Tcf1, and Wif1, established canonical Wnt target genes, is decreased; (3) expression of Lgr5, a RSPO receptor that activates canonical Wnt signaling, is reduced; and (4) expression of Dickkopfs (Dkks), inhibitors of canonical Wnt signaling, is not increased by TCDD.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Wnt", "object_type": "GENE-N"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "R-spondins", "object_type": "GENE-N"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Rspo2", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Rspo3", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Lef1", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Tcf1", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Wif1", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Lgr5", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "RSPO receptor", "object_type": "GENE-Y"}]}
{"text": "Thus, the TCDD-induced reduction in canonical Wnt signaling is associated with a decrease in activators (Rspo2 and Rspo3) rather than an increase in inhibitors (Dkk1 and Dkk2) of the pathway.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Wnt", "object_type": "GENE-N"}]}
{"text": "This study focuses on determining whether treatment of TCDD-exposed UGS organ cultures with RSPO2 and/or RSPO3 is capable of rescuing the inhibitory effects of TCDD on canonical Wnt signaling and prostatic bud formation.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Wnt", "object_type": "GENE-N"}]}
{"text": "We discovered that each RSPO alone or in combination partially rescues TCDD inhibition of both canonical Wnt signaling and prostatic bud formation.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Wnt", "object_type": "GENE-N"}]}
{"text": "Cyclooxygenase(COX)-2-derived prostanoids can influence several processes that are linked to carcinogenesis.", "spo_list": [{"subject": "prostanoids", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Cyclooxygenase(COX)-2", "object_type": "GENE-Y"}]}
{"text": "Platelet-induced COX-2-dependent PGE2 synthesis in HT29 cells was involved in downregulation of p21(WAF1/CIP1) and upregulation of cyclinB1, since these effects were prevented by rofecoxib(a selective COX-2 inhibitor) and rescued by exogenous PGE2.", "spo_list": [{"subject": "PGE2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p21", "object_type": "GENE-Y"}, {"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "WAF1", "object_type": "GENE-Y"}, {"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CIP1", "object_type": "GENE-Y"}, {"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cyclinB1", "object_type": "GENE-Y"}]}
{"text": "Cellular protein labeling occurs only upon activation of two different promoters that drive expression of the N- and C-terminal fragments of the bisected MetRS.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MetRS", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MetRS", "object_type": "GENE-Y"}]}
{"text": "The approach is demonstrated by selective labeling of proteins in bacterial cells immobilized in the center of a laminar-flow microfluidic channel, where they are exposed to overlapping, opposed gradients of inducers of the N- and C-terminal MetRS fragments.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MetRS", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MetRS", "object_type": "GENE-Y"}]}
{"text": "The peptide YR-11 (YLEIEFSLKHR), obtained by direct substitution of cysteine with a serine residue in the template sequence, significantly (p<0.05) inhibited RANK-RANKL binding, and RANKL induced TRAP activity and formation of multinucleated osteoclasts without any cytotoxicity.", "spo_list": [{"subject": "YR-11", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RANK", "object_type": "GENE-Y"}, {"subject": "YR-11", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RANKL", "object_type": "GENE-Y"}, {"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RANK", "object_type": "GENE-Y"}, {"subject": "serine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RANKL", "object_type": "GENE-Y"}, {"subject": "YR-11", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RANKL", "object_type": "GENE-Y"}, {"subject": "YR-11", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TRAP", "object_type": "GENE-Y"}, {"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RANKL", "object_type": "GENE-Y"}, {"subject": "serine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RANKL", "object_type": "GENE-Y"}, {"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TRAP", "object_type": "GENE-Y"}, {"subject": "serine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TRAP", "object_type": "GENE-Y"}, {"subject": "serine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RANK", "object_type": "GENE-Y"}, {"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RANKL", "object_type": "GENE-Y"}]}
{"text": "Results confirmed that YR-11 peptide inhibited pro-inflammatory cytokines in the sera and hind paw tissues of AIA rats through its suppressive effect on RANKL induced nuclear translocation of NF-ÎºB.", "spo_list": [{"subject": "YR-11", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cytokines", "object_type": "GENE-N"}, {"subject": "YR-11", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RANKL", "object_type": "GENE-Y"}, {"subject": "YR-11", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}]}
{"text": "Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.", "spo_list": [{"subject": "Lapatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human epidermal growth factor receptor", "object_type": "GENE-Y"}, {"subject": "Lapatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinases", "object_type": "GENE-N"}]}
{"text": "BACKGROUND: Lapatinib, the first dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinases, was approved by the US Food and Drug Administration (FDA) in 2007.", "spo_list": [{"subject": "Lapatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "epidermal growth factor receptor", "object_type": "GENE-Y"}, {"subject": "Lapatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EGFR", "object_type": "GENE-Y"}, {"subject": "Lapatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human epidermal growth factor receptor 2", "object_type": "GENE-Y"}, {"subject": "Lapatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HER2", "object_type": "GENE-Y"}, {"subject": "Lapatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinases", "object_type": "GENE-N"}]}
{"text": "Lapatinib is metabolized primarily by the cytochrome P450 3A4 isozyme, with 1 metabolite remaining active against EGFR but not HER2.", "spo_list": [{"subject": "Lapatinib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cytochrome P450 3A4", "object_type": "GENE-Y"}]}
{"text": "CONCLUSIONS: Lapatinib is a dual inhibitor of the EGFR and HER2 tyrosine kinases.", "spo_list": [{"subject": "Lapatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EGFR", "object_type": "GENE-Y"}, {"subject": "Lapatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HER2", "object_type": "GENE-Y"}, {"subject": "Lapatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinases", "object_type": "GENE-N"}]}
{"text": "Bupropion has an antidepressant effect through blocking the dopamine transporter.", "spo_list": [{"subject": "Bupropion", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dopamine transporter", "object_type": "GENE-Y"}]}
{"text": "After 3 weeks' bupropion treatment we studied the change in DAT activity, which corresponds to the occupancy of bupropion.", "spo_list": [{"subject": "bupropion", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DAT", "object_type": "GENE-Y"}]}
{"text": "The average occupancy of bupropion on DAT was similar to the international findings at 20.84% in 9 depressed patients.", "spo_list": [{"subject": "bupropion", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DAT", "object_type": "GENE-Y"}]}
{"text": "2. The DP, IP and TP receptors showed high ligand binding specificity and only bound their own putative ligands with high affinity such as PGD2, BW245C and BW868C for DP, cicaprost, iloprost and isocabacyclin for IP, and S-145, I-BOP and GR 32191 for TP.", "spo_list": [{"subject": "PGD2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DP", "object_type": "GENE-Y"}, {"subject": "BW245C", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DP", "object_type": "GENE-Y"}, {"subject": "BW868C", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DP", "object_type": "GENE-Y"}, {"subject": "cicaprost", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "IP", "object_type": "GENE-Y"}, {"subject": "iloprost", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "IP", "object_type": "GENE-Y"}, {"subject": "isocabacyclin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "IP", "object_type": "GENE-Y"}, {"subject": "S-145", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "TP", "object_type": "GENE-Y"}, {"subject": "I-BOP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "TP", "object_type": "GENE-Y"}, {"subject": "GR 32191", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "TP", "object_type": "GENE-Y"}]}
{"text": "3. The FP receptor bound PGF2 alpha and fluprostenol with Ki values of 3-4 nM.", "spo_list": [{"subject": "PGF2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "FP receptor", "object_type": "GENE-Y"}, {"subject": "fluprostenol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "FP receptor", "object_type": "GENE-Y"}]}
{"text": "4. The EP1 receptor bound 17-phenyl-PGE2, sulprostone and iloprost in addition to PGE2 and PGE1, with Ki values of 14-36 nM.", "spo_list": [{"subject": "17-phenyl-PGE2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP1", "object_type": "GENE-Y"}, {"subject": "sulprostone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP1", "object_type": "GENE-Y"}, {"subject": "iloprost", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP1", "object_type": "GENE-Y"}, {"subject": "PGE2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP1", "object_type": "GENE-Y"}, {"subject": "PGE1", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP1", "object_type": "GENE-Y"}]}
{"text": "16,16-dimethyl-PGE2 and two putative EP1 antagonists, AH6809 and SC-19220, did not show any significant binding to this receptor.", "spo_list": [{"subject": "AH6809", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "EP1", "object_type": "GENE-Y"}, {"subject": "SC-19220", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "EP1", "object_type": "GENE-Y"}]}
{"text": "M&B-28767, a putative EP3 agonist, and misoprostol, a putative EP2/EP3 agonist, also bound to this receptor with Ki values of 120 nM.", "spo_list": [{"subject": "M&B-28767", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "EP3", "object_type": "GENE-Y"}, {"subject": "misoprostol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "EP2", "object_type": "GENE-Y"}, {"subject": "misoprostol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "EP3", "object_type": "GENE-Y"}]}
{"text": "The two receptors were discriminated by butaprost, AH-13205 and AH-6809 that bound to the EP2 receptor but not to the EP4 receptor, and by 1-OH-PGE1 that bound to the EP4 but not to the EP2 receptor.", "spo_list": [{"subject": "butaprost", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP2", "object_type": "GENE-Y"}, {"subject": "AH-13205", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP2", "object_type": "GENE-Y"}, {"subject": "AH-6809", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP2", "object_type": "GENE-Y"}, {"subject": "1-OH-PGE1", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP4", "object_type": "GENE-Y"}]}
{"text": "6. The EP3 receptor showed the broadest binding profile, and bound sulprostone, M&B-28767, GR63799X, 11-deoxy-PGE1, 16,16-dimethyl-PGE2 and 17-phenyl-PGE2, in addition to PGE2 and PGE1, with Ki values of 0.6-3.7 nM.", "spo_list": [{"subject": "sulprostone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP3", "object_type": "GENE-Y"}, {"subject": "M&B-28767", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP3", "object_type": "GENE-Y"}, {"subject": "GR63799X", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP3", "object_type": "GENE-Y"}, {"subject": "11-deoxy-PGE1", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP3", "object_type": "GENE-Y"}, {"subject": "16,16-dimethyl-PGE2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP3", "object_type": "GENE-Y"}, {"subject": "17-phenyl-PGE2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP3", "object_type": "GENE-Y"}, {"subject": "PGE2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP3", "object_type": "GENE-Y"}, {"subject": "PGE1", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP3", "object_type": "GENE-Y"}]}
{"text": "In addition, three IP ligands, iloprost, carbacyclin and isocarbacyclin, and one TP ligand, STA2, bound to this receptor with Ki values comparable to the Ki values of these compounds for the IP and TP receptors, respectively.", "spo_list": [{"subject": "iloprost", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "IP", "object_type": "GENE-Y"}, {"subject": "carbacyclin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "IP", "object_type": "GENE-Y"}, {"subject": "isocarbacyclin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "IP", "object_type": "GENE-Y"}, {"subject": "STA2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "TP", "object_type": "GENE-Y"}]}
{"text": "7. 8-Epi-PGF2 alpha showed only weak binding to the IP, TP, FP, EP2 and EP3 receptor at 10 microM concentration.", "spo_list": [{"subject": "7. 8-Epi-PGF2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "IP", "object_type": "GENE-Y"}, {"subject": "7. 8-Epi-PGF2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "TP", "object_type": "GENE-Y"}, {"subject": "7. 8-Epi-PGF2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "FP", "object_type": "GENE-Y"}, {"subject": "7. 8-Epi-PGF2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP2", "object_type": "GENE-Y"}, {"subject": "7. 8-Epi-PGF2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EP3", "object_type": "GENE-Y"}]}
{"text": "Comparison of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II by using topiramate as a structural platform.", "spo_list": [{"subject": "sulfamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase-II", "object_type": "GENE-Y"}, {"subject": "sulfamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase-II", "object_type": "GENE-Y"}, {"subject": "topiramate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase-II", "object_type": "GENE-Y"}]}
{"text": "This paper examines the relative effectiveness of sulfamate and sulfamide groups for the inhibition of carbonic anhydrase-II (CA-II).", "spo_list": [{"subject": "sulfamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase-II", "object_type": "GENE-Y"}, {"subject": "sulfamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase-II", "object_type": "GENE-Y"}, {"subject": "sulfamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA-II", "object_type": "GENE-Y"}, {"subject": "sulfamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA-II", "object_type": "GENE-Y"}]}
{"text": "Topiramate (1) and its sulfamide analogue 4, and 4,5-cyclic sulfate 6 and its sulfamide analogue 5, were compared for inhibition of human CA-II.", "spo_list": [{"subject": "Topiramate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human CA-II", "object_type": "GENE-Y"}, {"subject": "sulfamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human CA-II", "object_type": "GENE-Y"}, {"subject": "4,5-cyclic sulfate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human CA-II", "object_type": "GENE-Y"}, {"subject": "sulfamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human CA-II", "object_type": "GENE-Y"}]}
{"text": "When OATP2B1-expressing Xenopus oocytes were preincubated with GFJ, orange juice (OJ), or apple juice (AJ), AJ induced a remarkable decrease in OATP2B1-mediated estrone-3-sulfate uptake in a concentration-dependent manner (IC(50) = 1.5%).", "spo_list": [{"subject": "estrone-3-sulfate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP2B1", "object_type": "GENE-Y"}]}
{"text": "Kinetic analysis revealed that coincubation and preincubation with AJ reduced OATP2B1-mediated estrone-3-sulfate uptake via competitive and noncompetitive mechanisms, respectively.", "spo_list": [{"subject": "estrone-3-sulfate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP2B1", "object_type": "GENE-Y"}]}
{"text": "Reactive oxygen species formation and release of pro-inflammatory/pro-atherogenic cytokines, that is, interleukin 1-beta and tumor necrosis factor-alpha, need the activation of the arachidonic acid cascade via the enzyme 5-lipoxygenase (5-Lox).", "spo_list": [{"subject": "arachidonic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "5-lipoxygenase", "object_type": "GENE-Y"}, {"subject": "arachidonic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "5-Lox", "object_type": "GENE-Y"}]}
{"text": "Omega-3 may interfere with the arachidonic acid cascade by inhibiting 5-Lox.", "spo_list": [{"subject": "arachidonic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "5-Lox", "object_type": "GENE-Y"}]}
{"text": "The organic cation/carnitine transporter OCTN2 mediates transport of carnitine and organic cations in Na(+)-dependent and Na(+)-independent manners, respectively.", "spo_list": [{"subject": "carnitine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "organic cation/carnitine transporter OCTN2", "object_type": "GENE-Y"}, {"subject": "Na(+)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "organic cation/carnitine transporter OCTN2", "object_type": "GENE-Y"}]}
{"text": "We previously found a single amino acid change in OCTN2, Ser467Cys (S467C), in the Japanese population and observed a decreased carnitine transport but unchanged organic cation transport compared with wild type.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "OCTN2", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Ser467Cys", "object_type": "GENE-N"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "S467C", "object_type": "GENE-N"}, {"subject": "carnitine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OCTN2", "object_type": "GENE-Y"}, {"subject": "carnitine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Ser467Cys", "object_type": "GENE-N"}, {"subject": "carnitine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "S467C", "object_type": "GENE-N"}]}
{"text": "Several organic anions such as valproate, as well as organic cations, significantly inhibited carnitine and TEA uptake by OCTN2, and valproate showed Na(+)-dependent inhibition of OCTN2-mediated TEA uptake.", "spo_list": [{"subject": "TEA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OCTN2", "object_type": "GENE-Y"}, {"subject": "TEA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OCTN2", "object_type": "GENE-Y"}, {"subject": "valproate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OCTN2", "object_type": "GENE-Y"}, {"subject": "valproate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OCTN2", "object_type": "GENE-Y"}, {"subject": "Na(+)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OCTN2", "object_type": "GENE-Y"}]}
{"text": "The Na(+)-activation kinetics of the S467C mutant was similar to that of the wild type.", "spo_list": [{"subject": "Na(+)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "S467C", "object_type": "GENE-N"}]}
{"text": "Furthermore, a significant decrease of the TEA uptake-inhibitory potency of valproate was observed in S467C-mutant OCTN2.", "spo_list": [{"subject": "valproate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "S467C", "object_type": "GENE-N"}, {"subject": "TEA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "S467C", "object_type": "GENE-N"}, {"subject": "valproate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OCTN2", "object_type": "GENE-Y"}, {"subject": "TEA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OCTN2", "object_type": "GENE-Y"}]}
{"text": "These observations suggest that the decrease in affinity of S467C-mutant OCTN2 for carnitine was caused by functional alteration of the anion (carboxyl moiety of carnitine) recognition site located in trans-membrane domain 11, which is closely related to the Na(+)-binding site, on OCTN2 protein.", "spo_list": [{"subject": "Na(+)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "OCTN2", "object_type": "GENE-Y"}]}
{"text": "These results demonstrate that OCTN2 has functional sites for carnitine and Na(+) and that the carnitine-binding site is involved, in part, in the recognition of organic cations.", "spo_list": [{"subject": "carnitine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "OCTN2", "object_type": "GENE-Y"}, {"subject": "Na(+)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "OCTN2", "object_type": "GENE-Y"}]}
{"text": "Mononuclear leukocyte beta 2-adrenergic receptor densities (and binding affinities), measured with 125I-labelled pindolol, and isoproterenol-stimulated cyclic AMP accumulation, in samples from patients with insulin-dependent diabetes mellitus (IDDM) with diabetic autonomic neuropathy (n = 8), were no different from those in samples from patients with IDDM without neuropathy (n = 8), or from non-diabetic subjects (n = 8).", "spo_list": [{"subject": "125I-labelled pindolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta 2-adrenergic receptor", "object_type": "GENE-Y"}, {"subject": "isoproterenol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta 2-adrenergic receptor", "object_type": "GENE-Y"}]}
{"text": "In addition, platelet alpha 2-adrenergic receptor densities (and binding affinities), measured with 3H-labelled yohimbine, and adrenaline-induced suppression of cyclic AMP contents did not differ among the three groups.", "spo_list": [{"subject": "3H-labelled yohimbine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 2-adrenergic receptor", "object_type": "GENE-N"}, {"subject": "adrenaline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 2-adrenergic receptor", "object_type": "GENE-N"}]}
{"text": "Although iloprost mainly acts as a vasodilator by binding to the I prostanoid (IP) receptor, recent evidence suggests that signaling via this receptor also has antiinflammatory effects through unclear mechanisms.", "spo_list": [{"subject": "iloprost", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "I prostanoid (IP) receptor", "object_type": "GENE-Y"}]}
{"text": "The effect of iloprost was DC autonomous, as iloprost-treated DCs no longer induced Th2 differentiation from naive T cells or boosted effector cytokine production in primed Th2 cells.", "spo_list": [{"subject": "iloprost", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytokine", "object_type": "GENE-N"}]}
{"text": "Truncated ErbB2 receptor (p95ErbB2) is regulated by heregulin through heterodimer formation with ErbB3 yet remains sensitive to the dual EGFR/ErbB2 kinase inhibitor GW572016.", "spo_list": [{"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ErbB2", "object_type": "GENE-Y"}]}
{"text": "The expression of the NH2 terminally truncated ErbB2 receptor (p95ErbB2) in breast cancer correlates with metastatic disease progression compared with the expression of full-length p185ErbB2.", "spo_list": [{"subject": "NH2", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ErbB2", "object_type": "GENE-Y"}, {"subject": "NH2", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "p95ErbB2", "object_type": "GENE-Y"}]}
{"text": "GW572016, a reversible small molecule inhibitor of EGFR and ErbB2 tyrosine kinases, inhibits baseline p95ErbB2 phosphorylation in BT474 cells and tumor xenografts.", "spo_list": [{"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EGFR", "object_type": "GENE-Y"}, {"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ErbB2", "object_type": "GENE-Y"}, {"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinases", "object_type": "GENE-N"}, {"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p95ErbB2", "object_type": "GENE-Y"}]}
{"text": "Inhibition of p95ErbB2, p185ErbB2, and EGFR phosphorylation by GW572016 resulted in the inhibition of downstream phospho-Erk1/2, phospho-AKT, and cyclin D steady-state protein levels.", "spo_list": [{"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p95ErbB2", "object_type": "GENE-Y"}, {"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p185ErbB2", "object_type": "GENE-Y"}, {"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EGFR", "object_type": "GENE-Y"}, {"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Erk1/2", "object_type": "GENE-N"}, {"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "AKT", "object_type": "GENE-N"}, {"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cyclin D", "object_type": "GENE-N"}]}
{"text": "Increased phosphorylation of p95ErbB2 and AKT in response to HRG was abrogated to varying degrees by GW572016.", "spo_list": [{"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p95ErbB2", "object_type": "GENE-Y"}, {"subject": "GW572016", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AKT", "object_type": "GENE-N"}]}
{"text": "In addition, minocycline treatment significantly reduced the specific caspase-3 activity after SCI as compared to that of vehicle control.", "spo_list": [{"subject": "minocycline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "caspase-3", "object_type": "GENE-Y"}]}
{"text": "Furthermore, RT-PCR analyses revealed that minocycline treatment increased expression of interleukin-10 mRNA but decreased tumor necrosis factor-alpha expression.", "spo_list": [{"subject": "minocycline", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "interleukin-10", "object_type": "GENE-Y"}, {"subject": "minocycline", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "tumor necrosis factor-alpha", "object_type": "GENE-Y"}]}
{"text": "Isoform-specific inhibition of L-type calcium channels by dihydropyridines is independent of isoform-specific gating properties.", "spo_list": [{"subject": "dihydropyridines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "L-type calcium channels", "object_type": "GENE-N"}]}
{"text": "Dihydropyridines (DHPs) block L-type Ca2+ channels more potently at depolarized membrane potentials, consistent with high affinity binding to the inactivated state.", "spo_list": [{"subject": "Dihydropyridines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "L-type Ca2+ channels", "object_type": "GENE-N"}, {"subject": "DHPs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "L-type Ca2+ channels", "object_type": "GENE-N"}]}
{"text": "Nisoldipine (a DHP antagonist) blocks the smooth muscle channel more potently than the cardiac one, a phenomenon observed not only in native channels but also in expressed channels.", "spo_list": [{"subject": "Nisoldipine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "smooth muscle channel", "object_type": "GENE-N"}, {"subject": "DHP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "smooth muscle channel", "object_type": "GENE-N"}]}
{"text": "We thus conclude that the more potent nisoldipine inhibition of smooth muscle versus cardiac L-type Ca2+ channels is not attributable to differences in channel inactivation or activation.", "spo_list": [{"subject": "nisoldipine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cardiac L-type Ca2+ channels", "object_type": "GENE-N"}]}
{"text": "Intrinsic, gating-independent DHP receptor binding affinity differences must be invoked to explain the isoform-specific sensitivity of the DHP block.", "spo_list": [{"subject": "DHP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DHP receptor", "object_type": "GENE-N"}]}
{"text": "OBJECTIVE: Farnesyl diphosphate synthase (FPPs) produces FPP which is considered a branch-point intermediate in the synthesis of sterols and isoprenylated cellular metabolites.", "spo_list": [{"subject": "sterols", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Farnesyl diphosphate synthase", "object_type": "GENE-Y"}, {"subject": "sterols", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "FPPs", "object_type": "GENE-Y"}]}
{"text": "In this study we investigated whether detectable FPPs activity was present in human colorectal cancer (CRC), also evaluating in vitro the role of this enzyme in the growth and apoptosis of CRC cells by using Pamidronate (PAM), a FPPs activity inhibitor.", "spo_list": [{"subject": "Pamidronate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FPPs", "object_type": "GENE-Y"}, {"subject": "PAM", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FPPs", "object_type": "GENE-Y"}]}
{"text": "Pharmacokinetics and metabolism of [(14)C]anagliptin, a novel dipeptidyl peptidase-4 inhibitor, in humans.", "spo_list": [{"subject": "[(14)C]anagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dipeptidyl peptidase-4", "object_type": "GENE-Y"}]}
{"text": "1. The disposition of anagliptin, an orally active, highly selective dipeptidyl peptidase-4 inhibitor, was investigated after a single oral dose of 100 mg/1.92 MBq [(14)C]anagliptin to six healthy men.", "spo_list": [{"subject": "anagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dipeptidyl peptidase-4", "object_type": "GENE-Y"}]}
{"text": "Renal clearance of unbound anagliptin and unbound M1 far exceeded glomerular filtration rate, indicating active renal elimination: that might reflect the fact that anagliptin may be a substrate of OAT1, OAT3, MDR1 and MRP2, and M1 a substrate of OAT3, BCRP, MRP2 and MRP4.", "spo_list": [{"subject": "anagliptin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OAT1", "object_type": "GENE-Y"}, {"subject": "anagliptin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OAT3", "object_type": "GENE-Y"}, {"subject": "anagliptin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MDR1", "object_type": "GENE-Y"}, {"subject": "anagliptin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MRP2", "object_type": "GENE-Y"}]}
{"text": "Celastrol, a TAK1 inhibitor and anti-inflammatory compound used in traditional Chinese medicine, also decreased TGF-Î²1-induced phosphorylation of TAK1 and RELA, and suppressed basal, TGF-Î²1- and tumor necrosis factor-alpha (TNF-Î±)-induced NF-ÎºB reporter gene activity.", "spo_list": [{"subject": "Celastrol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TAK1", "object_type": "GENE-Y"}, {"subject": "Celastrol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TAK1", "object_type": "GENE-Y"}, {"subject": "Celastrol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RELA", "object_type": "GENE-Y"}, {"subject": "Celastrol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}]}
{"text": "Celastrol also inhibited cell proliferation, while increasing sub-G0 DNA fragmentation and Annexin V markers of apoptosis.", "spo_list": [{"subject": "Celastrol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Annexin V", "object_type": "GENE-Y"}]}
{"text": "Celastrol highlights the therapeutic potential of agents targeting TAK1 as a key node in this pro-oncogenic TGF-Î²-NF-ÎºB signal pathway.", "spo_list": [{"subject": "Celastrol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TAK1", "object_type": "GENE-Y"}]}
{"text": "We observed that K562/Dox cells overexpressing P-gp contained a significantly reduced intracellular level of nilotinib when compared to their counter partner K562 cells, which do not express P-gp.", "spo_list": [{"subject": "nilotinib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-gp", "object_type": "GENE-Y"}]}
{"text": "Importantly, cells with downregulated expression of P-gp gradually lost their ability to decrease the intracellular level of nilotinib although they still significantly decreased the intracellular level of daunorubicin (DNR).", "spo_list": [{"subject": "daunorubicin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-gp", "object_type": "GENE-Y"}, {"subject": "DNR", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-gp", "object_type": "GENE-Y"}]}
{"text": "In order to address one aspect of the feasibility of performing time-resolved studies on AChE, a data set has been collected using the Laue technique on a trigonal crystal of Torpedo californica AChE soaked with the reversible inhibitor edrophonium, using a total X-ray exposure time of 24 ms.", "spo_list": [{"subject": "edrophonium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Torpedo californica AChE", "object_type": "GENE-Y"}]}
{"text": "In contrast to parenteral delivery of rBChE, which currently requires posttranslational modification for good plasma stability, an unmodified aer-rBChE pretreatment given 1-40h prior to >1 LD50 of aer-paraoxon (Px) was able to prevent inhibition of circulating cholinesterase in a dose-dependent manner.", "spo_list": [{"subject": "paraoxon", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "cholinesterase", "object_type": "GENE-Y"}]}
{"text": "TCDD induces the expression of insulin-like growth factor binding protein 4 in 5L rat hepatoma cells: a cautionary tale of the use of this cell line in studies on dioxin toxicity.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin-like growth factor binding protein 4", "object_type": "GENE-Y"}]}
{"text": "By \"working upwards\" from mTOR, we observed that TCDD inhibited endogenous and IGF-I-induced AKT and ERK activation by interfering with tyrosine phosphorylation of insulin receptor substrate 1.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IGF-I", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "AKT", "object_type": "GENE-N"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ERK", "object_type": "GENE-N"}]}
{"text": "The induction of IGFBP-4 protein was dependent on a functional aryl hydrocarbon receptor and was preceded by a rapid increase in the level of IGFBP-4 mRNA indicating that IGFBP-4 is a previously unknown transcriptional target of TCDD in 5L cells.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IGFBP-4", "object_type": "GENE-Y"}]}
{"text": "Monomeric carbonyl reductase 1 (CBR1, SDR21C1) is a member of the short-chain dehydrogenase/reductase superfamily and is involved in the metabolism of anthracycline anti-cancer drugs, prostaglandins, and isatin, which is an endogenous inhibitor of monoamine oxidases.", "spo_list": [{"subject": "isatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidases", "object_type": "GENE-N"}, {"subject": "anthracycline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Monomeric carbonyl reductase 1", "object_type": "GENE-Y"}, {"subject": "anthracycline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CBR1", "object_type": "GENE-Y"}, {"subject": "anthracycline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SDR21C1", "object_type": "GENE-Y"}, {"subject": "anthracycline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "dehydrogenase", "object_type": "GENE-N"}, {"subject": "anthracycline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "reductase", "object_type": "GENE-N"}, {"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Monomeric carbonyl reductase 1", "object_type": "GENE-Y"}, {"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CBR1", "object_type": "GENE-Y"}, {"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SDR21C1", "object_type": "GENE-Y"}, {"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "dehydrogenase", "object_type": "GENE-N"}, {"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "reductase", "object_type": "GENE-N"}, {"subject": "isatin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Monomeric carbonyl reductase 1", "object_type": "GENE-Y"}, {"subject": "isatin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CBR1", "object_type": "GENE-Y"}, {"subject": "isatin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SDR21C1", "object_type": "GENE-Y"}, {"subject": "isatin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "dehydrogenase", "object_type": "GENE-N"}, {"subject": "isatin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "reductase", "object_type": "GENE-N"}]}
{"text": "BHA induced the mRNA and protein expression of CBR1 in hepatoma HepG2 cells.", "spo_list": [{"subject": "BHA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CBR1", "object_type": "GENE-Y"}]}
{"text": "The transcription factor Nrf2 is known to be activated by BHA.", "spo_list": [{"subject": "BHA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Nrf2", "object_type": "GENE-Y"}]}
{"text": "Moreover, to determine whether the functional ARE of CBR1 is conserved with the promoter region of homologues in other species, the nucleotide sequences of the functional AREs of the Chcr1 and Chcr2 genes, which are the Chinese hamster homologues of CBR1, were determined.", "spo_list": [{"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "AREs", "object_type": "GENE-N"}, {"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Chcr1", "object_type": "GENE-Y"}, {"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Chcr2", "object_type": "GENE-Y"}]}
{"text": "In breast cancer (BC) epithelial cells, the mitogenic action of estradiol is transduced through binding to two receptors, ERÎ± and ERÎ², which act as transcription factors.", "spo_list": [{"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERÎ²", "object_type": "GENE-Y"}]}
{"text": "Procainamide is a specific inhibitor of DNA methyltransferase 1.", "spo_list": [{"subject": "Procainamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA methyltransferase 1", "object_type": "GENE-Y"}]}
{"text": "Procainamide has been shown to inhibit DNA methyltransferase activity and reactivate silenced gene expression in cancer cells by reversing CpG island hypermethylation.", "spo_list": [{"subject": "Procainamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA methyltransferase", "object_type": "GENE-N"}]}
{"text": "We report here that procainamide specifically inhibits the hemimethylase activity of DNA methyltransferase 1 (DNMT1), the mammalian enzyme thought to be responsible for maintaining DNA methylation patterns during replication.", "spo_list": [{"subject": "procainamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hemimethylase", "object_type": "GENE-N"}, {"subject": "procainamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA methyltransferase 1", "object_type": "GENE-Y"}, {"subject": "procainamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNMT1", "object_type": "GENE-Y"}]}
{"text": "At micromolar concentrations, procainamide was found to be a partial competitive inhibitor of DNMT1, reducing the affinity of the enzyme for its two substrates, hemimethylated DNA and S-adenosyl-l-methionine.", "spo_list": [{"subject": "procainamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNMT1", "object_type": "GENE-Y"}, {"subject": "S-adenosyl-l-methionine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DNMT1", "object_type": "GENE-Y"}]}
{"text": "By doing so, procainamide significantly decreased the processivity of DNMT1 on hemimethylated DNA.", "spo_list": [{"subject": "procainamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "DNMT1", "object_type": "GENE-Y"}]}
{"text": "As further evidence of the specificity of procainamide for DNMT1, procainamide failed to lower genomic 5-methyl-2'-deoxycytidine levels in HCT116 colorectal cancer cells when DNMT1 was genetically deleted but significantly reduced genomic 5-methyl-2'-deoxycytidine content in parental HCT116 cells and in HCT116 cells where DNMT3b was genetically deleted.", "spo_list": [{"subject": "procainamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNMT1", "object_type": "GENE-Y"}]}
{"text": "Because many reports have strongly linked DNMT1 with epigenetic alterations in carcinogenesis, procainamide may be a useful drug in the prevention of cancer.", "spo_list": [{"subject": "procainamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNMT1", "object_type": "GENE-Y"}]}
{"text": "In addition, the activity of nNOS was quantified by measurement of [(3)H]-L-arginine conversion to [(3)H]-L-citrulline in tissue extracts from SC superficial layers in opossums and rats.", "spo_list": [{"subject": "[(3)H]-L-arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "nNOS", "object_type": "GENE-Y"}, {"subject": "[(3)H]-L-citrulline", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "nNOS", "object_type": "GENE-Y"}]}
{"text": "The production of [(3)H]-L-citrulline from [(3)H]-L-arginine in tissue extracts enriched in superficial layers indicated that nNOS specific activity is as high in the opossum as in the rat.", "spo_list": [{"subject": "[(3)H]-L-citrulline", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "nNOS", "object_type": "GENE-N"}, {"subject": "[(3)H]-L-arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "nNOS", "object_type": "GENE-N"}]}
{"text": "Nocapyrone H (1) reduced the pro-inflammatory factor such as nitric oxide (NO), prostaglandin E2 (PGE2) and interleukin-1Î² (IL-1Î²).", "spo_list": [{"subject": "Nocapyrone H", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "interleukin-1Î²", "object_type": "GENE-Y"}, {"subject": "Nocapyrone H", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-1Î²", "object_type": "GENE-Y"}]}
{"text": "Indicating that the effect of mCPP was caused by a reversal of the serotonin transporter, it was antagonized by pretreatment with the serotonin re-uptake inhibitor citalopram (10 mg/kg) but was unaffected by local administration of the sodium channel blocker tetrodotoxin (TTX; 1 microns). mCPP was also shown to induce an increase in extracellular concentrations of dopamine in the nucleus accumbens and the striatum of SH rats and in the nucleus accumbens of rats of the Sprague-Dawley (SD) strain; this effect of mCPP was, however, much weaker (125-170% of baseline) than the effect on serotonin; moreover, it seems to be TTX-sensitive.", "spo_list": [{"subject": "tetrodotoxin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "sodium channel", "object_type": "GENE-N"}, {"subject": "TTX", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "sodium channel", "object_type": "GENE-N"}]}
{"text": "In anesthetized SD rats, mCPP induced a moderate reduction of nigral dopamine cell firing rate; supporting the assumption that this effect is secondary to the observed increase in dopamine release, it was blocked by pretreatment either with the dopamine synthesis inhibitor alpha-methyl-para-tyrosine or with the dopamine D2 receptor antagonist haloperidol.", "spo_list": [{"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D2 receptor", "object_type": "GENE-Y"}]}
{"text": "Mitochondrial electron transfer chain complexes inhibition by different organochalcogens.", "spo_list": [{"subject": "organochalcogens", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Mitochondrial electron transfer chain complexes", "object_type": "GENE-N"}]}
{"text": "All studied organochalcogens caused a statistically significant inhibition of the mitochondrial complex I activity.", "spo_list": [{"subject": "organochalcogens", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mitochondrial complex I", "object_type": "GENE-N"}]}
{"text": "Ebs and (PhTe)(2) caused a statistically significant inhibition of the mitochondrial complex II activity in both hepatic and renal membranes.", "spo_list": [{"subject": "(PhTe)(2)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mitochondrial complex II", "object_type": "GENE-N"}]}
{"text": "Hepatic mitochondrial complex II activity was practically unchanged by (PhSe)(2), whereas it significantly inhibited renal complex II activity.", "spo_list": [{"subject": "(PhSe)(2)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "renal complex II", "object_type": "GENE-N"}]}
{"text": "Furthermore, organochalcogens inhibited the mitochondrial respiration supported by complex I or complex II substrates.", "spo_list": [{"subject": "organochalcogens", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "complex I", "object_type": "GENE-N"}, {"subject": "organochalcogens", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "complex II", "object_type": "GENE-N"}]}
{"text": "The inhibitory effect of Ebs, (PhSe)(2) and (PhTe)(2) on mitochondrial complex I was prevented by NADH, but it was not prevented by catalase (CAT) and/or superoxide dismutase (SOD).", "spo_list": [{"subject": "(PhSe)(2)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mitochondrial complex I", "object_type": "GENE-N"}, {"subject": "(PhTe)(2)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mitochondrial complex I", "object_type": "GENE-N"}]}
{"text": "In conclusion, Ebs, (PhSe)(2) and (PhTe)(2) were more effective inhibitors of renal and hepatic mitochondrial complex I than complex II, whereas complexes III and IV were little modified by these compounds.", "spo_list": [{"subject": "(PhSe)(2)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mitochondrial complex I", "object_type": "GENE-N"}, {"subject": "(PhTe)(2)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mitochondrial complex I", "object_type": "GENE-N"}]}
{"text": "Verrucarin A enhances TRAIL-induced apoptosis via NF-ÎºB-mediated Fas overexpression.", "spo_list": [{"subject": "Verrucarin A", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRAIL", "object_type": "GENE-Y"}]}
{"text": "We found that VA upregulated the DNA binding activity of NF-ÎºB, but that the antioxidants glutathione and N-acetyl-l-cysteine, as well as NF-ÎºB inhibitor MG132, and mutant-IÎºB (m-IÎºB) transfection, significantly downregulated VA/TRAIL-induced cell death by inhibiting caspase-3 and NF-ÎºB activities.", "spo_list": [{"subject": "MG132", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "glutathione", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "caspase-3", "object_type": "GENE-Y"}, {"subject": "glutathione", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "N-acetyl-l-cysteine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "caspase-3", "object_type": "GENE-Y"}, {"subject": "N-acetyl-l-cysteine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "MG132", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "caspase-3", "object_type": "GENE-Y"}, {"subject": "MG132", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}]}
{"text": "Administration of bicuculline, a GABAA inhibitor, isolated a single response to Ï-agatoxin, which was characterized by a reduction in network activity.", "spo_list": [{"subject": "bicuculline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GABAA", "object_type": "GENE-N"}, {"subject": "bicuculline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Ï-agatoxin", "object_type": "GENE-N"}]}
{"text": "RESULTS: We found that a putative transcription repression domain in the NH2-terminus of FOXO1 is dispensable for FOXO1 inhibition of the AR.", "spo_list": [{"subject": "NH2", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "FOXO1", "object_type": "GENE-Y"}]}
{"text": "Stimulation of adenylyl cyclase, associated with cyclic AMP accumulations, was measured by a luciferase reporter gene assay.", "spo_list": [{"subject": "cyclic AMP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "adenylyl cyclase", "object_type": "GENE-N"}]}
{"text": "On human beta1-AR, the rank order of potency (EC50 values, maximal response relative to isoproterenol = 100%) was 1R,2S-ephedrine (0.5 microM, 68%) > 1S,2R-ephedrine (72 microM, 66%) > 1S,2S-pseudoephedrine (309 microM, 53%) = 1R,2R-pseudoephedrine (1122 microM, 53%).", "spo_list": [{"subject": "1R,2S-ephedrine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta1-AR", "object_type": "GENE-Y"}, {"subject": "1S,2R-ephedrine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta1-AR", "object_type": "GENE-Y"}, {"subject": "1S,2S-pseudoephedrine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta1-AR", "object_type": "GENE-Y"}, {"subject": "1R,2R-pseudoephedrine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta1-AR", "object_type": "GENE-Y"}]}
{"text": "On human beta2-AR, the rank order of potency was 1R,2S-ephedrine (0.36 microM, 78%) > 1R,2R-pseudoephedrine (7 microM, 50%) > or = 1S,2S-pseudoephedrine (10 microM, 47%) > 1S,2R-ephedrine (106 microM, 22%).", "spo_list": [{"subject": "1R,2S-ephedrine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta2-AR", "object_type": "GENE-Y"}, {"subject": "1R,2R-pseudoephedrine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta2-AR", "object_type": "GENE-Y"}, {"subject": "1S,2S-pseudoephedrine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta2-AR", "object_type": "GENE-Y"}, {"subject": "1S,2R-ephedrine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta2-AR", "object_type": "GENE-Y"}]}
{"text": "Only 1R,2S-ephedrine showed significant agonist activity on human beta3-AR with an EC50 = 45 betaM and a maximal response of 31%.", "spo_list": [{"subject": "1R,2S-ephedrine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta3-AR", "object_type": "GENE-Y"}]}
{"text": "Our studies demonstrated that (a) stereoselective and rank order differences exist among the direct effects of ephedrine isomers; (b) 1R,2S-ephedrine is the most potent of the four ephedrine isomers on all three human beta-AR; and (c) 1R,2S- ephedrine was nearly equipotent as a beta1-/beta2-AR agonist and the only isomer possessing weak partial agonist activity on beta3-AR.", "spo_list": [{"subject": "ephedrine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta-AR", "object_type": "GENE-N"}, {"subject": "1R,2S-ephedrine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta-AR", "object_type": "GENE-N"}, {"subject": "ephedrine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human beta-AR", "object_type": "GENE-N"}, {"subject": "1R,2S- ephedrine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta3-AR", "object_type": "GENE-Y"}]}
{"text": "Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation.", "spo_list": [{"subject": "carbetocin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Oxytocin receptor", "object_type": "GENE-Y"}]}
{"text": "Both carbetocin, carbetocin metabolite I and carbetocin metabolite II displayed binding affinities to the myometrial oxytocin receptor of a similar magnitude as oxytocin.", "spo_list": [{"subject": "carbetocin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "oxytocin receptor", "object_type": "GENE-Y"}, {"subject": "carbetocin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "oxytocin receptor", "object_type": "GENE-Y"}, {"subject": "carbetocin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "oxytocin receptor", "object_type": "GENE-Y"}, {"subject": "oxytocin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "oxytocin receptor", "object_type": "GENE-Y"}]}
{"text": "All three compounds displayed antagonistic properties against oxytocin in vitro, with carbetocin being the strongest inhibitor (pA2 = 8.21) and carbetocin metabolite II (pA2 = 8.01) being stronger than carbetocin metabolite I (pA2 = 7.81).", "spo_list": [{"subject": "carbetocin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "oxytocin", "object_type": "GENE-Y"}, {"subject": "carbetocin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "oxytocin", "object_type": "GENE-Y"}, {"subject": "carbetocin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "oxytocin", "object_type": "GENE-Y"}]}
{"text": "These results indicate that carbetocin is a partial agonist/antagonist to the oxytocin receptor while the two metabolites carbetocin metabolite I and carbetocin metabolite II are pure antagonists.", "spo_list": [{"subject": "carbetocin", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "oxytocin receptor", "object_type": "GENE-Y"}, {"subject": "carbetocin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "oxytocin receptor", "object_type": "GENE-Y"}, {"subject": "carbetocin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "oxytocin receptor", "object_type": "GENE-Y"}, {"subject": "carbetocin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "oxytocin receptor", "object_type": "GENE-Y"}]}
{"text": "Carbetocin metabolite II showed the weakest binding affinity of 33.7 +/- 7.34 nM compared to 7.24 +/- 0.29 nM for carbetocin and 9.89 + 2.80 nM for carbetocin metabolite I. Only carbetocin bound to the renal vasopressin V2 receptor though the binding affinity was very low (61.3 +/- 14.6 nM).", "spo_list": [{"subject": "carbetocin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "vasopressin V2 receptor", "object_type": "GENE-Y"}]}
{"text": "Electric mobility shift assay (EMSA) was performed to study whether the described polymorphic nucleotide sequences in the 5' region of the hCRH gene interfere with binding of nuclear proteins.", "spo_list": [{"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "hCRH", "object_type": "GENE-Y"}]}
{"text": "Both these MAPs were found to have two to three binding sites for estramustine phosphate which is compatible with the reported number of basic amino acid repeats of these MAPs, considered to be the ultimate tubulin binding domains.", "spo_list": [{"subject": "estramustine phosphate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MAPs", "object_type": "GENE-N"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MAPs", "object_type": "GENE-N"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "tubulin", "object_type": "GENE-N"}]}
{"text": "The Kd for the binding of estramustine phosphate to MAP2 was estimated to be 20 microM at 4 degrees, and for the binding of tau, 200 microM.", "spo_list": [{"subject": "estramustine phosphate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MAP2", "object_type": "GENE-N"}]}
{"text": "The uncharged estramustine bound to both tubulin and MAPs, but no effects were seen on microtubule assembly, the composition of coassembled MAPs or the microtubule morphology.", "spo_list": [{"subject": "estramustine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "tubulin", "object_type": "GENE-N"}, {"subject": "estramustine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MAPs", "object_type": "GENE-N"}]}
{"text": "The aim of the study was to determine whether the dihydroxylated antiestrogen LY117018, with a high affinity for the estrogen receptor and low intrinsic estrogenic activity, could inhibit the uterotropic actions of steroidal [estradiol-17 beta (E2)] and nonsteroidal [ICI 3188 and trianisylchloroethylene (TACE)] estrogens in immature rats and also the uterotropic actions of tamoxifen and monohydroxytamoxifen in the ovariectomized mouse and immature rat.", "spo_list": [{"subject": "LY117018", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}]}
{"text": "Overall, these findings suggest that monohydroxytamoxifen and LY117018 probably act through the same mechanism of action via the estrogen receptor.", "spo_list": [{"subject": "monohydroxytamoxifen", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "LY117018", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor", "object_type": "GENE-Y"}]}
{"text": "To compensate for reduced cell uptake caused by the hydrophilic shell of polyplex, the integrin-binding peptide, RGD, was conjugated to the hydrophilic chain end of P(OEGMA)(15)-b-P(GMA-TEPA)(50) copolymer by Michael-type addition reaction.", "spo_list": [{"subject": "P(OEGMA)(15)-b-P(GMA-TEPA)(50)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "integrin", "object_type": "GENE-N"}]}
{"text": "Using [14C]choline-labeled gastric mucosal cells in culture, we show that stimulatory effect of beta-adrenergic agonist, isoproterenol, on phospholipid release was subject to a dose-dependent suppression by EGFR kinase inhibitor, PD153035, as well as wortmannin, a specific inhibitor of PI3K.", "spo_list": [{"subject": "PD153035", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EGFR", "object_type": "GENE-Y"}, {"subject": "PD153035", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "wortmannin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PI3K", "object_type": "GENE-N"}]}
{"text": "Both inhibitors, moreover, caused the reduction in the gastric mucosal cell phospholipid secretory responses to beta-adrenergic agonist-generated second messenger, cAMP as well as adenyl cyclase activator, forskolin.", "spo_list": [{"subject": "forskolin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "adenyl cyclase", "object_type": "GENE-N"}]}
{"text": "The gastric mucosal phospholipid secretory responses to isoproterenol, furthermore, were inhibited by PP2, a selective inhibitor of tyrosine kinase Src responsible for ligand-independent EGFR phosphorylation, but not by ERK inhibitor, PD98059.", "spo_list": [{"subject": "PD98059", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ERK", "object_type": "GENE-N"}]}
{"text": "Multiple rat brain calpastatin forms are produced by distinct starting points and alternative splicing of the N-terminal exons.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "rat brain calpastatin", "object_type": "GENE-Y"}]}
{"text": "Evaluation of drug interactions of GSK1292263 (a GPR119 agonist) with statins: from in vitro data to clinical study design.", "spo_list": [{"subject": "GSK1292263", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "GPR119", "object_type": "GENE-Y"}]}
{"text": "1. This work investigated the drug interaction potential of GSK1292263, a novel GPR119 agonist, with the HMG-coA reductase inhibitors simvastatin and rosuvastatin.", "spo_list": [{"subject": "GSK1292263", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "GPR119", "object_type": "GENE-Y"}, {"subject": "simvastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HMG-coA reductase", "object_type": "GENE-Y"}, {"subject": "rosuvastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HMG-coA reductase", "object_type": "GENE-Y"}]}
{"text": "2. In vitro experiments assessed the inhibition of transporters and CYP enzymes by GSK1292263, and a clinical drug interaction study investigated the effect of GSK1292263 (300âmg BID) on the pharmacokinetic profile of simvastatin (40âmg single dose) and rosuvastatin (10âmg single dose).", "spo_list": [{"subject": "GSK1292263", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "transporters", "object_type": "GENE-N"}, {"subject": "GSK1292263", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP", "object_type": "GENE-N"}]}
{"text": "3. In vitro, GSK1292263 demonstrated little/weak inhibition (IC50 values >30 Î¼M) towards CYPs (CYP1A2, 2C9, 2C19, 2D6, 3A4), Pgp, OATP1B3, or OCT2.", "spo_list": [{"subject": "GSK1292263", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYPs", "object_type": "GENE-N"}, {"subject": "GSK1292263", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP1A2", "object_type": "GENE-Y"}, {"subject": "GSK1292263", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "2C9", "object_type": "GENE-Y"}, {"subject": "GSK1292263", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "2C19", "object_type": "GENE-Y"}, {"subject": "GSK1292263", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "2D6", "object_type": "GENE-Y"}, {"subject": "GSK1292263", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "3A4", "object_type": "GENE-Y"}, {"subject": "GSK1292263", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Pgp", "object_type": "GENE-N"}, {"subject": "GSK1292263", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP1B3", "object_type": "GENE-Y"}, {"subject": "GSK1292263", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OCT2", "object_type": "GENE-Y"}]}
{"text": "However, GSK1292263 inhibited BCRP and OATP1B1, which are transporters involved in statin disposition.", "spo_list": [{"subject": "GSK1292263", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BCRP", "object_type": "GENE-Y"}, {"subject": "GSK1292263", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP1B1", "object_type": "GENE-Y"}]}
{"text": "4. In the clinical study, small increases in the AUC(0-inf) of simvastatin [mean ratio (90% CI) of 1.34 (1.22, 1.48)] and rosuvastatin [mean ratio (90% CI) of 1.39 (1.30, 1.49)] were observed when co-administered with GSK1292263, which is consistent with an inhibitory effect on intestinal BCRP and CYP3A4.", "spo_list": [{"subject": "GSK1292263", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BCRP", "object_type": "GENE-Y"}, {"subject": "GSK1292263", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP3A4", "object_type": "GENE-Y"}]}
{"text": "This study provides a mechanistic understanding of the in vivo inhibition of transporters and enzymes by GSK1292263.", "spo_list": [{"subject": "GSK1292263", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "transporters", "object_type": "GENE-N"}]}
{"text": "The inhibitory effect of boceprevir (BOC), an inhibitor of hepatitis C virus nonstructural protein 3 protease was evaluated in vitro against a panel of drug-metabolizing enzymes and transporters.", "spo_list": [{"subject": "boceprevir", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hepatitis C virus nonstructural protein 3", "object_type": "GENE-Y"}, {"subject": "BOC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hepatitis C virus nonstructural protein 3", "object_type": "GENE-Y"}, {"subject": "boceprevir", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "protease", "object_type": "GENE-N"}, {"subject": "BOC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "protease", "object_type": "GENE-N"}]}
{"text": "BOC, a known substrate for cytochrome P450 (P450) CYP3A and aldo-ketoreductases, was a reversible time-dependent inhibitor (k(inact) = 0.12 minute(-1), K(I) = 6.1 ÂµM) of CYP3A4/5 but not an inhibitor of other major P450s, nor of UDP-glucuronosyltransferases 1A1 and 2B7.", "spo_list": [{"subject": "BOC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cytochrome P450", "object_type": "GENE-N"}, {"subject": "BOC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P450", "object_type": "GENE-N"}, {"subject": "BOC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "BOC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "aldo-ketoreductases", "object_type": "GENE-N"}]}
{"text": "In human hepatocytes, BOC inhibited CYP3A-mediated metabolism of midazolam, OATP1B-mediated hepatic uptake of pitavastatin, and both the uptake and metabolism of atorvastatin.", "spo_list": [{"subject": "BOC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "BOC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP1B", "object_type": "GENE-N"}, {"subject": "pitavastatin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B", "object_type": "GENE-N"}, {"subject": "atorvastatin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "atorvastatin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B", "object_type": "GENE-N"}]}
{"text": "The inhibitory potency of BOC was lower than known inhibitors of CYP3A (ketoconazole), OATP1B (rifampin), or both (telaprevir).", "spo_list": [{"subject": "ketoconazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "rifampin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP1B", "object_type": "GENE-N"}, {"subject": "telaprevir", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "telaprevir", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP1B", "object_type": "GENE-N"}]}
{"text": "BOC was a substrate for Pgp and BCRP but not for OATP1B1, OATP1B3, OATP2B1, organic cation transporter, or sodium/taurocholate cotransporting peptide.", "spo_list": [{"subject": "BOC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Pgp", "object_type": "GENE-N"}, {"subject": "BOC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "BCRP", "object_type": "GENE-Y"}]}
{"text": "Overall, our data suggest that BOC has the potential to cause pharmacokinetic interactions via inhibition of CYP3A and CYP3A/OATP1B interplay, with the interaction magnitude lower than those observed with known potent inhibitors.", "spo_list": [{"subject": "BOC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "BOC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "BOC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP1B", "object_type": "GENE-N"}]}
{"text": "Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter.", "spo_list": [{"subject": "Desvenlafaxine succinate", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "human norepinephrine transporter", "object_type": "GENE-Y"}]}
{"text": "Desvenlafaxine succinate (DVS) is a recently introduced antagonist of the human norepinephrine and serotonin transporters (hNET and hSERT, respectively), currently in clinical development for use in the treatment of major depressive disorder and vasomotor symptoms associated with menopause.", "spo_list": [{"subject": "Desvenlafaxine succinate", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "DVS", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "Desvenlafaxine succinate", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "hSERT", "object_type": "GENE-Y"}, {"subject": "DVS", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "hSERT", "object_type": "GENE-Y"}]}
{"text": "Initial evaluation of the pharmacological properties of DVS (J Pharmacol Exp Ther 318:657-665, 2006) revealed significantly reduced potency for the hNET expressed in membranes compared with whole cells when competing for [(3)H]nisoxetine (NIS) binding.", "spo_list": [{"subject": "[(3)H]nisoxetine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "NIS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hNET", "object_type": "GENE-Y"}]}
{"text": "Using hNET in transfected human embryonic kidney-293 cells, this difference in potency for DVS at sites labeled by [(3)H]NIS was found to distinguish DVS, the DVS analog rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol (WY-46824), methylphenidate, and the cocaine analog 3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester (RTI-55) from other hNET antagonists, such as NIS, mazindol, tricyclic antidepressants, and cocaine.", "spo_list": [{"subject": "DVS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "[(3)H]NIS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "NIS", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "mazindol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "tricyclic", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "rac-(1-[1-(3-chloro-phenyl)-2-(4-methylpiperazin-1-yl)-ethyl]cyclohexanol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "WY-46824", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "methylphenidate", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "3beta-(4-iodophenyl)tropane-2beta-carboxylic acid methyl ester", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "RTI-55", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "DVS", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "hNET", "object_type": "GENE-Y"}, {"subject": "DVS", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "hNET", "object_type": "GENE-Y"}]}
{"text": "Nicotinamide N-methyltransferase (NNMT) catalyses the conversion of nicotinamide to 1-methylnicotinamide and plays an important role in hepatic detoxification reactions.", "spo_list": [{"subject": "nicotinamide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Nicotinamide N-methyltransferase", "object_type": "GENE-Y"}, {"subject": "nicotinamide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NNMT", "object_type": "GENE-Y"}, {"subject": "1-methylnicotinamide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Nicotinamide N-methyltransferase", "object_type": "GENE-Y"}, {"subject": "1-methylnicotinamide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "NNMT", "object_type": "GENE-Y"}]}
{"text": "Homocysteine, the atherogenic product of the NNMT-catalyzed reaction, was secreted from 3T3-L1 cells or adipose tissue cultures.", "spo_list": [{"subject": "Homocysteine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "NNMT", "object_type": "GENE-Y"}]}
{"text": "Homocysteine release increased during 3T3-L1 differentiation and was reduced when adipose tissue was treated with the NNMT inhibitor 1-methylnicotinamide.", "spo_list": [{"subject": "1-methylnicotinamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NNMT", "object_type": "GENE-Y"}]}
{"text": "Nicotinic acid (NA), a widely used drug to lower elevated plasma lipid levels, induced NNMT enzyme activity in white adipose tissue of mice.", "spo_list": [{"subject": "Nicotinic acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NNMT", "object_type": "GENE-Y"}, {"subject": "NA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NNMT", "object_type": "GENE-Y"}]}
{"text": "These data support the concept that adipose tissue NNMT contributes to the increased plasma homocysteine levels in patients treated with NA.", "spo_list": [{"subject": "homocysteine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "NNMT", "object_type": "GENE-Y"}]}
{"text": "Although generally highly specific for angiotensin II type 1 receptors, some ARBs, particularly telmisartan, are partial agonists at peroxisome proliferator-activated receptor-Î³.", "spo_list": [{"subject": "telmisartan", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "peroxisome proliferator-activated receptor-Î³", "object_type": "GENE-Y"}, {"subject": "telmisartan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "angiotensin II type 1 receptors", "object_type": "GENE-Y"}]}
{"text": "The carbonic anhydrase V produced by a vector containing the full coding sequence, which includes a possible NH2-terminal mitochondrial targeting signal, was proteolytically processed by E. coli and contained several amino-terminal ends.", "spo_list": [{"subject": "NH2", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "The carbonic anhydrase V", "object_type": "GENE-Y"}, {"subject": "amino", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "The carbonic anhydrase V", "object_type": "GENE-Y"}]}
{"text": "The two NH2-terminal truncated vectors deleted, respectively, 1) the 29-amino acid putative targeting sequence and 2) 51 amino acids, yielding a protein equivalent to a carbonic anhydrase (CA) V isolated from mouse liver mitochondria; and both vectors produced homogeneous protein fractions.", "spo_list": [{"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "carbonic anhydrase (CA) V", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "carbonic anhydrase (CA) V", "object_type": "GENE-Y"}, {"subject": "NH2", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "carbonic anhydrase (CA) V", "object_type": "GENE-Y"}]}
{"text": "In catalytic properties, mouse CA V is closest to CA I; however, in inhibition by acetazolamide, ethoxzolamide, and cyanate, CA V is very similar to CA II.", "spo_list": [{"subject": "acetazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA V", "object_type": "GENE-Y"}, {"subject": "ethoxzolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA V", "object_type": "GENE-Y"}, {"subject": "cyanate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA V", "object_type": "GENE-Y"}, {"subject": "acetazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA II", "object_type": "GENE-Y"}, {"subject": "ethoxzolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA II", "object_type": "GENE-Y"}, {"subject": "cyanate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA II", "object_type": "GENE-Y"}]}
{"text": "Investigation of a site-specific mutant of CA V containing the replacement Tyr64-->His showed that the unique kinetic properties of CA V are not due to the presence of tyrosine at position 64.", "spo_list": [{"subject": "tyrosine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "CA V", "object_type": "GENE-Y"}, {"subject": "His", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "CA V", "object_type": "GENE-Y"}]}
{"text": "We have previously reported that TZDs reduce estrogen synthesis by inhibiting aromatase activity in human granulosa cells (HGC).", "spo_list": [{"subject": "TZDs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "estrogen", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "We studied mouse osteoblasts alone or in a co-culture with HGC to determine whether TZD inhibition of aromatase plays a role in their effects on bone metabolism.", "spo_list": [{"subject": "TZD", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "TZDs also inhibited alkaline phosphatase activity (58-75%, p<0.046) and osteocalcin production (52-75%, p<0.031).", "spo_list": [{"subject": "TZDs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "alkaline phosphatase", "object_type": "GENE-N"}, {"subject": "TZDs", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "osteocalcin", "object_type": "GENE-Y"}]}
{"text": "TZD effects on osteoblast viability, oleic acid uptake, alkaline phosphatase and osteocalcin production are independent of their effects on aromatase.", "spo_list": [{"subject": "TZD", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "alkaline phosphatase", "object_type": "GENE-N"}, {"subject": "TZD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "osteocalcin", "object_type": "GENE-Y"}]}
{"text": "Adrenal insufficiency may be caused by the destruction or altered function of the adrenal gland with a primary deficit in cortisol secretion (primary adrenal insufficiency) or by hypothalamic-pituitary pathologies determining a deficit of ACTH (secondary adrenal insufficiency).", "spo_list": [{"subject": "cortisol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ACTH", "object_type": "GENE-Y"}]}
{"text": "In the in vitro assay, kinsenoside (20 and 50Î¼g/mL) markedly inhibited changes in various biochemical substances (nitric oxide (NO), lactic dehydrogenase (LDH), superoxide dismutase (SOD), and catalase (CAT)) in human umbilical vein endothelial cells (HUVECs) damaged by high glucose (35mM) and restored vascular endothelial structure by balancing the matrix metalloproteinases-the tissue inhibitors of matrix metalloproteinases (MMP-TIMP) system.", "spo_list": [{"subject": "kinsenoside", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "lactic dehydrogenase", "object_type": "GENE-N"}, {"subject": "kinsenoside", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "LDH", "object_type": "GENE-N"}, {"subject": "kinsenoside", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "superoxide dismutase", "object_type": "GENE-N"}, {"subject": "kinsenoside", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "SOD", "object_type": "GENE-N"}, {"subject": "kinsenoside", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "catalase", "object_type": "GENE-Y"}, {"subject": "kinsenoside", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CAT", "object_type": "GENE-Y"}]}
{"text": "The vascular protective effects of kinsenoside were speculated to be attributed to oxidative stress inhibition and the reduction of nuclear factor kappa B (NF-ÎºB) mRNA expression levels in high glucose conditions.", "spo_list": [{"subject": "kinsenoside", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "nuclear factor kappa B", "object_type": "GENE-N"}, {"subject": "kinsenoside", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}]}
{"text": "The anticonvulsant activity of inhibitors of monoamine oxidase (MAO) was reported early after the development of irreversible MAO inhibitors such as tranylcypromine, but was never clinically used because of the adverse effects of these compounds.", "spo_list": [{"subject": "tranylcypromine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO", "object_type": "GENE-N"}]}
{"text": "We compared the following drugs in the kindling model of epilepsy: 1) L-deprenyl (selegiline), i.e., an irreversible inhibitor of MAO-B, which, however, also inhibits MAO-A at higher doses, 2) the novel reversible MAO-B inhibitor LU 53439 (3,4-dimethyl-7-(2-isopropyl-1,3, 4-thiadiazol-5-yl)-methoxy-coumarin), which is much more selective for MAO-B than L-deprenyl, 3) the novel reversible and highly selective MAO-A inhibitor LU 43839 (esuprone; 7-hydroxy-3, 4-dimethylcoumarin ethanesulfonate), and 4) the irreversible nonselective MAO inhibitor tranylcypromine.", "spo_list": [{"subject": "L-deprenyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "selegiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "L-deprenyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "selegiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "LU 53439", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "3,4-dimethyl-7-(2-isopropyl-1,3, 4-thiadiazol-5-yl)-methoxy-coumarin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "LU 53439", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "3,4-dimethyl-7-(2-isopropyl-1,3, 4-thiadiazol-5-yl)-methoxy-coumarin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "LU 43839", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "esuprone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "7-hydroxy-3, 4-dimethylcoumarin ethanesulfonate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "tranylcypromine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO", "object_type": "GENE-N"}]}
{"text": "In contrast to esuprone and L-deprenyl, the selective MAO-B inhibitor LU 53439 was not effective in the kindling model; this substantiates the previous notion that the anticonvulsant activity of L-deprenyl is not related to MAO-B inhibition, but to other effects of this drug, such as inhibition of MAO-A.", "spo_list": [{"subject": "esuprone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "L-deprenyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "L-deprenyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}]}
{"text": "Drugs inhibiting both MAO-A and MAO-B to a similar extent (tranylcypromine) or combinations of selective MAO-A and MAO-B inhibitors (esuprone plus LU 53439) had no advantage over MAO-A inhibition alone, but were less well tolerated.", "spo_list": [{"subject": "tranylcypromine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "tranylcypromine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "esuprone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "esuprone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "LU 53439", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "LU 53439", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "The data thus suggest that selective MAO-A inhibitors such as esuprone may be an interesting new approach for the treatment of epilepsy.", "spo_list": [{"subject": "esuprone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}]}
{"text": "A novel retinoic acid-responsive element regulates retinoic acid-induced BLR1 expression.", "spo_list": [{"subject": "retinoic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "BLR1", "object_type": "GENE-N"}]}
{"text": "RA is known to induce expression of the Burkitt's lymphoma receptor 1 (BLR1) gene which propels RA-induced cell cycle arrest and differentiation of HL-60 human myeloblastic leukemia cells, motivating the present analysis of transcriptional regulation of blr1 expression by RA.", "spo_list": [{"subject": "RA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Burkitt's lymphoma receptor 1", "object_type": "GENE-Y"}, {"subject": "RA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "BLR1", "object_type": "GENE-Y"}, {"subject": "RA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "blr1", "object_type": "GENE-Y"}]}
{"text": "A 5'-flanking region capable of supporting RA-induced blr1 activation in HL-60 cells was found to contain a 205-bp sequence in the distal portion that was necessary for transcriptional activation by RA.", "spo_list": [{"subject": "RA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "blr1", "object_type": "GENE-Y"}]}
{"text": "The ability of this cis-acting RAR-RXR binding element to activate transcription in response to RA also depended on downstream sequences where an octamer transcription factor 1 (Oct1) site and a nuclear factor of activated T cells (NFATc) site between this element and the transcriptional start, as well as a cyclic AMP response element binding factor (CREB) site between the transcriptional start and first exon of the blr1 gene, were necessary.", "spo_list": [{"subject": "RA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "nuclear factor of activated T cells", "object_type": "GENE-Y"}]}
{"text": "In sum the results of the present study indicate that RA-induced expression of blr1 expression depends on a novel RA response element.", "spo_list": [{"subject": "RA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "blr1", "object_type": "GENE-Y"}]}
{"text": "Diethyldithiocarbamate induces apoptosis in neuroblastoma cells by raising the intracellular copper level, triggering cytochrome c release and caspase activation.", "spo_list": [{"subject": "Diethyldithiocarbamate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytochrome c", "object_type": "GENE-Y"}, {"subject": "Diethyldithiocarbamate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "caspase", "object_type": "GENE-N"}]}
{"text": "The mechanism of DEDTC-induced apoptosis in neuronal model cells is thought to occur through the death receptor signaling triggered by DEDTC-copper complex in low concentration that is associated with the activation of caspase 8.", "spo_list": [{"subject": "DEDTC-copper", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "caspase 8", "object_type": "GENE-Y"}, {"subject": "DEDTC-copper", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "death receptor", "object_type": "GENE-N"}]}
{"text": "INTRODUCTION: In this study, we examined the effects of the alpha-glucosidase inhibitors acarbose and voglibose on postprandial plasma glucose and serum triglyceride levels in patients with type 2 diabetes mellitus.", "spo_list": [{"subject": "acarbose", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "alpha-glucosidase", "object_type": "GENE-N"}, {"subject": "voglibose", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "alpha-glucosidase", "object_type": "GENE-N"}]}
{"text": "Ruxolitinib is a small-molecule inhibitorÂ of JAK1 and JAK2 and recently became the first drug approved by the United States Food and Drug Administration for the treatment of symptomatic intermediate- or high-risk myelofibrosis.", "spo_list": [{"subject": "Ruxolitinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JAK1", "object_type": "GENE-Y"}, {"subject": "Ruxolitinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JAK2", "object_type": "GENE-Y"}]}
{"text": "Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases.", "spo_list": [{"subject": "hydralazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "prolyl hydroxylases", "object_type": "GENE-N"}, {"subject": "hydralazine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "vascular endothelial growth factor", "object_type": "GENE-Y"}]}
{"text": "Hydralazine induced rapid and transient expression of HIF-1alpha and downstream targets of HIF (endothelin-1, adrenomedullin, haem oxygenase 1, and vascular endothelial growth factor [VEGF]) in endothelial and smooth muscle cells and induced endothelial cell-specific proliferation.", "spo_list": [{"subject": "Hydralazine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "endothelin-1", "object_type": "GENE-Y"}, {"subject": "Hydralazine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "adrenomedullin", "object_type": "GENE-Y"}, {"subject": "Hydralazine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "haem oxygenase 1", "object_type": "GENE-Y"}, {"subject": "Hydralazine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "vascular endothelial growth factor", "object_type": "GENE-Y"}, {"subject": "Hydralazine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "VEGF", "object_type": "GENE-Y"}]}
{"text": "Hydralazine dose-dependently inhibited PHD activity and induced nonhydroxylated HIF-1alpha, evidence for HIF stabilization specifically by inhibition of PHD enzyme activity.", "spo_list": [{"subject": "Hydralazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PHD", "object_type": "GENE-N"}, {"subject": "Hydralazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PHD", "object_type": "GENE-N"}]}
{"text": "In vivo, hydralazine induced HIF-1alpha and VEGF protein in tissue extracts and elevated plasma VEGF levels.", "spo_list": [{"subject": "hydralazine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "VEGF", "object_type": "GENE-Y"}, {"subject": "hydralazine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "VEGF", "object_type": "GENE-Y"}]}
{"text": "Thus, hydralazine activates the HIF pathway through inhibition of PHD activity and initiates a pro-angiogenic phenotype.", "spo_list": [{"subject": "hydralazine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "HIF", "object_type": "GENE-N"}, {"subject": "hydralazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PHD", "object_type": "GENE-N"}]}
{"text": "Phlorotannin-rich Ecklonia cava reduces the production of beta-amyloid by modulating alpha- and gamma-secretase expression and activity.", "spo_list": [{"subject": "Phlorotannin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "beta-amyloid", "object_type": "GENE-Y"}]}
{"text": "Here, we show the reduction mechanism of AÎ² production using the butanol extract of Ecklonia cava through the examination of expression and activity of alpha-, beta-, and gamma-secretase.", "spo_list": [{"subject": "butanol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "AÎ²", "object_type": "GENE-Y"}]}
{"text": "A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions.", "spo_list": [{"subject": "Midazolam", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A", "object_type": "GENE-N"}]}
{"text": "We administered four escalating single doses of oral midazolam (0.0001-3âmg) to 12 healthy participants, stratified according to CYP3A5 carrier status, to assess pharmacokinetics linearity.", "spo_list": [{"subject": "midazolam", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A5", "object_type": "GENE-Y"}]}
{"text": "We then evaluated the interactions with the CYP3A inhibitor ketoconazole (400âmg q.d.) after nanogram and regular doses of midazolam.", "spo_list": [{"subject": "ketoconazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP3A", "object_type": "GENE-N"}]}
{"text": "Oxybutynin (1) is a non-selective muscarinic receptor antagonist that is used clinically for the treatment of urinary incontinence.", "spo_list": [{"subject": "Oxybutynin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic receptor", "object_type": "GENE-N"}]}
{"text": "Compounds 1 and 2 potently displaced (3)H-NMS binding at m1, m3 and m4 receptors, but were less potent at the m2 and m5 subtypes.", "spo_list": [{"subject": "(3)H-NMS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "m2", "object_type": "GENE-Y"}, {"subject": "(3)H-NMS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "m5", "object_type": "GENE-Y"}]}
{"text": "WS-CoQ10 did not alter the mRNA expression levels of Tp53 (at a concentration of 1.0Î¼gmL(-1)) and exhibited neuroprotective activity by stimulating cisplatin-inhibited neurite outgrowth in nerve growth factor (NGF)-differentiated PC12 cells (at a concentration of 0.1Î¼gmL(-1)).", "spo_list": [{"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "nerve growth factor", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NGF", "object_type": "GENE-Y"}, {"subject": "CoQ10", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "nerve growth factor", "object_type": "GENE-Y"}, {"subject": "CoQ10", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NGF", "object_type": "GENE-Y"}]}
{"text": "We identified one compound, E235 (N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide), that activated the ISR and dose-dependently increased levels of ATF4 in transformed cells.", "spo_list": [{"subject": "E235", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ATF4", "object_type": "GENE-Y"}, {"subject": "(N-(1-benzyl-piperidin-4-yl)-2-(4-fluoro-phenyl)-benzo[d]imidazo[2,1-b]thiazole-7-carboxamide)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ATF4", "object_type": "GENE-Y"}]}
{"text": "E235 also activated DNA damage response signaling, resulting in increased levels of Ser15-phosphorylated p53, Î³-H2AX, and phosphorylated checkpoint kinase 2 (Chk2), although E235 does not appear to cause physical DNA damage.", "spo_list": [{"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "phosphorylated p53", "object_type": "GENE-Y"}, {"subject": "E235", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "phosphorylated p53", "object_type": "GENE-Y"}, {"subject": "E235", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î³-H2AX", "object_type": "GENE-Y"}, {"subject": "E235", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "phosphorylated checkpoint kinase 2", "object_type": "GENE-Y"}, {"subject": "E235", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Chk2", "object_type": "GENE-Y"}]}
{"text": "Studies in rats, mice and monkeys show that GC-1 lowers cholesterol with 600- to 1400-fold more potency and approximately two- to threefold more efficacy than atorvastatin, a compound that blocks HMG-CoA reductase.", "spo_list": [{"subject": "atorvastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HMG-CoA reductase", "object_type": "GENE-Y"}]}
{"text": "We have previously shown that the inhibitor of pyruvate dehydrogenase kinase (PDK) dichloroacetate (DCA) activates glucose oxidation and induces apoptosis in cancer cells in vitro and in vivo.", "spo_list": [{"subject": "dichloroacetate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "pyruvate dehydrogenase kinase", "object_type": "GENE-N"}, {"subject": "dichloroacetate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDK", "object_type": "GENE-N"}, {"subject": "DCA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "pyruvate dehydrogenase kinase", "object_type": "GENE-N"}, {"subject": "DCA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDK", "object_type": "GENE-N"}]}
{"text": "We hypothesized that DCA will also reverse the 'pseudohypoxic' mitochondrial signals that lead to HIF1Î± activation in cancer, even in the absence of hypoxia and inhibit cancer angiogenesis.", "spo_list": [{"subject": "DCA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "HIF1Î±", "object_type": "GENE-Y"}]}
{"text": "Using pharmacologic and molecular approaches that suppress the prolyl-hydroxylase (PHD)-mediated inhibition of HIF1Î±, we show that DCA inhibits HIF1Î± by both a PHD-dependent mechanism (that involves a DCA-induced increase in the production of mitochondria-derived Î±-ketoglutarate) and a PHD-independent mechanism, involving activation of p53 via mitochondrial-derived H(2)O(2), as well as activation of GSK3Î².", "spo_list": [{"subject": "DCA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HIF1Î±", "object_type": "GENE-Y"}, {"subject": "DCA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p53", "object_type": "GENE-Y"}, {"subject": "DCA", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "GSK3Î²", "object_type": "GENE-Y"}]}
{"text": "Modification of the Catalytic Function of Human Hydroxysteroid Sulfotransferase hSULT2A1 by Formation of Disulfide Bonds.", "spo_list": [{"subject": "Disulfide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Human Hydroxysteroid Sulfotransferase hSULT2A1", "object_type": "GENE-Y"}]}
{"text": "The human cytosolic sulfotransferase hSULT2A1 catalyzes the sulfation of a broad range of xenobiotics, as well as endogenous hydroxysteroids and bile acids.", "spo_list": [{"subject": "hydroxysteroids", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human cytosolic sulfotransferase hSULT2A1", "object_type": "GENE-Y"}, {"subject": "bile acids", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human cytosolic sulfotransferase hSULT2A1", "object_type": "GENE-Y"}]}
{"text": "Studies on the kinetics of the hSULT2A1-catalyzed sulfation of dehydroepiandrosterone (DHEA) showed the effects of disulfide bond formation on the substrate inhibition characteristics of the enzyme.", "spo_list": [{"subject": "dehydroepiandrosterone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hSULT2A1", "object_type": "GENE-Y"}, {"subject": "DHEA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hSULT2A1", "object_type": "GENE-Y"}]}
{"text": "Thus, the formation of disulfide bonds in hSULT2A1 is a potentially important reversible mechanism for alterations in the rates of sulfation of both endogenous and xenobiotic substrates.", "spo_list": [{"subject": "disulfide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "hSULT2A1", "object_type": "GENE-Y"}]}
{"text": "The results showed that wogonoside promotes the expression of LC3-II and Beclin-1.", "spo_list": [{"subject": "wogonoside", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "LC3-II", "object_type": "GENE-Y"}, {"subject": "wogonoside", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Beclin-1", "object_type": "GENE-Y"}]}
{"text": "Wogonoside also suppressed the activation of mammalian target of rapamycin (mTOR) and p70-S6 kinase (p70S6K) by regulating the expression of the extracellular signal-regulated kinase (ERK1/2) and p38 involved mitogen-activated protein kinase (MAPK) signaling pathway.", "spo_list": [{"subject": "Wogonoside", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mammalian target of rapamycin", "object_type": "GENE-Y"}, {"subject": "Wogonoside", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}, {"subject": "Wogonoside", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p70-S6 kinase", "object_type": "GENE-N"}, {"subject": "Wogonoside", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p70S6K)", "object_type": "GENE-N"}]}
{"text": "Boron-based inhibitors of acyl protein thioesterases 1 and 2.", "spo_list": [{"subject": "Boron", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acyl protein thioesterases 1 and 2", "object_type": "GENE-N"}]}
{"text": "Here we present boronic and borinic acid derivatives as a new class of potent and nontoxic APT inhibitors.", "spo_list": [{"subject": "boronic", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "APT", "object_type": "GENE-N"}, {"subject": "borinic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "APT", "object_type": "GENE-N"}]}
{"text": "Our data showed that chronic ethanol over-activated CYP2E1 but suppressed HO-1 with concurrent hepatic oxidative damage, which was partially normalized by quercetin (100mg/kg.bw.).", "spo_list": [{"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CYP2E1", "object_type": "GENE-Y"}]}
{"text": "Ethanol-stimulated (100mM) CYP2E1 upregulation was suppressed by quercetin but further enhanced by HO-1 inhibition with resultant heme accumulation.", "spo_list": [{"subject": "Ethanol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HO-1", "object_type": "GENE-Y"}, {"subject": "heme", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "HO-1", "object_type": "GENE-Y"}]}
{"text": "Depleted heme pool and CO releasing limited protein synthesis and inhibited enzymatic activity of CYP2E1, respectively.", "spo_list": [{"subject": "CO", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2E1", "object_type": "GENE-Y"}]}
{"text": "In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone.", "spo_list": [{"subject": "CDB-2914", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}, {"subject": "CDB-4124", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}, {"subject": "mifepristone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}]}
{"text": "Monodemethylated mifepristone bound to rabbit thymic GR with higher affinity than monodemethylated CDB-2914 or CDB-4124.", "spo_list": [{"subject": "mifepristone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "rabbit thymic GR", "object_type": "GENE-Y"}, {"subject": "CDB-2914", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "rabbit thymic GR", "object_type": "GENE-Y"}, {"subject": "CDB-4124", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "rabbit thymic GR", "object_type": "GENE-Y"}]}
{"text": "At 10(-6)M in transcription assays, none of these compounds showed progestin agonist activity, whereas mifepristone and its monodemethylated metabolite manifested slight glucocorticoid agonist activity.", "spo_list": [{"subject": "mifepristone", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "glucocorticoid", "object_type": "GENE-Y"}]}
{"text": "Adenosine and N(6)-cyclopentyl-adenosine (CPA, A1R agonist) constricted MVs but not MAs.", "spo_list": [{"subject": "CPA", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "A1R", "object_type": "GENE-Y"}, {"subject": "Adenosine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "A1R", "object_type": "GENE-Y"}, {"subject": "N(6)-cyclopentyl-adenosine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "A1R", "object_type": "GENE-Y"}]}
{"text": "The A2A adenosine receptor agonist CGS21680 (C23H29N7O6.HCl.xH2O) (0.001-0.1 Î¼M) did not alter NE oxidation currents.", "spo_list": [{"subject": "CGS21680", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "A2A adenosine receptor", "object_type": "GENE-Y"}, {"subject": "C23H29N7O6.HCl.xH2O", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "A2A adenosine receptor", "object_type": "GENE-Y"}]}
{"text": "For periodic paralysis, dichlorphenamide--a carbonic anhydrase inhibitor--has been shown in a controlled trial to prevent attacks for many patients with both hypokalemic and hypokalemic periodic paralysis.", "spo_list": [{"subject": "dichlorphenamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase", "object_type": "GENE-N"}]}
{"text": "In a mouse model of DM-1, a morpholino antisense oligonucleuotide targeting the 3' splice site of CLCN1 exon 7a repaired the RNA splicing defect by promoting the production of full-length chloride channel transcripts.", "spo_list": [{"subject": "morpholino", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CLCN1", "object_type": "GENE-Y"}, {"subject": "morpholino", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "chloride channel transcripts", "object_type": "GENE-N"}]}
{"text": "Sustained resistance to acute MPTP toxicity by hypothalamic dopamine neurons following chronic neurotoxicant exposure is associated with sustained up-regulation of parkin protein.", "spo_list": [{"subject": "MPTP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "parkin", "object_type": "GENE-Y"}]}
{"text": "A similar pattern of susceptibility is observed following acute exposure to the neurotoxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), and the resistance of TIDA neurons to MPTP is associated with increased expression of parkin and ubiquitin carboxy-terminal hydrolase L-1 (UCHL- 1).", "spo_list": [{"subject": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "parkin", "object_type": "GENE-Y"}, {"subject": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ubiquitin carboxy-terminal hydrolase L-1", "object_type": "GENE-Y"}, {"subject": "1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "UCHL- 1", "object_type": "GENE-Y"}, {"subject": "MPTP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "parkin", "object_type": "GENE-Y"}, {"subject": "MPTP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ubiquitin carboxy-terminal hydrolase L-1", "object_type": "GENE-Y"}, {"subject": "MPTP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "UCHL- 1", "object_type": "GENE-Y"}, {"subject": "MPTP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "parkin", "object_type": "GENE-Y"}, {"subject": "MPTP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ubiquitin carboxy-terminal hydrolase L-1", "object_type": "GENE-Y"}, {"subject": "MPTP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "UCHL- 1", "object_type": "GENE-Y"}]}
{"text": "NSDA neurons displayed significant axon terminal degeneration (as indexed by decreases in DA, tyrosine hydroxylase (TH) and DA transporter concentrations in the striatum) as well as loss of TH-immunoreactive (IR) neurons in the substantia nigra (SN) following MPTP, whereas TIDA neurons revealed no overt axon terminal pathology or loss of TH-IR cell bodies.", "spo_list": [{"subject": "MPTP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "tyrosine hydroxylase", "object_type": "GENE-Y"}, {"subject": "MPTP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TH", "object_type": "GENE-Y"}, {"subject": "MPTP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "DA transporter", "object_type": "GENE-Y"}]}
{"text": "Resistance of TIDA neurons to MPTP toxicity was correlated with a transient increase in UCHL-1 and a sustained elevation in parkin in the arcuate nucleus.", "spo_list": [{"subject": "MPTP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "UCHL-1", "object_type": "GENE-Y"}, {"subject": "MPTP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "parkin", "object_type": "GENE-Y"}]}
{"text": "Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice.", "spo_list": [{"subject": "Anagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}]}
{"text": "To gain insights into their mechanism of action, 9-wk-old male apolipoprotein E (apoE)-deficient mice were fed a DPP-4 inhibitor, anagliptin-containing diet.", "spo_list": [{"subject": "anagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}]}
{"text": "Indeed, soluble DPP-4 augmented cultured SMC proliferation, and anagliptin suppressed the proliferation by inhibiting ERK phosphorylation.", "spo_list": [{"subject": "anagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ERK", "object_type": "GENE-N"}]}
{"text": "In THP-1 cells, anagliptin reduced lipopolysaccharide-induced TNF-Î± production with inhibiting ERK phosphorylation and nuclear translocation of nuclear factor-ÎºB.", "spo_list": [{"subject": "anagliptin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF-Î±", "object_type": "GENE-Y"}, {"subject": "anagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ERK", "object_type": "GENE-N"}, {"subject": "anagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "nuclear factor-ÎºB", "object_type": "GENE-N"}]}
{"text": "The aim of this study was to characterize the ISA of the beta-adrenoceptor blocker carteolol in healthy volunteers.", "spo_list": [{"subject": "carteolol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "beta-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "The beta(1)-adrenoceptor blocker bisoprolol did not attenuate these carteolol effects, but rather enhanced the effects on heart rate and systolic blood pressure.", "spo_list": [{"subject": "bisoprolol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "beta(1)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "carteolol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "beta(1)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Second, we treated volunteers for 7 days with 1 x 20 mg/day carteolol and assessed lymphocyte beta(2)-adrenoceptor density (by (-)-[(125)I]-iodocyanopindolol binding) and functional responsiveness (by 10 muM isoprenaline-induced increase in lymphocyte cyclic AMP content).", "spo_list": [{"subject": "(-)-[(125)I]-iodocyanopindolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Carteolol significantly reduced lymphocyte beta(2)-adrenoceptor density and function.", "spo_list": [{"subject": "Carteolol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "In conclusion, the fact that, on the one hand, the cardiovascular effects of carteolol were not attenuated by the beta(1)-adrenoceptor blocker bisoprolol and, on the other, carteolol significantly decreased lymphocyte beta(2)-adrenoceptor density and function is in favour of the idea that the ISA of carteolol is mediated by beta(2)-adrenoceptors.", "spo_list": [{"subject": "carteolol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "beta(1)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "bisoprolol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "beta(1)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "carteolol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Although considerable functional diversity exists, most C2 domains are activated by Ca2+ binding and then dock to a specific cellular membrane.", "spo_list": [{"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "C2 domains", "object_type": "GENE-N"}]}
{"text": "The C2 domains studied here both utilize the TAMA mechanism, in which the C2 domain Ca2+ affinity is too low to be activated by physiological Ca2+ signals in most regions of the cell.", "spo_list": [{"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "C2 domain", "object_type": "GENE-N"}]}
{"text": "Preclinical studies demonstrate that the therapeutic activity of citalopram resides in the S-isomer and that escitalopram binds with high affinity to the human serotonin transporter.", "spo_list": [{"subject": "escitalopram", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human serotonin transporter", "object_type": "GENE-Y"}]}
{"text": "Olopatadine hydrochloride (olopatadine) is an antiallergic drug with histamine H(1) receptor antagonistic activity.", "spo_list": [{"subject": "Olopatadine hydrochloride", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H(1) receptor", "object_type": "GENE-Y"}, {"subject": "olopatadine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H(1) receptor", "object_type": "GENE-Y"}]}
{"text": "Recently, olopatadine has been shown to bind to S100A12 which is a member of the S100 family of calcium-binding proteins, and exerts multiple proinflammatory activities including chemotaxis for monocytes and neutrophils.", "spo_list": [{"subject": "olopatadine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "S100A12", "object_type": "GENE-Y"}, {"subject": "olopatadine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "S100", "object_type": "GENE-N"}, {"subject": "olopatadine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calcium-binding proteins", "object_type": "GENE-N"}]}
{"text": "Pretreatment of olopatadine with S100A12 reduced migration of THP-1, a monocyte cell line, induced by S100A12 alone, but did not affect recombinant human regulated upon activation, normal T cell expressed and secreted (RANTES)-induced migration.", "spo_list": [{"subject": "olopatadine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "S100A12", "object_type": "GENE-Y"}]}
{"text": "Amlexanox, which also binds to S100A12, inhibited the THP-1 migration induced by S100A12.", "spo_list": [{"subject": "Amlexanox", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "S100A12", "object_type": "GENE-Y"}, {"subject": "Amlexanox", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "S100A12", "object_type": "GENE-Y"}]}
{"text": "The next large phase III adjuvant trial for this subset of breast cancer is an international collaboration designed to evaluate the added or alternative benefit of an oral tyrosine kinase inhibitor targeting HER2/neu as well as the epidermal growth factor receptor (EGFR), lapatinib.", "spo_list": [{"subject": "lapatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HER2", "object_type": "GENE-Y"}, {"subject": "lapatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "neu", "object_type": "GENE-Y"}, {"subject": "lapatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "epidermal growth factor receptor", "object_type": "GENE-Y"}, {"subject": "lapatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EGFR", "object_type": "GENE-Y"}]}
{"text": "The calcium homeostasis proteins sarcoendoplasmic reticulum ATPase 2a (SERCA2a), sodium calcium exchanger-1, phospholamban (PLB), phospho-PLB, and calsequestrin 2 are important for contraction and relaxation.", "spo_list": [{"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "sarcoendoplasmic reticulum ATPase 2a", "object_type": "GENE-Y"}, {"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SERCA2a", "object_type": "GENE-Y"}, {"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "sodium calcium exchanger-1", "object_type": "GENE-Y"}, {"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "phospholamban", "object_type": "GENE-Y"}, {"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PLB", "object_type": "GENE-Y"}, {"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "phospho-PLB", "object_type": "GENE-Y"}, {"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "calsequestrin 2", "object_type": "GENE-Y"}]}
{"text": "DNA methyltransferase 3a expression was increased in all BPA males and BPA 0.5 females and reduced in BPA 200 females.", "spo_list": [{"subject": "BPA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "DNA methyltransferase 3a", "object_type": "GENE-Y"}, {"subject": "BPA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "DNA methyltransferase 3a", "object_type": "GENE-Y"}, {"subject": "BPA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "DNA methyltransferase 3a", "object_type": "GENE-Y"}]}
{"text": "Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile.", "spo_list": [{"subject": "Dienogest", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "progesterone receptor", "object_type": "GENE-Y"}]}
{"text": "Dienogest activate PR (EC50=3.4 or 10.5 nmol/l) with antagonistic activity on AR (EC50=420.6 or 775.0 nmol/l) but not agonistic nor antagonistic action on GR, MR (3000 nmol/l).", "spo_list": [{"subject": "Dienogest", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PR", "object_type": "GENE-Y"}, {"subject": "Dienogest", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "AR", "object_type": "GENE-Y"}]}
{"text": "Progesterone activated PR with antagonistic activity on AR and on MR.", "spo_list": [{"subject": "Progesterone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PR", "object_type": "GENE-N"}, {"subject": "Progesterone", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "AR", "object_type": "GENE-Y"}, {"subject": "Progesterone", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "MR", "object_type": "GENE-Y"}]}
{"text": "Norethisterone activated PR, AR, and ERalpha.", "spo_list": [{"subject": "Norethisterone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PR", "object_type": "GENE-Y"}, {"subject": "Norethisterone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AR", "object_type": "GENE-Y"}, {"subject": "Norethisterone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ERalpha", "object_type": "GENE-Y"}]}
{"text": "Medroxyprogesterone acetate activated PR, AR, and GR.", "spo_list": [{"subject": "Medroxyprogesterone acetate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PR", "object_type": "GENE-Y"}, {"subject": "Medroxyprogesterone acetate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AR", "object_type": "GENE-Y"}, {"subject": "Medroxyprogesterone acetate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GR", "object_type": "GENE-Y"}]}
{"text": "Danazol activated PR and AR.", "spo_list": [{"subject": "Danazol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PR", "object_type": "GENE-Y"}, {"subject": "Danazol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AR", "object_type": "GENE-Y"}]}
{"text": "The estimated plasma concentration of dienogest at ED50 (3.66 nmol/l) was close to its EC50 value to activate PR.", "spo_list": [{"subject": "dienogest", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PR", "object_type": "GENE-Y"}]}
{"text": "Oral administration of APP at 250 and 500 mg/kg bw in mice was shown to be as effective as AFP in lowering the CCl(4)-caused increases of serum alanine aminotransferase, aspartate aminotransferase and lactic dehydrogenase activities, and hepatic malondialdehyde level, and antagonising the decreases in antioxidant superoxide dismutase and glutathione peroxidase activities caused by CCl(4) (p<0.05).", "spo_list": [{"subject": "CCl(4)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "serum alanine aminotransferase", "object_type": "GENE-N"}, {"subject": "CCl(4)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "aspartate aminotransferase", "object_type": "GENE-N"}, {"subject": "CCl(4)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "lactic dehydrogenase", "object_type": "GENE-N"}, {"subject": "CCl(4)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "superoxide dismutase", "object_type": "GENE-N"}, {"subject": "CCl(4)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "glutathione peroxidase", "object_type": "GENE-N"}]}
{"text": "The selective NK1 antagonist orvepitant (GW823296) was used to test this hypothesis.", "spo_list": [{"subject": "orvepitant", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NK1", "object_type": "GENE-Y"}, {"subject": "GW823296", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NK1", "object_type": "GENE-Y"}]}
{"text": "Potassium ions are non-essential activators of several aldehyde dehydrogenases (ALDHs), whereas a few others require the cation for activity.", "spo_list": [{"subject": "Potassium", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "aldehyde dehydrogenases", "object_type": "GENE-N"}, {"subject": "Potassium", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ALDHs", "object_type": "GENE-N"}]}
{"text": "Flutamide, a non-steroid-blocking androgen receptor, was subcutaneously administered to 30-d-old male Wistar rats for 4 wk.", "spo_list": [{"subject": "Flutamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "androgen receptor", "object_type": "GENE-Y"}]}
{"text": "Flutamide administration decreased body weight gain, serum IGF-I levels, hepatic IGF-I mRNA, and GH receptor mRNA content.", "spo_list": [{"subject": "Flutamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IGF-I", "object_type": "GENE-Y"}, {"subject": "Flutamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IGF-I", "object_type": "GENE-Y"}, {"subject": "Flutamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "GH receptor", "object_type": "GENE-Y"}]}
{"text": "Flutamide lowered hypothalamic somatostatin mRNA content and augmented hypothalamic immunoreactive somatostatin stores, but did not alter hypothalamic immunoreactive GH-releasing factor stores.", "spo_list": [{"subject": "Flutamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "somatostatin", "object_type": "GENE-Y"}, {"subject": "Flutamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "somatostatin", "object_type": "GENE-Y"}]}
{"text": "This riluzole-induced pCREB activation in LC neurons was also blocked by CNQX and CBX.", "spo_list": [{"subject": "riluzole", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "pCREB", "object_type": "GENE-N"}]}
{"text": "Contrary to expectations, these results suggest that activation of glutamate transporters in the LC results in increase of extracellular glutamate signaling, possibly via facilitation of glutamate release from astrocytes, and activation of LC neurons to induce descending inhibition, and that this paradoxical action of glutamate transporters in the LC requires gap-junction connections.", "spo_list": [{"subject": "glutamate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "glutamate transporters", "object_type": "GENE-N"}]}
{"text": "Areas covered: An extensive literature search was performed to analyze clinical cases of acute pancreatitis reported in the literature or to the Food and Drug Administration (FDA), in randomized clinical trials, and in observational studies with five DPP-4 inhibitors: sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin.", "spo_list": [{"subject": "sitagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}, {"subject": "vildagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}, {"subject": "saxagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}, {"subject": "alogliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}, {"subject": "linagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}]}
{"text": "In rather short-term clinical trials with well-selected diabetic patients, no increased risk of acute pancreatitis has been observed with any of the five commercialized DPP-4 inhibitors: sitagliptin, vildagliptin, saxagliptin, alogliptin, and linagliptin.", "spo_list": [{"subject": "sitagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}, {"subject": "vildagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}, {"subject": "saxagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}, {"subject": "alogliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}, {"subject": "linagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}]}
{"text": "In addition, during acute exposure tests performed at the end of the chronic exposure, biofilms chronically exposed to 75 and 150Î¼gL(-1) oxyfluorfen showed a higher CAT activity than controls.", "spo_list": [{"subject": "oxyfluorfen", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CAT", "object_type": "GENE-N"}]}
{"text": "Using radioligand receptor binding methods, the affinities (Ki) of amoxapine and loxapine for various receptors (adrenergic alpha 1, alpha 2, beta; dopaminergic D1, D2; serotoninergic 5-HT1, 5-HT2; Muscarinic, GABA, BZ) were investigated.", "spo_list": [{"subject": "amoxapine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1", "object_type": "GENE-N"}, {"subject": "amoxapine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT2", "object_type": "GENE-N"}]}
{"text": "For D1 receptor, loxapine was found to have moderate affinity which was nearly 20 fold greater than amoxapine, but amoxapine exhibited more potent inhibitory effects on serotonin receptors and weaker inhibitory affects on dopamine receptors.", "spo_list": [{"subject": "loxapine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "D1 receptor", "object_type": "GENE-Y"}, {"subject": "amoxapine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "serotonin receptors", "object_type": "GENE-N"}]}
{"text": "The mitogenic effect of DHT on bone cells was inhibited by antiandrogens (hydroxyflutamide and cyproterone acetate) which compete for binding to the androgen receptor.", "spo_list": [{"subject": "cyproterone acetate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "androgen receptor", "object_type": "GENE-N"}, {"subject": "hydroxyflutamide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "androgen receptor", "object_type": "GENE-N"}, {"subject": "DHT", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "androgen receptor", "object_type": "GENE-N"}]}
{"text": "In addition to effects on cell proliferation, DHT increased the percentage of alkaline phosphatase (ALP) positive cells in all three bone cell systems tested, and this effect was inhibited by antiandrogens.", "spo_list": [{"subject": "DHT", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "alkaline phosphatase", "object_type": "GENE-N"}, {"subject": "DHT", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ALP", "object_type": "GENE-N"}]}
{"text": "We conclude that androgens can stimulate human and murine osteoblastic cell proliferation in vitro, and induce expression of the osteoblast-line differentiation marker ALP, presumably by an androgen receptor mediated mechanism.", "spo_list": [{"subject": "androgens", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "osteoblast-line differentiation marker", "object_type": "GENE-N"}, {"subject": "androgens", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ALP", "object_type": "GENE-N"}]}
{"text": "However, recent clinical studies have shown that a single low-dose injection of ketamine, an N-methyl d-aspartate receptor (NMDAR) antagonist, has rapid antidepressant effects that are observed within hours and are long lasting.", "spo_list": [{"subject": "ketamine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "N-methyl d-aspartate receptor", "object_type": "GENE-N"}, {"subject": "ketamine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NMDAR", "object_type": "GENE-N"}]}
{"text": "Identification and synthesis of N-(thiophen-2-yl) benzamide derivatives as BRAF(V600E) inhibitors.", "spo_list": [{"subject": "N-(thiophen-2-yl) benzamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BRAF", "object_type": "GENE-Y"}, {"subject": "N-(thiophen-2-yl) benzamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "V600E", "object_type": "GENE-N"}]}
{"text": "In this study, we employed virtual screening and chemical synthesis to identify a series of N-(thiophen-2-yl) benzamide derivatives as potent BRAF(V600E) inhibitors.", "spo_list": [{"subject": "N-(thiophen-2-yl) benzamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BRAF", "object_type": "GENE-Y"}, {"subject": "N-(thiophen-2-yl) benzamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "V600E", "object_type": "GENE-N"}]}
{"text": "Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.", "spo_list": [{"subject": "PKC412", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "PKC412", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "D816V", "object_type": "GENE-N"}, {"subject": "PKC412", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "KIT", "object_type": "GENE-Y"}]}
{"text": "We evaluated whether PKC412, a small-molecule inhibitor of KIT with a different chemical structure from imatinib, may have therapeutic use in advanced SM with the D816V KIT mutation.", "spo_list": [{"subject": "PKC412", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "KIT", "object_type": "GENE-Y"}]}
{"text": "We treated a patient with MCL (with an associated myelodysplastic syndrome (MDS)/myeloproliferative disorder [MPD]) based on in vitro studies demonstrating that PKC412 could inhibit D816V KIT-transformed Ba/F3 cell growth with a 50% inhibitory concentration (IC50) of 30 nM to 40 nM.", "spo_list": [{"subject": "PKC412", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "D816V", "object_type": "GENE-N"}, {"subject": "PKC412", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "KIT", "object_type": "GENE-Y"}]}
{"text": "In addition, PKC412 treatment resulted in a significant decline in the percentage of peripheral blood mast cells and serum histamine level and was associated with a decrease in KIT phosphorylation and D816V KIT mutation frequency.", "spo_list": [{"subject": "PKC412", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "KIT", "object_type": "GENE-Y"}, {"subject": "PKC412", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "D816V", "object_type": "GENE-N"}, {"subject": "PKC412", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "KIT", "object_type": "GENE-Y"}]}
{"text": "FCEO significantly inhibited nitric oxide (NO) and prostaglandin E2 (PGE2) by suppressing the protein expression of inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2, respectively.", "spo_list": [{"subject": "nitric oxide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "inducible nitric oxide synthase", "object_type": "GENE-Y"}, {"subject": "nitric oxide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "inducible nitric oxide synthase", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "prostaglandin E2", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cyclooxygenase (COX)-2", "object_type": "GENE-Y"}, {"subject": "PGE2", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cyclooxygenase (COX)-2", "object_type": "GENE-Y"}]}
{"text": "FAUC 213, a highly selective dopamine D4 receptor full antagonist, exhibits atypical antipsychotic properties in behavioural and neurochemical models of schizophrenia.", "spo_list": [{"subject": "FAUC 213", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D4 receptor", "object_type": "GENE-Y"}]}
{"text": "RATIONALE: 2-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine (FAUC 213) is a highly selective antagonist at the dopamine D(4) receptor subtype.", "spo_list": [{"subject": "FAUC 213", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D(4) receptor", "object_type": "GENE-Y"}, {"subject": "2-[4-(4-Chlorophenyl)piperazin-1-ylmethyl]pyrazolo[1,5-a]pyridine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D(4) receptor", "object_type": "GENE-Y"}]}
{"text": "The selective D(4) antagonist FAUC 213, therefore, is not believed to mediate the above-mentioned effects via D(2) receptor antagonism, but a partial involvement of 5-HT(2)- and alpha(1)-receptors cannot be ruled out at present.", "spo_list": [{"subject": "FAUC 213", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "D(4)", "object_type": "GENE-Y"}, {"subject": "FAUC 213", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "D(2) receptor", "object_type": "GENE-Y"}]}
{"text": "Hydrophobic amino acids in the hinge region of the 5A apolipoprotein mimetic peptide are essential for promoting cholesterol efflux by the ABCA1 transporter.", "spo_list": [{"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "5A apolipoprotein", "object_type": "GENE-Y"}, {"subject": "cholesterol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ABCA1", "object_type": "GENE-Y"}]}
{"text": "The bihelical apolipoprotein mimetic peptide 5A effluxes cholesterol from cells and reduces inflammation and atherosclerosis in animal models.", "spo_list": [{"subject": "cholesterol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "apolipoprotein mimetic peptide 5A", "object_type": "GENE-Y"}]}
{"text": "Compared with active peptides containing F or W, peptides containing E in either of these two positions were more than 10-fold less effective in effluxing cholesterol by the ABCA1 transporter.", "spo_list": [{"subject": "cholesterol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ABCA1", "object_type": "GENE-Y"}]}
{"text": "These results provide a rationale for future design of therapeutic apolipoprotein mimetic peptides and provide new insights into the interaction of hydrophobic residues on apolipoproteins with phospholipids in the lipid microdomain created by the ABCA1 transporter during the cholesterol efflux process.", "spo_list": [{"subject": "cholesterol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ABCA1", "object_type": "GENE-Y"}]}
{"text": "Benzenesulfonamides incorporating cyanoacrylamide moieties strongly inhibit Saccharomyces cerevisiae Î²-carbonic anhydrase.", "spo_list": [{"subject": "Benzenesulfonamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Saccharomyces cerevisiae Î²-carbonic anhydrase", "object_type": "GENE-Y"}, {"subject": "cyanoacrylamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Saccharomyces cerevisiae Î²-carbonic anhydrase", "object_type": "GENE-Y"}]}
{"text": "A series of benzenesulfonamides incorporating cyanoacrylamide moieties (tyrphostine analogs) were assayed as inhibitors of the Î²-carbonic anhydrase (CA, EC 4.2.1.1) from Saccharomyces cerevisiae, ScCA.", "spo_list": [{"subject": "benzenesulfonamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Î²-carbonic anhydrase", "object_type": "GENE-Y"}, {"subject": "benzenesulfonamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA", "object_type": "GENE-N"}, {"subject": "benzenesulfonamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 4.2.1.1", "object_type": "GENE-Y"}, {"subject": "benzenesulfonamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ScCA", "object_type": "GENE-Y"}, {"subject": "cyanoacrylamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Î²-carbonic anhydrase", "object_type": "GENE-Y"}, {"subject": "cyanoacrylamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA", "object_type": "GENE-N"}, {"subject": "cyanoacrylamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 4.2.1.1", "object_type": "GENE-Y"}, {"subject": "cyanoacrylamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ScCA", "object_type": "GENE-Y"}, {"subject": "tyrphostine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Î²-carbonic anhydrase", "object_type": "GENE-Y"}, {"subject": "tyrphostine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA", "object_type": "GENE-N"}, {"subject": "tyrphostine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 4.2.1.1", "object_type": "GENE-Y"}, {"subject": "tyrphostine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ScCA", "object_type": "GENE-Y"}]}
{"text": "These data suggest that T-cells can be activated by abacavir through a direct interaction with surface and intracellular major histocompatibility complex (MHC) molecules.", "spo_list": [{"subject": "abacavir", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "major histocompatibility complex", "object_type": "GENE-N"}, {"subject": "abacavir", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MHC", "object_type": "GENE-N"}]}
{"text": "With the former, abacavir seemingly participates in the MHC T-cell receptor binding interaction.", "spo_list": [{"subject": "abacavir", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MHC", "object_type": "GENE-N"}, {"subject": "abacavir", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "T-cell receptor", "object_type": "GENE-N"}]}
{"text": "Consumption of alcohol for 8weeks induced severe liver damage with increases in prognostic indicators such as aspartate transaminase, alanine transaminase in serum whereas co-administration of CNF suppressed their increases.", "spo_list": [{"subject": "alcohol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "aspartate transaminase", "object_type": "GENE-N"}, {"subject": "alcohol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "alanine transaminase", "object_type": "GENE-N"}]}
{"text": "Chronic consumption of alcohol also stimulated abrupt increases in pro-inflammatory cytokines such as nuclear factor (NF)-ÎºB, tumor necrosis factor (TNF)-Î± and interleukin (IL)-1Î² in liver otherwise co-administration of CNF effectively suppressed production of these cytokines dose-dependently.", "spo_list": [{"subject": "alcohol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "nuclear factor (NF)-ÎºB", "object_type": "GENE-N"}, {"subject": "alcohol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "tumor necrosis factor (TNF)-Î±", "object_type": "GENE-Y"}, {"subject": "alcohol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "interleukin (IL)-1Î²", "object_type": "GENE-Y"}]}
{"text": "Pharmacological profile of parecoxib: a novel, potent injectable selective cyclooxygenase-2 inhibitor.", "spo_list": [{"subject": "parecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}]}
{"text": "The antinociceptive, anti-inflammatory, antipyretic effects along with gastric safety profile of parecoxib, a novel, potent selective cyclooxygenase-2 inhibiting prodrug, and those of ketorolac, a nonselective cyclooxygenase inhibitor, were evaluated in various animal models.", "spo_list": [{"subject": "parecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "ketorolac", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase", "object_type": "GENE-N"}]}
{"text": "The present results showed that the cyclooxygenase-2 inhibitor, parecoxib, when administered parenterally, has potent antihyperalgesic, anti-inflammatory, antipyretic effects and has a better safety profile than with ketorolac, with sparing of cyclooxygenase-1 in the stomach in these animal models.", "spo_list": [{"subject": "parecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "ketorolac", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-1", "object_type": "GENE-Y"}]}
{"text": "C-terminal amidation, a required post-translational modification for the bioactivation of many neuropeptides, entails sequential enzymic action by peptidylglycine alpha-mono-oxygenase (PAM, EC 1.14.17.3) and peptidylamidoglycolate lyase (PGL, EC 4.3.2.5).", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "peptidylglycine alpha-mono-oxygenase", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PAM", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "EC 1.14.17.3", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "peptidylamidoglycolate lyase", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PGL", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "EC 4.3.2.5", "object_type": "GENE-Y"}]}
{"text": "Kinetic parameters for PAM inactivation by 4-oxo-5-acetamido-6-phenyl-hex-2-enoic acid and 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid were obtained by using both the conventional dilution assay method and the more complex progress curve method.", "spo_list": [{"subject": "4-oxo-5-acetamido-6-phenyl-hex-2-enoic acid and 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PAM", "object_type": "GENE-Y"}]}
{"text": "Stereochemical studies established that PAM inactivation by 4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid is stereospecific with respect to the moiety at the P(2) position, which is consistent with previous results with substrates and reversible inhibitors.", "spo_list": [{"subject": "4-oxo-5-acetamido-6-(2-thienyl)-hex-2-enoic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PAM", "object_type": "GENE-Y"}]}
{"text": "In contrast, 2, 4-dioxo-5-acetamido-6-phenylhexanoic acid, which is a competitive inhibitor with respect to ascorbate, exhibits a low degree of stereospecificity in binding to the ascorbate sites of both PAM and dopamine-beta-hydroxylase.", "spo_list": [{"subject": "2, 4-dioxo-5-acetamido-6-phenylhexanoic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PAM", "object_type": "GENE-Y"}, {"subject": "2, 4-dioxo-5-acetamido-6-phenylhexanoic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "dopamine-beta-hydroxylase", "object_type": "GENE-Y"}, {"subject": "2, 4-dioxo-5-acetamido-6-phenylhexanoic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PAM", "object_type": "GENE-Y"}, {"subject": "2, 4-dioxo-5-acetamido-6-phenylhexanoic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dopamine-beta-hydroxylase", "object_type": "GENE-Y"}, {"subject": "ascorbate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PAM", "object_type": "GENE-Y"}, {"subject": "ascorbate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dopamine-beta-hydroxylase", "object_type": "GENE-Y"}, {"subject": "ascorbate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PAM", "object_type": "GENE-Y"}, {"subject": "ascorbate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "dopamine-beta-hydroxylase", "object_type": "GENE-Y"}]}
{"text": "Cholesterol esterase (CE) induced surface erosion of poly(ethylene carbonate) (PEC) and drug release from PEC under mild physiological environment was investigated.", "spo_list": [{"subject": "poly(ethylene carbonate)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Cholesterol esterase", "object_type": "GENE-Y"}, {"subject": "poly(ethylene carbonate)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CE", "object_type": "GENE-Y"}, {"subject": "PEC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Cholesterol esterase", "object_type": "GENE-Y"}, {"subject": "PEC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CE", "object_type": "GENE-Y"}]}
{"text": "Using PET, reduced glucose metabolism (rCMRglu) and increased binding of the mu opiate receptor ligand 11C-carfentanil have been demonstrated in lateral temporal cortex overlying mesial temporal epileptic foci.", "spo_list": [{"subject": "11C-carfentanil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mu opiate receptor", "object_type": "GENE-Y"}]}
{"text": "Binding of the non-specific opiate receptor ligand 11C-diprenorphine (DPN) to lateral temporal cortex has not shown consistent asymmetries.", "spo_list": [{"subject": "11C-diprenorphine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "opiate receptor", "object_type": "GENE-N"}, {"subject": "DPN", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "opiate receptor", "object_type": "GENE-N"}]}
{"text": "We report for the first time that VEGF-D binds heparin, and that the C-terminal propeptide significantly enhances this interaction (removal of this propeptide from full-length VEGF-D completely prevents heparin binding).", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "VEGF-D", "object_type": "GENE-Y"}]}
{"text": "We also show that removal of either the N- or C-terminal propeptide is required for VEGF-D to drive formation of VEGFR-2/VEGFR-3 heterodimers which have recently been shown to positively regulate angiogenic sprouting.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "VEGF-D", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "VEGF-D", "object_type": "GENE-Y"}]}
{"text": "In a mouse tumor model, removal of only the C-terminal propeptide from full-length VEGF-D was sufficient to enhance angiogenesis and tumor growth.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "VEGF-D", "object_type": "GENE-Y"}]}
{"text": "In the local presence into the LC of the Î±2-adrenoceptor antagonist RS79948 (1Â Î¼M), systemic citalopram increased NA in the LC (Emaxâ=â157âÂ±â25Â %) and PFC (Emaxâ=â175âÂ±â24Â %).", "spo_list": [{"subject": "RS79948", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "Î±2-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "Local LC citalopram effect was abolished by LC presence of the 5-HT3 receptor antagonist MDL72222 (1Â Î¼M) but not the 5-HT1/2 receptor antagonist methiothepin (1Â Î¼M).", "spo_list": [{"subject": "MDL72222", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT3", "object_type": "GENE-Y"}, {"subject": "methiothepin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT1/2", "object_type": "GENE-N"}]}
{"text": "Design, Synthesis, and Biological Evaluation of a Series of Benzo[de][1,7]naphthyridin-7(8H)-ones Bearing a Functionalized Longer Chain Appendage as Novel PARP1 Inhibitors.", "spo_list": [{"subject": "Benzo[de][1,7]naphthyridin-7(8H)-ones", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PARP1", "object_type": "GENE-Y"}]}
{"text": "A series of benzo[de][1,7]naphthyridin-7(8H)-ones possessing a functionalized long-chain appendage have been designed and evaluated as novel PARP1 inhibitors.", "spo_list": [{"subject": "benzo[de][1,7]naphthyridin-7(8H)-ones", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PARP1", "object_type": "GENE-Y"}]}
{"text": "The initial effort led to the first-generation PARP1 inhibitor 26 bearing a terminal phthalazin-1(2H)-one framework and showing remarkably high PARP1 inhibitory activity (0.31 nM) but only moderate potency in the cell.", "spo_list": [{"subject": "phthalazin-1(2H)-one", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PARP1", "object_type": "GENE-Y"}, {"subject": "phthalazin-1(2H)-one", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PARP1", "object_type": "GENE-Y"}]}
{"text": "(2) Exposure histories vary in secondary 11q23 leukemia, as the only topoisomerase II inhibitor was dactinomycin in one case, and, in another case, no topoisomerase II inhibitor was administered.", "spo_list": [{"subject": "dactinomycin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "topoisomerase II", "object_type": "GENE-Y"}]}
{"text": "In vitro activity, beta-lactamase stability and PBP affinity of RU 51,746-2, the active metabolite of the new orally absorbed cephalosporin ester, RU 51807.", "spo_list": [{"subject": "RU 51,746", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PBP", "object_type": "GENE-N"}]}
{"text": "RU 51,746-2 showed a good affinity for high molecular weight penicillin binding proteins (PBPs) of E. coli.", "spo_list": [{"subject": "RU 51,746", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "penicillin binding proteins", "object_type": "GENE-N"}, {"subject": "RU 51,746", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PBPs", "object_type": "GENE-N"}]}
{"text": "The Androgen Metabolite, 5Î±-Androstane-3Î²,17Î²-Diol (3Î²-Diol), Activates the Oxytocin Promoter Through an Estrogen Receptor-Î² Pathway.", "spo_list": [{"subject": "Androgen", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Oxytocin Promoter", "object_type": "GENE-N"}, {"subject": "5Î±-Androstane-3Î²,17Î²-Diol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Oxytocin Promoter", "object_type": "GENE-N"}, {"subject": "3Î²-Diol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Oxytocin Promoter", "object_type": "GENE-N"}]}
{"text": "The dihydrotestosterone metabolite, 5Î±-androstane-3Î²,17Î²-diol (3Î²-diol), binds and activates estrogen receptor-Î² (ER-Î²), the predominant ER in the PVN.", "spo_list": [{"subject": "dihydrotestosterone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor-Î²", "object_type": "GENE-Y"}, {"subject": "dihydrotestosterone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "estrogen receptor-Î²", "object_type": "GENE-Y"}, {"subject": "5Î±-androstane-3Î²,17Î²-diol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor-Î²", "object_type": "GENE-Y"}, {"subject": "5Î±-androstane-3Î²,17Î²-diol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "estrogen receptor-Î²", "object_type": "GENE-Y"}, {"subject": "3Î²-diol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor-Î²", "object_type": "GENE-Y"}, {"subject": "3Î²-diol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "estrogen receptor-Î²", "object_type": "GENE-Y"}, {"subject": "dihydrotestosterone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ER-Î²", "object_type": "GENE-Y"}, {"subject": "dihydrotestosterone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ER-Î²", "object_type": "GENE-Y"}, {"subject": "5Î±-androstane-3Î²,17Î²-diol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ER-Î²", "object_type": "GENE-Y"}, {"subject": "5Î±-androstane-3Î²,17Î²-diol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ER-Î²", "object_type": "GENE-Y"}, {"subject": "3Î²-diol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ER-Î²", "object_type": "GENE-Y"}, {"subject": "3Î²-diol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ER-Î²", "object_type": "GENE-Y"}, {"subject": "dihydrotestosterone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ER", "object_type": "GENE-Y"}, {"subject": "dihydrotestosterone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ER", "object_type": "GENE-Y"}, {"subject": "5Î±-androstane-3Î²,17Î²-diol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ER", "object_type": "GENE-Y"}, {"subject": "3Î²-diol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ER", "object_type": "GENE-Y"}, {"subject": "5Î±-androstane-3Î²,17Î²-diol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ER", "object_type": "GENE-Y"}, {"subject": "3Î²-diol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ER", "object_type": "GENE-Y"}]}
{"text": "Therefore, we tested the hypothesis that 3Î²-diol regulates OT expression through ER-Î² activation.", "spo_list": [{"subject": "3Î²-diol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "OT", "object_type": "GENE-Y"}, {"subject": "3Î²-diol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ER-Î²", "object_type": "GENE-Y"}]}
{"text": "Treatment of ovariectomized rats with estradiol benzoate or 3Î²-diol for 4 days increased OT mRNA selectively in the midcaudal, but not rostral PVN compared with vehicle-treated controls.", "spo_list": [{"subject": "estradiol benzoate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "OT", "object_type": "GENE-Y"}, {"subject": "3Î²-diol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "OT", "object_type": "GENE-Y"}]}
{"text": "3Î²-Diol treatment also increased OT mRNA in the hypothalamic N38 cell line in vitro.", "spo_list": [{"subject": "3Î²-Diol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "OT", "object_type": "GENE-Y"}]}
{"text": "In a dose-dependent manner, 3Î²-diol treatment increased OT-luc activity when cells were cotransfected with ER-Î², but not ER-Î±.", "spo_list": [{"subject": "3Î²-diol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "OT", "object_type": "GENE-Y"}]}
{"text": "These results indicate that 3Î²-diol induces OT promoter activity via ER-Î²-cHRE interactions.", "spo_list": [{"subject": "3Î²-diol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "OT promoter", "object_type": "GENE-N"}, {"subject": "3Î²-diol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ER-Î²", "object_type": "GENE-Y"}, {"subject": "3Î²-diol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "cHRE", "object_type": "GENE-N"}]}
{"text": "The homologous location in the alpha3beta4 AChR is between the serine and valine/phenylalanine rings.", "spo_list": [{"subject": "serine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "alpha3beta4 AChR", "object_type": "GENE-Y"}, {"subject": "valine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "alpha3beta4 AChR", "object_type": "GENE-Y"}, {"subject": "phenylalanine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "alpha3beta4 AChR", "object_type": "GENE-Y"}]}
{"text": "In this study, we cloned and sequenced a cDNA encoding a serine racemase from barley which contained an open reading frame encoding 337 amino acid residues.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "serine racemase", "object_type": "GENE-Y"}]}
{"text": "The deduced amino acid sequence showed significant identity to plant and mammalian serine racemases and contained conserved pyridoxal 5-phosphate (PLP)-binding lysine and PLP-interacting amino acid residues.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "serine racemases", "object_type": "GENE-N"}, {"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "serine racemases", "object_type": "GENE-N"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "serine racemases", "object_type": "GENE-N"}]}
{"text": "The enzyme requires PLP and divalent cations such as Ca(2+), Mg(2+), or Mn(2+), but not ATP, whereas mammalian serine racemase activity is increased by ATP.", "spo_list": [{"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "serine racemase", "object_type": "GENE-N"}]}
{"text": "In addition, the number and area of glutathione S-transferase placental form (GST-P) positive foci and proliferating cell nuclear antigen (PCNA) positive cell ratios in the hepatocytes were significantly increased in the male and female rats that were administered 100mg/kg MEG compared with the control animals.", "spo_list": [{"subject": "MEG", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "glutathione S-transferase placental form", "object_type": "GENE-N"}, {"subject": "MEG", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GST-P", "object_type": "GENE-N"}, {"subject": "MEG", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "proliferating cell nuclear antigen", "object_type": "GENE-Y"}, {"subject": "MEG", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PCNA", "object_type": "GENE-Y"}]}
{"text": "Thiazolidinediones are a new class of anti-diabetic agents which increase insulin sensitivity by binding to the peroxisome proliferator-activated receptor gamma (PPAR(gamma)) and stimulating the expression of insulin-responsive genes involved in glucose and lipid metabolism.", "spo_list": [{"subject": "Thiazolidinediones", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-Y"}, {"subject": "Thiazolidinediones", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "peroxisome proliferator-activated receptor gamma", "object_type": "GENE-Y"}, {"subject": "Thiazolidinediones", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PPAR(gamma)", "object_type": "GENE-Y"}, {"subject": "Thiazolidinediones", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-Y"}]}
{"text": "Although incubating HASMCs for 48h with thiazolidinediones had no effect on ENT1 mRNA and protein levels, troglitazone acutely inhibited [3H]adenosine uptake and [3H]NBMPR binding of HASMCs with IC50 values of 2.35+/-0.35 and 3.99+/-0.57microM, respectively.", "spo_list": [{"subject": "[3H]NBMPR", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ENT1", "object_type": "GENE-Y"}]}
{"text": "The effect of troglitazone on ENT1 was PPAR(gamma)-independent and kinetic studies revealed that troglitazone was a competitive inhibitor of ENT1.", "spo_list": [{"subject": "troglitazone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ENT1", "object_type": "GENE-Y"}]}
{"text": "The difference in structure of troglitazone did not account for its inhibitory effect on ENT1 because Vitamin E did not inhibit [3H]adenosine uptake by HASMCs.", "spo_list": [{"subject": "troglitazone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ENT1", "object_type": "GENE-Y"}]}
{"text": "Using the nucleoside transporter deficient PK15NTD cells stably expressing ENT1 and ENT2, it was found that troglitazone inhibited ENT1 but had no effect on ENT2.", "spo_list": [{"subject": "troglitazone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ENT1", "object_type": "GENE-Y"}]}
{"text": "From these results, it is suggested that troglitazone may enhance the vasodilatory effect of adenosine by inhibiting ENT1.", "spo_list": [{"subject": "troglitazone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ENT1", "object_type": "GENE-Y"}]}
{"text": "Pharmacologically, troglitazone is a novel inhibitor of ENT1.", "spo_list": [{"subject": "troglitazone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ENT1", "object_type": "GENE-Y"}]}
{"text": "The Turkish patient and her affected relatives all had a heterozygous A to G transition at codon 557 (AAG-->GAG) of exon 10 of MEN1 that results in a replacement of lysine by glutamic acid.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MEN1", "object_type": "GENE-Y"}, {"subject": "glutamic acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MEN1", "object_type": "GENE-Y"}]}
{"text": "Protein recognition of the S23906-1-DNA adduct by nuclear proteins: direct involvement of glyceraldehyde-3-phosphate dehydrogenase (GAPDH)1.", "spo_list": [{"subject": "S23906-1", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glyceraldehyde-3-phosphate dehydrogenase (GAPDH)1", "object_type": "GENE-Y"}]}
{"text": "We found that GAPDH (glyceraldehyde-3-phosphate dehydrogenase) is a protein that binds to S23906-alkylated single-stranded, double-stranded and telomeric sequences in a drug-dependent and DNA sequence/structure-dependent manner.", "spo_list": [{"subject": "S23906", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAPDH", "object_type": "GENE-Y"}, {"subject": "S23906", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glyceraldehyde-3-phosphate dehydrogenase", "object_type": "GENE-Y"}]}
{"text": "We used the CASTing (cyclic amplification of sequence targeting) method to identify GAPDH DNA-binding selectivity and then evaluated its binding to such selected S23906-alkylated sequences.", "spo_list": [{"subject": "S23906", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAPDH", "object_type": "GENE-Y"}]}
{"text": "At the cellular level, alkylation of S23906-1 results in an increase in the binding of GAPDH and its protein partner HMG (high-mobility group) B1 to the chromatin.", "spo_list": [{"subject": "S23906-1", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAPDH", "object_type": "GENE-Y"}]}
{"text": "2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors.", "spo_list": [{"subject": "2-Arylpropionic", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CXC chemokine receptor 1", "object_type": "GENE-Y"}, {"subject": "2-Arylpropionic", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CXCR1", "object_type": "GENE-Y"}, {"subject": "2-Arylpropionic", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CXCL8", "object_type": "GENE-Y"}]}
{"text": "(R)-Ketoprofen (1) was previously reported to be a potent and specific noncompetitive inhibitor of CXCL8-induced human PMNs chemotaxis.", "spo_list": [{"subject": "(R)-Ketoprofen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CXCL8", "object_type": "GENE-Y"}]}
{"text": "Involvement of organic anion-transporting polypeptides in the hepatic uptake of dioscin in rats and humans.", "spo_list": [{"subject": "dioscin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "organic anion-transporting polypeptides", "object_type": "GENE-N"}]}
{"text": "Uptake of dioscin by rat liver slices and isolated rat hepatocytes was inhibited significantly by Oatp modulators, such as ibuprofen (Oatp1a1 inhibitor), digoxin (Oatp1a4 substrate), and glycyrrhizic acid (Oatp1b2 inhibitor), but not by TEA or p-aminohippurate.", "spo_list": [{"subject": "dioscin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Oatp", "object_type": "GENE-N"}, {"subject": "ibuprofen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Oatp1a1", "object_type": "GENE-Y"}, {"subject": "digoxin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Oatp1a4", "object_type": "GENE-Y"}, {"subject": "glycyrrhizic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Oatp1b2", "object_type": "GENE-Y"}]}
{"text": "Uptake of dioscin in rat hepatocytes and OATP1B3-human embryonic kidney (HEK) 293 cells indicated a saturable process with a Km of 3.75 Â± 0.51 Î¼M and 2.08 Â± 0.27 Î¼M, respectively.", "spo_list": [{"subject": "dioscin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B3", "object_type": "GENE-Y"}]}
{"text": "(-)-Epigallocatechin gallate, cyclosporin A, rifampicin, and telmisartan inhibited transport of dioscin in OATP1B3-HEK293 cells.", "spo_list": [{"subject": "dioscin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B3", "object_type": "GENE-Y"}, {"subject": "(-)-Epigallocatechin gallate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP1B3", "object_type": "GENE-Y"}, {"subject": "cyclosporin A", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP1B3", "object_type": "GENE-Y"}, {"subject": "rifampicin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP1B3", "object_type": "GENE-Y"}, {"subject": "telmisartan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP1B3", "object_type": "GENE-Y"}]}
{"text": "However, transcellular transport of dioscin in OATP1B1- or OATP1B1/multidrug resistance-associated protein 2-Madin-Darby canine kidney strain II cells was not observed.", "spo_list": [{"subject": "dioscin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B1", "object_type": "GENE-N"}, {"subject": "dioscin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B1", "object_type": "GENE-N"}, {"subject": "dioscin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "multidrug resistance-associated protein 2", "object_type": "GENE-Y"}]}
{"text": "These results indicate that hepatic uptake of dioscin is involved in OATP1B3 in humans, and multiple Oatps might participate in this process in rats.", "spo_list": [{"subject": "dioscin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B3", "object_type": "GENE-Y"}, {"subject": "dioscin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Oatps", "object_type": "GENE-N"}]}
{"text": "Intrathecal injection of the specific NFATc inhibitor 11R-VIVIT or the calcineurin inhibitor FK-506 (tacrolimus) early after nerve injury significantly attenuated the development of tactile allodynia.", "spo_list": [{"subject": "FK-506", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calcineurin", "object_type": "GENE-N"}, {"subject": "tacrolimus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calcineurin", "object_type": "GENE-N"}]}
{"text": "In addition, treatment with FK-506 or 11R-VIVIT significantly reduced the mRNA levels of NFATc4 and CCR2 but not large-conductance Ca(2+)-activated K(+) channels, in the DRG after nerve injury.", "spo_list": [{"subject": "FK-506", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NFATc4", "object_type": "GENE-Y"}, {"subject": "FK-506", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CCR2", "object_type": "GENE-Y"}]}
{"text": "To determine if the up-regulation of PDGFÎ² receptors is neuroprotective, primary hippocampal neurons were incubated with the 5-HT7 receptor agonist, LP 12, for 24 h. Indeed, LP 12 treatment prevented NMDA-induced neurotoxicity and this effect was dependent on PDGFÎ² receptor kinase activity.", "spo_list": [{"subject": "LP 12", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT7", "object_type": "GENE-Y"}]}
{"text": "Treatment of primary neurons with LP 12 also differentially altered NMDA receptor subunit expression, reducing the expression of NR1 and NR2B, but not NR2A.", "spo_list": [{"subject": "LP 12", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NR1", "object_type": "GENE-Y"}, {"subject": "LP 12", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NR2B", "object_type": "GENE-Y"}]}
{"text": "In this phase IIb clinical trial, 258 patients with type 2 diabetes completed a 12-week protocol with 50, 100, or 150âmg of MSDC-0160 (an mTOT modulator), 45âmg pioglitazone HCl (a PPAR-Î³ agonist), or a placebo.", "spo_list": [{"subject": "pioglitazone HCl", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "PPAR-Î³", "object_type": "GENE-N"}]}
{"text": "The decreases in glycated hemoglobin (HbA1c) observed with the two higher doses of MSDC-0160 were not different from those associated with pioglitazone.", "spo_list": [{"subject": "MSDC-0160", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "glycated hemoglobin", "object_type": "GENE-N"}, {"subject": "MSDC-0160", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "HbA1c", "object_type": "GENE-N"}, {"subject": "pioglitazone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "glycated hemoglobin", "object_type": "GENE-N"}, {"subject": "pioglitazone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "HbA1c", "object_type": "GENE-N"}]}
{"text": "Thus, mTOT modulators may have glucose-lowering effects similar to those of pioglitazone but without the adverse effects associated with PPAR-Î³ agonists.", "spo_list": [{"subject": "pioglitazone", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "PPAR-Î³", "object_type": "GENE-N"}]}
{"text": "The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam.", "spo_list": [{"subject": "levetiracetam", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "synaptic vesicle protein SV2A", "object_type": "GENE-Y"}]}
{"text": "Here, we show that the synaptic vesicle protein SV2A is the brain binding site of levetiracetam (LEV), a new antiepileptic drug with a unique activity profile in animal models of seizure and epilepsy.", "spo_list": [{"subject": "levetiracetam", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "synaptic vesicle protein SV2A", "object_type": "GENE-Y"}, {"subject": "LEV", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "synaptic vesicle protein SV2A", "object_type": "GENE-Y"}]}
{"text": "Brain membranes and purified synaptic vesicles from mice lacking SV2A do not bind a tritiated LEV derivative, indicating that SV2A is necessary for LEV binding.", "spo_list": [{"subject": "LEV", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SV2A", "object_type": "GENE-Y"}]}
{"text": "LEV and related compounds bind to SV2A expressed in fibroblasts, indicating that SV2A is sufficient for LEV binding.", "spo_list": [{"subject": "LEV", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SV2A", "object_type": "GENE-Y"}, {"subject": "LEV", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SV2A", "object_type": "GENE-Y"}]}
{"text": "Furthermore, there is a high degree of correlation between binding affinities of a series of LEV derivatives to SV2A in fibroblasts and to the LEV-binding site in brain.", "spo_list": [{"subject": "LEV", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SV2A", "object_type": "GENE-Y"}]}
{"text": "These experimental results suggest that SV2A is the binding site of LEV in the brain and that LEV acts by modulating the function of SV2A, supporting previous indications that LEV possesses a mechanism of action distinct from that of other antiepileptic drugs.", "spo_list": [{"subject": "LEV", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SV2A", "object_type": "GENE-Y"}, {"subject": "LEV", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SV2A", "object_type": "GENE-Y"}]}
{"text": "This includes nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) required for the formation of the benzopyranopyrrole core unit, as well as a suite of tailoring enzymes (e.g., four halogenases, an O-methyltransferase, and an N-glycosyltransferase) necessary for further modifications of the core structure.", "spo_list": [{"subject": "benzopyranopyrrole", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PKS", "object_type": "GENE-N"}, {"subject": "benzopyranopyrrole", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "nonribosomal peptide synthetases", "object_type": "GENE-N"}, {"subject": "benzopyranopyrrole", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "NRPS", "object_type": "GENE-N"}, {"subject": "benzopyranopyrrole", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "polyketide synthases", "object_type": "GENE-N"}, {"subject": "benzopyranopyrrole", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "halogenases", "object_type": "GENE-N"}, {"subject": "benzopyranopyrrole", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "O-methyltransferase", "object_type": "GENE-N"}, {"subject": "benzopyranopyrrole", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "N-glycosyltransferase", "object_type": "GENE-N"}]}
{"text": "Targeted disruption of the gene encoding the N-glycosyltransferase, prlH, abolished pyralomicin production, and recombinant expression of PrlA confirms the activity of this enzyme as a sugar phosphate cyclase involved in the formation of the C7-cyclitol moiety.", "spo_list": [{"subject": "pyralomicin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "N-glycosyltransferase", "object_type": "GENE-N"}, {"subject": "pyralomicin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "prlH", "object_type": "GENE-Y"}, {"subject": "cyclitol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "sugar phosphate cyclase", "object_type": "GENE-N"}, {"subject": "C7", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "sugar phosphate cyclase", "object_type": "GENE-N"}, {"subject": "cyclitol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PrlA", "object_type": "GENE-Y"}, {"subject": "C7", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PrlA", "object_type": "GENE-Y"}]}
{"text": "Metformin and phenformin activate AMP-activated protein kinase in the heart by increasing cytosolic AMP concentration.", "spo_list": [{"subject": "Metformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMP-activated protein kinase", "object_type": "GENE-N"}, {"subject": "phenformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMP-activated protein kinase", "object_type": "GENE-N"}]}
{"text": "Metformin and phenformin, which are biguanides, have been reported to increase AMPK activity without increasing AMP/ATP.", "spo_list": [{"subject": "Metformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "phenformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "biguanides", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}]}
{"text": "In hearts treated with phenformin for 18 min and then perfused for 20 min with Krebs-Henseleit buffer, [AMP] began to increase at 26 min and AMPK activity was elevated at 36 min.", "spo_list": [{"subject": "phenformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}]}
{"text": "In hearts treated with metformin, [AMP] was increased at 50 min and AMPK activity, phosphorylated AMPK, and phosphorylated acetyl-CoA carboxylase were elevated at 61 min.", "spo_list": [{"subject": "metformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "metformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "metformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "phosphorylated acetyl-CoA carboxylase", "object_type": "GENE-N"}]}
{"text": "In summary, phenformin and metformin increase AMPK activity and phosphorylation in the isolated heart.", "spo_list": [{"subject": "phenformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "metformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}]}
{"text": "Cytosolic [AMP] reported metabolically active AMP, which triggered increased AMPK activity, but measures of total AMP did not.", "spo_list": [{"subject": "AMP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}]}
{"text": "The changes in CysLT1 receptor expression 24 h after NMDA injection and the effects of a CysLT1 receptor antagonist, pranlukast (0.01 and 0.1 mg/kg), an NMDA receptor antagonist, ketamine (30 mg/kg), and an antioxidant, edaravone (9 mg/kg) were observed.", "spo_list": [{"subject": "pranlukast", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CysLT1 receptor", "object_type": "GENE-Y"}, {"subject": "ketamine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NMDA receptor", "object_type": "GENE-N"}]}
{"text": "RESULTS: In the NMDA-injured brain, the CysLT1 receptor mRNA, and protein expression were upregulated, and the receptor was mainly localized in the neurons and not in the astrocytes.", "spo_list": [{"subject": "NMDA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CysLT1 receptor", "object_type": "GENE-Y"}]}
{"text": "Pranlukast, ketamine and edaravone decreased NMDA-induced injury; pranlukast (0.1 mg/kg) and ketamine inhibited the upregulated expression of the CysLT1 receptor.", "spo_list": [{"subject": "ketamine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CysLT1 receptor", "object_type": "GENE-Y"}, {"subject": "pranlukast", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CysLT1 receptor", "object_type": "GENE-Y"}]}
{"text": "CONCLUSION: CysLT1 receptor expression in neurons is upregulated after NMDA injection, and NMDA-induced responses are inhibited by CysLT1 receptor antagonists, indicating that the increased CysLT1 receptor is involved in NMDA excitotoxicity.", "spo_list": [{"subject": "NMDA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CysLT1 receptor", "object_type": "GENE-Y"}, {"subject": "NMDA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CysLT1 receptor", "object_type": "GENE-Y"}]}
{"text": "PC3 is a type I proinsulin-processing enzyme that initiates the sequential processing of proinsulin to insulin by cleaving the proinsulin molecule on the COOH-terminal side of the dibasic peptide, Arg31-Arg32, joining the B-chain and C-peptide.", "spo_list": [{"subject": "COOH", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "proinsulin", "object_type": "GENE-Y"}, {"subject": "COOH", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "proinsulin", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "proinsulin", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "proinsulin", "object_type": "GENE-Y"}]}
{"text": "Expressions of insulin and PC3, but not PC2, are coordinately regulated by glucose, consistent with the important role of PC3 in regulating proinsulin processing.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-Y"}, {"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PC3", "object_type": "GENE-Y"}]}
{"text": "Single-strand conformational analysis and nucleotide sequencing of the entire coding region of the PC3 gene in 102 Japanese subjects with NIDDM revealed missense mutations in exons 2 (Arg/Gln53) and 14 (Gln/Glu638), neither of which was associated with NIDDM in this population.", "spo_list": [{"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PC3", "object_type": "GENE-Y"}, {"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Arg/Gln53", "object_type": "GENE-N"}, {"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Gln/Glu638", "object_type": "GENE-N"}]}
{"text": "Cetrorelix completely blocked the rise of levels of the two most abundant species, 5.0 kb and 4.5 kb, of the GnRH-R mRNA, during both the infantile and the juvenile periods.", "spo_list": [{"subject": "Cetrorelix", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "GnRH-R", "object_type": "GENE-Y"}]}
{"text": "Cetrorelix also abolished the developmental rise of the gonadotropin beta subunit mRNAs during the two periods of the study.", "spo_list": [{"subject": "Cetrorelix", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "gonadotropin beta", "object_type": "GENE-N"}]}
{"text": "Endothelin-3 Expression in the Subfornical Organ Enhances the Sensitivity of Nax, the Brain Sodium-Level Sensor, to Suppress Salt Intake.", "spo_list": [{"subject": "Sodium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Nax", "object_type": "GENE-Y"}]}
{"text": "Here, we found that the sensitivity of Nax channels to [Na(+)]o is dose-dependently enhanced by endothelin-3 (ET-3).", "spo_list": [{"subject": "Na(+)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Nax channels", "object_type": "GENE-Y"}]}
{"text": "Nax channels began to open when [Na(+)]o exceeded â¼150Â mM without ET-3, but opened fully at a physiological [Na(+)]o (135-145Â mM) with 1Â nM ET-3.", "spo_list": [{"subject": "Na(+)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Nax channels", "object_type": "GENE-Y"}, {"subject": "Na(+)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Nax channels", "object_type": "GENE-Y"}]}
{"text": "These results indicate that ET-3 expression in the SFO is tightly coupled with body-fluid homeostasis through modulation of the [Na(+)]o sensitivity of Nax.", "spo_list": [{"subject": "Na(+)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Nax", "object_type": "GENE-Y"}]}
{"text": "Cellular zinc is controlled by zinc-chelating proteins and by zinc transporters.", "spo_list": [{"subject": "zinc", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "zinc transporters", "object_type": "GENE-N"}, {"subject": "zinc", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "zinc-chelating proteins", "object_type": "GENE-N"}]}
{"text": "The recent identification of zinc permeability of the lysosomal ion channel TRPML1 (transient receptor potential mucolipin 1), and the evidence of abnormal zinc levels in cells deficient in TRPML1, suggested a role for TRPML1Â in zinc transport.", "spo_list": [{"subject": "zinc", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "TRPML1", "object_type": "GENE-Y"}, {"subject": "zinc", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "transient receptor potential mucolipin 1", "object_type": "GENE-Y"}, {"subject": "zinc", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "TRPML1", "object_type": "GENE-Y"}]}
{"text": "These results underscore a role for TRPML1Â in zinc metabolism.", "spo_list": [{"subject": "zinc", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "TRPML1", "object_type": "GENE-Y"}]}
{"text": "Furthermore, they suggest that TRPML1 works in concert with ZnT4 to regulate zinc translocation between the cytoplasm and lysosomes.", "spo_list": [{"subject": "zinc", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "TRPML1", "object_type": "GENE-Y"}, {"subject": "zinc", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ZnT4", "object_type": "GENE-Y"}]}
{"text": "PURPOSE: We determined the response rate to and safety of a dual 5alpha-reductase inhibitor, dutasteride, in men with castration recurrent prostate cancer.", "spo_list": [{"subject": "dutasteride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5alpha-reductase", "object_type": "GENE-N"}]}
{"text": "Characterization of the nitrosyl adduct of substrate-bound mouse cysteine dioxygenase by electron paramagnetic resonance: electronic structure of the active site and mechanistic implications.", "spo_list": [{"subject": "nitrosyl", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mouse cysteine dioxygenase", "object_type": "GENE-Y"}]}
{"text": "Mammalian cysteine dioxygenase (CDO) is a non-heme iron metalloenzyme that catalyzes the first committed step in oxidative cysteine catabolism.", "spo_list": [{"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Mammalian cysteine dioxygenase", "object_type": "GENE-Y"}, {"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CDO", "object_type": "GENE-Y"}]}
{"text": "The active site coordination of CDO comprises a mononuclear iron ligated by the Nepsilon atoms of three protein-derived histidines, thus representing a new variant on the 2-histidine-1-carboxylate (2H1C) facial triad motif.", "spo_list": [{"subject": "histidines", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "CDO", "object_type": "GENE-Y"}, {"subject": "iron", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CDO", "object_type": "GENE-Y"}]}
{"text": "In these experiments, CDO exhibits an ordered binding of l-cysteine prior to NO (and presumably O2) similar to that observed for the 2H1C class of non-heme iron enzymes.", "spo_list": [{"subject": "l-cysteine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CDO", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CDO", "object_type": "GENE-Y"}, {"subject": "O2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CDO", "object_type": "GENE-Y"}, {"subject": "l-cysteine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "2H1C class of non-heme iron enzymes", "object_type": "GENE-N"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "2H1C class of non-heme iron enzymes", "object_type": "GENE-N"}, {"subject": "O2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "2H1C class of non-heme iron enzymes", "object_type": "GENE-N"}]}
{"text": "Moreover, the CDO active site is essentially unreactive toward NO in the absence of substrate, suggesting an obligate ordered binding of l-cysteine prior to NO. Typically, addition of NO to a mononuclear non-heme iron center results in the formation of an {FeNO}7 (S = 3/2) species characterized by an axial EPR spectrum with gx, gy, and gz values of approximately 4, approximately 4, and approximately 2, respectively.", "spo_list": [{"subject": "l-cysteine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CDO", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CDO", "object_type": "GENE-Y"}]}
{"text": "However, upon addition of NO to CDO in the presence of substrate l-cysteine, a low-spin {FeNO}7 (S = 1/2) signal that accounts for approximately 85% of the iron within the enzyme develops.", "spo_list": [{"subject": "l-cysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CDO", "object_type": "GENE-Y"}]}
{"text": "The unusual {FeNO}7 (S = 1/2) electronic configuration adopted by the substrate-bound iron-nitrosyl CDO (termed {ES-NO}7) is a result of the bidentate thiol/amine coordination of l-cysteine in the NO-bound CDO active site.", "spo_list": [{"subject": "NO", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CDO", "object_type": "GENE-Y"}]}
{"text": "RESULTS: Pretreatment of ucOC (30ng/ml) prevented LA-induced apoptosis in insulin-stimulated endothelial cells; effects were abolished by pretreatment with the phosphatidylinositol 3-kinase (PI3-kinase) inhibitor, wortmannin.", "spo_list": [{"subject": "wortmannin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphatidylinositol 3-kinase", "object_type": "GENE-N"}, {"subject": "wortmannin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PI3-kinase", "object_type": "GENE-N"}]}
{"text": "It is well known that chronic administration of pergolide and other dopamine agonists may induce a downregulation of dopamine D2 receptors in the rat model of Parkinson's disease (PD).", "spo_list": [{"subject": "pergolide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dopamine D2 receptors", "object_type": "GENE-Y"}]}
{"text": "This reduction appears to be related to downregulation of the receptor, although competitive binding of pergolide at the D2 receptor cannot be excluded.", "spo_list": [{"subject": "pergolide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "D2 receptor", "object_type": "GENE-Y"}]}
{"text": "Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain.", "spo_list": [{"subject": "kynurenate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "aspartate aminotransferase", "object_type": "GENE-Y"}]}
{"text": "The tryptophan metabolite kynurenic acid (KYNA), which is produced enzymatically by the irreversible transamination of l-kynurenine, is an antagonist of alpha7 nicotinic and NMDA receptors and may thus modulate cholinergic and glutamatergic neurotransmission.", "spo_list": [{"subject": "kynurenic acid", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha7 nicotinic and NMDA receptors", "object_type": "GENE-N"}, {"subject": "KYNA", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha7 nicotinic and NMDA receptors", "object_type": "GENE-N"}]}
{"text": "Two kynurenine aminotransferases (KAT I and II) are currently considered the major biosynthetic enzymes of KYNA in the brain.", "spo_list": [{"subject": "KYNA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "kynurenine aminotransferases", "object_type": "GENE-N"}]}
{"text": "The novel KAT had a pH optimum of 8.0 and a low capacity to transaminate glutamine or alpha-aminoadipate (the classic substrates of KAT I and KAT II, respectively).", "spo_list": [{"subject": "glutamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "KAT", "object_type": "GENE-N"}, {"subject": "alpha-aminoadipate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "KAT", "object_type": "GENE-N"}, {"subject": "glutamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "KAT I", "object_type": "GENE-Y"}, {"subject": "alpha-aminoadipate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "KAT I", "object_type": "GENE-Y"}, {"subject": "glutamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "KAT II", "object_type": "GENE-Y"}, {"subject": "alpha-aminoadipate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "KAT II", "object_type": "GENE-Y"}]}
{"text": "Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) and cyclooxygenase inhibitor that is frequently used as a research tool to study the process of adipocyte differentiation.", "spo_list": [{"subject": "Indomethacin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase", "object_type": "GENE-N"}]}
{"text": "In this report, we show that indomethacin binds and activates peroxisome proliferator-activated receptor gamma (PPARgamma), a ligand-activated transcription factor known to play a pivotal role in adipogenesis.", "spo_list": [{"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "peroxisome proliferator-activated receptor gamma", "object_type": "GENE-Y"}, {"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PPARgamma", "object_type": "GENE-Y"}, {"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "peroxisome proliferator-activated receptor gamma", "object_type": "GENE-Y"}, {"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PPARgamma", "object_type": "GENE-Y"}]}
{"text": "The concentration of indomethacin required to activate PPARgamma is in good agreement with that required to induce the differentiation of C3H10T1/2 cells to adipocytes.", "spo_list": [{"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PPARgamma", "object_type": "GENE-Y"}]}
{"text": "We demonstrate that several other NSAIDs, including fenoprofen, ibuprofen, and flufenamic acid, are also PPARgamma ligands and induce adipocyte differentiation of C3H10T1/2 cells.", "spo_list": [{"subject": "fenoprofen", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PPARgamma", "object_type": "GENE-Y"}, {"subject": "ibuprofen", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PPARgamma", "object_type": "GENE-Y"}, {"subject": "flufenamic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PPARgamma", "object_type": "GENE-Y"}]}
{"text": "To begin to examine whether these changes are mediated by alterations in gene expression for tryptophan hydroxylase (TPH), the rate-limiting enzyme in 5-HT biosynthesis, we quantitated its mRNA levels by competitive reverse transcription-polymerase chain reaction (RT-PCR).", "spo_list": [{"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "tryptophan hydroxylase", "object_type": "GENE-Y"}, {"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "TPH", "object_type": "GENE-Y"}]}
{"text": "In contrast, there was little change in mRNA levels for GTP cyclohydrolase I (GTPCH), the rate limiting enzyme in synthesis of the tetrahydrobiopterin (BH4), the obligate cofactor for TPH.", "spo_list": [{"subject": "tetrahydrobiopterin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "GTP cyclohydrolase I", "object_type": "GENE-Y"}, {"subject": "tetrahydrobiopterin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "GTPCH", "object_type": "GENE-Y"}, {"subject": "BH4", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "GTP cyclohydrolase I", "object_type": "GENE-Y"}, {"subject": "BH4", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "GTPCH", "object_type": "GENE-Y"}]}
{"text": "However, other steroids, including Î(5)-androstenediol, 5Î±-androstanediol and 27-hydroxycholesterol, which have a saturated A ring containing a 3Î²-hydroxyl and a C19 methyl group, also mediate physiological responses through binding to estrogen receptor-Î± (ERÎ±) and ERÎ².", "spo_list": [{"subject": "steroids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor-Î±", "object_type": "GENE-Y"}, {"subject": "steroids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "steroids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERÎ²", "object_type": "GENE-Y"}, {"subject": "Î(5)-androstenediol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor-Î±", "object_type": "GENE-Y"}, {"subject": "Î(5)-androstenediol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "Î(5)-androstenediol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERÎ²", "object_type": "GENE-Y"}, {"subject": "5Î±-androstanediol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor-Î±", "object_type": "GENE-Y"}, {"subject": "5Î±-androstanediol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "5Î±-androstanediol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERÎ²", "object_type": "GENE-Y"}, {"subject": "27-hydroxycholesterol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor-Î±", "object_type": "GENE-Y"}, {"subject": "27-hydroxycholesterol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "27-hydroxycholesterol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERÎ²", "object_type": "GENE-Y"}, {"subject": "3Î²-hydroxyl", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor-Î±", "object_type": "GENE-Y"}, {"subject": "3Î²-hydroxyl", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "3Î²-hydroxyl", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERÎ²", "object_type": "GENE-Y"}, {"subject": "methyl", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "estrogen receptor-Î±", "object_type": "GENE-Y"}, {"subject": "methyl", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERÎ±", "object_type": "GENE-Y"}, {"subject": "methyl", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERÎ²", "object_type": "GENE-Y"}]}
{"text": "Flavin adenine dinucleotide (FAD) is an essential coenzyme for glutathione reductase (GR) which catalyzes the reduction of oxidized glutathione to regenerate the reduced form involved in protection against oxidative stress.", "spo_list": [{"subject": "glutathione", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "glutathione reductase", "object_type": "GENE-Y"}, {"subject": "glutathione", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GR", "object_type": "GENE-Y"}]}
{"text": "Riboflavin kinase (RFK) also known as flavokinase is involved in the first step of bioactivation of riboflavin (RF) to form flavin mononucleotide (FMN) which can be subsequently converted to FAD in an ATP-dependent reaction catalyzed by FAD synthetase (FADS).", "spo_list": [{"subject": "riboflavin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Riboflavin kinase", "object_type": "GENE-Y"}, {"subject": "riboflavin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "RFK", "object_type": "GENE-Y"}, {"subject": "RF", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Riboflavin kinase", "object_type": "GENE-Y"}, {"subject": "RF", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "RFK", "object_type": "GENE-Y"}, {"subject": "flavin mononucleotide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Riboflavin kinase", "object_type": "GENE-Y"}, {"subject": "flavin mononucleotide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "RFK", "object_type": "GENE-Y"}, {"subject": "FMN", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Riboflavin kinase", "object_type": "GENE-Y"}, {"subject": "FMN", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "RFK", "object_type": "GENE-Y"}, {"subject": "riboflavin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "flavokinase", "object_type": "GENE-Y"}, {"subject": "RF", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "flavokinase", "object_type": "GENE-Y"}, {"subject": "flavin mononucleotide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "flavokinase", "object_type": "GENE-Y"}, {"subject": "FMN", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "flavokinase", "object_type": "GENE-Y"}, {"subject": "flavin mononucleotide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FAD synthetase", "object_type": "GENE-Y"}, {"subject": "FMN", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FAD synthetase", "object_type": "GENE-Y"}, {"subject": "flavin mononucleotide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FADS", "object_type": "GENE-Y"}, {"subject": "FMN", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FADS", "object_type": "GENE-Y"}, {"subject": "FAD", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "FAD synthetase", "object_type": "GENE-Y"}, {"subject": "FAD", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "FADS", "object_type": "GENE-Y"}]}
{"text": "We demonstrated that overexpression of RFK increased the levels of FAD, FMN and total glutathione and the expression of GR and glutathione S-transferase-pi (GSTpi).", "spo_list": [{"subject": "FAD", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "RFK", "object_type": "GENE-Y"}, {"subject": "FMN", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "RFK", "object_type": "GENE-Y"}]}
{"text": "Methimazole and propylthiouracil increase cellular thyroid peroxidase activity and thyroid peroxidase mRNA in cultured porcine thyroid follicles.", "spo_list": [{"subject": "Methimazole", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "thyroid peroxidase", "object_type": "GENE-Y"}, {"subject": "propylthiouracil", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "thyroid peroxidase", "object_type": "GENE-Y"}, {"subject": "Methimazole", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "thyroid peroxidase", "object_type": "GENE-Y"}, {"subject": "propylthiouracil", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "thyroid peroxidase", "object_type": "GENE-Y"}]}
{"text": "Methimazole (MMI) and propylthiouracil (PTU) are common antithyroid drugs for treating hyperthyroidism because the 2 drugs inhibit thyroid peroxidase (TPO)-catalyzed thyroid hormone formation.", "spo_list": [{"subject": "Methimazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thyroid peroxidase", "object_type": "GENE-Y"}, {"subject": "MMI", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thyroid peroxidase", "object_type": "GENE-Y"}, {"subject": "propylthiouracil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thyroid peroxidase", "object_type": "GENE-Y"}, {"subject": "PTU", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thyroid peroxidase", "object_type": "GENE-Y"}, {"subject": "Methimazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TPO", "object_type": "GENE-Y"}, {"subject": "MMI", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TPO", "object_type": "GENE-Y"}, {"subject": "propylthiouracil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TPO", "object_type": "GENE-Y"}, {"subject": "PTU", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TPO", "object_type": "GENE-Y"}]}
{"text": "Exposure to MMI (1 microM and 10 microM) or PTU (10 microM and 100 microM) for 2 days caused a significant increase in cellular TPO activity; 100 microM MMI inhibited cellular TPO activity.", "spo_list": [{"subject": "MMI", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TPO", "object_type": "GENE-Y"}, {"subject": "PTU", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TPO", "object_type": "GENE-Y"}, {"subject": "MMI", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TPO", "object_type": "GENE-Y"}]}
{"text": "The presence of cyclic adenosine monophosphate (cAMP)-generating system (forskolin) in TSH-free medium increased MMI-mediated TPO activity.", "spo_list": [{"subject": "MMI", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TPO", "object_type": "GENE-Y"}, {"subject": "forskolin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TPO", "object_type": "GENE-Y"}]}
{"text": "Cyclohexamide inhibited MMI-mediated TPO activation, indicating that new protein synthesis is required for increased TPO activity.", "spo_list": [{"subject": "MMI", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TPO", "object_type": "GENE-Y"}, {"subject": "Cyclohexamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TPO", "object_type": "GENE-Y"}]}
{"text": "Reverse transcriptase-polymerase chain reaction (RT-PCR) showed an increase in TPO mRNA by PTU or MMI.", "spo_list": [{"subject": "PTU", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TPO", "object_type": "GENE-Y"}, {"subject": "MMI", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TPO", "object_type": "GENE-Y"}]}
{"text": "In conclusion, MMI and PTU at therapeutic concentrations can increase TPO mRNA and cellular TPO activity, although the 2 drugs inhibit the TPO-H2O2-mediated catalytic reaction.", "spo_list": [{"subject": "PTU", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TPO", "object_type": "GENE-Y"}, {"subject": "MMI", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TPO", "object_type": "GENE-Y"}, {"subject": "MMI", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TPO", "object_type": "GENE-Y"}, {"subject": "PTU", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TPO", "object_type": "GENE-Y"}, {"subject": "MMI", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TPO", "object_type": "GENE-Y"}, {"subject": "PTU", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TPO", "object_type": "GENE-Y"}]}
{"text": "Histamine H1-receptor antagonists, promethazine and homochlorcyclizine, increase the steady-state plasma concentrations of haloperidol and reduced haloperidol.", "spo_list": [{"subject": "promethazine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "Histamine H1-receptor", "object_type": "GENE-Y"}, {"subject": "homochlorcyclizine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "Histamine H1-receptor", "object_type": "GENE-Y"}]}
{"text": "The effects of histamine H1-receptor antagonists, promethazine and homochlorcyclizine, both of which are inhibitors of CYP2D6, on the steady-state plasma concentrations (Css) of haloperidol and reduced haloperidol were studied in 23 schizophrenic inpatients receiving haloperidol, 12 to 36 mg/d, for 2 to 29 weeks.", "spo_list": [{"subject": "promethazine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}, {"subject": "homochlorcyclizine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1-receptor", "object_type": "GENE-Y"}, {"subject": "promethazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2D6", "object_type": "GENE-Y"}, {"subject": "homochlorcyclizine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2D6", "object_type": "GENE-Y"}]}
{"text": "Thus, the current study suggests that coadministration of clinical doses of promethazine and homochlorcyclizine increases the Css of haloperidol and reduced haloperidol via the inhibitory effects on the CYP2D6-catalyzed metabolism of haloperidol and reduced haloperidol.", "spo_list": [{"subject": "homochlorcyclizine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2D6", "object_type": "GENE-Y"}, {"subject": "promethazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2D6", "object_type": "GENE-Y"}, {"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2D6", "object_type": "GENE-Y"}, {"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2D6", "object_type": "GENE-Y"}]}
{"text": "We found that 6-OHDA initiates cell damage via mitochondrial complex I inhibition, cytochrome c and apoptosis-inducing factor (AIF) release, as well as activation of caspases 9 and 3 to induce apoptosis, kinase signaling modulation and NF-ÎºB-mediated inflammatory responses, accompanied by inhibition of antioxidant systems regulated by the Nrf2 pathway.", "spo_list": [{"subject": "6-OHDA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mitochondrial complex I", "object_type": "GENE-N"}, {"subject": "6-OHDA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytochrome c", "object_type": "GENE-Y"}, {"subject": "6-OHDA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "apoptosis-inducing factor", "object_type": "GENE-N"}, {"subject": "6-OHDA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AIF", "object_type": "GENE-N"}]}
{"text": "Our results suggest that kinases SAP/JNK and p38 up-regulation may play a role in the early stages of 6-OHDA toxicity to trigger intrinsic pathways for apoptosis and enhanced NF-ÎºB activation.", "spo_list": [{"subject": "6-OHDA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}]}
{"text": "Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus.", "spo_list": [{"subject": "AZD1656", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "glucokinase", "object_type": "GENE-Y"}]}
{"text": "AIM: To assess the glucose-lowering effects of monotherapy with the glucokinase activator AZD1656 in Japanese patients with type 2 diabetes mellitus.", "spo_list": [{"subject": "AZD1656", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "glucokinase", "object_type": "GENE-Y"}]}
{"text": "RESULTS: HbA1c was reduced numerically from baseline by 0.3-0.8% with AZD1656 and by 0.1% with placebo over the first 2âmonths of treatment, after which effects of AZD1656 started to decline.", "spo_list": [{"subject": "AZD1656", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "HbA1c", "object_type": "GENE-Y"}]}
{"text": "BACKGROUND: Chronic treatment with the dual serotonin/noradrenaline reuptake inhibitor (SNRI) duloxetine reduces the density of serotonin transporter sites in cortex and engenders an anxiolytic-like response.", "spo_list": [{"subject": "duloxetine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "serotonin transporter", "object_type": "GENE-Y"}]}
{"text": "RESULTS: Duloxetine and fluoxetine both reduced SERT density in cortex and induced anxiolytic-like effects.", "spo_list": [{"subject": "fluoxetine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "Duloxetine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "SERT", "object_type": "GENE-Y"}]}
{"text": "Only duloxetine reduced NET density in cortex, although not hippocampus.", "spo_list": [{"subject": "duloxetine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NET", "object_type": "GENE-Y"}]}
{"text": "CONCLUSIONS: The reduction in SERT density and anxiolytic-like effects with duloxetine, fluoxetine and, potentially, paroxetine suggest that down-regulation of the SERT may be a relevant mechanism in therapeutic response to these antidepressants.", "spo_list": [{"subject": "duloxetine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "fluoxetine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "paroxetine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "SERT", "object_type": "GENE-Y"}]}
{"text": "Lubiprostone [RU 0211, SPI 0211] is a bicyclic fatty acid that acts as a chloride channel opener, increasing intestinal water secretion.", "spo_list": [{"subject": "Lubiprostone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "chloride channel", "object_type": "GENE-N"}, {"subject": "RU 0211", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "chloride channel", "object_type": "GENE-N"}, {"subject": "SPI 0211", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "chloride channel", "object_type": "GENE-N"}, {"subject": "bicyclic fatty acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "chloride channel", "object_type": "GENE-N"}]}
{"text": "Lubiprostone activates a specific chloride channel (CLC2) on cells lining the gut, thereby naturally increasing intestinal fluid secretion.", "spo_list": [{"subject": "Lubiprostone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "chloride channel", "object_type": "GENE-N"}, {"subject": "Lubiprostone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CLC2", "object_type": "GENE-Y"}]}
{"text": "The chloride channel is a protein that controls cell membrane transport of chloride ion.", "spo_list": [{"subject": "chloride", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "chloride channel", "object_type": "GENE-N"}]}
{"text": "The three-step approach of CliEn-seq involves in vivo synthesis of S-adenosyl-L-methionine (SAM) analogues from cell-permeable methionine analogues by engineered SAM synthetase (methionine adenosyltransferase or MAT), in situ chromatin modification by engineered PMTs, subsequent enrichment and sequencing of the uniquely modified chromatins.", "spo_list": [{"subject": "S-adenosyl-L-methionine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "SAM synthetase", "object_type": "GENE-N"}, {"subject": "SAM", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "SAM synthetase", "object_type": "GENE-N"}, {"subject": "S-adenosyl-L-methionine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "methionine adenosyltransferase", "object_type": "GENE-N"}, {"subject": "SAM", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "methionine adenosyltransferase", "object_type": "GENE-N"}, {"subject": "S-adenosyl-L-methionine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "MAT", "object_type": "GENE-N"}, {"subject": "SAM", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "MAT", "object_type": "GENE-N"}]}
{"text": "Flibanserin has preferential affinity for serotonin 5-HT(1A), dopamine D(4k), and serotonin 5-HT(2A) receptors.", "spo_list": [{"subject": "Flibanserin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT(1A)", "object_type": "GENE-Y"}, {"subject": "Flibanserin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "dopamine D(4k)", "object_type": "GENE-Y"}, {"subject": "Flibanserin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT(2A)", "object_type": "GENE-Y"}]}
{"text": "In vitro and in microiontophoresis, flibanserin behaves as a 5-HT(1A) agonist, a very weak partial agonist on dopamine D(4) receptors, and a 5-HT(2A) antagonist.", "spo_list": [{"subject": "flibanserin", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT(1A)", "object_type": "GENE-Y"}, {"subject": "flibanserin", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "dopamine D(4) receptors", "object_type": "GENE-Y"}, {"subject": "flibanserin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT(2A)", "object_type": "GENE-Y"}]}
{"text": "In vivo flibanserin binds equally to 5-HT(1A) and 5-HT(2A) receptors.", "spo_list": [{"subject": "flibanserin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT(1A)", "object_type": "GENE-Y"}, {"subject": "flibanserin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT(2A)", "object_type": "GENE-Y"}]}
{"text": "However, under higher levels of brain 5-HT (i.e., under stress), flibanserin may occupy 5-HT(2A) receptors in higher proportion than 5-HT(1A) receptors.", "spo_list": [{"subject": "flibanserin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT(2A)", "object_type": "GENE-Y"}]}
{"text": "The effects of flibanserin on adenylyl cyclase are different from those of buspirone and 8-OH-DPAT, two other purported 5-HT(1A) receptor agonists.", "spo_list": [{"subject": "buspirone", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT(1A)", "object_type": "GENE-Y"}, {"subject": "8-OH-DPAT", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT(1A)", "object_type": "GENE-Y"}]}
{"text": "Flibanserin-induced reduction in firing rate in the cortex seems to be mediated through stimulation of postsynaptic 5-HT(1A) receptors, whereas the reduction of the number of active cells seems to be mediated through dopamine D(4) receptor stimulation.", "spo_list": [{"subject": "Flibanserin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "5-HT(1A)", "object_type": "GENE-Y"}, {"subject": "Flibanserin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "dopamine D(4) receptor", "object_type": "GENE-Y"}]}
{"text": "Flibanserin quickly desensitizes somatic 5-HT autoreceptors in the dorsal raphe and enhances tonic activation of postsynaptic 5-HT(1A) receptors in the CA3 region.", "spo_list": [{"subject": "Flibanserin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "5-HT(1A)", "object_type": "GENE-Y"}]}
{"text": "Flibanserin seems to act via direct or indirect stimulation of 5-HT(1A), DA, and opioid receptors in those animal models.", "spo_list": [{"subject": "Flibanserin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "5-HT(1A)", "object_type": "GENE-Y"}, {"subject": "Flibanserin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "5-HT(1A)", "object_type": "GENE-Y"}]}
{"text": "Cycloheximide stimulates suppressor of cytokine signaling-3 gene expression in 3T3-L1 adipocytes via the extracellular signal-regulated kinase pathway.", "spo_list": [{"subject": "Cycloheximide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "suppressor of cytokine signaling-3", "object_type": "GENE-Y"}]}
{"text": "Using 3T3-L1 adipocytes, we found that cycloheximide up-regulated SOCS-3 mRNA expression in dose- and time-dependent manners.", "spo_list": [{"subject": "cycloheximide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SOCS-3", "object_type": "GENE-Y"}]}
{"text": "Treatment with actinomycin D prevented cycloheximide-stimulated SOCS-3 mRNA expression, suggesting that the effect of cycloheximide requires new mRNA synthesis.", "spo_list": [{"subject": "cycloheximide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SOCS-3", "object_type": "GENE-Y"}, {"subject": "actinomycin D", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "SOCS-3", "object_type": "GENE-Y"}]}
{"text": "While cycloheximide was shown to increase activities of MEK1 and JNK, signaling was demonstrated to be inhibited by pretreatment with either MEK1 inhibitors U0126 and PD98059, or with the JNK inhibitor SP600125.", "spo_list": [{"subject": "cycloheximide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MEK1", "object_type": "GENE-Y"}, {"subject": "cycloheximide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "JNK", "object_type": "GENE-N"}, {"subject": "U0126", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MEK1", "object_type": "GENE-Y"}, {"subject": "PD98059", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MEK1", "object_type": "GENE-Y"}, {"subject": "SP600125", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JNK", "object_type": "GENE-N"}]}
{"text": "U0126 and PD98059, respectively, reduced cycloheximide-stimulated SOCS-3 mRNA expression, but SP600125 did not antagonize cycloheximide effect.", "spo_list": [{"subject": "cycloheximide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SOCS-3", "object_type": "GENE-Y"}, {"subject": "U0126", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "SOCS-3", "object_type": "GENE-Y"}, {"subject": "PD98059", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "SOCS-3", "object_type": "GENE-Y"}]}
{"text": "Moreover, cycloheximide was observed to up-regulate expression of other SOCS family members, such as SOCS-1, -2, -4, -5, -6, -7, and cytokine-inducible SH2-containing protein (CIS)-1 mRNAs.", "spo_list": [{"subject": "cycloheximide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SOCS", "object_type": "GENE-N"}, {"subject": "cycloheximide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytokine-inducible SH2-containing protein (CIS)-1", "object_type": "GENE-Y"}]}
{"text": "These results imply the functional MEK1/ERK-mediated pathway is necessary for the cycloheximide stimulation of SOCS-3 gene expression.", "spo_list": [{"subject": "cycloheximide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SOCS-3", "object_type": "GENE-Y"}]}
{"text": "Comparison of monoamine oxidase-A inhibition by moclobemide in vitro and ex vivo in rats.", "spo_list": [{"subject": "moclobemide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase-A", "object_type": "GENE-Y"}]}
{"text": "Inhibition of MAO activity was measured in rat brain homogenates using 5-HT as MAO-A substrate and phenylethylamine as MAO-B substrate.", "spo_list": [{"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "phenylethylamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "Moclobemide rather selectively inhibited MAO-A.", "spo_list": [{"subject": "Moclobemide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}]}
{"text": "Phenelzine, isocarboxazid and tranylcypromine were nonspecific, inhibiting MAO-A and MAO-B to about the same extent.", "spo_list": [{"subject": "Phenelzine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "isocarboxazid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "tranylcypromine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "Phenelzine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "isocarboxazid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "tranylcypromine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "Here again moclobemide preferentially inhibited MAO-A; it was equipotent to clorgyline and brofaromine in these tests, and 2-4 times as potent as cimoxatone and harmaline.", "spo_list": [{"subject": "moclobemide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "clorgyline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "brofaromine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "cimoxatone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "harmaline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}]}
{"text": "Moclobemide is a relatively weak MAO-A inhibitor in vitro and yet more potent in vivo than other reversible inhibitors, suggesting that the compound may be converted in vivo to an active form.", "spo_list": [{"subject": "Moclobemide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}]}
{"text": "Nevertheless, it has not been possible so far to identify activated derivatives, and recent findings that moclobemide markedly inhibits liver MAO-A within 5 min of an intravenous injection strongly suggests that the compound itself is responsible for the inhibition.", "spo_list": [{"subject": "moclobemide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}]}
{"text": "Combination treatment with the selective 5-HT1A antagonist WAY100635 produced a dose-dependent augmentation of venlafaxine-induced (3-30 mg/kg s.c) extracellular 5-HT concentrations, but had no further effect on NA above that produced by venlafaxine alone.", "spo_list": [{"subject": "WAY100635", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT1A", "object_type": "GENE-Y"}]}
{"text": "The beta-adrenergic/5-HT1A receptor antagonist (+/-)pindolol and the selective 5-HT1B/D antagonist GR127935 produced no significant augmentation of venlafaxine-induced changes in either 5-HT or NA.", "spo_list": [{"subject": "(+/-)pindolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT1A", "object_type": "GENE-Y"}]}
{"text": "Moderate inhibitory effect of LDL-C oxidation by phytosteryl phenolates was observed.", "spo_list": [{"subject": "phytosteryl phenolates", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "LDL", "object_type": "GENE-N"}]}
{"text": "MAO Inhibitory Activity of 2-Arylbenzofurans versus 3-Arylcoumarins: Synthesis, inâvitro Study, and Docking Calculations.", "spo_list": [{"subject": "2-Arylbenzofurans", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO", "object_type": "GENE-N"}, {"subject": "3-Arylcoumarins", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO", "object_type": "GENE-N"}]}
{"text": "Several 3-arylcoumarin derivatives were previously described as interesting selective MAO-B inhibitors.", "spo_list": [{"subject": "3-arylcoumarin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "5-Nitro-2-(4-methoxyphenyl)benzofuran (8) is the most active compound of the benzofuran series, presenting MAO-B selectivity and reversible inhibition (IC50 =140ânM).", "spo_list": [{"subject": "5-Nitro-2-(4-methoxyphenyl)benzofuran", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "benzofuran", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "3-(4'-Methoxyphenyl)-6-nitrocoumarin (15), with the same substitution pattern as that of compound 8, was found to be the most active MAO-B inhibitor of the coumarin series (IC50 =3ânM).", "spo_list": [{"subject": "3-(4'-Methoxyphenyl)-6-nitrocoumarin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "coumarin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "Docking experiments for the most active compounds into the MAO-B and MAO-A binding pockets highlighted different interactions between the derivative classes (2-arylbenzofurans and 3-arylcoumarins), and provided new information about the enzyme-inhibitor interaction and the potential therapeutic application of these scaffolds.", "spo_list": [{"subject": "2-arylbenzofurans", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "3-arylcoumarins", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "2-arylbenzofurans", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "3-arylcoumarins", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "2-arylbenzofurans", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "2-arylbenzofurans", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "3-arylcoumarins", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "3-arylcoumarins", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}]}
{"text": "The earliest known AChE inhibitors, namely, physostigmine and tacrine, performed poorly in clinical trials (e.g., poor oral activity, brain penetration, and hepatotoxic liability).", "spo_list": [{"subject": "physostigmine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "Donepezil hydrochloride inaugurates a new class of AChE inhibitors with longer and more selective action and with manageable adverse effects.", "spo_list": [{"subject": "Donepezil hydrochloride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "Thionamides inhibit the transcription factor nuclear factor-kappaB by suppression of Rac1 and inhibitor of kappaB kinase alpha.", "spo_list": [{"subject": "Thionamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "nuclear factor-kappaB", "object_type": "GENE-N"}, {"subject": "Thionamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Rac1", "object_type": "GENE-Y"}, {"subject": "Thionamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "inhibitor of kappaB kinase alpha", "object_type": "GENE-Y"}]}
{"text": "Thionamides, inhibitors of the thyroid peroxidase-mediated iodination, are clinically used in the treatment of hyperthyroidism.", "spo_list": [{"subject": "Thionamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thyroid peroxidase", "object_type": "GENE-Y"}]}
{"text": "Using primary human T-lymphocytes, we show that the heterocyclic thionamides carbimazole and propylthiouracil inhibit synthesis of the proinflammatory cytokines tumor necrosis factor (TNF)alpha and interferon (IFN)gamma.", "spo_list": [{"subject": "heterocyclic thionamides", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cytokines", "object_type": "GENE-N"}, {"subject": "carbimazole", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cytokines", "object_type": "GENE-N"}, {"subject": "propylthiouracil", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cytokines", "object_type": "GENE-N"}, {"subject": "heterocyclic thionamides", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "tumor necrosis factor (TNF)alpha", "object_type": "GENE-Y"}, {"subject": "carbimazole", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "tumor necrosis factor (TNF)alpha", "object_type": "GENE-Y"}, {"subject": "propylthiouracil", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "tumor necrosis factor (TNF)alpha", "object_type": "GENE-Y"}, {"subject": "heterocyclic thionamides", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "interferon (IFN)gamma", "object_type": "GENE-Y"}, {"subject": "carbimazole", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "interferon (IFN)gamma", "object_type": "GENE-Y"}, {"subject": "propylthiouracil", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "interferon (IFN)gamma", "object_type": "GENE-Y"}]}
{"text": "Carbimazole inhibited NF-kappaB via the small GTPase Rac-1, whereas propylthiouracil inhibited the phosphorylation of IkappaBalpha by its kinase inhibitor of kappaB kinase alpha.", "spo_list": [{"subject": "Carbimazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}, {"subject": "Carbimazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GTPase", "object_type": "GENE-N"}, {"subject": "Carbimazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Rac-1", "object_type": "GENE-Y"}, {"subject": "propylthiouracil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IkappaBalpha", "object_type": "GENE-Y"}, {"subject": "propylthiouracil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "propylthiouracil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "inhibitor of kappaB kinase alpha", "object_type": "GENE-Y"}]}
{"text": "Taken together, our data demonstrate that thioureylenes with a common, heterocyclic structure inhibit inflammation and immune function via the NF-kappaB pathway.", "spo_list": [{"subject": "heterocyclic", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}, {"subject": "thioureylenes", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}]}
{"text": "The response to the 5-HT1a agonist, 8-OHDPAT (0.003-0.5Â mg/kg, SC), was assessed using lower lip retraction (LLR), hypoactivity, and 5-hydroxytryptophan (5-HTP) accumulation following decarboxylase inhibition.", "spo_list": [{"subject": "8-OHDPAT", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT1a", "object_type": "GENE-Y"}, {"subject": "5-hydroxytryptophan", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "decarboxylase", "object_type": "GENE-N"}, {"subject": "5-HTP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "decarboxylase", "object_type": "GENE-N"}]}
{"text": "The data suggest that the decrease in tissue levels of 5-HT produced by MDMA is accompanied by a decrease in tryptophan hydroxylase activity but cannot be explained by supersensitivity of the 5-HT1a autoreceptor.", "spo_list": [{"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tryptophan hydroxylase", "object_type": "GENE-N"}]}
{"text": "Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors.", "spo_list": [{"subject": "4-phenyl-2-phenylaminopyridine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TNIK", "object_type": "GENE-Y"}]}
{"text": "A series of compounds based on a 4-phenyl-2-phenylaminopyridine scaffold that are potent and selective inhibitors of Traf2- and Nck-interacting kinase (TNIK) activity are described.", "spo_list": [{"subject": "4-phenyl-2-phenylaminopyridine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Traf2- and Nck-interacting kinase", "object_type": "GENE-Y"}, {"subject": "4-phenyl-2-phenylaminopyridine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TNIK", "object_type": "GENE-Y"}]}
{"text": "Transport of gemifloxacin, a 4th generation quinolone antibiotic, in the Caco-2 and engineered MDCKII cells, and potential involvement of efflux transporters in the intestinal absorption of the drug.", "spo_list": [{"subject": "gemifloxacin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "efflux transporters", "object_type": "GENE-N"}, {"subject": "quinolone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "efflux transporters", "object_type": "GENE-N"}]}
{"text": "The secretory transport in Caco-2 cells was significantly decreased by MRP2 (MK571) and BCRP (Ko143) inhibitors.", "spo_list": [{"subject": "MK571", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MRP2", "object_type": "GENE-Y"}, {"subject": "Ko143", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BCRP", "object_type": "GENE-Y"}]}
{"text": "Efflux transporters appeared to significantly limit the bioavailability of gemifloxacin in rats, suggesting their possible contribution to the low bioavailability of the drug in the human (70%).", "spo_list": [{"subject": "gemifloxacin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Efflux transporters", "object_type": "GENE-N"}]}
{"text": "Saturation experiments showed that [3H]prazosin labelled a single population of binding sites in the spleen (alpha 1B) and hippocampus (alpha 1A and alpha 1B) (dissociation constants (KD): 0.26 nM and 0.14 nM respectively).", "spo_list": [{"subject": "[3H]prazosin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 1B", "object_type": "GENE-Y"}, {"subject": "[3H]prazosin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 1A", "object_type": "GENE-Y"}, {"subject": "[3H]prazosin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 1B", "object_type": "GENE-Y"}]}
{"text": "Interphotoreceptor retinoid-binding protein (IRBP) is a component of the interphotoreceptor matrix (IPM) and is known to bind visual cycle retinoids.", "spo_list": [{"subject": "retinoids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Interphotoreceptor retinoid-binding protein", "object_type": "GENE-Y"}, {"subject": "retinoids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "IRBP", "object_type": "GENE-Y"}]}
{"text": "Serum albumin and serum retinol-binding protein (sRBP), proteins capable of binding retinoids, have also been reported to be components of the IPM.", "spo_list": [{"subject": "retinoids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Serum albumin", "object_type": "GENE-Y"}, {"subject": "retinoids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "serum retinol-binding protein", "object_type": "GENE-Y"}, {"subject": "retinoids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "sRBP", "object_type": "GENE-Y"}]}
{"text": "No immunopositive bands were observed in bovine neural retinal when probed with the anti-sRBP antibody; however, a single immunoreactive band at about 67 and about 133 kDa was detected in bovine neural retina by the anti-BSA and IRBP antibodies, respectively.", "spo_list": [{"subject": "retinal", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "sRBP", "object_type": "GENE-Y"}]}
{"text": "IRBP, on the other hand, is localized to the IPM where it is available for the binding and transport of visual cycle retinoids.", "spo_list": [{"subject": "cycle retinoids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "IRBP", "object_type": "GENE-Y"}, {"subject": "cycle retinoids", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "IRBP", "object_type": "GENE-Y"}]}
{"text": "Progression in the field has taken a recent step forward with the approval of ruxolitinib (Jakafi), a selective inhibitor of JAK1/2 and very recently tofacitinib (Xeljanz), a pan-JAK inhibitor.", "spo_list": [{"subject": "tofacitinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JAK", "object_type": "GENE-N"}, {"subject": "Xeljanz", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JAK", "object_type": "GENE-N"}]}
{"text": "EXPERT OPINION: JAK inhibitor therapy is entering a significant new era with the advent on the market of the JAK1/2 inhibitor ruxolitinib and the pan-JAK inhibitor tofacitinib, with unprecedented speed of development.", "spo_list": [{"subject": "tofacitinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JAK", "object_type": "GENE-N"}]}
{"text": "In the last decade, several inhibitors of CK2, have been discovered and characterized to be ATP-competitive compounds.", "spo_list": [{"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CK2", "object_type": "GENE-N"}]}
{"text": "In this review, we report all chemical classes of CK2 inhibitors available in literature, focusing our attention on conventional ATP-competitive and on non ATP-competitive inhibitors, which could represent a new frontier in CK2 inhibition and, consequently, a promising field of study in discovering new drug candidates.", "spo_list": [{"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CK2", "object_type": "GENE-N"}, {"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CK2", "object_type": "GENE-N"}]}
{"text": "Identification of N-terminal receptor activity-modifying protein residues important for calcitonin gene-related peptide, adrenomedullin, and amylin receptor function.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "calcitonin gene-related peptide", "object_type": "GENE-N"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "adrenomedullin", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "amylin receptor", "object_type": "GENE-N"}]}
{"text": "Omapatrilat is a member of the new drug class of vasopeptidase inhibitors that may offer benefit in the treatment of heart failure (HF) through simultaneous inhibition of angiotensin-converting enzyme and neutral endopeptidase.", "spo_list": [{"subject": "Omapatrilat", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "vasopeptidase", "object_type": "GENE-N"}, {"subject": "Omapatrilat", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "angiotensin-converting enzyme", "object_type": "GENE-Y"}, {"subject": "Omapatrilat", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "neutral endopeptidase", "object_type": "GENE-Y"}]}
{"text": "Iontophoresis of +/- propranolol, whose serotonergic actions include antagonism and partial agonism at 5-HT1 receptors, also increased serotonin and decreased firing (n=4).", "spo_list": [{"subject": "+/- propranolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT1", "object_type": "GENE-N"}, {"subject": "+/- propranolol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT1", "object_type": "GENE-N"}]}
{"text": "Methiothepin (intravenous, 1 mg/kg), whose serotonergic actions include 5-HT1 and 5-HT2 antagonism, typically raised serotonin levels (four of five cells) and always blocked inhibition by clomipramine (n = 3).", "spo_list": [{"subject": "Methiothepin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT1", "object_type": "GENE-N"}, {"subject": "Methiothepin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT2", "object_type": "GENE-N"}]}
{"text": "To assess the feasibility of targeting these high AAAD levels for chemotherapy, AAAD inhibitors carbidopa (alpha-methyl-dopahydrazine), alpha-monofluoromethyldopa (MFMD), and 3-hydroxybenzylhydrazine (NSD-1015) were incubated (72 h) with NCI-H727 human lung carcinoid cells.", "spo_list": [{"subject": "carbidopa", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AAAD", "object_type": "GENE-Y"}, {"subject": "alpha-methyl-dopahydrazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AAAD", "object_type": "GENE-Y"}, {"subject": "alpha-monofluoromethyldopa", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AAAD", "object_type": "GENE-Y"}, {"subject": "MFMD", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AAAD", "object_type": "GENE-Y"}, {"subject": "3-hydroxybenzylhydrazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AAAD", "object_type": "GENE-Y"}, {"subject": "NSD-1015", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AAAD", "object_type": "GENE-Y"}]}
{"text": "In contrast, EGCG markedly downregulated major bile acid transporters (Asbt and OstÎ±) and regulatory molecules (Shp and Fgf15) in the ileum.", "spo_list": [{"subject": "EGCG", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Shp", "object_type": "GENE-Y"}, {"subject": "EGCG", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Fgf15", "object_type": "GENE-Y"}]}
{"text": "This study shows ability of EGCG to raise plasma bile acid concentrations, mainly through Cyp7a1 upregulation, and to decrease bile production through reduction in Mrp2-mediated bile acid-independent bile flow.", "spo_list": [{"subject": "EGCG", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Cyp7a1", "object_type": "GENE-Y"}]}
{"text": "Vitamin K2 covalently binds to Bak and induces Bak-mediated apoptosis.", "spo_list": [{"subject": "Vitamin K2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Bak", "object_type": "GENE-Y"}, {"subject": "Vitamin K2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Bak", "object_type": "GENE-Y"}]}
{"text": "VK2 directly interacts with Bak and induces mitochondrial-mediated apoptosis.", "spo_list": [{"subject": "VK2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Bak", "object_type": "GENE-Y"}]}
{"text": "Although Bak and Bcl-2-associated X protein (Bax), another member of the Bcl-2 family, are generally thought to be functionally redundant, only Bak is necessary and sufficient for VK2-induced cytochrome c (cyt c) release and cell death.", "spo_list": [{"subject": "VK2", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytochrome c", "object_type": "GENE-Y"}, {"subject": "VK2", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cyt c", "object_type": "GENE-Y"}]}
{"text": "Moreover, VK2-2,3 epoxide, an intracellular metabolite of VK2, was shown to covalently bind to the cysteine-166 residue of Bak.", "spo_list": [{"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Bak", "object_type": "GENE-Y"}, {"subject": "VK2-2,3 epoxide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Bak", "object_type": "GENE-Y"}, {"subject": "VK2", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Bak", "object_type": "GENE-Y"}]}
{"text": "Nordihydroguaiaretic acid (NDGA) has been shown to inhibit both 5-lipoxygenase and ornithine decarboxylase and is active against several cancer cell lines and at least one mouse tumor model.", "spo_list": [{"subject": "NDGA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-lipoxygenase", "object_type": "GENE-Y"}, {"subject": "Nordihydroguaiaretic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-lipoxygenase", "object_type": "GENE-Y"}, {"subject": "Nordihydroguaiaretic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ornithine decarboxylase", "object_type": "GENE-Y"}, {"subject": "NDGA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ornithine decarboxylase", "object_type": "GENE-Y"}]}
{"text": "Acarbose served as inhibitor of an interfering acid alpha-glucosidase present in neutrophils, which allowed the lysosomal enzyme implicated in Pompe disease to be selectively analyzed.", "spo_list": [{"subject": "Acarbose", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acid alpha-glucosidase", "object_type": "GENE-Y"}]}
{"text": "The fine particulate (PM < 2.5 Î¼m) of wood smoke were the most potent TRPA1 agonists and several chemical constituents of wood smoke particulate, 3,5-ditert-butylphenol, coniferaldehyde, formaldehyde, perinaphthenone, agathic acid, and isocupressic acid, were TRPA1 agonists.", "spo_list": [{"subject": "3,5-ditert-butylphenol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "TRPA1", "object_type": "GENE-Y"}, {"subject": "coniferaldehyde", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "TRPA1", "object_type": "GENE-Y"}, {"subject": "formaldehyde", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "TRPA1", "object_type": "GENE-Y"}, {"subject": "perinaphthenone", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "TRPA1", "object_type": "GENE-Y"}, {"subject": "agathic acid", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "TRPA1", "object_type": "GENE-Y"}, {"subject": "isocupressic acid", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "TRPA1", "object_type": "GENE-Y"}]}
{"text": "Pine particulate activated TRPA1 in mouse trigeminal neurons and A549 cells in a concentration-dependent manner, which was inhibited by the TRPA1 antagonist HC-030031.", "spo_list": [{"subject": "HC-030031", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "TRPA1", "object_type": "GENE-N"}]}
{"text": "TRPA1 activation by wood smoke particles occurred through the electrophile/oxidant-sensing domain (i.e., C621/C641/C665/K710), based on the inhibition of cellular responses when the particles were pretreated with glutathione; a role for the menthol-binding site of TRPA1 (S873/T874) was demonstrated for 3,5-ditert-butylphenol.", "spo_list": [{"subject": "menthol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "TRPA1", "object_type": "GENE-Y"}]}
{"text": "The cortisol response to 5-HTP was significantly increased following clomipramine treatment, suggesting that clomipramine, like selective serotonin re-uptake inhibitors (SSRIs), enhances this 5-HT2 receptor mediated response.", "spo_list": [{"subject": "clomipramine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "5-HT2 receptor", "object_type": "GENE-N"}]}
{"text": "As thiamine metabolism deficiencies have been seen in placental infarcts previously, these indicate that PP20/hTPK may have a role in placental diseases.", "spo_list": [{"subject": "thiamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PP20", "object_type": "GENE-Y"}, {"subject": "thiamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hTPK", "object_type": "GENE-Y"}]}
{"text": "We have named this activity 11 beta HSD2 to distinguish it from the NADP-dependent 11 beta HSD.", "spo_list": [{"subject": "NADP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "11 beta HSD", "object_type": "GENE-Y"}]}
{"text": "Crystal structure of nitric oxide synthase bound to nitro indazole reveals a novel inactivation mechanism.", "spo_list": [{"subject": "nitro indazole", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "nitric oxide synthase", "object_type": "GENE-N"}]}
{"text": "Nitric oxide is generated under normal and pathophysiological conditions by three distinct isoforms of nitric oxide synthase (NOS).", "spo_list": [{"subject": "Nitric oxide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "nitric oxide synthase", "object_type": "GENE-N"}, {"subject": "Nitric oxide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "NOS", "object_type": "GENE-N"}]}
{"text": "A small-molecule inhibitor of NOS (3-Br-7-nitroindazole, 7-NIBr) is profoundly neuroprotective in mouse models of stroke and Parkinson's disease.", "spo_list": [{"subject": "3-Br-7-nitroindazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NOS", "object_type": "GENE-N"}, {"subject": "7-NIBr", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NOS", "object_type": "GENE-N"}]}
{"text": "We report the crystal structure of the catalytic heme domain of endothelial NOS complexed with 7-NIBr at 1.65 A resolution.", "spo_list": [{"subject": "7-NIBr", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "catalytic heme domain", "object_type": "GENE-N"}, {"subject": "7-NIBr", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "endothelial NOS", "object_type": "GENE-Y"}]}
{"text": "Critical to the binding of 7-NIBr at the substrate site is the adoption by eNOS of an altered conformation, in which a key glutamate residue swings out toward one of the heme propionate groups.", "spo_list": [{"subject": "glutamate", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "eNOS", "object_type": "GENE-Y"}, {"subject": "7-NIBr", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "eNOS", "object_type": "GENE-Y"}, {"subject": "heme propionate", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "eNOS", "object_type": "GENE-Y"}]}
{"text": "Ferredoxin 1 (FDX1; adrenodoxin) is an iron-sulfur protein that is involved in various metabolic processes, including steroid hormone synthesis in mammalian tissues.", "spo_list": [{"subject": "steroid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "FDX1", "object_type": "GENE-Y"}, {"subject": "steroid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Ferredoxin 1", "object_type": "GENE-Y"}, {"subject": "steroid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "adrenodoxin", "object_type": "GENE-Y"}, {"subject": "steroid hormone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Ferredoxin 1", "object_type": "GENE-Y"}, {"subject": "steroid hormone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "FDX1", "object_type": "GENE-Y"}, {"subject": "steroid hormone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "adrenodoxin", "object_type": "GENE-Y"}]}
{"text": "Luciferase reporter assays showed that transcription of FDX1 was synergistically activated by the NR5A family and 8Br-cAMP treatment through two SF-1 binding sites and a CRE-like sequence in a human ovarian granulosa cell line, KGN.", "spo_list": [{"subject": "8Br-cAMP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "FDX1", "object_type": "GENE-Y"}, {"subject": "8Br-cAMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SF-1", "object_type": "GENE-Y"}]}
{"text": "These results indicate transcription of FDX1 is regulated by the NR5A family and cAMP signaling, and participates in steroid hormone production in ovarian granulosa cells.", "spo_list": [{"subject": "steroid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "FDX1", "object_type": "GENE-Y"}, {"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "FDX1", "object_type": "GENE-Y"}]}
{"text": "The survey reveals that mometasone furoate, a new inhaled steroid with topical activity, has the greatest binding affinity for the glucocorticoid receptor, followed by fluticasone propionate, budesonide, triamcinolone acetonide, and dexamethasone.", "spo_list": [{"subject": "mometasone furoate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}, {"subject": "steroid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}, {"subject": "fluticasone propionate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}, {"subject": "budesonide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}, {"subject": "triamcinolone acetonide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}, {"subject": "dexamethasone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}]}
{"text": "Mometasone furoate also has strong anti-inflammatory activity, with IL-4 and IL-5 inhibition activities equivalent to those of fluticasone propionate.", "spo_list": [{"subject": "Mometasone furoate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IL-4", "object_type": "GENE-Y"}, {"subject": "Mometasone furoate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IL-5", "object_type": "GENE-Y"}, {"subject": "fluticasone propionate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IL-4", "object_type": "GENE-Y"}, {"subject": "fluticasone propionate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IL-5", "object_type": "GENE-Y"}]}
{"text": "Fentanyl-induced healing was inhibited by the opioid receptor antagonist naloxone, suggesting that peripheral opioid receptor(s) mediate the healing process.", "spo_list": [{"subject": "naloxone", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "opioid receptor", "object_type": "GENE-N"}]}
{"text": "The discovery that acarbose is a selective inhibitor of maltase glucoamylase allows the Pompe disease enzyme, acid alpha-glucosidase, to be selectively assayed in white blood cells and dried blood spots.", "spo_list": [{"subject": "acarbose", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "maltase glucoamylase", "object_type": "GENE-Y"}]}
{"text": "Results show the hypolipidemic property of FVW-FO and reduced HMG-CoA reductase activity which is proportional to the incorporation of EPA+DHA.", "spo_list": [{"subject": "EPA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HMG-CoA reductase", "object_type": "GENE-Y"}, {"subject": "DHA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HMG-CoA reductase", "object_type": "GENE-Y"}]}
{"text": "Beta-adrenoceptor-binding studies of the cardioselective beta blockers bisoprolol, H-I 42 BS, and HX-CH 44 BS to heart membranes and intact ventricular myocytes of adult rats: two beta 1-binding sites for bisoprolol. beta-Adrenoceptor binding of cardioselective drugs to intact ventricular myocytes was performed using [3H]CGP-12177, a hydrophilic non-beta 1/beta 2-selective antagonist radioligand.", "spo_list": [{"subject": "bisoprolol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Beta-adrenoceptor", "object_type": "GENE-N"}, {"subject": "bisoprolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta 1-binding sites", "object_type": "GENE-N"}, {"subject": "[3H]CGP-12177", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta-Adrenoceptor", "object_type": "GENE-N"}]}
{"text": "Our results suggest that viable adult rat ventricular myocytes may contain two beta 1-adrenoceptor binding sites exhibiting different affinities for bisoprolol, whereas beta 2-adrenergic receptors are completely absent.", "spo_list": [{"subject": "bisoprolol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "beta 1-adrenoceptor binding sites", "object_type": "GENE-N"}]}
{"text": "Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response.", "spo_list": [{"subject": "risperidone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Dopamine D2 receptor", "object_type": "GENE-Y"}]}
{"text": "The objective of the study is to investigate whether dopamine D2 receptor occupancy by risperidone and plasma levels over time can account for therapeutic efficacy and the latency period to response.", "spo_list": [{"subject": "risperidone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "dopamine D2 receptor", "object_type": "GENE-Y"}]}
{"text": "Therefore, if these results are confirmed, D2 receptor occupancy at the beginning of treatment with risperidone may be a predictor of subsequent clinical response.", "spo_list": [{"subject": "risperidone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "D2 receptor", "object_type": "GENE-Y"}]}
{"text": "The segments were contracted with the alpha(2)-adrenoceptor agonists brimonidine, apraclonidine, and oxymetazoline.", "spo_list": [{"subject": "brimonidine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha(2)-adrenoceptor", "object_type": "GENE-N"}, {"subject": "apraclonidine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha(2)-adrenoceptor", "object_type": "GENE-N"}, {"subject": "oxymetazoline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha(2)-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "The following alpha(2)-adrenoceptor antagonists were applied: BRL44408 (alpha(2A)-selective), ARC239 (alpha(2B)- and alpha(2C)-selective), and prazosin (alpha(2B)- and alpha(2C)-selective).", "spo_list": [{"subject": "BRL44408", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2A)", "object_type": "GENE-Y"}, {"subject": "ARC239", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2B)", "object_type": "GENE-Y"}, {"subject": "ARC239", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2C)", "object_type": "GENE-Y"}, {"subject": "prazosin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2B)", "object_type": "GENE-Y"}, {"subject": "prazosin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2C)", "object_type": "GENE-Y"}]}
{"text": "RESULTS: The alpha(2)-adrenoceptor agonists induced vasoconstriction in the porcine ciliary artery with the following potency order (EC(50)) expressed in nanomolar: brimonidine 2.11, oxymetazoline 5.26, and apraclonidine 13.0.", "spo_list": [{"subject": "brimonidine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha(2)-adrenoceptor", "object_type": "GENE-N"}, {"subject": "oxymetazoline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha(2)-adrenoceptor", "object_type": "GENE-N"}, {"subject": "apraclonidine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha(2)-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "Schild analyses for the antagonists against brimonidine yielded regression lines with slopes of unity and functional antagonist potencies (pK(B)) for BRL44408 (7.8), ARC 239 (5.8) and for prazosin (6.0) suggesting the presence of functional alpha(2A)-adrenoceptors.", "spo_list": [{"subject": "BRL44408", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2A)-adrenoceptors", "object_type": "GENE-Y"}, {"subject": "ARC 239", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2A)-adrenoceptors", "object_type": "GENE-Y"}, {"subject": "prazosin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2A)-adrenoceptors", "object_type": "GENE-Y"}]}
{"text": "CONCLUSIONS: The alpha(2)-adrenoceptor agonists brimonidine, apraclonidine, and oxymetazoline are potent vasoconstrictors in the porcine ciliary artery.", "spo_list": [{"subject": "brimonidine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha(2)-adrenoceptor", "object_type": "GENE-N"}, {"subject": "apraclonidine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha(2)-adrenoceptor", "object_type": "GENE-N"}, {"subject": "oxymetazoline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha(2)-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "Besides aspirin several new drugs for inhibition of platelet aggregation and 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibition are used in secondary stroke prevention.", "spo_list": [{"subject": "aspirin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase", "object_type": "GENE-Y"}]}
{"text": "The present data demonstrate a shared neuroprotective effect of agents known to inhibit platelets (acetylsalicylic acid, clopidogrel, and ticlopidine) and HMG-CoA reductase (atorvastatine).", "spo_list": [{"subject": "atorvastatine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HMG-CoA reductase", "object_type": "GENE-Y"}]}
{"text": "Rofecoxib is a selective cyclo-oxygenase (COX)-2 inhibitor which has little or no effect on the COX-1 isoenzyme at doses up to 1000 mg/day.", "spo_list": [{"subject": "Rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclo-oxygenase (COX)-2", "object_type": "GENE-Y"}]}
{"text": "Rofecoxib has greater selectivity for COX-2 than celecoxib, meloxicam, diclofenac and indomethacin.", "spo_list": [{"subject": "Rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Low TS expression levels, cytoplasmic expression pattern and C SNP arose as variables associated to longer progression-free survival (PFS) in patients treated with 5FU.", "spo_list": [{"subject": "5FU", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TS", "object_type": "GENE-Y"}]}
{"text": "In a recent study it has been shown that mitochondrial creatine kinase from chicken brain (Mia-CK) and heart (Mib-CK) are two distinct isoenzymes differing in ten out of the thirty N-terminal amino acids (Hossle, J.P., Schlegel, J., Wegmann, G., Wyss, M., Bohlen, P., Eppenberger, H.M., Wallimann, T., and Perriard J.C.", "spo_list": [{"subject": "N-terminal amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Mia-CK", "object_type": "GENE-Y"}, {"subject": "N-terminal amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Mib-CK", "object_type": "GENE-Y"}, {"subject": "N-terminal amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "mitochondrial creatine kinase", "object_type": "GENE-N"}]}
{"text": "We examined the effects of the calcium channel blockers nitrendipine, diltiazem, verapamil, bepridil, and mibefradil on the cloned HERG and KvLQT1/IsK K+ channels.", "spo_list": [{"subject": "nitrendipine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calcium channel", "object_type": "GENE-N"}, {"subject": "diltiazem", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calcium channel", "object_type": "GENE-N"}, {"subject": "verapamil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calcium channel", "object_type": "GENE-N"}, {"subject": "bepridil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calcium channel", "object_type": "GENE-N"}, {"subject": "mibefradil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calcium channel", "object_type": "GENE-N"}]}
{"text": "When expressed in transfected COS cells, HERG is blocked in a concentration-dependent manner by bepridil (EC50 = 0.55 microM), verapamil (EC50 = 0.83 microM), and mibefradil (EC50 = 1.43 microM), whereas nitrendipine and diltiazem have negligible effects.", "spo_list": [{"subject": "bepridil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HERG", "object_type": "GENE-Y"}, {"subject": "verapamil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HERG", "object_type": "GENE-Y"}, {"subject": "mibefradil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HERG", "object_type": "GENE-Y"}]}
{"text": "Similarly, KvLQT1/IsK is inhibited by bepridil (EC50 = 10.0 microM) and mibefradil (EC50 = 11.8 microM), while being insensitive to nitrendipine, diltiazem, or verapamil.", "spo_list": [{"subject": "bepridil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "KvLQT1", "object_type": "GENE-Y"}, {"subject": "bepridil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IsK", "object_type": "GENE-Y"}, {"subject": "mibefradil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "KvLQT1", "object_type": "GENE-Y"}, {"subject": "mibefradil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IsK", "object_type": "GENE-Y"}]}
{"text": "Thymidylate synthase and thymidine kinase are key enzymes involved in the de novo and salvage pathways for pyrimidine nucleotide synthesis, respectively.", "spo_list": [{"subject": "pyrimidine nucleotide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "thymidine kinase", "object_type": "GENE-Y"}, {"subject": "pyrimidine nucleotide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Thymidylate synthase", "object_type": "GENE-Y"}]}
{"text": "Thymidylate synthase is inhibited by 5-fluorodeoxyuridine monophosphate, forming an inactive ternary complex with intracellular folate.", "spo_list": [{"subject": "5-fluorodeoxyuridine monophosphate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Thymidylate synthase", "object_type": "GENE-Y"}]}
{"text": "Thirty-week administration of UFT with or without leucovorin markedly suppressed both colorectal carcinogenesis and tumor growth, resulted in the increase of thymidylate synthase inhibition and the decrease of thymidine kinase activity in the tumor cells.", "spo_list": [{"subject": "UFT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}, {"subject": "leucovorin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}, {"subject": "UFT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidine kinase", "object_type": "GENE-Y"}, {"subject": "leucovorin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidine kinase", "object_type": "GENE-Y"}]}
{"text": "5-hydroxytryptamine evokes endothelial nitric oxide synthase activation in bovine aortic endothelial cell cultures.", "spo_list": [{"subject": "5-hydroxytryptamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "endothelial nitric oxide synthase", "object_type": "GENE-Y"}]}
{"text": "Activation of endothelial nitric oxide synthase (eNOS) results in the production of nitric oxide (NO) that mediates the vasorelaxing properties of endothelial cells.", "spo_list": [{"subject": "nitric oxide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "endothelial nitric oxide synthase", "object_type": "GENE-Y"}, {"subject": "nitric oxide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "eNOS", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "endothelial nitric oxide synthase", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "eNOS", "object_type": "GENE-Y"}]}
{"text": "Here, we tested the hypothesis that 5-HT receptors mediate eNOS activation by measuring agonist-stimulated [3H]L-citrulline ([3H]L-Cit) formation in BAEC cultures.", "spo_list": [{"subject": "[3H]L-citrulline", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "eNOS", "object_type": "GENE-Y"}, {"subject": "[3H]L-Cit", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "eNOS", "object_type": "GENE-Y"}]}
{"text": "We found that 5-HT stimulated the conversion of [3H]L-arginine ([3H]L-Arg) to [3H]L-Cit, indicating eNOS activation.", "spo_list": [{"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "eNOS", "object_type": "GENE-Y"}, {"subject": "[3H]L-arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "eNOS", "object_type": "GENE-Y"}, {"subject": "[3H]L-Arg", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "eNOS", "object_type": "GENE-Y"}, {"subject": "[3H]L-Cit", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "eNOS", "object_type": "GENE-Y"}]}
{"text": "The high affinity 5-HT1B receptor agonist, 5-nonyloxytryptamine (5-NOT)-stimulated [3H]L-Cit turnover responses were concentration-(0.01 nM to 100 microM) and time-dependent.", "spo_list": [{"subject": "5-nonyloxytryptamine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT1B", "object_type": "GENE-Y"}]}
{"text": "These responses were effectively blocked by the 5-HT1B receptor antagonist, isamoltane, the 5-HT1B/5-HT2 receptor antagonist, methiothepin, and the eNOS selective antagonists (0.01-10 microM): L-Nomega -monomethyl-L-arginine (L-NMMA) and L-N omega-iminoethyl-L-ornithine (L-NIO).", "spo_list": [{"subject": "methiothepin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT1B", "object_type": "GENE-Y"}, {"subject": "methiothepin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT2 receptor", "object_type": "GENE-N"}, {"subject": "L-Nomega -monomethyl-L-arginine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "eNOS", "object_type": "GENE-Y"}, {"subject": "L-NMMA", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "eNOS", "object_type": "GENE-Y"}, {"subject": "L-N omega-iminoethyl-L-ornithine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "eNOS", "object_type": "GENE-Y"}, {"subject": "L-NIO", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "eNOS", "object_type": "GENE-Y"}]}
{"text": "These findings lend evidence of a 5-HT1B receptor/eNOS pathway, accounting in part for the activation of eNOS by 5-HT.", "spo_list": [{"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "eNOS", "object_type": "GENE-Y"}]}
{"text": "These results show that conventional doses of bisoprolol (10 mg) and atenolol (50 mg) produced equal antagonism of beta 1 and beta 2-adrenoceptors, and therefore possess equal degrees of beta 1-adrenoceptor selectivity.", "spo_list": [{"subject": "bisoprolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta 1-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "atenolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta 1-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Olopatadine (AL-4943A; KW-4679) [(z)-11-[3-(dimethylamino)propylidene]-6, 11-dihydrodibenz[b,e]oxepine-2 acetic acid hydrochloride] is an anti-allergic agent which inhibits mast cell mediator release and possesses histamine H1 receptor antagonist activity.", "spo_list": [{"subject": "Olopatadine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1 receptor", "object_type": "GENE-Y"}, {"subject": "AL-4943A", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1 receptor", "object_type": "GENE-Y"}, {"subject": "KW-4679", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1 receptor", "object_type": "GENE-Y"}, {"subject": "(z)-11-[3-(dimethylamino)propylidene]-6, 11-dihydrodibenz[b,e]oxepine-2 acetic acid hydrochloride", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1 receptor", "object_type": "GENE-Y"}]}
{"text": "The cysteine conserved among DNA cytosine methylases is required for methyl transfer, but not for specific DNA binding.", "spo_list": [{"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "DNA cytosine methylases", "object_type": "GENE-N"}]}
{"text": "All DNA (cytosine-5)-methyltransferases contain a single conserved cysteine.", "spo_list": [{"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DNA (cytosine-5)-methyltransferases", "object_type": "GENE-N"}]}
{"text": "Participation of glucose transporters on atrial natriuretic peptide-induced glucose uptake by adult and neonatal cardiomyocytes under oxygenation and hypoxia.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "glucose transporters", "object_type": "GENE-N"}]}
{"text": "We also explored if the calcium-calmodulin complex participates in ANP-induced increase in glucose uptake.", "spo_list": [{"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calmodulin", "object_type": "GENE-N"}]}
{"text": "Neonatal cells had a higher glucose uptake than adult cells and GLUT 1 participated in basal uptake in both cell types.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GLUT 1", "object_type": "GENE-Y"}]}
{"text": "Hypoxia increased glucose uptake in adult cardiomyocytes but not in neonatal cells and this increase in glucose uptake was mediated by GLUT4.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GLUT4", "object_type": "GENE-Y"}, {"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GLUT4", "object_type": "GENE-Y"}]}
{"text": "ANP increased glucose uptake in both adult and neonatal myocytes, under oxygenation and hypoxia, and GLUT4 favored this increase.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GLUT4", "object_type": "GENE-Y"}]}
{"text": "Trifluoperazine, a calcium-calmodulin blocker, inhibited the ANP-induced increase in glucose uptake.", "spo_list": [{"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "Trifluoperazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "calmodulin", "object_type": "GENE-N"}]}
{"text": "The incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic peptide are secreted by enteroendocrine cells and augment glucose-induced insulin secretion in response to food ingestion in a glucose-dependent manner.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-Y"}]}
{"text": "The specific pharmacological profile of the 19-norprogestin nomegestrol acetate (NOMAC) is, at least in part, defined by its pattern of binding affinities to the different steroid hormone receptors.", "spo_list": [{"subject": "19-norprogestin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "steroid hormone receptors", "object_type": "GENE-N"}, {"subject": "nomegestrol acetate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "steroid hormone receptors", "object_type": "GENE-N"}, {"subject": "NOMAC", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "steroid hormone receptors", "object_type": "GENE-N"}]}
{"text": "The characteristics of binding to the PgR in rat uterus were determined and Ki were found to be roughly similar with 22.8 and 34.3 nM for NOMAC and P, respectively.", "spo_list": [{"subject": "NOMAC", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PgR", "object_type": "GENE-Y"}]}
{"text": "The effects of NOMAC on the binding of androgen to the AR were investigated, using rat ventral prostate as target model.", "spo_list": [{"subject": "androgen", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AR", "object_type": "GENE-Y"}]}
{"text": "Regarding the ER, since none of the progestins were able to compete with estrogen for binding in rat uterus as well as in Ishikawa cells, the induction of alkaline phosphatase activity (APase) was used as an estrogen-specific response.", "spo_list": [{"subject": "estrogen", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ER", "object_type": "GENE-Y"}, {"subject": "estrogen", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "alkaline phosphatase", "object_type": "GENE-N"}, {"subject": "estrogen", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "APase", "object_type": "GENE-N"}]}
{"text": "Data from this study have demonstrated that NOMAC is a progestin that has greater steroid receptor selectivity compared to MPA or some other synthetic progestins.", "spo_list": [{"subject": "NOMAC", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "steroid receptor", "object_type": "GENE-N"}, {"subject": "progestin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "steroid receptor", "object_type": "GENE-N"}]}
{"text": "These diuretics inhibited organic anion uptake mediated by hOAT1, hOAT2, hOAT3, and hOAT4 in a competitive manner. hOAT1 exhibited the highest affinity interactions for thiazides, whereas hOAT3 did those for loop diuretics. hOAT1, hOAT3, and hOAT4 but not hOAT2, mediated the uptake of bumetanide. hOAT3 and hOAT4, but not hOAT1 mediated the efflux of bumetanide. hOAT1 and hOAT3, but not hOAT2 and hOAT4 mediated the uptake of furosemide.", "spo_list": [{"subject": "thiazides", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "bumetanide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "bumetanide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT3", "object_type": "GENE-Y"}, {"subject": "bumetanide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT4", "object_type": "GENE-Y"}, {"subject": "bumetanide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT3", "object_type": "GENE-Y"}, {"subject": "bumetanide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT4", "object_type": "GENE-Y"}, {"subject": "furosemide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT1", "object_type": "GENE-Y"}, {"subject": "furosemide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hOAT3", "object_type": "GENE-Y"}]}
{"text": "The mRNA levels of SOD1, CAT, GPx and Txnrd1 were increased significantly (P<0.05) in the combined Na2SeO3+NaAsO2 treatment group.", "spo_list": [{"subject": "Na2SeO3", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Txnrd1", "object_type": "GENE-Y"}, {"subject": "Na2SeO3", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GPx", "object_type": "GENE-N"}, {"subject": "Na2SeO3", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CAT", "object_type": "GENE-Y"}, {"subject": "Na2SeO3", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "SOD1", "object_type": "GENE-Y"}, {"subject": "NaAsO2", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Txnrd1", "object_type": "GENE-Y"}, {"subject": "NaAsO2", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "GPx", "object_type": "GENE-N"}, {"subject": "NaAsO2", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CAT", "object_type": "GENE-Y"}, {"subject": "NaAsO2", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "SOD1", "object_type": "GENE-Y"}]}
{"text": "The expressions of HSP70 and HO-1 were significantly (P<0.05) increased in the NaAsO2 group and reduced in the combined treatment group.", "spo_list": [{"subject": "NaAsO2", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HO-1", "object_type": "GENE-Y"}, {"subject": "NaAsO2", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HSP70", "object_type": "GENE-N"}]}
{"text": "Further results indicated that post-training intra-amygdala infusion of buspirone or the 5-HT1A agonist 8-hydroxy-di-n-propylaminotetralin (8-OH-DPAT) caused a time-dependent and dose-dependent retention deficit.", "spo_list": [{"subject": "8-hydroxy-di-n-propylaminotetralin", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "8-OH-DPAT", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT1A", "object_type": "GENE-Y"}]}
{"text": "Post-training intra-amygdala infusion of the 5-HT1A antagonist WAY100635 (N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)-N-(2-pyridyl) cyclohexane carboxamine maleate) attenuated the memory-impairing effects of buspirone.", "spo_list": [{"subject": "WAY100635", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)-N-(2-pyridyl) cyclohexane carboxamine maleate", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT1A", "object_type": "GENE-Y"}]}
{"text": "The 2,2',4,4'-tetrabromodiphenyl ether hydroxylated metabolites 5-OH-BDE-47 and 6-OH-BDE-47 stimulate estradiol secretion in the ovary by activating aromatase expression.", "spo_list": [{"subject": "2,2',4,4'-tetrabromodiphenyl ether", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "aromatase", "object_type": "GENE-N"}, {"subject": "5-OH-BDE-47", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "aromatase", "object_type": "GENE-N"}, {"subject": "6-OH-BDE-47", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "aromatase", "object_type": "GENE-N"}, {"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "aromatase", "object_type": "GENE-N"}]}
{"text": "The increased secretion of estradiol was due to the stimulation of aromatase gene and protein expression.", "spo_list": [{"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "aromatase", "object_type": "GENE-N"}]}
{"text": "Direct assessment of aromatase activity by dibenzylfluorescein assay and indirect assessment of aromatase activity by measurement of the conversion of testosterone to estradiol confirmed that 5-OH-BDE-47 and 6-OH-BDE-47 stimulate aromatase activity.", "spo_list": [{"subject": "5-OH-BDE-47", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "aromatase", "object_type": "GENE-N"}, {"subject": "6-OH-BDE-47", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "aromatase", "object_type": "GENE-N"}, {"subject": "testosterone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "aromatase", "object_type": "GENE-N"}, {"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "aromatase", "object_type": "GENE-N"}]}
{"text": "The aromatase inhibitor CGS 16949A abolished this stimulatory activity and reduced estradiol levels in the control and treatment groups.", "spo_list": [{"subject": "CGS 16949A", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-N"}, {"subject": "estradiol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "aromatase", "object_type": "GENE-N"}]}
{"text": "PURPOSE: Cellular retinaldehyde-binding protein (CRALBP), transcribed from the RLBP1 gene, is a 36-kDa water-soluble protein with 316 amino acids found in the retinal pigment epithelium (RPE) and in retinal Muller cells.", "spo_list": [{"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "36-kDa water-soluble protein", "object_type": "GENE-N"}]}
{"text": "It is thought to play a critical role in the visual cycle by functioning as an acceptor of 11-cis-retinol from the isomerohydrolase reaction.", "spo_list": [{"subject": "11-cis-retinol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "isomerohydrolase", "object_type": "GENE-N"}]}
{"text": "Chloroacetic acid induced neuronal cells death through oxidative stress-mediated p38-MAPK activation pathway regulated mitochondria-dependent apoptotic signals.", "spo_list": [{"subject": "Chloroacetic acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MAPK", "object_type": "GENE-N"}, {"subject": "Chloroacetic acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p38", "object_type": "GENE-N"}]}
{"text": "Pretreatment with NAC and specific p38-MAPK inhibitor (SB203580), but not JNK inhibitor (SP600125) effectively abrogated the phosphorylation of p38-MAPK and attenuated the apoptotic signals (including: decrease in cytotoxicity, caspase-3/-7 activation, the cytosolic cytochrome c release, and the reversed alteration of Bcl-2 and Bax mRNA) in CA-treated Neuro-2a cells.", "spo_list": [{"subject": "SB203580", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAPK", "object_type": "GENE-N"}, {"subject": "SB203580", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "SP600125", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JNK", "object_type": "GENE-N"}, {"subject": "NAC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAPK", "object_type": "GENE-N"}, {"subject": "NAC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "SB203580", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "SB203580", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAPK", "object_type": "GENE-N"}]}
{"text": "Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain.", "spo_list": [{"subject": "18F-AV-45", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Abeta", "object_type": "GENE-Y"}]}
{"text": "(E)-4-(2-(6-(2-(2-(2-(18)F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methy l benzenamine ((18)F-AV-45) is such as an agent currently in phase III clinical studies for PET of Abeta plaques in the brain.", "spo_list": [{"subject": "(18)F-AV-45", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Abeta", "object_type": "GENE-Y"}, {"subject": "(E)-4-(2-(6-(2-(2-(2-(18)F-fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methy l benzenamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Abeta", "object_type": "GENE-Y"}]}
{"text": "RESULTS: (18)F-AV-45 displayed a high binding affinity and specificity to Abeta plaques (K(d), 3.72 +/- 0.30 nM).", "spo_list": [{"subject": "(18)F-AV-45", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Abeta", "object_type": "GENE-Y"}]}
{"text": "(18)F-AV-45 displayed excellent binding affinity to Abeta plaques in the AD brain by ex vivo autoradiography in transgenic AD model mice.", "spo_list": [{"subject": "(18)F-AV-45", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Abeta", "object_type": "GENE-Y"}]}
{"text": "The results lend support that (18)F-AV-45 may be a useful PET agent for detecting Abeta plaques in the living human brain.", "spo_list": [{"subject": "(18)F-AV-45", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Abeta", "object_type": "GENE-Y"}]}
{"text": "Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4.", "spo_list": [{"subject": "Auranofin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TLR4", "object_type": "GENE-Y"}]}
{"text": "Our results demonstrated that auranofin suppressed TLR4-mediated activation of transcription factors, NF-kappaB and IRF3, and expression of COX-2, a pro-inflammatory enzyme.", "spo_list": [{"subject": "auranofin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TLR4", "object_type": "GENE-Y"}, {"subject": "auranofin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}, {"subject": "auranofin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IRF3", "object_type": "GENE-Y"}, {"subject": "auranofin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "This suppression was well correlated with the inhibitory effect of auranofin on the homodimerization of TLR4 induced by an agonist.", "spo_list": [{"subject": "auranofin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TLR4", "object_type": "GENE-Y"}]}
{"text": "Furthermore, auranofin inhibited NF-kappaB activation induced by MyD88-dependent downstream signaling components of TLR4, MyD88, IKKbeta, and p65.", "spo_list": [{"subject": "auranofin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}]}
{"text": "IRF3 activation induced by MyD88-independent signaling components, TRIF and TBK1, was also downregulated by auranofin.", "spo_list": [{"subject": "auranofin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TRIF", "object_type": "GENE-Y"}, {"subject": "auranofin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TBK1", "object_type": "GENE-Y"}]}
{"text": "Our results first demonstrate that auranofin suppresses the multiple steps in TLR4 signaling, especially the homodimerization of TLR4.", "spo_list": [{"subject": "auranofin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TLR4", "object_type": "GENE-Y"}, {"subject": "auranofin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TLR4", "object_type": "GENE-Y"}]}
{"text": "The results suggest that the suppression of TLR4 activity by auranofin may be the molecular mechanism through which auranofin exerts anti-rheumatic activity.", "spo_list": [{"subject": "auranofin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TLR4", "object_type": "GENE-Y"}]}
{"text": "These radiotracers are close analogues of reboxetine, a potent and selective ligand for the norepinephrine transporter (NET).", "spo_list": [{"subject": "reboxetine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "norepinephrine transporter", "object_type": "GENE-Y"}, {"subject": "reboxetine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "NET", "object_type": "GENE-Y"}]}
{"text": "In vitro autoradiography studies (rat brain slices) with (S,S)-[(11)C]-MeNER produced a regional distribution pattern that was consistent with the reported distribution of NET.", "spo_list": [{"subject": "(S,S)-[(11)C]-MeNER", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "NET", "object_type": "GENE-Y"}]}
{"text": "(S,S)-[(11)C]-MeNER has the potential to be the first successful PET ligand to image NET.", "spo_list": [{"subject": "(S,S)-[(11)C]-MeNER", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "NET", "object_type": "GENE-Y"}]}
{"text": "Lysosomal acidification was impaired in the 5XFAD brains as indicated by reduced cathepsin D activity and decreased N-glycoyslation of the vacuolar ATPase subunit V0a1, a modification required for lysosomal acidification.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "vacuolar ATPase subunit V0a1", "object_type": "GENE-N"}]}
{"text": "FINDINGS: Compared with other ARBs, candesartan demonstrates the strongest binding affinity to the angiotensin II type 1 receptor.", "spo_list": [{"subject": "candesartan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "angiotensin II type 1 receptor", "object_type": "GENE-Y"}]}
{"text": "After 7 days of treatment, 5 and 10 Î¼M of sodium metasilicate significantly increased intracellular alkaline phosphatase activity (p < 0.05) when compared to the control.", "spo_list": [{"subject": "sodium metasilicate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "alkaline phosphatase", "object_type": "GENE-N"}]}
{"text": "In the analysis of gene expression, 50 Î¼M of sodium metasilicate upregulated type I collagen (COL-I) compared to the control group.", "spo_list": [{"subject": "sodium metasilicate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "type I collagen", "object_type": "GENE-N"}, {"subject": "sodium metasilicate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "COL-I", "object_type": "GENE-N"}]}
{"text": "However, the increase of COL-I gene expression as a result of treatment with 1, 10, 25, and 100 Î¼M of sodium metasilicate did not reach statistical significance. mRNA expression of insulin-like growth factor-I and receptor activator of NF-ÎºB ligand was not significantly changed at any dose of sodium metasilicate (0, 1, 5, 10, 25, 50, and 100 Î¼M).", "spo_list": [{"subject": "sodium metasilicate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "COL-I", "object_type": "GENE-N"}]}
{"text": "In the present study, we have evaluated possible participation of monocarboxylate transporters (MCTs) responsible for the bidirectional membrane transport of pyruvate in the cytoprotective property in osteoblasts.", "spo_list": [{"subject": "pyruvate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MCTs", "object_type": "GENE-N"}]}
{"text": "Fenofibrate also increased myocardial hypertrophy, cardiac fibrosis, and the ratio of matrix metalloproteinase-2/tissue inhibitor of matrix metalloproteinase-2 in PO PPARalpha-deficient mice.", "spo_list": [{"subject": "Fenofibrate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "matrix metalloproteinase-2", "object_type": "GENE-Y"}, {"subject": "Fenofibrate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "tissue inhibitor of matrix metalloproteinase-2", "object_type": "GENE-Y"}]}
{"text": "Fenofibrate inhibited matrix metalloproteinase activity in vitro and aldosterone-induced increases in extracellular signal-regulated kinase phosphorylation.", "spo_list": [{"subject": "Fenofibrate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "matrix metalloproteinase", "object_type": "GENE-N"}, {"subject": "aldosterone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "Fenofibrate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}]}
{"text": "Aldosterone and tetrahydrocorticosterone production demonstrated modest suppression after prednisone administration, but allo-tetrahydrocorticosterone, which is highly sensitive to adrenocorticotropic hormone (ACTH) secretion, was suppressed to a greater extent.", "spo_list": [{"subject": "prednisone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "adrenocorticotropic hormone", "object_type": "GENE-Y"}, {"subject": "prednisone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ACTH", "object_type": "GENE-Y"}]}
{"text": "Prednisone administration results in a decrease in ACTH secretion by the anterior pituitary, suppressing synthesis of glucocorticoids, DHEA, and DHEA metabolites.", "spo_list": [{"subject": "Prednisone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ACTH", "object_type": "GENE-Y"}]}
{"text": "Aspirin (ASA) and other non-steroidal anti-inflammatory drugs, which are cyclooxygenase (COX) inhibitors, precipitate asthmatic attacks in ASA-intolerant patients, while sodium salicylate, hardly active on COX by itself, is well tolerated by these patients.", "spo_list": [{"subject": "Aspirin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase", "object_type": "GENE-N"}, {"subject": "ASA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase", "object_type": "GENE-N"}, {"subject": "Aspirin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX", "object_type": "GENE-N"}, {"subject": "ASA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX", "object_type": "GENE-N"}]}
{"text": "However, salicylate moiety appears to interfere with aspirin inhibitory action on platelets and vascular COX.", "spo_list": [{"subject": "aspirin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX", "object_type": "GENE-N"}]}
{"text": "Although the precise mechanism of the protective action of trilisate is unknown, our data support the possibility of interaction between salicylate and ASA on cyclo-oxygenase locus in the respiratory tract in ASA-intolerant patients.", "spo_list": [{"subject": "salicylate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclo-oxygenase", "object_type": "GENE-N"}, {"subject": "ASA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclo-oxygenase", "object_type": "GENE-N"}]}
{"text": "In contrast, in native rat liver microsomes, glucuronidation of 4-OHCIPC was increased by cadmium through activation of microsomal 4-OHCIPC glucuronosyl transferase.", "spo_list": [{"subject": "cadmium", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "glucuronosyl transferase", "object_type": "GENE-N"}, {"subject": "4-OHCIPC", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "glucuronosyl transferase", "object_type": "GENE-N"}]}
{"text": "In addition, in rat microsome incubations, the net amount of 4-OHCIPC glucuronide was also indirectly increased by cadmium through a reduction in the activity of beta-glucuronidase.", "spo_list": [{"subject": "cadmium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "beta-glucuronidase", "object_type": "GENE-Y"}, {"subject": "4-OHCIPC glucuronide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "beta-glucuronidase", "object_type": "GENE-Y"}]}
{"text": "Cadmium did not increase the breakdown of UDPGA by microsomal UDPGA pyrophosphatase but strongly decreased (30-66%) the synthesis of the cofactor in the cytosol by inhibiting UDP-glucose dehydrogenase (UDPGDH).", "spo_list": [{"subject": "Cadmium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UDP-glucose dehydrogenase", "object_type": "GENE-Y"}, {"subject": "Cadmium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UDPGDH", "object_type": "GENE-Y"}, {"subject": "UDPGA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "pyrophosphatase", "object_type": "GENE-N"}]}
{"text": "Cadmium (10-50 microM) was found to inhibit the purified enzyme from bovine liver (EC 1.1.1.22) non-competitively.", "spo_list": [{"subject": "Cadmium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 1.1.1.22", "object_type": "GENE-N"}]}
{"text": "Both in vitro and in vivo results support the conclusion that in intact cells the reduction in overall 4-OHCIPC glucuronidation caused by cadmium was due to a decrease in UDPGA availability which results from the inhibiting effect of cadmium on UDPGDH.", "spo_list": [{"subject": "cadmium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "UDPGDH", "object_type": "GENE-Y"}]}
{"text": "The results show that CYP2E1 inhibits CYP2B4-mediated metabolism of benzphetamine (BNZ) with a K(i) of 0.04 ÂµM.", "spo_list": [{"subject": "benzphetamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2B4", "object_type": "GENE-Y"}, {"subject": "BNZ", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2B4", "object_type": "GENE-Y"}]}
{"text": "However, CYP2B4 is not an inhibitor of CYP2E1-mediated p-nitrophenol hydroxylation.", "spo_list": [{"subject": "p-nitrophenol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2E1", "object_type": "GENE-Y"}]}
{"text": "Additionally, CYP2E1 increased the apparent K(M) of CYP2B4 for BNZ by 8-fold and the apparent K(M) did not decrease to its original value when saturating concentrations of CPR were used.", "spo_list": [{"subject": "BNZ", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CYP2B4", "object_type": "GENE-Y"}]}
{"text": "The 8-MOP analogs 19 and 24, incorporating at position 5 of the psoralen nucleus a butyl acrylate or a tert-butyl cinnamate moiety, were the most powerful inhibitors of soybean LOX and inhibited effectively lipid peroxidation.", "spo_list": [{"subject": "8-MOP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "soybean LOX", "object_type": "GENE-N"}, {"subject": "psoralen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "soybean LOX", "object_type": "GENE-N"}, {"subject": "butyl acrylate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "soybean LOX", "object_type": "GENE-N"}, {"subject": "tert-butyl cinnamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "soybean LOX", "object_type": "GENE-N"}]}
{"text": "Immunofluorescence staining and western blotting demonstrated that cilostazol treatment reduced GFAP and VEGF expression in the retinas of OLETF rats.", "spo_list": [{"subject": "cilostazol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "GFAP", "object_type": "GENE-Y"}, {"subject": "cilostazol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "VEGF", "object_type": "GENE-Y"}]}
{"text": "RESULTS: In quiescent rings of the previously deendothelialized left anterior descending coronary artery treated with the NO-synthase inhibitor nitro-L-arginine, endothelin-1 caused contractions which were larger in rings with than that in those without endothelium.", "spo_list": [{"subject": "nitro-L-arginine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NO-synthase", "object_type": "GENE-N"}]}
{"text": "In rings with endothelium of the previously deendothelialized left anterior descending coronary artery, indometacin (inhibitor of cyclooxygenase) and ridogrel (thromboxane A2 receptor antagonist and inhibitor of thromboxane synthase) inhibited contractions to endothelin-1.", "spo_list": [{"subject": "indometacin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase", "object_type": "GENE-N"}, {"subject": "ridogrel", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "thromboxane A2 receptor", "object_type": "GENE-Y"}, {"subject": "ridogrel", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thromboxane synthase", "object_type": "GENE-Y"}, {"subject": "ridogrel", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "endothelin-1", "object_type": "GENE-Y"}]}
{"text": "Dazoxiben (inhibitor of thromboxane synthase) inhibited, to the same extent as indometacin and ridogel, the response to higher concentrations of endothelin-1.", "spo_list": [{"subject": "Dazoxiben", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thromboxane synthase", "object_type": "GENE-Y"}, {"subject": "indometacin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thromboxane synthase", "object_type": "GENE-Y"}, {"subject": "ridogel", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thromboxane synthase", "object_type": "GENE-Y"}]}
{"text": "The endothelium-dependent component of the response to lower concentrations of endothelin-1 was inhibited by indometacin and ridogrel, but not by dazoxiben.", "spo_list": [{"subject": "indometacin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "endothelin-1", "object_type": "GENE-Y"}, {"subject": "ridogrel", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "endothelin-1", "object_type": "GENE-Y"}]}
{"text": "Selective inhibitory effects of mollugin on CYP1A2 in human liver microsomes.", "spo_list": [{"subject": "mollugin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP1A2", "object_type": "GENE-Y"}]}
{"text": "In the present study, a cocktail probe assay was performed for determination of the selective inhibitory effect of mollugin on cytochrome P450 (CYP) enzymes in human liver microsomes (HLM).", "spo_list": [{"subject": "mollugin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cytochrome P450", "object_type": "GENE-N"}, {"subject": "mollugin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP", "object_type": "GENE-N"}]}
{"text": "Incubation of isoform-specific substrate probes CYPs with mollugin (0-25Î¼M) in HLM resulted in strong inhibition of CYP1A2-catalyzed phenacetin O-deethylation, showing IC(50) values of 1.03 and 3.55Î¼M without and with pre-incubation, respectively.", "spo_list": [{"subject": "mollugin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYPs", "object_type": "GENE-N"}, {"subject": "mollugin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP1A2", "object_type": "GENE-Y"}, {"subject": "phenacetin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP1A2", "object_type": "GENE-Y"}, {"subject": "O", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP1A2", "object_type": "GENE-Y"}]}
{"text": "Taken together, the results suggested that mollugin might cause herb-drug interaction through selective inhibition of CYP1A2 in humans receiving herbal medications, including R. cordifolia.", "spo_list": [{"subject": "mollugin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP1A2", "object_type": "GENE-Y"}]}
{"text": "[Pharmacological effects of a mu-opioid receptor antagonist naltrexone on alcohol dependence].", "spo_list": [{"subject": "naltrexone", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "mu-opioid receptor", "object_type": "GENE-Y"}]}
{"text": "In many countries, a mu-opioid receptor antagonist naltrexone has been used in the treatment of alcohol dependence.", "spo_list": [{"subject": "naltrexone", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "mu-opioid receptor", "object_type": "GENE-Y"}]}
{"text": "Detection of kinetically abnormal argininosuccinate synthase in neonatal citrullinemia by conversion of citrulline to arginine in intact fibroblasts.", "spo_list": [{"subject": "citrulline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "argininosuccinate synthase", "object_type": "GENE-Y"}, {"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "argininosuccinate synthase", "object_type": "GENE-Y"}]}
{"text": "The apparent Km values of argininosuccinate synthase toward citrulline and aspartate were significantly increased in cultured skin fibroblasts from one patient with neonatal citrullinemia, whereas, those determined in cells from three other patients were within the normal range.", "spo_list": [{"subject": "citrulline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "argininosuccinate synthase", "object_type": "GENE-Y"}, {"subject": "aspartate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "argininosuccinate synthase", "object_type": "GENE-Y"}]}
{"text": "The putative chemopreventive actions include the inhibition of inflammatory cascades and/or reactions involved in cell growth and proliferation, such as cyclo-oxygenase (COX-1 and COX-2), which regulate cell proliferation through the formation of prostaglandins; lipoxygenase; nuclear factor kappaB (NFkappaB), responsible for the subsequent expression of pro-inflammatory molecules; MAP kinases and Bcl-2, as well as the activation of apoptotic processes, such as the stimulation of intestinal sphingomyelinase.", "spo_list": [{"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclo-oxygenase", "object_type": "GENE-N"}, {"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "It is hypothesized that 5-ASAs may prevent the enhancing effect of prostaglandins on PPARdelta binding to DNA by its COX inhibitory properties, decreasing proliferation of colorectal mucosal cells in non-inflammatory bowel disease patients with sporadic polyps of the large bowel.", "spo_list": [{"subject": "5-ASAs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX", "object_type": "GENE-N"}]}
{"text": "Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.", "spo_list": [{"subject": "sitagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}]}
{"text": "Sitagliptin (MK-0431) is an oral, potent, and selective dipeptidyl peptidase-IV (DPP-4) inhibitor developed for the treatment of type 2 diabetes.", "spo_list": [{"subject": "Sitagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dipeptidyl peptidase-IV", "object_type": "GENE-Y"}, {"subject": "MK-0431", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dipeptidyl peptidase-IV", "object_type": "GENE-Y"}, {"subject": "Sitagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}, {"subject": "MK-0431", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}]}
{"text": "Sitagliptin treatment led to approximately 90% inhibition of plasma DPP-4 activity, increased active glucagon-like peptide-1 (GLP-1) levels by 2.7-fold (P < .001), and decreased post-oral glucose tolerance test glucose excursion by 35% (P < .050) compared to placebo.", "spo_list": [{"subject": "Sitagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}, {"subject": "Sitagliptin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "glucagon-like peptide-1", "object_type": "GENE-Y"}, {"subject": "Sitagliptin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GLP-1", "object_type": "GENE-Y"}]}
{"text": "In nondiabetic obese subjects, treatment with sitagliptin 200 mg bid was generally well tolerated without associated hypoglycemia and led to maximal inhibition of plasma DPP-4 activity, increased active GLP-1, and reduced glycemic excursion.", "spo_list": [{"subject": "sitagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPP-4", "object_type": "GENE-Y"}, {"subject": "sitagliptin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GLP-1", "object_type": "GENE-Y"}]}
{"text": "Targeted agents currently approved or under investigation for SCCHN include epidermal growth factor receptor (EGFR) monoclonal antibodies (cetuximab, panitumumab, zalutumumab, nimotuzumab), EGFR tyrosine kinase inhibitors (gefitinib, erlotinib, lapatinib, afatanib, dacomitinib), vascular endothelial growth factor receptor (VEGFR) inhibitors (bevacizumab, sorafenib, sunitinib, vandetanib) and various inhibitors of other pathways and targets, including phosphatidylinositol 3' kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR), MET and insulin-like growth factor receptor (IGF-1R).", "spo_list": [{"subject": "gefitinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EGFR", "object_type": "GENE-Y"}, {"subject": "gefitinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "erlotinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EGFR", "object_type": "GENE-Y"}, {"subject": "erlotinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "lapatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EGFR", "object_type": "GENE-Y"}, {"subject": "lapatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "afatanib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EGFR", "object_type": "GENE-Y"}, {"subject": "afatanib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "dacomitinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EGFR", "object_type": "GENE-Y"}, {"subject": "dacomitinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "vascular endothelial growth factor receptor", "object_type": "GENE-N"}, {"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR", "object_type": "GENE-N"}, {"subject": "sunitinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "vascular endothelial growth factor receptor", "object_type": "GENE-N"}, {"subject": "sunitinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR", "object_type": "GENE-N"}, {"subject": "vandetanib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "vascular endothelial growth factor receptor", "object_type": "GENE-N"}, {"subject": "vandetanib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR", "object_type": "GENE-N"}]}
{"text": "Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study.", "spo_list": [{"subject": "Sitagliptin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Dipeptidyl Peptidase-4", "object_type": "GENE-Y"}]}
{"text": "Fasting plasma glucose (FPG), fasting plasma insulin, C-peptide (insulin secretory rate [ISR]), fasting plasma glucagon, and bioactive glucagon-like peptide (GLP-1) and gastrointestinal insulinotropic peptide (GIP) was measured.RESULTSFPG decreased from P, 160 Â± 4 to M, 150 Â± 4; S, 154 Â± 4; and M+S, 125 Â± 3 mg/dL.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "C-peptide", "object_type": "GENE-Y"}]}
{"text": "We present our studies to demonstrate that HM74A, but not HM74, binds niacin at high affinities and effectively mediates Gi signaling events in human embryonic kidney HEK293 cells as well as in 3T3L1 adipocytes expressing HM74A.", "spo_list": [{"subject": "niacin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "HM74A", "object_type": "GENE-N"}, {"subject": "niacin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Gi", "object_type": "GENE-N"}]}
{"text": "One conductance featured a Na(+)-independent and K(+)-dependent net current that displayed rectification and was suppressed by micromolar concentrations of Ba(2+) and two GIRK antagonists, tertiapin Q and SCH 23390.", "spo_list": [{"subject": "SCH 23390", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "GIRK", "object_type": "GENE-N"}]}
{"text": "This conductance was suppressed by nonselective TRPC channel blockers 2-APB, flufenamic acid and ML204, enhanced by La(3+) in a subpopulation of cells, and unchanged by the TRPV1 antagonist capsazepine or a Na(+) /Ca(2+) exchanger blocker KB-R7943.", "spo_list": [{"subject": "2-APB", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TRPC", "object_type": "GENE-N"}, {"subject": "flufenamic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TRPC", "object_type": "GENE-N"}, {"subject": "ML204", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TRPC", "object_type": "GENE-N"}, {"subject": "capsazepine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "TRPV1", "object_type": "GENE-Y"}, {"subject": "KB-R7943", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Na(+) /Ca(2+) exchanger", "object_type": "GENE-N"}, {"subject": "La(3+)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRPC", "object_type": "GENE-N"}]}
{"text": "Labetalol (> or = 3 x 10(-8) M) and dilevalol (> or = 10(-8) M) caused surmountable antagonism of the isoprenaline responses of the atria and the pA2 values were 8.60 and 8.98 at the beta 1-adrenoceptors of the rat left atria and 7.90 and 8.31, respectively, on the guinea-pig left atria which has functional beta 1- and beta 2-adrenoceptors.", "spo_list": [{"subject": "Labetalol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta 1-adrenoceptors", "object_type": "GENE-N"}, {"subject": "dilevalol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta 1-adrenoceptors", "object_type": "GENE-N"}, {"subject": "isoprenaline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta 1-adrenoceptors", "object_type": "GENE-N"}]}
{"text": "The isoprenaline attenuation responses of the portal vein were inhibited by labetalol and dilevalol (both at > or = 10(-7) M) and the pA2 value for the labetalol at beta 2-adrenoceptors was 7.59.", "spo_list": [{"subject": "labetalol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta 2-adrenoceptors", "object_type": "GENE-N"}]}
{"text": "It is concluded that labetalol and dilevalol are beta 1-adrenoceptor selective antagonists.", "spo_list": [{"subject": "labetalol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta 1-adrenoceptor", "object_type": "GENE-N"}, {"subject": "dilevalol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta 1-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "Mammalian mitochondrial dihydrolipoamide dehydrogenase (DLDH, EC 1.8.1.4) catalyzes NAD(+)-dependent oxidation of dihydrolipoamide in vivo and can also act as a diaphorase catalyzing in vitro nicotinamide adenine dinucleotide (reduced form) (NADH)-dependent reduction of electron-accepting molecules such as ubiquinone and nitroblue tetrazolium (NBT).", "spo_list": [{"subject": "dihydrolipoamide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Mammalian mitochondrial dihydrolipoamide dehydrogenase", "object_type": "GENE-Y"}, {"subject": "dihydrolipoamide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DLDH", "object_type": "GENE-Y"}, {"subject": "dihydrolipoamide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 1.8.1.4", "object_type": "GENE-Y"}, {"subject": "nitroblue tetrazolium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Mammalian mitochondrial dihydrolipoamide dehydrogenase", "object_type": "GENE-Y"}, {"subject": "nitroblue tetrazolium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DLDH", "object_type": "GENE-Y"}, {"subject": "nitroblue tetrazolium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 1.8.1.4", "object_type": "GENE-Y"}, {"subject": "nitroblue tetrazolium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "diaphorase", "object_type": "GENE-N"}, {"subject": "NBT", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Mammalian mitochondrial dihydrolipoamide dehydrogenase", "object_type": "GENE-Y"}, {"subject": "NBT", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DLDH", "object_type": "GENE-Y"}, {"subject": "NBT", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 1.8.1.4", "object_type": "GENE-Y"}, {"subject": "NBT", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "diaphorase", "object_type": "GENE-N"}]}
{"text": "Moreover, this in-gel activity-staining method was demonstrated to be in good agreement with the conventional spectrophotometric method that measures DLDH dehydrogenase activity using dihydrolipoamide as the substrate.", "spo_list": [{"subject": "dihydrolipoamide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "DLDH", "object_type": "GENE-Y"}, {"subject": "dihydrolipoamide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "dehydrogenase", "object_type": "GENE-N"}]}
{"text": "MK-801 ((+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate), a noncompetitive NMDA receptor antagonist, partially prevented the decrease in cell viability and the energy impairment.", "spo_list": [{"subject": "(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine maleate", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NMDA receptor", "object_type": "GENE-N"}, {"subject": "MK-801", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NMDA receptor", "object_type": "GENE-N"}]}
{"text": "A recent study showed that anastrozole, an aromatase inhibitor, is as effective or even superior to tamoxifen when used as a first-line therapy.", "spo_list": [{"subject": "anastrozole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "Fulvestrant, the first agent in this new class, not only induces the degradation of the estrogen receptor but also is an estrogen antagonist; further, its lack of agonist activity provides a better safety profile.", "spo_list": [{"subject": "Fulvestrant", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "estrogen receptor", "object_type": "GENE-Y"}]}
{"text": "Results showed that increase in leukocytes infiltration and overexpressions of TNF-Î± and TGF-Î²1 caused by 8h of PQ exposure were dose-dependently ameliorated by naringin.", "spo_list": [{"subject": "naringin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF-Î±", "object_type": "GENE-Y"}, {"subject": "naringin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TGF-Î²1", "object_type": "GENE-Y"}]}
{"text": "Results showed that naringin of 60 and 120mg/kg significantly reduced PQ-induced upregulations of TNF-Î±, TGF-Î²1, MMP-9 and TIMP-1, levels of pulmonary malonaldehyde and hydroxyproline, as well as pulmonary fibrosis deposition, while increased activities of SOD, GSH-Px and HO-1.", "spo_list": [{"subject": "naringin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF-Î±", "object_type": "GENE-Y"}, {"subject": "naringin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TGF-Î²1", "object_type": "GENE-Y"}, {"subject": "naringin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MMP-9", "object_type": "GENE-Y"}, {"subject": "naringin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TIMP-1", "object_type": "GENE-Y"}, {"subject": "naringin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "SOD", "object_type": "GENE-N"}, {"subject": "naringin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GSH-Px", "object_type": "GENE-N"}, {"subject": "naringin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "HO-1", "object_type": "GENE-Y"}]}
{"text": "Of the proteins with known function, 17 beta HSDXI is most closely related to the retinol-metabolizing enzyme retSDR1, with which it has 30% identity.", "spo_list": [{"subject": "retinol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "retSDR1", "object_type": "GENE-Y"}]}
{"text": "There is a polymorphic stretch of 15 adenosines in the 5' untranslated region of the cDNA sequence and a silent polymorphism at C719T.", "spo_list": [{"subject": "adenosines", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "C719T", "object_type": "GENE-N"}]}
{"text": "A 17 beta HSDXI construct with a stretch of 20 adenosines was found to produce significantly more enzyme activity than constructs containing 15 or less adenosines (43% vs. 26%, P < 0.005).", "spo_list": [{"subject": "adenosines", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "17 beta HSDXI", "object_type": "GENE-Y"}]}
{"text": "Regulation studies in mouse Y1 cells showed that cAMP down-regulates 17 beta HSDXI enzymatic activity (40% vs. 32%, P < 0.05) and reduces gene expression to undetectable levels.", "spo_list": [{"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "17 beta HSDXI", "object_type": "GENE-Y"}]}
{"text": "All-trans-retinoic acid did not affect 17 beta HSDXI expression or activity, but addition of the retinoid together with cAMP significantly decreased activity over cAMP alone (32% vs. 23%, P < 0.05).", "spo_list": [{"subject": "retinoid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "17 beta HSDXI", "object_type": "GENE-Y"}, {"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "17 beta HSDXI", "object_type": "GENE-Y"}, {"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "17 beta HSDXI", "object_type": "GENE-Y"}]}
{"text": "Collectively, these results suggest a role for 17 beta HSDXI in androgen metabolism during steroidogenesis and a possible role in nonsteroidogenic tissues including paracrine modulation of 5 alpha-androstane-3 alpha, 17 beta-diol levels.", "spo_list": [{"subject": "androgen", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "17 beta HSDXI", "object_type": "GENE-Y"}, {"subject": "5 alpha-androstane-3 alpha, 17 beta-diol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "17 beta HSDXI", "object_type": "GENE-Y"}]}
{"text": "17 beta HSDXI could act by metabolizing compounds that stimulate steroid synthesis and/or by generating metabolites that inhibit it.", "spo_list": [{"subject": "steroid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "17 beta HSDXI", "object_type": "GENE-Y"}]}
{"text": "Histidine decarboxylase (HDC) catalyses the formation of histamine, a bioactive amine.", "spo_list": [{"subject": "histamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Histidine decarboxylase", "object_type": "GENE-Y"}, {"subject": "histamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "HDC", "object_type": "GENE-Y"}, {"subject": "amine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Histidine decarboxylase", "object_type": "GENE-Y"}, {"subject": "amine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "HDC", "object_type": "GENE-Y"}]}
{"text": "We searched for inhibitors of HDC from the ethyl acetate extract of the petal of Filipendula ulmaria, also called meadowsweet.", "spo_list": [{"subject": "ethyl acetate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDC", "object_type": "GENE-Y"}]}
{"text": "Delta6-fatty acid desaturase (D6D) is the rate-limiting enzyme, which catalyzes the conversion of linoleic acid (LA) and alpha-linolenic acid (ALA) to GLA and octadecatetraenoic acid (OTA).", "spo_list": [{"subject": "linoleic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Delta6-fatty acid desaturase", "object_type": "GENE-Y"}, {"subject": "LA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Delta6-fatty acid desaturase", "object_type": "GENE-Y"}, {"subject": "alpha-linolenic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Delta6-fatty acid desaturase", "object_type": "GENE-Y"}, {"subject": "ALA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Delta6-fatty acid desaturase", "object_type": "GENE-Y"}, {"subject": "linoleic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "D6D", "object_type": "GENE-Y"}, {"subject": "LA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "D6D", "object_type": "GENE-Y"}, {"subject": "ALA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "D6D", "object_type": "GENE-Y"}, {"subject": "alpha-linolenic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "D6D", "object_type": "GENE-Y"}, {"subject": "GLA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Delta6-fatty acid desaturase", "object_type": "GENE-Y"}, {"subject": "GLA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "D6D", "object_type": "GENE-Y"}, {"subject": "octadecatetraenoic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Delta6-fatty acid desaturase", "object_type": "GENE-Y"}, {"subject": "octadecatetraenoic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "D6D", "object_type": "GENE-Y"}, {"subject": "OTA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Delta6-fatty acid desaturase", "object_type": "GENE-Y"}, {"subject": "OTA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "D6D", "object_type": "GENE-Y"}]}
{"text": "Vardenafil (Levitra), recently launched in Belgium by Bayer and Glaxo-SmithKline, is a new drug that potently and selectively inhibits phosphodiesterase type 5 (PDE5) in the cavernosum tissue of the penis.", "spo_list": [{"subject": "Vardenafil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase type 5", "object_type": "GENE-Y"}, {"subject": "Vardenafil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "Levitra", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase type 5", "object_type": "GENE-Y"}, {"subject": "Levitra", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE5", "object_type": "GENE-Y"}]}
{"text": "Inhibition of PDE5 blocks the hydrolysis of cyclic guanosine monophosphate (GMPc) and results in increased arterial blood flow leading to enlargement of the corpus cavernosum and resulting in erection.", "spo_list": [{"subject": "cyclic guanosine monophosphate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "GMPc", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PDE5", "object_type": "GENE-Y"}]}
{"text": "Vardenafil has a more potent inhibitory activity of PDE5 in vitro than sildenafil or tadalafil while its pharmacokinetics in vivo is somewhat more rapid than that of the two other compounds.", "spo_list": [{"subject": "Vardenafil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE5", "object_type": "GENE-Y"}]}
{"text": "Contra-indications (co-administration with drugs increasing nitric oxide) and side-effects (headache and flushing due to vasodilatation) of vardenafil are similar to those of other PDE5 inhibitors.", "spo_list": [{"subject": "vardenafil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE5", "object_type": "GENE-Y"}]}
{"text": "The interactions between glutamate decarboxylase (GAD) and its cofactor pyridoxal phosphate (PLP) play a key role in the regulation of GAD activity.", "spo_list": [{"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "glutamate decarboxylase", "object_type": "GENE-N"}, {"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GAD", "object_type": "GENE-N"}]}
{"text": "GAD67 exhibits a higher binding constant for PLP binding, making it more difficult to dissociate PLP from holoGAD67 than holoGAD65.", "spo_list": [{"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD67", "object_type": "GENE-Y"}, {"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "holoGAD67", "object_type": "GENE-Y"}, {"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "holoGAD65", "object_type": "GENE-Y"}]}
{"text": "Meanwhile, PLP binding occurs at a much slower rate for GAD67 than GAD65, as evidenced by lower rate constants and a slower initial rate of the holoenzyme formation.", "spo_list": [{"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD67", "object_type": "GENE-Y"}, {"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD65", "object_type": "GENE-Y"}]}
{"text": "Job's plots revealed a stoichiometry of 1:1 for PLP binding to GAD65 before and after the saturation level of PLP, while 1:2 for PLP binding to GAD67 prior to the saturation of PLP and 1:1 at the saturation level of PLP.", "spo_list": [{"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD65", "object_type": "GENE-Y"}, {"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD67", "object_type": "GENE-Y"}]}
{"text": "These results suggested that the two binding sites of GAD65 exhibit similar affinities for PLP.", "spo_list": [{"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD65", "object_type": "GENE-Y"}]}
{"text": "In contrast, one binding site of GAD67 exhibits a significantly higher affinity for PLP than the other binding site.", "spo_list": [{"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD67", "object_type": "GENE-Y"}]}
{"text": "Based on these findings, it was proposed that a slower PLP binding to GAD67 than GAD65 and a less ease to dissociate PLP from holoGAD67 than holoGAD65 are important underlying factors.", "spo_list": [{"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD67", "object_type": "GENE-Y"}, {"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD65", "object_type": "GENE-Y"}, {"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "holoGAD67", "object_type": "GENE-Y"}, {"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "holoGAD65", "object_type": "GENE-Y"}]}
{"text": "This attributes to GAD67 being more highly saturated by PLP and GAD65 being less saturated by PLP.", "spo_list": [{"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD67", "object_type": "GENE-Y"}]}
{"text": "A larger conformation change constant for GAD67 than GAD65 supported a significant conformational change induced by the initial PLP binding to GAD67, which affects the other binding site affinity of GAD67.", "spo_list": [{"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD67", "object_type": "GENE-Y"}, {"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD67", "object_type": "GENE-Y"}]}
{"text": "The in vivo estrogenicity of BzP was supported by in vitro results from the human estrogen receptor Î± (hERÎ±)-coactivator recruiting assay and in silico molecular docking analysis performed in this study.", "spo_list": [{"subject": "BzP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "human estrogen receptor Î±", "object_type": "GENE-Y"}, {"subject": "BzP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "hERÎ±", "object_type": "GENE-Y"}]}
{"text": "Molecular docking analysis showed that BzP fits well into the agonist pocket of hERÎ±.", "spo_list": [{"subject": "BzP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hERÎ±", "object_type": "GENE-Y"}]}
{"text": "The inhibitory effects of the nitrogen-containing BPs (including alendronate, risedronate, ibandronate, and zoledronate) on osteoclasts appear to result from their inhibition of farnesyl pyrophosphate synthase (FPPS), a key branch-point enzyme in the mevalonate pathway.", "spo_list": [{"subject": "alendronate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "farnesyl pyrophosphate synthase", "object_type": "GENE-Y"}, {"subject": "risedronate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "farnesyl pyrophosphate synthase", "object_type": "GENE-Y"}, {"subject": "ibandronate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "farnesyl pyrophosphate synthase", "object_type": "GENE-Y"}, {"subject": "zoledronate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "farnesyl pyrophosphate synthase", "object_type": "GENE-Y"}, {"subject": "alendronate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FPPS", "object_type": "GENE-Y"}, {"subject": "risedronate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FPPS", "object_type": "GENE-Y"}, {"subject": "ibandronate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FPPS", "object_type": "GENE-Y"}, {"subject": "zoledronate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FPPS", "object_type": "GENE-Y"}]}
{"text": "Saccharopine dehydrogenase [N6-(glutaryl-2)-L-lysine:NAD oxidoreductase (L-lysine forming)] catalyzes the final step in the alpha-aminoadipate pathway for lysine biosynthesis.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Saccharopine dehydrogenase", "object_type": "GENE-Y"}, {"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "[N6-(glutaryl-2)-L-lysine:NAD oxidoreductase (L-lysine forming)]", "object_type": "GENE-Y"}]}
{"text": "TWIK-1 channel activity is blocked by Ba2+(IC50=100 microM), quinine (IC50=50 microM) and quinidine (IC50=95 microM).", "spo_list": [{"subject": "Ba2+", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TWIK-1", "object_type": "GENE-Y"}, {"subject": "quinine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TWIK-1", "object_type": "GENE-Y"}, {"subject": "quinidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TWIK-1", "object_type": "GENE-Y"}]}
{"text": "TWIK-1 channels are probably involved in the control of background K+ membrane conductances.", "spo_list": [{"subject": "K+", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "TWIK-1", "object_type": "GENE-Y"}]}
{"text": "Bupropion and its metabolites lacked affinity for nicotinic acetylcholinergic receptors, but all antagonized (-)nicotine-induced 86Rb+ efflux in cells expressing alpha3beta4 nicotinic cholinergic receptors.", "spo_list": [{"subject": "Bupropion", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha3beta4 nicotinic cholinergic receptors", "object_type": "GENE-Y"}, {"subject": "(-)nicotine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha3beta4 nicotinic cholinergic receptors", "object_type": "GENE-Y"}]}
{"text": "S,S-Hydroxybupropion possessed affinity at the dopamine transporter comparable to bupropion, and was also found to bind at the norepinephrine transporter.", "spo_list": [{"subject": "S,S-Hydroxybupropion", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "dopamine transporter", "object_type": "GENE-Y"}, {"subject": "S,S-Hydroxybupropion", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "norepinephrine transporter", "object_type": "GENE-Y"}]}
{"text": "In the present study, S-adenosylmethionine decarboxylase (SAMDC), a key gene involved in polyamine biosynthesis, has been targeted in tapetal tissue of tomato using RNAi to examine its effect on tapetum development and pollen viability.", "spo_list": [{"subject": "polyamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "S-adenosylmethionine decarboxylase", "object_type": "GENE-Y"}, {"subject": "polyamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "SAMDC", "object_type": "GENE-Y"}]}
{"text": "The other polyamine biosynthesis genes, ADC and SPDSYN exhibited ~1.5 fold decrease in their transcript levels.", "spo_list": [{"subject": "polyamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ADC", "object_type": "GENE-Y"}, {"subject": "polyamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "SPDSYN", "object_type": "GENE-Y"}]}
{"text": "Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.", "spo_list": [{"subject": "imiquimod", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "TLR7", "object_type": "GENE-Y"}, {"subject": "resiquimod", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "TLR7", "object_type": "GENE-Y"}]}
{"text": "The immune response modifiers, imiquimod and resiquimod, are TLR7 agonists that induce type I interferon in numerous species, including humans.", "spo_list": [{"subject": "imiquimod", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "TLR7", "object_type": "GENE-Y"}, {"subject": "resiquimod", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "TLR7", "object_type": "GENE-Y"}, {"subject": "imiquimod", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "type I interferon", "object_type": "GENE-N"}, {"subject": "resiquimod", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "type I interferon", "object_type": "GENE-N"}]}
{"text": "Here, we characterize the activation of human pDC with the TLR7 agonists imiquimod and resiquimod.", "spo_list": [{"subject": "imiquimod", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "TLR7", "object_type": "GENE-Y"}, {"subject": "resiquimod", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "TLR7", "object_type": "GENE-Y"}]}
{"text": "Results indicate that imiquimod and resiquimod induce IFN-alpha and IFN-omega from purified pDC, and pDC are the principle IFN-producing cells in the blood.", "spo_list": [{"subject": "imiquimod", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IFN-alpha", "object_type": "GENE-N"}, {"subject": "imiquimod", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IFN-omega", "object_type": "GENE-N"}]}
{"text": "Resiquimod-stimulated pDC also produce a number of other cytokines including TNF-alpha and IP-10.", "spo_list": [{"subject": "Resiquimod", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytokines", "object_type": "GENE-N"}, {"subject": "Resiquimod", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TNF-alpha", "object_type": "GENE-Y"}, {"subject": "Resiquimod", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IP-10", "object_type": "GENE-Y"}]}
{"text": "Resiquimod enhances co-stimulatory marker expression, CCR7 expression, and pDC viability.", "spo_list": [{"subject": "Resiquimod", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CCR7", "object_type": "GENE-Y"}]}
{"text": "These results demonstrate that imidazoquinoline molecules directly induce pDC maturation as determined by cytokine induction, CCR7 and co-stimulatory marker expression and prolonging viability.", "spo_list": [{"subject": "imidazoquinoline", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytokine", "object_type": "GENE-N"}]}
{"text": "The transport amiloride-sensitive mechanism, that decreased the acidic intracellular pH change occurring in this medium, would correspond to Na+-H+ exchange (NHE1 isoform).", "spo_list": [{"subject": "Na+", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NHE1", "object_type": "GENE-Y"}, {"subject": "H+", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "NHE1", "object_type": "GENE-Y"}]}
{"text": "Recent studies have indicated that the basic residues Arg(93), Lys(96), Arg(125), Arg(165), Lys(169), Lys(236), and Arg(240) (chymotrypsin numbering) constitute an exosite in the catalytic domain of factor Xa that can effectively bind heparin only if the acidic N-terminal Gla domain of the proteinase was neutralized by physiological levels of calcium.", "spo_list": [{"subject": "Arg", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "chymotrypsin", "object_type": "GENE-N"}, {"subject": "Lys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "chymotrypsin", "object_type": "GENE-N"}, {"subject": "Arg", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "chymotrypsin", "object_type": "GENE-N"}, {"subject": "Arg", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "chymotrypsin", "object_type": "GENE-N"}, {"subject": "Lys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "chymotrypsin", "object_type": "GENE-N"}, {"subject": "Lys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "chymotrypsin", "object_type": "GENE-N"}, {"subject": "Arg", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "chymotrypsin", "object_type": "GENE-N"}, {"subject": "Arg", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "factor Xa", "object_type": "GENE-Y"}, {"subject": "Lys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "factor Xa", "object_type": "GENE-Y"}, {"subject": "Arg", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "factor Xa", "object_type": "GENE-Y"}, {"subject": "Arg", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "factor Xa", "object_type": "GENE-Y"}, {"subject": "Lys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "factor Xa", "object_type": "GENE-Y"}, {"subject": "Lys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "factor Xa", "object_type": "GENE-Y"}, {"subject": "Arg", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "factor Xa", "object_type": "GENE-Y"}]}
{"text": "Moreover, certain basic residues of this site, particularly Arg(165) and Lys(169), play a key role in factor Va and/or prothrombin recognition by factor Xa in the prothrombinase complex.", "spo_list": [{"subject": "Arg", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "factor Xa", "object_type": "GENE-Y"}, {"subject": "Lys", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "factor Xa", "object_type": "GENE-Y"}]}
{"text": "Amitriptyline, clomipramine, doxepin, imipramine, and trimipramine are demethylated by CYP2C19 to pharmacologically active metabolites.", "spo_list": [{"subject": "Amitriptyline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C19", "object_type": "GENE-Y"}, {"subject": "clomipramine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C19", "object_type": "GENE-Y"}, {"subject": "doxepin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C19", "object_type": "GENE-Y"}, {"subject": "imipramine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C19", "object_type": "GENE-Y"}, {"subject": "trimipramine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C19", "object_type": "GENE-Y"}]}
{"text": "These drugs and their metabolites, along with desipramine and nortriptyline, undergo hydroxylation by CYP2D6 to less active metabolites.", "spo_list": [{"subject": "desipramine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2D6", "object_type": "GENE-Y"}, {"subject": "nortriptyline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2D6", "object_type": "GENE-Y"}]}
{"text": "Thus, in order to examine the anatomical substrates and physiological effects of group III mGluRs activation upon striatal and pallidal neurons in monkeys, we used electron microscopy immunohistochemistry to localize mGluR4, combined with local administration of the group III mGluR agonist L-AP4, or the mGluR4 positive allosteric modulator VU0155041, to assess the effects of group III mGluR activation on the firing rate and pattern of striatal and pallidal neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated parkinsonian monkeys.", "spo_list": [{"subject": "L-AP4", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "group III mGluR", "object_type": "GENE-N"}]}
{"text": "Our findings indicate that glutamate can mediate multifarious physiological effects upon striatal and pallidal neurons through activation of pre-synaptic group III mGluRs at inhibitory and excitatory synapses in parkinsonian monkeys.", "spo_list": [{"subject": "glutamate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "group III mGluRs", "object_type": "GENE-N"}]}
{"text": "Type 2 11Î²-hydroxysteroid dehydrogenase encoded by the HSD11B2 gene converts cortisol to inactive cortisone, and alteration in this enzymatic activity might affect glucose homeostasis by affecting circulating levels or tissue availability of glucocorticoids.", "spo_list": [{"subject": "cortisol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE_PRODUCT-OF", "object": "Type 2 11Î²-hydroxysteroid dehydrogenase", "object_type": "GENE-Y"}, {"subject": "cortisol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE_PRODUCT-OF", "object": "HSD11B2", "object_type": "GENE-Y"}, {"subject": "cortisone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE_PRODUCT-OF", "object": "Type 2 11Î²-hydroxysteroid dehydrogenase", "object_type": "GENE-Y"}, {"subject": "cortisone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE_PRODUCT-OF", "object": "HSD11B2", "object_type": "GENE-Y"}]}
{"text": "Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.", "spo_list": [{"subject": "ramelteon", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "MT1", "object_type": "GENE-Y"}, {"subject": "TAK-375", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "MT1", "object_type": "GENE-Y"}, {"subject": "ramelteon", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "MT2 receptor", "object_type": "GENE-Y"}, {"subject": "TAK-375", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "MT2 receptor", "object_type": "GENE-Y"}]}
{"text": "Ramelteon (TAK-375) is a novel melatonin receptor agonist currently under investigation for the treatment of insomnia.", "spo_list": [{"subject": "Ramelteon", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "melatonin receptor", "object_type": "GENE-N"}, {"subject": "TAK-375", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "melatonin receptor", "object_type": "GENE-N"}]}
{"text": "Ramelteon showed very high affinity for human MT1 (Mel1a) and MT2 (Mel1b) receptors (expressed in Chinese hamster ovary [CHO] cells), and chick forebrain melatonin receptors (consisting of Mel1a and Mel1c receptors) with Ki values of 14.0, 112, and 23.1 pM, respectively, making the affinities of ramelteon for these receptors 3-16 times higher than those of melatonin.", "spo_list": [{"subject": "Ramelteon", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human MT1", "object_type": "GENE-Y"}, {"subject": "Ramelteon", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Mel1a", "object_type": "GENE-Y"}, {"subject": "Ramelteon", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MT2", "object_type": "GENE-Y"}, {"subject": "Ramelteon", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Mel1b", "object_type": "GENE-Y"}, {"subject": "Ramelteon", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Mel1a", "object_type": "GENE-Y"}, {"subject": "Ramelteon", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Mel1c", "object_type": "GENE-Y"}]}
{"text": "The affinity of ramelteon for hamster brain MT3 binding sites was extremely weak (Ki: 2.65 microM) compared to melatonin's affinity for the MT3 binding site (Ki: 24.1 nM).", "spo_list": [{"subject": "ramelteon", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MT3", "object_type": "GENE-N"}]}
{"text": "Taken together, these results indicate that ramelteon is a potent and highly selective agonist of MT1/MT2 melatonin receptors.", "spo_list": [{"subject": "ramelteon", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "MT1", "object_type": "GENE-Y"}, {"subject": "ramelteon", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "MT2 melatonin receptors", "object_type": "GENE-Y"}]}
{"text": "GnRH pulse frequency-dependent stimulation of FSHÎ² transcription is mediated via activation of PKA and CREB.", "spo_list": [{"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "FSHÎ²", "object_type": "GENE-Y"}, {"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PKA", "object_type": "GENE-N"}, {"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CREB", "object_type": "GENE-N"}]}
{"text": "Expression of pituitary FSH and LH, under the control of pulsatile GnRH, is essential for fertility. cAMP response element-binding protein (CREB) has been implicated in the regulation of FSHÎ² gene expression, but the molecular mechanisms by which pulsatile GnRH regulates CREB activation remain poorly understood.", "spo_list": [{"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CREB", "object_type": "GENE-N"}]}
{"text": "We hypothesized that CREB is activated by a distinct signaling pathway in response to pulsatile GnRH in a frequency-dependent manner to dictate the FSHÎ² transcriptional response.", "spo_list": [{"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CREB", "object_type": "GENE-N"}]}
{"text": "GnRH stimulation of CREB phosphorylation (pCREB) in the gonadotrope-derived LÎ²T2 cell line was attenuated by a protein kinase A (PKA) inhibitor, H89.", "spo_list": [{"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CREB", "object_type": "GENE-N"}, {"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "pCREB", "object_type": "GENE-N"}, {"subject": "H89", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "protein kinase A", "object_type": "GENE-N"}, {"subject": "H89", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PKA", "object_type": "GENE-N"}, {"subject": "H89", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CREB", "object_type": "GENE-N"}, {"subject": "H89", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "pCREB", "object_type": "GENE-N"}]}
{"text": "A dominant negative PKA (DNPKA) reduced GnRH-stimulated pCREB and markedly decreased GnRH stimulation of FSHÎ² mRNA and FSHÎ²LUC activity, but had little effect on LHÎ²LUC activity, indicating relative specificity of this pathway.", "spo_list": [{"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "pCREB", "object_type": "GENE-N"}, {"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "FSHÎ²", "object_type": "GENE-Y"}, {"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "FSHÎ²", "object_type": "GENE-Y"}]}
{"text": "In perifusion studies, FSHÎ² mRNA levels and FSHÎ²LUC activities were increased by pulsatile GnRH, with significantly greater increases at low compared with high pulse frequencies.", "spo_list": [{"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "FSHÎ²", "object_type": "GENE-Y"}, {"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "FSHÎ²", "object_type": "GENE-Y"}]}
{"text": "DNPKA markedly reduced these GnRH-stimulated FSHÎ² responses at both low and high pulse frequencies.", "spo_list": [{"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "FSHÎ²", "object_type": "GENE-Y"}]}
{"text": "Correlating with FSHÎ² activation, both PKA activity and levels of pCREB were increased to a greater extent by low compared with high GnRH pulse frequencies, and the induction of pCREB was also attenuated by overexpression of DNPKA at both low and high pulse frequencies.", "spo_list": [{"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "FSHÎ²", "object_type": "GENE-Y"}, {"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PKA", "object_type": "GENE-N"}, {"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "pCREB", "object_type": "GENE-N"}, {"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "pCREB", "object_type": "GENE-N"}]}
{"text": "Taken together, these data indicate that a PKA-mediated signaling pathway mediates GnRH activation of CREB at low-pulse frequencies, playing a significant role in the decoding of the hypothalamic GnRH signal to result in frequency-dependent FSHÎ² activation.", "spo_list": [{"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CREB", "object_type": "GENE-N"}, {"subject": "GnRH", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "FSHÎ²", "object_type": "GENE-Y"}]}
{"text": "The phosphodiesterase inhibitor pentoxifylline (PTX) exerts multiple beneficial immunomodulatory effects in states of hyperinflammation.", "spo_list": [{"subject": "pentoxifylline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase", "object_type": "GENE-N"}, {"subject": "PTX", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "phosphodiesterase", "object_type": "GENE-N"}]}
{"text": "In T cells, adenosine plus PTX revealed similar synergistic inhibitory effects on proinflammatory cytokine production.", "spo_list": [{"subject": "adenosine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cytokine", "object_type": "GENE-N"}, {"subject": "PTX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cytokine", "object_type": "GENE-N"}]}
{"text": "Inhibition of interferon gamma and TNF-alpha production increased from 7% (+/-1%) and 31% (+/-6%) (PTX alone) to 49% (+/-2%) and 69% (+/-6%), respectively.", "spo_list": [{"subject": "PTX", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "interferon gamma", "object_type": "GENE-Y"}, {"subject": "PTX", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TNF-alpha", "object_type": "GENE-Y"}]}
{"text": "Synthesis and biological evaluation of 1,3,4-thiadiazole analogues as novel AChE and BuChE inhibitors.", "spo_list": [{"subject": "1,3,4-thiadiazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "1,3,4-thiadiazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BuChE", "object_type": "GENE-Y"}]}
{"text": "In this paper a series of new 1,3,4-thiadiazole derivatives has been designed, synthesized and evaluated as the acetyl- and butyrylcholinesterase inhibitors.", "spo_list": [{"subject": "1,3,4-thiadiazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetyl- and butyrylcholinesterase", "object_type": "GENE-N"}]}
{"text": "Lovastatin, a specific inhibitor of HMG-CoA reductase, induces a pronounced apoptotic response in a specific subset of tumor types, including HNSCC and CC.", "spo_list": [{"subject": "Lovastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HMG-CoA reductase", "object_type": "GENE-Y"}]}
{"text": "Dihydrotachysterol3, a reduced (or hydrogenated) analog of vitamin D3 in which the A ring has been rotate through 180 degrees , is, after hepatic 25-hydroxylation, converted in vivo to a dihydroxylated metabolite, termed peak H, which is at present unidentified but with good affinity for the vitamin D receptor.", "spo_list": [{"subject": "Dihydrotachysterol3", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "vitamin D receptor", "object_type": "GENE-Y"}]}
{"text": "We found that in vitro rapamycin also regulates the proteasome, an essential intracellular protease of the ubiquitin-proteasome pathway.", "spo_list": [{"subject": "rapamycin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "proteasome", "object_type": "GENE-N"}, {"subject": "rapamycin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ubiquitin", "object_type": "GENE-N"}, {"subject": "rapamycin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "proteasome", "object_type": "GENE-N"}]}
{"text": "Rapamycin inhibits proteinase and selected peptidase activities of the catalytic core proteasome at low micromolar concentrations.", "spo_list": [{"subject": "Rapamycin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "proteinase", "object_type": "GENE-N"}, {"subject": "Rapamycin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "peptidase", "object_type": "GENE-N"}, {"subject": "Rapamycin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "proteasome", "object_type": "GENE-N"}]}
{"text": "Control of hypercholesterolemia and atherosclerosis using the cholesterol recognition/interaction amino acid sequence of the translocator protein TSPO.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "translocator protein TSPO", "object_type": "GENE-Y"}]}
{"text": "The translocator protein (18-kDa) TSPO is an ubiquitous high affinity cholesterol-binding protein reported to be present in the endothelial and smooth muscle cells of the blood vessels; its expression dramatically increased in macrophages found in atherosclerotic plaques.", "spo_list": [{"subject": "cholesterol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "translocator protein (18-kDa) TSPO", "object_type": "GENE-Y"}]}
{"text": "A domain in the carboxy-terminus of TSPO was identified and characterized as the cholesterol recognition/interaction amino acid consensus (CRAC).", "spo_list": [{"subject": "carboxy", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "TSPO", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "TSPO", "object_type": "GENE-Y"}, {"subject": "cholesterol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "TSPO", "object_type": "GENE-Y"}]}
{"text": "The treatment also prevented the high cholesterol diet-induced increase in serum creatine kinase, total and isoforms, markers of neurological, cardiac and muscular damage.", "spo_list": [{"subject": "cholesterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "creatine kinase", "object_type": "GENE-N"}]}
{"text": "Thalidomide--removed from widespread clinical use by 1962 because of severe teratogenicity--has anti-angiogenic and immunomodulatory effects, including the inhibition of TNF alpha.", "spo_list": [{"subject": "Thalidomide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TNF alpha", "object_type": "GENE-Y"}]}
{"text": "Pelargonidin activates the AhR and induces CYP1A1 in primary human hepatocytes and human cancer cell lines HepG2 and LS174T.", "spo_list": [{"subject": "Pelargonidin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AhR", "object_type": "GENE-Y"}]}
{"text": "AhR-dependent reporter gene expression in transfected HepG2 cells was increased by pelargonidin in a concentration-dependent manner at 24h.", "spo_list": [{"subject": "pelargonidin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AhR", "object_type": "GENE-Y"}]}
{"text": "Similarly, pelargonidin induced the expression of CYP1A1 mRNA up to 5-fold in HepG2 and LS174T cells relative to the induction by 5 nM 2,3,7,8-tetrachlorodibenzodioxin (TCDD), the most potent activator of AhR.", "spo_list": [{"subject": "pelargonidin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP1A1", "object_type": "GENE-Y"}, {"subject": "2,3,7,8-tetrachlorodibenzodioxin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AhR", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AhR", "object_type": "GENE-Y"}, {"subject": "2,3,7,8-tetrachlorodibenzodioxin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP1A1", "object_type": "GENE-Y"}]}
{"text": "CYP1A1 and CYP1A2 mRNAs were also increased by pelargonidin in three primary human hepatocytes cultures (approximately 5% of TCDD potency) and the increase in CYP1A1 protein in HepG2 and LS174T cells was comparable to the increase in catalytic activity of CYP1A1 enzyme.", "spo_list": [{"subject": "pelargonidin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP1A1", "object_type": "GENE-Y"}, {"subject": "pelargonidin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP1A2", "object_type": "GENE-Y"}]}
{"text": "Ligand binding analysis demonstrated that pelargonidin was a weak ligand of AhR.", "spo_list": [{"subject": "pelargonidin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AhR", "object_type": "GENE-Y"}]}
{"text": "Enzyme kinetic analyses using human liver microsomes revealed inhibition of CYP1A1 activity by delphinidin (IC50 78 Î¼M) and pelargonidin (IC50 33 Î¼M).", "spo_list": [{"subject": "delphinidin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP1A1", "object_type": "GENE-Y"}, {"subject": "pelargonidin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP1A1", "object_type": "GENE-Y"}]}
{"text": "Overall, although most anthocyanidins had no effects on AhR-CYP1A1 signaling, pelargonidin can bind to and activate the AhR and AhR-dependent gene expression, and pelargonidin and delphinidin inhibit the CYP1A1 catalytic activity.", "spo_list": [{"subject": "pelargonidin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AhR", "object_type": "GENE-Y"}, {"subject": "pelargonidin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AhR", "object_type": "GENE-Y"}, {"subject": "pelargonidin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP1A1", "object_type": "GENE-Y"}, {"subject": "delphinidin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP1A1", "object_type": "GENE-Y"}]}
{"text": "We found that helenalin markedly induced endoplasmic reticulum (ER) stress-related genes, such as regulated in development and DNA damage responses (REDD) 1, activating transcription factor-4 (ATF4) and/or the CCAAT enhancer-binding protein-homologous protein (CHOP).", "spo_list": [{"subject": "helenalin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "regulated in development and DNA damage responses (REDD) 1", "object_type": "GENE-Y"}, {"subject": "helenalin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "activating transcription factor-4", "object_type": "GENE-Y"}, {"subject": "helenalin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ATF4", "object_type": "GENE-Y"}, {"subject": "helenalin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CCAAT enhancer-binding protein-homologous protein", "object_type": "GENE-Y"}, {"subject": "helenalin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CHOP", "object_type": "GENE-Y"}]}
{"text": "Overexpression of proline oxidase induces proline-dependent and mitochondria-mediated apoptosis.", "spo_list": [{"subject": "proline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "proline oxidase", "object_type": "GENE-Y"}]}
{"text": "Proline oxidase (POX), a mitochondrial inner-membrane protein, catalyzes the rate-limiting oxidation of proline to pyrroline- 5-carboxylate (P5C).", "spo_list": [{"subject": "proline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Proline oxidase", "object_type": "GENE-Y"}, {"subject": "proline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "POX", "object_type": "GENE-Y"}, {"subject": "pyrroline- 5-carboxylate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Proline oxidase", "object_type": "GENE-Y"}, {"subject": "pyrroline- 5-carboxylate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "POX", "object_type": "GENE-Y"}, {"subject": "P5C", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Proline oxidase", "object_type": "GENE-Y"}, {"subject": "P5C", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "POX", "object_type": "GENE-Y"}]}
{"text": "To further investigate the molecular basis of POX-induced apoptosis, we utilized the DLD-1.POX cells to show that cells overproducing POX exhibit an L-proline-dependent apoptotic response.", "spo_list": [{"subject": "L-proline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "POX", "object_type": "GENE-Y"}]}
{"text": "The apoptotic effect is specific for L-proline, detectable at 0.2 mM, maximal at 1 mM, and occurs during 48-72 h following the addition of L-proline to cells with maximally induced POX.", "spo_list": [{"subject": "L-proline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "POX", "object_type": "GENE-Y"}]}
{"text": "We conclude that in the presence of proline, high POX activity is sufficient to induce mitochondria-mediated apoptosis.", "spo_list": [{"subject": "proline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "POX", "object_type": "GENE-Y"}]}
{"text": "The antipsychotic drugs sertindole and pimozide block erg3, a human brain K(+) channel.", "spo_list": [{"subject": "pimozide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "erg3", "object_type": "GENE-Y"}, {"subject": "sertindole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "erg3", "object_type": "GENE-Y"}, {"subject": "sertindole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human brain K(+) channel", "object_type": "GENE-N"}, {"subject": "pimozide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human brain K(+) channel", "object_type": "GENE-N"}]}
{"text": "The antipsychotic drugs sertindole and pimozide are known to prolong the QT interval on the electrocardiogram via a high affinity block of the cardiac K(+) channel known as HERG (human ether-a-go-go-related gene; erg1).", "spo_list": [{"subject": "sertindole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cardiac K(+) channel", "object_type": "GENE-N"}, {"subject": "pimozide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cardiac K(+) channel", "object_type": "GENE-N"}, {"subject": "sertindole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HERG", "object_type": "GENE-Y"}, {"subject": "pimozide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HERG", "object_type": "GENE-Y"}, {"subject": "sertindole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human ether-a-go-go-related gene", "object_type": "GENE-Y"}, {"subject": "pimozide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human ether-a-go-go-related gene", "object_type": "GENE-Y"}, {"subject": "sertindole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "erg1", "object_type": "GENE-Y"}, {"subject": "pimozide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "erg1", "object_type": "GENE-Y"}]}
{"text": "Block of erg3 by sertindole also displayed a positive voltage-dependence.", "spo_list": [{"subject": "sertindole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "erg3", "object_type": "GENE-Y"}]}
{"text": "Pimozide blocked erg3 channel currents with an IC(50) of 103 nM and significant inhibition was noted at concentrations of 10 nM and higher.", "spo_list": [{"subject": "Pimozide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "erg3", "object_type": "GENE-Y"}]}
{"text": "We conclude that erg3 can be blocked by certain antipsychotic drugs like sertindole and pimozide.", "spo_list": [{"subject": "sertindole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "erg3", "object_type": "GENE-Y"}, {"subject": "pimozide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "erg3", "object_type": "GENE-Y"}]}
{"text": "This response was: (1) partly blocked in dogs pretreated intravenously with the antagonists SB224289 (5-HT(1B); 2,3,6,7-tetrahydro-1'-methyl-5-[2'-methyl-4' (5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carbonyl]furo[2,3-f]indole-3-spiro-4'-p iperidine hydrochloride), rauwolscine (alpha(2)), BRL44408 (alpha(2A); 2-[2H-(1-methyl-1,3-dihydroisoindole)methyl]-4,5-dihydroimidazole) or MK912 (alpha(2C); (2S,12bS)-1'3'-dimethylspiro(1,3,4,5',6,6',7,12b-octahydro-2Hbenzo[b]furo[2,3-a]q uinazoline)-2,4'-pyrimidin-2'-one); (2) markedly blocked after SB224289 plus rauwolscine; and (3) unaffected after BRL15572 (5-HT(1D); 1-(3-chlorophenyl)-4-[3,3-diphenyl (2-(S,R) hydroxypropanyl) piperazine] hydrochloride) or imiloxan (alpha(2B)).", "spo_list": [{"subject": "SB224289", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT(1B)", "object_type": "GENE-Y"}, {"subject": "2,3,6,7-tetrahydro-1'-methyl-5-[2'-methyl-4' (5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-carbonyl]furo[2,3-f]indole-3-spiro-4'-p iperidine hydrochloride", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2)", "object_type": "GENE-N"}, {"subject": "rauwolscine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2)", "object_type": "GENE-N"}, {"subject": "BRL44408", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2A)", "object_type": "GENE-Y"}, {"subject": "2-[2H-(1-methyl-1,3-dihydroisoindole)methyl]-4,5-dihydroimidazole", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2C)", "object_type": "GENE-N"}, {"subject": "MK912", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2C)", "object_type": "GENE-N"}, {"subject": "1-(3-chlorophenyl)-4-[3,3-diphenyl (2-(S,R) hydroxypropanyl) piperazine] hydrochloride", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2B)", "object_type": "GENE-Y"}, {"subject": "imiloxan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2B)", "object_type": "GENE-Y"}]}
{"text": "Novel racemic tetrahydrocurcuminoid dihydropyrimidinone analogues as potent acetylcholinesterase inhibitors.", "spo_list": [{"subject": "tetrahydrocurcuminoid dihydropyrimidinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}]}
{"text": "It increased the activity of ALP, and osteocalcin was also elevated in response to sweroside (P<0.05).", "spo_list": [{"subject": "sweroside", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ALP", "object_type": "GENE-N"}, {"subject": "sweroside", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "osteocalcin", "object_type": "GENE-N"}]}
{"text": "Characterisation of the 5-HT receptor binding profile of eletriptan and kinetics of [3H]eletriptan binding at human 5-HT1B and 5-HT1D receptors.", "spo_list": [{"subject": "eletriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT receptor", "object_type": "GENE-N"}, {"subject": "[3H]eletriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human 5-HT1B", "object_type": "GENE-Y"}, {"subject": "[3H]eletriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-Y"}]}
{"text": "The affinity of eletriptan ((R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole) for a range of 5-HT receptors was compared to values obtained for other 5-HT1B/1D receptor agonists known to be effective in the treatment of migraine.", "spo_list": [{"subject": "eletriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT receptors", "object_type": "GENE-N"}, {"subject": "(R)-3-(1-methyl-2-pyrrolidinylmethyl)-5-[2-(phenylsulphonyl )ethyl]-1H-indole", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT receptors", "object_type": "GENE-N"}]}
{"text": "Eletriptan, like sumatriptan, zolmitriptan, naratriptan and rizatriptan had highest affinity for the human 5-HT1B, 5-HT1D and putative 5-ht1f receptor.", "spo_list": [{"subject": "Eletriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human 5-HT1B", "object_type": "GENE-Y"}, {"subject": "sumatriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human 5-HT1B", "object_type": "GENE-Y"}, {"subject": "zolmitriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human 5-HT1B", "object_type": "GENE-Y"}, {"subject": "naratriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human 5-HT1B", "object_type": "GENE-Y"}, {"subject": "rizatriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human 5-HT1B", "object_type": "GENE-Y"}, {"subject": "Eletriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-Y"}, {"subject": "sumatriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-Y"}, {"subject": "zolmitriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-Y"}, {"subject": "naratriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-Y"}, {"subject": "rizatriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-Y"}, {"subject": "Eletriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-ht1f", "object_type": "GENE-Y"}, {"subject": "sumatriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-ht1f", "object_type": "GENE-Y"}, {"subject": "zolmitriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-ht1f", "object_type": "GENE-Y"}, {"subject": "naratriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-ht1f", "object_type": "GENE-Y"}, {"subject": "rizatriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-ht1f", "object_type": "GENE-Y"}]}
{"text": "Kinetic studies comparing the binding of [3H]eletriptan and [3H]sumatriptan to the human recombinant 5-HT1B and 5-HT1D receptors expressed in HeLa cells revealed that both radioligands bound with high specificity (>90%) and reached equilibrium within 10-15 min.", "spo_list": [{"subject": "[3H]eletriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human recombinant 5-HT1B", "object_type": "GENE-Y"}, {"subject": "[3H]sumatriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human recombinant 5-HT1B", "object_type": "GENE-Y"}, {"subject": "[3H]eletriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-Y"}, {"subject": "[3H]sumatriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-Y"}]}
{"text": "However, [3H]eletriptan had over 6-fold higher affinity than [3H]sumatriptan at the 5-HT1D receptor (K(D)): 0.92 and 6.58 nM, respectively) and over 3-fold higher affinity than [3H]sumatriptan at the 5-HT1B receptor (K(D): 3.14 and 11.07 nM, respectively).", "spo_list": [{"subject": "[3H]eletriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-Y"}, {"subject": "[3H]sumatriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1D", "object_type": "GENE-Y"}, {"subject": "[3H]sumatriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1B", "object_type": "GENE-Y"}, {"subject": "[3H]eletriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1B", "object_type": "GENE-Y"}, {"subject": "[3H]sumatriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1B", "object_type": "GENE-Y"}]}
{"text": "Expression of particular steroidogenic genes, including the one encoding for aromatase (CYP19A1), was significantly upregulated after incubation of H295R cells with 2-ITX, 4-ITX, and 2,4-diethyl-TX.", "spo_list": [{"subject": "2-ITX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "2-ITX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP19A1", "object_type": "GENE-Y"}, {"subject": "4-ITX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "4-ITX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP19A1", "object_type": "GENE-Y"}, {"subject": "2,4-diethyl-TX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "2,4-diethyl-TX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP19A1", "object_type": "GENE-Y"}]}
{"text": "In line with the increased CYP19A1 mRNA expression, 2-ITX increased catalytic activity of aromatase in H295R cells as measured by cognate aromatase assays.", "spo_list": [{"subject": "2-ITX", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "2-ITX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP19A1", "object_type": "GENE-Y"}]}
{"text": "Structure-based design of aliskiren, a novel orally effective renin inhibitor.", "spo_list": [{"subject": "aliskiren", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "renin", "object_type": "GENE-Y"}]}
{"text": "This led to the discovery of aliskiren, a highly potent and selective inhibitor of human renin in vitro, and in vivo; once-daily oral doses of aliskiren inhibit renin and lower blood pressure in sodium-depleted marmosets and hypertensive human patients.", "spo_list": [{"subject": "aliskiren", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human renin", "object_type": "GENE-Y"}, {"subject": "aliskiren", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "renin", "object_type": "GENE-Y"}]}
{"text": "Aliskiren represents the first in a novel class of renin inhibitors with the potential for treatment of hypertension and related cardiovascular diseases.", "spo_list": [{"subject": "Aliskiren", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "renin", "object_type": "GENE-Y"}]}
{"text": "Cyclooxygenase-1 (COX-1) inhibition by a selective inhibitor valeryl salicylate, or nonselective inhibitors at 10 mg/kg, including aspirin, ibuprofen, indomethacin, and picroxicam, attenuated by 29%-46% the duration of loss of righting reflex induced by diazepam (20 mg/kg) in mice.", "spo_list": [{"subject": "valeryl salicylate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Cyclooxygenase-1", "object_type": "GENE-Y"}, {"subject": "valeryl salicylate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "aspirin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Cyclooxygenase-1", "object_type": "GENE-Y"}, {"subject": "aspirin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "ibuprofen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Cyclooxygenase-1", "object_type": "GENE-Y"}, {"subject": "ibuprofen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Cyclooxygenase-1", "object_type": "GENE-Y"}, {"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "picroxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Cyclooxygenase-1", "object_type": "GENE-Y"}, {"subject": "picroxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}]}
{"text": "These findings strongly suggest that one or more COX products, most likely prostaglandins, play a significant role in modulating the hypnotic effect of diazepam.", "spo_list": [{"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX", "object_type": "GENE-N"}]}
{"text": "Cyclooxygenase-1-coupled prostaglandin biosynthesis constitutes an essential prerequisite for skin repair.", "spo_list": [{"subject": "prostaglandin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Cyclooxygenase-1", "object_type": "GENE-Y"}]}
{"text": "This investigation demonstrated a functional coupling between cyclooxygenase-1 (cox) and prostaglandin E2/D2 biosynthesis in murine skin repair.", "spo_list": [{"subject": "prostaglandin E2/D2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclooxygenase-1", "object_type": "GENE-Y"}, {"subject": "prostaglandin E2/D2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cox", "object_type": "GENE-N"}]}
{"text": "Cyclooxygenase-1 expression decreased transiently after excisional wounding, and this was followed by a marked fall in the rate of prostaglandin E2/D2 biosynthesis at the wound site.", "spo_list": [{"subject": "prostaglandin E2/D2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Cyclooxygenase-1", "object_type": "GENE-Y"}]}
{"text": "Expression of cyclooxygenase-1, prostaglandin synthases, and prostaglandin E2/D2 production were colocalized in new tissue at the margin of the wound.", "spo_list": [{"subject": "prostaglandin E2/D2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclooxygenase-1", "object_type": "GENE-Y"}, {"subject": "prostaglandin E2/D2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "prostaglandin synthases", "object_type": "GENE-N"}]}
{"text": "Accordingly, wound tissue from SC-560-treated mice (selective cyclooxygenase-1 inhibitor) and diclofenac-treated mice (nonselective cyclooxygenase inhibitor), but not celecoxib-treated mice (selective cyclooxygenase-2 inhibitor), and wound tissue from cyclooxygenase-1-deficient animals exhibited a severe loss of prostaglandin E2/D2 at the wound site, and this change was associated with an impairment in the normal wound morphology.", "spo_list": [{"subject": "diclofenac", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase", "object_type": "GENE-N"}, {"subject": "celecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "prostaglandin E2/D2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclooxygenase-1", "object_type": "GENE-Y"}, {"subject": "prostaglandin E2/D2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclooxygenase", "object_type": "GENE-N"}, {"subject": "prostaglandin E2/D2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}]}
{"text": "In contrast to the presence of an injury-induced cyclooxygenase-2, these data constitute strong evidence that cyclooxygenase-1-coupled prostaglandin E2/D2 biosynthesis has a central role in skin repair.", "spo_list": [{"subject": "prostaglandin E2/D2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclooxygenase-1", "object_type": "GENE-Y"}]}
{"text": "We have used homology modelling, based on the crystal structure of the human glutathione S-transferase (GST) A1-1, to obtain the three-dimensional structures of rat GSTA3 and rat GSTA5 subunits bound to S-aflatoxinyl-glutathione.", "spo_list": [{"subject": "S-aflatoxinyl-glutathione", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "rat GSTA3", "object_type": "GENE-Y"}, {"subject": "S-aflatoxinyl-glutathione", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "rat GSTA5", "object_type": "GENE-Y"}]}
{"text": "The resulting models highlight two residues, at positions 208 and 108, that could be important for determining, either directly or indirectly, substrate specificity for aflatoxin-exo-8,9-epoxide among the Alpha-class GSTs.", "spo_list": [{"subject": "aflatoxin-exo-8,9-epoxide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Alpha-class GSTs", "object_type": "GENE-N"}]}
{"text": "These studies show clearly that, in all three GSTs, an aspartate residue at position 208 is a prerequisite for high activity in aflatoxin-exo-8,9-epoxide conjugation, although this alone is not sufficient; other residues in the vicinity, particularly residues 103-112, are important, perhaps for the optimal orientation of the aflatoxin-exo-8,9-epoxide in the active site for catalysis to occur.", "spo_list": [{"subject": "aflatoxin-exo-8,9-epoxide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GSTs", "object_type": "GENE-N"}]}
{"text": "We have evaluated the biochemical selectivity of novel cyclo-oxygenase (COX)-2 inhibitors, etoricoxib, valdecoxib, DFU and DFP, vs rofecoxib and celecoxib, using the human whole blood assays of COX-isozyme activity, in vitro.", "spo_list": [{"subject": "etoricoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclo-oxygenase (COX)-2", "object_type": "GENE-Y"}, {"subject": "valdecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclo-oxygenase (COX)-2", "object_type": "GENE-Y"}, {"subject": "DFU", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclo-oxygenase (COX)-2", "object_type": "GENE-Y"}, {"subject": "DFP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclo-oxygenase (COX)-2", "object_type": "GENE-Y"}, {"subject": "rofecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclo-oxygenase (COX)-2", "object_type": "GENE-Y"}, {"subject": "celecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclo-oxygenase (COX)-2", "object_type": "GENE-Y"}]}
{"text": "Compounds were incubated with human whole blood samples, allowed to clot for 1 h at 37 degrees C, or stimulated with lipopolysaccharide (10 microg/ml) for 24 h at 37 degrees C. Serum thromboxane (TX) B2 and plasma prostaglandin (PG) E2 levels were measured by specific radioimmunoassays as indices of platelet COX-1 and monocyte COX-2 activity, respectively.", "spo_list": [{"subject": "thromboxane (TX) B2", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "thromboxane (TX) B2", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "prostaglandin (PG) E2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "prostaglandin (PG) E2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Valdecoxib, etoricoxib, DFU and DFP inhibited platelet COX-1 and monocyte COX-2 with the following COX-1/COX-2 IC50 ratios: 61.5, 344, 660 and 1918, respectively.", "spo_list": [{"subject": "Valdecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "etoricoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "DFU", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "DFP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "Valdecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "etoricoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "DFU", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "DFP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "Valdecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "Valdecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "etoricoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "etoricoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "DFU", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "DFU", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "DFP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "DFP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "In conclusion, a second wave of COX-2 inhibitors with higher biochemical selectivity than the existing coxibs has been developed.", "spo_list": [{"subject": "coxibs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Additionally, we performed a molecular docking of compound 1 into the ligand binding pocket of peroxisome proliferator-activated receptor Î± and peroxisome proliferator-activated receptor Î³. In these binding models, compound 1 may bind into the active site of both isoforms showing important short contacts with the peroxisome proliferator-activated receptor Î³ residues: Tyr 473, His 449, Ser 289, His 323; and peroxisome proliferator-activated receptor Î± residues: Tyr 464, His 440, Ser 280 and Tyr 314.", "spo_list": [{"subject": "Tyr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "peroxisome proliferator-activated receptor Î³", "object_type": "GENE-Y"}, {"subject": "His", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "peroxisome proliferator-activated receptor Î³", "object_type": "GENE-Y"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "peroxisome proliferator-activated receptor Î³", "object_type": "GENE-Y"}, {"subject": "His", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "peroxisome proliferator-activated receptor Î³", "object_type": "GENE-Y"}, {"subject": "Tyr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "peroxisome proliferator-activated receptor Î±", "object_type": "GENE-Y"}, {"subject": "His", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "peroxisome proliferator-activated receptor Î±", "object_type": "GENE-Y"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "peroxisome proliferator-activated receptor Î±", "object_type": "GENE-Y"}, {"subject": "Tyr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "peroxisome proliferator-activated receptor Î±", "object_type": "GENE-Y"}]}
{"text": "5. MAO-A was inhibited by the following drugs (in ascending order of potency) : nortriptyline, amitriptyline, imipramine, maprotiline, zimeldine, nomifensine, and viloxazine.", "spo_list": [{"subject": "nortriptyline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "amitriptyline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "imipramine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "maprotiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "zimeldine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "nomifensine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "viloxazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}]}
{"text": "6. MAO-B was inhibited by the following drugs (in ascending order of potency): nortriptyline, imipramine, maprotiline, amitriptyline, zimeldine, nomifensine, and viloxazine.", "spo_list": [{"subject": "nortriptyline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "imipramine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "maprotiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "amitriptyline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "zimeldine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "nomifensine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}, {"subject": "viloxazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "The conjugate combines two strategies: the anti-HER2 activity of trastuzumab, and the targeted intracellular delivery of mertansine, a tubulin polymerisation inhibitor which interferes with mitosis and promotes apoptosis.", "spo_list": [{"subject": "mertansine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tubulin", "object_type": "GENE-N"}]}
{"text": "Tyrosinase catalyzes an unusual oxidative decarboxylation of 3,4-dihydroxymandelate.", "spo_list": [{"subject": "3,4-dihydroxymandelate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Tyrosinase", "object_type": "GENE-Y"}]}
{"text": "Tyrosinase usually catalyzes the conversion of monophenols to o-diphenols and oxidation of diphenols to the corresponding quinones.", "spo_list": [{"subject": "monophenols", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Tyrosinase", "object_type": "GENE-Y"}, {"subject": "diphenols", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Tyrosinase", "object_type": "GENE-Y"}]}
{"text": "Phenol oxidase inhibitors such as phenylthiourea, potassium cyanide, and sodium azide inhibited the reaction drastically, suggesting the participation of the active site copper of the enzyme in the catalysis.", "spo_list": [{"subject": "phenylthiourea", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Phenol oxidase", "object_type": "GENE-N"}, {"subject": "potassium cyanide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Phenol oxidase", "object_type": "GENE-N"}, {"subject": "sodium azide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Phenol oxidase", "object_type": "GENE-N"}, {"subject": "copper", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Phenol oxidase", "object_type": "GENE-N"}]}
{"text": "Mimosine, a well-known competitive inhibitor of tyrosinase, competitively inhibited the new reaction also.", "spo_list": [{"subject": "Mimosine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosinase", "object_type": "GENE-Y"}]}
{"text": "Present studies demonstrate that mushroom tyrosinase will also catalyze quinone methide production with the same active site copper if a suitable substrate such as 3,4-dihydroxymandelic acid is provided.", "spo_list": [{"subject": "quinone methide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "mushroom tyrosinase", "object_type": "GENE-N"}, {"subject": "3,4-dihydroxymandelic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "mushroom tyrosinase", "object_type": "GENE-N"}]}
{"text": "At not-cytotoxic concentrations (cell viability higher of 80%, as assessed by MTT reduction assay), all contact sensitizers, including pre-pro-haptens, induced a dose-related increase in IL-18, whereas both irritants, with the exception of sulfamic acid, and respiratory allergens failed.", "spo_list": [{"subject": "sulfamic acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-18", "object_type": "GENE-Y"}]}
{"text": "6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives potently and selectively activate ATP sensitive potassium channels of pancreatic beta-cells.", "spo_list": [{"subject": "6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ATP sensitive potassium channels", "object_type": "GENE-N"}]}
{"text": "6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivatives were synthesized and characterized as activators of adenosine 5'-triphosphate (ATP) sensitive potassium (K(ATP)) channels in the beta-cells by measuring effects on membrane potential and insulin release in vitro.", "spo_list": [{"subject": "6-Chloro-3-alkylamino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "adenosine 5'-triphosphate (ATP) sensitive potassium (K(ATP)) channels", "object_type": "GENE-N"}]}
{"text": "Selected compounds were characterized as competitive inhibitors of [(3)H]glibenclamide binding to membranes of HEK293 cells expressing human SUR1/Kir6.2 and as potent inhibitors of insulin release in isolated rat islets.", "spo_list": [{"subject": "[(3)H]glibenclamide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human SUR1", "object_type": "GENE-Y"}, {"subject": "[(3)H]glibenclamide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Kir6.2", "object_type": "GENE-Y"}]}
{"text": "6-Chloro-3-(1-methylcyclobutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (54) was found to bind and activate the SUR1/Kir6.2 K(ATP) channels in the low nanomolar range and to be at least 1000 times more potent than the reference compound diazoxide with respect to inhibition of insulin release from rat islets.", "spo_list": [{"subject": "6-Chloro-3-(1-methylcyclobutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "SUR1", "object_type": "GENE-Y"}, {"subject": "6-Chloro-3-(1-methylcyclobutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Kir6.2", "object_type": "GENE-Y"}, {"subject": "6-Chloro-3-(1-methylcyclobutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "K(ATP) channels", "object_type": "GENE-N"}, {"subject": "6-Chloro-3-(1-methylcyclobutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SUR1", "object_type": "GENE-Y"}, {"subject": "6-Chloro-3-(1-methylcyclobutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Kir6.2", "object_type": "GENE-Y"}, {"subject": "6-Chloro-3-(1-methylcyclobutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "K(ATP) channels", "object_type": "GENE-N"}, {"subject": "diazoxide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "SUR1", "object_type": "GENE-Y"}, {"subject": "diazoxide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "K(ATP) channels", "object_type": "GENE-N"}, {"subject": "diazoxide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Kir6.2", "object_type": "GENE-Y"}, {"subject": "diazoxide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "insulin", "object_type": "GENE-N"}, {"subject": "6-Chloro-3-(1-methylcyclobutyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "insulin", "object_type": "GENE-N"}]}
{"text": "Several compounds, e.g., 3-propylamino- (30), 3-isopropylamino- (34), 3-(S)-sec-butylamino- (37), and 3-(1-methylcyclopropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide (53), which were found to be potent and beta-cell selective activators of K(ATP) channels in vitro, were found to inhibit insulin secretion in rats with minimal effects on blood pressure and to exhibit good oral pharmacokinetic properties.", "spo_list": [{"subject": "3-propylamino", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "K(ATP) channels", "object_type": "GENE-N"}, {"subject": "3-isopropylamino", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "K(ATP) channels", "object_type": "GENE-N"}, {"subject": "3-(S)-sec-butylamino", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "K(ATP) channels", "object_type": "GENE-N"}, {"subject": "3-(1-methylcyclopropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "K(ATP) channels", "object_type": "GENE-N"}, {"subject": "3-propylamino", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "insulin", "object_type": "GENE-N"}, {"subject": "3-isopropylamino", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "insulin", "object_type": "GENE-N"}, {"subject": "3-(S)-sec-butylamino", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "insulin", "object_type": "GENE-N"}, {"subject": "3-(1-methylcyclopropyl)amino-4H-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "insulin", "object_type": "GENE-N"}]}
{"text": "5-Ethynyluracil is a potent mechanism-based inactivator of dihydropyrimidine dehydrogenase (DPD, EC 1.3.1.2) in vitro (Porter et al., J Biol Chem 267: 5236-5242, 1992) and in vivo (Spector et al., Biochem Pharmacol, 46: 2243-2248, 1993.", "spo_list": [{"subject": "5-Ethynyluracil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "dihydropyrimidine dehydrogenase", "object_type": "GENE-Y"}, {"subject": "5-Ethynyluracil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPD", "object_type": "GENE-Y"}, {"subject": "5-Ethynyluracil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 1.3.1.2", "object_type": "GENE-Y"}]}
{"text": "5-Ethynyl-2(1H)-pyrimidinone was rapidly oxidized to 5-ethynyluracil by aldehyde oxidase.", "spo_list": [{"subject": "5-Ethynyl-2(1H)-pyrimidinone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "aldehyde oxidase", "object_type": "GENE-Y"}, {"subject": "5-ethynyluracil", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "aldehyde oxidase", "object_type": "GENE-Y"}]}
{"text": "In contrast, xanthine oxidase oxidized 5-ethynyl-2(1H)-pyrimidinone to 5-ethynyluracil with a substrate efficiency that was only 0.02% that of xanthine.", "spo_list": [{"subject": "5-ethynyl-2(1H)-pyrimidinone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "xanthine oxidase", "object_type": "GENE-Y"}, {"subject": "5-ethynyluracil", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "xanthine oxidase", "object_type": "GENE-Y"}, {"subject": "xanthine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "xanthine oxidase", "object_type": "GENE-Y"}]}
{"text": "Because 5-ethynyl-2(1H)-pyrimidinone did not itself inactivate purified DPD in vitro and aldehyde oxidase is predominately found in liver, we hypothesized that 5-ethynyl-2(1H)-pyrimidinone could be a liver-specific inactivator of DPD.", "spo_list": [{"subject": "5-ethynyl-2(1H)-pyrimidinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPD", "object_type": "GENE-Y"}]}
{"text": "We found that 5-ethynyl-2(1H)-pyrimidinone administered orally to rats at 2 micrograms/kg inactivated DPD in all tissues studied.", "spo_list": [{"subject": "5-ethynyl-2(1H)-pyrimidinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPD", "object_type": "GENE-Y"}]}
{"text": "Although 5-ethynyl-2(1H)-pyrimidinone produced slightly less inactivation than 5-ethynyluracil, the two compounds showed fairly similar patterns of inactivation of DPD in these tissues.", "spo_list": [{"subject": "5-ethynyl-2(1H)-pyrimidinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPD", "object_type": "GENE-Y"}, {"subject": "5-ethynyluracil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPD", "object_type": "GENE-Y"}]}
{"text": "At doses of 20 micrograms/kg, however, 5-ethynyl-2-pyrimidinone and 5-ethynyluracil produced equivalent inactivation of DPD.", "spo_list": [{"subject": "5-ethynyluracil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPD", "object_type": "GENE-Y"}, {"subject": "5-ethynyl-2-pyrimidinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DPD", "object_type": "GENE-Y"}]}
{"text": "We have previously demonstrated that, in the presence of the lysine analogue epsilon-aminocaproic acid, apolipoprotein(a) [apo(a)] undergoes a conformational change from a closed to an open structure that is characterized by a change in tryptophan fluorescence, an increase in the radius of gyration, an alteration of domain stability, and an enhancement in the efficiency of covalent lipoprotein(a) [Lp(a)] formation.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "apolipoprotein(a)", "object_type": "GENE-Y"}, {"subject": "epsilon-aminocaproic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "apolipoprotein(a)", "object_type": "GENE-Y"}, {"subject": "tryptophan", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "apolipoprotein(a)", "object_type": "GENE-Y"}, {"subject": "tryptophan", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "apo(a)", "object_type": "GENE-Y"}]}
{"text": "In the present study, to identify sequences within apo(a) that maintain its closed conformation, we used epsilon-aminocaproic acid to probe the conformational status of a variety of recombinant apo(a) isoforms using analytical ultracentrifugation, differential scanning calorimetry, intrinsic fluorescence, and in vitro covalent Lp(a) formation assays.", "spo_list": [{"subject": "epsilon-aminocaproic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "apo(a)", "object_type": "GENE-Y"}]}
{"text": "We observed that the closed conformation of apo(a) is maintained by intramolecular interaction(s) between sequences within the amino- and carboxyl-terminal halves of the molecule.", "spo_list": [{"subject": "amino", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "apo(a)", "object_type": "GENE-Y"}, {"subject": "carboxyl", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "apo(a)", "object_type": "GENE-Y"}]}
{"text": "Using site-directed mutagenesis, we have identified the strong lysine-binding site present within apo(a) kringle IV type 10 as an important site within the C-terminal half of the molecule, which is involved in maintaining the closed conformation of apo(a).", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "apo(a) kringle IV type 10", "object_type": "GENE-N"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "apo(a) kringle IV type 10", "object_type": "GENE-N"}]}
{"text": "Apo(a) exhibits marked isoform size heterogeneity because of the presence of varying numbers of copies of the kringle IV type-2 domain located within the amino-terminal half of the molecule.", "spo_list": [{"subject": "amino", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Apo(a)", "object_type": "GENE-Y"}, {"subject": "amino", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "kringle IV type-2 domain", "object_type": "GENE-N"}]}
{"text": "Studies mainly in osteoporosis rodent models and limited data in postmenopausal women suggest that N-terminal PTHrP peptides might be considered a promising bone anabolic therapy.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PTHrP", "object_type": "GENE-Y"}]}
{"text": "In addition, putative osteogenic actions of PTHrP might be ascribed not only to its N-terminal domain but also to its PTH-unrelated C-terminal region.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PTHrP", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PTH", "object_type": "GENE-Y"}]}
{"text": "Estrogens are biosynthesised from androgens by the CYP450 enzyme complex called aromatase.", "spo_list": [{"subject": "Estrogens", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CYP450", "object_type": "GENE-N"}]}
{"text": "In breast cancer, intratumoural aromatase is the source for local estrogen production in the tissue.", "spo_list": [{"subject": "estrogen", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "The potent and selective third-generation aromatase inhibitors anastrozole, letrozole and exemestane were introduced to the market as endocrine therapy in postmenopausal patients failing anti-estrogen therapy alone, or multiple hormonal therapies.", "spo_list": [{"subject": "anastrozole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "letrozole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "Anastrozole and letrozole are both non-steroidal aromatase inhibitors that compete with the substrate for binding to the enzyme active site.", "spo_list": [{"subject": "Anastrozole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "letrozole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "Radioligand binding assay, using [3H]N-methyl-scopolamine as tracer, showed the existence of acetylcholine muscarinic receptors in brush-border (Kd 0.28 +/- 0.04 nM; Bmax 9.4 +/- 1.6 fmol/mg protein) and basal plasma membranes (Kd 0.24 +/- 0.05 nM; Bmax 34.3 +/- 6.3 fmol/mg protein).", "spo_list": [{"subject": "[3H]N-methyl-scopolamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "acetylcholine muscarinic receptors", "object_type": "GENE-N"}]}
{"text": "In order to perform a pharmacological characterization of these receptors, competition binding experiments were carried out using the muscarinic receptor antagonists pirenzepine, (11(2-diethyl-amino)methyl)-1-piperidinylacetyl-5-11-dihydro-6H-py rido(14) benzodiazepine (AF-DX 116), himbacine, 4-diphenylacetoxy-N-methylpiperidine methiodide (4-DAMP), dicyclomine and hexahydro-sila-difenidol (HHSD).", "spo_list": [{"subject": "pirenzepine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic receptor", "object_type": "GENE-N"}, {"subject": "(11(2-diethyl-amino)methyl)-1-piperidinylacetyl-5-11-dihydro-6H-py rido(14) benzodiazepine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic receptor", "object_type": "GENE-N"}, {"subject": "AF-DX 116", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic receptor", "object_type": "GENE-N"}, {"subject": "himbacine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic receptor", "object_type": "GENE-N"}, {"subject": "4-diphenylacetoxy-N-methylpiperidine methiodide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic receptor", "object_type": "GENE-N"}, {"subject": "4-DAMP", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic receptor", "object_type": "GENE-N"}, {"subject": "dicyclomine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic receptor", "object_type": "GENE-N"}, {"subject": "hexahydro-sila-difenidol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic receptor", "object_type": "GENE-N"}, {"subject": "HHSD", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic receptor", "object_type": "GENE-N"}]}
{"text": "In brush-border membranes, the receptor found match in terms of affinity for the antagonists with the muscarinic M1 receptor subtype (Ki pirenzepine, 13.6 +/- 8.2 nM; Ki AF-DX 116, 1680 +/- 271 nM; Ki himbacine, 212 +/- 6.5 nM; Ki 4-DAMP. 1.5 +/- 0.4 nM; Ki dicyclomine, 5.1 +/- 0.8 nM; Ki HHSD, 34.3 +/- 7.3 nM), whereas the receptor in basal plasma membrane seems to be of the muscarinic M2 receptor subtype (Ki pirenzepine, 202 +/- 48 nM; Ki AF-DX 116, 124 +/- 60 nM; Ki himbacine, 20.6 +/- 4.8 nM; Ki 4-DAMP, 4.5 +/- 1.2 nM; Ki dicyclomine, 54.6 +/- 22 nM; Ki HHSD, 89.2 +/- 15.8 nM).", "spo_list": [{"subject": "pirenzepine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic M1 receptor subtype", "object_type": "GENE-Y"}, {"subject": "AF-DX 116", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic M1 receptor subtype", "object_type": "GENE-Y"}, {"subject": "himbacine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic M1 receptor subtype", "object_type": "GENE-Y"}, {"subject": "pirenzepine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "muscarinic M1 receptor subtype", "object_type": "GENE-Y"}, {"subject": "AF-DX 116", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "muscarinic M1 receptor subtype", "object_type": "GENE-Y"}, {"subject": "himbacine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "muscarinic M1 receptor subtype", "object_type": "GENE-Y"}, {"subject": "4-DAMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "muscarinic M1 receptor subtype", "object_type": "GENE-Y"}, {"subject": "4-DAMP", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic M1 receptor subtype", "object_type": "GENE-Y"}, {"subject": "dicyclomine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic M1 receptor subtype", "object_type": "GENE-Y"}, {"subject": "dicyclomine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "muscarinic M1 receptor subtype", "object_type": "GENE-Y"}, {"subject": "HHSD", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic M1 receptor subtype", "object_type": "GENE-Y"}, {"subject": "HHSD", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "muscarinic M1 receptor subtype", "object_type": "GENE-Y"}, {"subject": "pirenzepine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic M2 receptor subtype", "object_type": "GENE-Y"}, {"subject": "AF-DX 116", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic M2 receptor subtype", "object_type": "GENE-Y"}, {"subject": "pirenzepine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "muscarinic M2 receptor subtype", "object_type": "GENE-Y"}, {"subject": "AF-DX 116", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "muscarinic M2 receptor subtype", "object_type": "GENE-Y"}, {"subject": "himbacine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic M2 receptor subtype", "object_type": "GENE-Y"}, {"subject": "4-DAMP", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic M2 receptor subtype", "object_type": "GENE-Y"}, {"subject": "dicyclomine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic M2 receptor subtype", "object_type": "GENE-Y"}, {"subject": "HHSD", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic M2 receptor subtype", "object_type": "GENE-Y"}, {"subject": "himbacine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "muscarinic M2 receptor subtype", "object_type": "GENE-Y"}, {"subject": "4-DAMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "muscarinic M2 receptor subtype", "object_type": "GENE-Y"}, {"subject": "dicyclomine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "muscarinic M2 receptor subtype", "object_type": "GENE-Y"}, {"subject": "HHSD", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "muscarinic M2 receptor subtype", "object_type": "GENE-Y"}]}
{"text": "After 4 months of PIO, fasting plasma glucose concentration (Delta = -2.7 mol/liter), mean plasma glucose during OGTT (Delta = -3.8 mol/liter), and hemoglobin A(1c) (Delta = 1.7%) decreased (P < 0.05 vs. placebo) without change in fasting or post-OGTT plasma insulin levels.", "spo_list": [{"subject": "PIO", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "hemoglobin A(1c)", "object_type": "GENE-Y"}]}
{"text": "Furthermore, we found that rhubarb suppressed the p-ser(9) GSK-3-Î² protein level to inactivate Wnt signalling and reduce Î²-catenin protein level.", "spo_list": [{"subject": "ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GSK-3-Î²", "object_type": "GENE-Y"}]}
{"text": "Fluorescence lifetime analysis and effect of magnesium ions on binding of NADH to human aldehyde dehydrogenase 1.", "spo_list": [{"subject": "NADH", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human aldehyde dehydrogenase 1", "object_type": "GENE-Y"}]}
{"text": "Aldehyde dehydrogenase 1 (ALDH1A1) catalyzes the oxidation of toxic aldehydes to carboxylic acids.", "spo_list": [{"subject": "aldehydes", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Aldehyde dehydrogenase 1", "object_type": "GENE-Y"}, {"subject": "aldehydes", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ALDH1A1", "object_type": "GENE-Y"}, {"subject": "carboxylic acids", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Aldehyde dehydrogenase 1", "object_type": "GENE-Y"}, {"subject": "carboxylic acids", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ALDH1A1", "object_type": "GENE-Y"}]}
{"text": "Physiologic levels of Mg(2+) ions decrease ALDH1 activity in part by increasing NADH binding affinity to the enzyme.", "spo_list": [{"subject": "Mg(2+)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ALDH1", "object_type": "GENE-Y"}, {"subject": "NADH", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ALDH1", "object_type": "GENE-Y"}]}
{"text": "From the resolved free and bound NADH fluorescence signatures, the KD values for both NADH conformations in ALDH1A1 ranged from about 24 Î¼M to 1 Î¼M for Mg(2+) ion concentrations of 0-6000 Î¼M, respectively.", "spo_list": [{"subject": "NADH", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ALDH1A1", "object_type": "GENE-Y"}]}
{"text": "As the Mg(2+) ion concentration was increased, there was a consistent decrease of the enzyme catalytic turnover from 0.31 s(-1) (0 Î¼M Mg(2+)) to 0.050 s(-1) (6000 Î¼M Mg(2+)) and a distinct shift in steady-state conformational population from one that favors the ALDH1-NADH complex with the shorter fluorescence lifetime (33% excess) in the absence of magnesium ion to one that favors the ALDH1-NADH complex with the longer fluorescence lifetime (13% excess) at 6000 Î¼M Mg(2+).", "spo_list": [{"subject": "NADH", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ALDH1", "object_type": "GENE-Y"}, {"subject": "NADH", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ALDH1", "object_type": "GENE-Y"}]}
{"text": "This shift in conformational population at higher Mg(2+) ion concentrations and to lower enzyme activity may be due to longer residence time of the NADH in the ALDH1 pocket.", "spo_list": [{"subject": "NADH", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ALDH1", "object_type": "GENE-Y"}]}
{"text": "The results from monitoring enzyme catalysis in the absence of magnesium suggests that the ALDH1-NADH complex with the shorter fluorescence lifetime is the form initially produced, and the complex with the longer fluorescence lifetime is produced through isomerization.", "spo_list": [{"subject": "NADH", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ALDH1", "object_type": "GENE-Y"}]}
{"text": "The catecholamines were found to inhibit the binding of the alpha 2-adrenoceptor agonist, [3H]-clonidine, to the recombinant wild type alpha 2a-adrenoceptor (Table 1) with potencies that are consistent with their functional activity in alpha 2-adrenoceptor test systems [6,7].", "spo_list": [{"subject": "[3H]-clonidine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha 2-adrenoceptor", "object_type": "GENE-N"}, {"subject": "catecholamines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "alpha 2a-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "[3H]-clonidine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha 2a-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "catecholamines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "alpha 2-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "Mutation of Ser165 to alanine had no significant effect (less than 2-fold) on the affinity of any of the catecholamines for the alpha 2a-adrenoceptor, and in particular, the ratios of affinities between the corresponding (-)- and (+)-enantiomers of the catecholamines were not altered by the point mutation at Ser165.", "spo_list": [{"subject": "alanine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "alpha 2a-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "The alpha 2a-adrenoceptor contains three hydroxyl bearing amino acids at a position corresponding to this site (Thr393-Tyr394-Thr395).", "spo_list": [{"subject": "hydroxyl", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "alpha 2a-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "alpha 2a-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Imatinib is a small-molecule tyrosine kinase inhibitor of the ABL fusion gene, platelet derived growth factor receptors (PDGFR) and KIT.", "spo_list": [{"subject": "Imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "Imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ABL", "object_type": "GENE-Y"}, {"subject": "Imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "platelet derived growth factor receptors", "object_type": "GENE-N"}, {"subject": "Imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDGFR", "object_type": "GENE-N"}, {"subject": "Imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "KIT", "object_type": "GENE-Y"}]}
{"text": "NMDA receptors in postmortem human spinal cord were analyzed using [3H]MK-801 ligand binding and immunoblotting with NMDA receptor subunit-specific antibodies.", "spo_list": [{"subject": "[3H]MK-801", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "NMDA receptors", "object_type": "GENE-N"}]}
{"text": "In extending these initial findings, we have shown that cardiac fibrosis (i) is not reversed by correction of mineralocorticoid-induced hypokalemia; (ii) appears not to involve the plasma or tissue renin-angiotensin systems, as fibrosis is largely unaffected by concurrent administration of Losartan or Perindopril; (iii) is independent of cardiac hypertrophy, in that it is equally seen in right and left ventricles, and in rats rendered hypertensive without cardiac hypertrophy by the administration of 9 alpha-fluorocortisol; (iv) is independent of elevated blood pressure, in that it is found in normotensive animals infused peripherally with aldosterone and intracerebroventricularly with the mineralocorticoid receptor (MR) antagonist RU28318; (v) is via classical MR, in that it is blocked by concurrent administration of the MR antagonist potassium canrenoate; and (vi) may or may not be a direct cardiac effect, inasmuch as data for in vivo effects on collagen formation by cardiac fibroblasts are conflicting.", "spo_list": [{"subject": "RU28318", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "mineralocorticoid receptor", "object_type": "GENE-Y"}, {"subject": "RU28318", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "MR", "object_type": "GENE-Y"}, {"subject": "potassium canrenoate", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "MR", "object_type": "GENE-Y"}, {"subject": "potassium canrenoate", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "MR", "object_type": "GENE-Y"}]}
{"text": "Although there is a high probability that the action of aldosterone to cause cardiac fibrosis in this experimental model is an effect via non-epithelial MR, the locus of aldosterone action remains to be established, as do the molecular mechanisms linking MR occupancy by aldosterone and collagen deposition.", "spo_list": [{"subject": "aldosterone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MR", "object_type": "GENE-Y"}]}
{"text": "KCNK1, a member of the family of two-pore K(+) ion channels, is specifically induced in the livers of male mice after phenobarbital treatment.", "spo_list": [{"subject": "phenobarbital", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "K(+) ion channels", "object_type": "GENE-N"}, {"subject": "phenobarbital", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "KCNK1", "object_type": "GENE-Y"}]}
{"text": "Here, we have determined the molecular mechanism of this male-specific activation of the Kcnk1 gene and characterized KCNK1 as a phenobarbital-inducible antihyperplasia factor.", "spo_list": [{"subject": "phenobarbital", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Kcnk1", "object_type": "GENE-Y"}, {"subject": "phenobarbital", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "KCNK1", "object_type": "GENE-Y"}]}
{"text": "Upon activation by phenobarbital, nuclear receptor CAR binds the 97-bp response element (-2441/-2345) within the Kcnk1 promoter.", "spo_list": [{"subject": "phenobarbital", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "nuclear receptor", "object_type": "GENE-N"}, {"subject": "phenobarbital", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CAR", "object_type": "GENE-Y"}]}
{"text": "These results indicate that phenobarbital treatment induces KCNK1 to elicit a male-specific and growth-suppressing signal.", "spo_list": [{"subject": "phenobarbital", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "KCNK1", "object_type": "GENE-Y"}]}
{"text": "Microsomal epoxide hydrolase (mEH, EPHX1) is a critical xenobiotic-metabolizing enzyme, catalyzing both detoxification and bioactivation reactions that direct the disposition of chemical epoxides, including the carcinogenic metabolites of several polycyclic aromatic hydrocarbons.", "spo_list": [{"subject": "epoxides", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Microsomal epoxide hydrolase", "object_type": "GENE-Y"}, {"subject": "epoxides", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "mEH", "object_type": "GENE-Y"}, {"subject": "epoxides", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EPHX1", "object_type": "GENE-Y"}, {"subject": "polycyclic aromatic hydrocarbons", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Microsomal epoxide hydrolase", "object_type": "GENE-Y"}, {"subject": "polycyclic aromatic hydrocarbons", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "mEH", "object_type": "GENE-Y"}, {"subject": "polycyclic aromatic hydrocarbons", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EPHX1", "object_type": "GENE-Y"}]}
{"text": "On the other hand, holocarboxylase synthetase (HCS) mRNA levels were markedly low in the deficient animals, and increased upon biotin injection.", "spo_list": [{"subject": "biotin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "holocarboxylase synthetase", "object_type": "GENE-Y"}, {"subject": "biotin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HCS", "object_type": "GENE-Y"}]}
{"text": "Cystathionine-gamma-lyase (CSE) and cystathionine-beta-synthase (CBS) utilize L-cysteine as substrate to form H2S.", "spo_list": [{"subject": "L-cysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Cystathionine-gamma-lyase", "object_type": "GENE-Y"}, {"subject": "L-cysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CSE", "object_type": "GENE-Y"}, {"subject": "L-cysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cystathionine-beta-synthase", "object_type": "GENE-Y"}, {"subject": "L-cysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CBS", "object_type": "GENE-Y"}, {"subject": "H2S", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Cystathionine-gamma-lyase", "object_type": "GENE-Y"}, {"subject": "H2S", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CSE", "object_type": "GENE-Y"}, {"subject": "H2S", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cystathionine-beta-synthase", "object_type": "GENE-Y"}, {"subject": "H2S", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CBS", "object_type": "GENE-Y"}]}
{"text": "Of these two enzymes, cystathionine-gamma-lyase (CSE) is believed to be the key enzyme that forms H2S in the cardiovascular system.", "spo_list": [{"subject": "H2S", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cystathionine-gamma-lyase", "object_type": "GENE-Y"}, {"subject": "H2S", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CSE", "object_type": "GENE-Y"}]}
{"text": "Also, prophylactic, as well as therapeutic, treatment with the CSE inhibitor, DL-propargylglycine (PAG), significantly reduced the severity of caerulein-induced pancreatitis and associated lung injury, as determined by 1) hyperamylasemia [plasma amylase (U/L) (control, 1204+/-59); prophylactic treatment: placebo, 10635+/-305; PAG, 7904+/-495; therapeutic treatment: placebo, 10427+/-470; PAG, 7811+/-428; P<0.05 PAG c.f. placebo; n=24 animals in each group]; 2) neutrophil sequestration in the pancreas [pancreatic myeloperoxidase oxidase (MPO) activity (fold increase over control) (prophylactic treatment: placebo, 5.78+/-0.63; PAG, 2.97+/-0.39; therapeutic treatment: placebo, 5.48+/-0.52; PAG, 3.03+/-0.47; P<0.05 PAG c.f. placebo; n=24 animals in each group)]; 3) pancreatic acinar cell injury/necrosis; 4) lung MPO activity (fold increase over control) [prophylactic treatment: placebo, 1.99+/-0.16; PAG, 1.34+/-0.14; therapeutic treatment: placebo, 2.03+/-0.12; PAG, 1.41+/-0.97; P<0.05 PAG c.f. placebo; n=24 animals in each group]; and 5) histological evidence of lung injury.", "spo_list": [{"subject": "DL-propargylglycine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CSE", "object_type": "GENE-Y"}, {"subject": "PAG", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CSE", "object_type": "GENE-Y"}, {"subject": "PAG", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "myeloperoxidase oxidase", "object_type": "GENE-Y"}, {"subject": "PAG", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MPO", "object_type": "GENE-Y"}]}
{"text": "The mutant beta1,4-galactosyltransferase (beta4Gal-T1), beta4Gal-T1-Y289L, in contrast to wild-type beta4Gal-T1, can transfer GalNAc from the sugar donor UDP-GalNAc to the acceptor, GlcNAc, with efficiency as good as that of galactose from UDP-Gal.", "spo_list": [{"subject": "UDP-GalNAc", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "beta1,4-galactosyltransferase", "object_type": "GENE-Y"}, {"subject": "UDP-GalNAc", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "beta4Gal-T1", "object_type": "GENE-Y"}, {"subject": "UDP-Gal", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "beta1,4-galactosyltransferase", "object_type": "GENE-Y"}, {"subject": "UDP-Gal", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "beta4Gal-T1", "object_type": "GENE-Y"}, {"subject": "UDP-Gal", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Y289L", "object_type": "GENE-N"}, {"subject": "UDP-GalNAc", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Y289L", "object_type": "GENE-N"}]}
{"text": "Moreover, the PNGase F treatment of the glycoproteins, which cleaves the N-linked oligosaccharide chain, shows that the modified sugar has been transferred to the N-glycan chains of the glycoproteins and not to the protein portion.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PNGase F", "object_type": "GENE-Y"}]}
{"text": "Design and synthesis of 2-substituted benzoxazoles as novel PTP1B inhibitors.", "spo_list": [{"subject": "2-substituted benzoxazoles", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PTP1B", "object_type": "GENE-Y"}]}
{"text": "A series of benzoxazole compounds containing oxamic acid were synthesized and screened for the PTP1B inhibition.", "spo_list": [{"subject": "oxamic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PTP1B", "object_type": "GENE-Y"}, {"subject": "benzoxazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PTP1B", "object_type": "GENE-Y"}]}
{"text": "Chelidonine and the alkaloid extract inhibited P-gp/MDR1 activity in a concentration-dependent manner in Caco-2 and CEM/ADR5000 and reversed their doxorubicin resistance.", "spo_list": [{"subject": "Chelidonine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P-gp", "object_type": "GENE-N"}, {"subject": "Chelidonine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MDR1", "object_type": "GENE-Y"}]}
{"text": "In addition, chelidonine and the alkaloid extract inhibited the activity of the drug modifying enzymes CYP3A4 and GST in a dose-dependent manner.", "spo_list": [{"subject": "chelidonine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP3A4", "object_type": "GENE-Y"}, {"subject": "chelidonine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GST", "object_type": "GENE-N"}]}
{"text": "Treatment of Caco-2 cells with 50 Î¼g/ml alkaloid extract and 50 Î¼M chelidonine for up to 48 h resulted in a significant decrease in mRNA levels of P-gp/MDR1, MRP1, BCRP, CYP3A4, GST, and hPXR and in a significant increase in caspase-3 and caspase-8 mRNA.", "spo_list": [{"subject": "chelidonine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "P-gp", "object_type": "GENE-N"}, {"subject": "chelidonine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MDR1", "object_type": "GENE-Y"}, {"subject": "chelidonine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MRP1", "object_type": "GENE-Y"}, {"subject": "chelidonine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "BCRP", "object_type": "GENE-Y"}, {"subject": "chelidonine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CYP3A4", "object_type": "GENE-Y"}, {"subject": "chelidonine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "GST", "object_type": "GENE-N"}, {"subject": "chelidonine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "hPXR", "object_type": "GENE-Y"}, {"subject": "chelidonine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "caspase-3", "object_type": "GENE-Y"}, {"subject": "chelidonine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "caspase-8", "object_type": "GENE-Y"}]}
{"text": "Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-Î² type I receptor inhibitor as a topical drug for alopecia.", "spo_list": [{"subject": "7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "transforming growth factor-Î² type I receptor", "object_type": "GENE-Y"}, {"subject": "TASP0382088", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "transforming growth factor-Î² type I receptor", "object_type": "GENE-Y"}]}
{"text": "7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole 11 (TASP0382088) was synthesized and evaluated as transforming growth factor-Î² (TGF-Î²) type I receptor (also known as activin receptor-like kinase 5 or ALK5) inhibitor.", "spo_list": [{"subject": "7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "transforming growth factor-Î² (TGF-Î²) type I receptor", "object_type": "GENE-Y"}, {"subject": "TASP0382088", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "transforming growth factor-Î² (TGF-Î²) type I receptor", "object_type": "GENE-Y"}, {"subject": "7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "activin receptor-like kinase 5", "object_type": "GENE-Y"}, {"subject": "7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ALK5", "object_type": "GENE-Y"}, {"subject": "TASP0382088", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "activin receptor-like kinase 5", "object_type": "GENE-Y"}, {"subject": "TASP0382088", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ALK5", "object_type": "GENE-Y"}]}
{"text": "It lowered the production of tumour necrosis factor-alpha (TNF-alpha) in the beginning of acute liver failure induced by D-GalN/LPS.", "spo_list": [{"subject": "D-GalN", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "tumour necrosis factor-alpha", "object_type": "GENE-Y"}, {"subject": "D-GalN", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TNF-alpha", "object_type": "GENE-Y"}]}
{"text": "In addition, pseudoephedrine significantly suppressed the production of p-IkappaB-alpha, reducing the degradation of sequestered nuclear factor kappa B (NF-kappaB) in the cytoplasm, and inhibited the translocation of NF-kappaB/p65 to the nucleus, the transcription of TNF-alpha mRNA and the production of TNF-alpha in primary KCs.", "spo_list": [{"subject": "pseudoephedrine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "p-IkappaB-alpha", "object_type": "GENE-Y"}, {"subject": "pseudoephedrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}, {"subject": "pseudoephedrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p65", "object_type": "GENE-Y"}, {"subject": "pseudoephedrine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF-alpha", "object_type": "GENE-Y"}, {"subject": "pseudoephedrine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF-alpha", "object_type": "GENE-Y"}]}
{"text": "These results suggest that pseudoephedrine and ephedrine have a potent anti-inflammatory activity against D-GalN/LPS-induced acute liver failure in rats, and this comprehensive anti-inflammatory effect may result from the inhibition of TNF-alpha production.", "spo_list": [{"subject": "pseudoephedrine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF-alpha", "object_type": "GENE-Y"}, {"subject": "ephedrine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF-alpha", "object_type": "GENE-Y"}]}
{"text": "DBA/2J-mated CBA/J female mice were randomized in three groups: 1) control females, 2) mice exposed to stress on gestation day 5.5, and 3) mice exposed to stress and substituted with dydrogesterone, a progestogen with a binding profile highly selective for the progesterone receptor on gestation day 5.5.", "spo_list": [{"subject": "dydrogesterone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "progesterone receptor", "object_type": "GENE-Y"}, {"subject": "progestogen", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "progesterone receptor", "object_type": "GENE-Y"}]}
{"text": "Antiestrogens, principally tamoxifen, and aromatase inhibitors have been used as the first- and second-line therapy in patients with advanced postmenopausal breast cancer for many years.", "spo_list": [{"subject": "tamoxifen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "Toxicological profiles of selected synthetic cannabinoids showing high binding affinities to the cannabinoid receptor subtype CB1.", "spo_list": [{"subject": "cannabinoids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "cannabinoid receptor subtype CB1", "object_type": "GENE-Y"}]}
{"text": "Because data concerning their toxicological properties are scarce, the cytotoxic, genotoxic, immunomodulatory, and hormonal activities of four naphthoylindole compounds (JWH-018, JWH-073, JWH-122 and JWH-210) and of one benzoylindole (AM-694) were studied in human cell lines and primary cells; tetrahydrocannabinol was included as the classical non-endogenous cannabinoid receptor ligand.", "spo_list": [{"subject": "tetrahydrocannabinol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "cannabinoid receptor", "object_type": "GENE-N"}]}
{"text": "Furthermore, no impact on cytokine release (i.e., on IL-10, IL-6, IL-12/23p40 and TNFÎ± levels) was seen in LPS-stimulated human PBMCs, except with JWH-210 and JWH-122 which caused a decrease of TNFÎ± and IL-12/23p40.", "spo_list": [{"subject": "JWH-122", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNFÎ±", "object_type": "GENE-Y"}, {"subject": "JWH-210", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNFÎ±", "object_type": "GENE-Y"}, {"subject": "JWH-210", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-12", "object_type": "GENE-N"}, {"subject": "JWH-210", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "23p40", "object_type": "GENE-Y"}, {"subject": "JWH-122", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-12", "object_type": "GENE-N"}, {"subject": "JWH-122", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "23p40", "object_type": "GENE-Y"}]}
{"text": "Catalpol reduced the expression of pro-inflammatory mediates, such as monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor-Î± (TNF-Î±), inducible NO synthase (iNOS), and receptor for AGE (RAGE).", "spo_list": [{"subject": "Catalpol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "monocyte chemotactic protein-1", "object_type": "GENE-Y"}, {"subject": "Catalpol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MCP-1", "object_type": "GENE-Y"}, {"subject": "Catalpol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "tumor necrosis factor-Î±", "object_type": "GENE-Y"}, {"subject": "Catalpol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF-Î±", "object_type": "GENE-Y"}, {"subject": "Catalpol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "inducible NO synthase", "object_type": "GENE-Y"}, {"subject": "Catalpol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "iNOS", "object_type": "GENE-Y"}, {"subject": "Catalpol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "receptor for AGE", "object_type": "GENE-Y"}, {"subject": "Catalpol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "RAGE", "object_type": "GENE-Y"}]}
{"text": "Promoter and electromobility shift assays showed that transcriptional activation of NF-ÎºB was significantly reduced by catalpol treatment, while AP-1 was not.", "spo_list": [{"subject": "catalpol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}]}
{"text": "Catalpol also suppressed AGE-induced phosphorylation of mitogen activated protein (MAP) kinases, degradation of IÎºBÎ± and the nuclear localization of NF-ÎºB.", "spo_list": [{"subject": "Catalpol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mitogen activated protein (MAP) kinases", "object_type": "GENE-N"}, {"subject": "Catalpol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IÎºBÎ±", "object_type": "GENE-Y"}, {"subject": "Catalpol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}]}
{"text": "Moreover, the production of intracellular reactive oxygen species (ROS) elicited by AGE was also suppressed by catalpol treatment, through dual action of reducing ROS itself and inhibiting NADPH oxidase activity.", "spo_list": [{"subject": "catalpol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NADPH oxidase", "object_type": "GENE-N"}]}
{"text": "Our findings indicate that catalpol suppresses AGE-mediated inflammation by inhibiting ROS production and NF-ÎºB activity.", "spo_list": [{"subject": "catalpol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-ÎºB", "object_type": "GENE-N"}]}
{"text": "OBJECTIVE: To introduce entacapone, a new catechol-O-methyltransferase inhibitor, and discuss its pharmacology, pharmacodynamics, pharmacokinetics, clinical efficacy, drug interactions, adverse events, dosage guidelines, and therapeutic and formulary considerations.", "spo_list": [{"subject": "entacapone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "catechol-O-methyltransferase", "object_type": "GENE-Y"}]}
{"text": "DATA SYNTHESIS: Entacapone is the second medication of a new class of drugs, the catechol-O-methyltransferase inhibitors, indicated for clinical use as an adjunct to levodopa/carbidopa to treat patients with idiopathic Parkinson's disease who experience the signs and symptoms of end-of-dose wearing-off.", "spo_list": [{"subject": "Entacapone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "catechol-O-methyltransferase", "object_type": "GENE-Y"}]}
{"text": "Synthesis and SAR of novel Re/99mTc-labeled benzenesulfonamide carbonic anhydrase IX inhibitors for molecular imaging of tumor hypoxia.", "spo_list": [{"subject": "99mTc", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase IX", "object_type": "GENE-Y"}, {"subject": "Re", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase IX", "object_type": "GENE-Y"}, {"subject": "benzenesulfonamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase IX", "object_type": "GENE-Y"}]}
{"text": "A series of small molecule benzenesulfonamide based CA-IX inhibitors containing novel tridentate chelates complexed with the M(CO)(3) core (M = Re or (99m)Tc) were designed and synthesized.", "spo_list": [{"subject": "benzenesulfonamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA-IX", "object_type": "GENE-Y"}]}
{"text": "The in vitro binding affinity of the benzenesulfonamide rhenium complexes yielded IC(50) values ranging from 3 to 116 nM in hypoxic CA-IX expressing HeLa cells.", "spo_list": [{"subject": "benzenesulfonamide rhenium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CA-IX", "object_type": "GENE-Y"}, {"subject": "benzenesulfonamide rhenium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA-IX", "object_type": "GENE-Y"}]}
{"text": "(99m)Tc(CO)(3)-3d bound specifically to CA-IX expressing hypoxic HeLa cells.", "spo_list": [{"subject": "(99m)Tc(CO)(3)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CA-IX", "object_type": "GENE-Y"}]}
{"text": "This effort led to the identification of a diverse series of promising high affinity {(99m)Tc(CO)(3)}(+) radiolabeled CA-IX inhibitors with the potential to significantly impact diagnosis, staging, and treatment selection of hypoxic solid tumors.", "spo_list": [{"subject": "{(99m)Tc(CO)(3)}(+)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CA-IX", "object_type": "GENE-Y"}, {"subject": "{(99m)Tc(CO)(3)}(+)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA-IX", "object_type": "GENE-Y"}]}
{"text": "Alanine uptake into astrocytes was largely mediated by system L isoform LAT2, whereas alanine uptake into neurons was mediated by Na(+)-dependent transporters with properties similar to system B(0) isoform B(0)AT2.", "spo_list": [{"subject": "Alanine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "system L", "object_type": "GENE-N"}, {"subject": "Alanine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT2", "object_type": "GENE-Y"}, {"subject": "alanine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "B(0)AT2", "object_type": "GENE-N"}]}
{"text": "To investigate the role of alanine transport in metabolism, its uptake was inhibited in cortical tissue slices under depolarizing conditions using the system L transport inhibitors 2-aminobicyclo[2.2.1]heptane-2-carboxylic acid and cycloleucine (1-aminocyclopentanecarboxylic acid; cLeu).", "spo_list": [{"subject": "2-aminobicyclo[2.2.1]heptane-2-carboxylic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "system L", "object_type": "GENE-N"}, {"subject": "cycloleucine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "system L", "object_type": "GENE-N"}, {"subject": "1-aminocyclopentanecarboxylic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "system L", "object_type": "GENE-N"}, {"subject": "cLeu", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "system L", "object_type": "GENE-N"}, {"subject": "alanine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "system L", "object_type": "GENE-N"}]}
{"text": "The results indicated that alanine cycling occurs subsequent to glutamate/glutamine cycling and that a significant proportion of cycling occurs via amino acid transport system L. Our results show that system L isoform LAT2 is critical for alanine uptake into astrocytes.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "system L", "object_type": "GENE-N"}, {"subject": "alanine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "system L", "object_type": "GENE-N"}, {"subject": "glutamate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "system L", "object_type": "GENE-N"}, {"subject": "glutamine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "system L", "object_type": "GENE-N"}]}
{"text": "Moreover, we demonstrated that in utero exposure to low-level MeHg suppresses the expression of Rac1, Cdc42, and RhoA, which play key roles in the migration of cerebrocortical neurons during the early stage of brain development, suggesting that the MeHg-induced migratory disturbance of cerebrocortical neurons is likely associated with the Rho GTPases signal pathway.", "spo_list": [{"subject": "MeHg", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Rac1", "object_type": "GENE-Y"}, {"subject": "MeHg", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Cdc42", "object_type": "GENE-Y"}, {"subject": "MeHg", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "RhoA", "object_type": "GENE-Y"}]}
{"text": "CONCLUSION: The high density of [3H]-pranlukast binding sites on the local leukocytes in human nasal mucosa suggests that CysLT1 receptor antagonists may directly modulate cellular function of the local leukocytes through binding to CysLT1 receptor on allergic nasal mucosa.", "spo_list": [{"subject": "[3H]-pranlukast", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CysLT1", "object_type": "GENE-Y"}, {"subject": "[3H]-pranlukast", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CysLT1", "object_type": "GENE-Y"}]}
{"text": "Ibrutinib (Imbruvica(R)) is a first-in-class, potent, orally administered, covalent inhibitor of Bruton's tyrosine kinase (BTK) that inhibits B-cell antigen receptor signalling downstream of BTK.", "spo_list": [{"subject": "Ibrutinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Bruton's tyrosine kinase", "object_type": "GENE-Y"}, {"subject": "Imbruvica(R)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Bruton's tyrosine kinase", "object_type": "GENE-Y"}, {"subject": "Ibrutinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BTK", "object_type": "GENE-Y"}, {"subject": "Imbruvica(R)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BTK", "object_type": "GENE-Y"}, {"subject": "Ibrutinib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "B-cell antigen receptor", "object_type": "GENE-N"}, {"subject": "Imbruvica(R)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "B-cell antigen receptor", "object_type": "GENE-N"}, {"subject": "Ibrutinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BTK", "object_type": "GENE-Y"}]}
{"text": "Three new cholinesterase inhibitors, donepezil, rivastigmine, and galantamine, all inhibit the enzyme AChE.", "spo_list": [{"subject": "donepezil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cholinesterase", "object_type": "GENE-Y"}, {"subject": "rivastigmine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cholinesterase", "object_type": "GENE-Y"}, {"subject": "galantamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cholinesterase", "object_type": "GENE-Y"}, {"subject": "donepezil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "rivastigmine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "galantamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "Rivastigmine also inhibits BuChE, which could lead to additional benefits in late-stage Alzheimer's disease, but also cause more GI side effects at initiation of therapy.", "spo_list": [{"subject": "Rivastigmine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BuChE", "object_type": "GENE-Y"}]}
{"text": "The results showed that collagen content from the chondrocytes extracellular matrix increased with increasing strontium concentration.", "spo_list": [{"subject": "strontium", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "collagen", "object_type": "GENE-N"}]}
{"text": "Moreover, 3 and 5Â mM strontium strongly stimulated protein expression and mRNA levels of type II collagen and IGF-1.", "spo_list": [{"subject": "strontium", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "type II collagen", "object_type": "GENE-N"}, {"subject": "strontium", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IGF-1", "object_type": "GENE-Y"}]}
{"text": "Conversely, MMP-13 expression in chondrocytes decreased dose-dependently with increasing strontium concentration.", "spo_list": [{"subject": "strontium", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MMP-13", "object_type": "GENE-Y"}]}
{"text": "Strontium could promote collagen synthesis and suppress collagen degradation via the repression of MMP-13 expression.", "spo_list": [{"subject": "Strontium", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "MMP-13", "object_type": "GENE-Y"}, {"subject": "Strontium", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "collagen", "object_type": "GENE-N"}]}
{"text": "Liver X Receptor (LXR) Î± and LXR Î² are nuclear receptors activated by oxysterols, oxidized derivatives of cholesterol.", "spo_list": [{"subject": "oxysterols", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Liver X Receptor (LXR) Î±", "object_type": "GENE-Y"}, {"subject": "oxysterols", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "LXR Î²", "object_type": "GENE-Y"}]}
{"text": "Cholinesterase and carboxylesterase inhibition in Planorbarius corneus exposed to binary mixtures of azinphos-methyl and chlorpyrifos.", "spo_list": [{"subject": "azinphos-methyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Cholinesterase", "object_type": "GENE-N"}, {"subject": "azinphos-methyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carboxylesterase", "object_type": "GENE-N"}, {"subject": "chlorpyrifos", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Cholinesterase", "object_type": "GENE-N"}, {"subject": "chlorpyrifos", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carboxylesterase", "object_type": "GENE-N"}]}
{"text": "The present investigation was undertaken to explore the in vivo inhibition of the freshwater gastropod snail Planorbarius corneus cholinesterase (ChE) and carboxylesterases (CES) activities by the organophosphorus pesticides azinphos-methyl (AZM) and chlorpyrifos (CPF).", "spo_list": [{"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Planorbarius corneus cholinesterase", "object_type": "GENE-N"}, {"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ChE", "object_type": "GENE-N"}, {"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carboxylesterases", "object_type": "GENE-N"}, {"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CES", "object_type": "GENE-N"}, {"subject": "azinphos-methyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Planorbarius corneus cholinesterase", "object_type": "GENE-N"}, {"subject": "azinphos-methyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ChE", "object_type": "GENE-N"}, {"subject": "azinphos-methyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carboxylesterases", "object_type": "GENE-N"}, {"subject": "azinphos-methyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CES", "object_type": "GENE-N"}, {"subject": "AZM", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Planorbarius corneus cholinesterase", "object_type": "GENE-N"}, {"subject": "AZM", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ChE", "object_type": "GENE-N"}, {"subject": "AZM", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carboxylesterases", "object_type": "GENE-N"}, {"subject": "AZM", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CES", "object_type": "GENE-N"}, {"subject": "chlorpyrifos", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Planorbarius corneus cholinesterase", "object_type": "GENE-N"}, {"subject": "chlorpyrifos", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ChE", "object_type": "GENE-N"}, {"subject": "chlorpyrifos", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carboxylesterases", "object_type": "GENE-N"}, {"subject": "chlorpyrifos", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CES", "object_type": "GENE-N"}, {"subject": "CPF", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Planorbarius corneus cholinesterase", "object_type": "GENE-N"}, {"subject": "CPF", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ChE", "object_type": "GENE-N"}, {"subject": "CPF", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carboxylesterases", "object_type": "GENE-N"}, {"subject": "CPF", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CES", "object_type": "GENE-N"}]}
{"text": "ChE activity was measured with acetylthiocholine as substrate and CES activity was measured with four substrates: p-nitrophenyl acetate, p-nitrophenyl butyrate, 1- and 2-naphthyl acetate.", "spo_list": [{"subject": "acetylthiocholine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ChE", "object_type": "GENE-N"}, {"subject": "p-nitrophenyl acetate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CES", "object_type": "GENE-N"}, {"subject": "p-nitrophenyl butyrate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CES", "object_type": "GENE-N"}, {"subject": "1- and 2-naphthyl acetate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CES", "object_type": "GENE-N"}]}
{"text": "Single-chemical experiments showed that CPF was a more potent inhibitor of ChE activity than AZM (350 and 27 times for the whole soft tissue and hemolymph, respectively).", "spo_list": [{"subject": "CPF", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ChE", "object_type": "GENE-N"}, {"subject": "AZM", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ChE", "object_type": "GENE-N"}]}
{"text": "CES were 15 times more sensitive than ChE when the activities were measured in the whole soft tissue of the animals exposed to AZM.", "spo_list": [{"subject": "AZM", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CES", "object_type": "GENE-N"}, {"subject": "AZM", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ChE", "object_type": "GENE-N"}]}
{"text": "Based on a default assumption of concentration addition, P. corneus snails were exposed to mixtures of AZM+CPF designed to yield predicted soft tissue ChE inhibitions of 31% (mixture 1), 50% (mixture 2) and 61% (mixture 3).", "spo_list": [{"subject": "CPF", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ChE", "object_type": "GENE-N"}, {"subject": "AZM", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ChE", "object_type": "GENE-N"}]}
{"text": "In addition, results obtained when the snails were exposed sequentially to the pesticides showed that the sequence AZM/CPF produced at 48 h a higher ChE inhibition than the sequence CPF/CPF.", "spo_list": [{"subject": "CPF", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ChE", "object_type": "GENE-N"}, {"subject": "AZM", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ChE", "object_type": "GENE-N"}, {"subject": "CPF", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ChE", "object_type": "GENE-N"}, {"subject": "CPF", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ChE", "object_type": "GENE-N"}]}
{"text": "In particular, the data presented in the present study indicate that CES enzymes would be important factors in determining the effects of the mixtures of OPs on P. corneus ChE activity.", "spo_list": [{"subject": "OPs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ChE", "object_type": "GENE-N"}]}
{"text": "Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.", "spo_list": [{"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "phosphodiesterase-5", "object_type": "GENE-Y"}, {"subject": "cyclic guanosine monophosphate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "phosphodiesterase-5", "object_type": "GENE-Y"}]}
{"text": "The molecular bases for phosphodiesterase 5 (PDE5) catalytic-site affinity for cyclic guanosine monophosphate (cGMP) and potency of inhibitors are poorly understood.", "spo_list": [{"subject": "cyclic guanosine monophosphate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "phosphodiesterase 5", "object_type": "GENE-Y"}, {"subject": "cyclic guanosine monophosphate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "cGMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "phosphodiesterase 5", "object_type": "GENE-Y"}, {"subject": "cGMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDE5", "object_type": "GENE-Y"}]}
{"text": "Cocrystal structures of PDE5 catalytic (C) domain with inhibitors reveal a hydrogen bond and hydrophobic interactions with Tyr-612, hydrogen bonds with Gln-817, a hydrophobic clamp formed by Phe-820 and Val-782, and contacts with His-613, Leu-765, and Phe-786 [Sung et al.", "spo_list": [{"subject": "Tyr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDE5 catalytic (C) domain", "object_type": "GENE-N"}, {"subject": "Gln", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDE5 catalytic (C) domain", "object_type": "GENE-N"}, {"subject": "Phe", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDE5 catalytic (C) domain", "object_type": "GENE-N"}, {"subject": "Val", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDE5 catalytic (C) domain", "object_type": "GENE-N"}, {"subject": "His", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDE5 catalytic (C) domain", "object_type": "GENE-N"}, {"subject": "Leu", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDE5 catalytic (C) domain", "object_type": "GENE-N"}, {"subject": "Phe", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDE5 catalytic (C) domain", "object_type": "GENE-N"}]}
{"text": "Catalytic-site affinities for cGMP, vardenafil, sildenafil, tadalafil, or 3-isobutyl-1-methylxanthine (IBMX) were respectively weakened 14-, 123-, 30-, 51-, and 43-fold for Y612A; 63-, 511-, 43-, 95- and 61-fold for Q817A; and 59-, 448-, 71-, 137-, and 93-fold for F820A.", "spo_list": [{"subject": "cGMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Y612A", "object_type": "GENE-N"}, {"subject": "vardenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Y612A", "object_type": "GENE-N"}, {"subject": "sildenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Y612A", "object_type": "GENE-N"}, {"subject": "tadalafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Y612A", "object_type": "GENE-N"}, {"subject": "3-isobutyl-1-methylxanthine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Y612A", "object_type": "GENE-N"}, {"subject": "IBMX", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Y612A", "object_type": "GENE-N"}, {"subject": "cGMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Q817A", "object_type": "GENE-N"}, {"subject": "cGMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "F820A", "object_type": "GENE-N"}, {"subject": "vardenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Q817A", "object_type": "GENE-N"}, {"subject": "vardenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "F820A", "object_type": "GENE-N"}, {"subject": "sildenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Q817A", "object_type": "GENE-N"}, {"subject": "tadalafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "F820A", "object_type": "GENE-N"}, {"subject": "3-isobutyl-1-methylxanthine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Q817A", "object_type": "GENE-N"}, {"subject": "3-isobutyl-1-methylxanthine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "F820A", "object_type": "GENE-N"}, {"subject": "sildenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "F820A", "object_type": "GENE-N"}, {"subject": "IBMX", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Q817A", "object_type": "GENE-N"}, {"subject": "IBMX", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "F820A", "object_type": "GENE-N"}]}
{"text": "Affinity of V782A for cGMP, vardenafil, sildenafil, tadalafil, or IBMX was reduced 5.5-, 23-, 10-, 3-, and 12-fold, respectively.", "spo_list": [{"subject": "cGMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "V782A", "object_type": "GENE-N"}, {"subject": "vardenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "V782A", "object_type": "GENE-N"}, {"subject": "sildenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "V782A", "object_type": "GENE-N"}, {"subject": "tadalafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "V782A", "object_type": "GENE-N"}, {"subject": "IBMX", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "V782A", "object_type": "GENE-N"}]}
{"text": "Change in affinity for cGMP, vardenafil, sildenafil, or IBMX in Y612F, H613A, L765A, or F786A was less, but affinity of H613A or F786A for tadalafil was weakened 37- and 17-fold, respectively.", "spo_list": [{"subject": "tadalafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "H613A", "object_type": "GENE-N"}, {"subject": "tadalafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "F786A", "object_type": "GENE-N"}, {"subject": "cGMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Y612F", "object_type": "GENE-N"}, {"subject": "cGMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "H613A", "object_type": "GENE-N"}, {"subject": "cGMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "L765A", "object_type": "GENE-N"}, {"subject": "cGMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "F786A", "object_type": "GENE-N"}, {"subject": "vardenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Y612F", "object_type": "GENE-N"}, {"subject": "vardenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "H613A", "object_type": "GENE-N"}, {"subject": "vardenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "L765A", "object_type": "GENE-N"}, {"subject": "vardenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "F786A", "object_type": "GENE-N"}, {"subject": "sildenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Y612F", "object_type": "GENE-N"}, {"subject": "sildenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "H613A", "object_type": "GENE-N"}, {"subject": "sildenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "L765A", "object_type": "GENE-N"}, {"subject": "sildenafil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "F786A", "object_type": "GENE-N"}, {"subject": "IBMX", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Y612F", "object_type": "GENE-N"}, {"subject": "IBMX", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "H613A", "object_type": "GENE-N"}, {"subject": "IBMX", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "L765A", "object_type": "GENE-N"}, {"subject": "IBMX", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "F786A", "object_type": "GENE-N"}]}
{"text": "The results quantify the role of PDE5 catalytic-site residues for cGMP and inhibitors, indicate that Tyr-612, Gln-817, and Phe-820 are the most important cGMP or inhibitor contacts studied, and identify residues that contribute to selectivity among different classes of inhibitors.", "spo_list": [{"subject": "cGMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "Tyr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "Gln", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "Phe", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "cGMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDE5", "object_type": "GENE-Y"}]}
{"text": "Phe-308 and Phe-312 in transmembrane domain 7 are major sites of alpha 1-adrenergic receptor antagonist binding.", "spo_list": [{"subject": "Phe", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "alpha 1-adrenergic receptor", "object_type": "GENE-N"}, {"subject": "Phe", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "alpha 1-adrenergic receptor", "object_type": "GENE-N"}]}
{"text": "We now report the identification of two phenylalanine residues in transmembrane domain 7 of the alpha(1a)-adrenergic receptor (Phe-312 and Phe-308) that are a major site of antagonist affinity.", "spo_list": [{"subject": "phenylalanine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "alpha(1a)-adrenergic receptor", "object_type": "GENE-Y"}, {"subject": "Phe", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "alpha(1a)-adrenergic receptor", "object_type": "GENE-Y"}, {"subject": "Phe", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "alpha(1a)-adrenergic receptor", "object_type": "GENE-Y"}]}
{"text": "Increased urinary excretion of albumin, hemopexin, transferrin and VDBP correlates with chronic sensitization to gentamicin nephrotoxicity in rats.", "spo_list": [{"subject": "gentamicin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "albumin", "object_type": "GENE-N"}, {"subject": "gentamicin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "hemopexin", "object_type": "GENE-Y"}, {"subject": "gentamicin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "transferrin", "object_type": "GENE-Y"}, {"subject": "gentamicin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "VDBP", "object_type": "GENE-Y"}]}
{"text": "Deprenyl is a selective, irreversible inhibitor of monoamine oxidase type-B (MAO-B).", "spo_list": [{"subject": "Deprenyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase type-B", "object_type": "GENE-Y"}, {"subject": "Deprenyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-B", "object_type": "GENE-Y"}]}
{"text": "The latter reaction, catalyzed by aspartoacylase (ASPA), produces acetyl groups plus aspartate and has been proposed to occur in both soluble and membranous subfractions of white matter.", "spo_list": [{"subject": "acetyl", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "aspartoacylase", "object_type": "GENE-Y"}, {"subject": "acetyl", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ASPA", "object_type": "GENE-Y"}, {"subject": "aspartate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "aspartoacylase", "object_type": "GENE-Y"}, {"subject": "aspartate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "ASPA", "object_type": "GENE-Y"}]}
{"text": "That observation, together with previous demonstrations of numerous lipid-synthesizing enzymes in myelin, suggests utilization of acetyl groups liberated by myelin-localized ASPA for lipid synthesis within the myelin sheath.", "spo_list": [{"subject": "acetyl", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ASPA", "object_type": "GENE-Y"}]}
{"text": "Moreover, we have found that resveratrol activated the AMP-activated protein kinase, SIRT1, and mitochondrial transcription factor A (p<0.05).", "spo_list": [{"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMP-activated protein kinase", "object_type": "GENE-N"}, {"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "SIRT1", "object_type": "GENE-Y"}, {"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "mitochondrial transcription factor A", "object_type": "GENE-Y"}]}
{"text": "These data indicate, that resveratrol supplementation enhances aerobic performance due to the activation of the AMPK-SIRT1-PGC-1Î± pathway.", "spo_list": [{"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "SIRT1", "object_type": "GENE-Y"}, {"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PGC-1Î±", "object_type": "GENE-Y"}]}
{"text": "For this purpose, we used hydroxy methyl glutaryl Coenzyme A (HMG-CoA) reductase inhibitors such as lovastatin.", "spo_list": [{"subject": "lovastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hydroxy methyl glutaryl Coenzyme A (HMG-CoA) reductase", "object_type": "GENE-Y"}]}
{"text": "The involvement of prostaglandins synthesized by constitutive (COX-1) and inducible cyclooxygenase (COX-2) in central stimulation of the hypothalamic-pituitary-adrenal (HPA) axis by adrenergic receptor agonists was investigated in conscious rats.", "spo_list": [{"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclooxygenase", "object_type": "GENE-N"}, {"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "COX-1 and COX-2 inhibitor, piroxicam (0.02 and 0.2 microg) and compound NS-398 (0.01 and 0.1 microg), respectively, were given intracerebroventricularly (i.c.v.) 15 min prior to i.c.v. adrenergic receptor agonists: phenylephrine (30 microg) and clonidine (10 microg), an alpha1- and alpha2-adrenergic agonist, and isoprenaline (20 microg) a non-selective beta-adrenergic agonist and clenbuterol (10 microg) a selective beta2-adrenergic agonist.", "spo_list": [{"subject": "piroxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "piroxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "phenylephrine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "adrenergic receptor", "object_type": "GENE-N"}, {"subject": "clonidine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "adrenergic receptor", "object_type": "GENE-N"}, {"subject": "isoprenaline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "adrenergic receptor", "object_type": "GENE-N"}, {"subject": "clenbuterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "adrenergic receptor", "object_type": "GENE-N"}]}
{"text": "Piroxicam and NS-398 considerably and dose-dependently reduced the phenylephrine-induced increase in ACTH and corticosterone secretion.", "spo_list": [{"subject": "phenylephrine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ACTH", "object_type": "GENE-Y"}, {"subject": "Piroxicam", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ACTH", "object_type": "GENE-Y"}, {"subject": "NS-398", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ACTH", "object_type": "GENE-Y"}]}
{"text": "Pretreatment with piroxicam and NS-398 markedly impaired the clonidine-evoked ACTH and corticosterone secretion.", "spo_list": [{"subject": "clonidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ACTH", "object_type": "GENE-Y"}, {"subject": "piroxicam", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ACTH", "object_type": "GENE-Y"}, {"subject": "NS-398", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ACTH", "object_type": "GENE-Y"}]}
{"text": "Piroxicam moderately diminished the isoprenaline-elicited increase in ACTH and corticosterone, while NS-398 did not markedly alter ACTH secretion.", "spo_list": [{"subject": "Piroxicam", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ACTH", "object_type": "GENE-Y"}]}
{"text": "The clenbuterol-induced ACTH and corticosterone responses were considerably impaired by pretreatment with piroxicam, and slightly less potently by NS-398.", "spo_list": [{"subject": "clenbuterol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ACTH", "object_type": "GENE-Y"}, {"subject": "piroxicam", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ACTH", "object_type": "GENE-Y"}, {"subject": "NS-398", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ACTH", "object_type": "GENE-Y"}]}
{"text": "RESULTS: The density of AR in liver tissue in NP group was higher than that in control group (P < 0.05).", "spo_list": [{"subject": "NP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AR", "object_type": "GENE-Y"}]}
{"text": "CONCLUSION: Nandrolone phenylpropionate up-regulated the density of AR in liver tissue, whereas it had no significant effects on the density of AR in testis and ovary tissues.", "spo_list": [{"subject": "Nandrolone phenylpropionate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AR", "object_type": "GENE-Y"}]}
{"text": "Cross-inhibition of SR-BI- and ABCA1-mediated cholesterol transport by the small molecules BLT-4 and glyburide.", "spo_list": [{"subject": "glyburide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SR-BI", "object_type": "GENE-Y"}, {"subject": "glyburide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ABCA1", "object_type": "GENE-Y"}]}
{"text": "The activities of ABCA1 and other ATP binding cassette superfamily members are inhibited by the drug glyburide, and SR-BI-mediated lipid transport is blocked by small molecule inhibitors called BLTs.", "spo_list": [{"subject": "glyburide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ABCA1", "object_type": "GENE-Y"}, {"subject": "glyburide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ATP binding cassette superfamily", "object_type": "GENE-N"}]}
{"text": "Here, we show that one BLT, [1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea] (BLT-4), blocked ABCA1-mediated cholesterol efflux to lipid-poor apoA-I at a potency similar to that for its inhibition of SR-BI (IC(50) approximately 55-60 microM).", "spo_list": [{"subject": "BLT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ABCA1", "object_type": "GENE-Y"}, {"subject": "1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ABCA1", "object_type": "GENE-Y"}, {"subject": "BLT-4", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ABCA1", "object_type": "GENE-Y"}, {"subject": "BLT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SR-BI", "object_type": "GENE-Y"}, {"subject": "1-(2-methoxy-phenyl)-3-naphthalen-2-yl-urea", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SR-BI", "object_type": "GENE-Y"}, {"subject": "BLT-4", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SR-BI", "object_type": "GENE-Y"}]}
{"text": "Reciprocally, glyburide blocked SR-BI-mediated selective lipid uptake and efflux at a potency similar to that for its inhibition of ABCA1 (IC(50) approximately 275-300 microM).", "spo_list": [{"subject": "glyburide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SR-BI", "object_type": "GENE-Y"}, {"subject": "glyburide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ABCA1", "object_type": "GENE-Y"}]}
{"text": "As is the case with BLTs, glyburide increased the apparent affinity of HDL binding to SR-BI.", "spo_list": [{"subject": "glyburide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "HDL", "object_type": "GENE-N"}, {"subject": "glyburide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SR-BI", "object_type": "GENE-Y"}]}
{"text": "The reciprocal inhibition of SR-BI and ABCA1 by BLT-4 and glyburide raises the possibility that these proteins may share similar or common steps in their mechanisms of lipid transport.", "spo_list": [{"subject": "glyburide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SR-BI", "object_type": "GENE-Y"}, {"subject": "glyburide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ABCA1", "object_type": "GENE-Y"}]}
{"text": "The X-ray crystal structure of human isoform II in adduct with an adamantyl analogue of acetazolamide resides in a less utilized binding pocket than most hydrophobic inhibitors.", "spo_list": [{"subject": "adamantyl", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human isoform II", "object_type": "GENE-Y"}, {"subject": "acetazolamide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human isoform II", "object_type": "GENE-Y"}]}
{"text": "We investigated the inhibitory activity of several 1,3,4-thiadiazole-sulfonamides against all catalytically active CA (EC 4.2.1.1), CA I-XV.", "spo_list": [{"subject": "1,3,4-thiadiazole-sulfonamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA", "object_type": "GENE-N"}, {"subject": "1,3,4-thiadiazole-sulfonamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 4.2.1.1", "object_type": "GENE-N"}]}
{"text": "The high resolution X-ray crystal structure of hCA II in complex with 5-(1-adamantylcarboxamido)-1,3,4-thiadiazole-2-sulfonamide, showed the adamantyl moiety of the inhibitor residing in a less utilized binding pocket than that of most hydrophobic inhibitors, lined by the amino acid residues Ile91, Val121 and Phe131.", "spo_list": [{"subject": "5-(1-adamantylcarboxamido)-1,3,4-thiadiazole-2-sulfonamide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hCA II", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "hCA II", "object_type": "GENE-Y"}, {"subject": "adamantyl", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hCA II", "object_type": "GENE-Y"}]}
{"text": "Unexpectedly, both the mGluR(5)specific agonist, CHPG, and the group II mGluR (mGlu(2/3)) agonist, LY379268 (LY), induced a TTX-insensitive outward current/hyperpolarization.", "spo_list": [{"subject": "CHPG", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mGluR(5)", "object_type": "GENE-Y"}, {"subject": "LY379268", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "group II mGluR", "object_type": "GENE-N"}]}
{"text": "Both outward currents were significantly reduced by the mGluR antagonist MCPG and the CHPG-induced current was blocked by the specific mGluR(5) antagonist MTEP.", "spo_list": [{"subject": "MCPG", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "mGluR", "object_type": "GENE-N"}, {"subject": "MTEP", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "mGluR(5)", "object_type": "GENE-Y"}]}
{"text": "K203 is an experimental bis-pyridinium mono-aldoxime type cholinesterase reactivator of potential use in organophosphate/ organophosphonate poisoning.", "spo_list": [{"subject": "bis-pyridinium mono-aldoxime", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "cholinesterase", "object_type": "GENE-Y"}, {"subject": "organophosphate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cholinesterase", "object_type": "GENE-Y"}, {"subject": "organophosphonate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cholinesterase", "object_type": "GENE-Y"}]}
{"text": "Other dams received 1.8ng/kg/day of a mixture of aryl hydrocarbon receptor (AhR) agonists (non-ortho PCBs, PC-dibenzodioxins and PC-dibenzofurans) without or with 0.5M (0.5MAhR).", "spo_list": [{"subject": "non-ortho PCB", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "aryl hydrocarbon receptor", "object_type": "GENE-Y"}, {"subject": "PC-dibenzodioxins", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "aryl hydrocarbon receptor", "object_type": "GENE-Y"}, {"subject": "PC-dibenzofurans", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "aryl hydrocarbon receptor", "object_type": "GENE-Y"}, {"subject": "non-ortho PCB", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "AhR", "object_type": "GENE-Y"}, {"subject": "PC-dibenzodioxins", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "AhR", "object_type": "GENE-Y"}, {"subject": "PC-dibenzofurans", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "AhR", "object_type": "GENE-Y"}]}
{"text": "Structural optimization of 2,5-thiophene amides as highly potent and selective 17Î²-hydroxysteroid dehydrogenase type 2 inhibitors for the treatment of osteoporosis.", "spo_list": [{"subject": "2,5-thiophene amides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "17Î²-hydroxysteroid dehydrogenase type 2", "object_type": "GENE-Y"}]}
{"text": "We report here the optimization of human 17Î²-HSD2 inhibitors in the 2,5-thiophene amide class by varying the size of the linker (n equals 0 and 2) between the amide moiety and the phenyl group.", "spo_list": [{"subject": "2,5-thiophene amide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human 17Î²-HSD2", "object_type": "GENE-Y"}]}
{"text": "While none of the phenethylamides (n = 2) were active, most of the anilides (n = 0) turned out to moderately or strongly inhibit 17Î²-HSD2.", "spo_list": [{"subject": "anilides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "17Î²-HSD2", "object_type": "GENE-Y"}]}
{"text": "Glutathione peroxidase 1 and glutathione are required to protect mouse astrocytes from iron-mediated hydrogen peroxide toxicity.", "spo_list": [{"subject": "hydrogen peroxide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Glutathione peroxidase 1", "object_type": "GENE-Y"}]}
{"text": "The enzyme glutathione peroxidase 1 (GPx1) is involved in the cellular detoxification of peroxides.", "spo_list": [{"subject": "peroxides", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "glutathione peroxidase 1", "object_type": "GENE-Y"}, {"subject": "peroxides", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GPx1", "object_type": "GENE-Y"}]}
{"text": "These results demonstrate that GPx1 contributes to the rapid clearance of H(2)O(2) by mouse astrocytes and that both GPx1 and a high concentration of glutathione are required to protect these cells from iron-dependent peroxide damage.", "spo_list": [{"subject": "H(2)O(2)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GPx1", "object_type": "GENE-Y"}, {"subject": "peroxide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GPx1", "object_type": "GENE-Y"}]}
{"text": "METHODS AND RESULTS: To determine the role for PI3Kgamma in hypertrophy induced by G-protein-coupled receptors and cardiomyopathy, we infused isoproterenol, a beta-adrenergic receptor agonist, into PI3Kgamma-deficient mice.", "spo_list": [{"subject": "isoproterenol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta-adrenergic receptor", "object_type": "GENE-N"}]}
{"text": "The inhibitory effects of icariin on PDE5 and PDE4 activities were investigated by the two-step radioisotope procedure with [(3)H]-cGMP/[(3)H]-cAMP.", "spo_list": [{"subject": "icariin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "icariin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}, {"subject": "[(3)H]-cGMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "[(3)H]-cGMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDE4", "object_type": "GENE-N"}, {"subject": "[(3)H]-cAMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "[(3)H]-cAMP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PDE4", "object_type": "GENE-N"}]}
{"text": "RESULTS: Icariin and papaverine showed dose-dependent inhibitory effects on PDE5 and PDE4 activities.", "spo_list": [{"subject": "Icariin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "Icariin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}, {"subject": "papaverine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "papaverine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}]}
{"text": "The IC(50) of Icariin and papaverine on PDE5 were 0.432 micromol/L and 0.680 micromol/L, respectively and those on PDE4, 73.50 micromol/L and 3.07 micromol/L, respectively.", "spo_list": [{"subject": "Icariin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "papaverine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "Icariin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}, {"subject": "papaverine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}]}
{"text": "The potencies of selectivity of icariin and papaverine on PDE5 (PDE4/PDE5 of IC(50)) were 167.67 times and 4.54 times, respectively.", "spo_list": [{"subject": "icariin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "papaverine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "icariin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}, {"subject": "papaverine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE4", "object_type": "GENE-N"}, {"subject": "icariin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "papaverine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE5", "object_type": "GENE-Y"}]}
{"text": "CONCLUSION: Icariin is a cGMP-specific PDE5 inhibitor that may be developed into an oral effective agent for the treatment of ED.", "spo_list": [{"subject": "cGMP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "Icariin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE5", "object_type": "GENE-Y"}]}
{"text": "Kinetics of inhibition of human and rat dihydroorotate dehydrogenase by atovaquone, lawsone derivatives, brequinar sodium and polyporic acid.", "spo_list": [{"subject": "atovaquone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human and rat dihydroorotate dehydrogenase", "object_type": "GENE-N"}, {"subject": "lawsone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human and rat dihydroorotate dehydrogenase", "object_type": "GENE-N"}, {"subject": "brequinar sodium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human and rat dihydroorotate dehydrogenase", "object_type": "GENE-N"}, {"subject": "polyporic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human and rat dihydroorotate dehydrogenase", "object_type": "GENE-N"}]}
{"text": "Mitochondrially-bound dihydroorotate dehydrogenase (EC 1.3.99.11) catalyzes the fourth sequential step in the de novo synthesis of uridine monophosphate.", "spo_list": [{"subject": "uridine monophosphate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "dihydroorotate dehydrogenase", "object_type": "GENE-Y"}, {"subject": "uridine monophosphate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "EC 1.3.99.11", "object_type": "GENE-Y"}]}
{"text": "With respect to the quinone co-substrate of the dihydroorotate dehydrogenase, atovaquone (Kic = 2.7 microM) and dichloroally-lawsone (Kic = 9.8 nM) were shown to be competitive inhibitors of human dihydroorotate dehydrogenase.", "spo_list": [{"subject": "quinone", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "dihydroorotate dehydrogenase", "object_type": "GENE-Y"}, {"subject": "atovaquone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human dihydroorotate dehydrogenase", "object_type": "GENE-Y"}, {"subject": "dichloroally-lawsone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human dihydroorotate dehydrogenase", "object_type": "GENE-Y"}]}
{"text": "Dichloroally]-lawsone was found to be a time-dependent inhibitor of the rat enzyme, with the lowest inhibition constant (Ki* = 0.77 nM) determined so far for mammalian dihydroorotate dehydrogenases.", "spo_list": [{"subject": "Dichloroally]-lawsone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mammalian dihydroorotate dehydrogenases", "object_type": "GENE-N"}]}
{"text": "Another inhibitor, brequinar was previously reported to be a slow-binding inhibitor of the human dihydroorotate dehydrogenase [W. Knecht, M. Loffler, Species-related inhibition of human and rat dihyroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives, Biochem.", "spo_list": [{"subject": "brequinar", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human dihydroorotate dehydrogenase", "object_type": "GENE-Y"}, {"subject": "isoxazol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human and rat dihyroorotate dehydrogenase", "object_type": "GENE-N"}, {"subject": "cinchoninic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human and rat dihyroorotate dehydrogenase", "object_type": "GENE-N"}]}
{"text": "With respect to the substrate dihydroorotate, atovaquone was an uncompetitive inhibitor of human dihydroorotate dehydrogenase (Kiu = 11.6 microM) and a non-competitive inhibitor of the rat enzyme (Kiu = 905/ Kic = 1,012 nM).", "spo_list": [{"subject": "dihydroorotate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human dihydroorotate dehydrogenase", "object_type": "GENE-Y"}, {"subject": "atovaquone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human dihydroorotate dehydrogenase", "object_type": "GENE-Y"}]}
{"text": "In this report, we evaluated the growth-inhibitory effects of sulindac sulfide, a COX-1 and COX-2 inhibitor; exisulind (sulindac sulfone), a novel proapoptotic agent that does not inhibit COX enzymes; and nordihydroguaiaretic acid (NDGA), a lipoxygenase inhibitor on human lung cancer cell lines.", "spo_list": [{"subject": "sulindac sulfide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "sulindac sulfide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "nordihydroguaiaretic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "lipoxygenase", "object_type": "GENE-N"}, {"subject": "NDGA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "lipoxygenase", "object_type": "GENE-N"}]}
{"text": "Synthesis and evaluation of carbamoylmethylene linked prodrugs of BMS-582949, a clinical p38Î± inhibitor.", "spo_list": [{"subject": "BMS-582949", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38Î±", "object_type": "GENE-Y"}, {"subject": "carbamoylmethylene", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38Î±", "object_type": "GENE-Y"}]}
{"text": "A series of carbamoylmethylene linked prodrugs of 1 (BMS-582949), a clinical p38Î± inhibitor, were synthesized and evaluated.", "spo_list": [{"subject": "BMS-582949", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38Î±", "object_type": "GENE-Y"}, {"subject": "carbamoylmethylene", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38Î±", "object_type": "GENE-Y"}]}
{"text": "Inhibition of the NF-kappaB pathway was responsible for this effect since the colchicoside inhibited RANKL-induced NF-kappaB activation, activation of IkappaB kinase (IKK) and suppressed inhibitor of NF-kappaBalpha (IkappaBalpha) phosphorylation and degradation, an inhibitor of NF-kappaB.", "spo_list": [{"subject": "colchicoside", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RANKL", "object_type": "GENE-Y"}, {"subject": "colchicoside", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}, {"subject": "colchicoside", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IkappaB kinase", "object_type": "GENE-N"}, {"subject": "colchicoside", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IKK", "object_type": "GENE-N"}, {"subject": "colchicoside", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaBalpha", "object_type": "GENE-Y"}, {"subject": "colchicoside", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IkappaBalpha", "object_type": "GENE-Y"}, {"subject": "colchicoside", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}]}
{"text": "CONCLUSIONS AND IMPLICATIONS: Together, these data suggest that thiocolchicoside significantly suppressed osteoclastogenesis induced by RANKL and tumour cells via the NF-kappaB signalling pathway.", "spo_list": [{"subject": "thiocolchicoside", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "RANKL", "object_type": "GENE-Y"}, {"subject": "thiocolchicoside", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}]}
{"text": "The dilatation of meningeal vessels disappears due to the stimulation of zolmitriptan of 5-HT1B receptors.", "spo_list": [{"subject": "zolmitriptan", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "5-HT1B", "object_type": "GENE-Y"}]}
{"text": "Contrary to most of their counterparts in animal cells, the higher plant GPX homologues identified so far possess cysteine instead of selenocysteine in their active site.", "spo_list": [{"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GPX", "object_type": "GENE-N"}, {"subject": "selenocysteine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GPX", "object_type": "GENE-N"}]}
{"text": "In its monophosphate form, TFT can inhibit thymidylate synthase (TS) activity after binding to the TS-nucleotide binding site leading to dTTP depletion, and in its triphosphate form TFT is incorporated into DNA, eventually leading to DNA damage.", "spo_list": [{"subject": "TFT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}, {"subject": "TFT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "TFT", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "TS", "object_type": "GENE-Y"}]}
{"text": "In this in vitro study, we investigated whether TFT could potentiate cytotoxicity of the antifolate-based TS inhibitors AG337 (Nolatrexed), ZD1694 (Raltitrexed) and GW1843; and whether increased TS inhibition or DNA damage would be related to this result.", "spo_list": [{"subject": "AG337", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "Nolatrexed", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "ZD1694", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "Raltitrexed", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "GW1843", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}]}
{"text": "TS inhibition (14.3%) and DNA damage (8%) were more pronounced than expected (P<0.05) when TFT was combined with GW1843 in WiDr/F cells, in contrast to AG337 and ZD1694, which showed inhibiting effects as expected (additive).", "spo_list": [{"subject": "TFT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "GW1843", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "AG337", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "ZD1694", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}]}
{"text": "CONCLUSIONS: The combination of TFT with the antifolates AG337, ZD1694 and GW1843 is mainly additive when the drugs are given simultaneously and this is mediated by an additive TS inhibition and DNA damage.", "spo_list": [{"subject": "TFT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "AG337", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "ZD1694", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "GW1843", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}]}
{"text": "The drug interaction may partly be dependent on the folate homeostasis since WiDr/F cells growing at low folate conditions show pronounced synergism in growth inhibition, two-sided TS inhibition and DNA damage, especially when TFT is combined with the tight-binding TS inhibitor GW1843.", "spo_list": [{"subject": "TFT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "GW1843", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "GW1843", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}]}
{"text": "Involvement of alpha(1)-adrenoceptors was established as mydriatic responses were inhibited by systemic administration of nonselective alpha-adrenoceptor antagonists, phentolamine (0.3-3 mg/kg) and phenoxybenzamine (0.03-0.3 mg/kg), as well as by the selective alpha(1)-adrenoceptor antagonist, prazosin (0.3 mg/kg).", "spo_list": [{"subject": "phentolamine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha-adrenoceptor", "object_type": "GENE-N"}, {"subject": "phenoxybenzamine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha-adrenoceptor", "object_type": "GENE-N"}, {"subject": "prazosin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(1)-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "The alpha(2)-adrenoceptor antagonist, rauwolscine (0.5 mg/kg), was without antagonistic effects. alpha(1A)-Adrenoceptor selective antagonists, 2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB-4101; 0.1-1 mg/kg) and 5-methylurapidil (0.1-1 mg/kg), the alpha(1B)-adrenoceptor selective antagonist, 4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline (L-765314; 0.3-1 mg/kg), as well as the alpha(1D)-adrenoceptor selective antagonist, 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY-7378; 1 mg/kg), were used to delineate the adrenoceptor subtypes involved.", "spo_list": [{"subject": "rauwolscine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2)-adrenoceptor", "object_type": "GENE-N"}, {"subject": "2-([2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(1A)-Adrenoceptor", "object_type": "GENE-Y"}, {"subject": "WB-4101", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(1A)-Adrenoceptor", "object_type": "GENE-Y"}, {"subject": "5-methylurapidil", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(1A)-Adrenoceptor", "object_type": "GENE-Y"}, {"subject": "4-amino-2-[4-[1-(benzyloxycarbonyl)-2(S)- [[(1,1-dimethylethyl)amino]carbonyl]-piperazinyl]-6,7-dimethoxyquinazoline", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(1B)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "L-765314", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(1B)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(1D)-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "BMY-7378", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(1D)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "To identify selective compounds for nonadrenergic I1-imidazoline receptors (I1), the affinities of 22 ligands for [125I]p-iodoclonidine binding have been compared at human platelet I1-imidazoline binding sites (analyzed under norepinephrine mask of alpha-2 AR) and at human alpha-2A, alpha-2B and alpha-2C adrenoceptors stably expressed on transfected Chinese hamster ovary cells.", "spo_list": [{"subject": "[125I]p-iodoclonidine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human platelet I1-imidazoline binding sites", "object_type": "GENE-N"}]}
{"text": "Naphazoline was the most selective compound for the high affinity state of the alpha-2A adrenoceptor, displaying 7-, 23- and 9-fold higher affinity than alpha-2B, alpha-2C and platelet I1-midazoline binding sites, respectively.", "spo_list": [{"subject": "Naphazoline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha-2A adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Preclinical pharmacology of lumiracoxib: a novel selective inhibitor of cyclooxygenase-2.", "spo_list": [{"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}]}
{"text": "1. This manuscript presents the preclinical profile of lumiracoxib, a novel cyclooxygenase-2 (COX-2) selective inhibitor.", "spo_list": [{"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-2", "object_type": "GENE-Y"}, {"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "2. Lumiracoxib inhibited purified COX-1 and COX-2 with K(i) values of 3 and 0.06 microM, respectively.", "spo_list": [{"subject": "Lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "Lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "In cellular assays, lumiracoxib had an IC(50) of 0.14 microM in COX-2-expressing dermal fibroblasts, but caused no inhibition of COX-1 at concentrations up to 30 microM (HEK 293 cells transfected with human COX-1).", "spo_list": [{"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "3. In a human whole blood assay, IC(50) values for lumiracoxib were 0.13 microM for COX-2 and 67 microM for COX-1 (COX-1/COX-2 selectivity ratio 515).", "spo_list": [{"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "5. Ex vivo, lumiracoxib inhibited COX-1-derived thromboxane B(2) (TxB(2)) generation with an ID(50) of 33 mg kg(-1), whereas COX-2-derived production of prostaglandin E(2) (PGE(2)) in the lipopolysaccharide-stimulated rat air pouch was inhibited with an ID(50) value of 0.24 mg kg(-1).", "spo_list": [{"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "thromboxane B(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "TxB(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "prostaglandin E(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "PGE(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "However, consistent with its low COX-1 inhibitory activity, lumiracoxib at a dose of 100 mg kg(-1) orally caused no ulcers and was significantly less ulcerogenic than diclofenac (P<0.05).", "spo_list": [{"subject": "lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "diclofenac", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}]}
{"text": "7. Lumiracoxib is a highly selective COX-2 inhibitor with anti-inflammatory, analgesic and antipyretic activities comparable with diclofenac, the reference NSAID, but with much improved gastrointestinal safety.", "spo_list": [{"subject": "Lumiracoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "diclofenac", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Sprague-Dawley rats treated with a non-selective cannabinoid agonist (CP55940, 50Î¼g/kg, 7 days, i.p.) showed enhanced co-immunoprecipitation of Î²-Arrestin 2 and ERK1/2, enhanced pERK protein levels, and enhanced expression of Î²-Arrestin 2 mRNA and protein levels in PFCx.", "spo_list": [{"subject": "CP55940", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î²-Arrestin 2", "object_type": "GENE-Y"}, {"subject": "CP55940", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "pERK", "object_type": "GENE-N"}, {"subject": "CP55940", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î²-Arrestin 2", "object_type": "GENE-Y"}]}
{"text": "In a neuronal cell line, we found that selective CB(2) receptor agonists upregulate Î²-Arrestin 2, an effect that was prevented by selective CB(2) receptor antagonist JTE-907 and CB(2) shRNA lentiviral particles.", "spo_list": [{"subject": "JTE-907", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CB(2)", "object_type": "GENE-Y"}, {"subject": "JTE-907", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CB(2)", "object_type": "GENE-Y"}, {"subject": "JTE-907", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Î²-Arrestin 2", "object_type": "GENE-Y"}]}
{"text": "The induced 'ischemic depression' was lasting and sensitive to an acute administration of brain-derived neurotrophic factor or bryostatin-1, a relatively selective activator of protein kinase CÎµ, during the induction phase.", "spo_list": [{"subject": "bryostatin-1", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "protein kinase CÎµ", "object_type": "GENE-Y"}]}
{"text": "In this article the data supporting the use of the aromatase inhibitor anastrozole in postmenopausal women across this continuum are reviewed.", "spo_list": [{"subject": "anastrozole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "Protein tyrosine phosphatase 1B inhibitory effect by dammarane-type triterpenes from hydrolyzate of total Gynostemma pentaphyllum saponins.", "spo_list": [{"subject": "dammarane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Protein tyrosine phosphatase 1B", "object_type": "GENE-Y"}, {"subject": "triterpenes", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Protein tyrosine phosphatase 1B", "object_type": "GENE-Y"}, {"subject": "saponins", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Protein tyrosine phosphatase 1B", "object_type": "GENE-Y"}]}
{"text": "Autoinhibition of CYP3A4 leads to important role of CYP2C8 in imatinib metabolism: variability in CYP2C8 activity may alter plasma concentrations and response.", "spo_list": [{"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C8", "object_type": "GENE-Y"}]}
{"text": "Recent data suggest that the role of CYP3A4 in imatinib metabolism is smaller than presumed.", "spo_list": [{"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A4", "object_type": "GENE-Y"}]}
{"text": "In vitro, CYP2C8 inhibitors and CYP3A4 inhibitors inhibited the depletion of 0.1 ÂµM imatinib by 45 and 80%, respectively, and the formation of the main metabolite of imatinib, N-desmethylimatinib, by >50%.", "spo_list": [{"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C8", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A4", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C8", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A4", "object_type": "GENE-Y"}, {"subject": "N-desmethylimatinib", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CYP2C8", "object_type": "GENE-Y"}, {"subject": "N-desmethylimatinib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A4", "object_type": "GENE-Y"}]}
{"text": "Likewise, recombinant CYP2C8 and CYP3A4 metabolized imatinib extensively, whereas other isoforms had minor effect on imatinib concentrations.", "spo_list": [{"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C8", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A4", "object_type": "GENE-Y"}]}
{"text": "In the beginning of imatinib treatment, the fractions of its hepatic clearance mediated by CYP2C8 and CYP3A4 were predicted to approximate 40 and 60%, respectively.", "spo_list": [{"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C8", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A4", "object_type": "GENE-Y"}]}
{"text": "During long-term treatment with imatinib 400 mg once or twice daily, up to 65 or 75% of its hepatic elimination was predicted to occur via CYP2C8, and only about 35 or 25% by CYP3A4, due to dose- and time-dependent autoinactivation of CYP3A4 by imatinib.", "spo_list": [{"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C8", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A4", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP3A4", "object_type": "GENE-Y"}]}
{"text": "Thus, although CYP2C8 and CYP3A4 are the main enzymes in imatinib metabolism in vitro, in silico predictions indicate that imatinib inhibits its own CYP3A4-mediated metabolism, assigning a key role for CYP2C8.", "spo_list": [{"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C8", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A4", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP3A4", "object_type": "GENE-Y"}]}
{"text": "During multiple dosing, pharmacogenetic polymorphisms and drug interactions affecting CYP2C8 activity may cause marked interindividual variation in the exposure and response to imatinib.", "spo_list": [{"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C8", "object_type": "GENE-Y"}]}
{"text": "The AGE-induced increases in VEGF expression and PKC activation were inhibited by the pan-specific PKC inhibitor, calphostin C, and by the antioxidant drug and compounds, gliclazide, N-acetylcysteine, and vitamin E. In contrast, glyburide which does not exhibit antioxidant properties, did not affect the AGE-induced VEGF expression.", "spo_list": [{"subject": "calphostin C", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PKC", "object_type": "GENE-N"}, {"subject": "calphostin C", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "VEGF", "object_type": "GENE-Y"}, {"subject": "calphostin C", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PKC", "object_type": "GENE-N"}, {"subject": "gliclazide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PKC", "object_type": "GENE-N"}, {"subject": "N-acetylcysteine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PKC", "object_type": "GENE-N"}, {"subject": "vitamin E", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PKC", "object_type": "GENE-N"}, {"subject": "N-acetylcysteine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "VEGF", "object_type": "GENE-Y"}, {"subject": "vitamin E", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "VEGF", "object_type": "GENE-Y"}]}
{"text": "Astrocytes may play a role in these manifestations because astrocytes are essential in the regulation of released glutamate and its conversion to glutamine through the enzyme glutamine synthetase (GS).", "spo_list": [{"subject": "glutamate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "glutamine synthetase", "object_type": "GENE-Y"}, {"subject": "glutamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "glutamine synthetase", "object_type": "GENE-Y"}, {"subject": "glutamate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GS", "object_type": "GENE-Y"}, {"subject": "glutamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "GS", "object_type": "GENE-Y"}]}
{"text": "A mechanism of action for such chemoprevention has been provided by the agonism of the peroxisome proliferator-activated receptor-gamma by 5-ASA, which unifies its efficacy as an anti-inflammatory and chemopreventive agent.", "spo_list": [{"subject": "5-ASA", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "peroxisome proliferator-activated receptor-gamma", "object_type": "GENE-Y"}]}
{"text": "In the future, even more effective agents based on 5-ASA are expected, based on more powerful agonism of peroxisome proliferator-activated receptor-gamma; 5-ASA preparations have become 'trendy' again.", "spo_list": [{"subject": "5-ASA", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "peroxisome proliferator-activated receptor-gamma", "object_type": "GENE-Y"}]}
{"text": "The xanthine oxidase class of molybdenum enzyzmes requires a terminal sulfur ligand at the active site.", "spo_list": [{"subject": "sulfur", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "xanthine oxidase", "object_type": "GENE-N"}, {"subject": "molybdenum", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "xanthine oxidase", "object_type": "GENE-N"}]}
{"text": "Previous analyses of mutants in plants indicated that the genetic locus aba3 is involved in this step leading to activation of the molybdenum enzymes aldehyde oxidase and xanthine dehydrogenase.", "spo_list": [{"subject": "molybdenum", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "aldehyde oxidase", "object_type": "GENE-N"}, {"subject": "molybdenum", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "xanthine dehydrogenase", "object_type": "GENE-N"}]}
{"text": "ABA3 is a two-domain protein with a N-terminal NifS-like sulfurase domain and a C-terminal domain that might be involved in recognizing the target enzymes.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ABA3", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ABA3", "object_type": "GENE-Y"}]}
{"text": "ABA3 contains highly conserved binding motifs for pyridoxal phosphate and for a persulfide.", "spo_list": [{"subject": "pyridoxal phosphate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ABA3", "object_type": "GENE-Y"}, {"subject": "persulfide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ABA3", "object_type": "GENE-Y"}]}
{"text": "The purified recombinant protein possesses a cysteine desulfurase activity, is yellow in color, and shows a NifS-like change in absorbance in the presence of L-cysteine.", "spo_list": [{"subject": "L-cysteine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cysteine desulfurase", "object_type": "GENE-N"}]}
{"text": "Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit.", "spo_list": [{"subject": "Felbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "N-methyl-D-aspartate receptors", "object_type": "GENE-N"}, {"subject": "Felbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR2B", "object_type": "GENE-Y"}]}
{"text": "The anticonvulsant felbamate blocks N-methyl-D-asparate (NMDA) receptors but fails to exhibit the neurobehavioral toxicity characteristic of other NMDA receptor antagonists.", "spo_list": [{"subject": "felbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "N-methyl-D-asparate (NMDA) receptors", "object_type": "GENE-N"}]}
{"text": "To investigate the possibility that felbamate's favorable toxicity profile could be related to NMDA receptor subtype selectivity, we examined the specificity of felbamate block of recombinant NMDA receptors composed of the NR1a subunit and various NR2 subunits.", "spo_list": [{"subject": "felbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NMDA receptors", "object_type": "GENE-N"}, {"subject": "felbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR1a", "object_type": "GENE-Y"}, {"subject": "felbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR2", "object_type": "GENE-N"}]}
{"text": "Felbamate produced a rapid, concentration-dependent block of currents evoked by 50 microM NMDA and 10 microM glycine in human embryonic kidney 293 cells expressing the rat NR1a subunit, and either the NR2A, NR2B or NR2C subunits; the IC50 values for block were 2.6, 0.52 and 2.4 mM, respectively (holding potential, - 60 mV).", "spo_list": [{"subject": "Felbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "rat NR1a", "object_type": "GENE-Y"}, {"subject": "Felbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR2A", "object_type": "GENE-Y"}, {"subject": "Felbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR2B", "object_type": "GENE-Y"}, {"subject": "Felbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR2C", "object_type": "GENE-Y"}]}
{"text": "The higher affinity of felbamate block of NMDA receptors containing the NR2B subunit could be accounted for by more rapid association and slower dissociation from these sites.", "spo_list": [{"subject": "felbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NMDA receptors", "object_type": "GENE-N"}, {"subject": "felbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR2B", "object_type": "GENE-Y"}]}
{"text": "We conclude that felbamate exhibits modest selectivity for NMDA receptors composed of NR1a/NR2B subunits.", "spo_list": [{"subject": "felbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NMDA receptors", "object_type": "GENE-N"}, {"subject": "felbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR2B", "object_type": "GENE-Y"}, {"subject": "felbamate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NR1a", "object_type": "GENE-Y"}]}
{"text": "Previously, we reported that l-glutamic acid decarboxylase isoform 65 (GAD65) could be cleaved in vitro to release a stable truncated form which lacks amino acid 1-69 from the N-terminus, GAD65(Delta1-69).", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GAD65(Delta1-69)", "object_type": "GENE-Y"}]}
{"text": "Thiazide and high ceiling diuretics were recently shown to inhibit all mammalian isoforms of carbonic anhydrase (CA, EC 4.2.1.1) with a very different profile as compared to classical inhibitors, such as acetazolamide, methazolamide, and ethoxzolamide.", "spo_list": [{"subject": "Thiazide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase", "object_type": "GENE-N"}, {"subject": "Thiazide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA", "object_type": "GENE-N"}, {"subject": "Thiazide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 4.2.1.1", "object_type": "GENE-Y"}, {"subject": "acetazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase", "object_type": "GENE-N"}, {"subject": "methazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase", "object_type": "GENE-N"}, {"subject": "ethoxzolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase", "object_type": "GENE-N"}, {"subject": "acetazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA", "object_type": "GENE-N"}, {"subject": "methazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA", "object_type": "GENE-N"}, {"subject": "ethoxzolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA", "object_type": "GENE-N"}, {"subject": "acetazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 4.2.1.1", "object_type": "GENE-Y"}, {"subject": "methazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 4.2.1.1", "object_type": "GENE-Y"}, {"subject": "ethoxzolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EC 4.2.1.1", "object_type": "GENE-Y"}]}
{"text": "Some of these structurally related compounds have a very different behavior against the widespread isozyme CA II, with chlorthalidone, trichloromethiazide, and furosemide being efficient inhibitors against CA II (K(I)s of 65-138 nM), whereas indapamide is a much weaker one (K(I) of 2520 nM).", "spo_list": [{"subject": "furosemide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA II", "object_type": "GENE-Y"}, {"subject": "trichloromethiazide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA II", "object_type": "GENE-Y"}, {"subject": "chlorthalidone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA II", "object_type": "GENE-Y"}, {"subject": "indapamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA II", "object_type": "GENE-Y"}]}
{"text": "Examining the four X-ray crystal structures of their CA II adducts, we observed several (2-3) active site water molecules interacting with the chlorthalidone, trichloromethiazide, and furosemide scaffolds which may be responsible for this important difference of activity.", "spo_list": [{"subject": "chlorthalidone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CA II", "object_type": "GENE-Y"}, {"subject": "trichloromethiazide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CA II", "object_type": "GENE-Y"}, {"subject": "furosemide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CA II", "object_type": "GENE-Y"}]}
{"text": "Indeed, indapamide bound to CA II has no interactions with active site water molecules.", "spo_list": [{"subject": "indapamide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CA II", "object_type": "GENE-Y"}]}
{"text": "Chlorthalidone bound within the CA II active site is in an enolic (lactimic) tautomeric form, with the enolic OH also participating in two strong hydrogen bonds with Asn67 and a water molecule.", "spo_list": [{"subject": "Chlorthalidone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CA II", "object_type": "GENE-Y"}]}
{"text": "The mannose 6-phosphate-binding sites of M6P/IGF2R determine its capacity to suppress matrix invasion by squamous cell carcinoma cells.", "spo_list": [{"subject": "mannose 6-phosphate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "IGF2R", "object_type": "GENE-Y"}]}
{"text": "These findings highlight that the interaction between M6P/IGF2R and M6P-modified ligands is not only important for intracellular accumulation of lysosomal enzymes and formation of dense lysosomes, but is also crucial for the ability of the receptor to suppress SCC-VII growth and invasion.", "spo_list": [{"subject": "M6P", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "IGF2R", "object_type": "GENE-Y"}]}
{"text": "The present study also shows that some of the biological activities of M6P/IGF2R in SCC-VII cells strongly depend on a functional M6P-binding site within domain 3, thus providing further evidence for the non-redundant cellular functions of the individual carbohydrate-binding domains of the receptor.", "spo_list": [{"subject": "M6P", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "IGF2R", "object_type": "GENE-Y"}]}
{"text": "Hydrosoluble benzo[e]pyridoindolones as potent inhibitors of aurora kinases.", "spo_list": [{"subject": "benzo[e]pyridoindolones", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aurora kinases", "object_type": "GENE-N"}]}
{"text": "We identified benzo[e]pyridoindoles (BePI) as powerful aurora kinase inhibitors.", "spo_list": [{"subject": "benzo[e]pyridoindoles", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aurora kinase", "object_type": "GENE-N"}, {"subject": "BePI", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aurora kinase", "object_type": "GENE-N"}]}
{"text": "Tetracyclic BePI derivatives are characterized by a particular curved shape, and the presence of an oxo group on the pyridine ring was found to be required for aurora kinase B inhibition.", "spo_list": [{"subject": "pyridine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aurora kinase B", "object_type": "GENE-Y"}, {"subject": "Tetracyclic BePI", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aurora kinase B", "object_type": "GENE-Y"}, {"subject": "oxo", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aurora kinase B", "object_type": "GENE-Y"}]}
{"text": "Dexamethasone suppresses histamine synthesis by repressing both transcription and activity of HDC in allergic rats.", "spo_list": [{"subject": "Dexamethasone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDC", "object_type": "GENE-Y"}, {"subject": "Dexamethasone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "HDC", "object_type": "GENE-Y"}]}
{"text": "BACKGROUND: Histamine synthesized by histidine decarboxylase (HDC) from L-histidine is a major chemical mediator in the development of nasal allergy which is characterized by nasal hypersensitivity.", "spo_list": [{"subject": "Histamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "histidine decarboxylase", "object_type": "GENE-Y"}, {"subject": "Histamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "HDC", "object_type": "GENE-Y"}, {"subject": "L-histidine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "histidine decarboxylase", "object_type": "GENE-Y"}, {"subject": "L-histidine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "HDC", "object_type": "GENE-Y"}]}
{"text": "However the regulatory mechanism of histamine synthesis by HDC remains to be elucidated.", "spo_list": [{"subject": "histamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "HDC", "object_type": "GENE-Y"}]}
{"text": "Histamine content, HDC activity and HDC mRNA expression in nasal mucosa were also significantly increased after TDI provocation.", "spo_list": [{"subject": "TDI", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "HDC", "object_type": "GENE-Y"}, {"subject": "TDI", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HDC", "object_type": "GENE-Y"}]}
{"text": "Pretreatment with dexamethasone significantly suppressed nasal allergy-like behaviors, up-regulation of histamine content, HDC activity and HDC mRNA induced by TDI in TDI-sensitized rats.", "spo_list": [{"subject": "TDI", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "HDC", "object_type": "GENE-Y"}, {"subject": "TDI", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HDC", "object_type": "GENE-Y"}, {"subject": "dexamethasone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDC", "object_type": "GENE-Y"}, {"subject": "dexamethasone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "HDC", "object_type": "GENE-Y"}]}
{"text": "CONCLUSIONS: These findings indicate that increased synthesis of histamine through up-regulation of HDC gene expression and HDC activity in nasal mucosa plays an important role in the development of nasal hypersensitivity.", "spo_list": [{"subject": "histamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "HDC", "object_type": "GENE-Y"}, {"subject": "histamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "HDC", "object_type": "GENE-Y"}]}
{"text": "Repression of HDC gene expression and HDC activity by dexamethasone may underlie its therapeutic effect in the treatment of allergy.", "spo_list": [{"subject": "dexamethasone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "HDC", "object_type": "GENE-Y"}, {"subject": "dexamethasone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDC", "object_type": "GENE-Y"}]}
{"text": "The Kv channel blockers amiodarone, tetraethylammonium and verapamil, as well as increased extracellular K+ levels, inhibited proliferation of cultured MSC.", "spo_list": [{"subject": "amiodarone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Kv channel", "object_type": "GENE-N"}, {"subject": "tetraethylammonium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Kv channel", "object_type": "GENE-N"}, {"subject": "verapamil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Kv channel", "object_type": "GENE-N"}]}
{"text": "However, mutation of the highly conserved serine-994 to alanine in the ATP hydrolysis motif in the SMC6 C-terminal domain, resulted in mice with a surprisingly mild phenotype.", "spo_list": [{"subject": "serine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "SMC6", "object_type": "GENE-Y"}, {"subject": "alanine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "SMC6", "object_type": "GENE-Y"}]}
{"text": "This suggests that the NAD(+)-binding domain is not destroyed by cleavage of the N-terminal part of MMSDH.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MMSDH", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "NAD(+)-binding domain", "object_type": "GENE-N"}]}
{"text": "However, CoA esters reduced the protective effect of NAD+ with an order of effectiveness of acetyl-CoA greater than propionyl-CoA greater than butyryl-CoA. p-Nitrophenyl acetate, substrate for esterase activity by the enzyme, partially prevented the protective effect of NAD+ against proteolysis.", "spo_list": [{"subject": "p-Nitrophenyl acetate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "esterase", "object_type": "GENE-N"}]}
{"text": "These results suggest that S-acylation of the enzyme prevents a stabilizing conformational change induced in MMSDH by NAD+ binding.", "spo_list": [{"subject": "S", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MMSDH", "object_type": "GENE-Y"}, {"subject": "NAD+", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MMSDH", "object_type": "GENE-Y"}]}
{"text": "Using date- and culture-matched cells (each n > or = 16 from 4 different lungs), the pannexon inhibitors carbenoxolone (10 microM) and probenecid (1 mM), but not the connexon inhibitor flufenamic acid (100 microM), inhibited ATP release by approximately 60%.", "spo_list": [{"subject": "carbenoxolone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "pannexon", "object_type": "GENE-N"}, {"subject": "probenecid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "pannexon", "object_type": "GENE-N"}]}
{"text": "Discovery of Thieno[3,2-d]pyrimidine-6-carboxamides as Potent Inhibitors of SIRT1, SIRT2, and SIRT3.", "spo_list": [{"subject": "Thieno[3,2-d]pyrimidine-6-carboxamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SIRT1", "object_type": "GENE-Y"}, {"subject": "Thieno[3,2-d]pyrimidine-6-carboxamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SIRT2", "object_type": "GENE-Y"}, {"subject": "Thieno[3,2-d]pyrimidine-6-carboxamides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SIRT3", "object_type": "GENE-Y"}]}
{"text": "Crystallographic studies of 11c, 28, and 31 bound in the SIRT3 active site revealed that the common carboxamide binds in the nicotinamide C-pocket and the aliphatic portions of the inhibitors extend through the substrate channel, explaining the observable SAR.", "spo_list": [{"subject": "carboxamide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SIRT3", "object_type": "GENE-Y"}, {"subject": "nicotinamide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "SIRT3", "object_type": "GENE-Y"}]}
{"text": "Biotin uptake by rabbit corneal epithelial cells: role of sodium-dependent multivitamin transporter (SMVT).", "spo_list": [{"subject": "Biotin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "sodium-dependent multivitamin transporter", "object_type": "GENE-Y"}, {"subject": "Biotin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SMVT", "object_type": "GENE-Y"}]}
{"text": "CONCLUSIONS: Results obtained from both in vitro and exvivo studies suggest the possible role of SMVT expressed on corneal epithelial cells for the uptake of biotin, which co-transports pantothenic acid and lipoic acid.", "spo_list": [{"subject": "biotin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SMVT", "object_type": "GENE-Y"}, {"subject": "pantothenic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SMVT", "object_type": "GENE-Y"}, {"subject": "lipoic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SMVT", "object_type": "GENE-Y"}]}
{"text": "Our studies demonstrate that thalidomide, lenalidomide and another immunomodulatory drug, pomalidomide, bound endogenous CRBN and recombinant CRBN-DNA damage binding protein-1 (DDB1) complexes.", "spo_list": [{"subject": "thalidomide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CRBN", "object_type": "GENE-Y"}, {"subject": "lenalidomide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CRBN", "object_type": "GENE-Y"}, {"subject": "pomalidomide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CRBN", "object_type": "GENE-Y"}, {"subject": "thalidomide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CRBN", "object_type": "GENE-Y"}, {"subject": "lenalidomide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CRBN", "object_type": "GENE-Y"}, {"subject": "pomalidomide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CRBN", "object_type": "GENE-Y"}, {"subject": "thalidomide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DNA damage binding protein-1", "object_type": "GENE-Y"}, {"subject": "lenalidomide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DNA damage binding protein-1", "object_type": "GENE-Y"}, {"subject": "pomalidomide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DNA damage binding protein-1", "object_type": "GENE-Y"}, {"subject": "thalidomide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DDB1", "object_type": "GENE-Y"}, {"subject": "lenalidomide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DDB1", "object_type": "GENE-Y"}, {"subject": "pomalidomide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DDB1", "object_type": "GENE-Y"}]}
{"text": "CRBN mediated antiproliferative activities of lenalidomide and pomalidomide in myeloma cells, as well as lenalidomide- and pomalidomide-induced cytokine production in T cells.", "spo_list": [{"subject": "lenalidomide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytokine", "object_type": "GENE-N"}, {"subject": "pomalidomide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytokine", "object_type": "GENE-N"}]}
{"text": "Lenalidomide and pomalidomide inhibited autoubiquitination of CRBN in HEK293T cells expressing thalidomide-binding competent wild-type CRBN, but not thalidomide-binding defective CRBN(YW/AA).", "spo_list": [{"subject": "Lenalidomide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CRBN", "object_type": "GENE-Y"}, {"subject": "pomalidomide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CRBN", "object_type": "GENE-Y"}, {"subject": "thalidomide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CRBN", "object_type": "GENE-Y"}, {"subject": "thalidomide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CRBN", "object_type": "GENE-Y"}, {"subject": "Lenalidomide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CRBN", "object_type": "GENE-Y"}, {"subject": "pomalidomide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CRBN", "object_type": "GENE-Y"}]}
{"text": "Overexpression of CRBN wild-type protein, but not CRBN(YW/AA) mutant protein, in KMS12 myeloma cells, amplified pomalidomide-mediated reductions in c-myc and IRF4 expression and increases in p21(WAF-1) expression.", "spo_list": [{"subject": "pomalidomide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "c-myc", "object_type": "GENE-Y"}, {"subject": "pomalidomide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IRF4", "object_type": "GENE-Y"}, {"subject": "pomalidomide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p21", "object_type": "GENE-Y"}, {"subject": "pomalidomide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "WAF-1", "object_type": "GENE-Y"}]}
{"text": "Long-term selection for lenalidomide resistance in H929 myeloma cell lines was accompanied by a reduction in CRBN, while in DF15R myeloma cells resistant to both pomalidomide and lenalidomide, CRBN protein was undetectable.", "spo_list": [{"subject": "lenalidomide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CRBN", "object_type": "GENE-Y"}]}
{"text": "Caffeic Acid Phenethyl Ester Suppresses Proliferation and Survival of TW2.6 Human Oral Cancer Cells via Inhibition of Akt Signaling.", "spo_list": [{"subject": "Caffeic Acid Phenethyl Ester", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Akt", "object_type": "GENE-N"}]}
{"text": "Treatment with CAPE decreased protein abundance of Akt, Akt1, Akt2, Akt3, phospho-Akt Ser473, phospho-Akt Thr 308, GSK3Î², FOXO1, FOXO3a, phospho-FOXO1 Thr24, phospho-FoxO3a Thr32, NF-ÎºB, phospho-NF-ÎºB Ser536, Rb, phospho-Rb Ser807/811, Skp2, and cyclin D1, but increased cell cycle inhibitor p27Kip.", "spo_list": [{"subject": "CAPE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "CAPE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Akt1", "object_type": "GENE-Y"}, {"subject": "CAPE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Akt2", "object_type": "GENE-Y"}, {"subject": "CAPE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Akt3", "object_type": "GENE-Y"}, {"subject": "CAPE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "phospho-Akt", "object_type": "GENE-N"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "phospho-Akt", "object_type": "GENE-N"}, {"subject": "CAPE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "phospho-Akt", "object_type": "GENE-N"}, {"subject": "CAPE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "GSK3Î²", "object_type": "GENE-Y"}, {"subject": "CAPE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "FOXO1", "object_type": "GENE-Y"}, {"subject": "CAPE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "FOXO3a", "object_type": "GENE-Y"}, {"subject": "CAPE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "phospho-FOXO1", "object_type": "GENE-Y"}, {"subject": "CAPE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "phospho-FoxO3a", "object_type": "GENE-Y"}, {"subject": "CAPE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "CAPE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "phospho-NF-ÎºB", "object_type": "GENE-N"}, {"subject": "CAPE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Rb", "object_type": "GENE-Y"}, {"subject": "CAPE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "phospho-Rb", "object_type": "GENE-Y"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "phospho-Rb", "object_type": "GENE-Y"}, {"subject": "CAPE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Skp2", "object_type": "GENE-Y"}, {"subject": "CAPE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cyclin D1", "object_type": "GENE-Y"}, {"subject": "CAPE", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p27Kip", "object_type": "GENE-Y"}]}
{"text": "Transport of gabapentin by LAT1 (SLC7A5).", "spo_list": [{"subject": "gabapentin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT1", "object_type": "GENE-Y"}, {"subject": "gabapentin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SLC7A5", "object_type": "GENE-Y"}]}
{"text": "Gabapentin was demonstrated to be a LAT1 substrate in brain endothelial cells (LAT1-process; Km=530Î¼M and Vmax=7039pmoles/million cells/min versus other-processes; Km=923Î¼M and Vmax=3656pmoles/million cells/min) and in transfected HEK 293 LAT1 cells (LAT1-process; Km=217Î¼M and Vmax=5192pmoles/million cells/min versus otherprocesses; Km=1546Î¼M and Vmax=3375pmoles/million cells/min).", "spo_list": [{"subject": "Gabapentin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT1", "object_type": "GENE-Y"}, {"subject": "Gabapentin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT1", "object_type": "GENE-Y"}, {"subject": "Gabapentin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT1", "object_type": "GENE-Y"}, {"subject": "Gabapentin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT1", "object_type": "GENE-Y"}]}
{"text": "At physiological concentrations of gabapentin, LAT1 mediated transport was 3 or ~10-fold higher than the other transport processes in the two systems, respectively, demonstrating clear selectivity for gabapentin.", "spo_list": [{"subject": "gabapentin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT1", "object_type": "GENE-Y"}, {"subject": "gabapentin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT1", "object_type": "GENE-Y"}]}
{"text": "Our data shows that gabapentin is a substrate for the influx transporter LAT1 at therapeutic concentrations.", "spo_list": [{"subject": "gabapentin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "LAT1", "object_type": "GENE-Y"}]}
{"text": "Differences in the determinants of eplerenone, spironolactone and aldosterone binding to the mineralocorticoid receptor.", "spo_list": [{"subject": "eplerenone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mineralocorticoid receptor", "object_type": "GENE-Y"}, {"subject": "spironolactone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mineralocorticoid receptor", "object_type": "GENE-Y"}, {"subject": "aldosterone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "mineralocorticoid receptor", "object_type": "GENE-Y"}]}
{"text": "The importance of mineralocorticoid receptor (MR) antagonists in the treatment of cardiovascular disease has been emphasised by two recent clinical trials, one using spironolactone and the other using a new selective MR antagonist, namely eplerenone.", "spo_list": [{"subject": "eplerenone", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "MR", "object_type": "GENE-Y"}]}
{"text": "These chimeras had been used previously to investigate aldosterone and spironolactone binding specificity to the MR.", "spo_list": [{"subject": "aldosterone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MR", "object_type": "GENE-Y"}, {"subject": "spironolactone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MR", "object_type": "GENE-Y"}]}
{"text": "Eplerenone competed strongly for [(3)H]-dexamethasone binding to a MR/GR chimera containing amino acids 804-874 of the MR and weakly to a chimera containing amino acids 672-803 of the MR.", "spo_list": [{"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MR", "object_type": "GENE-Y"}, {"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MR", "object_type": "GENE-Y"}, {"subject": "[(3)H]-dexamethasone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MR", "object_type": "GENE-Y"}, {"subject": "[(3)H]-dexamethasone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GR", "object_type": "GENE-Y"}, {"subject": "Eplerenone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MR", "object_type": "GENE-Y"}, {"subject": "Eplerenone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GR", "object_type": "GENE-Y"}]}
{"text": "Within the 804-874 region, eplerenone competed for [(3)H]-dexamethasone binding to a chimera containing amino acids 820-844 of the MR, although the calculated affinity was approximately 10-fold lower than for binding to the full-length MR LBD.", "spo_list": [{"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MR", "object_type": "GENE-Y"}, {"subject": "[(3)H]-dexamethasone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MR", "object_type": "GENE-Y"}, {"subject": "eplerenone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MR", "object_type": "GENE-Y"}, {"subject": "eplerenone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MR LBD", "object_type": "GENE-N"}, {"subject": "[(3)H]-dexamethasone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MR LBD", "object_type": "GENE-N"}]}
{"text": "Similar results were obtained using another MR antagonist, namely spironolactone.", "spo_list": [{"subject": "spironolactone", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "MR", "object_type": "GENE-Y"}]}
{"text": "Modelling of eplerenone binding to the MR LBD, based on the GR LBD crystal structure, suggests that amino acids 820-844 affect the overall shape of the ligand-binding pocket and that eplerenone acts as an MR antagonist because it fails to stabilize the active conformation of the receptor.", "spo_list": [{"subject": "eplerenone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MR LBD", "object_type": "GENE-N"}, {"subject": "eplerenone", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "MR", "object_type": "GENE-Y"}]}
{"text": "In contrast with results with the MR antagonists eplerenone and spironolactone, amino acids 820-844 are sufficient in themselves to confer high-affinity aldosterone binding to the MR, suggesting that the binding determinants of the two antagonists are similar to each other but differ from those of aldosterone.", "spo_list": [{"subject": "eplerenone", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "MR", "object_type": "GENE-Y"}, {"subject": "spironolactone", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "MR", "object_type": "GENE-Y"}, {"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MR", "object_type": "GENE-Y"}, {"subject": "aldosterone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "MR", "object_type": "GENE-Y"}]}
{"text": "Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors.", "spo_list": [{"subject": "5-(benzyloxy)pyridin-2(1H)-one", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "c-Met", "object_type": "GENE-Y"}]}
{"text": "These data, together with the fact that serine racemase is a pyridoxal phosphate-dependent enzyme, suggest that the aminooxyacetic acid-induced reduction of the extracellular D-serine may be at least in part due to the drug's ability to inhibit serine racemase.", "spo_list": [{"subject": "aminooxyacetic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "serine racemase", "object_type": "GENE-Y"}, {"subject": "D-serine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "serine racemase", "object_type": "GENE-Y"}]}
{"text": "ICI 182,780 (fulvestrant) (Faslodex) and ICI 164,384 are competitive inhibitors of estrogen by binding to the estrogen receptor (ER).", "spo_list": [{"subject": "ICI 182,780", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "fulvestrant", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "Faslodex", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "ICI 164,384", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "estrogen receptor", "object_type": "GENE-Y"}, {"subject": "ICI 182,780", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ER", "object_type": "GENE-Y"}, {"subject": "fulvestrant", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ER", "object_type": "GENE-Y"}, {"subject": "Faslodex", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ER", "object_type": "GENE-Y"}, {"subject": "ICI 164,384", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ER", "object_type": "GENE-Y"}]}
{"text": "EM-800 and EM-652 are the most potent pure antiestrogens and EM-652 has the highest affinity of all antiestrogens to ER.", "spo_list": [{"subject": "EM-652", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ER", "object_type": "GENE-Y"}]}
{"text": "The beneficial estrogenic activities of raloxifene include a lowering of total and low-density lipoprotein cholesterol levels and an augmentation of bone mineral density.", "spo_list": [{"subject": "raloxifene", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "low-density lipoprotein", "object_type": "GENE-N"}]}
{"text": "We found a strong interaction of baseline FEV(1) with the Arg16Glycine (Gly) polymorphism in predicting bronchodilator response.", "spo_list": [{"subject": "Gly", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Arg16Glycine", "object_type": "GENE-N"}]}
{"text": "Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma.", "spo_list": [{"subject": "batimastat", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "gelatinase A", "object_type": "GENE-Y"}, {"subject": "batimastat", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-2", "object_type": "GENE-Y"}, {"subject": "captopril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "gelatinase A", "object_type": "GENE-Y"}, {"subject": "captopril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-2", "object_type": "GENE-Y"}]}
{"text": "We have examined the effects of the synthetic matrix metalloproteinase inhibitor, batimastat (BB-94) and the angiotensin-converting enzyme inhibitor, captopril, on metalloproteinase activity of murine Lewis-lung-carcinoma cells (3LL) in vitro, and on local growth and lung metastasis of the same tumor implanted intramuscularly in syngeneic C57BL/6 mice.", "spo_list": [{"subject": "batimastat", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "matrix metalloproteinase", "object_type": "GENE-N"}, {"subject": "BB-94", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "matrix metalloproteinase", "object_type": "GENE-N"}, {"subject": "captopril", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "angiotensin-converting enzyme", "object_type": "GENE-Y"}]}
{"text": "Here we report that captopril treatment resulted in decreased transcription and protein levels of gelatinase A by 3LL cells.", "spo_list": [{"subject": "captopril", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "gelatinase A", "object_type": "GENE-Y"}]}
{"text": "Both BB-94 and captopril also prevented substrate degradation by gelatinase A and B released in conditioned medium by cultured cells.", "spo_list": [{"subject": "BB-94", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "gelatinase A and B", "object_type": "GENE-N"}]}
{"text": "Intracellular K+ is required for the inactivation-induced high-affinity binding of cisapride to HERG channels.", "spo_list": [{"subject": "cisapride", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "HERG", "object_type": "GENE-Y"}]}
{"text": "In the present study, we examined the effect of inactivation gating on cisapride block of HERG.", "spo_list": [{"subject": "cisapride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HERG", "object_type": "GENE-Y"}]}
{"text": "We found that although inactivation facilitated cisapride block of the HERG K+ current, it was not coupled with cisapride block of HERG when the Cs+ current was recorded.", "spo_list": [{"subject": "cisapride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HERG", "object_type": "GENE-Y"}]}
{"text": "Our results suggest that inactivation facilitates cisapride block of HERG channels through affecting the positioning of Phe-656.", "spo_list": [{"subject": "cisapride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HERG", "object_type": "GENE-Y"}, {"subject": "Phe", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "HERG", "object_type": "GENE-Y"}]}
{"text": "Ellagitannins and hexahydroxydiphenoyl esters as inhibitors of vertebrate squalene epoxidase.", "spo_list": [{"subject": "Ellagitannins", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "squalene epoxidase", "object_type": "GENE-Y"}, {"subject": "hexahydroxydiphenoyl esters", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "squalene epoxidase", "object_type": "GENE-Y"}]}
{"text": "Ellagitannins isolated from various plant sources as well as newly synthesized n-alkyl (C(1)-C(18)) esters of hexahydroxydiphenyl (HHDP) dicarboxylic acid were evaluated as enzyme inhibitors of recombinant rat squalene epoxidase, a rate-limiting enzyme of cholesterol biosynthesis.", "spo_list": [{"subject": "cholesterol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "rat squalene epoxidase", "object_type": "GENE-Y"}]}
{"text": "Sulfated glucosamine inhibits MMP-2 and MMP-9 expressions in human fibrosarcoma cells.", "spo_list": [{"subject": "Sulfated glucosamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-2", "object_type": "GENE-Y"}, {"subject": "Sulfated glucosamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-9", "object_type": "GENE-Y"}]}
{"text": "In the present study, sulfated glucosamine (SGlc) that has been reported to relieve joint pain and inflammation in many arthritis patients was studied for its inhibitory effects on MMP-2 and MMP-9 in human fibrosarcoma cells.", "spo_list": [{"subject": "sulfated glucosamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-2", "object_type": "GENE-Y"}, {"subject": "sulfated glucosamine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-9", "object_type": "GENE-Y"}, {"subject": "SGlc", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-2", "object_type": "GENE-Y"}, {"subject": "SGlc", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-9", "object_type": "GENE-Y"}]}
{"text": "Expression and activity of above MMPs studied using gelatin zymography suggested SGlc as a potent MMP inhibitor.", "spo_list": [{"subject": "SGlc", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP", "object_type": "GENE-N"}]}
{"text": "Since MMPs involve in joint inflammation, it can be presumed that inhibition of MMP-2 and MMP-9 can be one of the mechanisms of SGlc to be an effective drug in relieving the symptoms of osteoarthritis.", "spo_list": [{"subject": "SGlc", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-2", "object_type": "GENE-Y"}, {"subject": "SGlc", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MMP-9", "object_type": "GENE-Y"}]}
{"text": "This cDNA clone, designated EAA3a, shares a 90% nucleotide identity with the previously reported rat GluR5-2b cDNA splice variant and differed from human GluR5-1d in the amino and carboxy terminal regions.", "spo_list": [{"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "EAA3a", "object_type": "GENE-Y"}, {"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "rat GluR5-2b", "object_type": "GENE-Y"}, {"subject": "amino", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "human GluR5-1d", "object_type": "GENE-Y"}, {"subject": "carboxy", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "human GluR5-1d", "object_type": "GENE-Y"}]}
{"text": "Cell lines stably expressing EAA3a protein formed homomeric ligand-gated ion channels responsive, in order of decreasing affinity to domoate, kainate, L-glutamate and (RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate (AMPA).", "spo_list": [{"subject": "kainate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAA3a", "object_type": "GENE-Y"}, {"subject": "L-glutamate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAA3a", "object_type": "GENE-Y"}, {"subject": "(RS)-alpha-amino-3-hydroxy-5- methylisoxazole-propionate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAA3a", "object_type": "GENE-Y"}, {"subject": "AMPA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAA3a", "object_type": "GENE-Y"}]}
{"text": "Kainate-evoked currents showed partial desensitization that was reduced on incubation with concanavalin A (conA) but not cyclothiazide and were attenuated by the non-N-methyl-D-aspartate (NMDA) receptor antagonist CNQX (6-cyano-7-nitro-quinoxalinedione).", "spo_list": [{"subject": "CNQX", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "N-methyl-D-aspartate (NMDA) receptor", "object_type": "GENE-N"}, {"subject": "6-cyano-7-nitro-quinoxalinedione", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "N-methyl-D-aspartate (NMDA) receptor", "object_type": "GENE-N"}]}
{"text": "Kainate and AMPA activated the heteromeric channel with significantly higher affinities than observed for EAA3a alone.", "spo_list": [{"subject": "Kainate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAA3a", "object_type": "GENE-Y"}, {"subject": "AMPA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAA3a", "object_type": "GENE-Y"}]}
{"text": "Ligand binding studies with the recombinant EAA3a receptor expressed in mammalian cells indicated a high affinity kainate binding site (Kd = 120 +/- 15.0 nM).", "spo_list": [{"subject": "kainate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAA3a", "object_type": "GENE-Y"}]}
{"text": "The relative potency of compounds in displacing [3H]-kainate binding to EAA3a receptor was: domoate > kainate > L-glutamate = quisqualate > 6,7-dinitroquinoxaline-2,3-dione (DNQX) = CNQX > AMPA > dihydrokainate > NMDA.", "spo_list": [{"subject": "[3H]-kainate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAA3a", "object_type": "GENE-Y"}, {"subject": "kainate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAA3a", "object_type": "GENE-Y"}, {"subject": "L-glutamate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAA3a", "object_type": "GENE-Y"}, {"subject": "quisqualate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAA3a", "object_type": "GENE-Y"}, {"subject": "6,7-dinitroquinoxaline-2,3-dione", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAA3a", "object_type": "GENE-Y"}, {"subject": "DNQX", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAA3a", "object_type": "GENE-Y"}, {"subject": "CNQX", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAA3a", "object_type": "GENE-Y"}, {"subject": "AMPA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAA3a", "object_type": "GENE-Y"}, {"subject": "dihydrokainate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAA3a", "object_type": "GENE-Y"}, {"subject": "NMDA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAA3a", "object_type": "GENE-Y"}]}
{"text": "Amrinone and milrinone, selective PDE3 inhibitors, suppressed TNF secretion to a lesser extent.", "spo_list": [{"subject": "Amrinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE3", "object_type": "GENE-N"}, {"subject": "milrinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE3", "object_type": "GENE-N"}, {"subject": "Amrinone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF", "object_type": "GENE-Y"}, {"subject": "milrinone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF", "object_type": "GENE-Y"}]}
{"text": "The effects of theophylline (unspecific PDE inhibitor), vinpocetine (PDE1 inhibitor), EHNA (PDE2 inhibitor) and the PDE5 inhibitors zaprinast and E 4021 were weak.", "spo_list": [{"subject": "theophylline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE", "object_type": "GENE-N"}, {"subject": "vinpocetine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE1", "object_type": "GENE-N"}, {"subject": "zaprinast", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE5", "object_type": "GENE-Y"}, {"subject": "E 4021", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE5", "object_type": "GENE-Y"}]}
{"text": "In human blood, the tested glucocorticoids beclomethasone, dexamethasone and fluticasone inhibited the LPS induced TNF release potently in a concentration dependent manner, whereas in dispersed human nasal polyp cells, the effect of the glucocorticoids on allergically induced TNF release, with the exception of dexamethasone, was much less pronounced.", "spo_list": [{"subject": "beclomethasone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF", "object_type": "GENE-Y"}, {"subject": "dexamethasone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF", "object_type": "GENE-Y"}, {"subject": "fluticasone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TNF", "object_type": "GENE-Y"}]}
{"text": "The selective PDE 4 inhibitors, and to a certain extent the PDE3 inhibitors amrinone and milrinone, reduced the GM-CSF release in a concentration dependent manner.", "spo_list": [{"subject": "amrinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE3", "object_type": "GENE-N"}, {"subject": "milrinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE3", "object_type": "GENE-N"}, {"subject": "amrinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE 4", "object_type": "GENE-N"}, {"subject": "milrinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDE 4", "object_type": "GENE-N"}, {"subject": "amrinone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "GM-CSF", "object_type": "GENE-Y"}, {"subject": "milrinone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "GM-CSF", "object_type": "GENE-Y"}]}
{"text": "In addition, pretreatment with Z-Val-Ala-Asp-fluoromethylketone (Z-VAD-fmk), a broad spectrum of caspase inhibitor, could not rescue apoptotic cells from ClpP toxicity.", "spo_list": [{"subject": "Z-VAD-fmk", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "caspase", "object_type": "GENE-N"}, {"subject": "Z-Val-Ala-Asp-fluoromethylketone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "caspase", "object_type": "GENE-N"}]}
{"text": "The direct inhibition of stathmin by CCNU is likely a contributing factor.", "spo_list": [{"subject": "CCNU", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "stathmin", "object_type": "GENE-Y"}]}
{"text": "It was found that clozapine is selective for the dopamine D4 vs. the D2 receptor by a factor of 2.8.", "spo_list": [{"subject": "clozapine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D4", "object_type": "GENE-Y"}]}
{"text": "Other compounds with dopamine D4 receptor selectivity were (+)-apomorphine (8.7), (+)-N-propyl-norapomorphine (NPA) (2.4) and melperone (1.3).", "spo_list": [{"subject": "(+)-apomorphine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D4 receptor", "object_type": "GENE-Y"}, {"subject": "(+)-N-propyl-norapomorphine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D4 receptor", "object_type": "GENE-Y"}, {"subject": "melperone", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D4 receptor", "object_type": "GENE-Y"}]}
{"text": "Compounds with considerable selectivity for the dopamine D2 receptor were haloperidol (0.31), chlorpromazine (0.084), trifluoperazine (0.034) and raclopride (0.001).", "spo_list": [{"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D2 receptor", "object_type": "GENE-Y"}, {"subject": "chlorpromazine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "dopamine D2 receptor", "object_type": "GENE-Y"}, {"subject": "trifluoperazine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D2 receptor", "object_type": "GENE-Y"}, {"subject": "raclopride", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D2 receptor", "object_type": "GENE-Y"}]}
{"text": "However, it was recently shown that ibuprofen acts as a competitive inhibitor in the blockage of COX-1.", "spo_list": [{"subject": "ibuprofen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}]}
{"text": "Stimulated P-selectin and integrin alpha(IIb)beta(3) expression were also higher in the upper tertile both before and after aspirin.", "spo_list": [{"subject": "aspirin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "P-selectin", "object_type": "GENE-Y"}, {"subject": "aspirin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "integrin alpha(IIb)beta(3)", "object_type": "GENE-N"}]}
{"text": "The data show that CP[c]Ph is less potent at inducing CYP1A gene expression in rainbow trout than benzo[a]pyrene (B[a]P), a well-known Ah-receptor agonist.", "spo_list": [{"subject": "CP[c]Ph", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP1A", "object_type": "GENE-N"}, {"subject": "benzo[a]pyrene", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP1A", "object_type": "GENE-N"}, {"subject": "B[a]P", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP1A", "object_type": "GENE-N"}]}
{"text": "Interestingly, the CP[c]Ph dependent up-regulation of CYP1A mRNA is positively correlated with the incidences of clastogenic changes in rainbow trout erythrocytes.", "spo_list": [{"subject": "CP[c]Ph", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP1A", "object_type": "GENE-N"}]}
{"text": "CP[c]Ph has, comparably to B[a]P, a potential to repress expression of tumor suppressor p53, in the head kidney of rainbow trout.", "spo_list": [{"subject": "CP[c]Ph", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "tumor suppressor p53", "object_type": "GENE-Y"}, {"subject": "B[a]P", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "tumor suppressor p53", "object_type": "GENE-Y"}]}
{"text": "Cilostazol decreases levels of serum triglycerides and causes some increase in HDL-cholesterol levels.", "spo_list": [{"subject": "Cilostazol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HDL", "object_type": "GENE-N"}]}
{"text": "Cilostazol undergoes intensive and finally complete hepatic metabolism via the cytochrome P450 systems.", "spo_list": [{"subject": "Cilostazol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cytochrome P450", "object_type": "GENE-N"}]}
{"text": "Cofactor and tryptophan accessibility and unfolding of brain glutamate decarboxylase.", "spo_list": [{"subject": "tryptophan", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "glutamate decarboxylase", "object_type": "GENE-Y"}]}
{"text": "Cofactor and tryptophan accessibility of the 65-kDa form of rat brain glutamate decarboxylase (GAD) was investigated by fluorescence quenching measurements using acrylamide, I-, and Cs+ as the quenchers.", "spo_list": [{"subject": "tryptophan", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "rat brain glutamate decarboxylase", "object_type": "GENE-Y"}, {"subject": "tryptophan", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GAD", "object_type": "GENE-Y"}]}
{"text": "I- was less able and Cs+ was more able to quench the fluorescence of Trp residues in the holoenzyme of GAD (holoGAD) than the apoenzyme (apoGAD).", "spo_list": [{"subject": "Trp", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GAD", "object_type": "GENE-Y"}, {"subject": "Trp", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "holoGAD", "object_type": "GENE-Y"}, {"subject": "Trp", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "apoGAD", "object_type": "GENE-Y"}]}
{"text": "In contrast, pyridoxal-P bound to the active site of GAD was exposed to solvent.", "spo_list": [{"subject": "pyridoxal-P", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD", "object_type": "GENE-Y"}]}
{"text": "I- was more able and Cs+ was less able to quench the fluorescence of pyridoxal-P in holoGAD.", "spo_list": [{"subject": "pyridoxal-P", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "holoGAD", "object_type": "GENE-Y"}]}
{"text": "Changes in the accessibility of Trp residues upon pyridoxal-P binding strongly supported a significant conformational change in GAD.", "spo_list": [{"subject": "Trp", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GAD", "object_type": "GENE-Y"}, {"subject": "pyridoxal-P", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GAD", "object_type": "GENE-Y"}]}
{"text": "Recent studies, however, have demonstrated a promising potential treatment option with the help of the serum enzyme butyrylcholinesterase (BChE), which is capable of breaking down naturally occurring (-)-cocaine before the drug can influence the reward centers of the brain or affect other areas of the body.", "spo_list": [{"subject": "(-)-cocaine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "(-)-cocaine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "BChE", "object_type": "GENE-Y"}]}
{"text": "This prompted the design of variants of BChE which exhibit significantly improved catalytic activity against (-)-cocaine.", "spo_list": [{"subject": "(-)-cocaine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "BChE", "object_type": "GENE-Y"}]}
{"text": "Here, in expressing cocaine-hydrolyzing mutants of BChE in Nicotiana benthamiana using the MagnICON virus-assisted transient expression system, and in reporting their initial biochemical analysis, we provide proof-of-principle that plants can express engineered BChE proteins with desired properties.", "spo_list": [{"subject": "cocaine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "BChE", "object_type": "GENE-N"}]}
{"text": "One of the receptors involved in ADP-induced platelet activation is the P2Y12 receptor, which is a target for antithrombotic drugs.", "spo_list": [{"subject": "ADP", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "P2Y12", "object_type": "GENE-Y"}]}
{"text": "Anesthetized rabbits were treated with the selective P2Y12 antagonists AR-C69931 MX (3 microg x kg x min(-1) IV) or clopidogrel (25 mg/kg orally).", "spo_list": [{"subject": "AR-C69931 MX", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "P2Y12", "object_type": "GENE-Y"}, {"subject": "clopidogrel", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "P2Y12", "object_type": "GENE-Y"}]}
{"text": "Our study aims to explore the potent effects of AC, as a marker component of Aconitum, on CYP3A using the probe buspirone in rats.", "spo_list": [{"subject": "buspirone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CYP3A", "object_type": "GENE-N"}]}
{"text": "CYP3A activity and protein levels in rat liver microsomes pretreated with oral AC were also measured using in vitro buspirone metabolism and Western blot.", "spo_list": [{"subject": "buspirone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CYP3A", "object_type": "GENE-N"}]}
{"text": "Pharmacophore identification of c-Myc inhibitor 10074-G5.", "spo_list": [{"subject": "10074-G5", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "c-Myc", "object_type": "GENE-Y"}]}
{"text": "A structure-activity relationship (SAR) study of the c-Myc (Myc) inhibitor 10074-G5 (N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine, 1) - which targets a hydrophobic domain of the Myc oncoprotein that is flanked by arginine residues - was executed in order to determine its pharmacophore.", "spo_list": [{"subject": "10074-G5", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "c-Myc", "object_type": "GENE-Y"}, {"subject": "10074-G5", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Myc", "object_type": "GENE-Y"}, {"subject": "N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "c-Myc", "object_type": "GENE-Y"}, {"subject": "N-([1,1'-biphenyl]-2-yl)-7-nitrobenzo[c][1,2,5]oxadiazol-4-amine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Myc", "object_type": "GENE-Y"}, {"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Myc", "object_type": "GENE-Y"}]}
{"text": "Importantly, the carboxylic acid of JY-3-094 improves the physicochemical properties of the lead compound, which will facilitate the incorporation of additional hydrophobicity that might enhance Myc inhibitory activity further still.", "spo_list": [{"subject": "JY-3-094", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Myc", "object_type": "GENE-Y"}]}
{"text": "Modulation of receptor phosphorylation contributes to activation of peroxisome proliferator activated receptor alpha by dehydroepiandrosterone and other peroxisome proliferators.", "spo_list": [{"subject": "dehydroepiandrosterone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "peroxisome proliferator activated receptor alpha", "object_type": "GENE-Y"}, {"subject": "dehydroepiandrosterone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "peroxisome proliferators", "object_type": "GENE-N"}]}
{"text": "Dehydroepiandrosterone (DHEA), a C19 human adrenal steroid, activates peroxisome proliferator-activated receptor alpha (PPARalpha) in vivo but does not ligand-activate PPARalpha in transient transfection experiments.", "spo_list": [{"subject": "Dehydroepiandrosterone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "peroxisome proliferator-activated receptor alpha", "object_type": "GENE-Y"}, {"subject": "DHEA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "peroxisome proliferator-activated receptor alpha", "object_type": "GENE-Y"}, {"subject": "Dehydroepiandrosterone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PPARalpha", "object_type": "GENE-Y"}, {"subject": "DHEA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PPARalpha", "object_type": "GENE-Y"}]}
{"text": "We demonstrate that DHEA regulates PPARalpha action by altering both the levels and phosphorylation status of the receptor.", "spo_list": [{"subject": "DHEA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PPARalpha", "object_type": "GENE-Y"}, {"subject": "DHEA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PPARalpha", "object_type": "GENE-Y"}]}
{"text": "Okadaic acid treatment of primary rat hepatocytes decreased both DHEA- and nafenopin-induced FACO activity in primary rat hepatocytes.", "spo_list": [{"subject": "DHEA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "FACO", "object_type": "GENE-N"}, {"subject": "nafenopin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "FACO", "object_type": "GENE-N"}, {"subject": "Okadaic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FACO", "object_type": "GENE-N"}]}
{"text": "DHEA induced both PPARalpha mRNA and protein levels, as well as PP2A message in primary rat hepatocytes.", "spo_list": [{"subject": "DHEA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PPARalpha", "object_type": "GENE-Y"}, {"subject": "DHEA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PP2A", "object_type": "GENE-N"}]}
{"text": "DHEA action involves induction of PPARalpha mRNA and protein levels as well as increased PPARalpha transcriptional activity through decreasing receptor phosphorylation at serines in the AF1 region.", "spo_list": [{"subject": "DHEA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PPARalpha", "object_type": "GENE-Y"}, {"subject": "DHEA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PPARalpha", "object_type": "GENE-Y"}, {"subject": "serines", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PPARalpha", "object_type": "GENE-Y"}]}
{"text": "Intraplantar or intrathecal administered PhÎ±1Î² reduced both nocifensive behavior and mechanical hypersensitivity induced by capsaicin similarly to that observed with SB366791, a specific TRPV1 antagonist.", "spo_list": [{"subject": "SB366791", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "TRPV1", "object_type": "GENE-Y"}]}
{"text": "1. TRPM8 (CMR1) is a Ca(2+)-permeable channel, which can be activated by low temperatures, menthol, eucalyptol and icilin.", "spo_list": [{"subject": "menthol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRPM8", "object_type": "GENE-Y"}, {"subject": "menthol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CMR1", "object_type": "GENE-Y"}, {"subject": "menthol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Ca(2+)-permeable channel", "object_type": "GENE-N"}, {"subject": "eucalyptol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRPM8", "object_type": "GENE-Y"}, {"subject": "eucalyptol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CMR1", "object_type": "GENE-Y"}, {"subject": "eucalyptol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Ca(2+)-permeable channel", "object_type": "GENE-N"}, {"subject": "icilin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRPM8", "object_type": "GENE-Y"}, {"subject": "icilin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CMR1", "object_type": "GENE-Y"}, {"subject": "icilin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Ca(2+)-permeable channel", "object_type": "GENE-N"}]}
{"text": "4. Known VR1 antagonists (BCTC, thio-BCTC and capsazepine) were also able to block the response of TRPM8 to menthol (IC(50): 0.8+/-1.0, 3.5+/-1.1 and 18+/-1.1 microM, respectively).", "spo_list": [{"subject": "BCTC", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "VR1", "object_type": "GENE-Y"}, {"subject": "thio-BCTC", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "VR1", "object_type": "GENE-Y"}, {"subject": "capsazepine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "VR1", "object_type": "GENE-Y"}, {"subject": "BCTC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TRPM8", "object_type": "GENE-Y"}, {"subject": "thio-BCTC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TRPM8", "object_type": "GENE-Y"}, {"subject": "capsazepine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TRPM8", "object_type": "GENE-Y"}, {"subject": "menthol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRPM8", "object_type": "GENE-Y"}]}
{"text": "5. The Ca(2+) response of hVR1-transfected HEK293 cells to the endogenous VR1 agonist N-arachidonoyl-dopamine was potentiated by low pH.", "spo_list": [{"subject": "N-arachidonoyl-dopamine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "VR1", "object_type": "GENE-Y"}, {"subject": "N-arachidonoyl-dopamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "hVR1", "object_type": "GENE-Y"}]}
{"text": "In contrast, menthol- and icilin-activated TRPM8 currents were suppressed by low pH.", "spo_list": [{"subject": "menthol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRPM8", "object_type": "GENE-Y"}, {"subject": "icilin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TRPM8", "object_type": "GENE-Y"}]}
{"text": "Metabolism of Beclomethasone Dipropionate by Cytochrome P450 3A Enzymes.", "spo_list": [{"subject": "Beclomethasone Dipropionate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Cytochrome P450 3A", "object_type": "GENE-N"}]}
{"text": "It is possible that variations in cytochrome P450 3A enzyme-mediated metabolism of BDP may contribute to this phenomenon.", "spo_list": [{"subject": "BDP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cytochrome P450 3A", "object_type": "GENE-N"}]}
{"text": "This hypothesis was explored by evaluating the contributions of CYP3A4, 3A5, 3A7, and esterase enzymes in the metabolism of BDP in vitro and relating metabolism to changes in CYP3A enzyme mRNA expression via the glucocorticoid receptor in lung and liver cells.", "spo_list": [{"subject": "BDP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "esterase", "object_type": "GENE-N"}]}
{"text": "CYP3A4 and CYP3A5 metabolized BDP via hydroxylation ([M4] and [M6]) and dehydrogenation ([M5]) at similar rates; CYP3A7 did not metabolize BDP.", "spo_list": [{"subject": "BDP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A5", "object_type": "GENE-Y"}, {"subject": "BDP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A4", "object_type": "GENE-Y"}]}
{"text": "These studies show that CYP3A4 and CYP3A5 metabolize BDP to inactive metabolites and suggest that differences in the expression or function of these enzymes in the lung and/or liver could influence BDP disposition in humans.", "spo_list": [{"subject": "BDP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A5", "object_type": "GENE-Y"}, {"subject": "BDP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A4", "object_type": "GENE-Y"}]}
{"text": "Here, we investigated the role of NPS in memory formation, and determined whether NPS could mitigate memory impairment induced by selective N-methyl-d-aspartate receptor antagonist MK801, muscarinic cholinergic receptor antagonist scopolamine or AÎ²1-42 in mice, using novel object and object location recognition tasks.", "spo_list": [{"subject": "MK801", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "N-methyl-d-aspartate receptor", "object_type": "GENE-N"}, {"subject": "scopolamine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic cholinergic receptor", "object_type": "GENE-N"}]}
{"text": "The improvement of object recognition memory induced by NPS could be blocked by the selective NPSR antagonist SHA 68, indicating pharmacological specificity.", "spo_list": [{"subject": "SHA 68", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NPSR", "object_type": "GENE-Y"}, {"subject": "SHA 68", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NPS", "object_type": "GENE-Y"}]}
{"text": "The decrease in insulin and nitric oxide in rats fed the diet high in iron, fat, fructose, and salt was associated with disorders of zinc, copper, and calcium status, as well as with an increase in the relative mass of the gonads.", "spo_list": [{"subject": "iron", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "insulin", "object_type": "GENE-N"}, {"subject": "fructose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "insulin", "object_type": "GENE-N"}]}
{"text": "Regucalcin (RGN/SMP30) was originally discovered in 1978 as a unique calcium-binding protein that does not contain the EF-hand motif of calcium-binding domain.", "spo_list": [{"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Regucalcin", "object_type": "GENE-Y"}, {"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RGN", "object_type": "GENE-Y"}, {"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "SMP30", "object_type": "GENE-Y"}]}
{"text": "The expression of regucalcin is stimulated through the action of insulin in liver cells in vitro and in vivo and it is decreased in the liver of rats with type I diabetes induced by streptozotocin administration in vivo.", "spo_list": [{"subject": "streptozotocin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "regucalcin", "object_type": "GENE-Y"}]}
{"text": "Sutent and sorafenib are orally available inhibitors of the VEGFR and platelet derived growth factor receptor (PDGFR).", "spo_list": [{"subject": "Sutent", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR", "object_type": "GENE-N"}, {"subject": "Sutent", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "platelet derived growth factor receptor", "object_type": "GENE-N"}, {"subject": "Sutent", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDGFR", "object_type": "GENE-N"}, {"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "VEGFR", "object_type": "GENE-N"}, {"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "platelet derived growth factor receptor", "object_type": "GENE-N"}, {"subject": "sorafenib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PDGFR", "object_type": "GENE-N"}]}
{"text": "Temsirolimus is an mTOR inhibitor that leads to G1 cell cycle arrest and may affect VEGF production.", "spo_list": [{"subject": "Temsirolimus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mTOR", "object_type": "GENE-Y"}]}
{"text": "Expression and 1,4-dihydropyridine-binding properties of brain L-type calcium channel isoforms.", "spo_list": [{"subject": "1,4-dihydropyridine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "L-type calcium channel", "object_type": "GENE-N"}]}
{"text": "The L-type calcium channel (LTCC) isoforms Ca(v)1.2 and Ca(v)1.3 display similar 1,4-dihydropyridine (DHP) binding properties and are both expressed in mammalian brain.", "spo_list": [{"subject": "1,4-dihydropyridine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "L-type calcium channel", "object_type": "GENE-N"}, {"subject": "1,4-dihydropyridine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "LTCC", "object_type": "GENE-N"}, {"subject": "1,4-dihydropyridine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Ca(v)1.2", "object_type": "GENE-Y"}, {"subject": "1,4-dihydropyridine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Ca(v)1.3", "object_type": "GENE-Y"}, {"subject": "DHP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "L-type calcium channel", "object_type": "GENE-N"}, {"subject": "DHP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "LTCC", "object_type": "GENE-N"}, {"subject": "DHP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Ca(v)1.2", "object_type": "GENE-Y"}, {"subject": "DHP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Ca(v)1.3", "object_type": "GENE-Y"}]}
{"text": "(+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) and Ca(v)-DM brains was reduced to 15.1 and 4.4% of wild type, respectively, indicating that Ca(v)1.3 accounts for 10.7% of brain LTCCs. qPCR revealed that Ca(v)1.1 and Ca(v)1.4 alpha(1) subunits comprised 0.08% of the LTCC transcripts in mouse whole brain, suggesting that they cannot account for the residual binding.", "spo_list": [{"subject": "(+)-[(3)H]isradipine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Ca(v)", "object_type": "GENE-N"}, {"subject": "(+)-[(3)H]isradipine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Ca(v)1.3", "object_type": "GENE-Y"}, {"subject": "(+)-[(3)H]isradipine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "LTCCs", "object_type": "GENE-N"}]}
{"text": "Inhibition of (+)-[(3)H]isradipine binding to Ca(v)1.2DHP(-/-) (predominantly Ca(v)1.3) and wild-type (predominantly Ca(v)1.2) brain membranes by unlabeled DHPs revealed a 3- to 4-fold selectivity of nitrendipine and nifedipine for the Ca(v)1.2 binding pocket, a finding further confirmed with heterologously expressed channels.", "spo_list": [{"subject": "(+)-[(3)H]isradipine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Ca(v)1.3", "object_type": "GENE-Y"}, {"subject": "(+)-[(3)H]isradipine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Ca(v)1.2", "object_type": "GENE-Y"}, {"subject": "nitrendipine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Ca(v)1.2", "object_type": "GENE-Y"}, {"subject": "nifedipine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Ca(v)1.2", "object_type": "GENE-Y"}]}
{"text": "Fumarate reductase (FRD) is the key enzyme in fumarate respiration induced by anaerobic growth of bacteria.", "spo_list": [{"subject": "fumarate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Fumarate reductase", "object_type": "GENE-N"}]}
{"text": "Given that FRD, present in all H. pylori strains, is immunogenic in H. pylori -infected patients and H. pylori growth in vitro can be inhibited by three anthelmintics (morantel, oxantel and thiabendazole), this enzyme could potentially be used both as a novel drug target as well as in the development of vaccines for H. pylori prevention and eradication.", "spo_list": [{"subject": "morantel", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FRD", "object_type": "GENE-N"}, {"subject": "oxantel", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FRD", "object_type": "GENE-N"}, {"subject": "thiabendazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FRD", "object_type": "GENE-N"}]}
{"text": "Poly(ethylene glycol)-block-poly(Îµ-caprolactone) (PEG-b-PCL) micelles were loaded with paclitaxel (cytotoxic agent), cyclopamine (hedgehog inhibitor), and gossypol (Bcl-2 inhibitor).", "spo_list": [{"subject": "gossypol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Bcl-2", "object_type": "GENE-Y"}]}
{"text": "2. We hypothesized that styrene metabolites have lower affinity than styrene toward CYP2E1 and limited ability to induce cooperative effects during metabolism.", "spo_list": [{"subject": "styrene", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CYP2E1", "object_type": "GENE-Y"}, {"subject": "styrene", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CYP2E1", "object_type": "GENE-Y"}]}
{"text": "Styrene oxide and 4-vinylphenol possessed similar affinity for CYP2E1.", "spo_list": [{"subject": "Styrene oxide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CYP2E1", "object_type": "GENE-Y"}, {"subject": "4-vinylphenol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CYP2E1", "object_type": "GENE-Y"}]}
{"text": "BACKGROUND AND PURPOSE: AMP-activated protein kinase (AMPK) is activated by metformin, phenformin, and the AMP mimetic, 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside (AICAR).", "spo_list": [{"subject": "metformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMP-activated protein kinase", "object_type": "GENE-Y"}, {"subject": "metformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-Y"}, {"subject": "phenformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMP-activated protein kinase", "object_type": "GENE-Y"}, {"subject": "phenformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-Y"}, {"subject": "5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMP-activated protein kinase", "object_type": "GENE-Y"}, {"subject": "5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-Y"}, {"subject": "AICAR", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMP-activated protein kinase", "object_type": "GENE-Y"}, {"subject": "AICAR", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-Y"}]}
{"text": "KEY RESULTS: Phenformin, AICAR and metformin increased AMPK (alpha1) activity and decreased I(amiloride).", "spo_list": [{"subject": "Phenformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK (alpha1)", "object_type": "GENE-Y"}, {"subject": "AICAR", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK (alpha1)", "object_type": "GENE-Y"}, {"subject": "metformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK (alpha1)", "object_type": "GENE-Y"}]}
{"text": "The AMPK inhibitor Compound C prevented the action of metformin and AICAR but not phenformin.", "spo_list": [{"subject": "phenformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-Y"}]}
{"text": "Additional pharmacological effects evoked by AICAR and phenformin on I(ouabain), with potential secondary effects on apical Na+ conductance, ENaC activity and monolayer resistance, have important consequences for their use as pharmacological activators of AMPK in cell systems where Na+K+ATPase is an important component.", "spo_list": [{"subject": "AICAR", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-Y"}, {"subject": "phenformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-Y"}, {"subject": "ouabain", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-Y"}]}
{"text": "Melatonin, an endogenous-specific inhibitor of estrogen receptor alpha via calmodulin.", "spo_list": [{"subject": "Melatonin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "estrogen receptor alpha", "object_type": "GENE-Y"}]}
{"text": "Here we present the characterization of its mechanism of action showing that melatonin is a specific inhibitor of E(2)-induced ERalpha-mediated transcription in both estrogen response element- and AP1-containing promoters, whereas ERbeta-mediated transactivation is not inhibited or even activated at certain promoters.", "spo_list": [{"subject": "melatonin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ERalpha", "object_type": "GENE-Y"}]}
{"text": "Melatonin acts as a calmodulin antagonist inducing conformational changes in the ERalpha-calmodulin (CaM) complex, thus impairing the binding of E(2).ERalpha.CaM complex to DNA and, therefore, preventing ERalpha-dependent transcription.", "spo_list": [{"subject": "Melatonin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "Melatonin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERalpha", "object_type": "GENE-Y"}, {"subject": "Melatonin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calmodulin", "object_type": "GENE-N"}, {"subject": "Melatonin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CaM", "object_type": "GENE-N"}, {"subject": "Melatonin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERalpha", "object_type": "GENE-Y"}, {"subject": "Melatonin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CaM", "object_type": "GENE-N"}, {"subject": "Melatonin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERalpha", "object_type": "GENE-Y"}]}
{"text": "We reported previously that Ca(2+) influx through N-methly-d-aspartate-gated channels evokes ATP-sensitive K(+) (K-ATP) currents in rat subthalamic nucleus (STN) neurons.", "spo_list": [{"subject": "Ca(2+)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "N-methly-d-aspartate-gated channels", "object_type": "GENE-N"}]}
{"text": "By using whole-cell patch clamp recordings in brain slices, we investigated the ability of (RS)-3,5-dihydroxyphenylglycine (DHPG), a group I metabotropic glutamate receptor (mGluR) agonist, to evoke K-ATP currents.", "spo_list": [{"subject": "(RS)-3,5-dihydroxyphenylglycine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "group I metabotropic glutamate receptor", "object_type": "GENE-N"}, {"subject": "DHPG", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "group I metabotropic glutamate receptor", "object_type": "GENE-N"}, {"subject": "(RS)-3,5-dihydroxyphenylglycine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mGluR", "object_type": "GENE-N"}, {"subject": "DHPG", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mGluR", "object_type": "GENE-N"}]}
{"text": "The nitric oxide synthase inhibitor N(G)-nitro-l-arginine methyl ester and inhibitors of protein kinase G activity also suppressed DHPG-induced outward current.", "spo_list": [{"subject": "N(G)-nitro-l-arginine methyl ester", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "nitric oxide synthase", "object_type": "GENE-N"}]}
{"text": "Probing the salmeterol binding site on the beta 2-adrenergic receptor using a novel photoaffinity ligand, [(125)I]iodoazidosalmeterol.", "spo_list": [{"subject": "salmeterol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta 2-adrenergic receptor", "object_type": "GENE-N"}, {"subject": "[(125)I]iodoazidosalmeterol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta 2-adrenergic receptor", "object_type": "GENE-N"}]}
{"text": "Salmeterol is a long-acting beta2-adrenergic receptor (beta 2AR) agonist used clinically to treat asthma.", "spo_list": [{"subject": "Salmeterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta2-adrenergic receptor", "object_type": "GENE-N"}, {"subject": "Salmeterol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta 2AR", "object_type": "GENE-N"}]}
{"text": "Carrier-free radioiodinated [125I]IAS was used to photolabel epitope-tagged human beta 2AR in membranes prepared from stably transfected HEK 293 cells.", "spo_list": [{"subject": "[125I]IAS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human beta 2AR", "object_type": "GENE-N"}]}
{"text": "Labeling with [(125)I]IAS was blocked by 10 microM (-)-alprenolol and inhibited by addition of GTP gamma S, and [125I]IAS migrated at the same position on an SDS-PAGE gel as the beta 2AR labeled by the antagonist photoaffinity label [125I]iodoazidobenzylpindolol ([125I]IABP).", "spo_list": [{"subject": "[(125)I]IAS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta 2AR", "object_type": "GENE-N"}, {"subject": "(-)-alprenolol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "beta 2AR", "object_type": "GENE-N"}, {"subject": "GTP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "beta 2AR", "object_type": "GENE-N"}, {"subject": "[125I]iodoazidobenzylpindolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta 2AR", "object_type": "GENE-N"}, {"subject": "[125I]IABP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta 2AR", "object_type": "GENE-N"}]}
{"text": "A model of IAS binding to the beta 2AR is proposed.", "spo_list": [{"subject": "IAS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta 2AR", "object_type": "GENE-N"}]}
{"text": "We compared small intestinal function and morphology in untreated wild-type, COX-1- and COX-2-deficient mice and the effect of indomethacin, selective COX-1 (SC-560), and COX-2 (celecoxib) inhibition.", "spo_list": [{"subject": "SC-560", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "celecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Selective inhibition of COX-1 decreased intestinal PGE(2) levels in COX-2(+/+) and COX-2(-/-) animals by 95%-97%, but caused only small bowel ulcers in the latter group.", "spo_list": [{"subject": "PGE(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-1", "object_type": "GENE-Y"}]}
{"text": "Long-term COX-2 deficiency or inhibition is associated with significant intestinal pathology despite normal intestinal PGE(2) levels, suggesting a role for COX-2 in the maintenance of small intestinal integrity in the mouse.", "spo_list": [{"subject": "PGE(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Highly predictive ligand-based pharmacophore and homology models of ABHD6. Î±/Î²-Hydrolase domain-containing 6 (ABHD6) represents a potentially attractive therapeutic target for indirectly potentiating 2-arachidonoylglycerol signaling; however, the enzyme is currently largely uncharacterized.", "spo_list": [{"subject": "2-arachidonoylglycerol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Î±/Î²-Hydrolase domain-containing 6", "object_type": "GENE-Y"}, {"subject": "2-arachidonoylglycerol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ABHD6", "object_type": "GENE-Y"}]}
{"text": "The most frequent DHPS mutations occur at nucleotide positions 165 and 171, which lead to an amino acid change at positions 55 and 57.", "spo_list": [{"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "DHPS", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "DHPS", "object_type": "GENE-Y"}]}
{"text": "Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine.", "spo_list": [{"subject": "almotriptan", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT receptor", "object_type": "GENE-N"}]}
{"text": "Almotriptan showed low nanomolar affinity for the 5-HT(1B) and 5-HT(1D) receptors in several species, including the human, while affinity for 5-HT receptors other than 5-HT(1B/1D) was clearly less.", "spo_list": [{"subject": "Almotriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT(1B)", "object_type": "GENE-N"}, {"subject": "Almotriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT(1D)", "object_type": "GENE-N"}, {"subject": "Almotriptan", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT receptors", "object_type": "GENE-N"}]}
{"text": "The results suggest that almotriptan is a potent and selective 5-HT(1B/1D) receptor agonist, with selectivity for the cranial vasculature as compared with peripheral vessels.", "spo_list": [{"subject": "almotriptan", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT(1B/1D)", "object_type": "GENE-N"}]}
{"text": "Recent studies have reported that imatinib mesylate, a kinase inhibitor that targets the intracellular tyrosine kinase BCR-ABL and the platelet derived growth factor (PDGF) receptor, is an effective inhibitor of the macrophage colony stimulating factor (M-CSF) receptor, c-FMS.", "spo_list": [{"subject": "imatinib mesylate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "imatinib mesylate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tyrosine kinase", "object_type": "GENE-N"}, {"subject": "imatinib mesylate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ABL", "object_type": "GENE-Y"}, {"subject": "imatinib mesylate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BCR", "object_type": "GENE-Y"}, {"subject": "imatinib mesylate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "platelet derived growth factor (PDGF) receptor", "object_type": "GENE-N"}, {"subject": "imatinib mesylate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "macrophage colony stimulating factor (M-CSF) receptor", "object_type": "GENE-Y"}, {"subject": "imatinib mesylate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "c-FMS", "object_type": "GENE-Y"}]}
{"text": "Given that M-CSF signalling through c-FMS plays an important role in osteoclast biology, we speculated that blocking such a pathway with imatinib may modulate osteoclast activity.", "spo_list": [{"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "c-FMS", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "M-CSF", "object_type": "GENE-Y"}]}
{"text": "Imatinib was also found to inhibit M-CSF-induced osteoclast survival as well as M-CSF-induced osteoclast bone resorbing activity, but was without effect on interleukin 1alpha (IL-1alpha) and receptor activator of nuclear factor kappa B ligand (RANKL)-induced inhibition of osteoclasts apoptosis, further supporting the hypothesis that imatinib may affect mature osteoclasts through the inhibition of c-FMS.", "spo_list": [{"subject": "Imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "M-CSF", "object_type": "GENE-Y"}, {"subject": "Imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "M-CSF", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "c-FMS", "object_type": "GENE-Y"}]}
{"text": "Metabolism of nomifensine to a dihydroisoquinolinium ion metabolite by human myeloperoxidase, hemoglobin, monoamine oxidase A, and cytochrome P450 enzymes.", "spo_list": [{"subject": "nomifensine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human myeloperoxidase", "object_type": "GENE-Y"}, {"subject": "nomifensine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hemoglobin", "object_type": "GENE-N"}, {"subject": "nomifensine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "monoamine oxidase A", "object_type": "GENE-Y"}, {"subject": "nomifensine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cytochrome P450", "object_type": "GENE-N"}, {"subject": "dihydroisoquinolinium", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "human myeloperoxidase", "object_type": "GENE-Y"}, {"subject": "dihydroisoquinolinium", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "hemoglobin", "object_type": "GENE-N"}, {"subject": "dihydroisoquinolinium", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "monoamine oxidase A", "object_type": "GENE-Y"}, {"subject": "dihydroisoquinolinium", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cytochrome P450", "object_type": "GENE-N"}]}
{"text": "Metformin, but not leptin, regulates AMP-activated protein kinase in pancreatic islets: impact on glucose-stimulated insulin secretion.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-N"}]}
{"text": "Metformin, a drug widely used in the treatment of type 2 diabetes, has recently been shown to act on skeletal muscle and liver in part through the activation of AMP-activated protein kinase (AMPK).", "spo_list": [{"subject": "Metformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMP-activated protein kinase", "object_type": "GENE-N"}, {"subject": "Metformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}]}
{"text": "Whether metformin or the satiety factor leptin, which also stimulates AMPK in muscle, regulates this enzyme in pancreatic islets is unknown.", "spo_list": [{"subject": "metformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}]}
{"text": "Increases in glucose concentration from 0 to 3 and from 3 to 17 mM inhibited AMPK activity in primary islets from mouse, rat, and human, confirming previous findings in insulinoma cells.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AMPK", "object_type": "GENE-N"}]}
{"text": "Incubation with metformin (0.2-1 mM) activated AMPK in both human islets and MIN6 beta-cells in parallel with an inhibition of insulin secretion, whereas leptin (10-100 nM) was without effect in MIN6 cells.", "spo_list": [{"subject": "metformin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-N"}, {"subject": "metformin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "insulin", "object_type": "GENE-N"}]}
{"text": "The inhibitory effects of metformin on insulin secretion may therefore need to be considered with respect to the use of this drug for the treatment of type 2 diabetes.", "spo_list": [{"subject": "metformin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "insulin", "object_type": "GENE-N"}]}
{"text": "The principal aim of the study was to find amiodarone analogues that retained human ether-a-go-go-related protein (hERG) channel inhibition but with reduced cytotoxicity.", "spo_list": [{"subject": "amiodarone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human ether-a-go-go-related protein (hERG) channel", "object_type": "GENE-Y"}]}
{"text": "Pharmacological and in silico investigations concerning the interactions of these compounds with the hERG channel revealed that compounds carrying a basic nitrogen in the side chain display a much higher affinity than those lacking such a group.", "spo_list": [{"subject": "nitrogen", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hERG", "object_type": "GENE-Y"}]}
{"text": "Specifically, B2-O-CH(2)-CH(2)-N-piperidine and B2-O-CH(2)-CH(2)-N-pyrrolidine revealed a higher affinity towards hERG channels than amiodarone.", "spo_list": [{"subject": "B2-O-CH(2)-CH(2)-N-pyrrolidine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hERG", "object_type": "GENE-Y"}, {"subject": "B2-O-CH(2)-CH(2)-N-piperidine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hERG", "object_type": "GENE-Y"}, {"subject": "amiodarone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hERG", "object_type": "GENE-Y"}]}
{"text": "CONCLUSIONS AND IMPLICATIONS: Amiodarone analogues with better hERG channel inhibition and cytotoxicity profiles than the parent compound have been identified, demonstrating that cytotoxicity and hERG channel interaction are mechanistically distinct and separable properties of the compounds.", "spo_list": [{"subject": "Amiodarone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hERG", "object_type": "GENE-Y"}]}
{"text": "Retinoid is a collective term for compounds which bind to and activate retinoic acid receptors (RARalpha, beta, gamma and RXRalpha, beta, gamma), members of nuclear hormone receptor superfamily.", "spo_list": [{"subject": "Retinoid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "retinoic acid receptors", "object_type": "GENE-N"}, {"subject": "Retinoid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "retinoic acid receptors", "object_type": "GENE-N"}, {"subject": "Retinoid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "nuclear hormone receptor", "object_type": "GENE-N"}, {"subject": "Retinoid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "nuclear hormone receptor", "object_type": "GENE-N"}]}
{"text": "Among them, tamibarotene (Am80) is an RARalpha- and RARbeta-specific (but RARgamma- and RXRs-nonbinding) synthetic retinoid that is effective in the treatment of psoriasis patients and relapsed APL.", "spo_list": [{"subject": "tamibarotene", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RARalpha", "object_type": "GENE-Y"}, {"subject": "tamibarotene", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RARbeta", "object_type": "GENE-Y"}, {"subject": "Am80", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RARalpha", "object_type": "GENE-Y"}, {"subject": "Am80", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RARbeta", "object_type": "GENE-Y"}, {"subject": "retinoid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RARalpha", "object_type": "GENE-Y"}, {"subject": "retinoid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RARbeta", "object_type": "GENE-Y"}]}
{"text": "Consensus interferon (Infergen) is a wholly synthetic type I interferon (IFN), developed by scanning several interferon-alpha nonallelic subtypes and assigning the most frequently observed amino acid in each position, resulting in a consensus sequence.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "interferon-alpha", "object_type": "GENE-N"}]}
{"text": "2. The effect of sex and cytochrome P450 (P450) enzyme induction on the enantioselective metabolism of PCB 136 was studied using liver tissue slices prepared from naÃ¯ve control (CTL), phenobarbital (PB; CYP2B inducer) or dexamethasone (DEX; CYP3A inducer) pretreated adult Sprague-Dawley rats.", "spo_list": [{"subject": "PCB 136", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cytochrome P450", "object_type": "GENE-N"}, {"subject": "PCB 136", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P450", "object_type": "GENE-N"}]}
{"text": "4. Our results suggest that enantioselective metabolism, sex and induction status of P450 enzymes in the liver may modulate the neurotoxic outcomes of developmental exposure to chiral PCBs.", "spo_list": [{"subject": "PCBs", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P450 enzymes", "object_type": "GENE-N"}]}
{"text": "Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist.", "spo_list": [{"subject": "Tamsulosin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha 1A-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "[3H]dofetilide binding to HERG transfected membranes: a potential high throughput preclinical screen.", "spo_list": [{"subject": "[3H]dofetilide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "HERG", "object_type": "GENE-Y"}]}
{"text": "These data indicate that a [3H]dofetilide binding assay using HERG membranes may help identify compounds that prolong the QT interval.", "spo_list": [{"subject": "[3H]dofetilide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "HERG", "object_type": "GENE-Y"}]}
{"text": "Selective inhibition of cyclooxygenase 2 spares renal function and prostaglandin synthesis in cirrhotic rats with ascites.", "spo_list": [{"subject": "prostaglandin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "cyclooxygenase 2", "object_type": "GENE-Y"}]}
{"text": "The current study evaluates the effects of a selective COX-2 inhibitor (SC-236) on renal function in cirrhotic rats with ascites.", "spo_list": [{"subject": "SC-236", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "RESULTS: Administration of SC-236 to cirrhotic animals did not produce significant renal effects, whereas administration of the nonselective COX-1/COX-2 inhibitor, ketorolac, resulted in a marked reduction in urine volume, urinary excretion of prostaglandins, and glomerular filtration rate and in a significant impairment in renal water metabolism.", "spo_list": [{"subject": "ketorolac", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "ketorolac", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "RESULTS: The function of Î¼-opioid receptor was increased by treatment with ethanol in the lower midbrain using [(35)S] GTPÎ³S binding assay.", "spo_list": [{"subject": "[(35)S] GTPÎ³S", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Î¼-opioid receptor", "object_type": "GENE-Y"}]}
{"text": "Furthermore, the GRK2 protein level was significantly increased by treatment with ethanol.", "spo_list": [{"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GRK2", "object_type": "GENE-Y"}]}
{"text": "On the other hand, this enhancement of the rewarding effects of morphine by ethanol treatment was significantly inhibited by the GRK2 inhibitor Î²-adrenergic receptor kinase 1 inhibitor.", "spo_list": [{"subject": "morphine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GRK2", "object_type": "GENE-Y"}, {"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GRK2", "object_type": "GENE-Y"}]}
{"text": "CONCLUSIONS: The present study demonstrated that chronic treatment with ethanol enhanced the rewarding effects of morphine by up-regulating functional changes in Î¼-opioid receptor, mediated by GRK2.", "spo_list": [{"subject": "ethanol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GRK2", "object_type": "GENE-Y"}, {"subject": "morphine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GRK2", "object_type": "GENE-Y"}]}
{"text": "PIP5K1B encodes phosphatidylinositol 4-phosphate 5-kinase Î² type I (pip5k1Î²), an enzyme functionally linked to actin cytoskeleton dynamics that phosphorylates phosphatidylinositol 4-phosphate [PI(4)P] to generate phosphatidylinositol-4,5-bisphosphate [PI(4,5)P2].", "spo_list": [{"subject": "phosphatidylinositol 4-phosphate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PIP5K1B", "object_type": "GENE-Y"}, {"subject": "PI(4)P", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "PIP5K1B", "object_type": "GENE-Y"}, {"subject": "phosphatidylinositol-4,5-bisphosphate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PIP5K1B", "object_type": "GENE-Y"}, {"subject": "PI(4,5)P2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PIP5K1B", "object_type": "GENE-Y"}, {"subject": "phosphatidylinositol 4-phosphate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "pip5k1Î²", "object_type": "GENE-Y"}, {"subject": "PI(4)P", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "pip5k1Î²", "object_type": "GENE-Y"}, {"subject": "PI(4,5)P2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "pip5k1Î²", "object_type": "GENE-Y"}, {"subject": "phosphatidylinositol-4,5-bisphosphate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "pip5k1Î²", "object_type": "GENE-Y"}, {"subject": "phosphatidylinositol 4-phosphate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "phosphatidylinositol 4-phosphate 5-kinase Î² type I", "object_type": "GENE-Y"}, {"subject": "PI(4)P", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "phosphatidylinositol 4-phosphate 5-kinase Î² type I", "object_type": "GENE-Y"}, {"subject": "phosphatidylinositol-4,5-bisphosphate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "phosphatidylinositol 4-phosphate 5-kinase Î² type I", "object_type": "GENE-Y"}, {"subject": "PI(4,5)P2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "phosphatidylinositol 4-phosphate 5-kinase Î² type I", "object_type": "GENE-Y"}]}
{"text": "Accordingly, loss of pip5k1Î² function in FRDA cells was accompanied by decreased PI(4,5)P2 levels and was shown instrumental for destabilization of the actin network and delayed cell spreading.", "spo_list": [{"subject": "PI(4,5)P2", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "pip5k1Î²", "object_type": "GENE-Y"}]}
{"text": "Guided by co-crystal structures of compounds 15, 22 and 30, an SBDD approach led to the discovery of the 6-methyl pyridone series as a novel class of GKAs that potently activate GK in enzyme and cell assays.", "spo_list": [{"subject": "6-methyl pyridone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "GK", "object_type": "GENE-Y"}]}
{"text": "We have changed three acidic amino acids and two arginine residues that are conserved in the sequence of mammalian PH-20 polypeptides as well as in the hyaluronidases from bee and hornet venom.", "spo_list": [{"subject": "acidic amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "hyaluronidases", "object_type": "GENE-N"}, {"subject": "acidic amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PH-20", "object_type": "GENE-N"}, {"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PH-20", "object_type": "GENE-N"}, {"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "hyaluronidases", "object_type": "GENE-N"}]}
{"text": "This indicates that the PH-20 hyaluronidases, like numerous enzymes that hydrolyze glycosidic bonds, have acidic amino acids in their active site.", "spo_list": [{"subject": "acidic amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "PH-20 hyaluronidases", "object_type": "GENE-Y"}]}
{"text": "Furthermore, deferasirox was generally similar or slightly more effective than DFO at mobilizing cellular (59)Fe and inhibiting iron uptake from human transferrin depending on the cell type.", "spo_list": [{"subject": "deferasirox", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human transferrin", "object_type": "GENE-Y"}, {"subject": "DFO", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human transferrin", "object_type": "GENE-Y"}]}
{"text": "We demonstrated that deferasirox increased expression of the metastasis suppressor protein N-myc downstream-regulated gene 1 and upregulated the cyclin-dependent kinase inhibitor p21(CIP1/WAF1) while decreasing cyclin D1 levels.", "spo_list": [{"subject": "deferasirox", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "protein N-myc downstream-regulated gene 1", "object_type": "GENE-Y"}, {"subject": "deferasirox", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cyclin-dependent kinase inhibitor p21", "object_type": "GENE-Y"}, {"subject": "deferasirox", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CIP1", "object_type": "GENE-Y"}, {"subject": "deferasirox", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "WAF1", "object_type": "GENE-Y"}, {"subject": "deferasirox", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cyclin D1", "object_type": "GENE-Y"}]}
{"text": "Perhexiline reduces fatty acid metabolism through the inhibition of carnitine palmitoyltransferase, the enzyme responsible for mitochondrial uptake of long-chain fatty acids.", "spo_list": [{"subject": "Perhexiline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carnitine palmitoyltransferase", "object_type": "GENE-N"}, {"subject": "long-chain fatty acids", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "carnitine palmitoyltransferase", "object_type": "GENE-N"}, {"subject": "fatty acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "carnitine palmitoyltransferase", "object_type": "GENE-N"}]}
{"text": "Tazarotene is an acetylenic retinoid which is metabolised to tazarotenic acid and which binds selectively to the retinoid receptors RARbeta and RARgamma.", "spo_list": [{"subject": "Tazarotene", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "retinoid receptors", "object_type": "GENE-N"}, {"subject": "Tazarotene", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RARbeta", "object_type": "GENE-Y"}, {"subject": "Tazarotene", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RARgamma", "object_type": "GENE-Y"}, {"subject": "acetylenic retinoid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "retinoid receptors", "object_type": "GENE-N"}, {"subject": "acetylenic retinoid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RARbeta", "object_type": "GENE-Y"}, {"subject": "acetylenic retinoid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RARgamma", "object_type": "GENE-Y"}, {"subject": "tazarotenic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "retinoid receptors", "object_type": "GENE-N"}, {"subject": "tazarotenic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RARbeta", "object_type": "GENE-Y"}, {"subject": "tazarotenic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RARgamma", "object_type": "GENE-Y"}]}
{"text": "Identification of substituted 2-thio-6-oxo-1,6-dihydropyrimidines as inhibitors of human lactate dehydrogenase.", "spo_list": [{"subject": "2-thio-6-oxo-1,6-dihydropyrimidines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human lactate dehydrogenase", "object_type": "GENE-N"}]}
{"text": "A novel 2-thio-6-oxo-1,6-dihydropyrimidine-containing inhibitor of human lactate dehydrogenase (LDH) was identified by high-throughput screening (IC50=8.1Î¼M).", "spo_list": [{"subject": "2-thio-6-oxo-1,6-dihydropyrimidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human lactate dehydrogenase", "object_type": "GENE-N"}, {"subject": "2-thio-6-oxo-1,6-dihydropyrimidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "LDH", "object_type": "GENE-N"}]}
{"text": "Biochemical, surface plasmon resonance, and saturation transfer difference NMR experiments indicated that the compound specifically associated with human LDHA in a manner that required simultaneous binding of the NADH co-factor.", "spo_list": [{"subject": "NADH", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human LDHA", "object_type": "GENE-Y"}]}
{"text": "Coumarin 7-hydroxylation, catalyzed by P450 2A13, was strongly inhibited by 2'-methoxy-5,7-dihydroxyflavone, 2-ethynylnaphthalene, 2'-methoxyflavone, 2-naphththalene propargyl ether, acenaphthene, acenaphthylene, naphthalene, 1-acetylpyrene, flavanone, chrysin, 3-ethynylphenanthrene, flavone, and 7-hydroxyflavone; these chemicals induced Type I spectral changes with low Ks values.", "spo_list": [{"subject": "Coumarin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P450 2A13", "object_type": "GENE-Y"}, {"subject": "2'-methoxy-5,7-dihydroxyflavone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P450 2A13", "object_type": "GENE-Y"}, {"subject": "2-ethynylnaphthalene", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P450 2A13", "object_type": "GENE-Y"}, {"subject": "1-acetylpyrene", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P450 2A13", "object_type": "GENE-Y"}, {"subject": "flavanone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P450 2A13", "object_type": "GENE-Y"}, {"subject": "chrysin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P450 2A13", "object_type": "GENE-Y"}, {"subject": "3-ethynylphenanthrene", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P450 2A13", "object_type": "GENE-Y"}, {"subject": "flavone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P450 2A13", "object_type": "GENE-Y"}, {"subject": "7-hydroxyflavone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P450 2A13", "object_type": "GENE-Y"}, {"subject": "2'-methoxyflavone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P450 2A13", "object_type": "GENE-Y"}, {"subject": "2-naphththalene propargyl ether", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P450 2A13", "object_type": "GENE-Y"}, {"subject": "acenaphthene", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P450 2A13", "object_type": "GENE-Y"}, {"subject": "acenaphthylene", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P450 2A13", "object_type": "GENE-Y"}, {"subject": "naphthalene", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "P450 2A13", "object_type": "GENE-Y"}]}
{"text": "Disruption of contact inhibition, which was induced by toxic AhR ligands 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) or polycyclic aromatic hydrocarbons in epithelial WB-F344 cells, reduced Cx43 protein levels, possibly via enhanced proteasomal degradation, significantly decreased the amount of gap junction plaques and downregulated GJIC, in an AhR-dependent manner.", "spo_list": [{"subject": "2,3,7,8-tetrachlorodibenzo-p-dioxin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AhR", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AhR", "object_type": "GENE-Y"}, {"subject": "polycyclic aromatic hydrocarbons", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AhR", "object_type": "GENE-Y"}, {"subject": "2,3,7,8-tetrachlorodibenzo-p-dioxin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Cx43", "object_type": "GENE-Y"}, {"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Cx43", "object_type": "GENE-Y"}, {"subject": "polycyclic aromatic hydrocarbons", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Cx43", "object_type": "GENE-Y"}]}
{"text": "Although both intracellular and membrane Cx43 pools were markedly reduced in cells released from contact inhibition by TCDD, siRNA-mediated Cx43 knock-down was not sufficient to stimulate proliferation in contact-inhibited cells.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Cx43", "object_type": "GENE-Y"}]}
{"text": "Interestingly, despite the presence of the anchoring fragment to the Trk kinase domain composing its structure, this molecule does not inhibit TrkA like lestaurtinib, constituting a new chemical with a yet unknown mechanism of action.", "spo_list": [{"subject": "lestaurtinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TrkA", "object_type": "GENE-N"}]}
{"text": "Subconjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression.", "spo_list": [{"subject": "budesonide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "VEGF", "object_type": "GENE-Y"}, {"subject": "corticosteroid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "VEGF", "object_type": "GENE-Y"}]}
{"text": "To determine the involvement of glucocorticoid receptor in the observed effects of budesonide, secretion and mRNA expression studies were also performed in the presence of a glucocorticoid receptor antagonist (RU486).", "spo_list": [{"subject": "RU486", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "glucocorticoid receptor", "object_type": "GENE-Y"}]}
{"text": "RESULTS: At concentrations devoid of cytotoxicity, budesonide inhibited VEGF secretion as well as mRNA expression in ARPE-19 cells in a dose-dependent manner.", "spo_list": [{"subject": "budesonide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "VEGF", "object_type": "GENE-Y"}]}
{"text": "RU486 treatment prevented budesonide-mediated inhibition of VEGF secretion and VEGF mRNA expression.", "spo_list": [{"subject": "budesonide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "VEGF", "object_type": "GENE-Y"}, {"subject": "budesonide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "VEGF", "object_type": "GENE-Y"}, {"subject": "RU486", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "VEGF", "object_type": "GENE-Y"}, {"subject": "RU486", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "VEGF", "object_type": "GENE-Y"}]}
{"text": "CONCLUSIONS: Budesonide is capable of inhibiting VEGF expression through glucocorticoid receptor activity.", "spo_list": [{"subject": "Budesonide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "VEGF", "object_type": "GENE-Y"}]}
{"text": "1,3,4-Oxadiazol-2-ones as fatty-acid amide hydrolase and monoacylglycerol lipase inhibitors: Synthesis, in vitro evaluation and insight into potency and selectivity determinants by molecular modelling.", "spo_list": [{"subject": "1,3,4-Oxadiazol-2-ones", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "fatty-acid amide hydrolase", "object_type": "GENE-Y"}, {"subject": "1,3,4-Oxadiazol-2-ones", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoacylglycerol lipase", "object_type": "GENE-Y"}]}
{"text": "Continuing our previous work, we take the first steps of structure-activity relationship exploration and show that 1,3,4-oxadiazol-2-ones can serve as scaffold for both selective FAAH and MAGL inhibitors, and also function as a dual FAAH/MAGL inhibitor at sub-micromolar IC50 values.", "spo_list": [{"subject": "1,3,4-oxadiazol-2-ones", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FAAH", "object_type": "GENE-Y"}, {"subject": "1,3,4-oxadiazol-2-ones", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAGL", "object_type": "GENE-Y"}, {"subject": "1,3,4-oxadiazol-2-ones", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAGL", "object_type": "GENE-Y"}, {"subject": "1,3,4-oxadiazol-2-ones", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FAAH", "object_type": "GENE-Y"}]}
{"text": "Herein, we report the identification and characterization of 3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile (ESI-09), a novel noncyclic nucleotide EPAC antagonist that is capable of specifically blocking intracellular EPAC-mediated Rap1 activation and Akt phosphorylation, as well as EPAC-mediated insulin secretion in pancreatic Î² cells.", "spo_list": [{"subject": "3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "EPAC", "object_type": "GENE-Y"}, {"subject": "ESI-09", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "EPAC", "object_type": "GENE-Y"}, {"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "EPAC", "object_type": "GENE-Y"}, {"subject": "3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Rap1", "object_type": "GENE-Y"}, {"subject": "3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EPAC", "object_type": "GENE-Y"}, {"subject": "ESI-09", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EPAC", "object_type": "GENE-Y"}, {"subject": "ESI-09", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Rap1", "object_type": "GENE-Y"}, {"subject": "3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "ESI-09", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EPAC", "object_type": "GENE-Y"}, {"subject": "ESI-09", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EPAC", "object_type": "GENE-Y"}, {"subject": "3-(5-tert-butyl-isoxazol-3-yl)-2-[(3-chloro-phenyl)-hydrazono]-3-oxo-propionitrile", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "insulin", "object_type": "GENE-Y"}, {"subject": "ESI-09", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "insulin", "object_type": "GENE-Y"}, {"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EPAC", "object_type": "GENE-Y"}, {"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Rap1", "object_type": "GENE-Y"}, {"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}, {"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EPAC", "object_type": "GENE-Y"}, {"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "insulin", "object_type": "GENE-Y"}]}
{"text": "Number and area of preneoplastic foci positive for glutathione S-transferase placental form (GST-P) were consistently higher in these groups than the sum of individual values in the groups treated with HEP or HCB alone.", "spo_list": [{"subject": "HEP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "glutathione S-transferase placental form", "object_type": "GENE-N"}, {"subject": "HCB", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "glutathione S-transferase placental form", "object_type": "GENE-N"}, {"subject": "HEP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GST-P", "object_type": "GENE-N"}, {"subject": "HCB", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GST-P", "object_type": "GENE-N"}]}
{"text": "On the basis of these findings, we conclude that HEP and HCB have additive and synergistic effects on the development of GST-P-positive foci and that higher risks are associated with a combination of residual organochlorine pesticides in foods than with individual residual organochlorine pesticides.", "spo_list": [{"subject": "HEP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GST-P", "object_type": "GENE-N"}, {"subject": "HCB", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "GST-P", "object_type": "GENE-N"}]}
{"text": "Alkyl substituted 2'-benzoylpyridine thiosemicarbazone chelators with potent and selective anti-neoplastic activity: novel ligands that limit methemoglobin formation.", "spo_list": [{"subject": "Alkyl substituted 2'-benzoylpyridine thiosemicarbazone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "methemoglobin", "object_type": "GENE-N"}]}
{"text": "Major findings include that methemoglobin formation mediated by the lipophilic t-BuBpT series was significantly (p < 0.05-0.001) decreased in comparison to 3-AP in intact red blood cells and were generally comparable to the control.", "spo_list": [{"subject": "t-BuBpT", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "methemoglobin", "object_type": "GENE-N"}, {"subject": "3-AP", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "methemoglobin", "object_type": "GENE-N"}]}
{"text": "However, pretreatment with agents that block late I(Na), like lidocaine, mexiletine, and RSD1235, a novel mixed ion channel blocker for the rapid pharmacologic conversion of atrial fibrillation, significantly attenuates the prolonging effects of Class III agents or those induced by ATX-II, a specific toxin that delays Na channel inactivation and amplifies late I(Na) greatly, mimicking LQT3.", "spo_list": [{"subject": "RSD1235", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ion channel", "object_type": "GENE-N"}]}
{"text": "The Na channel block caused by lidocaine and RSD1235 can be through the open or inactivated states of the channel, but both equivalently inhibit a late component of Na current (I(Na)), recorded at 22 degrees C using whole-cell patch clamp of Nav 1.5 expressed in HEK cells.", "spo_list": [{"subject": "lidocaine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Na channel", "object_type": "GENE-N"}, {"subject": "RSD1235", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Na channel", "object_type": "GENE-N"}]}
{"text": "Methods: Stabilized anaplastic thyroid cancer cell lines (BHT-101 and CAL-62) and primary cultures from patients who underwent thyroidectomy for anaplastic thyroid cancer were treated with the histone deacetylase inhibitor LBH589.", "spo_list": [{"subject": "LBH589", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "histone deacetylase", "object_type": "GENE-N"}]}
{"text": "Results: Our results demonstrate that treatment with LBH589 leads to NIS RNA expression as shown by RT-PCR and luciferase assay, and to protein expression as determined by immunofluorescence in vitro and by immunohistochemistry in xenograft tumors.", "spo_list": [{"subject": "LBH589", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NIS", "object_type": "GENE-Y"}]}
{"text": "Results of equilibrium studies were consistent with two classes of binding sites for MTZ within the erythrocyte: a low affinity, high capacity site (CA-I) and a high affinity, low capacity site (CA-II).", "spo_list": [{"subject": "MTZ", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CA", "object_type": "GENE-N"}, {"subject": "MTZ", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CA", "object_type": "GENE-N"}]}
{"text": "The model assumed that penetration of MTZ into the red blood cells was passive but drug binding to the carbonic anhydrase isozymes was not instantaneous.", "spo_list": [{"subject": "MTZ", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "carbonic anhydrase", "object_type": "GENE-N"}]}
{"text": "We examined in cats the 1) ulcerogenic effects of selective COX-1 (SC-560, ketorolac) and COX-2 (celecoxib, meloxicam) inhibitors on the gastrointestinal mucosa, 2) effect of feeding and cimetidine on the expression of COX isoforms and prostaglandin E(2) (PGE(2)) level in the duodenum, and 3) localization of COX isoforms in the duodenum.", "spo_list": [{"subject": "SC-560", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "ketorolac", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "celecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "meloxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Second, feeding increased both the expression of COX isoforms and PGE(2) level in the duodenum, and the effects were markedly inhibited by pretreatment with cimetidine.", "spo_list": [{"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "COX", "object_type": "GENE-N"}]}
{"text": "Cytochrome P450 (P450)-derived arachidonic acid (AA) metabolites serve pivotal physiological roles.", "spo_list": [{"subject": "arachidonic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Cytochrome P450", "object_type": "GENE-N"}, {"subject": "arachidonic acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "P450", "object_type": "GENE-N"}]}
{"text": "Profenofos is a direct acting phosphorothioate organophosphorus (OP) pesticide capable of inhibiting Î²-esterases such as acetylcholinesterase, butyrylcholinesterase, and carboxylesterase.", "spo_list": [{"subject": "Profenofos", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Î²-esterases", "object_type": "GENE-N"}, {"subject": "phosphorothioate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Î²-esterases", "object_type": "GENE-N"}, {"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Î²-esterases", "object_type": "GENE-N"}, {"subject": "Profenofos", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "Profenofos", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "Profenofos", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carboxylesterase", "object_type": "GENE-N"}]}
{"text": "Of the nine human CYPs studied, only CYPs 3A4, 2B6, and 2C19 were able to metabolize profenofos to BCP.", "spo_list": [{"subject": "profenofos", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human CYPs", "object_type": "GENE-N"}, {"subject": "BCP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "human CYPs", "object_type": "GENE-N"}]}
{"text": "The Vmax for BCP formation was 47.9, 25.1, and 19.2nmol/min/nmol CYP for CYP2B6, 2C19, and 3A4, respectively.", "spo_list": [{"subject": "BCP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CYP", "object_type": "GENE-N"}]}
{"text": "Intrinsic clearance (Vmax/Km) values of 48.8, 46.9, and 1.02ml/min/nmol CYP 2C19, 2B6, and 3A4, respectively, indicate that CYP2C19 and CYP2B6 are primarily responsible for the detoxification of profenofos.", "spo_list": [{"subject": "profenofos", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2C19", "object_type": "GENE-Y"}, {"subject": "profenofos", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2B6", "object_type": "GENE-Y"}]}
{"text": "Clinical studies in cancer patients treated with the new fluoropyrimidine analogue capecitabine (N4-pentoxycarbonyl-5'-5-fluorocytidine) have shown that plasma 2'-deoxyuridine was significantly elevated after 1 week of treatment, consistent with inhibition of thymidylate synthase (TS).", "spo_list": [{"subject": "fluoropyrimidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}, {"subject": "capecitabine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}, {"subject": "N4-pentoxycarbonyl-5'-5-fluorocytidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}, {"subject": "2'-deoxyuridine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "thymidylate synthase", "object_type": "GENE-Y"}, {"subject": "fluoropyrimidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "capecitabine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "N4-pentoxycarbonyl-5'-5-fluorocytidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "2'-deoxyuridine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}]}
{"text": "These findings suggest that the mechanism of antiproliferative toxicity of capecitabine is at least partly due to TS inhibitory activity of its active metabolite 5-fluoro-2'-deoxyuridine monophosphate (FdUMP).", "spo_list": [{"subject": "capecitabine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "5-fluoro-2'-deoxyuridine monophosphate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}, {"subject": "FdUMP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TS", "object_type": "GENE-Y"}]}
{"text": "Glyphosate affects aromatic amino acid biosynthesis by inhibiting 5-enolpyruvylshikimate-3-phosphate synthase (EPSPS).", "spo_list": [{"subject": "Glyphosate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-enolpyruvylshikimate-3-phosphate synthase", "object_type": "GENE-N"}, {"subject": "Glyphosate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EPSPS", "object_type": "GENE-N"}]}
{"text": "Glufosinate inhibits glutamine synthetase and blocks biosynthesis of glutamine.", "spo_list": [{"subject": "Glufosinate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "glutamine synthetase", "object_type": "GENE-N"}, {"subject": "glutamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "glutamine synthetase", "object_type": "GENE-N"}]}
{"text": "The newer generation of aromatase inhibitors (letrozole, anastrozole, exemestane) appears to be more active (in terms of overall response rates and conservative surgery rate) than tamoxifen.", "spo_list": [{"subject": "letrozole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "anastrozole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "exemestane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "tamoxifen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "Inhibition of tumor necrosis factor alpha-stimulated aromatase activity by microtubule-stabilizing agents, paclitaxel and 2-methoxyestradiol.", "spo_list": [{"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tumor necrosis factor alpha", "object_type": "GENE-Y"}, {"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "2-methoxyestradiol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tumor necrosis factor alpha", "object_type": "GENE-Y"}, {"subject": "2-methoxyestradiol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "The aromatase enzyme, which converts androstenedione to oestrone, regulates the availability of oestrogen to support the growth of hormone-dependent breast tumours.", "spo_list": [{"subject": "androstenedione", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "oestrone", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "oestrogen", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "Cytokines, such as interleukin 6 (IL-6) and tumour necrosis factor alpha (TNFalpha) or prostaglandin E(2) (PGE(2)), can stimulate aromatase activity.", "spo_list": [{"subject": "prostaglandin E(2)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "PGE(2)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "Paclitaxel inhibited basal and TNFalpha-stimulated aromatase activities by 88% and 91% respectively.", "spo_list": [{"subject": "Paclitaxel", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TNFalpha", "object_type": "GENE-Y"}, {"subject": "Paclitaxel", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "2-MeOE2 also reduced basal and TNFalpha-stimulated aromatase activities by 46% and 56% respectively.", "spo_list": [{"subject": "2-MeOE2", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TNFalpha", "object_type": "GENE-Y"}, {"subject": "2-MeOE2", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "Both paclitaxel and 2-meOE2 also inhibited stimulation of aromatase activity by IL-6 plus its soluble receptor and PGE(2).", "spo_list": [{"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "2-meOE2", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IL-6", "object_type": "GENE-Y"}, {"subject": "PGE(2)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "The enzymatic basis for the metabolism and inhibitory effects of valproic acid: dehydrogenation of valproyl-CoA by 2-methyl-branched-chain acyl-CoA dehydrogenase.", "spo_list": [{"subject": "valproyl-CoA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "2-methyl-branched-chain acyl-CoA dehydrogenase", "object_type": "GENE-Y"}]}
{"text": "We tested these five acyl-CoA dehydrogenases for their ability to dehydrogenate valproyl-CoA using pure enzyme preparations isolated from rat liver mitochondria.", "spo_list": [{"subject": "valproyl-CoA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "acyl-CoA dehydrogenases", "object_type": "GENE-N"}]}
{"text": "Valproyl-CoA was dehydrogenated at a significant rate (0.167 mumol/min per mg protein) only by rat 2-methyl-branched-chain acyl-CoA dehydrogenase.", "spo_list": [{"subject": "Valproyl-CoA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "2-methyl-branched-chain acyl-CoA dehydrogenase", "object_type": "GENE-Y"}]}
{"text": "Since four other human acyl-CoA dehydrogenases did not dehydrogenate isobutyryl-CoA, 2-methylbutyryl-CoA (obligatory intermediates from valine and isoleucine, respectively) nor valproyl-CoA, it is reasonable to assume that valproyl-CoA is dehydrogenated by 2-methyl-branch-chain acyl-CoA dehydrogenase in man as well.", "spo_list": [{"subject": "valproyl-CoA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "2-methyl-branch-chain acyl-CoA dehydrogenase", "object_type": "GENE-Y"}]}
{"text": "Valproyl-CoA, at 0.3 mM, moderately inhibited human acyl-CoA dehydrogenases with the exception of the long-chain enzyme.", "spo_list": [{"subject": "Valproyl-CoA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human acyl-CoA dehydrogenases", "object_type": "GENE-N"}]}
{"text": "5 mM free valproic acid inhibited the activities of various acyl-CoA dehydrogenases only very weakly.", "spo_list": [{"subject": "valproic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acyl-CoA dehydrogenases", "object_type": "GENE-N"}]}
{"text": "The ARB eprosartan is a nonbiphenyl nontetrazole angiotensin II type 1 receptor (AT1) antagonist, which acts to decrease total peripheral resistance.", "spo_list": [{"subject": "eprosartan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "angiotensin II type 1 receptor", "object_type": "GENE-Y"}, {"subject": "eprosartan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "AT1", "object_type": "GENE-Y"}]}
{"text": "Degradation of submandibular gland AQP5 by parasympathetic denervation of chorda tympani and its recovery by cevimeline, an M3 muscarinic receptor agonist.", "spo_list": [{"subject": "cevimeline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "M3 muscarinic receptor", "object_type": "GENE-Y"}, {"subject": "cevimeline", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AQP5", "object_type": "GENE-Y"}]}
{"text": "Administration of cevimeline hydrochloride, an M3 muscarinic receptor agonist (10 mg/kg for 7 days po), but not pilocarpine (0.3 mg/kg for 7 days po), recovered the AQP5 protein level reduced by CTD and increased the AQP1 protein level above the control one.", "spo_list": [{"subject": "cevimeline hydrochloride", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "M3 muscarinic receptor", "object_type": "GENE-Y"}, {"subject": "cevimeline hydrochloride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AQP1", "object_type": "GENE-Y"}, {"subject": "cevimeline hydrochloride", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AQP5", "object_type": "GENE-Y"}]}
{"text": "Administration of chloroquine (50 mg/kg for 7 days po), a denaturant of lysosomes, increased the AQP5 protein level reduced by CTD.", "spo_list": [{"subject": "chloroquine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AQP5", "object_type": "GENE-Y"}]}
{"text": "EPR studies on the photo-induced intermediates of ferric NO complexes of rat neuronal nitric oxide synthase trapped at low temperature.", "spo_list": [{"subject": "ferric NO", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "rat neuronal nitric oxide synthase", "object_type": "GENE-Y"}]}
{"text": "Although the nitric oxide (NO) complex of the ferric heme was EPR-silent, photo-illumination at 5 K to the NO complex of the ferric nNOS in the substrate-free form produced a new high spin EPR signal similar to that of the ferric heme of N(omega)-nitro-L-arginine-bound nNOS, suggesting that the photo-dissociated NO might move away from the heme.", "spo_list": [{"subject": "ferric heme", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "nNOS", "object_type": "GENE-Y"}, {"subject": "N(omega)-nitro-L-arginine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "nNOS", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "nNOS", "object_type": "GENE-Y"}]}
{"text": "Low photo-dissociability of NO in this complex indicated less restricted movement of the dissociated NO in the distal region of the heme, which might result in the rapid rebinding of the NO to the ferric heme at 5 K. In the presence of substrate L-arginine, derivatives, or product L-citrulline, the photo-products from the ferric NO complexes exhibited large novel EPR signals with a spin-coupled interaction between the ferric heme (S = 5/2) and the photolyzed NO (S = 1/2), suggesting a stereochemically restricted interaction between the photo-dissociated NO and the guanidino- or the ureido-group of the substrate analogues at the distal heme region of nNOS.", "spo_list": [{"subject": "guanidino", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "nNOS", "object_type": "GENE-Y"}, {"subject": "ureido", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "nNOS", "object_type": "GENE-Y"}, {"subject": "ferric heme", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "nNOS", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "nNOS", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "nNOS", "object_type": "GENE-Y"}, {"subject": "L-arginine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "nNOS", "object_type": "GENE-Y"}, {"subject": "L-citrulline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "nNOS", "object_type": "GENE-Y"}, {"subject": "ferric NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "nNOS", "object_type": "GENE-Y"}]}
{"text": "The photo-product from the NO complex produced from citrulline-bound nNOS might be the same intermediate species as that formed in the last step of the catalytic cycle.", "spo_list": [{"subject": "citrulline", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "nNOS", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "nNOS", "object_type": "GENE-Y"}]}
{"text": "Addition in the cultures of 4-deoxypyridoxine (dB6), a potent antagonist of vitamin B6 coenzymes, concurrently with the mitogen, inhibits the induction of SHMT.", "spo_list": [{"subject": "4-deoxypyridoxine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SHMT", "object_type": "GENE-N"}]}
{"text": "The aim of this study was to determine if macaque represents a suitable species for the pre-clinical evaluation of novel CCR5 antagonists, such as maraviroc (UK-427,857).", "spo_list": [{"subject": "maraviroc", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CCR5", "object_type": "GENE-Y"}, {"subject": "UK-427,857", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CCR5", "object_type": "GENE-Y"}]}
{"text": "To do this we cloned and expressed CCR5 from rhesus macaque and compared the binding properties of [125I]-MIP-1beta and [3H]-maraviroc with human recombinant CCR5.", "spo_list": [{"subject": "125I", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human recombinant CCR5", "object_type": "GENE-Y"}, {"subject": "[3H]-maraviroc", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human recombinant CCR5", "object_type": "GENE-Y"}]}
{"text": "[125I]-MIP-1beta bound with similar high affinity to CCR5 from macaque (K(d) = 0.24 +/- 0.05 nM) and human (K(d) = 0.23 +/- 0.05 nM) and with similar kinetic properties.", "spo_list": [{"subject": "125I", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CCR5", "object_type": "GENE-N"}]}
{"text": "Maraviroc inhibited binding of [125I]-MIP-1beta to CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 1.24 nM and 7.18 +/- 0.93 nM, respectively) and antagonised MIP-1beta induced intracellular calcium release mediated through CCR5 from macaque and human with similar potency (IC50 = 17.50 +/- 3.30 nM and 12.07 +/- 1.89, respectively).", "spo_list": [{"subject": "125I", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CCR5", "object_type": "GENE-N"}, {"subject": "Maraviroc", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CCR5", "object_type": "GENE-N"}, {"subject": "Maraviroc", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CCR5", "object_type": "GENE-N"}]}
{"text": "[3H]-maraviroc bound with high affinity to CCR5 from macaque (K(d) = 1.36+/-0.07 nM) and human (K(d) = 0.86 +/- 0.08 nM), but was found to dissociate approximately 10-fold more quickly from macaque CCR5.", "spo_list": [{"subject": "[3H]-maraviroc", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CCR5", "object_type": "GENE-N"}, {"subject": "[3H]-maraviroc", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "macaque CCR5", "object_type": "GENE-Y"}]}
{"text": "However, as with the human receptor, maraviroc was shown to be a high affinity, potent functional antagonist of macaque CCR5 thereby indicating that the macaque should be a suitable species in which to evaluate the pharmacology, safety and potential mechanism-related toxicology of novel CCR5 antagonists.", "spo_list": [{"subject": "maraviroc", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "macaque CCR5", "object_type": "GENE-Y"}, {"subject": "maraviroc", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CCR5", "object_type": "GENE-Y"}]}
{"text": "PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency.", "spo_list": [{"subject": "pyrazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "KAT II", "object_type": "GENE-Y"}, {"subject": "PF-04859989", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "KAT II", "object_type": "GENE-Y"}]}
{"text": "The structure-based design, synthesis, and biological evaluation of a new pyrazole series of irreversible KAT II inhibitors are described herein.", "spo_list": [{"subject": "pyrazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "KAT II", "object_type": "GENE-Y"}]}
{"text": "The modification of the inhibitor scaffold of 1 and 2 from a dihydroquinolinone core to a tetrahydropyrazolopyridinone core led to discovery of a new series of potent KAT II inhibitors with excellent physicochemical properties.", "spo_list": [{"subject": "dihydroquinolinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "KAT II", "object_type": "GENE-Y"}, {"subject": "tetrahydropyrazolopyridinone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "KAT II", "object_type": "GENE-Y"}]}
{"text": "The herbicide paraquat (PQ) is a P-gp substrate responsible for thousands of fatal intoxications worldwide that still lacks an effective antidote.", "spo_list": [{"subject": "paraquat", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P-gp", "object_type": "GENE-N"}]}
{"text": "The aim of the present work was to evaluate the effectiveness of such an antidote by testing whether doxorubicin (DOX), a known P-gp inducer, could efficiently protect Caco-2 cells against PQ cytotoxicity, 6 h after the incubation with the herbicide, reflecting a real-life intoxication scenario.", "spo_list": [{"subject": "doxorubicin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "P-gp", "object_type": "GENE-N"}, {"subject": "DOX", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "P-gp", "object_type": "GENE-N"}]}
{"text": "In conclusion, in this cellular model, DOX effectively protects against PQ toxicity by inducing P-gp and through the interaction with the choline transporter, suggesting that compounds presenting this double feature of promoting the efflux and limiting the uptake of PQ could be used as effective antidotes to treat intoxications.", "spo_list": [{"subject": "DOX", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "P-gp", "object_type": "GENE-N"}]}
{"text": "The affinity and functional profile of opioids possessing activity at the nociceptin receptor was determined using [3H]nociceptin and nociceptin-stimulated [35S]GTPgammaS binding.", "spo_list": [{"subject": "[35S]GTPgammaS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "nociceptin receptor", "object_type": "GENE-Y"}]}
{"text": "The mu-opioid receptor-selective agonist lofentanil potently and competitively displaced [3H]nociceptin at rat brain receptors (IC(50) 62 nM).", "spo_list": [{"subject": "lofentanil", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "mu-opioid receptor", "object_type": "GENE-Y"}]}
{"text": "Lofentanil exhibited full agonism for enhancement of [35S]GTPgammaS binding to human recombinant ORL1 receptors (EC(50) 50 nM).", "spo_list": [{"subject": "[35S]GTPgammaS", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ORL1", "object_type": "GENE-Y"}, {"subject": "Lofentanil", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "ORL1", "object_type": "GENE-Y"}]}
{"text": "The related piperidines ohmefentanyl and sufentanil and the nonselective opioid receptor agonist etorphine were less potent nociceptin receptor agonists.", "spo_list": [{"subject": "etorphine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "opioid receptor", "object_type": "GENE-N"}, {"subject": "etorphine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "nociceptin receptor", "object_type": "GENE-Y"}, {"subject": "piperidines", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "nociceptin receptor", "object_type": "GENE-Y"}, {"subject": "ohmefentanyl", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "nociceptin receptor", "object_type": "GENE-Y"}, {"subject": "sufentanil", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "nociceptin receptor", "object_type": "GENE-Y"}]}
{"text": "The kappa(1)+kappa(3)-opioid receptor agonist/mu-opioid receptor antagonist naloxone benzoylhydrazone was a pure antagonist at both rat brain and human ORL1 receptors.", "spo_list": [{"subject": "naloxone benzoylhydrazone", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "mu-opioid receptor", "object_type": "GENE-Y"}, {"subject": "naloxone benzoylhydrazone", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "ORL1", "object_type": "GENE-N"}]}
{"text": "The nonselective opioid receptor partial agonist buprenorphine and the nonselective opioid receptor antagonist (-)-quadazocine exhibited pure antagonism at rat brain receptors, but displayed partial agonism at human ORL1 receptors.", "spo_list": [{"subject": "buprenorphine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "opioid receptor", "object_type": "GENE-N"}, {"subject": "(-)-quadazocine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "opioid receptor", "object_type": "GENE-N"}, {"subject": "(-)-quadazocine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "human ORL1", "object_type": "GENE-Y"}]}
{"text": "Bisphenol A (BPA) and diethylstilbestrol (DES) are endocrine-disrupting chemicals that interact with the human pregnane X receptor (PXR).", "spo_list": [{"subject": "Bisphenol A", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human pregnane X receptor", "object_type": "GENE-Y"}, {"subject": "BPA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human pregnane X receptor", "object_type": "GENE-Y"}, {"subject": "diethylstilbestrol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human pregnane X receptor", "object_type": "GENE-Y"}, {"subject": "DES", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human pregnane X receptor", "object_type": "GENE-Y"}, {"subject": "Bisphenol A", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PXR", "object_type": "GENE-Y"}, {"subject": "BPA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PXR", "object_type": "GENE-Y"}, {"subject": "diethylstilbestrol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PXR", "object_type": "GENE-Y"}, {"subject": "DES", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PXR", "object_type": "GENE-Y"}]}
{"text": "CYP3A4 enzyme is essential in the hydroxylation of steroid hormones and is regulated by PXR.", "spo_list": [{"subject": "steroid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A4", "object_type": "GENE-Y"}]}
{"text": "Both BPA and DES (10-50Î¼M) caused a significant activation of the CYP3A4 promoter via the PXR in the DPX2 human hepatoma cell line.", "spo_list": [{"subject": "BPA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CYP3A4 promoter", "object_type": "GENE-N"}, {"subject": "DES", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CYP3A4 promoter", "object_type": "GENE-N"}, {"subject": "BPA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PXR", "object_type": "GENE-Y"}, {"subject": "DES", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PXR", "object_type": "GENE-Y"}]}
{"text": "BPA and DES treated DPX2 cells demonstrated increased expression of CYP3A4 mRNA, and increased enzyme activity.", "spo_list": [{"subject": "BPA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP3A4", "object_type": "GENE-Y"}, {"subject": "DES", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP3A4", "object_type": "GENE-Y"}]}
{"text": "In summary, BPA, in concentrations relevant to current safety levels of human exposure, activates the human PXR and demonstrates an increase in CYP3A4 mRNA expression and enzyme activity.", "spo_list": [{"subject": "BPA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "human PXR", "object_type": "GENE-Y"}, {"subject": "BPA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP3A4", "object_type": "GENE-Y"}, {"subject": "BPA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CYP3A4", "object_type": "GENE-Y"}]}
{"text": "IL-1, TNF alpha, PGE2, parathyroid hormone (PTH) and 1 alpha,25-dihydroxyvitamin D3 (1 alpha,25(OH)2D3) similarly induced production of IL-11 by osteoblasts, but IL-6, IL-4, and TGF beta did not.", "spo_list": [{"subject": "PGE2", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-11", "object_type": "GENE-Y"}, {"subject": "1 alpha,25-dihydroxyvitamin D3", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-11", "object_type": "GENE-Y"}, {"subject": "1 alpha,25(OH)2D3", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-11", "object_type": "GENE-Y"}]}
{"text": "Osteotropic factors did not modulate IL-11R alpha mRNA at 24 h, but steady-state gp130 mRNA expression in osteoblasts was upregulated by 1 alpha,25(OH)2D3, PTH, or IL-1.", "spo_list": [{"subject": "1 alpha,25(OH)2D3", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "gp130", "object_type": "GENE-Y"}]}
{"text": "UBR2 expression in C2C12 myotubes was up-regulated by conditioned medium from Lewis lung carcinoma cells or C26 colon adenocarcinoma cells, which was blocked by a pharmacological inhibitor of p38Î±/Î² mitogen-activated protein kinase (MAPK), SB202190.", "spo_list": [{"subject": "SB202190", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38Î±/Î² mitogen-activated protein kinase", "object_type": "GENE-N"}, {"subject": "SB202190", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAPK", "object_type": "GENE-N"}]}
{"text": "In addition, UBR2 up-regulation required p38Î²-mediated phosphorylation of CCAAT/enhancer binding protein (C/EBP)-Î² Thr-188, which was critical to C/EBPÎ² binding to the UBR2 promoter.", "spo_list": [{"subject": "Thr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "CCAAT/enhancer binding protein (C/EBP)-Î²", "object_type": "GENE-Y"}]}
{"text": "Signaling mechanism of tumor cell-induced up-regulation of E3 ubiquitin ligase UBR2.", "spo_list": [{"subject": "SB202190", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38Î±/Î² mitogen-activated protein kinase", "object_type": "GENE-N"}, {"subject": "SB202190", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAPK", "object_type": "GENE-N"}, {"subject": "Thr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "CCAAT/enhancer binding protein (C/EBP)-Î²", "object_type": "GENE-Y"}]}
{"text": "Calcium-permeable acid-sensing ion channel is a molecular target of the neurotoxic metal ion lead.", "spo_list": [{"subject": "Calcium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "acid-sensing ion channel", "object_type": "GENE-N"}]}
{"text": "Here we showed that lead (Pb2+), a well known neurotoxic metal ion, reversibly and concentration-dependently inhibited ASIC currents in the acutely dissociated spinal dorsal horn and hippocampal CA1 neurons of rats.", "spo_list": [{"subject": "Pb2+", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ASIC", "object_type": "GENE-N"}]}
{"text": "Moreover, Pb2+ inhibited the ASIC-mediated membrane depolarization and the elevation of intracellular Ca2+ concentration.", "spo_list": [{"subject": "Pb2+", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ASIC", "object_type": "GENE-N"}, {"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ASIC", "object_type": "GENE-N"}]}
{"text": "In addition, we compared the effect of Pb2+ with that of Ca2+ or amiloride to explore the possible interactions of Pb2+ and Ca2+ in regulating ASICs, and we found that Pb2+ inhibited ASIC currents independent of the amiloride/Ca2+ blockade.", "spo_list": [{"subject": "Pb2+", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ASIC", "object_type": "GENE-N"}]}
{"text": "Because ASIC1b and -3 subunits are mainly expressed in peripheral neurons, our data identified ASIC1a-containing Ca2+-permeable ASIC as a novel central target of Pb2+ action, which may contribute to Pb2+ neurotoxicity.", "spo_list": [{"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ASIC1a", "object_type": "GENE-Y"}, {"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ASIC", "object_type": "GENE-N"}]}
{"text": "The crystallographic structure of human coagulation factor VIIa/tissue factor complex bound with calcium ions was used to model the solution structure of the light chain of factor VIIa (residues 1-142) in the absence of tissue factor.", "spo_list": [{"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human coagulation factor VIIa", "object_type": "GENE-Y"}, {"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "tissue factor", "object_type": "GENE-Y"}]}
{"text": "Removal of the EGF1-bound calcium ion is shown by simulation to lead to minor structural changes within the EGF1 domain, but also leads to substantial relative reorientation of the Gla and EGF1 domains.", "spo_list": [{"subject": "calcium", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EGF1", "object_type": "GENE-N"}]}
{"text": "BACKGROUND: The gene DRD4, coding for dopamine receptor D4, was considered a candidate for association with schizophrenia based on its upregulation in postmortem schizophrenic brain and affinity for clozapine.", "spo_list": [{"subject": "clozapine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "dopamine receptor D4", "object_type": "GENE-Y"}, {"subject": "clozapine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "DRD4", "object_type": "GENE-Y"}]}
{"text": "Activation of AMPK using AICAR resulted in STIM1 phosphorylation on serine residues and prevented PAR-1-induced Ca2+ entry.", "spo_list": [{"subject": "AICAR", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AMPK", "object_type": "GENE-Y"}, {"subject": "AICAR", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "STIM1", "object_type": "GENE-Y"}, {"subject": "serine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "STIM1", "object_type": "GENE-Y"}, {"subject": "AICAR", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "PAR-1", "object_type": "GENE-Y"}]}
{"text": "Further, AICAR pretreatment blocked PAR-1-induced increase in permeability of mouse-lung microvessels.", "spo_list": [{"subject": "AICAR", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PAR-1", "object_type": "GENE-Y"}]}
{"text": "Interestingly, SB203580, a selective inhibitor of p38 MAPK, blocked STIM1 phosphorylation and led to sustained STIM1-puncta formation and Ca2+ entry.", "spo_list": [{"subject": "SB203580", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "SB203580", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAPK", "object_type": "GENE-N"}, {"subject": "SB203580", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "STIM1", "object_type": "GENE-Y"}]}
{"text": "A number of integral membrane G protein-coupled receptors (GPCRs) share common structural features (including palmytoilated aminoacid residues and consensus sequences specific for interaction with cholesterol) that allow them to interact with lipid rafts, membrane cholesterol-rich microdomains able to regulate GPCR signalling and functions.", "spo_list": [{"subject": "palmytoilated aminoacid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GPCRs", "object_type": "GENE-N"}, {"subject": "palmytoilated aminoacid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "G protein-coupled receptors", "object_type": "GENE-N"}]}
{"text": "Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3Î² (GSK-3Î²).", "spo_list": [{"subject": "benzothiazepinones", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GSK-3Î²", "object_type": "GENE-Y"}, {"subject": "benzothiazepinones", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "glycogen synthase kinase-3Î²", "object_type": "GENE-Y"}, {"subject": "BTZs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "glycogen synthase kinase-3Î²", "object_type": "GENE-Y"}, {"subject": "BTZs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GSK-3Î²", "object_type": "GENE-Y"}, {"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "glycogen synthase kinase-3Î²", "object_type": "GENE-Y"}, {"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GSK-3Î²", "object_type": "GENE-Y"}]}
{"text": "Glycogen synthase kinase-3Î² (GSK-3Î²) plays a key role in type II diabetes and Alzheimer's diseases, to which non-ATP competitive inhibitors represent an effectively therapeutical approach due to their good specificity.", "spo_list": [{"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Glycogen synthase kinase-3Î²", "object_type": "GENE-Y"}, {"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GSK-3Î²", "object_type": "GENE-Y"}]}
{"text": "Herein, a series of small molecules benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of GSK-3Î² have been designed and synthesized.", "spo_list": [{"subject": "benzothiazepinones", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GSK-3Î²", "object_type": "GENE-Y"}, {"subject": "BTZs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GSK-3Î²", "object_type": "GENE-Y"}, {"subject": "ATP", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "GSK-3Î²", "object_type": "GENE-Y"}]}
{"text": "2. Rats were adrenalectomized (ADX), and 7 days after this procedure the intradermal injection of B(1) receptor agonist des-Arg(9)-BK produced a significant increase in the paw volume, while only a weak effect was observed in sham-operated animals.", "spo_list": [{"subject": "des-Arg(9)-BK", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "B(1) receptor", "object_type": "GENE-Y"}]}
{"text": "A similar increase in the contractile responses mediated by B(1) agonist des-Arg(9)-BK was also observed in the rat portal vein in vitro.", "spo_list": [{"subject": "des-Arg(9)-BK", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "B(1)", "object_type": "GENE-Y"}]}
{"text": "5. Additionally, both paw oedema and contraction of portal vein mediated by B(1) agonist des-Arg(9)-BK in ADX rats, were markedly inhibited by treatment with dexamethasone, or COX-2 inhibitor meloxican, or with the NF-kappaB inhibitor PDTC.", "spo_list": [{"subject": "des-Arg(9)-BK", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "B(1)", "object_type": "GENE-Y"}, {"subject": "meloxican", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "PDTC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}]}
{"text": "It was also confirmed that the treatment of ADX rats with dexamethasone, PDTC or dexamethasone plus PDTC completely inhibit NF-kappaB activation caused by absence of endogenous glucucorticoid.", "spo_list": [{"subject": "PDTC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}, {"subject": "dexamethasone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}, {"subject": "dexamethasone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}, {"subject": "PDTC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}]}
{"text": "5-HT also enhanced pituitary adenylate cyclase activating peptide (PACAP) 38-induced cAMP levels and CFTR currents in oocytes expressing PACAP receptor, CFTR and 5-HT(1A)R. The 5-HT-induced enhancement of G(s)-coupled receptor-mediated currents was abrogated by pretreatment with pertussis toxin (PTX) and coexpression of G transducin alpha (G(t)alpha).", "spo_list": [{"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "pituitary adenylate cyclase activating peptide", "object_type": "GENE-Y"}, {"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PACAP", "object_type": "GENE-Y"}]}
{"text": "A novel series of pyrido[2,3-d]pyrimidines as selective and potent DHFR inhibitors against these opportunistic infections are presented.", "spo_list": [{"subject": "pyrido[2,3-d]pyrimidines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DHFR", "object_type": "GENE-Y"}]}
{"text": "These findings suggest that RhBG and RhCG may play important and cell-specific roles in ammonium transport and signaling in these regions of the kidney.", "spo_list": [{"subject": "ammonium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "RhBG", "object_type": "GENE-Y"}, {"subject": "ammonium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "RhCG", "object_type": "GENE-Y"}]}
{"text": "Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2.", "spo_list": [{"subject": "Statins", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p21", "object_type": "GENE-Y"}, {"subject": "Statins", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "histone deacetylase", "object_type": "GENE-N"}]}
{"text": "Statins are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors broadly used for the control of hypercholesterolemia.", "spo_list": [{"subject": "Statins", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "3-hydroxy-3-methylglutaryl-CoA reductase", "object_type": "GENE-Y"}]}
{"text": "Computational modeling showed the direct interaction of the carboxylic acid moiety of statins with the catalytic site of HDAC2.", "spo_list": [{"subject": "carboxylic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "HDAC2", "object_type": "GENE-Y"}]}
{"text": "In the subsequent enzymatic assay, it was shown that lovastatin inhibited HDAC2 activity competitively with a K(i) value of 31.6 micromol/L.", "spo_list": [{"subject": "lovastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC2", "object_type": "GENE-Y"}]}
{"text": "Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta.", "spo_list": [{"subject": "sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}]}
{"text": "The aim of this study was to define the molecular mechanism by which sulfasalazine inhibits NF-kappaB activation.", "spo_list": [{"subject": "sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}]}
{"text": "RESULTS: NF-kappaB/Rel activity induced by tumor necrosis factor alpha, 12-O-tetradecanoylphorbol-13-acetate, or overexpression of NF-kappaB-inducing kinase, IKK-alpha, IKK-beta, or constitutively active IKK-alpha and IKK-beta mutants was inhibited dose dependently by sulfasalazine.", "spo_list": [{"subject": "12-O-tetradecanoylphorbol-13-acetate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "NF-kappaB", "object_type": "GENE-N"}, {"subject": "12-O-tetradecanoylphorbol-13-acetate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Rel", "object_type": "GENE-Y"}, {"subject": "sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}, {"subject": "sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Rel", "object_type": "GENE-Y"}, {"subject": "sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB-inducing kinase", "object_type": "GENE-Y"}, {"subject": "sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IKK-alpha", "object_type": "GENE-Y"}, {"subject": "sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IKK-beta", "object_type": "GENE-Y"}, {"subject": "sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IKK-alpha", "object_type": "GENE-Y"}, {"subject": "sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IKK-beta", "object_type": "GENE-Y"}]}
{"text": "Sulfasalazine inhibited tumor necrosis factor alpha-induced activation of endogenous IKK in Jurkat T cells and SW620 colon cells, as well as the catalytic activity of purified IKK-alpha and IKK-beta in vitro.", "spo_list": [{"subject": "Sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "tumor necrosis factor alpha", "object_type": "GENE-Y"}, {"subject": "Sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IKK", "object_type": "GENE-N"}, {"subject": "Sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IKK-alpha", "object_type": "GENE-Y"}, {"subject": "Sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IKK-beta", "object_type": "GENE-Y"}]}
{"text": "The decrease in substrate phosphorylation by IKK-alpha and -beta is associated with a decrease in autophosphorylation of IKKs and can be antagonized by excess adenosine triphosphate.", "spo_list": [{"subject": "adenosine triphosphate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IKKs", "object_type": "GENE-N"}]}
{"text": "The suppression of NF-kappaB activation by inhibition of the IKKs contributes to the well-known anti-inflammatory and immunosuppressive effects of sulfasalazine.", "spo_list": [{"subject": "sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "NF-kappaB", "object_type": "GENE-N"}, {"subject": "sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IKKs", "object_type": "GENE-N"}]}
{"text": "Amino-functionalized MCM-41 (AM-41) shows an effect on the amount of OVA binding, with 2.5-fold increase in binding capacity (72 mg OVA/g AM-41) compared to nonfunctionalized MCM-41 (29 mg OVA/g MCM-41).", "spo_list": [{"subject": "Amino", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "OVA", "object_type": "GENE-Y"}, {"subject": "MCM-41", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "OVA", "object_type": "GENE-Y"}, {"subject": "Amino", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "OVA", "object_type": "GENE-Y"}, {"subject": "MCM-41", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "OVA", "object_type": "GENE-Y"}]}
{"text": "UNLABELLED: The effect of dopamine D2 receptor antagonists, such as chlorpromazine and haloperidol, on pupil size in awake subjects suggests that these drugs might also alter pupillary reflex dilation and pupil size during general anesthesia.", "spo_list": [{"subject": "chlorpromazine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D2 receptor", "object_type": "GENE-Y"}, {"subject": "haloperidol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "dopamine D2 receptor", "object_type": "GENE-Y"}]}
{"text": "Sal toxicity coincided with reduced pAkt level and its downstream effectors: pCREB, pGSK-3Î², Bcl-2 and neurotrophins GDNF, BDNF suggesting repressed PI3K/Akt signaling.", "spo_list": [{"subject": "Sal", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "pAkt", "object_type": "GENE-N"}, {"subject": "Sal", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "pCREB", "object_type": "GENE-N"}, {"subject": "Sal", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "pGSK-3Î²", "object_type": "GENE-Y"}, {"subject": "Sal", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Bcl-2", "object_type": "GENE-Y"}, {"subject": "Sal", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "neurotrophins", "object_type": "GENE-N"}, {"subject": "Sal", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "GDNF", "object_type": "GENE-Y"}, {"subject": "Sal", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "BDNF", "object_type": "GENE-Y"}, {"subject": "Sal", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "PI3K", "object_type": "GENE-N"}, {"subject": "Sal", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Akt", "object_type": "GENE-N"}]}
{"text": "This was confirmed on adding LY294002 the PI3K inhibitor which abolished the protection.", "spo_list": [{"subject": "LY294002", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PI3K", "object_type": "GENE-N"}]}
{"text": "The failure of the myometrium to respond to ritodrine (desensitization) was associated with significant reductions in agonist-induced cyclic adenosine monophosphate production and beta 2-adrenergic receptor concentration in myometrial tissue collected from these animals compared with the saline solution-treated controls.", "spo_list": [{"subject": "ritodrine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "beta 2-adrenergic receptor", "object_type": "GENE-Y"}]}
{"text": "In addition to OT and to a lesser extent AVP (pitressin), a number of OT and AVP analogues; such as carbetocin (OT agonist) dDAVP (desmopressin, V(2) agonist), terlipressin (V(1a) agonist), felypressin (V(1a) agonist) and atosiban (Tractocile OT antagonist) are also in clinical use.", "spo_list": [{"subject": "carbetocin", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "OT", "object_type": "GENE-Y"}, {"subject": "desmopressin", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "V(2)", "object_type": "GENE-Y"}, {"subject": "terlipressin", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "V(1a)", "object_type": "GENE-Y"}, {"subject": "felypressin", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "V(1a)", "object_type": "GENE-Y"}, {"subject": "atosiban", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "OT", "object_type": "GENE-Y"}, {"subject": "Tractocile", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "OT", "object_type": "GENE-Y"}]}
{"text": "While a number of orally active non-peptide V(2) antagonists (Vaptans); notably, Tolvaptan, Lixivaptan and Satavaptan, are currently in Phase III clinical trials; to date, only the mixed V(2)/V(1a), antagonist Conivaptan (Vaprisol), has been approved by the US FDA for clinical use (by i.v. administration), for the treatment of euvolemic and hypervolemic hyponatremia in hospitalized patients.", "spo_list": [{"subject": "Tolvaptan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "V(2)", "object_type": "GENE-Y"}, {"subject": "Lixivaptan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "V(2)", "object_type": "GENE-Y"}, {"subject": "Satavaptan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "V(2)", "object_type": "GENE-Y"}, {"subject": "Conivaptan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "V(2)", "object_type": "GENE-Y"}, {"subject": "Conivaptan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "V(1a)", "object_type": "GENE-Y"}, {"subject": "Vaprisol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "V(2)", "object_type": "GENE-Y"}, {"subject": "Vaprisol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "V(1a)", "object_type": "GENE-Y"}]}
{"text": "In all cases at both the 5-HT2A and 5-HT2C receptors, the affinities of the isomers of MDMA and MDA were at least 2-3 orders of magnitude less than 5-HT.", "spo_list": [{"subject": "MDMA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT2A", "object_type": "GENE-Y"}, {"subject": "MDA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT2A", "object_type": "GENE-Y"}, {"subject": "MDMA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT2C", "object_type": "GENE-Y"}, {"subject": "MDA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT2C", "object_type": "GENE-Y"}, {"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT2A", "object_type": "GENE-Y"}, {"subject": "5-HT", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT2C", "object_type": "GENE-Y"}]}
{"text": "Reactive Metabolite Trapping Studies on Imidazo- and 2-Methylimidazo[2,1-b]thiazole-based Inverse Agonists of the Ghrelin Receptor.", "spo_list": [{"subject": "Imidazo- and 2-Methylimidazo[2,1-b]thiazole", "subject_type": "CHEMICAL", "predicate": "AGONIST-INHIBITOR", "object": "Ghrelin Receptor", "object_type": "GENE-Y"}]}
{"text": "The current study examined the bioactivation potential of ghrelin receptor inverse agonists, 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone (1) and 1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone (2), containing a fused imidazo[2,1-b]thiazole motif in the core structure.", "spo_list": [{"subject": "1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(imidazo[2,1-b]thiazol-6-yl)ethanone", "subject_type": "CHEMICAL", "predicate": "AGONIST-INHIBITOR", "object": "ghrelin receptor", "object_type": "GENE-Y"}, {"subject": "1-(2-(2-chloro-4-(2H-1,2,3-triazol-2-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)-2-(2-methylimidazo[2,1-b]thiazol-6-yl)ethanone", "subject_type": "CHEMICAL", "predicate": "AGONIST-INHIBITOR", "object": "ghrelin receptor", "object_type": "GENE-Y"}, {"subject": "imidazo[2,1-b]thiazole", "subject_type": "CHEMICAL", "predicate": "AGONIST-INHIBITOR", "object": "ghrelin receptor", "object_type": "GENE-Y"}]}
{"text": "Hydrogen sulfide increases nitric oxide production with calcium-dependent activation of endothelial nitric oxide synthase in endothelial cells.", "spo_list": [{"subject": "Hydrogen sulfide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "endothelial nitric oxide synthase", "object_type": "GENE-Y"}, {"subject": "nitric oxide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "endothelial nitric oxide synthase", "object_type": "GENE-Y"}]}
{"text": "The NaHS-induced NO production was partially blocked by inhibitors of ryanodine receptor (dantrolene) or inositol 1,4,5-triphosphate receptor (xestospongin C).", "spo_list": [{"subject": "dantrolene", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ryanodine receptor", "object_type": "GENE-N"}, {"subject": "xestospongin C", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "inositol 1,4,5-triphosphate receptor", "object_type": "GENE-N"}]}
{"text": "NaHS significantly increased intracellular calcium concentrations, and this effect was attenuated by dantrolene or xestospongin C. NaHS induced phosphorylation of eNOS at the activating phosphoserine residue 1179.", "spo_list": [{"subject": "NaHS", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "eNOS", "object_type": "GENE-Y"}, {"subject": "phosphoserine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "eNOS", "object_type": "GENE-Y"}]}
{"text": "The NaHS-induced eNOS phosphorylation and NO production were not affected by a PI3K/Akt inhibitor (wortmannin).", "spo_list": [{"subject": "NaHS", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "eNOS", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "eNOS", "object_type": "GENE-Y"}, {"subject": "wortmannin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PI3K", "object_type": "GENE-N"}, {"subject": "wortmannin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}]}
{"text": "The data of this study suggest that H(2)S directly acts on endothelial cells to induce eNOS activation and NO production by releasing calcium from the intracellular store in endoplasmic reticulum, which may explain one of mechanisms of its vasodilator function.", "spo_list": [{"subject": "H(2)S", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "eNOS", "object_type": "GENE-Y"}, {"subject": "NO", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "eNOS", "object_type": "GENE-Y"}]}
{"text": "Discovery of aryl ureas and aryl amides as potent and selective histamine H3 receptor antagonists for the treatment of obesity (Part I).", "spo_list": [{"subject": "aryl ureas", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H3 receptor", "object_type": "GENE-Y"}, {"subject": "aryl amides", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H3 receptor", "object_type": "GENE-Y"}]}
{"text": "A series of structurally novel aryl ureas was derived from optimization of the HTS lead as selective histamine H3 receptor (H3R) antagonists.", "spo_list": [{"subject": "aryl ureas", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H3 receptor", "object_type": "GENE-Y"}, {"subject": "aryl ureas", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "H3R", "object_type": "GENE-Y"}]}
{"text": "Pharmacological inhibitors of Fatty Acid Synthase (FASN)--catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents?", "spo_list": [{"subject": "fatty acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Fatty Acid Synthase", "object_type": "GENE-Y"}, {"subject": "fatty acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "FASN", "object_type": "GENE-Y"}]}
{"text": "The expression and activity of Fatty Acid Synthase (FASN; the sole enzyme capable of the reductive de novo synthesis of long-chain fatty acids from acetyl-CoA, malonyl-CoA, and nicotinamide adenine dinucleotide phosphate -NADPH-) is extremely low in nearly all nonmalignant adult tissues, whereas it is significantly up-regulated or activated in many cancer types, thus creating the potential for a large therapeutic index.", "spo_list": [{"subject": "long-chain fatty acids", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Fatty Acid Synthase", "object_type": "GENE-Y"}, {"subject": "long-chain fatty acids", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "FASN", "object_type": "GENE-Y"}, {"subject": "acetyl-CoA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Fatty Acid Synthase", "object_type": "GENE-Y"}, {"subject": "acetyl-CoA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FASN", "object_type": "GENE-Y"}, {"subject": "malonyl-CoA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Fatty Acid Synthase", "object_type": "GENE-Y"}, {"subject": "malonyl-CoA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FASN", "object_type": "GENE-Y"}, {"subject": "nicotinamide adenine dinucleotide phosphate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Fatty Acid Synthase", "object_type": "GENE-Y"}, {"subject": "nicotinamide adenine dinucleotide phosphate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FASN", "object_type": "GENE-Y"}, {"subject": "NADPH", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Fatty Acid Synthase", "object_type": "GENE-Y"}, {"subject": "NADPH", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FASN", "object_type": "GENE-Y"}]}
{"text": "Since the pioneering observation that inhibition of FASN activity by the mycotoxin cerulenin preferentially kills cancer cells and retards the growth of tumors in xenografts models, numerous in vitro and in vivo studies have confirmed the potential of FASN as a target for antineoplastic intervention.", "spo_list": [{"subject": "cerulenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FASN", "object_type": "GENE-Y"}]}
{"text": "Other FASN inhibitors such as the cerulenin derivative C75, the beta-lactone orlistat, the green tea polyphenol epigallocatechin-3-gallate (EGCG) and other naturally occurring flavonoids (i.e., luteolin, quercetin, and kaempferol), as well as the antibiotic triclosan, have been identified and have been shown to limit cancer cell growth by inducing apoptotic cell death.", "spo_list": [{"subject": "cerulenin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FASN", "object_type": "GENE-Y"}, {"subject": "beta-lactone orlistat", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FASN", "object_type": "GENE-Y"}, {"subject": "polyphenol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FASN", "object_type": "GENE-Y"}, {"subject": "epigallocatechin-3-gallate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FASN", "object_type": "GENE-Y"}, {"subject": "EGCG", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FASN", "object_type": "GENE-Y"}, {"subject": "flavonoids", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FASN", "object_type": "GENE-Y"}, {"subject": "luteolin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FASN", "object_type": "GENE-Y"}, {"subject": "quercetin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FASN", "object_type": "GENE-Y"}, {"subject": "kaempferol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FASN", "object_type": "GENE-Y"}, {"subject": "triclosan", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "FASN", "object_type": "GENE-Y"}]}
{"text": "Though the exact mode of action of these FASN inhibitors is under discussion, it has been revealed that depletion of end-product fatty acids, toxic intracellular accumulation of supra-physiological concentrations of the FASN substrate malonyl-CoA and/or limited membrane synthesis and/or functioning by altered production of phospholipids partitioning into detergent-resistant membrane microdomains (lipid raft-aggregates), can explain, at least in part, the cytostatic, cytotoxic as well as the apoptotic effects occurring upon pharmacological inhibition of FASN activity in cancer cells.", "spo_list": [{"subject": "malonyl-CoA", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FASN", "object_type": "GENE-Y"}, {"subject": "fatty acids", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "FASN", "object_type": "GENE-Y"}]}
{"text": "We developed a computational model of the hypothalamic-pituitary-gonadal (HPG) axis in female fathead minnows to predict dose-response and time-course (DRTC) behaviors for endocrine effects of the aromatase inhibitor, fadrozole (FAD).", "spo_list": [{"subject": "fadrozole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}, {"subject": "FAD", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "aromatase", "object_type": "GENE-Y"}]}
{"text": "We demonstrate unknown facets of calnuc, which is a serine protease in which Ser-378 of GXSXG motif, Asp-328 of DTG motif, and His-339 form the \"catalytic triad,\" locating the enzyme active site in the C-terminal region.", "spo_list": [{"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GXSXG motif", "object_type": "GENE-N"}, {"subject": "Asp", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "DTG motif", "object_type": "GENE-N"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "serine protease", "object_type": "GENE-N"}, {"subject": "Asp", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "serine protease", "object_type": "GENE-N"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "calnuc", "object_type": "GENE-Y"}, {"subject": "Asp", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "calnuc", "object_type": "GENE-Y"}, {"subject": "His", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "serine protease", "object_type": "GENE-N"}, {"subject": "His", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "calnuc", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "calnuc", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "serine protease", "object_type": "GENE-N"}]}
{"text": "Analogous to the active site of Zn(2+) carboxypeptidases, calnuc has two high affinity (K(d) â¼ 20 nm), well conserved Zn(2+)-binding sites near its N terminus, although it is inactive as a peptidase.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "calnuc", "object_type": "GENE-Y"}]}
{"text": "Zn(2+) binding allosterically and negatively regulates the serine protease activity of calnuc, inhibition being caused by an \"open to close\" change in its conformation not seen upon Ca(2+) binding.", "spo_list": [{"subject": "Ca(2+)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "calnuc", "object_type": "GENE-Y"}]}
{"text": "Calnuc, therefore, exists dynamically in two different forms, (i) as a Ca(2+)-binding protein in Zn(2+)-bound form and (ii) as a protease in Zn(2+)-free form, commissioning it to perform multiple functions.", "spo_list": [{"subject": "Zn(2+)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Calnuc", "object_type": "GENE-Y"}]}
{"text": "Sulfide enhanced the cleavage of caspase-3 and poly (ADP-ribose) polymerase and induced early cellular apoptosis.", "spo_list": [{"subject": "Sulfide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "caspase-3", "object_type": "GENE-Y"}, {"subject": "Sulfide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "poly (ADP-ribose) polymerase", "object_type": "GENE-N"}]}
{"text": "Both ROCK-1 and ROCK-2 (Rho kinases) were activated by sulfide, and sulfide-induced cell blebbing was suppressed by a ROCK inhibitor, suggesting that a Rho pathway is involved in sulfide-induced blebbing in lymphocytes.", "spo_list": [{"subject": "sulfide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ROCK-1", "object_type": "GENE-Y"}, {"subject": "sulfide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ROCK-2", "object_type": "GENE-Y"}, {"subject": "sulfide", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Rho kinases", "object_type": "GENE-N"}]}
{"text": "Atorvastatin progressively lowered plasma LDL in each group, but no differences in liver cholesterol, cholesterol ester, or total bile acid concentrations, or in plasma total bile acid levels were seen.", "spo_list": [{"subject": "Atorvastatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "LDL", "object_type": "GENE-N"}]}
{"text": "Expression of key liver bile acid synthesis genes CYP7A1 and CYP8B1 were ~2.5-fold higher with atorvastatin in both strains, but mRNA for liver bile acid export and reuptake transporters and conjugating enzymes were not unaffected.", "spo_list": [{"subject": "bile acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CYP7A1", "object_type": "GENE-Y"}, {"subject": "bile acid", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "CYP8B1", "object_type": "GENE-Y"}]}
{"text": "By using the technique of site-directed spin labeling combined with EPR spectroscopy, we have observed that binding of arachidonic acid and nonsteroidal anti-inflammatory drugs induces conformational changes in the human prostaglandin endoperoxide H(2) synthase enzyme (PGHS-2).", "spo_list": [{"subject": "arachidonic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human prostaglandin endoperoxide H(2) synthase enzyme", "object_type": "GENE-N"}, {"subject": "arachidonic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PGHS-2", "object_type": "GENE-Y"}]}
{"text": "Line shape broadening resulting from spin-spin coupling of nitroxide pairs introduced into the membrane-binding helices of PGHS-2 was used to calculate the inter-helical distances and changes in these distances that occur in response to binding various ligands.", "spo_list": [{"subject": "nitroxide", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PGHS-2", "object_type": "GENE-Y"}]}
{"text": "However, inter-helical distances calculated and determined by EPR for PGHS-2 complexed with arachidonic acid, flurbiprofen, and SC-58125 were in close agreement with those obtained from the cognate crystal structures.", "spo_list": [{"subject": "arachidonic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PGHS-2", "object_type": "GENE-Y"}, {"subject": "flurbiprofen", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PGHS-2", "object_type": "GENE-Y"}, {"subject": "SC-58125", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PGHS-2", "object_type": "GENE-Y"}]}
{"text": "Proteolysis protection assays had previously provided circumstantial evidence that binding of heme and non-steroidal anti-inflammatory drugs alters the conformation of PGHS, but the present experiments are the first to directly measure such changes.", "spo_list": [{"subject": "steroidal", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PGHS", "object_type": "GENE-N"}]}
{"text": "The finding that arachidonate can also induce a conformational change in PGHS-2 was unexpected, and the magnitude of changes suggests this structural flexibility may be integral to the cyclooxygenase catalytic mechanism.", "spo_list": [{"subject": "arachidonate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PGHS-2", "object_type": "GENE-Y"}, {"subject": "arachidonate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "cyclooxygenase", "object_type": "GENE-N"}]}
{"text": "Using neurochemical method, evidence was obtained that cannabinoid CB(1) receptors are localized on noradrenergic terminals and their stimulation by WIN-55,212-2 reduces the release of [3H]noradrenaline evoked by axonal activity in a frequency-dependent manner.", "spo_list": [{"subject": "WIN-55,212-2", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "cannabinoid CB(1) receptors", "object_type": "GENE-Y"}]}
{"text": "Cannabinoid CB(1) receptor antagonist SR 141716A completely prevented WIN-55,212-2 from reducing the release.", "spo_list": [{"subject": "SR 141716A", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "Cannabinoid CB(1) receptor", "object_type": "GENE-Y"}, {"subject": "WIN-55,212-2", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Cannabinoid CB(1) receptor", "object_type": "GENE-Y"}]}
{"text": "Because BRL-44408, an alpha(2B)-adrenoceptor, and prazosin, an alpha(1)- and alpha(2B)-adrenoceptor antagonist, both increased the release of [(3)H]noradrenaline, it seems likely that the alpha(2B) subtype is responsible for the negative feedback modulation of noradrenaline release.", "spo_list": [{"subject": "BRL-44408", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha(2B)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "In the presence of alpha(2)-adrenoceptor antagonism, cannabinoid CB(1) receptor activation by WIN-55,212-2 was much more effective in inhibiting the release of [(3)H]noradrenaline.", "spo_list": [{"subject": "WIN-55,212-2", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "cannabinoid CB(1) receptor", "object_type": "GENE-Y"}]}
{"text": "Using a specific antibody against the C-terminus of the rat cannabinoid CB(1) receptor and also against neuropeptide Y, ultrastructural evidence was obtained that cannabinoid CB(1) receptors are exclusively localized on neuropeptide Y-positive noradrenergic varicosities.", "spo_list": [{"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "rat cannabinoid CB(1) receptor", "object_type": "GENE-Y"}]}
{"text": "Since the sympathetic innervation of the human airway smooth muscle is sparse, and mainly the circulating adrenaline relaxes the airways via activation of beta(2)-adrenoceptor localized on the smooth muscle, it is suggested that inhibition of noradrenaline release by cannabinoids, and the subsequent bronchospasm, may be limited to those cases when noradrenaline released from sympathetic varicosities is involved in airway relaxation.", "spo_list": [{"subject": "adrenaline", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "beta(2)-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor.", "spo_list": [{"subject": "Rosuvastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "3-hydroxy-3-methylglutaryl coenzyme A reductase", "object_type": "GENE-Y"}]}
{"text": "Rosuvastatin (formerly ZD4522) is a new 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor (statin) with distinct pharmacologic properties.", "spo_list": [{"subject": "Rosuvastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase", "object_type": "GENE-Y"}, {"subject": "ZD4522", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase", "object_type": "GENE-Y"}]}
{"text": "Rosuvastatin has been shown to be a comparatively potent inhibitor of HMG-CoA reductase activity in a purified preparation of the catalytic domain of the human enzyme, as well as in rat and human hepatic microsomes.", "spo_list": [{"subject": "Rosuvastatin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HMG-CoA reductase", "object_type": "GENE-Y"}]}
{"text": "Ramelteon [TAK 375] is a melatonin (MT1/MT2) receptor agonist that is being developed by Takeda as a treatment for sleep disorders.", "spo_list": [{"subject": "Ramelteon", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "MT1", "object_type": "GENE-Y"}, {"subject": "Ramelteon", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "MT2", "object_type": "GENE-Y"}, {"subject": "TAK 375", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "MT1", "object_type": "GENE-Y"}, {"subject": "TAK 375", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "MT2", "object_type": "GENE-Y"}]}
{"text": "The aim of this study was to investigate the effect of complementary immune suppression with the IL-2 synthesis inhibitor cyclosporin and the IL-2 receptor antagonist basiliximab on the incidence of transplant rejection after high-risk keratoplasty.", "spo_list": [{"subject": "cyclosporin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IL-2", "object_type": "GENE-Y"}]}
{"text": "Synthesis and antagonistic activity at muscarinic receptor subtypes of some 2-carbonyl derivatives of diphenidol.", "spo_list": [{"subject": "2-carbonyl", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic receptor", "object_type": "GENE-N"}, {"subject": "diphenidol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "muscarinic receptor", "object_type": "GENE-N"}]}
{"text": "This work showed that appropriate structural modification of diphenidol can lead to M2-selective muscarinic antagonists of possible interest in the field of Alzheimer's disease.", "spo_list": [{"subject": "diphenidol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "M2", "object_type": "GENE-Y"}]}
{"text": "Previous studies showed increased RRM1 expression on continuous exposure of cell lines to gemcitabine and suggested improved survival for patients with low as opposed to high tumoral RRM1 expression when treated with gemcitabine-containing chemotherapy.", "spo_list": [{"subject": "gemcitabine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "RRM1", "object_type": "GENE-Y"}, {"subject": "gemcitabine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "RRM1", "object_type": "GENE-Y"}]}
{"text": "2-(2-Aminoethyl)-quinoline (D-1997): a novel agonist at 5-hydroxytryptamine1-like receptors in the canine basilar artery.", "spo_list": [{"subject": "2-(2-Aminoethyl)-quinoline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-hydroxytryptamine1-like receptors", "object_type": "GENE-N"}, {"subject": "D-1997", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-hydroxytryptamine1-like receptors", "object_type": "GENE-N"}]}
{"text": "The effects of D-1997 in the basilar artery were not modified by incubation with either the 5-HT2 receptor antagonist ketanserin (0.01-1 microM), the 5-HT3 and 5-HT4 receptor antagonist ICS205930 (tropisetron; 0.1-10 microM), the 5-HT1A receptor antagonist spiroxatrine (0.01-1 microM), the beta-adrenoceptor blocker with high affinity for 5-HT1A and 5-HT1B binding sites (+/-)-pindolol (0.01-1 microM), or the alpha 1-adrenoceptor antagonist prazosin (0.01-1 microM).", "spo_list": [{"subject": "ketanserin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT2 receptor", "object_type": "GENE-N"}, {"subject": "tropisetron", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT3", "object_type": "GENE-N"}, {"subject": "tropisetron", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT4", "object_type": "GENE-Y"}, {"subject": "spiroxatrine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "(+/-)-pindolol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "beta-adrenoceptor", "object_type": "GENE-N"}, {"subject": "(+/-)-pindolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "(+/-)-pindolol", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5-HT1B", "object_type": "GENE-Y"}, {"subject": "prazosin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha 1-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "In contrast, the D-1997-induced responses were potently and concentration-dependently antagonized by the mixed 5-HT1-like and 5-HT2 receptor antagonist methiothepin (0.01-1 microM).", "spo_list": [{"subject": "methiothepin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT1-like", "object_type": "GENE-N"}, {"subject": "methiothepin", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5-HT2 receptor", "object_type": "GENE-N"}, {"subject": "D-1997", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT1-like", "object_type": "GENE-N"}, {"subject": "D-1997", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT2 receptor", "object_type": "GENE-N"}]}
{"text": "It is concluded that D-1997 contracts the canine basilar artery by stimulating 5-HT1-like receptors unrelated to either the 5-HT1A or 5-HT1B receptor subtypes.", "spo_list": [{"subject": "D-1997", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "5-HT1-like receptors", "object_type": "GENE-N"}, {"subject": "D-1997", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "5-HT1A", "object_type": "GENE-Y"}, {"subject": "D-1997", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "5-HT1B", "object_type": "GENE-Y"}]}
{"text": "Exogenous stimulation of PKA activity, achieved by forskolin treatment, protected K-ras-transformed cells from apoptosis induced by glucose deprivation, enhanced complex I activity, intracellular adenosine triphosphate (ATP) levels, mitochondrial fusion and decreased intracellular reactive oxygen species (ROS) levels.", "spo_list": [{"subject": "forskolin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PKA", "object_type": "GENE-N"}, {"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "K-ras", "object_type": "GENE-Y"}, {"subject": "forskolin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "complex I", "object_type": "GENE-N"}]}
{"text": "Identification of binding sites for bepridil and trifluoperazine on cardiac troponin C. The solution structure of cardiac troponin C (cTnC) (Sia, S., Li, M. X., Spyracopoulos, L., Gagne, S. M., Liu, W., Putkey, J. A.", "spo_list": [{"subject": "bepridil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "cardiac troponin C", "object_type": "GENE-Y"}, {"subject": "trifluoperazine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "cardiac troponin C", "object_type": "GENE-Y"}]}
{"text": "For example, it is clear that the closed conformation of the regulatory N-terminal domain in Ca2+-bound cardiac troponin C (cTnC) presents a much different binding surface for Ca2+-sensitizing compounds than previously thought.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "cardiac troponin C", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "cTnC", "object_type": "GENE-Y"}, {"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "cardiac troponin C", "object_type": "GENE-Y"}, {"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "cTnC", "object_type": "GENE-Y"}]}
{"text": "We report here the use of Met methyl groups as site-specific structural markers to identify drug binding sites for trifluoperazine and bepridil on cTnC.", "spo_list": [{"subject": "trifluoperazine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "cTnC", "object_type": "GENE-Y"}, {"subject": "bepridil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "cTnC", "object_type": "GENE-Y"}]}
{"text": "Drug dependent changes in the NMR heteronuclear single-quantum coherence spectra of [methyl-13C]Met-labeled cTnC indicate that bepridil and trifluoperazine bind to similar sites but only in the presence of Ca2+.", "spo_list": [{"subject": "methyl-13C", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "cTnC", "object_type": "GENE-Y"}, {"subject": "bepridil", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "cTnC", "object_type": "GENE-Y"}, {"subject": "trifluoperazine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "cTnC", "object_type": "GENE-Y"}]}
{"text": "There are 3-4 drug binding sites in the N- and C-terminal domains of intact cTnC that exhibit fast exchange on the NMR time scale.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "cTnC", "object_type": "GENE-Y"}, {"subject": "C", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "cTnC", "object_type": "GENE-Y"}]}
{"text": "In skeletal muscle, in vivo as well as ex vivo myo-inositol treatment increased protein kinase B/Akt phosphorylation under baseline and insulin-stimulated conditions, suggesting a synergistic action of myo-inositol treatment and insulin on proteins of the insulin signalling pathway.", "spo_list": [{"subject": "myo-inositol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "protein kinase B", "object_type": "GENE-N"}, {"subject": "myo-inositol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Akt", "object_type": "GENE-N"}]}
{"text": "Based on IC50 ratios, the dimeric analog bis(7)-tacrine was, in a reversible manner, up to 150-fold more potent and 250-fold more selective than tacrine for acetylcholinesterase (AChE) over butyrylcholinesterase (BChE).", "spo_list": [{"subject": "bis(7)-tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "bis(7)-tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "bis(7)-tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "bis(7)-tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BChE", "object_type": "GENE-Y"}, {"subject": "tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BChE", "object_type": "GENE-Y"}]}
{"text": "Following a single oral administration, both bis(7)-tacrine and tacrine produced dose-dependent inhibitions of AChE in rat brain, but bis(7)-tacrine exhibited higher efficacy and AChE/BChE selectivity than tacrine.", "spo_list": [{"subject": "bis(7)-tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "bis(7)-tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "bis(7)-tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BChE", "object_type": "GENE-Y"}, {"subject": "tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BChE", "object_type": "GENE-Y"}]}
{"text": "The anti-AChE efficacy of bis(7)-tacrine was quite similar following an oral or i.p. administration, but tacrine showed much lower efficacy when administered orally than when given i.p. These findings suggest bis(7)-tacrine, a highly potent and selective inhibitor of AChE, can probably be used as an improved drug in the palliative treatment of AD.", "spo_list": [{"subject": "bis(7)-tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "bis(7)-tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "As a result of further structure-activity investigations, AL-34662, a selective 5HT(2) agonist (relative to other 5HT receptor types and sub-types) with high affinity, potency and efficacy at 5HT(2A), 5HT(2B) and 5HT(2C) receptors was discovered that efficaciously lowered IOP in the monkey model of ocular hypertension (33 +/- 3 % reduction out to 6 hrs post with a 300 microg topical ocular dose).", "spo_list": [{"subject": "AL-34662", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5HT(2)", "object_type": "GENE-Y"}, {"subject": "AL-34662", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5HT(2A)", "object_type": "GENE-Y"}, {"subject": "AL-34662", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5HT(2B)", "object_type": "GENE-N"}, {"subject": "AL-34662", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5HT(2C)", "object_type": "GENE-Y"}, {"subject": "AL-34662", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5HT(2A)", "object_type": "GENE-Y"}, {"subject": "AL-34662", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5HT(2B)", "object_type": "GENE-N"}, {"subject": "AL-34662", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5HT(2C)", "object_type": "GENE-Y"}]}
{"text": "Furthermore, quantitative autoradiography revealed a relatively high specific binding of [(3)H]-5HT and [(3)H]-ketanserin to 5HT(2) receptors in human CE and longitudinal ciliary muscle (CM).", "spo_list": [{"subject": "[(3)H]-5HT", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5HT(2)", "object_type": "GENE-Y"}, {"subject": "[(3)H]-ketanserin", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5HT(2)", "object_type": "GENE-Y"}]}
{"text": "Second messenger studies revealed the presence of phospholipase C-coupled 5HT(2A) receptors in h-CM and h-TM cells where they stimulated phosphoinositide (PI) hydrolysis and mobilized intracellular Ca(2+) when challenged with a variety of 5HT(2A-C) receptor agonists (e.g. alpha-methyl-5HT, (R)-DOI, alpha-methyl-5HT, BW-723C86, MK-212, mCPP, cabergoline, AL-34662).", "spo_list": [{"subject": "phosphoinositide", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "phospholipase C", "object_type": "GENE-N"}, {"subject": "PI", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "phospholipase C", "object_type": "GENE-N"}, {"subject": "alpha-methyl-5HT", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5HT(2A)", "object_type": "GENE-Y"}, {"subject": "(R)-DOI", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5HT(2A)", "object_type": "GENE-Y"}, {"subject": "alpha-methyl-5HT", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5HT(2A)", "object_type": "GENE-Y"}, {"subject": "BW-723C86", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5HT(2A)", "object_type": "GENE-Y"}, {"subject": "MK-212", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5HT(2A)", "object_type": "GENE-Y"}, {"subject": "mCPP", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5HT(2A)", "object_type": "GENE-Y"}, {"subject": "cabergoline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5HT(2A)", "object_type": "GENE-Y"}, {"subject": "AL-34662", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5HT(2A)", "object_type": "GENE-Y"}]}
{"text": "These functional responses were blocked by selective 5HT(2) receptor antagonists with the 5HT(2A) antagonist, M-100970, exhibiting the highest potency.", "spo_list": [{"subject": "M-100970", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5HT(2A)", "object_type": "GENE-Y"}, {"subject": "M-100970", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "5HT(2)", "object_type": "GENE-Y"}]}
{"text": "Gene expression profiling (GEP) of GIST-S, GIST-R cells and two IM resistant GIST patients demonstrated that KIT is downregulated implying a major role in IM resistance.", "spo_list": [{"subject": "IM", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "KIT", "object_type": "GENE-Y"}, {"subject": "IM", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "KIT", "object_type": "GENE-Y"}]}
{"text": "In GIST-R, AXL is tyrosine phosphorylated and its ligand growth-arrest-specific gene 6 is overexpressed implying autocrine activation.", "spo_list": [{"subject": "tyrosine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "AXL", "object_type": "GENE-Y"}]}
{"text": "Molecular modeling of the kinase domain of mutant c-Kit (V654A) and AXL showed no binding to IM but efficient binding to MP470, a novel c-Kit/AXL kinase inhibitor.", "spo_list": [{"subject": "MP470", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "c-Kit", "object_type": "GENE-Y"}, {"subject": "MP470", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AXL", "object_type": "GENE-Y"}, {"subject": "MP470", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "MP470", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "kinase domain", "object_type": "GENE-N"}, {"subject": "MP470", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "c-Kit", "object_type": "GENE-Y"}, {"subject": "MP470", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "AXL", "object_type": "GENE-Y"}, {"subject": "MP470", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "V654A", "object_type": "GENE-N"}]}
{"text": "Single strand conformational polymorphism analysis and nucleotide sequencing of the promoter and entire coding region of the CPE gene in 269 Japanese subjects with NIDDM, 28 nondiabetic obese subjects and 104 nonobese and nondiabetic controls revealed three nucleotide changes, a G-to-T substitution at nucleotide -53, a G-to-A substitution at nucleotide -144 (relative to start of transcription) in the promoter region and a silent G-to-A substitution in codon 219.", "spo_list": [{"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "CPE", "object_type": "GENE-Y"}, {"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "CPE", "object_type": "GENE-Y"}, {"subject": "nucleotide", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "CPE", "object_type": "GENE-Y"}]}
{"text": "As CRABPI was elevated far more than any other genes, we observed that the retinoids, all-trans retinoic acid and 9-cis retinoic acid, that bind CRABPI, promoted nitroblue tetrazolium-associated functional cell differentiation in p75NTR PC-3 cells, but not in neo control PC-3 cells.", "spo_list": [{"subject": "retinoids", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CRABPI", "object_type": "GENE-Y"}, {"subject": "all-trans retinoic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CRABPI", "object_type": "GENE-Y"}, {"subject": "9-cis retinoic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "CRABPI", "object_type": "GENE-Y"}]}
{"text": "Hence, re-expression of the p75NTR appears to partially reverse de-differentiation of prostate cancer cells by up-regulating the expression of CRABPI for localized sequestration of retinoids that are available to newly up-regulated RAR-beta, RXR-alpha, and RXR-beta.", "spo_list": [{"subject": "retinoids", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CRABPI", "object_type": "GENE-Y"}]}
{"text": "Manipulation of kinetic profiles in 2-aryl propionic acid cyclooxygenase inhibitors.", "spo_list": [{"subject": "2-aryl propionic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase", "object_type": "GENE-N"}]}
{"text": "This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to factor Xa (rivaroxaban and apixaban) and IIa (dabigatran).", "spo_list": [{"subject": "rivaroxaban", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "factor Xa", "object_type": "GENE-Y"}, {"subject": "apixaban", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "factor Xa", "object_type": "GENE-Y"}]}
{"text": "Synthesis and biological evaluation of new N-alkylcarbazole derivatives as STAT3 inhibitors: preliminary study.", "spo_list": [{"subject": "N-alkylcarbazole", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "STAT3", "object_type": "GENE-Y"}]}
{"text": "Recent study demonstrated that carbazoles can inhibit STAT3 mediated transcription.", "spo_list": [{"subject": "carbazoles", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "STAT3", "object_type": "GENE-Y"}]}
{"text": "[A new inherited metabolic disease: delta1-pyrroline 5-carboxylate synthetase deficiency]. delta 1-pyrroline 5-carboxylate synthetase (P5C synthetase) catalyzes the ATP and the NAD(P)H-dependent conversion of L-glutamate to glutamate semialdehyde (GSA) which is the metabolic precursor for proline biosynthesis.", "spo_list": [{"subject": "L-glutamate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "delta 1-pyrroline 5-carboxylate synthetase", "object_type": "GENE-Y"}, {"subject": "L-glutamate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "P5C synthetase", "object_type": "GENE-Y"}, {"subject": "glutamate semialdehyde", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "delta 1-pyrroline 5-carboxylate synthetase", "object_type": "GENE-Y"}, {"subject": "glutamate semialdehyde", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "P5C synthetase", "object_type": "GENE-Y"}, {"subject": "GSA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "delta 1-pyrroline 5-carboxylate synthetase", "object_type": "GENE-Y"}, {"subject": "GSA", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "P5C synthetase", "object_type": "GENE-Y"}, {"subject": "proline", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "delta 1-pyrroline 5-carboxylate synthetase", "object_type": "GENE-Y"}, {"subject": "proline", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "P5C synthetase", "object_type": "GENE-Y"}]}
{"text": "We cloned human P5C synthetase-cDNA by database cloning strategy: this cDNA has an open reading frame of 2,385 bases coding for a polypeptide of 795 amino acids.", "spo_list": [{"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "human P5C synthetase", "object_type": "GENE-Y"}]}
{"text": "Both patients are homozygous for an L396S substitution, this amino acid being highly conserved across species.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "L396S", "object_type": "GENE-N"}]}
{"text": "Time-dependent changes in hepatic and intestinal induction of cytochrome P450 3A after administration of dexamethasone to rats.", "spo_list": [{"subject": "dexamethasone", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "cytochrome P450 3A", "object_type": "GENE-N"}]}
{"text": "We investigated the effects of the dose of and the number of times an inducer was administered and the duration of induction of hepatic and intestinal cytochrome P450 3A (CYP3A) in rats using dexamethasone 21-phosphate (DEX-P) and midazolam (MDZ) as an inducer and a substrate to CYP3A, respectively.", "spo_list": [{"subject": "dexamethasone 21-phosphate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "DEX-P", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "midazolam", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "MDZ", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "dexamethasone 21-phosphate", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "DEX-P", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "midazolam", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "MDZ", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CYP3A", "object_type": "GENE-N"}]}
{"text": "4. Administration of a single dose of DEX-P showed a temporal increase in CYP3A activity in both tissues and the induction ratios reached maximum values at 12âh after DEX-P administration.", "spo_list": [{"subject": "DEX-P", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CYP3A", "object_type": "GENE-N"}, {"subject": "DEX-P", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CYP3A", "object_type": "GENE-N"}]}
{"text": "Disruption of 5-HT2A receptor-dependent signaling in mice was associated with decreased acetylation of histone H3 (H3ac) and H4 (H4ac), and increased tri-methylation of histone H3 at lysine 27 (H3K27me3) at the mGlu2 promoter-epigenetic changes that correlate with transcriptional repression.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "histone H3", "object_type": "GENE-N"}, {"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "mGlu2 promoter", "object_type": "GENE-N"}]}
{"text": "Neither methylation of histone H3 at lysine 4 (H3K4me1/2/3) nor tri-methylation of histone H3 at lysine 9 (H3K9me3) was affected.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "histone H3", "object_type": "GENE-N"}, {"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "histone H3", "object_type": "GENE-N"}]}
{"text": "We found that Egr1, a transcription factor whose promoter activity was positively regulated by the 5-HT2A receptor agonist TCB-2, binds less to the mGlu2 promoter in frontal cortex of 5-HT2A-KO as compared to wild-type mice.", "spo_list": [{"subject": "TCB-2", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "5-HT2A", "object_type": "GENE-Y"}, {"subject": "TCB-2", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Egr1", "object_type": "GENE-Y"}]}
{"text": "Am-80, Tamibarotene, binds to retinoic acid receptor alpha (RARalpha) more specifically than all-trans retinoic acid.", "spo_list": [{"subject": "Am-80", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "retinoic acid receptor alpha", "object_type": "GENE-Y"}, {"subject": "Tamibarotene", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "retinoic acid receptor alpha", "object_type": "GENE-Y"}, {"subject": "Am-80", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RARalpha", "object_type": "GENE-Y"}, {"subject": "Tamibarotene", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "RARalpha", "object_type": "GENE-Y"}]}
{"text": "Pharmacokinetic Interactions between Monoamine Oxidase A Inhibitor Harmaline and 5-Methoxy-N,N-Dimethyltryptamine, and the Impact of CYP2D6 Status.", "spo_list": [{"subject": "Harmaline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Monoamine Oxidase A", "object_type": "GENE-Y"}]}
{"text": "Our recent study has demonstrated that coadministration of monoamine oxidase A (MAO-A) inhibitor harmaline (5 mg/kg) increases systemic exposure to 5-MeO-DMT (2 mg/kg) and active metabolite bufotenine.", "spo_list": [{"subject": "harmaline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "monoamine oxidase A", "object_type": "GENE-Y"}, {"subject": "harmaline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}]}
{"text": "Our data revealed that inhibition of MAO-A-mediated metabolic elimination by harmaline (2, 5, and 15 mg/kg) led to a sharp increase in systemic and cerebral exposure to 5-MeO-DMT (2 and 10 mg/kg) at all dose combinations.", "spo_list": [{"subject": "harmaline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}]}
{"text": "The in vivo inhibitory effect of harmaline on CYP2D6-catalyzed bufotenine formation was confirmed by in vitro study using purified CYP2D6.", "spo_list": [{"subject": "bufotenine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2D6", "object_type": "GENE-Y"}, {"subject": "harmaline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2D6", "object_type": "GENE-Y"}]}
{"text": "Given these findings, a unified PK model including the inhibition of MAO-A- and CYP2D6-catalyzed 5-MeO-DMT metabolism by harmaline was developed to describe blood harmaline, 5-MeO-DMT, and bufotenine PK profiles in both wild-type and Tg-CYP2D6 mouse models.", "spo_list": [{"subject": "5-MeO-DMT", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "5-MeO-DMT", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "CYP2D6", "object_type": "GENE-Y"}, {"subject": "harmaline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MAO-A", "object_type": "GENE-Y"}, {"subject": "harmaline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CYP2D6", "object_type": "GENE-Y"}]}
{"text": "To examine the role of Cox, the cultures were also treated with resveratrol (a specific inhibitor of Cox-1), NS-398 (a specific inhibitor of Cox-2), or indomethacin (a general Cox inhibitor).", "spo_list": [{"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Cox-1", "object_type": "GENE-Y"}, {"subject": "NS-398", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Cox-2", "object_type": "GENE-Y"}, {"subject": "indomethacin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Cox", "object_type": "GENE-N"}]}
{"text": "Inhibition of Cox-1 also blocked 24R,25-(OH)(2)D(3)-dependent increases in PKC.", "spo_list": [{"subject": "24R,25-(OH)(2)D(3)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PKC", "object_type": "GENE-N"}]}
{"text": "Activation of PLA(2) with melittin inhibited 24R, 25-(OH)(2)D(3)-dependent stimulation of PKC, and inhibition of PLA(2) with quinacrine stimulated PKC in response to 24R, 25-(OH)(2)D(3).", "spo_list": [{"subject": "24R, 25-(OH)(2)D(3)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PKC", "object_type": "GENE-N"}, {"subject": "quinacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PLA(2)", "object_type": "GENE-N"}, {"subject": "24R, 25-(OH)(2)D(3)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PKC", "object_type": "GENE-N"}]}
{"text": "Inclusion of resveratrol reduced the melittin-dependent inhibition of PLA(2) and caused an increase in quinacrine-stimulated PLA(2) activity.", "spo_list": [{"subject": "quinacrine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PLA(2)", "object_type": "GENE-N"}, {"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PLA(2)", "object_type": "GENE-N"}, {"subject": "resveratrol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PLA(2)", "object_type": "GENE-N"}]}
{"text": "Metabolism of arachidonic acid to leukotrienes is not involved in the response to 24R, 25-(OH)(2)D(3) because inhibition of lipoxygenase had no effect.", "spo_list": [{"subject": "arachidonic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "lipoxygenase", "object_type": "GENE-N"}, {"subject": "leukotrienes", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "lipoxygenase", "object_type": "GENE-N"}]}
{"text": "Inhibitors of MRP1 (sulfinpyrazone, verapamil) and GST (dicumarol, curcumin) completely reversed the GSTM1-associated resistance to VCR, indicating that a MRP efflux function is necessary to potentiate GSTM1-mediated resistance to VCR.", "spo_list": [{"subject": "sulfinpyrazone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MRP1", "object_type": "GENE-Y"}, {"subject": "verapamil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "MRP1", "object_type": "GENE-Y"}]}
{"text": "The unique role of the enzyme 5-lipoxygenase (5-LO) in the production of leukotrienes (LTs) makes it a likely target for biochemical manipulation.", "spo_list": [{"subject": "leukotrienes", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "5-lipoxygenase", "object_type": "GENE-Y"}, {"subject": "leukotrienes", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "5-LO", "object_type": "GENE-Y"}, {"subject": "LTs", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "5-lipoxygenase", "object_type": "GENE-Y"}, {"subject": "LTs", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "5-LO", "object_type": "GENE-Y"}]}
{"text": "The compounds identified as 5-LO inhibitors can be divided into antioxidants, substrate-analogous, and a large miscellaneous group of inhibitors, where hydroxamic acids are potent and more selective inhibitors of 5-LO.", "spo_list": [{"subject": "hydroxamic acids", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-LO", "object_type": "GENE-Y"}]}
{"text": "The benzothiophene hydroxyurea, zileuton, is the first selective 5-LO inhibitor evaluated for the treatment of patients with IBD.", "spo_list": [{"subject": "benzothiophene hydroxyurea", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-LO", "object_type": "GENE-Y"}, {"subject": "zileuton", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-LO", "object_type": "GENE-Y"}]}
{"text": "To better understand SFK-mediated nuclear translocation of EGFR, we investigated which SFK member(s) controlled this process as well as the EGFR tyrosine residues that are involved.", "spo_list": [{"subject": "tyrosine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "EGFR", "object_type": "GENE-Y"}]}
{"text": "Brief exposure to NMDA (5 min; 100 microM) elicited a time-dependent accumulation of PGs in the culture medium that preceded neuronal cell death and correlated with the induction of COX-2 mRNA.", "spo_list": [{"subject": "NMDA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Flurbiprofen, a nonselective COX-1/COX-2 inhibitor, blocked NMDA-stimulated PG production and attenuated neuronal death in a concentration-dependent manner.", "spo_list": [{"subject": "Flurbiprofen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "Flurbiprofen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Similar results were obtained with the specific COX-2 inhibitor NS-398 (10-30 microM) but not with the selective COX-1 inhibitor valeryl salicylate (10-300 microM).", "spo_list": [{"subject": "NS-398", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "valeryl salicylate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}]}
{"text": "Inhibition of total constitutive COX activity with aspirin (100 microM, 1.5 h) before NMDA exposure did not prevent subsequent NMDA-mediated neuronal cell death.", "spo_list": [{"subject": "aspirin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX", "object_type": "GENE-N"}]}
{"text": "Anorexia induced by (+)-amphetamine, phentermine, diethylpropion and phenylpropanolamine seems to be the result of their ability to increase the release of noradrenaline and/or dopamine from nerve terminals and inhibit their reuptake or, in the case of phenylpropanolamine, to stimulate directly alpha 1-adrenoceptors.", "spo_list": [{"subject": "phenylpropanolamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "alpha 1-adrenoceptors", "object_type": "GENE-N"}]}
{"text": "Effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery.", "spo_list": [{"subject": "losartan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "AT1-receptor", "object_type": "GENE-N"}, {"subject": "irbesartan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "AT1-receptor", "object_type": "GENE-N"}, {"subject": "telmisartan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "AT1-receptor", "object_type": "GENE-N"}]}
{"text": "SUMMARY: The effect of the AT1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II (Ang II)-induced facilitation of noradrenergic neurotransmission was investigated in the isolated rat mesenteric artery under isometric conditions.", "spo_list": [{"subject": "losartan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "AT1-receptor", "object_type": "GENE-N"}, {"subject": "irbesartan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "AT1-receptor", "object_type": "GENE-N"}, {"subject": "telmisartan", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "AT1-receptor", "object_type": "GENE-N"}]}
{"text": "RESULTS: Protein levels of RARgamma were significantly lower by approximately 68% in SCC compared to normal surrounding tissue in patients with SCC that smoked and/or consumed elevated amounts of alcohol.", "spo_list": [{"subject": "alcohol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "RARgamma", "object_type": "GENE-Y"}]}
{"text": "Furthermore, RARalpha protein levels were significantly lower (approximately- 45%) in SCC in comparison to normal esophageal mucosa in patients with elevated alcohol intake.", "spo_list": [{"subject": "alcohol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "RARalpha", "object_type": "GENE-Y"}]}
{"text": "We have previously demonstrated that phosphorylation of Fas-associated death domain-containing protein (FADD) at 194 serine through c-jun NH2-terminal kinase (JNK) activation sensitizes breast cancer cells to chemotherapy through accelerating cell cycle arrest at G2/M, and that Bcl-2 phosphorylation downstream of JNK/FADD plays an important role in cell growth suppression by paclitaxel.", "spo_list": [{"subject": "serine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Fas-associated death domain-containing protein", "object_type": "GENE-Y"}, {"subject": "serine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "FADD", "object_type": "GENE-Y"}, {"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "FADD", "object_type": "GENE-Y"}, {"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "JNK", "object_type": "GENE-N"}, {"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "c-jun NH2-terminal kinase", "object_type": "GENE-N"}, {"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "JNK", "object_type": "GENE-N"}, {"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Fas-associated death domain-containing protein", "object_type": "GENE-Y"}, {"subject": "paclitaxel", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "FADD", "object_type": "GENE-Y"}]}
{"text": "Specificity of zebrafish retinol saturase: formation of all-trans-13,14-dihydroretinol and all-trans-7,8- dihydroretinol.", "spo_list": [{"subject": "all-trans-13,14-dihydroretinol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "zebrafish retinol saturase", "object_type": "GENE-Y"}, {"subject": "all-trans-7,8- dihydroretinol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "zebrafish retinol saturase", "object_type": "GENE-Y"}]}
{"text": "Specifically, all-trans-13,14-dihydroretinol is transiently oxidized to all-trans-13,14-dihydroretinoic acid before being oxidized further by Cyp26 enzymes.", "spo_list": [{"subject": "all-trans-13,14-dihydroretinol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Cyp26", "object_type": "GENE-Y"}]}
{"text": "Unlike mouse RetSat (mRetSat), zRetSat A had an altered bond specificity saturating either the 13-14 or 7-8 double bonds of all-trans-retinol to produce either all-trans-13,14-dihydroretinol or all-trans-7,8-dihydroretinol, respectively. zRetSat A also saturated the 13-14 or 7-8 double bonds of all-trans-3,4-didehydroretinol (vitamin A2), a second endogenous form of vitamin A in zebrafish.", "spo_list": [{"subject": "all-trans-13,14-dihydroretinol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "zRetSat A", "object_type": "GENE-Y"}, {"subject": "all-trans-7,8-dihydroretinol", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "zRetSat A", "object_type": "GENE-Y"}, {"subject": "all-trans-retinol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "zRetSat A", "object_type": "GENE-Y"}, {"subject": "all-trans-3,4-didehydroretinol", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "zRetSat A", "object_type": "GENE-Y"}, {"subject": "vitamin A2", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "zRetSat A", "object_type": "GENE-Y"}]}
{"text": "It inhibits the inducible isoform of the enzyme inosine-monophosphate dehydrogenase (IMPDH II) via its active metabolite mycophenolic acid (MPA).", "spo_list": [{"subject": "mycophenolic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "inosine-monophosphate dehydrogenase", "object_type": "GENE-N"}, {"subject": "mycophenolic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IMPDH II", "object_type": "GENE-Y"}, {"subject": "MPA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "inosine-monophosphate dehydrogenase", "object_type": "GENE-N"}, {"subject": "MPA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "IMPDH II", "object_type": "GENE-Y"}]}
{"text": "IMPDH II is necessary for de novo purine synthesis in activated lymphocytes.", "spo_list": [{"subject": "purine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "IMPDH II", "object_type": "GENE-Y"}]}
{"text": "The active-site residue tyr-175 in human glyoxalase II contributes to binding of glutathione derivatives.", "spo_list": [{"subject": "tyr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "human glyoxalase II", "object_type": "GENE-Y"}, {"subject": "glutathione", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human glyoxalase II", "object_type": "GENE-Y"}]}
{"text": "Tyrosine-175 located in the active site of human glyoxalase II was replaced by phenylalanine in order to study the contribution of this residue to catalysis.", "spo_list": [{"subject": "Tyrosine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "human glyoxalase II", "object_type": "GENE-Y"}, {"subject": "phenylalanine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "human glyoxalase II", "object_type": "GENE-Y"}]}
{"text": "Similarly, BrO3 (-) treatment increased clusterin and Kim-1 staining in the proximal tubules; however, staining for these proteins did not differ appreciably between males and females.", "spo_list": [{"subject": "BrO3 (-)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "clusterin", "object_type": "GENE-Y"}, {"subject": "BrO3 (-)", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Kim-1", "object_type": "GENE-Y"}]}
{"text": "All these data unveil a new miRNA-dependent mechanism of regulation of hexokinase expression potentially important in the regulation of glucose metabolism of cancer cells.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hexokinase", "object_type": "GENE-N"}]}
{"text": "In vitro and in vivo, LIN28 preferentially bound single-stranded RNA containing a uridine-rich element and one or more flanking guanosines and appeared to be able to disrupt base-pairing to access these elements when embedded in predicted secondary structure.", "spo_list": [{"subject": "uridine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "LIN28", "object_type": "GENE-Y"}, {"subject": "guanosines", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "LIN28", "object_type": "GENE-Y"}]}
{"text": "The efficacy of cetirizine in comparison with meclizine, another piperazine H1 receptor antagonist, in rat pleurisy caused by allergen or autacoid was investigated.", "spo_list": [{"subject": "piperazine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "H1 receptor", "object_type": "GENE-Y"}, {"subject": "cetirizine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "H1 receptor", "object_type": "GENE-Y"}, {"subject": "meclizine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "H1 receptor", "object_type": "GENE-Y"}]}
{"text": "The natural alkaloid (-)-huperzine A is a potent inhibitor of AChE and has been demonstrated to exert neuroprotection at an appropriate dose.", "spo_list": [{"subject": "(-)-huperzine A", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "It is hypothesized that analogs of both (+)- and (-)-huperzine A with an improved ability to interact with NMDA receptors together with reduced AChE inhibition will exhibit more effective neuroprotection against nerve agents.", "spo_list": [{"subject": "(+)- and (-)-huperzine A", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "Manganese exposure induces Î±-synuclein aggregation in the frontal cortex of non-human primates.", "spo_list": [{"subject": "Manganese", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î±-synuclein", "object_type": "GENE-Y"}]}
{"text": "These findings suggest that Mn exposure promotes Î±-syn aggregation in neuronal and glial cells that may ultimately lead to degeneration in the frontal cortex gray and white matter.", "spo_list": [{"subject": "Mn", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î±-syn", "object_type": "GENE-Y"}]}
{"text": "To our knowledge, this is the first report of Mn-induced neuronal and glial cell Î±-syn accumulation and aggregation in the frontal cortex of non-human primates.", "spo_list": [{"subject": "Mn", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î±-syn", "object_type": "GENE-Y"}]}
{"text": "Synthesis and Biological Evaluation of Urea Derivatives as Highly Potent and Selective Rho Kinase Inhibitors.", "spo_list": [{"subject": "Urea", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Rho Kinase", "object_type": "GENE-N"}]}
{"text": "In 2010, our group reported urea-based ROCK inhibitors as potential antiglaucoma agents.", "spo_list": [{"subject": "urea", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ROCK", "object_type": "GENE-N"}]}
{"text": "Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans.", "spo_list": [{"subject": "rivastigmine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}]}
{"text": "Inhibition of AChE in the CSF after rivastigmine administration was significantly greater than after placebo for up to 8.4 hours after the dose and was maximal (40%) at 2.4 hours.", "spo_list": [{"subject": "rivastigmine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "Plasma BuChE activity was significantly lower after rivastigmine than after placebo, but this was not clinically relevant.", "spo_list": [{"subject": "rivastigmine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BuChE", "object_type": "GENE-Y"}]}
{"text": "BuChE activity in CSF was significantly lower after rivastigmine than after placebo for up to 3.6 hours after dosing, but this difference was not sustained.", "spo_list": [{"subject": "rivastigmine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BuChE", "object_type": "GENE-Y"}]}
{"text": "This study confirms the feasibility of using continuous measurement of AChE activity in CSF over prolonged periods, that rivastigmine markedly inhibits CSF AChE after a single oral dose of 3 mg, and that the inhibition of central AChE is substantially greater than that of peripheral AChE or BuChE.", "spo_list": [{"subject": "rivastigmine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "rivastigmine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "rivastigmine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "rivastigmine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BuChE", "object_type": "GENE-Y"}]}
{"text": "Transport of A1 adenosine receptor agonist tecadenoson by human and mouse nucleoside transporters: evidence for blood-brain barrier transport by murine equilibrative nucleoside transporter 1 mENT1.", "spo_list": [{"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "A1 adenosine receptor", "object_type": "GENE-Y"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human and mouse nucleoside transporters", "object_type": "GENE-N"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "murine equilibrative nucleoside transporter 1", "object_type": "GENE-Y"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "mENT1", "object_type": "GENE-Y"}]}
{"text": "Tecadenoson is a selective A1 adenosine receptor agonist with close similarity to adenosine.", "spo_list": [{"subject": "Tecadenoson", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "A1 adenosine receptor", "object_type": "GENE-Y"}, {"subject": "adenosine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "A1 adenosine receptor", "object_type": "GENE-Y"}]}
{"text": "We studied the binding and transmembrane transport of tecadenoson by recombinant human equilibrative nucleoside transporters (hENTs) hENT1 and hENT2, and human concentrative nucleoside transporters (hCNTs) hCNT1, hCNT2, and hCNT3 in vitro and by mouse mENT1 in vivo.", "spo_list": [{"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human equilibrative nucleoside transporters", "object_type": "GENE-N"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hENTs", "object_type": "GENE-N"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hENT1", "object_type": "GENE-Y"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hENT2", "object_type": "GENE-Y"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human concentrative nucleoside transporters", "object_type": "GENE-N"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hCNTs", "object_type": "GENE-N"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hCNT1", "object_type": "GENE-Y"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hCNT2", "object_type": "GENE-Y"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hCNT3", "object_type": "GENE-Y"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "mouse mENT1", "object_type": "GENE-Y"}]}
{"text": "Binding affinities of the five recombinant human nucleoside transporters for tecadenoson differed (hENT1 > hCNT1 > hCNT3 > hENT2 > hCNT2), and tecadenoson was transported largely by hENT1.", "spo_list": [{"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hENT1", "object_type": "GENE-N"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hENT1", "object_type": "GENE-Y"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hCNT1", "object_type": "GENE-Y"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hCNT3", "object_type": "GENE-Y"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hENT2", "object_type": "GENE-Y"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hCNT2", "object_type": "GENE-Y"}]}
{"text": "Pretreatment of mice with a phosphorylated prodrug of nitrobenzylmercaptopurine riboside, an inhibitor of mENT1, significantly decreased brain exposure to tecadenoson compared with that of the untreated (control) group, suggesting involvement of mENT1 in transport of tecadenoson across the blood-brain barrier (BBB).", "spo_list": [{"subject": "nitrobenzylmercaptopurine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mENT1", "object_type": "GENE-Y"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "mENT1", "object_type": "GENE-Y"}]}
{"text": "In summary, ENT1 was shown to mediate the transport of tecadenoson in vitro with recombinant and native human protein and in vivo with mice.", "spo_list": [{"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "ENT1", "object_type": "GENE-Y"}]}
{"text": "The micromolar apparent Km value of tecadenoson for transport by native hENT1 in cultured cells suggests that hENT1 will not be saturated at clinically relevant (i.e., nanomolar) concentrations of tecadenoson, and that hENT1-mediated passage across the BBB may contribute to the adverse CNS effects observed in clinical trials.", "spo_list": [{"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hENT1", "object_type": "GENE-Y"}, {"subject": "tecadenoson", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hENT1", "object_type": "GENE-Y"}]}
{"text": "Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril.", "spo_list": [{"subject": "Aliskiren", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "renin", "object_type": "GENE-Y"}, {"subject": "SPP100", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "renin", "object_type": "GENE-Y"}, {"subject": "Aliskiren", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Angiotensin II", "object_type": "GENE-Y"}, {"subject": "SPP100", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Angiotensin II", "object_type": "GENE-Y"}]}
{"text": "We tested the new orally active nonpeptidic renin inhibitor SPP100 (Aliskiren, an octanamide with a 50% inhibitory concentration [IC50] in the low nanomolar range) in 18 healthy volunteers on a constant 100 mmol/d sodium diet using a double-blind, 3-way crossover protocol.", "spo_list": [{"subject": "SPP100", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "renin", "object_type": "GENE-Y"}, {"subject": "Aliskiren", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "renin", "object_type": "GENE-Y"}, {"subject": "octanamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "renin", "object_type": "GENE-Y"}]}
{"text": "There was a dose-dependent decrease in plasma renin activity, Ang I, and Ang II following single doses of Aliskiren starting with 40 mg.", "spo_list": [{"subject": "Aliskiren", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "renin", "object_type": "GENE-Y"}, {"subject": "Aliskiren", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Ang I", "object_type": "GENE-Y"}, {"subject": "Aliskiren", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Ang II", "object_type": "GENE-Y"}]}
{"text": "Inhibition was still marked and significant after repeated dosing with maximal decreases in Ang II levels by 89% and 75% on Days 1 and 8, respectively, when the highest dose of Aliskiren was compared with placebo.", "spo_list": [{"subject": "Aliskiren", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Ang II", "object_type": "GENE-Y"}]}
{"text": "At the same time, mean plasma active renin was increased 16- and 34-fold at the highest dose of Aliskiren.", "spo_list": [{"subject": "Aliskiren", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "renin", "object_type": "GENE-Y"}]}
{"text": "In conclusion, the renin inhibitor Aliskiren dose-dependently decreases Ang II levels in humans following oral administration.", "spo_list": [{"subject": "Aliskiren", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "renin", "object_type": "GENE-Y"}, {"subject": "Aliskiren", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Ang II", "object_type": "GENE-Y"}]}
{"text": "Aliskiren has the potential to become the first orally active renin inhibitor that provides a true alternative to ACE-inhibitors and Ang II receptor antagonists in therapy for hypertension and other cardiovascular and renal diseases.", "spo_list": [{"subject": "Aliskiren", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "renin", "object_type": "GENE-Y"}, {"subject": "Aliskiren", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACE", "object_type": "GENE-Y"}, {"subject": "Aliskiren", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "Ang II receptor", "object_type": "GENE-N"}]}
{"text": "Cyclosporine A (CsA) is an immunosuppressive cyclic peptide that binds with a high affinity to 18 kDa human cyclophilin-A (hCyPA).", "spo_list": [{"subject": "Cyclosporine A", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human cyclophilin-A", "object_type": "GENE-Y"}, {"subject": "CsA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human cyclophilin-A", "object_type": "GENE-Y"}, {"subject": "Cyclosporine A", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hCyPA", "object_type": "GENE-Y"}, {"subject": "CsA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "hCyPA", "object_type": "GENE-Y"}]}
{"text": "Here, we discuss structural and functional aspects of the human cyclophilins and their interaction with various intra-cellular targets that can be under the control of CsA or its complexes with diverse cyclophilins that are selectively expressed in different cellular compartments.", "spo_list": [{"subject": "CsA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "human cyclophilins", "object_type": "GENE-N"}, {"subject": "CsA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "cyclophilins", "object_type": "GENE-N"}]}
{"text": "3-Hydroxypyridin-2-thione as Novel Zinc Binding Group for Selective Histone Deacetylase Inhibition.", "spo_list": [{"subject": "3-Hydroxypyridin-2-thione", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Histone Deacetylase", "object_type": "GENE-N"}, {"subject": "Zinc", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Histone Deacetylase", "object_type": "GENE-N"}]}
{"text": "Small molecules bearing hydroxamic acid as the zinc binding group (ZBG) have been the most effective histone deacetylase inhibitors (HDACi) to date.", "spo_list": [{"subject": "zinc", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "histone deacetylase", "object_type": "GENE-N"}, {"subject": "zinc", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC", "object_type": "GENE-N"}]}
{"text": "We have identified 3-hydroxypyridin-2-thione (3-HPT) as a novel ZBG that is compatible with HDAC inhibition.", "spo_list": [{"subject": "3-hydroxypyridin-2-thione", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC", "object_type": "GENE-N"}, {"subject": "3-HPT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC", "object_type": "GENE-N"}]}
{"text": "3-HPT inhibits HDAC 6 and HDAC 8 with an IC50 of 681 and 3675 nM, respectively.", "spo_list": [{"subject": "3-HPT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC 6", "object_type": "GENE-Y"}, {"subject": "3-HPT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC 8", "object_type": "GENE-Y"}]}
{"text": "Subsequent optimization led to several novel 3HPT-based HDACi that are selective for HDAC 6 and HDAC 8.", "spo_list": [{"subject": "3HPT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC", "object_type": "GENE-N"}, {"subject": "3HPT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC 6", "object_type": "GENE-Y"}, {"subject": "3HPT", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC 8", "object_type": "GENE-Y"}]}
{"text": "To clarify if the behavioral interaction between ethanol and adenosine reported previously occur centrally or due to a peripheral hemodynamic change, the effect of i.c.v. adenosine agonists, N6-(R-phenylisopropyl)adenosine (R-PIA), N6-(S-phenylisopropyl)adenosine, 5'-(N-cyclopropyl)-carboxamidoadenosine, antagonists, theophylline and 8-p-(sulfophenyl)theophylline as well as enprofylline on ethanol-(i.p.)-induced motor incoordination was evaluated by rotorod.", "spo_list": [{"subject": "N6-(R-phenylisopropyl)adenosine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "adenosine", "object_type": "GENE-N"}, {"subject": "R-PIA", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "adenosine", "object_type": "GENE-N"}, {"subject": "N6-(S-phenylisopropyl)adenosine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "adenosine", "object_type": "GENE-N"}, {"subject": "5'-(N-cyclopropyl)-carboxamidoadenosine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "adenosine", "object_type": "GENE-N"}, {"subject": "theophylline", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "adenosine", "object_type": "GENE-N"}, {"subject": "8-p-(sulfophenyl)theophylline", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "adenosine", "object_type": "GENE-N"}, {"subject": "enprofylline", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "adenosine", "object_type": "GENE-N"}]}
{"text": "Adenosine agonists and antagonists dose dependently accentuated and attenuated, respectively, ethanol-induced motor incoordination, thereby suggesting a central mechanism of adenosine modulation of this effect of ethanol and confirmed our previous reports in which adenosine agonists and antagonists were given i.p. Enprofylline, a weak adenosine antagonist but potent inhibitor of cyclic AMP phosphodiesterase, did not alter ethanol's motor incoordination, further supporting involvement of brain adenosine receptor mechanism(s) in ethanol-adenosine interactions.", "spo_list": [{"subject": "Enprofylline", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "adenosine", "object_type": "GENE-N"}, {"subject": "Enprofylline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclic AMP phosphodiesterase", "object_type": "GENE-N"}]}
{"text": "Microarray analysis revealed that mRNA levels of several cytokines and chemokines, such as interleukin-1beta, chemokine (C-C motif) ligand (CCL) 2, CCL20, chemokine (C-X-C motif) ligand (CXCL) 1, and CXCL10 were significantly increased after cisplatin treatment in both isolated proximal tubules and whole kidney.", "spo_list": [{"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytokines", "object_type": "GENE-N"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "chemokines", "object_type": "GENE-N"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "interleukin-1beta", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "chemokine (C-C motif) ligand (CCL) 2", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CCL20", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "chemokine (C-X-C motif) ligand (CXCL) 1", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CXCL10", "object_type": "GENE-Y"}]}
{"text": "Interestingly, tubular CCL2 mRNA levels increased soon after cisplatin administration, whereas CCL2 mRNA levels in whole kidney first decreased and then increased.", "spo_list": [{"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CCL2", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "CCL2", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CCL2", "object_type": "GENE-Y"}]}
{"text": "Levels of both CCL2 and kidney injury molecule-1 (KIM-1) in the whole kidney increased after cisplatin administration.", "spo_list": [{"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CCL2", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "kidney injury molecule-1", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "KIM-1", "object_type": "GENE-Y"}]}
{"text": "Urinary CCL2 excretion significantly increased approximately 3-fold compared with controls the day after cisplatin administration (5mg/kg), when no changes were observed plasma creatinine and blood urea nitrogen levels.", "spo_list": [{"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CCL2", "object_type": "GENE-Y"}]}
{"text": "Urinary levels of KIM-1 also increased 3-fold after cisplatin administration.", "spo_list": [{"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "KIM-1", "object_type": "GENE-Y"}]}
{"text": "In addition, urinary CCL2 rather than KIM-1 increased in chronic renal failure rats after administration of low-dose cisplatin (2mg/kg), suggesting that urinary CCL2 was selective for cisplatin-induced nephrotoxicity in renal impairment.", "spo_list": [{"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CCL2", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "KIM-1", "object_type": "GENE-Y"}]}
{"text": "These results indicated that the increase in cytokine and chemokine expression in renal epithelial cells might be responsible for kidney deterioration in cisplatin-induced nephrotoxicity, and that urinary CCL2 is associated with tubular injury and serves as a sensitive and noninvasive marker for the early detection of cisplatin-induced tubular injury.", "spo_list": [{"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytokine", "object_type": "GENE-N"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "chemokine", "object_type": "GENE-N"}]}
{"text": "Recent studies highlight the capacity of sucralfate to bind basic fibroblast growth factor (bFGF) and deliver it in high concentration to the ulcer.", "spo_list": [{"subject": "sucralfate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "basic fibroblast growth factor", "object_type": "GENE-Y"}, {"subject": "sucralfate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "bFGF", "object_type": "GENE-Y"}]}
{"text": "Using microhelix substrates containing only the first four base pairs of the alanine tRNA acceptor helix, we demonstrated that the catalytic center of AlaRS with the three class-defining sequence motifs contains determinants for recognition of A73 and G2.C71.", "spo_list": [{"subject": "alanine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "AlaRS", "object_type": "GENE-N"}]}
{"text": "In subjects with dysmenorrhea the increase in pain following the administration of vasopressin was significantly lower during atosiban than during placebo infusion.", "spo_list": [{"subject": "atosiban", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "vasopressin", "object_type": "GENE-Y"}]}
{"text": "CONCLUSIONS: Atosiban reduces vasopressin-induced intrauterine pressure in both healthy volunteers and dysmenorrheics, and reported pain in subjects with dysmenorrhea.", "spo_list": [{"subject": "Atosiban", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "vasopressin", "object_type": "GENE-Y"}]}
{"text": "Conserved amino acid residues that are important for ligand binding in the type I gonadotropin-releasing hormone (GnRH) receptor are required for high potency of GnRH II at the type II GnRH receptor.", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "type I gonadotropin-releasing hormone (GnRH) receptor", "object_type": "GENE-Y"}, {"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "type II GnRH receptor", "object_type": "GENE-Y"}]}
{"text": "Amino acids of the type I GnRH receptor required for binding of GnRH I (Asp2.61(98), Asn2.65(102), and Lys3.32(121)) are conserved in the type II GnRH receptor, but their roles in receptor function are unknown.", "spo_list": [{"subject": "Amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "type I GnRH receptor", "object_type": "GENE-Y"}, {"subject": "GnRH I", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "type I GnRH receptor", "object_type": "GENE-Y"}, {"subject": "Amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "type II GnRH receptor", "object_type": "GENE-Y"}]}
{"text": "Mutating Asp2.61(97) to Glu or Ala, Asn2.65(101) to Ala, or Lys3.32(120) to Gln decreased potency of GnRH II-stimulated inositol phosphate production.", "spo_list": [{"subject": "Ala", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GnRH II", "object_type": "GENE-Y"}, {"subject": "Glu", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GnRH II", "object_type": "GENE-Y"}, {"subject": "Ala", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GnRH II", "object_type": "GENE-Y"}, {"subject": "Gln", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GnRH II", "object_type": "GENE-Y"}]}
{"text": "This suggests that Asp2.61(97) contributes to recognition of His2 of GnRH I, but not of GnRH II.", "spo_list": [{"subject": "His2", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GnRH I", "object_type": "GENE-Y"}]}
{"text": "This suggests that Asn2.65(101) recognizes Gly10NH2 of GnRH II.", "spo_list": [{"subject": "Gly10NH2", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "GnRH II", "object_type": "GENE-Y"}]}
{"text": "Preservation of glucose-stimulated insulin secretion.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-N"}]}
{"text": "We have previously reported that glucose-stimulated insulin secretion (GSIS) is tightly correlated with pyruvate carboxylase (PC)-catalyzed anaplerotic flux into the tricarboxylic acid cycle and stimulation of pyruvate cycling activity.", "spo_list": [{"subject": "glucose", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "insulin", "object_type": "GENE-N"}]}
{"text": "A series of studies have recently demonstrated that the release of interleukin 1Î² induced by monosodium urate crystals is central to the experimental gouty arthritis.", "spo_list": [{"subject": "monosodium urate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "interleukin 1Î²", "object_type": "GENE-Y"}]}
{"text": "These findings elucidate that emodinol exhibits a prominent effect on improving symptoms of acute gouty arthritis induced by monosodium urate crystals through inhibiting the generation of proinflammatory cytokines.", "spo_list": [{"subject": "emodinol", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cytokines", "object_type": "GENE-N"}, {"subject": "monosodium urate", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "cytokines", "object_type": "GENE-N"}]}
{"text": "Results: Inhibition of immunophilins by tacrolimus (FK506) and sirolimus (rapamycin) reduced Ca2+ entry in platelets from healthy donors and DM2 patients.", "spo_list": [{"subject": "tacrolimus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "immunophilins", "object_type": "GENE-N"}, {"subject": "FK506", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "immunophilins", "object_type": "GENE-N"}, {"subject": "sirolimus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "immunophilins", "object_type": "GENE-N"}, {"subject": "rapamycin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "immunophilins", "object_type": "GENE-N"}, {"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "immunophilins", "object_type": "GENE-N"}]}
{"text": "Conclusions: We suggest that, among others, FKBP52 expression and function are altered in platelets from DM2 patients, contributing to the altered Ca(2+) entry and hyperaggregability in these cells.", "spo_list": [{"subject": "Ca(2+)", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FKBP52", "object_type": "GENE-Y"}]}
{"text": "Trilostane, a potent new inhibitor of the delta 5-3 beta-HSD system, was found to inhibit the activity of delta 5-3 beta-HSD in ovulatory ova in 1 ml of phosphate buffer solution at a concentration of 10(-7)M. After these results were obtained, steroidogenesis of hamster ova was suggested in an indirect immunofluorescence study, and the implications of steroidogenesis for oocyte maturation and subsequent fertilization are discussed.", "spo_list": [{"subject": "Trilostane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "delta 5-3 beta-HSD", "object_type": "GENE-N"}, {"subject": "Trilostane", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "delta 5-3 beta-HSD", "object_type": "GENE-N"}]}
{"text": "Acetazolamide inhibits aquaporin-1 protein expression and angiogenesis.", "spo_list": [{"subject": "Acetazolamide", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "aquaporin-1", "object_type": "GENE-Y"}]}
{"text": "The inhibitory effect of clonidine (non-selective alpha2-adrenoceptor agonist) and oxymetazoline (alpha2A-adrenoceptor selective agonist) was compared on basal and stimulated gastric motor activity (gastric tone and contractions) using the balloon method in the rat.", "spo_list": [{"subject": "clonidine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha2-adrenoceptor", "object_type": "GENE-N"}, {"subject": "oxymetazoline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha2A-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "However, while the effect of clonidine was antagonized by the non-selective alpha2-adrenoceptor antagonist yohimbine (5 micromol/kg, i.v.) and the alpha2A-adrenoceptor selective antagonist BRL 44408 (3 micromol/kg, i.v.), the effect of oxymetazoline was only partially affected.", "spo_list": [{"subject": "yohimbine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha2-adrenoceptor", "object_type": "GENE-N"}, {"subject": "clonidine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha2-adrenoceptor", "object_type": "GENE-N"}, {"subject": "BRL 44408", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "alpha2A-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "oxymetazoline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha2A-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Furthermore, when gastric motility was stimulated peripherally by activation of postsynaptic cholinergic muscarinic receptors by the combination of carbachol (0.14 micromol/kg, i.v.) and hexamethonium (37 micromol/kg, i.v.), clonidine (3.8 micromol/kg, i.v.) failed to affect the increased motor activity, however, oxymetazoline (0.8-3.4 micromol/kg, i.v.) exerted a pronounced inhibition.", "spo_list": [{"subject": "carbachol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "muscarinic receptors", "object_type": "GENE-N"}, {"subject": "hexamethonium", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "muscarinic receptors", "object_type": "GENE-N"}, {"subject": "oxymetazoline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "muscarinic receptors", "object_type": "GENE-N"}]}
{"text": "These results suggest that different mechanisms may be involved in the inhibitory effect of clonidine and oxymetazoline; while clonidine reduces the gastric motility by activation of presynaptic alpha2-adrenoceptors, postsynaptic component in the effect of oxymetazoline has also been raised.", "spo_list": [{"subject": "clonidine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "alpha2-adrenoceptors", "object_type": "GENE-N"}, {"subject": "oxymetazoline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "alpha2-adrenoceptors", "object_type": "GENE-N"}]}
{"text": "The acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitory activities of a series of pyrano[2,3-b]quinolines (2, 3), [1,8]naphthyridines (5, 6), 4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines (11-13)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine (14), 4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline (15)/ 4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine (16) are described.", "spo_list": [{"subject": "pyrano[2,3-b]quinolines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "pyrano[2,3-b]quinolines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "pyrano[2,3-b]quinolines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "pyrano[2,3-b]quinolines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BuChE", "object_type": "GENE-Y"}, {"subject": "[1,8]naphthyridines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "[1,8]naphthyridines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "[1,8]naphthyridines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "[1,8]naphthyridines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BuChE", "object_type": "GENE-Y"}, {"subject": "4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "4-amino-2,3-diaryl-5,6,7,8-tetrahydrofuro[2,3-b]quinolines", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BuChE", "object_type": "GENE-Y"}, {"subject": "4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]furo[2,3-b]pyridine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BuChE", "object_type": "GENE-Y"}, {"subject": "4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "4-amino-5,6,7,8-tetrahydro-2,3-diphenylthieno[2,3-b]quinoline", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BuChE", "object_type": "GENE-Y"}, {"subject": "4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "4-amino-6,7,8,9-tetrahydro-2,3-diphenyl-5H-cyclohepta[e]thieno[2,3-b]pyridine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BuChE", "object_type": "GENE-Y"}]}
{"text": "These compounds are competitive and, in a few cases, non-competitive inhibitors for AChE, the most potent being compound (14), though three-fold less active than tacrine.", "spo_list": [{"subject": "tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "The BuChE inhibitory activity is only significant in compounds 11 and 14, ten-fold less active than tacrine.", "spo_list": [{"subject": "tacrine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BuChE", "object_type": "GENE-Y"}]}
{"text": "The role of cytochrome P450-dependent metabolism in the regulation of mouse hepatic growth hormone signaling components and target genes by 3-methylcholanthrene.", "spo_list": [{"subject": "3-methylcholanthrene", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "cytochrome P450", "object_type": "GENE-N"}]}
{"text": "3-Methylcholanthrene (MC) is a readily metabolized aryl hydrocarbon receptor (AHR) agonist.", "spo_list": [{"subject": "3-Methylcholanthrene", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "aryl hydrocarbon receptor", "object_type": "GENE-Y"}, {"subject": "3-Methylcholanthrene", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "AHR", "object_type": "GENE-Y"}]}
{"text": "The antiarrhythmic effects of exogenous adenosine and Valsalva on this form of VT may be due to receptor-mediated inhibition of adenylate cyclase or to noncardiac receptor-mediated effects, i.e., exogenous adenosine may modulate VT through alterations in autonomic tone by activation of arterial chemoreceptors, and Valsalva has been shown to decrease venous return, resulting in a reduction in cardiac dimensions and myocardial stretch.", "spo_list": [{"subject": "adenosine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "chemoreceptors", "object_type": "GENE-N"}]}
{"text": "VT recurred with the addition of aminophylline, a competitive adenosine A1-receptor antagonist.", "spo_list": [{"subject": "aminophylline", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "adenosine A1-receptor", "object_type": "GENE-Y"}]}
{"text": "Edrophonium (10 mg i.v.), a cholinesterase inhibitor that potentiates the effects of acetylcholine at the muscarinic cholinergic receptor, terminated VT in four of four patients, an effect that was reversed by atropine.", "spo_list": [{"subject": "Edrophonium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cholinesterase", "object_type": "GENE-Y"}]}
{"text": "Binding sites for hERG blockers have been mapped within the inner cavity of the channel and include aromatic residues in the S6 helix (Tyr-652, Phe-656) and residues in the pore helix (Thr-623, Ser-624, Val-625).", "spo_list": [{"subject": "Tyr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "hERG", "object_type": "GENE-Y"}, {"subject": "Phe", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "hERG", "object_type": "GENE-Y"}, {"subject": "Thr", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "hERG", "object_type": "GENE-Y"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "hERG", "object_type": "GENE-Y"}, {"subject": "Val", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "hERG", "object_type": "GENE-Y"}]}
{"text": "We used mutagenesis of these residues, combined with an investigation of hERG block by close analogs of clofilium and ibutilide, to assess how specific alterations in drug structure affected potency and binding interactions.", "spo_list": [{"subject": "clofilium", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hERG", "object_type": "GENE-Y"}, {"subject": "ibutilide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hERG", "object_type": "GENE-Y"}]}
{"text": "We describe here the isolation and biochemical characterization of the marine natural sesquiterpene palinurin as a GSK-3Î² inhibitor.", "spo_list": [{"subject": "sesquiterpene", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GSK-3Î²", "object_type": "GENE-Y"}, {"subject": "palinurin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GSK-3Î²", "object_type": "GENE-Y"}]}
{"text": "Experimental studies performed for characterizing the inhibitory mechanism indicate that GSK-3Î² inhibition by palinurin cannot be competed out by ATP nor peptide substrate.", "spo_list": [{"subject": "palinurin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GSK-3Î²", "object_type": "GENE-Y"}]}
{"text": "Moreover, molecular dynamics simulations have identified an allosteric mechanism by which binding of palinurin leads to GSK-3Î² inhibition.", "spo_list": [{"subject": "palinurin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "GSK-3Î²", "object_type": "GENE-Y"}]}
{"text": "UCCB01-125, a dimeric inhibitor of PSD-95, reduces inflammatory pain without disrupting cognitive or motor performance: comparison with the NMDA receptor antagonist MK-801.", "spo_list": [{"subject": "MK-801", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NMDA receptor", "object_type": "GENE-N"}]}
{"text": "Here, we compared the effects of a dimeric PSD-95 inhibitor, UCCB01-125, and the NMDAR antagonist, MK-801, on mechanical hypersensitivity in the complete Freund's adjuvant (CFA) model of inflammatory pain.", "spo_list": [{"subject": "UCCB01-125", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PSD-95", "object_type": "GENE-Y"}, {"subject": "MK-801", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "NMDAR", "object_type": "GENE-N"}]}
{"text": "Cocaine significantly decreased the abundance of the SERT mRNA within the dlDR and DAT mRNA abundance within the SNc and the PBP, and increased the abundance of the NET mRNA within the LC.", "spo_list": [{"subject": "Cocaine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "SERT", "object_type": "GENE-Y"}, {"subject": "Cocaine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NET", "object_type": "GENE-Y"}, {"subject": "Cocaine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "DAT", "object_type": "GENE-Y"}]}
{"text": "MTA predictions identified OATP1B1 and OATP1B3 as major determinants of atorvastatin uptake in vivo.", "spo_list": [{"subject": "atorvastatin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B1", "object_type": "GENE-Y"}, {"subject": "atorvastatin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP1B3", "object_type": "GENE-Y"}]}
{"text": "Clinical studies in patients with polycystic ovary syndrome (characterized by insulin resistance, hyperinsulinemia, ovarian androgen overproduction, and impaired fibrinolytic capacity) demonstrated that treatment with troglitazone, an insulin-sensitizing agent, can markedly reduce blood levels of PAI-1.", "spo_list": [{"subject": "troglitazone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "PAI-1", "object_type": "GENE-Y"}]}
{"text": "HDAC inhibition was observed for 3, to a lesser extent than SAHA, and rationalized by molecular docking into the active site of HDAC8.", "spo_list": [{"subject": "SAHA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "HDAC", "object_type": "GENE-N"}, {"subject": "SAHA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "HDAC8", "object_type": "GENE-Y"}]}
{"text": "Functional analysis of differentially expressed genes revealed distinct expression profiles at 24h post fertilization for 0.1Î¼M versus 80Î¼M BPA and 0.1Î¼M versus 15Î¼M E2 exposure, identification of prothrombin activation as a top canonical pathway impacted by both 0.1Î¼M BPA and 0.1Î¼M E2 exposure, and suppressed expression of several genes involved in nervous system development and function following 0.1Î¼M BPA exposure.", "spo_list": [{"subject": "BPA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "prothrombin", "object_type": "GENE-Y"}]}
{"text": "Neither mepyramine (3 mg/kg x 2), an H1 antagonist, nor cimetidine (15 mg/kg x 2), an H2 antagonist, affected the outcome in histamine-treated rats.", "spo_list": [{"subject": "mepyramine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "H1", "object_type": "GENE-Y"}, {"subject": "cimetidine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "H2", "object_type": "GENE-Y"}]}
{"text": "However, thioperamide (5 mg/kg x 2), an H3/H4 antagonist, completely abolished the alleviation caused by histamine.", "spo_list": [{"subject": "thioperamide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "H3", "object_type": "GENE-Y"}, {"subject": "thioperamide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "H4", "object_type": "GENE-Y"}, {"subject": "histamine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "H4", "object_type": "GENE-Y"}, {"subject": "histamine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "H3", "object_type": "GENE-Y"}]}
{"text": "Administration of dimaprit (1-10 mg/kg x 2), an H2/H4 agonist, mimicked the protective effect of histamine, and the effect of dimaprit is reversed by thioperamide, whereas neither H1 nor H2 antagonists altered the outcome caused by dimaprit.", "spo_list": [{"subject": "dimaprit", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "H2", "object_type": "GENE-Y"}, {"subject": "dimaprit", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "H4", "object_type": "GENE-Y"}, {"subject": "histamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "H4", "object_type": "GENE-Y"}, {"subject": "histamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "H2", "object_type": "GENE-Y"}, {"subject": "dimaprit", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "H4", "object_type": "GENE-Y"}, {"subject": "dimaprit", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "H2", "object_type": "GENE-Y"}, {"subject": "thioperamide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "H2", "object_type": "GENE-Y"}, {"subject": "thioperamide", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "H4", "object_type": "GENE-Y"}]}
{"text": "Clozapine (15 mg/kg x 2), an H4 agonist, also mimicked the protective effect of histamine.", "spo_list": [{"subject": "Clozapine", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "H4", "object_type": "GENE-Y"}, {"subject": "histamine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "H4", "object_type": "GENE-Y"}]}
{"text": "Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid.", "spo_list": [{"subject": "arachidonic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "5-lipoxygenase", "object_type": "GENE-Y"}, {"subject": "sulfasalazine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-lipoxygenase", "object_type": "GENE-Y"}, {"subject": "5-aminosalicylic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "5-lipoxygenase", "object_type": "GENE-Y"}]}
{"text": "Interference with lipoxygenase enzymes, rather than a steroid-like inhibition of arachidonic acid release from intracellular phospholipids, seems to be the mode of action.", "spo_list": [{"subject": "arachidonic acid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "lipoxygenase", "object_type": "GENE-N"}, {"subject": "steroid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "lipoxygenase", "object_type": "GENE-N"}]}
{"text": "A new series of N2-substituted-5-(p-toluenesulfonylamino)phthalimide analogues as Î±-glucosidase inhibitors.", "spo_list": [{"subject": "N2-substituted-5-(p-toluenesulfonylamino)phthalimide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Î±-glucosidase", "object_type": "GENE-N"}]}
{"text": "Several members of a new family of non-sugar-type Î±-glycosidase inhibitors, bearing a 5-(p-toluenesulfonylamino)phthalimide moiety and various substituent at the N2 position, were synthesized and their activities were investigated.", "spo_list": [{"subject": "5-(p-toluenesulfonylamino)phthalimide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Î±-glycosidase", "object_type": "GENE-N"}]}
{"text": "Structure-activity relationship studies indicated that 5-(p-toluenesulfonylamino)phthalimide moiety is a favorable scaffold to exert the Î±-glucosidase inhibitory activity and substituents at the N2 position have considerable influence on the efficacy of the inhibition activities.", "spo_list": [{"subject": "5-(p-toluenesulfonylamino)phthalimide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Î±-glucosidase", "object_type": "GENE-N"}]}
{"text": "Methylation of histone H3 on lysine 4 by the lysine methyltransferase SET1 protein is needed for normal clock gene expression.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "histone H3", "object_type": "GENE-N"}]}
{"text": "Aromatic L-amino acid decarboxylase catalyzes the decarboxylation of L-5-hydroxytryptophan to serotonin and that of L-3,4-dihydroxyphenylalanine to dopamine.", "spo_list": [{"subject": "L-5-hydroxytryptophan", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Aromatic L-amino acid decarboxylase", "object_type": "GENE-Y"}, {"subject": "serotonin", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Aromatic L-amino acid decarboxylase", "object_type": "GENE-Y"}, {"subject": "L-3,4-dihydroxyphenylalanine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Aromatic L-amino acid decarboxylase", "object_type": "GENE-Y"}, {"subject": "dopamine", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Aromatic L-amino acid decarboxylase", "object_type": "GENE-Y"}]}
{"text": "LTC4 synthase (LTC4S), the pivotal enzyme for the biosynthesis of LTC4 (ref.", "spo_list": [{"subject": "LTC4", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "LTC4 synthase", "object_type": "GENE-Y"}, {"subject": "LTC4", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "LTC4S", "object_type": "GENE-Y"}]}
{"text": "10), is an 18-kDa integral nuclear membrane protein that belongs to a superfamily of membrane-associated proteins in eicosanoid and glutathione metabolism that includes 5-lipoxygenase-activating protein, microsomal glutathione S-transferases (MGSTs), and microsomal prostaglandin E synthase 1 (ref.", "spo_list": [{"subject": "glutathione", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "microsomal glutathione S-transferases", "object_type": "GENE-N"}, {"subject": "glutathione", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MGSTs", "object_type": "GENE-N"}, {"subject": "eicosanoid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "microsomal glutathione S-transferases", "object_type": "GENE-N"}, {"subject": "eicosanoid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "MGSTs", "object_type": "GENE-N"}, {"subject": "eicosanoid", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "microsomal prostaglandin E synthase 1", "object_type": "GENE-Y"}, {"subject": "glutathione", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "microsomal prostaglandin E synthase 1", "object_type": "GENE-Y"}]}
{"text": "We analysed the role of the MBD in MeCP2-chromatin associations in vivo using an MeCP2 mutant Rett syndrome mouse model (Mecp2(tm)(1)(.)(1)(Jae)) in which exon 3 deletion results in an N-terminal truncation of the protein, including most of the MBD. Our results show that in mutant mice, the truncated form of MeCP2 (ÎMeCP2) is expressed in different regions of the brain and liver, albeit at 50% of its wild-type (wt) counterpart.", "spo_list": [{"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MeCP2", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "MeCP2", "object_type": "GENE-Y"}, {"subject": "N", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Mecp2", "object_type": "GENE-Y"}]}
{"text": "ICA-105574 interacts with a common binding site to elicit opposite effects on inactivation gating of EAG and ERG potassium channels.", "spo_list": [{"subject": "ICA-105574", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "EAG", "object_type": "GENE-Y"}, {"subject": "ICA-105574", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ERG", "object_type": "GENE-Y"}, {"subject": "ICA-105574", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "potassium channels", "object_type": "GENE-N"}, {"subject": "ICA-105574", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAG", "object_type": "GENE-Y"}, {"subject": "ICA-105574", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERG", "object_type": "GENE-Y"}, {"subject": "ICA-105574", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "potassium channels", "object_type": "GENE-N"}]}
{"text": "Although ICA greatly attenuates ERG inactivation by shifting its voltage dependence to more positive potentials, it enhances the rate and extent of EAG inactivation without altering its voltage dependence.", "spo_list": [{"subject": "ICA", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ERG", "object_type": "GENE-Y"}, {"subject": "ICA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "EAG", "object_type": "GENE-Y"}]}
{"text": "ICA is a mixed agonist of mutant EAG and EAG/ERG chimera channels that inactivate by a combination of slow and fast mechanisms.", "spo_list": [{"subject": "ICA", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "EAG", "object_type": "GENE-Y"}, {"subject": "ICA", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "EAG", "object_type": "GENE-Y"}, {"subject": "ICA", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "ERG", "object_type": "GENE-Y"}]}
{"text": "With the exception of three residues, the specific amino acids that form the putative binding pocket for ICA in ERG are conserved in EAG.", "spo_list": [{"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "ERG", "object_type": "GENE-Y"}, {"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "EAG", "object_type": "GENE-Y"}, {"subject": "ICA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERG", "object_type": "GENE-Y"}, {"subject": "ICA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAG", "object_type": "GENE-Y"}]}
{"text": "Mutations introduced into EAG to replicate the ICA binding site in ERG did not alter the functional response to ICA.", "spo_list": [{"subject": "ICA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAG", "object_type": "GENE-Y"}, {"subject": "ICA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERG", "object_type": "GENE-Y"}, {"subject": "ICA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAG", "object_type": "GENE-Y"}, {"subject": "ICA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERG", "object_type": "GENE-Y"}]}
{"text": "Together these findings suggest that ICA binds to the same site in EAG and ERG channels to elicit opposite functional effects.", "spo_list": [{"subject": "ICA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "EAG", "object_type": "GENE-Y"}, {"subject": "ICA", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "ERG", "object_type": "GENE-Y"}]}
{"text": "Responses to an orally active renin inhibitor, remikiren (Ro 42-5892), after controlled salt depletion in humans.", "spo_list": [{"subject": "remikiren", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "renin", "object_type": "GENE-Y"}, {"subject": "Ro 42-5892", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "renin", "object_type": "GENE-Y"}]}
{"text": "We studied remikiren (Ro42-4892), a selective renin inhibitor, in normal volunteers after activation of the renin-angiotensin system (RAS) based on salt depletion.", "spo_list": [{"subject": "remikiren", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "renin", "object_type": "GENE-Y"}, {"subject": "Ro42-4892", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "renin", "object_type": "GENE-Y"}]}
{"text": "Epithelial glycoprotein 330 (gp330) is structurally similar to the multifunctional alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein (alpha 2MR/LRP), gp330 and alpha 2MR/LRP bind Ca2+ with high affinity, and both receptors bind and mediate endocytosis of alpha 2MR-associated protein (RAP).", "spo_list": [{"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Epithelial glycoprotein 330", "object_type": "GENE-Y"}, {"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "gp330", "object_type": "GENE-Y"}, {"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 2-macroglobulin receptor", "object_type": "GENE-Y"}, {"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "low density lipoprotein receptor-related protein", "object_type": "GENE-N"}, {"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 2MR", "object_type": "GENE-Y"}, {"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "LRP", "object_type": "GENE-N"}, {"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "gp330", "object_type": "GENE-Y"}, {"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 2MR", "object_type": "GENE-Y"}, {"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "LRP", "object_type": "GENE-N"}]}
{"text": "In the present report, we describe that affinity-purified gp330 from rabbit renal cortex binds plasminogen activator inhibitor type-1 (PAI-1) complexed with urokinase-type plasminogen activator (uPA). alpha 2M-methylamine, which binds with high affinity to alpha 2MR/LRP, did not bind to gp330.", "spo_list": [{"subject": "methylamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "alpha 2MR", "object_type": "GENE-Y"}, {"subject": "methylamine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "LRP", "object_type": "GENE-N"}]}
{"text": "Thin sections of rabbit renal proximal tubules bound 125I-labeled uPA.PAI-1 and rRAP in the apical part of proximal tubules corresponding to the localization of gp330.", "spo_list": [{"subject": "125I", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "uPA", "object_type": "GENE-Y"}, {"subject": "125I", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PAI-1", "object_type": "GENE-Y"}]}
{"text": "The binding of 125I-uPA.PAI-1 complexes in tubules was abolished by excess unlabeled rRAP, and a rRAP-inhibitable endocytosis and degradation of labeled uPA.PAI-1 complexes was demonstrated by perfusion of isolated rabbit proximal tubules.", "spo_list": [{"subject": "125I", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "uPA", "object_type": "GENE-Y"}, {"subject": "125I", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PAI-1", "object_type": "GENE-Y"}]}
{"text": "Initial in vitro studies utilizing HEP-G2 liver cells revealed that addition of eicosapentaenoic acid (EPA) blocked Delta-5-desaturase activity, the terminal enzymatic step in AA synthesis.", "spo_list": [{"subject": "eicosapentaenoic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Delta-5-desaturase", "object_type": "GENE-Y"}, {"subject": "EPA", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Delta-5-desaturase", "object_type": "GENE-Y"}]}
{"text": "In addition, we have previously shown an important role for COX-produced prostanoids in recovery of ischaemic-injured equine jejunum.", "spo_list": [{"subject": "prostanoids", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX", "object_type": "GENE-N"}]}
{"text": "It was hypothesised that the nonselective COX inhibitor flunixin would retard repair of bile-injured colon by preventing production of reparative prostaglandins, whereas the selective COX-2 inhibitor, etodolac would not inhibit repair as a result of continued COX-1 activity.", "spo_list": [{"subject": "flunixin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX", "object_type": "GENE-N"}, {"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX", "object_type": "GENE-N"}, {"subject": "etodolac", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Therefore, although recovery from bile-induced colonic injury maybe independent of COX-elaborated prostanoids, treatment of control tissues with nonselective COX inhibitors may lead to marked increases in permeability.", "spo_list": [{"subject": "prostanoids", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "COX", "object_type": "GENE-N"}]}
{"text": "Selenoproteins are proteins carrying the rare amino acid Sec (selenocysteine).", "spo_list": [{"subject": "amino acid", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Selenoproteins", "object_type": "GENE-N"}, {"subject": "Sec", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Selenoproteins", "object_type": "GENE-N"}, {"subject": "selenocysteine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Selenoproteins", "object_type": "GENE-N"}]}
{"text": "Incubation of in vitro transcribed tRNA[Ser]Sec with recombinant Trit1 transfers [(14)C]dimethylallyl pyrophosphate to tRNA([Ser]Sec).", "spo_list": [{"subject": "[(14)C]dimethylallyl pyrophosphate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Trit1", "object_type": "GENE-Y"}, {"subject": "[(14)C]dimethylallyl pyrophosphate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "tRNA([Ser]Sec)", "object_type": "GENE-Y"}]}
{"text": "One major route involves the tetrahydrofolate (THF)-dependent activities of the glycine decarboxylase complex (GDC, EC 2.1.1.10) and serine hydroxymethyltransferase (SHMT, EC 2.1.2.1) with glycine (Gly) as one-carbon (1-C) source.", "spo_list": [{"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "glycine decarboxylase complex", "object_type": "GENE-N"}, {"subject": "Gly", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "glycine decarboxylase complex", "object_type": "GENE-N"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GDC", "object_type": "GENE-N"}, {"subject": "Gly", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GDC", "object_type": "GENE-N"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 2.1.1.10", "object_type": "GENE-Y"}, {"subject": "Gly", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 2.1.1.10", "object_type": "GENE-Y"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "serine hydroxymethyltransferase", "object_type": "GENE-N"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SHMT", "object_type": "GENE-N"}, {"subject": "glycine", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 2.1.2.1", "object_type": "GENE-Y"}, {"subject": "Gly", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "serine hydroxymethyltransferase", "object_type": "GENE-N"}, {"subject": "Gly", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SHMT", "object_type": "GENE-N"}, {"subject": "Gly", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 2.1.2.1", "object_type": "GENE-Y"}]}
{"text": "An alternative THF-dependent pathway involves the C1-THF synthase/SHMT activities with formate as 1-C source.", "spo_list": [{"subject": "formate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "SHMT", "object_type": "GENE-N"}, {"subject": "formate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "C1-THF synthase", "object_type": "GENE-Y"}]}
{"text": "Firstly, transgenic plants overexpressing formate dehydrogenase (FDH, EC 1.2.1.2) were used to continue our previous studies on the function of FDH in formate metabolism.", "spo_list": [{"subject": "formate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FDH", "object_type": "GENE-Y"}, {"subject": "formate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "formate dehydrogenase", "object_type": "GENE-Y"}, {"subject": "formate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FDH", "object_type": "GENE-Y"}, {"subject": "formate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "EC 1.2.1.2", "object_type": "GENE-Y"}]}
{"text": "We concluded that FDH has no direct role in the regulation of the above two pathways of Ser synthesis; the breakdown of formate to CO(2) by the FDH reaction is the primary and preferred fate of the organic acid in Arabidopsis.", "spo_list": [{"subject": "formate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "FDH", "object_type": "GENE-Y"}, {"subject": "CO(2)", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "FDH", "object_type": "GENE-Y"}]}
{"text": "The ratio between the GDC/SHMT and C1-THF synthase/SHMT pathways of Ser synthesis from [alpha-(13)C]Gly and [(13)C]formate, respectively, in Arabidopsis shoots was 21 : 1; in roots, 9 : 1.", "spo_list": [{"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "SHMT", "object_type": "GENE-N"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "SHMT", "object_type": "GENE-N"}, {"subject": "[alpha-(13)C]Gly", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GDC", "object_type": "GENE-N"}, {"subject": "[(13)C]formate", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "C1-THF synthase", "object_type": "GENE-Y"}]}
{"text": "On the other hand, the accumulation of Ser through the C1-THF synthase/SHMT pathway in glyD plants was 2.5-fold greater than that in WT plants.", "spo_list": [{"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "SHMT", "object_type": "GENE-N"}]}
{"text": "In this report, we demonstrate the utility of reversed-phase protein chromatography and FT-ICR mass spectrometry in analyzing CCNU (lomustine, 1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea, MW: 233.7Da) modification of stathmin.", "spo_list": [{"subject": "lomustine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "stathmin", "object_type": "GENE-Y"}, {"subject": "1-(2-chloroethyl)-3-cyclohexyl-1-nitroso-urea", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "stathmin", "object_type": "GENE-Y"}]}
{"text": "The expression of ER-alpha and PR isoform A in virgin mice was surprisingly much higher in BALB/c than in C57BL/6 mammary glands, and both receptors were downregulated in progestin-treated BALB/c mice (P < 0.05).", "spo_list": [{"subject": "progestin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ER-alpha", "object_type": "GENE-Y"}, {"subject": "progestin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "PR isoform A", "object_type": "GENE-Y"}]}
{"text": "PR isoform B levels were low in virgin control mice and increased after progestin treatment in both strains.", "spo_list": [{"subject": "progestin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "PR isoform B", "object_type": "GENE-Y"}]}
{"text": "Salidroside or salidroside+PI3K inhibitor (LY294002) was administered via intracoronary injections at the onset of reperfusion.", "spo_list": [{"subject": "LY294002", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PI3K", "object_type": "GENE-N"}]}
{"text": "The results showed that intracoronary injection of salidroside at the onset of reperfusion markedly reduced the apoptosis of cardiomyocytes, significantly increasing Bcl-2 and p-Akt proteins expressions and decreasing Bax and caspase-3 expressions in the hearts subjected to ischemia followed by 120-min reperfusion.", "spo_list": [{"subject": "salidroside", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bcl-2", "object_type": "GENE-Y"}, {"subject": "salidroside", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p-Akt", "object_type": "GENE-N"}, {"subject": "salidroside", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Bax", "object_type": "GENE-Y"}, {"subject": "salidroside", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "caspase-3", "object_type": "GENE-Y"}]}
{"text": "However, the anti-apoptotic effect induced by salidroside was inhibited by LY294002, which blocked the activation of Akt.", "spo_list": [{"subject": "LY294002", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}]}
{"text": "Michaelis-Menten constants and turnover numbers for PGH2 were 141 microM and 10.8 min(-1) for GSTM2-2 and 1.5 mM and 130 min(-1) for GSTM3-3, respectively.", "spo_list": [{"subject": "PGH2", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GSTM2-2", "object_type": "GENE-Y"}, {"subject": "PGH2", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GSTM3-3", "object_type": "GENE-Y"}]}
{"text": "In comparison to homozygous, wild type (WT) mice, HZ mice show a 40% reduction of AChE activity in the brain, while their hippocampal ACh levels are increased by 56% as measured by microdialysis; choline acetyltransferase levels remain unaltered, and choline uptake increases 2-fold.", "spo_list": [{"subject": "choline", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "choline acetyltransferase", "object_type": "GENE-N"}]}
{"text": "We demonstrate that HZ mice are significantly more sensitive to local AChE inhibition (BW284c51), but remain insensitive to butyrylcholinesterase (BuChE) inhibition (bambuterol).", "spo_list": [{"subject": "BW284c51", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "bambuterol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "bambuterol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BuChE", "object_type": "GENE-Y"}]}
{"text": "HZ mice are also more sensitive to the peripheral application of the selective AChE inhibitor donepezil or the mixed inhibitor physostigmine; extracellular ACh levels rise significantly after administration of both drugs; also glucose levels are moderately increased indicating potentially non-cholinergic effects of donepezil.", "spo_list": [{"subject": "donepezil", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "physostigmine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "Tamoxifen represses miR-200 microRNAs and promotes epithelial-to-mesenchymal transition by up-regulating c-Myc in endometrial carcinoma cell lines.", "spo_list": [{"subject": "Tamoxifen", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "miR-200", "object_type": "GENE-N"}]}
{"text": "When treated with TAM, ECC-1 and Ishikawa cells were characterized by higher invasiveness and motility and underwent EMT. miR-200, a miRNA family with tumor suppressive functions in a wide range of cancers, was found reduced in response to TAM treatment.", "spo_list": [{"subject": "TAM", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "miR-200", "object_type": "GENE-N"}]}
{"text": "Consistent with zinc finger E-box binding homeobox 2, which was confirmed as a direct target of miR-200b in endometrial cancer cell lines, some other key factors of EMT such as Snail and N-cadherin increased, whereas E-cadherin decreased in the TAM-treated cells, contributing to TAM-induced EMT in these endometrial cancer cells.", "spo_list": [{"subject": "TAM", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Snail", "object_type": "GENE-Y"}, {"subject": "TAM", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "N-cadherin", "object_type": "GENE-Y"}, {"subject": "TAM", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "E-cadherin", "object_type": "GENE-Y"}]}
{"text": "In addition, we showed that c-Myc directly binds to and represses the promoter of miR-200 miRNAs, and its up-regulation in TAM-treated endometrial cancer cells leads to the down-regulation of miR-200 and eventually to EMT.", "spo_list": [{"subject": "TAM", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "miR-200", "object_type": "GENE-N"}]}
{"text": "Collectively, our data suggest that TAM can repress the miR-200 family and induce EMT via the up-regulation of c-Myc in endometrial cancer cells.", "spo_list": [{"subject": "TAM", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "miR-200", "object_type": "GENE-N"}]}
{"text": "Cannabinoid receptor 1 (CB(1)) inverse agonists (e.g., rimonabant) have been reported to produce adverse effects including nausea, emesis, and anhedonia that limit their clinical applications.", "spo_list": [{"subject": "rimonabant", "subject_type": "CHEMICAL", "predicate": "AGONIST-INHIBITOR", "object": "Cannabinoid receptor 1", "object_type": "GENE-N"}, {"subject": "rimonabant", "subject_type": "CHEMICAL", "predicate": "AGONIST-INHIBITOR", "object": "CB(1)", "object_type": "GENE-N"}]}
{"text": "In the present studies, the CB(1) inverse agonist SR141716A (rimonabant) and the CB(1) neutral antagonist AM4113 were compared for their ability to modify CB(1) receptor-mediated discriminative stimulus effects in nonhuman primates trained to discriminate the novel CB(1) full agonist AM4054.", "spo_list": [{"subject": "SR141716A", "subject_type": "CHEMICAL", "predicate": "AGONIST-INHIBITOR", "object": "CB(1)", "object_type": "GENE-N"}, {"subject": "rimonabant", "subject_type": "CHEMICAL", "predicate": "AGONIST-INHIBITOR", "object": "CB(1)", "object_type": "GENE-N"}, {"subject": "AM4113", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CB(1)", "object_type": "GENE-N"}, {"subject": "AM4054", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "CB(1)", "object_type": "GENE-N"}]}
{"text": "Results indicate that AM4054 serves as an effective CB(1) discriminative stimulus, with an onset and time course of action comparable with that of the CB(1) agonist Î(9)-tetrahydrocannabinol, and that the inverse agonist rimonabant and the neutral antagonist AM4113 produce dose-related rightward shifts in the AM4054 dose-effect curve, indicating that both drugs surmountably antagonize the discriminative stimulus effects of AM4054.", "spo_list": [{"subject": "AM4054", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CB(1)", "object_type": "GENE-N"}, {"subject": "Î(9)-tetrahydrocannabinol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "CB(1)", "object_type": "GENE-N"}, {"subject": "rimonabant", "subject_type": "CHEMICAL", "predicate": "AGONIST-INHIBITOR", "object": "CB(1)", "object_type": "GENE-N"}, {"subject": "AM4113", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "CB(1)", "object_type": "GENE-N"}, {"subject": "AM4054", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "CB(1)", "object_type": "GENE-N"}, {"subject": "AM4054", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "CB(1)", "object_type": "GENE-N"}]}
{"text": "Alprenolol and bromoacetylalprenololmenthane are competitive slowly reversible antagonists at the beta 1-adrenoceptors of rat left atria.", "spo_list": [{"subject": "Alprenolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta 1-adrenoceptors", "object_type": "GENE-Y"}, {"subject": "bromoacetylalprenololmenthane", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta 1-adrenoceptors", "object_type": "GENE-Y"}]}
{"text": "Alprenolol and BAAM at 10(-7), 3 x 10(-7), and 10(-6) M inhibited the cardiac stimulation response slightly, which is indicative of membrane-stabilizing activity independent of beta-adrenoceptor blockade.", "spo_list": [{"subject": "Alprenolol", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "beta-adrenoceptor", "object_type": "GENE-N"}, {"subject": "BAAM", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "beta-adrenoceptor", "object_type": "GENE-N"}]}
{"text": "Alprenolol and BAAM also caused surmountable antagonism of isoprenaline responses, and this beta 1-adrenoceptor antagonism was slowly reversible.", "spo_list": [{"subject": "Alprenolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta 1-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "BAAM", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta 1-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "isoprenaline", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta 1-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "We conclude that alprenolol and BAAM are competitive slowly reversible beta 1-adrenoceptor antagonists on rat left atria.", "spo_list": [{"subject": "alprenolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta 1-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "BAAM", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta 1-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "The cytosine analog 5-aza-2'-deoxycytidine (decitabine) hypomethylates DNA by inhibiting DNA methyltransferase.", "spo_list": [{"subject": "cytosine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA methyltransferase", "object_type": "GENE-N"}, {"subject": "5-aza-2'-deoxycytidine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA methyltransferase", "object_type": "GENE-N"}, {"subject": "decitabine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "DNA methyltransferase", "object_type": "GENE-N"}]}
{"text": "We examined if subcutaneous decitabine could increase HbF levels and improve SSD pathophysiology without cytotoxicity.", "spo_list": [{"subject": "decitabine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HbF", "object_type": "GENE-N"}]}
{"text": "Weekly subcutaneous decitabine produces cumulative increases in HbF and total hemoglobin through a noncytotoxic mechanism of action.", "spo_list": [{"subject": "decitabine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HbF", "object_type": "GENE-N"}, {"subject": "decitabine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "hemoglobin", "object_type": "GENE-N"}]}
{"text": "The synthesis, preclinical profile, and in vivo efficacy in rat xenograft models of the novel and selective anaplastic lymphoma kinase inhibitor 15b (LDK378) are described.", "spo_list": [{"subject": "LDK378", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "anaplastic lymphoma kinase", "object_type": "GENE-Y"}]}
{"text": "In this initial report, preliminary structure-activity relationships (SARs) are described as well as the rational design strategy employed to overcome the development deficiencies of the first generation ALK inhibitor 4 (TAE684).", "spo_list": [{"subject": "TAE684", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ALK", "object_type": "GENE-Y"}]}
{"text": "Role of edrophonium in prevention of the re-inhibition of acetylcholinesterase by phosphorylated oxime.", "spo_list": [{"subject": "oxime", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-Y"}]}
{"text": "With DEPQ-inhibited wild-type mouse acetylcholinesterase (AChE), the reactivation kinetic profile demonstrated one-phase exponential association only when 2-[hydroxyimino methyl]-1-methylpyridinium chloride (2-PAM) and 1-(2-hydroxy-iminomethyl-1-pyridinium)-1-(4-carboxy-aminopyridi nium)-dimethyl ether hydrochloride (HI-6) were used as reactivators.", "spo_list": [{"subject": "DEPQ", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mouse acetylcholinesterase", "object_type": "GENE-Y"}, {"subject": "DEPQ", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "2-[hydroxyimino methyl]-1-methylpyridinium chloride", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "2-PAM", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "1-(2-hydroxy-iminomethyl-1-pyridinium)-1-(4-carboxy-aminopyridi nium)-dimethyl ether hydrochloride", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "HI-6", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "Edrophonium had no effect on reactivation by 2-PAM and HI-6, but significantly accelerated LuH6- and TMB4-induced reactivation of DEPQ-inhibited wild-type mouse AChE.", "spo_list": [{"subject": "DEPQ", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "mouse AChE", "object_type": "GENE-Y"}, {"subject": "TMB4", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "mouse AChE", "object_type": "GENE-Y"}, {"subject": "LuH6", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "mouse AChE", "object_type": "GENE-Y"}, {"subject": "2-PAM", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "mouse AChE", "object_type": "GENE-Y"}, {"subject": "HI-6", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "mouse AChE", "object_type": "GENE-Y"}]}
{"text": "In experiments with D74N AChE, for which the inhibition potency of charged organophosphate (OP) was two to three orders less than wild-type enzyme, edrophonium had no effect on the reactivation by LuH6 and TMB4 and the time courses of reactivation were monophasic.", "spo_list": [{"subject": "LuH6", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "D74N", "object_type": "GENE-N"}, {"subject": "TMB4", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "D74N", "object_type": "GENE-N"}, {"subject": "LuH6", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "TMB4", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "organophosphate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "D74N", "object_type": "GENE-N"}, {"subject": "organophosphate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "The results showed that administration of AlCl3 resulted in a significant elevation in the levels of AchE activity, CRP, NF-ÎºB, and MCP-1 accompanied with a significant depletion in the Ach level.", "spo_list": [{"subject": "AlCl3", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AchE", "object_type": "GENE-Y"}, {"subject": "AlCl3", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CRP", "object_type": "GENE-Y"}, {"subject": "AlCl3", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "NF-ÎºB", "object_type": "GENE-N"}, {"subject": "AlCl3", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "MCP-1", "object_type": "GENE-Y"}]}
{"text": "This anti-lipolytic effect of nicotinic acid involves the inhibition of cyclic adenosine monophosphate (cAMP) accumulation in adipose tissue through a G(i)-protein-mediated inhibition of adenylyl cyclase.", "spo_list": [{"subject": "cyclic adenosine monophosphate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "adenylyl cyclase", "object_type": "GENE-N"}, {"subject": "cAMP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "adenylyl cyclase", "object_type": "GENE-N"}, {"subject": "nicotinic acid", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "adenylyl cyclase", "object_type": "GENE-N"}]}
{"text": "Binding of nicotinic acid to PUMA-G or HM74 results in a G(i)-mediated decrease in cAMP levels.", "spo_list": [{"subject": "nicotinic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "PUMA-G", "object_type": "GENE-Y"}, {"subject": "nicotinic acid", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "HM74", "object_type": "GENE-Y"}]}
{"text": "GCS therapy results in reduced mRNA expression of interleukin-4 (IL-4) and IL-5 in cells from bronchoalveolar lavage (BAL) but not of IFN-gamma.", "spo_list": [{"subject": "GCS", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "interleukin-4", "object_type": "GENE-Y"}, {"subject": "GCS", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-4", "object_type": "GENE-Y"}, {"subject": "GCS", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-5", "object_type": "GENE-Y"}]}
{"text": "In vitro studies with blood-derived T cells, however, show inhibition of all three cytokines by GCS.", "spo_list": [{"subject": "GCS", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cytokines", "object_type": "GENE-N"}]}
{"text": "Dexamethasone (DEX) inhibited the anti-CD3-induced production of IL-4, IL-5 and IFN-gamma in all 20 clones tested.", "spo_list": [{"subject": "Dexamethasone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CD3", "object_type": "GENE-N"}, {"subject": "DEX", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CD3", "object_type": "GENE-N"}, {"subject": "Dexamethasone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-4", "object_type": "GENE-Y"}, {"subject": "Dexamethasone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-5", "object_type": "GENE-Y"}, {"subject": "Dexamethasone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IFN-gamma", "object_type": "GENE-Y"}, {"subject": "DEX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-4", "object_type": "GENE-Y"}, {"subject": "DEX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-5", "object_type": "GENE-Y"}, {"subject": "DEX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IFN-gamma", "object_type": "GENE-Y"}]}
{"text": "Interestingly, two categories of clones were distinguished based on the effects of GCS on IL-2 production and IL-2R alpha expression and proliferation; 1) In low IL-2 producers DEX blocked IL-2 production and decreased IL-2R alpha expression and proliferation; 2) In high IL-2 producers DEX inhibited IL-2 production partially and enhanced IL-2R alpha expression and proliferation.", "spo_list": [{"subject": "DEX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-2", "object_type": "GENE-Y"}, {"subject": "DEX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-2R alpha", "object_type": "GENE-Y"}, {"subject": "DEX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-2", "object_type": "GENE-Y"}, {"subject": "DEX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "IL-2R alpha", "object_type": "GENE-Y"}]}
{"text": "In conclusion, the production of IL-4 and IL-5 by T-cell clones (derived either from BAL or blood) was more sensitive to inhibition by DEX than that of IFN-gamma, which may account for the therapeutic effects of glucocorticosteroids in patients with asthma.", "spo_list": [{"subject": "DEX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-4", "object_type": "GENE-Y"}, {"subject": "DEX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IL-5", "object_type": "GENE-Y"}, {"subject": "DEX", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "IFN-gamma", "object_type": "GENE-Y"}]}
{"text": "Previous studies by this research team proved that vasodilating prostaglandins (PGs) E1, E2 and I2 inhibit carbonic anhydrase (CA) in vitro and in vivo, which suggested involvement of CA in gastric acid secretion inhibition and the increase of gastric mucosa blood flow produced by this group of PGs.", "spo_list": [{"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase", "object_type": "GENE-N"}, {"subject": "prostaglandins", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA", "object_type": "GENE-N"}, {"subject": "PGs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "carbonic anhydrase", "object_type": "GENE-N"}, {"subject": "PGs", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA", "object_type": "GENE-N"}]}
{"text": "Indomethacin abolished the inhibitory effect of acetazolamide on CA I and CA II.", "spo_list": [{"subject": "acetazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA I", "object_type": "GENE-Y"}, {"subject": "acetazolamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CA II", "object_type": "GENE-Y"}, {"subject": "Indomethacin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CA I", "object_type": "GENE-Y"}, {"subject": "Indomethacin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "CA II", "object_type": "GENE-Y"}]}
{"text": "This was confirmed by their ability to selectively abrogate the induction of IL-8 transcription, whereas the ICAM-1 gene, which is not transcribed selectively by an NF-ÎºB complex containing a form of p65 phosphorylated on Ser536, did not change.", "spo_list": [{"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "p65", "object_type": "GENE-Y"}]}
{"text": "Biochemical analysis revealed that systemic 3-NP administration significantly increased lipid peroxidation and nitrite levels, depleted reduced glutathione levels and reduced succinate dehydrogenase (SDH) activity in the brains of rats, whereas administration of naproxen, a nonselective COX inhibitor (10 and 20 mg/kg p.o.) and valdecoxib, a selective COX-2 inhibitor (5 and 10 mg/kg p.o.) significantly attenuated 3-NP-induced oxidative stress.", "spo_list": [{"subject": "3-NP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "succinate dehydrogenase", "object_type": "GENE-N"}, {"subject": "3-NP", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SDH", "object_type": "GENE-N"}, {"subject": "naproxen", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX", "object_type": "GENE-N"}, {"subject": "valdecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "However, a fundamental difference was found; unlike NTR-1, NTR-2 recognizes, with high affinity, levocabastine, a histamine H1 receptor antagonist previously shown to compete with NT for low-affinity binding sites in brain.", "spo_list": [{"subject": "levocabastine", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "histamine H1 receptor", "object_type": "GENE-Y"}]}
{"text": "Sex differences in ACTH pulsatility following metyrapone blockade in patients with major depression.", "spo_list": [{"subject": "metyrapone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "ACTH", "object_type": "GENE-Y"}]}
{"text": "Predicting cardiomyopathic phenotypes by altering Ca2+ affinity of cardiac troponin C. Cardiac diseases associated with mutations in troponin subunits include hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and restrictive cardiomyopathy (RCM).", "spo_list": [{"subject": "Ca2+", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "cardiac troponin C", "object_type": "GENE-Y"}]}
{"text": "Mutations in the Ca(2+) sensor, troponin C (TnC), were generated to increase/decrease the Ca(2+) sensitivity of cardiac skinned fibers to create the characteristic effects of DCM, HCM, and RCM.", "spo_list": [{"subject": "Ca(2+)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "troponin C", "object_type": "GENE-Y"}, {"subject": "Ca(2+)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "TnC", "object_type": "GENE-Y"}]}
{"text": "Steady-state fluorescence was utilized to assess Ca(2+) affinity in isolated cardiac (c)TnCs containing F27W and did not necessarily mirror the fiber Ca(2+) sensitivity.", "spo_list": [{"subject": "Ca(2+)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "cardiac (c)TnCs", "object_type": "GENE-Y"}, {"subject": "Ca(2+)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "F27W", "object_type": "GENE-N"}]}
{"text": "We examined the effects of PHD inhibiton by dimethyloxalylglycine on the vasomotor responses of isolated rat aorta and aortic vascular smooth muscle cells (VSMCs) in a model of cold ischemia/warm reperfusion.", "spo_list": [{"subject": "dimethyloxalylglycine", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PHD", "object_type": "GENE-N"}]}
{"text": "Inducible heme-oxygenase 1 mRNA expressions were significantly higher in the DMOG group.", "spo_list": [{"subject": "DMOG", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "heme-oxygenase 1", "object_type": "GENE-Y"}]}
{"text": "Phosphoacetylcholinesterase: toxicity of phosphorus oxychloride to mammals and insects that can be attributed to selective phosphorylation of acetylcholinesterase by phosphorodichloridic acid.", "spo_list": [{"subject": "phosphorodichloridic acid", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "acetylcholinesterase", "object_type": "GENE-N"}]}
{"text": "Phosphorus oxychloride (POCl(3)) is an intermediate in the synthesis of many organophosphorus insecticides and chemical warfare nerve gases that are toxic to insects and mammals by inhibition of acetylcholinesterase (AChE) activity.", "spo_list": [{"subject": "Phosphorus oxychloride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-N"}, {"subject": "POCl(3)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-N"}, {"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "acetylcholinesterase", "object_type": "GENE-N"}, {"subject": "Phosphorus oxychloride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-N"}, {"subject": "POCl(3)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-N"}, {"subject": "organophosphorus", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-N"}]}
{"text": "In mice, POCl(3) inhibits serum butyrylcholinesterase (BuChE) at a sublethal dose and muscle but not brain AChE at a lethal dose.", "spo_list": [{"subject": "POCl(3)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "butyrylcholinesterase", "object_type": "GENE-Y"}, {"subject": "POCl(3)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BuChE", "object_type": "GENE-Y"}]}
{"text": "In houseflies, POCl(3)-induced brain AChE inhibition is correlated with poisoning and the probable cause thereof.", "spo_list": [{"subject": "POCl(3)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "POCl(3) in vitro is selective for AChE (IC(50) = 12-36 microM) compared with several other serine hydrolases (BuChE, carboxylesterase, elastase, alpha-chymotrypsin, and thrombin) (IC(50) = 88-2000 microM).", "spo_list": [{"subject": "POCl(3)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "With electric eel AChE, methylcarbamoylation of the active site with eserine reversibly protects against subsequent irreversible inhibition by POCl(3).", "spo_list": [{"subject": "POCl(3)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "electric eel AChE", "object_type": "GENE-Y"}]}
{"text": "Most importantly, POCl(3)-induced electric eel AChE inhibition prevents postlabeling with [(3)H]diisopropyl phosphorofluoridate; i.e., both compounds phosphorylate at Ser-200 in the catalytic triad.", "spo_list": [{"subject": "POCl(3)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "electric eel AChE", "object_type": "GENE-Y"}, {"subject": "Ser", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "electric eel AChE", "object_type": "GENE-Y"}, {"subject": "[(3)H]diisopropyl phosphorofluoridate", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "electric eel AChE", "object_type": "GENE-Y"}]}
{"text": "Pyridine-2-aldoxime methiodide does not reactivate POCl(3)-inhibited AChE, consistent with an anionic phosphoserine residue at the esteratic site.", "spo_list": [{"subject": "POCl(3)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "phosphoserine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "POCl(3) on reaction with water and HOP(O)Cl(2) have the same potency for inhibition of AChE from either electric eel or housefly head as well as the same toxicity for mice.", "spo_list": [{"subject": "POCl(3)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "HOP(O)Cl(2)", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "In summary, the acute toxicity of POCl(3) is attributable to hydrolytic activation to HOP(O)Cl(2) that phosphorylates AChE at the active site to form enzymatically inactive [O-phosphoserine]AChE.", "spo_list": [{"subject": "HOP(O)Cl(2)", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AChE", "object_type": "GENE-Y"}, {"subject": "O-phosphoserine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "AChE", "object_type": "GENE-Y"}]}
{"text": "Calcium entry mediated by GLR3.3, an Arabidopsis glutamate receptor with a broad agonist profile.", "spo_list": [{"subject": "Calcium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "GLR3.3", "object_type": "GENE-Y"}, {"subject": "Calcium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Arabidopsis glutamate receptor", "object_type": "GENE-N"}]}
{"text": "Six amino acids commonly present in soils (Glu, Gly, alanine, serine, asparagine, and cysteine) as well as the tripeptide glutathione (gamma-glutamyl-cysteinyl-Gly) were found to be strong agonists of the GLR3.3-mediated responses.", "spo_list": [{"subject": "amino acids", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "GLR3.3", "object_type": "GENE-Y"}, {"subject": "Glu", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "GLR3.3", "object_type": "GENE-Y"}, {"subject": "Gly", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "GLR3.3", "object_type": "GENE-Y"}, {"subject": "alanine", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "GLR3.3", "object_type": "GENE-Y"}, {"subject": "serine", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "GLR3.3", "object_type": "GENE-Y"}, {"subject": "asparagine", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "GLR3.3", "object_type": "GENE-Y"}, {"subject": "cysteine", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "GLR3.3", "object_type": "GENE-Y"}, {"subject": "tripeptide glutathione", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "GLR3.3", "object_type": "GENE-Y"}, {"subject": "gamma-glutamyl-cysteinyl-Gly", "subject_type": "CHEMICAL", "predicate": "AGONIST-ACTIVATOR", "object": "GLR3.3", "object_type": "GENE-Y"}]}
{"text": "Direct and exome sequencing identified the presence of a T-to-C exchange in exon 1 of SIRT1, corresponding to a leucine-to-proline mutation at residue 107.", "spo_list": [{"subject": "leucine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "SIRT1", "object_type": "GENE-Y"}, {"subject": "proline", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "SIRT1", "object_type": "GENE-Y"}]}
{"text": "Expression of SIRT1-L107P in insulin-producing cells resulted in overproduction of nitric oxide, cytokines, and chemokines.", "spo_list": [{"subject": "nitric oxide", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "SIRT1", "object_type": "GENE-Y"}]}
{"text": "Cucurbitacin I inhibits rac1 activation in breast cancer cells by a reactive oxygen species-mediated mechanism and independently of janus tyrosine kinase 2 and p-rex1.", "spo_list": [{"subject": "Cucurbitacin I", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "rac1", "object_type": "GENE-Y"}]}
{"text": "Here we found that the anticancer agent cucurbitacin I, a Jak2 inhibitor, reduced the activation of Rac1 and motility in response to the ErbB3 ligand heregulin in breast cancer cells.", "spo_list": [{"subject": "cucurbitacin I", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Jak2", "object_type": "GENE-N"}, {"subject": "cucurbitacin I", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Rac1", "object_type": "GENE-Y"}]}
{"text": "Subsequent analysis revealed that cucurbitacin I strongly activates RhoA and the Rho effector Rho kinase (ROCK) in breast cancer cells and induces the formation of stress fibers.", "spo_list": [{"subject": "cucurbitacin I", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "RhoA", "object_type": "GENE-N"}, {"subject": "cucurbitacin I", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Rho", "object_type": "GENE-N"}, {"subject": "cucurbitacin I", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Rho kinase", "object_type": "GENE-N"}, {"subject": "cucurbitacin I", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "ROCK", "object_type": "GENE-N"}]}
{"text": "Interestingly, disruption of the RhoA-ROCK pathway prevented the inhibitory effect of cucurbitacin I on Rac1 activation by heregulin.", "spo_list": [{"subject": "cucurbitacin I", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Rac1", "object_type": "GENE-Y"}]}
{"text": "Lastly, we found that RhoA activation by cucurbitacin I is mediated by reactive oxygen species (ROS).", "spo_list": [{"subject": "cucurbitacin I", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "RhoA", "object_type": "GENE-N"}]}
{"text": "The ROS scavenger N-acetyl l-cysteine and the mitochondrial antioxidant Mito-TEMPO rescued the inhibitory effect of cucurbitacin I on Rac1 activation.", "spo_list": [{"subject": "cucurbitacin I", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Rac1", "object_type": "GENE-Y"}, {"subject": "N-acetyl l-cysteine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Rac1", "object_type": "GENE-Y"}]}
{"text": "Moreover, they established that the inhibitory effect of cucurbitacin I on Rac1 activity involves the alteration of the balance between Rho and Rac.", "spo_list": [{"subject": "cucurbitacin I", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Rac1", "object_type": "GENE-Y"}]}
{"text": "Levels of Cx43 protein were also decreased in a dose- and time-dependent manner following antofine treatment.", "spo_list": [{"subject": "antofine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Cx43", "object_type": "GENE-Y"}]}
{"text": "Co-treatment of astrocytes with antofine and the intracellular Ca(2+) chelator BAPTA-AM prevented downregulation of Cx43 and inhibition of GJIC.", "spo_list": [{"subject": "antofine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Cx43", "object_type": "GENE-Y"}, {"subject": "BAPTA-AM", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Cx43", "object_type": "GENE-Y"}]}
{"text": "Moreover, co-treatment with antofine and a specific PKCÎ² inhibitor prevented endocytosis of gap junctions, downregulation of Cx43, and inhibition of GJIC.", "spo_list": [{"subject": "antofine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Cx43", "object_type": "GENE-Y"}]}
{"text": "Taken together, these findings indicate that antofine induces Cx43 gap junction disassembly by the PKCÎ² signaling pathway.", "spo_list": [{"subject": "antofine", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "PKCÎ²", "object_type": "GENE-Y"}]}
{"text": "Testosterone significantly decreased ER-Î² and increased ER-Î± and AR expressions as compared to the control group and these effects were significantly ameliorated by SIL.", "spo_list": [{"subject": "Testosterone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "ER-Î²", "object_type": "GENE-Y"}, {"subject": "Testosterone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "ER-Î±", "object_type": "GENE-Y"}, {"subject": "Testosterone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "AR", "object_type": "GENE-Y"}]}
{"text": "Furthermore, SIL significantly protected against testosterone-provoked decline in mRNA expression of P21(WAF1/Cip1) and Bax/Bcl-xl ratio as well as caspase-3 activity.", "spo_list": [{"subject": "testosterone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "P21", "object_type": "GENE-Y"}, {"subject": "testosterone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "WAF1", "object_type": "GENE-Y"}, {"subject": "testosterone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Cip1", "object_type": "GENE-Y"}, {"subject": "testosterone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Bax", "object_type": "GENE-Y"}, {"subject": "testosterone", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Bcl-xl", "object_type": "GENE-Y"}, {"subject": "testosterone", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "caspase-3", "object_type": "GENE-Y"}]}
{"text": "Herein, we investigated the effect of a natural neuroprotective flavonoid, calycopterin, on H2O2-induced disruption of phase II detoxifying enzyme system and cAMP response element binding protein (CREB) phosphorylation.", "spo_list": [{"subject": "H2O2", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cAMP response element binding protein", "object_type": "GENE-N"}, {"subject": "H2O2", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "CREB", "object_type": "GENE-N"}]}
{"text": "In H2O2-treated cells, calycopterin also suppressed cytochrome C release to cytosol that is necessary for maintaining mitochondrial homeostasis in survived cells.", "spo_list": [{"subject": "calycopterin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "cytochrome C", "object_type": "GENE-Y"}]}
{"text": "Moreover, calycopterin, in presence of H2O2 inhibited the decrease caused by oxidative stress in stress-sensing transcription factors, CREB and Nrf2, which play an important role in antioxidant capacity of the cell.", "spo_list": [{"subject": "calycopterin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CREB", "object_type": "GENE-N"}, {"subject": "calycopterin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Nrf2", "object_type": "GENE-Y"}]}
{"text": "There was also an increase in Î³-GCS and HO-1 levels in calycopterin pretreated cells.", "spo_list": [{"subject": "calycopterin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Î³-GCS", "object_type": "GENE-Y"}, {"subject": "calycopterin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "HO-1", "object_type": "GENE-Y"}]}
{"text": "In the presence of H2O2, calycopterin inhibited decrease in GSH level and SOD activity.", "spo_list": [{"subject": "calycopterin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "SOD", "object_type": "GENE-N"}]}
{"text": "In rats, rifamycin SV and rifampicin were shown to interfere with hepatic organic anion uptake by inhibition of the organic anion transporting polypeptides Oatp1 and Oatp2.", "spo_list": [{"subject": "rifamycin SV", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "organic anion transporting polypeptides", "object_type": "GENE-N"}, {"subject": "rifamycin SV", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Oatp1", "object_type": "GENE-Y"}, {"subject": "rifamycin SV", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Oatp2", "object_type": "GENE-Y"}, {"subject": "rifampicin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "organic anion transporting polypeptides", "object_type": "GENE-N"}, {"subject": "rifampicin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Oatp1", "object_type": "GENE-Y"}, {"subject": "rifampicin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Oatp2", "object_type": "GENE-Y"}]}
{"text": "In complementary RNA (cRNA)-injected Xenopus laevis oocytes, rifamycin SV (10 micromol/L) cis-inhibited human organic anion transporting polypeptide C (SLC21A6) (OATP-C), human organic anion transporting polypeptide 8 (SLC21A8) (OATP8), human organic anion transporting polypeptide B (SLC21A9) (OATP-B), and human organic anion transporting polypeptide A (SLC21A3) (OATP-A) mediated BSP uptake by 69%, 79%, 89%, and 57%, respectively, as compared with uptake into control oocytes.", "spo_list": [{"subject": "rifamycin SV", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human organic anion transporting polypeptide C", "object_type": "GENE-Y"}, {"subject": "rifamycin SV", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SLC21A6", "object_type": "GENE-Y"}, {"subject": "rifamycin SV", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP-C", "object_type": "GENE-Y"}, {"subject": "rifamycin SV", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human organic anion transporting polypeptide 8", "object_type": "GENE-Y"}, {"subject": "rifamycin SV", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SLC21A8", "object_type": "GENE-Y"}, {"subject": "rifamycin SV", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP8", "object_type": "GENE-Y"}, {"subject": "rifamycin SV", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human organic anion transporting polypeptide B", "object_type": "GENE-Y"}, {"subject": "rifamycin SV", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SLC21A9", "object_type": "GENE-Y"}, {"subject": "rifamycin SV", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP-B", "object_type": "GENE-Y"}, {"subject": "rifamycin SV", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human organic anion transporting polypeptide A", "object_type": "GENE-Y"}, {"subject": "rifamycin SV", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "SLC21A3", "object_type": "GENE-Y"}, {"subject": "rifamycin SV", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP-A", "object_type": "GENE-Y"}]}
{"text": "Rifampicin (10 micromol/L) inhibited OATP8-mediated BSP uptake by 50%, whereas inhibition of OATP-C-, OATP-B-, and OATP-A-mediated BSP transport was below 15%.", "spo_list": [{"subject": "Rifampicin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP8", "object_type": "GENE-Y"}, {"subject": "BSP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP8", "object_type": "GENE-Y"}, {"subject": "Rifampicin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP-C", "object_type": "GENE-Y"}, {"subject": "Rifampicin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP-B", "object_type": "GENE-Y"}, {"subject": "Rifampicin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP-A", "object_type": "GENE-Y"}, {"subject": "BSP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP-C", "object_type": "GENE-Y"}, {"subject": "BSP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP-B", "object_type": "GENE-Y"}, {"subject": "BSP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP-A", "object_type": "GENE-Y"}]}
{"text": "100 micromol/L rifampicin inhibited OATP-C- and OATP8-, OATP-B- and OATP-A-mediated BSP uptake by 66%, 96%, 25%, and 49%, respectively.", "spo_list": [{"subject": "rifampicin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP-C", "object_type": "GENE-Y"}, {"subject": "rifampicin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP8", "object_type": "GENE-Y"}, {"subject": "rifampicin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP-B", "object_type": "GENE-Y"}, {"subject": "rifampicin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "OATP-A", "object_type": "GENE-Y"}, {"subject": "BSP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP-C", "object_type": "GENE-Y"}, {"subject": "BSP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP8", "object_type": "GENE-Y"}, {"subject": "BSP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP-B", "object_type": "GENE-Y"}, {"subject": "BSP", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP-A", "object_type": "GENE-Y"}]}
{"text": "Direct transport of rifampicin could be shown for OATP-C (apparent K(m) value 13 micromol/L) and OATP8 (2.3 micromol/L).", "spo_list": [{"subject": "rifampicin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP-C", "object_type": "GENE-Y"}, {"subject": "rifampicin", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "OATP8", "object_type": "GENE-Y"}]}
{"text": "Inhibition of human liver OATPs can explain the previously observed effects of rifamycin SV and rifampicin on hepatic organic anion elimination.", "spo_list": [{"subject": "rifamycin SV", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human liver OATPs", "object_type": "GENE-N"}, {"subject": "rifampicin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human liver OATPs", "object_type": "GENE-N"}]}
{"text": "The AhR target gene CYP1A1 mRNA expression was induced by TCDD, but was not affected by the AR CAG length.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "CYP1A1", "object_type": "GENE-Y"}]}
{"text": "TCDD had no effect on AR activity in PC-3 cells, whereas the shortest AR variant was induced by TCDD in PNT1A cells.", "spo_list": [{"subject": "TCDD", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "AR", "object_type": "GENE-Y"}]}
{"text": "Levodopa is absorbed in the small bowel and is rapidly catabolized by aromatic-L-amino-acid decarboxylase (AADC) and catechol-O-methyltransferase (COMT).", "spo_list": [{"subject": "Levodopa", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "aromatic-L-amino-acid decarboxylase", "object_type": "GENE-Y"}, {"subject": "Levodopa", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AADC", "object_type": "GENE-Y"}, {"subject": "Levodopa", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "catechol-O-methyltransferase", "object_type": "GENE-Y"}, {"subject": "Levodopa", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "COMT", "object_type": "GENE-Y"}]}
{"text": "Because gastric AADC and COMT degrade levodopa, the drug is given with inhibitors of AADC (carbidopa or benserazide), and inhibitors of COMT will also enter clinical use.", "spo_list": [{"subject": "carbidopa", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AADC", "object_type": "GENE-Y"}, {"subject": "benserazide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "AADC", "object_type": "GENE-Y"}, {"subject": "levodopa", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "AADC", "object_type": "GENE-Y"}, {"subject": "levodopa", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "COMT", "object_type": "GENE-Y"}]}
{"text": "Recently, the c-Abl kinase inhibitor imatinib mesylate (imatinib) has become the focus of research as a fertoprotective drug against cisplatin.", "spo_list": [{"subject": "imatinib mesylate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "imatinib mesylate", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "c-Abl", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "c-Abl", "object_type": "GENE-Y"}]}
{"text": "We found that, before apoptosis, cisplatin induces c-Abl and TAp73 expression in the oocyte.", "spo_list": [{"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "c-Abl", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TAp73", "object_type": "GENE-Y"}]}
{"text": "While imatinib was unable to block cisplatin-induced DNA damage and damage response, such as the upregulation of p53, imatinib inhibited the cisplatin-induced nuclear accumulation of c-Abl/TAp73 and the subsequent downregulation of TAp63 and upregulation of Bax, thereby abrogating oocyte cell death.", "spo_list": [{"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p53", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "c-Abl", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "c-Abl", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TAp73", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TAp73", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TAp63", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "TAp63", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "Bax", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bax", "object_type": "GENE-Y"}]}
{"text": "Surprisingly, the conditional deletion of Trp63, but not ÎNp63, in oocytes inhibited apoptosis, as well as the accumulation of c-Abl and TAp73 caused by cisplatin.", "spo_list": [{"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "c-Abl", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TAp73", "object_type": "GENE-Y"}]}
{"text": "The expression kinetics of TAp63, c-Abl and TAp73 suggest that cisplatin activates TAp63-dependent expression of c-Abl and TAp73 and, in turn, the activation of TAp73 by c-Abl-induced BAX expression.", "spo_list": [{"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TAp63", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "c-Abl", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "TAp73", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TAp73", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "c-Abl", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "BAX", "object_type": "GENE-Y"}]}
{"text": "Our findings indicate that imatinib protects oocytes from cisplatin-induced cell death by inhibiting c-Abl kinase, which would otherwise activate TAp73-BAX-mediated apoptosis.", "spo_list": [{"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "c-Abl", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "TAp73", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "BAX", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "c-Abl", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "kinase", "object_type": "GENE-N"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "TAp73", "object_type": "GENE-Y"}, {"subject": "cisplatin", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "BAX", "object_type": "GENE-Y"}]}
{"text": "Thus, imatinib and other c-Abl kinase inhibitors provide an intriguing new way to halt cisplatin-induced oocyte death in early follicles and perhaps conserve the endocrine function of the ovary against chemotherapy.Cell Death and Differentiation advance online publication, 19 April 2013; doi:10.1038/cdd.2013.31.", "spo_list": [{"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "c-Abl", "object_type": "GENE-Y"}, {"subject": "imatinib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "kinase", "object_type": "GENE-N"}]}
{"text": "The administration of 700Â mg/kg/day melamine by nasal-gastric gavage to monkeys resulted in test article-related clinical signs including turbid and whitish urine, urine crystals, red blood cell changes, increased serum alanine aminotransferase and kidney and/or liver weights, and microscopic findings including nephrotoxicity, pericarditis, and increased hematopoiesis.", "spo_list": [{"subject": "melamine", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "alanine aminotransferase", "object_type": "GENE-N"}]}
{"text": "Reversible inhibition of human carboxylesterases by acyl glucuronides.", "spo_list": [{"subject": "acyl glucuronides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human carboxylesterases", "object_type": "GENE-N"}]}
{"text": "Carboxylesterases hydrolyze esters, amides, and thioesters to produce carboxylic acids and resulting alcohols, amines, and thiols, respectively.", "spo_list": [{"subject": "esters", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Carboxylesterases", "object_type": "GENE-N"}, {"subject": "amides", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Carboxylesterases", "object_type": "GENE-N"}, {"subject": "thioesters", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Carboxylesterases", "object_type": "GENE-N"}, {"subject": "carboxylic acids", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Carboxylesterases", "object_type": "GENE-N"}, {"subject": "alcohols", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Carboxylesterases", "object_type": "GENE-N"}, {"subject": "amines", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Carboxylesterases", "object_type": "GENE-N"}, {"subject": "thiols", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Carboxylesterases", "object_type": "GENE-N"}]}
{"text": "Uridine 5'-diphosphate- glucuronosyltransferases are colocalized with carboxylesterases and have the potential to further metabolize carboxylic acids to acyl glucuronides, but it is currently unknown if acyl glucuronides, being esters, also interact with carboxylesterases.", "spo_list": [{"subject": "carboxylic acids", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Uridine 5'-diphosphate- glucuronosyltransferases", "object_type": "GENE-N"}, {"subject": "acyl glucuronides", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "Uridine 5'-diphosphate- glucuronosyltransferases", "object_type": "GENE-N"}, {"subject": "carboxylic acids", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "carboxylesterases", "object_type": "GENE-N"}, {"subject": "acyl glucuronides", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "carboxylesterases", "object_type": "GENE-N"}]}
{"text": "Objective: This study explores the ability of acyl glucuronides to act as substrates or inhibitors of human carboxylesterases 1 (hCES1) and 2 (hCES2).", "spo_list": [{"subject": "acyl glucuronides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "human carboxylesterases 1", "object_type": "GENE-Y"}, {"subject": "acyl glucuronides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hCES1", "object_type": "GENE-Y"}, {"subject": "acyl glucuronides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hCES2", "object_type": "GENE-Y"}, {"subject": "acyl glucuronides", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "human carboxylesterases 1", "object_type": "GENE-Y"}, {"subject": "acyl glucuronides", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hCES1", "object_type": "GENE-Y"}, {"subject": "acyl glucuronides", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hCES2", "object_type": "GENE-Y"}]}
{"text": "Methods: The stability of six acyl glucuronides in the presence of hCES1, hCES2, and buffer alone (100 mM potassium phosphate, pH 7.4, 37Â°C) were investigated.", "spo_list": [{"subject": "acyl glucuronides", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hCES1", "object_type": "GENE-Y"}, {"subject": "acyl glucuronides", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "hCES2", "object_type": "GENE-Y"}]}
{"text": "Diclofenac-Î²-d-glucuronide, clopidogrel-Î²-d-glucuronide, ibuprofen-Î²-d-glucuronide, (R)-naproxen-Î²-d-glucuronide, and (S)-naproxen-Î²-d-glucuronide selectively inhibited hCES1, with Ki values of 4.32 Â± 0.47, 24.8 Â± 4.2, 355 Â± 38, 468 Â± 21, 707 Â± 64 ÂµM, respectively, but did not significantly inhibit hCES2.", "spo_list": [{"subject": "Diclofenac-Î²-d-glucuronide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hCES1", "object_type": "GENE-Y"}, {"subject": "clopidogrel-Î²-d-glucuronide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hCES1", "object_type": "GENE-Y"}, {"subject": "ibuprofen-Î²-d-glucuronide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hCES1", "object_type": "GENE-Y"}, {"subject": "(R)-naproxen-Î²-d-glucuronide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hCES1", "object_type": "GENE-Y"}, {"subject": "(S)-naproxen-Î²-d-glucuronide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hCES1", "object_type": "GENE-Y"}]}
{"text": "Conclusion: Drug-drug interaction studies may be warranted for drugs that metabolize to acyl glucuronides due to the potential inhibition of hCESs.", "spo_list": [{"subject": "acyl glucuronides", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "hCESs", "object_type": "GENE-N"}]}
{"text": "Mutation of arginine 228 to lysine enhances the glucosyltransferase activity of bovine beta-1,4-galactosyltransferase I. Beta-1,4-galactosyltransferase I (beta4Gal-T1) normally transfers Gal from UDP-Gal to GlcNAc in the presence of Mn(2+) ion (Gal-T activity) and also transfers Glc from UDP-Glc to GlcNAc (Glc-T activity), albeit at only 0.3% efficiency.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "bovine beta-1,4-galactosyltransferase I", "object_type": "GENE-Y"}, {"subject": "arginine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "bovine beta-1,4-galactosyltransferase I", "object_type": "GENE-Y"}, {"subject": "UDP-Gal", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Beta-1,4-galactosyltransferase I", "object_type": "GENE-Y"}, {"subject": "UDP-Gal", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "beta4Gal-T1", "object_type": "GENE-Y"}, {"subject": "UDP-Gal", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Gal-T", "object_type": "GENE-N"}, {"subject": "UDP-Glc", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Glc-T", "object_type": "GENE-N"}]}
{"text": "Comparison of the crystal structures of UDP-Gal- and UDP-Glc-bound beta4Gal-T1 reveals that the O4 hydroxyl group in both Gal and Glc moieties forms a hydrogen bond with the side chain carboxylate group of Glu317.", "spo_list": [{"subject": "UDP-Glc", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta4Gal-T1", "object_type": "GENE-Y"}, {"subject": "UDP-Gal", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "beta4Gal-T1", "object_type": "GENE-Y"}, {"subject": "carboxylate", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "beta4Gal-T1", "object_type": "GENE-Y"}]}
{"text": "The orientation of the O4 hydroxyl of glucose causes a steric hindrance to the side chain carboxylate group of Glu317, accounting for the enzyme's low Glc-T activity.", "spo_list": [{"subject": "carboxylate", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Glc-T", "object_type": "GENE-N"}]}
{"text": "In this study, we show that mutation of Arg228, a residue in the vicinity of Glu317, to lysine (R228K-Gal-T1) results in a 15-fold higher Glc-T activity, which is further enhanced by LA to nearly 25% of the Gal-T activity of the wild type.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Gal-T1", "object_type": "GENE-N"}, {"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Glc-T", "object_type": "GENE-N"}, {"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Gal-T", "object_type": "GENE-N"}]}
{"text": "The kinetic parameters indicate that the main effect of the mutation of Arg228 to lysine is on the k(cat) of Glc-T, which increases 3-4-fold, both in the absence and in the presence of LA; simultaneously, the k(cat) for the Gal-T reaction is reduced 30-fold.", "spo_list": [{"subject": "lysine", "subject_type": "CHEMICAL", "predicate": "PART-OF", "object": "Glc-T", "object_type": "GENE-N"}]}
{"text": "The crystal structure of R228K-Gal-T1 complexed with LA, UDP-Gal, and Mn(2+) determined at 1.9 A resolution shows that the Asp318 side chain exhibits a minor alternate conformation, compared to that in the wild type.", "spo_list": [{"subject": "UDP-Gal", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Gal-T1", "object_type": "GENE-N"}, {"subject": "Mn(2+)", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "Gal-T1", "object_type": "GENE-N"}, {"subject": "UDP-Gal", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "R228K", "object_type": "GENE-N"}]}
{"text": "We also observed that Ca(2+) is a weak agonist of PTH1R, and Ca(2+) in millimolar concentration can switch PTH(1-34) from an inverse agonist to an agonist.", "spo_list": [{"subject": "Ca(2+)", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "PTH1R", "object_type": "GENE-Y"}]}
{"text": "In the present study, age-related changes of pyridoxal 5'-phosphate (PLP) synthesizing enzymes, pyridoxal kinase (PLK) and pyridoxine 5'-phosphate oxidase (PNPO), their protein contents and activities were examined in the gerbil hippocampus proper.", "spo_list": [{"subject": "pyridoxal 5'-phosphate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "pyridoxal kinase", "object_type": "GENE-N"}, {"subject": "pyridoxal 5'-phosphate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PLK", "object_type": "GENE-N"}, {"subject": "pyridoxal 5'-phosphate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "pyridoxine 5'-phosphate oxidase", "object_type": "GENE-N"}, {"subject": "pyridoxal 5'-phosphate", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PNPO", "object_type": "GENE-N"}, {"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "pyridoxal kinase", "object_type": "GENE-N"}, {"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PLK", "object_type": "GENE-N"}, {"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "pyridoxine 5'-phosphate oxidase", "object_type": "GENE-N"}, {"subject": "PLP", "subject_type": "CHEMICAL", "predicate": "PRODUCT-OF", "object": "PNPO", "object_type": "GENE-N"}]}
{"text": "Therefore, decreases of PLK and PNPO in the hippocampal CA1 region of aged brains may be involved in aging processes related with gamma-aminobutyric acid (GABA) function.", "spo_list": [{"subject": "gamma-aminobutyric acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "PLK", "object_type": "GENE-N"}, {"subject": "gamma-aminobutyric acid", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "PNPO", "object_type": "GENE-N"}, {"subject": "GABA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "PLK", "object_type": "GENE-N"}, {"subject": "GABA", "subject_type": "CHEMICAL", "predicate": "INDIRECT-DOWNREGULATOR", "object": "PNPO", "object_type": "GENE-N"}]}
{"text": "Metaproterenol (10(-6) M), a selective beta 2-agonist, stimulated Na-K-ATPase activity by 36 +/- 6% above control (P < 0.05).", "spo_list": [{"subject": "Metaproterenol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Na-K-ATPase", "object_type": "GENE-N"}]}
{"text": "Both dimethylamiloride and monensin prevented metaproterenol activation of Na-K-ATPase.", "spo_list": [{"subject": "metaproterenol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Na-K-ATPase", "object_type": "GENE-N"}, {"subject": "dimethylamiloride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Na-K-ATPase", "object_type": "GENE-N"}, {"subject": "monensin", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Na-K-ATPase", "object_type": "GENE-N"}]}
{"text": "Metaproterenol-mediated increases in Na-K-ATPase activity were associated with increases in sodium transport (27 +/- 10% above control, P < 0.05), which was prevented by dimethylamiloride.", "spo_list": [{"subject": "Metaproterenol", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "Na-K-ATPase", "object_type": "GENE-N"}, {"subject": "sodium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Na-K-ATPase", "object_type": "GENE-N"}, {"subject": "dimethylamiloride", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Na-K-ATPase", "object_type": "GENE-N"}]}
{"text": "In summary, we have shown that functional beta 2-adrenoceptors are present on cultured rat proximal tubules. beta 2-Adrenoceptor activation results in increases in Na-K-ATPase and Na transport as a consequence of increased apical sodium entry.", "spo_list": [{"subject": "Na", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Na-K-ATPase", "object_type": "GENE-N"}, {"subject": "sodium", "subject_type": "CHEMICAL", "predicate": "SUBSTRATE", "object": "Na-K-ATPase", "object_type": "GENE-N"}]}
{"text": "The aim of this study was to compare the in vivo effects on free radical metabolism of 2 non-steroidal anti-inflammatory drugs (NSAIDs): tenoxicam, an oxicam preferentially cyclooxygenase-1 (COX-1) inhibitor, and celecoxib, a sulfonamide selective COX-2 inhibitor.", "spo_list": [{"subject": "tenoxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "cyclooxygenase-1", "object_type": "GENE-Y"}, {"subject": "tenoxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-1", "object_type": "GENE-Y"}, {"subject": "celecoxib", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}, {"subject": "sulfonamide", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "COX-2", "object_type": "GENE-Y"}]}
{"text": "Tenoxicam-treated patients had significant decrease in nitrite levels (p = 0.036) and XO activity (p = 0.01), but their SOD, GSH-Px enzyme activities, and MDA levels were unchanged from baseline.", "spo_list": [{"subject": "Tenoxicam", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "XO", "object_type": "GENE-Y"}]}
{"text": "The patients were divided into two groups according to the 5HT-2A affinity of the individual medications (high 5HT-2A affinity--clozapine, olanzapine, risperidone vs. low 5HT-2A affinity--quetiapine, amisulpride).", "spo_list": [{"subject": "clozapine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5HT-2A", "object_type": "GENE-Y"}, {"subject": "olanzapine", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5HT-2A", "object_type": "GENE-Y"}, {"subject": "risperidone", "subject_type": "CHEMICAL", "predicate": "DIRECT-REGULATOR", "object": "5HT-2A", "object_type": "GENE-Y"}]}
{"text": "ISO is able to induce apoptosis through mitochondrial dysfunction and inhibition of PI3K/Akt signaling pathway in HepG2 cells, however, the effects of ISO on MAPK signaling pathways remain unknown.", "spo_list": [{"subject": "ISO", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "PI3K", "object_type": "GENE-N"}, {"subject": "ISO", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "Akt", "object_type": "GENE-N"}]}
{"text": "ISO significantly inhibited the levels of ERK1/2 kinase and increased the expression of JNK and p38 kinases.", "spo_list": [{"subject": "ISO", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "JNK", "object_type": "GENE-N"}, {"subject": "ISO", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "ISO", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "kinases", "object_type": "GENE-N"}]}
{"text": "Furthermore, U0126 (an ERK1/2 inhibitor) significantly enhanced the ISO-induced the Bax/Bcl-2 ratio, the release of cytochrome c to the cytosol fraction, and the levels of cleaved caspase-3.", "spo_list": [{"subject": "ISO", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bax", "object_type": "GENE-Y"}, {"subject": "ISO", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bcl-2", "object_type": "GENE-Y"}, {"subject": "U0126", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bcl-2", "object_type": "GENE-Y"}, {"subject": "U0126", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "Bax", "object_type": "GENE-Y"}]}
{"text": "While SP600125 (a JNK inhibitor) and SB203580 (a p38 inhibitor) markedly prevented the expression of these proteins induced by ISO.", "spo_list": [{"subject": "SP600125", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JNK", "object_type": "GENE-N"}, {"subject": "SB203580", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "ISO", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "ISO", "subject_type": "CHEMICAL", "predicate": "INDIRECT-UPREGULATOR", "object": "JNK", "object_type": "GENE-N"}]}
{"text": "NAC also suppressed the p-JNK and p-p38, but failed to reverse the effects of ISO.", "spo_list": [{"subject": "NAC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "JNK", "object_type": "GENE-N"}, {"subject": "NAC", "subject_type": "CHEMICAL", "predicate": "INHIBITOR", "object": "p-p38", "object_type": "GENE-N"}]}
{"text": "These results demonstrated for the first time that ISO induces apoptosis in HepG2 cells through inactivating ERK1/2 kinase and activating JNK and p38 kinases, and ROS stimulated by ISO is able to activate the MAPK singaling pathway as the upstream signaling molecules.", "spo_list": [{"subject": "ISO", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "JNK", "object_type": "GENE-N"}, {"subject": "ISO", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "p38", "object_type": "GENE-N"}, {"subject": "ISO", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "kinases", "object_type": "GENE-N"}, {"subject": "ISO", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "MAPK", "object_type": "GENE-N"}]}
{"text": "Cardiac effects of the beta 3-adrenoceptor agonist BRL35135 in man.", "spo_list": [{"subject": "BRL35135", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta 3-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "The aim of the present study was to evaluate the cardiac effects of the beta 3-adrenoceptor agonist BRL35135, and determine whether beta 3-receptors are involved in mediating chronotropic or inotropic responses in man.", "spo_list": [{"subject": "BRL35135", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta 3-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Eight normal males received single oral doses of BRL35135 8 mg (BRL) or the selective beta 2-adrenoceptor agonist salbutamol 8 mg (SAL), after pretreatment with either placebo (PL), bisoprolol 5 mg (B5) as a selective beta 1-adrenoceptor antagonist, or nadolol 20 mg (N20) to block beta 1- and beta 2- but not beta 3-receptors.", "spo_list": [{"subject": "salbutamol", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta 2-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "SAL", "subject_type": "CHEMICAL", "predicate": "AGONIST", "object": "beta 2-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "bisoprolol", "subject_type": "CHEMICAL", "predicate": "ANTAGONIST", "object": "beta 1-adrenoceptor", "object_type": "GENE-Y"}]}
{"text": "Both BRL and SAL produced a significant increase in postural finger tremor in keeping with beta 2-adrenoceptor stimulation, and this response was totally abolished by pretreatment with N20.", "spo_list": [{"subject": "SAL", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "beta 2-adrenoceptor", "object_type": "GENE-Y"}, {"subject": "BRL", "subject_type": "CHEMICAL", "predicate": "ACTIVATOR", "object": "beta 2-adrenoceptor", "object_type": "GENE-Y"}]}
